<SEC-DOCUMENT>0001213900-25-044880.txt : 20250516
<SEC-HEADER>0001213900-25-044880.hdr.sgml : 20250516
<ACCEPTANCE-DATETIME>20250516160704
ACCESSION NUMBER:		0001213900-25-044880
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		120
FILED AS OF DATE:		20250516
DATE AS OF CHANGE:		20250516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276500
		FILM NUMBER:		25959193

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>ea0241941-posam1_abvcbio.htm
<DESCRIPTION>POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 15 15:05:50 UTC 2025 -->
<html xmlns:abvc="http://metuboutique.com/20250331" xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b style="-keep: true">As filed with the
Securities and Exchange Commission on May 16, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No. 333-276500</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No. 333-271416</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-keep: true"><b><span style="-sec-ix-hidden: hidden-fact-0">POST-EFFECTIVE
</span></b></span><b style="-keep: true">AMENDMENT NO. 1</b> <br/>
<b>TO</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM S-1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>REGISTRATION STATEMENT
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>UNDER</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>THE SECURITIES ACT
OF 1933</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-69"><b>ABVC BIOPHARMA, INC.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Exact name of registrant
as specified in its charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-81"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5084</b></span></td> <td style="vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>26-0014658</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or other jurisdiction of<br/> incorporation or organization)</b></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Primary Standard Industrial<br/> Classification Code Number)</b></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification Number)</b></p></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>44370 Old Warm Springs
Blvd., </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Fremont, CA 94538</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(510) 668-0881</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Address, including zip
code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Dr. Uttam Patil</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Chief Executive Officer
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>44370 Old Warm Springs
Blvd., </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Fremont, CA 94538</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(510) 668-0881- telephone</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Name, address, including
zip code, and telephone number, including area code, of agent for service)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>With copies to:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Louis Taubman,
                            Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Joan Wu, Esq.</b></p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hunter Taubman Fischer
    &amp; Li LLC</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>950 Third Avenue, 19th
    Floor</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New York, New York 10022</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(917) 512-0827- telephone</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Louis Taubman, Esq.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Approximate date of commencement of proposed
sale of the securities to the public: </b>As soon as practicable after this registration statement is declared effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
box. &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span></td> <td style="width: 3%">&#9744;</td> <td style="width: 20%">&#160;</td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td> <td style="width: 4%">&#9744;</td> <td style="width: 28%">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-46371">Non-accelerated filer</ix:nonNumeric> </span></td> <td>&#9746;</td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-46372">&#9746;</ix:nonNumeric></td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td>&#160;</td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-46373">&#9744;</ix:nonNumeric></td> <td>&#160;</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to said Section 8(a), may determine.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: Red"><b>The information in
this prospectus is not complete and may be changed. Neither we nor the Selling Stockholders may sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell and is not soliciting
an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"></p><div>

</div><p style="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">SUBJECT TO COMPLETION,
DATED MAY 16, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PRELIMINARY PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>11,714,683 shares of Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the resale, from time
to time, by the selling stockholders identified in this prospectus under the caption &#8220;Selling Stockholders,&#8221; of up to 11,714,683
shares of Common Stock of ABVC BioPharma, Inc., a Nevada corporation (the &#8220;Company&#8221;), $0.001 par value (the &#8220;Common
Stock&#8221;). These shares include: (i) 3,527,778 shares of Common Stock underlying a secured, convertible note pursuant to that certain
securities purchase agreement dated as of February 23, 2023 between the Company and Lind Global Fund II, LP (the &#8220;Lind Transaction&#8221;);
(ii) 5,291,667 shares of Common Stock underlying a common stock purchase warrant pursuant to the Lind Transaction; (iii) 211,667 shares
of Common Stock underlying a placement agent common stock purchase warrant pursuant to the Lind Transaction (the &#8220;PA Warrant&#8221;);
(iv) 342,857 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain securities purchase
agreement dated as of November 17, 2023 between the Company and Lind Global Fund II, LP (the &#8220;2<sup>nd</sup> Lind Transaction&#8221;);
(v) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 2<sup>nd</sup> Lind Transaction; (vi)
30,000 shares of Common Stock underlying a placement agent common stock purchase warrant pursuant to the 2<sup>nd</sup> Lind Transaction
(the &#8220;2<sup>nd</sup> PA Warrant&#8221;); (vii) 285,714 shares of Common Stock of the Company underlying a secured, convertible
note pursuant to that certain securities purchase agreement dated as of January 17, 2024 between the Company and Lind (the &#8220;3<sup>rd
</sup>Lind Transaction&#8221;); (viii) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 3<sup>rd
</sup>Lind Transaction; and (ix) 25,000 shares of Common Stock underlying a placement agent common stock purchase warrant pursuant to
the 3<sup>rd</sup> Lind Transaction (the &#8220;3<sup>rd</sup> PA Warrant&#8221;).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the details about the selling stockholder,
please see &#8220;Selling Stockholders.&#8221; The selling stockholder may sell these shares from time to time in the principal market
on which our Common Stock is traded at the prevailing market price, in negotiated transactions, or through any other means described
in the section titled &#8220;Plan of Distribution.&#8221; The selling stockholder may be deemed an underwriter within the meaning of
the Securities Act of 1933, as amended, of the shares of Common Stock that they are offering. We will pay the expenses of registering
these shares. We will not receive proceeds from the sale of our shares by the selling stockholder that are covered by this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares are being registered to permit the
selling stockholder, or its respective pledgees, donees, transferees or other successors-in-interest, to sell the shares from time to
time in the public market. We do not know when or in what amount the selling stockholder may offer the securities for sale. The selling
stockholder may sell some, all or none of the securities offered by this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Our
                                            common stock is quoted on the Nasdaq Capital Markets under the symbol ABVC. On May 14, 2025,
                                            the closing price &#160;of our common stock was $1.46 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            Selling Stockholders may sell their shares of Common Stock described in this prospectus in
                                            a number of different ways, at prevailing market prices or privately negotiated prices and
                                            there is no termination date of the Selling Stockholders&#8217; offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus, together with
additional information described under the headings &#8220;Incorporation of Certain Information by Reference&#8221; and &#8220;Where
You Can Find More Information&#8221;, carefully before you invest in any of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investing in our securities involves a high
degree of risk. See &#8220;Risk Factors&#8221; starting on page  9 of this prospectus.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">The
                                            date of this prospectus is May 16, 2025</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXPLANATORY NOTE</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><ix:nonNumeric contextRef="c0" continuedAt="_AmendmentDescription-c0_cont_1" name="dei:AmendmentDescription" id="ixv-370"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">This Amendment No. 4 to the registration statement on Form S-1 (Registration No. 333-276500) is filed for the purpose of including information contained in the registrant&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 and Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on April 30, 2025 and April 15, 2025.</span></p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:continuation continuedAt="_AmendmentDescription-c0_cont_2" id="_AmendmentDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">No
                                            additional securities are being registered under this Post-Effective Amendment No. 4. All
                                            applicable registration fees were paid at the time of the original filing of the Registration
                                            Statement on April 24, 2023.</span></p></ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_AmendmentDescription-c0_cont_3" id="_AmendmentDescription-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Pursuant to Section 84001 of the FAST Act,
all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended,
after the date of this Post-Effective Amendment and prior to the termination of the offering covered hereby shall also be deemed to be
incorporated by reference into this Post-Effective Amendment and to be a part hereof from the date of filing of such documents.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_AmendmentDescription-c0_cont_4" id="_AmendmentDescription-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b style="-keep: true"><i>Post-Effective Amendment No. 1 to Registration
Statement on Form S-1 (File No. 333-276500)</i></b></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_AmendmentDescription-c0_cont_5" id="_AmendmentDescription-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the resale, from time
to time, by the selling stockholders identified in this prospectus under the caption &#8220;Selling Stockholders,&#8221; of: (a) up to
342,857 shares of Common Stock of the Company, which are issuable upon conversion of a secured, convertible note pursuant to that certain
securities purchase agreement dated as of November 17, 2023 (the &#8220;2<sup>nd</sup> Lind Transaction&#8221;) between the Company and
Lind Global Fund II, LP (&#8220;Lind&#8221;) in the principal amount of $1,200,000 (the &#8220;2<sup>nd</sup> Lind Note&#8221;), at a
conversion price, which shall be the lesser of (i) $3.50 (the &#8220;Fixed Price&#8221;) and (ii) 90% of the three lowest VWAPs (as defined
in the 2<sup>nd</sup> Lind Note) during the 20 trading days prior to conversion, (b) 1,000,000 shares of Common Stock underlying a common
stock purchase warrant (the &#8220;2<sup>nd</sup> Lind Warrant&#8221;) at an initial exercise price of $2 per share, (c) 30,000 shares
of Common Stock underlying a placement agent common stock purchase warrant pursuant to the 2<sup>nd</sup> Lind Transaction, (the &#8220;2<sup>nd</sup>
PA Warrant&#8221;); (d) 285,714 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain
securities purchase agreement dated as of January 17, 2024 between the Company and Lind (the &#8220;3<sup>rd</sup> Lind Transaction&#8221;);
(e) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 3<sup>rd</sup> Lind Transaction; and
(f) 25,000 shares of Common Stock underlying a placement agent common stock purchase warrant pursuant to the 3<sup>rd </sup>Lind Transaction
(the &#8220;3<sup>rd</sup> PA Warrant&#8221;).</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_AmendmentDescription-c0_cont_6" id="_AmendmentDescription-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b style="-keep: true"><i>Post-Effective Amendment No. 4 to Registration
Statement on Form S-1 (File No. </i>333-271416<i>)</i></b></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><ix:continuation continuedAt="_AmendmentDescription-c0_cont_7" id="_AmendmentDescription-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2023, we filed a registration statement
with the SEC, on Form S-1 (File No. 333-271416) (the &#8220;Prior Registration Statement&#8221;), to initially register for resale 9,031,112
shares of our common stock, which includes: (i) 3,527,778 shares of common stock underlying secured convertible note (the &#8220;Lind
Note&#8221;) pursuant to that certain securities purchase agreement dated as of February 23, 2023, (ii) 5,291,667 shares of common stock
underlying a warrant dated February 23, 2023 (the &#8220;Lind Warrant&#8221;) and (iii) 211,667 shares of common stock underlying a placement
agent warrant dated February 23, 2023.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><ix:continuation id="_AmendmentDescription-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The
                                            Prior Registration Statement was declared effective by the SEC on June 8, 2023. Pursuant
                                            to Rule 429 this registration statement shall constitute Post-Effective Amendment No. 4 to
                                            the Prior Registration Statement with respect to the offering of any unsold shares thereunder
                                            and is being filed to update certain other information in the Prior Registration Statement.
                                            No additional securities are being registered under this Post-Effective Amendment No. 4.
                                            All applicable registration fees for the Prior Registration Statement were paid at the time
                                            of the original filing of the Prior Registration Statement. Accordingly, upon effectiveness,
                                            this Registration Statement shall act as a post-effective amendment to the Prior Registration
                                            Statement.</span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 92%"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS
    CONVENTIONS</b></span></a></td>
    <td style="width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDUSTRY
    AND MARKET DATA</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS
    SUMMARY</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
    OFFERING</b></span></a></td>
    <td style="text-align: center">8</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
    FACTORS</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPECIAL
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USE
    OF PROCEEDS</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT&#8217;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BUSINESS</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
    COMPENSATION</b></span></a></td>
    <td style="text-align: center">85</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RELATED
    PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMBINED COMPANY</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION
    OF SECURITIES</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SELLING
    STOCKHOLDERS</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PLAN
    OF DISTRIBUTION</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEGAL
    MATTERS</b></span></a></td>
    <td style="text-align: center">100</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPERTS</b></span></a></td>
    <td style="text-align: center">100</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHERE
    YOU CAN FIND MORE INFORMATION</b></span></a></td>
    <td style="text-align: center">100</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
in this prospectus or in any free writing prospectus that we may specifically authorize to be delivered or made available to you. We
and our Underwriter have not authorized anyone to provide you with any information other than that contained in this prospectus or in
any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide
no assurance as to the reliability of, any other information that others may give you. This prospectus may only be used where it is legal
to offer and sell our securities. The information in this prospectus is accurate only as of the date of this prospectus, regardless of
the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects
may have changed since that date. We are not making an offer of these securities in any jurisdiction where the offer is not permitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the context otherwise requires, the terms
&#8220;ABVC,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this prospectus refer to ABVC BIOPHARMA, INC., and &#8220;this
offering&#8221; refers to the offering contemplated in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS CONVENTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except where the context otherwise requires and
for purposes of this prospectus only:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#8220;AiBtl&#8221; means AiBtl BioPharma,
Inc. refers to a Delaware corporation and controlling subsidiary of ABVC;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;American BriVision Corporation&#8221;
refers to a Delaware corporation and wholly-owned subsidiary of ABVC;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;APR&#8221; or &#8220;annual percentage
rate&#8221; refers to the annual rate that is charged to borrowers, including a fixed interest rate and a transaction fee rate, expressed
as a single percentage number that represents the actual yearly cost of borrowing over the life of a loan;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;BioKey&#8221; means BioKey, Inc. refers
to a California corporation and wholly-owned subsidiary of ABVC;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#8220;BioKey Cayman&#8221; means BioKey (Cayman),
Inc. refers to a Cayman corporation and wholly-owned subsidiary of ABVC;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;BioLite&#8221; means BioLite Holding,
Inc. refers to a Nevada corporation and a wholly-owned subsidiary of ABVC;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &#8220;Board&#8221; or &#8220;Board of Directors&#8221;
refers to the board of directors of the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#8220;CDMO&#8221; refers to the Contract
Development &amp; Manufacturing Organization services&#160;BioKey provides, such as an API characterization, pre-formulation studies,
formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical
trial materials (phase I through phase III) and commercial manufacturing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;China&#8221; and &#8220;P.R.C.&#8221;
refer to the People&#8217;s Republic of China, including Hong Kong Special Administrative Region or Macau Special Administrative Region,
unless referencing specific laws and regulations adopted by the PRC and other legal or tax matters only applicable to mainland China,
excluding Taiwan for purposes of this prospectus;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Common Stock&#8221; is the Common Stock
of ABVC Biopharma, Inc., par value US$0.001 per share;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Lind&#8221; refers to Lind Global Fund
II, LP;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Series A Convertible Preferred Stock&#8221;
is the Series A convertible preferred stock of ABVC Biopharma, Inc., par value US$0.001 per share;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The terms &#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our,&#8221; &#8220;the Company,&#8221; &#8220;our Company&#8221; or &#8220;ABVC&#8221; refers to ABVC Biopharma, Inc., a Nevada
corporation, and all of the Subsidiaries as defined herein unless the context specifies;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;R.O.C.&#8221; or &#8220;Taiwan&#8221;
refers to Taiwan, the Republic of China;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#8220;Subsidiary&#8221;
                                            or &#8220;Subsidiaries,&#8221; refer to American BriVision Corporation, sometimes referred
                                            to as &#8220;BriVision&#8221;, AiBtl, BioLite, BioKey, BioKey Cayman, and Yunzhiyi Co., Ltd
                                            (&#8220;Yunzhiyi&#8221;), a Taiwan corporation;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All references to &#8220;NTD&#8221; and &#8220;New
Taiwan Dollars&#8221; are to the legal currency of R.O.C.; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All references to &#8220;U.S. dollars&#8221;,
&#8220;dollars&#8221;, and &#8220;$&#8221; are to the legal currency of the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus specifies certain NTD amounts
and in parenthesis the approximate U.S. dollar amounts at the exchange rate on the date of this prospectus. The conversion rates regarding
NTD and U.S. dollars are subject to change and, therefore, we can provide no assurance that U.S. dollar amounts specified in this prospectus
will not change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For clarification, this prospectus follows English
naming convention of first name followed by last name, regardless of whether an individual&#8217;s name is Chinese or English.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDUSTRY AND MARKET DATA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus includes information with respect
to market and industry conditions and market share from third-party sources or based upon estimates using such sources when available.
We have not, directly or indirectly, sponsored or participated in the publication of any of such materials. We believe that such information
and estimates are reasonable and reliable. We also assume the information extracted from publications of third-party sources has been
accurately reproduced. We understand that the Company would be liable for the information included in this prospectus if any part of
the information was incorrect, misleading or imprecise to a material extent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<a id="a_003"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS SUMMARY</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>This summary highlights information contained
elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision.
Before investing in our securities, you should carefully read this entire prospectus, including our financial statements and the related
notes and the information set forth under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221; in each case included elsewhere in this prospectus.</i></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Company Overview</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Mission</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We
                                            devote our resources to building a sophisticated biotech company and becoming a pioneer in
                                            the biopharmaceutical industry. Dr. Uttam Patil, our Chief Executive Officer, and Dr. Tsung-Shann
                                            Jiang, the founder and majority shareholder of the Company, understand the challenges and
                                            opportunities of the biotech industry and intend to provide therapeutic solutions to significant
                                            unmet medical needs and to improve health and quality of human life by developing innovative
                                            botanical drugs to treat central nervous system (&#8220;CNS&#8221;) and oncology/ hematology
                                            diseases.</p><p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Overview</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As
                                            of the date of this Report, the Company&#8217;s revenue has come from outlicensing our intellectual
                                            properties and providing CDMO services. The Company&#8217;s focus is on developing a pipeline
                                            of products by carefully tracking new medical discoveries or medical device technologies
                                            in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and
                                            Phase I safety studies are examined closely by the Company&#8217;s scientists and other specialists
                                            known to the Company to identify drugs or medical devices that it believes demonstrate efficacy
                                            and safety based on the Company&#8217;s internal qualifications. Once a drug or medical device
                                            is shown to be a good candidate for further development and ultimately commercialization,
                                            ABVC licenses the drug or medical device from the original researchers and introduces the
                                            drug or medical device clinical trial plan to highly respected principal investigators in
                                            the United States, Australia and Taiwan. In almost all cases, ABVC has found that research
                                            institutions in each of those countries are eager to work with the Company to move forward
                                            with Phase II clinical trials.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Institutions that have or are now conducting
phase II clinical trials in partnership with ABVC include:</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug:
                                            ABV-1504, Major Depressive Disorder (MDD), Phase II completed. NCE drug Principal Investigators:
                                            Charles DeBattista M.D. and Alan F. Schatzberg, MD, Stanford University Medical Center, Cheng-Ta
                                            Li, MD, Ph.D - Taipei Veterans General Hospital</span></td>
</tr></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Drug:
                                            ABV-1505, Adult Attention-Deficit Hyperactivity Disorder (ADHD), Phase II Part 1 completed.
                                            Principal Investigators: Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D., University of
                                            California San Francisco (UCSF), School of Medicine. Phase II, Part 2 clinical study sites
                                            include UCSF and 5 locations in Taiwan. The Principal Investigators are Keith McBurnett,
                                            Ph.D. and Linda Pfiffner, Ph.D., University of California San Francisco (UCSF), School of
                                            Medicine; Susan Shur-Fen Gau, M.D., National Taiwan University Hospital; Xinzhang Ni, M.D.
                                            Linkou Chang Gung Memorial Hospital; Wenjun Xhou, M.D.; Kaohsiung Chang Gung Memorial Hospital;
                                            Ton-Ping Su, M.D., Cheng Hsin General Hospital; Cheng-Ta Li, M.D., Taipei Veterans General
                                            Hospital. Phase II, Part 2 began in the 1st quarter of 2022 at the 5 Taiwan sites. The UCSF
                                            site joined the study in the 2nd quarter of 2023. The subjects enrolled in the study has
                                            reached the number for interim analysis in December 2023, and the interim analysis of the
                                            study is in progress.</span></p></td>
</tr></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">Drug:
                                            ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator:
                                            Scott Irwin, MD, Ph.D. - Cedars Sinai Medical Center (CSMC). The Phase I clinical study will
                                            be initiated around the end of 2025.</span><p style="margin: 0"></p>


</td>
</tr></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
                                            Device: ABV-1701, Vitargus&#174; in vitrectomy surgery, Phase II Study has been initiated
                                            in Australia and Thailand, Principal Investigator: Duangnate Rojanaporn, M.D., Ramathibodi
                                            Hospital; Thuss Sanguansak, M.D., Srinagarind Hospital of the two Thailand Sites and Professor/Dr.
                                            Matthew Simunovic, Sydney Eye Hospital; Dr. Elvis Ojaimi, East Melbourne Eye Group &amp;
                                            East Melbourne Retina. The Phase II study started in the 2nd quarter of 2023, and the company
                                            is working on improvements to the Vitargus Product through the new batch of investigational
                                            product.</span></td>
</tr></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following trials are expected to begin
in the third quarter of 2025:</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug:
                                            ABV-1519, Non-Small Cell Lung Cancer treatment, Phase I/II Study in Taiwan, Principal Investigator:
                                            Dr. Yung-Hung Luo, M.D., Taipei Veterans General Hospital (TVGH)</span></td>
</tr></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug:
                                            ABV-1703, Advanced Inoperable or Metastatic Pancreatic Cancer, Phase II, Principal Investigator:
                                            Andrew E. Hendifar, MD - Cedars Sinai Medical Center (CSMC)</span></td>
</tr></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon successful completion of a Phase II trial,
ABVC will seek a partner, typically a large pharmaceutical company, to complete a Phase III study and commercialize the drug or medical
device upon approval by the US FDA, Taiwan TFDA and other country regulatory authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Structure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ABVC was incorporated under the laws of the
State of Nevada on February 6, 2002 and has four wholly-owned Subsidiaries: BriVision, BioLite Holding, Inc., BioKey Cayman, and BioKey,
Inc. BriVision was incorporated in July 2015 in the State of Delaware and is in the business of developing pharmaceutical products in
North America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite Holding was incorporated under the laws
of the State of Nevada on July 27, 2016, with 500,000,000 shares authorized, par value $0.0001. Its key Subsidiaries include BioLite
BVI, Inc. (&#8220;BioLite BVI&#8221;) that was incorporated in the British Virgin Islands on September 13, 2016 and BioLite Inc. (&#8220;BioLite
Taiwan&#8221;), a Taiwanese corporation that was founded in February 2006. BioLite Taiwan has been in the business of developing new
drugs for over twelve years. Certain shareholders of BioLite Taiwan exchanged approximately 73% of equity securities in BioLite Taiwan
for the Common Stock in BioLite Holding in accordance with a share purchase/ exchange agreement (the &#8220;Share Purchase/ Exchange
Agreement&#8221;). As a result, BioLite Holding owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who
did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Yunzhiyi, a Taiwan corporation, was incorporated in August 2024,
with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, one of the Company&#8217;s director. This entity is set up for holding
the land in Taiwan that AiBtl is in the process of acquiring, which land will be used for developing health related business. As of the
date hereof, the transfer of the land&#8217;s title is currently under government review, pending completion of the title transfer registration.
Due to Taiwan&#8217;s legal restrictions prohibiting foreign entities from directly owning farmland, the parties agreed to structure
the arrangement through nominee holdings.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Incorporated in California on November 20, 2000,
BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon closing of the Mergers on February 8, 2019,
BioLite and BioKey became two wholly-owned subsidiaries of ABVC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioKey Cayman was incorporated in Cayman Islands
in July 2023, which is 100% owned by ABVC. This subsidiary has no activities since inception.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following chart illustrates the corporate structure of ABVC:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg" style="height: 377px; width: 650px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 5, 2022, the Company&#8217;s
Board for Directors approved amending the Company&#8217;s Bylaws to remove Section 2.8, which permitted cumulative voting for directors
since cumulative voting is specifically prohibited by our Articles of Incorporation. Since it is not otherwise stated in our Articles
of Incorporation or Bylaws, directors shall be elected by a plurality of the votes cast at the election, as provided in the Nevada Revised
Statutes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective March 14, 2024, the Company&#8217;s
Board for Directors approved amending Section 2.8 of the Company&#8217;s Bylaws to revise the number of shares needed to establish a
quorum at shareholder meetings. The amendment changes the quorum requirement from a majority to 33-1/3% of the votes entitled to be cast
on a matter. The full text of our current Bylaws, as amended is attached hereto as Exhibit 3.2.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>
</div><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NASDAQ Listing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2021, we closed a public offering
(the &#8220;Offering&#8221;) of 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of our common stock
(the &#8220;Common Stock&#8221;), one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at
an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the
&#8220;Series B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of
common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise
price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed
the Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange
Commission (the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared
effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective
on August 4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;).
The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.
The Offering was conducted on a firm commitment basis. The Common Stock was approved for listing on The Nasdaq Capital Market and commenced
trading under the ticker symbol &#8220;ABVC&#8221; on August 3, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 19, 2022, we received a deficiency
letter from the Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)
notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock was below the minimum $1.00
per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (&#8220;Rule 5550(a)(2)&#8221;).
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were initially given until February 14, 2023 to regain compliance with Rule
5550(a)(2). Since we did not regain compliance by such date, we requested and received an additional 180 days, until August 14, 2023,
to comply with Rule 5550(a)(2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>1</sup></td><td style="text-align: justify"><b><i>J
                                            Cancer Res Clin Oncol (2009) 135:1215-1221</i></b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 10, 2024, we received a notification
letter from the Nasdaq notifying the Company that the minimum bid price per share for its common shares has been below $1.00 for a period
of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing
Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company&#8217;s common stock on Nasdaq. Under
the Nasdaq Listing Rules, the Company has until January 6, 2025, to regain compliance. On January 9, 2025, the Company received a notification
from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share,
as outlined in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Rule&#8221;). To satisfy the Rule, the Company&#8217;s common stock must achieve
a closing bid price of at least $1.00 for a minimum of ten consecutive trading days within this extension period; if successful, Nasdaq
will confirm compliance with the Rule and close this matter. If compliance is not achieved by the new deadline, Nasdaq may initiate delisting
procedures, which the Company would have the right to appeal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 24, 2025, we received a letter from
the listing qualifications staff (the &#8220;Staff&#8221;) of Nasdaq informing us that, as reported in our Annual Report on Form 10-K
for the year ended December 31, 2024, because our <i>stockholders&#8217; equity</i> was $723,959, as of April 23, 2025, we did not meet
the alternatives of market value of listed securities or net income from continuing operations, and we no longer comply with Listing
Rule 5550(b)(1) (the &#8220;Rule 5550&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We have 45 calendar days to submit a plan
to the Staff to regain compliance. If our plan is accepted, we may be granted an extension of up to 180 calendar days from the date of
the letter, or until October 21, 2025, to evidence compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In determining whether to accept our plan,
the Staff will consider such things as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria,
our past compliance history, the reasons for our current non-compliance, other corporate events that may occur within our review period,
our overall financial condition, and our public disclosures. If the Staff does not accept our plan, we will have the opportunity to appeal
that decision to a Hearings Panel.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Nasdaq notification has no immediate effect
on the listing of our Common Stock on the Nasdaq Capital Market. We intend to actively monitor our <i>stockholders&#8217; equity</i>
and will consider options available to us to achieve compliance with Rule 5550. There can be no assurance that we will be able to regain
compliance with the Listing Rule or will otherwise be in compliance with the other listing standards for the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If our Common Stock ultimately were to be
delisted for any reason, it could negatively impact us by (i) reducing the liquidity and market price of our Common Stock; (ii) reducing
the number of investors willing to hold or acquire our Common Stock; (ii) limiting our ability to use a registration statement to offer
and sell freely tradable securities, thereby preventing us from accessing the public capital markets; and (iv) impairing our ability
to provide equity incentives to our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 30, 2025, the Company reported that
it received a letter from the listing qualifications staff (the &#8220;Staff&#8221;) of Nasdaq informing it that, as reported in its
Annual Report on Form 10-K for the year ended December 31, 2024, because its stockholders&#8217; equity was $723,959, as of April 23,
2025, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations, and it
no longer comply with Listing Rule 5550(b)(1) (the &#8220;Listing Rule&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 5, 2025, the Company received a notification
letter (the &#8220;Notification Letter&#8221;) from Nasdaq notifying the Company that the Staff has determined that based on the Company&#8217;s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which evidenced stockholders&#8217; equity of $7,956,295, the Company
complies with the Listing Rule and the matter is closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Key elements of our business strategy include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advancing to
    the pivotal trial phase of ABV-1701 Vitargus&#174; for the treatments of Retinal Detachment or Vitreous Hemorrhage, which we expect
    to generate revenues in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Focusing on
    licensing ABV-1504 for the treatment of major depressive disorder, MDD, after the successful completion of its Phase II clinical
    trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    Phase II, Part 2 clinical trial for ABV-1505 for the treatment of attention deficit hyperactivity disorder, ADHD.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out licensing
    drug candidates and medical device candidates to major pharmaceutical companies for phase III and pivotal clinical trials, as applicable,
    and further marketing if approved by the FDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to augment our core research and development
capability and assets by conducting Phase I and II clinical trials for investigational new drugs and medical devices in the fields of
CNS, Hematology/Oncology and Ophthalmology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management team has extensive experiences
across a wide range of new drug and medical device development and we have in-licensed new drug and medical device candidates from large
research institutes and universities in both the U.S. and Taiwan. Through an assertive product development approach, we expect that we
will build a substantial portfolio of Oncology/ Hematology, CNS and Ophthalmology products. We primarily focus on Phase I and II research
of new drug candidates and out license the post-Phase-II products to pharmaceutical companies; we do not expect to devote substantial
efforts and resources to building the disease-specific distribution channels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material Risks and Challenges</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face substantial competition from a great
many established and emerging pharmaceutical and biotech companies that develop, distribute or sell therapeutics to treat the same
indications that our drug candidates are designed to treat. Our current and potential competitors include large pharmaceutical and
biotechnology companies, and specialty pharmaceutical and generic drug companies. Many of our current and potential competitors have
substantially greater financial, technical and human resources than we do and significantly more experience in the marketing,
commercialization, discovery, development and regulatory approvals of products, which could place us at a significant competitive
disadvantage or deny our marketing exclusivity rights. Typically, our competitors will most likely have more capital resources to
support their products than we do. In addition, you should carefully consider the risks described under the &#8220;Risk
Factors&#8221; section beginning on page 9 before investing in us. Some of these risks are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            associated with our profitability including, but not limited to:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have never generated revenue and will continue to be unprofitable in the foreseeable future.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business, operations and plans and timelines could be adversely affected by the effects of
                                            health epidemics, including the recent COVID-19 pandemic.</span></td>
</tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            associated with clinical trials and the development of our products, including but not limited
                                            to:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            trials are expensive and time consuming, and their outcome is uncertain.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            clinical trials could be delayed or unsuccessful, and we may not be able to obtain regulatory
                                            approval for any of our drug candidates when expected, or at all.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may experience delays in our clinical trials that could adversely affect our business and
                                            operations.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            rely on third parties to conduct our preclinical studies and clinical trials and if such
                                            third parties do not meet our deadlines or otherwise conduct the studies as required, we
                                            may be delayed in progressing, or ultimately may not be able to progress, our drug candidates
                                            to clinical trials.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to secure and maintain research institutions to conduct our future trials.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to secure co-developers or partners to further post-Phase II clinical trials
                                            and eventually commercialize our drug candidates.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may need to prioritize
    the development of our most promising candidates at the expense of the development of other products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physicians,
                                            patients, third-party payors or others in the medical community may not be receptive to our
                                            products, and we may not generate any future revenue from the sale or licensing of our products.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            associated with intellectual property including but not limited to:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be successful in obtaining or maintaining patent or other relating rights necessary
                                            to the development of our drug candidates in the pipeline;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            intellectual property rights underlying our exclusive licensing rights may expire or be terminated
                                            due to lack of maintenance;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            associated with competition and manufacturing including, but not limited to:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            face competition from entities that have developed or are developing products for our target
                                            disease indications, including companies developing novel treatments and technologies similar
                                            to ours; and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            depend primarily upon a sole supplier of our key extract for three drug candidates and could
                                            incur significant costs and delays if we are unable to promptly find a replacement for such
                                            supplier if the supplier fails to deliver the extract pursuant to our orders.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            associated with government regulations including without limitation:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we do not obtain the necessary governmental approvals, we will be unable to sub-license or
                                            commercialize our pharmaceutical products; and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                            if we obtain regulatory approval for a drug candidate, our products may remain subject to
                                            regulatory scrutiny.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            associated with our Common Stock including without limitation:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            market prices and trading volumes of the Common may be volatile and may be affected by economic
                                            conditions beyond our control; and,</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is only a limited trading market for our Common Stock and such market may never develop.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These and other risks described in this prospectus
could materially and adversely impact our business, financial condition, operating results and cash flow, which could cause the trading
price of our Common Stock to decline and could result in a loss of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The below is a summary of principal risks to
our business and risks associated with this offering. It is only a summary. You should read the more detailed discussion of risks set
forth below and elsewhere in this prospectus for a more complete discussion of the risks listed below and other risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            associated with our competition, including, but not limited to:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
                                            of our current and potential competitors have substantially greater financial, technical
                                            and human resources than we do, which could place us at a significant competitive disadvantage
                                            or deny our marketing exclusivity rights.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
                                            of our current and potential competitors have significantly more experience in the marketing,
                                            commercialization, discovery, development and regulatory approvals of products, which could
                                            place us at a significant competitive disadvantage or deny our marketing exclusivity rights</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            associated with our profitability including, but not limited to:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have never generated revenue and will continue to be unprofitable in the foreseeable future.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business, operations and plans and timelines could be adversely affected by the effects of
                                            health epidemics, including the recent COVID-19 pandemic.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            associated with clinical trials and the development of our products, including but not limited
                                            to:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            trials are expensive and time consuming, and their outcome is uncertain.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            clinical trials could be delayed or unsuccessful, and we may not be able to obtain regulatory
                                            approval for any of our drug candidates when expected, or at all.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may experience delays in our clinical trials that could adversely affect our business and
                                            operations.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            rely on third parties to conduct our preclinical studies and clinical trials and if such
                                            third parties do not meet our deadlines or otherwise conduct the studies as required, we
                                            may be delayed in progressing, or ultimately may not be able to progress, our drug candidates
                                            to clinical trials.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to secure
    and maintain research institutions to conduct our future trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to secure
    co-developers or partners to further post-Phase II clinical trials and eventually commercialize our drug candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may need to prioritize the development of our most promising candidates at the expense of
                                            the development of other products.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physicians,
    patients, third-party payors or others in the medical community may not be receptive to our products, and we may not generate any
    future revenue from the sale or licensing of our products.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated
    with intellectual property including but not limited to: </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not
    be successful in obtaining or maintaining patent or other relating rights necessary to the development of our drug candidates in
    the pipeline;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intellectual
    property rights underlying our exclusive licensing rights may expire or be terminated due to lack of maintenance;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated
    with competition and manufacturing including, but not limited to:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face competition
    from entities that have developed or are developing products for our target disease indications, including companies developing novel
    treatments and technologies similar to ours; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend primarily
    upon a sole supplier of our key extract for three drug candidates and could incur significant costs and delays if we are unable to
    promptly find a replacement for such supplier if the supplier fails to deliver the extract pursuant to our orders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated
    with government regulations including without limitation: </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we do not
    obtain the necessary governmental approvals, we will be unable to sub-license or commercialize our pharmaceutical products; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we
    obtain regulatory approval for a drug candidate, our products may remain subject to regulatory scrutiny.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk associated
    with our Common Stock including without limitation: </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market
    prices and trading volumes of the Common may be volatile and may be affected by economic conditions beyond our control; and,</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is only
    a limited trading market for our Common Stock and such market may never develop.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These and other risks described in this prospectus
could materially and adversely impact our business, financial condition, operating results and cash flow, which could cause the trading
price of our Common Stock to decline and could result in a loss of your investment. In addition, you should carefully consider the risks
described under &#8220;Risk Factors&#8221; beginning on page 9.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC was incorporated under the laws of the State
of Nevada on February 6, 2002. BriVision was incorporated in the State of Delaware on July 21, 2015. BioLite was incorporated in the
State of Nevada on July 27, 2016. BioKey was incorporated in the State of California on November 20, 2000. BriVision, BioLite and BioKey
are three operating subsidiaries that are wholly owned by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s shareholders approved an
amendment to the Company&#8217;s Articles of Incorporation to change the Company&#8217;s corporate name from American BriVision (Holding)
Corporation to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of
shareholders (the &#8220;<b>Annual Meeting</b>&#8221;). The name change amendment to the Company&#8217;s Articles of Incorporation was
filed with Nevada&#8217;s Secretary of State and became effective on March 8, 2021 and FINRA approved our application for the name change
as of May 3, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Stock was approved for listing on
The Nasdaq Capital Market and commenced trading under the ticker symbol &#8220;ABVC&#8221; on August 3, 2021. The Company&#8217;s CUSIP
number is 0091F106.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive office is located at
44370 Old Warm Springs Blvd., Fremont, CA 94538. Our telephone number at our principal executive office is (510)-668-0881. Our corporate
website of BriVision is http://www.abvcpharma.com<i>.</i> The information on our corporate website is not part of, and is not incorporated
by reference into, this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<a id="a_004"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock being offered by Selling Stockholders</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Up
                                            to 11,714,683 shares of Common Stock, including: (i) up to 3,527,778 shares of Common Stock,
                                            issuable upon full conversion of the Lind Note in the principal amount of $3,704,167, (ii)
                                            up to 5,291,667 shares of Common Stock underlying the Lind Warrant, (iii) up to 211,667 shares
                                            of Common Stock underlying the PA Warrant, (iv) up to 342,857 shares of Common Stock, issuable
                                            upon full conversion of the 2nd Lind Note in the principal amount of $1,200,000, (v) up to
                                            1,000,000 shares of Common Stock underlying the 2<sup>nd</sup> Lind Warrant; (vi) 30,000
                                            shares of Common Stock underlying a placement agent common stock purchase warrant pursuant
                                            to the 2<sup>nd</sup> Lind Transaction; (vii) 285,714&#160; shares of Common Stock, issuable
                                            upon full conversion of the 3<sup>rd</sup> Lind Note in the principal amount of $1,000,000;
                                            (viii) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant
                                            to the 3rd Lind Transaction; and (ix) 25,000 shares of Common Stock underlying a placement
                                            agent common stock purchase warrant pursuant to the 3rd Lind Transaction.</p>
                                                                     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Selling Stockholders may sell their shares of Common Stock at prevailing market prices or privately negotiated prices. We will not
    receive any proceeds from the sales by the Selling Stockholders.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of Proceeds</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any proceeds from the sale of shares by the Selling Stockholders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    securities offered by this prospectus are speculative and involve a high degree of risk and investors purchasing securities should
    not purchase the securities unless they can afford the loss of their entire investment. You should read &#8220;Risk Factors,&#8221;
    beginning on page 9  for a discussion of factors to consider before deciding to invest in our securities. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
    Agent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VStock
    Transfer, LLC</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investing in our securities includes a high
degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific factors discussed
below, together with all of the other information contained in this prospectus. If any of the following risks actually occurs, our business,
financial condition, results of operations and future prospects would likely be materially and adversely affected. This could cause the
market price of our Common Stock to decline and could cause you to lose all or part of your investment.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to the Company&#8217;s Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unfavorable global economic conditions,
including as a result of health and safety concerns, could adversely affect our business, financial condition or results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our results of operations could be adversely
affected by general conditions in the global economy, including conditions that are outside of our control, such as the impact of health
and safety concerns from the current outbreak of the COVID-19 coronavirus (&#8220;COVID-19&#8221;). The spread of the COVID-19, which
was declared a pandemic by the World Health Organization in March 2020, has caused different countries and cities to mandate curfews,
including &#8220;shelter-in-place&#8221; and closures of most non-essential businesses as well as other measures to mitigate the spread
of the virus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The negative impact of COVID-19 on our operations
is ongoing and the extent of which remains uncertain and potentially wide-spread, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to successfully execute our long-term growth strategy during these uncertain times;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit the necessary number of patients
    to complete future clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">supply chain disruptions
    in projects ABV-1504, ABV-1505 and ABV-1601, resulting from reduced workforces, scarcity of raw materials, and scrutiny or embargoing
    of goods produced in infected areas;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to perform
    on-site due-diligence for project ABV-1505 (MDD Phase II completed new drug candidate) and ABV-1701 (Vitargus FIH completed medical
    device) with our potential partners/collaborators in US, Mainland China, and Japan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to access capital
    sources, as well as the ability of our key customers, suppliers, and vendors to do the same in regard to their own obligations; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management
    and employee attention and resources from key business activities and risk management outside of COVID-19 response efforts, including
    maintenance of internal controls. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The COVID-19 pandemic remains highly volatile
and continues to evolve on a daily basis and therefore, despite our efforts and developments to combat the virus, there can be no assurance
that these measures will prove successful. The extent to which COVID-19 continues to impact the Company&#8217;s business, sales, and
results of operations will depend on future developments, which are highly uncertain and cannot be predicted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company is a development stage biopharmaceutical
company and is thus subject to the risks associated with new businesses in that industry.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired the sole licensing rights
to develop and commercialize for therapeutic purposes six compounds from BioLite and the right to co-develop with BioFirst a medical
device (collectively the &#8220;ABVC Pipeline Products&#8221;). As such, the Company is a clinical stage biopharmaceutical company with
operations that generate unsubstantial revenues. The Company is establishing and implementing many important functions necessary to operate
a business, including the clinical research and development of the ABVC Pipeline Products, further establishment of the Company&#8217;s
managerial and administrative structure, accounting systems and internal financial controls</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite and BioKey are expected to continue to
have limited revenue and remain unprofitable for an indefinite period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, you should consider the Company&#8217;s
prospects in light of the risks and uncertainties that a pharmaceutical company with a limited operating history and revenue faces. In
particular, potential investors should consider that there are significant risks that the Company will not be able to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement
                                            or execute its current business plan, or generate profits;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
                                            and maintain a skillful management team;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise
                                            sufficient funds in the capital markets or otherwise to effectuate its business plan;</span></td>
</tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
                                            that the processes and technologies that it has developed are commercially viable; and/or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
                                            into contracts with commercial partners, such as licensors and suppliers.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the above risks occurs, the Company&#8217;s
business may fail, in which case you may lose the entire amount of your investment in the Company. The Company cannot assure that any
of its efforts in business operations will be successful or result in the timely development of new products, or ultimately produce any
material revenue and profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a pre-profit biopharmaceutical company, the
Company needs to transition from a company with a research and development focus to a company capable of supporting commercial activities.
The Company may not be able to reach such transition point or make such a transition, which would have affect our business, financial
condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the Company fails to raise additional
capital, its ability to implement its business model and strategy could be compromised.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has limited capital resources and
operations. The CDMO services provided by BioKey generates a limited amount of revenue that can only partially support the operations
of the Company. To date, the Company&#8217;s operations have been funded partially from the proceeds from financings or loans from its
shareholders . From time to time, we may seek additional financing to provide the capital required to expand research and development
(&#8220;R&amp;D&#8221;) initiatives and/or working capital, as well as to repay outstanding loans if cash flow from operations is insufficient
to do so. We cannot predict with certainty the timing or amount of any such capital requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company does not raise sufficient capital
to fund its ongoing development activities, it is likely that it will be unable to carry out its business plans, including R&amp;D development
and expansion of production facilities. Currently, the Company has had to put several projects on hold due to a lack of funding. Even
if the Company obtains financing for near term operations and product development, the Company may require additional capital beyond
the near term. Furthermore, additional capital may not be available in sufficient amounts or on reasonable terms, if at all, and our
ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions
to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.
If the Company is unable to raise capital when needed, its business, financial condition and results of operations would be materially
adversely affected, and it could be forced to reduce or discontinue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company has no history in obtaining
regulatory approval for, or commercializing, any new drug candidate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With limited operating history, the Company has
never obtained regulatory approval for, or commercialized, any new drug candidate. It is possible that the FDA may refuse to accept our
planned New Drug Application (or &#8220;NDA&#8221;) for any of the six drug products for substantive review or may conclude after review
of our data that our application is insufficient to obtain regulatory approval of the new drug candidates or the medical device. Although
our CDMO strategic business department has experience in obtaining abbreviated new drug application (or &#8220;ANDA&#8221;) approvals,
the processes and timelines of obtaining an NDA approval and ANDA approval can differentiate substantially. If the FDA does not accept
or approve our planned NDA for our product candidates, it may require that we conduct additional clinical, preclinical or manufacturing
validation studies, which may be costly. Depending on the FDA required studies, approval of any NDA or application that we submit may
be significantly delayed, possibly for several years, or may require us to expend more resources than we have. Any delay in obtaining,
or inability to obtain, regulatory approvals of any of our drug candidate will prevent us from sublicensing such product. It is also
possible that additional studies, if performed and completed, may not be considered sufficient by the FDA. If any of these outcomes occurs,
we may be forced to abandon our planned NDA for such drug candidate, which materially adversely affects our business and could potentially
cause us to cease operations. We face similar regulatory risks in a foreign jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our growth is dependent on our ability
to successfully develop, acquire or license new drugs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our growth is supported by continuous investment
in time, resources and capital to identify and develop new products or new formulations for the market and market penetration. If we
are unable to either develop new products on our own or acquire licenses for new products from other parties, our ability to grow revenues
and market share will be adversely affected. In addition, we may not be able to recover our investment in the development of new drugs
and medical devices, given that projects may be interrupted, unsuccessful, not as profitable as initially contemplated or we may not
be able to obtain necessary financing for such development. Similarly, there is no assurance that we can successfully secure such rights
from third parties on an economically feasible basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our current products have certain side
effects. If the side effects associated with our current or future products are not identified prior to their marketing and sale, we
may be required to withdraw such products from the market, perform lengthy additional clinical trials or change the labeling of our products,
any of which could adversely impact our growth.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company researches and develops the following
seven drug products and one medical device: ABV-1501, ABV-1504, ABV-1505, ABV-1519, ABV-1702, ABV-1601 and ABV-1703. Each of these seven
products may cause serious adverse effects to their users. For example, the API of ABV-1501, ABV-1702 and ABV-1703 is Maitake mushroom
extract. Side effects, or adverse events, associated with Maitake mushroom extract include blood bilirubin increase, lymphocyte count
decrease, neutrophil count decrease, platelet count decrease, white blood cell decrease, headache, and hyperglycemia. Serious adverse
events (collectively, the &#8220;SAE&#8221;) associated with this compound include leukocytosis, platelet count decrease, eye disorders,
abdominal pain, gastrointestinal disorders, aphonia, lung infection, muscle weakness right-sided, confusion, edema cerebral, stroke,
dyspnea, wheezing, and pruritus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABV-1504 and ABV-1505 have the same API, &#8220;Radix
Polygala&#8221;, which is known as Polygala tenuifolia Willd or PDC-1421 Capsule (&#8220;Polygala tenuifolia Willd&#8221;). Side effects,
or adverse events, associated with ABV-1504 and ABV-1505, coming from administration of the trial medicine or examination procedure such
as the procedure of taking blood (fainting, pain and/or bruising), may lead to gastrointestinal disorders (abdominal fullness and constipation),
nervous system disorders (drowsiness, sleepiness, and oral ulcer). In addition, long-term use may cause miscarriages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The safety and preliminary efficacy findings
from this study, combined with the unique properties of ABV-1701, are supportive of further investigation for its use following vitrectomy
surgery in patients requiring vitreous replacement. However, new serious side effects of ABV-1701 may be uncovered as the clinical trials
continue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of any of those adverse events
would harm our future sales of these medicines and substantially increase the costs and expenses of marketing these medicines, which
in turn could cause our revenues and net income to decline. In addition, the reputation and sales of our future medicines could be adversely
affected due to the severe side effects discovered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to product liability
claims in the future, which could divert our resources, cause us to incur substantial liabilities and limit commercialization of any
products that we may develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face an inherent business risk of exposure
to product liability claims in the event that the uses of our products are alleged to have caused adverse side effects. Side effects
or marketing or manufacturing problems pertaining to any of our products could result in product liability claims or adverse publicity.
These risks will exist for those products in clinical development and with respect to those products that receive regulatory approval
for commercial sale. Furthermore, although we have not historically experienced any problems associated with claims by users of our products,
we do not currently maintain product liability insurance and there could be no assurance that we are able to acquire product liability
insurance with terms that are commercially feasible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face an inherent risk of product liability
claims as a result of the clinical testing of our products and potentially commercially selling any products that we may develop. For
example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing,
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design,
a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted
under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities or be required to limit commercialization of our product candidate. Regardless of the merits or eventual outcome, liability
claims may result in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased demand for our product candidates or products
    that we may develop;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury to our reputation and significant negative media
    attention;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical trial participants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant costs to defend resulting litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards to trial participants or
    patients;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of revenue;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced resources of our management to pursue our business
    strategy; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to commercialize any products that we
    may develop.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have insurance policies to cover
liabilities under the clinic trials but do not maintain general liability insurance; and even if we have a general liability insurance
in the future, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation
or other proceeding, even if resolved in our favor, could be substantial. We would need to increase our insurance coverage if and when
we begin selling any product candidate that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive.
If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential
product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidate, which
could adversely affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have conducted, and may in the future
conduct, clinical trials for certain of our product candidates at sites outside the United States, and the FDA may not accept data from
trials conducted in such locations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have conducted and may in the future choose
to conduct one or more of our clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted
outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial
must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population
must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice
in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws,
FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations.
There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept
the data from any of our clinical trials that we determine to conduct outside the United States, it would likely result in the need for
additional trials, which would be costly and time-consuming and delay or permanently halt our development of the product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the conduct of clinical trials outside
the United States could have a significant impact on us. Risks inherent in conducting international clinical trials include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign regulatory requirements that could restrict
    or limit our ability to conduct our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative burdens of conducting clinical trials
    under multiple foreign regulatory schema;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign exchange fluctuations; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diminished protection of intellectual property in some
    countries.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If clinical trials of our product candidates
fail to demonstrate safety and efficacy to the satisfaction of the FDA and comparable non-U.S. regulators, we may incur additional costs
or experience delays in completing, or ultimately be unable to complete the development and commercialization of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not permitted to commercialize, market,
promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Comparable non-U.S. regulatory
authorities impose similar restrictions. We may never receive such approvals. We must complete extensive preclinical development and
clinical trials to demonstrate the safety and efficacy of our product candidate in humans before we will be able to obtain these approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical testing is expensive, difficult to design
and implement, can take many years to complete and is inherently uncertain as to outcome. Any inability to successfully complete preclinical
and clinical development could result in additional costs to us and impair our ability to generate revenues from product sales, regulatory
and commercialization milestones and royalties. In addition, if (1) we are required to conduct additional clinical trials or other testing
of our product candidate beyond the trials and testing that we contemplate, (2) we are unable to successfully complete clinical trials
of our product candidate or other testing, (3) the results of these trials or tests are unfavorable, uncertain or are only modestly favorable,
or (4) there are unacceptable safety concerns associated with our product candidate, we, in addition to incurring additional costs, may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be delayed in obtaining
    marketing approval for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not obtain marketing approval
    at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain approval for indications
    or patient populations that are not as broad as we intended or desired;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain approval with labeling
    that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be subject to additional
    post-marketing testing or other requirements; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be required to remove the
    product from the market after obtaining marketing approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if any of our product candidates receives
marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third party payors and others in
the medical community necessary for commercial success and the market opportunity for the product candidate may be smaller than we estimate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never completed a new drug or new medical
device FDA application process from Phase I to FDA approval and commercialization. Even if our products are approved by the appropriate
regulatory authorities for marketing and sale, they may nonetheless fail to gain sufficient market acceptance by physicians, patients,
third party payors and others in the medical community. For example, physicians are often reluctant to switch their patients from existing
therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to
the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are
required to switch therapies due to lack of reimbursement for existing therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential market opportunities for our products
are difficult to estimate precisely. Our estimates of the potential market opportunities are predicated on many assumptions, including
industry knowledge and publications, third party research reports and other surveys. While we believe that our internal assumptions are
reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and
the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate,
the actual markets for our products could be smaller than our estimates of the potential market opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may seek to enter into collaborations
with third parties for the development and commercialization of our product candidates. If we fail to enter into such collaborations,
or such collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may seek third-party collaborators for development
and commercialization of our products. Our likely collaborators for any marketing, distribution, development, licensing or broader collaboration
arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, non-profit organizations,
government agencies, and biotechnology companies. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217;
abilities to successfully perform the functions assigned to them in these arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaborations involving our products will pose
the following risks to us:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may have significant discretion in determining the efforts and resources that they will apply
                                            to these collaborations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may not pursue development and commercialization of our product candidate or may elect not
                                            to continue or renew development or commercialization programs based on preclinical or clinical
                                            trial results, changes in the collaborators&#8217; strategic focus or available funding,
                                            or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may delay clinical trials, provide insufficient funding for a clinical trial program, stop
                                            a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or
                                            require a new formulation of a product candidate for clinical testing;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            could independently develop, or develop with third parties, products that compete directly
                                            or indirectly with our product candidate if the collaborators believe that competitive products
                                            are more likely to be successfully developed or can be commercialized under terms that are
                                            more economically attractive than ours;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            with marketing and distribution rights to one or more products may not commit sufficient
                                            resources to the marketing and distribution of such product or products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may not properly maintain or defend our intellectual property rights or may use our proprietary
                                            information in such a way as to invite litigation that could jeopardize or invalidate our
                                            intellectual property or proprietary information or expose us to potential litigation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may infringe the intellectual property rights of third parties, which may expose us to litigation
                                            and potential liability;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
                                            may arise between the collaborators and us that result in the delay or termination of the
                                            research, development or commercialization of our product candidate or that result in costly
                                            litigation or arbitration that diverts management attention and resources; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
                                            may be terminated and, if terminated, may result in a need for additional capital to pursue
                                            further development or commercialization of the applicable product candidates.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaborative agreements may not lead to development
or commercialization of our product candidate in the most efficient manner or at all. If a collaborator of ours were to be involved in
a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed,
diminished or terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>ABVC, through BioLite, may not be able
to receive the full amounts available under the collaboration agreement by and between BioLite, Inc. and BioHopeKing, which could increase
its burden to seek additional capital to fund the business operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February and December 2015, BioLite, Inc.,
a subsidiary of BioLite, entered into a total of three collaboration agreements with BioHopeKing to jointly develop ABV-1501 for TNBC
(or BLI-1401-2 as used by BioLite internally) and ABV-1504 for MDD (or BLI-1005 as used by BioLite internally) in most Asian countries
and BLI-1006, which has been later replaced with BLI-1008 for ADHD in Asia, excluding Japan. ABVC and BioLite are co-developing ABV-1501
for TNBC and ABV-1504 for MDD pursuant to the Collaboration Agreement and its Addendum entered by and between BriVision and BioLite Taiwan
where ABVC and BriVision are responsible for the clinical trials of such two new drug candidates. In accordance with the terms of the
BioHopeKing Collaboration Agreement for ABV-1501 or BLI-1401-2 and the Addendum thereto, BioLite shall receive payments of a total of
$10 million in cash and equity of BioHopeKing or equity securities owned by it at various stages on a schedule dictated by BioLite&#8217;s
achievements of certain milestones and twelve per cent (12%) of net sales of the drug products when ABV-1501 or BLI-1401-2 is approved
for sale in the licensed territories. If BioLite fails to reach any of the milestones in a timely manner, it may not receive the rest
of the payments from BioHopeKing. As a result of BioLite&#8217;s potential inability to receive the full payments under those collaboration
agreements with BioHopeKing, ABVC may have to seek other sources of financing to fund its operation activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0; font-family: Times New Roman, Times, Serif"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>ABVC
and its Subsidiaries may not be successful in establishing and maintaining additional strategic partnerships, which could adversely affect
ABVC&#8217;s ability to develop and commercialize products, negatively impacting its operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition to ABVC&#8217;s current collaboration with BioHopeKing for selected Asian markets, a part of its strategy is to evaluate and,
as deemed appropriate, enter into additional partnerships in the future with major biotechnology or pharmaceutical companies. ABVC&#8217;s
products may prove to be difficult to effectively license out as planned. Various regulatory, commercial and manufacturing factors may
impact ABVC&#8217;s ability to seek co-developers of or grow revenues from licensing out any of the seven products in the pipeline, none
of which has been fully licensed out. Specifically, ABVC may encounter difficulty by virtue of:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    inability to effectively identify and align with commercial partners in the U.S. to collaborate the development of ABV-1504 for the
    treatment of Major Depressive Disorder, ABV-1505 to treat Attention-Deficit Hyperactivity Disease, ABV-1501 for the treatment of
    Triple Negative Breast Cancer, ABV-1519 to treat of Non-Small Cell Lung Cancer, ABV-1703 to the treatment of Pancreatic Cancer, ABV-1601
    to treat Depression in Cancer Patients and ABV-1702 to treat Myelodysplastic syndromes and ABV-1701 Vitargus for the treatments of
    Retinal Detachment or Vitreous Hemorrhage;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    inability to secure appropriate contract research organizations (&#8220;CRO&#8221;s) to conduct data analysis, lab research and FDA
    communication; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    inability to effectively continue clinical studies on and secure positive research results of all of our investigational new drugs
    to attract additional commercial collaborators outside the U.S.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABVC
faces significant competition in seeking appropriate partners for its therapeutic candidates, and the negotiation process is time-consuming
and complex. In order for ABVC to successfully partner its autoimmune, CNS and hematology therapeutic candidates, as well as Vitargus,
its medical device, potential partners must view these medicinal candidates as economically valuable in markets they determine to be
attractive in light of the terms that ABVC is seeking and compared to other available products for licensing by other companies. Even
if ABVC is successful in its efforts to establish new strategic partnerships, the terms that ABVC agrees upon may not be favorable, and
it may not be able to maintain such strategic partnerships if, for example, development or approval of an autoimmune therapeutic is delayed
or sales of an approved product are disappointing. Any delay in entering into new strategic partnership agreements related to any of
ABVC&#8217;s therapeutic candidates could delay the development and commercialization of such candidates and reduce its competitiveness
even if it reaches the market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
ABVC fails to establish and maintain additional strategic partnerships or collaboration related to its therapeutic candidates that have
not been fully licensed, it will bear all of the risk and costs related to the development of any such drug candidate, and it may need
to seek additional financing, hire additional employees and otherwise develop expertise for which it has not budgeted. This could negatively
affect the development of any incompletely partnered new drug candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>ABVC&#8217;s
licensors may choose to terminate any of the license agreements with ABVC. As a result, ABVC&#8217;s research and development of new
drug candidates that contain the underlying API may be terminated abruptly. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
ABVC&#8217;s Subsidiary BioLite materially breaches any license agreements it has with Yukiguni Maitake Co. (&#8220;Yukiguni&#8221;),
Medical and Pharmaceutical Industry Technology and Development Center (&#8220;MPITDC&#8221;) or Industrial Technology Research Institute
(&#8220;ITRI&#8221;), or any of such license agreement terminates unexpectedly, BioLite may not be able to continue its research and
development of the new drug candidate which contains the underlying API whose license has been terminated. Pursuant to the Yukiguni License
Agreement, if BioLite fails to meet the milestone sales requirement or submit certain applications to the appropriate health authorities
on a schedule prescribed therein, Yukiguni shall have the right to terminate the Yukiguni License Agreement. If the Yukiguni License
Agreement is terminated involuntarily, BioLite will be forced to discontinue its new drug development of ABV-1703, ABV-1502 and ABV-1501
and terminate the collaboration agreements relating to the three new drug candidates. The termination of the right to use the underlying
API will materially disrupt the operations of ABVC. Pursuant to the license agreement between BioLite Taiwan and ITRI, if BioLite Taiwan
fails to complete the research submission milestones according to the schedule set forth therein without reasons or with reasons unstatisfied
with ITRI, ITRI shall have the right to terminate the license agreement with BioLite Taiwan without refund to BioLite Taiwan. BioLite
Taiwan and BioLite have submitted the IND for PDC-1421 and subsequently conducted Phase II clinical trials of two drug candidiates developed
from PDC-1421 according to the schedule listed in the license agreement between BioLite Taiwan and MPITDC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>ABVC&#8217;s
Subsidiary BioLite depends on one supplier for the API of ABV-1703, ABV-1519, ABV-1502 and ABV-1501 and any failure of such supplier
to deliver sufficient quantities of the API that meets its quality standard could have a material adverse effect on its research of these
four drug candidates. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Currently
BioLite relies primarily on Yukiguni, a Japanese supplier, to provide Yukiguni Maitake Extract 404, the API which is contained in ABV-1703,
ABV-1519, ABV-1502 and ABV-1501, four of the seven drug candidates in BioLite&#8217;s oncology/hematology portfolio. It has entered into
the Yukiguni License Agreement, among other things, for the delivery of Yukiguni Maitake Extract 404. BioLite agrees to fulfill its demand
of the Yukiguni Maitake Extract 404 by purchasing first from Yukiguni respecting the therapeutic products and Yukiguni represents that
it will provide sufficient quantities of such API that meets cGMP standards. If the supplies of Yukiguni Maitake Extract 404 were interrupted
for any reason, BioLite&#8217;s research and development activities of these four drug candidates could be delayed. These delays could
be extensive and expensive, especially in situations where a substitution is not readily available.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">BioLite
is currently negotiating with another supplier of Yukiguni Maitake Extract 404 that is located in Canada. However, there can be no assurance
that the negotiation will be successful. Failure to obtain adequate supplies of high quality Yukiguni Maitake Extract 404 in a timely
manner could have a disruptive effect on ABVC and BioLite&#8217;s research and development activities of ABV-1703, ABV-1519, ABV-1502
and ABV-1501, resulting in a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>ABVC
may use hazardous chemicals and biological materials in its business. Any claims relating to improper handling, storage or disposal of
these materials could be time consuming and costly. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABVC&#8217;s
research and development may involve the controlled use of hazardous materials, including chemicals and biological materials. ABVC cannot
eliminate the risk of accidental contamination or discharge and any resulting injury from these materials. ABVC may be sued for any injury
or contamination that results from its use or the use by third parties of these materials, and its liability may exceed any insurance
coverage and its total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal
of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health
and safety matters. Although ABVC makes its best efforts to comply with environmental laws and regulations despite the associated high
costs and inconvenience, ABVC cannot guarantee that it will not mishandle any hazardous materials in the future. If it fails to comply
with these requirements or any improper handling of hazardous materials occurs, it could incur substantial costs, including civil or
criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve
and maintain compliance. In addition, ABVC cannot predict the impact on its business of new or amended environmental laws or regulations
or any changes in the way existing and future laws and regulations are interpreted and enforced.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
facilities where the samples of drug candidates are manufactured need to be maintained and monitored in compliance with the good manufacturing
practice standards, the failure of such maintenance could contaminate the results of our clinical trials and adversely affect our operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABVC&#8217;s
Subsidiary BioKey operates a laboratory facility that is a certified good manufacturing practice facility (&#8220;cGMP&#8221;) and some
of its contract clinical trial service providers use cGMP facilities to conduct clinical studies. ABVC cannot be certain that ABVC or
its present or future contract manufacturers or suppliers will be able to comply with cGMPs regulations and other FDA regulatory requirements.
Failure to comply with these requirements may result in, among other things, total or partial suspension of production activities, failure
of the FDA to grant approval for marketing, and withdrawal, suspension, or revocation of marketing approvals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pharmaceutical
patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to the Company, could
negatively impact its respective licensors&#8217; patent position and interrupt its research activities. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
patent positions of pharmaceutical companies and research institutions can be highly uncertain and involve complex legal and factual
questions. The interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and
difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and
the related patent claims. The standards of the U.S. Patent and Trademark Office, or USPTO, are sometimes uncertain and could change
in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged,
invalidated or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may
be subject to re-examination proceedings, post-grant review and/or inter parties review in the USPTO. Foreign patents may be subject
to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or
denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application.
In addition, such interference, re-examination, post-grant review, inter parties review and opposition proceedings may be costly. Accordingly,
rights under any issued patents may not provide the Company with sufficient protection against competitive products or processes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, changes in or different interpretations of patent laws in the U.S. and foreign countries may permit others to use discoveries
of the Company or to develop and commercialize their new drug candidates without providing any compensation thereto, or may limit the
number of patents or claims the Company can obtain. The laws of some countries do not protect intellectual property rights to the same
extent as U.S. laws and those countries may lack adequate rules and procedures for defending the intellectual property rights of the
Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
the Company fails to obtain and maintain patent protection and trade secret protection of its respective products, the Company could
lose their competitive advantages and competition it faces would increase, reducing any potential revenues and adversely affecting its
ability to attain or maintain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Developments
in patent law could have a negative impact on the Company&#8217;s Licensors&#8217; patent positions and the Company&#8217;s business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress or the USPTO may change the standards of patentability
and any such changes could have a negative impact on the Company&#8217;s business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant
changes to U.S. patent law. These changes include a transition from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221;
system, changes the way issued patents are challenged, and changes the way patent applications are disputed during the examination process.
These changes may favor larger and more established companies that have greater resources to devote to patent application filing and
prosecution. The USPTO has developed regulations and procedures to govern the full implementation of the America Invents Act, and many
of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions, became
effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect the Company, BioLite
and BioKey&#8217;s ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any,
impact the America Invents Act will ultimately have on the cost of prosecuting the Company&#8217;s patent applications, its ability to
obtain patents based on its discoveries and its ability to enforce or defend its patents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
the Company is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed, respectively.
</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition to patent protection, because the Company operates in the highly technical field of discovery and development of therapies,
it relies in part on trade secret protection in order to protect its proprietary technology and processes. However, trade secrets are
difficult to protect. The Company has entered into confidentiality and non-disclosure agreements with its employees, consultants, outside
scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require that the other
party keep confidential and not disclose to third parties any confidential information developed by the party or made known to the party
by the Company during the course of the party&#8217;s relationship therewith. These agreements also generally provide that inventions
conceived by the party in the course of rendering services to the Company will be ABVC&#8217;s exclusive property. However, these agreements
may not be honored and may not effectively assign intellectual property rights to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition to contractual measures, the Company tries to protect the confidential nature of its proprietary information using physical
and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee
or third party with authorized access, provide adequate protection for the Company. The Company&#8217;s security measures may not prevent
an employee or consultant from misappropriating its trade secrets and providing them to a competitor, and recourse it takes against such
misconduct may not provide an adequate remedy to protect the Company&#8217;s interests fully. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition,
courts outside the U.S. may be less willing to protect trade secrets. Trade secrets may be independently developed by others in a manner
that could prevent legal recourse by the Company. If the Company&#8217;s confidential or proprietary information, such as the trade secrets,
were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, its competitive position
could be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Third
parties may assert that the Company&#8217;s employees or consultants have wrongfully used or disclosed confidential information or misappropriated
trade secrets. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company might employ individuals who were previously employed at universities or other biopharmaceutical companies, including its competitors
or potential competitors. Although through certain non-disclosure covenants and employment agreements with its officers and employees,
the Company tries to ensure that its employees and consultants do not use the proprietary information or know-how of others in the work
for the Company, the Company may be subject to claims that it or its employees, consultants or independent contractors have inadvertently
or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer
or other third parties. Litigation may be necessary to defend against these claims. If the Company fails in defending any such claims,
in addition to paying monetary damages, the Company may lose valuable intellectual property rights or personnel. Even if the Company
is successful in defending against such claims, litigation could result in substantial costs and be a distraction to the Company&#8217;s
management and other employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>ABVC&#8217;s
ability to compete may decline if it does not adequately protect its proprietary rights or if it is barred by the intellectual property
rights of others. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABVC&#8217;s
commercial success depends on obtaining and maintaining proprietary rights to its drug candidates as well as successfully defending these
rights against third-party challenges. ABVC obtains its rights to use and research certain proprietary information to further develop
the drug candidates primarily from three institutions, MPITDC, ITRI and Yukiguni (collectively the &#8220;Licensors&#8221;). These three
institutions own the intellectual property rights in the products that have been licensed to us and may prosecute new patents of the
drug candidates that are invented or discovered within the licensed scope of use under the respective license agreements. ABVC will only
be able to protect its new drug candidates from unauthorized use by third parties to the extent that its valid and enforceable patents,
or effectively protected trade secrets and know-how, cover them.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABVC&#8217;s
ability to obtain new patent protection for its new drug candidates is uncertain due to a number of factors, including that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC
    may not have been the first to make the inventions covered by pending patent applications or issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC
    may not have been the first to file patent applications for its new drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may independently develop identical, similar or alternative products or compositions and uses thereof;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s
    disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    or all of ABVC&#8217;s pending patent applications may not result in issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC
    may not seek or obtain patent protection in countries that may eventually provide a significant business opportunity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    patents issued to ABVC may not provide a basis for commercially viable products, may not provide any competitive advantages, or may
    be successfully challenged by third parties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s
    methods may not be patentable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s
    licensors may successfully challenge that ABVC&#8217;s new patent application fall outside the licensed use of the products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may design around ABVC&#8217;s patent claims to produce competitive products which fall outside of the scope of its patents.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Even
if ABVC has or obtains new patents covering its new drug candidates, ABVC may still be barred from making, using and selling them because
of the patent rights of others. Others may have filed, and in the future may file, patent applications covering products that are similar
or identical to ABVC. There are many issued U.S. and foreign patents relating to therapeutic products and some of these relate to ABVC&#8217;s
new drug candidates. These could materially affect ABVC&#8217;s ability to develop its drug candidates. Because patent applications can
take many years to issue, there may be currently pending applications unknown to ABVC that may later result in issued patents that its
new drug candidates may infringe. These patent applications may have priority over patent applications filed by ABVC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
Company and its respective licensors may not be able to enforce their intellectual property rights throughout the world. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Many companies
have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The
legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property
protection, especially those relating to pharmaceuticals and medical devices. This could make it difficult for the Company and its respective
licensors to stop the infringement of some of the Licensors&#8217; patents, or the misappropriation of their other intellectual property
rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties.
In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors.
In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis,
which is an expensive and time-consuming process with uncertain outcomes. Accordingly, the Company and its licensors have chosen in the
past and may choose in the future not to seek patent protection in certain countries, and as a result the Company will not have the benefit
of patent protection in such countries. Moreover, the Company may choose in the future not to seek patent protection in certain countries,
and as a result it will not have the benefit of patent protection in such countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Proceedings
to enforce the Company&#8217;s and its licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and
divert its efforts and attention from other aspects of the businesses. Accordingly, the efforts to protect the Company&#8217;s intellectual
property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the U.S. and foreign
countries may affect the Company&#8217;s ability to obtain adequate protection for its technology and the enforcement of intellectual
property.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Regulatory
Risks Relating to Biopharmaceutical Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
Company is subject to various government regulations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
manufacture and sale of human therapeutic and diagnostic products in the U.S. and foreign jurisdictions are governed by a variety of
statutes and regulations. These laws require approval of manufacturing facilities, controlled research and testing of products and government
review and approval of a submission containing manufacturing, preclinical and clinical data in order to obtain marketing approval based
on establishing the safety and efficacy of the product for each use sought, including adherence to current PIC/S Guide to Good Manufacturing
Practice for Medicinal products during production and storage, and control of marketing activities, including advertising and labeling.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
products the Company is currently developing will require significant development, preclinical and clinical testing and investment of
substantial funds prior to its commercialization. The process of obtaining required approvals can be costly and time-consuming, and there
can be no assurance that future products will be successfully developed and will prove to be safe and effective in clinical trials or
receive applicable regulatory approvals. Markets other than the U.S. have similar restrictions. Potential investors and shareholders
should be aware of the risks, problems, delays, expenses and difficulties which we may encounter in view of the extensive regulatory
environment which controls our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
Company cannot be certain that it will be able to obtain regulatory approval for, or successfully commercialize, any of its current or
future product candidates. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company may not be able to develop any current or future product candidates. The Company&#8217;s new drug candidates will require substantial
additional clinical development, testing, and regulatory approval before the commencement of commercialization. The clinical trials of
the Company&#8217;s drug candidates are, and the manufacturing and marketing of our new drug candidates will be subject to extensive
and rigorous review and regulation by numerous government authorities in the U.S. and in other countries where the Company intend to
test and, if approved, market any new drug candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate,
the Company must demonstrate through pre-clinical testing and clinical trials that the product candidate is safe and effective for use
in each target indication. This process can take many years and may include post-marketing studies and surveillance, which will require
the expenditure of substantial resources. Of the large number of drugs in development in the U.S., only a small percentage successfully
completes the FDA regulatory approval process and is commercialized. Accordingly, even if the Company is able to obtain the requisite
financing to continue to fund its development and clinical programs, it cannot assure the investors that any of the product candidates
will be successfully developed or commercialized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company is not permitted to market a therapeutic product in the U.S. until it receives approval of an NDA or ANDA, for that product from
the FDA, or in any foreign countries until they receive the requisite approval from such countries. Obtaining approval of an NDA is a
complex, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of any product candidate for many reasons,
including, among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unable
    to demonstrate that a product candidate is safe and effective to the satisfaction of the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of the Company&#8217;s clinical trials may not meet the level of statistical or clinical significance required by the FDA
    for marketing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may not approve the formulation of any product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    CROs, that BioLite or the Company retains to conduct its clinical trials may take actions outside of its control that materially
    adversely impact its clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in patient enrollment, variability in the number and types of patients available for clinical trials, and lower-than anticipated
    retention rates for patients in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate that a product candidate&#8217;s
    clinical and other benefits outweigh its safety risks, such as the risk of drug abuse by patients or the public in general;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the interpretation of data from the Company&#8217;s pre-clinical studies and clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may not accept data generated at the Company&#8217;s clinical trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    an NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee
    meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the
    FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or
    distribution and use restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval or post-approval; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may change its approval policies or adopt new regulations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
same risks apply to applicable foreign regulatory agencies from which the Company, through BioLite, may seek approval for any of our
new drug candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Any
of these factors, many of which are beyond the Company&#8217;s control, could jeopardize its ability to obtain regulatory approval for
and successfully market any new drug candidate. As a result, any such setback in the Company&#8217;s pursuit of initial or additional
regulatory approval would have a material adverse effect on its business and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
the Company does not successfully complete pre-clinical and Phase I and II clinical development, it will be unable to receive full payments
under their respective collaboration agreements, find future collaborators or partners to take the drug candidates to Phase III clinical
trials. Even if the Company successfully completes all Phase I and II clinical trials, those results are not necessarily predictive of
results of additional trials that may be needed before an NDA for Phase III trials may be submitted to the FDA. Although there are a
large number of drugs in development in the U.S. and other countries, only a very small percentage result in commercialization, and even
fewer achieve widespread physician and consumer acceptance following the regulatory approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Company may encounter delays or drug candidate rejections based on new governmental regulations, future legislative or
administrative actions, or changes in FDA policy or interpretation during the period of product development. If the Company obtains required
regulatory approvals, such approvals may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
    interpretations of data and commitments by the FDA and similar foreign regulatory agencies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diminishment
    of any competitive advantages that such drug candidates may have or attain.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
if the Company fails to comply with applicable FDA and other regulatory requirements at any stage during this regulatory process, the
Company may encounter or be subject to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or termination in clinical trials or commercialization;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    by the FDA or similar foreign regulatory agencies to review pending applications or supplements to approved applications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls or seizures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    of manufacturing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals
    of previously approved marketing applications; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    civil penalties, and criminal prosecutions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
Company faces substantial competition from companies with considerably more resources and experience than the Company has, which may
result in others discovering, developing, receiving approval for, or commercializing products before or more successfully than the Company.
</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company competes with companies that research, develop, manufacture and market already-existing and new pharmaceutical products in the
fields of CNS, hematology/oncology and autoimmune. The Company anticipates that it will face increased competition in the future as new
companies enter the market with new drugs and/or technologies and/or their competitors improve their current products. One or more of
their competitors may offer new drugs superior to the Company&#8217;s and render the Company&#8217;s drugs uneconomical. A lot of the
Company&#8217;s current competitors, as well as many of its respective potential competitors, have greater name recognition, more substantial
intellectual property portfolios, longer operating histories, significantly greater resources to invest in new drug development, more
substantial experience in product marketing and new product development, greater regulatory expertise, more extensive manufacturing capabilities
and the distribution channels to deliver products to customers. If the Company is not able to compete successfully, it may not generate
sufficient revenue to become profitable. The Company&#8217;s ability to compete successfully will depend largely on its ability to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    commercialize its drug candidates with commercial partners;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discover
    and develop new drug candidates that are superior to other products in the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    its collaborators, obtain required regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    and retain qualified personnel; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    patent and/or other proprietary protection for its product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Established
pharmaceutical companies devote significant financial resources to discovering, developing or licensing novel compounds that could make
the Company&#8217;s products and product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and
commercialize medicines before we do. Other companies are or may become engaged in the discovery of compounds or botanical materials
that may compete with the drug candidates the Company is developing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company competes with a large number of well-established pharmaceutical companies that may have more resources than the Company does
in developing therapeutics in the fields of CNS, oncology/hematology and ophthalmology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Any
new drug candidate the Company is developing or commercializing that competes with a currently-approved product must demonstrate compelling
advantages in efficacy, convenience, tolerability and/or safety in order to address price competition and be commercially successful.
If the Company is not able to compete effectively against its current and future competitors, its business will not grow and its financial
condition and operations will suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Relating to Doing Business Outside the United States</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Because
part of ABVC&#8217;s pharmaceutical research and development is conducted outside of the U.S., the Company is subject to the risks of
doing business internationally, including periodic foreign economic downturns and political instability, which may adversely affect the
Company&#8217;s revenue and cost of doing business in Taiwan.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABVC
collaborates with partners whose primary place of business is in Taiwan, Republic of China and the Company has certain key employees
in Taiwan. Foreign economic downturns may affect our results of operations in the future. Additionally, other facts relating to the operation
of the Company&#8217;s business outside of the U.S. may have a material adverse effect on the Company&#8217;s business, financial condition
and results of operations, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">international
    economic and political changes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    imposition of governmental controls or changes in government regulations, including tax laws, regulations and treaties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in, or impositions of, legislative or regulatory requirements regarding the pharmaceutical industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with U.S. and international laws involving international operations, including the Foreign Corrupt Practices Act and export control
    laws;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in achieving headcount reductions due to unionized labor and works councils;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on transfers of funds and assets between jurisdictions; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China-
    Taiwan geo-political instability.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
the Company continues to operate its business globally, its success will depend in part, on its ability to anticipate and effectively
manage these risks. The impact of any one or more of these factors could materially adversely affect the Company&#8217;s business, financial
condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
Company may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and Chinese anti-corruption law.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to the FCPA, and other laws that prohibit improper payments or offers of payments to foreign governments, foreign
government officials and political parties by U.S. persons as defined by the statute for purposes of obtaining or retaining businesses.
The Company may have agreements with third parties who may make sales in mainland China and the U.S., during the process of which the
Company may be exposed to corruption. Activities in Taiwan create the risk of unauthorized payments or offers of payments by an employee,
consultant or agent of the Company, because these parties are not always subject to the Company&#8217;s control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Although
the Company believes to date it has complied in all material aspects with the provisions of the FCPA and Chinese anti-corruption law,
the existing safeguards and any future improvements may prove to be less than effective and any of the Company&#8217;s employees, consultants
or agents may engage in corruptive conduct for which the Company might be held responsible. Violations of the FCPA or Chinese anti-corruption
law may result in severe criminal or civil sanctions against the Company and individuals and therefore could negatively affect the Company&#8217;s
business, operating results and financial condition. In addition, the Taiwanese government may seek to hold the Company liable as a successor
for FCPA violations committed by companies in which the Company invests or acquires.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>International
operations expose the Company to currency exchange and repatriation risks, and the Company cannot predict the effect of future exchange
rate fluctuations on its business and operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company has business operations in Taiwan and collaborative activities in the U.S. and Japan. Substantial amounts of revenues are received
and expenses are incurred in New Taiwan Dollars and U.S. dollars. Thus, the Company has exposure to currency fluctuations. The Company
cannot assure you that the effect of currency exchange fluctuations will not materially affect its revenues and net income in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
conduct our operations internationally and the effect of business, legal and political risks associated with international operations
may seriously harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The
                                            Company generated no revenues during the quarter ended March 31, 2025. Sales to customers
                                            outside the United States accounted for 100% and 93% &#160;&#160;for the years ended December
                                            31, 2024 and 2023, respectively. Our international sales and operations are subject to a
                                            wide range of risks, which may vary from country to country or region to region. These risks
                                            include the following:</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">export
    and import duties, changes to import and export regulations, and restrictions on the transfer of funds;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">political
    and economic instability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues
    arising from cultural or language differences and labor unrest;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer
    payment cycles and greater difficulty in collecting accounts receivable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with trade and technical standards in a variety of jurisdictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in staffing and managing international operations, including the risks associated with fraud, theft and other illegal conduct;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with laws and regulations, including environmental, employment and tax laws, which vary from country to country and over time, increasing
    the costs of compliance and potential risks of non-compliance; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect
    intellectual property rights to the same extent as the United States and European countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations
    may be affected by political tensions, trade disputes and similar matters, particularly between China and Taiwan or between China
    and the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States and foreign trade restrictions, including those that may limit the importation of technology or components to or from various
    countries or impose tariffs or quotas; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of currency exchange controls or taxes that make it impracticable or costly to repatriate funds from foreign countries.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
cannot assure you that risks relating to our international operations will not seriously harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
the Company becomes directly subject to the recent scrutiny, criticism and negative publicity involving U.S.-listed Chinese companies,
we may have to expend significant resources to investigate and resolve the matters. Any unfavorable results from the investigations could
harm our business operations, this offering and our reputation.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Recently,
U.S. public companies that have substantially all of their operations in China, have been subjects of intense scrutiny, criticism and
negative publicity by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and
negative publicity has centered on financial and accounting irregularities, lack of effective internal control over financial accountings,
inadequate corporate governance and ineffective implementation thereof and, in many cases, allegations of fraud. As a result of enhanced
scrutiny, criticism and negative publicity, the publicly traded stocks of many U.S. listed Chinese companies have sharply decreased in
value and, in some cases, have become virtually worthless or illiquid. Many of these companies are now subject to shareholder lawsuits
and SEC enforcement actions and are conducting internal and external investigations into the allegations. It is not clear what effects
the sector-wide investigations will have on the Company. If the Company becomes a subject of any unfavorable allegations, whether such
allegations are proven to be true or untrue, the Company will have to expend significant resources to investigate such allegations and
defend the Company. If such allegations were not proven to be baseless, the Company would be severely hampered and the price of the stock
of the Company could decline substantially. If such allegations were proven to be groundless, the investigation might have significantly
distracted the attention of the Company&#8217;s management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to the Company&#8217;s Financial Condition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
existing indebtedness may adversely affect our ability to obtain additional funds and may increase our vulnerability to economic or business
downturns. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We
                                            are subject to a number of risks associated with our indebtedness, including: 1) we must
                                            dedicate a portion of our cash flows from operations to pay debt service costs, and therefore
                                            we have less funds available for operations and other purposes; 2) it may be more difficult
                                            and expensive to obtain additional funds through financings, if available at all; 3) we are
                                            more vulnerable to economic downturns and fluctuations in interest rates, less able to withstand
                                            competitive pressures and less flexible in reacting to changes in our industry and general
                                            economic conditions; and 4) if we default under any of our existing credit facilities or
                                            if our creditors demand payment of a portion or all of our indebtedness, we may not have
                                            sufficient funds to make such payments. As of March 31, 2025, the Company&#8217;s working
                                            capital deficit was $5.3 million, , consisting of outstanding current liabilities were approximately
                                            $6.7 million, which consisted primarily of short-term bank loans and accrued expenses.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Failure
to remediate a material weakness in internal accounting controls could result in material misstatements in our financial statements.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Our
                                            management has identified a material weakness in our internal control over financial reporting
                                            related to not having sufficient and skilled accounting personnel with appropriate level
                                            of technical accounting knowledge and experience in the application of accounting principles
                                            generally accepted in the United States commensurate with the Company&#8217;s financial reporting
                                            requirements and has concluded that, due to such material weakness, our disclosure controls
                                            and procedures were not effective as of March 31, 2025. Due to such material weakness, we
                                            were unable to maintain effective disclosure controls over financial reporting, which did
                                            result in material misstatements in our financial statements and led to a restatement of
                                            our financial statements for the year ended December 31, 2023 and the quarter ended March
                                            31, 2024. If not remediated, or if we identify additional material weaknesses, our failure
                                            to maintain effective internal controls could continue to adversely impact our ability to
                                            meet our reporting and financial obligations and could have a material adverse effect on
                                            our financial condition and the trading price of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Failure to maintain the effectiveness
of our disclosure controls and procedures has led to a misstatement in our financial statements and a restatement. If we do not remediate
the identified material weakness and continue to lack effective internal controls, we may be unable to prevent additional errors or misstatements
in the future, which could harm our operating results, subject us to regulatory scrutiny or sanctions, cause investors to lose confidence
in our reported financial information, and negatively impact the market price of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Sarbanes-Oxley Act of 2002 and the Securities
and Exchange Commission (SEC) have requirements that we may fail to meet or we may fall out of compliance with, such as the internal
controls auditor attestation required under Section 404 of the Sarbanes-Oxley Act of 2002, with which we are not currently required to
comply as we are a smaller reporting company. If we fail to achieve and maintain the adequacy of our internal controls, as such standards
are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we
have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002. Moreover,
effective internal controls, particularly those related to revenue recognition, are necessary for us to produce reliable financial reports
and are important to help prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and
operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our
stock could drop significantly.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
articles of incorporation allow for our board to create new series of preferred stock without further approval by our shareholders, which
could adversely affect the rights of the holders of our Common Stock. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock without shareholder
approval. As a result, our Board of Directors could authorize the issuance of a series of preferred stock that would grant to holders
the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders
of Common Stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our Common Stock.
In addition, our Board of Directors could authorize the issuance of a series of preferred stock that has greater voting power than our
Common Stock or that is convertible into our Common Stock, which could decrease the relative voting power of our Common Stock or result
in dilution to our existing shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may create any additional series of preferred stock and issue such shares in the future although we do not have any present intention
of doing so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not be able to secure financing needed for future operating needs on acceptable terms, or on any terms at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may seek additional financing to provide the capital required to expand our production facilities, Research and development
(&#8220;R&amp;D&#8221;) initiatives and/or working capital, as well as to repay outstanding loans if cash flow from operations is insufficient
to do so. We cannot predict with certainty the timing or amount of any such capital requirements. If such financing is not available
on satisfactory terms, we may be unable to expand our business or to develop new business at the rate desired. If we are able to incur
debt, we may be subject to certain restrictions imposed by the terms of the debt and the repayment of such debt may limit our cash flow
and growth. If we are unable to incur debt, we may be forced to issue additional equity, which could have a dilutive effect on our current
shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
internal computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, which could
result in a material disruption of our product development programs. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Despite
the implementation of security measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable
to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.
While we do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were
to occur and cause interruptions in our operations, it could result in a loss of clinical trial data for our new drug candidates which
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the
extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications
relating to our technology or new drug candidates, or inappropriate disclosure of confidential or proprietary information, we could incur
liabilities and the further development of our product candidates could be delayed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
elimination of personal liability against our directors and officers under Nevada law and the existence of indemnification rights held
by our directors, officers and employees may result in substantial expenses. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABVC
Bylaws eliminate the personal liability of our directors and officers to us and our shareholders for damages for breach of fiduciary
duty as a director or officer to the extent permissible under Nevada law. Further, our Bylaws provide that we are obligated to indemnify
each of our directors or officers to the fullest extent authorized by Nevada law and, subject to certain conditions, advance the expenses
incurred by any director or officer in defending any action, suit or proceeding prior to its final disposition. Those indemnification
obligations could expose us to substantial expenditures to cover the cost of settlement or damage awards against our directors or officers,
which we may be unable to afford. Further, those provisions and resulting costs may discourage us or our shareholders from bringing a
lawsuit against any of our current or former directors or officers for breaches of their fiduciary duties, even if such actions might
otherwise benefit our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to the Company&#8217;s Common Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
share price of our Common Stock is volatile and may be influenced by numerous factors, some of which are beyond our control. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">There
is currently only a limited public market for our Common Stock, which is listed on the Nasdaq Capital Market, and there can be no assurance
that a trading market will develop further or be maintained for our Common Stock in the future. The trading price of our Common Stock
is likely to be highly volatile, and could be subject to wide fluctuations in response to various factors, some of which are beyond our
control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere herein, these factors include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    new drug candidates we acquire for commercialization;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product candidates we seek to pursue, and our ability to obtain rights to develop those product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated adverse results or delays in our pre-clinical studies and clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to get any of our new drug candidates approved;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    serious safety and environmental concerns related to the use and research activities of any of our new drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
    performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance
    of our competitors, including changes in market valuations of similar companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    or trends in the healthcare, biotechnology and pharmaceutical industries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
    of new products offered by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain an adequate rate of growth and manage such growth;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuances
    of debt or equity securities by us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our securities by us or our shareholders in the future, or the perception that such sales could occur;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our Common Stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness
    of our internal control over financial reporting or disclosure controls and procedures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    political and economic conditions in U.S. and other countries and territories where we conduct our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effects
    of natural or man-made catastrophic events; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    regulatory decisions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key scientific or management personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws or regulations applicable to our product candidates, including without limitation clinical trial requirements for approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    or other developments relating to patents and other proprietary rights and our ability to obtain protection for our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on third parties, including CROs and scientific and medical advisors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in quarterly operating results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet or exceed the estimates and projections of the investment community;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which are beyond our control.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, the stock market in general, and the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular,
have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance
of these companies. Broad market and industry factors may negatively affect the market price of our Common Stock, regardless of our actual
operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in
these &#8220;Risk Factors,&#8221; could have a dramatic and material adverse impact on the market price of our Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Insiders
have substantial control over us, and they could delay or prevent a change in our corporate control even if our other shareholders wanted
it to occur.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive officers, directors, and principal
shareholders own, in the aggregate, approximately 61.4% of our outstanding Common Stock. As a result of their stockholdings, these shareholders
are able to assert substantial control over matters requiring shareholder approval, including the election of directors and approval
of significant corporate transactions. This could delay or prevent an outside party from acquiring or merging with us even if our other
shareholders wanted it to occur.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
market price of our Common Stock may be volatile</i> and <i>there may not be sufficient liquidity in the market for our securities in
order for investors to sell their securities.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
market price of our Common Stock has been and will likely continue to be highly volatile, as is the stock market in general. Factors
that may materially affect the market price of our Common Stock are beyond our control, these factors may materially adversely affect
the market price of our Common Stock, regardless of our performance. In addition, the public stock markets have experienced extreme price
and trading volume volatility. These broad market fluctuations may influence the market price of our Common Stock. There is currently
only a limited public market for our Common Stock, which is listed on the Nasdaq Capital Market, and there can be no assurance that a
trading market will develop further or be maintained in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity
securities of many companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased
stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These
fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry
factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19
pandemic, political, regulatory and other market conditions, may negatively affect the market price of shares of our common stock, regardless
of our actual operating performance. The market price of shares of our common stock may decline and you may lose some or all of your
investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to
the value of our shares.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have never paid any cash dividends on our Common Stock and do not anticipate paying any cash dividends in the foreseeable future, and
any return on investment may be limited to the value of our Common Stock. We plan to retain any future earnings to finance growth.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Under
applicable Nevada law, we, as a Nevada corporation, generally may not make a distribution if i) we would not be able to pay our debts
as they become due in the usual course of business, or ii) our total assets would be less than the sum of our total liabilities plus
the amount that would be needed, if we were to be dissolved at the time of distribution, to satisfy the preferential rights upon dissolution
of shareholders whose preferential rights are superior to those receiving the distribution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
and any trading volume could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Any
trading market for our Common Stock that may develop will depend in part on the research and reports that securities or industry analysts
publish about us or our business. As of the date hereof, there is only 1 publish research report about our business. If securities or
industry analysts provide additional coverage, and one or more of those analysts downgrade our stock or publish inaccurate or unfavorable
research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or
fail to publish reports on us regularly, demand for our Common Stock could decrease, which might cause our stock price and any trading
volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Future
sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plan or otherwise,
could result in dilution of the percentage ownership of our shareholders and could cause our stock price to fall. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
expect that we will need significant additional capital in the future to continue our planned operations. To raise capital, we may sell
Common Stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from
time to time. If we sell Common Stock, convertible securities or other equity securities in more than one transaction, including issuance
of equity securities pursuant to any future stock incentive plan to our officers, directors, employees and non-employee consultants for
their services to us, investors in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales may
result in material dilution to our existing shareholders, and new investors could gain rights, preferences and privileges senior to those
of holders of our Common Stock. Further, any future sales of our Common Stock by us or resales of our Common Stock by our existing shareholders
could cause the market price of our Common Stock to decline. Any future grants of options, warrants or other securities exercisable or
convertible into our Common Stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could have
an adverse effect on the market price of our Common Stock. On October 29, 2021, we filed a registration statement on Form S-3, as amended
on November 16, 2021, which was declared effective on November 29, 2021. On May 11, 2022, we agreed to issue 2,000,000 shares of Common
Stock, par value $0.001 per share, at a price of $2.11 per share and 5-year warrants to purchase up to 2,000,000 shares of Common Stock,
exercisable at a price of $2.45 per share pursuant to certain securities purchase agreement dated May 11, 2022, which was effected as
a takedown off the Company&#8217;s shelf registration statement on Form S-3, as amended. We also issued the co-placement agents warrants
to purchase up to 160,000 shares of Common Stock, on the same terms as the investors warrants in connection with the transaction. We
may issue shares of Common Stock through the Form S-3 in the future, which would further dilute your ownership.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
Common Stock may be subject to the &#8220;penny stock&#8221; rules of the Securities and Exchange Commission, which may make it more
difficult for shareholders to sell our Common Stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
SEC has adopted Rule 15g-9 which establishes the definition of a &#8220;penny stock,&#8221; for the purposes relevant to us, as any equity
security that has a market price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock,
unless exempt, the rules require that a broker or dealer approve a person&#8217;s account for transactions in penny stocks, and the broker
or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock
to be purchased.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
order to approve a person&#8217;s account for transactions in penny stocks, the broker or dealer must obtain financial information and
investment experience objectives of the person, and make a reasonable determination that the transactions in penny stocks are suitable
for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of
transactions in penny stocks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to
the penny stock market, which, in highlight form sets forth the basis on which the broker or dealer made the suitability determination,
and that the broker or dealer received a signed, written agreement from the investor prior to the transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Generally,
brokers may be less willing to execute transactions in securities subject to the &#8220;penny stock&#8221; rules. This may make it more
difficult for investors to dispose of the Company&#8217;s Common Stock if and when such shares are eligible for sale and may cause a
decline in the market value of its stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Disclosure
also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions
payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies
available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent
price information for the penny stock held in the account and information on the limited market in penny stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our Common Stock</i>.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
we fail to satisfy the continued listing requirements of the Nasdaq Capital Market, such as the corporate governance requirements or
the minimum closing bid price requirement, the Nasdaq Capital Market may take steps to delist our common stock. Such a delisting would
likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when
you wish to do so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
August 19, 2022, we received a deficiency letter from the Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq
Stock Market LLC (&#8220;Nasdaq&#8221;) notifying us that, for the last 30 consecutive business days, the closing bid price for our common
stock was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule
5550(a)(2) (&#8220;Rule 5550(a)(2)&#8221;). Under the Nasdaq Listing Rules, we have until February 14, 2023 to regain compliance. Since
we did not regain compliance by such date, we requested and received an additional 180 days, until August 14, 2023, to comply with Rule
5550(a)(2).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On May 24, 2023, the
Company received a deficiency letter from the Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock
Market LLC (&#8220;Nasdaq&#8221;) notifying the Company that it is not currently in compliance with the minimum stockholders&#8217; equity
requirement, or the alternatives of market value of listed securities or net income from continuing operations, for continued listing
on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders&#8217; equity of at least
$2,500,000, and the Company&#8217;s stockholders&#8217; equity was $1,734,507 as of March 31, 2023. In accordance with Nasdaq rules,
the Company had 45 calendar days, or until July 10, 2023, to submit a plan to regain compliance.&#160;After submitting a plan to regain
compliance, on July 10, 2023,Nasdaq granted the Company an extension until August 30, 20203, to comply with Listing Rule 5550(b)(1).&#160;On
July 31, 2023, the Company issued 300,000 shares of Common Stock and 200,000 pre-funded warrants, at an exercise price of $0.01 per share,
in a registered direct offering. Pursuant to this transaction, the stockholders&#8217; equity was increased by $1.75M. On August 1, 2023,
$500,000 of Notes were converted at $3.50 per share and the holder received 142,857 shares of Common Stock. As a result of this conversion,
the stockholders&#8217; equity was increased by $0.5M. Additionally, on August 14, 2023, the Company entered into a cooperation agreement
with Zhonghui United Technology (Chengdu) Group Co., Ltd., pursuant to which the Company acquired a 20% ownership of certain property
and a parcel of the land owned by Zhonghui in exchange for an aggregate of 370,000 shares of Common Stock. Accordingly, stockholders&#8217;
equity increased by $7.4M. On February 23, 2023, the Company entered into a securities purchase agreement with Lind, pursuant to which
the Company issued Lind a secured, convertible note in the principal amount of $3,704,167 (the &#8220;Lind Offering&#8221;), for a purchase
price of $3,175,000 (the &#8220;Lind Note&#8221;), that is convertible into shares of Common Stock at an initial conversion price of
$1.05 per share, subject to adjustment.&#160;On August 24, 2023, the Company started repaying Lind the monthly installments due under
the Lind Notes; $308,000 was repaid via the issuance of 176,678 shares of Common Stock (the &#8220;Monthly Shares&#8221;) at the Redemption
Share Price (as defined in the Lind Note) of $1.698 per share. Pursuant to the terms of the Lind Note, Lind increased the amount of the
next monthly payment to one million dollars, such that as of September and together with the Monthly Shares, the Company repaid Lind
a total of $1M by September 2023. As a result, the stockholders&#8217; equity increased by an additional $1M. As a result of the four
transactions referenced above, the Company&#8217; estimated that its stockholders&#8217; equity would increase by approximately $10.65M.
On September 6, 2023, Nasdaq issued a letter that the Company is in compliance with Rule 5550(b)(1), but noted that if at the time of
the Company&#8217;s next periodic report the Company does not evidence compliance, it may be subject to delisting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 10, 2024, we received a notification
letter from the Nasdaq notifying the Company that the minimum bid price per share for its common shares has been below $1.00 for a period
of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing
Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company&#8217;s common stock on Nasdaq. Under
the Nasdaq Listing Rules, the Company has until January 6, 2025, to regain compliance. On January 9, 2025, the Company received a notification
from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share,
as outlined in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Rule&#8221;). To satisfy the Rule, the Company&#8217;s common stock must achieve
a closing bid price of at least $1.00 for a minimum of ten consecutive trading days within this extension period; if successful, Nasdaq
will confirm compliance with the Rule and close this matter. If compliance is not achieved by the new deadline, Nasdaq may initiate delisting
procedures, which the Company would have the right to appeal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 24, 2025, we received a letter from
the listing qualifications staff (the &#8220;Staff&#8221;) of Nasdaq informing us that, as reported in our Annual Report on Form 10-K
for the year ended December 31, 2024, because our <i>stockholders&#8217; equity</i> was $723,959, as of April 23, 2025, we did not meet
the alternatives of market value of listed securities or net income from continuing operations, and we no longer comply with Listing
Rule 5550(b)(1) (the &#8220;Rule 5550&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We have 45 calendar days to submit a plan
to the Staff to regain compliance. If our plan is accepted, we may be granted an extension of up to 180 calendar days from the date of
the letter, or until October 21, 2025, to evidence compliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In determining whether to accept our plan,
the Staff will consider such things as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria,
our past compliance history, the reasons for our current non-compliance, other corporate events that may occur within our review period,
our overall financial condition, and our public disclosures. If the Staff does not accept our plan, we will have the opportunity to appeal
that decision to a Hearings Panel.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Nasdaq notification has no immediate effect
on the listing of our Common Stock on the Nasdaq Capital Market. We intend to actively monitor our <i>stockholders&#8217; equity</i>
and will consider options available to us to achieve compliance with Rule 5550. There can be no assurance that we will be able to regain
compliance with the Listing Rule or will otherwise be in compliance with the other listing standards for the Nasdaq Capital Market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If our Common Stock ultimately were to be
delisted for any reason, it could negatively impact us by (i) reducing the liquidity and market price of our Common Stock; (ii) reducing
the number of investors willing to hold or acquire our Common Stock; (ii) limiting our ability to use a registration statement to offer
and sell freely tradable securities, thereby preventing us from accessing the public capital markets; and (iv) impairing our ability
to provide equity incentives to our employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 30, 2025, the Company reported that
it received a letter from the listing qualifications staff (the &#8220;Staff&#8221;) of Nasdaq informing it that, as reported in its
Annual Report on Form 10-K for the year ended December 31, 2024, because its stockholders&#8217; equity was $723,959, as of April 23,
2025, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations, and it
no longer comply with Listing Rule 5550(b)(1) (the &#8220;Listing Rule&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 5, 2025, the Company received a notification
letter (the &#8220;Notification Letter&#8221;) from Nasdaq notifying the Company that the Staff has determined that based on the Company&#8217;s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which evidenced stockholders&#8217; equity of $7,956,295, the Company
complies with the Listing Rule and the matter is closed.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
our common stock were delisted from the Nasdaq, trading of our common stock would most likely take place on an over-the-counter market
established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely
find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market,
and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing
them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock
would be subject to SEC rules as a &#8220;penny stock,&#8221; which impose additional disclosure requirements on broker-dealers. The
regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors
such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would
further limit the ability of investors to trade in our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the event of a delisting, we anticipate that we would take actions to restore our compliance with the Nasdaq Capital Market or another
national exchange&#8217;s listing requirements, but we can provide no assurance that any such action taken by us would allow our Common
Stock to remain listed on the Nasdaq Capital Market, stabilize our market price, improve the liquidity of our common stock, prevent our
common stock from dropping below the Nasdaq Capital Market&#8217;s minimum bid price requirement, or prevent future non-compliance with
the Nasdaq Capital Market or another national exchange&#8217;s listing requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
will continue to incur significant increased costs as a result of operating as a public company, and our management will be required
to devote substantial time to new compliance requirements as a result of our Common Stock being listed on the Nasdaq Capital Market.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
will continue to incur significant increased costs as a result of operating as a public company, and our management will be required
to devote substantial time to new compliance requirements of the Nasdaq Capital Market. As a public company, we will continue to incur
significant legal, accounting and other expenses. We are subject to mandatory reporting requirements of the Exchange Act, which require,
among other things, that we continue to file with the SEC annual, quarterly and current reports with respect to our business and financial
condition, that we were not required to file as a voluntary reporting company (though we did file such reports with the SEC on a voluntary
basis). We have incurred and will continue to incur costs associated with the preparation and filing of these SEC reports. Furthermore,
we are subject to mandatory new corporate governance and other compliance requirements of the Nasdaq Capital Market. In addition, the
Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, the Dodd-Frank Wall Street Reform and Consumer Protection Act
and the Nasdaq Capital Market or another national exchange have imposed various other requirements on public companies. Stockholder activism,
the current political environment and the current high level of government intervention and regulatory reform may lead to substantial
new regulations and disclosure obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate)
the way we operate our business. Our management and other personnel will need to devote a substantial amount of time to these compliance
initiatives. Moreover, these rules and regulations have and will continue to increase our legal and financial compliance costs and will
make some activities more time-consuming and costly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, if and when we cease to be a smaller reporting company and become subject to Section 404(b) of the Sarbanes-Oxley Act, we will
be required to furnish an attestation report on internal control over financial reporting issued by our independent registered public
accounting firm. To achieve compliance with Section 404 within the prescribed time period, we will continue to be engaged in a process
to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will
need to dedicate substantially greater internal resources, potentially engage outside consultants and adopt a detailed work plan to assess
and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate
through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal
control over financial reporting. Despite our efforts, there is a risk that our independent registered public accounting firm, when required,
will not be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required
by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our
financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
prospectus contains forward-looking statements that involve risks and uncertainties, including statements based on our current expectations,
assumptions, estimates and projections about us, our industry and the regulatory environment in which we and companies integral to our
ecosystem operate. The forward-looking statements are contained principally in the sections entitled &#8220;Prospectus Summary,&#8221;
&#8220;Risk Factors,&#8221; &#8220;Use of Proceeds,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations&#8221; and &#8220;Business.&#8221; These statements involve known and unknown risks, uncertainties and other factors
that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking
statements. In some cases, these forward-looking statements can be identified by words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;is/are likely to&#8221; or other similar expressions.
The forward-looking statements included in this prospectus relate to, among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    and uncertainties associated with our research and development activities, including our clinical trials and preclinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing or likelihood of regulatory filings and approvals or of alternative regulatory pathways for our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential market opportunities for commercializing our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding the potential market size and the size of the patient populations for our drug candidates, if approved for
    commercial use, and our ability to serve such markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates
    of our expenses, future revenue, capital requirements and our needs for additional financing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop, acquire and advance our product candidates into, and successfully complete, clinical trials and preclinical studies
    and obtain regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model and strategic plans for our business and drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, cost, timing, progress and results of future preclinical studies and clinical trials, and our research and development
    programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms of future licensing arrangements, and whether we can enter into such arrangements at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    and receipt or payments of licensing and milestone revenues, if any;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and our ability
    to operate our business without infringing the intellectual property rights of others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    developments in the United States and foreign countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    performance of our third party suppliers and manufacturers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain and establish collaborations or obtain additional funding;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competing therapies that are currently or may become available;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue as a going concern;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of the ongoing COVID-19 pandemic;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    and projections relating to our competitors and our industry.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
caution you that the forward-looking statements highlighted above do not encompass all of the forward-looking statements made in this
prospectus or in the documents incorporated by reference in this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">There are important factors that could cause
actual results to vary materially from those described herein as anticipated, estimated or expected, including, but not limited to: the
effects of the COVID-19 outbreak, including on the demand for our products&#894; the duration of the COVID-19 outbreak and severity of
such outbreak in regions where we operate&#894; the pace of recovery following the COVID-19 outbreak&#894; our ability to implement cost
containment and business recovery strategies&#894; the adverse effects of the COVID-19 outbreak on our business or the market price of
our common stock; competition in the industry in which we operate and the impact of such competition on pricing, revenues and margins,
volatility in the securities market due to the general economic downturn; SEC regulations which affect trading in the securities of &#8220;penny
stocks,&#8221; and other risks and uncertainties described herein and the risk factors set forth in Part I - Item 1A, &#8220;Risk Factors&#8221;,
in our Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on April 15, 2025, and elsewhere in the
documents incorporated by reference into this prospectus. Moreover, we operate in a very competitive and challenging environment. New
risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have
an impact on the forward-looking statements contained in this prospectus and in the documents incorporated by reference in this prospectus.
We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur,
and actual results, events or circumstances could differ materially from those described in the forward-looking statements. Except as
required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could
differ materially from those anticipated in any forward- looking statements, even if new information becomes available in the future.
Depending on the market for our stock and other conditional tests, a specific safe harbor under the Private Securities Litigation Reform
Act of 1995 may be available. Notwithstanding the above, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) expressly state that
the safe harbor for forward-looking statements does not apply to companies that issue penny stock. Because we may from time to time be
considered to be an issuer of penny stock, the safe harbor for forward-looking statements may not apply to us at certain times.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
forward-looking statements contained in this prospectus and in the documents incorporated by reference in this prospectus relate only
to events as of the date on which the statements are made. We do not undertake any obligation to release publicly any revisions to such
forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated
events. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should
not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any
future acquisitions, mergers, dispositions, joint ventures, other strategic transactions or investments we may make.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>USE
OF PROCEEDS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
will not receive any proceeds from the sale of the shares of Common Stock by the selling stockholders pursuant to this prospectus. All
proceeds from the sale of the shares will be for the account of the selling stockholder. The selling stockholder may sell these shares
in the open market or otherwise, at market prices prevailing at the time of sale, at prices related to the prevailing market price, or
at negotiated prices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
selling stockholder will pay any underwriting discounts and commissions and expenses incurred by the selling stockholder for brokerage
or legal services or any other expenses incurred by the selling stockholder in disposing of the shares included in this prospectus. We
will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including
all registration and filing fees and fees and expenses of our counsel and accountants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>DETERMINATION
OF OFFERING PRICE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
selling stockholders may sell these shares in the over-the-counter market or otherwise, at market prices prevailing at the time of sale,
at prices related to the prevailing market price, or at negotiated prices. We will not receive any proceeds from the sale of shares by
the selling stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>The
following discussion and analysis should be read together with our financial statements and the related notes appearing elsewhere in
this prospectus. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties.
See &#8220;Cautionary Note Regarding Forward-Looking Statements and Industry Data&#8221; for a discussion of the uncertainties, risks
and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed
in our forward-looking statements as a result of many factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere
in this prospectus.</i></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">From its inception, the Company has not generated
substantial revenue from its medical device and new drug development. For the quarter ended March 31, 2025, the Company did not generate
any revenue..</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Business
Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABVC
BioPharma Inc., which was incorporated under the laws of the State of Nevada on February 6, 2002, is a clinical stage biopharmaceutical
company focused on development of new drugs and medical devices, all of which are derived from plants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Medicines
derived from plants have a long history of relieving or preventing many diseases and, typically, have exhibited fewer side effects than
drugs developed from animals or chemical ingredients. Perhaps the most famous example is aspirin, which evolved from a compound found
in the bark and leaves of the willow tree and was later marketed by Bayer starting in 1899. Aspirin has very few serious side effects
and has proven to be one of the most successful drugs in medical history. Some 50 years later, scientists identified anticancer compounds
in the rosy periwinkle, which Eli Lilly subsequently produced for the treatment of leukemia and Hodgkins disease. Other well-known examples
of successful botanical drugs include the cancer-fighting Taxol, isolated from the Pacific yew tree.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company develops its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in
the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company&#8217;s scientists
and other specialists known to the Company to identify drugs that it believes demonstrate efficacy and safety based on the Company&#8217;s
internal qualifications. Once a drug is shown to be a good candidate for further development and ultimately commercialization, BriVision
licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly respected
principal investigators in the United States, Australia and Taiwan. In almost all cases, we have found that research institutions in
each of those countries are eager to work with the Company to move forward with Phase II clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Currently,
institutions conducting phase II clinical trials in partnership with ABVC include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0pt 0">Medical Device: ABV-1701, Vitargus<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#174;
                                            </sup>in vitrectomy surgery, Phase II Study in Australia and Thailand, Principal Investigator:
                                            Professor/Dr. Matthew Simunovic, Sydney Eye Hospital; Dr. Elvis Ojaimi, East Melbourne Eye
                                            Group &amp; East Melbourne Retina, Duangnate Rojanaporn, M.D., Ramathibodi Hospital; Thuss
                                            Sanguansak, M.D., Srinagarind Hospital.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0pt 0">Drug: ABV-1505, Adult Attention-Deficit
                                            Hyperactivity Disorder (ADHD), Phase <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II,
                                            NCE drug Principal Investigators: Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D., University
                                            of California San Francisco (UCSF), School of Medicine</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0pt 0">Drug: ABV-1601, Major Depression
                                            in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott Irwin, MD, Ph.D. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            Cedars Sinai Medical Center (CSMC)</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug:
    ABV-1519, A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined with Pemetrexed + Carboplatin
    Therapy in Patients with Advanced Inoperable or Metastatic EGFR wild-type Non-Small Cell Lung Cancer Patients</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon successful completion of the Phase II trial,
the Company will seek a partner - a large pharmaceutical company - to complete a Phase III study, submit the New Drug Application (NDA),
and commercialize the drug upon approval by the FDA and Taiwan FDAs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another part of the Company&#8217;s business
is conducted by BioKey, a wholly owned subsidiary, that is engaged in a wide range of services, including, API characterization, pre-formulation
studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing
clinical trial materials (phase I through phase III) and commercial manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 21, 2023, Dr. Howard Doong resigned from
his position as the Company&#8217;s CEO. The Company&#8217;s board of directors appointed Dr. Uttam Patil to replace Dr. Doong as the
Company&#8217;s CEO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On
                                            August 14, 2023, the Company entered into a cooperation agreement with Zhonghui United Technology
                                            (Chengdu) Group Co., Ltd., pursuant to which the Company acquired a 20% ownership of certain
                                            property and a parcel of the land (collectively, the &#8220;Property&#8221;) owned by Zhonghui
                                            in exchange for an aggregate of 370,000 shares of Common Stock at $1.87 per share (the &#8220;Zhonghui
                                            Shares&#8221;).</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Zhonghui plan to jointly develop
the Property into a healthcare center for senior living, long-term care, and medical care in the areas of ABVCs&#8217; special interests,
such as Ophthalmology, Oncology, and Central Nervous Systems. The plan is to establish a base for the China market and global development
of these interests. The asset ownership certification is in the application process and pending approval from the Chinese government.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the third quarter of 2023, the Company
issued the Zhonghui Shares. The Zhonghui Shares are subject to a lock-up period of one year following the closing date of this Transaction.
In addition, the parties agreed that, after one year following the closing of the transaction, if the market value of the shares issued
or the value of the Property increase or decrease, the parties will negotiate in good faith to make reasonable adjustments thereto; provided,
however that in no event shall Zhonghui&#8217;s ownership exceed 19.99% of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2023, the Company entered into a
binding term sheet with Xinnovation Therapeutics Co., Ltd., a Company incorporated under the Law of People&#8217;s Republic of China.
The term sheet contemplates that, pursuant to definitive agreements, Xinnovation will be granted an exclusive license to develop, manufacture,
market, and distribute ABV-1504 for Major Depressive Disorder (MDD) and ABV-1505 for Attention-Deficit/Hyperactivity Disorder, in the
Chinese market and shall bear the costs for clinical trials and product registration in China and the Company would receive an initial
license fee and royalty payments ranging from 5% to 12% based on the projected annual net sales of the licensed drugs by Xinnovation
in China. This transaction remains subject to the negotiation of definitive documents and therefore there is no guarantee that this transaction
will occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In November 2023, the Company and one of its
subsidiaries, BioLite, Inc. (&#8220;BioLite&#8221;) each entered into a multi-year, global licensing agreement with AiBtl for the Company
and BioLite&#8217;s CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder)
(the &#8220;Licensed Products&#8221;). The potential license will cover the Licensed Products&#8217; clinical trial, registration, manufacturing,
supply, and distribution rights. The Licensed Products for MDD and ADHD, owned by ABVC and BioLite, were valued at $667 million by a
third-party evaluation. The parties are determined to collaborate on the global development of the Licensed Products. The parties are
also working to strengthen new drug development and business collaboration, including technology, interoperability, and standards development.
As per each of the respective agreements, each of ABVC and BioLite received 23 million shares of AiBtl stock at $10 per share, and if
certain milestones are met, each of ABVC and BioLite may receive $3,500,000 and royalties equaling 5% of net sales, up to $100 million.
Upon the issuance of the shares, AiBtl became a subsidiary of ABVC. On June 23, 2024, the Company and BioLite, each entered into an amendment
to the licensing agreement with AiBtl, pursuant to which the Company and BioLite have agreed to allow AiBtl to pay the second milestone
payment in the amount of $3,500,000 per licensing agreement, incrementally (such as $50,000), at any given time, rather than in one lump
sum.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 6, 2024, the Company entered into
a definitive agreement with Shuling Jiang (&#8220;Shuling&#8221;), pursuant to which Shuling shall transfer the ownership of certain
land she owns located at Taoyuan City, Taiwan (the &#8220;Shuling Land&#8221;) to the Company (the &#8220;Agreement&#8221;). Shuling
is a director of the Company and owns approximately 15.4% of the Company&#8217;s issued and outstanding shares of common stock. On May
16, 2024, the Company&#8217;s board of directors determined that it was in the best interest of the Company and its shareholders to terminate
the Agreement and not proceed with the transfer of land ownership. The shares originally issued were returned and the warrants were not
issued. The parties are now re-negotiating the terms of the Company&#8217;s purchase of the Shuling Land, but will not enter into a definitive
agreement unless and until shareholder approval of the proposed compensation is obtained.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 25, 2024, the Company, and one of
its co-development partners, BioFirst Corporation, a company registered in Taiwan (&#8220;BioFirst&#8221;), each entered into a twenty-year,
global definitive licensing agreement (the &#8220;Licensing Agreement&#8221;) with ForSeeCon Eye Corporation, a company registered in
the British Virgin Islands (&#8220;FEYE&#8221;) for the products in the Company and BioFirst&#8217;s Ophthalmology pipeline, including
Vitargus (the &#8220;Licensed Products&#8221;). The license covers the Licensed Products&#8217; clinical trial, registration, manufacturing,
supply, and distribution rights; FEYE also has the rights to sublicense or partner with a third party to develop the Licensed Products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 16, 2024, the Company entered into
a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (&#8220;Oncox&#8221;),
pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the &#8220;Licensed
Products&#8221;), within North America for 20 years (the &#8220;Oncox Agreement&#8221;). In consideration thereof, Oncox shall pay ABVC
$6,250,000 (or 1,250,000 Oncox shares valued at $5 per share1) 30 days after entering into the Oncox Agreement and $625,000 30 days following
the completion of Oncox&#8217;s next round of fundraising, of which there is no guarantee; ABVC is also entitled to 5% royalties based
on the Net Sales, as defined in the Oncox Agreement, from the first commercial sale of the Licensed Product in North America, of which
there can be no guarantee. Oncox entered into the same agreement with ABVC&#8217;s affiliate, Rgene Corporation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 8, 2024, the Company entered into a
definitive agreement with OncoX BioPharma, Inc, pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize
ABVC&#8217;s BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment
of Pancreatic Cancer (the &#8220;Licensed Products&#8221;), within a certain territory, specified as 50% of the Worldwide Marketsfor
20 years (the &#8220;May 2024 Oncox Agreement&#8221;). In consideration thereof, Oncox shall pay ABVC a total of $6,250,000 (or 1,250,000
Oncox shares valued at $5 per share1) within 30 days of entering into the May 2024 Oncox Agreement, with an additional milestone payment
of $625,000 in cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments
of at least $100,000 towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties
of 5% of Net Sales, as defined in the May 2024 Oncox Agreement, from the first commercial sale of the Licensed Product in the noted territory,
which remains uncertain. The Company will permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to
use its revenue to fund such payments. Oncox entered into the same agreement with ABVC&#8217;s affiliate, Rgene Corporation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 14, 2024, the Company entered into
a definitive agreement with OncoX BioPharma, Inc, pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize
ABVC&#8217;s BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment
of Tripple Negative Breast Cancer (the &#8220;Licensed Products&#8221;), within a certain territory, specified as 50% of the Worldwide
Markets for 20 years (the &#8220;Oncox Agreement&#8221;). In consideration thereof, Oncox shall pay ABVC a total of $6,250,000 (or 1,250,000
Oncox shares valued at $5 per share1) 30 days after entering into the Oncox Agreement, with an additional milestone payment of $625,000
in cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least
$100,000 towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties of 5% of Net
Sales, as defined in the Oncox Agreement, from the first commercial sale of the Licensed Product in the noted territory, which remains
uncertain. The Company will permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue
to fund such payments. Oncox entered into the same agreement with ABVC&#8217;s affiliate, Biolite, Inc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 23, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the &#8220;MS Products&#8221;),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 23, 2024 Oncox Agreements&#8221;).
In consideration thereof, Oncox shall pay each licensor a total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share4) 30
days after entering the May 23, 2024 Oncox Agreements, with an additional milestone payment of $625,000 in cash after OncoX&#8217;s next
round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000 towards the licensing fees
and deductible from the second milestone payment; each licensor is also entitled to royalties of 5% of Net Sales, from the first commercial
sale of the MS Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing fees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of acquired land</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ABVC acquired the real estate described above
for the long-term purpose of supporting its pipeline of products and reducing costs. As per FDA guidelines, the raw material of botanical
drugs must be grown in a specific area under Good Agricultural Practices (GAP) or in an environmentally fully controlled plant factory
to maintain quality. By acquiring land, ABVC plans to grow its botanical drug raw materials under its control; doing this will help the
Company maintain the quality of the product and lower the cost of raw materials, which in turn will lower the cost of the drug substance
and the drug product when its botanical drugs become commercialized.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Common
Stock Reverse Split</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 25, 2023, the Company filed a Certificate
of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its
common stock. The Company&#8217;s stockholders previously approved the Reverse Stock Split at the Company&#8217;s Special Shareholder
Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase
the per share trading value of the Company&#8217;s common stock, although that outcome is not guaranteed. Unless otherwise noted, all
shares and related financial information in this Form 10-K reflect this 1-for-10 reverse stock split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NASDAQ Listing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
August 2022, we received a deficiency letter from the Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) notifying us
that, for the last 30 consecutive business days, the closing bid price for our common stock was below the minimum $1.00 per share required
for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (&#8220;Rule 5550(a)(2)&#8221;). In accordance
with Nasdaq Listing Rule 5810(c)(3)(A), we were initially given until February 14, 2023 to regain compliance with Rule 5550(a)(2). Since
the Company did not regain compliance by such date, it requested and received an additional 180 days, until August 14, 2023, to comply
with Rule 5550(a)(2).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
deficiency has no immediate effect on the listing of the Company&#8217;s common stock, and its common stock continues to trade on The
Nasdaq Capital Market under the symbol &#8220;ABVC&#8221; at this time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
at any time before August 14, 2023, the bid price of the Company&#8217;s common stock closes at $1.00 per share or more for a minimum
of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance and the matter
will be closed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
the Company does not regain compliance with Rule 5550(a)(2) by August 14, 2023, the Staff will provide written notification that the
Company&#8217;s securities will be delisted, although the Company maintains the right to appeal such determination. The Company intends
to actively monitor the closing bid price for its common stock and will consider available options to resolve the deficiency and regain
compliance with Rule 5550(a)(2).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
August 8, 2023, the Company received a notification letter from Nasdaq notifying the Company that the Staff has determined that for 10
consecutive business days, from July 25, 2023 to August 7, 2023, the closing bid price of the Company&#8217;s common stock has been at
least $1.00 per share or greater. Accordingly, the Staff determined that the Company regained compliance with Listing Rule 5550(a)(2)
and indicated that the matter is now closed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2023, we received a deficiency letter
from the Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying
the Company that it is not currently in compliance with the minimum stockholders&#8217; equity requirement, or the alternatives of market
value of listed securities or net income from continuing operations, for continued listing on the Nasdaq Capital Market. Nasdaq Listing
Rule 5550(b)(1) requires listed companies to maintain stockholders&#8217; equity of at least $2,500,000, and the Company&#8217;s stockholders&#8217;
equity was $1,734,507 as of March 31, 2023. In accordance with Nasdaq rules, the Company had 45 calendar days, or until July 10, 2023,
to submit a plan to regain compliance. After submitting a plan to regain compliance, on July 10, 2023, Nasdaq granted the Company an
extension until August 30, 20203, to comply with Listing Rule 5550(b)(1). On July 31, 2023, the Company issued 300,000 shares of Common
Stock and 200,000 pre-funded warrants, at an exercise price of $0.01 per share, in a registered direct offering. Pursuant to this transaction,
the stockholders&#8217; equity was increased by $1.75M. On August 1, 2023, $500,000 of Notes were converted at $3.50 per share and the
holder received 142,857 shares of Common Stock. As a result of this conversion, the stockholders&#8217; equity was increased by $0.5M.
Additionally, on August 14, 2023, the Company entered into a cooperation agreement with Zhonghui United Technology (Chengdu) Group Co.,
Ltd., pursuant to which the Company acquired a 20% ownership of certain property and a parcel of the land owned by Zhonghui in exchange
for an aggregate of 370,000 shares of Common Stock. Accordingly, stockholders&#8217; equity increased by $7.4M. On February 23, 2023,
the Company entered into a securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible
note in the principal amount of $3,704,167 (the &#8220;Lind Offering&#8221;), for a purchase price of $3,175,000 (the &#8220;Lind Note&#8221;),
that is convertible into shares of Common Stock at an initial conversion price of $1.05 per share, subject to adjustment. On August 24,
2023, the Company started repaying Lind the monthly installments due under the Lind Notes; $308,000 was repaid via the issuance of 176,678
shares of Common Stock (the &#8220;Monthly Shares&#8221;) at the Redemption Share Price (as defined in the Lind Note) of $1.698 per share.
Pursuant to the terms of the Lind Note, Lind increased the amount of the next monthly payment to one million dollars, such that as of
September and together with the Monthly Shares, the Company repaid Lind a total of $1M by September 2023. As a result, the stockholders&#8217;
equity increased by an additional $1M. As a result of the four transactions referenced above, the Company&#8217; estimated that its stockholders&#8217;
equity would increase by approximately $10.65M. On September 6, 2023, Nasdaq issued a letter that the Company is in compliance with Rule
5550(b)(1), but noted that if at the time of the Company&#8217;s next periodic report the Company does not evidence compliance, it may
be subject to delisting.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 10, 2024, we received a notification
letter from the Nasdaq notifying the Company that the minimum bid price per share for its common shares has been below $1.00 for a period
of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing
Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company&#8217;s common stock on Nasdaq. Under
the Nasdaq Listing Rules, the Company has until January 6, 2025, to regain compliance. On January 9, 2025, the Company received a notification
from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share,
as outlined in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Rule&#8221;). To satisfy the Rule, the Company&#8217;s common stock must achieve
a closing bid price of at least $1.00 for a minimum of ten consecutive trading days within this extension period; if successful, Nasdaq
will confirm compliance with the Rule and close this matter. If compliance is not achieved by the new deadline, Nasdaq may initiate delisting
procedures, which the Company would have the right to appeal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 24, 2025, we received a letter from
the listing qualifications staff (the &#8220;<b>Staff</b>&#8221;) of Nasdaq informing us that, as reported in our Annual Report on Form
10-K for the year ended December 31, 2024, because our <i>stockholders&#8217; equity</i> was $723,959, as of April 23, 2025, we did not
meet the alternatives of market value of listed securities or net income from continuing operations, and we no longer comply with Listing
Rule 5550(b)(1) (the &#8220;<b>Rule 5550</b>&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We have 45 calendar days to submit a plan
to the Staff to regain compliance. If our plan is accepted, we may be granted an extension of up to 180 calendar days from the date of
the letter, or until October 21, 2025, to evidence compliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In determining whether to accept our plan,
the Staff will consider such things as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria,
our past compliance history, the reasons for our current non-compliance, other corporate events that may occur within our review period,
our overall financial condition, and our public disclosures. If the Staff does not accept our plan, we will have the opportunity to appeal
that decision to a Hearings Panel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Nasdaq notification has no immediate effect
on the listing of our Common Stock on the Nasdaq Capital Market. We intend to actively monitor our <i>stockholders&#8217; equity</i>
and will consider options available to us to achieve compliance with Rule 5550. There can be no assurance that we will be able to regain
compliance with the Listing Rule or will otherwise be in compliance with the other listing standards for the Nasdaq Capital Market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If our Common Stock ultimately were to be
delisted for any reason, it could negatively impact us by (i) reducing the liquidity and market price of our Common Stock; (ii) reducing
the number of investors willing to hold or acquire our Common Stock; (ii) limiting our ability to use a registration statement to offer
and sell freely tradable securities, thereby preventing us from accessing the public capital markets; and (iv) impairing our ability
to provide equity incentives to our employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 30, 2025, the Company reported that
it received a letter from the listing qualifications staff (the &#8220;Staff&#8221;) of Nasdaq informing it that, as reported in its
Annual Report on Form 10-K for the year ended December 31, 2024, because its stockholders&#8217; equity was $723,959, as of April 23,
2025, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations, and it
no longer comply with Listing Rule 5550(b)(1) (the &#8220;Listing Rule&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 5, 2025, the Company received a notification
letter (the &#8220;Notification Letter&#8221;) from Nasdaq notifying the Company that the Staff has determined that based on the Company&#8217;s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which evidenced stockholders&#8217; equity of $7,956,295, the Company
complies with the Listing Rule and the matter is closed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Recent
Research Results</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Vitargus&#174; Clinical Development:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Phase II clinical study of Vitargus&#174;
commenced in the second quarter of 2023. Study sites include Ramathibodi Hospital (Principal Investigator: Dr. Duangnate Rojanaporn)
and Srinagarind Hospital (Principal Investigator: Dr. Thuss Sanguansak) in Thailand, and Sydney Eye Hospital (Principal Investigator:
Professor Dr. Matthew Simunovic) and East Melbourne Eye Group/East Melbourne Retina (Principal Investigator: Dr. Elvis Ojaimi) in Australia.
The Company is currently producing a new investigational batch to support product improvements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ABV-2002 Corneal Storage Solution:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company is developing ABV-2002, a corneal
storage solution intended for use prior to penetrating keratoplasty or endothelial keratoplasty. ABV-2002 is formulated with a poly amino
acid polymer that adjusts osmolarity to maintain hydration and prevent corneal swelling. It also contains a phenolic phytochemical providing
antioxidant and antibacterial properties. Preliminary internal testing by BioFirst indicated potential advantages over existing storage
media. Further clinical development has been temporarily suspended due to funding constraints.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioFirst Corporation Operations:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioFirst Corporation, incorporated in 2006,
focuses on research, development, manufacturing, and commercialization of patented pharmaceutical products, primarily through global
exclusive licensing agreements with domestic R&amp;D institutions. BioFirst&#8217;s principal product under development is Vitargus&#174;,
licensed from the National Health Research Institutes. BioFirst is currently constructing a GMP-compliant manufacturing facility in Hsinchu
Biomedical Science Park, Taiwan, with targeted completion in 2025. This facility is intended to support global supply of Vitargus&#174;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ABV-1505 ADHD Clinical Study:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 12, 2022, the Company announced enrollment
progress in the Phase II Part II clinical study of ABV-1505, a treatment candidate for adult Attention-Deficit Hyperactivity Disorder
(ADHD). As of the date of this report, 69 subjects have been enrolled, including 50 subjects who have completed the 56-day treatment.
The study is a randomized, double-blind, placebo-controlled trial involving research centers in Taiwan and the University of California,
San Francisco (UCSF). UCSF&#8217;s Institutional Review Board approved participation, and the site initiation visit was completed in
March 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Public Offering &amp; Financings</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">2025 Financings</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the first quarter of 2025, the Company
continued to strategically manage its outstanding convertible debt obligations with Lind Global Fund II, LP. In connection with the Senior
Convertible Promissory Note issued in November 2023 (2nd Lind Note), the Company has successfully completed all conversions through equity
issuances, thereby extinguishing the remaining principal balance. As of the date of this filing, only the corresponding cash components
for four prior conversions remain to be settled, which the Company intends to address through the exercise of outstanding warrants-demonstrating
a proactive and non-dilutive repayment approach. Additionally, for the Senior Convertible Promissory Note issued in January 2024 (3rd
Lind Note), the Company has reduced the outstanding balance to $600,000, following two equity conversions of $200,000 each. The remaining
cash obligations for these conversions are also expected to be fulfilled in a similar warrant-based strategy, although no definitive
agreement has been entered as of the date hereof and there is no guarantee that a definitive agreement will be entered. These steps reflect
the Company&#8217;s commitment to meeting its obligations while preserving long-term shareholder value and capitalizing on structured
equity mechanisms to support operational continuity and financial health.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 5, 2025, the Company and Lind entered
into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, 1,029,167
of the Existing Warrants (the number of warrants so exercised is herein referred to as the &#8220;Outstanding Exercised Warrants&#8221;)
to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share.
Other than the Outstanding Exercised Warrants, the exercise price of the remaining warrants held by Lind remained unchanged. Pursuant
to the December Letter Agreement, the Company also agreed not to sell or issue any additional shares of common stock for a period of
15 days following the closing, with some noted exceptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">2024 Financings</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 4, 2024, the Company and Lind
entered into another letter agreement (the &#8220;November Letter Agreement&#8221;), pursuant to which Lind agreed to exercise, for cash,
500,000 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise
price of $0.42 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 18, 2024, the Company issued Lind
200,000 shares of the Company&#8217;s common stock as a repayment of $200,000 principal of 2nd Lind Note. According to the amended agreement
pursuant to Nasdaq requirements, the conversion price is subject to $1.00 floor price if the conversion price was below such floor. Based
on the conversion price of $0.4229, the Company made an additional $147,892 cash repayment in addition to the issuance of 200,000 shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 11, 2024, the Company issued
Lind 200,000 shares of the Company&#8217;s common stock as a repayment of $200,000 principal of 2nd Lind Note. According to the amended
agreement pursuant to Nasdaq requirements, the conversion price is subject to $1.00 floor price if the conversion price was below such
floor. Based on the conversion price of $0.6575, the Company made an additional $90,722 cash repayment in addition to the issuance of
200,000 shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 12, 2024, the Company issued Lind
200,000 shares of the Company&#8217;s common stock as a repayment of $200,000 principal of 2nd Lind Note. According to the amended agreement
pursuant to Nasdaq requirements, the conversion price is subject to $1.00 floor price if the conversion price was below such floor. Based
on the conversion price of $0.7907, the Company made an additional $88,403 cash repayment in addition to the issuance of 200,000 shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 22, 2024, the Company and Lind entered
into a letter agreement, pursuant to which Lind Global Fund II, LP (&#8220;Lind&#8221;) exercised, for cash, 1,000,000 of its Pre-Existing
Warrants (all of the warrants issued to Lind on February 23, 2023, November 17, 2023 and January 17, 2024 are hereinafter referred to
as the &#8220;Pre-Existing Warrants&#8221;) to purchase shares of Common Stock at a reduced exercise price of $0.75 per share. Lind also
received a new warrant to purchase 1,000,000 shares Common Stock, exercisable at any time on or after the date of its issuance and until
the five-year anniversary thereof, for $1.00 per share (the &#8220;New Lind Warrant&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 17, 2024, the Company entered into
a securities purchase agreement with Lind Global Fund II, LP (&#8220;Lind&#8221;), pursuant to which the Company issued Lind a secured,
convertible note in the principal amount of $1,000,000, for a purchase price of $833,333 (the &#8220;3<sup>rd</sup> Lind Note&#8221;),
that is convertible into shares of the Company&#8217;s common stock at a conversion price, which shall be the lesser of (i) $3.50 (the
&#8220;Fixed Price&#8221;) and (ii) 90% of the average of the three lowest VWAPs (as defined in the 3<sup>rd</sup> Lind Note) during
the 20 trading days prior to conversion (&#8220;Variable Price&#8221;), subject to adjustment (the &#8220;Note Shares&#8221;). Notwithstanding
the foregoing, provided that no Event of Default (as defined in the 3<sup>rd</sup> Lind Note) shall have occurred, conversions under
the 3<sup>rd</sup> Lind Note shall be at the Fixed Price for the first 180 days following the closing date. Lind will also receive a
5-year, common stock purchase warrant (the &#8220;3<sup>rd</sup> Lind Warrant&#8221;) to purchase up to 1,000,000 shares of the Company&#8217;s
common stock at an initial exercise price of $2.00 per share, subject to adjustment (each, a &#8220;Warrant Share,&#8221; together with
the 3<sup>rd</sup> Lind Note, Note Shares and 3<sup>rd</sup> Lind Warrant, the &#8220;Securities&#8221;). The parties later agreed to
a floor price of $1.00 for the Variable Price and that the Company would compensate Lind in cash if the Variable Price was less than
such floor price at the time of conversion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the occurrence of any Event of Default (as
defined in the 3<sup>rd</sup> Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount
of the 3<sup>rd</sup> Lind Note, in addition to any other remedies under the 3<sup>rd</sup> Lind Note or the other Transaction Documents
(as defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 3<sup>rd</sup> Lind Warrant may be exercised
via cashless exercise in the event a registration statement covering the Warrant Shares is not available for the resale of such Warrant
Shares or upon exercise of the 3<sup>rd</sup> Lind Warrant in connection with a Fundamental Transaction (as defined in the 3<sup>rd</sup>
Lind Warrant).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the securities purchase
agreement, if at any time prior to a date that is 18 months following the closing of the offering, the Company proposes to offer or sell
any additional securities in a subsequent financing, the Company shall first offer Lind the opportunity to purchase up to 10% of such
new securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Offering, the Company
and its subsidiaries: (i) Biokey, Inc., a California corporation (&#8220;BioKey&#8221;), (ii) Biolite Holding, Inc., a Nevada corporation
(&#8220;BioLite&#8221;), (iii) Biolite BVI, Inc., a British Virgin Islands corporation (&#8220;BioLite BVI&#8221;) and (iv) American
BriVision Corporation, a Delaware corporation (&#8220;American BriVision&#8221; and, collectively with the Company, BioKey, BioLite,
and BioLite BVI, the &#8220;Guarantors&#8221;), jointly and severally guaranteed all of the obligations of the Company in connection
with the offering (the &#8220;Guaranty&#8221;) with certain collateral, as set forth in the related Transaction Documents (as hereinafter
defined). The sale of the 3<sup>rd</sup> Lind Note and the terms of the offering, including the Guaranty are set forth in the securities
purchase agreement, the 3<sup>rd</sup> Lind Note, the 3<sup>rd</sup> Lind Warrant, the Second Amendment to Guaranty, the Second Amendment
to Security Agreement, and the Second Amendment to Guarantor Security Agreement (collectively, the &#8220;Transaction Documents&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allele Capital Partners, LLC (&#8220;Allele&#8221;)
together with its executing broker dealer, Wilmington Capital Securities, LLC (together with its affiliates, &#8220;Wilmington&#8221;),
served as the exclusive placement agent (the &#8220;Placement Agent&#8221;) of the offering. the Company has agreed to pay certain expenses
of the placement agent in connection with the offering and issued them a warrant to purchase up to 25,000 shares of common stock, on
the same terms as set forth in the 3<sup>rd</sup> Lind Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The securities purchase
agreement also contains customary representation and warranties of the Company and the Investors, indemnification obligations of the
Company, termination provisions, and other obligations and rights of the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Transaction
Documents is qualified by reference to the full text of the forms of the Transaction Documents, which are filed as Exhibits hereto and
incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">2023 Financings</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On November 17, 2023,
the Company entered into a securities purchase agreement (the &#8220;2<sup>nd</sup> Lind Securities Purchase Agreement&#8221;) with Lind
Global Fund II, LP (&#8220;Lind&#8221;), pursuant to which the Company issued Lind a secured, convertible note in the principal amount
of $1,200,000 (the &#8220;2<sup>nd</sup> Lind Offering&#8221;), for a purchase price of $1,000,000 (the &#8220;2<sup>nd</sup> Lind Note&#8221;),
that is convertible into shares of the Company&#8217;s common stock at a conversion price, which shall be the lesser of (i) $3.50 (the
&#8220;Fixed Price&#8221;) and (ii) 90% of the average of the three lowest VWAPs (as defined in the 2<sup>nd</sup> Lind Note) during
the 20 trading days prior to conversion, subject to adjustment. Notwithstanding the foregoing, provided that no Event of Default (as
defined in the 2<sup>nd</sup> Lind Note) shall have occurred, conversions under the 2<sup>nd</sup> Lind Note shall be at the Fixed Price
for the first 180 days following the closing date. Lind will also receive a 5-year, common stock purchase warrant (the &#8220;2<sup>nd
</sup>Lind Warrant&#8221;) to purchase up to 1,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $2
per share, subject to adjustment. The parties later agreed to a floor price of $1.00 for the Variable Price and that the Company would
compensate Lind in cash if the variable price was less than such floor price at the time of conversion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the occurrence of any Event of Default (as
defined in the 2<sup>nd</sup> Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount
of the 2<sup>nd</sup> Lind Note, in addition to any other remedies under the 2<sup>nd</sup> Lind Note or the other Transaction Documents
(as defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the 2<sup>nd</sup> Lind
Securities Purchase Agreement, if at any time prior to a date that is 18 months following the closing of the 2<sup>nd</sup> Lind Offering,
the Company proposes to offer or sell any additional securities in a subsequent financing, the Company shall first offer Lind the opportunity
to purchase up to 10% of such new securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2<sup>nd</sup> Lind Offering,
the Company and its subsidiaries: (i) Biokey, Inc., a California corporation (&#8220;BioKey&#8221;), (ii) Biolite Holding, Inc., a Nevada
corporation (&#8220;BioLite&#8221;), (iii) Biolite BVI, Inc., a British Virgin Islands corporation (&#8220;BioLite BVI&#8221;) and (iv)
American BriVision Corporation, a Delaware corporation (&#8220;American BriVision&#8221; and, collectively with the Company, BioKey,
BioLite, and BioLite BVI, the &#8220;Guarantors&#8221;), jointly and severally guaranteed all of the obligations of the Company in connection
with the 2<sup>nd</sup> Lind Offering (the &#8220;Guaranty&#8221;) with certain collateral, as set forth in the related Transaction Documents
(as hereinafter defined).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The sale of the Note and the terms of the 2<sup>nd</sup>
Lind Offering, including the Guaranty are set forth in the 2<sup>nd</sup> Lind Securities Purchase Agreement, the 2<sup>nd</sup> Lind
Note, the 2<sup>nd</sup> Lind Warrant, the First Amendment to Guaranty, the First Amendment to Security Agreement, and the First Amendment
to Guarantor Security Agreement (collectively, the &#8220;Transaction Documents&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allele Capital Partners, LLC (&#8220;Allele&#8221;)
together with its executing broker dealer, Wilmington Capital Securities, LLC (together with its affiliates, &#8220;Wilmington&#8221;),
served as the exclusive placement agent (the &#8220;Placement Agent&#8221;) of the 2<sup>nd</sup> Lind Offering. We have agreed to pay
certain expenses of the placement agent in connection with the 2<sup>nd</sup> Lind Offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An amendment was filed on February 29, 2024 to
disclose that due to Nasdaq requirements, the parties entered into an amendment to the Note, pursuant to which the conversion price shall
have a floor price of $1.00 (the &#8220;Amendment&#8221;). Additionally, the Amendment requires the Company to make a cash payment to
Lind if in connection with a conversion, the conversion price is deemed to be the floor price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities Purchase Agreement also contains
customary representation and warranties of the Company and the Investors, indemnification obligations of the Company, termination provisions,
and other obligations and rights of the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Transaction
Documents is qualified by reference to the full text of the forms of the Transaction Documents, which are filed as Exhibits hereto and
incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into
a securities purchase agreement (the &#8220;Lind Securities Purchase Agreement&#8221;) with Lind Global Fund II, LP (&#8220;Lind&#8221;),
pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $3,704,167 (the &#8220;Lind Offering&#8221;),
for a purchase price of $3,175,000 (the &#8220;Lind Note&#8221;), that is convertible into shares of the Company&#8217;s common stock
at an initial conversion price of $1.05 per share, subject to adjustment (the &#8220;Note Shares&#8221;). The Company also issued Lind
a common stock purchase warrant (the &#8220;Lind Warrant&#8221;) to purchase up to 5,291,667 shares of the Company&#8217;s common stock
at an initial exercise price of $1.05 per share, subject to adjustment (each, a &#8220;Warrant Share,&#8221; together with the Note,
Note Shares and Warrants, the &#8220;Lind Securities&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Lind Note does not carry any Interest. Beginning
with the date that is six months from the issuance date of the Lind Note and on each one (1) month anniversary thereafter, the Company
shall pay Lind an amount equal to $308,650.58, until the outstanding principal amount of the Lind Note has been paid in full prior to
or on the Maturity Date or, if earlier, upon acceleration, conversion or redemption of the Lind Note in accordance with the terms thereof
(the &#8220;Monthly Payments&#8221;). At the Company&#8217;s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares
of the Company&#8217;s common stock, or (iii) a combination of cash and Shares; if made in shares, the number of shares shall be determined
by dividing (x) the principal amount being paid in shares by (y) 90% of the average of the 5 lowest daily VWAPs during the 20 trading
days prior to the applicable payment date. The Lind Notes sets forth certain conditions that must be satisfied before the Company may
make any Monthly Payments in shares of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a
cash premium of 5% of such Monthly Payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the occurrence of any Event of Default (as
defined in the Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind Note,
in addition to any other remedies under the Note or the other Transaction Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Lind Warrant may be exercised via cashless
exercise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Lind Securities
Purchase Agreement, if at any time prior to a date that is 18 months following the closing of the Lind Offering, the Company proposes
to offer or sell any additional securities in a subsequent financing, the Company shall first offer Lind the opportunity to purchase
up to 10% of such new securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Lind Offering, the Company
and its subsidiaries: (i) Biokey, Inc., a California corporation (&#8220;BioKey&#8221;), (ii) Biolite Holding, Inc., a Nevada corporation
(&#8220;BioLite&#8221;), (iii) Biolite BVI, Inc., a British Virgin Islands corporation (&#8220;BioLite BVI&#8221;) and (iv) American
BriVision Corporation, a Delaware corporation (&#8220;American BriVision&#8221; and, collectively with the Company, BioKey, BioLite,
and BioLite BVI, the &#8220;Guarantors&#8221;), jointly and severally guaranteed all of the obligations of the Company in connection
with the Lind Offering (the &#8220;Guaranty&#8221;) with certain collateral, as set forth in the related Transaction Documents (as hereinafter
defined).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The sale of the Lind Note and the terms of the
Lind Offering, including the Guaranty are set forth in the Lind Securities Purchase Agreement, the Note, the Warrant, a Security Agreement,
Guarantor Security, Guaranty, a Trademark Security Agreement with Rgene Corporation, a Trademark Security Agreement with BioFirst, a
Patent Security Agreement, a Copyright Security Agreement and a Stock Pledge Agreement (collectively, the &#8220;Transaction Documents&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allele Capital Partners, LLC (&#8220;Allele&#8221;)
together with its executing broker dealer, Wilmington Capital Securities, LLC (together with its affiliates, &#8220;Wilmington&#8221;),
served as the exclusive placement agent (the &#8220;Placement Agent&#8221;) of the Lind Offering. As a result of the Lind Offering, the
Company will pay the Placement Agent (i) a cash fee of 6% of the gross proceeds from the sale of the Securities, and (ii) common stock
purchase warrants to purchase 6% of the number of shares of common stock issuable under the Lind Note. We also agreed to pay certain
expenses of the placement agent in connection with the Lind Offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Lind Securities Purchase Agreement,
the Company agreed to register all of the Lind Securities and the shares of common stock underlying the warrant issued to the placement
agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities Purchase Agreement also contains
customary representation and warranties of the Company and the Investors, indemnification obligations of the Company, termination provisions,
and other obligations and rights of the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the occurrence of any Event of Default (as
defined in the Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind Note
(the &#8220;Mandatory Default Amount&#8221;), in addition to any other remedies under the Note or the other Transaction Documents. The
Company and Lind entered into a letter agreement on September 12, 2023, pursuant to which the Mandatory Default Amount was reduced to
115% of the then outstanding principal amount of the Lind Note; pursuant to the letter agreement, Lind also agreed to waive any default
associated with the Company&#8217;s market capitalization being below $12.5 million for 10 consecutive days through February 23, 2024,
but retained its right to convert its Note. In addition, if the Company is unable to increase its market capitalization and is unable
to obtain a further waiver or amendment to the Lind Note, then the Company could experience an event of default under the Lind Note,
which could have a material adverse effect on the Company&#8217;s liquidity, financial condition, and results of operations. The Company
cannot make any assurances regarding the likelihood, certainty, or exact timing of the Company&#8217;s ability to increase its market
capitalization, as such metric is not within the immediate control of the Company and depends on a variety of factors outside the Company&#8217;s
control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Transaction
Documents is qualified by reference to the full text of the forms of the Transaction Documents, which are filed as Exhibits hereto and
incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">2022 Financing</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 11, 2022, the Company entered into certain
securities purchase agreement (the &#8220;May SPA&#8221;) with certain investors (the &#8220;Purchasers&#8221;). Pursuant to the May
SPA, the Company agreed to issue 2,000,000 shares of its Common Stock, at a price of $2.11 per share and 5-year warrants to purchase
up to 2,000,000 shares of Common Stock, exercisable at a price of $2.45 per share (the &#8220;May Warrants&#8221;) to the Purchasers.
The gross proceeds before deducting any estimated offering expenses are $4,220,000. The transaction contemplated by the May SPA was closed
on May 16, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid to the co-placement agents an
aggregate cash fee equal to 8% of the aggregate sales price of the securities sold and issued them warrants to purchase up to 160,000
shares of Common Stock, on the same terms as the May Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Key elements of our business strategy include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Advancing
                                            to the pivotal trial phase of ABV-1701 Vitargus&#174; for the treatments of Retinal Detachment
                                            or Vitreous Hemorrhage, which we expect to generate revenues in the future.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Focusing
                                            on licensing ABV-1504 for the treatment of major depressive disorder, MDD, after the successful
                                            completion of its Phase II clinical trials.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Completing
                                            Phase II, Part 2 clinical trial for ABV-1505 for the treatment of attention deficit hyperactivity
                                            disorder, ADHD.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Out
                                            licensing drug candidates and medical device candidates to major pharmaceutical companies
                                            for phase III and pivotal clinical trials, as applicable, and further marketing if approved
                                            by the FDA.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to augment our core research and development
capability and assets by conducting Phase I and II clinical trials for investigational new drugs and medical devices in the fields of
CNS, Hematology/Oncology and Ophthalmology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management team has extensive experiences
across a wide range of new drug and medical device development and we have in-licensed new drug and medical device candidates from large
research institutes and universities in both the U.S. and Taiwan. Through an assertive product development approach, we expect that we
will build a substantial portfolio of Oncology/ Hematology, CNS and Ophthalmology products. We primarily focus on Phase I and II research
of new drug candidates and out license the post-Phase-II products to pharmaceutical companies; we do not expect to devote substantial
efforts and resources to building the disease-specific distribution channels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Objectives</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is operating its core business based
on collaborative activities that can generate current and future revenues through research, development and/or commercialization joint
venture agreements. The terms of these agreements typically include payment to the Company related to one or more of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">nonrefundable
                                            upfront license fees,</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">development
                                            and commercial milestones,</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">partial
                                            or complete reimbursement of research and development costs and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">royalties
                                            on net sales of licensed products.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each type of payments results in revenue except
for revenue from royalties on net sales of licensed products, which are classified as royalty revenues. To date, we have not received
any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service
to the joint venture partner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            Company had multiple deliverables under the collaborative agreements, including deliverables
                                            relating to grants of technology licenses, regulatory and clinical development, and marketing
                                            activities. Estimation of the performance periods of the Company&#8217;s deliverables requires
                                            the use of management&#8217;s judgment. Significant factors considered in management&#8217;s
                                            evaluation of the estimated performance periods include, but are not limited to, the Company&#8217;s
                                            experience in conducting clinical development, regulatory and manufacturing activities. The
                                            Company reviews the estimated duration of its performance periods under its collaborative
                                            agreements on an annually basis, and makes any appropriate adjustments on a prospective basis.
                                            Future changes in estimates of the performance period under its collaborative agreements
                                            could impact the timing of future revenue recognition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further details about these difference payment
arrangements, see &#8220;Summary of Critical Accounting Policies&#8221; below. Examples of recent collaborative agreements the Company
has entered into are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreement with ForSeeCon
Eye Corporation, a related party</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 25, 2024, the Company and BioFirst
each entered into a twenty-year, global definitive licensing agreement (the &#8220;FEYE Licensing Agreement&#8221;) with ForSeeCon Eye
Corporation, a company registered in the British Virgin Islands (&#8220;FEYE&#8221;) for the products in the Company and BioFirst&#8217;s
Ophthalmology pipeline, including Vitargus (the &#8220;Vitargus Products&#8221;). The license covers the Vitargus Products&#8217; clinical
trial, registration, manufacturing, supply, and distribution rights; FEYE also has the rights to sublicense or partner with a third party
to develop the Licensed Products. As per each of the respective FEYE Licensing Agreements, each of the Company and BioFirst shall receive
a total licensing fee of $33,500,000, composed of an upfront payment of $30,000,000, which can instead be paid with 5 million shares
of FEYE stock at $6 per share within 30 days after the execution of the FEYE Licensing Agreement, and a $3,500,000 cash milestone payment,
due 30 days upon completion of next round fundraising. Additionally, each of the Company and BioFirst are eligible to receive royalties
of 5% of net Sales. As of March 31, 2025, the Company has received 5,000,000 FEYE shares but did not recognize such licensing revenue
since the fair value of FEYE stock is uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 18, 2024, the Company and BioFirst,
each entered into an amendment (the &#8220;<b>Amendment</b>&#8221;) to the Licensing Agreement with FEYE, pursuant to which the Company
and BioFirst have agreed to allow FEYE to pay the second milestone payment in the amount of $3,500,000 per Licensing Agreement, incrementally
(such as $100,000), at any given time, rather than in one lump sum. In 2024 the Company received in cash and recognized revenue $296,000,
pursuant to the Amendment. There was no transaction incurred during the period ended March 31, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreement with OncoX BiopPharma,
Inc., a related party</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 16, 2024, the Company entered into
a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (&#8220;Oncox&#8221;),
pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the &#8220;Lung Cancer
Products&#8221;), within North America for 20 years (the &#8220;April 2024 Oncox Agreement&#8221;). In consideration thereof, Oncox shall
pay ABVC $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share<sup>1</sup>) 30 days after entering into the agreement and $625,000,
30 days following the completion of Oncox&#8217;s next round of fundraising, of which there is no guarantee; ABVC is also entitled to
5% royalties based on the Net Sales, as defined in the April 2024 Oncox Agreement, from the first commercial sale of the Lung Cancer
Product in North America, of which there can be no guarantee. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene
Corporation, on the same terms.In 2024 the Company received in cash and recognized revenue of $200,000, pursuant to the agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 8, 2024, the Company entered into a
definitive agreement with OncoX, pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s
BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Pancreatic
(the Pancreatic Product), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 8, 2024
Oncox Agreement&#8221;). In consideration thereof, Oncox shall pay ABVC a total of $6,250,000 (or 1,250,000 Oncox shares valued at $5
per share<sup>2</sup>) within 30 days of entering into the May 8, 2024 Oncox Agreement, with an additional milestone payment of $625,000
in cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least
$100,000 towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties of 5% of Net
Sales, as defined in the May 8, 2024 Oncox Agreement, from the first commercial sale of the Pancreatic Product in the noted territory,
which remains uncertain. The Company will permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to
use its revenue to fund such payments. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene Corporation, on the same
terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 14, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the TNBC Product),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 14, 2024 Oncox Agreements&#8221;).
In each agreement for consideration thereof, Oncox shall pay each licensor a total of $6,250,000 (or 1,250,000 Oncox shares valued at
$5 per share<sup>3</sup>) within 30 days of entering into the May 14, 2024 Oncox Agreements, with an additional milestone payment of
$625,000 in cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of
at least $100,000 towards the licensing fees and deductible from the second milestone payment; each licensor is also entitled to royalties
of 5% of Net Sales, from the first commercial sale of the TNBC Product in the noted territory, which remains uncertain. The Company will
permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue to fund such payments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 23, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the &#8220;MS Products&#8221;),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 23, 2024 Oncox Agreements&#8221;).
In consideration thereof, Oncox shall pay each licensor a total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share<sup>4</sup>)
30 days after entering the May 23, 2024 Oncox Agreements, with an additional milestone payment of $625,000 in cash after OncoX&#8217;s
next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000 towards the licensing
fees and deductible from the second milestone payment; each licensor is also entitled to royalties of 5% of Net Sales, from the first
commercial sale of the MS Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing fees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Collaborative agreements with BHK, a related
party</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">(i)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">In February and December of 2015, BioLite, Inc. entered
    into a total of three joint venture agreements with BioHopeKing to jointly develop ABV-1501 for Triple Negative Breast Cancer (TNBC),
    ABV-1504 for MDD and ABV-1505 for ADHD. The agreements granted marketing rights to BioHopeKing for certain Asian countries in return
    for a series of milestone payments totaling $10 million in cash and equity of BioHopeKing or equity securities owned by BioHopeKing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The milestone payments are determined by a schedule
of BioLite development achievements as shown below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Execution of BHK Co-Development Agreement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Investigational New Drug (IND) Submission</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Phase II Clinical Trial Complete</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Initiation of Phase III Clinical Trial</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">New Drug Application (NDA) Submission</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">In December of 2015, BHK paid the initial cash payment of $1 million
    upon the execution of the BHK Agreement. The Company concluded that certain deliverables are considered separate units of accounting
    as the delivered items have value to the customer on a standalone basis and recognized this cash payment as collaboration revenue
    when all research, technical, and development data was delivered to BHK in 2015. The payment included compensation for past research
    efforts and contributions made by BioLite Taiwan before the BHK agreement was signed and does not relate to any future commitments
    made by BioLite Taiwan and BHK in the BHK Agreement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">In August 2016, the Company
                                    received the second milestone payment of $1 million, and recognized collaboration revenue for the
                                    year ended December 31, 2016. The Company completed the phase II clinical trial for ABV-1504 MDD
                                    on October 31, 2019, but has not yet completed the phase II clinical trial for ABV-1505 ADHD.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">In addition to the milestone
                                    payments, BioLite Inc. is entitled to receive a royalty equal to 12% of BHK&#8217;s net sales related
                                    to ABV-1501, ABV-1504 and ABV-1505 Products. As of March 31, 2025, the Company has not earned royalties
                                    under the BHK Co-Development Agreement.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(v)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The BHK Co-Development Agreement will remain in effect for fifteen
    years from the date of first commercial sale of the Product in in Asia excluding Japan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Co-Development agreement with Rgene Corporation,
a related party</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2017, the Company entered into a co-development
agreement (the &#8220;Rgene Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party under common control
by the controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to the Rgene Agreement, BriVision
and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1703 Pancreatic Cancer
Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Rgene Agreement, Rgene is required to pay the
Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017 as compensation of BriVision&#8217;s past research
efforts and contributions made by BriVision before the Rgene Agreement was executed. The payment does not relate to any future milestones
attained by BriVision. In addition to $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales
profit earned by Rgene. All development costs shall be equally shared by both BriVision and Rgene.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2017, the Company delivered all research,
technical data and development data to Rgene pursuant to the Rgene Agreement in return for a cash payment of $450,000 and 1,530,000 common
shares of Rgene stock valued at $2,550,000, which in 2018 was accounted for using the equity method long-term investment. On December
31, 2018, the Company determined to fully write off this investment based on the Company&#8217;s assessment of the severity and duration
of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market
conditions, the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements and Rgene&#8217;s
ability to remain in business. All research projects that were initiated will be managed and funded equally by the Company and Rgene.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Rgene signed an amendment to
the Rgene Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination
Therapy and AB-1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and
ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions
of the Rgene Agreement remain in full force and effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Clinical Development Service Agreement
with Rgene Corporation, a related party</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 10, 2022, the Company expanded its co-development
partnership with Rgene. The Company&#8217;s subsidiary, BioKey, entered into a Clinical Development Service Agreement with Rgene (&#8220;Service
Agreement&#8221;) to guide certain Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for
the treatment of pancreatic cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical
studies under U.S. FDA IND regulatory requirements (the &#8220;Rgene Studies&#8221;). Under the terms of the Service Agreement, BioKey
is eligible to receive payments totaling up to $3.0 million over a 3-year period with each payment amount to be determined by certain
regulatory milestones obtained during the agreement period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through a series of transactions over the past
5 years, the Company and Rgene have co-developed the three drug products covered by the Service Agreement, which has resulted in the
Company owning 31.62% of Rgene.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the Rgene Studies, the Company agreed
to loan $1.0 million to Rgene, for which Rgene has provided the Company with a 5% working capital convertible loan (the &#8220;Note&#8221;).
If the Note is fully converted, the Company will own an additional 6.4% of Rgene. The Company is expected to receive the outstanding
loan from the related party by the first half of 2024, either by cash or conversion of shares of Rgene. The Company may convert the Note
at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount
of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in
the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service
Agreement will trigger an event of default under the Note if not cured after 5 business days of written notice regarding the breach is
provided. Upon an event of default, the outstanding principal and any accrued and unpaid interest shall be immediately due and payable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Service Agreement shall remain in effect
until the expiration date of the last patent and automatically renew for 5 more years unless terminated earlier by either party with
six months written notice. Either party may terminate the Service Agreement for cause by providing 30 days written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rgene has further agreed, effective July 1, 2022,
to provide the Company with a seat on Rgene&#8217;s Board of Directors until the loan is repaid in full. The Company has nominated Dr.
Jiang, its Chief Strategy Officer and Director to occupy that seat; Dr. Jiang is also one of the Company&#8217;s largest shareholders,
owning 12.8% of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Rgene Studies is a related party transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Collaborative agreement with BioFirst Corporation,
a related party</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, the Company entered into a
collaborative agreement (the &#8220;BioFirst Agreement&#8221;) with BioFirst Corporation, a corporation incorporated under the laws of
Taiwan (&#8220;BioFirst&#8221;), pursuant to which BioFirst granted the Company global licensing rights to medical use of ABV-1701 Vitreous
Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation
and the Company is a Director and shareholders of BioFirst (See Note 12).</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the BioFirst Agreement, the Company
and BioFirst will co-develop and commercialize BFC-1401. The Company will pay BioFirst a total amount of $3,000,000 in cash or stock
of the Company before September 30, 2018 as payment in full for BioFirst&#8217;s past research efforts and contributions made by BioFirst
before the BioFirst Agreement was executed. The Company is entitled to receive 50% of any future net licensing revenue or net profit
associated with Vitargus&#174;. All development cost will be equally shared by both BriVision and BioFirst.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 25, 2017, BioFirst delivered all
research, technical, data and development data to the Company. For the year ended September 30, 2017, the Company determined to fully
expense the entire amount of $3,000,000 since the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1,
absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to
research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense
during the year ended September 30, 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2019, the Company entered into a
Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued
428,571 shares of the Company&#8217;s common stock to BioFirst as payment for $3,000,000 owed by the Company to BioFirst in connection
with the BioFirst Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On August 5, 2019, the Company entered into a
second Stock Purchase Agreement with BioFirst whereby the Company issued 414,702 shares of the Company&#8217;s common stock to BioFirst
as repayment in full for a loan in the amount of $2,902,911 provided to BriVision from BioFirst.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 4, 2020, the Company executed an
amendment to the BioFirst Agreement with BioFirst to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal Storage Solution
to the agreement. ABV-2002 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while ABV-2001 has
broader utilization during a variety of ocular procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Initially
                                            the Company will focus on ABV-2002, a solution utilized to store a donor cornea prior to
                                            either penetrating keratoplasty (full thickness cornea transplant) or endothelial keratoplasty
                                            (back layer cornea transplant). ABV-2002 is a solution comprised of a specific poly amino
                                            acid that protects ocular tissue from damage caused by external osmolarity exposure during
                                            pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity to maintain a
                                            range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the
                                            storage period. Stromal hydration results in (a) maintaining acceptable corneal transparency
                                            and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant phenolic phytochemical
                                            found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can
be manufactured at lower cost. Further clinical development was put on hold due to the lack of funding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, BioFirst was incorporated on November
7, 2006, focusing on the R&amp;D, manufacturing, and sales of innovative patented pharmaceutical products. The technology of BioFirst
comes from the global exclusive licensing agreements BioFirst maintains with domestic R &amp; D institutions. Currently, BioFirst&#8217;s
main research and development product is the vitreous substitute (Vitargus&#174;), licensed by the National Health Research Institutes.
Vitargus is the world&#8217;s first bio-degradable vitreous substitute and offers a number of advantages over current vitreous substitutes
by minimizing medical complications and reducing the need for additional surgeries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioFirst
                                            has started the construction of a GMP factory in Hsinchu Biomedical Science Park, Taiwan,
                                            with the aim at building a production base to supply the global market, and promote the construction
                                            of bio-degradable vitreous substitute manufacturing centers in Taiwan. Completion of this
                                            factory would allow ABVC to manufacture Vitargus with world-class technology in a GMP certified
                                            pharmaceutical factory. BioFirst is targeting to complete the construction in 2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Co-Development agreement with BioLite Japan
K.K., a related party</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2021 (the &#8220;<b>Completion
Date</b>&#8221;), the Company, Lucidaim Co., Ltd., a Japanese corporation (&#8220;<b>Lucidaim</b>,&#8221; together with the Company,
the &#8220;<b>Shareholders</b>&#8221;), and BioLite Japan K.K., a Japanese corporation (&#8220;<b>Biolite JP&#8221;</b>) entered into
a Joint Venture Agreement (the &#8220;<b>Agreement</b>&#8221;). Biolite JP is a private limited company (a Japanese <i>Kabushiki Kaisha</i>)
incorporated on December 18, 2018 and at the date of the Agreement has 10,000 ordinary shares authorized, with 3,049 ordinary shares
issued and outstanding (the &#8220;<b>Ordinary Shares</b>&#8221;). Immediately prior to the execution of the Agreement, Lucidaim owned
1,501 ordinary shares and the Company owned the 1,548 ordinary shares. The Shareholders entered into the joint venture to formally reduce
to writing their desire to invest in and operate Biolite as a joint venture. The business of the joint venture shall be the research
and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements
carried on by Biolite and its subsidiaries in Japan, or any other territory or businesses as may from time to time be agreed by an amendment
to the Agreement. The closing of the transaction is conditioned upon the approval and receipt of all necessary government approvals,
which have been received.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement and the related share
transfer agreement, the Company shall transfer 54 of its Ordinary Shares to Lucidaim for no consideration, such that following the transfer,
Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). Also pursuant to the Agreement,
there shall be 3 directors of Biolite JP, consisting of 1 director appointed by the Company and 2 appointed by Lucidiam. The Company
shall appoint Eugene Jiang, the Company&#8217;s current Chairman and Chief Business Officer and Lucidaim shall appoint Michihito Onishi;
the current director of Biolite JP, Toru Seo (who is also a director of BioLite Japan&#8217;s other shareholder), is considered the second
Lucidaim director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement further provides that the Company
and Biolite shall assign the research collaboration and license agreement between them to Biolite or prepare the same (the &#8220;<b>License
Agreement</b>&#8221;). The aforementioned transactions occurred on the Completion Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As
                                            per the Agreement, the Shareholders shall supervise and manage the business and operations
                                            of Biolite JP. The directors shall not be entitled to any renumeration for their services
                                            as a director and each Shareholder can remove and replace the director he/she/it appointed.
                                            If a Shareholder sells or disposes of all of its Ordinary Shares, the director such Shareholder
                                            appointed must tender his/her resignation. The Agreement also sets forth certain corporate
                                            actions that must be pre-approved by all Shareholders (the &#8220;<b>Reserved Matters</b>&#8221;).
                                            If the Shareholders are unable to make a decision on any Reserved Matter, then either Shareholder
                                            can submit a deadlock notice to the other shareholder, 5 days after which they must refer
                                            the matter to each Shareholder&#8217;s chairman and use good faith to resolve the dispute.
                                            If such dispute is not resolved within 10 days thereafter, then either Shareholder can offer
                                            to buy all of the other Shareholder&#8217;s Ordinary Shares for cash at a specified price;
                                            if there is not affirmative acceptance of the sale, the sale shall proceed as set forth in
                                            the sale offer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each
                                            of the Shareholders maintains a pre-emptive right to purchase such number of additional Ordinary
                                            Shares as would allow such Shareholder to maintain its ownership percentage in Biolite JP
                                            if Biolite JP issues any new Ordinary Shares. However, the Agreement provides that the Company
                                            shall lose its pre-emptive rights under certain conditions. The Shareholders also maintain
                                            a right of first refusal if the other Shareholder receives an offer to buy such shareholder&#8217;s
                                            Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement also requires Biolite JP to obtain
a bank facility in the amount of JPY 30,460,000 (approximately USD272,000), for its initial working capital purposes. Pursuant to the
Agreement, each Shareholder agrees to guarantee such bank facility if the bank requires a guarantee. Accordingly, the Company may be
liable for the bank facility in an amount up to JPY 14,925,400 (approximately USD134,000), which represents 49% of the maximum bank facility.
The Agreement further provides that Biolite JP shall issue annual dividends at the rate of at least 1.5% of Biolite JP&#8217;s profits,
if it has sufficient cash to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Pursuant
                                            to the agreement between the Company and BioLite JP, both parties agreed to use their best
                                            efforts to execute a License Agreement by the end of December 2021. Under the terms of the
                                            agreement, negotiations on behalf of BioLite JP are conducted by directors appointed by Lucidaim.
                                            If the Company and such directors do not reach agreement on the terms, BioLite JP may, at
                                            its sole discretion, elect not to execute the License Agreement without any liability to
                                            the Company. The company is negotiating on the licensing terms and expects to conclude soon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement contains non-solicitation and non-compete
clauses for a period of 2 years after a Shareholder or its subsidiaries ceases to be a Shareholder, with such restrictive covenants limited
to business within the ophthalmologic filed or central neurological field. Any rights to intellectual property that arise from Biolite
JP&#8217;s activities, shall belong to Biolite JP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The Agreement contains standard indemnification
terms, except that no indemnifying party shall have any liability for an individual liability unless it exceeds JPY 500,000 (approximately
USD4,500) and until the aggregate amount of all liabilities exceeds JPY 2,000,000 (approximately USD18,000) and then only to the extent
such liability exceed such limit.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid $150,000 towards the setup of
the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement shall continue for 10 years, unless
earlier terminated. The Agreement also allows a Shareholder to terminate the agreement upon certain defaults committed by another Shareholder,
as set forth in the Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This was a related party transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2021, the Company received $4,244,452
in gross proceeds from the exercise of warrants issued in the Company&#8217;s August 3, 2021, public offering of securities. Investors
exercised a total of 673,405 Series A warrants at a price of $6.30 per share, and 200 Series B warrants at a price of $10 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>BioKey Revenues</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to collaborative agreements, ABVC
earns revenue through its wholly owned BioKey subsidiary which provides a wide range of Contract Development &amp; Manufacturing Organization
(&#8220;CDMO&#8221;) services including API characterization, pre-formulation studies, formulation development, analytical method development,
stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (from Phase I through Phase III) and commercial
manufacturing of pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, BioKey provides a variety of regulatory
services tailored to the needs of its customers, which include proofreading and regulatory review of submission documents related to
formulation development, clinical trials, marketed products, generics, nutraceuticals and OTC products and training presentations. In
addition to supporting ABVC&#8217;s new drug development, BioKey submits INDs, NDAs, ANDAs, and DMFs to the FDA, on ABVC&#8217;s behalf
in compliance with new electronic submission guidelines of the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Impact of COVID-19 Outbreak</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 30, 2020, the World Health Organization
declared the coronavirus outbreak a &#8220;Public Health Emergency of International Concern&#8221; and on March 10, 2020, declared it
to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines
in certain areas, and forced closures for certain types of public places and businesses. The coronavirus and actions taken to mitigate
it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including
the geographical area in which the Company operates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the COVID-19 pandemic, our revenue for
the fiscal 2022 were significantly impacted. In 2023, our business started recovering from the COVID-19 impact. We have been working
on new contracts towards revenue generation and increase in sales of existing products and incorporating new products for sale.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The COVID-19 pandemic, including variants, has
adversely affected, and is expected to continue to adversely affect, elements of our CDMO business sector. The COVID-19 pandemic government
imposed restrictions constrained researcher access to labs globally. These constraints limited scientific discovery capacity and we observed
that demand in those labs fell well below historic levels. As constraints on social distancing were gradually lifted around the world
recently, labs have been able to increase research activity. While we believe that underlying demand is still not yet at pre-COVID-19
levels since lab operations remain below their normal capacity, we are hopeful that the vaccination programs that are underway combined
with policy changes planned for the summer will further increase research activity and support a return to pre-COVID-19 demand levels
worldwide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The global pandemic of COVID-19 continues to
evolve rapidly, and we will continue to monitor the situation closely, including its potential effect on our plans and timelines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, it is reasonably possible that
estimates made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these
conditions, including losses on inventory; impairment losses related to goodwill and other long-lived assets and current obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Restatement of Consolidated Financial Statements</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company restated its financial statements
as of and for the year ended December 31, 2023 (the &#8220;2023 Restatement&#8221;), to correct misstatements in those prior periods
related to improperly applying accounting guidance on the share-based payments, incorrectly recognizing interest expenses upon the conversion
of convertible debts, and misidentifying the existence of non-controlling interest of our subsidiary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company entered into a cooperation agreement
on August 14, 2023, with Zhong Hui Lian He Ji Tuan, Ltd. (the &#8220;Zhonghui&#8221;) to acquire 20% of the ownership of certain property
and a parcel of the land. According to the agreement, the Company issued 370,000 shares of its common stock as the consideration, and
used $20 dollar per share to recognize the right as construction in progress on the balance sheet.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the time of preparing its financial statements
for fiscal 2024, the Company reviewed the entire transaction, its relevant agreements and documentation, as well as the applicable accounting
guidance. The Company applied FASB Accounting Standard Codification (&#8220;ASC&#8221;) 845 Nonmonetary Transactions to determine the
fair value of the asset acquired would be more evident than the fair value of the consideration in exchange, the Company&#8217;s restricted
common stocks. The real estates acquired comes with a third-party valuation of $7,400,000 per the Company&#8217;s stake, which the value
of the acquired assets is guaranteed by Zhonghui. Upon further review, the Company considered ASC 718 Compensation - Stock Compensation,
should have been the appropriate guidance to apply given the Company&#8217;s common stocks are listed in Nasdaq with more observable
fair value (Level 1). Furthermore, at the time of issuance of these financial statements, no real estate title was transferred to the
Company. As a result, the Company adjusted the carrying value of the asset and reclassified the balance to &#8220;Prepayment for asset
acquisition&#8221; account to reflect the value of 370,000 shares issued at $1.87, the closing price as of the contract date. The Company
also corrected the share price used to recognize stock compensation expense from $20 to $1.87 for the 29,600 shares of common stock issued
on the same day to several consultants. As a result, these adjustments reduced $6,708,100 for asset recognized and $536,648 for stock-compensation
expense incurred in 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In February 2023, the Company issued a convertible
note to LIND Global Fund II, LP. Due to misapplication of ASC 470-20 instead of ASC 815-40, the Company overstated interest expenses
$1,179,667 for the year ended December 31, 2023. The overstatement is offsetting against additional paid-in capital due to the convertible
note being converted to the Company&#8217;s own common stocks instead of being repaid or disposition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In November 2023, the Company and one of its
subsidiaries entered into a licensing agreement with AiBtl. The Company accounted for a 100% control of AiBtl as of December 31, 2023,
but later discovered that AiBtl had outstanding founder shares that were not deposited to the stock transfer agent in the timely manner.
Such shares reduced the Company&#8217;s controlling interest from 100% to 69.70%. Accordingly, the Company adjusted the relevant accounts
in our consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As discussed in Note 12 to the financial statements
for the year ended December 31, 2024, in July 2019 the Company issued 644,972 shares (post-split) of the Company&#8217;s common stock
to four consultants for their services. Such stock-based expenses were amortized over 5 years starting from the issuance date. Per the
Company&#8217;s further review, the services, along with the agreements, were completed by December 31, 2022. Pursuant to ASC 718, the
costs of services should be recognized along with the period when services are received. Therefore, the Company reversed share-based
compensation expenses of $451,480 and $902,960 for the years ended December 31, 2024 and 2023, respectively. The accumulated deficit
as of December 31, 2022, was corrected with the Stock Subscription Receivables for $1,354,440 as a result of such adjustments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For further details about the impact of the
Restatement, please see the Notes to the Company&#8217;s financial statements for the year ended December 31, 2024, included in its Annual
Report on Form 10-K that was filed with the SEC on April 15, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Impact of the Restatement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the year ended December 31, 2023 is presented below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Consolidated Balance Sheets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">Construction in progress</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">7,400,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(7,400,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Prepayment for acquisition of assets</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">691,900</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">691,900</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Assets</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">14,492,599</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(6,708,100</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">7,784,499</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,696,380</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(148,028</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,548,352</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Convertible notes payable</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">569,456</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">317,066</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">886,522</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Due to related parties</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">173,132</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">361</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">173,493</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Current Liabilities</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5,932,490</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">169,399</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">6,101,889</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Liabilities</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">6,361,627</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">169,399</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">6,531,026</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Total stockholders&#8217; deficit attributable to the Company</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">8,388,050</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(6,833,940</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,554,110</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Noncontrolling interest</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(257,078</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(43,559</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(300,637</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total stockholders&#8217; equity</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">8,130,972</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(6,877,499</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1,253,473</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Liabilities and equity</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">14,492,599</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(6,708,100</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">7,784,499</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Consolidated Statements of Operations</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">Stock based compensation</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,635,708</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(1,449,775</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">185,933</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Interest (expenses)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,493,340</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,179,669</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(1,313,671</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Net loss attributable to noncontrolling interests</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(394,632</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(98,162</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(492,794</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net income (loss)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(10,910,288</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">2,629,444</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(8,280,844</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Basic and diluted net loss per common share</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(2.43</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">0.63</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(1.80</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Consolidated Statements of Cash Flows</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left"><span style="-keep: true">Net income (loss)</span></td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">(10,910,288</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">2,629,444</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">(8,280,844</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock-based compensation</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,635,708</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(1,449,775</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">185,933</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Other non-cash income and expenses</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,413,746</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(1,169,504</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,244,242</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">786,793</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(148,028</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">638,765</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net cash used in operating activities</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(4,048,985</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(137,863</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(4,186,848</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Due to related parties*</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(186,860</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">361</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(186,499</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Proceeds from subsidiary&#8217;s common stock subscription</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">137,500</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">137,500</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net cash provided by financing activities</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">3,732,100</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">137,861</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">3,918,961</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Due
                                            to related parties previously reported amount was reclassified to financing activities based
                                            on current year&#8217;s presentation.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Impact of the Restatement to the March
31, 2024 interim financial statements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the three months ended March 31, 2024 is presented below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Unaudited Condensed</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Consolidated
                                            Balance Sheets</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">Prepaid expense and other current asset</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">159,602</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">223,707</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">383,309</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,949,150</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(7,400,000</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">549,150</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Prepayment for asset acquisition</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">691,900</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">691,900</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Assets</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">14,460,402</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(6,484,392</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">7,976,010</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,050,845</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(605,178</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,445,667</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Convertible notes payable - third parties, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">842,567</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">29,769</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">872,336</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Due to related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">301,972</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">89,502</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">391,474</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Current Liabilities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">6,633,614</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(455,908</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">6,177,706</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Liabilities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">6,973,447</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(455,908</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">6,517,539</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">86,029,237</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(9,025,036</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">77,004,201</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Total stockholders&#8217; equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,792,076</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(6,092,525</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,699,551</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Noncontrolling interest</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(305,121</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">64,040</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(241,081</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Equity</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">7,486,955</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(6,028,485</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1,458,470</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Liabilities and Equity</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">14,460,402</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(6,484,393</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">7,976,009</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Three Months Ended March 31,
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Unaudited Condensed</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Consolidated
                                            Statements of Operations</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">Selling, general and administrative expenses</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">831,257</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(92,771</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">738,486</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,544,995</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(513,364</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,031,631</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Interest expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(684,683</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">503,007</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(181,676</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Net loss attributable to noncontrolling interests</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(48,043</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(45,425</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(93,468</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net loss</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(3,981,019</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1,053,352</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(2,927,667</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Basic and diluted net loss per common share</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(0.40</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">0.11</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(0.29</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Three Months Ended March 31,
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Unaudited Condensed</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Consolidated
                                            Statements of Cash Flows</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left"><span style="-keep: true">Net loss</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">(3,981,019</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">1,053,355</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">(2,927,664</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock-based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,544,995</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(513,364</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,031,631</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Other non-cash income and expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">672,016</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(495,736</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">176,280</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">354,465</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(398,070</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(43,605</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Due to related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">128,840</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(128,840</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net cash used in operating activities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(602,001</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(353,815</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(955,816</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Due to related parties*</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(217,981</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(217,981</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net cash provided by financing activities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">805,006</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">119,141</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">924,147</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(260,783</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">234,674</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(26,109</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Issuance of common stock for conversion of debt</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">681,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">213,426</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">467,574</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Due
                                            to related parties previously reported amount was reclassified to financing activities based
                                            on current year&#8217;s presentation.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Critical Accounting Policies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis of Presentation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;).
All significant intercompany transactions and account balances have been eliminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&#8217;s financial statements are expressed in U.S. dollars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Fiscal Year</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the
period beginning on October 1<sup>st</sup> and ending on September 30<sup>th</sup> to the period beginning on January 1<sup>st</sup>
and ending on December 31<sup>st</sup>, beginning January 1, 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stock Reverse Split</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 25, 2023, the Company filed a Certificate
of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its
common stock. The Company&#8217;s stockholders previously approved the Reverse Stock Split at the Company&#8217;s Special Shareholder
Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase
the per share trading value of the Company&#8217;s common stock, although that outcome is not guaranteed. In turn, the Company believes
that the Reverse Stock Split will enable the Company to restore compliance with certain continued listing standards of NASDAQ Capital
Market. All shares and related financial information in this Form 10-K reflect this 1-for-10 reverse stock split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair Value Measurements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 - Inputs are quoted prices in active markets for identical assets or liabilities that the
                                            Company has the ability to access at the measurement date. Valuation of these instruments
                                            does not require a high degree of judgment as the valuations are based on quoted prices in
                                            active markets that are readily and regularly available.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 - Inputs other than quoted prices in active markets that are either directly or indirectly
                                            observable as of the measurement date, such as quoted prices for similar assets or liabilities;
                                            quoted prices in markets that are not active; or other inputs that are observable or can
                                            be corroborated by observable market data for substantially the full term of the assets or
                                            liabilities.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 - Valuations based on inputs that are unobservable and not corroborated by market data.
                                            The fair value for such assets and liabilities is generally determined using pricing models,
                                            discounted cash flow methodologies, or similar techniques that incorporate the assumptions
                                            a market participant would use in pricing the asset or liability.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&#8217;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is
short. The carrying value of the Company&#8217;s long-term bank loan approximates fair value because the interest rates approximate market
rates that the Company could obtain for debt with similar terms and maturities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Clients</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 31, 2025 and December 31, 2024,
management estimated all accounts receivable balances are uncollectible. Provision credit loss balances were $11,993 and $11,993 as of
March 31, 2025 and December 31, 2024, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2024, management estimated
all accounts receivable balances are uncollectible and recognized $11,993 of credit loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2023, the most major client,
specializes in developing and commercializing of dietary supplements and therapeutics in dietary supplement industry, accounted for 87%
of the Company&#8217;s total account receivable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the year ended December 31, 2024, the
out-licensing income from our two major licensees, accounts for 58% and 39% of the Company&#8217;s total revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">For the year ended December 31, 2023, the most major client, distributing
nutritional supplement in Asia Pacific, accounted for 80% of the Company&#8217;s total revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cash and Cash Equivalents</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of March 31, 2025 and December 31, 2024, the Company&#8217;s
cash and cash equivalents amounted to $152,206 and $248,382, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of December 31, 2024 and 2023, the Company&#8217;s
cash and cash equivalents amounted to $248,382 and $60,155, respectively. Some of the Company&#8217;s cash deposits are held in financial
institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes
this financial institution is of high credit quality.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Restricted Cash </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 31, 2025 and December 31, 2024,
the Company&#8217;s restricted cash amounted $607,362 (NTD 20.2 million) and $615,433 (NTD 20.2 million), respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2024 and 2023, the Company&#8217;s
restricted cash amounted $615,433 (NTD 20.2 million) and $656,625 (NTD 20.1 million), respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration
                                            of Credit Risk</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We perform ongoing credit evaluation of our customers
and requires no collateral. An allowance for doubtful accounts is provided based on a review of the collectability of accounts receivable.
We determine the amount of allowance for doubtful accounts by examining its historical collection experience and current trends in the
credit quality of its customers as well as its internal credit policies. Actual credit losses may differ from our estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable and allowance for expected
credit losses accounts</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable is recorded and carried at
the original invoiced amount less an allowance for any potential uncollectible amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company make estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#8217;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Allowance
                                            for expected credit losses accounts were $616,397 and $616,414 as of March 31, 2025 and December
                                            31, 2024, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Allowance for expected credit losses accounts was $616,414 and
$616,505 as of December 31, 2024 and 2023, respectively.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The
                                            Company recognizes revenue in accordance with ASC Topic 606 (ASC 606), Revenue from Contracts
                                            with Customers.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is
within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify
the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only
applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled
to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are
performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborative Revenues - </b>The Company recognizes
collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these
agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development
and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed
products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products,
which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized upon satisfaction
of a performance obligation by transferring control of a good or service to the collaboration partners.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and
marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s
judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) Non-refundable upfront payments</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) Milestone payments</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative
agreement with collaboration partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) Multiple Element Arrangements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iv) Royalties and Profit Sharing Payments</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency
is resolved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues Derived from Research and Development
Activities Services - Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the
inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option
to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding
offset to research and development expenses as it satisfies the related performance obligations.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and Equipment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Estimated<br/>
    Life in<br/>
    Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Buildings and leasehold improvements</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 ~ 50</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Machinery and equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 ~ 10</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Office equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 ~ 6</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The
                                            Company has adopted ASC subtopic 360-10, Property, Plant and Equipment (&#8220;ASC 360-10&#8221;).
                                            ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and
                                            used by the Company be reviewed for impairment whenever events or changes in circumstances
                                            indicate that the carrying amount of an asset may not be recoverable. The Company evaluates
                                            its long-lived assets for impairment annually or more often if events and circumstances warrant.
                                            Events relating to recoverability may include significant unfavorable changes in business
                                            conditions, recurring losses, or a forecasted inability to achieve break-even operating results
                                            over an extended period. Should impairment in value be indicated, the carrying value of intangible
                                            assets will be adjusted, based on estimates of future discounted cash flows resulting from
                                            the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed
                                            of be reported at the lower of the carrying amount or the fair value less costs to sell.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Long-term Equity Investment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company acquires the equity investments
to promote business and strategic objectives. The accounting treatment for equity investments, where the Company does not have control
over the investees, is as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Marketable
                                            equity investments: The Company measures marketable equity securities at fair value at each
                                            reporting date, with unrealized gains and losses recognized in net income in accordance with
                                            ASC 321. Fair value is determined based on quoted market prices or other observable inputs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Non-marketable equity investments: When the equity method does not
    apply, non-marketable equity investments are accounted for at cost, adjusted for observable price changes in orderly transactions
    for identical or similar investments and for impairments, if applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Equity method investments: Investments in which the Company has
    the ability to exercise significant influence, but not control, over the investee, are accounted for using the equity method. The
    Company recognizes its proportionate share of the investee&#8217;s income or loss in gains (losses) on equity investments on a monthly
    basis.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, considering this a critical accounting
estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#8217;s
fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee,
changes in general market conditions in the investee&#8217;s industry or geographic area, and the management and governance structure
of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches.
The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The
income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#8217;
revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment exists could
change in the future due to new developments or changes in applied assumptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Other-Than-Temporary Impairment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company periodically reviews its non-marketable
equity investments and equity method investments, with recognition in earnings when declines in value are considered other than temporary.
the Company assesses the severity and duration of any impairment, along with qualitative and quantitative factors, such as the investee&#8217;s
financial performance, adverse market or regulatory conditions, operational changes, or additional funding needs. Evidence of a loss
in value might include the inability to recover the carrying amount of the investment or the investee&#8217;s failure to sustain earnings
capacity to justify its valuation. Impairments deemed other than temporary are recorded in gains (losses) on equity investments, even
if the decline exceeds the losses recognized under the equity method, where applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Convertible Notes Payable</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for convertible notes
payable in accordance with ASC 470-20, Debt with Conversion and Other Options, and ASC 815, Derivatives and Hedging, as applicable. Upon
issuance, the Company evaluates whether the embedded conversion feature should be bifurcated as a derivative under ASC 815 or classified
within equity under ASC 470-20. This assessment includes analyzing the terms of the conversion feature and determining if it requires
separate accounting. If the conversion feature is classified as equity, the proceeds from the issuance are allocated between the debt
and equity components. The debt component is recorded at its fair value, and the residual amount is allocated to equity. The debt component
is carried at amortized cost, with any discount amortized to interest expense over the term of the note using the effective interest
method. Upon conversion, the carrying amount of the debt is reclassified to equity, and no gain or loss is recognized. If the note is
settled in cash, any difference between the carrying amount and the settlement amount is recognized in earnings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Warrants</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for warrants as either
equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative
guidance in ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC
815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including
whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net
cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This
assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly
period end date while the warrants are outstanding. The Company determined that upon further review of the warrant agreement, the Public
Warrants issued pursuant to the warrant agreement qualify for equity accounting treatment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For issued or modified warrants that meet
all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance.
For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded
as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated
fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Research and Development Expenses</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            Company accounts for R&amp;D costs in accordance with Accounting Standards Codification (&#8220;ASC&#8221;)
                                            730, Research and Development (&#8220;ASC 730&#8221;). Research and development expenses
                                            are charged to expense as incurred unless there is an alternative future use in other research
                                            and development projects or otherwise. Research and development expenses are comprised of
                                            costs incurred in performing research and development activities, including personnel-related
                                            costs, facilities-related overhead, and outside contracted services including clinical trial
                                            costs, manufacturing and process development costs for both clinical and preclinical materials,
                                            research costs, and other consulting services. Non-refundable advance payment for goods and
                                            services that will be used in future research and development activities are expensed when
                                            the activity has been performed or when the goods have been received rather than when the
                                            payment is made. In instances where the Company enters into agreements with third parties
                                            to provide research and development services, costs are expensed as services are performed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Post-retirement and post-employment benefits</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company&#8217;s subsidiaries in Taiwan
adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor
regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of
the worker&#8217;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#8217; salaries
to the employees&#8217; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts
for such employee benefits, which were expensed as incurred, were $11,642 and $10,314 for the years ended December 31, 2024 and 2023,
respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stock-based Compensation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Total director, officer, and employee stock-based
compensation expenses were $0 and $1,935,755 for the three months ended March 31, 2025 and 2024, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Total employee stock-based compensation expenses
were $1,995,049 and $0 for the years ended December 31, 2024 and 2023, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221; and FASB ASC Topic 505-50 &#8220;Equity-Based
Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Total non-employee stock-based compensation
expenses were $48,773 for rent for the three months ended March 31, 2025, and $95,876 for consulting services for the three months ended
March 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Total non-employee stock-based compensation expenses were $506,583
and $185,933 for the years ended December 31, 2024 and 2023, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income Taxes</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the
Company is able to realize their benefits, or future deductibility is uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under
                                            ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than
                                            not&#8221; that the tax position would be sustained in a tax examination, with a tax examination
                                            being presumed to occur. The evaluation of a tax position is a two-step process. The first
                                            step is to determine whether it is more-likely-than-not that a tax position will be sustained
                                            upon examination, including the resolution of any related appeals or litigations based on
                                            the technical merits of that position. The second step is to measure a tax position that
                                            meets the more-likely-than-not threshold to determine the amount of benefits recognized in
                                            the financial statements. A tax position is measured at the largest amount of benefit that
                                            is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions
                                            that previously failed to meet the more-likely-than-not recognition threshold should be recognized
                                            in the first subsequent period in which the threshold is met. Previously recognized tax positions
                                            that no longer meet the more-likely-than-not criteria should be de-recognized in the first
                                            subsequent financial reporting period in which the threshold is no longer satisfied. Penalties
                                            and interest incurred related to underpayment of income tax are classified as income tax
                                            expense in the year incurred. No significant penalty or interest relating to income taxes
                                            has been incurred for the years ended December 31, 2024 and 2023. GAAP also provides guidance
                                            on de-recognition, classification, interest and penalties, accounting in interim periods,
                                            disclosures and transition.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Loss Per Share of Common Stock</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company calculates net loss per share
in accordance with ASC 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the
weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per
share except that the denominator is increased to include the number of additional common shares that would have been outstanding if
the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share
excludes all dilutive potential shares if their effect is anti-dilutive.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commitments and Contingencies</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has adopted ASC 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Foreign-currency Transactions</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income
in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated
at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated
investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#8217;
Equity (Deficit).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Segment Reporting</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ASC 280 &#8220;Segment Reporting&#8221; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company currently has one reportable segment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In August 2023, the FASB issued ASU 2023-05,
Business Combinations-Joint Venture Formations (Subtopic 805-60) which requires certain joint ventures to apply a new basis of accounting
upon formation by recognizing and initially measuring most of their assets and liabilities at fair value. The guidance does not apply
to joint ventures that may be proportionately consolidated and those that are collaborative arrangements. ASU 2023-05 is effective for
joint venture with a formation date on or after January 1, 2025, early adoption is permitted. The Company is currently evaluating the
impact that the standard will have on its unaudited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization. The ASU is
effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Estimates and Assumptions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing our consolidated financial statements,
we use estimates and assumptions that affect the reported amounts and disclosures. Our estimates are often based on complex judgments,
probabilities and assumptions that we believe to be reasonable, but that are inherently uncertain and unpredictable. We are also subject
to other risks and uncertainties that may cause actual results to differ from estimated amounts.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Results of Operations - Three Months Ended
March 31, 2025 Compared to Three Months Ended March 31, 2024 (Restated).</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following table presents, for the three
months indicated, our unaudited consolidated statements of operations information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Increase<br/> (Decrease)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="-keep: true">Revenue</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,205</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(1,205</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-100</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Gross Profits</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">928</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(928</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-100</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating Expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">693,005</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">2,839,183</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(2,146,178</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-76</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Loss from Operations</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(693,005</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(2,838,255</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">2,145,250</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-76</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Other Income (Expense)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(251,185</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(89,412</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(161,773</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">181</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Interest (Expense), Net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(203,896</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(177,627</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(26,269</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Net Income (Loss)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(944,190</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(2,927,667</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">1,983,477</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-68</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Revenues. </i></b>We generated $0 and
$1,205 in revenues for the three months ended March 31, 2025 and 2024, respectively. Besides assisting our licensees seeking for potential
business opportunities and investors, the Company also is exploring other revenue streams, including the FDA application services which
generated limited revenue in the three months ended March 31, 2024. For out-licensing agreements, please refer to the above collaborative
agreements for details.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Operating Expenses.</i></b> Our operating
expenses have decreased by $2,146,178 or 76%, to $693,005 for the three months ended March 31, 2025 from $2,839,183 for the three months
ended March 31, 2024. Such a decrease in operating expenses was mainly attributable to the decrease in selling, general and administrative
expenses and research and development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Interest income (expense), net.</i></b>
Our net interest expense was $(203,896) for the three months ended March 31, 2025, compared to ($177,627) for the three months ended
March 31, 2024. The increase in net interest expense of $26,269, or approximately 15%, was primarily due to the increase in recognition
of interest expense for the converted notes for proper accounting purposes<b>.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Other Expense</i>. </b>Our other expense
was $251,185 for the three months ended March 31, 2025, compared to other expense of $89,412 for the three months ended March 31, 2024.
The change was principally caused by the increase in loss on equity investment, interest expense, and offsetting by decrease in gain
on foreign exchanges in the three months ended March 31, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Net Loss.</i>&#160;</b>As a result of
the above factors, our net loss was $944,190 for the three months ended March 31, 2025 compared to $2,927,667 for the three months ended
March 31, 2024, representing a decrease of $1,983,477, or 68%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Asset Recognition and Investment Reclassification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the three months ended March 31, 2025,
the Company recognized certain updates to its financial position. The Company recorded the acquisition of land located in Puli, Taiwan,
with a carrying value of approximately $7.67 million, based on control obtained over the asset during the period. The Company intends
to utilize the land for future development of its health-related business operations. In addition, amounts previously classified as "Due
from Related Parties" were reclassified to "Long-Term Investments" to reflect the nature of the Company&#8217;s ongoing
investment in Rgene Corporation. The reclassification was based on management&#8217;s ongoing evaluation of the investment&#8217;s expected
holding period and strategic purpose, after entering into the convertible note loan in 2023. These changes increased total assets and
stockholders&#8217; equity as of March 31, 2025. Notwithstanding these improvements in the Company&#8217;s asset base, management continues
to evaluate liquidity risks and is seeking to address working capital needs through operational activities and external financing options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Liquidity and Capital Resources</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i><span style="text-decoration:underline">Working Capital</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of<br/> March 31, <br/> 2025<br/>
    </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of <br/> December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>(Unaudited)</b></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Current Assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,469,561</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2,179,815</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Current Liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">6,730,739</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">6,557,461</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Working Capital (Deficit)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(5,261,178</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(4,677,646</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>Going Concern and Liquidity Consideration</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the three months ended March 31, 2025,
the Company reported net loss of $944,190. As of March 31, 2025, the Company&#8217;s working capital deficit was $5,261,178. In addition,
the Company had net cash outflows of $539,833 from operating activities for the three months ended March 31, 2025. These conditions give
rise to substantial doubt as to whether the Company will be able to continue as a going concern.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Management&#8217;s plan is to continue to
improve operations to generate positive cash flows by 1) ensuring our cash consideration from our licensing agreements be fully collected
soon, 2) raising additional capital through private or public offerings, 3) strictly controlling cash operating expenses, and 4) reducing
debts and interest expense.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Notably, the Company has generated cash inflow
and reduced a substantial amount of convertible debts during the first three months ended March 31, 2025, from $0.95 million to $0.84
million. We also reduced our outstanding warrants from 2.0 million shares to 1 million shares in three months ended March 31, 2025, receiving
around $411,667 in cash. If the Company is not able to generate positive operating cash flows, and raise additional capital, there is
the risk that the Company may not be able to meet its short-term obligations. Management is committed to enhancing operations to generate
positive cash flows to meet our operation needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Three Months Ended March 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024 (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Change</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-keep: true">Cash Flow Used In Operating Activities</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(539,833</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(955,816</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">415,983</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-44</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Cash Flow Used in Investing Activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Cash Flow Provided by Financing Activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">428,756</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">924,147</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(495,391</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-54</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Cash Flow from Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the three months ended March 31, 2025
and 2024, the net cash used in operating activities were $539,833 and $955,816, respectively. The decrease was primarily due to the decrease
in operating expenses. Company has been strictly controlling the operating cash outflow, such as making certain payments with shares
in lieu of cash, extending vendors&#8217; payment terms, and other initiatives to save the cash burn.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Cash Flow from Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the three months ended March 31, 2025
and 2024, the net cash used in investing activities were $0 and $0 respectively. The Company does not plan to make further cash investment
with cash in the near future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Cash Flow from Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the three months ended March 31, 2025
and 2024, the net cash provided by financing activities were $428,756 and $924,147, respectively. The decrease in net cash provided by
financing activities were primarily due to the proceeds from issuance of convertible notes, Lind&#8217;s exercise of warrants, and less
short-term funding from our related parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"></b></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Results of Operations - Year Ended December
31, 2024 Compared to Year Ended December 31, 2023.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Year Ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023 (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Increase / (Decrease)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="-keep: true">Revenue</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">509,589</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">152,430</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">357,159</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">234</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Gross Profit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">508,826</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(149,607</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">658,433</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-440</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating Expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">5,214,068</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">6,617,127</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(1,403,059</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-21</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Loss from Operations</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(4,705,242</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(6,766,734</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">2,061,492</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-30</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Other (Expense), Net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(664,334</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(1,258,104</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">593,770</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-47</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Interest (Expense), Net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(738,541</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(1,128,190</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">389,649</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-35</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Net (Loss)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(5,259,037</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(8,280,844</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">3,021,807</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-36</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Revenues.</i></b> We generated $509,589
and $152,430 in revenues for the years ended December 31, 2024 and 2023, respectively. The increase of $357,159, or approximately 234%,
was primarily caused by outlicensing our intellectual properties completed in 2024, comparing to certain CDOM service provided in 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Operating Expenses</i>.</b> Our operating
expenses were $5,214,068 for the year ended December 31, 2024, compared to $6,617,127 for the year ended December 31, 2023. Such decrease
in operating expenses was mainly attributable to the decreased in selling, general and administrative expenses, decreased in research
and development expenses, but offset by increasing in stock-based compensation expenses. We have been focusing our cost control initiatives
to reduce to cash burns, with payments made with our restricted stocks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Other Expense, Net.</i></b> Other expense
was $664,334 for the year ended December 31, 2024, compared to other expense of $1,258,104 for the year ended December 31, 2023. The
change was principally caused by the decrease in interest expense, mainly from the convertible notes payable (pay off the 1<sup>st</sup>
Lind Note and monthly repayment of 2<sup>nd</sup> Lind Note), while being offset by increase in loss on investment in equity securities
for the year ended December 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Interest Income (Expense), Net</i></b>,
was $(738,541) for the year ended December 31, 2024, compared to $(1,128,190) for the year ended December 31, 2023. The decrease of $389,649
(or approximately 35%, was primarily due to the decrease in interest expense related to recognition of less interest expense for the
converted notes for proper accounting purpose.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b><i>Net Loss.</i></b> The net loss was $5,259,037
for the year ended December 31, 2024, compared to $8,280,844 for the year ended December 31, 2023. The Company reduce its net loss by
$3,021,807 or approximately 36% during the year ended December 31, 2024, through more cost efficient funding resources and discontinuing
certain consulting services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liquidity
                                            and Capital Resources</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Working Capital</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of<br/> December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">As
                                            of<br/> December 31,<br/> 2023</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(Restated)</b></p></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Current Assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2,179,815</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,656,709</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Current Liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">6,557,461</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">6,101,889</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Working Deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(4,377,646</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(4,445,180</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Year Ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023 (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Change</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-keep: true">Cash Flow Used In Operating Activities</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(1,809,145</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(4,186,848</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2,377,703</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-57</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Cash Flow Used in Investing Activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(360,186</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">360,186</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-100</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Cash Flow Provided by Financing Activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">1,980,769</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">3,869,961</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(1,889,192</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-49</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Cash Flow from Operating Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the years ended December 31, 2024 and
2023, the net cash used in operating activities were $1,809,145 and $4,186,848, respectively. The decrease in the amount of outflow $2,377,703
was primarily due to the increased in stock-based compensation as a payment for certain operating expenses, reduced in provision of credit
losses, and increased in due to related parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Cash Flow from Investing Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the years ended December 31, 2024 and
2023, the net cash used in investing activities were $0 and $360,186, respectively. The decrease in the amount of $360,186 was primarily
due to the decrease in prepayment for equity investment and purchase of equipment, while being offset by the increase in prepayment for
long-term investments during the year ended December 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Cash Flow from Financing Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the years ended December 31, 2024 and
2023, the net cash provided by financing activities were $1,980,769 and $3,869,961, respectively. The Company&#8217;s financing activities
in year 2024 are mainly focusing on reducing our debt and interest burden, while initiating certain fund raising activities through our
subsidiary, AiBtl. During the year, we only sold the 3<sup>rd</sup> convertible note to Lind but paid off the 1st Lind Note and 2/3 of
the 2nd Lind Note. We also issued certain common stock warrants as part of our financing activities in 2024. Comparing to 2023, we mainly
relied on Lind Notes and warrants as our financing resource. We are on the process to reduce the reliance to the private equity funding
as our out-licensing activities have remarkable breakthrough in 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Industry Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The biotechnology industry focuses on developing
breakthrough products and technologies to combat various types of diseases through efficient industrial manufacturing process. Biotechnology
is an important business sector in the world&#8217;s economies and plays a key role in human health. Companies engaged in biotechnology
generally require large amounts of capital investment for their research &amp; development activities and it may take up to tens of years
to develop and commercialize a new drug or a new medical device. ABVC (&#8220;we&#8221; or the &#8220;Company&#8221;) is an early stage
biotechnology company with a pipeline of seven new drugs and one medical device under development, all of which are licensed from related
parties of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Mission</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We devote our resources to building a sophisticated
biotech company and becoming a pioneer in the biopharmaceutical industry. Dr. Uttam Patil, our Chief Executive Officer, and Dr. Tsung-Shann
Jiang, the founder and majority shareholder of the Company, understand the challenges and opportunities of the biotech industry and intend
to provide therapeutic solutions to significant unmet medical needs and to improve health and quality of human life by developing innovative
botanical drugs to treat central nervous system (&#8220;CNS&#8221;) and oncology/ hematology diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Business Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, the Company&#8217;s minimal
revenue has come from the sale of CDMO services through BioKey. However, the Company&#8217;s focus is on developing a pipeline of products
by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical,
disease animal model and Phase I safety studies are examined closely by the Company&#8217;s scientists and other specialists known to
the Company to identify drugs or medical devices that it believes demonstrate efficacy and safety based on the Company&#8217;s internal
qualifications. Once a drug or medical device is shown to be a good candidate for further development and ultimately commercialization,
ABVC licenses the drug or medical device from the original researchers and introduces the drug or medical device clinical trial plan
to highly respected principal investigators in the United States, Australia and Taiwan. In almost all cases, ABVC has found that research
institutions in each of those countries are eager to work with the Company to move forward with Phase II clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Institutions that have or are now conducting
phase II clinical trials in partnership with ABVC include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug:
                                            ABV-1504, Major Depressive Disorder (MDD), Phase II completed. NCE drug Principal Investigators:
                                            Charles DeBattista M.D. and Alan F. Schatzberg, MD, Stanford University Medical Center, Cheng-Ta
                                            Li, MD, Ph.D - Taipei Veterans General Hospital</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Drug:
                                            ABV-1505, Adult Attention-Deficit Hyperactivity Disorder (ADHD), Phase II Part 1 completed.
                                            Principal Investigators: Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D., University of
                                            California San Francisco (UCSF), School of Medicine. Phase II, Part 2 clinical study sites
                                            includes UCSF and 5 locations in Taiwan.The Principal Investigators are Keith McBurnett,
                                            Ph.D. and Linda Pfiffner, Ph.D., University of California San Francisco (UCSF), School of
                                            Medicine; Susan Shur-Fen Gau, M.D., National Taiwan University Hospital; Xinzhang Ni, M.D.
                                            Linkou Chang Gung Memorial Hospital; Wenjun Xhou, M.D., Kaohsiung Chang Gung Memorial Hospital;
                                            Ton-Ping Su, M.D., Cheng Hsin General Hospital, Cheng-Ta Li, M.D., Taipei Veterans General
                                            Hospital. The Phase II, Part 2 began in the 1<sup>st</sup> quarter of 2022 at the 5 Taiwan
                                            sites. The UCSF site joined the study in the 2<sup>nd</sup> quarter of 2023. The subjects
                                            enrolled in the study has reached the number for interim analysis in 2023 December, and the
                                            interim analysis of the study is in progress.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">Drug:
                                            ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator:
                                            Scott Irwin, MD, Ph.D. - Cedars Sinai Medical Center (CSMC). The Phase I clinical study will
                                            be initiated around the end of 2025.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Medical
                                            Device: ABV-1701, Vitargus&#174; in vitrectomy surgery, Phase II Study has been initiated
                                            in Australia and Thailand, Principal Investigator: Duangnate Rojanaporn, M.D., Ramathibodi
                                            Hospital; Thuss Sanguansak, M.D., Srinagarind Hospital of the two Thailand Sites and Professor/Dr.
                                            Matthew Simunovic, Sydney Eye Hospital; Dr. Elvis Ojaimi, East Melbourne Eye Group &amp;
                                            East Melbourne Retina. The Phase II study started in the 2nd quarter of 2023, and the company
                                            is working on improvements to the Vitargus Product through the new batch of investigational
                                            product.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following trials are expected to begin in
the third quarter of 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug:
                                            ABV-1519, Non-Small Cell Lung Cancer treatment, Phase I/II Study in Taiwan, Principal Investigator:
                                            Dr. Yung-Hung Luo, M.D., Taipei Veterans General Hospital (TVGH)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug:
                                            ABV-1703, Advanced Inoperable or Metastatic Pancreatic Cancer, Phase II, Principal Investigator:
                                            Andrew E. Hendifar, MD - Cedars Sinai Medical Center (CSMC)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completing a Phase II trial, ABVC will seek
a partner, typically a large pharmaceutical company, to complete a Phase III study and commercialize the drug or medical device upon
approval by the US FDA, Taiwan TFDA and other country regulatory authorities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>GMP Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC owns a certified GMP manufacturing facility,
through BioKey, that is qualified to deliver small quantities of drugs for use by its clients in clinical trials from Phase I to Phase
III. The GMP facility can manufacture direct API or blend fill-in capsules, manual and automated encapsulation, wet granulation or tray
drying process, tablet compression and coating process, packaging solid dosage forms for ANDA and IND submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The BioKey facility consists of a GMP suite,
product development area, analytical laboratory, food processing area, caged GMP storage area, receiving area and two warehouses. The
facility was remodeled in December 2008 and received its first drug manufacturing license in June 2009. ABVC&#8217;s current drug manufacturing
license allows it to manufacture drug products under IND for human clinical trials until the expiration of the license on December 2,
2024. The renewal of licenses is in progress.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2022, BioKey began manufacturing a dietary
supplement based on the maitake mushroom. The mushrooms, supplied by Shogun Maitake Canada, Co. Ltd., are grown in a controlled temperature
and humid environment free of pesticides and chemicals. Initially, sales of the new supplement in the US and Canada will be targeted
to high end grocery stores and worldwide via online distribution. While there are many mushroom-based supplements currently available
to customers, BioKey believes its new line has a significant competitive advantage since the purity and consistency of the mushrooms
themselves exceeds any maitake mushrooms currently available and the extraction process employed by BioKey delivers a particularly strong
dose. The maitake mushroom is rich in bioactive polysaccharides, especially beta-glucans. These polysaccharides have well-documented
immune-protecting and antitumor properties. BioKey has developed both a tablet and a liquid version of the supplement. GMP manufacturing
of bulk quantities Maitake mushroom tablets and Maitake mushroom drinks were completed in 2 and 1 batches respectively for commercial
launches in Taiwan and Canada in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beta-glucans in maitake mushrooms has been shown
to reduce cholesterol, resulting in improved artery functionality and overall better cardiovascular health that lowers the risk of heart
disease. Further, studies have shown that the beta-glucans in maitake mushroom have the effect of strengthening the immune system<sup>1</sup>.
In a trial of postmenopausal breast cancer patients, oral administration of a maitake extract was shown to have immunomodulatory effects.
In a different trial done at Memorial Sloan Kettering Cancer Center, maitake extracts were shown to enhance neutrophil and monocyte function
in patients with myelodysplastic syndrome. It boosts production of lymphokines (protein mediators) and interleukins (secreted proteins)
resulting in improved immune response. Further, beta-glucans, has been shown in clinical trials to lower blood glucose levels thereby
helping to activate insulin receptors, while reducing insulin resistance in diabetes management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioKey has entered into a three-year distribution
agreement with Define Biotech Co. Ltd., a Taiwan-based pharmaceutical marketing company that focuses on sales of drugs, dietary supplements
and medical products in the Asia-Pacific region. The agreement grants Define Biotech the exclusive right to distribute this new dietary
supplement in China and Taiwan in exchange for the commitment to purchase $3.0 million worth of the new product over the three-year period.
Renewal of the contract is under negotiation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NASDAQ Listing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2023, we received a deficiency letter
from the Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying
the Company that it is not currently in compliance with the minimum stockholders&#8217; equity requirement, or the alternatives of market
value of listed securities or net income from continuing operations, for continued listing on the Nasdaq Capital Market. Nasdaq Listing
Rule 5550(b)(1) requires listed companies to maintain stockholders&#8217; equity of at least $2,500,000, and the Company&#8217;s stockholders&#8217;
equity was $1,734,507 as of March 31, 2023. In accordance with Nasdaq rules, the Company had 45 calendar days, or until July 10, 2023,
to submit a plan to regain compliance. After submitting a plan to regain compliance, on July 10, 2023,Nasdaq granted the Company an extension
until August 30, 20203, to comply with Listing Rule 5550(b)(1). On July 31, 2023, the Company issued 300,000 shares of Common Stock and
200,000 pre-funded warrants, at an exercise price of $0.01 per share, in a registered direct offering. Pursuant to this transaction,
the stockholders&#8217; equity was increased by $1.75M. On August 1, 2023, $500,000 of Notes were converted at $3.50 per share and the
holder received 142,857 shares of Common Stock. As a result of this conversion, the stockholders&#8217; equity was increased by $0.5M.
Additionally, on August 14, 2023, the Company entered into a cooperation agreement with Zhonghui United Technology (Chengdu) Group Co.,
Ltd., pursuant to which the Company acquired a 20% ownership of certain property and a parcel of the land owned by Zhonghui in exchange
for an aggregate of 370,000 shares of Common Stock. Accordingly, stockholders&#8217; equity increased by $7.4M. On February 23, 2023,
the Company entered into a securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible
note in the principal amount of $3,704,167 (the &#8220;Lind Offering&#8221;), for a purchase price of $3,175,000 (the &#8220;Lind Note&#8221;),
that is convertible into shares of Common Stock at an initial conversion price of $1.05 per share, subject to adjustment. On August 24,
2023, the Company started repaying Lind the monthly installments due under the Lind Notes; $308,000 was repaid via the issuance of 176,678
shares of Common Stock (the &#8220;Monthly Shares&#8221;) at the Redemption Share Price (as defined in the Lind Note) of $1.698 per share.
Pursuant to the terms of the Lind Note, Lind increased the amount of the next monthly payment to one million dollars, such that as of
September and together with the Monthly Shares, the Company repaid Lind a total of $1M by September 2023. As a result, the stockholders&#8217;
equity increased by an additional $1M. As a result of the four transactions referenced above, the Company&#8217; estimated that its stockholders&#8217;
equity would increase by approximately $10.65M. On September 6, 2023, Nasdaq issued a letter that the Company is in compliance with Rule
5550(b)(1), but noted that if at the time of the Company&#8217;s next periodic report the Company does not evidence compliance, it may
be subject to delisting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 10, 2024, we received a notification
letter from the Nasdaq notifying the Company that the minimum bid price per share for its common shares has been below $1.00 for a period
of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing
Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company&#8217;s common stock on Nasdaq. Under
the Nasdaq Listing Rules, the Company has until January 6, 2025, to regain compliance. On January 9, 2025, the Company received a notification
from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share,
as outlined in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Rule&#8221;). To satisfy the Rule, the Company&#8217;s common stock must achieve
a closing bid price of at least $1.00 for a minimum of ten consecutive trading days within this extension period; if successful, Nasdaq
will confirm compliance with the Rule and close this matter. If compliance is not achieved by the new deadline, Nasdaq may initiate delisting
procedures, which the Company would have the right to appeal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 24, 2025, we received a letter from
the listing qualifications staff (the &#8220;Staff&#8221;) of Nasdaq informing us that, as reported in our Annual Report on Form 10-K
for the year ended December 31, 2024, because our <i>stockholders&#8217; equity</i> was $723,959, as of April 23, 2025, we did not meet
the alternatives of market value of listed securities or net income from continuing operations, and we no longer comply with Listing
Rule 5550(b)(1) (the &#8220;Rule 5550&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We have 45 calendar days to submit a plan
to the Staff to regain compliance. If our plan is accepted, we may be granted an extension of up to 180 calendar days from the date of
the letter, or until October 21, 2025, to evidence compliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In determining whether to accept our plan,
the Staff will consider such things as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria,
our past compliance history, the reasons for our current non-compliance, other corporate events that may occur within our review period,
our overall financial condition, and our public disclosures. If the Staff does not accept our plan, we will have the opportunity to appeal
that decision to a Hearings Panel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Nasdaq notification has no immediate effect
on the listing of our Common Stock on the Nasdaq Capital Market. We intend to actively monitor our <i>stockholders&#8217; equity</i>
and will consider options available to us to achieve compliance with Rule 5550. There can be no assurance that we will be able to regain
compliance with the Listing Rule or will otherwise be in compliance with the other listing standards for the Nasdaq Capital Market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If our Common Stock ultimately were to be
delisted for any reason, it could negatively impact us by (i) reducing the liquidity and market price of our Common Stock; (ii) reducing
the number of investors willing to hold or acquire our Common Stock; (ii) limiting our ability to use a registration statement to offer
and sell freely tradable securities, thereby preventing us from accessing the public capital markets; and (iv) impairing our ability
to provide equity incentives to our employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 30, 2025, the Company reported that
it received a letter from the listing qualifications staff (the &#8220;Staff&#8221;) of Nasdaq informing it that, as reported in its
Annual Report on Form 10-K for the year ended December 31, 2024, because its stockholders&#8217; equity was $723,959, as of April 23,
2025, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations, and it
no longer comply with Listing Rule 5550(b)(1) (the &#8220;Listing Rule&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 5, 2025, the Company received a notification
letter (the &#8220;Notification Letter&#8221;) from Nasdaq notifying the Company that the Staff has determined that based on the Company&#8217;s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which evidenced stockholders&#8217; equity of $7,956,295, the Company
complies with the Listing Rule and the matter is closed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our Pipeline</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Central
                                            Nervous System</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-1504
                                            to treat Major Depressive Disorder (&#8220;MDD&#8221;)</span></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We are developing and researching
ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. Prior to clinical trials, we conducted radioligand-binding assay
tests on ABV-1504. Radioligand-binding assays are used to characterize the binding effects of a drug to its target receptor. In the case
of ABV-1504, the receptors of radioligand-binding assays are norepinephrine, dopamine and serotonin. The radioligand-binding assay test
on norepinephrine was conducted from May 3 to May 8, 2007 and the radioligand-binding assay test on dopamine and serotonin was administered
from November 26 to December 5, 2007. The result of radioligand-binding assay to norepinephrine of ABV-1504was 2.102 &#956;g/ml of IC50,
which indicated ABV-1504&#8217;s high inhibitory efficiency on norepinephrine. The results of radioligand-binding assay to dopamine and
serotonin were not as good as to norepinephrine, which indicated lower inhibitory efficiency. Because research has shown that norepinephrine
inhibitors can alleviate the level of depression, our research team saw ABV-1504&#8217;s potential to treat depression and decided to
commence the clinical trial process of ABV-1504.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In 2013, ABVC successfully completed
the Phase I clinical trial of ABV-1504. The primary objective of the Phase I study was to assess the safety profile of ABV-1504. The
safety endpoint was assessed based on the results of physical examinations, vital signs, laboratory data, electrocardiograms (&#8220;ECG&#8221;),
Columbia-Suicide Severity Rating Scale evaluation and a number of adverse events during the study period. We began recruiting healthy
people as subjects for the Phase I trial in Taiwan on October 30, 2012. For the Phase I trial, we screened 85 healthy volunteers at the
Taipei Veterans General Hospital and eventually enrolled 30 people as trial subjects. We divided the subjects into four cohort groups
and administered ABV-1504oral capsules of 380 mg, 1140 mg, 2280 mg, and 3800 mg to the subjects in each cohort group, respectively. BioLite
visited the first subject the first time on November 13, 2012 and the last subject the last time on July 5, 2013. During the said period,
no subject had a serious adverse event nor discontinued the trial due to any adverse events. ABVC did not observe any clinically significant
findings in physical examinations, vital signs, electrocardiogram, laboratory measurements, and C-SSRS throughout the treatment period.
However, ABVC observed the following mild adverse events: two subjects with flatulence and one subject with constipation in the single-dose
380mg cohort of seven subjects; one subject with somnolence and one subject with stomatitis ulcer in the single-dose 2,280 mg cohort.
Comparatively, two subjects with somnolence and one subject with stomatitis ulcer were observed in the placebo group of seven subjects.
ABVC did not observe any suicidal ideation or behavior throughout the trial period. ABV-1504&#8217;s Phase I clinical trial results reflected
that the oral administration of ABV-1504 to healthy volunteers was safe and well-tolerated at the dose levels of from 380 mg to 3,800
mg.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">ABVC received an IND approval to proceed
with the Phase II clinical trial of ABV-1504 from the F.D.A. in March 2014 and an IND approval of its Phase II trial from the Taiwan
F.D.A. in June 2014. For the Phase II trial, BioLite administered oral capsules to 72 MDD patients (the trial subjects) in a randomized,
double-blind study with a placebo control group to assess ABV-1504&#8217;s efficacy and safety profile, primarily in accordance with
the Montgomery-&#197;sberg Depression Rating Scale (&#8220;MADRS&#8221;). ABVC via BioLite began recruiting Phase II subjects in March
2015 at the following study sites, Taipei Veterans General Hospital, Linkou Chang Gung Memorial Hospital, Taipei City Hospital-Songde
Branch, Tri-Service General Hospital, Wan Fang Hospital and started recruiting MDD patients at Stanford Depression Research Clinic. The
first five sites are in Taiwan and the last one is in the United States. The primary endpoint of the Phase II trial is to see changes
of the subjects&#8217; MADRS total scores from the baseline scores of the placebo subjects within the first six weeks. The secondary
objectives of the Phase II trial are to evaluate the efficacy and safety profile of ABV-1504 on other rating scales with secondary endpoints
of (i) demonstrating changes in MADRS total scores from baseline scores within the second to seventh weeks and (ii) showing changes in
the total scores on Hamilton Rating Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Depression and Somatic
Symptoms Scale (DSSS), Clinical Global Impression Scale (CGI) from the baseline scores in the second, fourth, sixth and seventh week.
ABVC plans to measure the percentages of partial responders (subjects with a 25% to 50% decrease of total MADRS scores from the baseline
score) and responders (subjects with 50% or more decrease of total MADRS scores from the baseline score) by the second, fourth, sixth
and seventh week. Additionally, ABVC intends to monitor the subjects&#8217; performance in accordance with the Safety Assessments and
Columbia-Suicide Severity Rating Scale from the screening stage to each subject&#8217;s last visit as well as to analyze the differences
in the mean changes of MADRS, HAM-D-17, HAM-A, DSSS, CGI and Columbia-Suicide Severity Rating Scale scores of the subjects administered
with ABV-1504 and the placebo group in the second, fourth, sixth and seventh week.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On May 23, 2019, the Company announced
the Phase II clinical study results of ABV-1504. The clinical study results showed that PDC-1421, the active pharmaceutical ingredient
of ABV-1504, met the pre-specified primary endpoint of the Phase II clinical trial and significantly improved the symptoms of MDD. The
Phase II clinical study was a randomized, double-blind, placebo-controlled, multi-center trial, in which sixty (60) adult patients with
confirmed moderate to severe MDD were treated with PDC-1421 in either low dose (380 mg) or high dose (2 x 380 mg) compared with placebo
administration, three times a day for six weeks. PDC-1421 high dose (2 x 380 mg) met the pre-specified primary endpoint by demonstrating
a highly significant 13.2-point reduction in the Montgomery-&#197;sberg Depression Rating Scale (MADRS) total score by Intention-To-Treat
(ITT) analysis, averaged over the 6-week treatment period (overall treatment effect) from baseline, as compared to 9.2-point reduction
of the placebo group. By Per-Protocol (PP) analysis, PDC-1421 showed a dose dependent efficacy toward MDD in which high dose (2 x 380
mg) gave 13.4-point reduction in MADRS total score from baseline and low dose (380 mg) gave 10.4-point reduction as compared to a 8.6-point
in the placebo group. Based on the trial results as set forth above, the Company has decided to use the high dose formula for ABV-1504&#8217;s
Phase III clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-1505
    to treat Attention Deficit Hyperactivity Disorder (&#8220;ADHD&#8221;)</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We developed the ADHD indication from
the same API of ABV-1504. Also, ABV-1505 shares similar pharmaceutical mechanism of action as ABV-1504 in as much as ABV-1505 shows the
potential of increasing the level of norepinephrine in the human&#8217;s nervous system by inhibiting its reabsorption. Because of ABV-1505&#8217;s
sufficient similarity with ABV-1504, in January 2016 the FDA approved our IND application to conduct ABV-1505&#8217;s Phase II clinical
trial based on its preclinical research and the Phase I trial results of ABV-1504.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For the ADHD Phase II trial, ABVC
plans to recruit a maximum of 105 ADHD patients as trial subjects in the United States and Taiwan, to whom ABVC intends to administer
ABV-1505 oral capsules. ABVC has designed a randomized, double-blind dose escalation study with a placebo-controlled group to assess
the efficacy and safety profile of ABV-1505, primarily against the ADHD Rating Scale-IV (&#8220;ADHD-RS-IV&#8221;). The primary endpoint
of the Phase II trial is a 40% or higher improvement on the ADHD-RS-IV from the respective baseline scores within a period of up to eight
weeks. The secondary objective is to determine the efficacy and safety profile of ABV-1505 on other rating scales with secondary endpoints
of (i) improvements of the total ADHD symptom scores from the respective baseline scores on the Conners&#8217; Adult ADHD Rating Scale-Self
Report: Short Version (&#8220;CAARS-S:S&#8221;) 18-Item for a treatment period of eight weeks at maximum; and (ii) achievement of scores
of two or lower on both the Clinical Global Impression-ADHD- Severity (&#8220;CGI-ADHD-S&#8221;) and Clinical Global Impression-ADHD-Improvement
(&#8220;CGI-ADHD-I&#8221;) from the subjects&#8217; respective baseline scores. The University of California San Francisco (&#8220;UCSF&#8221;)
initiated the Phase II, Part 1 clinical trial entitled &#8220;A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult
Patients with Attention-Deficit Hyperactivity Disorder (ADHD). Part I, on January 14, 2020. The Part 1 trial is a single center, open
label, dose escalation evaluation with two dosage levels in six subjects. Six subjects were initially evaluated for safety and efficacy
assessments at low-dose (1 capsule of PDC-1421, three times a day (TID)) for 28 days. A safety checkpoint was evaluated at day-28 for
entering the high-dose (2 capsules TID). The subjects who passed the checkpoint were evaluated for safety and efficacy assessments at
high-dose (2 capsules of PDC-1421 TID) for 28 days. On July 15, 2020, the last patient last visit (LPLV) marked the final step toward
the completion of the ABV-1505 Phase II Part I clinical trial for the treatment of adult ADHD. On October 24, 2020, a full clinical study
report (CSR) of ABV-1505 Phase II Part I clinical trial was issued. The study results showed that the PDC-1421 Capsule was safe, well
tolerated and efficacious during its treatment and the follow-up period with six adult patients. For the primary endpoints, the percentages
of improvement in ADHD-RS-IV score from baseline to 8 weeks treatment were 83.3% (N=5) in the ITT population and 80.0% (N=4) in the PP
population. Both low and high doses of PDC-1421 Capsule met the primary end points by passing the required 40% population in ADHD-RS-IV
test scores. Overall, the results from this study, which demonstrate the therapeutic value of PDC-1421, support further Phase II Part
II clinical development of ABV-1505 for the treatment of adult ADHD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Phase II Part II study with its
clinical protocol entitled &#8220;A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit
Hyperactivity Disorder (ADHD), Part II&#8221; is a randomized, double-blind, placebo-controlled, parallel three-groups with a maximum
99 subjects to be enrolled. This study was started at five Taiwan medical centers beginning in April 2022. The University of California,
San Francisco site was initiated in the 2<sup>nd</sup> quarter of 2023. The subjects enrolled in the study has reached the number for
interim analysis (69 subjects) in 2023 December, and the interim analysis of the study is now in progress.&#160;&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1601
                                            to treat Depression in Cancer Patients</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We developed a treatment for depression
in cancer patient from the same active pharmaceutical ingredients as ABV-1504. ABV-1601 shares similar pharmaceutical mechanisms of action
as ABV-1504 in that ABV-1601 shows the potential of increasing the level of norepinephrine in the human nervous system by inhibiting
its reabsorption. Due to ABV-1601&#8217;s similarity with ABV-1504, the FDA approved our ABV-1601-001 clinical protocol under the same
IND as for ABV-1504 (IND 112567) in December 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">For the Phase II trial of ABV-1601,
ABVC plans to recruit a maximum number of 54 cancer patients with depression, to whom ABVC intends to administer ABV-1601 oral capsules.
ABVC is engaging the Principal Investigator at Cedars-Sinai Medical Center in the U.S. which designed a randomized, double-blind dose
escalation study with a comparator-controlled group to assess the efficacy and safety profile of ABV-1601, primarily against Montgomery-&#197;sberg
Depression Rating Scale (MADRS) total score. The primary endpoint of the Phase II trial is a change in MADRS, Hospital Anxiety and Depression
Scale (HADS), subscales (HADS-A and HADS-D), and Clinical Global Impression Scale (CGI) total scores from baseline in patients taking
PDC-1421 compared to the comparator. As of the date hereof, the Part I of Phase II clinical protocol, which is an open trial, has been
approved by Cedars-Sinai Medical Center IRB Committee. This study will be initiated around the end of 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>II.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Oncology</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-</span>1702
                                            <span style="text-decoration:underline">to treat </span>Myelodysplastic Syndrome <span style="text-decoration:underline">(&#8220;</span>MDS<span style="text-decoration:underline">&#8221;)</span></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">ABVC started the preparation for ABV-1702&#8217;s
Phase II clinical trials after receiving its IND approval from the FDA in July 2016. ABVC plans to recruit fifty-two subjects in the
United States who are diagnosed with either IPSS int-1, IPSS int-2 or high risk MDS or CMML and may take azacitidine as part of the subjects&#8217;
prescription. Azacitidine is an FDA-approved drug used to treat MDS. ABVC intends to administer ABV-1702 in the oral liquid form along
with azacitidine. The Phase II trial is divided into two parts, where Part 1 is to determine the safety and recommended dose level (&#8220;RDL&#8221;)
of ABV-1702 in combination with azacitidine and Part 2 is to determine whether ABV-1702 under the established RDL reduces bactericidal
and fungicidal infection in the subjects&#8217; respiratory systems. The primary endpoint of Part 1 Phase II trial is to assess the safety
and RDL profile of ABV-1702 administered with azacitidine by measuring ABV-1702&#8217;s prohibited toxicity. The secondary endpoints
of Phase II Part 1 are to determine the safety, time-to-first infection after first dose (Day 1) of the first azacitidine treatment cycle,
reduction in treatment requirements and duration of infections, enhancement of immune responses, improvements of response rates, progression,
and survival rates of the subjects under such ABV-1702 - azacitidine combination treatment. The primary endpoint of Part 2 of Phase II
is to determine whether ABV-1702 under the established RDL reduces bactericidal and fungicidal infection risks in the subjects&#8217;
respiratory systems in combination with azacitidine as compared to the control group with incidence of infections and incidence/frequency
of inpatient hospitalization due to infections. The secondary endpoints of Part 2 of Phase II are to determine the safety, time-to-first
infection after first dose (Day 1) of the first azacitidine treatment cycle, reduction in required dosage and duration of infection,
enhancement of immune responses, improvement of response rate, progression, and survival rates of the subjects under the trial conditions.
In April 2016, BioLite submitted a letter to the FDA in response to its queries with additional information about the proposed Phase
II trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">The Company expects to begin Phase
II clinical trials of ABV-1702 in the fourth quarter of 2025 and is actively looking for qualified principal investigators and an appropriate
site for the study and therefore the timing cannot be guaranteed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-1703
                                            to treat Pancreatic Cancer</span></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">ABVC developed a new indication
for Pancreatic Cancer from Maitake Extract, which is named as ABV-1703 and out licensed it to Rgene for the preparation of its IND application
with the FDA. On August 25, 2017, ABV-1703&#8217;s Phase II trial was approved by FDA. Pursuant to the ABVC-Rgene Co-development Agreement,
ABVC is responsible for coordinating and conducting the clinical trials of ABV-1703 globally and Rgene is responsible for preparing the
related FDA applications. As of the date hereof, we are engaging Cedars-Sinai Medical Center in the U.S. to conduct the Phase II clinical
trial and plan to initiate the Phase II trial in 2025. We plan to submit ABV-1703&#8217;s Phase II clinical trial IND to the Taiwan FDA
after we commence the clinical trials in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-
                                            1501 Triple Negative Breast Cancer - Combination therapy for Triple Negative Breast Cancer
                                            (&#8220;TNBC&#8221;)</span></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-
                                            1501 is developed from BLI-1401-2 whose active pharmaceutical ingredient is Yukiguni Maitake
                                            Extract 404. Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;) conducted the Phase
                                            I clinical trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom), which
                                            is very similar to Yukiguni Maitake Extract 404. The Phase I trial focused on Grifola frondosa
                                            extract&#8217;s immunological effects on breast cancer patients. The results of the Phase
                                            I trial showed that oral administration of a polysaccharide extract from Maitake mushroom
                                            is associated with both immunologically stimulatory and inhibitory measurable effects in
                                            peripheral blood.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ABV-1501 Investigational New Drug (&#8220;IND&#8221;) application to the US FDA for the Phase
                                            II clinical trials referencing the MSKCC maitake research resulted in a Phase II IND approval
                                            in March of 2016 by the U.S. FDA.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            collaboration with BHK to file clinical trial application to the Taiwan FDA (&#8220;TFDA&#8221;)
                                            for conducting this combination therapy trial in Taiwan was temporarily put on hold due to
                                            the lack of funding.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Collaborative Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-1701
                                            Vitreous Substitute for Vitrectomy and Collaboration Agreement with BioFirst</span></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 24, 2017, BriVision, one of
our wholly-owned subsidiaries entered into a collaboration agreement (the &#8220;BioFirst Agreement&#8221;) with BioFirst, pursuant to
which BioFirst granted BriVision the global license to co-develop BFC-1401 Vitreous Substitute for Vitrectomy (&#8220;BFC-1401&#8221;)
for medical purposes. BioFirst is a related party to the Company because BioFirst and YuanGene Corporation (&#8220;YuanGene&#8221;),
the Company&#8217;s controlling shareholder, are under common control, being both controlled by the controlling beneficiary shareholder
of YuanGene.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">According to the BioFirst Agreement,
we are to co-develop and commercialize BFC-1401 or ABV-1701 with BioFirst and are obligated to pay BioFirst $3,000,000 (the &#8220;Total
Payment&#8221;) in cash or common stock of BriVision on or before September 30, 2018 in two installments. An upfront payment of $300,000,
representing 10% of the Total Payment due under the Collaboration Agreement, was to be paid upon execution of the BioFirst Agreement.
BriVision is entitled to receive 50% of the future net licensing income or net sales profit when ABV-1701 is sublicensed or commercialized.
On June 30, 2019, the Company and BioFirst entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to
which the Company will issue 428,571 shares of the Company&#8217;s common stock to BioFirst in consideration for $3,000,000 owed by the
Company to BioFirst in connection with the BioFirst Collaborative Agreement. For more information about the BioFirst Agreement and Purchase
Agreement, please refer to the current reports on Form 8-K filed on July 24, 2017 and July 12, 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On November 7, 2016, the application
of Phase I clinical trial prepared and submitted by BioFirst was approved by the Human Research Ethics Committee, Australia (&#8220;HREC&#8221;),
and on November 14, 2016, it was approved by the Therapeutic Goods Administration, Australia (&#8220;TGA&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We successfully finished the Phase
I clinical trial of ABV-1701 at Sydney Retina Clinic and Day Surgery, a clinic located in Sydney, Australia. This was the only site for
this Phase I clinical trial. The trial started on November 17, 2016, and was completed with positive results in July 2018. The Protocol
Title is &#8220;A Phase I, single center, safety and tolerability study of Vitargus in the treatment of Retinal Detachment.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The primary endpoint of this Phase
I clinical trial was to evaluate the safety and tolerability of a single intravitreal dose of Vitargus in patients as a vitreous substitute
during vitrectomy surgery for retinal detachment. Intravitreal is a route of administration of a drug or other substance, in which the
substance is delivered into the eyes. The secondary endpoint of this Phase I clinical trial is to assess retinal attachment and Virtagus
degradation at day 90 and to assess best corrected visual acuity (&#8220;BVCA&#8221;) after vitrectomy surgery. BVCA refers to the best
possible vision a person can achieve. The primary and second endpoints are required by HREC for the purpose of evaluation of our Phase
I clinical trial application. We enrolled an aggregate number of 10 patient subjects in this trial. On November 17, 2016, we received
the approval from the Data and Safety Monitoring Board for the first subject, and nine more subjects were enrolled thereafter. In this
trial, Vitargus was injected into the vitreous cavity of vitrectomised eyes, whose vitreous gel was removed from the vitreous cavity
after a vitrectomy surgery. On August 24, 2020, a full clinical study report (CSR) of ABV-1701 Phase I clinical trial was issued. The
study results showed that ABV-1701 (Vitargus) was well-tolerated as a vitreous substitute without any apparent toxicity to ocular tissues.
Further, there was no indication of an increased overall safety risk with Vitargus. For efficacy, participants showed significant improvement
in visual acuity. The optical properties of Vitargus allowed the patients to see well and facilitated visualisation of the fundus immediately
following surgery. In addition, since Vitargus set as a stable semisolid gel adhering to the retina, it maintained its position without
requiring the patient to remain face-down following surgery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">ABV-1701, Vitargus&#174; in vitrectomy
surgery, Phase II Study was started in the 2nd quarter of 2023. Four (4) study sites in Australia and Thailand join this multi-nation
and multi-site clinical study. The company is working on improvements to the Vitargus Product through the new batch of investigational
product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>II.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Co-development
                                            Agreement with Rgene</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On May 26, 2017, American BriVision
Corporation entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;),
a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company. Pursuant to Co-Dev
Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-17
Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is
required to pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation
of BriVision&#8217;s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not
relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to the $3,000,000, the Company is
entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall
be equally shared by both BriVision and Rgene.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">By June 1, 2017, the Company had delivered
all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. During the year ended
December 31, 2017, the Company received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000
in the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share),
for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the
year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully
write off this investment based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and
quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic
environment, changes in operating structure of Rgene, additional funding requirements, and Rgene&#8217;s ability to remain in business.
All projects that have been initiated will be managed and supported by the Company and Rgene.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company and Rgene signed an amendment
to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer
Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination
Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized.
Other provisions of the Co-Dev Agreement remain in full force and effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>III.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical Development
    Service Agreement with Rgene</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On June 10, 2022, the Company expanded
its co-development partnership with Rgene. BioKey entered into a Clinical Development Service Agreement with Rgene (&#8220;Service Agreement&#8221;)
to guide certain Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of
pancreatic cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under
U.S. FDA IND regulatory requirements (the &#8220;Rgene Studies&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Under the terms of the Service Agreement,
BioKey is eligible to receive payments totaling up to $3.0 million over a 3-year period with each payment amount to be determined by
certain regulatory milestones obtained during the agreement period. Through a series of transactions over the past 5 years, the Company
and Rgene have co-developed the three drug products covered by the Service Agreement, which has resulted in the Company owning 31.62%
of Rgene.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As part of the Rgene Studies, the
Company agreed to loan $1.0 million to Rgene, for which Rgene has provided the Company with a 5% working capital convertible loan (the
&#8220;Note&#8221;). If the Note is fully converted, the Company will own an additional 6.4% of Rgene. The Company is expected to receive
the outstanding loan from the related party by the 2023 Q1, either by cash or conversion of shares of Rgene. The Company may convert
the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii)
20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as
set forth in the Note. The Service Agreement shall remain in effect until the expiration date of the last patent and automatically renew
for 5 more years unless terminated earlier by either party with six months written notice. Either party may terminate the Service Agreement
for cause by providing 30 days written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Rgene has further agreed, effective
July 1, 2022, to provide the Company with a seat on Rgene&#8217;s Board of Directors until the loan is repaid in full. The Company has
nominated Dr. Jiang, its Chief Strategy Officer and Director to occupy that seat; Dr. Jiang is also one of the Company&#8217;s largest
shareholders, owning 12.8% of the Company. For more information about the Service Agreement and Note, please refer to the current reports
on Form 8-K filed on June 21, 2022.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">BLEX 404, a new drug under clinical
development covered by the Service Agreement, is extracted from Maitake mushroom (Grifola frondosa), an edible mushroom. Its immunological
effects and the safety have been demonstrated in two Phase I/II clinical studies performed at Memorial Sloan Kettering Cancer Center
(MSKCC) with breast cancer and myelodysplastic syndromes (MDS) patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Market Distribution Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We focus primarily on developing botanical drugs,
which are intended for use in the diagnosis, cure, mitigation or treatment of disease in humans. Together with our strategic partners,
we plan to market, distribute and sell our drug products internationally once those drug candidates comply with the local authorities
regulating drugs and foods. Currently, many countries follow the International Council for Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (the &#8220;ICH&#8221;) guidelines that are published by European Medicines to provide
guidance on quality and safety of pharmaceutical development and new drug commercialization in Japan, the United States and Europe. All
of our drug candidates first go through the United States FDA process for new drug development first and then seek regulatory approval
from regulators equivalent to the FDA in the jurisdictions where we plan to distribute those candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The new drug candidates are dependent on or are the subject of the
following patents and patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 5%; vertical-align: bottom"><span style="font-size: 10pt"><b>No.</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 6%; vertical-align: bottom"><span style="font-size: 10pt"><b>Status</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 12%; vertical-align: bottom"><span style="font-size: 10pt"><b>Patent
    No.</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 12%; vertical-align: bottom"><span style="font-size: 10pt"><b>Patent<br/>
    Starting <br/>
    Date</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 12%; vertical-align: bottom"><span style="font-size: 10pt"><b>Patent<br/>
    Expiration<br/>
    Date</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 25%; vertical-align: bottom"><span style="font-size: 10pt"><b>Patent
    Name</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 12%; vertical-align: bottom"><span style="font-size: 10pt"><b>Territory</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%; vertical-align: bottom"><span style="font-size: 10pt"><b>Patent<br/>
    Owner<sup>(1)(2)</sup></b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">1</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">DE202007003503 U1</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8/23/2007</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">9/20/2026</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Novel Polygalatenosides and use thereof as an
    antidepressant agent</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Germany</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">MPITDC</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">7531519</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">5/12/2009</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">9/20/2026</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Novel Polygalatenosides and use thereof as an
    antidepressant agent</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">The U.S.</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">MPITDC</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">3</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">4620652</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">11/20/2006</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">11/19/2026</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Novel Polygalatenosides and use thereof as an
    antidepressant agent</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Japan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">MPITDC</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">4</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">I 314453</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">9/21/2006</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">9/20/2026</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Novel Polygalatenosides and use thereof as an
    antidepressant agent</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Taiwan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">MPITDC</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">5</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">I389713</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">3/21/2013</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10/13/2030</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute <b><sup>(3)</sup></b></span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Taiwan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">6</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">US 8197849 B2</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">6/12/2012</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8/30/2030</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">The U.S.</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">7</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">AU 2011/215775 B2</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">4/17/2014</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2/9/2031</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Australia</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">KR 10-1428898</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8/4/2014</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2/9/2031</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Korea</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">9</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">CA 2786911 (C)</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10/6/2015</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2/10/2031</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Canada</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">WO2011100469 A1</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">N/A<sup>(4)</sup></span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">N/A<sup>(4)</sup></span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">PCT</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">11</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">EP 2534200</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">4/8/2015</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2/9/2031</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">European Union (Germany, United Kingdom, France,
    Switzerland, Spain, Italy)</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">12</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true"><span style="font-family: Times New Roman, Times, Serif">&#29305;&#35377;&#31532;</span>
    5885349<span style="font-family: Times New Roman, Times, Serif">&#34399;<br/>
    </span>(P5885349)</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2/9/2011</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2/9/2031</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Japan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">13</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">ZL 201180005494.7</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">12/24/2014</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2/9/2031</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute<b><sup>(3)</sup></b></span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">14</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">HK1178188</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">3/6/2015</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">6/21/2030</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use
    as a vitreous substitute<b><sup>(3)</sup></b></span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Hong Kong <sup>(5)</sup></span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">15</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">US 16/936,032</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">9/4/2020</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">9/4/2040</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala extract for the treatment of major
    depressive disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">BioLite</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">16</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">TW I821593</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">11/1/2023</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">7/22/2040</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala extract for the treatment of major
    depressive disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Taiwan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">BioLite</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">17</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">US17/120,965</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">12/20/2020</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">12/20/2040</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Attention
    Deficit Hyperactive Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">U.S.</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">BioLite</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">18</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">TW 110106546</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2/24/2021</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2/24/2041</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Attention
    Deficit Hyperactive Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Taiwan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">BioLite</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">19</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">TW I792427</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">02/11/2023</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">07/19/2041</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Storage Media For Preservation of Corneal Tissue</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Taiwan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">NHRI</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top; width: 5%"><span style="font-size: 10pt">20</span></td>
    <td style="text-align: center; vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 6%"><span style="font-size: 10pt">granted</span></td>
    <td style="text-align: center; vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 12%"><span style="font-size: 10pt">AU2021314052B2</span></td>
    <td style="text-align: center; vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 12%"><span style="font-size: 10pt">04/09/2024</span></td>
    <td style="text-align: center; vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 12%"><span style="font-size: 10pt">04/09/2041</span></td>
    <td style="text-align: center; vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 25%"><span style="font-size: 10pt">Polygala Extract for the Treatment
    of Major Depressive Disorder</span></td>
    <td style="text-align: center; vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 12%"><span style="font-size: 10pt">Australia</span></td>
    <td style="text-align: center; vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 9%"><span style="font-size: 10pt">BioLite</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">21</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">applied</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">202180001626. 2</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Major
    Depressive Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">22</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">applied</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#29305;&#39000;
    </span><span style="font-size: 10pt">2023502736</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Major
    Depressive Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Japan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">23</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">applied</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">21 846 424.6</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Major
    Depressive Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Europe</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">24</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">applied</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">110106546</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Attention-Deficient
    and Hyperactivity Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Taiwan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">25</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">applied</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">202180001615. 4</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Attention-Deficient
    and Hyperactivity Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">26</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">applied</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#29305;&#39000;
    </span><span style="font-size: 10pt">2023536203</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Attention-Deficient
    and Hyperactivity Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Japan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">27</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">applied</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">21 907 345.9</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Attention-Deficient
    and Hyperactivity Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Europe</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">28</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">applied</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">2021403197</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Polygala Extract for the Treatment of Attention-Deficient
    and Hyperactivity Disorder</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Australia</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;MPITDC&#8221;
    stands for Medical and Pharmaceutical Industry Technology and Development Center, Taiwan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NHRI&#8221;
    stands for National Health Research Institutes, Taiwan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patent
    name is translated into English and the original patent name is written as &#8220;&#20132;&#32852;&#27687;&#21270;&#36879;&#26126;&#36136;&#37240;&#20316;&#20026;&#30524;&#29699;&#29627;&#29827;&#20307;&#20043;&#26367;&#20195;&#29289;.&#8221;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The starting
    date and expiration date of patents under PTC are subject to the laws of the specific participating jurisdiction where the patent
    application is filed. We have subsequently submitted such patent to the jurisdictions listed in No.22 herein above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI has obtained
    standard patent in Hong Kong based on the registration of the patent (listed as No.24 herein) granted by the State Intellectual Property
    Office, People&#8217;s Republic of China.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate History and Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ABVC was incorporated under the laws of the
State of Nevada on February 6, 2002 and has four wholly-owned Subsidiaries: BriVision, BioLite Holding, Inc., BioKey Cayman, and BioKey,
Inc. BriVision was incorporated in July 2015 in the State of Delaware and is in the business of developing pharmaceutical products in
North America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite Holding was incorporated under the laws
of the State of Nevada on July 27, 2016, with 500,000,000 shares authorized, par value $0.0001. Its key Subsidiaries include BioLite
BVI, Inc. (&#8220;BioLite BVI&#8221;) that was incorporated in the British Virgin Islands on September 13, 2016 and BioLite Inc. (&#8220;BioLite
Taiwan&#8221;), a Taiwanese corporation that was founded in February 2006. BioLite Taiwan has been in the business of developing new
drugs for over twelve years. Certain shareholders of BioLite Taiwan exchanged approximately 73% of equity securities in BioLite Taiwan
for the Common Stock in BioLite Holding in accordance with a share purchase/ exchange agreement (the &#8220;Share Purchase/ Exchange
Agreement&#8221;). As a result, BioLite Holding owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who
did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Yunzhiyi, a Taiwan corporation, was incorporated
in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, one of the Company&#8217;s director. This entity is
set up for holding the land in Taiwan that AiBtl is in the process of acquiring, which land will be used for developing health related
business. As of the date hereof, the transfer of the land&#8217;s title is currently under government review, pending completion of the
title transfer registration. Due to Taiwan&#8217;s legal restrictions prohibiting foreign entities from directly owning farmland, the
parties agreed to structure the arrangement through nominee holdings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Incorporated in California on November 20, 2000,
BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon closing of the Mergers on February 8, 2019,
BioLite and BioKey became two wholly-owned subsidiaries of ABVC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioKey Cayman was incorporated in Cayman Islands
in July 2023, which is 100% owned by ABVC. This subsidiary has no activities since inception.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="-keep: true">In November 2023, the Company and one of its
subsidiaries, BioLite, Inc. (&#8220;BioLite&#8221;) each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc.
(&#8220;AiBtl&#8221;, or &#8220;AiBtl&#8221;) for the Company and BioLite&#8217;s CNS drugs with the indications of MDD (Major Depressive
Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the &#8220;Licensed Products&#8221;). The license covers the Licensed
Products&#8217; clinical trial, registration, manufacturing, supply, and distribution rights. The parties are determined to collaborate
on the global development of the Licensed Products. The parties are also working to strengthen new drug development and business collaboration,
including technology, interoperability, and standards development. As per each of the respective agreements, each of ABVC and BioLite
received 23 million shares of AiBtl stock at $10 per share, and if certain milestones are met, each may receive $3,500,000 and royalties
equaling 5% of net sales, up to $100 million. Upon the issuance of the shares, AiBtl became a subsidiary of ABVC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following chart illustrates the corporate structure of ABVC:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 5, 2022, the Company&#8217;s
Board for Directors approved amending the Company&#8217;s Bylaws to remove Section 2.8, which permitted cumulative voting for directors
since cumulative voting is specifically prohibited by our Articles of Incorporation. Since it is not otherwise stated in our Articles
of Incorporation or Bylaws, directors shall be elected by a plurality of the votes cast at the election, as provided in the Nevada Revised
Statutes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 14, 2024, the Company&#8217;s
Board for Directors approved amending the Company&#8217;s Bylaws to amend Section 2.8 of the Company&#8217;s Bylaws to revise the number
of shares needed to establish a quorum at shareholder meetings. The Amendment changes the quorum requirement from a majority to 33-1/3%
of the votes entitled to be cast on a matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The healthcare industry is highly competitive
and subject to significant and rapid technological change as researchers learn more about diseases and develop new technologies and treatments.
Significant competitive factors in our industry include product efficacy and safety; quality and breadth of an organization&#8217;s technology;
skill of an organization&#8217;s employees and its ability to recruit and retain key employees; timing and scope of regulatory approvals;
the average selling price of products; the availability of raw materials and qualified manufacturing capacity; manufacturing costs; intellectual
property and patent rights and their protection; and our capabilities of securing competent collaborators. Market acceptance of our current
products and product candidates will depend on a number of factors, including: (i) potential advantages over existing or alternative
therapies or tests, (ii) the actual or perceived safety of similar classes of products, (iii) the effectiveness of sales, marketing,
and distribution capabilities, and (iv) the scope of any approval provided by the FDA or foreign regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since we are a small biopharmaceutical company
compared to other companies that we may compete against, it is our intention to license our products to much larger pharmaceutical, specialty
pharmaceutical and generic drug companies with the financial, technical and human resources to compete effectively in the markets we
address.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that our license partners will
face intense and increasing competition when and as our new drug candidates enter the markets, as advanced technologies become available
and as generic forms of currently branded products become available. Finally, the development of new treatment methods for the diseases
we are targeting could render our products non-competitive or obsolete. There can be no assurance that any of our new drug candidates
will be clinically superior or scientifically preferable to products developed or introduced by our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following chart lists some, not all, of the
biopharmaceutical companies that research, develop, commercialize, distribute or sell drugs that are in competition with our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: black 1.5pt solid; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disease</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 29%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Drug
    Name</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pharmaceutical
    <br/>
    Companies</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Headquarters</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major
    Depressive Disorder</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cymbalta oral</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eli Lilly and Co., Inc.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lexapro oral</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forest Laboratories, Inc.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NJ</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pfizer Pharmaceuticals, Inc.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CT</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attention-Deficit</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adderall XR</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shire Development LLC</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MA</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hyperactivity
    Disease</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritalin</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novartis Pharmaceuticals Corporation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NJ</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dexedrine</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amedra Pharmaceuticals LLC</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PA</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Myelodysplastic</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vidaza</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celgene Corporation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NJ</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Syndromes</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dacogen</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Astex Pharmaceuticals, Inc.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Triple
    Negative Breast Cancer</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avastin</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genentech, Inc.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erbitux (Cetuximab)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ImClone Systems Incorporated</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NY</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pancreatic
    Cancer</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abraxane, Abraxis BioScience LLC</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los Angeles</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novartis Pharma Stein AG</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stein</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Switzerland</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vitargus
    for the treatments</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alcon Laboratories, Inc.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fort Worth</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TX</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: -0.25in"><b>of
                                            Retinal Detachment or Vitreous Hemorrhage</b></p></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arcadophta</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toulouse</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Government Regulations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, we are focusing on the research and
development of six therapeutic candidates in the fields of CNS, oncology/hematology and autoimmune, for which regulatory approval must
be received before we can commence marketing. In addition, our cGMP facility is subject to review by the FDA. Regulatory approval processes
and FDA regulations for ABVC&#8217;s current and any future product candidates are discussed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Approval Process for Pharmaceutical Products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>FDA Approval Process for Pharmaceutical Products</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S., pharmaceutical products are subject
to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act (the &#8220;FDC Act&#8221;), and other federal and state
statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval,
labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical
products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions,
such as FDA refusal to approve pending NDAs, warning letters, product recalls, product seizures, total or partial suspension of production
or distribution, injunctions, fines, civil penalties, and criminal prosecution. Pharmaceutical product development in the U.S. typically
involves the performance of satisfactory nonclinical, also referred to as pre-clinical, laboratory and animal studies under the FDA&#8217;s
Good Laboratory Practice, or GLP, regulation, the development and demonstration of manufacturing processes, which conform to FDA mandated
current good manufacturing requirements, or cGMPs, including a quality system regulating manufacturing, the submission and acceptance
of an IND application, which must become effective before human clinical trials may begin in the U.S., obtaining the approval of Institutional
Review Boards, or IRBs, at each site where we plan to conduct a clinical trial to protect the welfare and rights of human subjects in
clinical trials, adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication
for which FDA approval is sought, and the submission to the FDA for review and approval of an NDA. Satisfaction of FDA requirements typically
takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-clinical tests generally include laboratory
evaluation of a product candidate, its chemistry, formulation, stability and toxicity, as well as certain animal studies to assess its
potential safety and efficacy. Results of these pre-clinical tests, together with chemistry, manufacturing controls and analytical data
and the clinical trial protocol, which details the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated, along with other requirements must be submitted to the FDA as part of an IND, which must become effective before
human clinical trials can begin. The entire clinical trial and its protocol must be in compliance with what are referred to as good clinical
practice, or GCP, requirements. The term, GCP, is used to refer to various FDA laws and regulations, as well as international scientific
standards intended to protect the rights, health and safety of patients, define the roles of clinical trial sponsors and assure the integrity
of clinical trial data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An IND automatically becomes effective 30 days
after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the intended conduct of the
trials and imposes what is referred to as a clinical hold. Pre-clinical studies generally take several years to complete, and there is
no guarantee that an IND based on those studies will become effective, allowing clinical testing to begin. In addition to FDA review
of an IND, each medical site that desires to participate in a proposed clinical trial must have the protocol reviewed and approved by
an independent IRB or Ethics Committee, or EC. The IRB considers, among other things, ethical factors, and the selection and safety of
human subjects. Clinical trials must be conducted in accordance with the FDA&#8217;s GCP requirements. The FDA and/or IRB may order the
temporary, or permanent, discontinuation of a clinical trial or that a specific clinical trial site be halted at any time, or impose
other sanctions for failure to comply with requirements under the appropriate entity jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials to support NDAs for marketing
approval are typically conducted in three sequential phases, but the phases may overlap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In Phase I clinical trials, a product candidate
is typically introduced either into healthy human subjects or patients with the medical condition for which the new drug is intended
to be used. The main purpose of the trial is to assess a product candidate&#8217;s safety and the ability of the human body to tolerate
the product candidate. Phase I clinical trials generally include less than 50 subjects or patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During Phase 2 trials, a product candidate is
studied in an exploratory trial or trials in a limited number of patients with the disease or medical condition for which it is intended
to be used in order to: (i) further identify any possible adverse side effects and safety risks, (ii) assess the preliminary or potential
efficacy of the product candidate for specific target diseases or medical conditions, and (iii) assess dosage tolerance and determine
the optimal dose for Phase III trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase III trials are generally undertaken to
demonstrate clinical efficacy and to further test for safety in an expanded patient population with the goal of evaluating the overall
risk-benefit relationship of the product candidate. Phase III trials are generally designed to reach a specific goal or endpoint, the
achievement of which is intended to demonstrate the candidate product&#8217;s clinical efficacy and adequate information for labeling
of the approved drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has 60 days from its receipt of an
NDA to determine whether the application will be accepted for filing based on the FDA&#8217;s threshold determination that it is
sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review.
The FDA has agreed to certain performance goals in the review of NDAs. Most applications for standard review drug products are
reviewed within ten months; most applications for priority review drugs are reviewed within six months. Priority review can be
applied to drugs that the FDA determines offer major advances in treatment, or provide a treatment where no adequate therapy exists.
The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain
late-submitted information, or information intended to clarify information already provided in the submission. The FDA may also
refer applications for novel drug products, or drug products which present difficult questions of safety or efficacy, to an advisory
committee - typically a panel that includes clinicians and other experts  - for review, evaluation, and a recommendation as to
whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally
follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure
compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA
will not approve the product unless compliance with cGMPs is satisfactory and the NDA contains data that provide substantial
evidence that the drug is safe and effective in the indication studied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the FDA evaluates the NDA and the manufacturing
facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies
in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If
and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval
letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition
of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug
outweigh the potential risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">REMS can include medication guides, communication
plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training
or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient
registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval
may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product
approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Post-Approval Regulations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if a product candidate receives regulatory
approval, the approval is typically limited to specific clinical indications. Further, even after regulatory approval is obtained, subsequent
discovery of previously unknown problems with a product may result in restrictions on its use or even complete withdrawal of the product
from the market. Any FDA-approved products manufactured or distributed by us are subject to continuing regulation by the FDA, including
record-keeping requirements and reporting of adverse events or experiences. Further, drug manufacturers and their subcontractors are
required to register their establishments with the FDA and state agencies, and are subject to periodic inspections by the FDA and state
agencies for compliance with cGMPs, which impose rigorous procedural and documentation requirements upon us and our contract manufacturers.
ABVC cannot be certain that ABVC or its present or future contract manufacturers or suppliers will be able to comply with cGMPs regulations
and other FDA regulatory requirements. Failure to comply with these requirements may result in, among other things, total or partial
suspension of production activities, failure of the FDA to grant approval for marketing, and withdrawal, suspension, or revocation of
marketing approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA approves one or more of our product
candidates, ABVC must provide certain updated safety and efficacy information. Product changes, as well as certain changes in the manufacturing
process or facilities where the manufacturing occurs or other post-approval changes may necessitate additional FDA review and approval.
The labeling, advertising, promotion, marketing and distribution of a drug must be in compliance with FDA and Federal Trade Commission,
or FTC, requirements which include, among others, standards and regulations for direct-to-consumer advertising, off-label promotion,
industry sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA and FTC have very
broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter
directing us to correct deviations from regulatory standards and enforcement actions that can include seizures, fines, injunctions and
criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Foreign Regulatory Approval</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside of the U.S., ABVC&#8217;s ability to
market our product candidates will be contingent also upon its receiving marketing authorizations from the appropriate foreign regulatory
authorities, whether or not FDA approval has been obtained. The foreign regulatory approval process in most industrialized countries
generally encompasses risks similar to those ABVC will encounter in the FDA approval process. The requirements governing conduct of clinical
trials and marketing authorizations, and the time required to obtain requisite approvals, may vary widely from country to country and
differ from those required for FDA approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC will be subject to additional regulations
in other countries in which we market, sell and import our products, including Canada. ABVC or its distributors must receive all necessary
approvals or clearance prior to marketing and/or importing our products in those markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other Regulatory Matters</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturing, sales, promotion and other activities
following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the
U.S., the Centers for Medicare &amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement
Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp;Health Administration,
the Environmental Protection Agency and state and local governments. In the U.S., sales, marketing and scientific/educational programs
must also comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements
of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Health Care Reform Law, as amended by the Health
Care and Education Affordability Reconciliation Act, or ACA. If products are made available to authorized users of the Federal Supply
Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must
comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant
packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also
potentially subject to federal and state consumer protection and unfair competition laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The distribution of pharmaceutical products is
subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended
to prevent the unauthorized sale of pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The failure to comply with regulatory requirements
subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements
can result in criminal prosecution, fines, imprisonment or other penalties, injunctions, recall or seizure of products, total or partial
suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including
government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or effectiveness
of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future
products marketed by us could materially affect our business in an adverse way.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes in regulations, statutes or the interpretation
of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements;
(ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping
requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 31, 2025, we, including
the subsidiaries, have 19 employees, 16 of which are full-time, located in the U.S. and Taiwan.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Functional Area</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Employees</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Senior management</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Administration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Accounting</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">23</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC believes that it maintains a good working
relationship with its employees. ABVC offers its employees competitive benefits, including a pleasant and rewarding work environment,
career-oriented training, and career growth opportunities. ABVC believes its employees are devoted to delivering superb services. ABVC
did not experience any significant labor disputes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time ABVC and its Subsidiaries may
become involved in legal proceedings and claims, or be threatened with other legal actions and claims, arising in the ordinary course
of business relating to its intellectual property, product liability, regulatory compliance and/or marketing and advertising of its products.
As of the date of this prospectus, ABVC and its Subsidiaries were not involved or threatened with any legal actions and regulatory proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Environment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC seeks to comply with all applicable statutory
and administrative requirements concerning environmental quality. Expenditures for compliance with federal state and local environmental
laws have not had, and are not expected to have, a material effect on ABVC&#8217;s capital expenditures, results of operations or competitive
position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Properties </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Our Subsidiary BioLite has its laboratories
located in Hsinchu Biomedical Science Park, with an address of 2nd Floor, No. 20, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County 302,
Taiwan (R.O.C.). On January 1, 2015, BioLite Taiwan entered into a lease agreement with the National Science Park Administrative Office
(Hsinchu City) under which it rents two dormitory buildings in Hsinchu County, Taiwan for a period of five years. The aggregate leasing
area amounts to approximately 678 square meters (equivalent to approximately 7,298 square feet) on the second floor of the building.
The leased space counts for approximately 1.9% of the total space of the building. On January 1, 2020 and January 1, 2024, BioLite Taiwan
extended the contract for another five and five years respectively. The new expiration date is on December 31, 2029. The rent increases
by a small percentage each year during the term of the lease agreement. BioLite paid $48,406 and $50,572 in rental expense for the laboratory
space for the years ended December 31, 2024 and 2023, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Another subsidiary BioKey is headquartered
in Fremont, California. BioKey&#8217;s office lease will end on February 28, 2026 and the office occupies approximately 28,186 square
feet. BioKey&#8217;s space consists of offices, research and production laboratories, and manufacturing facilities, which are GMP certified.
BioKey has an option to extend the lease for its offices in Fremont for a period of five years commencing February 28, 2026, and BioKey
may exercise this option for 5 more years. The total BioKey&#8217;s rental expenses were $421,894 and $353,466 for the years ended December
31, 2024 and 2023, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MANAGEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth as of the date
of this prospectus, the name, age, and position of each executive officer and director and the term of office of each such person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 30%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 7%"><span style="font-size: 10pt"><b>Age&#160;</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 61%"><span style="font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Eugene Jiang</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">38</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Chairman of the Board and Chief Business Officer (&#8220;CBO&#8221;)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Dr. Uttam Patil</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">39</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer (&#8220;CEO&#8221;), Interim CFO</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Dr. Tsung-Shann (T.S.) Jiang</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">71</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Chief Scientific Officer (&#8220;CSO&#8221;), Chief Strategy Officer (&#8220;CSTRO&#8221;) and
    Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Dr. Tsang Ming Jiang</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">64</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Dr. Chang-Jen Jiang</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">69</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Norimi Sakamoto</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">54</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Yen-Hsin Chou</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">36</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Hsin-Hui Miao</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">59</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Yoshinobu Odaira</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">77</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Che-Wei Hsu </span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">43</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Independent Director </span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Shuling Jiang </span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">69</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Director </span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Yu-Min (Francis) Chung </span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">60</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Independent Director </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below is certain biographical information
regarding each of our directors and executive officers as of the date of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Eugene Jiang, Chairman,</b> served as our
CEO and President from the Company&#8217;s inception in July 2015 until he resigned on September 15, 2017. He remains the Chairman of
the Board. He also serves as our CBO since September 2019 and serves as the CBO of BioKey, Inc. Since March 13, 2025, Eugene Jiang was
appointed as AiBtl&#8217;s Chief Financial Officer. Since 2019. Mr. Jiang also serves as Director for BioLite Incorporation since June
2015 and as Director for BioFirst Corp. since 2012. He also serves as CEO for Genepro Investment Company since March 2010. Mr. Jiang
obtained a PMBA degree from National Taiwan University in 2017 and an EMBA degree from the University of Texas in Arrington in 2010.
And in 2009, Mr. Jiang received a bachelor&#8217;s degree in Physical Education from Fu-Jen Catholic University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Dr. Uttam Patil, CEO,</b> was appointed
as the Company&#8217;s Chief Executive Officer on June 21, 2023; he now serves as interim CFO too. Since March 13, 2025, Dr. Patil was
also appointed as AiBtl&#8217;s co-CEO. Dr. Patil has served as the Chief Operating and Scientific Officer of the Company&#8217;s subsidiary,
BioKey, Inc. since May 2023; he also works for Rgene Corporation (a related party), as the R&amp;D Manager since May 2023, after being
promoted from Project Manager, to which he serves from August 2022 to May 2023. Prior to that, Dr. Patil was a Post-Doctoral Research
Fellow at NTNU from March 2020 to July 2022. In 2019, Dr. Patil received the &#8220;Platinum Award&#8221; for an Oral Presentation on
the topic, &#8220;Nucleobase Functionalized Single-Walled Carbon Nanotubes Hybridization with Single-Stranded DNA&#8221; at a Workshop
on Organic Chemistry for Junior Chemists held in South Korea. Dr. Patil received his Ph.D. in Chemistry from National Tsing Hua University
and a Masters in Analytical Chemistry from Pune University, as well as a Bachelors in industrial chemistry from Pune University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Dr. T.S. Jiang, Chief Strategy Officer
and Director,</b> has served as the Company&#8217;s Chief Strategy Officer since September 2019. Since March 13, 2025, Dr. Jiang was
also appointed as AiBtl&#8217;s Chief Strategy Officer. Dr. Jiang serves as the CEO of Biokey, Inc. since December 2021, as a director
of BioFirst Corp. since 2013, and has been the CEO and chairman of BioLite, Inc., a subsidiary of BioLite BVI, Inc., since January 2010.
Prior to BioLite, Dr. Jiang served as the president and/or chairman of multiple biotech companies in Taiwan, including PhytoHealth Corporation
from 1998 to 2009 and AmCad BioMed Corporation from 2008 to 2009. In addition, Dr. Jiang is a director on various biotech associations,
such as the Taiwan Bio Industry Organization (Taiwan) from 2006 to 2008 and the Chinese Herbs and Biotech Development Association in
Taiwan from 2003 to 2006. Dr. Jiang was an assistant professor at University of Illinois from 1981 to 1987 and an associate professor
at Rutgers, the State University of New Jersey from 1987 to 1990 and served as a professor at a few Taiwanese universities during a period
from 1990 to 1993, such as National Taiwan University, National Cheng Kung University and Tunghai University. Dr. Jiang obtained his
bachelor degree in Engineering and Chemical Engineering from National Taiwan University in Taiwan in 1976, masters and Ph.D. from Northwestern
University in the U.S. in 1981 and Executive Master of Business Administration (&#8220;EMBA&#8221;) from National Taiwan University in
Taiwan in 2007. As a successful entrepreneur, Dr. Jiang has developed and commercialized PG2 Lyo Injection, a new drug to treat cancer
related fatigue. From 1998 to 2009, Dr. T. S. Jiang served as President of Phyto Health Corporation where he led a project team to develop
PG2 Injectable. This product was extracted, isolated and purified from a type of Traditional Chinese Medicine. PG2 Injection was intended
for cancer patients who had trouble recovering from severe fatigue. Dr. Jiang oversaw and managed the R&amp;D department, daily corporate
operations and business of Phyto Health Corporation when he was the President. PG2 Lyo Injection received approval on its NDA from Taiwan
Food and Drug Administration in 2010 and later was launched into the Taiwan market in 2012. We believe that Dr. Jiang provides leadership
and technological guidance on our strategic development and operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dr. Tsang Ming Jiang, Director</b>, has served
as a director of BioFirst Corp. since 2017 and as a technical director at Supermicro Computer, Inc. since August 2022. Dr. Jiang served
as a technical director at the Industrial Technology Research Institute in Taiwan from February 2017 to July 2021. Prior to joining the
Industrial Technology Research Institute as a technical director, Dr. Jiang worked at the Company as chief information officer from November
2016 to January 2017, Ericsson as engineering manager from 2013 to 2016 and the Industrial Technology Research Institute as deputy director
from October 2011 to February 2013. In addition, Dr. Jiang worked at several other research institutes, including University of Alaska
Fairbanks, National Taiwan University and Chung Cheng University, with his research interest in cloud computing and Internet security,
especially in the areas of virtualization, software-defined data centers, SDN enabled networks and big data analytics. Dr. Jiang received
his Bachelor of Science in electrical engineering in 1983 and Master of Science in electrical engineering in 1984, both from National
Taiwan University, and his Ph.D. in electrical engineering and computer science from University of Illinois at Chicago in 1988. Dr. Tsang
Ming Jiang is a brother of Dr. Tsung-Shann Jiang, who together with his wife collectively owns 80% of Lion Arts Promotion, Inc. which
has approximately 69.3% of ownership interest in the Company through YuanGene Corporation, a wholly-owned subsidiary of Lion Arts Promotion,
Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dr. Chang-Jen Jiang, Director,</b> has served
as a director of BioLite Inc. since 2013 and as a director of BioFirst Corp. since 2015. Dr. Jiang has been a pediatrician at the department
of pediatrics of Eugene Women and Children Clinic since 2016. Previously, Dr. Chang-Jen worked as an attending doctor at the department
of pediatrics of Keelung Hospital, the Ministry of Health and Welfare in Taiwan from 1994 to 2009. Before his position at Keelung Hospital,
he was a chief doctor at the department of pediatrics, hematology and oncology of Mackay Memorial Hospital in Taiwan for three years
until 1994. Dr. Chang-Jen Jiang obtained his doctor of medicine degree (the Taiwanese equivalent degree of MD) from Taipei Medical University
in Taiwan in 1982 and started his career in Mackay Memorial Hospital. We believe that the Company will benefit from Dr. Jiang&#8217;s
knowledge in biology and experiences in medical practice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Norimi Sakamoto, Director</b>, currently serves
a director at Shogun Maitake Canada Co., Ltd. from June 2016. Ms. Sakamoto served as the chief executive officer of MyLife Co., Ltd.
from June 2013 to March 2020. Ms. Sakamoto started her career in 1997 from Sumitomo Corporation Hokkaido Co., Ltd. in Japan. Ms. Sakamoto
received her Bachelor Degree of Arts in travel and tourism from Davis and Elkins College in 1993 and Master of Science in urban studies
from the University of New Orleans in 1995.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yen-Hsin Chou, Director</b>, has served as
a financial specialist at Mega Bank since 2011. Ms. Chou&#8217;s responsibilities primarily include customer services and financial consultations.
Ms. Chou received a Bachelor Degree in finance and economics from Yuan Ze University School of Economics in 2010.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Hsin-Hui Miao, Director,</b> served as counter
manager at Yueh Shan Chi Cram School from August 2021 to May 2022. From August 1988 to July 2021, Ms. Miao was a kindergarten teacher
and also severed as the leader of general affairs team at the affiliated high school of Tunghai University, Kindergarten Division. Ms.
Miao received her Bachelor Degree of Education from Taichung University of Education in 1998.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yoshinobu Odaira, Director,</b> was elected
as a director on our Board of Directors on February 8, 2019. He is an entrepreneur and has founded a number of Japanese agricultural
companies, including Yukiguni Maitake, our licensing partner. In 1983, Mr. Odaira established Yukiguni Maitake, which became a public
company in Japan in 1994. In 2015, Bain Capital Private Equity purchased Yukiguni Maitake through a tender offer. In addition to his
success with Yukiguni Maitake, Mr. Odaira served as the CEO of Yukiguni Shoji Co., Ltd. since 1988, as the CEO of Odaira Shoji Co., Ltd.
from 1989 and as a director of Shogun Maitake Japan Co., Ltd. since June 1989. In 2015, Mr. Odaira founded two new companies, Shogun
Maitake Canada Co., Ltd. in Canada and Odaira Kinoko Research Co., Ltd. in Japan. Mr. Odaira has served as the CEO and director of Shogun
Maitake Canada Co., Ltd. since June 2016. Mr. Odaira served as a director of BioLite Inc. from February 2019 to April 2019. Yoshinobu
Odaira graduated from the Ikazawa Junior High School in 1963. We believe that we will benefit from Mr. Odaira&#8217;s successful business
experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Che Wei Hsu, Director,</b> is currently employed
as a clerk by Chunghwa Post Co., Ltd. since August 2016; previously she was a teacher in a Junior High School. Ms. Hsu received a Bachelor
Degree from Tunghai University School of Chinese Literature in 2004.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shuling Jiang, Director,</b> has served as
a director for various companies, including BioLite, Inc. and BioFirst Corp, since 2017 and started to serve as Managing Director for
Biokey, Inc. in 2022. Ms. Jiang received a Bachelor Degree from National Taiwan Normal University School of Music in 1978 and a Master
Degree from Northwestern University School of Music in 1983.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yu-Min (Francis) Chung, Director</b>, was
a Partner at Maxpro Ventures, an investment firm in Taiwan focused on breakthrough biomedical technology companies, from July 2018 to
May 2022. Prior to that, he served as Vice President at TaiAn Technology, which is a biotechnology service company and a management company
for biotechnology venture capital funds in Taiwan, from June 2016 to June 2018. Mr. Chung received his Bachelor&#8217;s Degree of Science
in Chemistry from National Taiwan University in 1987, Master&#8217;s Degree in Business Administration from National Taiwan University
in 2006, and Ph.D. in Pharmacy from University of Iowa in 1995.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">There are no family relationships among the
executive officers and directors of the Company, except that Dr. Tsang Ming Jiang, Dr. Tsung-Shann Jiang and Dr. Chang-Jen Jiang are
brothers, Mr. Eugene Jiang is Dr. Tsung-Shann Jiang&#8217;s son, and the marital relationship between Yoshinobu Odaira and Norimi Sakamoto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Involvement in Certain Legal Proceedings</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the past ten years, none of our current directors, executive
officers, promoters, control persons, or nominees has been:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the subject of any bankruptcy
    petition filed by or against any business of which such person was a general partner or executive officer either at the time of the
    bankruptcy or within two years prior to that time;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convicted in a criminal
    proceeding or is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to any order, judgment,
    or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or any Federal or State authority,
    permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities
    or banking activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">found by a court of competent
    jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state
    securities or commodities law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the subject of, or a party
    to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or
    vacated, relating to an alleged violation of (a) any Federal or State securities or commodities law or regulation; (b) any law or
    regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction,
    order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition
    order; or (c) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the subject of, or a party
    to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section
    3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange
    Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its
    members or persons associated with a member.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless disclosed otherwise, we are currently
not a party to any material legal or administrative proceedings and are not aware of any pending legal or administrative proceedings
against us. We may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NASDAQ Rules require that a majority of the
Board be independent. The Board consists of 11 directors, of which nine are non-management directors. Each year the Board reviews the
materiality of any relationship that each of our directors has with the Company, either directly or indirectly. No member of the Board
has any relationship or arrangement that would require disclosure under Item 404 of Regulation S-K. For additional information see &#8220;Certain
Relationships and Related-Party Transactions&#8221; in this report. Based on this review, the Board has determined that the following
current directors are &#8220;independent directors&#8221; as defined by the NASDAQ Rules: Messrs. Odaira and Chung and Mses. Sakamoto,
Chou and Miao.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each director who is a member of the Audit and
Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee is an independent director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board Committees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Audit Committee</i>. The Audit Committee of
the Board of Directors currently consists of Ms. Chou, Yen-Hsin (Chair), Ms. Miao, Hsin-Hui, and Ms. Hsu, Che-Wei. The functions of the
Audit Committee include the retention of our independent registered public accounting firm, reviewing and approving the planned scope,
proposed fee arrangements and results of the Company&#8217;s annual audit, reviewing the adequacy of the Company&#8217;s accounting and
financial controls and reviewing the independence of the Company&#8217;s independent registered public accounting firm. The Board has
determined that Ms. Chou, Ms. Miao and Ms. Hsu are each an &#8220;independent director&#8221; under the listing standards of The NASDAQ
Stock Market. The Board of Directors has also determined Ms. Chou is an &#8220;audit committee financial expert&#8221; within the applicable
definition of the SEC. The Audit Committee is governed by a written charter approved by the Board of Directors, a copy of which is available
on our website at www.abvcpharma.com. Information contained on our website are not incorporated by reference into and do not form any
part of this reports. We have included the website address as a factual reference and do not intend it to be an active link to the website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Committee</i>. The Compensation
Committee of the Board of Directors currently consists of Ms. Norimi Sakamoto (Chair), Ms. Miao, Hsin-Hui, and Ms. Hsu, Che-Wei. The
functions of the Compensation Committee include the approval of the compensation offered to our executive officers and recommending to
the full Board of Directors the compensation to be offered to our directors, including our Chairman. The Board has determined that Ms.
Sakamoto, Ms. Miao and Ms. Hsu are each an &#8220;independent director&#8221; under the listing standards of The NASDAQ Stock Market
LLC. In addition, the members of the Compensation Committee qualify as &#8220;non-employee directors&#8221; for purposes of Rule 16b-3
under the Exchange Act and as &#8220;outside directors&#8221; for purposes of Section 162(m) of the Internal Revenue Code of 1986, as
amended. The Compensation Committee is governed by a written charter approved by the Board of Directors, a copy of which is available
on our website at www.abvcpharma.com. Information contained on our website are not incorporated by reference into and do not form any
part of this report. We have included the website address as a factual reference and do not intend it to be an active link to the website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Corporate Governance and Nominating Committee</i>.
The Corporate Governance and Nominating Committee of the Board of Directors consists of Mr. Yoshinobu Odaira (Chair), Ms. Miao, Hsin-Hui,
and Ms. Hsu, Che-Wei, each of whom is an independent director under Nasdaq&#8217;s listing standards. The corporate governance and nominating
committee is responsible for overseeing the selection of persons to be nominated to serve on our board of directors. The corporate governance
and nominating committee considers persons identified by its members, management, shareholders, investment bankers and others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Guidelines for Selecting Director Nominees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The guidelines for selecting nominees, which
are specified in the Corporate Governance and Nominating Committee Charter, generally provide that persons to be nominated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should
                                            have demonstrated notable or significant achievements in business, education or public service;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should
                                            possess the requisite intelligence, education and experience to make a significant contribution
                                            to the board of directors and bring a range of skills, diverse perspectives and backgrounds
                                            to its deliberations; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should
                                            have the highest ethical standards, a strong sense of professionalism and intense dedication
                                            to serving the interests of the shareholders.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The corporate governance and nominating committee
will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism
in evaluating a person&#8217;s candidacy for membership on the board of directors. The nominating committee may require certain skills
or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider
the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The board of directors will also
consider director candidates recommended for nomination by our shareholders during such times as they are seeking proposed nominees to
stand for election at the next annual meeting of shareholders (or, if applicable, a special meeting of shareholders). Our shareholders
that wish to nominate a director for election to the Board should follow the procedures set forth in our bylaws. The nominating committee
does not distinguish among nominees recommended by shareholders and other persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Leadership Structure and Role in Risk
Oversight</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two separate individuals serving as our
CEO and Chairman. Our Board of Directors, or the Board, is primarily responsible for overseeing our risk management processes on behalf
of our company. The Board receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate
regarding our company&#8217;s assessment of risks. In addition, the Board focuses on the most significant risks facing our company and
our company&#8217;s general risk management strategy, and also ensures that risks undertaken by our company are consistent with the board&#8217;s
appetite for risk. While the Board oversees our company&#8217;s risk management, management is responsible for day-to-day risk management
processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing our company and
that our board leadership structure supports this approach.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted a code of ethics, a copy of which
is attached herein as Exhibit 14.1. The Code of Ethics applies to all of our employees, officers and directors. This Code constitutes
a &#8220;code of ethics&#8221; as defined by the rules of the SEC. Copies of the code may be obtained free of charge from our website,
www.abvcpharma.com. Any amendments to, or waivers from, a provision of our code of ethics that applies to any of our executive officers
will be posted on our website in accordance with the rules of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither our Articles of Incorporation nor Bylaws
prevent us from indemnifying our officers, directors and agents to the extent permitted under the Nevada Revised Statute (&#8220;NRS&#8221;).
NRS Section 78.7502 provides that a corporation shall indemnify any director, officer, employee or agent of a corporation against expenses,
including attorneys&#8217; fees, actually and reasonably incurred by him in connection with any the defense to the extent that a director,
officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding
referred to Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the Company pursuant to Wyoming law,
we are informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed
in the Securities Act and is therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables set forth, for each of the
last two completed fiscal years of us, the total compensation awarded to, earned by or paid to any person who was a principal executive
officer during the last two fiscal years and every other highest compensated executive officers earning more than $100,000 during the
last fiscal year (together, the &#8220;Named Executive Officers&#8221;). The tables set forth below reflect the compensation of the Named
Executive Officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Name and Principal Position</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Salary<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Bonus<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Stock Awards<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Option Awards<br/> ($)(7)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Non-Equity Incentive Plan Compensation<br/>
    ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Change in Pension<br/> Value and<br/>
    Nonqualified Deferred Compensation Earnings<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">All Other Compensation<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="-keep: true">Uttam Patil (1)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 7%; text-align: center"><span style="-keep: true">2042</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"/><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">107,623</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"/><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"/><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"/><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">107,623</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2023</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Leeds Chow (2)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2024</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">33,968</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">76,873</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">110,571</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2023</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">180,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">180,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Tsung-Shann Jiang (3)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2024</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">200,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">153,746</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">353,746</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td/><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2023</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">200,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">200,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Richard Chi-Hsin King (4)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2024</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">90,556</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">90,556</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2023</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">90,556</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">90,556</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Eugene Jiang (5)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2024</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">200,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">215,244</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">415,244</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2023</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">200,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">200,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Chihliang An (6)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2024</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">2023</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Dr. Doong was appointed as the CEO on September
    15, 2017. Dr. Doong later resigned from his position as the Company&#8217;s CEO on June 21, 2023. The Company&#8217;s board of directors
    appointed Dr. Uttam Patil to replace Dr. Doong as the Company&#8217;s CEO.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify; width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Mr. Chow was appointed as the CFO on September
    4, 2022 and resigned on March 5, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(3) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dr. Jiang was appointed as the CSTRO on September 1, 2019. Dr. Jiang
    was also appointed as the Company&#8217;s CSO on June 15, 2023, to replace Dr. King, who resigned from his position as CSO.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dr. King was appointed as the CSO on September 15, 2017. Dr. King
    later resigned from his position as the Company&#8217;s CSO on June 15, 2023. The Company&#8217;s board of directors appointed Dr.
    Jiang to replace Dr. King as the Company&#8217;s CSO.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Eugene Jiang was appointed as CBO on September 1, 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mr. An resigned from his positions as the Company&#8217;s CFO on
    September 4, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Narrative Disclosure to Summary Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than set out below, there are no arrangements
or plans in which we provide pension, retirement or similar benefits for directors or executive officers. Our directors and executive
officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit
sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share
options may be granted at the discretion of our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Option Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board approved and adopted the Amended and
Restated 2016 Equity Incentive Plan on September 12, 2020 (the &#8220;Plan&#8221;), a copy of which is attached hereto as exhibit 10.17.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Grants of Plan-Based Awards</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 16, 2022, the Company entered into
stock option agreements with 5 directors, pursuant to which the Company granted options to purchase an aggregate of 76,190 shares (post-split)
of common stock under the Plan, as amended, at an exercise price of $30.0 per share (post-split). The options were vested at the grant
date and become exercisable for 10 years from the grant date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">As of the date of this report, we have granted options under the
Plan that can be exercised for an aggregate of 258,710 shares of Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The
                                            following table summarizes outstanding unexercised options, unvested stocks and equity incentive
                                            plan awards held by each of our named executive officers, as of December 31, 2024:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="12" style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; font-weight: bold; text-align: center"><span style="-keep: true">OPTION AWARDS*</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="20" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>STOCK AWARDS</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="-keep: true">Name</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Number
                                            of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options (#)<br/> Exercisable</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Number
                                            of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options (#)<br/> Unexercisable</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Equity
                                            Incentive<br/> Plan Awards:<br/> Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/>
                                            Unearned Options<br/> (#)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Options<br/>
                                            Exercise<br/> Prices<br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Option<br/> Expiration<br/> Date</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Number
                                            of<br/> Shares or<br/> Units of<br/> Stock That<br/> Have Not<br/> Vested<br/> (#)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Market<br/>
                                            Value of<br/> Shares or<br/> Units of<br/> Stock That<br/> Have Not<br/> Vested<br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Equity<br/>
                                            Incentive Plan<br/> Awards:<br/> Number of<br/> Unearned<br/> Shares, Units<br/> or Other<br/>
                                            Rights That<br/> Have Not<br/> Been Issued<br/> (#)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Equity
                                            Incentive<br/> Plan Awards:<br/> Market or Payout<br/> Value of Unearned<br/> Shares, Units or<br/>
                                            Other Rights That<br/> Have Not Been<br/> Issued<br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left"><span style="-keep: true">Howard Doong</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">8,572</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">1,071</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">20.0</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="-keep: true">Nov 20, 2031</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-size: 10pt">&#8239;-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">40,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Oct 15, 2032</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15,238</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Apr 16, 2033</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Chihliang An</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,476</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">952</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Nov 20, 2031</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">23,333</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Oct 15, 2032</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15,238</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Apr 16, 2033</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Tsung-Shann Jiang</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,411</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Nov 20, 2031</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Oct 15, 2032</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15,238</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Apr 16, 2033</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Richard Chi-Hsin King</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">8,214</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,429</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Nov 20, 2031</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">31,667</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Oct 15, 2032</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15,238</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Apr 16, 2033</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Eugene Jiang</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,242</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,219</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Nov 20, 2031</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Oct 15, 2032</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15,238</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Apr 16, 2033</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Uttam Patil</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">-</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">All
                                            number of options and exercise prices are adjusted for 1:10 reverse stock split in 2023.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We
                                            did not pay stock options to directors in fiscal year 2024.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pension, Retirement or Similar Benefit Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no arrangements or plans in which we
provide pension, retirement or similar benefits for directors or executive officers. We have no material bonus or profit sharing plans
pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may
be granted at the discretion of the board of directors or a committee thereof.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Contracts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Dr. Uttam Patil has entered into an employment
agreement (&#8220;Patil Employment Agreement&#8221;) with the Company on June 23, 2023, pursuant to which he shall receive the initial
base salary by stock options in accordance with Company&#8217;s standard payroll practice. As of the date of this prospectus, Dr. Patil
has yet to receive any stock options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 4, 2022, the Board appointed
Mr. Leeds Chow as the Company&#8217;s Chief Financial Officer (&#8220;CFO&#8221;) and Principal Accounting Officer effective from September
4, 2022 for a term of 3 years. On March 5, 2025, Mr. Chow resigned as CFO.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We maintain an employment agreement with Dr.
Chi-Hsin Richard King (&#8220;King Employment Agreement&#8221;), pursuant to which he shall receive an annual base salary of $50,000.
As of December 31, 2017, we paid Mr. King 10,416 shares of the Company&#8217;s common stock at a per share price of $1.60 as opposed
to cash compensation. Under King Employment Agreement, Dr. King is employed as the CSO of the Company. We may terminate the employment
for cause, at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty
to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. In such case,
the executive officer will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination,
and the executive officer&#8217;s right to all other benefits will terminate, except as required by any applicable law. We may also terminate
an executive officer&#8217;s employment without cause upon one-month advance written notice. In such case of termination by us, we are
required to provide compensation to the executive officer, including severance pay equal to 12 months of base salary. The executive officer
may terminate the employment at any time with a one-month advance written notice if there is any significant change in the executive
officer&#8217;s duties and responsibilities or a material reduction in the executive officer&#8217;s annual salary. In such case, the
executive officer will be entitled to receive compensation equivalent to 12 months of the executive officer&#8217;s base salary. On August
21, 2019, all of the Board members present at the Meeting, unanimously reelected Dr. Richard King as the Chief Scientific Officer (&#8220;CSO&#8221;),
which became effective on September 1, 2019 for a term of three years. On June 13, 2023, Dr. Richard King resigned from his position
as the CSO after being related in 2022. The Company&#8217;s board of directors appointed Dr. Jiang to replace Dr. Richard King as the
CSO.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 21, 2019, all of the Board members
present at the Meeting, except Eugene Jiang, appointed Mr. Eugene Jiang, the current Chairman of the Board, as the Chief Business Officer,
effective since September 1, 2019 for a term of three years. Mr. Eugene Jiang excused himself from the discussion regarding his appointment
as the Chief Business Officer of the Company during the Board meeting. Mr. Jiang was reelcted in 2022 and he contract was renewed for
another three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 21, 2019, all of the Board members
present at the Meeting, except Dr. Tsung-Shann Jiang, reelected Dr. Tsung-Shann Jiang as the Chief Strategy Officer, effective since
September 1, 2019 for a term of three years. Dr. Tsung-Shann Jiang excused himself from the discussion regarding his appointment as the
Chief Strategy Officer of the Company during the Board meeting. Dr. Jiang was reelected in 2022 and the contract was renewed for another
three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">Disclosure of Registrant's Action to Recover Erroneously Awarded
Compensation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In response to Item 402(w) of Regulation S-K,
there was no time during or after the last completed fiscal year that the Company was required to either prepare an accounting restatement
that required recovery of erroneously awarded compensation pursuant to the Company&#8217;s compensation recovery policy, or had an outstanding
balance as of the end of the last completed fiscal year of erroneously awarded compensation to be recovered from the application of the
policy to a prior restatement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth certain information
regarding beneficial ownership of our common stock as of the date hereof (i) each person (or group of affiliated persons) who is known
by us to own more than five percent (5%) of the outstanding shares of our Common Stock, (ii) each director, executive officer and director
nominee, and (iii) all of our directors, executive officers and director nominees as a group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership is determined in accordance
with SEC rules and generally includes voting or investment power with respect to securities. For purposes of this table, a person or
group of persons is deemed to have &#8220;beneficial ownership&#8221; of any shares of common stock that such person has the right to
acquire within 60 days of the date of the respective table. For purposes of computing the percentage of outstanding shares of our common
stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within 60
days of the date of the respective table is deemed to be outstanding for such person, but is not deemed to be outstanding for the purpose
of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute
an admission of beneficial ownership.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise noted, the business address
of each beneficial owner listed is 44370 Old Warm Springs Blvd., Fremont, CA 94538. Except as otherwise indicated, the persons listed
below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent that power
may be shared with a spouse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As
                                            of May 16, 2025, we had 16,773,261 shares of common stock issued and outstanding.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Name of Beneficial Owner</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount and Nature of Beneficial Ownership</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Percent of Class</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Dr. Uttam Patil</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">72,428</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Eugene Jiang (1)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">131,159</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Yen-Hsin Chou</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">41,956</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Hsin-Hui Miao</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">41,505</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Dr. Tsang-Ming Jiang</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">41,994</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Norimi Sakamoto</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">41,854</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Dr. Tsung-Shann Jiang (2)(4)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">543,589</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3.4</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Dr. Chang-Jen Jiang (3)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">42,026</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Yoshinobu Odaira</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">57,758</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Che-Wei Hsu</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">41,489</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Shuling Jiang (4)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,665,015</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10.6</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Yu-Min Chung</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">41,387</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">All officers and directors as a group (Twelve (12) persons)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,762,139</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">17.5</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">YuanGene Corporation (5)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">829,699</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5.3</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">less
                                            than 1%.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Eugene Jiang held 131,159 shares through direct
    ownership.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Dr. Tsung-Shann Jiang held 167,599 shares of common
    stock through his ownership in YuanGene Corporation, 722 shares through Rgene Corporation, 608 shares through BioFirst, 13,630 shares
    through Lion Arts, and the rest of 361,030 shares through direct ownership.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Dr. Chang-Jen Jiang held 158 shares of common stock
    in the Company through his ownership in BioFirst, 1 share through Rgene, and the rest of 41,847 shares through direct ownership.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(4)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Ms. Shuling Jiang held 662,100 shares of common
    stock through his ownership in YuanGene Corporation, 964 shares through Rgene Corporation, 8,833 shares through BioFirst, 112 shares
    through BioLite, 48,761 shares through Liongene, 21,313 shares through Keypoint, 1,012 shares through Genepro, 53,845 shares through
    Lion Arts, and the rest of 868,075 shares through direct ownership.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(5)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">YuanGene Corporation is a company wholly-owned
    by Lion Arts, which is owned by Shu-Ling Chiang (80%) and Dr. Tsung-Shann Jiang (20%); however, YuanGene appointed Eugene Jiang to
    have sole voting control over the shares held by YuanGene, the principal office address of which is 2<sup>nd </sup>floor, Building
    B, SNPF Plaza, Savalalo, Apia, Samoa.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RELATED PARTY TRANSACTIONS
OF DIRECTORS AND EXECUTIVE OFFICERS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed herein, no director, executive
officer, shareholder holding at least 5% of shares of our common stock, or any family member thereof, had any material interest, direct
or indirect, in any transaction, or proposed transaction since January 1, 2022, in which the amount involved in the transaction exceeds
the lesser of $120,000 or one percent of the average of our total assets at the year-end for the last two completed fiscal years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Since March 13, 2025, the following officers and directors of the
Company were appointed to the following positions at AiBtl: Eugene Jiang as AiBtl&#8217;s Chief Financial Officer, Uttam Patil as AiBtl&#8217;s
co-CEO and T.S. Jiang as AiBtl&#8217;s Chief Strategy Officer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Co-Development agreement with Rgene Corporation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 10, 2020, the Company and Rgene signed
an amendment to the Co-Dev Agreement dated May 26, 2017, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast
Cancer Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination
Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized.
Other provisions of the Co-Dev Agreement remain in full force and effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Clinical Development Service Agreement
with Rgene Corporation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 10, 2022, the Company expanded its co-development
partnership with Rgene. BioKey, Inc. entered into a Clinical Development Service Agreement with Rgene (&#8220;Service Agreement&#8221;)
to guide certain Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of
pancreatic cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under
U.S. FDA IND regulatory requirements (the &#8220;Rgene Studies&#8221;). The Service Agreement shall remain in effect until the expiration
date of the last patent and automatically renew for 5 more years unless terminated earlier by either party with six months written notice.
Under the terms of the Service Agreement, BioKey is eligible to receive payments totaling up to $3.0 million over a 3-year period with
each payment amount to be determined by certain regulatory milestones obtained during the agreement period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Collaborative agreement with BioFirst Corporation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 4, 2020, we executed an amendment
to our collaboration agreement with BioFirst dated July 24, 2017, to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal
Storage Solution to our agreement. ABV-2002 is intended to be utilized during a corneal transplant procedure to replace a damaged or
diseased cornea while ABV-2001 has broader utilization during a variety of ocular procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Initially ABVC will focus on ABV-2002, a solution
utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial keratoplasty
(back layer cornea transplant). Designated ABV-2002 under ABVC&#8217;s product identification system, the solution is comprised of a
specific poly amino acid that protects ocular tissue from damage caused by external osmolarity exposure during pre-surgery storage. The
specific polymer in ABV 2002 can adjust osmolarity to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal
stroma during the storage period. Stromal hydration results in (a) maintaining acceptable corneal transparency and (b) prevents donor
cornea swelling. ABV-2002 also contains an abundant phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial
properties and neuroprotection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can
be manufactured at lower cost. ABV-2002 is categorized as a Class I Medical Device that has the lowest risk to patients; however, further
clinical development was put on hold due to the lack of funding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On
                                            May 11, 2018, the Company and BioFirst (Australia) entered into a loan agreement for a total
                                            amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and
                                            are due on demand prior to September 30, 2020. Afterwards, all outstanding load will bear
                                            interest rate at 12% per annum. On July 1, 2020, the Company entered into a loan agreement
                                            with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation
                                            based on co-development contract executed on July 24, 2017. The loan was originally set to
                                            mature on September 30, 2021 with an interest rate of 6.5% per annum, however, on September
                                            7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873
                                            to meet its new project needs. On December 1, 2021, the Company entered into a loan agreement
                                            with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan
                                            has an interest rate of 6.5% per annum and matured on November 30, 2022. For accounting purpose,
                                            the due from and due to related party balances was being net off. As of March 31, 2025 and
                                            December 31, 2024, the outstanding loan balances and allocated research fee were both amounted
                                            to $681,185, and accrued interest balances were both amounted $158,798. The business conditions
                                            of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit
                                            losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest
                                            income recognizing such losses.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Joint Venture Agreement</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2021 (the &#8220;<b>Completion
Date</b>&#8221;), the Company, Lucidaim Co., Ltd., a Japanese corporation (&#8220;<b>Lucidaim</b>,&#8221; together with the Company,
the &#8220;<b>Shareholders</b>&#8221;), and BioLite Japan K.K., a Japanese corporation (&#8220;<b>Biolite JP&#8221;</b>) entered into
a Joint Venture Agreement (the &#8220;<b>Agreement</b>&#8221;). Biolite JP is a private limited company (a Japanese <i>Kabushiki Kaisha</i>)
incorporated on December 18, 2018 and at the date of the Agreement has 10,000 ordinary shares authorized, with 3,049 ordinary shares
issued and outstanding (the &#8220;<b>Ordinary Shares</b>&#8221;). Immediately prior to the execution of the Agreement, Lucidaim owned
1,501 Ordinary Shares and the Company owned 1,548 Ordinary Shares. The Shareholders entered into the joint venture to formally reduce
to writing their desire to invest in and operate Biolite JP as a joint venture. The business of the joint venture shall be the research
and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements
carried on by Biolite JP and its subsidiaries in Japan, or any other territory or businesses as may from time to time be agreed by an
amendment to the Agreement. The closing of the transaction is conditioned upon the approval and receipt of all necessary government approvals,
which have been received.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement and the related share
transfer agreement, the Company shall transfer 54 of its Ordinary Shares to Lucidaim for no consideration, such that following the transfer,
Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). Also pursuant to the Agreement,
there shall be 3 directors of Biolite JP, consisting of 1 director appointed by the Company and 2 appointed by Lucidiam. The Company
shall appoint Eugene Jiang, the Company&#8217;s current Chairman and Chief Business Officer and Lucidaim shall appoint Michihito Onishi;
the current director of Biolite JP, Toru Seo (who is also a director of BioLite Japan&#8217;s other shareholder), is considered the second
Lucidaim director. The Agreement further provides that the Company and Biolite JP shall assign the research collaboration and license
agreement between them to Biolite JP or prepare the same (the &#8220;<b>License Agreement</b>&#8221;). The aforementioned transactions
occurred on the Completion Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As per the Agreement, the Shareholders shall
supervise and manage the business and operations of Biolite JP. The directors shall not be entitled to any renumeration for their services
as a director and each Shareholder can remove and replace the director he/she/it appointed. If a Shareholder sells or disposes of all
of its Ordinary Shares, the director such Shareholder appointed must tender his/her resignation. The Agreement also sets forth certain
corporate actions that must be pre-approved by all Shareholders (the &#8220;<b>Reserved Matters</b>&#8221;). If the Shareholders are
unable to make a decision on any Reserved Matter, then either Shareholder can submit a deadlock notice to the other shareholder, 5 days
after which they must refer the matter to each Shareholder&#8217;s chairman and use good faith to resolve the dispute. If such dispute
is not resolved within 10 days thereafter, then either Shareholder can offer to buy all of the other Shareholder&#8217;s Ordinary Shares
for cash at a specified price; if there is not affirmative acceptance of the sale, the sale shall proceed as set forth in the sale offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the Shareholders maintains a pre-emptive
right to purchase such number of additional Ordinary Shares as would allow such Shareholder to maintain its ownership percentage in Biolite
JP if Biolite JP issues any new Ordinary Shares. However, the Agreement provides that the Company shall lose its pre-emptive rights under
certain conditions. The Shareholders also maintain a right of first refusal if the other Shareholder receives an offer to buy such shareholder&#8217;s
Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement also requires Biolite JP to obtain
a bank facility in the amount of JPY 30,460,000 (approximately USD272,000), for its initial working capital purposes. Pursuant to the
Agreement, each Shareholder agrees to guarantee such bank facility if the bank requires a guarantee. Accordingly, the Company may be
liable for the bank facility in an amount up to JPY 14,925,400 (approximately USD134,000), which represents 49% of the maximum bank facility.
The Agreement further provides that Biolite JP shall issue annual dividends at the rate of at least 1.5% of Biolite JP&#8217;s profits,
if it has sufficient cash to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement, the Company and Biolite
JP agree to use their best efforts to execute the License Agreement by the end of December 2021, but since it was not yet executed, the
parties continue such efforts. The Company agreed that any negotiation on behalf of Biolite JP regarding the terms of the License Agreement
shall be handled by the directors appointed by Lucidaim. If the Company and such Lucidaim directors do not reach agreement on the terms,
Biolite JP may at its sole discretion determine not to execute the License Agreement without any liability to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement contains non-solicitation and non-compete
clauses for a period of 2 years after a Shareholder or its subsidiaries ceases to be a Shareholder, with such restrictive covenants limited
to business within the ophthalmologic filed or central neurological field. Any rights to intellectual property that arise from Biolite
JP&#8217;s activities, shall belong to Biolite JP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement contains standard indemnification
terms, except that no indemnifying party shall have any liability for an individual liability unless it exceeds JPY 500,000 (approximately
USD4,500) and until the aggregate amount of all liabilities exceeds JPY 2,000,000 (approximately USD18,000) and then only to the extent
such liability exceed such limit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid $150,000 towards the setup of
the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement shall continue for 10 years, unless
earlier terminated. The Agreement also allows a Shareholder to terminate the agreement upon certain defaults committed by another Shareholder,
as set forth in the Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In 2024, the Company recognized fully $150,000
loss in equity method investment based on continuing operating losses of BioLite JP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">In April 2024, the Japan Patent Office granted a new patent protection
for the Company&#8217;s Major Depressive Disorder (MDD) candidate, ABV-1504. The patent is valid through 2040 and will help BioLite Japan
market and commercialize the product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Agreement with BioLite, Inc.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We entered into a Collaborative Agreement with
BioLite, Inc., a company incorporated under the laws of Taiwan, and a subsidiary of the Company, (&#8220;BioLite&#8221;) on December
29, 2015, and then entered into two addendums to such agreement (as amended and revised, (the &#8220;Agreement&#8221;). The majority
shareholder of BioLite is one of the Company&#8217;s subsidiaries, the Company&#8217;s Chairman is a director of BioLite and Dr. Jiang,
the Company&#8217;s Chief Strategy Officer and a director, is the Chairman of BioLite.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement, the Company acquired
the sole licensing rights to develop and commercialize for therapeutic purposes six compounds from BioLite. In accordance with the terms
of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity
securities owned by it at various stages on a schedule dictated by BioLite&#8217;s achievements of certain milestones, as set forth in
the Agreement (the &#8220;Milestone Payments&#8221;) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501
is approved for sale in the licensed territories. If BioLite fails to reach any of the milestones in a timely manner, it may not receive
the rest of the payments from the Company. According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone
Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the &#8220;December 2021 Payment&#8221;)
and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company&#8217;s Board of Directors determined that the December
2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000,
that BioLite owes the Company as of December 31, 2021. On February 22, 2022, the parties entered into an amendment to the Agreement allowing
the Company to make all payments due under the Agreement via the forgiveness of debt, in equal value, owed by BioLite to the Company.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This was a related party transaction and was
conducted at arm&#8217;s length. In addition to the Company&#8217;s board of directors approving the modification of terms of the Agreement,
the Company&#8217;s audit committee approved them too. The Board believes it is in the Company&#8217;s best interest to cancel outstanding
debt and apply it to the December 2021 Payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following such approval, the Company and BioLite
entered into an amendment to the Agreement reflecting the modified payment method.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Real Estate Purchase</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 6, 2024, the Company entered into
a definitive agreement with Shuling Jiang (&#8220;Shuling&#8221;), pursuant to which Shuling shall transfer the ownership of certain
land she owns located at Taoyuan City, Taiwan (the &#8220;Shuling Land&#8221;) to the Company (the &#8220;Agreement&#8221;). Shuling
is a director of the Company and owns approximately 15.4% of the Company&#8217;s issued and outstanding shares of common stock. On May
16, 2024, the Company&#8217;s board of directors determined that it was in the best interest of the Company and its shareholders to terminate
the Agreement and not proceed with the transfer of land ownership. The shares originally issued were returned and the warrants were not
issued. The parties are now re-negotiating the terms of the Company&#8217;s purchase of the Shuling Land, but will not enter into a definitive
agreement unless and until shareholder approval of the proposed compensation is obtained.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Other related party transactions</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due from related parties:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">(1)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 16, 2022, the Company entered
        into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 and made $500,000 to Rgene which
        bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional
        6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion
        price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower;
        the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well
        as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible
        note if not cured after 5 business days of written notice regarding the breach is provided. The loan was converted to Rgene&#8217;s
        common stock in May 2024 but the Company was not informed until April 2025. Please see detail discussion in Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 31, 2025 and December 31, 2024,
the outstanding loan balance were $0 and $500,000; and accrued interest was $0and $63,819, respectively. Both principal and accrued interest
were converted to Rgene&#8217;s common stocks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">As of March 31, 2025 and December 31, 2024, the Company has other
receivables amounted to $1,867 and $1,892, respectively, from Rgene due to daily operations.</span></p>

</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">On
                                            December 31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal
                                            amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum
                                            for the use of working capital. During the year ended December 31, 2024, the Company entered
                                            into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately
                                            $347,883), which bears interest at 12% per annum for the use of working capital. As of March
                                            31, 2025 and December 31, 2024, the outstanding loan balance were NTD 15,458,360 (approximately
                                            $465,297) and NTD 17,571,076 (approximately $535,918), respectively; accrued interests were$68,971
                                            and $53,422, respectively. The Company has received NTD 2,080,000 (approximately $64,896)
                                            and $0 repayment during the three months ended March 31, 2025 and 2024, respectively.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 1, 2020, the Company entered into
    a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development
    contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5%
    per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its
    new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company
    entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be
    matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with
    BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. During the first quarter of 2023,
    the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for
    upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia)
    for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest
    rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of March 31,
    2025 and December 31, 2024, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued
    interest balances were both amounted $158,798.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The business conditions of BioFirst (Australia)
    deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The
    Company stopped accruing interest income recognizing such losses.</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify; width: 0.25in"><span style="font-size: 10pt">(4)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing
    Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see
    Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued
    relevant development cost to BHK. As of March 31, 2025 and December 31, 2024, due from BHK was both NTD 3,941,299 (approximately$118,633
    and $120,210, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit
    losses of NTD 3,941,299 as of December 31, 2024. No recovery was made during three months ended March 31, 2025.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company&#8217;s due from related parties
are subject to certain risks that our collaborative parties, including OncoX and FEYE, would face. Such risks exist in future market
conditions, macro economy, legal and regulatory, results of clinical trials and product developments, and among others. As of March 31,
2025, the Company&#8217;s comprehensive review of these due from related party balances indicates that there are no expected losses except
those being recognized above. This conclusion is based on the business relationships with our related parties and the absence of any
significant indicators of potential default.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Due to related parties</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Amount due to related parties consisted of
the following as of the periods indicated:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March 31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December 31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">AiBtl Holding (1)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">348,219</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">348,219</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">The Jiangs (2)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">222,522</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">274,170</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Shareholders (3)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">140,266</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">142,130</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Lion Art Promotions Inc (4)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">65,738</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Directors (5)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">12,953</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">8,526</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">819,384</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">773,045</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24,
    2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000,
    $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working
    capital purpose. As of March 31, 2025 and December 31, 2024, the outstanding balance due to the Jiangs amounted to $222,522 and $274,170,
    respectively. These loans bear no interest and are due on demand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify; width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Since 2018, the Company&#8217;s shareholders have
    advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of March 31,
    2025 and December 31, 2024, the outstanding principal and accrued interest was $140,266 and $142,130, respectively. Interest expenses
    in connection with these loans were $4,963 and $5,938 for the three months ended March 31, 2025 and 2024, respectively.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Accrued consulting services fee for the three months ended March
    31, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">As of March 31, 2025 and December 31, 2024, due to Directors amounted
    to $12,953 and $8,526, respectively, were related to the daily operating expenses since inception in 2023 paid by the Directors of
    AiBtl on behalf of the entity.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Promoters and Certain Control Persons</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of our management or other control persons
were &#8220;promoters&#8221; (within the meaning of Rule 405 under the Securities Act), and none of such persons took the initiative
in the formation of our business or received any of our debt or equity securities or any of the proceeds from the sale of such securities
in exchange for the contribution of property or services, during the last five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DESCRIPTION OF SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s authorized capital stock
consists of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000,000
                                            shares of Common Stock, $0.001 par value per share; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000,000
                                            shares of preferred stock, $0.001 par value per share.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Common Stock may be issued for such consideration
as may be fixed from time to time by our board of directors. Our board of directors may issue such shares of our Common Stock in one
or more series, with such voting powers, shall be stated in the resolution or resolutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C<b>ommon Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As
                                            of the date hereof, there are 16,773,261 shares of our Common Stock issued and outstanding.
                                            Holders of Common Stock are entitled to cast one vote for each share on all matters submitted
                                            to a vote of stockholders, including the election of directors. The holders of Common Stock
                                            are entitled to receive ratably such dividends, if any, as may be declared by the Board out
                                            of funds legally available therefore. Such holders do not have any preemptive or other rights
                                            to subscribe for additional shares. All holders of Common Stock are entitled to share ratably
                                            in any assets for distribution to stockholders upon the liquidation, dissolution or winding
                                            up of the Company, subject to prior distribution rights of preferred stock then outstanding.
                                            There are no conversions, redemptions or sinking fund provisions applicable to the Common
                                            Stock. All outstanding shares of Common Stock are fully paid and non-assessable.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, there is no preferred
stock outstanding. Pursuant to the articles of incorporation of the Company, the Board of Directors is expressly granted the authority
to issue preferred stock up to 20,000,000 shares and prescribe its designations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of preferred stock
and the description of the terms of any particular series of preferred stock of the Company are not complete. The Company&#8217;s Board
of Directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series
and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock. Any or all of these rights
may be greater than the rights of the Company&#8217;s Common Stock. These descriptions are qualified in their entirety by reference to
the Company&#8217;s Articles of Incorporation, as amended, and the certificate of designation relating to each such series.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of Series A Convertible Preferred
Stock is initially convertible at any time at the option of the holders into one share of Common Stock and automatically converts into
one share of Common Stock (the &#8220;Conversion Ratio&#8221;) on its four-year anniversary of issuance and without the payment of additional
consideration by the holder thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No fractional shares shall be issued upon conversion
of Series A Convertible Preferred Stock into Common Stock and no payment. In lieu of delivering fractional shares, we will pay to the
holder, to the extent permitted by law, an amount in cash equal to the current fair market value of such fractional share as determined
in good faith by our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>No Maturity, Sinking Fund or Mandatory Redemption</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Convertible Preferred Stock has
no maturity date and we are not required to redeem the Series A Convertible Preferred Stock at any time. However, we may choose to convert
all the outstanding shares of the Series A Convertible Preferred Stock into our Common Stock at the same Conversion Ratio at any time,
provided that we have prepaid and distributed all the dividend accrued and to be accrued at the end of the four-year period since issuance
thereof. Accordingly, the Series A Convertible Preferred Stock will remain outstanding until automatically converted to Common Stock
on the four-year anniversary of issuance, unless the holders of the Series A Convertible Preferred Stock or we choose to convert the
Series A Convertible Preferred Stock into the Common Stock. The Series A Convertible Preferred Stock is also not subject to any sinking
fund.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Voting Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of shares of the Series A Convertible
Preferred Stock shall have the same voting rights as of the holders of our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants and Options</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As
                                            of the date hereof, we have 258,710 and 1,000,000 &#160;&#160;options and warrants, respectively
                                            of the Company outstanding. We are not registering shares of common stock underlying any
                                            warrants in this S1.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our Common
Stock is: VStock Transfer, LLC; Address: 18 Lafayette Place, Woodmere, New York 11598; Phone: (212) 828-8436; website: www.VStockTransfer.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Anti-Takeover Provisions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nevada Revised Statutes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Acquisition of Controlling Interest Statutes</span>.
Nevada&#8217;s &#8220;acquisition of controlling interest&#8221; statutes contain provisions governing the acquisition of a controlling
interest in certain Nevada corporations. These &#8220;control share&#8221; laws provide generally that any person that acquires a &#8220;controlling
interest&#8221; in certain Nevada corporations may be denied certain voting rights, unless a majority of the disinterested stockholders
of the corporation elects to restore such voting rights. These statutes provide that a person acquires a &#8220;controlling interest&#8221;
whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the Nevada Revised Statutes,
would enable that person to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority
or (3) a majority or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of
these thresholds, shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding
the date when the acquiring person acquired or offered to acquire a controlling interest become &#8220;control shares&#8221; to which
the voting restrictions described above apply. Our articles of incorporation and bylaws currently contain no provisions relating to these
statutes, and unless our articles of incorporation or bylaws in effect on the tenth day after the acquisition of a controlling interest
were to provide otherwise, these laws would apply to us if we were to (i) have 200 or more stockholders of record (at least 100 of which
have addresses in the State of Nevada appearing on our stock ledger) and (ii) do business in the State of Nevada directly or through
an affiliated corporation. If these laws were to apply to us, they might discourage companies or persons interested in acquiring a significant
interest in or control of the Company, regardless of whether such acquisition may be in the interest of our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Combinations with Interested Stockholders
Statutes</span>. Nevada&#8217;s &#8220;combinations with interested stockholders&#8221; statutes prohibit certain business &#8220;combinations&#8221;
between certain Nevada corporations and any person deemed to be an &#8220;interested stockholder&#8221; for two years after such person
first becomes an &#8220;interested stockholder&#8221; unless (i) the corporation&#8217;s board of directors approves the combination
(or the transaction by which such person becomes an &#8220;interested stockholder&#8221;) in advance, or (ii) the combination is approved
by the board of directors and sixty percent of the corporation&#8217;s voting power not beneficially owned by the interested stockholder,
its affiliates and associates. Furthermore, in the absence of prior approval certain restrictions may apply even after such two-year
period. For purposes of these statutes, an &#8220;interested stockholder&#8221; is any person who is (x) the beneficial owner, directly
or indirectly, of ten percent or more of the voting power of the outstanding voting shares of the corporation, or (y) an affiliate or
associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of ten percent
or more of the voting power of the then outstanding shares of the corporation. The definition of the term &#8220;combination&#8221; is
sufficiently broad to cover most significant transactions between the corporation and an &#8220;interested stockholder&#8221;. Subject
to certain timing requirements set forth in the statutes, a corporation may elect not to be governed by these statutes. We have not included
any such provision in our articles of incorporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effect of these statutes may be to potentially
discourage parties interested in taking control of the Company from doing so if it cannot obtain the approval of our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SELLING STOCKHOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">This
                                            prospectus relates to the offering and sale, from time to time, of up to 3,527,778 shares
                                            of our Common Stock issuable upon conversion of the Lind Note, up to 5,291,667 shares of
                                            Common Stock underlying the Lind Warrant, up to 211,667 shares of Common Stock underlying
                                            the PA Warrant, up to 342,857 shares of Common Stock, issuable upon full conversion of the
                                            2<sup>nd</sup> Lind Note in the principal amount of $1,200,000, up to 1,000,000 shares of
                                            Common Stock underlying the 2<sup>nd</sup> Lind Warrant, up to 30,000 shares of Common Stock
                                            underlying the 2<sup>nd</sup> PA Warrant, up to 285,714 shares of Common Stock, issuable
                                            upon full conversion of the 3<sup>rd</sup> Lind Note in the principal amount of $1,000,000,
                                            up to 1,000,000 shares of Common Stock underlying the 3<sup>rd</sup> Lind Warrant; and up
                                            to 25,000 shares of Common Stock underlying the 3<sup>rd</sup> PA Warrant, held by the stockholders
                                            named in the table below. We are registering the shares to permit the selling stockholders
                                            and their pledgees, donees, transferees and other successors-in-interest that receive their
                                            shares from a selling stockholder as a gift, partnership distribution or other non-sale related
                                            transfer after the date of this prospectus to resell the shares when and as they deem appropriate
                                            in the manner described in the &#8220;Plan of Distribution.&#8221; As of May 16, 2025,
                                            there were 16,773,261 shares of Common Stock issued and outstanding.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            name of the selling stockholders,</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of shares of our Common Stock that the selling stockholders beneficially owned prior
                                            to the offering for resale of the shares under this prospectus,</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            maximum number of shares of our Common Stock that may be offered for resale for the account
                                            of the selling stockholders under this prospectus, and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number and percentage of shares of our Common Stock beneficially owned by the selling stockholders
                                            after the offering of the shares (assuming all of the offered shares are sold by the selling
                                            stockholders).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless set forth below, the selling stockholders
received their securities in a private transaction with the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each selling stockholder may offer for sale all
or part of the Shares from time to time. The table below assumes that the selling stockholders will sell all of the Shares offered for
sale. A selling stockholder is under no obligation, however, to sell any Shares pursuant to this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of selling stockholder</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares of<br/> Common<br/> Stock<br/>
    Beneficially<br/> Owned Prior<br/> To offering</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum<br/> Number of<br/> Shares
    of<br/> Common<br/> Stock To Be<br/> Sold</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares of<br/> Common<br/>
    Stock<br/> Owned<br/> After<br/> offering (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage<br/> Ownership<br/> After<br/>
    offering (1)(2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Lind Global Fund II LP</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,448,016</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,448,016</td><td style="white-space: nowrap; width: 1%; text-align: left">(3)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.99</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Wilmington Capital Securities, LLC (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266,667</td><td style="text-align: center; white-space: nowrap">(4)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: right">-</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify; width: 95%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            Beneficial Ownership of Less Than One Percent of Our Outstanding Shares.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since we do
    not have the ability to control how many, if any, of their shares each of the selling stockholders listed above will sell, we have
    assumed that the selling stockholders will sell all of the shares offered herein for purposes of determining how many shares they
    will own after the offering and their percentage of ownership following the offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All percentages have been
    rounded up to the nearest one hundredth of one percent.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of: (i) 3,527,778&#160;
                                    shares of Common Stock issuable upon the conversion of the Lind Note, which is calculated based on
                                    the initial Conversion Price (as defined in the Lind Note) of $1.05 per share, (ii) 5,291,667 shares
                                    of Common Stock underlying the Lind Warrant, (iii) 342,857 shares of Common Stock issuable upon conversion
                                    of 2<sup>nd</sup> Lind Note, which is calculated based on the Fixed Price (as defined in the 2<sup>nd
                                    </sup>Lind Note) of $3.5 per share, (iv) 1,000,000 shares of Common Stock underlying the 2<sup>nd
                                    </sup>Lind Warrant; (vii) 285,714&#160; shares of Common Stock issuable upon the conversion of the
                                    3<sup>rd</sup> Lind Note, which is calculated based on the Fixed Price (as defined in the 3<sup>rd
                                    </sup>Lind Note) of $3.5 per share and (viii) 1,000,000 shares of Common Stock underlying the 3<sup>rd
                                    </sup>Lind Warrant. All of the notes and warrants issued to Lind contain blocker provisions such
                                    that they cannot be exercised to the extent such exercise would cause the holder, together with its
                                    affiliates, to beneficially own in excess of 9.99% of the outstanding Equity Interests (as defined
                                    in the notes and warrants issued to Lind) of such class. The number of shares of Common Stock set
                                    forth in the second column does not give effect to such blocker provisions. The address for Lind
                                    Global Fund II LP is c/o The Lind Partners LLC,&#160;&#160;444 Madison Avenue, Floor 41, New York,
                                    NY 10022. Lind Global Partners II LLC, the general partner of&#160;Lind&#160;Global&#160;Fund&#160;II&#160;LP,
                                    may be deemed to have sole voting and dispositive power with respect to the shares held by&#160;Lind&#160;Global&#160;Fund&#160;II&#160;LP.
                                    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting
                                    and dispositive power with respect to the shares held by&#160;Lind&#160;Global&#160;Fund&#160;II&#160;LP.</p></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify; font-size: 10pt; width: 95%"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents
                                            shares of Common Stock underlying the PA Warrants, 2<sup>nd</sup> PA Warrants and 3<sup>rd
                                            </sup>PA Warrants issued pursuant to the three transactions with Lind: 211,667 from the initial
                                            transaction with Lind, 30,000 from the second transaction with Lind and 25,000 from the third
                                            transaction with Lind. The PA Warrants, 2<sup>nd</sup> PA Warrants and 3<sup>rd</sup> PA
                                            Warrants contain blocker provisions such that they cannot be exercised to the extent such
                                            exercise would cause the holder, together with its affiliates, to beneficially own in excess
                                            of 9.99% of the outstanding Equity Interests (as defined in the PA Warrants, 2<sup>nd</sup>
                                            PA Warrants and 3<sup>rd</sup> PA Warrants) of such class. The number of shares of Common
                                            Stock set forth in the second column does not give effect to such blocker provisions. Investment
                                            and voting control held by John Mikes, president. The address for Wilmington Capital Securities,
                                            LLC is 600 Old Country Road, Suite 200, Garden City, NY 11530. Wilmington is a FINRA registered
                                            broker dealer.</p></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PLAN OF DISTRIBUTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering up to 11,714,683 shares of
our Common Stock, including&#160;9,031,112&#160;shares of Common Stock previously registered on Registration Statement on Form S-1 (File
No. 333-271416), for resale by the Selling Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders and any of their respective
pledgees, donees, assignees and other successors-in-interest may, from time to time, sell any or all of their shares of common stock
on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed
or negotiated prices. The selling stockholders may use any one or more of the following methods when selling shares:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
                                            brokerage transactions and transactions in which the broker-dealer solicits the purchaser;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
                                            trades in which the broker-dealer will attempt to sell the shares as agent but may position
                                            and resell a portion of the block as principal;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilitate
                                            the transaction;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
                                            by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            exchange distribution in accordance with the rules of the applicable exchange;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately-negotiated
                                            transactions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers
                                            may agree with the selling stockholders to sell a specified number of such shares at a stipulated
                                            price per share;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                            the writing of options on the shares;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            combination of any such methods of sale; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            other method permitted pursuant to applicable law.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders may also sell shares
under Rule 144 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), if available, rather than under this prospectus.
The selling stockholders shall have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if it
deems the purchase price to be unsatisfactory at any particular time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders or their respective
pledgees, donees, transferees or other successors in interest, may also sell the shares directly to market makers acting as principals
and/or broker-dealers acting as agents for themselves or their customers. Such broker-dealers may receive compensation in the form of
discounts, concessions or commissions from the selling stockholders and/or the purchasers of shares for whom such broker-dealers may
act as agents or to whom they sell as principal or both, which compensation as to a particular broker-dealer might be in excess of customary
commissions. Market makers and block purchasers purchasing the shares will do so for their own account and at their own risk. It is possible
that a selling stockholder will attempt to sell shares of common stock in block transactions to market makers or other purchasers at
a price per share which may be below the then existing market price. We cannot assure that all or any of the shares offered in this prospectus
will be issued to, or sold by, the selling stockholders. The selling stockholders and any brokers, dealers or agents, upon effecting
the sale of any of the shares offered in this prospectus, may be deemed to be &#8220;underwriters&#8221; as that term is defined under
the Securities Act, the Exchange Act and the rules and regulations of such acts. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under
the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are required to pay all fees and expenses
incident to the registration of the shares, including fees and disbursements of counsel to the selling stockholders, but excluding brokerage
commissions or underwriter discounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders, alternatively, may
sell all or any part of the shares offered in this prospectus through an underwriter. The selling stockholders have not entered into
any agreement with a prospective underwriter and there is no assurance that any such agreement will be entered into.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders may pledge their shares
to their brokers under the margin provisions of customer agreements. If a selling stockholder defaults on a margin loan, the broker may,
from time to time, offer and sell the pledged shares. The selling stockholders and any other persons participating in the sale or distribution
of the shares will be subject to applicable provisions of the Exchange Act, and the rules and regulations under such act, including,
without limitation, Regulation M. These provisions may restrict certain activities of, and limit the timing of purchases and sales of
any of the shares by, the selling stockholders or any other such person. In the event that any of the selling stockholders are deemed
an affiliated purchaser or distribution participant within the meaning of Regulation M, then the selling stockholders will not be permitted
to engage in short sales of common stock. Furthermore, under Regulation M, persons engaged in a distribution of securities are prohibited
from simultaneously engaging in market making and certain other activities with respect to such securities for a specified period of
time prior to the commencement of such distributions, subject to specified exceptions or exemptions. In addition, if a short sale is
deemed to be a stabilizing activity, then the selling stockholders will not be permitted to engage in a short sale of our common stock.
All of these limitations may affect the marketability of the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a selling stockholder notifies us that it
has a material arrangement with a broker-dealer for the resale of the common stock, then we would be required to amend the registration
statement of which this prospectus is a part, and file a prospectus supplement to describe the agreements between the selling stockholder
and the broker-dealer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In compliance with the guidelines of the Financial
Industry Regulatory Authority, Inc., or FINRA, the maximum consideration or discount to be received by any member of the FINRA may not
exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MARKET FOR OUR COMMON STOCK, DIVIDENDS AND</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RELATED STOCKHOLDER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Market Information</b>. Our common stock,
par value $0.001 per share (the &#8220;Common Stock&#8221;), is currently quoted on the Nasdaq Capital Markets under the symbol &#8220;ABVC&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><b>Holders. </b>As of May 16, 2025, we had approximately
656 shareholders of record of our common stock.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b>.
                                            Holders of our common stock are entitled to receive such dividends as may be declared by
                                            our board of directors. No dividends on our common stock have ever been paid, and we do not
                                            anticipate that dividends will be paid on our common stock in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities Authorized for Issuance under Equity
Compensation Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The
                                            following table discloses information as of the year ended December 31, 2024, with respect
                                            to compensation plans (including individual compensation arrangements) under which our equity
                                            securities are authorized for issuance, aggregated as follows:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Equity Compensation Plan Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Plan category</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of<br/> securities<br/> to
    be issued<br/> upon<br/> exercise of<br/> outstanding<br/> options,<br/> warrants<br/> and rights</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted-<br/> average<br/> exercise<br/>
    price of<br/> outstanding<br/> options,<br/> warrants<br/> and rights</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares of<br/> common<br/> stock<br/>
    remaining<br/> available for<br/> future<br/> issuance<br/> under equity<br/> compensation<br/> plans</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">Equity compensation plans approved by security holders</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">258,710</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">27.90</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">386,021</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Equity compensation plans not approved by security holders</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Total</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">258,710</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">27.90</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">386,021</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>LEGAL MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the securities being offered
by this prospectus been passed upon for us by Hunter Taubman Fischer &amp; Li LLC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPERTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The consolidated financial statements of ABVC
BioPharma, Inc. as of December 31, 2024 and 2023 included elsewhere in this prospectus have been audited by Simon &amp; Edward, LLP,
independent registered public accounting firm, as set forth in their report appearing elsewhere herein, and are included in reliance
upon such report given on the authority of such firm as experts in accounting and auditing. The financial statements as of March 31,
2025 included in this prospectus are not audited.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WHERE
                                            YOU CAN FIND MORE INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a reporting company and file annual, quarterly
and special reports, and other information with the SEC. Copies of the reports and other information may be read and copied at the SEC&#8217;s
Public Reference Room at 100 F Street N.E., Washington, D.C. 20549. You can request copies of such documents by writing to the SEC and
paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.
The SEC maintains a web site at http://www.sec.gov that contains reports, proxy and information statements and other information regarding
registrants that file electronically with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
on Form S-1 that we filed with the SEC. Certain information in the registration statement has been omitted from this prospectus in accordance
with the rules and regulations of the SEC. We have also filed exhibits and schedules with the registration statement that are excluded
from this prospectus. For further information you may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">read
                                            a copy of the registration statement, including the exhibits and schedules, without charge
                                            at the SEC&#8217;s Public Reference Room; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            a copy from the SEC upon payment of the fees prescribed by the SEC.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file periodic reports, proxy statements, and
other information with the SEC. These periodic reports, proxy statements, and other information will be available for inspection and
copying at the SEC&#8217;s public reference facilities and the website of the SEC referred to above. After the closing of this offering,
you may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those
reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge as soon as reasonably practicable
after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through,
our website is not incorporated by reference into this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION
FOR SECURITIES ACT LIABILITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions,
or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
by us of expenses incurred or paid by one of our directors, officers or controlling persons in the successful defense of any action,
suit or proceeding) is asserted by that director, officer or controlling person in connection with the securities being registered, we
will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether that indemnification by us is against public policy as expressed in the Securities Act and will be governed by the
final adjudication of that issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Financial Statements and
Supplementary Data&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Our
                                            Consolidated Financial Statements and Notes thereto and the report of Simon &amp; Edward,
                                            LLP, our independent registered public accounting firm, are set forth on pages F-2 through
                                            F-75 of this Report.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CONTENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-size: 10pt">PAGE</span></td>
    <td style="text-align: center; width: 5%"><span style="font-size: 10pt">F-2</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt; width: 87%"><a href="#F_002"><span style="font-size: 10pt">REPORT
    OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID 2485)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGE</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-5</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_003"><span style="font-size: 10pt">CONSOLIDATED
    BALANCE SHEETS AS OF DECEMBER 31, 2024 AND DECEMBER 31, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGE</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-6</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_004"><span style="font-size: 10pt">CONSOLIDATED
    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE YEARS ENDED DECEMBER 31, 2024 AND DECEMBER 31, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGE</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-7</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_005"><span style="font-size: 10pt">CONSOLIDATED
    STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND DECEMBER 31, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGES</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-8</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_006"><span style="font-size: 10pt">CONSOLIDATED
    STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT) FOR THE YEARS ENDED DECEMBER 31, 2024 AND DECEMBER 31, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGES</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-9</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_007"><span style="font-size: 10pt">NOTES
    TO CONSOLIDATED FINANCIAL STATEMENTS.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGE</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-43</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_008"><span style="font-size: 10pt">Unaudited
    Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGE</span></td>
    <td style="text-align: center"><span style="-keep: true"><span style="font-size: 10pt">F-</span>44</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_009"><span style="font-size: 10pt">Unaudited
    Consolidated Statements of Operations and Comprehensive Loss for the Three months Ended March 31, 2025 and 2024 (Restated)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGE</span></td>
    <td style="text-align: center"><span style="-keep: true"><span style="font-size: 10pt">F-</span>45</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_010"><span style="font-size: 10pt">Unaudited
    Consolidated Statements of Cash Flows for the Three months Ended March 31, 2025 and 2024 (Restated)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGES</span></td>
    <td style="text-align: center"><span style="-keep: true"><span style="font-size: 10pt">F-</span>46</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_011"><span style="font-size: 10pt">Unaudited
    Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Three months Ended March 31, 2025 and 2024 (Restated)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">PAGES</span></td>
    <td style="text-align: center"><span style="-keep: true"><span style="font-size: 10pt">F-</span>47</span></td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><a href="#F_012"><span style="font-size: 10pt">Notes
    to Unaudited Consolidated Financial Statements.</span></a></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 107; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><p style="margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="border-bottom: Black 4pt solid; width: 60%"><p style="margin-top: 0; margin-bottom: 0"><img alt="" src="image_003.jpg"/></p>
                       <p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p></td><td style="border-bottom: Black 4pt solid; text-align: justify; width: 40%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">17506
                                            Colima Road, Ste 101,</b></p>
                                                                                                        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Rowland
                                            Heights, CA 91748</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Tel: +1 (626) 581-0818</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Fax: +1 (626) 581-0809</b></p></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="F_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Shareholders and Board of Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ABVC BioPharma, Inc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="-keep: true">Fremont, CA</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b style="-keep: true">Opinion on the Consolidated
Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="-keep: true">We have audited the accompanying
consolidated balance sheets of ABVC BioPharma, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the
related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity (deficit), and cash flows for each of
the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended<b>,</b> in conformity with accounting
principles generally accepted in the United States of America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b style="-keep: true">Substantial Doubt
About the Company&#8217;s Ability to Continue as a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="-keep: true">The accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note
2 to the consolidated financial statements, the Company incurred substantial losses during the year ended December 31, 2024. As of December
31, 2024, the Company had a working capital deficit and net cash outflows from operating activities. These conditions raise substantial
doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also
described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this
uncertainty. Our opinion is not modified with respect to this matter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b style="-keep: true">Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="-keep: true">These consolidated financial
statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain
an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of
the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.<span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Our audits included performing procedures
to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b style="-keep: true">Critical Audit Matters
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The critical audit matters communicated below
are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and
(2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matters does not alter
in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Prepayment for asset acquisition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As described in Notes 5 of the consolidated
financial statements, the Company entered into a cooperation agreement on August 14, 2023, under which it is expected to acquire ownership
of certain properties and a parcel of land in Chengdu, China, by issuing 370,000 shares of common stock.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We identified the accounting for the initial
recognition of the prepayment as a critical audit matter due to the Company&#8217;s use of its own common stock as consideration, coupled
with the fact that the target assets were still under construction. This led to a high degree of auditor judgment, subjectivity and significant
audit effort was required in performing procedures to evaluate management&#8217;s determination of the cost and timing of control obtained.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The primary procedures we performed to address
this critical audit matter included:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Obtained
                                            and reviewed the cooperation agreement and other related legal documents, to evaluate the
                                            terms and conditions.</span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                                                                         </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inquired
                                            with the management regarding the arrangement outlined in the agreement</span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                          </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inspected
                                            the real property ownership certificate issued by the PRC authorities.</span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                               </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inspected
                                            the appraisal report of the real property under construction. </span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                     </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Tested
                                            the issuance of common stock through transfer agent confirmation procedure.</span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                              </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Examined
                                            the fair value applied in determining the cost of the acquired asset.</span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                                </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Verified
                                            the recognition of the asset by recalculating the cost to ensure accuracy.</span></td></tr></table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Issuance and Conversion of Senior Convertible Promissory Note
(the &#8220;Notes&#8221;)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As outlined in Note 7 to the consolidated
financial statements, during the reporting period, the Company issued multiple convertible notes with detachable warrants. These financial
instruments involved complex terms related to conversion features, fair value allocation, and classification between liabilities and
equity under applicable accounting standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We identified the issuance and subsequent
conversion of these notes as a critical audit matter due to the complexity of the financial instruments and the significant auditor judgment
required. Auditing these matters involved extensive procedures and effort to evaluate management&#8217;s accounting conclusions and application
of the relevant guidance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The primary procedures we performed to address
this critical audit matter included:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Obtained
                                            and reviewed the agreements for the convertible notes and detachable warrants to understand
                                            the key terms.</span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                                                                       </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Evaluated
                                            management&#8217;s analysis of the classification and measurement of the convertible notes
                                            and warrants.</span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                                                                      </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Tested
                                            the fair value measurements used in allocating proceeds and assessing conversion features.
                                            </span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                                             </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Verified
                                            the initial recognition of the Notes by reviewing the amortization schedules, testing the
                                            inputs, and independently recalculating the schedules for accuracy.</span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                                                                                                                         </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Assessed
                                            the accuracy and completeness of subsequent accounting entries, including verification of
                                            principal repayments and conversions to equity.</span></td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
                                                                                                              </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Confirmed
                                            the ending balances through direct confirmations obtained from the creditors.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">/s/ Simon &amp; Edward, LLP</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We have served as the Company's auditor since
2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">PCAOB ID: 2485</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Rowland Heights, California</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">April 15, 2025</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="F_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="-keep: true">ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December 31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December 31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">(Restated)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">ASSETS</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">Current Assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="-keep: true">Cash and cash equivalents</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-46374">248,382</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-46375">60,155</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-46376">615,433</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-46377">656,625</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Accounts receivable, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-46378">1,530</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Accounts receivable - related parties, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-46379">10,463</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Due from related parties - current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-46380">1,155,051</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-46381">747,573</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Short-term investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd" id="ixv-46382">64,736</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd" id="ixv-46383">79,312</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Prepaid expense and other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-46384">96,213</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-46385">101,051</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Total Current Assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-46386">2,179,815</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-46387">1,656,709</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-46388">511,088</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-46389">569,278</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating lease right-of-use assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-46390">640,387</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-46391">809,283</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Long-term investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-46392">2,258,754</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-46393">2,527,740</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Prepayment for long-term investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentForLongtermInvestmentsNoncurrent" scale="0" unitRef="usd" id="ixv-46394">1,124,842</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentForLongtermInvestmentsNoncurrent" scale="0" unitRef="usd" id="ixv-46395">1,274,842</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Prepayment for asset acquisition</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-46396">691,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-46397">691,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Other non-current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-46398">133,121</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-46399">141,231</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Due from related parties - non-current, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-46400">113,516</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><span style="-keep: true">Total Assets</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-46401">7,539,907</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-46402">7,784,499</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">LIABILITIES AND EQUITY</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Current Liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Short-term bank and other loans</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-46403">840,252</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-46404">899,250</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46405">3,509,422</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46406">3,548,352</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Contract liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-46407">81,115</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-46408">79,500</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Taxes payables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-46409">112,946</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Operating lease liabilities - current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-46410">403,581</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-46411">401,826</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Due to related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46412">773,045</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46413">173,493</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Convertible notes payable - third parties, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-46414">950,046</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-46415">886,522</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Total Current Liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46416">6,557,461</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46417">6,101,889</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Tenant security deposit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDepositLiability" scale="0" unitRef="usd" id="ixv-46418">21,680</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDepositLiability" scale="0" unitRef="usd" id="ixv-46419">21,680</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Operating lease liability - non-current</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-46420">236,807</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-46421">407,457</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="-keep: true">Total Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-46422">6,815,948</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-46423">6,531,026</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">COMMITMENTS AND CONTINGENCIES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">Equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Preferred stock, $<ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-46424"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-46425">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-46426"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-46427">20,000,000</ix:nonFraction></ix:nonFraction> authorized, <span style="-sec-ix-hidden: hidden-fact-8"><span style="-sec-ix-hidden: hidden-fact-9"><span style="-sec-ix-hidden: hidden-fact-10"><span style="-sec-ix-hidden: hidden-fact-11">nil</span></span></span></span> shares issued and outstanding</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="-keep: true">Common stock, $<ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction> authorized, <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">13,868,484</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">7,940,298</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2024 and 2023, respectively (1)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">13,868</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">7,940</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Stock to be issued</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockSubscriptionReceivedInAdvance" scale="0" unitRef="usd" id="ixv-46438">31,040</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-46439">78,595,065</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-46440">73,978,380</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Accumulated deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-46441">68,949,807</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-46442">64,046,929</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Accumulated other comprehensive income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-46443">445,665</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-46444">516,387</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Treasury stock</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd" id="ixv-46445">8,909,691</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd" id="ixv-46446">8,901,668</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Total Stockholders&#8217; equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-46447">1,226,140</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-46448">1,554,110</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Noncontrolling interest</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-46449">502,181</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-46450">300,637</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="-keep: true">Total Equity</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46451">723,959</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46452">1,253,473</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: normal; font-weight: normal; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total Liabilities and Equity</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-46453">7,539,907</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-46454">7,784,499</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>





</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i style="-keep: true">The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="F_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="-keep: true">ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b style="-keep: true">FOR THE YEARS ENDED
DECEMBER 31, 2024 AND 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023 (Restated)</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold"><span style="-keep: true">Revenue</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-46455">509,589</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-46456">152,430</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">Cost of revenue</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-46457">763</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-46458">302,037</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Gross profit (loss)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-46459">508,826</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-46460">149,607</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Operating expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Selling, general and administrative expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-46461">2,261,336</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-46462">5,368,278</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Research and development expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-46463">179,272</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-46464">1,062,916</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Stock-based compensation</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46465">2,773,460</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46466">185,933</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-46467">5,214,068</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-46468">6,617,127</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Loss from operations</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-46469">4,705,242</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-46470">6,766,734</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Other income (expense)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Interest income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-46471">87,358</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-46472">185,481</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Interest expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-46473">825,899</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-46474">1,313,671</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Operating sublease income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" unitRef="usd" id="ixv-46475">48,478</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" unitRef="usd" id="ixv-46476">65,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Gain (loss) on foreign exchange changes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd" id="ixv-46477">25,135</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" unitRef="usd" id="ixv-46478">22,690</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Loss on investment in equity securities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-46479">339,171</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-46480">221,888</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Write off unclaimed accrued liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:WriteOffUnclaimedAccruedLiabilites" scale="0" unitRef="usd" id="ixv-46481">255,592</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-46482">134,443</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-46483">3,384</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total other income (expenses)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-46484">664,334</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-46485">1,258,104</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Loss before provision for income tax</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46486">5,369,576</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46487">8,024,838</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Provision for income tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-46488">110,539</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-46489">256,006</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net loss</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46490">5,259,037</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46491">8,280,844</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Net loss attributable to noncontrolling interests</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46492">356,159</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46493">492,794</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Net loss attributed to ABVC and subsidiaries</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-46494">4,902,878</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-46495">7,788,050</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Foreign currency translation adjustment</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-46496">70,722</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-46497">741</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Comprehensive loss</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-46498">4,973,600</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-46499">7,788,791</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Net loss per share:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-46500"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-46501">0.42</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-46502"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-46503">1.80</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">Weighted average number of common shares outstanding (1):</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">11,673,980</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">4,335,650</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>





</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i style="-keep: true">The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="F_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="-keep: true">ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">FOR THE YEAR ENDED DECEMBER 31, 2024 AND
2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023<br/> (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Cash flows from operating activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt"><span style="-keep: true">Net loss</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46508">5,259,037</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46509">8,280,844</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="-keep: true">Depreciation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-46510">32,025</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-46511">28,531</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Stock-based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46512">2,773,460</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46513">185,933</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Provision for doubtful accounts</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-46514">11,993</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-46515">1,455,101</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Other non-cash expenses, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-46516">532,769</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-46517">1,244,245</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Loss on investment in equity securities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-46518">339,171</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-46519">221,888</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Amortization of right-of-use asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-46520">168,896</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-46521">351,859</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Deferred tax expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-46522">115,668</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Changes in operating assets and liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt"><span style="-keep: true">Accounts receivable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd" id="ixv-46523">228,557</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt"><span style="-keep: true">Prepaid expenses and other current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" sign="-" unitRef="usd" id="ixv-46524">12,948</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" sign="-" unitRef="usd" id="ixv-46525">101,926</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt"><span style="-keep: true">Due from related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" unitRef="usd" id="ixv-46526">293,962</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" unitRef="usd" id="ixv-46527">321,776</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd" id="ixv-46528">152,819</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd" id="ixv-46529">638,762</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt"><span style="-keep: true">Contract liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-46530">1,615</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-46531">68,515</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt"><span style="-keep: true">Tenant security deposit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" scale="0" unitRef="usd" id="ixv-46532">13,700</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt"><span style="-keep: true">Taxes payables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" sign="-" unitRef="usd" id="ixv-46533">112,946</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" unitRef="usd" id="ixv-46534">112,946</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27pt"><span style="-keep: true">Operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-46535">168,896</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-46536">351,859</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in"><span style="-keep: true">Net cash used in operating activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-46537">1,809,145</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-46538">4,186,848</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Cash flows from investing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="-keep: true">Purchase of equipment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-46539">21,201</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">Prepayment for equity investment</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="0" unitRef="usd" id="ixv-46540">338,985</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 27pt"><span style="-keep: true">Net cash used in investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-46541">360,186</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Cash flows from financing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Issuance of common stock</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-46542">1,050,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Repayment of short-term bank loans</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" unitRef="usd" id="ixv-46543">29,152</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" unitRef="usd" id="ixv-46544">1,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Proceeds from issuance of warrants</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd" id="ixv-46545">394,071</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd" id="ixv-46546">2,406,338</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="-keep: true">Proceeds from exercise of warrants</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd" id="ixv-46547">947,500</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Proceeds from (repayment of) related party payables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-46548">599,552</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" sign="-" unitRef="usd" id="ixv-46549">186,499</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Proceeds from convertible notes payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-46550">342,095</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-46551">1,462,622</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Repayment of convertible notes payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-46552">327,017</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Repurchase of treasury stocks</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:RepurchaseOfTreasuryStocks" scale="0" unitRef="usd" id="ixv-46553">7,320</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Proceeds from issuance of a promissory note</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:ProceedsFromIssuanceOfAPromissoryNote" scale="0" unitRef="usd" id="ixv-46554">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Proceeds from common stock subscription</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockPlans" scale="0" unitRef="usd" id="ixv-46555">31,040</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">Proceeds from subsidiary's executive contribution</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:ProceedsFromSubsidiarysShareholderContribution" scale="0" unitRef="usd" id="ixv-46556">137,500</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Net cash provided by financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-46557">1,980,769</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-46558">3,869,961</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-46559">24,589</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-46560">2,125</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-46561">147,035</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-46562">674,948</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Cash and cash equivalents and restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Beginning</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-46563">716,780</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-46564">1,391,728</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Ending</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-46565">863,815</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-46566">716,780</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Supplemental disclosure of cash flows</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Cash paid during the year for:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Interest expense paid</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-46567">22,539</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-46568">33,180</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Income taxes paid</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd" id="ixv-46569">25,863</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd" id="ixv-46570">27,392</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Non-cash financing and investing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Prepayment for asset acquisition by issuing common stock to a third party</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" scale="0" unitRef="usd" id="ixv-46571">691,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Issuance of common stock for conversion of debt</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" unitRef="usd" id="ixv-46572">593,714</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" unitRef="usd" id="ixv-46573">1,786,686</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Issuance of subsidiary&#8217;s common stock for consulting services</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfSubsidiarysCommonStockForConsultingServices" scale="0" unitRef="usd" id="ixv-46574">383,500</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i style="-keep: true">The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="F_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="-keep: true">ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">FOR THE YEAR ENDED DECEMBER 31, 2024 AND
2023 (Restated)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 7pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><b style="-keep: true">Common
    Stock</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="font: 7pt Times New Roman, Times, Serif; text-align: center"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="font: 7pt Times New Roman, Times, Serif; text-align: center"><b style="-keep: true">Stock<br/>
    Sub</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="font: 7pt Times New Roman, Times, Serif; text-align: center"><b style="-keep: true">Additional</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="font: 7pt Times New Roman, Times, Serif; text-align: center"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="font: 7pt Times New Roman, Times, Serif; text-align: center"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><b style="-keep: true">Treasury
    Stock</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="font: 7pt Times New Roman, Times, Serif; text-align: center"><b style="-keep: true">Non</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="font: 7pt Times New Roman, Times, Serif; text-align: center"/><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">Number
    of <br/>
    shares&#160;(1)</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">Amounts&#160;(1)</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">Subscribed<br/>
    stock</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">scription
    <br/>
    Receivable</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">Paid-in
    <br/>
    Capital</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">Accumulated<br/>
    Deficit</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">Comprehensive<br/>
    Income</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">Number
    of<br/>
    Shares</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">Amount</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">controlling<br/>
    Interest</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b style="-keep: true">Stockholders&#8217;<br/>
     Equity</b></td><td style="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 17.5%"><span style="-keep: true">Balance at
    December 31, 2022</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">3,286,190</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">3,286</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46577">1,354,440</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46578">67,937,050</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46579">54,904,439</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46580">517,128</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-46581">27,535</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46582">9,100,000</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46583">137,554</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46584">3,236,139</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: bold 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt; font-style: normal; font-variant: normal; font-weight: normal">Prior
    period adjustment</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">-</span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="-sec-ix-hidden: hidden-fact-57; font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">-</span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="-sec-ix-hidden: hidden-fact-58; font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">-</span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="abvc:PriorPeriodAdjustment" scale="0" unitRef="usd" id="ixv-46585">1,354,440</ix:nonFraction></span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="-sec-ix-hidden: hidden-fact-59; font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">-</span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="abvc:PriorPeriodAdjustment" scale="0" sign="-" unitRef="usd" id="ixv-46586">1,354,440</ix:nonFraction></span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="-sec-ix-hidden: hidden-fact-60; font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">-</span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="-sec-ix-hidden: hidden-fact-61; font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">-</span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="-sec-ix-hidden: hidden-fact-62; font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">-</span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><p style="-sec-ix-hidden: hidden-fact-63; font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">-</span></p></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Issuance of
    common shares for cash</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">300,000</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">300</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-46589">1,049,700</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-46590">1,050,000</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Issuance of
    common shares for consulting service</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" id="ix_18_fact" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">51,941</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">52</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-46593">196,048</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-46594">196,100</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Issuance of
    common shares for acquiring of Property</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" id="ix_20_fact" name="abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="shares">370,000</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" id="ix_21_fact" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="usd">370</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="usd" id="ixv-46597">691,530</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="usd" id="ixv-46598">691,900</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Issuance of common shares for
    exercise of convertible notes</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" id="ix_22_fact" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">3,732,167</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" id="ix_23_fact" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">3,732</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-46601">1,782,954</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-46602">1,786,686</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Warrant issued
    with convertible notes payable</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-46603">1,729,029</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-46604">1,729,029</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Issuance of
    pre-funded warrant</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-46605">700,000</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-46606">700,000</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Exercise of pre-funded warrant</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" id="ix_24_fact" name="abvc:StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" scale="0" unitRef="shares">200,000</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" id="ix_25_fact" name="abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" scale="0" unitRef="usd">200</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" scale="0" sign="-" unitRef="usd" id="ixv-46609">200</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Subsidiary
    executive contribution</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" scale="0" unitRef="usd" id="ixv-46610">82,897</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" scale="0" unitRef="usd" id="ixv-46611">54,603</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" scale="0" unitRef="usd" id="ixv-46612">137,500</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Net loss for
    the period</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46613">7,788,050</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46614">492,794</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46615">8,280,844</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Cumulative
    transaction adjustments</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-46616">741</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-46617">741</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Distribute
    as employee compensation</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="0" sign="-" unitRef="usd" id="ixv-46618">190,628</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" scale="0" unitRef="shares" id="ixv-46619">982</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="0" unitRef="usd" id="ixv-46620">198,332</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="0" unitRef="usd" id="ixv-46621">7,704</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: bold 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Balance at December 31,
    2023</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c37" decimals="INF" format="ixt:num-dot-decimal" id="ix_26_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">7,940,298</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" id="ix_27_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">7,940</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46624">73,978,380</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46625">64,046,929</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46626">516,387</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-46627">26,553</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46628">8,901,668</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46629">300,637</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46630">1,253,473</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Issuance of
    common shares for Lind CN</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" id="ix_28_fact" name="abvc:IssuanceOfCommonShareForLindCNRepayment" scale="0" unitRef="shares">1,705,303</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" id="ix_29_fact" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" scale="0" unitRef="usd">1,706</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" scale="0" unitRef="usd" id="ixv-46633">592,008</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" scale="0" unitRef="usd" id="ixv-46634">593,714</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Issuance of
    pre-funded warrant</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-46635">394,071</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-46636">394,071</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Issuance of
    common shares for acquisition of property</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" id="ix_30_fact" name="abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="shares">703,496</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" id="ix_31_fact" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="usd">703</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c51" decimals="INF" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" scale="0" sign="-" unitRef="shares" id="ixv-46639">703,496</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" sign="-" unitRef="usd" id="ixv-46640">703</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Stock-based
    compensation</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" id="ix_32_fact" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares">2,019,387</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" id="ix_33_fact" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">2,019</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46643">2,451,854</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46644">2,453,873</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Issuance of common shares for
    exercise of warrants</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" id="ix_34_fact" name="abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" scale="0" unitRef="shares">1,500,000</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" id="ix_35_fact" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" scale="0" unitRef="usd">1,500</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" scale="0" unitRef="usd" id="ixv-46647">946,000</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" scale="0" unitRef="usd" id="ixv-46648">947,500</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Repurchase
    of common stock from a prior employee</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c51" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" sign="-" unitRef="shares" id="ixv-46649">592</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd" id="ixv-46650">7,320</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd" id="ixv-46651">7,320</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Stock subscription
    received</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockSubscriptionReceived" scale="0" unitRef="usd" id="ixv-46652">31,040</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockSubscriptionReceived" scale="0" unitRef="usd" id="ixv-46653">31,040</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Issuance of
    subsidiary's common shares for consulting service</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" scale="0" unitRef="usd" id="ixv-46654">225,690</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" scale="0" unitRef="usd" id="ixv-46655">157,810</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" scale="0" unitRef="usd" id="ixv-46656">383,500</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Debt discount
    recognized from Issuance of subsidiary's convertible note</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="0" unitRef="usd" id="ixv-46657">2,276</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="0" unitRef="usd" id="ixv-46658">1,591</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="0" unitRef="usd" id="ixv-46659">3,867</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Decrease in
    ownership of subsidiary due to share issuance</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" unitRef="usd" id="ixv-46660">4,786</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" sign="-" unitRef="usd" id="ixv-46661">4,786</ix:nonFraction>)</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Net loss for
    the period</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46662">4,902,878</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46663">356,159</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46664">5,259,037</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Cumulative
    transaction adjustments</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-46665">70,722</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-46666">70,722</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt"><span style="-keep: true">Balance
    at December 31, 2024</span></td><td style="font: 7pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c53" decimals="INF" format="ixt:num-dot-decimal" id="ix_36_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">13,868,484</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" id="ix_37_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">13,868</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46669">31,040</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210"><span style="-keep: true">-</span></div></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46670">78,595,065</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46671">68,949,807</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46672">445,665</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c59" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-46673">730,641</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46674">8,909,691</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46675">502,181</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46676">723,959</ix:nonFraction></span></td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>





</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i style="-keep: true">The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="F_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="-keep: true">ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-23906"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ABVC BioPharma, Inc. (the &#8220;Company&#8221;),
formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#8217;s operating entity, American
BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology
to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops
its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision
believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization,
BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly
respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical
trials for the Company&#8217;s drugs and medical devices are being conducted at such world-famous institutions including Stanford University,
University of California San Fransisco (UCSF) and Cedar Sinai Medical Centre (CSMC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has four wholly-owned subsidiaries,
BriVision, BioLite Holding Inc. (&#8220;BioLite Holding&#8221;), BioKey Inc. (&#8220;BioKey&#8221;), BioKey (Cayman), Inc (&#8220;BioKey
Cayman&#8221;), and a majority-owned subsidiary, AiBtl BioPharma Inc. (&#8220;AiBtl&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioLite Holding was incorporated in the State
of Nevada with wholly owned subsidiary BioLite BVI, Inc. (&#8220;BioLite BVI&#8221;) that was incorporated in the British Virgin Islands.
BioLite BVI holds <ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46677">73</ix:nonFraction>% ownership of BioLite Inc. (&#8220;BioLite Taiwan&#8221;), a Taiwanese corporation that was founded in February
2006. BioLite Taiwan has been in the business of developing new drugs since it was incorporated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Yunzhiyi, a Taiwanese corporation, was incorporated
in August 2024, with <ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46678">90</ix:nonFraction>% owned by BioLite Taiwan and <ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46679">10</ix:nonFraction>% owned by Shuling Jiang, the Company&#8217;s director. This entity is set up
for holding the land that AiBtl acquired in Taiwan for developing health related business in Taiwan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Incorporated in California on November 20,
2000, BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioKey Cayman was incorporated in Cayman Islands
in July 2023, which is <ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-46680">100</ix:nonFraction>% owned by ABVC. This subsidiary has no activities since inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Acquisition of AiBtl BioPharma Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 12, 2023, the Company and BioLite
Taiwan each entered into a multi-year, global licensing agreement with AiBtl for the Company and BioLite Taiwan&#8217;s CNS drugs with
the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the &#8220;Licensed
Products&#8221;). The potential license will cover the Licensed Products&#8217; clinical trial, registration, manufacturing, supply,
and distribution rights. The parties are determined to collaborate on the global development of the Licensed Products. The parties are
also working to strengthen new drug development and business collaboration, including technology, interoperability, and standards development.
As per each of the respective agreements, each of ABVC and BioLite Taiwan received <ix:nonFraction contextRef="c91" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="6" unitRef="shares" id="ixv-46681">23</ix:nonFraction> million shares of AiBtl stock and as a result,
the Company has a controlling interest over AiBtl. If certain milestones are met, the Company and BioLite Taiwan are each eligible to
receive $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:BenefitsReceivableForMilestoneAttained" scale="0" unitRef="usd" id="ixv-46682">3,500,000</ix:nonFraction> and royalties equaling <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfRoyaltiesEqualing" scale="-2" unitRef="pure" id="ixv-46683">5</ix:nonFraction>% of net sales, up to $<ix:nonFraction contextRef="c7" decimals="-6" format="ixt:num-dot-decimal" name="abvc:AcquisitionForNetSales" scale="6" unitRef="usd" id="ixv-46684">100</ix:nonFraction> million. The financial statements of AiBtl are included in the
Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company concluded the assets acquired
and liabilities assumed did not meet the definition of a business as a limited number of inputs were acquired but no substantive business
processes or signs of output were acquired. As such, the acquisition was accounted for as an asset purchase. The purchase consideration
was nonmonetary assets (patent) and transfer on November 12, 2023. The equity interest transferred to ABVC and BioLite Taiwan on December
15, 2023.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="abvc_LiquidityGoingConcernAndRestatementTextBlock-c7_cont_1" escape="true" name="abvc:LiquidityGoingConcernAndRestatementTextBlock" id="ixv-23960"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">2. LIQUIDITY, GOING CONCERN, AND RESTATEMENT</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Liquidity and Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The accompanying financial statements have
been prepared in conformity with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;)
which contemplates continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and
liabilities are settled in the ordinary course of business at amounts disclosed in the financial statements. The Company&#8217;s ability
to continue as a going concern depends upon its ability to market and sell its products to generate positive operating cash flows. For
the year ended December 31, 2024, the Company reported net loss of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" unitRef="usd" id="ixv-46685">5,259,037</ix:nonFraction>. As of December 31, 2024, the Company&#8217;s working capital
deficit was $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:WorkingCapitalDeficit" scale="0" unitRef="usd" id="ixv-46686">4,377,646</ix:nonFraction>.&#160; In addition, the Company had net cash outflows of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-46687">1,809,145</ix:nonFraction>&#160;from operating activities for the year
ended December 31, 2024. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going
concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">To sustain its ability to support the Company&#8217;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash generated from
    operations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    available sources of financing from banks and other financial institutions in the U.S. and in Taiwan; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-keep: true">financial support from the Company&#8217;s related parties and shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Management&#8217;s plan is to continue to
improve operations to generate positive cash flows and raise additional capital through private or public offerings, or financial support
from related parties or shareholders. If the Company is not able to generate positive operating cash flows, and raise additional capital,
there is the risk that the Company may not be able to meet its short-term obligations. All of these factors raise substantial doubt about
the ability of the Company to continue as a going concern. The consolidated financial statements for the years ended December 31, 2024
and 2023 have been prepared on a going concern basis and do not include any adjustments to reflect the possible future effects on the
recoverability and classifications of assets or the amounts and classifications of liabilities that may result from the inability of
the Company to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Restatement Background and Explanation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has restated its financial statements
as of and for the year ended December 31, 2023, to correct misstatements in those prior periods related to improperly applying accounting
guidance on the share-based payments, incorrectly recognizing interest expenses upon the conversion of convertible debts, and misidentifying
the existence of non-controlling interest of our subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As disclosed in Note 5, the Company entered
into a cooperation agreement on August 14, 2023 with Zhong Hui Lian He Ji Tuan, Ltd. (the &#8220;Zhonghui&#8221;) to acquire <ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-46688">20</ix:nonFraction>% of the
ownership of certain property and a parcel of the land. According to the agreement, the Company issued <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="shares" id="ixv-46689">370,000</ix:nonFraction> shares of its common stock
as the consideration, and used $<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46690">20</ix:nonFraction> dollar per share to recognize the right as construction in progress on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the time of preparing its 2024 financial
statements, the Company reviewed the entire transaction, its relevant agreements and documentation, as well as the applicable accounting
guidance. The Company applied FASB Accounting Standard Codification (&#8220;ASC&#8221;) 845 Nonmonetary Transactions to determine the
fair value of the asset acquired would be more evident than the fair value of the consideration in exchange, the Company&#8217;s restricted
common stocks. The real estates acquired comes with a third-party valuation of $<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateOwnedValuationAllowance" scale="0" unitRef="usd" id="ixv-46691">7,400,000</ix:nonFraction> per the Company&#8217;s stake, which the value
of the acquired assets is guaranteed by Zhonghui. Upon further review, the Company considered ASC 718 Compensation &#8211; Stock Compensation,
should have been the appropriate guidance to apply given the Company&#8217;s common stocks are listed in Nasdaq with more observable
fair value (Level 1). Furthermore, at the time of issuance of these financial statements, no real estate title was transferred to the
Company. As a result, the Company adjusted the carrying value of the asset and reclassified the balance to &#8220;Prepayment for asset
acquisition&#8221; account to reflect the value of <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares" id="ixv-46692">370,000</ix:nonFraction> shares issued at $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46693">1.87</ix:nonFraction>, the closing price as of the contract date. The Company
also corrected the share price used to recognize stock compensation expense from $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46694">20</ix:nonFraction> to $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46695">1.87</ix:nonFraction> for the <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-46696">29,600</ix:nonFraction> shares of common stock issued
on the same day to several consultants. As a result, these adjustments reduced $<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" sign="-" unitRef="usd" id="ixv-46697">6,708,100</ix:nonFraction> for asset recognized and $<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="0" unitRef="usd" id="ixv-46698">536,648</ix:nonFraction> for stock-compensation
expense incurred in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In February 2023, the Company issued a convertible
note to LIND Global Fund II, LP (Note 7). Due to misapplication of ASC 470-20 instead of ASC 815-40, the Company overstated interest
expenses $<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-46699">1,179,669</ix:nonFraction> for the year ended December 31, 2023. The overstatement is offsetting against additional paid-in capital due to the
convertible note being converted to the Company&#8217;s own common stocks instead of being repaid or disposition.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify">&#160;</p><div>

</div><ix:continuation id="abvc_LiquidityGoingConcernAndRestatementTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In November 2023, the Company and one of its
subsidiaries entered into a licensing agreement with AiBtl. The Company accounted for a <ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-46700">100</ix:nonFraction>% control of AiBtl as of December 31, 2023,
but later discovered that AiBtl had outstanding founder shares that were not deposited to the stock transfer agent in the timely manner.
Such shares reduced the Company&#8217;s controlling interest from <ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-46701">100</ix:nonFraction>% to <ix:nonFraction contextRef="c101" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-46702">69.70</ix:nonFraction>%. Accordingly, the Company adjusted the relevant accounts
in our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As discussed in Note 12, in July 2019 the
Company issued <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-46703">644,972</ix:nonFraction> shares (post-split) of the Company&#8217;s common stock to four consultants for their services. Such stock-based
expenses were amortized over <ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="abvc:StockBasedExpensesAmortizationPeriod" id="ixv-46704">5</ix:nonNumeric> years starting from the issuance date. Per the Company&#8217;s further review, the services, along with
the agreements, were completed by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with the period
when services are received. Therefore, the Company reversed share-based compensation expenses of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-46705">451,480</ix:nonFraction> and $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-46706">902,960</ix:nonFraction> for the years
ended December 31, 2024 and 2023, respectively. The accumulated deficit as of December 31, 2022 was corrected with the Stock Subscription
Receivables for $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-46707">1,354,440</ix:nonFraction> as a result of such adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><span style="-keep: true">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Impact of the Restatement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c7" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" id="ixv-24064"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the year ended December 31, 2023 is presented below.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-keep: true">Consolidated Balance Sheets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">Property and equipment, net</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" unitRef="usd" id="ixv-46708">7,969,278</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" sign="-" unitRef="usd" id="ixv-46709">7,400,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" unitRef="usd" id="ixv-46710">569,278</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Prepayment for asset acquisition</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-46711">691,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-46712">691,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Assets</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-46713">14,492,599</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" sign="-" unitRef="usd" id="ixv-46714">6,708,100</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-46715">7,784,499</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46716">3,696,380</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" sign="-" unitRef="usd" id="ixv-46717">148,028</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46718">3,548,352</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Convertible notes payable &#8211; third parties, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-46719">569,456</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-46720">317,066</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-46721">886,522</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Due to related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46722">173,132</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46723">361</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46724">173,493</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Current Liabilities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46725">5,932,490</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46726">169,399</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-46727">6,101,889</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Liabilities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-46728">6,361,627</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-46729">169,399</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-46730">6,531,026</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-46731">82,636,966</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" sign="-" unitRef="usd" id="ixv-46732">8,658,586</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-46733">73,978,380</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Total stockholders&#8217; equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-46734">8,388,050</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-46735">6,833,940</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-46736">1,554,110</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Noncontrolling interest</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-46737">257,078</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-46738">43,559</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-46739">300,637</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Equity</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46740">8,130,972</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46741">6,877,499</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-46742">1,253,473</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Liabilities and Equity</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-46743">14,492,599</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-46744">6,708,100</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-46745">7,784,499</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-keep: true">Consolidated Statements of Operations</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">Stock based compensation</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46746">1,635,708</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" sign="-" unitRef="usd" id="ixv-46747">1,449,775</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46748">185,933</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Interest expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-46749">2,493,340</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" sign="-" unitRef="usd" id="ixv-46750">1,179,669</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-46751">1,313,671</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Net loss attributable to noncontrolling interests</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46752">394,632</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46753">98,162</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46754">492,794</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net loss</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46755">10,910,288</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-46756">2,629,444</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46757">8,280,844</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Basic and diluted net loss per common share</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-46758"><ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-46759">2.43</ix:nonFraction></ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-46760"><ix:nonFraction contextRef="c28" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-46761">0.63</ix:nonFraction></ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-46762"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-46763">1.80</ix:nonFraction></ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">Year Ended December
    31, 2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold"><span style="-keep: true">Consolidated Statements of Cash Flows</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">Net income (loss)</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46764">10,910,288</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-46765">2,629,444</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-46766">8,280,844</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Stock-based compensation</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46767">1,635,708</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" sign="-" unitRef="usd" id="ixv-46768">1,449,775</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46769">185,933</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Other non-cash income and expenses</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-46770">2,413,746</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" unitRef="usd" id="ixv-46771">1,169,501</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-46772">1,244,245</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd" id="ixv-46773">786,793</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-46774">148,031</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd" id="ixv-46775">638,762</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Due to related parties</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-46776">186,860</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" unitRef="usd" id="ixv-46777">186,860</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">Net cash used in operating activities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" sign="-" unitRef="usd" id="ixv-46778">4,235,845</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" sign="-" unitRef="usd" id="ixv-46779">48,997</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" sign="-" unitRef="usd" id="ixv-46780">4,186,848</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Due to related parties*</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" id="ix_38_fact" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" sign="-" unitRef="usd">186,499</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" id="ix_39_fact" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" sign="-" unitRef="usd">186,499</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Proceeds from subsidiary&#8217;s executive contribution</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="abvc:ProceedsFromSubsidiarysCommonStockSubscription" scale="0" unitRef="usd" id="ixv-46783">137,500</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:ProceedsFromSubsidiarysCommonStockSubscription" scale="0" unitRef="usd" id="ixv-46784">137,500</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">Net cash provided by financing activities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="0" unitRef="usd" id="ixv-46785">3,918,960</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="0" sign="-" unitRef="usd" id="ixv-46786">48,999</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="0" unitRef="usd" id="ixv-46787">3,869,961</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,125-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" scale="0" sign="-" unitRef="usd" id="ixv-46788">2</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" scale="0" unitRef="usd" id="ixv-46789">2,123</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Purchase of Property and equipment by issuing common stock to a third party</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="abvc:PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" scale="0" unitRef="usd" id="ixv-46790">7,400,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="abvc:PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" scale="0" sign="-" unitRef="usd" id="ixv-46791">7,400,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Prepayment for asset acquisition by issuing common stock to a third party</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" scale="0" unitRef="usd" id="ixv-46792">691,600</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" scale="0" unitRef="usd" id="ixv-46793">691,900</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Issuance of common stock for conversion of debt</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" unitRef="usd" id="ixv-46794">3,306,112</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" sign="-" unitRef="usd" id="ixv-46795">1,519,426</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" unitRef="usd" id="ixv-46796">1,786,686</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>


<p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#8217;s presentation.</span></ix:footnote></td>
</tr></table></ix:nonNumeric></ix:continuation><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_SignificantAccountingPoliciesTextBlock-c7_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-25089"><p style="margin: 0"><b style="-keep: true">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-25094"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis of Presentation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The accompanying consolidated financial statements
have been prepared in accordance with the U.S. GAAP and pursuant to the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).
All significant intercompany transactions and account balances have been eliminated. The Company&#8217;s fiscal year is the calendar
year.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_PriorPeriodReclassificationAdjustmentDescription-c7_cont_1" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="ixv-25104"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Reclassifications of Prior Year Presentation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_PriorPeriodReclassificationAdjustmentDescription-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Certain amounts on prior year&#8217;s consolidated
financial statements have been reclassified for consistency with the current year presentation. These reclassifications had no effect
on the reported results of operations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_UseOfEstimates-c7_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-25114"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="abvc_StockReverseSplitPolicyTextBlock-c7_cont_1" escape="true" name="abvc:StockReverseSplitPolicyTextBlock" id="ixv-25124"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stock Reverse Split</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abvc_StockReverseSplitPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 25, 2023, the Company filed a Certificate
of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its
common stock. The Company&#8217;s stockholders previously approved the Reverse Stock Split at the Company&#8217;s Special Shareholder
Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase
the per share trading value of the Company&#8217;s common stock, although that outcome is not guaranteed. All shares and related financial
information in this Form 10-K reflect this 1-for-10 reverse stock split.&#160;</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-25134"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair Value Measurements</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ASC 820 &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8211;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8211;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8211;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c7_cont_2" id="_SignificantAccountingPoliciesTextBlock-c7_cont_1"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_ConcentrationRiskCreditRisk-c7_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-25196"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c7_cont_2" id="_ConcentrationRiskCreditRisk-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company&#8217;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $<ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyExcessExpenseReimbursable" scale="0" unitRef="usd" id="ixv-46797">91,500</ix:nonFraction> (NTD <ix:nonFraction contextRef="c107" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyExcessExpenseReimbursable" scale="6" unitRef="twd" id="ixv-46798">3.0</ix:nonFraction> million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyExcessExpenseReimbursable" scale="0" unitRef="usd" id="ixv-46799">250,000</ix:nonFraction> covered by the U.S. Federal Deposit Insurance Corporation&#8217;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="abvc_ConcentrationOfClientsPolicyTextBlock-c7_cont_1" escape="true" name="abvc:ConcentrationOfClientsPolicyTextBlock" id="ixv-25211"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Clients</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="abvc_ConcentrationOfClientsPolicyTextBlock-c7_cont_2" id="abvc_ConcentrationOfClientsPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2024, management estimated
all accounts receivable balances are uncollectible and recognized $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-46800">11,993</ix:nonFraction> of credit loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="abvc_ConcentrationOfClientsPolicyTextBlock-c7_cont_3" id="abvc_ConcentrationOfClientsPolicyTextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2023, the most major clients,
specializes in developing and commercializing of dietary supplements and therapeutics in dietary supplement industry, accounted for <ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-46801">87</ix:nonFraction>%
of the Company&#8217;s total account receivable.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="abvc_ConcentrationOfClientsPolicyTextBlock-c7_cont_4" id="abvc_ConcentrationOfClientsPolicyTextBlock-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the year ended December 31, 2024, the
out-licensing income from our two major licensees, accounts for <ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-46802">58</ix:nonFraction>% and <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-46803">39</ix:nonFraction>% of the Company&#8217;s total revenues.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abvc_ConcentrationOfClientsPolicyTextBlock-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the year ended December 31, 2023, the
major client, distributing nutritional supplements in Asia Pacific, accounted for <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-46804">80</ix:nonFraction>% of the Company&#8217;s total revenues.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-25236"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cash and Cash Equivalents</span>&#160;</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of December 31, 2024 and 2023, the Company&#8217;s
cash and cash equivalents amounted to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-46805">248,382</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-46806">60,155</ix:nonFraction>, respectively. Some&#160;of the Company&#8217;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c7_cont_3" id="_SignificantAccountingPoliciesTextBlock-c7_cont_2"><ix:nonNumeric contextRef="c7" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c7_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-25260"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Restricted Cash </span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of December 31, 2024 and 2023, the Company&#8217;s restricted cash amounted $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-46807">615,433</ix:nonFraction> (NTD
<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="6" unitRef="twd" id="ixv-46808">20.2</ix:nonFraction> million) and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-46809">656,625</ix:nonFraction> (NTD <ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="6" unitRef="twd" id="ixv-46810">20.1</ix:nonFraction> million), respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c7_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ixv-25270"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Accounts receivable and allowance for expected credit losses
accounts</span>&#160;</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c7_cont_2" id="_TradeAndOtherAccountsReceivablePolicy-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Accounts receivable is recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c7_cont_3" id="_TradeAndOtherAccountsReceivablePolicy-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company make estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#8217;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Allowance for expected credit losses accounts
was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-46811">616,414</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-46812">616,505</ix:nonFraction> as of December 31, 2024 and 2023, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-25290"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c7_cont_4" id="_SignificantAccountingPoliciesTextBlock-c7_cont_3"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_4" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Collaborative Revenues &#8212; </b>The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_5" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_6" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s
judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_7" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">(i) Non-refundable upfront payments</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_8" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_9" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">(ii) Milestone payments</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_10" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative
agreement with collaboration partners.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_11" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_12" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">(iii) Multiple Element Arrangements</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_13" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c7_cont_5" id="_SignificantAccountingPoliciesTextBlock-c7_cont_4"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_14" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_15" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_16" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">(iv) Royalties and Profit Sharing Payments</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_17" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_18" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp; Manufacturing Organization Services (&#8220;CDMO&#8221;))</b> &#8212;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_19" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_20" id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c7_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c7_cont_6" id="_SignificantAccountingPoliciesTextBlock-c7_cont_5"><ix:nonNumeric contextRef="c7" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-25437"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and Equipment, net</span></p></ix:nonNumeric>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c7_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Property and equipment, net is carried at
cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of
the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related
gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of
the remaining lease term or estimated useful life of the asset. <ix:nonNumeric contextRef="c7" continuedAt="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock-c7_cont_1" escape="true" name="abvc:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" id="ixv-46813">Depreciation is calculated on the straight-line method generally based
on the following useful lives:</ix:nonNumeric></span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock-c7_cont_1"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c7_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Estimated&#160;Life<br/> in Years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 91%; text-align: justify"><span style="-keep: true">Buildings and leasehold improvements</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="-keep: true"><ix:nonNumeric contextRef="c118" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-46814">5</ix:nonNumeric> ~ <ix:nonNumeric contextRef="c119" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-46815">50</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Machinery and equipment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true"><ix:nonNumeric contextRef="c120" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-46816">5</ix:nonNumeric> ~ <ix:nonNumeric contextRef="c121" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-46817">10</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Office equipment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true"><ix:nonNumeric contextRef="c122" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-46818">3</ix:nonNumeric> ~ <ix:nonNumeric contextRef="c123" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-46819">6</ix:nonNumeric></span></td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-25482"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></p></ix:nonNumeric>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has adopted ASC subtopic 360-10,
Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles
held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances
warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a
forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying
value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition
of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less
costs to sell.</span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_EquityMethodInvestmentsPolicy-c7_cont_1" escape="true" name="us-gaap:EquityMethodInvestmentsPolicy" id="ixv-25492"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Long-term Equity Investment</span>&#160;</p></ix:nonNumeric>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EquityMethodInvestmentsPolicy-c7_cont_2" id="_EquityMethodInvestmentsPolicy-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company acquires the equity investments
to promote business and strategic objectives. The accounting treatment for equity investments, where the Company does not have control
over the investees, is as follows:</span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EquityMethodInvestmentsPolicy-c7_cont_3" id="_EquityMethodInvestmentsPolicy-c7_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Marketable equity investments: The Company measures marketable equity
    securities at fair value at each reporting date, with unrealized gains and losses recognized in net income in accordance with <span style="font-style: normal; font-weight: normal">ASC
    321. Fair value is</span> determined based on quoted market prices or other observable inputs.</span></td></tr>
  </table></ix:continuation>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EquityMethodInvestmentsPolicy-c7_cont_4" id="_EquityMethodInvestmentsPolicy-c7_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable equity
    investments: When the equity method does not apply, non-marketable equity investments are accounted for at cost, adjusted for observable
    price changes in orderly transactions for identical or similar investments and for impairments, if applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity method investments:
    Investments in which the Company has the ability to exercise significant influence, but not control, over the investee, are accounted
    for using the equity method. The Company recognizes its proportionate share of the investee&#8217;s income or loss in gains (losses)
    on equity investments on a monthly basis.</span></td></tr>
  </table></ix:continuation>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_EquityMethodInvestmentsPolicy-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, considering this a critical accounting
estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#8217;s
fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee,
changes in general market conditions in the investee&#8217;s industry or geographic area, and the management and governance structure
of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches.
The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The
income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#8217;
revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment exists could
change in the future due to new developments or changes in applied assumptions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="abvc_OtherThanTemporaryImpairmentPolicyTextBlock-c7_cont_1" escape="true" name="abvc:OtherThanTemporaryImpairmentPolicyTextBlock" id="ixv-25544"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Other-Than-Temporary Impairment</span></p></ix:nonNumeric>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abvc_OtherThanTemporaryImpairmentPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company periodically reviews its non-marketable
equity investments and equity method investments, with recognition in profit and loss when declines in value are considered other than
temporary. the Company assesses the severity and duration of any impairment, along with qualitative and quantitative factors, such as
the investee&#8217;s financial performance, adverse market or regulatory conditions, operational changes, or additional funding needs.
Evidence of a loss in value might include the inability to recover the carrying amount of the investment or the investee&#8217;s failure
to sustain earnings capacity to justify its valuation. Impairments deemed other than temporary are recorded in gains (losses) on equity
investments, even if the decline exceeds the losses recognized under the equity method, where applicable.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c7_cont_7" id="_SignificantAccountingPoliciesTextBlock-c7_cont_6"><ix:nonNumeric contextRef="c7" continuedAt="abvc_ConvertibleNotesPayablePolicyTextBlock-c7_cont_1" escape="true" name="abvc:ConvertibleNotesPayablePolicyTextBlock" id="ixv-25568"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Convertible Notes Payable</span></p></ix:nonNumeric>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abvc_ConvertibleNotesPayablePolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for convertible notes
payable in accordance with ASC 470-20, Debt with Conversion and Other Options, and ASC 815, Derivatives and Hedging, as applicable. Upon
issuance, the Company evaluates whether the embedded conversion feature should be bifurcated as a derivative under ASC 815 or classified
within equity under ASC 470-20. This assessment includes analyzing the terms of the conversion feature and determining if it requires
separate accounting. If the conversion feature is classified as equity, the proceeds from the issuance are allocated between the debt
and equity components. The debt component is recorded at its fair value, and the residual amount is allocated to equity. The debt component
is carried at amortized cost, with any discount amortized to interest expense over the term of the note using the effective interest
method. Upon conversion, the carrying amount of the debt is reclassified to equity, and no gain or loss is recognized. If the note is
settled in cash, any difference between the carrying amount and the settlement amount is recognized in profit and loss.</span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_DerivativesPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:DerivativesPolicyTextBlock" id="ixv-25578"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Warrants</span></p></ix:nonNumeric>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_DerivativesPolicyTextBlock-c7_cont_2" id="_DerivativesPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for warrants as either
equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative
guidance in ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC
815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including
whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net
cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This
assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly
period end date while the warrants are outstanding. The Company determined that upon further review of the warrant agreement, the Public
Warrants issued pursuant to the warrant agreement qualify for equity accounting treatment.</span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_DerivativesPolicyTextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For issued or modified warrants that meet
all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance.
For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded
as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated
fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.&#160;</span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_ResearchAndDevelopmentExpensePolicy-c7_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-25593"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Research and Development Expenses</span></p></ix:nonNumeric>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c7_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for the cost of using
licensing rights in research and development cost according to ASC 730-10-25-1. This guidance provides that absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses when incurred.</span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for R&amp;D costs in
accordance with ASC 730, Research and Development (&#8220;ASC 730&#8221;). Research and development expenses are charged to expense as
incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development
expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related
overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical
and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that
will be used in future research and development activities are expensed when the activity has been performed or when the goods have been
received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research
and development services, costs are expensed as services are performed.</span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_PostemploymentBenefitPlansPolicy-c7_cont_1" escape="true" name="us-gaap:PostemploymentBenefitPlansPolicy" id="ixv-25608"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Post-retirement and post-employment benefits</span></p></ix:nonNumeric>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<ix:continuation id="_PostemploymentBenefitPlansPolicy-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company&#8217;s subsidiaries in Taiwan
adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor
regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="abvc:LaborPensionFundPerMonth" scale="-2" unitRef="pure" id="ixv-46820">6</ix:nonFraction>% of
the worker&#8217;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-46821">6</ix:nonFraction>% of employees&#8217; salaries
to the employees&#8217; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts
for such employee benefits, which were expensed as incurred, were $<ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-46822">11,642</ix:nonFraction> (NTD <ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="6" unitRef="twd" id="ixv-46823"><ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="6" unitRef="twd" id="ixv-46824">0.4</ix:nonFraction></ix:nonFraction> million) and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-46825">10,314</ix:nonFraction>&#160;(NTD 0.4 million) for the
years ended December 31, 2024 and 2023, respectively. Other than the above, the Company does not provide any other post-retirement or
post-employment benefits.</span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c7_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-25619"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stock-based Compensation</span></p></ix:nonNumeric>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c7_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221;.
Total director, officer, and employee stock-based compensation expenses were $<ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46826">1,995,049</ix:nonFraction> and $<ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46827">0</ix:nonFraction> for the years ended December 31, 2024
and 2023, respectively.</span></p></ix:continuation>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221; and ASC 505-50 &#8220;Equity-Based Payments
to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $<ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-46828">506,583</ix:nonFraction> for consulting services and $<ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="0" unitRef="usd" id="ixv-46829">271,828</ix:nonFraction> for rent for the year ended December 31, 2024, and
$<ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-46830">185,933</ix:nonFraction>&#160;for consulting services for the year ended December 31, 2023.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c7_cont_8" id="_SignificantAccountingPoliciesTextBlock-c7_cont_7"><ix:nonNumeric contextRef="c7" continuedAt="_IncomeTaxPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-25649"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income Taxes</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c7_cont_2" id="_IncomeTaxPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for income taxes using
the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood
of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects
of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire
before the Company is able to realize their benefits, or future deductibility is uncertain.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under ASC 740, a tax position is recognized
as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax
examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it
is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations
based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold
to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit
that is greater than <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="abvc:DefinedBenefitPlanFundedPercentages" scale="-2" unitRef="pure" id="ixv-46831">50</ix:nonFraction> percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not
recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions
that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which
the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income
tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended December
31, 2024 and 2023. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods,
disclosures and transition.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock-c7_cont_1" escape="true" name="abvc:ValuationOfDeferredTaxAssetsPolicyTextBlock" id="ixv-25664"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">A valuation allowance is recorded to reduce
the Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_EarningsPerSharePolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-25674"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Loss Per Share of Common Stock</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company calculates net loss per share
in accordance with ASC 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</span></p></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-25684"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commitments and Contingencies</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has adopted ASC 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.</span></p></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-25694"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Foreign-currency Transactions</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#8217;
Equity.</span></p></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c7_cont_9" id="_SignificantAccountingPoliciesTextBlock-c7_cont_8"><ix:nonNumeric contextRef="c7" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-25716"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Segment Reporting</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c7_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ASC 280 &#8220;Segment Reporting&#8221; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c7_cont_2">The Company currently has&#160;<ix:nonFraction contextRef="c7" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-46833">one</ix:nonFraction>&#160;reportable
segment and assets are reviewed on a consolidated basis.</ix:continuation> As such, segment data is not provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-25730"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following tables present revenue and gross
profit information for each of our only reportable segment:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">For The Years Ended<br/>
    December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023 (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-keep: true">Revenue</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-46834">509,589</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-46835">152,430</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Cost of Revenue</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-46836">763</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-46837">302,037</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Segment Gross Profit (Loss)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-46838">508,826</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-46839">149,607</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Depreciation expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-46840">32,025</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-46841">28,531</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="ixv-25858"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">For The Years Ended<br/>
    December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023 (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Segment Gross Profit (Loss)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-46842">508,826</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-46843">149,607</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">Less:</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Selling, general and administrative expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-46844">2,261,336</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-46845">5,368,278</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Research and development expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-46846">179,272</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-46847">1,062,916</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Stock-based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46848">2,773,460</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-46849">185,933</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Add (Less):</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Interest income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-46850">87,358</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-46851">185,481</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Interest expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-46852">825,899</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-46853">1,313,671</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating sublease income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" unitRef="usd" id="ixv-46854">48,478</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" unitRef="usd" id="ixv-46855">65,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Gain (loss) on foreign exchange changes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd" id="ixv-46856">25,135</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" unitRef="usd" id="ixv-46857">22,690</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Loss on investment in equity securities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-46858">339,171</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-46859">221,888</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Write off unclaimed accrued liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:WriteOffUnclaimedAccruedLiabilites" scale="0" unitRef="usd" id="ixv-46860">255,592</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-46861">134,443</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-46862">3,384</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Loss before provision for income tax</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46863">5,369,576</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-46864">8,024,838</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c7_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-26158"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c7_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In August 2023, the FASB issued ASU 2023-05,
Business Combinations&#8212;Joint Venture Formations (Subtopic 805-60) which requires certain joint ventures to apply a new basis of
accounting upon formation by recognizing and initially measuring most of their assets and liabilities at fair value. The guidance does
not apply to joint ventures that may be proportionately consolidated and those that are collaborative arrangements. ASU 2023-05 is effective
for joint venture with a formation date on or after January 1, 2025, early adoption is permitted. The Company is currently evaluating
the impact that the standard will have on its unaudited consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c7_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c7_cont_9"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_CollaborativeArrangementDisclosureTextBlock-c7_cont_1" escape="true" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="ixv-26194"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">4. COLLABORATIVE AGREEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreements with BHK, a
related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015,
    BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development
    Agreement&#8221;), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple
    Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual
    property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be
    shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date
    of first commercial sale of the Product in in Asia excluding Japan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c124" continuedAt="_LongTermPurchaseCommitmentMilestones-c124_cont_1" name="us-gaap:LongTermPurchaseCommitmentMilestones" id="ixv-26215"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_LongTermPurchaseCommitmentMilestones-c124_cont_2" id="_LongTermPurchaseCommitmentMilestones-c124_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_LongTermPurchaseCommitmentMilestones-c124_cont_3" id="_LongTermPurchaseCommitmentMilestones-c124_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_LongTermPurchaseCommitmentMilestones-c124_cont_4" id="_LongTermPurchaseCommitmentMilestones-c124_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_LongTermPurchaseCommitmentMilestones-c124_cont_5" id="_LongTermPurchaseCommitmentMilestones-c124_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_LongTermPurchaseCommitmentMilestones-c124_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In December 2015, BHK has paid a non-refundable
upfront cash payment of $<ix:nonFraction contextRef="c125" decimals="-6" format="ixt:num-dot-decimal" name="abvc:NonrefundableUpfrontCashPayment" scale="6" unitRef="usd" id="ixv-46865">1</ix:nonFraction> million, or <ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure" id="ixv-46866">10</ix:nonFraction>% of $<ix:nonFraction contextRef="c125" decimals="-5" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="6" unitRef="usd" id="ixv-46867">10.0</ix:nonFraction> million, upon the signing of BHK Co-Development Agreement. The Company concluded
that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis
and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in
2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative
agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement.
In August 2016, the Company has received the second milestone payment of <span style="-sec-ix-hidden: hidden-fact-264">NTD31,649,000</span>, approximately equivalent to $<ix:nonFraction contextRef="c126" decimals="-6" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="6" unitRef="usd" id="ixv-46868">1</ix:nonFraction> million, and recognized
collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase
II clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-46869">12</ix:nonFraction>% of BHK&#8217;s net sales related to BLI-1401-2 Products. As of December 31, 2024 and 2023,
the Company has not earned the royalty under the BHK Co-Development Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#8220;BHK Collaborative Agreements&#8221;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#8220;Targeting Major Depressive Disorder&#8221; (BLI-1005 Products) and BLI-1006 for
&#8220;Targeting Inflammatory Bowel Disease&#8221; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property
rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50
between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial
sale of the Product in in Asia excluding Japan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In 2015, the Company recognized the cash receipt
in a total of <span style="-sec-ix-hidden: hidden-fact-265">NTD50 million</span>, approximately equivalent to $<ix:nonFraction contextRef="c128" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" unitRef="usd" id="ixv-46870">1.6</ix:nonFraction> million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition to the total of <span style="-sec-ix-hidden: hidden-fact-266">NTD50 million</span>,
approximately equivalent to $<ix:nonFraction contextRef="c130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" unitRef="usd" id="ixv-46871">1.6</ix:nonFraction> million, BioLite Taiwan is entitled to receive <ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="abvc:NetSalesProfitPercentage" scale="-2" unitRef="pure" id="ixv-46872">50</ix:nonFraction>% of the future net licensing income or net sales profit.
As of December 31, 2024 and 2023, the Company has not earned the royalty under the BHK Collaborative Agreements.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c7_cont_2" id="_CollaborativeArrangementDisclosureTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Co-Development agreement with Rgene
Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 26, 2017, the Company through its subsidiary,
BriVision, entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;),
a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant
to Co-Dev Agreement, the Company and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination
Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev
Agreement, Rgene is required to&#160;pay the Company $<ix:nonFraction contextRef="c131" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForParticipationLiabilities" scale="6" unitRef="usd" id="ixv-46873">3.0</ix:nonFraction> million in cash or stock of Rgene with equivalent value by August 15, 2017.
The payment is for the compensation of the Company&#8217;s past research efforts and contributions before the Co-Dev Agreement was signed
and it does not relate to any future commitments made by the Company and Rgene in this Co-Dev Agreement. In addition to $<ix:nonFraction contextRef="c132" decimals="-5" format="ixt:num-dot-decimal" name="abvc:AdditionCashPayment" scale="6" unitRef="usd" id="ixv-46874">3.0</ix:nonFraction> million,
the Company is entitled to receive <ix:nonFraction contextRef="c132" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure" id="ixv-46875">50</ix:nonFraction>% of the future net licensing income or net sales profit earned by Rgene, if any, and any development
costs shall be equally shared by both the Company and Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 1, 2017, the Company has delivered
all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $<ix:nonFraction contextRef="c133" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" unitRef="usd" id="ixv-46876">3.0</ix:nonFraction> million
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended
December 31, 2017, the Company has received $<ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-46877">450,000</ix:nonFraction> in cash. On December 24, 2018, the Company received the remaining balance of $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-46878">2,550,000</ix:nonFraction>
in the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of NTD50 per share (approximately equivalent to $<ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46879">1.60</ix:nonFraction>
per share), for an aggregate number of <ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="abvc:EquityMethodLongTermInvestment" scale="0" unitRef="shares" id="ixv-46880">1,530,000</ix:nonFraction> shares, which accounted for equity method long-term investment as of December 31, 2018.
On December 31, 2018, the Company determined to fully write off this investment based on the Company&#8217;s assessment of the severity
and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes
in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements,
and Rgene&#8217;s ability to remain in business. All projects that have been initiated will be managed and supported by the Company and
Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company and Rgene signed an amendment
to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer
Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination
Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized.
Other provisions of the Co-Dev Agreement remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 10, 2022, the Company expanded its
co-development partnership with Rgene. On that date, BioKey, ABVC has entered into a Clinical Development Service Agreement with Rgene
to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic
cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under the U.S. FDA
IND regulatory requirements. Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $<ix:nonFraction contextRef="c137" decimals="-5" format="ixt:num-dot-decimal" name="abvc:ServiceAgreementEligibilityAmount" scale="6" unitRef="usd" id="ixv-46881">3.0</ix:nonFraction> million
over a <ix:nonNumeric contextRef="c138" format="ixt-sec:duryear" name="abvc:MilestoneRegulatoryPaymentAmountPeriod" id="ixv-46882">3</ix:nonNumeric>-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period.
The Service Agreement shall remain in effect until the expiration date of the last patent and automatically renew for 5 more years unless
terminated earlier by either party with six months written notice. Either party may terminate the Service Agreement for cause by providing
30 days written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Through a series of transactions over the
past 5 years, the Company and Rgene have co-developed the three drug products covered by the Service Agreement, which has resulted in
the Company owning <ix:nonFraction contextRef="c139" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46883">31.62</ix:nonFraction>% of Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As part of the Rgene Studies, the Company
agreed to loan $<ix:nonFraction contextRef="c140" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="6" unitRef="usd" id="ixv-46884">1.0</ix:nonFraction> million to Rgene, for which Rgene has provided the Company with a <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="abvc:WorkingCapitalConvertibleLoanPercentage" scale="-2" unitRef="pure" id="ixv-46885">5</ix:nonFraction>% working capital convertible loan (the &#8220;Note&#8221;).
If the Note is fully converted, the Company will own an additional <ix:nonFraction contextRef="c141" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46886">6.4</ix:nonFraction>% of Rgene. The Company is expected to receive the outstanding
loan from the related party by the first half of 2025, either by cash or conversion of shares of Rgene. The Company may convert the Note
at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-46887">1.00</ix:nonFraction> per share or (ii) <ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46888">20</ix:nonFraction>% discount
of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in
the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service
Agreement will trigger an event of default under the Note if not cured after 5 business days of written notice regarding the breach is
provided. Upon an event of default, the outstanding principal and any accrued and unpaid interest shall be immediately due and payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Service Agreement shall remain in effect
until the expiration date of the last patent and automatically renew for 5 more years unless terminated earlier by either party with
six months written notice. Either party may terminate the Service Agreement for cause by providing 30 days written notice.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c7_cont_3" id="_CollaborativeArrangementDisclosureTextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Rgene has further agreed, effective July 1,
2022, to provide the Company with a seat on Rgene&#8217;s Board of Directors until the loan is repaid in full. The Company has nominated
Dr. Jiang, its Chief Strategy Officer and Director to occupy that seat; Dr. Jiang is also one of the Company&#8217;s largest shareholders,
owning <ix:nonFraction contextRef="c143" decimals="3" format="ixt:num-dot-decimal" name="abvc:EquityMethodInvestmentsOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46889">12.8</ix:nonFraction>% of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Rgene Studies is a related party transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreement with BioFirst
Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 24, 2017, the Company through its
subsidiary, BriVision, entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst Corporation
(&#8220;BioFirst&#8221;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the
&#8220;Product&#8221;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling
beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See
Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $<ix:nonFraction contextRef="c144" decimals="-5" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="6" unitRef="usd" id="ixv-46890">3.0</ix:nonFraction> million in cash or
stock of the Company before September 30, 2018. The amount of $<ix:nonFraction contextRef="c145" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForParticipationLiabilities" scale="6" unitRef="usd" id="ixv-46891">3.0</ix:nonFraction> million is in connection with the compensation for BioFirst&#8217;s
past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate
to any future commitments in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive <ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure" id="ixv-46892">50</ix:nonFraction>% of the future
net licensing income or net sales profit, if any, and any development cost shall be equally shared by both the Company and BioFirst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to the Company. The Company determined to fully expense the entire amount of $<ix:nonFraction contextRef="c146" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" unitRef="usd" id="ixv-46893">3.0</ix:nonFraction>
millionsince currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative
future uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses immediately. Hence, the entire amount of $<ix:nonFraction contextRef="c147" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-46894">3.0</ix:nonFraction> million is fully expensed as research and development expense during the year
ended December 31, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 30, 2019, BriVision entered into a
Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued
<span style="-sec-ix-hidden: hidden-fact-267">42,857 shares</span> (post-split) of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" unitRef="usd" id="ixv-46895">3.0</ix:nonFraction> million owed by the Company to BioFirst
(the &#8220;Total Payment&#8221;) in connection with BioFirst Collaborative Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 5, 2019, BriVision entered into
a second Stock Purchase Agreement (&#8220;Purchase Agreement 2&#8221;) with BioFirst. Pursuant to Purchase Agreement 2, the Company issued
<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-46896">41,470</ix:nonFraction> shares (post-split) of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="0" unitRef="usd" id="ixv-46897">2,902,911</ix:nonFraction> owed by the Company to BioFirst
in connection with a loan provided to BriVision from BioFirst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="-keep: true">On November 4, 2020, the Company executed
an amendment to the BioFirst Collaborative Agreement to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal Storage Solution
to the agreement. ABV-2002 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while ABV-2001 has
broader utilization during a variety of ocular procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Initially the Company will focus on ABV-2002,
a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial
keratoplasty (back layer cornea transplant). ABV-2002 is a solution comprised of a specific poly amino acid that protects ocular tissue
from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity
to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration
results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant
phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can
be manufactured at lower cost. Further ABV-2002 product development was put on hold due the lack of funding.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c7_cont_4" id="_CollaborativeArrangementDisclosureTextBlock-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition, BioFirst was incorporated on
November 7, 2006, focusing on the R&amp;D, manufacturing, and sales of innovative patented pharmaceutical products. The technology of
BioFirst comes from the global exclusive licensing from domestic R &amp; D institutions. Currently, the main research and development
product is the vitreous substitute (Vitargus&#174;) Licensed by the National Health Research Institutes. Vitargus is the world&#8217;s
first bio-degradable vitreous substitute and offers a number of advantages over current vitreous substitutes by minimizing medical complications
and reducing the need for additional surgeries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioFirst has started the construction of a
GMP factory in Hsinchu Biomedical Science Park, Taiwan, with the aim at building a production base to supply the global market, and promote
the construction of bio-degradable vitreous substitute manufacturing centers in Taiwan. Completion of this factory would allow ABVC to
manufacture Vitargus with world-class technology in a GMP certified pharmaceutical factory. BioFirst is targeting to complete the construction
in 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2024, the Company has not
earned any net licensing income or net sales profit earned by BioFirst under these collaborative agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreement with ForSeeCon
Eye Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 25, 2024, the Company and BioFirst
each entered into a twenty-year, global definitive licensing agreement (the &#8220;FEYE Licensing Agreement&#8221;) with ForSeeCon Eye
Corporation, a company registered in the British Virgin Islands (&#8220;FEYE&#8221;) for the products in the Company and BioFirst&#8217;s
Ophthalmology pipeline, including Vitargus (the &#8220;Vitargus Products&#8221;). The license covers the Vitargus Products&#8217; clinical
trial, registration, manufacturing, supply, and distribution rights; FEYE also has the rights to sublicense or partner with a third party
to develop the Licensed Products. As per each of the respective FEYE Licensing Agreements, each of the Company and BioFirst shall receive
a total licensing fee of $<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxesAndLicenses" scale="6" unitRef="usd" id="ixv-46898">33.5</ix:nonFraction> million, composed of an upfront payment of $<ix:nonFraction contextRef="c151" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="usd" id="ixv-46899">30</ix:nonFraction> million, which can instead be paid with <ix:nonFraction contextRef="c152" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="6" unitRef="shares" id="ixv-46900">5</ix:nonFraction> million shares
of FEYE stock at $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46901">6</ix:nonFraction> per share within 30 days after the execution of the FEYE Licensing Agreement, and a $<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="abvc:MilestoneRegulatoryPaymentAmount" scale="6" unitRef="usd" id="ixv-46902">3.5</ix:nonFraction> million cash milestone payment,
due 30 days upon completion of next round fundraising. Additionally, each of the Company and BioFirst are eligible to receive royalties
of <ix:nonFraction contextRef="c153" decimals="2" format="ixt:num-dot-decimal" name="abvc:RoyaltiesPercentage" scale="-2" unitRef="pure" id="ixv-46903">5</ix:nonFraction>% of net sales.&#160;As of December 31, 2024, the Company received <ix:nonFraction contextRef="c154" decimals="-6" format="ixt:num-dot-decimal" name="abvc:ReceivedShares" scale="6" unitRef="shares" id="ixv-46904">5</ix:nonFraction> million FEYE shares but did not recognize such licensing revenue
since the fair value of FEYE stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 18, 2024, the Company and BioFirst,
each entered into an amendment (the <span style="font-style: normal; font-weight: normal">&#8220;Amendment&#8221;) t</span>o the Licensing
Agreement with FEYE, pursuant to which the Company and BioFirst have agreed to allow FEYE to pay the second milestone payment in the
amount of $<ix:nonFraction contextRef="c155" decimals="-5" format="ixt:num-dot-decimal" name="abvc:MilestoneRegulatoryPaymentAmount" scale="6" unitRef="usd" id="ixv-46905">3.5</ix:nonFraction> million per Licensing Agreement, incrementally (such as $<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="abvc:LicensingAgreement" scale="0" unitRef="usd" id="ixv-46906">100,000</ix:nonFraction>), at any given time, rather than in one lump sum. During
year ended December 31, 2024, the Company received in cash and recognized revenue of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-46907">296,000</ix:nonFraction>, respectively, pursuant to the Amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreement with OncoX BiopPharma,
Inc., a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 16, 2024, the Company entered into
a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (&#8220;Oncox&#8221;),
pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the &#8220;Lung Cancer
Products&#8221;), within North America for 20 years (the &#8220;April 2024 Oncox Agreement&#8221;). In consideration thereof, Oncox shall
pay ABVC $<ix:nonFraction contextRef="c157" decimals="-4" format="ixt:num-dot-decimal" name="abvc:ConsiderationPaidForAgreement" scale="6" unitRef="usd" id="ixv-46908">6.25</ix:nonFraction> million (or <ix:nonFraction contextRef="c157" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="6" unitRef="shares" id="ixv-46909">1.25</ix:nonFraction> million Oncox shares valued at $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46910">5</ix:nonFraction> per share) 30 days after entering into the agreement and $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionalMilestonePaymentInCash" scale="0" unitRef="usd" id="ixv-46911">625,000</ix:nonFraction>,
30 days following the completion of Oncox&#8217;s next round of fundraising, of which there is no guarantee; ABVC is also entitled to
<ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-46912">5</ix:nonFraction>% royalties based on the net sales, as defined in the April 2024 Oncox Agreement, from the first commercial sale of the Lung Cancer
Product in North America, of which there can be no guarantee. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene
Corporation, on the same terms. During the year ended December 31, 2024, the Company received in cash and recognized revenue of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd" id="ixv-46913">200,000</ix:nonFraction>
pursuant to the agreement. At the time of transferring the license, the Company also received <ix:nonFraction contextRef="c159" decimals="-4" format="ixt:num-dot-decimal" name="abvc:NumberOfSharesReceived" scale="6" unitRef="shares" id="ixv-46914">1.25</ix:nonFraction> million OncoX shares but did not recognize
such licensing revenue since the fair value of Oncox stock is uncertain.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CollaborativeArrangementDisclosureTextBlock-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 8, 2024, the Company entered into a
definitive agreement with OncoX, pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s
BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Pancreatic
(the Pancreatic Product), within a certain territory, specified as <ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfDevelopAndCommercialize" scale="-2" unitRef="pure" id="ixv-46915">50</ix:nonFraction>% of the Worldwide Markets for 20 years (the &#8220;May 8, 2024
Oncox Agreement&#8221;). In consideration thereof, Oncox shall pay ABVC a total of $<ix:nonFraction contextRef="c160" decimals="-4" format="ixt:num-dot-decimal" name="abvc:ConsiderationPaidForAgreement" scale="6" unitRef="usd" id="ixv-46916">6.25</ix:nonFraction> million (or <ix:nonFraction contextRef="c160" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="6" unitRef="shares" id="ixv-46917">1.25</ix:nonFraction> million Oncox shares valued
at $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46918">5</ix:nonFraction> per share) within 30 days of entering into the May 8, 2024 Oncox Agreement, with an additional milestone payment of $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionalMilestonePaymentInCash" scale="0" unitRef="usd" id="ixv-46919">625,000</ix:nonFraction> in
cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="abvc:LicensingFees" scale="0" unitRef="usd" id="ixv-46920">100,000</ix:nonFraction>
towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties of <ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-46921">5</ix:nonFraction>% of net sales, as
defined in the May 8, 2024 Oncox Agreement, from the first commercial sale of the Pancreatic Product in the noted territory, which remains
uncertain. The Company will permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue
to fund such payments. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene Corporation, on the same terms. At the
time of transferring the license, the Company also received <ix:nonFraction contextRef="c160" decimals="-4" format="ixt:num-dot-decimal" name="abvc:NumberOfSharesReceived" scale="6" unitRef="shares" id="ixv-46922">1.25</ix:nonFraction> million OncoX shares but did not recognize such licensing revenue since
the fair value of Oncox stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 14, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the TNBC Product),
within a certain territory, specified as <ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfDevelopAndCommercialize" scale="-2" unitRef="pure" id="ixv-46923">50</ix:nonFraction>% of the Worldwide Markets for 20 years (the &#8220;May 14, 2024 Oncox Agreements&#8221;).
In each agreement for consideration thereof, Oncox shall pay each licensor a total of $<ix:nonFraction contextRef="c162" decimals="-4" format="ixt:num-dot-decimal" name="abvc:ConsiderationPaidForAgreement" scale="6" unitRef="usd" id="ixv-46924">6.25</ix:nonFraction> million (or <ix:nonFraction contextRef="c162" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="6" unitRef="shares" id="ixv-46925">1.25</ix:nonFraction> million Oncox shares valued
at $<ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46926">5</ix:nonFraction> per share) within 30 days of entering into the May 14, 2024 Oncox Agreements, with an additional milestone payment of $<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionalMilestonePaymentInCash" scale="0" unitRef="usd" id="ixv-46927">625,000</ix:nonFraction>
in cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least
$<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="abvc:LicensingFees" scale="0" unitRef="usd" id="ixv-46928">100,000</ix:nonFraction> towards the licensing fees and deductible from the second milestone payment; each licensor is also entitled to royalties of
<ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-46929">5</ix:nonFraction>% of net sales, from the first commercial sale of the TNBC Product in the noted territory, which remains uncertain. The Company will
permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue to fund such payments. At
the time of transferring the license, the Company and BioLite also each received <ix:nonFraction contextRef="c162" decimals="-4" format="ixt:num-dot-decimal" name="abvc:NumberOfSharesReceived" scale="6" unitRef="shares" id="ixv-46930">1.25</ix:nonFraction> million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 23, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the &#8220;MS Products&#8221;),
within a certain territory, specified as <ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfDevelopAndCommercialize" scale="-2" unitRef="pure" id="ixv-46931">50</ix:nonFraction>% of the Worldwide Markets for 20 years (the &#8220;May 23, 2024 Oncox Agreements&#8221;).
In consideration thereof, Oncox shall pay each licensor a total of $<ix:nonFraction contextRef="c164" decimals="-4" format="ixt:num-dot-decimal" name="abvc:ConsiderationPaidForAgreement" scale="6" unitRef="usd" id="ixv-46932">6.25</ix:nonFraction> million (or <ix:nonFraction contextRef="c164" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="6" unitRef="shares" id="ixv-46933">1.25</ix:nonFraction> million Oncox shares valued at $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-46934">5</ix:nonFraction> per share)
30 days after entering the May 23, 2024 Oncox Agreements, with an additional milestone payment of $<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionalMilestonePaymentInCash" scale="0" unitRef="usd" id="ixv-46935">625,000</ix:nonFraction> in cash after OncoX&#8217;s
next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $<ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="abvc:LicensingFees" scale="0" unitRef="usd" id="ixv-46936">100,000</ix:nonFraction> towards the licensing
fees and deductible from the second milestone payment; each licensor is also entitled to royalties of <ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-46937">5</ix:nonFraction>% of net sales, from the first
commercial sale of the MS Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing fees.
At the time of transferring the license, the Company and BioLite also each received <ix:nonFraction contextRef="c166" decimals="-4" format="ixt:num-dot-decimal" name="abvc:NumberOfSharesReceived" scale="6" unitRef="shares" id="ixv-46938">1.25</ix:nonFraction> million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Above mentioned p<span>rice
of OncoX&#8217;s shares was determined through private negotiations between the parties; no third-party valuation was completed.</span></span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c7_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-26487"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">5. PROPERTY AND EQUIPMENT, AND PREPAMENT FOR ASSET ACQUISITION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-keep: true">Property
and Equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-26496"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of December 31, 2024 and 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: justify"><span style="-keep: true">Land</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46939">338,966</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46940">363,416</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify"><span style="-keep: true">Buildings and leasehold improvements</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46941">2,219,244</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46942">2,227,431</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify"><span style="-keep: true">Machinery and equipment</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46943">1,131,169</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46944">1,138,675</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Office equipment</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46945">163,448</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46946">174,797</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46947">3,852,827</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46948">3,904,319</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Less: accumulated depreciation</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-46949">3,341,739</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-46950">3,335,041</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Property and equipment, net</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd" id="ixv-46951">511,088</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd" id="ixv-46952">569,278</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Depreciation expenses were $<ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-46953">28,627</ix:nonFraction>&#160;and
$<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-46954">28,531</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, Land with book value amounted
to approximately $<ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46955">338,966</ix:nonFraction> and $<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-46956">363,416</ix:nonFraction>, respectively, were pledged for obtaining bank loan (see Notes 9 Bank loans).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-keep: true">Prepayment
for asset acquisition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Prepayment for asset acquisition consists
of the properties in Chengdu, China. The Company entered into a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan,
Ltd. (the &#8220;Zhonghui&#8221;). Pursuant thereto, the Company will acquire <ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" unitRef="pure" id="ixv-46957">20</ix:nonFraction>% of the ownership of certain property and a parcel of
the land, with a view to jointly develop the property into a healthcare center for senior living, long-term care, and medical care in
the areas of ABVC&#8217;s special interests, such as Ophthalmology, Oncology, and Central Nervous Systems. The plan is to establish a
base for the China market and global development of these interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The valuation of such property is $<ix:nonFraction contextRef="c1" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" unitRef="usd" id="ixv-46958">37</ix:nonFraction> million;
based on the Company&#8217;s <ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46959">20</ix:nonFraction>% ownership, the Company would acquire the value of $<ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd" id="ixv-46960">7,400,000</ix:nonFraction>. In exchange, the Company issued to Zhonghui
an aggregate of <ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-46961">370,000</ix:nonFraction> shares (the &#8220;Shares&#8221;) of common stock, at a per share price of $<ix:nonFraction contextRef="c171" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-46962">20.0</ix:nonFraction>. The Shares are subject to a
lock-up period of one year following the closing date of the transaction. In addition, the parties agreed that, after one year following
the closing of the transaction, if the market value of the Shares or the value of the property increases or decreases, the parties will
negotiate in good faith to make reasonable adjustments. The Company&#8217;s ownership rights to the property and the associated land
parcel, or a suitable replacement property, are safeguarded under the terms of the cooperation agreement, which is legally binding and
enforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As discussed in Note 2, the Company incorrectly
applied ASC 845 instead of ASC 718, resulting in an adjustment of the reported value to from $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" unitRef="usd" id="ixv-46963">7,400,000</ix:nonFraction> to $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" unitRef="usd" id="ixv-46964">691,900</ix:nonFraction>, and reclassification
from Construction-in-Progress to Prepayment for Asset Acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The construction-in-progress property is planned
to finish before the end of 2025.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_InvestmentTextBlock-c7_cont_1" escape="true" name="us-gaap:InvestmentTextBlock" id="ixv-26694"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b style="-keep: true">6. LONG-TERM INVESTMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b style="-keep: true">&#160;&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><ix:nonNumeric contextRef="c7" continuedAt="_ScheduleOfOtherOwnershipInterestsTextBlock-c7_cont_1" escape="true" name="us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock" id="ixv-26704"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ScheduleOfOtherOwnershipInterestsTextBlock-c7_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">Ownership percentage</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td style="text-align: center; font-weight: bold"><span style="-keep: true">Accounting</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-keep: true">Name of investees</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">treatments</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="-keep: true">Braingenesis Biotechnology Co., Ltd.*</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c189" decimals="4" format="ixt:num-dot-decimal" id="ix_40_fact" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.17</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c190" decimals="4" format="ixt:num-dot-decimal" id="ix_41_fact" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.17</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 11%; text-align: left"><ix:nonNumeric contextRef="c191" id="ix_42_fact" name="us-gaap:EquityMethodInvestmentAdditionalInformation"><span style="-keep: true">Cost Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Genepharm Biotech Corporation</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c192" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46967">0.67</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c193" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46968">0.67</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><ix:nonNumeric contextRef="c194" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-26807"><span style="-keep: true">Cost Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">BioHopeKing Corporation</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c195" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46969">5.90</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c196" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46970">5.90</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><ix:nonNumeric contextRef="c197" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-26831"><span style="-keep: true">Cost Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">ForSeeCon Eye Corporation (see Note 10)</span></p></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c198" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46971">19.78</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-268"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><ix:nonNumeric contextRef="c200" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-26857"><span style="-keep: true">Cost Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">BioFirst Corporation</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c185" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46972">18.68</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c201" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46973">18.68</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><ix:nonNumeric contextRef="c179" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-26881"><span style="-keep: true">Equity&#160;Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">OncoX BioPharma, Inc. (see Note 10)</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c202" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46974">24.97</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-269"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><ix:nonNumeric contextRef="c204" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-26906"><span style="-keep: true">Equity Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">Rgene Corporation</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46975">26.65</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c205" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-46976">26.65</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><ix:nonNumeric contextRef="c206" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-26930"><span style="-keep: true">Equity Method</span></ix:nonNumeric></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">*</span></td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="-keep: true">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td><ix:nonNumeric contextRef="c7" continuedAt="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock-c7_cont_1" escape="true" name="abvc:ScheduleOfExtentTheInvesteeReliesTableTextBlock" id="ixv-26949"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The extent the investee relies on the company for its business is summarized as follows:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock-c7_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of investees</b></span></td> <td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 69%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The extent the investee relies on the Company for its business &#160;</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c207" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-26971"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c208" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-26979"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c209" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-26987"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c210" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-46977">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan</ix:nonNumeric> </span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c211" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-27002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c212" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-27010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned from the investee and provides research and development support service</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. </span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c213" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-27018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c214" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-27026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></ix:nonNumeric></td></tr> </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_InvestmentTextBlock-c7_cont_2" id="_InvestmentTextBlock-c7_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><ix:nonNumeric contextRef="c7" continuedAt="_InvestmentTableTextBlock-c7_cont_1" escape="true" name="us-gaap:InvestmentTableTextBlock" id="ixv-27050"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term investment mainly consists of the following:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:continuation continuedAt="_InvestmentTableTextBlock-c7_cont_2" id="_InvestmentTableTextBlock-c7_cont_1"><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="-keep: true">Non-marketable Cost Method Investments, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-keep: true">Braingenesis Biotechnology Co., Ltd.</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-46978">6,727</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-46979">7,213</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-keep: true">Genepharm Biotech Corporation</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-46980">20,540</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-46981">22,021</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon
    Eye Corporation<sup>(d) </sup></span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">BioHopeKing Corporation</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-46982">762,983</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-46983">818,018</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 0.25in"><span style="-keep: true">Subtotal</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-46984">790,250</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-46985">847,252</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Equity Method Investments, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst
    Corporation<sup>(a)</sup></span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" id="ix_43_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">1,468,504</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" id="ix_44_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">1,680,488</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene
    Corporation<sup>(b)</sup></span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    Japan K.K. (BioLite JP)<sup>(c)</sup></span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX
    BioPharma, Inc.<sup>(e)</sup></span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 0.25in"><span style="-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-46988">2,258,754</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-46989">2,527,740</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and
2023, the Company owns <ix:nonFraction contextRef="c179" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-46990">18.68</ix:nonFraction>% and <ix:nonFraction contextRef="c180" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-46991">18.68</ix:nonFraction>% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment
in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-46992">2,688,578</ix:nonFraction>, recorded as prepayment for
long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this
investment. The initial prepayment was $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-46993">1,895,556</ix:nonFraction>, which is a portion of the prepayment as of December 31, 2022, and was converted into
<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-46994">994,450</ix:nonFraction> shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $<ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-46995">1,124,842</ix:nonFraction>.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c7_cont_1" escape="true" name="srt:CondensedStatementOfComprehensiveIncomeTableTextBlock" id="ixv-27325"><ix:nonNumeric contextRef="c7" continuedAt="_ScheduleOfCondensedBalanceSheetTableTextBlock-c7_cont_1" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="ixv-27326"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Summarized unaudited financial information
for the Company&#8217;s equity method investee, BioFirst, is as follows:</span></p></ix:nonNumeric></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><i style="-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Balance Sheets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfCondensedBalanceSheetTableTextBlock-c7_cont_2" id="_ScheduleOfCondensedBalanceSheetTableTextBlock-c7_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-keep: true">Current Assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-46996">1,323,952</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-46997">1,451,877</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Non-current Assets</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-46998">1,083,472</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-46999">686,206</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">Current Liabilities</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47000">3,508,413</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47001">2,286,058</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Non-current Liabilities</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-47002">114,606</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-47003">347,193</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-keep: true">Stockholders&#8217; Deficit</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-47004">1,215,595</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-47005">495,168</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Statements of operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c7_cont_2" id="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c7_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Net sales</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-47006">357</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-47007">734</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Gross profit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-47008">216</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-47009">289</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Net loss</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47010">770,877</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47011">1,194,797</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Share of losses from investments accounted for using the equity method</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-47012">339,171</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-47013">221,888</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_InvestmentTextBlock-c7_cont_3" id="_InvestmentTextBlock-c7_cont_2"><ix:continuation continuedAt="_InvestmentTableTextBlock-c7_cont_3" id="_InvestmentTableTextBlock-c7_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">Both Rgene and the Company are
under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise
significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment
as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include
the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of
December 31, 2024 and 2023, the Company owns <ix:nonFraction contextRef="c182" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-47014">26.65</ix:nonFraction>% and <ix:nonFraction contextRef="c183" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-47015">26.65</ix:nonFraction>% common stock shares of Rgene, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<ix:continuation continuedAt="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c7_cont_3" id="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c7_cont_2"><ix:continuation continuedAt="_ScheduleOfCondensedBalanceSheetTableTextBlock-c7_cont_3" id="_ScheduleOfCondensedBalanceSheetTableTextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Summarized unaudited financial information
for the Company&#8217;s equity method investee, Rgene, is as follows:</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Balance Sheets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ScheduleOfCondensedBalanceSheetTableTextBlock-c7_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/> 2024</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/> 2023</b></span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Assets</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-47016">46,491</ix:nonFraction></span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-47017">50,538</ix:nonFraction></span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current Assets</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-47018">222,988</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-47019">250,716</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Liabilities</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47020">1,546,123</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47021">2,591,960</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current Liabilities</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-47022">319</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-47023">811</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&#8217; Deficit</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-47024">1,276,963</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-47025">2,291,517</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Statements of operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c7_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    Ended<br/>
    December 31,</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net sales</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-278"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross Profit</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-280"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-281"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47026">118,367</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47027">1,550,123</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share of loss from investments accounted for using
    the equity method</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposition of long-term
    investment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">During the years ended December
31, 2024 and 2023, there is no disposition of long-term investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on investment in
    equity securities</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:EquityMethodInvestmentsTextBlock" id="ixv-27855"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The components of loss on investment in equity
securities for each period were as follows (not recognized since the carrying value of the investment was reduced to $0):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">Year Ended<br/>
    December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Share of equity method investee losses</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-47028">339,171</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-47029">221,888</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_InvestmentTableTextBlock-c7_cont_3"><ix:continuation id="_InvestmentTextBlock-c7_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K. (BioLite JP)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#8220;Lucidaim,&#8221; together with the Company, the &#8220;Shareholders&#8221;), and BioLite Japan
K.K., a Japanese corporation (&#8220;BioLite JP&#8221;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has <ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-47030">10,000</ix:nonFraction> ordinary shares authorized, with
<ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-47031"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-47032">3,049</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding (the &#8220;Ordinary Shares&#8221;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own <ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" unitRef="shares" id="ixv-47033">1,555</ix:nonFraction> Ordinary Shares (<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-47034">51</ix:nonFraction>%) and the Company shall own <ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" unitRef="shares" id="ixv-47035">1,494</ix:nonFraction> Ordinary Shares (<ix:nonFraction contextRef="c188" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-47036">49</ix:nonFraction>%). The Company paid $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="0" unitRef="usd" id="ixv-47037">150,000</ix:nonFraction>
towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $<ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="0" unitRef="usd" id="ixv-47038">150,000</ix:nonFraction> after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#8217;s business
and financial conditions and determined to fully impair such prepayment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation (FEYE)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. (OncoX)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#8217;s ownership. See Note 4 for detail of such transactions.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_DebtDisclosureTextBlock-c7_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-27960"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">7. CONVERTIBLE NOTES PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Lind Notes Payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 23, 2023, the Company entered
into a securities purchase agreement with Lind Global Fund II, LP (&#8220;Lind&#8221;), pursuant to which the Company issued Lind a secured,
convertible note in the principal amount of $<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-47039">3,704,167</ix:nonFraction>, for a purchase price of $<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForPreviousAcquisition" scale="0" unitRef="usd" id="ixv-47040">3,175,000</ix:nonFraction> (the &#8220;Lind Note&#8221;), that is convertible
into shares of the Company&#8217;s common stock at an initial conversion price of $<ix:nonFraction contextRef="c239" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-47041">10.5</ix:nonFraction> per share, subject to adjustment. The Company
also issued Lind a common stock purchase warrant (the &#8220;Lind Warrant&#8221;) to purchase up to <ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-47042">529,167</ix:nonFraction> shares (post-split) of the
Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c240" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47043">10.5</ix:nonFraction> per share for a period of 5 years, subject to adjustment that immediately
upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance or sale shall be reduced (and in no event
increased) to an Exercise Price equal to the consideration per share paid for such Additional Shares of Common Stock. The warrants were
valued using the Black-Scholes model. The fair value of the warrants was determined to be $<ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-47044">1,225,543</ix:nonFraction>, which was recorded to debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Beginning with the date that is six months
from the issuance date of the Lind Note and on each one (1) month anniversary thereafter, the Company shall pay Lind an amount equal
to $<ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingBalanceAmount" scale="0" unitRef="usd" id="ixv-47045">308,651</ix:nonFraction>, until the outstanding principal amount of the Lind Note has been paid in full prior to or on the Maturity Date or, if earlier,
upon acceleration, conversion or redemption of the Lind Note in accordance with the terms thereof (the &#8220;Monthly Payments&#8221;).
At the Company&#8217;s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares of the Company&#8217;s common stock, or
(iii) a combination of cash and Shares; if made in shares, the number of shares shall be determined by dividing (x) the principal amount
being paid in shares by (y) <ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfAverageAmount" scale="-2" unitRef="pure" id="ixv-47046">90</ix:nonFraction>% of the average of the 5 lowest daily VWAPs during the 20 trading days prior to the applicable payment
date. The Lind Notes sets forth certain conditions that must be satisfied before the Company may make any Monthly Payments in shares
of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash premium of <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfCashPermium" scale="-2" unitRef="pure" id="ixv-47047">5</ix:nonFraction>% of such Monthly
Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Upon the occurrence of any Event of Default
(as defined in the Lind Note), the Company must pay Lind an amount equal to <ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfOutstandingPrincipalAmount" scale="-2" unitRef="pure" id="ixv-47048">120</ix:nonFraction>%&#160;of the then outstanding principal amount of the
Lind Note (the &#8220;Mandatory Default Amount&#8221;), in addition to any other remedies under the Note or the other Transaction Documents.
The Company and Lind entered into a letter agreement on September 12, 2023, pursuant to which the Mandatory Default Amount was reduced
to <ix:nonFraction contextRef="c244" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfOutstandingPrincipalAmount" scale="-2" unitRef="pure" id="ixv-47049">115</ix:nonFraction>% of the then outstanding principal amount of the Lind Note; pursuant to the letter agreement, Lind also agreed to waive any default
associated with the Company&#8217;s market capitalization being below $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GeneralPartnersCapitalAccount" scale="6" unitRef="usd" id="ixv-47050">12.5</ix:nonFraction> million for 10 consecutive days through February 23, 2024,
but retained its right to convert its Note. In addition, if the Company is unable to increase its market capitalization and is unable
to obtain a further waiver or amendment to the Lind Note, then the Company could experience an event of default under the Lind Note,
which could have a material adverse effect on the Company&#8217;s liquidity, financial condition, and results of operations. The Company
cannot make any assurances regarding the likelihood, certainty, or exact timing of the Company&#8217;s ability to increase its market
capitalization, as such metric is not within the immediate control of the Company and depends on a variety of factors outside the Company&#8217;s
control. &#160;</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c7_cont_2" id="_DebtDisclosureTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Lind Warrant may be exercised via cashless
exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The warrant exercise price was reset to $<ix:nonFraction contextRef="c245" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-47051">3.5</ix:nonFraction>
in accordance to the issuance of common stock in relation to securities purchase agreement on July 2023.&#160;On May 22, 2024, the exercise
price of these warrants was reset to $<ix:nonFraction contextRef="c246" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-47052">0.75</ix:nonFraction> along with the immediate exercise of existing warrants and issuance of the New Warrants. As
of December 31, 2024, these Lind Warrants associated with the first Lind Note were fully exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 17, 2023, the Company entered
another securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#8220;2<sup>nd</sup>
Lind Note&#8221;) in the principal amount of $<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivableWithImputedInterestFaceAmount" scale="0" unitRef="usd" id="ixv-47053">1,200,000</ix:nonFraction>, for a purchase price of $<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForPreviousAcquisition" scale="0" unitRef="usd" id="ixv-47054">1,000,000</ix:nonFraction>, that is convertible into shares of the Company&#8217;s
common stock at a conversion price, which shall be the lesser of (i) $<ix:nonFraction contextRef="c249" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-47055">3.50</ix:nonFraction> and (ii) <ix:nonFraction contextRef="c248" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfAverageAmount" scale="-2" unitRef="pure" id="ixv-47056">90</ix:nonFraction>% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 2<sup>nd</sup> Lind Note shall be due and payable on May 19, 2025 and bear no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to the maturity, and Lind shall have the right
to convert up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined
in the 2<sup>nd</sup> Lind Note), the Company must pay Lind an amount equal to <ix:nonFraction contextRef="c250" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-47057">120</ix:nonFraction>% of the then outstanding principal amount of the Lind
Note, in addition to any other remedies under the Note or the other transaction documents. Lind also received a 5-year common stock purchase
warrant to purchase up to <ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-47058">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice" scale="0" unitRef="usdPershares" id="ixv-47059">2</ix:nonFraction> per share for a period
of <ix:nonNumeric contextRef="c251" format="ixt-sec:duryear" name="abvc:PurchaseWarrantTerm" id="ixv-47060">5</ix:nonNumeric> years. The warrants were valued using the Black-Scholes model. The fair value of the warrants was determined to be $<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-47061">480,795</ix:nonFraction>, which
was recorded to debt discount. An amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements,
the parties entered into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $<ix:nonFraction contextRef="c253" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47062">1.00</ix:nonFraction>. Additionally,
the amendment requires the Company to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed
to be the floor price. During the year ended December 31, 2024, Lind converted $<ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-47063">800,000</ix:nonFraction> of 2<sup>nd</sup> Lind Note principal amounts
into the Company&#8217;s common stocks. Refer to the common stock issuance details in Note 12, Equity. As of April 1, 2025, Lind has
converted the remaining $<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-47064">400,000</ix:nonFraction> principal balance into the Company&#8217;s common stocks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 17, 2024, the Company entered another
securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#8220;3<sup>rd</sup>
Lind Note&#8221;) in the principal amount of $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivableWithImputedInterestFaceAmount" scale="0" unitRef="usd" id="ixv-47065">1,000,000</ix:nonFraction>, for a purchase price of $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="abvc:PurchasePriceAmount" scale="0" unitRef="usd" id="ixv-47066">833,333</ix:nonFraction>, that is convertible into shares of the Company&#8217;s
common stock at a conversion price, which shall be the lesser of (i) $<ix:nonFraction contextRef="c257" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-47067">3.50</ix:nonFraction> and (ii) <ix:nonFraction contextRef="c257" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfAverageAmount" scale="-2" unitRef="pure" id="ixv-47068">90</ix:nonFraction>% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 3<sup>rd</sup> Lind Note shall be due and payable on July 17, 2025 and bear no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to the maturity, and Lind shall have the right
to convert up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined
in the 3<sup>rd</sup> Lind Note), the Company must pay Lind an amount equal to <ix:nonFraction contextRef="c257" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-47069">120</ix:nonFraction>% of the then outstanding principal amount of the Lind
Note, in addition to any other remedies under the Note or the other transaction documents Lind also received a <ix:nonNumeric contextRef="c258" format="ixt-sec:duryear" name="abvc:PurchaseWarrantTerm" id="ixv-47070">5</ix:nonNumeric>-year, common stock purchase
warrant to purchase up to <ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="0" unitRef="usd" id="ixv-47071">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-47072">2</ix:nonFraction> per share. The warrants
were valued using the Black-Scholes model. The fair value of the warrants was determined to be $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-47073">394,071</ix:nonFraction>, which was recorded to debt discount.
An amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements, the parties entered into an amendment
to the Note, pursuant to which the conversion price shall have a floor price of $<ix:nonFraction contextRef="c260" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47074">1.00</ix:nonFraction>. Additionally, the amendment requires the Company
to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor price. No conversion
or repayment to 3<sup>rd</sup> Lind Note has occurred during the year ended December 31, 2024. As of April 1, 2025, Lind has converted
$<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-47075">400,000</ix:nonFraction> principal balance into the Company&#8217;s common stock, leaving outstanding principal of $<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentOutstandingPrincipal" scale="0" unitRef="usd" id="ixv-47076">600,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In connection with above three Lind Note offerings,
the Company and its subsidiaries: BioKey, BioLite, Biolite BVI, and American BriVision, jointly and severally guaranteed all of the obligations
of the Company in connection with the offering with certain collateral, as set forth in the related transaction documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 22, 2024 and November 19, 2024, Lind
has exercised <ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-47077">1,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c262" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-47078">500,000</ix:nonFraction> of the existing warrants to purchase shares of Common Stock at a reduced exercise price of $<ix:nonFraction contextRef="c263" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-47079">0.75</ix:nonFraction>
and $<ix:nonFraction contextRef="c264" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-47080">0.42</ix:nonFraction> per share, respectively. Refer to the details in Note 12, Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Total interest expenses in connection with
the above three Lind Notes were $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-47081">773,139</ix:nonFraction> and $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-47082">1,233,284</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively.</span></p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other Convertible Notes Payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 1, 2024 and November 5, 2024,
the Company&#8217;s subsidiary, AiBtl, issued two convertible note payable, each with a principal amount of $<ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-47083">30,000</ix:nonFraction> to two separate individuals,
for total consideration of $<ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConsiderationAmount" scale="0" unitRef="usd" id="ixv-47084">60,000</ix:nonFraction>. Each note has a <ix:nonNumeric contextRef="c267" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-47085">1</ix:nonNumeric>-year term and an implied annual discount rate of <ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageOfAnnualDiscountRate" scale="-2" unitRef="pure" id="ixv-47086">6.89</ix:nonFraction>%. These convertible notes
bear <ix:nonFraction contextRef="c268" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-47087">0</ix:nonFraction>% interest rate and are convertible by the holders into the AiBtl&#8217;s common stock at $<ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-47088">5</ix:nonFraction> per share at any time before the maturity.
AiBtl reserves the right to repurchase the note in full at any time before the maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The convertible notes payable is accounted
for in accordance with ASC 470-20, Debt with Conversion and Other Options. The Company evaluated the conversion feature and determined
that it qualifies for equity classification as it meets the &#8220;fixed-for-fixed&#8221; criteria. The proceeds from the issuance were
allocated to the present value of the liability component in aggregate for $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-47089">56,132</ix:nonFraction>, and to debt discount for $<ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd" id="ixv-47090">3,868</ix:nonFraction>. The debt discount
is recorded in additional paid-in capital in the statement of change in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The debt discount is being amortized over
the <ix:nonNumeric contextRef="c254" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-47091">1</ix:nonNumeric>-year term using the effective interest method. During the year ended December 31, 2024, the Company recognized $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-47092">646</ix:nonFraction> in interest
expense related to the amortization of the debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" id="ixv-28061"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The carrying amounts of the liability component
are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"><td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">December 31, 2024</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance<br/> Entity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance<br/> Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Maturity<br/> Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Principal<br/> Amount at<br/> Issuance</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion<br/> Price</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common<br/> Stock<br/> to&#160;be<br/> converted</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Unamortized<br/> Discount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carrying<br/> Value</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fair<br/> Value</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2nd LIND Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"><ix:nonNumeric contextRef="c271" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-28163"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"><ix:nonNumeric contextRef="c271" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-28168"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">November 17, <br/> 2023</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"><ix:nonNumeric contextRef="c271" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-28174"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">May 19,<br/> 2025</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-47093">1,200,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-47094">0</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-47095">86.94</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47096">1.00</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: center"><ix:nonNumeric contextRef="c271" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-28212"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-47097">400,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-47098">118,048</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-47099">281,952</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-47100">480,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3rd LIND Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c273" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-28254"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c273" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-28259"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">January 17, <br/> 2024</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c273" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-28265"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">July 17,<br/> 2025</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-47101">1,000,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-47102">0</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-47103">87.40</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47104">1.00</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c273" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-28303"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-47105">1,000,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-47106">388,685</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-47107">611,315</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-47108">1,200,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c275" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-28345"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c275" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-28350"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">November 1, <br/> 2024</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c275" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-28356"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">November 1, <br/> 2025</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-47109">30,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-47110">0</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-47111">6.89</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47112">5.00</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c275" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-28394"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-47113">30,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-47114">1,610</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-47115">28,390</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-47116">30,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c277" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-28436"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c277" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-28441"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">November 5,<br/> 2024</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c277" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-28447"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">November 5, <br/> 2025</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-47117">30,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-47118">0</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-47119">6.89</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47120">5.00</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c277" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-28485"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-47121">30,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-47122">1,611</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-47123">28,389</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-47124">30,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-47125">2,260,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-47126">1,460,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-47127">509,954</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-47128">950,046</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-47129">1,740,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="font-size: 8pt; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="font-size: 8pt"><b>December 31, 2023</b></span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Issuance<br/> Entity</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Issuance<br/> Date</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Maturity<br/> Date</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Principal<br/> Amount</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Conversion<br/> Price</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Common<br/> Stock<br/> to be<br/> converted</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Unamortized<br/> Discount</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Carrying<br/> Value</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Fair<br/> Value</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; vertical-align: top; width: 10%; text-align: left"><span style="font-size: 8pt">1st LIND Note</span></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 6%; text-align: center"><ix:nonNumeric contextRef="c279" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-28699"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"><ix:nonNumeric contextRef="c279" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-28704"><span style="font-size: 8pt">February 23,<br/> 2023</span></ix:nonNumeric></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"><ix:nonNumeric contextRef="c279" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-28710"><span style="font-size: 8pt">August 23,<br/> 2024</span></ix:nonNumeric></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-47130">3,704,167</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c280" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-47131">0</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c280" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-47132">61.42</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c280" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47133">3.50</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 6%; text-align: center"><ix:nonNumeric contextRef="c279" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-28748"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-47134">811,175</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-47135">290,063</ix:nonFraction></span></p></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-47136">521,112</ix:nonFraction></span></p></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-47137">973,410</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; "> <td style="font-size: 8pt; vertical-align: top; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 8pt">2nd LIND Note</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c281" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-28790"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c281" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-28795"><span style="font-size: 8pt">November 17,<br/> 2023</span></ix:nonNumeric></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c281" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-28801"><span style="font-size: 8pt">May 19,<br/> 2025</span></ix:nonNumeric></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-47138">1,200,000</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c282" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-47139">0</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">%</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c282" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-47140">86.94</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">%</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c282" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47141">1.00</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c281" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-28839"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-47142">1,200,000</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-47143">834,590</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-47144">365,410</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-47145">1,440,000</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-47146">4,904,167</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-47147">2,011,175</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-47148">1,124,653</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-47149">886,522</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-47150">2,413,410</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> </table></ix:nonNumeric></ix:continuation><div>


</div><p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-28972"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-28977"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Accrued research and development expense</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-47151">1,799,583</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-47152">1,799,583</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Accrued directors and officers (owners) compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedDirectorAndOfficerCompensation" scale="0" unitRef="usd" id="ixv-47153">1,025,867</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedDirectorAndOfficerCompensation" scale="0" unitRef="usd" id="ixv-47154">1,018,253</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Accrued royalties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="0" unitRef="usd" id="ixv-47155">255,592</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="0" unitRef="usd" id="ixv-47156">274,028</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Accrued compensation and employee benefits</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47157">126,106</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47158">29,138</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Others</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-47159">302,274</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-47160">427,350</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-47161">3,509,422</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-47162">3,548,352</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ShortTermDebtTextBlock" id="ixv-29131"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">9. SHORT-TERM LOANS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font-size: 10pt"><ix:nonNumeric contextRef="c7" continuedAt="_ScheduleOfShortTermDebtTextBlock-c7_cont_1" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="ixv-29141"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term loans consists of the following:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ScheduleOfShortTermDebtTextBlock-c7_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-keep: true">Cathay United Bank</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47163">200,252</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47164">245,250</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">CTBC Bank</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c299" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47165">610,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c300" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47166">654,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Other individual</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47167">30,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-284"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47168">840,252</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47169">899,250</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cathay United Bank</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 28, 2016, BioLite Taiwan and Cathay
United Bank entered into a one-year bank loan agreement (the &#8220;Cathay United Loan Agreement&#8221;) in a credit limit amount of
NTD <ix:nonFraction contextRef="c283" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" unitRef="twd" id="ixv-47170">7.5</ix:nonFraction> million, equivalent to $<ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" unitRef="usd" id="ixv-47171">228,750</ix:nonFraction>. The term started <ix:nonNumeric contextRef="c284" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-47172">June 28, 2016</ix:nonNumeric> with maturity date at June 28, 2017. The loan balance bears interest
at a floating rate of prime rate plus <ix:nonFraction contextRef="c285" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-47173">1.31</ix:nonFraction>%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. The
Company renews the agreement with the bank every year, and the next renewal date is September 6, 2025. As of December 31, 2024&#160;and
December 31, 2023, the effective interest rates per annum was <ix:nonFraction contextRef="c286" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-47174">2.99</ix:nonFraction>%&#160;and <ix:nonFraction contextRef="c287" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-47175">2.87</ix:nonFraction>%, respectively. The loan is collateralized by the building
and improvement of BioLite Taiwan, and is also personal guaranteed by the Company&#8217;s chairman. During the year ended December 31,
2024, the Company made payments of the loan in total of NTD <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" unitRef="twd" id="ixv-47176">934,366</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" unitRef="usd" id="ixv-47177">29,152</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Interest expenses were $<ix:nonFraction contextRef="c288" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47178">6,891</ix:nonFraction> and $<ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47179">6,856</ix:nonFraction> for
the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">CTBC Bank</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 12, 2017 and July 19, 2017, BioLite
Taiwan and CTBC Bank entered into two short-term saving secured bank loan agreements (the &#8220;CTBC Loan Agreements&#8221;) in a credit
limit amount of NTD <ix:nonFraction contextRef="c290" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" unitRef="twd" id="ixv-47180"><ix:nonFraction contextRef="c291" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" unitRef="twd" id="ixv-47181">10</ix:nonFraction></ix:nonFraction> million, equivalent to $<ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" unitRef="usd" id="ixv-47182">327,500</ix:nonFraction>, and NTD 10 million, equivalent to $<ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" unitRef="usd" id="ixv-47183">327,500</ix:nonFraction>, respectively. Both two loans with
the same maturity date at <ix:nonNumeric contextRef="c293" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-47184"><ix:nonNumeric contextRef="c292" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-47185">January 19, 2018</ix:nonNumeric></ix:nonNumeric>. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC
for <ix:nonNumeric contextRef="c294" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="ixv-47186">one year</ix:nonNumeric>. The Company renews the agreement with the bank every year, and the next renewal date is February 28, 2025.&#160;The loan
balances bear interest at a fixed rate of <ix:nonFraction contextRef="c295" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsSavings" scale="-2" unitRef="pure" id="ixv-47187">2.5</ix:nonFraction>% per annum, and is secured by the money deposited in a savings account with the CTBC Bank.
This loan was also personal guaranteed by the Company&#8217;s chairman and BioFirst. During the year ended December 31, 2020, BioLite
Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Interest expenses were $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47188">15,557</ix:nonFraction> and $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47189">15,610</ix:nonFraction>
for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other individual &#8211; Third party</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 21, 2024, the Company issued an unsecured
promissory note to a third party for the proceeds of $<ix:nonFraction contextRef="c296" decimals="0" format="ixt:num-dot-decimal" name="abvc:ProceedsFromIssuanceOfAPromissoryNote" scale="0" unitRef="usd" id="ixv-47190">30,000</ix:nonFraction>. The note bears interest rate of <ix:nonFraction contextRef="c297" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingVariableInterestRate" scale="-2" unitRef="pure" id="ixv-47191">12</ix:nonFraction>% per annum and matures on <ix:nonNumeric contextRef="c297" format="ixt:date-monthname-day-year-en" name="abvc:ShortTermDebtMaturityDate" id="ixv-47192">March 21,
2025</ix:nonNumeric>, or upon the occurrence of an event of default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Interest expenses were $<ix:nonFraction contextRef="c298" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47193">2,811</ix:nonFraction> for the year
ended December 31, 2024.</span></p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c7_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-29305"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">10. RELATED PARTIES TRANSACTIONS</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-29310"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The related parties of the company with whom
transactions are reported in these financial statements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of entity or Individual</b></span></td> <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c334" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29331"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c335" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29339"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c336" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29347"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c337" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29355"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Jiangs</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c338" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29363"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</span></p></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan &#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c339" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29388"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation (&#8220;BHK&#8221;)</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c340" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29396"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AiBtl (Holding) BioPharma, Inc. (&#8220;AiBtl Holding&#8221;) &#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c341" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29404"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founding shareholder of AiBtl BioPharma Inc.</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jaimes Vargas Russman &#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c342" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29412"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO of AiBtl BioPharma Inc.</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lion Arts Promotion, Inc.</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c343" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-29420"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by the Jiangs.</span></ix:nonNumeric></td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Revenues  &#8211; related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="abvc:ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" id="ixv-29428"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the years ended December 31, 2024,
the Company received $<ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="abvc:LicensingAgreement" scale="0" unitRef="usd" id="ixv-47194">296,000</ix:nonFraction> in cash, pursuant to the licensing agreement and related amendment with FEYE, and recognized $<ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-47195">296,000</ix:nonFraction> revenue
correspondingly. In addition, the Company received $<ix:nonFraction contextRef="c304" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" unitRef="usd" id="ixv-47196">200,000</ix:nonFraction> during the year ended December 31, 2024, pursuant to the licensing agreement
with OncoX, and recognized revenue correspondingly. Please refer to Note 4, Collaborative Agreements for details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Year Ended<br/>
    December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-keep: true">OncoX</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-47197">200,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-285"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">FEYE</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c346" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-47198">296,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Rgene</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-47199">2,055</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-47200">496,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-47201">2,055</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Consulting fees - related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In March 2024, the Company engaged Lion International
to provide operation, business development, human resources, and capital finance consulting services. The agreement is for 12 months
expiring in February 2025, and is optional for renewal upon mutual agreement. The Company incurred $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" unitRef="usd" id="ixv-47202">104,083</ix:nonFraction> for the year ended December
31, 2024. No such consulting service was engaged in year 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable - related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="abvc:ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock" id="ixv-29552"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Accounts receivable due from related parties
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">GenePharm Inc.</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288"><span style="-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt"><span style="-keep: true">Rgene</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-290"><span style="-keep: true">-</span></div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-47203">10,463</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-47204">10,463</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2024, management considered
the outstanding accounts receivable from Rgene may not be recoverable, and recognized credit loss in full.</span></p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c7_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Due from related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Amount due from related parties consisted
of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" continuedAt="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock-c7_cont_1" escape="true" name="abvc:ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" id="ixv-29676"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Due from related party- Current</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene (1)</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c354" decimals="0" format="ixt:num-dot-decimal" id="ix_45_fact" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">565,711</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c355" decimals="0" format="ixt:num-dot-decimal" id="ix_46_fact" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">541,486</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (2)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" id="ix_47_fact" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">589,340</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" id="ix_48_fact" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">206,087</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c356" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-47209">1,155,051</ix:nonFraction></b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-47210">747,573</ix:nonFraction></b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">Due from related parties- Non-current, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-keep: true">BioFirst (Australia) (3)</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c357" decimals="0" format="ixt:num-dot-decimal" id="ix_49_fact" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd">839,983</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c358" decimals="0" format="ixt:num-dot-decimal" id="ix_50_fact" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd">839,983</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">BioHopeKing Corporation (4)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" id="ix_51_fact" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd">120,210</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" id="ix_52_fact" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd">113,516</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c356" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-47215">1,014,193</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-47216">953,499</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Less: allowance for expected credit losses accounts</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c356" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-47217">1,014,193</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-47218">839,983</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 9pt"><span style="-keep: true">Net</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-47219">113,516</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-keep: true">(1) &#160;</span></td> <td style="text-align: justify"><ix:footnote id="ix_10_footnote" xml:lang="en-US"><p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $<ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-47220">1,000,000</ix:nonFraction> to Rgene which bears interest at <ix:nonFraction contextRef="c306" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-47221">5</ix:nonFraction>% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional <ix:nonFraction contextRef="c307" decimals="3" format="ixt:num-dot-decimal" name="abvc:WorkingCapitalPercentage" scale="-2" unitRef="pure" id="ixv-47222">6.4</ix:nonFraction>% of Rgene. The Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $<ix:nonFraction contextRef="c306" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47223">1.00</ix:nonFraction> per share or (ii) <ix:nonFraction contextRef="c308" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-47224">20</ix:nonFraction>% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2024 and December 31, 2023, the outstanding loan balance were both $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-47225">500,000</ix:nonFraction>; and accrued interest was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" unitRef="usd" id="ixv-47226">63,819</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" unitRef="usd" id="ixv-47227">38,819</ix:nonFraction>, respectively.</span></p>
<p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">As of December 31, 2024 and 2023, the Company has other receivables amounted $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-47228">1,892</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-47229">2,667</ix:nonFraction>, respectively, from Rgene due to daily operations.</span></p></ix:footnote></td></tr>
</table>

<p style="margin: 0"><span style="-keep: true">&#160;</span></p>


<table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify; font-size: 12pt"><ix:footnote id="ix_11_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD <ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd" id="ixv-47230">11,072,360</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-47231">337,707</ix:nonFraction>), which bears interest at <ix:nonFraction contextRef="c310" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-47232">12</ix:nonFraction>% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD <ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd" id="ixv-47233">11,406,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-47234">347,883</ix:nonFraction>), which bears interest at <ix:nonFraction contextRef="c311" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-47235">12</ix:nonFraction>% per annum for the use of working capital. As of December 31, 2024 and 2023, the outstanding loan balance were NTD <ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="twd" id="ixv-47236">17,571,076</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-47237">535,918</ix:nonFraction>) and NTD <ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="twd" id="ixv-47238">6,302,360</ix:nonFraction> ($<ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-47239">206,087</ix:nonFraction>), respectively; accrued interest was $<ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-47240">53,422</ix:nonFraction> and $<ix:nonFraction contextRef="c314" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-47241">0</ix:nonFraction>, respectively. The Company has received NTD <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="twd" id="ixv-47242">4,040,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd" id="ixv-47243">126,048</ix:nonFraction>) repayment and expects to receive other repayment within next 12 months.</span></ix:footnote></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><ix:footnote id="ix_12_footnote" xml:lang="en-US"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c315" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-47244">361,487</ix:nonFraction> to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on <ix:nonNumeric contextRef="c316" format="ixt:date-monthname-day-year-en" name="us-gaap:RelatedPartyTransactionDate" id="ixv-47245">September 30, 2021</ix:nonNumeric> with an interest rate of <ix:nonFraction contextRef="c316" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionRate" scale="-2" unitRef="pure" id="ixv-47246">6.5</ix:nonFraction>% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-47247">67,873</ix:nonFraction> to meet its new project needs. On July 27, 2021, the Company repaid a loan <ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="0" unitRef="usd" id="ixv-47248">249,975</ix:nonFraction> to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c319" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-47249">250,000</ix:nonFraction> to increase the cost for upcoming projects. The loan will be matured on <ix:nonNumeric contextRef="c7" format="ixt:date-monthname-day-year-en" name="us-gaap:RelatedPartyTransactionDate" id="ixv-47250">November 30, 2022</ix:nonNumeric> with an interest rate of <ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionRate" scale="-2" unitRef="pure" id="ixv-47251">6.5</ix:nonFraction>% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAgreementAmount" scale="0" unitRef="usd" id="ixv-47252">507,000</ix:nonFraction> to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $<ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAgreementAmount" scale="0" unitRef="usd" id="ixv-47253">88,091</ix:nonFraction> to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $<ix:nonFraction contextRef="c321" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAgreementAmount" scale="0" unitRef="usd" id="ixv-47254">25,500</ix:nonFraction> to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of <ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionRate" scale="-2" unitRef="pure" id="ixv-47255">6.5</ix:nonFraction>% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of December 31, 2024 and 2023, the outstanding loan balances and allocated research fee were both amounted to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-47256">681,185</ix:nonFraction>, and accrued interest balances were both amounted $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-47257">158,798</ix:nonFraction>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-47258">839,983</ix:nonFraction> for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</span></p></ix:footnote></td></tr> </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c7_cont_2"><ix:continuation id="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock-c7_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="ix_13_footnote" xml:lang="en-US">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 4). <ix:nonNumeric contextRef="c322" name="us-gaap:DebtInstrumentInterestRateTerms" id="ixv-47260">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.</ix:nonNumeric> As of December 31, 2024 and 2023, due from BHK was both NTD <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" scale="0" unitRef="twd" id="ixv-47261">3,941,299</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-47262">120,210</ix:nonFraction> and $<ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-47263">113,516</ix:nonFraction>, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of $<ix:nonFraction contextRef="c325" decimals="0" format="ixt:num-dot-decimal" name="abvc:RecognizedCreditLosses" scale="0" unitRef="usd" id="ixv-47264">120,210</ix:nonFraction> for the year ended December 31, 2024.</ix:footnote> </span></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company&#8217;s due from related parties
are subject to certain risks that our collaborative parties, including OncoX and FEYE, would face. Such risks exist in future market
conditions, macro economy, legal and regulatory, results of clinical trials and product developments, and among others. As of December
31, 2024, the Company&#8217;s comprehensive review of these due from related party balances indicates that there are no expected losses
except those being recognized above. This conclusion is based on the business relationships with our related parties and the absence
of any significant indicators of potential default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Due to related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c7" escape="true" name="abvc:ScheduleOfAmountDueToRelatedPartiesTableTextBlock" id="ixv-29984"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Amount due to related parties consisted of
the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">AiBtl Holding (1)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c359" decimals="0" format="ixt:num-dot-decimal" id="ix_53_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">348,219</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-293"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left"><span style="-keep: true">The Jiangs (2)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"/><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c361" decimals="0" format="ixt:num-dot-decimal" id="ix_54_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">274,170</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"/><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c362" decimals="0" format="ixt:num-dot-decimal" id="ix_55_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">19,789</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Shareholders (3)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c363" decimals="0" format="ixt:num-dot-decimal" id="ix_56_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">142,130</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" id="ix_57_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">152,382</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Directors (4)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c365" decimals="0" format="ixt:num-dot-decimal" id="ix_58_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">8,526</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c366" decimals="0" format="ixt:num-dot-decimal" id="ix_59_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">1,322</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c356" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47272">773,045</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47273">173,493</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="ix_14_footnote" xml:lang="en-US">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $<ix:nonFraction contextRef="c326" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47275">40,000</ix:nonFraction>, $<ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47276">60,000</ix:nonFraction>, $<ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47277">33,732</ix:nonFraction>, and $<ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47278">214,487</ix:nonFraction>, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand.</ix:footnote> </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><ix:footnote id="ix_15_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2024 and 2023, the outstanding balance due to the Jiangs amounted to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingBalanceAmount" scale="0" unitRef="usd" id="ixv-47279">274,170</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingBalanceAmount" scale="0" unitRef="usd" id="ixv-47280">19,789</ix:nonFraction>, respectively. These loans bear no interest and are due on demand.</span></ix:footnote></td></tr> </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><ix:footnote id="ix_16_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around <ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-47281">12</ix:nonFraction>% per annum. As of December 31, 2024 and 2023, the outstanding principal and accrued interest was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingPrincipalAmount" scale="0" unitRef="usd" id="ixv-47282">172,112</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingPrincipalAmount" scale="0" unitRef="usd" id="ixv-47283">152,382</ix:nonFraction>, respectively. Interest expenses in connection with these loans were $<ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-47284">21,101</ix:nonFraction> and $<ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-47285">20,094</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively.</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify; font-size: 12pt"><ix:footnote id="ix_17_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024 and 2023, due to Directors amounted to $<ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-47286">8,526</ix:nonFraction> and $<ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-47287">1,322</ix:nonFraction>, respectively, were related to the daily operating expenses in 2024 and entity setup fee in 2023 paid by the Directors of AiBtl on behalf of the entity.</span></ix:footnote></td></tr> </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-30166"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">11. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-30171"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="-keep: true">Income tax
(benefit) expense for the years ended December 31, 2024 and 2023 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Current:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Federal</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-294"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-295"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">State</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-296"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt"><span style="-keep: true">Foreign</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-47288">110,539</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-47289">140,338</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total Current</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-47290">110,539</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-47291">140,338</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Deferred:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">Federal</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">State</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-300"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-301"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-302"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-47292">115,668</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total Deferred</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-303"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-47293">115,668</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total provision for income tax (benefit) expense</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-47294">110,539</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-47295">256,006</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-30419"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="-keep: true">Deferred tax assets (liability)
as of December 31, 2024 and 2023 consist approximately of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Loss on impairment of Assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" sign="-" unitRef="usd" id="ixv-47296">713,223</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" sign="-" unitRef="usd" id="ixv-47297">713,223</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Net operating loss carryforwards</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" unitRef="usd" id="ixv-47298">5,677,413</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" unitRef="usd" id="ixv-47299">5,018,343</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeaseLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-47300">178,014</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeaseLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-47301">213,482</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Operating lease assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:DeferredTaxAssetsOperatingLeaseAssets" scale="0" sign="-" unitRef="usd" id="ixv-47302">178,014</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:DeferredTaxAssetsOperatingLeaseAssets" scale="0" sign="-" unitRef="usd" id="ixv-47303">213,482</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Deferred tax assets, Gross</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-47304">6,390,636</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-47305">5,731,566</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-47306">6,390,636</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-47307">5,731,566</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Deferred tax assets, net</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-304"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c7_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-30594"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">12. EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company previously reported that during
the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related
party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related
party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to
the agreements, the Company issued <ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-47308">644,972</ix:nonFraction> shares of the Company&#8217;s common stock for the consulting service from July 2019 to July
2024 for the service fee of $<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-47309">4,514,800</ix:nonFraction> in aggregate, and recorded as stock subscription receivable. For the years ended December 31,
2024 (through June 30, 2024) and 2023, stock subscription receivable recognized as stock-based compensation in equity was $<ix:nonFraction contextRef="c368" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47310">451,480</ix:nonFraction> and
$<ix:nonFraction contextRef="c369" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47311">902,960</ix:nonFraction>, respectively.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">After further reviewed and investigation,
above services were completely provided by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with
the period when services are received. Therefore, the Company reversed share-based compensation expenses of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-47312">451,480</ix:nonFraction> and $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-47313">902,960</ix:nonFraction> for
the years ended December 31, 2024 and 2023, respectively. The accumulated deficit as of December 31, 2022 was corrected with the Stock
Subscription Receivables for $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-47314">1,354,440</ix:nonFraction> as a result of such adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 3, 2023, the Company issued&#160;<ix:nonFraction contextRef="c370" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-47315">22,341</ix:nonFraction>&#160;common
stock (post-split) to a consultant for providing consulting services on listing to NASDAQ in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 27, 2023, the Company entered into
that certain securities purchase agreement. relating to the offer and sale of <ix:nonFraction contextRef="c371" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-47316">30,000</ix:nonFraction> shares of common stock (post-split) and <ix:nonFraction contextRef="c372" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-47317">20,000</ix:nonFraction> pre-funded
warrants (post-split), at an exercise price of $<ix:nonFraction contextRef="c373" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47318">0.001</ix:nonFraction> per share, in a registered direct offering. Pursuant to the Purchase Agreement,
the Company agreed to sell the Shares and/or Pre-funded Warrants at a per share purchase price of $<ix:nonFraction contextRef="c374" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47319">3.50</ix:nonFraction>, for gross proceeds of $<ix:nonFraction contextRef="c375" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-47320">1,750,000</ix:nonFraction>,
before deducting any estimated offering expenses. On August 1, 2023, <ix:nonFraction contextRef="c376" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-47321">200,000</ix:nonFraction>&#160;pre-funded warrants were exercised.</span></p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c7_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 14, 2023, the Company entered into
a cooperation agreement with Zhonghui. Pursuant thereto, the Company expect to receive <ix:nonFraction contextRef="c377" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" unitRef="pure" id="ixv-47322">20</ix:nonFraction>% of the ownership of a property and the parcel
of the land owned by Zhonghui in Leshan, Sichuan, China. During the third quarter of 2023, the Company issued to Zhonghui, an aggregate
of <ix:nonFraction contextRef="c378" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateCommonStockShares" scale="0" unitRef="shares" id="ixv-47323">370,000</ix:nonFraction> shares (post-split) of the Company&#8217;s common stock, at a per share price of $<ix:nonFraction contextRef="c379" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47324">1.87</ix:nonFraction>, for $<ix:nonFraction contextRef="c378" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-47325">691,900</ix:nonFraction>.&#160;The Company also
issued <ix:nonFraction contextRef="c377" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-47326">29,600</ix:nonFraction> common stock to consultants for providing consulting services on the above transaction. Please refer Note 2 for the restatement
of prior year reported amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 27, 2024, the Company granted <ix:nonFraction contextRef="c380" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-47327">1,302,726</ix:nonFraction>
restricted shares to its employees and directors under the 2016 Equity Incentive Plan as compensation for their previous services, with
an issuance date of February 2, 2024. These shares are subject to a three-year restriction period.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 6, 2024, the Company entered into
a definitive agreement with Shuling Jiang (&#8220;Shuling&#8221;), pursuant to which Shuling shall transfer the ownership of certain
land she owns located at Taoyuan City, Taiwan (the &#8220;Land&#8221;) to the Company (the &#8220;Agreement&#8221;). Shuling is a director
of the Company, is married to TS Jiang, the Company&#8217;s Chief Strategic Officer and owns approximately <ix:nonFraction contextRef="c381" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47328">15.4</ix:nonFraction>% of the Company&#8217;s
issued and outstanding shares of common stock. In consideration for the Land, the Company was to pay Shuling (i) <ix:nonFraction contextRef="c382" decimals="0" format="ixt:num-dot-decimal" name="abvc:AssetConsiderationCommonStock" scale="0" unitRef="shares" id="ixv-47329">703,496</ix:nonFraction> restricted shares
of the Company&#8217;s common stock (the &#8220;Shares&#8221;) at a price of $<ix:nonFraction contextRef="c383" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-47330">3.50</ix:nonFraction> per share and (ii) five-year warrants to purchase
up to <ix:nonFraction contextRef="c384" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-47331">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock, with an exercise price of $<ix:nonFraction contextRef="c385" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47332">2.00</ix:nonFraction> per share. Under the Agreement, Shuling was
to also transfer outstanding liability owed on the Land (approximately $<ix:nonFraction contextRef="c386" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingLiabilityOwnedAmount" scale="0" unitRef="usd" id="ixv-47333">500,000</ix:nonFraction>) to the Company. On May 16, 2024, the Company&#8217;s
board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not
proceed with the transfer of land ownership; the Company may reconsider the transaction at a later date. The shares were returned and
booked as treasury stock, and the warrants were not issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 24, 2024, the Company issued <ix:nonFraction contextRef="c387" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-47334">200,000</ix:nonFraction>
shares of common stock to a consultant for providing business and funding opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In June 2024, the Company entered into a stock
purchase agreement with an investor, which the Company issued <ix:nonFraction contextRef="c388" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-47335">41,387</ix:nonFraction> shares of common stock at $<ix:nonFraction contextRef="c388" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-47336">0.75</ix:nonFraction> per share to the investor for cash.
Due to certain stock transfer processes, one of the Company&#8217;s shareholders transferred such shares to the investor on behalf of
the company in July 2024; the company plans to issue the same number of shares to the transferring shareholder soon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In July 2024, the Company entered into an
agreement with its landlord in California, pursuant that the Company will make the rent payments in the Company&#8217;s common stocks.
As of December 31, 2024, the Company has issued <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-47337">399,384</ix:nonFraction> shares with average issuance price of $<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="abvc:AverageIssuancePricePerShare" scale="0" unitRef="usdPershares" id="ixv-47338">0.68</ix:nonFraction> per share, for the monthly rent from
April 2024 and half month of December 2024, in total of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-47339">271,827</ix:nonFraction>. The Company subsequently issued <ix:nonFraction contextRef="c389" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockSharesIssuedForRent" scale="0" unitRef="shares" id="ixv-47340">80,654</ix:nonFraction> shares of its common stock for
each of the half month rent in the first quarter of 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Noncontrolling Interests</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5pt"><span style="-keep: true">AiBtl was incorporated
in January 2023 and issued <span style="-sec-ix-hidden: hidden-fact-310"><span style="-sec-ix-hidden: hidden-fact-311"><ix:nonFraction contextRef="c392" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-47341">20,000,000</ix:nonFraction></span></span> shares of its common stocks to the founding shareholder AiBtl Holding with the par value $<ix:nonFraction contextRef="c393" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47342">0.0001</ix:nonFraction>,
for $<ix:nonFraction contextRef="c394" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-47343">2,000</ix:nonFraction> at the time of incorporation. Due to certain administrative process, the previous issuance was not correctly and timely recorded
at AiBtl&#8217;s book which resulted in the correction of the previous reported non-controlling interest equity balance. Later in December
2023, AiBtl issued <ix:nonFraction contextRef="c395" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonControllingInterestConsiderationShare" scale="0" unitRef="shares" id="ixv-47344">23,000,000</ix:nonFraction> shares to ABVC and <ix:nonFraction contextRef="c396" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonControllingInterestConsiderationShare" scale="0" unitRef="shares" id="ixv-47345">23,000,000</ix:nonFraction> shares to BioLite, respectively, as a consideration for the Company&#8217;s
out-licensing products, as disclosed in Note 4. At the close of the transaction, AiBtl became the Company&#8217;s <ix:nonFraction contextRef="c397" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-47346">60.70</ix:nonFraction>% owned subsidiary
included in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 14, 2024, AiBtl issued <ix:nonFraction contextRef="c398" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-47347">1,610,700</ix:nonFraction>
AiBtl&#8217;s common stocks to a land acquisition transaction in Taiwan, including the 1-year business consulting fee of $<ix:nonFraction contextRef="c399" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConsultingFee" scale="0" unitRef="usd" id="ixv-47348">383,500</ix:nonFraction> incurred
beginning in November 2023, and the cost of land $<ix:nonFraction contextRef="c400" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Land" scale="0" unitRef="usd" id="ixv-47349">7,670,000</ix:nonFraction>. Due to certain administrative processes and restrictions, AiBtl has not
acquired ownership of the land and no asset was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Yunzhiyi, a Taiwan corporation, was incorporated
in August 2024, with <ix:nonFraction contextRef="c401" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-47350">90</ix:nonFraction>% owned by BioLite Taiwan and <ix:nonFraction contextRef="c402" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-47351">10</ix:nonFraction>% owned by Shuling Jiang, the Company&#8217;s director. This entity is set up
for holding the land that AiBtl acquired in Taiwan for developing health related business in Taiwan. Due to certain administrative processes
and restrictions, the title transfer has not completed, and no asset was recognized as of the issuance of this report. However, AiBtl
entered a series of agreements with the sellers in March 2025, to obtain the complete rights and obligations of the land while in the
process of transferring the title. These agreements are effective until the tile transfer is completed. AiBtl recognized such asset on
its balance sheet in March 2025.</span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Lind Offerings and Repayments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 23, 2023, in connection with the
issuance of the Lind Note (referring to Note 7), the Company issued Lind a <ix:nonNumeric contextRef="c403" format="ixt-sec:duryear" name="abvc:PurchaseWarrantTerm" id="ixv-47352">5</ix:nonNumeric>-year term of common stock purchase warrant to purchase up
to <ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-47353">529,167</ix:nonFraction> shares (post-split) of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c405" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-47354">10.5</ix:nonFraction> per share (post-split), subject
to adjustment. The warrant exercise price was reset to $<ix:nonFraction contextRef="c406" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47355">3.5</ix:nonFraction> in accordance with the issuance of common stock in relation to securities
purchase agreement in July 2023. On May 22, 2024, the exercise price of these warrants was further reset to $<ix:nonFraction contextRef="c407" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-47356">0.75</ix:nonFraction> along with the immediate
exercise of existing warrants and issuance of the New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the years ended December 31, 2024 and
2023, the Company has made repayment of Lind Note with the Company&#8217;s common stock for <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssueDuringPeriodCommonShares" scale="0" unitRef="shares" id="ixv-47357">1,705,303</ix:nonFraction> shares and <ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssueDuringPeriodCommonShares" scale="0" unitRef="shares" id="ixv-47358">3,732,167</ix:nonFraction> shares, respectively,
totaling $<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-47359">593,714</ix:nonFraction> and $<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-47360">1,786,686</ix:nonFraction>, respectively. As of December 31, 2024, the first Lind Note was fully repaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 17, 2023, in connection with the
issuance of the 2<sup>nd</sup> Lind Note (referring to Note 7), Lind also received a <ix:nonNumeric contextRef="c250" format="ixt-sec:duryear" name="us-gaap:CreditDerivativeTerm1" id="ixv-47361">5</ix:nonNumeric>-year term of common stock purchase warrants to
purchase up to <ix:nonFraction contextRef="c408" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-47362">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-47363">2</ix:nonFraction> per share. The warrants were valued
using the Black-Scholes model and the fair value was determined to be $<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-47364">480,795</ix:nonFraction>, which was recorded as a debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 17, 2024, in connection with the
issuance of the 3<sup>rd</sup> Lind Note (referring to Note 7), Lind also received <ix:nonNumeric contextRef="c257" format="ixt-sec:duryear" name="us-gaap:CreditDerivativeTerm1" id="ixv-47365">5</ix:nonNumeric>-year term of common stock purchase warrants to purchase
up to <ix:nonFraction contextRef="c409" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-47366">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c409" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47367">2</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 22, 2024, the Company and Lind entered
into a letter agreement, pursuant to which Lind will exercise, for cash, <ix:nonFraction contextRef="c410" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-47368">1,000,000</ix:nonFraction> of its Pre-Existing Warrants (all of the warrants
issued to Lind on February 23, 2023, November 17, 2023 and January 17, 2024 are hereinafter referred to as the &#8220;Pre-Existing Warrants&#8221;),
to purchase shares of Common Stock at a reduced exercise price of $<ix:nonFraction contextRef="c411" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-47369">0.75</ix:nonFraction> per share. Such <ix:nonFraction contextRef="c407" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-47370">1,000,000</ix:nonFraction> Pre-Existing Warrants exercised include
<ix:nonFraction contextRef="c412" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-47371">529,167</ix:nonFraction> warrants issued in February 2023 and <ix:nonFraction contextRef="c413" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-47372">470,833</ix:nonFraction> warrants issued in November 2023. Concurrently, the exercise price of all Pre-Existing
Warrants was reduced to $<ix:nonFraction contextRef="c407" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-47373">0.75</ix:nonFraction> per share according to this agreement. Lind also received new warrants to purchase <ix:nonFraction contextRef="c414" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-47374">1,000,000</ix:nonFraction> shares of
common stock, exercisable at any time on or after the date of its issuance and until the five-year anniversary thereof, for $<ix:nonFraction contextRef="c415" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47375">1.00</ix:nonFraction> per
share (the &#8220;New Warrants&#8221;). The fair value of the New Warrants was determined to be $<ix:nonFraction contextRef="c407" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-47376">925,210</ix:nonFraction> using the Black-Scholes model.
The New Warrants may be exercised via cashless exercise or resale pursuant to the registration statement that was declared effective.
As of December 31, 2024, Lind has exercised <ix:nonFraction contextRef="c416" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-47377">1,000,000</ix:nonFraction> shares of Pre-Existing Warrants and received <ix:nonFraction contextRef="c417" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-47378">1,000,000</ix:nonFraction> shares of New Warrants according
to this agreement. All warrants issued to Lind may be exercised via cashless exercise.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the year ended December 31, 2024, the
Company issued Lind in total of <ix:nonFraction contextRef="c418" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-47379">800,000</ix:nonFraction> shares of the Company&#8217;s common stock as the repayment of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock" scale="0" unitRef="usd" id="ixv-47380">800,000</ix:nonFraction> principal of 2<sup>nd</sup>
Lind Note. According to the amended agreement pursuant to Nasdaq requirements, the conversion price is subject to $<ix:nonFraction contextRef="c419" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47381">1.00</ix:nonFraction> floor price if
the conversion price was below such floor, resulting in effective conversion price between $<ix:nonFraction contextRef="c97" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47382">0.7907</ix:nonFraction> to $<ix:nonFraction contextRef="c96" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-47383">0.4932</ix:nonFraction>. The Company made additional
$<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-47384">327,017</ix:nonFraction> cash repayments, with $<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-47385">127,759</ix:nonFraction> unpaid cash booked in Accrued Expenses and Other Current Liabilities. As of the date of this
report, Lind has converted the remaining <span style="-sec-ix-hidden: hidden-fact-309">$400,000</span> principal balance on <ix:nonFraction contextRef="c420" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-47386">2</ix:nonFraction><sup>nd</sup> Lind Note into <ix:nonFraction contextRef="c420" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47387">400,000</ix:nonFraction> shares of the Company&#8217;s
common stocks.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Subsequent to December 31, 2024 through the
date of this report, Lind has converted $<ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-47388">400,000</ix:nonFraction> of 3<sup>rd</sup> Lind Note principal balance into <ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-47389">400,000</ix:nonFraction> the Company&#8217;s common
stock, leaving outstanding principal of $<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-47390">600,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-30723"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Warrants issued and outstanding in connection
with above Lind convertible notes as of December 31, 2024, and their activities during the year ended are as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Underlying<br/> Shares</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per Share</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-<br/> Average<br/> Contractual<br/> Life<br/> Remaining<br/> in Years</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value</b></span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2024</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-47391">1,529,167</ix:nonFraction></span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-47392">0.40</ix:nonFraction></span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c424" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-30797"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15</span></ix:nonNumeric></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-47393">5,542</ix:nonFraction></span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" scale="0" unitRef="shares" id="ixv-47394">2,000,000</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-47395">0.70</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" id="ixv-30833"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></ix:nonNumeric></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" scale="0" unitRef="usd" id="ixv-47396">190,000</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" unitRef="shares" id="ixv-47397">1,500,000</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-306"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-307"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2024</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-47398">2,029,167</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" id="ix_60_fact" name="abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.70</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-30907"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></ix:nonNumeric></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-47400">195,542</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="-keep: true">*</span></td><td style="text-align: justify"><ix:footnote id="ix_18_footnote" xml:lang="en-US"><span style="-keep: true">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, <ix:nonFraction contextRef="c421" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-47401">1,029,167</ix:nonFraction> of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $<ix:nonFraction contextRef="c422" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47402">0.75</ix:nonFraction> per share, at a reduced exercise price of $<ix:nonFraction contextRef="c423" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47403">0.40</ix:nonFraction> per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</span></ix:footnote></td>
</tr></table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-30943"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">13. STOCK OPTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has not granted any options during
years ended December 31, 2024 and 2023. The Company&#8217;s most recent option grant was in 2022 that <ix:nonFraction contextRef="c425" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-47404">76,190</ix:nonFraction>&#160;shares (post-split)
of common stock were granted to employees and certain consultants.&#160;The weighted average grant date fair value of options granted
in 2022 was $<ix:nonFraction contextRef="c425" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-47405">27.9</ix:nonFraction> (post-split). There are <ix:nonFraction contextRef="c426" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-47406">386,021</ix:nonFraction>&#160;options available for grant under the 2016 Equity Incentive Plan as of December
31, 2024. Compensation costs associated with the Company&#8217;s stock options are recognized, based on the grant-date fair values of
these options over vesting period. As of December 31, 2024 and 2023, there were no unvested options.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-30952"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Options issued and outstanding as of December
31, 2024, and their activities during the year then ended are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number&#160;of</b></span></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-keep: true">Contractual</b></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"/> <td><b style="-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying<br/> Shares<br/> (post-split)</b></span></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price<br/> Per&#160;Share (post-split)</b></span></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b style="-keep: true">Life<br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining<br/> in Years</span></b></td> <td><b style="-keep: true">&#160;</b></td> <td><b style="-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value</b></span></td> <td><b style="-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2024</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c427" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-47407">258,710</ix:nonFraction></span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c427" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-47408">27.9</ix:nonFraction></span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c428" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-31106"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.74</span></ix:nonNumeric></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-313"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-314"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-315"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-316"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-318"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-319"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-320"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2024</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-47409">258,710</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-47410">27.9</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-31221"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.74</span></ix:nonNumeric></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable as of December 31, 2024</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-47411">258,710</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-47412">27.9</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-31258"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.74</span></ix:nonNumeric></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested and expected to vest</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-47413">258,710</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-47414">27.9</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-31295"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.74</span></ix:nonNumeric></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-323"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-keep: true">&#160;</span></td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-31312"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">14. LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Basic loss per share is computed by dividing
net loss by the weighted-average number of common shares outstanding during the year. <ix:nonNumeric contextRef="c7" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c7_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-47415">Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the years ended December
31, 2024 and 2023.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c7_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the Year Ended</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2024</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2023</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator:</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss attributable to ABVC&#8217;s
    common stockholders</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47416">4,902,878</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47417">7,788,050</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average shares outstanding &#8211;  Basic
    &amp; Diluted</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-47418"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-47419">11,673,980</ix:nonFraction></ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-47420"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-47421">4,335,650</ix:nonFraction></ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss per share</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-Basic &amp; Diluted</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-47422"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-47423">0.42</ix:nonFraction></ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-47424"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-47425">1.80</ix:nonFraction></ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Diluted loss per share takes into account
the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common
Stock. Since the Company suffered net loss for both years, any diluted shares would have anti-diluted effect.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_LesseeOperatingLeasesTextBlock-c7_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-31538"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">15. LEASE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#8220;ASC 842&#8221;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company applied the following practical
expedients in the transition to the new standard and allowed under ASC 842:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of expired
    or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained
    leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing
    leases.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of hindsight: The
    Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease
    and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of existing
    or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted
    for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will
    be evaluated under ASU No. 2016-02.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation of lease
    and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease recognition
    exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities
    for leases with a term less than 12 months.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities. ROU assets represent the
Company&#8217;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#8217;s obligation to
make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#8217;s future minimum based payments used
to determine the Company&#8217;s lease liabilities mainly include minimum based rent payments. As most of Company&#8217;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company recognized lease liabilities,
with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="ixv-31609"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has no finance leases. The Company&#8217;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#8217;s operating leases have remaining lease terms of up to approximately five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#8239;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">ASSETS</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Operating lease right-of-use assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-47426">640,387</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-47427">809,283</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="-keep: true">LIABILITIES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating lease liabilities (current)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-47428">403,581</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-47429">401,826</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Operating lease liabilities (non-current)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-47430">236,807</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-47431">407,457</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>Supplemental Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-31744"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following provides details of the Company&#8217;s
lease expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Operating lease expenses</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd" id="ixv-47432">514,420</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd" id="ixv-47433">358,576</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Other information related to leases is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c429" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="0" unitRef="usd" id="ixv-47434">484,181</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c430" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="0" unitRef="usd" id="ixv-47435">358,576</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">Weighted Average Remaining Lease Term:</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-keep: true">Operating leases</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c1" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-47436">2.48</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-47437">1.73</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-keep: true">Weighted Average Discount Rate:</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Operating leases</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-47438">1.19</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-47439">1.50</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr> </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-31958"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">Operating<br/>
    leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-keep: true">2025</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-47440">409,587</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">2026</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-47441">104,236</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">2027</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd" id="ixv-47442">47,320</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">2028</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd" id="ixv-47443">47,320</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">2029</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" unitRef="usd" id="ixv-47444">47,320</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-324"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Total future minimum lease payments, undiscounted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-47445">655,782</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Less: Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-47446">15,395</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Present value of future minimum lease payments</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-47447">640,387</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-32089"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">16. COMMITMENTS AND CONTINGENCIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of December 31, 2024 and up through the date
of the consolidated financial statements was available to the issued.</span></p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:AssetAcquisitionTextBlock" id="ixv-32100"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">17. ACQUISITION</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 12, 2023, the Company and one
of its subsidiaries, BioLite, Inc. (&#8220;BioLite Taiwan&#8221;)&#160; each entered into a multi-year, global licensing agreement with
AiBtl BioPharma Inc. (&#8220;AiBtl&#8221;, or the acquired company) for the Company and BioLite Taiwan&#8217;s CNS drugs with the indications
of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the &#8220;Licensed Products&#8221;).
The potential license will cover the Licensed Products&#8217; clinical trial, registration, manufacturing, supply, and distribution rights.
The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen
new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the
respective agreements, each of ABVC and BioLite Taiwan received <ix:nonFraction contextRef="c431" decimals="-6" format="ixt:num-dot-decimal" name="abvc:SharesReceived" scale="6" unitRef="shares" id="ixv-47448">23</ix:nonFraction> million shares of AiBtl stock and as a result, the Company has a controlling
interest over AiBtl. If certain milestones are met, the Company and BioLite Taiwan are each eligible to receive $<ix:nonFraction contextRef="c432" decimals="0" format="ixt:num-dot-decimal" name="abvc:BenefitsReceivableForMilestoneAttained" scale="0" unitRef="usd" id="ixv-47449">3,500,000</ix:nonFraction> and royalties
equaling <ix:nonFraction contextRef="c431" decimals="2" format="ixt:num-dot-decimal" name="abvc:royaltiesPercentage" scale="-2" unitRef="pure" id="ixv-47450">5</ix:nonFraction>% of net sales, up to $<ix:nonFraction contextRef="c431" decimals="-6" format="ixt:num-dot-decimal" name="abvc:AcquisitionForNetSales" scale="6" unitRef="usd" id="ixv-47451">100</ix:nonFraction> million.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company concluded the assets acquired
and liabilities assumed did not meet the definition of a business as a limited number of inputs were acquired but no substantive business
processes or signs of output were acquired. As such, the acquisition was accounted for as an asset purchase. The purchase consideration
was nonmonetary assets (patent) and transfer on November12, 2023. <ix:nonNumeric contextRef="c7" continuedAt="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c7_cont_1" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="ixv-47452">The equity interest transferred to ABVC and BioLite Taiwan on December
15, 2023.</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c7_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Cash and cash equivalents</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">S</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-325"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Total assets acquired</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-326"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-keep: true">Accrued expense</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c433" decimals="0" format="ixt:num-dot-decimal" name="abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-47453">243,888</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Due to Director</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c433" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="0" unitRef="usd" id="ixv-47454">498</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total liabilities acquired</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c433" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" sign="-" unitRef="usd" id="ixv-47455">243,386</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total consideration (Intangible assets)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-32188"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">18. SUBSEQUENT EVENTS</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 5, 2025, the Company and Lind entered
into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, <ix:nonFraction contextRef="c434" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-47456">1,029,167</ix:nonFraction>
of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $<ix:nonFraction contextRef="c434" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-47457">0.75</ix:nonFraction> per share, at a reduced exercise
price of $<ix:nonFraction contextRef="c435" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-47458">0.40</ix:nonFraction> per share.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the first quarter of 2025, Lind has
converted the remaining $<ix:nonFraction contextRef="c436" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" unitRef="usd" id="ixv-47459">400,000</ix:nonFraction> principal balance on 2<sup>nd</sup> Lind Note into <ix:nonFraction contextRef="c436" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares" id="ixv-47460">400,000</ix:nonFraction> shares of the Company&#8217;s common stocks,
and converted $<ix:nonFraction contextRef="c437" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" unitRef="usd" id="ixv-47461">400,000</ix:nonFraction> of 3<sup>rd</sup> Lind Note principal balance into <ix:nonFraction contextRef="c437" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares" id="ixv-47462">400,000</ix:nonFraction> the Company&#8217;s common stock, leaving 3<sup>rd</sup>
Lind Note with outstanding principal of $<ix:nonFraction contextRef="c389" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" unitRef="usd" id="ixv-47463">600,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In April 2025, the Company conducted a private
offering of its common stock to several individual investors, issuing <ix:nonFraction contextRef="c438" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-47464">502,081</ix:nonFraction> unregistered shares at $<ix:nonFraction contextRef="c439" decimals="2" format="ixt:num-dot-decimal" name="abvc:UnregisteredPricePerShares" scale="0" unitRef="usdPershares" id="ixv-47465">0.60</ix:nonFraction> per share, raising a total
of $<ix:nonFraction contextRef="c438" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-47466">301,250</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="-keep: true">In April 2025, AiBtl issued <ix:nonFraction contextRef="c440" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-47467">1,800</ix:nonFraction> shares of
its common stock at $<ix:nonFraction contextRef="c441" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47468">5</ix:nonFraction> per share, raising a total of $<ix:nonFraction contextRef="c440" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributedCapital" scale="0" unitRef="usd" id="ixv-47469">9,000</ix:nonFraction> from an individual investor.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><div><a id="F_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">UNAUDITED CONDENSED CONSOLIDATED BALANCE
SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March 31</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December 31</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">ASSETS</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Current Assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="-keep: true">Cash and cash equivalents</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-47470">152,206</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-47471">248,382</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-47472">607,362</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-47473">615,433</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="-keep: true">Inventories</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-47474">11,460</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Due from related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-47475">537,119</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-47476">1,155,051</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Short-term investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd" id="ixv-47477">65,052</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd" id="ixv-47478">64,736</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Prepaid expense and other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-47479">96,362</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-47480">96,213</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="-keep: true">Total Current Assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-47481">1,469,561</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-47482">2,179,815</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-47483">8,168,746</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-47484">511,088</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Operating lease right-of-use assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-47485">533,460</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-47486">640,387</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Long-term investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-47487">2,760,062</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-47488">2,258,754</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Prepayment for long-term investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentForLongtermInvestmentsNoncurrent" scale="0" unitRef="usd" id="ixv-47489">1,124,842</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentForLongtermInvestmentsNoncurrent" scale="0" unitRef="usd" id="ixv-47490">1,124,842</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Prepayment for asset acquisition</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-47491">691,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-47492">691,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Other non-current assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-47493">127,128</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-47494">133,121</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Total Assets</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-47495">14,875,699</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-47496">7,539,907</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">LIABILITIES AND EQUITY</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Current Liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Short-term bank and other loans</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47497">801,407</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-47498">840,252</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47499">3,826,819</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47500">3,509,422</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Contract liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-47501">81,115</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-47502">81,115</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Operating lease liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-47503">366,475</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-47504">403,581</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Due to related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47505">819,384</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47506">773,045</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Convertible notes payable &#8211; third parties, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-47507">835,539</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-47508">950,046</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="-keep: true">Total Current Liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47509">6,730,739</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47510">6,557,461</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Tenant security deposit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDepositLiability" scale="0" unitRef="usd" id="ixv-47511">21,680</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDepositLiability" scale="0" unitRef="usd" id="ixv-47512">21,680</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Operating lease liability &#8211; non-current</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-47513">166,985</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-47514">236,807</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-47515">6,919,404</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-47516">6,815,948</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">COMMITMENTS AND CONTINGENCIES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Preferred stock, $<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-47517"><ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-47518">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-47519"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-47520">20,000,000</ix:nonFraction></ix:nonFraction> authorized, <span style="-sec-ix-hidden: hidden-fact-15"><span style="-sec-ix-hidden: hidden-fact-16"><span style="-sec-ix-hidden: hidden-fact-17"><span style="-sec-ix-hidden: hidden-fact-18">nil</span></span></span></span> shares issued and outstanding</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><span style="-keep: true">Common stock, $<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-47521"><ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-47522">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-47523"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-47524">100,000,000</ix:nonFraction></ix:nonFraction> authorized, <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-47525"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-47526">15,378,305</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-47527"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-47528">13,868,484</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-47529">15,378</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-47530">13,868</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Stock to be issued</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockSubscriptionReceivedInAdvance" scale="0" unitRef="usd" id="ixv-47531">31,040</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockSubscriptionReceivedInAdvance" scale="0" unitRef="usd" id="ixv-47532">31,040</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-47533">83,615,369</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-47534">78,595,065</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Accumulated deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-47535">69,791,882</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-47536">68,949,807</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Accumulated other comprehensive income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-47537">444,172</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-47538">445,665</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Treasury stock</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd" id="ixv-47539">8,909,691</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd" id="ixv-47540">8,909,691</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Total Stockholders&#8217; equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-47541">5,404,386</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-47542">1,226,140</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Noncontrolling interest</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" unitRef="usd" id="ixv-47543">2,551,909</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-47544">502,181</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Equity</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47545">7,956,295</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47546">723,959</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Total Liabilities and Equity</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-47547">14,875,699</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-47548">7,539,907</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i style="-keep: true">The accompanying notes
are an integral part of these unaudited condensed consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="F_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Three Months Ended</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March 31</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March 31<br/>
    2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024 <br/> (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold"><span style="-keep: true">Revenues</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-47549">1,205</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">Cost of revenues</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-47550">277</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Gross (loss)
    profit</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-47551">928</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Operating expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="-keep: true">Selling, general and administrative expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-47552">615,371</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-47553">738,486</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="-keep: true">Research and development expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-47554">28,861</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-47555">69,066</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Stock-based compensation</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47556">48,773</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47557">2,031,631</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-47558">693,005</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-47559">2,839,183</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Loss from
    operations</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47560">693,005</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47561">2,838,255</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Other income (expense)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="-keep: true">Interest income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-47562">19,071</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-47563">4,049</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="-keep: true">Interest expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-47564">222,967</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-47565">181,676</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="-keep: true">Operating sublease income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" unitRef="usd" id="ixv-47566">12,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" unitRef="usd" id="ixv-47567">8,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="-keep: true">Gain (loss) on foreign exchange changes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd" id="ixv-47568">9,912</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" unitRef="usd" id="ixv-47569">60,730</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="-keep: true">Loss on investment in equity securities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-47570">50,877</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Other income (expenses)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-47571">1,500</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-47572">19,485</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total other income (expenses)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-47573">251,185</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-47574">89,412</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Loss before provision income tax</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47575">944,190</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47576">2,927,667</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Provision for income tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Net loss</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47577">944,190</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47578">2,927,667</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Net loss attributable to noncontrolling
    interests</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47579">102,115</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47580">93,468</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Net loss attributed to ABVC and subsidiaries</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47581">842,075</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-47582">2,834,199</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Foreign currency translation
    adjustment</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-47583">1,493</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-47584">48,236</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Comprehensive loss</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-47585">843,568</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-47586">2,882,435</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Net loss per share:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-47587"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-47588">0.06</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-47589"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-47590">0.29</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Weighted average number of common shares outstanding:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-47591"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-47592">14,968,232</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-47593"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-47594">9,736,150</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i style="-keep: true">The accompanying notes
are an integral part of these unaudited condensed consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="F_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Three Months Ended</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March 31</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March 31<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024 <br/> (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Cash flows from operating activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="-keep: true">Net loss</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47595">944,190</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47596">2,927,667</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="-keep: true">Depreciation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-47597">7,021</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-47598">1,286</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Stock-based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47599">48,773</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47600">2,031,631</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Provision for doubtful accounts</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Other non-cash expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-47601">210,040</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-47602">176,283</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Loss on investment in equity securities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-47603">50,877</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Amortization of right-of-use asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-47604">106,927</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-47605">101,260</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Changes in operating assets and liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in"><span style="-keep: true">Inventories</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-47606">11,460</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.375in"><span style="-keep: true">Prepaid expenses and other current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" unitRef="usd" id="ixv-47607">149</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" unitRef="usd" id="ixv-47608">53,380</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.375in"><span style="-keep: true">Due from related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-47609">54,113</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" unitRef="usd" id="ixv-47610">140,364</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.375in"><span style="-keep: true">Other assets &#8211; tenant security deposit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" scale="0" unitRef="usd" id="ixv-47611">5,029</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.375in"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd" id="ixv-47612">40,113</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-47613">43,605</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.375in"><span style="-keep: true">Operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-47614">106,927</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-47615">101,260</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in"><span style="-keep: true">Net cash used in operating activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-47616">539,833</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-47617">955,816</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Cash flows from investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in"><span style="-keep: true">Net cash used in investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Cash flows from financing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Proceeds from short-term loans</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" unitRef="usd" id="ixv-47618">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Repayment of short-term loans</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" unitRef="usd" id="ixv-47619">29,250</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Proceeds from issuance of warrants</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd" id="ixv-47620">394,071</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="-keep: true">Proceeds from exercise of warrants</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd" id="ixv-47621">411,667</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Proceeds from convertible notes payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-47622">282,095</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Due to related parties, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-47623">46,339</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-47624">217,981</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in"><span style="-keep: true">Net cash provided by financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-47625">428,756</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-47626">924,147</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-47627">6,830</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-47628">26,109</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net decrease in cash and cash equivalents and restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-47629">104,247</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-47630">57,778</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Cash and cash equivalents and restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Beginning</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-47631">863,815</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-47632">716,780</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Ending</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-47633">759,568</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-47634">659,002</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Supplemental disclosure of cash flows</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Cash paid during the year for:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Interest expense paid</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-47635">5,231</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-47636">5,701</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in"><span style="-keep: true">Income taxes paid</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Non-cash financing and investing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Acquiring control of the land</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd" id="ixv-47637">7,670,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Issuance of common stock for conversion of debt</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" unitRef="usd" id="ixv-47638">47,579</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" unitRef="usd" id="ixv-47639">467,574</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Conversion of convertible note due from related parties to equity investment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-47640">563,819</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i style="-keep: true">The accompanying notes
are an integral part of these unaudited condensed consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="F_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="-keep: true">ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Common
    Stock</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;Additional</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Treasury
    Stock</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Stockholders&#8217;</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number
    of</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Subscribed</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Paid-in</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Accumulated</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Comprehensive</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number
    of</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Noncontrolling</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Equity</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>shares</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amounts</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>stock</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Capital</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Deficit</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Income</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Interest</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(Deficit)</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; width: 30%"><span style="font-size: 8pt">Balance at
    December 31, 2023</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-47641">7,940,298</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47642">7,940</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47643">73,978,380</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47644">64,046,929</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47645">516,387</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-47646">26,553</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47647">8,901,668</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47648">300,637</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47649">1,253,473</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Issuance of common shares
    for Lind CN Repayment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonShareForLindCNRepayment" scale="0" unitRef="shares" id="ixv-47650">751,795</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" scale="0" unitRef="usd" id="ixv-47651">752</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" scale="0" unitRef="usd" id="ixv-47652">466,822</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" scale="0" unitRef="usd" id="ixv-47653">467,574</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Issuance of pre-funded
    warrant in connection to the 3rd Lind Note</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-218"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-47654">394,071</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-47655">394,071</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Issuance of common shares
    for acquisition of property</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="shares" id="ixv-47656">703,496</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="usd" id="ixv-47657">703</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c66" decimals="INF" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" scale="0" sign="-" unitRef="shares" id="ixv-47658">703,496</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" sign="-" unitRef="usd" id="ixv-47659">703</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Stock-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-47660">1,302,726</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47661">1,303</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47662">1,934,452</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47663">1,935,755</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Issuance of subsidiary's
    common shares for consulting service</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-235"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" scale="0" unitRef="usd" id="ixv-47664">225,690</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" scale="0" unitRef="usd" id="ixv-47665">157,810</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" scale="0" unitRef="usd" id="ixv-47666">383,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Decrease in ownership of
    subsidiary due to share issuance</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" unitRef="usd" id="ixv-47667">4,786</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" sign="-" unitRef="usd" id="ixv-47668">4,786</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Net loss for the period</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47669">2,834,199</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47670">93,468</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47671">2,927,667</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 8pt">Cumulative
    transaction adjustments</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-47672">48,236</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-47673">48,236</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 8pt">Balance
    at March 31, 2024 (Restated)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c68" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-47674">10,698,315</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47675">10,698</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47676">77,004,201</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47677">66,881,128</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47678">468,151</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c73" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-47679">730,049</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47680">8,902,371</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47681">241,081</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47682">1,458,470</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="font-size: 8pt">Balance at December 31,
    2024</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c53" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-47683">13,868,484</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47684">13,868</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47685">31,040</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47686">78,595,065</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47687">68,949,807</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47688">445,665</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c59" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-47689">730,641</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47690">8,909,691</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47691">502,181</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47692">723,959</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Issuance of common shares
    for Lind CN Repayment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c75" decimals="INF" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonShareForLindCNRepayment" scale="0" unitRef="shares" id="ixv-47693">400,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" scale="0" unitRef="usd" id="ixv-47694">400</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" scale="0" unitRef="usd" id="ixv-47695">47,179</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" scale="0" unitRef="usd" id="ixv-47696">47,579</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><span style="font-size: 8pt">Issuance of common shares for exercise of
    warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c75" decimals="INF" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" scale="0" unitRef="shares" id="ixv-47697">1,029,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" scale="0" unitRef="usd" id="ixv-47698">1,029</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" scale="0" unitRef="usd" id="ixv-47699">410,638</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" scale="0" unitRef="usd" id="ixv-47700">411,667</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Stock-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c75" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-47701">80,654</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47702">81</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47703">48,692</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47704">48,773</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Acquiring control of the
    land</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" unitRef="usd" id="ixv-47705">4,513,795</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" unitRef="usd" id="ixv-47706">3,156,205</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" unitRef="usd" id="ixv-47707">7,670,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 8pt">Net loss</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47708">842,075</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47709">102,115</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-47710">944,190</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 8pt">Cumulative
    transaction adjustments</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-47711">1,493</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-47712">1,493</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 8pt">Balance
    at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c80" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-47713">15,378,305</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47714">15,378</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47715">31,040</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47716">83,615,369</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47717">69,791,882</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47718">444,172</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c85" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-47719">730,641</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47720">8,909,691</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47721">2,551,909</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47722">7,956,295</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i style="-keep: true">The accompanying notes
are an integral part of these unaudited condensed consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><div><a id="F_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-36885"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ABVC BioPharma, Inc. (the &#8220;Company&#8221;),
formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#8217;s operating entity, American
BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology
to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops
its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision
believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization,
BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly
respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical
trials for the Company&#8217;s drugs and medical devices are being conducted at such world-famous institutions including Stanford University,
University of California San Fransisco (UCSF) and Cedar Sinai Medical Centre (CSMC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has four wholly-owned subsidiaries,
BriVision, BioLite Holding Inc. (&#8220;BioLite Holding&#8221;), BioKey Inc. (&#8220;BioKey&#8221;), BioKey (Cayman), Inc (&#8220;BioKey
Cayman&#8221;), and a majority-owned subsidiary, AiBtl BioPharma Inc. (&#8220;AiBtl&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioLite Holding was incorporated in the State
of Nevada with wholly owned subsidiary BioLite BVI, Inc. (&#8220;BioLite BVI&#8221;) that was incorporated in the <ix:nonNumeric contextRef="c442" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-47723">British Virgin Islands</ix:nonNumeric>.
BioLite BVI holds <ix:nonFraction contextRef="c442" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-47724">73</ix:nonFraction>% ownership of BioLite Inc. (&#8220;BioLite Taiwan&#8221;), a Taiwanese corporation that was founded in February
2006. BioLite Taiwan has been in the business of developing new drugs since it was incorporated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Yunzhiyi, a Taiwanese corporation, was incorporated
in August 2024, with <ix:nonFraction contextRef="c443" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-47725">90</ix:nonFraction>% owned by BioLite Taiwan and <ix:nonFraction contextRef="c444" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-47726">10</ix:nonFraction>% owned by Shuling Jiang, the Company&#8217;s director. This entity is set up
for holding the land that AiBtl is working to acquire in Puli, Taiwan for developing health related business in Taiwan.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Incorporated in California on November 20,
2000, BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioKey Cayman was incorporated in Cayman Islands
in July 2023, which is <ix:nonFraction contextRef="c445" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-47727">100</ix:nonFraction>% owned by ABVC. This subsidiary has no activities since inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">AiBtl BioPharma, Inc. was acquired by the
Company with the transaction of the collaborative licensing agreements. On November 12, 2023, the Company and BioLite Taiwan each entered
into a multi-year, global licensing agreement with AiBtl for the Company and BioLite Taiwan&#8217;s CNS drugs with the indications of
MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the &#8220;Licensed Products&#8221;).
The potential license will cover the Licensed Products&#8217; clinical trial, registration, manufacturing, supply, and distribution rights.
The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen
new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the
respective agreements, each of ABVC and BioLite Taiwan received <ix:nonFraction contextRef="c446" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" unitRef="shares" id="ixv-47728">23</ix:nonFraction> million shares of AiBtl stock and as a result, the Company has a controlling
interest over AiBtl. If certain milestones are met, the Company and BioLite Taiwan are each eligible to receive $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:BenefitsReceivableForMilestoneAttained" scale="0" unitRef="usd" id="ixv-47729">3,500,000</ix:nonFraction> and royalties
equaling <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfRoyaltiesEqualing" scale="-2" unitRef="pure" id="ixv-47730">5</ix:nonFraction>% of net sales, up to $<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="abvc:AcquisitionForNetSales" scale="6" unitRef="usd" id="ixv-47731">100</ix:nonFraction> million. The financial statements of AiBtl are included in the Company&#8217;s consolidated financial
statements. As a result of these transactions, the Company became a controlling parent of AiBtl, with <ix:nonFraction contextRef="c447" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-47732">58.85</ix:nonFraction>% of group ownership over
AiBtl.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 40.2pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="abvc_LiquidityGoingConcernAndRestatementTextBlock-c0_cont_1" escape="true" name="abvc:LiquidityGoingConcernAndRestatementTextBlock" id="ixv-36929"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">2. LIQUIDITY, GOING CONCERN, AND RESTATEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Liquidity and Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The accompanying financial statements have
been prepared in conformity with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;)
which contemplates continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and
liabilities are settled in the ordinary course of business at amounts disclosed in the financial statements. The Company&#8217;s ability
to continue as a going concern depends upon its ability to market and sell its products to generate positive operating cash flows. For
the three months ended March 31, 2025, the Company reported net loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" unitRef="usd" id="ixv-47733">944,190</ix:nonFraction>. As of March 31, 2025, the Company&#8217;s working capital
deficit was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:WorkingCapitalDeficit" scale="0" unitRef="usd" id="ixv-47734">5,261,178</ix:nonFraction>.&#160; In addition, the Company had net cash outflows of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-47735">539,833</ix:nonFraction>&#160;from operating activities for the three
months ended March 31, 2025. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a
going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">To sustain its ability to support the Company&#8217;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash
    generated from operations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other available sources
    of financing from banks and other financial institutions in the U.S. and in Taiwan; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial support from
    the Company&#8217;s related parties and shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Management&#8217;s plan is to continue to
improve operations to generate positive cash flows and raise additional capital through private or public offerings, or financial support
from related parties or shareholders. If the Company is not able to generate positive operating cash flows, and raise additional capital,
there is the risk that the Company may not be able to meet its short-term obligations. All of these factors raise substantial doubt about
the ability of the Company to continue as a going concern. The interim condensed consolidated financial statements as of March 31, 2025,
and for the three months ended March 31, 2025 and 2024 have been prepared on a going concern basis and do not include any adjustments
to reflect the possible future effects on the recoverability and classifications of assets or the amounts and classifications of liabilities
that may result from the inability of the Company to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Restatement Background and Explanation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has restated its financial statements
as of and for the year ended December 31, 2023, to correct misstatements in those prior periods related to improperly applying accounting
guidance on the share-based payments, incorrectly recognizing interest expenses upon the conversion of convertible debts, and misidentifying
the existence of non-controlling interest of our subsidiary. These restatements also resulted in the restatements of the relevant accounts
as of and for the three months ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As disclosed in Note 5, the Company entered
into a cooperation agreement on August 14, 2023 with Zhong Hui Lian He Ji Tuan, Ltd. (the &#8220;Zhonghui&#8221;) to acquire <ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-47736">20</ix:nonFraction>% of the
ownership of certain property and a parcel of the land. According to the agreement, the Company issued <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" scale="0" unitRef="shares" id="ixv-47737">370,000</ix:nonFraction> shares of its common stock
as the consideration, and used $<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47738">20</ix:nonFraction> dollar per share to recognize the right as construction in progress on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the time of preparing its 2024 financial
statements, the Company reviewed the entire transaction, its relevant agreements and documentation, as well as the applicable accounting
guidance. The Company applied FASB Accounting Standard Codification (&#8220;ASC&#8221;) 845 Nonmonetary Transactions to determine the
fair value of the asset acquired would be more evident than the fair value of the consideration in exchange, the Company&#8217;s restricted
common stocks. The real estates acquired comes with a third-party valuation of $<ix:nonFraction contextRef="c448" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateOwnedValuationAllowance" scale="0" unitRef="usd" id="ixv-47739">7,400,000</ix:nonFraction> per the Company&#8217;s stake, which the value
of the acquired assets is guaranteed by Zhonghui. Upon further review, the Company considered ASC 718 Compensation &#8211; Stock Compensation,
should have been the appropriate guidance to apply given the Company&#8217;s common stocks are listed in Nasdaq with more observable
fair value (Level 1). Furthermore, at the time of issuance of these financial statements, no real estate title was transferred to the
Company. As a result, the Company adjusted the carrying value of the asset and reclassified the balance to &#8220;Prepayment for asset
acquisition&#8221; account to reflect the value of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares" id="ixv-47740">370,000</ix:nonFraction> shares issued at $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47741">1.87</ix:nonFraction>, the closing price as of the contract date. The Company
also corrected the share price used to recognize stock compensation expense from $<ix:nonFraction contextRef="c449" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47742">20</ix:nonFraction> to $<ix:nonFraction contextRef="c450" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47743">1.87</ix:nonFraction> for the <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-47744">29,600</ix:nonFraction> shares of common stock issued
on the same day to several consultants. As a result, these adjustments reduced $<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" sign="-" unitRef="usd" id="ixv-47745">6,708,100</ix:nonFraction> for asset recognized and $<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="0" unitRef="usd" id="ixv-47746">536,648</ix:nonFraction> for stock-compensation
expense incurred in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In February 2023, the Company issued a convertible
note to LIND Global Fund II, LP (Note 7). Due to misapplication of ASC 470-20 instead of ASC 815-40, the Company overstated interest
expenses $<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-47747">1,179,669</ix:nonFraction> for the year ended December 31, 2023. The overstatement is offsetting against additional paid-in capital due to the
convertible note being converted to the Company&#8217;s own common stocks instead of being repaid or disposition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In November 2023, the Company and one of its
subsidiaries entered into a licensing agreement with AiBtl. The Company accounted for a <ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-47748">100</ix:nonFraction>% control of AiBtl as of December 31, 2023,
but later discovered that AiBtl had outstanding founder shares that were not deposited to the stock transfer agent in the timely manner.
Such shares reduced the Company&#8217;s controlling interest from <ix:nonFraction contextRef="c451" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-47749">100</ix:nonFraction>% to <ix:nonFraction contextRef="c452" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-47750">69.70</ix:nonFraction>% as of December 31, 2023. Accordingly, the Company adjusted
the relevant accounts in our consolidated financial statements.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="abvc_LiquidityGoingConcernAndRestatementTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As discussed in Note 12, in July 2019 the
Company issued <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-47751">644,972</ix:nonFraction> shares (post-split) of the Company&#8217;s common stock to four consultants for their services. Such stock-based
expenses were amortized over <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="abvc:StockBasedExpensesAmortizationPeriod" id="ixv-47752">5</ix:nonNumeric> years starting from the issuance date. Per the Company&#8217;s further review, the services, along with
the agreements, were completed by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with the period
when services are received. Therefore, the Company reversed share-based compensation expenses of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-47753">451,480</ix:nonFraction> and $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-47754">902,960</ix:nonFraction> for the years
ended December 31, 2024 and 2023, respectively. The accumulated deficit as of December 31, 2022 was corrected with the Stock Subscription
Receivables for $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-47755">1,354,440</ix:nonFraction> as a result of such adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Please read the impacts of the 2023 restatement
in our audited 2024 consolidated financial statements filed in our Form 10-K with the SEC on April 15, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Impact of the Restatement to the March
31, 2024 interim financial statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" id="ixv-37035"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the three months ended March 31, 2024 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">Unaudited
                                            Condensed</b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">Consolidated Balance Sheets</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">Prepaid expense and other current asset</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-47756">159,602</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-47757">223,707</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-47758">383,309</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" unitRef="usd" id="ixv-47759">7,949,150</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" sign="-" unitRef="usd" id="ixv-47760">7,400,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" unitRef="usd" id="ixv-47761">549,150</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Prepayment for asset acquisition</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-328"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-47762">691,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-47763">691,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Assets</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-47764">14,460,402</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" sign="-" unitRef="usd" id="ixv-47765">6,484,392</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-47766">7,976,010</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47767">4,050,845</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" sign="-" unitRef="usd" id="ixv-47768">605,178</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47769">3,445,667</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Convertible notes payable &#8211; third parties, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-47770">842,567</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-47771">29,769</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-47772">872,336</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Due to related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c456" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47773">301,972</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c457" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47774">89,502</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c458" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47775">391,474</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Current Liabilities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47776">6,633,614</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" sign="-" unitRef="usd" id="ixv-47777">455,908</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-47778">6,177,706</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Liabilities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-47779">6,973,447</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" sign="-" unitRef="usd" id="ixv-47780">455,908</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-47781">6,517,539</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-47782">86,029,237</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" sign="-" unitRef="usd" id="ixv-47783">9,025,036</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-47784">77,004,201</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Total stockholders&#8217; equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-47785">7,792,076</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-47786">6,092,525</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-47787">1,699,551</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Noncontrolling interest</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-47788">305,121</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" unitRef="usd" id="ixv-47789">64,040</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-47790">241,081</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Equity</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47791">7,486,955</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47792">6,028,485</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47793">1,458,470</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Liabilities and Equity</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-47794">14,460,402</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-47795">6,484,393</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-47796">7,976,009</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Three Months Ended March 31,
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">Unaudited
                                            Condensed</b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">Consolidated Statements of Operations</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">Selling, general and administrative expenses</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-47797">831,257</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" sign="-" unitRef="usd" id="ixv-47798">92,771</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-47799">738,486</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47800">2,544,995</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" sign="-" unitRef="usd" id="ixv-47801">513,364</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47802">2,031,631</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Interest expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-47803">684,683</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" sign="-" unitRef="usd" id="ixv-47804">503,007</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-47805">181,676</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Net loss attributable to noncontrolling interests</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47806">48,043</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47807">45,425</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47808">93,468</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net loss</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47809">3,981,019</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-47810">1,053,352</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47811">2,927,667</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Basic and diluted net loss per common share</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c459" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-47812"><ix:nonFraction contextRef="c459" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-47813">0.40</ix:nonFraction></ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c460" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-47814"><ix:nonFraction contextRef="c460" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-47815">0.11</ix:nonFraction></ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c461" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-47816"><ix:nonFraction contextRef="c461" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-47817">0.29</ix:nonFraction></ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Three Months Ended March 31,
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">Unaudited Condensed</span></p>
                                                                    <p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">Consolidated Statements
                                            of Cash Flows</span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left"><span style="-keep: true">Net loss</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-47818">3,981,019</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" unitRef="usd" id="ixv-47819">1,053,355</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-47820">2,927,664</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock-based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47821">2,544,995</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" sign="-" unitRef="usd" id="ixv-47822">513,364</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47823">2,031,631</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Other non-cash income and expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-47824">672,016</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" unitRef="usd" id="ixv-47825">495,736</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-47826">176,280</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd" id="ixv-47827">354,465</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-47828">398,070</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-47829">43,605</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Due to related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" unitRef="usd" id="ixv-47830">128,840</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-47831">128,840</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-329"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net cash used in operating activities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-47832">602,001</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-47833">353,815</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-47834">955,816</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Due to related parties*</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-330"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" id="ix_61_fact" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">217,981</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" id="ix_62_fact" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">217,981</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net cash provided by financing activities</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-47837">805,006</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-47838">119,141</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-47839">924,147</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" scale="0" sign="-" unitRef="usd" id="ixv-47840">260,783</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" scale="0" unitRef="usd" id="ixv-47841">234,674</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" scale="0" sign="-" unitRef="usd" id="ixv-47842">26,109</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Issuance of common stock for conversion of debt</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" unitRef="usd" id="ixv-47843">681,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" unitRef="usd" id="ixv-47844">213,426</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStockForConversionOfDebt" scale="0" unitRef="usd" id="ixv-47845">467,574</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_19_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#8217;s presentation.</span></ix:footnote></td>
</tr></table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-38090"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-38095"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis of Presentation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: none">The accompanying
unaudited interim condensed consolidated financial statements have been prepared in accordance with the generally accepted accounting
principles in the United States of America (the &#8220;U.S. GAAP&#8221;). All significant intercompany transactions and account balances
have been eliminated. These financial statements do not include all the information and footnotes required by the U.S. GAAP for complete
financial statements. Certain information and note disclosures normally included in the annual financial statements prepared in accordance
with the U.S. GAAP have been condensed or omitted consistent with Article 8 of Regulation S-X. In the opinion of the Company&#8217;s
management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial
statements and include all adjustments, in a normal recurring nature, as necessary for the fair statement of the Company&#8217;s financial
position as of March 31, 2025, and results of operations and cash flows for the three months ended March 31, 2025 and 2024. The unaudited
interim condensed consolidated balance sheet as of March 31, 2025 has been derived from the audited financial statements at December
31, 2024, and interim results of operations are not necessarily indicative of the results expected for the full fiscal year or for any
future period. These financial statements should be read in conjunction with the audited consolidated financial statements as of and
for the years ended December 31, 2024 and 2023, and related notes included in the Company&#8217;s audited consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: none">This basis
of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses
and losses are recognized when incurred. The Company&#8217;s unaudited financial statements are expressed in U.S. dollars.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="ixv-38110"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><span style="text-decoration:underline">Reclassifications</span>:</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: none">Certain
amounts on the prior year&#8217;s condensed consolidated balance sheets, condensed consolidated statements of operations and condensed
cash flows were reclassified to conform to the current-year presentation, with no effect on ending stockholders&#8217; equity.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-38121"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-38131"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair Value Measurements</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ASC 820 &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8211;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8211;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8211;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-38191"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company&#8217;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $<ix:nonFraction contextRef="c462" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyExcessExpenseReimbursable" scale="0" unitRef="usd" id="ixv-47846">91,500</ix:nonFraction> (NTD <ix:nonFraction contextRef="c462" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyExcessExpenseReimbursable" scale="6" unitRef="twd" id="ixv-47847">3.0</ix:nonFraction> million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $<ix:nonFraction contextRef="c463" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyExcessExpenseReimbursable" scale="0" unitRef="usd" id="ixv-47848">250,000</ix:nonFraction> covered by the U.S. Federal Deposit Insurance Corporation&#8217;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="abvc_ConcentrationOfClientsPolicyTextBlock-c0_cont_1" escape="true" name="abvc:ConcentrationOfClientsPolicyTextBlock" id="ixv-38206"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Clients</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="abvc_ConcentrationOfClientsPolicyTextBlock-c0_cont_2" id="abvc_ConcentrationOfClientsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 31, 2025 and December 31, 2024,
management estimated all accounts receivable balances are uncollectible. Provision credit loss balances were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" unitRef="usd" id="ixv-47849">11,993</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" unitRef="usd" id="ixv-47850">11,993</ix:nonFraction> as of
March 31, 2025 and December 31, 2024, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abvc_ConcentrationOfClientsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the three months ended March 31, 2024,
the Company&#8217;s revenue was generated from one customer.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-38221"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cash and Cash Equivalents</span>&#160;</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of March 31, 2025 and December 31, 2024, the Company&#8217;s
cash and cash equivalents amounted to $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-47851">152,206</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-47852">248,382</ix:nonFraction>, respectively. Some&#160;of the Company&#8217;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-38231"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Restricted Cash </span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of March 31, 2025 and December 31, 2024, the Company&#8217;s restricted cash amounted $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-47853">607,362</ix:nonFraction>
(NTD <ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="6" unitRef="twd" id="ixv-47854"><ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="6" unitRef="twd" id="ixv-47855">20.2</ix:nonFraction></ix:nonFraction> million) and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-47856">615,433</ix:nonFraction> (NTD 20.2 million), respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ixv-38241"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Accounts receivable and allowance for expected credit losses
accounts</span>&#160;</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2" id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Accounts receivable are recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_3" id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company makes estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#8217;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Allowance for expected credit losses accounts
were $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-47857">616,397</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-47858">616,414</ix:nonFraction> as of March 31, 2025 and December 31, 2024, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-38261"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Collaborative Revenues &#8212; </b>The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s
judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">(i) Non-refundable upfront payments</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">(ii) Milestone payments</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative
agreement with collaboration partners.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">(iii) Multiple Element Arrangements</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_15" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_16" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">(iv) Royalties and Profit Sharing Payments</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_17" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_18" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp; Manufacturing Organization Services (&#8220;CDMO&#8221;))</b> &#8212;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_19" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_20" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advances from customers upon receipt
or when due, and may require deferral of revenue recognition for a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-38404"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stock-based Compensation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221;.
Total director, officer, and employee stock-based compensation expenses were $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-47859">0</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-47860">1,935,755</ix:nonFraction> for the three months ended March 31, 2025
and 2024, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="-keep: true">The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221; and ASC 505-50 &#8220;Equity-Based Payments
to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $<ix:nonFraction contextRef="c464" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd" id="ixv-47861">48,773</ix:nonFraction> for rent for the three months ended March 31, 2025, and $<ix:nonFraction contextRef="c465" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="0" unitRef="usd" id="ixv-47862">95,876</ix:nonFraction>&#160;for consulting services
for the three months ended March 31, 2024.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-38419"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commitments and Contingencies</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has adopted ASC 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in financial statements when
it is at least reasonably possible that a material loss could be incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-38429"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Foreign-currency Transactions</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#8217;
Equity.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-38440"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Segment Reporting</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ASC 280 &#8220;Segment Reporting&#8221; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company currently has&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-47863">one</ix:nonFraction>&#160;reportable
segment, and assets are reviewed on a consolidated basis. As such, segmental data is not provided.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-38469"><ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_4" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following tables present revenue and gross
profit information for each of our only reportable segment:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_5" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">For The Three-Month<br/> Periods
    Ended<br/> March 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024<br/> (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-keep: true">Revenue</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-331"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-47864">1,205</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Cost of Revenue</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-332"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-47865">277</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Segment Gross Profit (Loss)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-333"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-47866">928</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Depreciation expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-47867">7,021</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-47868">1,286</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="ixv-38604"><ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_6" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">For The Three-Month<br/>
    Periods Ended<br/> March 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024<br/>
    (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Segment Gross Profit (Loss)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-47869">928</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">Less:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Selling, general and administrative expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-47870">615,371</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-47871">738,486</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Research and development expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-47872">28,861</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-47873">69,066</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Stock-based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-47874">48,773</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-47875">2,031,631</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Add (Less):</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Interest income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-47876">19,071</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-47877">4,049</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Interest expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-47878">222,967</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-47879">181,676</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating sublease income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" unitRef="usd" id="ixv-47880">12,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" unitRef="usd" id="ixv-47881">8,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Gain (loss) on foreign exchange changes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd" id="ixv-47882">9,912</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" unitRef="usd" id="ixv-47883">60,730</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Loss on investment in equity securities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="abvc:WriteOffUnclaimedAccruedLiabilites" scale="0" sign="-" unitRef="usd" id="ixv-47884">50,877</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-335"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-47885">1,500</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-47886">19,485</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Loss before provision for income tax</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47887">944,190</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-47888">2,927,667</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-38909"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="ixv-38937"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">4. COLLABORATIVE AGREEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreements with BHK, a
related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015,
    BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development
    Agreement&#8221;), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple
    Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual
    property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be
    shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date
    of first commercial sale of the Product in in Asia excluding Japan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c468" continuedAt="_LongTermPurchaseCommitmentMilestones-c468_cont_1" name="us-gaap:LongTermPurchaseCommitmentMilestones" id="ixv-38958"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_LongTermPurchaseCommitmentMilestones-c468_cont_2" id="_LongTermPurchaseCommitmentMilestones-c468_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_LongTermPurchaseCommitmentMilestones-c468_cont_3" id="_LongTermPurchaseCommitmentMilestones-c468_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_LongTermPurchaseCommitmentMilestones-c468_cont_4" id="_LongTermPurchaseCommitmentMilestones-c468_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_LongTermPurchaseCommitmentMilestones-c468_cont_5" id="_LongTermPurchaseCommitmentMilestones-c468_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_LongTermPurchaseCommitmentMilestones-c468_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In December 2015, BHK has paid a non-refundable
upfront cash payment of $<ix:nonFraction contextRef="c469" decimals="-6" format="ixt:num-dot-decimal" name="abvc:NonrefundableUpfrontCashPayment" scale="6" unitRef="usd" id="ixv-47889">1</ix:nonFraction> million, or <ix:nonFraction contextRef="c469" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure" id="ixv-47890">10</ix:nonFraction>% of $<ix:nonFraction contextRef="c469" decimals="-5" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="6" unitRef="usd" id="ixv-47891">10.0</ix:nonFraction> million, upon the signing of BHK Co-Development Agreement. The Company concluded
that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis
and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in
2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative
agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement.
In August 2016, the Company received the second milestone payment of <span style="-sec-ix-hidden: hidden-fact-336">NTD31,649,000</span>, approximately equivalent to $<ix:nonFraction contextRef="c126" decimals="-6" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="6" unitRef="usd" id="ixv-47892">1</ix:nonFraction> million, and recognized
collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase
II clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on <ix:nonFraction contextRef="c471" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-47893">12</ix:nonFraction>% of BHK&#8217;s net sales related to BLI-1401-2 Products. As of March 31, 2025, the Company
has not earned the royalty under the BHK Co-Development Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#8220;BHK Collaborative Agreements&#8221;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#8220;Targeting Major Depressive Disorder&#8221; (BLI-1005 Products) and BLI-1006 for
&#8220;Targeting Inflammatory Bowel Disease&#8221; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property
rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50
between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial
sale of the Product in in Asia excluding Japan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In 2015, the Company recognized the cash receipt
in a total of <span style="-sec-ix-hidden: hidden-fact-337">NTD50 million</span>, approximately equivalent to $<ix:nonFraction contextRef="c128" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" unitRef="usd" id="ixv-47894">1.6</ix:nonFraction> million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition to the total of <span style="-sec-ix-hidden: hidden-fact-338">NTD50 million</span>,
approximately equivalent to $<ix:nonFraction contextRef="c130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" unitRef="usd" id="ixv-47895">1.6</ix:nonFraction> million, BioLite Taiwan is entitled to receive <ix:nonFraction contextRef="c472" decimals="2" format="ixt:num-dot-decimal" name="abvc:NetSalesProfitPercentage" scale="-2" unitRef="pure" id="ixv-47896">50</ix:nonFraction>% of the future net licensing income or net sales profit.
As of March 31, 2025, the Company has not earned the royalty under the BHK Collaborative Agreements.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_2" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Co-Development agreement with Rgene
Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 26, 2017, the Company through its subsidiary, BriVision, entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party controlled by the controlling beneficiary shareholder of YuanGene Corporation (See Note 10). Pursuant to Co-Dev Agreement, the Company and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to&#160;pay the Company $<ix:nonFraction contextRef="c131" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForParticipationLiabilities" scale="6" unitRef="usd" id="ixv-47897">3.0</ix:nonFraction> million in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of the Company&#8217;s past research efforts and contributions before the Co-Dev Agreement was signed and it does not relate to any future commitments made by the Company and Rgene in this Co-Dev Agreement. In addition to $<ix:nonFraction contextRef="c473" decimals="-5" format="ixt:num-dot-decimal" name="abvc:AdditionCashPayment" scale="6" unitRef="usd" id="ixv-47898">3.0</ix:nonFraction> million, the Company is entitled to receive <ix:nonFraction contextRef="c473" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure" id="ixv-47899">50</ix:nonFraction>% of the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both the Company and Rgene.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 1, 2017, the Company has delivered
all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under control by
a controlling beneficiary shareholder of YuanGene Corporation and a director and officer of the Company, the Company has recorded the
full amount of $<ix:nonFraction contextRef="c133" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" unitRef="usd" id="ixv-47900">3.0</ix:nonFraction> million in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31,
2017. During the year ended December 31, 2017, the Company received $<ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-47901">450,000</ix:nonFraction> in cash. On December 24, 2018, the Company received the
remaining balance of $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-47902">2,550,000</ix:nonFraction> in the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of <span style="-sec-ix-hidden: hidden-fact-340">NTD50</span> per share (approximately
equivalent to $<ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47903">1.60</ix:nonFraction> per share), for an aggregate number of <ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="abvc:EquityMethodLongTermInvestment" scale="0" unitRef="shares" id="ixv-47904">1,530,000</ix:nonFraction> shares, which accounted for equity method long-term investment as
of December 31, 2018. On December 31, 2018, the Company determined to fully write off this investment based on the Company&#8217;s assessment
of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee,
adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional
funding requirements, and Rgene&#8217;s ability to remain in business. All projects that have been initiated will be managed and supported
by the Company and Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company and Rgene signed an amendment
to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer
Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination
Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized.
Other provisions of the Co-Dev Agreement remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 10, 2022, the Company expanded its
co-development partnership with Rgene. On that date, BioKey, ABVC has entered into a Clinical Development Service Agreement with Rgene
to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic
cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under the U.S. FDA
IND regulatory requirements. Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $<ix:nonFraction contextRef="c137" decimals="-5" format="ixt:num-dot-decimal" name="abvc:ServiceAgreementEligibilityAmount" scale="6" unitRef="usd" id="ixv-47905">3.0</ix:nonFraction> million
over a <ix:nonNumeric contextRef="c138" format="ixt-sec:duryear" name="abvc:MilestoneRegulatoryPaymentAmountPeriod" id="ixv-47906">3</ix:nonNumeric>-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period.
The Service Agreement shall remain in effect until the expiration date of the last patent and automatically renew for 5 more years unless
terminated earlier by either party with six months&#8217; written notice. Either party may terminate the Service Agreement for cause
by providing 30 days written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Through a series of transactions over the
past 5 years, the Company and Rgene have co-developed the three drug products covered by the Service Agreement, which has resulted in
the Company owning <ix:nonFraction contextRef="c475" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47907">26.65</ix:nonFraction>% of Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As part of the Rgene Studies, the Company
agreed to loan $<ix:nonFraction contextRef="c476" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="6" unitRef="usd" id="ixv-47908">1.0</ix:nonFraction> million and made $<ix:nonFraction contextRef="c476" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="6" unitRef="usd" id="ixv-47909">0.5</ix:nonFraction> million to Rgene, for which Rgene has provided the Company with a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abvc:WorkingCapitalConvertibleLoanPercentage" scale="-2" unitRef="pure" id="ixv-47910">5</ix:nonFraction>% interest rate convertible
loan (the &#8220;Note&#8221;). If the Note is fully converted, the Company will own an additional <ix:nonFraction contextRef="c477" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47911">6.4</ix:nonFraction>% of Rgene. The Company is expected
to receive the outstanding loan from the related party by the first half of 2025, either by cash or conversion of shares of Rgene. The
Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-47912">1.00</ix:nonFraction>
per share or (ii) <ix:nonFraction contextRef="c478" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47913">20</ix:nonFraction>% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject
to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to
which a breach of the Service Agreement will trigger an event of default under the Note if not cured after 5 business days of written
notice regarding the breach is provided. Upon an event of default, the outstanding principal and any accrued and unpaid interest shall
be immediately due and payable. The Note was fully converted to Rgene&#8217;s common stocks in 2024. See Note 6 for details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Service Agreement shall remain in effect
until the expiration date of the last patent and automatically renew for 5 more years unless terminated earlier by either party with
six months&#8217; written notice. Either party may terminate the Service Agreement for cause by providing 30 days written notice.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_3" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Rgene has further agreed, effective July 1,
2022, to provide the Company with a seat on Rgene&#8217;s Board of Directors until the loan is repaid in full. The Company has nominated
Dr. Jiang, its Chief Strategy Officer and Director to occupy that seat; Dr. Jiang is also one of the Company&#8217;s director and officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Rgene Studies is a related party transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreement with BioFirst
Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 24, 2017, the Company through its
subsidiary, BriVision, entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst Corporation
(&#8220;BioFirst&#8221;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the
&#8220;Product&#8221;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling
beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and common stock shareholders of BioFirst (See
Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $<ix:nonFraction contextRef="c144" decimals="-5" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="6" unitRef="usd" id="ixv-47914">3.0</ix:nonFraction> million in cash or
stock of the Company before September 30, 2018. The amount of $<ix:nonFraction contextRef="c479" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForParticipationLiabilities" scale="6" unitRef="usd" id="ixv-47915">3.0</ix:nonFraction> million is in connection with the compensation for BioFirst&#8217;s
past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate
to any future commitments in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive <ix:nonFraction contextRef="c479" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure" id="ixv-47916">50</ix:nonFraction>% of the future
net licensing income or net sales profit, if any, and any development cost shall be equally shared by both the Company and BioFirst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 25, 2017, BioFirst delivered
all research, technical, data and development data to the Company. The Company determined to fully expense the entire amount of $<ix:nonFraction contextRef="c146" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" unitRef="usd" id="ixv-47917">3.0</ix:nonFraction>
million since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative
future uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses immediately. Hence, the entire amount of $<ix:nonFraction contextRef="c147" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-47918">3.0</ix:nonFraction> million is fully expensed as research and development expense during the year
ended December 31, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 30, 2019, BriVision entered into a
Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued
<span style="-sec-ix-hidden: hidden-fact-339">42,857 shares</span> (post-split) of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" unitRef="usd" id="ixv-47919">3.0</ix:nonFraction> million owed by the Company to BioFirst
(the &#8220;Total Payment&#8221;) in connection with BioFirst Collaborative Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 5, 2019, BriVision entered into
a second Stock Purchase Agreement (&#8220;Purchase Agreement 2&#8221;) with BioFirst. Pursuant to Purchase Agreement 2, the Company issued
<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-47920">41,470</ix:nonFraction> shares (post-split) of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="0" unitRef="usd" id="ixv-47921">2,902,911</ix:nonFraction> owed by the Company to BioFirst
in connection with a loan provided to BriVision from BioFirst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 4, 2020, the Company executed
an amendment to the BioFirst Collaborative Agreement to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal Storage Solution
to the agreement. ABV-2002 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while ABV-2001 has
broader utilization during a variety of ocular procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Initially the Company will focus on ABV-2002,
a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial
keratoplasty (back layer cornea transplant). ABV-2002 is a solution comprised of a specific poly amino acid that protects ocular tissue
from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity
to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration
results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant
phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can
be manufactured at lower cost. Further ABV-2002 product development was put on hold due to the lack of funding.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_4" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition, BioFirst was incorporated on
November 7, 2006, focusing on the R&amp;D, manufacturing, and sales of innovative patented pharmaceutical products. The technology of
BioFirst comes from the global exclusive licensing from domestic R &amp; D institutions. Currently, the main research and development
product is the vitreous substitute (Vitargus&#174;) Licensed by the National Health Research Institutes. Vitargus is the world&#8217;s
first bio-degradable vitreous substitute and offers a number of advantages over current vitreous substitutes by minimizing medical complications
and reducing the need for additional surgeries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">BioFirst has started the construction of a
GMP factory in Hsinchu Biomedical Science Park, Taiwan, with the aim at building a production base to supply the global market, and promote
the construction of bio-degradable vitreous substitute manufacturing centers in Taiwan. Completion of this factory would allow ABVC to
manufacture Vitargus with world-class technology in a GMP certified pharmaceutical factory. BioFirst is targeting to complete the construction
in 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 31, 2025, the Company has not
earned any net licensing income or net sales profit earned by BioFirst under these collaborative agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreement with ForSeeCon
Eye Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 25, 2024, the Company and BioFirst
each entered into a twenty-year, global definitive licensing agreement (the &#8220;FEYE Licensing Agreement&#8221;) with ForSeeCon Eye
Corporation, a company registered in the British Virgin Islands (&#8220;FEYE&#8221;) for the products in the Company and BioFirst&#8217;s
Ophthalmology pipeline, including Vitargus (the &#8220;Vitargus Products&#8221;). The license covers Vitargus Products&#8217; clinical
trial, registration, manufacturing, supply, and distribution rights; FEYE also has the rights to sublicense or partner with a third party
to develop the Licensed Products. As per each of the respective FEYE Licensing Agreements, each of the Company and BioFirst shall receive
a total licensing fee of $<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxesAndLicenses" scale="6" unitRef="usd" id="ixv-47922">33.5</ix:nonFraction> million, composed of an upfront payment of $<ix:nonFraction contextRef="c151" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="usd" id="ixv-47923">30</ix:nonFraction> million, which can instead be paid with <ix:nonFraction contextRef="c152" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="6" unitRef="shares" id="ixv-47924">5</ix:nonFraction> million shares
of FEYE stock at $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47925">6</ix:nonFraction> per share within 30 days after the execution of the FEYE Licensing Agreement, and a $<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="abvc:MilestoneRegulatoryPaymentAmount" scale="6" unitRef="usd" id="ixv-47926">3.5</ix:nonFraction> million cash milestone payment,
due 30 days upon completion of next round fundraising. Additionally, each of the Company and BioFirst are eligible to receive royalties
of <ix:nonFraction contextRef="c153" decimals="2" format="ixt:num-dot-decimal" name="abvc:RoyaltiesPercentage" scale="-2" unitRef="pure" id="ixv-47927">5</ix:nonFraction>% of net sales.&#160;As of March 31, 2025, the Company received <ix:nonFraction contextRef="c480" decimals="-6" format="ixt:num-dot-decimal" name="abvc:ReceivedShares" scale="6" unitRef="shares" id="ixv-47928">5</ix:nonFraction> million FEYE shares but did not recognize such licensing revenue
since the fair value of FEYE stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 18, 2024, the Company and BioFirst,
each entered into an amendment (the &#8220;Amendment&#8221;) to the Licensing Agreement with FEYE, pursuant to which the Company and
BioFirst have agreed to allow FEYE to pay the second milestone payment in the amount of $<ix:nonFraction contextRef="c155" decimals="-5" format="ixt:num-dot-decimal" name="abvc:MilestoneRegulatoryPaymentAmount" scale="6" unitRef="usd" id="ixv-47929">3.5</ix:nonFraction> million per Licensing Agreement, incrementally
(such as $<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="abvc:LicensingAgreement" scale="0" unitRef="usd" id="ixv-47930">100,000</ix:nonFraction>), at any given time, rather than in one lump sum. During the year ended December 31, 2024, the Company received in
cash and recognized revenue of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-47931">296,000</ix:nonFraction>, pursuant to the Amendment. There was no cash receipt in the three months periods ended March
31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><span style="text-decoration:underline">Collaborative agreement with OncoX BiopPharma,
Inc., a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 16, 2024, the Company entered into
a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (&#8220;Oncox&#8221;),
pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the &#8220;Lung Cancer
Products&#8221;), within North America for 20 years (the &#8220;April 2024 Oncox Agreement&#8221;). In consideration thereof, Oncox shall
pay ABVC $<ix:nonFraction contextRef="c157" decimals="-4" format="ixt:num-dot-decimal" name="abvc:ConsiderationPaidForAgreement" scale="6" unitRef="usd" id="ixv-47932">6.25</ix:nonFraction> million (or <ix:nonFraction contextRef="c157" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="6" unitRef="shares" id="ixv-47933">1.25</ix:nonFraction> million Oncox shares valued at $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47934">5</ix:nonFraction> per share) 30 days after entering into the agreement and $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionalMilestonePaymentInCash" scale="0" unitRef="usd" id="ixv-47935">625,000</ix:nonFraction>,
30 days following the completion of Oncox&#8217;s next round of fundraising, of which there is no guarantee; ABVC is also entitled to
<ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-47936">5</ix:nonFraction>% royalties based on the net sales, as defined in the April 2024 Oncox Agreement, from the first commercial sale of the Lung Cancer
Product in North America, of which there can be no guarantee. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene
Corporation, on the same terms. During the year ended December 31, 2024, the Company received in cash and recognized revenue of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd" id="ixv-47937">200,000</ix:nonFraction>
pursuant to the agreement. At the time of transferring the license, the Company also received <ix:nonFraction contextRef="c481" decimals="-4" format="ixt:num-dot-decimal" name="abvc:NumberOfSharesReceived" scale="6" unitRef="shares" id="ixv-47938">1.25</ix:nonFraction> million OncoX shares but did not recognize
such licensing revenue since the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended
March 31, 2025 and 2024, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 8, 2024, the Company entered into a
definitive agreement with OncoX, pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s
BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Pancreatic
(the Pancreatic Product), within a certain territory, specified as <ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfDevelopAndCommercialize" scale="-2" unitRef="pure" id="ixv-47939">50</ix:nonFraction>% of the Worldwide Markets for 20 years (the &#8220;May 8, 2024
Oncox Agreement&#8221;). In consideration thereof, Oncox shall pay ABVC a total of $<ix:nonFraction contextRef="c160" decimals="-4" format="ixt:num-dot-decimal" name="abvc:ConsiderationPaidForAgreement" scale="6" unitRef="usd" id="ixv-47940">6.25</ix:nonFraction> million (or <ix:nonFraction contextRef="c160" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="6" unitRef="shares" id="ixv-47941">1.25</ix:nonFraction> million Oncox shares valued
at $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47942">5</ix:nonFraction> per share) within 30 days of entering into the May 8, 2024 Oncox Agreement, with an additional milestone payment of $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionalMilestonePaymentInCash" scale="0" unitRef="usd" id="ixv-47943">625,000</ix:nonFraction> in
cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="abvc:LicensingFees" scale="0" unitRef="usd" id="ixv-47944">100,000</ix:nonFraction>
towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties of <ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-47945">5</ix:nonFraction>% of net sales, as
defined in the May 8, 2024 Oncox Agreement, from the first commercial sale of the Pancreatic Product in the noted territory, which remains
uncertain. The Company will permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue
to fund such payments. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene Corporation, on the same terms. At the
time of transferring the license, the Company also received <ix:nonFraction contextRef="c160" decimals="-4" format="ixt:num-dot-decimal" name="abvc:NumberOfSharesReceived" scale="6" unitRef="shares" id="ixv-47946">1.25</ix:nonFraction> million OncoX shares but did not recognize such licensing revenue since
the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 14, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the TNBC Product),
within a certain territory, specified as <ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfDevelopAndCommercialize" scale="-2" unitRef="pure" id="ixv-47947">50</ix:nonFraction>% of the Worldwide Markets for 20 years (the &#8220;May 14, 2024 Oncox Agreements&#8221;).
In each agreement for consideration thereof, Oncox shall pay each licensor a total of $<ix:nonFraction contextRef="c162" decimals="-4" format="ixt:num-dot-decimal" name="abvc:ConsiderationPaidForAgreement" scale="6" unitRef="usd" id="ixv-47948">6.25</ix:nonFraction> million (or <ix:nonFraction contextRef="c162" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="6" unitRef="shares" id="ixv-47949">1.25</ix:nonFraction> million Oncox shares valued
at $<ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47950">5</ix:nonFraction> per share) within 30 days of entering into the May 14, 2024 Oncox Agreements, with an additional milestone payment of $<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionalMilestonePaymentInCash" scale="0" unitRef="usd" id="ixv-47951">625,000</ix:nonFraction>
in cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least
$<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="abvc:LicensingFees" scale="0" unitRef="usd" id="ixv-47952">100,000</ix:nonFraction> towards the licensing fees and deductible from the second milestone payment; each licensor is also entitled to royalties of
<ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-47953">5</ix:nonFraction>% of net sales, from the first commercial sale of the TNBC Product in the noted territory, which remains uncertain. The Company will
permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue to fund such payments. At
the time of transferring the license, the Company and BioLite also each received <ix:nonFraction contextRef="c162" decimals="-4" format="ixt:num-dot-decimal" name="abvc:NumberOfSharesReceived" scale="6" unitRef="shares" id="ixv-47954">1.25</ix:nonFraction> million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended March
31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 23, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the &#8220;MS Products&#8221;),
within a certain territory, specified as <ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfDevelopAndCommercialize" scale="-2" unitRef="pure" id="ixv-47955">50</ix:nonFraction>% of the Worldwide Markets for 20 years (the &#8220;May 23, 2024 Oncox Agreements&#8221;).
In consideration thereof, Oncox shall pay each licensor a total of $<ix:nonFraction contextRef="c164" decimals="-4" format="ixt:num-dot-decimal" name="abvc:ConsiderationPaidForAgreement" scale="6" unitRef="usd" id="ixv-47956">6.25</ix:nonFraction> million (or <ix:nonFraction contextRef="c164" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="6" unitRef="shares" id="ixv-47957">1.25</ix:nonFraction> million Oncox shares valued at $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47958">5</ix:nonFraction> per share)
30 days after entering the May 23, 2024 Oncox Agreements, with an additional milestone payment of $<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionalMilestonePaymentInCash" scale="0" unitRef="usd" id="ixv-47959">625,000</ix:nonFraction> in cash after OncoX&#8217;s
next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="abvc:LicensingFees" scale="0" unitRef="usd" id="ixv-47960">100,000</ix:nonFraction> towards the licensing
fees and deductible from the second milestone payment; each licensor is also entitled to royalties of <ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-47961">5</ix:nonFraction>% of net sales, from the first
commercial sale of the MS Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing fees.
At the time of transferring the license, the Company and BioLite also each received <ix:nonFraction contextRef="c164" decimals="-4" format="ixt:num-dot-decimal" name="abvc:NumberOfSharesReceived" scale="6" unitRef="shares" id="ixv-47962">1.25</ix:nonFraction> million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended March
31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Above mentioned price of OncoX&#8217;s shares
was determined through private negotiations between the parties; no third-party valuation was completed.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-39224"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">5. PROPERTY AND EQUIPMENT, AND PREPAMENT FOR ASSET ACQUISITION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="text-decoration:underline">Property
and Equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-39233"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of March 31, 2025 and December 31, 2024 are summarized
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-keep: true">Land</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c490" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47963">8,004,520</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47964">338,966</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Buildings and leasehold improvements</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c491" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47965">2,217,756</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47966">2,219,244</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Machinery and equipment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c492" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47967">1,129,804</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47968">1,131,169</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c493" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47969">161,384</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47970">163,448</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47971">11,513,464</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-47972">3,852,827</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-47973">3,344,718</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-47974">3,341,739</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-47975">8,168,746</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-47976">511,088</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Depreciation expenses were $<ix:nonFraction contextRef="c482" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-47977">7,021</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c483" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-47978">1,286</ix:nonFraction> for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025 and December 31, 2024, the land with book value amounted to approximately $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LandAndLandImprovements" scale="0" unitRef="usd" id="ixv-47979">334,520</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LandAndLandImprovements" scale="0" unitRef="usd" id="ixv-47980">338,966</ix:nonFraction> (except for the recently acquired land in Puli, Taiwan, amounted to $<ix:nonFraction contextRef="c484" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-47981">7,670,000</ix:nonFraction>), respectively, were pledged for obtaining bank loan (see Notes 9 Bank loans).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="text-decoration:underline">Prepayment
for asset acquisition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Prepayment for asset acquisition consists
of the properties in Chengdu, China. The Company entered into a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan,
Ltd. (the &#8220;Zhonghui&#8221;). Pursuant thereto, the Company will acquire <ix:nonFraction contextRef="c485" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" unitRef="pure" id="ixv-47982">20</ix:nonFraction>% of the ownership of certain property and a parcel of
the land, with a view to jointly develop the property into a healthcare center for senior living, long-term care, and medical care in
the areas of ABVC&#8217;s special interests, such as Ophthalmology, Oncology, and Central Nervous Systems. The plan is to establish a
base for the China market and global development of these interests.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The valuation of such property is $<ix:nonFraction contextRef="c5" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" unitRef="usd" id="ixv-47983">37</ix:nonFraction> million;
based on the Company&#8217;s <ix:nonFraction contextRef="c486" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47984">20</ix:nonFraction>% ownership, the Company would acquire the value of $<ix:nonFraction contextRef="c487" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd" id="ixv-47985">7,400,000</ix:nonFraction>. In exchange, the Company issued to Zhonghui
an aggregate of <ix:nonFraction contextRef="c486" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-47986">370,000</ix:nonFraction> shares (the &#8220;Shares&#8221;) of common stock, at a per share price of $<ix:nonFraction contextRef="c486" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-47987">20.0</ix:nonFraction>. The Shares are subject to a
lock-up period of one year following the closing date of the transaction. In addition, the parties agreed that, after one year following
the closing of the transaction, if the market value of the Shares or the value of the property increases or decreases, the parties will
negotiate in good faith to make reasonable adjustments. The Company&#8217;s ownership rights to the property and the associated land
parcel, or a suitable replacement property, are safeguarded under the terms of the cooperation agreement, which is legally binding and
enforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As discussed in Note 2, the Company incorrectly
applied ASC 845 instead of ASC 718, resulting in an adjustment of the reported value to from $<ix:nonFraction contextRef="c449" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" unitRef="usd" id="ixv-47988">7,400,000</ix:nonFraction> to $<ix:nonFraction contextRef="c450" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="0" unitRef="usd" id="ixv-47989">691,900</ix:nonFraction>, and reclassification
from Construction-in-Progress to Prepayment for Asset Acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The construction-in-progress property is planned
to finish before the end of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Acquisition of land in Taiwan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In March 2024, AiBtl issued <ix:nonFraction contextRef="c488" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares" id="ixv-47990">1,534,000</ix:nonFraction> AiBtl&#8217;s
common stocks to acquire farmland in Taiwan, which land will be used for developing health related businesses. As of the date of issuance
of these financial statements, the transfer of the land&#8217;s title is under government review, pending completion of the title transfer
registration. However, upon the closing of the transaction, both parties are aware of such Taiwan&#8217;s legal restrictions prohibiting
foreign entities directly owning farmland. In addition to newly incorporated controlling subsidiary, Yunzhiyi, to be holding the title
of the land upon government&#8217;s approval, on March 31, 2025, the Company and the landowners executed the Nominee Holding Agreement,
Land Lease Agreement, and Consulting Agreement, under the witness of and confirmed by a legal counsel in Taiwan, in which the landowners
unconditionally grant the full legal rights to the land to the Company before the completion of the title transfer. Based on the execution
of the agreement, the Company recognized $<ix:nonFraction contextRef="c488" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-47991">7,670,000</ix:nonFraction> ($<ix:nonFraction contextRef="c489" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-47992">5</ix:nonFraction> per share of AiBtl&#8217;s common stock) of land on its balance sheet.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentTextBlock" id="ixv-39440"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b style="-keep: true">6. LONG-TERM INVESTMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b style="-keep: true">&#160;&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfOtherOwnershipInterestsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock" id="ixv-39450"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ScheduleOfOtherOwnershipInterestsTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership percentage</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March&#160;31,</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting</b></span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of investees</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>treatments</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.*</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c503" decimals="4" format="ixt:num-dot-decimal" id="ix_63_fact" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.17</ix:nonFraction></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c189" decimals="4" format="ixt:num-dot-decimal" id="ix_64_fact" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.17</ix:nonFraction></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 20%"><ix:nonNumeric contextRef="c504" id="ix_65_fact" name="us-gaap:EquityMethodInvestmentAdditionalInformation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c505" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47995">0.67</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c192" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47996">0.67</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c506" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-39561"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c507" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47997">5.90</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c195" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47998">5.90</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c508" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-39585"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation (see Note 10)</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c509" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-47999">19.78</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c198" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48000">19.78</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c510" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-39609"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c511" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48001">18.68</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c185" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48002">18.68</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c494" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-39633"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity&#160;Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. (see Note 10)</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c512" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48003">24.97</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c202" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48004">24.97</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c513" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-39657"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c476" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48005">37.00</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48006">26.65</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c514" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-39681"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c515" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48007">49.00</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c184" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48008">49.00</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c516" name="us-gaap:EquityMethodInvestmentAdditionalInformation" id="ixv-39705"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0%"><span style="-keep: true">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><ix:footnote id="ix_20_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td><ix:nonNumeric contextRef="c0" continuedAt="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock-c0_cont_1" escape="true" name="abvc:ScheduleOfExtentTheInvesteeReliesTableTextBlock" id="ixv-39725"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The extent the investee relies on the company for its business is summarized as follows:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of investees</b></span></td> <td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 69%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The extent the investee relies on the Company for its business &#160;</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c517" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-39746"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c518" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-39754"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c519" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-39762"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c520" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-48009">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan</ix:nonNumeric> </span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c521" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-39777"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c522" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-39785"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned from the investee and provides research and development support service</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. </span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c523" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-39793"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c524" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-39801"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></ix:nonNumeric></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_InvestmentTextBlock-c0_cont_2" id="_InvestmentTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentTableTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentTableTextBlock" id="ixv-39824"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term investment mainly consists of the following:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:continuation continuedAt="_InvestmentTableTextBlock-c0_cont_2" id="_InvestmentTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">Non-marketable Cost Method Investments, net</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt"><span style="-keep: true">Braingenesis Biotechnology Co., Ltd.</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c525" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-48010">6,640</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-48011">6,727</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Genepharm Biotech Corporation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c526" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-48012">20,271</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-48013">20,540</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon
    Eye Corporation<sup>(d)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-341"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-342"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">BioHopeKing Corporation</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c528" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-48014">752,880</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-48015">762,983</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="-keep: true">Subtotal</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-48016">779,791</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="0" unitRef="usd" id="ixv-48017">790,250</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Equity Method Investments, net</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst
    Corporation<sup>(a)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c529" decimals="0" format="ixt:num-dot-decimal" id="ix_66_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">1,420,800</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" id="ix_67_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">1,468,504</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene
    Corporation<sup>(b)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c530" decimals="0" format="ixt:num-dot-decimal" id="ix_68_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">559,471</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-343"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    Japan K.K. (BioLite JP)<sup>(c)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-344"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-345"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX
    BioPharma, Inc.<sup>(e)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.25in"><span style="-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-48021">2,760,062</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-48022">2,258,754</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2025 and
December 31, 2024, the Company owns <ix:nonFraction contextRef="c494" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-48023">18.68</ix:nonFraction>% and <ix:nonFraction contextRef="c179" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-48024">18.68</ix:nonFraction>% common stock shares of BioFirst, respectively. The Company made a prepayment for
equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-48025">2,688,578</ix:nonFraction>, recorded
as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration
process for this investment. The initial prepayment was $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-48026">1,895,556</ix:nonFraction>, which is a portion of the prepayment as of December 31, 2022, and
was converted into <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-48027">994,450</ix:nonFraction> shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term
investments in Biofirst is both $<ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-48028">1,124,842</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">As described in Note 4, the Company
acquired <ix:nonFraction contextRef="c495" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-48029">26.65</ix:nonFraction>% of Rgene&#8217;s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting
this equity investment with equity method as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;).
Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required
by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with
Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment
Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request
for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to
the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company
owns <ix:nonFraction contextRef="c496" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-48030">37</ix:nonFraction>% of outstanding shares of Rgene.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposition of long-term
    investment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">During the three-month periods
ended March 31, 2025and 2024, there is no disposition of long-term investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on investment in
    equity securities</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EquityMethodInvestmentsTextBlock" id="ixv-40130"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The components of loss on investment in equity
securities for each period were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Three Months Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Share of equity method investee losses</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-48031">50,877</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation id="_InvestmentTableTextBlock-c0_cont_2"><ix:continuation id="_InvestmentTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K. (BioLite JP)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#8220;Lucidaim,&#8221; together with the Company, the &#8220;Shareholders&#8221;), and BioLite Japan
K.K., a Japanese corporation (&#8220;BioLite JP&#8221;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has <ix:nonFraction contextRef="c497" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-48032">10,000</ix:nonFraction> ordinary shares authorized, with
<ix:nonFraction contextRef="c498" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-48033"><ix:nonFraction contextRef="c498" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-48034">3,049</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding (the &#8220;Ordinary Shares&#8221;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own <ix:nonFraction contextRef="c499" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" unitRef="shares" id="ixv-48035">1,555</ix:nonFraction> Ordinary Shares (<ix:nonFraction contextRef="c500" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-48036">51</ix:nonFraction>%) and the Company shall own <ix:nonFraction contextRef="c501" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" unitRef="shares" id="ixv-48037">1,494</ix:nonFraction> Ordinary Shares (<ix:nonFraction contextRef="c502" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageCommonStocksShares" scale="-2" unitRef="pure" id="ixv-48038">49</ix:nonFraction>%). The Company paid $<ix:nonFraction contextRef="c500" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="0" unitRef="usd" id="ixv-48039">150,000</ix:nonFraction>
towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $<ix:nonFraction contextRef="c502" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="0" unitRef="usd" id="ixv-48040">150,000</ix:nonFraction> after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#8217;s business
and financial conditions and determined to fully impair such prepayment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation (FEYE)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. (OncoX)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#8217;s ownership. See Note 4 for detail of such transactions.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-40237"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">7. CONVERTIBLE NOTES PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Lind Notes Payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 23, 2023, the Company entered
into a securities purchase agreement with Lind Global Fund II, LP (&#8220;Lind&#8221;), pursuant to which the Company issued Lind a secured,
convertible note in the principal amount of $<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-48041">3,704,167</ix:nonFraction>, for a purchase price of $<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForPreviousAcquisition" scale="0" unitRef="usd" id="ixv-48042">3,175,000</ix:nonFraction> (the &#8220;Lind Note&#8221;), that is convertible
into shares of the Company&#8217;s common stock at an initial conversion price of $<ix:nonFraction contextRef="c239" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-48043">10.5</ix:nonFraction> per share, subject to adjustment. The Company
also issued Lind a common stock purchase warrant (the &#8220;Lind Warrant&#8221;) to purchase up to <ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-48044">529,167</ix:nonFraction> shares (post-split) of the
Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c533" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-48045">10.5</ix:nonFraction> per share for a period of 5 years, subject to adjustment that immediately
upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance or sale shall be reduced (and in no event
increased) to an Exercise Price equal to the consideration per share paid for such Additional Shares of Common Stock. The warrants were
valued using the Black-Scholes model. The fair value of the warrants was determined to be $<ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-48046">1,225,543</ix:nonFraction>, which was recorded to debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Beginning with the date that is six months
from the issuance date of the Lind Note and on each one (1) month anniversary thereafter, the Company shall pay Lind an amount equal
to $<ix:nonFraction contextRef="c534" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingBalanceAmount" scale="0" unitRef="usd" id="ixv-48047">308,651</ix:nonFraction>, until the outstanding principal amount of the Lind Note has been paid in full prior to or on the Maturity Date or, if earlier,
upon acceleration, conversion or redemption of the Lind Note in accordance with the terms thereof (the &#8220;Monthly Payments&#8221;).
At the Company&#8217;s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares of the Company&#8217;s common stock, or
(iii) a combination of cash and Shares; if made in shares, the number of shares shall be determined by dividing (x) the principal amount
being paid in shares by (y) <ix:nonFraction contextRef="c535" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfAverageAmount" scale="-2" unitRef="pure" id="ixv-48048">90</ix:nonFraction>% of the average of the 5 lowest daily VWAPs during the <ix:nonNumeric contextRef="c0" format="ixt-sec:durday" name="abvc:TradingDays" id="ixv-48049">20</ix:nonNumeric> trading days prior to the applicable payment
date. The Lind Notes sets forth certain conditions that must be satisfied before the Company may make any Monthly Payments in shares
of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash premium of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfCashPermium" scale="-2" unitRef="pure" id="ixv-48050">5</ix:nonFraction>% of such Monthly
Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Upon the occurrence of any Event of Default
(as defined in the Lind Note), the Company must pay Lind an amount equal to <ix:nonFraction contextRef="c535" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfOutstandingPrincipalAmount" scale="-2" unitRef="pure" id="ixv-48051">120</ix:nonFraction>%&#160;of the then outstanding principal amount of the
Lind Note (the &#8220;Mandatory Default Amount&#8221;), in addition to any other remedies under the Note or the other Transaction Documents.
The Company and Lind entered into a letter agreement on September 12, 2023, pursuant to which the Mandatory Default Amount was reduced
to <ix:nonFraction contextRef="c244" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfOutstandingPrincipalAmount" scale="-2" unitRef="pure" id="ixv-48052">115</ix:nonFraction>% of the then outstanding principal amount of the Lind Note; pursuant to the letter agreement, Lind also agreed to waive any default
associated with the Company&#8217;s market capitalization being below $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GeneralPartnersCapitalAccount" scale="6" unitRef="usd" id="ixv-48053">12.5</ix:nonFraction> million for <ix:nonNumeric contextRef="c0" format="ixt-sec:durday" name="abvc:ConsecutiveDays" id="ixv-48054">10</ix:nonNumeric> consecutive days through February 23, 2024,
but retained its right to convert its Note. In addition, if the Company is unable to increase its market capitalization and is unable
to obtain a further waiver or amendment to the Lind Note, then the Company could experience an event of default under the Lind Note,
which could have a material adverse effect on the Company&#8217;s liquidity, financial condition, and results of operations. The Company
cannot make any assurances regarding the likelihood, certainty, or exact timing of the Company&#8217;s ability to increase its market
capitalization, as such metric is not within the immediate control of the Company and depends on a variety of factors outside the Company&#8217;s
control. &#160;</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Lind Warrant may be exercised via cashless
exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The warrant exercise price was reset to $<ix:nonFraction contextRef="c245" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-48055">3.5</ix:nonFraction>
in accordance to the issuance of common stock in relation to securities purchase agreement on July 2023.&#160;On May 22, 2024, the exercise
price of these warrants was reset to $<ix:nonFraction contextRef="c246" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-48056">0.75</ix:nonFraction> along with the immediate exercise of existing warrants and issuance of the New Warrants. As
of March 31, 2025, these Lind Warrants associated with the first Lind Note were fully exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 17, 2023, the Company entered
another securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#8220;2<sup>nd</sup>
Lind Note&#8221;) in the principal amount of $<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivableWithImputedInterestFaceAmount" scale="0" unitRef="usd" id="ixv-48057">1,200,000</ix:nonFraction>, for a purchase price of $<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForPreviousAcquisition" scale="0" unitRef="usd" id="ixv-48058">1,000,000</ix:nonFraction>, that is convertible into shares of the Company&#8217;s
common stock at a conversion price, which shall be the lesser of (i) $<ix:nonFraction contextRef="c249" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-48059">3.50</ix:nonFraction> and (ii) <ix:nonFraction contextRef="c248" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfAverageAmount" scale="-2" unitRef="pure" id="ixv-48060">90</ix:nonFraction>% of the average of the three lowest VWAPs during
the <ix:nonNumeric contextRef="c250" format="ixt-sec:duryear" name="abvc:TradingDays" id="ixv-48061">20</ix:nonNumeric> trading days prior to conversion. The 2<sup>nd</sup> Lind Note shall be due and payable on May 19, 2025, and bears no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to maturity, and Lind shall have the right to convert
up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined in the 2<sup>nd</sup>
Lind Note), the Company must pay Lind an amount equal to <ix:nonFraction contextRef="c250" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-48062">120</ix:nonFraction>% of the then outstanding principal amount of the Lind Note, in addition
to any other remedies under the Note or the other transaction documents. Lind also received a 5-year common stock purchase warrant to
purchase up to <ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-48063">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice" scale="0" unitRef="usdPershares" id="ixv-48064">2</ix:nonFraction> per share for a period of <ix:nonNumeric contextRef="c251" format="ixt-sec:duryear" name="abvc:PurchaseWarrantTerm" id="ixv-48065">5</ix:nonNumeric> years.
The warrants were valued using the Black-Scholes model. The fair value of the warrants was determined to be $<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-48066">480,795</ix:nonFraction>, which was recorded
to debt discount. An amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements, the parties entered
into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $<ix:nonFraction contextRef="c253" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48067">1.00</ix:nonFraction>. Additionally, the amendment
requires the Company to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor
price. During the year ended December 31, 2024, Lind converted $<ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-48068">800,000</ix:nonFraction> of 2<sup>nd</sup> Lind Note principal amounts into the Company&#8217;s
common stocks. Refer to the common stock issuance details in Note 12, Equity. On March 3 and April 1, 2025, Lind converted the remaining
$<ix:nonFraction contextRef="c536" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-48069">400,000</ix:nonFraction> principal balance ($<ix:nonFraction contextRef="c537" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-48070">200,000</ix:nonFraction> for each conversion) into the Company&#8217;s common stocks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 17, 2024, the Company entered another
securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#8220;3<sup>rd</sup>
Lind Note&#8221;) in the principal amount of $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivableWithImputedInterestFaceAmount" scale="0" unitRef="usd" id="ixv-48071">1,000,000</ix:nonFraction>, for a purchase price of $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="abvc:PurchasePriceAmount" scale="0" unitRef="usd" id="ixv-48072">833,333</ix:nonFraction>, that is convertible into shares of the Company&#8217;s
common stock at a conversion price, which shall be the lesser of (i) $<ix:nonFraction contextRef="c257" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-48073">3.50</ix:nonFraction> and (ii) <ix:nonFraction contextRef="c257" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfAverageAmount" scale="-2" unitRef="pure" id="ixv-48074">90</ix:nonFraction>% of the average of the three lowest VWAPs during
the <ix:nonNumeric contextRef="c257" format="ixt-sec:durday" name="abvc:TradingDays" id="ixv-48075">20</ix:nonNumeric> trading days prior to conversion. The 3<sup>rd</sup> Lind Note shall be due and payable on July 17, 2025 and bear no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to maturity, and Lind shall have the right to convert
up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined in the 3<sup>rd</sup>
Lind Note), the Company must pay Lind an amount equal to <ix:nonFraction contextRef="c257" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-48076">120</ix:nonFraction>% of the then outstanding principal amount of the Lind Note, in addition
to any other remedies under the Note or the other transaction documents Lind also received a <ix:nonNumeric contextRef="c258" format="ixt-sec:duryear" name="abvc:PurchaseWarrantTerm" id="ixv-48077">5</ix:nonNumeric>-year, common stock purchase warrant to
purchase up to <ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-48078">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-48079">2</ix:nonFraction> per share. The warrants were valued
using the Black-Scholes model. The fair value of the warrants was determined to be $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-48080">394,071</ix:nonFraction>, which was recorded to debt discount. An
amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements, the parties entered into an amendment
to the Note, pursuant to which the conversion price shall have a floor price of $<ix:nonFraction contextRef="c260" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48081">1.00</ix:nonFraction>. Additionally, the amendment requires the Company
to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor price. No conversion
or repayment to 3<sup>rd</sup> Lind Note has occurred during the year ended December 31, 2024. On March 3 and April 1, 2025, Lind converted
$<ix:nonFraction contextRef="c536" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-48082">400,000</ix:nonFraction> principal balance ($<ix:nonFraction contextRef="c537" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="0" unitRef="usd" id="ixv-48083">200,000</ix:nonFraction> for each conversion) into the Company&#8217;s common stock, leaving outstanding principal of $<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentOutstandingPrincipal" scale="0" unitRef="usd" id="ixv-48084">600,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In connection with above three Lind Note offerings,
the Company and its subsidiaries: BioKey, BioLite, Biolite BVI, and American BriVision, jointly and severally guaranteed all of the obligations
of the Company in connection with the offering with certain collateral, as set forth in the related transaction documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 22, 2024, November 19, 2024, and January
9, 2025, Lind exercised <ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-48085">1,000,000</ix:nonFraction>, <ix:nonFraction contextRef="c262" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-48086">500,000</ix:nonFraction>, <ix:nonFraction contextRef="c538" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-48087">1,029,167</ix:nonFraction> of the existing warrants to purchase shares of Common Stock at a reduced exercise
price of $<ix:nonFraction contextRef="c246" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-48088">0.75</ix:nonFraction>, $<ix:nonFraction contextRef="c539" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-48089">0.42</ix:nonFraction>, and $<ix:nonFraction contextRef="c540" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-48090">0.40</ix:nonFraction> per share, respectively. Refer to the details in Note 12, Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Total interest expenses in connection with the above three Lind Notes were $<ix:nonFraction contextRef="c541" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-48091">209,372</ix:nonFraction> and $<ix:nonFraction contextRef="c542" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-48092">172,884</ix:nonFraction> for the three months ended March 31, 2025 and 2024, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other Convertible Notes Payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 1, 2024 and November 5, 2024,
the Company&#8217;s subsidiary, AiBtl, issued two convertible notes payable, each with a principal amount of $<ix:nonFraction contextRef="c543" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-48093">30,000</ix:nonFraction> to two separate
individuals, for total consideration of $<ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConsiderationAmount" scale="0" unitRef="usd" id="ixv-48094">60,000</ix:nonFraction>. Each note has a <ix:nonNumeric contextRef="c544" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-48095">1</ix:nonNumeric>-year term and an implied annual discount rate of <ix:nonFraction contextRef="c545" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageOfAnnualDiscountRate" scale="-2" unitRef="pure" id="ixv-48096">6.89</ix:nonFraction>%. These convertible
notes bear a <ix:nonFraction contextRef="c546" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-48097">0</ix:nonFraction>% interest rate and are convertible by the holders into the AiBtl&#8217;s common stock at $<ix:nonFraction contextRef="c547" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-48098">5</ix:nonFraction> per share at any time before
the maturity. AiBtl reserves the right to repurchase the note in full at any time before maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The convertible notes payable is accounted
for in accordance with ASC 470-20, Debt with Conversion and Other Options. The Company evaluated the conversion feature and determined
that it qualifies for equity classification as it meets the &#8220;fixed-for-fixed&#8221; criteria. The proceeds from the issuance were
allocated to the present value of the liability component in aggregate for $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-48099">56,132</ix:nonFraction>, and to debt discount for $<ix:nonFraction contextRef="c548" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd" id="ixv-48100">3,868</ix:nonFraction>. The debt discount
is recorded in additional paid-in capital in the statement of change in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The debt discount is being amortized over
the <ix:nonNumeric contextRef="c549" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-48101">1</ix:nonNumeric>-year term using the effective interest method. During the three months ended March 31, 2025, the Company recognized $<ix:nonFraction contextRef="c548" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-48102">984</ix:nonFraction> in interest
expense related to the amortization of the debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" id="ixv-40336"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The carrying amounts of the liability component
are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: left; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">March 31, <br/> 2025</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Issuance<br/> Entity</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Issuance<br/> Date</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Maturity<br/> Date</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Principal<br/> Amount at<br/> Issuance</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Conversion<br/> Price</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Common<br/> Stock<br/> to&#160;be<br/> converted</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Unamortized<br/> Discount</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Carrying<br/> Value</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 8pt">Fair<br/> Value</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"><span style="font-size: 8pt">2nd LIND Note</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><ix:nonNumeric contextRef="c550" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-40435"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><ix:nonNumeric contextRef="c550" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-40440"><span style="font-size: 8pt">November 17, 2023</span></ix:nonNumeric></td><td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><ix:nonNumeric contextRef="c550" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-40445"><span style="font-size: 8pt">May 19, 2025</span></ix:nonNumeric></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c550" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48103">1,200,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c551" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-48104">0</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c551" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48105">86.94</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c551" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48106">1.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><ix:nonNumeric contextRef="c550" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-40482"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c550" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48107">200,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c551" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48108">26,110</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c550" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48109">173,890</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c551" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48110">240,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 8pt">3rd LIND Note</span></td><td style="text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c552" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-40522"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c552" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-40527"><span style="font-size: 8pt">January 17, 2024</span></ix:nonNumeric></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c552" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-40532"><span style="font-size: 8pt">July 17, 2025</span></ix:nonNumeric></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c552" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48111">1,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c553" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-48112">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c553" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48113">87.40</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c553" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48114">1.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c552" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-40569"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c552" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48115">800,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c553" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48116">196,114</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c552" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48117">603,886</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c553" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48118">960,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 8pt">Other Note</span></td><td style="text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c554" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-40609"><span style="font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c554" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-40614"><span style="font-size: 8pt">November 1, 2024</span></ix:nonNumeric></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c554" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-40619"><span style="font-size: 8pt">November 1, 2025</span></ix:nonNumeric></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c554" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48119">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c555" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-48120">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c555" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48121">6.89</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c555" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48122">5.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c554" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-40656"><span style="font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c554" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48123">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c555" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48124">1,119</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c554" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48125">28,881</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c555" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48126">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 8pt">Other Note</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c556" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-40696"><span style="font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c556" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-40701"><span style="font-size: 8pt">November 5, 2024</span></ix:nonNumeric></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c556" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-40706"><span style="font-size: 8pt">November 5, 2025</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c556" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48127">30,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c557" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-48128">0</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c557" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48129">6.89</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c557" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48130">5.00</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c556" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-40743"><span style="font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c556" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48131">30,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c557" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48132">1,118</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c556" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48133">28,882</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c557" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48134">30,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48135">2,260,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48136">1,060,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48137">224,460</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48138">835,539</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48139">1,260,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; text-align: left; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">December 31, <br/> 2024</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Issuance<br/> Entity</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Issuance<br/> Date</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Maturity<br/> Date</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Principal<br/> Amount at<br/> Issuance</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Conversion<br/> Price</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Common<br/> Stock<br/> to&#160;be<br/> converted</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Unamortized<br/> Discount</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Carrying<br/> Value</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 8pt">Fair<br/> Value</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"><span style="font-size: 8pt">2nd LIND Note</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><ix:nonNumeric contextRef="c271" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-40956"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><ix:nonNumeric contextRef="c271" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-40961"><span style="font-size: 8pt">November 17, 2023</span></ix:nonNumeric></td><td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><ix:nonNumeric contextRef="c271" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-40966"><span style="font-size: 8pt">May 19, 2025</span></ix:nonNumeric></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48140">1,200,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-48141">0</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48142">86.94</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48143">1.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><ix:nonNumeric contextRef="c271" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-41003"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48144">400,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48145">118,048</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48146">281,952</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48147">480,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 8pt">3rd LIND Note</span></td><td style="text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c273" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-41043"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td style="text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c273" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-41048"><span style="font-size: 8pt">January 17, 2024</span></ix:nonNumeric></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c273" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-41053"><span style="font-size: 8pt">July 17, 2025</span></ix:nonNumeric></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48148">1,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-48149">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48150">87.40</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48151">1.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c273" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-41090"><span style="font-size: 8pt">ABVC</span></ix:nonNumeric></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48152">1,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48153">388,685</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48154">611,315</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48155">1,200,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 8pt">Other Note</span></td><td style="text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c275" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-41130"><span style="font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c275" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-41135"><span style="font-size: 8pt">November 1, 2024</span></ix:nonNumeric></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c275" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-41140"><span style="font-size: 8pt">November 1, 2025</span></ix:nonNumeric></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48156">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-48157">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48158">6.89</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48159">5.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c275" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-41177"><span style="font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48160">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48161">1,610</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48162">28,390</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48163">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 8pt">Other Note</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c277" name="abvc:DebtInstrumentIssuanceEntity" id="ixv-41217"><span style="font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c277" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-41222"><span style="font-size: 8pt">November 5, 2024</span></ix:nonNumeric></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c277" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-41227"><span style="font-size: 8pt">November 5, 2025</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48164">30,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-48165">0</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48166">6.89</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48167">5.00</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c277" name="abvc:DebtInstrumentCommonStockToBeConverted" id="ixv-41264"><span style="font-size: 8pt">AiBtl</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48168">30,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48169">1,611</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48170">28,389</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48171">30,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-48172">2,260,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate" scale="0" unitRef="usd" id="ixv-48173">1,460,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-48174">509,954</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentCarryingValue" scale="0" unitRef="usd" id="ixv-48175">950,046</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" unitRef="usd" id="ixv-48176">1,740,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr> </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-41396"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-41401"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Accrued research and development expense</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-48177">1,799,583</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-48178">1,799,583</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Accrued directors and officers (owners) compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="0" unitRef="usd" id="ixv-48179">991,821</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="0" unitRef="usd" id="ixv-48180">1,025,867</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Cash portion of the Lind Note repayments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:CashPortionOfTheLindNoteRepayments" scale="0" unitRef="usd" id="ixv-48181">227,284</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:CashPortionOfTheLindNoteRepayments" scale="0" unitRef="usd" id="ixv-48182">127,759</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Accrued compensation and employee benefits</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-48183">140,252</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-48184">126,106</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Others</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-48185">617,879</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-48186">557,866</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-48187">3,826,819</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-48188">3,509,422</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ShortTermDebtTextBlock" id="ixv-41555"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">9. SHORT-TERM LOANS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShortTermDebtTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="ixv-41565"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term loans consists of the following:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ScheduleOfShortTermDebtTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-keep: true">Cathay United Bank</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c559" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48189">169,407</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48190">200,252</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">CTBC Bank</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c567" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48191">602,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c299" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48192">610,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Other individual</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c568" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48193">30,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48194">30,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48195">801,407</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48196">840,252</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cathay United Bank</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 28, 2016, BioLite Taiwan and Cathay
United Bank entered into a one-year bank loan agreement (the &#8220;Cathay United Loan Agreement&#8221;) in a credit limit amount of
NTD <ix:nonFraction contextRef="c283" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" unitRef="twd" id="ixv-48197">7.5</ix:nonFraction> million, equivalent to $<ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" unitRef="usd" id="ixv-48198">228,750</ix:nonFraction>. The term started June 28, 2016 with maturity date at <ix:nonNumeric contextRef="c558" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-48199">June 28, 2017</ix:nonNumeric>. The loan balance bears interest
at a floating rate of prime rate plus <ix:nonFraction contextRef="c285" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-48200">1.31</ix:nonFraction>%. The prime rate is based on the term deposit saving interest rate of Cathay United Bank.
The Company renews the agreement with the bank every year, and the next renewal date is September 6, 2025. As of March 31, 2025 and December
31, 2024, the effective interest rates per annum was <ix:nonFraction contextRef="c559" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48201"><ix:nonFraction contextRef="c286" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-48202">2.99</ix:nonFraction></ix:nonFraction>% and 2.99%, respectively. The loan is collateralized by the building and improvement
of BioLite Taiwan, and is also personal guaranteed by the Company&#8217;s chairman. During the three months ended March 31, 2025, the
Company made payments of the loan in total of NTD <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" unitRef="twd" id="ixv-48203">937,500</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" unitRef="usd" id="ixv-48204">29,250</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Interest expenses were $<ix:nonFraction contextRef="c560" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48205">1,470</ix:nonFraction> and $<ix:nonFraction contextRef="c561" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48206">1,736</ix:nonFraction> for
the three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">CTBC Bank</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 12, 2017 and July 19, 2017, BioLite
Taiwan and CTBC Bank entered into two short-term saving secured bank loan agreements (the &#8220;CTBC Loan Agreements&#8221;) in a credit
limit amount of NTD <ix:nonFraction contextRef="c290" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" unitRef="twd" id="ixv-48207"><ix:nonFraction contextRef="c291" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" unitRef="twd" id="ixv-48208">10</ix:nonFraction></ix:nonFraction> million, equivalent to $<ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" unitRef="usd" id="ixv-48209">327,500</ix:nonFraction>, and NTD 10 million, equivalent to $<ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" unitRef="usd" id="ixv-48210">327,500</ix:nonFraction>, respectively. Both two loans with
the same maturity date at <ix:nonNumeric contextRef="c293" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-48211"><ix:nonNumeric contextRef="c292" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-48212">January 19, 2018</ix:nonNumeric></ix:nonNumeric>. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC
for <ix:nonNumeric contextRef="c294" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="ixv-48213">one year</ix:nonNumeric>. The Company renews the agreement with the bank every year, and the next renewal date is February 28, 2025.&#160;The loan
balances bear interest at a fixed rate of <ix:nonFraction contextRef="c562" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsSavings" scale="-2" unitRef="pure" id="ixv-48214">2.5</ix:nonFraction>% per annum, and is secured by the money deposited in a savings account with the CTBC Bank.
This loan was also personal guaranteed by the Company&#8217;s chairman and BioFirst. During the year ended December 31, 2020, BioLite
Taiwan opened a TCD account with CTBC bank to guarantee the loan going forward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Interest expenses were $<ix:nonFraction contextRef="c563" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48215">3,761</ix:nonFraction> and $<ix:nonFraction contextRef="c564" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48216">3,964</ix:nonFraction> for
the three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other individual &#8211; Third party</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 21, 2024, the Company issued an unsecured
promissory note to a third party for the proceeds of $<ix:nonFraction contextRef="c296" decimals="0" format="ixt:num-dot-decimal" name="abvc:ProceedsFromIssuanceOfAPromissoryNote" scale="0" unitRef="usd" id="ixv-48217">30,000</ix:nonFraction>. The note bears interest rate of <ix:nonFraction contextRef="c297" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingVariableInterestRate" scale="-2" unitRef="pure" id="ixv-48218">12</ix:nonFraction>% per annum and matures on <ix:nonNumeric contextRef="c297" format="ixt:date-monthname-day-year-en" name="abvc:ShortTermDebtMaturityDate" id="ixv-48219">March 21,
2025</ix:nonNumeric>, or upon the occurrence of an event of default. The promissory note was extended for anther year and matures on March 21, 2026,
with the same terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Interest expenses were $<ix:nonFraction contextRef="c565" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48220">888</ix:nonFraction> and $<ix:nonFraction contextRef="c566" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48221">0</ix:nonFraction> for the
three months ended March 31, 2025 and 2024, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-41728"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">10. RELATED PARTIES TRANSACTIONS</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-41733"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The related parties of the company with whom
transactions are reported in these financial statements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of entity or Individual</b></span></td> <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c583" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41754"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c584" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41762"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c585" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41770"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c586" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41778"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Jiangs</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><ix:nonNumeric contextRef="c587" continuedAt="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_1" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41788">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst<br/> </ix:nonNumeric><br/></span></p><ix:continuation continuedAt="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_2" id="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_1"> </ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><ix:continuation continuedAt="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_3" id="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_2">Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.<br/> </ix:continuation><br/></span></p><ix:continuation continuedAt="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_4" id="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_3"> </ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><ix:continuation continuedAt="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_5" id="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_4">Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.<br/> </ix:continuation><br/></span></p><ix:continuation continuedAt="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_6" id="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_5"> </ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><ix:continuation continuedAt="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_7" id="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_6">Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company.<br/> </ix:continuation><br/></span></p><ix:continuation id="_RelatedPartyTransactionDescriptionOfTransaction-c587_cont_7"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</span></p></ix:continuation></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan &#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c588" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41815"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation (&#8220;BHK&#8221;)</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c589" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41823"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AiBtl (Holding) BioPharma, Inc. (&#8220;AiBtl Holding&#8221;) &#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c590" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41831"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founding shareholder of AiBtl BioPharma Inc.</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jaimes Vargas Russman &#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c591" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41839"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO of AiBtl BioPharma Inc.</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lion Arts Promotion, Inc.</span></td> <td><span style="-keep: true">&#160;</span></td> <td><ix:nonNumeric contextRef="c592" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-41847"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by the Jiangs.</span></ix:nonNumeric></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Revenues &#8211; related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">There was no cash receipt for the three months
ended March 31, 2025 and 2024 from related parties on the licensing agreements or other services. Therefore, no related party revenue
was recognized during these periods. Please refer to Note 4, Collaborative Agreements for details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Consulting fees &#8211; related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In March 2024, the Company engaged Lion Arts
Promotion Inc to provide operation, business development, human resources, and capital finance consulting services. The agreement is
for 12 months expiring in February 2025, and is optional for renewal upon mutual agreement. The Company incurred $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" unitRef="usd" id="ixv-48225">68,141</ix:nonFraction> and $<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" unitRef="usd" id="ixv-48226">14,628</ix:nonFraction>
for the three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable - related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Accounts receivable due from related parties
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt"><span style="-keep: true">Rgene</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349"><span style="-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-350"><span style="-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-351"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-352"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2024, management considered
the outstanding accounts receivable from Rgene may not be recoverable, and recognized credit loss in full.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Due from related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Amounts due from related parties consisted
of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_3" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Due from related party- Current</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-keep: true">Rgene (1)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c593" decimals="0" format="ixt:num-dot-decimal" id="ix_69_fact" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">1,867</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" id="ix_70_fact" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">565,711</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">BioFirst (2)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c594" decimals="0" format="ixt:num-dot-decimal" id="ix_71_fact" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">535,252</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" id="ix_72_fact" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">589,340</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-48231">537,119</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-48232">1,155,051</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">Due from related parties- Non-current, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">BioFirst (Australia) (3)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c595" decimals="0" format="ixt:num-dot-decimal" id="ix_73_fact" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd">839,983</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c596" decimals="0" format="ixt:num-dot-decimal" id="ix_74_fact" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd">839,983</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">BioHopeKing Corporation (4)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c597" decimals="0" format="ixt:num-dot-decimal" id="ix_75_fact" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd">118,633</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c598" decimals="0" format="ixt:num-dot-decimal" id="ix_76_fact" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd">120,210</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Total</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-48237">958,616</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-48238">1,014,193</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Less: allowance for expected credit losses accounts</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-48239">958,616</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-48240">1,014,193</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="-keep: true">Net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-353"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-354"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) &#160;</span></td> <td><ix:footnote id="ix_23_footnote" xml:lang="en-US"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $<ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-48241">1,000,000</ix:nonFraction> and made $<ix:nonFraction contextRef="c569" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-48242">500,000</ix:nonFraction> to Rgene which bears interest at <ix:nonFraction contextRef="c306" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-48243">5</ix:nonFraction>% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional <ix:nonFraction contextRef="c570" decimals="3" format="ixt:num-dot-decimal" name="abvc:PercentageOfWorkingCapital" scale="-2" unitRef="pure" id="ixv-48244">6.4</ix:nonFraction>% of Rgene. The Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $<ix:nonFraction contextRef="c571" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48245">1.00</ix:nonFraction> per share or (ii) <ix:nonFraction contextRef="c572" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-48246">20</ix:nonFraction>% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided. The loan was converted to Rgene&#8217;s common stock in May 2024 but the Company was not informed until April 2025. Please see detail discussion in Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 31, 2025 and December 31, 2024, the outstanding loan balance were $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" unitRef="usd" id="ixv-48247">0</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-48248">500,000</ix:nonFraction>; and accrued interest was $<span style="-sec-ix-hidden: hidden-fact-356">0and</span> $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" unitRef="usd" id="ixv-48249">63,819</ix:nonFraction>, respectively. Both principal and accrued interest were converted to Rgene&#8217;s common stocks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 31, 2025 and December 31, 2024, the Company has other receivables amounted to $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-48250">1,867</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-48251">1,892</ix:nonFraction>, respectively, from Rgene due to daily operations.</span></p></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="ix_24_footnote" xml:lang="en-US">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD <ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd" id="ixv-48253">11,072,360</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-48254">337,707</ix:nonFraction>), which bears interest at <ix:nonFraction contextRef="c310" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-48255">12</ix:nonFraction>% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD <ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd" id="ixv-48256">11,406,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-48257">347,883</ix:nonFraction>), which bears interest at <ix:nonFraction contextRef="c311" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-48258">12</ix:nonFraction>% per annum for the use of working capital. As of March 31, 2025 and December 31, 2024, the outstanding loan balance were NTD <ix:nonFraction contextRef="c573" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="twd" id="ixv-48259">15,458,360</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c574" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-48260">465,297</ix:nonFraction>) and NTD <ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="twd" id="ixv-48261">17,571,076</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-48262">535,918</ix:nonFraction>), respectively; accrued interests were$<ix:nonFraction contextRef="c575" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-48263">68,971</ix:nonFraction> and $<ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-48264">53,422</ix:nonFraction>, respectively. The Company has received NTD <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="twd" id="ixv-48265">2,080,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd" id="ixv-48266">64,896</ix:nonFraction>) and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-48267">0</ix:nonFraction> repayment during the three months ended March 31, 2025 and 2024, respectively.</ix:footnote> </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><ix:footnote id="ix_25_footnote" xml:lang="en-US"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c315" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-48268">361,487</ix:nonFraction> to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on <ix:nonNumeric contextRef="c316" format="ixt:date-monthname-day-year-en" name="us-gaap:RelatedPartyTransactionDate" id="ixv-48269">September 30, 2021</ix:nonNumeric> with an interest rate of <ix:nonFraction contextRef="c316" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionRate" scale="-2" unitRef="pure" id="ixv-48270">6.5</ix:nonFraction>% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-48271">67,873</ix:nonFraction> to meet its new project needs. On July 27, 2021, the Company repaid a loan <ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="0" unitRef="usd" id="ixv-48272">249,975</ix:nonFraction> to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c319" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-48273">250,000</ix:nonFraction> to increase the cost for upcoming projects. The loan will be matured on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:RelatedPartyTransactionDate" id="ixv-48274">November 30, 2022</ix:nonNumeric> with an interest rate of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionRate" scale="-2" unitRef="pure" id="ixv-48275">6.5</ix:nonFraction>% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAgreementAmount" scale="0" unitRef="usd" id="ixv-48276">507,000</ix:nonFraction> to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $<ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAgreementAmount" scale="0" unitRef="usd" id="ixv-48277">88,091</ix:nonFraction> to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $<ix:nonFraction contextRef="c576" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAgreementAmount" scale="0" unitRef="usd" id="ixv-48278">25,500</ix:nonFraction> to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionRate" scale="-2" unitRef="pure" id="ixv-48279">6.5</ix:nonFraction>% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of March 31, 2025 and December 31, 2024, the outstanding loan balances and allocated research fee were both amounted to $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-48280">681,185</ix:nonFraction>, and accrued interest balances were both amounted $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="0" unitRef="usd" id="ixv-48281">158,798</ix:nonFraction>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-48282">839,983</ix:nonFraction> for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</span></p></ix:footnote></td></tr> </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_4" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><ix:footnote id="ix_26_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 4). <ix:nonNumeric contextRef="c577" name="us-gaap:DebtInstrumentInterestRateTerms" id="ixv-48283">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.</ix:nonNumeric> As of March 31, 2025 and December 31, 2024, due from BHK was both NTD <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" scale="0" unitRef="twd" id="ixv-48284">3,941,299</ix:nonFraction> (approximately$<ix:nonFraction contextRef="c528" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-48285">118,633</ix:nonFraction> and $<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" scale="0" unitRef="usd" id="ixv-48286">120,210</ix:nonFraction>, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of NTD <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="abvc:RecognizedCreditLosses" scale="0" unitRef="usd" id="ixv-48287">3,941,299</ix:nonFraction> as of December 31, 2024. No recovery was made during three months ended March 31, 2025.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company&#8217;s due from related parties
are subject to certain risks that our collaborative parties, including OncoX and FEYE, would face. Such risks exist in future market
conditions, macro economy, legal and regulatory, results of clinical trials and product developments, and among others. As of March 31,
2025, the Company&#8217;s comprehensive review of these due from related party balances indicates that there are no expected losses except
those being recognized above. This conclusion is based on the business relationships with our related parties and the absence of any
significant indicators of potential default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Due to related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Amount due to related parties consisted of
the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">AiBtl Holding (1)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c599" decimals="0" format="ixt:num-dot-decimal" id="ix_77_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">348,219</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c600" decimals="0" format="ixt:num-dot-decimal" id="ix_78_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">348,219</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">The Jiangs (2)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c601" decimals="0" format="ixt:num-dot-decimal" id="ix_79_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">222,522</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c602" decimals="0" format="ixt:num-dot-decimal" id="ix_80_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">274,170</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Shareholders (3)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c603" decimals="0" format="ixt:num-dot-decimal" id="ix_81_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">140,266</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c604" decimals="0" format="ixt:num-dot-decimal" id="ix_82_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">142,130</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Lion Art Promotions Inc (4)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c605" decimals="0" format="ixt:num-dot-decimal" id="ix_83_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">65,738</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-355"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Directors (5)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c607" decimals="0" format="ixt:num-dot-decimal" id="ix_84_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">12,953</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c608" decimals="0" format="ixt:num-dot-decimal" id="ix_85_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">8,526</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-48297">819,384</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-48298">773,045</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="ix_27_footnote" xml:lang="en-US">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $<ix:nonFraction contextRef="c326" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48300">40,000</ix:nonFraction>, $<ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48301">60,000</ix:nonFraction>, $<ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48302">33,732</ix:nonFraction>, and $<ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-48303">214,487</ix:nonFraction>, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand.</ix:footnote> </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><ix:footnote id="ix_28_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2025 and December 31, 2024, the outstanding balance due to the Jiangs amounted to $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingBalanceAmount" scale="0" unitRef="usd" id="ixv-48304">222,522</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingBalanceAmount" scale="0" unitRef="usd" id="ixv-48305">274,170</ix:nonFraction>, respectively. These loans bear no interest and are due on demand.</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><ix:footnote id="ix_29_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around <ix:nonFraction contextRef="c450" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure" id="ixv-48306">12</ix:nonFraction>% per annum. As of March 31, 2025 and December 31, 2024, the outstanding principal and accrued interest was $<ix:nonFraction contextRef="c578" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingPrincipalAmount" scale="0" unitRef="usd" id="ixv-48307">140,266</ix:nonFraction> and $<ix:nonFraction contextRef="c579" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingPrincipalAmount" scale="0" unitRef="usd" id="ixv-48308">142,130</ix:nonFraction>, respectively. Interest expenses in connection with these loans were $<ix:nonFraction contextRef="c580" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-48309">4,963</ix:nonFraction> and $<ix:nonFraction contextRef="c581" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-48310">5,938</ix:nonFraction> for the three months ended March 31, 2025 and 2024, respectively.</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><ix:footnote id="ix_30_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued consulting services fee for the three months ended March 31, 2025.</span></ix:footnote></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify"><ix:footnote id="ix_31_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2025 and December 31, 2024, due to Directors amounted to $<ix:nonFraction contextRef="c582" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-48311">12,953</ix:nonFraction> and $<ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-48312">8,526</ix:nonFraction>, respectively, were related to the daily operating expenses since inception in 2023 paid by the Directors of AiBtl on behalf of the entity.</span></ix:footnote></td></tr> </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-42491"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">11. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="-keep: true">Income tax
(benefit) expense for the three months ended March 31, 2025 and 2024 were <span style="-sec-ix-hidden: hidden-fact-359">$0</span> and <span style="-sec-ix-hidden: hidden-fact-360">$0</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-42502"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="-keep: true">Deferred tax assets (liability)
as of March 31, 2025 and December 31, 2024 consist approximately of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Loss on impairment of assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" sign="-" unitRef="usd" id="ixv-48313">713,223</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" sign="-" unitRef="usd" id="ixv-48314">713,223</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Net operating loss carryforwards</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" unitRef="usd" id="ixv-48315">5,870,805</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" unitRef="usd" id="ixv-48316">5,677,413</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating lease liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeaseLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-48317">155,559</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeaseLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-48318">178,014</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Operating lease assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:DeferredTaxAssetsOperatingLeaseAssets" scale="0" sign="-" unitRef="usd" id="ixv-48319">155,559</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:DeferredTaxAssetsOperatingLeaseAssets" scale="0" sign="-" unitRef="usd" id="ixv-48320">178,014</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Deferred tax assets, gross</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-48321">6,584,028</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-48322">6,390,636</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-48323">6,584,028</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-48324">6,390,636</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Deferred tax assets, net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-357"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-358"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-42677"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">12. EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company previously reported that during
the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related
party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related
party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to
the agreements, the Company issued <ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-48325">644,972</ix:nonFraction> shares of the Company&#8217;s common stock for the consulting service from July 2019 to July
2024 for the service fee of $<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-48326">4,514,800</ix:nonFraction> in aggregate, and recorded as stock subscription receivable. For the three months ended March
31, 2024, stock subscription receivable recognized as stock-based compensation in equity was $<ix:nonFraction contextRef="c609" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-48327">225,740</ix:nonFraction>.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">After further reviewed and investigation,
above services were completely provided by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with
the period when services are received. Therefore, the Company reversed share-based compensation expenses of $<ix:nonFraction contextRef="c610" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-48328">225,740</ix:nonFraction> for the three months
ended March 31, 2024.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 14, 2023, the Company entered into
a cooperation agreement with Zhonghui. Pursuant thereto, the Company expect to receive <ix:nonFraction contextRef="c377" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" unitRef="pure" id="ixv-48329">20</ix:nonFraction>% of the ownership of a property and the parcel
of the land owned by Zhonghui in Leshan, Sichuan, China. During the third quarter of 2023, the Company issued to Zhonghui, an aggregate
of <ix:nonFraction contextRef="c611" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateCommonStockShares" scale="0" unitRef="shares" id="ixv-48330">370,000</ix:nonFraction> shares (post-split) of the Company&#8217;s common stock, at a per share price of $<ix:nonFraction contextRef="c612" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-48331">1.87</ix:nonFraction>, for $<ix:nonFraction contextRef="c611" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-48332">691,900</ix:nonFraction>.&#160;The Company also
issued <ix:nonFraction contextRef="c377" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-48333">29,600</ix:nonFraction> common stock to consultants for providing consulting services on the above transaction. Please refer Note 2 for the restatement
of prior period reported amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 27, 2024, the Company granted <ix:nonFraction contextRef="c380" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-48334">1,302,726</ix:nonFraction>
restricted shares to its employees and directors under the 2016 Equity Incentive Plan as compensation for their previous services, with
an issuance date of February 2, 2024. These shares are subject to a three-year restriction period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 6, 2024, the Company entered into
a definitive agreement with Shuling Jiang (&#8220;Shuling&#8221;), pursuant to which Shuling shall transfer the ownership of certain
land she owns located at Taoyuan City, Taiwan (the &#8220;Land&#8221;) to the Company (the &#8220;Agreement&#8221;). Shuling is a director
of the Company, is married to TS Jiang, the Company&#8217;s Chief Strategic Officer and owns approximately <ix:nonFraction contextRef="c381" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-48335">15.4</ix:nonFraction>% of the Company&#8217;s
issued and outstanding shares of common stock. In consideration for the Land, the Company was to pay Shuling (i) <ix:nonFraction contextRef="c382" decimals="0" format="ixt:num-dot-decimal" name="abvc:AssetConsiderationCommonStock" scale="0" unitRef="shares" id="ixv-48336">703,496</ix:nonFraction> restricted shares
of the Company&#8217;s common stock (the &#8220;Shares&#8221;) at a price of $<ix:nonFraction contextRef="c383" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-48337">3.50</ix:nonFraction> per share and (ii) five-year warrants to purchase
up to <ix:nonFraction contextRef="c384" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-48338">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock, with an exercise price of $<ix:nonFraction contextRef="c385" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-48339">2.00</ix:nonFraction> per share. Under the Agreement, Shuling was
to also transfer outstanding liability owed on the Land (approximately $<ix:nonFraction contextRef="c386" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingLiabilityOwnedAmount" scale="0" unitRef="usd" id="ixv-48340">500,000</ix:nonFraction>) to the Company. On May 16, 2024, the Company&#8217;s
board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not
proceed with the transfer of land ownership; the Company may reconsider the transaction at a later date. The shares were returned and
booked as treasury stock, and the warrants were not issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In July 2024, the Company entered into an
agreement with its landlord in California, pursuant that the Company issued <ix:nonFraction contextRef="c613" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48341">169,992</ix:nonFraction> shares of common stock for the rent payable through
July 2024, in total of $<ix:nonFraction contextRef="c614" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-48342">127,494</ix:nonFraction>. The Company also issued <ix:nonFraction contextRef="c615" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48343">43,458</ix:nonFraction> shares on August 14, 2024 for the August 2024 rent, and <ix:nonFraction contextRef="c616" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48344">46,072</ix:nonFraction> shares
were issued on September 3, 2024 for the September 2024 rent. Further, we issued <ix:nonFraction contextRef="c617" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48345">64,147</ix:nonFraction> shares on October 29, 2024 for October rent,
<ix:nonFraction contextRef="c618" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48346">45,293</ix:nonFraction> shares on November 13, 2024 for November rent, and <ix:nonFraction contextRef="c619" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48347">30,422</ix:nonFraction> shares on December 26, 2024 for half month of December rent. In 2025,
the Company issued <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48348">28,135</ix:nonFraction> shares, <ix:nonFraction contextRef="c620" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48349">22,031</ix:nonFraction> shares, and <ix:nonFraction contextRef="c621" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48350">30,488</ix:nonFraction> shares for each of the half month rent from January 2025 to March 2025, respectively.
On April 9, 2025, the Company entered another agreement with the landlord to settle remaining balance of each half month of February
and March 2025 rent, and April 2025 rent, by issuing <ix:nonFraction contextRef="c622" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48351">120,398</ix:nonFraction> of the Company&#8217;s common stock, in the value of $<ix:nonFraction contextRef="c623" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48352">66,219</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Noncontrolling Interests</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 14, 2024, AiBtl issued <ix:nonFraction contextRef="c398" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-48353">1,610,700</ix:nonFraction>
AiBtl&#8217;s common stocks to a land acquisition transaction in Taiwan, including the 1-year business consulting fee of $<ix:nonFraction contextRef="c399" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConsultingFee" scale="0" unitRef="usd" id="ixv-48354">383,500</ix:nonFraction> incurred
beginning in November 2023, and the cost of land $<ix:nonFraction contextRef="c400" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Land" scale="0" unitRef="usd" id="ixv-48355">7,670,000</ix:nonFraction>. Due to certain administrative processes and restrictions, AiBtl has not
acquired ownership of the land and no asset was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Yunzhiyi, a Taiwan corporation, was incorporated
in August 2024, with <ix:nonFraction contextRef="c624" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-48356">90</ix:nonFraction>% owned by BioLite Taiwan and <ix:nonFraction contextRef="c625" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-48357">10</ix:nonFraction>% owned by Shuling Jiang, the Company&#8217;s director. This entity is set up
for holding the land that AiBtl acquired in Taiwan for developing health related business in Taiwan. Due to certain administrative processes
and restrictions, the title transfer has not completed, and no asset was recognized as of the issuance of this report. However, AiBtl
entered a series of agreements with the sellers in March 2025, to obtain the complete rights and obligations of the land while in the
process of transferring the title. These agreements are effective until the title transfer is completed. AiBtl recognized such asset
on its balance sheet on March 31, 2025. Refer to Note 6 for details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Lind Offerings and Repayments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 23, 2023, in connection with the
issuance of the Lind Note (referring to Note 7), the Company issued Lind a <ix:nonNumeric contextRef="c403" format="ixt-sec:duryear" name="abvc:PurchaseWarrantTerm" id="ixv-48358">5</ix:nonNumeric>-year term of common stock purchase warrant to purchase up
to <ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-48359">529,167</ix:nonFraction> shares (post-split) of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c405" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-48360">10.5</ix:nonFraction> per share (post-split), subject
to adjustment. The warrant exercise price was reset to $<ix:nonFraction contextRef="c406" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-48361">3.5</ix:nonFraction> in accordance with the issuance of common stock in relation to securities
purchase agreement in July 2023. On May 22, 2024, the exercise price of these warrants was further reset to $<ix:nonFraction contextRef="c407" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-48362">0.75</ix:nonFraction> along with the immediate
exercise of existing warrants and issuance of the New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the three months ended March 31, 2024,
the Company has made repayment of Lind Note with the Company&#8217;s common stock for <ix:nonFraction contextRef="c626" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48363">751,795</ix:nonFraction> shares, totaling $<ix:nonFraction contextRef="c626" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-48364">681,000</ix:nonFraction>. As of December
31, 2024, the first Lind Note was fully repaid.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 17, 2023, in connection with the
issuance of the 2<sup>nd</sup> Lind Note (referring to Note 7), Lind also received a <ix:nonNumeric contextRef="c250" format="ixt-sec:duryear" name="us-gaap:CreditDerivativeTerm1" id="ixv-48365">5</ix:nonNumeric>-year term of common stock purchase warrants to
purchase up to <ix:nonFraction contextRef="c408" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-48366">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-48367">2</ix:nonFraction> per share. The warrants were valued
using the Black-Scholes model and the fair value was determined to be $<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-48368">480,795</ix:nonFraction>, which was recorded as a debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 17, 2024, in connection with the
issuance of the 3<sup>rd</sup> Lind Note (referring to Note 7), Lind also received <ix:nonNumeric contextRef="c257" format="ixt-sec:duryear" name="us-gaap:CreditDerivativeTerm1" id="ixv-48369">5</ix:nonNumeric>-year term of common stock purchase warrants to purchase
up to <ix:nonFraction contextRef="c409" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-48370">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction contextRef="c409" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-48371">2</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 22, 2024, the Company and Lind entered
into a letter agreement, pursuant to which Lind will exercise, for cash, <ix:nonFraction contextRef="c410" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-48372">1,000,000</ix:nonFraction> of its Pre-Existing Warrants (all of the warrants
issued to Lind on February 23, 2023, November 17, 2023 and January 17, 2024 are hereinafter referred to as the &#8220;Pre-Existing Warrants&#8221;),
to purchase shares of Common Stock at a reduced exercise price of $<ix:nonFraction contextRef="c411" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-48373">0.75</ix:nonFraction> per share. Such <ix:nonFraction contextRef="c407" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-48374">1,000,000</ix:nonFraction> Pre-Existing Warrants exercised include
<ix:nonFraction contextRef="c412" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-48375">529,167</ix:nonFraction> warrants issued in February 2023 and <ix:nonFraction contextRef="c413" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-48376">470,833</ix:nonFraction> warrants issued in November 2023. Concurrently, the exercise price of all Pre-Existing
Warrants was reduced to $<ix:nonFraction contextRef="c407" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-48377">0.75</ix:nonFraction> per share according to this agreement. Lind also received new warrants to purchase <ix:nonFraction contextRef="c414" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-48378">1,000,000</ix:nonFraction> shares of
common stock, exercisable at any time on or after the date of its issuance and until the five-year anniversary thereof, for $<ix:nonFraction contextRef="c415" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-48379">1.00</ix:nonFraction> per
share (the &#8220;New Warrants&#8221;). The fair value of the New Warrants was determined to be $<ix:nonFraction contextRef="c407" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-48380">925,210</ix:nonFraction> using the Black-Scholes model.
The New Warrants may be exercised via cashless exercise or resale pursuant to the registration statement that was declared effective.
As of December 31, 2024, Lind has exercised <ix:nonFraction contextRef="c416" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-48381">1,000,000</ix:nonFraction> shares of Pre-Existing Warrants and received <ix:nonFraction contextRef="c417" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-48382">1,000,000</ix:nonFraction> shares of New Warrants according
to this agreement. All warrants issued to Lind may be exercised via cashless exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the year ended December 31, 2024, the
Company issued Lind in total of <ix:nonFraction contextRef="c418" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-48383">800,000</ix:nonFraction> shares of the Company&#8217;s common stock as the repayment of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock" scale="0" unitRef="usd" id="ixv-48384">800,000</ix:nonFraction> principal of 2<sup>nd</sup>
Lind Note. According to the amended agreement pursuant to Nasdaq requirements, the conversion price is subject to $<ix:nonFraction contextRef="c419" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48385">1.00</ix:nonFraction> floor price if
the conversion price was below such floor, resulting in effective conversion price between $<ix:nonFraction contextRef="c97" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48386">0.7907</ix:nonFraction> to $<ix:nonFraction contextRef="c96" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-48387">0.4932</ix:nonFraction>. The Company made additional
$<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-48388">327,017</ix:nonFraction> cash repayments, with $<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-48389">127,759</ix:nonFraction> unpaid cash booked in Accrued Expenses and Other Current Liabilities as of December 31, 2024.
On March 3, 2025 and April 1, 2025, Lind converted the remaining $<ix:nonFraction contextRef="c627" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-48390">400,000</ix:nonFraction> ($<ix:nonFraction contextRef="c628" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-48391">200,000</ix:nonFraction> in each conversion) principal balance on 2<sup>nd</sup>
Lind Note into <ix:nonFraction contextRef="c629" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-48392">400,000</ix:nonFraction> shares of the Company&#8217;s common stocks. All principal balance of 2<sup>nd</sup> Lind Note was fully converted
as of April 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 3, 2025 and April 1, 2025, Lind converted
$<ix:nonFraction contextRef="c630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-48393">400,000</ix:nonFraction> ($<ix:nonFraction contextRef="c631" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-48394">200,000</ix:nonFraction> in each conversion) principal balance on 3<sup>rd</sup> Lind Note into <ix:nonFraction contextRef="c630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-48395">400,000</ix:nonFraction> shares of the Company&#8217;s common
stocks, leaving outstanding principal of $<ix:nonFraction contextRef="c632" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-48396">600,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 5, 2025, the Company and Lind entered
into a third letter agreement, pursuant to which Lind agreed to exercise for cash, <ix:nonFraction contextRef="c633" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-48397">1,029,167</ix:nonFraction> of the Existing Warrants to purchase shares
of Common Stock, with a current exercise price of $<ix:nonFraction contextRef="c634" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-48398">0.75</ix:nonFraction> per share, at a reduced exercise price of $<ix:nonFraction contextRef="c635" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-48399">0.40</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-42789"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Warrants issued and outstanding in connection
with above Lind convertible notes as of March 31, 2025, and their activities during the three-month period ended are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Number of<br/> Underlying<br/> Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Weighted-<br/> Average<br/> Contractual<br/> Life<br/> Remaining<br/> in Years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Outstanding as of January 1, 2025</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c638" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-48400">2,029,167</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c638" decimals="2" format="ixt:num-dot-decimal" name="abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-48401">0.70</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">*</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c639" format="ixt-sec:duryear" id="ix_86_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"><span style="-keep: true">4.20</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c638" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-48402">195,542</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Issued</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-361"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-362"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-363"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-364"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c640" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" unitRef="shares" id="ixv-48403">1,029,167</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c640" decimals="2" format="ixt:num-dot-decimal" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-48404">0.40</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-365"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-366"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Outstanding as of March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c641" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-48405">1,000,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c641" decimals="2" format="ixt:num-dot-decimal" name="abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-48406">0.40</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c640" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-42971"><span style="-keep: true">4.14</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c641" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-48407">60,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_32_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, <ix:nonFraction contextRef="c636" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-48408">1,029,167</ix:nonFraction> of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $<ix:nonFraction contextRef="c637" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-48409">0.75</ix:nonFraction> per share, at a reduced exercise price of $<ix:nonFraction contextRef="c637" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-48410">0.40</ix:nonFraction> per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</span></ix:footnote></td>
</tr></table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-43006"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">13. STOCK OPTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has <span style="-sec-ix-hidden: hidden-fact-377"><span style="-sec-ix-hidden: hidden-fact-378">not</span></span> granted any options during
three months ended March 31, 2025 and 2024. The Company&#8217;s most recent option grant was in 2022 that <ix:nonFraction contextRef="c425" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-48411">76,190</ix:nonFraction>&#160;shares (post-split)
of common stock were granted to employees and certain consultants.&#160;The weighted average grant date fair value of options granted
in 2022 was $<ix:nonFraction contextRef="c425" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-48412">27.9</ix:nonFraction> (post-split). There are <ix:nonFraction contextRef="c426" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-48413">386,021</ix:nonFraction>&#160;options available for grant under the 2016 Equity Incentive Plan as of December
31, 2024. Compensation costs associated with the Company&#8217;s stock options are recognized, based on the grant-date fair values of
these options over vesting period. As of March 31, 2025 and December 31, 2024, there were <span style="-sec-ix-hidden: hidden-fact-379"><span style="-sec-ix-hidden: hidden-fact-380">no</span></span> unvested options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-43019"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Options issued and outstanding as of March
31, 2025, and their activities during the year then ended are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Weighted-</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Weighted-</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Average</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Average</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Number&#160;of</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Exercise</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Contractual</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Underlying<br/> Shares<br/> (post-split)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Price<br/> Per&#160;Share<br/> (post-split)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Life<br/> Remaining<br/> in Years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-keep: true">Outstanding as of January 1, 2025</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c642" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-48414">258,710</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c642" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-48415">27.9</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c643" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-43165"><span style="-keep: true">6.74</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-367"><span style="-keep: true">&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-keep: true">Granted</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-368"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-369"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-370"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-keep: true">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-371"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-372"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-373"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt"><span style="-keep: true">Outstanding as of March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-48416">258,710</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-48417">27.9</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-43278"><span style="-keep: true">6.50</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-374"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="-keep: true">Exercisable as of March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-48418">258,710</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-48419">27.9</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-43315"><span style="-keep: true">6.50</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-375"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Vested and expected to vest</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-48420">258,710</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-48421">27.9</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-43352"><span style="-keep: true">6.50</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-376"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-43369"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">14. LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Basic loss per share is computed by dividing
net loss by the weighted-average number of common shares outstanding during the year. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-48422">Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended
March 31, 2025 and 2024.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Three Months &#160;Ended</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Numerator:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Net loss attributable to ABVC&#8217;s common stockholders</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-48423">842,075</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-48424">2,834,199</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Denominator:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Weighted-average shares outstanding &#8211; Basic &amp; Diluted</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-48425"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-48426">14,968,232</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-48427"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-48428">9,736,150</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Loss per share</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">-Basic &amp; Diluted</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-48429"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-48430">0.06</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-48431"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-48432">0.29</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Diluted loss per share takes into account
the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common
Stock. Since the Company suffered net loss for both years, any diluted shares would have anti-diluted effect.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-43592"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">15. LEASE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#8220;ASC 842&#8221;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company applied the following practical
expedients in the transition to the new standard and allowed under ASC 842:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of expired
    or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained
    leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing
    leases.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of hindsight: The
    Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease
    and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of existing
    or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted
    for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will
    be evaluated under ASU No. 2016-02.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation of lease
    and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease recognition
    exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities
    for leases with a term less than 12 months.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities. ROU assets represent the
Company&#8217;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#8217;s obligation to
make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#8217;s future minimum based payments used
to determine the Company&#8217;s lease liabilities mainly include minimum based rent payments. As most of Company&#8217;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company recognized lease liabilities,
with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has no finance leases. The Company&#8217;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#8217;s operating leases have remaining lease terms of up to approximately five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-43667"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#8239;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">ASSETS</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Operating lease right-of-use assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-48433">533,460</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-48434">640,387</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="-keep: true">LIABILITIES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating lease liabilities (current)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-48435">366,475</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-48436">403,581</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Operating lease liabilities (non-current)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-48437">166,985</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-48438">236,807</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>Supplemental Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following provides details of the Company&#8217;s
lease expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Three Months Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Operating lease expenses</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd" id="ixv-48439">117,166</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd" id="ixv-48440">98,502</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Other information related to leases is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Three Months Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-48441">117,166</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-48442">98,502</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">Weighted Average Remaining Lease Term:</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-keep: true">Operating leases</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-48443">2.43</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c1" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-48444">2.48</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-keep: true">Weighted Average Discount Rate:</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Operating leases</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-48445">1.32</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-48446">1.19</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-44010"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Operating<br/> leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="-keep: true">2025 (Excluding current period)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-48447">302,071</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">2026</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-48448">104,849</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">2027</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-48449">46,699</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">2028</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd" id="ixv-48450">46,699</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">2029</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd" id="ixv-48451">46,699</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-381"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Total future minimum lease payments, undiscounted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-48452">547,017</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Less: Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-48453">13,557</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Present value of future minimum lease payments</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-48454">533,460</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-44129"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">16. COMMITMENTS AND CONTINGENCIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of March 31, 2025 and up through the date
of the consolidated financial statements was available to the issued.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-44140"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">17. SUBSEQUENT EVENTS</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In April 2025, the Company conducted a private
offering of its common stock to several individual investors, issuing <ix:nonFraction contextRef="c644" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48455">724,372</ix:nonFraction> unregistered shares at $<ix:nonFraction contextRef="c645" decimals="2" format="ixt:num-dot-decimal" name="abvc:UnregisteredPricePerShares" scale="0" unitRef="usdPershares" id="ixv-48456">0.60</ix:nonFraction> to $<ix:nonFraction contextRef="c646" decimals="2" format="ixt:num-dot-decimal" name="abvc:UnregisteredPricePerShares" scale="0" unitRef="usdPershares" id="ixv-48457">0.65</ix:nonFraction> per share, raising
a total of $<ix:nonFraction contextRef="c644" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-48458">436,125</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In April 2025, the Company issued <ix:nonFraction contextRef="c647" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48459">9,909</ix:nonFraction> unregistered
restricted shares to an individual consultant as a consideration of $<ix:nonFraction contextRef="c647" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributedCapital" scale="0" unitRef="usd" id="ixv-48460">9,800</ix:nonFraction> ($<ix:nonFraction contextRef="c648" decimals="2" format="ixt:num-dot-decimal" name="abvc:UnregisteredPricePerShares" scale="0" unitRef="usdPershares" id="ixv-48461">0.99</ix:nonFraction> per share) for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In April 2025, the Company issued <ix:nonFraction contextRef="c649" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48462">50,000</ix:nonFraction> and
<ix:nonFraction contextRef="c650" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48463">90,277</ix:nonFraction> shares of common stock to two advisors for their financial and business advisory services, as the consideration of $<ix:nonFraction contextRef="c649" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributedCapital" scale="0" unitRef="usd" id="ixv-48464">52,500</ix:nonFraction> and
$<ix:nonFraction contextRef="c650" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributedCapital" scale="0" unitRef="usd" id="ixv-48465">94,791</ix:nonFraction> ($<ix:nonFraction contextRef="c651" decimals="2" format="ixt:num-dot-decimal" name="abvc:UnregisteredPricePerShares" scale="0" unitRef="usdPershares" id="ixv-48466">1.05</ix:nonFraction> and $<ix:nonFraction contextRef="c652" decimals="2" format="ixt:num-dot-decimal" name="abvc:UnregisteredPricePerShares" scale="0" unitRef="usdPershares" id="ixv-48467">1.05</ix:nonFraction> per share), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In April 2025, AiBtl issued <ix:nonFraction contextRef="c653" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-48468">1,800</ix:nonFraction> shares of
its common stock at $<ix:nonFraction contextRef="c654" decimals="0" format="ixt:num-dot-decimal" name="abvc:UnregisteredPricePerShares" scale="0" unitRef="usdPershares" id="ixv-48469">5</ix:nonFraction> per share, raising a total of $<ix:nonFraction contextRef="c653" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributedCapital" scale="0" unitRef="usd" id="ixv-48470">9,000</ix:nonFraction> from an individual investor.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART II - INFORMATION NOT REQUIRED IN
PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 13. <i>Other Expenses of Issuance and
Distribution</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all expenses to
be paid by the Registrant, other than estimated placement agents&#8217; fees, in connection with our public offering. All amounts shown
are estimates except for the SEC registration fee and the FINRA filing fee:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">SEC registration fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,019.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">FINRA filing fee</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,985.47</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">95,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Transfer agent and registrar fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,238</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Miscellaneous fees and expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">133,492.48</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 14. <i>Indemnification of Directors and
Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither our Articles of Incorporation nor Bylaws
prevent us from indemnifying our officers, directors and agents to the extent permitted under the Nevada Revised Statute (&#8220;NRS&#8221;).
NRS Section 78.7502 provides that a corporation shall indemnify any director, officer, employee or agent of a corporation against expenses,
including attorneys&#8217; fees, actually and reasonably incurred by him in connection with any the defense to the extent that a director,
officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding
referred to Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS 78.7502(1) provides that a corporation may
indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason
of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses,
including attorneys&#8217; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection
with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which
he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe his conduct was unlawful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS Section 78.7502(2) provides that a corporation
may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or
suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement
and attorneys&#8217; fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit
if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or
not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such
a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation
or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought
or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is
fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 182; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS Section 78.747 provides that except as otherwise
provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation,
unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of
whether a director or officer acts as the alter ego of a corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have
been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant
of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we
will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by us is against public policy as expressed hereby in the Securities Act and we will be governed
by the final adjudication of such issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Articles of Incorporation and Bylaws</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our articles of incorporation, as amended, do
not include specific provisions relating to the indemnification of our directors or officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bylaws provide that the Company may indemnify
and advance litigation expenses to its directors, officers, employees and agents to the extent permitted by law, the Company&#8217;s
Articles or Bylaws, and shall indemnify and advance litigation expenses to its directors, officers, employees and agents to the extent
required by law, the Company&#8217;s Articles of Incorporation or Bylaws. The Company&#8217;s obligations of indemnification, if any,
shall be conditioned on the Company receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Company
may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee
or agent of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 15. <i>Recent Sales of Unregistered Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During
                                            the last three years, the Company has not issued unregistered securities to any person, except
                                            as described below. None of these transactions involved any underwriters, underwriting discounts
                                            or commissions, except as specified below, or any public offering, and, unless otherwise
                                            indicated below, the Registrant believes that each transaction was exempt from the registration
                                            requirements of the Securities Act by virtue of Section 4(a)(2) thereof and/or Rule 506 of
                                            Regulation D promulgated thereunder, and/or Regulation S promulgated thereunder regarding
                                            offshore offers and sales. All recipients had adequate access, though their relationships
                                            with the Registrant, to information about the Registrant. All following number of shares
                                            are post-split.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In January 2022, the Company agreed to pay
the deferred service fees related to the public offering closed on August 5, 2021 amounting to $4,296,763 by issuing 130,601 shares of
unrestricted common shares, valued at $32.9 per share on the grant date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In March 2022, the Company issued 7,500 shares
to BarLew Holdings, LLC, a consultant (&#8220;Barlew&#8221;). On January 1, 2022, the Company engaged Barlew for consulting and advisory
services for six months, with a monthly payment of USD15,000, as well as additional compensation of 7,500 shares of restricted common
stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In March 2022, the Company issued 24,225 warrants
to a FINRA member firm.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 11, 2022, the Company and certain investors
entered into certain securities purchase agreement relating to the offer and sale of 200,000 shares of common stock, par value $0.001
per share in a registered direct offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On July 10, 2022, the Board approved the issuance
of 7,500 shares of common stock to Barlew Holdings, LLC pursuant to the consulting agreement by and between Barlew Holdings, LLC and
the Company dated July 1, 2022, and 25,000 shares of common stock to Inverlew Advisors, LLC, in accordance with the consulting agreement
by and between Inverlew Advisors, LLC and the Company dated July 1, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On December 1, 2022, the Company issued 12,5000
and 10,000 common shares to Euro-Asia Investment &amp; Finance Corp Ltd. and Thalia Media Ltd. for consulting and advisory services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 3, 2023, the Company issued 22,341
common shares to a consultant for providing consulting services on listing to NASDAQ in 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2023, the Company entered into that
certain securities purchase agreement relating to the offer and sale of 300,000 shares of common stock, par value $0.001 per share and
200,000 pre-funded warrants, at an exercise price of $0.001 per share, in a registered direct offering. Pursuant to the Purchase Agreement,
the Company agreed to sell the Shares and/or Pre-funded Warrants at a per share purchase price of $3.50, for gross proceeds of $1,750,000,
before deducting any estimated offering expenses. On August 1, 2023, the pre-funded warrants were exercised.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 14, 2023, the Company entered into
a cooperation agreement with Zhonghui. Pursuant thereto, the Company acquired 20% of the ownership of a property and the parcel of the
land owned by Zhonghui in Leshan, Sichuan, China (collectively, the &#8220;Property&#8221;). During the third quarter of 2023, the Company
issued to Zhonghui, an aggregate of 370,000 shares of the Company&#8217;s common stock, at a per share price of $1.87. The Company also
issued 29,600 common stock to consultants for providing consulting services on the above transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 27, 2024, the company granted 1,302,726
restricted shares to its employees and directors under the 2016 Equity Incentive Plan, with an issuance date of February 2, 2024. These
shares are subject to a three-year restriction period.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On May 24, 2024, the Company issued 200,000
shares of common stock to a consultant for providing business and funding opportunities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In July 2024, the Company entered into an
agreement with its landlord in California, pursuant that the Company issued 169,992 shares of common stock for the rent payable through
July 2024, in total of $127,494. The Company also issued 43,458 shares on August 14, 2024 for the August 2024 rent, and 46,072 shares
were issued on September 3, 2024 for the September 2024 rent. Further, we issued 64,147 shares on October 29, 2024 for October rent,
45,293 shares on November 13, 2024 for November rent, and 30,422 shares on December 26, 2024 for half month of December rent. In 2025,
we issued 28,135 shares, 22,031 shares, and 30,488 shares for each of the half month rent from January 2025 to March 2025, respectively.
On April 9, 2025, the Company entered another agreement with the landlord to settle remaining balance of each half month of February
and March 2025 rent, and April 2025 rent, by issuing 120,398 of the Company&#8217;s common stock, in the value of $66,219.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In December 2024, the Company issued 117,277
shares of its common stock to employees as compensation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In April 2025, the Company conducted a private
offering of its common stock to several individual non-US investors, issuing an aggregate of 724,372 unregistered shares of common stock
at $0.60 to $0.65 per share, raising a total of $436,125.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In April 2025, the Company issued 9,909 unregistered
restricted shares to an individual consultant as a consideration of $9,800 for the services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In April 2025, the Company issued 50,000 and
90,277 shares of common stock to two advisors for their financial and business advisory services, as the consideration of $52,500 and
$94,791 ($1.05 and $1.05 per share), respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Between April 11, 2025 and April 30, 2025,
the Company sold an aggregate of an aggregate of 724,372 shares of its Common Stock to 15 Non-U.S. Persons. The Company received aggregate
gross proceeds of a little more than $436,000 for the Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16. <i>Exhibits and Financial Statement
Schedules </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">2.1 </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000101489716000457/exhibit101.htm"><span style="font-size: 10pt">Share
    Exchange Agreement, dated February 8, 2016 (1)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000113789202000063/fex301ai.txt"><span style="font-size: 10pt">Articles
    of Incorporation of the Company (2)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024025197/ea020231801ex3-2_abvcbio.htm"><span style="font-size: 10pt">Bylaws of the Company, as amended (48)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000161577416004635/s102891_4-1.htm"><span style="font-size: 10pt">Certificate
    of Amendment to Articles of Incorporation filed on March 21, 2016 (4)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000161577416007154/s104086_ex3-4.htm"><span style="font-size: 10pt">Certificate
    of Amendment to Articles of Incorporation filed on December 30, 2015 (5)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020008785/ea120454ex3-1_americanbri.htm"><span style="font-size: 10pt">Certificate
    of Amendment to Articles of Incorporation filed on March 30, 2020 (6)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390021025389/f10q0321ex3-6_abvcbio.htm"><span style="font-size: 10pt">Certificate
    of Amendment to Articles of Incorporation filed on February 17, 2021 (10)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020010040/ea121013ex4-1_american.htm"><span style="font-size: 10pt">Form
    of Warrant (7)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1173313/000121390022032865/ea158525-posam2_abvcbio.htm"><span style="font-size: 10pt">Form of the Registrant&#8217;s Common Stock certificate (16)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">5.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024012141/ea192587ex5-1_abvcbio.htm"><span style="font-size: 10pt">Legal
    Opinion of Hunter Taubman Fischer &amp; Li LLC (45)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000101489716000457/exhibit102.htm"><span style="font-size: 10pt">Collaboration
    Agreement dated December 29, 2015 (8)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000161577416005823/s103448_ex99-1.htm"><span style="font-size: 10pt">Collaborative
    Agreement and Milestone Payment Agreement dated May 6, 2016 (9)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390017001707/f8k0217ex99i_americanbri.htm"><span style="font-size: 10pt">Addendum
    to the Collaboration Agreement dated January 12, 2017 (11)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390017007869/f8k072417ex10i_americanbri.htm"><span style="font-size: 10pt">Collaboration
    Agreement with BioFirst dated July 24, 2017 (12)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390017005978/f8k052617ex99i_american.htm"><span style="font-size: 10pt">Co-Development
    Agreement with Rgene dated May 26, 2017 (13)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/ea180822ex10-1_abvcbiopharm.htm"><span style="font-size: 10pt; text-decoration: none">Employment
    Agreement with Dr. </span><span style="font-size: 10pt">Uttam Patil <span style="text-decoration: none">(42)</span></span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Reserved</span></p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Reserved.</span></p></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390019001553/f8k012119ex10-2_americanbri.htm"><span style="font-size: 10pt">Promissory
    Note entered by American BriVision (Holding) Corporation (17)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390019001553/f8k012119ex10-3_americanbri.htm"><span style="font-size: 10pt">Form
    of Commercial Security Agreement (18)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390020009167/ea120625ex10-2_americanbri.htm"><span style="font-size: 10pt">Form
    of Exchange Agreement entered into by and between the Company and non-US persons (19)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020009167/ea120625ex10-1_americanbri.htm"><span style="font-size: 10pt">Form
    of Exchange Agreement entered into by and between the Company and US persons (20)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390020010040/ea121013ex10-1_american.htm"><span style="font-size: 10pt">Form
    of Exchange Agreement entered into by and between the Company and non-US person (21)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/f10k2019ex10-15_americanbriv.htm"><span style="font-size: 10pt">Form
    of Securities Purchase Agreement entered into by and between the Company and U.S. investors (22)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/f10k2019ex10-16_americanbriv.htm"><span style="font-size: 10pt">Form
    of Securities Purchase Agreement entered into by and between the Company and non-U.S. investors (24)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390021015729/f10k2020ex10-17_americanbriv.htm"><span style="font-size: 10pt">Amended
    and Restated American BriVision (Holding) Corporation 2016 Equity Incentive (28)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390021052090/ea148616ex10-1_abvcbiopharma.htm"><span style="font-size: 10pt">Joint
    Venture Agreement between the Company, Lucidaim Co., Ltd. And BioLite Japan K.K.(26)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390022027157/f10q0322ex10-22_abvcbio.htm"><span style="font-size: 10pt">Amendment
    to the Collaboration Agreement dated December 29, 2015 (32)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.19</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390022025731/ea159780ex1-1_abvcbio.htm"><span style="font-size: 10pt">Form
    of Securities Purchase Agreement entered into by and between the Company and certain investors dated May 11, 2022 (34)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.20</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390022033890/ea161846ex10-1_abvcbio.htm"><span style="font-size: 10pt">Clinical
    Development Service Agreement between the Company and Rgene dated June 10, 2022 (portions of the exhibit have been omitted because
    they (i) are not material and (ii) is the type of information that the registrant treats as private or confidential) (35)</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%"><span style="font-size: 10pt">10.21</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390022033890/ea161846ex10-2_abvcbio.htm"><span style="font-size: 10pt">Promissory
    Note dated June 16, 2022 issued by Rgene Corporation to the Company (36)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.22</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-1_abvcbio.htm"><span style="font-size: 10pt">Securities
    Purchase Agreement (37)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-2_abvcbio.htm"><span style="font-size: 10pt">Form
    of Note (37)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-3_abvcbio.htm"><span style="font-size: 10pt">Form
    of Warrant (37)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-4_abvcbio.htm"><span style="font-size: 10pt">Security
    Agreement (37)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-5_abvcbio.htm"><span style="font-size: 10pt">Guarantor
    Security Agreement (37)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.27</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-6_abvcbio.htm"><span style="font-size: 10pt">Guaranty
    (37)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.28</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-7_abvcbio.htm"><span style="font-size: 10pt">Trademark
    Security Agreement with Rgene Corporation (37)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.29</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-8_abvcbio.htm"><span style="font-size: 10pt">Trademark
    Security Agreement with BioFirst Corporation (37)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.30</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-9_abvcbio.htm"><span style="font-size: 10pt">Patent
    Security Agreement (37)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.31</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-10_abvcbio.htm"><span style="font-size: 10pt">Copyright
    Security Agreement (37)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.32</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex10-11_abvcbio.htm"><span style="font-size: 10pt">Stock
    Pledge Agreement (37)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.33</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178ex4-1_abvcbio.htm"><span style="font-size: 10pt">Form
    of Placement Agent Warrant (37)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.34</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390023088524/ea188623ex10-2_abvcbio.htm"><span style="font-size: 10pt">Form
    of 2<sup>nd</sup> Lind Note (41)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.35</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390023088524/ea188623ex10-3_abvcbio.htm"><span style="font-size: 10pt">Form
    of 2<sup>nd</sup> Lind Warrant (41)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.36</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390023088524/ea188623ex10-1_abvcbio.htm"><span style="font-size: 10pt">Securities
    Purchase Agreement dated November 17, 2023 (41)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.37</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390023088524/ea188623ex10-4_abvcbio.htm"><span style="font-size: 10pt">First
    Amendment To Security Agreement (41)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.38</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390023088524/ea188623ex10-5_abvcbio.htm"><span style="font-size: 10pt">First
    Amendment To Guarantor Security Agreement (41)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.39</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390023088524/ea188623ex10-6_abvcbio.htm"><span style="font-size: 10pt">First
    Amendment to Guaranty (41)</span></a></td></tr>

<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/ea191664ex10-1_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Purchase Agreement dated January 17, 2024 (43)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024012141/ea192587ex10-41_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of 3<sup>rd</sup> Placement Agent Warrant (45)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/ea191664ex10-4_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Amendment To Security Agreement (43) </span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/ea191664ex10-5_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Amendment To Guarantor Security Agreement (43)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/ea191664ex10-6_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Amendment to Guaranty (43)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/ea191664ex10-2_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of 3<sup>rd</sup> Lind Note (43) </span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/ea191664ex10-3_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of 3<sup>rd</sup> Lind Warrant (43)</span></a></td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><p style="margin: 0pt 0; font: 10pt/107% Times New Roman, Times, Serif">10.47</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt/107% Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/ea180822ex10-1_abvcbiopharm.htm">Employment
                                    Agreement with Uttam Patil (44)</a></p></td></tr>

<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.48</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024018526/ea0200876ex10-2_abvcbio.htm"><span style="font-size: 10pt">Amendment
    (46)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.49</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024018524/ea0200878ex10-2_abvcbio.htm"><span style="font-size: 10pt">Amendment
    (47)</span></a></td></tr>



<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024018526/ea0200876ex10-2_abvcbio.htm"><span style="font-size: 10pt">Amendment No. 1 to 3<sup>rd</sup> Lind Note (49)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.51</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/ea020556901ex10-1_abvcbio.htm"><span style="font-size: 10pt">Definitive License Agreement between the Company and OncoX BioPharma, Inc. May 8, 2024 (51)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.52</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/ea020556901ex10-2_abvcbio.htm"><span style="font-size: 10pt">Definitive License Agreement between Rgene and OncoX BioPharma, Inc. dated May 8, 2024 (51)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.53</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024046313/ea020671501ex10-1_abvcbio.htm"><span style="font-size: 10pt">Lind Letter Agreement dated May 22, 2024 (52)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.54</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024046313/ea020671501ex10-2_abvcbio.htm"><span style="font-size: 10pt">Lind Form of Warrant dated May 22, 2024 (52)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.55</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024046419/ea020679001ex10-1_abvcbio.htm"><span style="font-size: 10pt">Definitive License Agreement between the Company and OncoX BioPharma, Inc. May 23, 2024 (53)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.56</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024046419/ea020679001ex10-2_abvcbio.htm"><span style="font-size: 10pt">Definitive License Agreement between Biolite, Inc. and OncoX BioPharma, Inc. dated May 23, 2024 (53)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.57</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024055288/ea020838301ex10-1_abvcbio.htm"><span style="font-size: 10pt">Amendment to the Definitive License Agreement between the Company and ForSeeCon Eye Corporation (54)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.58</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024055288/ea020838301ex10-2_abvcbio.htm"><span style="font-size: 10pt">Amendment to the Definitive License Agreement between BioFirst Corporation and ForSeeCon Eye Corporation (54)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.59</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024055809/ea020845301ex10-1_abvcbio.htm"><span style="font-size: 10pt">Amendment to the License Agreement between the Company and AiBtl BioPharma Inc. (55)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.60</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024055809/ea020845301ex10-2_abvcbio.htm"><span style="font-size: 10pt">Amendment to the License Agreement between BioLite, Inc. and AiBtl BioPharma Inc. (55)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.61</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025001211/ea022648701ex10-1_abvcbio.htm"><span style="font-size: 10pt">Letter Agreement dated January 5, 2025 (56)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.62</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea023254001ex10-56_abvcbio.htm"><span style="font-size: 10pt">Land Transfer Plan dated March 31, 2025 (49)</span></a></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.63</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea023254001ex10-57_abvcbio.htm"><span style="font-size: 10pt">Nominee Holding Agreement dated April 1, 2024 (49)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.64</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea023254001ex10-58_abvcbio.htm"><span style="font-size: 10pt">Land Lease Agreement dated April 1, 2024 (49)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.65</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea023254001ex10-59_abvcbio.htm"><span style="font-size: 10pt">Addendum to Definitive Licensing Agreement between ABVC and AiBtl dated March 11, 2025 (49)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.66</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea023254001ex10-60_abvcbio.htm"><span style="font-size: 10pt">Addendum to Definitive Licensing Agreement between BioLite and AiBtl dated March 11, 2025 (49)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.67</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea023254001ex10-61_abvcbio.htm"><span style="font-size: 10pt">Yunzhiyi Land Holding Agreement dated October 28, 2024 (49)</span></a></td></tr>


<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.68</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025037654/ea023974001ex10-1_abvcbio.htm"><span style="font-size: 10pt; text-decoration: none">Form of Purchase Agreement (57)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.69</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025037654/ea023974001ex4-2_abvcbio.htm"><span style="font-size: 10pt; text-decoration: none">Form of Voting Rights Proxy Agreement (57)</span></a></td></tr>

<tr>
    <td style="vertical-align: top; width: 9%"><span style="font-size: 10pt">14.1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000161577416008325/s104643_ex14-1.htm"><span style="font-size: 10pt">Code
    of Ethics (23)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">15.1</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024012141/ea192587ex15-1_abvcbio.htm">Letter
    in Lieu of Consent for Review Report (45)</a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea023254001ex21-1_abvcbio.htm"><span style="font-size: 10pt">List of subsidiaries (49)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">23.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1173313/000121390024012141/ea192587ex5-1_abvcbio.htm"><span style="font-size: 10pt">Consent
    of Hunter Taubman Fischer &amp; Li LLC (Included in Exhibit 5.1)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">23.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea024194101ex23-2_abvcbio.htm">Consent of Simon &amp; Edward, LLP (Filed herewith)</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020038891/ea130363ex99-1_american.htm"><span style="font-size: 10pt">Charter
    of the Audit Committee (29) </span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">99.2</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020038891/ea130363ex99-2_american.htm"><span style="font-size: 10pt">Charter
    of the Compensation Committee (30) </span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">99.3</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020038891/ea130363ex99-3_american.htm"><span style="font-size: 10pt">Charter
    of the Nominating and Corporate Governance Committee (31) </span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Instance Document (Fiscal year ended December 31, 2024)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">107</span></td>
    <td>&#160;</td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390024012141/ea192587ex-fee_abvcbio.htm">Filing
        Fees Exhibit (45)</a></p></td></tr>
  </table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on February 16, 2016.</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 3.01 to the Company&#8217;s Form SB-2 filed on June 28, 2002</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="width: 96%; text-align: justify"><p style="margin: 0pt 0">Reserved.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed on March 28, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 3.4 to the Company&#8217;s Form S-1, filed on September 13, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K, filed on April 7, 2020</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 4.1 the Company&#8217;s Current Report on Form 8-K, filed on April 24, 2020</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.2 the Company&#8217;s Current Report on Form 8-K, filed on February 16, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K, filed on June 9, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 3.6 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2021. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K, filed on February 22, 2017.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on July 24, 2017.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K, filed on May 30, 2017.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on September 20, 2017.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed on September 20, 2017.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company&#8217;s Form S-1, filed on June 14, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on February 1, 2019.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed on February 1, 2019.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on April 14, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed April 14, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed April 24, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K, filed May 15, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 14.1 to the Company&#8217;s Amendment No.1 to Form S-1, filed on November 14, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K, filed May 15, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.6 to the Company&#8217;s Annual Report on Form 10-K, filed March 31, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on October 8, 2021. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Exhibit 10.17 to the Company&#8217;s Annual Report on Form 10-K, filed March 16, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29) </span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 99.1 to the Company&#8217;s Form S-1, filed on November 24, 2020. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Exhibit 99.2 to the Company&#8217;s Form S-1, filed on November 24, 2020. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Exhibit 99.3 to the Company&#8217;s Form S-1, filed on November 24, 2020. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32) </span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.22 to the Company&#8217;s Quarterly Report on Form 10-Q, filed on May 16, 2022. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to the Company&#8217;s Annual Report on Form 10-K, filed March 31, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K, filed May 12, 2022. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(35)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on June 21, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(36)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on June 21, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to the Company&#8217;s Current Report on Form 8-K, filed on February 24, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(38)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K, filed March 31, 2023.</span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(39)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Incorporated by reference to the
                                    Company&#8217;s Quarterly Report on Form 10-Q, filed on November 15, 2023.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(40)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to Exhibit 107 to the Company&#8217;s Form
    S-1, filed on June 1, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(41)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report on
    Form 8-K, filed on November 20, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(42)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report on
    Form 8-K, filed on June 23, 2023.</span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(43) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to the Company&#8217;s Current Report on Form 8-K, filed on January 17, 2024.</span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to the Company&#8217;s Current Report on Form 8-K, filed on June 23, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(45)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to the Company&#8217;s Form S-1, filed on February 9, 2024.</span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(46)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report on
    Form 8-K, filed on February 29, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(47)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report on
    Form 8-K, filed on February 29, 2024.</span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(48)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Form S-1, filed
    on March 22, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(49)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Annual Report on
    Form 10-K, filed on April 15, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(50)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report
    on Form 8-K, filed on February 29, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(51)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report
    on Form 8-K, filed on May 9, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(52)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report
    on Form 8-K, filed on May 23, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(53)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report
    on Form 8-K, filed on May 24, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(54)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report
    on Form 8-K, filed on June 24, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(55)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report
    on Form 8-K, filed on June 25, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(56)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s Current Report
    on Form 8-K, filed on January 6, 2025</span></td></tr>

<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(57)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Incorporated by reference to the Company&#8217;s
    Current Report on Form 8-K, filed on April 30, 2025</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 17. <i>Undertakings</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The undersigned Registrant
hereby undertakes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) To file, during any
period in which offers or sales are being made, a post-effective amendment to this registration statement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) To include any prospectus
required by section 10(a)(3) of the Securities Act of 1933;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) To reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table
in the effective registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to
such information in the registration statement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) That, for the purpose
of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) That, for the purpose
of determining liability under the Securities Act of 1933 to any purchaser:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) If the Registrant is
relying on Rule 430B (&#167;230.430B of this chapter):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(A) Each prospectus filed
by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus
was deemed part of and included in the registration statement; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt"></p><div>

</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(B) Each prospectus required
to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an
offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of
the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such
form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described
in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an Underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement
to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement
or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of
the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such effective date; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) If the Registrant is
subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other
than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part
of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser
with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(5) That, for the purpose
of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities,
the undersigned Registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) Any preliminary prospectus
or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Any free writing prospectus
relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) The portion of any
other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities
provided by or on behalf of the undersigned registrant; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The undersigned Registrant
hereby undertakes to provide to the Underwriters at the closing specified in the underwriting agreement certificates in such denominations
and registered in such names as required by the Underwriters to permit prompt delivery to each purchaser.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 63pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, and controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director,
officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director,
officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Pursuant to the requirements of the Securities
Act of 1933, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto
duly authorized in the City of Taipei and City of Hong Kong, on May 16, 2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BioPharma, Inc.</b></span></td></tr>
  <tr>
    <td style="width: 60%; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="width: 5%; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="width: 35%; text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Uttam Patil</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uttam
    Patil</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BioPharma, Inc.</b></span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Uttam Patil</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uttam
    Patil</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 40%"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 40%"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 18%"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Uttam Patil</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">President and Chief Executive Officer</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Uttam Patil</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Uttam Patil</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Interim Chief Financial Officer</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Uttam Patil</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Eugene Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chairman of the Board of Directors</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Eugene Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Yen-Hsin Chou</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Yen-Hsin Chou</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Hsin-Hui Miao</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Hsin-Hui Miao</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Tsang-Ming Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Tsang-Ming Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Shuling Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Shuling Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Norimi Sakamoto</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Norimi Sakamoto</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Tsung-Shann Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Tsung-Shann Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Chang-Jen Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Chang-Jen Jiang</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Yoshinobu Odaira</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Yoshinobu Odaira</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Che-Wei Hsu</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Che-Wei Hsu </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Yu-Min (Francis) Chung</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Yu-Min (Francis) Chung </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-11</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>







































































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">POS AM</ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-1" name="us-gaap:AccountsReceivableNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-4" name="us-gaap:TaxesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-5" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-6" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-7" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-8" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-9" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-10" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-11" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-12" name="abvc:StockSubscriptionReceivedInAdvance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-13" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-14" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-15" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-16" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-17" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-18" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-19" name="abvc:WriteOffUnclaimedAccruedLiabilites" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-20" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-21" name="us-gaap:CostOfRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-22" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-23" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-24" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-25" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-26" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-27" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-28" name="us-gaap:IncreaseDecreaseInSecurityDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-29" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-30" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-32" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-33" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-34" name="us-gaap:RepaymentsOfConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-35" name="abvc:RepurchaseOfTreasuryStocks" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-36" name="abvc:ProceedsFromIssuanceOfAPromissoryNote" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-37" name="us-gaap:ProceedsFromStockPlans" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-38" name="abvc:ProceedsFromSubsidiarysShareholderContribution" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-39" name="abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-40" name="abvc:IssuanceOfSubsidiarysCommonStockForConsultingServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-41" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-42" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-43" name="us-gaap:IncreaseDecreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-44" name="us-gaap:IncreaseDecreaseInSecurityDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-45" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-46" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-47" name="us-gaap:ProceedsFromShortTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-48" name="us-gaap:RepaymentsOfShortTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-49" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-50" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-51" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-53" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-54" name="us-gaap:FairValueOfAssetsAcquired" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-55" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-56" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-57" name="abvc:PriorPeriodAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-58" name="abvc:PriorPeriodAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-59" name="abvc:PriorPeriodAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-60" name="abvc:PriorPeriodAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-61" name="abvc:PriorPeriodAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-62" name="abvc:PriorPeriodAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-63" name="abvc:PriorPeriodAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-64" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-65" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-66" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-67" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-68" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-69" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-70" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-71" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-72" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-73" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-74" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-75" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-76" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-77" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-78" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-79" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-80" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-81" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-82" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-83" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-84" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-85" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-86" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-87" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-88" name="abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-89" name="abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-90" name="abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-91" name="abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-92" name="abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-93" name="abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-94" name="abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-95" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-96" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-97" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-98" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-99" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-100" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-101" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-102" name="abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-103" name="abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-104" name="abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-105" name="abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-106" name="abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-107" name="abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-108" name="abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-109" name="abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-110" name="abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-111" name="abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-112" name="abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-113" name="abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-114" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-115" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-116" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-117" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-118" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-119" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-120" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-121" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-122" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-123" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-124" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-125" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-126" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-127" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-128" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-129" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-130" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-131" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-132" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-133" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-134" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-135" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-136" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-137" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-138" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-139" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-140" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-141" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-142" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-143" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-144" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-145" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-146" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-147" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-148" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-149" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-150" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-151" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-152" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-153" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-154" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-155" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-156" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-157" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-158" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-159" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-160" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-161" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-162" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-163" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-164" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-165" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-166" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-167" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-168" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-169" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-170" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-171" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-172" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-173" name="abvc:StockSubscriptionReceived" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-174" name="abvc:StockSubscriptionReceived" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-175" name="abvc:StockSubscriptionReceived" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-176" name="abvc:StockSubscriptionReceived" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-177" name="abvc:StockSubscriptionReceived" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-178" name="abvc:StockSubscriptionReceived" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-179" name="abvc:StockSubscriptionReceived" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-180" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-181" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-182" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-183" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-184" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-185" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-186" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-187" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-188" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-189" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-190" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-191" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-192" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-193" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-194" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-195" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-196" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-197" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-198" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-199" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-200" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-201" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-202" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-203" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-204" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-205" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-206" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-207" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-208" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-209" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-210" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-211" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-212" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-213" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-214" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-215" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-216" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-217" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-218" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-219" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-220" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-221" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-222" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-223" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-224" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-225" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-226" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-227" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-228" name="abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-229" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-230" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-231" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-232" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-233" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-234" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-235" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-236" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-237" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-238" name="abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-239" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-240" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-241" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-242" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-243" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-244" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-245" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-246" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-247" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-248" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-249" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-250" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-251" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-252" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-253" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-254" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c69" id="hidden-fact-255" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-256" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-257" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c106" id="hidden-fact-258" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c106" id="hidden-fact-259" name="abvc:ProceedsFromSubsidiarysCommonStockSubscription" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c106" decimals="0" id="hidden-fact-260" name="abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" unitRef="usd">2125</ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-261" name="abvc:PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c106" id="hidden-fact-262" name="abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-263" name="abvc:WriteOffUnclaimedAccruedLiabilites" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c126" decimals="0" id="hidden-fact-264" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="twd">31649000</ix:nonFraction>
<ix:nonFraction contextRef="c127" decimals="-6" id="hidden-fact-265" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd">50000000</ix:nonFraction>
<ix:nonFraction contextRef="c129" decimals="-6" id="hidden-fact-266" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd">50000000</ix:nonFraction>
<ix:nonFraction contextRef="c148" decimals="0" id="hidden-fact-267" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" unitRef="shares">42857</ix:nonFraction>
<ix:nonFraction contextRef="c199" id="hidden-fact-268" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-269" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-270" name="us-gaap:DebtSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c220" id="hidden-fact-271" name="us-gaap:DebtSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c225" id="hidden-fact-272" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c226" id="hidden-fact-273" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c227" id="hidden-fact-274" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c228" id="hidden-fact-275" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c229" id="hidden-fact-276" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c230" id="hidden-fact-277" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_5_footnote" xml:lang="en-US">BioFirst Corporation (the &#8220;BioFirst&#8221;):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $1,124,842.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Long-Term Investment-->
<ix:footnote id="ix_6_footnote" xml:lang="en-US">Rgene Corporation (the &#8220;Rgene&#8221;)
Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Long-Term Investment-->
<ix:footnote id="ix_7_footnote" xml:lang="en-US">BioLite Japan K.K. (BioLite JP)
In October 2021, the Company, Lucidaim Co., Ltd., a Japanese corporation (&#8220;Lucidaim,&#8221; together with the Company, the &#8220;Shareholders&#8221;), and BioLite Japan K.K., a Japanese corporation (&#8220;BioLite JP&#8221;) entered into a Joint Venture Agreement. BioLite JP is a private limited company incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with 3,049 ordinary shares issued and outstanding (the &#8220;Ordinary Shares&#8221;). Pursuant to the Agreement and the related share transfer agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000 towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed. This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#8217;s business and financial conditions and determined to fully impair such prepayment.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Long-Term Investment-->
<ix:footnote id="ix_8_footnote" xml:lang="en-US">ForSeeCon Eye Corporation (FEYE)
FEYE is a private company registered in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus. The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Long-Term Investment-->
<ix:footnote id="ix_9_footnote" xml:lang="en-US">OncoX BioPharma, Inc. (OncoX)
OncoX is a private company registered in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain licensed products in exchange of OncoX&#8217;s ownership. See Note 4 for detail of such transactions.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Long-Term Investment-->
<ix:nonFraction contextRef="c237" id="hidden-fact-278" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c238" id="hidden-fact-279" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c237" id="hidden-fact-280" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c238" id="hidden-fact-281" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c237" id="hidden-fact-282" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c238" id="hidden-fact-283" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c302" id="hidden-fact-284" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c345" id="hidden-fact-285" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c347" id="hidden-fact-286" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c348" id="hidden-fact-287" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c352" id="hidden-fact-288" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c353" id="hidden-fact-289" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c233" id="hidden-fact-290" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-291" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c356" id="hidden-fact-292" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c360" id="hidden-fact-293" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-294" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-295" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-296" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-297" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-298" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-299" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-300" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-301" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-302" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-303" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-304" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-305" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-306" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c7" id="hidden-fact-307" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c7" id="hidden-fact-308" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c248" id="hidden-fact-309" name="us-gaap:DebtInstrumentTerm">P400000Y</ix:nonNumeric>
<ix:nonFraction contextRef="c390" decimals="0" id="hidden-fact-310" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="shares">20000</ix:nonFraction>
<ix:nonFraction contextRef="c391" decimals="0" id="hidden-fact-311" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="shares">20000</ix:nonFraction>
<ix:nonFraction contextRef="c427" id="hidden-fact-312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-313" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-314" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c7" id="hidden-fact-315" name="abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c7" id="hidden-fact-316" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-318" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c7" id="hidden-fact-319" name="abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c7" id="hidden-fact-320" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-321" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-322" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-323" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-324" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c433" id="hidden-fact-325" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c433" id="hidden-fact-326" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c433" id="hidden-fact-327" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c453" id="hidden-fact-328" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c461" id="hidden-fact-329" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c459" id="hidden-fact-330" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-331" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-332" name="us-gaap:CostOfRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-333" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c466" id="hidden-fact-334" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c467" id="hidden-fact-335" name="abvc:WriteOffUnclaimedAccruedLiabilites" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c470" decimals="0" id="hidden-fact-336" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="twd">31649000</ix:nonFraction>
<ix:nonFraction contextRef="c127" decimals="-6" id="hidden-fact-337" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="twd">50000000000000</ix:nonFraction>
<ix:nonFraction contextRef="c472" decimals="-6" id="hidden-fact-338" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="twd">50000000000000</ix:nonFraction>
<ix:nonFraction contextRef="c148" decimals="0" id="hidden-fact-339" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" unitRef="shares">42857</ix:nonFraction>
<ix:nonFraction contextRef="c474" decimals="0" id="hidden-fact-340" name="us-gaap:SharesIssuedPricePerShare" unitRef="usdPershares">50</ix:nonFraction>
<ix:nonFraction contextRef="c527" id="hidden-fact-341" name="us-gaap:DebtSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-342" name="us-gaap:DebtSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c225" id="hidden-fact-343" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c531" id="hidden-fact-344" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c227" id="hidden-fact-345" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c532" id="hidden-fact-346" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c229" id="hidden-fact-347" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_21_footnote" xml:lang="en-US">BioFirst Corporation (the &#8220;BioFirst&#8221;):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2025 and December 31, 2024, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term investments in Biofirst is both $1,124,842.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Long-Term Investment-->
<ix:footnote id="ix_22_footnote" xml:lang="en-US">Rgene Corporation (the &#8220;Rgene&#8221;)
As described in Note 4, the Company acquired 26.65% of Rgene&#8217;s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting this equity investment with equity method as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company owns 37% of outstanding shares of Rgene.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Long-Term Investment-->
<ix:nonFraction contextRef="c11" id="hidden-fact-348" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c593" id="hidden-fact-349" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c233" id="hidden-fact-350" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-351" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-352" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-353" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-354" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c606" id="hidden-fact-355" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="0" id="hidden-fact-356" name="us-gaap:DepositLiabilitiesAccruedInterest" unitRef="usd">0</ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-357" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-358" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-359" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-360" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c640" id="hidden-fact-361" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c640" id="hidden-fact-362" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c640" id="hidden-fact-363" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c640" id="hidden-fact-364" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c640" id="hidden-fact-365" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c640" id="hidden-fact-366" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c642" id="hidden-fact-367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-368" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-369" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-370" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-371" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-372" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-373" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-374" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-375" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-376" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-377" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-378" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-379" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-380" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-381" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-48862">0001173313</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-48863">true</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="abvc-20250331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact ix_4_fact ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_10_fact ix_11_fact ix_12_fact ix_13_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_14_fact ix_15_fact ix_16_fact ix_17_fact ix_18_fact ix_19_fact ix_20_fact ix_21_fact ix_22_fact ix_23_fact hidden-fact-88 hidden-fact-95 ix_24_fact ix_25_fact hidden-fact-114 hidden-fact-120 hidden-fact-127 ix_26_fact ix_27_fact ix_28_fact ix_29_fact hidden-fact-141 ix_30_fact ix_31_fact ix_32_fact ix_33_fact ix_34_fact ix_35_fact hidden-fact-166 hidden-fact-173 hidden-fact-180 hidden-fact-186 hidden-fact-197 hidden-fact-203 ix_36_fact ix_37_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-258 ix_38_fact ix_39_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_40_fact ix_41_fact ix_42_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_43_fact ix_44_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-272 hidden-fact-273" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-274 hidden-fact-275 hidden-fact-344 hidden-fact-345" toRefs="ix_7_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-270 hidden-fact-271 hidden-fact-341 hidden-fact-342" toRefs="ix_8_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-276 hidden-fact-277 hidden-fact-346 hidden-fact-347" toRefs="ix_9_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_45_fact ix_46_fact" toRefs="ix_10_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_47_fact ix_48_fact" toRefs="ix_11_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_49_fact ix_50_fact" toRefs="ix_12_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_51_fact ix_52_fact" toRefs="ix_13_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_53_fact hidden-fact-293" toRefs="ix_14_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_54_fact ix_55_fact" toRefs="ix_15_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_56_fact ix_57_fact" toRefs="ix_16_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_58_fact ix_59_fact" toRefs="ix_17_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_60_fact" toRefs="ix_18_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-330 ix_61_fact ix_62_fact" toRefs="ix_19_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_63_fact ix_64_fact ix_65_fact" toRefs="ix_20_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_66_fact ix_67_fact" toRefs="ix_21_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_68_fact hidden-fact-343" toRefs="ix_22_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_69_fact ix_70_fact" toRefs="ix_23_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_71_fact ix_72_fact" toRefs="ix_24_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_73_fact ix_74_fact" toRefs="ix_25_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_75_fact ix_76_fact" toRefs="ix_26_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_77_fact ix_78_fact" toRefs="ix_27_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_79_fact ix_80_fact" toRefs="ix_28_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_81_fact ix_82_fact" toRefs="ix_29_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_83_fact hidden-fact-355" toRefs="ix_30_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_84_fact ix_85_fact" toRefs="ix_31_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_86_fact" toRefs="ix_32_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteBVIIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ShulingJiangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ABVCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ABVCAndBioLiteTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ZhongHuiLianHeJiTuanLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abvc:PostSplitMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2019-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">abvc:TaiwanCentralDepositInsuranceCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">abvc:USFederalDepositInsuranceCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abvc:ClientMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abvc:ClientMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abvc:TwoClientMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abvc:ClientMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:PostretirementAndPostemploymentBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-12-31</xbrli:startDate>
    <xbrli:endDate>2015-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-08-31</xbrli:startDate>
    <xbrli:endDate>2016-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-01-01</xbrli:startDate>
    <xbrli:endDate>2015-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2015-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-12-31</xbrli:startDate>
    <xbrli:endDate>2015-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2015-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-08-15</xbrli:startDate>
    <xbrli:endDate>2017-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-12-24</xbrli:startDate>
    <xbrli:endDate>2018-12-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneCorporationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-10</xbrli:startDate>
    <xbrli:endDate>2022-06-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneStudiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-09-30</xbrli:startDate>
    <xbrli:endDate>2018-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-09-25</xbrli:startDate>
    <xbrli:endDate>2017-09-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-31</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-06-30</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-05</xbrli:startDate>
    <xbrli:endDate>2019-08-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-25</xbrli:startDate>
    <xbrli:endDate>2024-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:CollaborativeAgreementWithForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-25</xbrli:startDate>
    <xbrli:endDate>2024-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:CollaborativeAgreementWithForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:CollaborativeAgreementWithForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-18</xbrli:startDate>
    <xbrli:endDate>2024-06-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-18</xbrli:startDate>
    <xbrli:endDate>2024-06-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-16</xbrli:startDate>
    <xbrli:endDate>2024-04-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-08</xbrli:startDate>
    <xbrli:endDate>2024-05-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-14</xbrli:startDate>
    <xbrli:endDate>2024-05-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-23</xbrli:startDate>
    <xbrli:endDate>2024-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-01</xbrli:startDate>
    <xbrli:endDate>2024-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:LucidaimCoLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanKKBioLiteJPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanKKBioLiteJPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LindGlobalFundIILPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-23</xbrli:startDate>
    <xbrli:endDate>2023-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:WarrantDebtDiscountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-23</xbrli:startDate>
    <xbrli:endDate>2023-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-12</xbrli:startDate>
    <xbrli:endDate>2023-09-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-31</xbrli:startDate>
    <xbrli:endDate>2023-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-22</xbrli:startDate>
    <xbrli:endDate>2024-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:SecondLindNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-17</xbrli:startDate>
    <xbrli:endDate>2023-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-17</xbrli:startDate>
    <xbrli:endDate>2023-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-17</xbrli:startDate>
    <xbrli:endDate>2023-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:WarrantDebtDiscountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-17</xbrli:startDate>
    <xbrli:endDate>2023-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-17</xbrli:startDate>
    <xbrli:endDate>2024-01-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-17</xbrli:startDate>
    <xbrli:endDate>2024-01-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:WarrantDebtDiscountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-17</xbrli:startDate>
    <xbrli:endDate>2024-01-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-22</xbrli:startDate>
    <xbrli:endDate>2024-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-19</xbrli:startDate>
    <xbrli:endDate>2024-11-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-19</xbrli:startDate>
    <xbrli:endDate>2024-11-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-19</xbrli:startDate>
    <xbrli:endDate>2024-11-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:FirstLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:FirstLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-06-12</xbrli:startDate>
    <xbrli:endDate>2017-06-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-06-19</xbrli:startDate>
    <xbrli:endDate>2017-06-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-02-28</xbrli:startDate>
    <xbrli:endDate>2018-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:CTBCLoanAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-21</xbrli:startDate>
    <xbrli:endDate>2024-03-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:FEYEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-16</xbrli:startDate>
    <xbrli:endDate>2022-06-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNpoXXXMi0ISiQMYRhfARCZqodsmYe5mpcuap9v90/VTIewyY3i091+2fVbljGWA+oIMmRhsCng8ZWIeu6RFmHqDuVsiXSHIAQzP/FPyRsu9wu9TXs5L6z+Vj4GR0/VqMj6bP7RRDRffTIrCvruey21RYJVvSYvm8JzoyEd3sAAsHQvXn9Y7S1Ved6CWb7JQpLhY=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-16</xbrli:startDate>
    <xbrli:endDate>2022-06-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-07</xbrli:startDate>
    <xbrli:endDate>2021-09-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationtheBioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmInctheGenePharmMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationBHKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AiBtlHoldingBioPharmaIncAiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JaimesVargasRussmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionArtsPromotionIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:OncoXMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:OncoXMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:FEYEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:FEYEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c353">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c354">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c355">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c356">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c357">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c358">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c359">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c360">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c361">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c362">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c363">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ShareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c364">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ShareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c365">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c366">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c367">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:EuroAsiaInvestmentFinanceCorpLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c368">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c369">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c370">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:ConsultantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c371">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-27</xbrli:startDate>
    <xbrli:endDate>2023-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c372">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c373">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c374">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c375">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-27</xbrli:startDate>
    <xbrli:endDate>2023-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c376">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c377">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c378">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c379">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c380">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c381">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ChiefStrategicOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c382">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c383">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c384">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c385">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c386">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c387">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c388">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c389">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c390">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-10</xbrli:startDate>
    <xbrli:endDate>2024-05-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c391">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-15</xbrli:startDate>
    <xbrli:endDate>2024-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c392">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-11</xbrli:startDate>
    <xbrli:endDate>2024-04-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c393">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c394">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c395">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ABVCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c396">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteBVIIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c397">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c398">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c399">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-30</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c400">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c401">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c402">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ShulingJiangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c403">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindGlobalFundIILPLindMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-23</xbrli:startDate>
    <xbrli:endDate>2023-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c404">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c405">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-23</xbrli:startDate>
    <xbrli:endDate>2023-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c406">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c407">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-22</xbrli:startDate>
    <xbrli:endDate>2024-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c408">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c409">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c410">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:PreExistingWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-22</xbrli:startDate>
    <xbrli:endDate>2024-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c411">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindGlobalFundIILPLindMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-22</xbrli:startDate>
    <xbrli:endDate>2024-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c412">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-28</xbrli:startDate>
    <xbrli:endDate>2023-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c413">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-30</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c414">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c415">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:NewWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c416">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c417">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c418">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindGlobalFundIILPLindMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c419">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindGlobalFundIILPLindMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c420">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c421">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c422">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c423">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c424">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c425">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c426">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c427">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c428">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c429">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">abvc:CashPaidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c430">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">abvc:CashPaidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c431">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-12</xbrli:startDate>
    <xbrli:endDate>2023-11-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c432">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c433">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c434">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:DecemberLetterAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c435">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:DecemberLetterAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-05</xbrli:startDate>
    <xbrli:endDate>2025-01-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c436">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLindNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c437">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c438">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-30</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c439">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c440">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-30</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c441">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c442">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:BioLiteBVIIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c443">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c444">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ShulingJiangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c445">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ABVCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c446">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ABVCAndBioLiteTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c447">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c448">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c449">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c450">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c451">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c452">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c453">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c454">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c455">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">abvc:AsRestatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c456">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c457">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c458">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">abvc:AsRestatedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c459">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c460">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c461">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">abvc:AsRestatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c462">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">abvc:TaiwanCentralDepositInsuranceCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c463">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">abvc:USFederalDepositInsuranceCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c464">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c465">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c466">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c467">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c468">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c469">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-01-31</xbrli:startDate>
    <xbrli:endDate>2015-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c470">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-08-01</xbrli:startDate>
    <xbrli:endDate>2016-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c471">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-01-31</xbrli:startDate>
    <xbrli:endDate>2015-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c472">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-01-01</xbrli:startDate>
    <xbrli:endDate>2015-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c473">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c474">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c475">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c476">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c477">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c478">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneStudiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c479">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c480">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:CollaborativeAgreementWithForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c481">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c482">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c483">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c484">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c485">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c486">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c487">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c488">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c489">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c490">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c491">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c492">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c493">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c494">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c495">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c496">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c497">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c498">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c499">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:LucidaimCoLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c500">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-31</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c501">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c502">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-31</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c503">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c504">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c505">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c506">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c507">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c508">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c509">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c510">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c511">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c512">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c513">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c514">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c515">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c516">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c517">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c518">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c519">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c520">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c521">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c522">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c523">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c524">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c525">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c526">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c527">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c528">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c529">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c530">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c531">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanKKBioLiteJPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c532">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c533">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c534">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c535">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c536">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-03</xbrli:startDate>
    <xbrli:endDate>2025-03-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c537">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c538">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-09</xbrli:startDate>
    <xbrli:endDate>2025-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c539">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-19</xbrli:startDate>
    <xbrli:endDate>2024-11-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c540">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-09</xbrli:startDate>
    <xbrli:endDate>2025-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c541">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LindNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c542">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LindNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c543">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c544">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-05</xbrli:startDate>
    <xbrli:endDate>2024-11-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c545">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-05</xbrli:startDate>
    <xbrli:endDate>2024-11-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c546">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c547">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c548">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c549">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c550">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c551">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c552">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c553">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c554">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c555">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c556">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c557">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c558">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c559">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c560">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c561">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c562">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:CTBCLoanAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c563">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c564">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c565">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualThirdPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c566">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualThirdPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c567">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c568">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c569">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c570">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c571">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ConversionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c572">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ConversionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-16</xbrli:startDate>
    <xbrli:endDate>2022-06-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c573">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c574">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c575">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c576">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c577">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c578">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JiangsAdvancedFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c579">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JiangsAdvancedFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c580">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JiangsAdvancedFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c581">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JiangsAdvancedFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c582">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c583">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationtheBioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c584">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c585">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c586">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenePharmInctheGenePharmMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c587">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c588">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c589">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationBHKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c590">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingBioPharmaIncAiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c591">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JaimesVargasRussmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c592">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LionArtsPromotionIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c593">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c594">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c595">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c596">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c597">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c598">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c599">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c600">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c601">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c602">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c603">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ShareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c604">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ShareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c605">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LionArtPromotionIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c606">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LionArtPromotionIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c607">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c608">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c609">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:EuroAsiaInvestmentFinanceCorpLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c610">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c611">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c612">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c613">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c614">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c615">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-14</xbrli:startDate>
    <xbrli:endDate>2024-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c616">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-03</xbrli:startDate>
    <xbrli:endDate>2024-09-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c617">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-29</xbrli:startDate>
    <xbrli:endDate>2024-10-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c618">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-13</xbrli:startDate>
    <xbrli:endDate>2024-11-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c619">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-26</xbrli:startDate>
    <xbrli:endDate>2024-12-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c620">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c621">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-01</xbrli:startDate>
    <xbrli:endDate>2025-03-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c622">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-01</xbrli:startDate>
    <xbrli:endDate>2025-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c623">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c624">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c625">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ShulingJiangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c626">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:LindOfferingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c627">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-03</xbrli:startDate>
    <xbrli:endDate>2025-03-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c628">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c629">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c630">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-03</xbrli:startDate>
    <xbrli:endDate>2025-03-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c631">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c632">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c633">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ThirdLetterAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-05</xbrli:startDate>
    <xbrli:endDate>2025-01-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c634">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-05</xbrli:startDate>
    <xbrli:endDate>2025-01-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c635">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-05</xbrli:startDate>
    <xbrli:endDate>2025-01-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c636">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c637">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:ExistingWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-05</xbrli:startDate>
    <xbrli:endDate>2025-01-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c638">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c639">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-31</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c640">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c641">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c642">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c643">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c644">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c645">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c646">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c647">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredRestrictedSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c648">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredRestrictedSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c649">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:AdvisorsOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c650">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:AdvisorsTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c651">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:AdvisorsOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c652">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:AdvisorsTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c653">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c654">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="twd">
  <xbrli:measure>iso4217:TWD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>2
<FILENAME>ea024194101ex23-2_abvcbio.htm
<DESCRIPTION>CONSENT OF SIMON & EDWARD, LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0; text-align: right; text-indent: 0in"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0; text-align: center; text-indent: 0in">&nbsp;&nbsp;<IMG SRC="ex23-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">CONSENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">ABVC BioPharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We hereby consent to the
inclusion in this POST-EFFECTIVE AMENDMENT NO. 1 to Form S-1 of ABVC BioPharma, Inc. (the &ldquo;Company&rdquo;), to be filed on or about
May 16, 2025, of our report dated April 15, 2024, with respect to our audit of the Company&rsquo;s consolidated financial statements as
of December 31, 2024, and 2023 and for the years then ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><IMG SRC="ex23-2_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5pt">Rowland Heights, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5pt">May 15, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +C!/H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *3WZTM)UH /PYHYKGM4EF_M+RUF=%"Y^4U4WS_P#/U-^= '64
MM<ENG_Y^IOSHW3_\_4WYT =;17);I_\ GZF_.C=/_P _4WYT =;17);I_P#G
MZF_.C=/_ ,_4WYT =;17);I_^?J;\Z-T_P#S]3?G0!UM%<ENG_Y^IOSHW3_\
M_4WYT =;17);I_\ GZF_.C=/_P _4WYT =;17);I_P#GZF_.C=/_ ,_4WYT
M=;17);I_^?J;\Z-T_P#S]3?G0!UM%<ENG_Y^IOSHW3_\_4WYT =;17);I_\
MGZF_.C=/_P _4WYT =;17);I_P#GZF_.C=/_ ,_4WYT =;17);I_^?J;\Z-T
M_P#S]3?G0!UM%<ENG_Y^IOSHW3_\_4WYT =;17);I_\ GZF_.C=/_P _4WYT
M =;17);I_P#GZF_.C=/_ ,_4WYT =;17);I_^?J;\Z-T_P#S]3?G0!UM%<EN
MG_Y^IOSHW3_\_4WYT =;17);I_\ GZF_.C=/_P _4WYT =;17);I_P#GZF_.
MC=/_ ,_4WYT =;17);I_^?J;\Z-T_P#S]3?G0!UM%<ENG_Y^IOSHW3_\_4WY
MT =9S1S7)[Y_^?J;\Z"\^#BZF_.@#J_6E P:SM&=I=/#.Q9MQY-:0H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2.M:7*C!.&_I0 [-&:;[G!'KFC)(;^'C)8] * '9HS6$_C3PQ%(R/K,"NO#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4.56LCP+X2OO$*ZQ/;ZW/IR)<,"D9Z\U?M[74?A9XQM#<S?;K;4R$$[C,@H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA>']3EUFP\3Z"GGWUB<O#W<5'#XS\6:W=6UM8>'FLV+#[5-*/E4=\5Z "1@
ME>P8=<>]'F-S[\=,9H Y;5M4\16OC'3["SL_-TEU'GS <*>YKJB?F&!@4@SD
M#CIR3023UH 7O1311F@#HM _Y!H_WC6H*RO#_P#R#!_O&M44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBN=\1>*O^$?U2PL_[/FNA=MM+QCA/K70MD8X[ F@!<T9I >_\/;ZT@.3R,4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*L?^?9/RH XO>O\ >6C>OJM=I_95C_S[)^5']E6/_/LGY4 <670\,5QZTKL
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M7:?V58_\^R?E1_95C_S[)^5 '%[U_O+1O7U6NT_LJQ_Y]D_*C^RK'_GV3\J
M.+WK_>6@R+@DLM=I_95C_P ^R?E1_95C_P ^R?E0!4\.E3I2X)^\36O44<"0
MQB.)0J#L*E P* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KQSX1_\ (^^-?^OK^M>QUXY\(_\ D??&O_7U_6@#V.BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA7_Y-_A1_P +B\3?]"%?_DW^% 'LE%>-_P#"XO$W_0A7_P"3?X4?\+B\3?\
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MO\*/^%Q>)O\ H0K_ /)O\* /9**\;_X7%XF_Z$*__)O\*/\ A<7B;_H0K_\
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MO&_^%Q>)O^A"O_R;_"C_ (7%XF_Z$*__ ";_  H ]DHKQO\ X7%XF_Z$*_\
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M^=:WP]_Y$/1_^O=: .G'2BD'2EH **** "BBB@ HHHH **** "BBB@ HHHH
M***0D#J: %HHS10 449I">GO0 M%-WJ&VEAN],\TI95&6('UH 6B@'(R** "
MBBB@ K \;';X*U@C_GV?^5;]<_XW_P"1)UC_ *]G_E0!S7P2 'PSL<?WV_G7
MHM>=_!/_ ))G8_[S?SKT2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]: /5DZT^F@<G%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI.XI:0]: /'+S_DY:T_Z\?Z5[)7C=V0?VE;4Y&!8^OM7L6\<X[4 .HI <TM
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MQQGB@#G/@G_R3.Q_WF_G7HE>=?!1T_X5M8H'4N&;*YY'->BT %%%% !1110
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MMP9(B/J*!/"/^6J?7=7$>1'ZO^='D1^K_G1]7\P]MY':B>+C]_'P<\$4[SX
M<B6,'UR.:XCR(_\ ;_.CR(_5_P Z/8>8>V\CN!<09.)H_?YJ=]HA_P">J?\
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M9)EF;Y$'H!ZT<PN4Z3N1GD=?I2'*_>/OP>U<O'XZCN;P)::3=7%CYGEFZ5.
MW]14^I^*GTVX:*WTFYO @WO(B\!:.8.4Z'W)X[4?GD=17.W?C33K30[36=KR
MVUS)Y0C Y5O2DT[QA!>ZLFFW-A<6,KC? \HP)!1S!RG2 $^H^O%*%W$[9%;'
MHW-9GB*1X_#6I2+E76$[6!Z&O+HVTVW\*:=J%AK<[>(6<?N#,2&.>014RE8J
M,+GL61MSDYZ 4XA0=S$8''7O[5SNM>+8?#HL(;VWDENKJ(-MB&26QTJGJFJV
MM];:/<ZG:W=J\MQMC@4E6!]6I\V@N74ZX@CC(R.6]A2 ?*"3UZ#OCUKD?"D\
M]EXJUG0[N620[_M$)D.25/:HK&>36/$^O:DT[BPM(3&B(V 3WHY@Y3LR,#[X
M;/3:<YH(P?F.!CK7&V'B33M&\-V9M(+BX:YD80PL<NQSS6A>ZJM]X2OKG4+&
MYLHHQAXL[9/P-/F%RG18/KGTP>U&"2%!);OZ"N:D\2V>C:5ID$$,MS-<(#%;
M@Y<CW-3Z'XIAUFXN+*6TEL;^)"[6\HP2OJ*.8.4WB,9Y/'?M2<]03BN0/Q"M
MW2<VNDW5PEJVV9E'RCU-=-87T&J:?#>VK9AF&:=QV+:]<UN>&"392_[YK"#9
M.1TZ5N>%_P#CQD_WS65?X"Z7Q&\****X#K%HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I:2EH :>]<
M-<?\A"[_ -^NY]:X6X_Y"%W_ +]=.'5[G/6&YI>XP<CN!UIE/CQY@).WMCUK
ML>B.;J1-/;(VR2YA!'\+. ?I3W=(E9FD1.F,GY0/K7DEO)X9;5?$AU^28SK*
MPAV,WR^E;MC<*GPP2XU3=?0"XQ%AL-LSQDU"F:.)WP96YW#!'![&CU //?;7
M/ZGXC31;?3K:UM6NKRZC!@MA_"/>F:?XHFO+RYTC5+%M/U#R6=,='&.U/F%R
MG1AE90497C'H>]()8VD*B96(^^%/S#ZBN7^')+^&"S,S'[2^=QSGFDM;R*/5
M_$9T^P/]H0QG.6)#'%+F%RG6%2I*L  >>#SBF]#@D >@K@_ &M:M<:7.^HVN
M;179WNG;D8_AJV_CJ[$9O8=(WZ0&VF?<-V/6GS+J-1.S^Z=V<J.U-5D8$QRK
M( <$ ]#3;2>&[BAGMW#PS)N4UY[X2\5Z7HM[K$6IW<GF->N I!( S3NA*)Z(
M&3.P2!B."%Y*_6E!SE0W X.>]<'X4U>SNO%'B?489V^PHBD,Q.!CK@58?QS?
MR6G]I0:'*VD1-CSOXF7N?I2YHCY#KYKNWMG0S2K&TAVQ*3]XU+C:V. <9R.<
M?6N,\3W$.H7'A>\@&8Y+A63G^=6[SQC<OJU[9:1I#WL-HI%Q*O8X[4.2Z#43
MH8;RSN(GD@NHWCC.'<'@-Z&I@R2*IWJ0_0@UYMX;N;8?#W6;BZ@=[=KDNT.<
M-G/2MZY\5C1_[)L+/3&N6NH \,8YV_6A2$XG6<D[1NR.Y'%''7=S7/Z)XF;4
M[JZL=3M&L+JU7S'C/0IZUCWGCW4(;674+/0FFTQ)/*$S?Q'U%',)1.XY(Y *
MCT-'!&2P"CDD\8JO9327-A;SRPB*:1 Y0'H#4>L\Z%J)Y'[AB"O8T[]0MJ6P
MZR*'1U=&Z%32YZ'AB?0]*X32/$/_  COPZTV]FB>Y#RE..23FM*R\6W;:S;V
M.IZ2]DE\N;=S_6BZ'RG4YYVDC/O1[$8QWKFM3\47<.L2Z5HVFM?S6ZYF;^%1
M[>];5A=S7MA'-/;FVF(RT;=5IW):+><\T \TE ZT" GYH?\ KJ*[R/\ U:_2
MN!/WH?\ KJ*[Z/\ U:_2N/$G10W''[IK@W/^FW/^_7>'[IK@9#B]NO9ZG#[E
M5MA<\"C--[45WVU.3H.S1U'OVI*0],'IG-);#.%U>SO[WXK0PZ;?&RN1;9:4
MC/&*CT43Z)K^O:)?RB[O[BV,_P!L7J0!T/I6_K'A2+5]:75QJ-Q:7839^Z'&
M*DTKPM::5'=E9I;JYND*2W4GWROH*RY-37FT.0FN[B+X;:9!'<.B7EV8IYP>
M0F?6M#Q)H-AX6CT?4M&=X[D3(G$F1*#US71)X9TU?#@T*56EM02RL>JD]ZJ6
M'@JSL[Z"ZN+VXOA;\PI,?E6CD%S'#:U9W<_BK5]0C0RV5K(DMW: _?7'-=1X
MVULS>$=-FT;FTO75 (SCC^[[5T=CHMK8:OJ.HJ6E;4!B9&'R@>@JA;^#M,@T
M^\T_=(UK=/Y@ASQ"WJOI1R#YCG;'0]7M=?T^XL=#:P@'%R_G;O,4CTIO]I/X
M6_X272#(6:8[[/>>27["NETSPJNFW27,FL7EYLX1)'.VLOQ)H_\ ;?Q!T@-;
M,(K8;YI<?*<=!1RV#FN=!X8L5TOP[:6[R;IV7?*C-EMQZU!XT_Y$C4^<_N^G
MH*BL=,O)O&EYK=WNB@5!'!#GC'KBM74["+5M*N-/G)6.<89EZXJ[:$7U.'UR
MV%]I7@^T:62)9@BR>6V"5QTJW<V$7A;QRB:5YB0S63.T;-N#,.]=#+X>M)AI
M2&9U_LW'E>K >M37&D6]SKL&KNS":%#$L?4,#ZU'*[CN<QX4\-Z;KNA_VQJ+
M2SWLDS,9?,QY>#TKME:.-4C\U0^/E1CR:Y@^!;-;UYK74+NU@=][6\9^7-:D
M^@V]UKMIJSS2I-;1[%C4_*P]35I WH:P(!P1@'I]:3G'/7O1DY!//.32<]^M
M58@=FC-)13Z#0R?_ %#_ $KNK+_CQ@_W!_*N$G/[AA[5W=G_ ,>4'^X/Y5R8
MGH;4-V6****Y#J"BBB@ KQSX1_\ (^^-?^OK^M>QUXY\(_\ D??&O_7U_6@#
MV.BBB@ J*Y_X]I?]P_RJ6HKG_CVE_P!P_P J%N)['"6F=L>.N[^M>>V&FZKJ
MGCOQ&NE:JVG84"3Y022?2N_MSMB4XSAC7.77@N*XUBYU2WU6ZLY[CB3RNC"O
M2E&Z..,CF;"X>V\(>)=%FXO+)]TERA_UF>^:OZJS7R^$M'GN&33KF -*V[:7
M([9]ZZ&#PGIMKHESI<1<BY.9IVY=_K4NH^&K#4])MM.G+A;4 03+PR$4N70?
M,8-_IEOX4\;Z2-'WPFY5DEMR^X,,=:Y+2XFT[56UJ\0SZ/#?,CQ]1$Y/WR*]
M&TGPK:Z7?F_ENI[V["[4DGYV#VJ;3_#FGZ=IMY8-NN+>]D+S+(.I-3RL.8YW
MQ[?7%WJFB6%HOVFSN_WAC5]HE]LU'HNA:I'XAG3^R?L&E7,)BEA,N[YNQ%;1
M\&V+:''IC7,Y\IR\,X/SP^P]JMZ+X?\ [)NOM#:C<WKD;096X4>M/D#F.(&K
M7$'A:?PSYK'4EO?LZ8//EYZYKT>"T_L_1A9QDEH;<C/J<5R-KHJZA\4KC4S;
M-';6T6 Y'$C^HKMU;+,6Y0_*33Y17/.M&1Y/A9K7E9$S2REL=ZZSP;+#<>#-
M.:T9-JQX9%;&UAUK.\)VT^F:CJ^CS0DVK2&:,D?*X;J*9+\/K+[1*UEJ=Y90
MR-N>&(_+SZ46"X_QA/ITUY86,UO+J-W(,Q6L3[0_N37-Z/IMQ>S>)=%>)[,+
M%YD< DW>4PYP#767W@ZRNX+-8;J>VN+/B*Z0_/CN#4^@^&;3P_>W%['/-<37
M _>M*<YI.+&FCDEU23Q19^&]&#GS?,S>!3@JJG'-78-"L]9^(6LQ7YEDM[>#
M:D*.0HXZU+X+T@1>)M<UM[=H/-EV0HP[>HKI+/1[>QUF[U6.1_/NEVO&>A%"
MC<&['"^'_#-E?:/KBWLTLHM'=;?,A_= #BK$6I6LG@32HM3\^ZE:0Q6\<9P9
M"/4UU]CHEKIMM?P1NS1WK,S@C[N:H2^#-/DT>VTU)YH_L[EX;A?OH:?(+F,/
MPI'/IWQ$FLC9MI\$EOO:V\S>"<?I47A[PW9:R/$-UJ+3R,DKB,B0@1^E=/I/
MA6VTG5CJ@O9[F[9-C-*<[AZU;TS1;?28[M(9&87CEGW=LTE%C<CE+6>2Y^$5
M^MS,9#!O0%N<@'CFNJ\/2*OA33'G=8OW0P6/7VK U[16T_PO#X?T]99$NKK+
M-CH"<G/M5SQ!HES?_P!C:7;9CM+8J\SJ>N.U.*U%)W1TES@VER<80PL>/I7E
M\>3\(-L<K1%KS!8'!QNKU&15>%XN@9-AQVXQ6 OA*Q7P[_8GFN;;SO.)/7=G
M-.2%%F#K&AVGAZ?PW>Z8TB74LJI,[2$[@>N:M-80^*/B)J=IJ0D>ULX5\FWW
M[>3U:NBU71;?6(K*.XD=19L'C*]21ZU4USPK::U?I?K<365XJ[#- <%U]ZEQ
M'<T]/L+/1[46=O((XMV<2/DGV!JV<\_I7/S^$[:YT^RLY;ZY/V27S5ES\SGT
M/M6^3D=,8%;+8ELZCPY_R!HOJ?YUKUD>&_\ D#1?4_SK7[UY4_B.R&P4&B@T
MBS,UW_D#3_2N3C_U2\XP*ZS7?^0-/]*Y%#F).,\5V8?9G+7=FCE_'LMS<:=:
MZ-:;A/J$@5I0.%%8GB/POKFFZ5:7LFK&[32F5D@1,':.N*]$V@G+*K,#P2/N
M_2E."2" 5]^<_6MW R4CD%G&H?$'1;Y(SMDLBY8C[A/:K6B*W_"Q==N/+*EH
M\"0KUXKHPJ9#;%5AT*KTI> S,%"NQY8#DTE$?,>7/IEUJ'A77X8XI 5OO,VX
MY9>^/6K%A;^&]5NM/MVU/4KBYC=66"0';&1_*O25(C)=(U7GD =::D4$;[HX
M80W=UC /YTN0?.<WH:LGQ(UF5XF7$2A9".WM52VMIKOQ7XHB"MF6UQ&2,!B?
M?UKLMFTDA0&;^/N:3Y ^X*N[.20.]5RBYCB?"/BFPTK1H-#OHKF&]BEV&()\
MK9/4FLW5=4EN-7U.VUF\N[&)%Q:PVZ?ZSZFO17BADE,KP0F0_P 109_.GNL<
MK*\D43LHPI9 2*3@',>76L$G_"$: OV=]XU')1EYVYZFNJ\5!Y/&'AUE1F4'
M#,!PM=+LBZ>2F!R.._K2D*<956QT8CD&FH!S%'Q,,^&=64;MQA.P8ZFO-HKK
MPW/X @LH]/=M?V8C9(\,LF>N:]8)/?#9[$9!J-;>W0%H[2 /UR$ .:4H7"$[
M'%M!=KKOA'^T8V:X6+][D9VMBM'QWYDESHK!7?\ TH9P.5Y[UT^ 7R0#WW$9
M(_&D.SABH=NP89Q[U7+H#EJ<9\0)KK1-4M/$=E$TLBJT$BH.N1@5I:!IITWP
M+.I4"XN8WGDSURW.*Z-ESQ(BN@'&\9!-(.<!CP?O<=JE0#G/.+;^R!X0TR+6
M!=0,)':*[A4[H6SQ5J'4=4U+X?ZS]N,LZ1G;;3%?GE7/7%=XT<+KL>")H_[I
M0$4H"",1A%"CL!QCZ4<@<QY^LPT'6]$UN[@DDLFLQ$TB+GRS[^AJ]97*^)O'
MSZM912_8+:U9#,ZX+'T]Z[)DC>/RGC1HQT4KQ^5*NU!MCC2)>XC&,T<@^<X_
MPDK)X5UX&,Y>24!2,$C!K0\"CR_!MLKAE.3\I&.];VU,$"-57.< 8S]:<OR@
M!0%4=% XJE$AR'9Z8X%;WA?_ (\9/]\USXZY/4UT'A;_ (\9/]\UEB/A+H_$
M;U%%'>N!G:+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 )2TE+0 WUK@[DXU"[_ZZ5WIZ&N"N_\ D)7G
M^_73AMV<]<9FEC90X)XY_.F4<$8[5VO4Y5H><Z3JUGHFMZ_'JVDSSF:=FCQ%
MNW ^],BTS48O NH%K618[F[$EK:M]Y$S7I8;G[J$GN5%-R<$GD@\YZ5'(:<Y
MQNL?:M(US1?$*VLMQ;16PBFC49:/CM21S3^+/%J:I;VT]M9V=NZ[Y1AF8CI7
M:!NJ@@_4<4A/R8( 7L%&*.0.<\]\'^*;;0]/?3KS3+WSOM#X(0XY/6MKP_%.
M?%&OR&-T2=/E9AU!%=2QYY5"3W"CI03N&?6CD$YG!>&)96T;5/"LMK/!>L7V
M2,/D(.<<UB:?I^C6NGKI6K:9JC7D;;&CC)V2G/7TQ7K!8XQ@?7'/YT!B0.%X
M[E1FDZ8*:(M.ACMK&W@C41P1QX$9^\OM7+>!;",2ZP;VQ0F6[8IYJ DKGWKK
M<]R:4DYYP..PZU;BK"YCA;+299M9\66L5O\ 9HYX0L1Q@$^U00>)9[;PB_AU
MM)NO[15# J%?D;T->@=P.-WKBE+$$D[-W<[>:GV:*YSA+K2;G3+'PK:&)Y)8
MI@TN.0A/:G:?J<W@_5]7L;O3[B;[5(9;>2$9#Y'0UW )7F,9'J: >. "/<9H
M]GV#G/.]-MKY?A[KBRVDD-S-/O$)'4$]JT[:"X7Q5X<D6!C%%:A7<C[IKLMQ
MSV_*DR1Q@4^47,<LR2I\0-7N9(V%N;'!D;[K>Q-<+87MXVD"UOYKE-$%R9#L
M7@8/;VKU^XACN;2:UE4&.5=K^PKED\#2) ;1-;G&FG_EC@=/2HE!LI31HZAX
MDM=-ATE;6,W"WV$BQR=OK6IJZ$Z+?*H/F- 0$'?BJT.AZ?;3VLT<9/V5/+A!
MZ+[UI'(8DD;L8]<FKC'2S);5SSG[-<GX<Z)!]E?S5O<M'CE1GK70^*DFEUSP
MRZH7C@E7>5&=O%=*3G@\?A29 XQD>XI^S0^8XH:@_@_Q;JLUY8W4]G?-YD4D
M(R<^E;,_BAD33I%TV9H]1?:Q(YC'O6[NP>5SZ9&<4 GD87!Z\4* G)#C\IP3
MDTFZF\#ITHJMB=Q<Y>'_ *ZBN_C_ -6OTKSX?ZV$?]-17H*?ZM?I7#B3HH#C
M]TUP$W%[=_\ 72N_/2N G_X_[O\ ZZ4L-N.ML-#4N:;17H=3EZ#LT9IM&:0-
MCLU#<7D%H\2RR;9)#M1?6I,USMWB[\?V%M("PAA9U Z9]:F3L4M3H9+B&"5$
MFGCBWG"*QY;VIV<J<9!!^Z:\\\4SV^JZU?3O=HCZ0H:!0<;VKM;74S>^'DU1
M0"S6V3CD;@*5RN4L3ZA9V]PL,MY'',?X<_SJ=<ODI@9[]FKEO"FFVM_H(OKJ
M$7,]P[-+(W4<\8IOB'5I-)C?R-25#;*"EJBEN/\ :-#:0K&_/JEE;SRP/*JS
M0KYDD8'0>U-N-;L;>*WEDG^6YYC 7YFKD+K4';7+C5 D8DDTY9-I&<^V*15O
M+WQ7H=RUVL8:UWM&%X7V J>9#2.^^8C<?F8C.[MB@9(^Z:Y)-2UC4;"^UBWN
M$BMK60J+?'WPO4_6FZ+K.J>(M<F2.=+>PA17QCYF)'(JN9!RG7X<@A1^%5UO
M[9[]K)"WGJN=I'%<B=7UR>QU'48[F..&QFP(\?ZQ<]ZO0:S+<:_,I\F*$V@E
M64C!!QT-',DA<IU#%QU!%(#7)Z3KLY\21Z:UY]M@GC+B0J1M/I75D;20"&7/
M7'0^E-.Y+5AV:,TVBJ =FC=3:* N-F/[IOI7>V?_ !Y0_P"X/Y5P$W^J:N_L
MO^/*'_<'\JY,3I8WH;LL4445QG4%%%% !7CGPC_Y'WQK_P!?7]:]CKQSX1_\
MC[XU_P"OK^M 'L=%%% !4-S_ ,>TO^X?Y5-4-S_Q[2_[A_E0MT*6QP$)_<CZ
MFI,U%"?W(^II^:]=;(\WJ.S1FFYHZ\9IZ#%SDU%/>V]K-%%-)B2;Y43U]ZDZ
M'\<5SSXN_B'!%)DK;VY(],U+T&MS?DFAAD2*65%FD^XI."_TI_("CH2> *\Y
M\1W,&H:O?:CY^)='PMNH;J<\UVZZAY_ATZG <L]L73'8X[U-RFBQ+J-G%,(9
M+B-95X* ]ZLXZ=U(SQTKF?"VE6EYH$%[<0"YNKDEY)2<D-GI5?7M9FTIW:VU
M.(&'"BU"$@CW/8T-I$[LZXELE2H!49!'>@*Q (!]Q7%Q>*KN'2[U+ID&H#:U
MNHZ$-T%3-?ZW=:Z^EQ7*6ZQV@F=F'._&<"ES(KE9UIR/X30 S$#!VGJ?2N(M
M]>UP:;9:O<R1%&N?LS1*.",XW5;\1ZW/IC27,6I)^[9<VJ*2&!]3VI\R#E9U
MA)=!E>AP-HZ^] ZAL99N /2N7?4-6U'76LK.>.WA6S\__:!QFM/PSJ=QJFDQ
MW%QL\]&,;!>_O0F-HTHYHY7=895D93AP.=M13W]M;2QP32[)9CB)3WK@(=1O
M-,O]46UWQV\EV1/<*-Q0>PK3U*87FJ^&Y6NH[O#MMFCXX]Z3D"B=J0PZJ:0!
MG.-O'K7(7_B&>QUF$IJ*74<L_E/"J'" ^])-J.MW,VL-!<Q11Z>0R+_?'H::
MDA.#.P4L<8&YCQTZ>]0VE[!=F06LA8(=K?6N>BU?4=8OK2QT^1+=GMS+/)CG
M..@]JQ-,O=0TO0;^6%-TK7FV>55SY:^H%*Z'RGH0X'0@MR<T9K,T2[-W8[VO
MH[P@_P"L08(]B/6M*M-R-A<T9I**+ +FD+=?I12'^E CJ_#7_(%B^I_G6QWK
M(\-?\@6+ZG^=:U>3/XCT(;"T&BDI%&;KO_(&G^E<=&?W2_2NRU[_ ) T_P!*
MXR/_ %:?2NW#;,Y*^Z)-U&:;1FNJQ@.S1FFYHS18.HX98%5^][>E8M[XO\/Z
M?=&VN-0CWKUVJ3@^^*?XFO9=/\,ZA=P$^<D6U3Z9JAX3T/3(/#-JSVL5Q/<I
MOFED7)<GWJ'<M)'0P3PW4$4T+AXIAE)%J0DC"E3D>O>N8US4KG3;VR\/:#&D
M=U<'.YAE85]:9I^IZSI7B>'1-<FANDNUS#<1<8([4<P^4ZO!Z[30 3T!KB=)
MU'Q1KVN7D%M/;PV=E<%&9A]]?2H[+4/%FO3ZG!8SVUO'9R$*SCEP.U','*=S
MGVYI>1]Y2!7%P^-I_P#A#VU!X5_M-9_LHCQP7SC-,N=0\4^'ELM1U26"YM)Y
M%26)!_J\T^<.0[?D_P )H7)<  UQ3ZIXCU7Q1?:7I<T$-O %D\QQDD'L*?K^
MI:U9R%UUBQLQ%'E(V&6D(ZYI.0E$Z^2:&&/,THB0MA2Q^\?2H+S4[733 MVY
MB:9MJ8&<FO.?$]]J/B'PKHFIPW"1*9PA0#'SY^]]*Z/6;K4]*M=&BO)(+JYF
MG"L^W@ ^E3SW&XG6X)_A&3SQZ4F><8YKE]3U/5]2\3RZ'H4D5N;5 ]Q-+T]@
M*HIXEU6QM-6L+_RVU&SC\V*91\KBFYBY#M\/CH<4F:X%];\56.CV7B"ZEMS:
MR,J/;!>0#WKO$<2QQRC@.@;\ZI2N)JP_-&:;1FJ)'9HS3<T4#T'!N:Z+PKS8
MR?[YKFQUKH_"G_(.<_[9K#$+W#2E\1O]Z.]%+WKSSM"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EI
M*6@!#T-<#=G_ (F5Y_OUWOK7 7?&I7?^_75AMV<U<CHI,T9KNL<MQR@,<'IW
MK)T;4Y=4N[^1SMM8'\M3ZXZUJ$%HY%'4H<5Q%A>O8^"]42++W;W#Q!%[$GJ:
MB1<37T;Q,=7UFYT]X!%'&Q^SN#_K0.M7/$VMR>'M&;4(;?SY-X01UR=Q::SH
MT&AWMQ:QK%;,$D,'WFW=S6_XT;?HMJ\2LZM<(VS&3@^M+4K0<?% _LO2[RVB
MWF_E$;@_P'O6O<:MIUO>"UFN@LQZ"N"U>TN-'\2Z99QH\EA=2K-'A>(VQ3S9
MRS3ZG97]XEM*\X92\>7(_P!DU*E('&)WL=[;2^?Y<RD0?ZW_ &:KOKNE1HC-
M=C:_W6 X_.N3U>*31[[[+"DICU:-8RP&2#ZG\*AUB=K>VO='2**VCMX0D>Z/
M<9O<>E5SLGDB=Q=7]E8[3=72H'&4QSNK+T/7EOM,NKN[E5(8YRL; 9W 5A:?
M)!::II\^K(S6C6(6,LFX!JKZ;J#Z?H+RPVBA9[Y@&D3B%<]<4<['R([NTOK7
M4(O-M)A,I;!(ZK]1VK.NM8NWU6;2](B26:!0TSOT'M63X-+#7-89G#QLRX=$
MV*WT%2V<PT/Q3JGV[,4%WAH9\<-CM038V_[0%K8^=JVRU8' V\[C["GKJEB]
MHUV+I/LZ_>?ICZUSNIWEM-XCTO4Y@\NE1J4)*\(_J:R-5C2[LM?FLXG&F3NH
M'R\,<]11=H:BGN=HNO:0T/F_;0$)P"1U^GK4\&H6=S;/<0W"F&/[[$XVUR>K
MI866I^&6N+=!;(H^51[=36??02W2ZO>:=%)_9CS*=@&-X!YQ1SL?(CNK/5M/
MU .+6X#[!N(88./6HTUS2YMXBO$8I]X@<#V^M<Y=S6FH:[92Z/&1#!;,9V5<
M #;]T^M5=+D72/!+W$&GK)-+='=O7D G[V/2CF8N5'4R^(=-CTVYU".<R10#
MYX\<_7%54UV+48+&?3KM(H97&Y)!R3[5S5FLMSJ6M_<NBUID>6FU3QTQWJ3S
M()K/PP+9,F*8"3"8V'WHYF'*CLKS5M.L;D0W-R%E)YQR!]?2GW&IV5J$:YND
M0.NY,'.X>U<HD]G8W_B%-6B+SS']T=N=P[8JOIMC*=3\/)>P>:0C'YQP@SQF
MES2#E1OZKKH@LK:_T^=9;=IMDK?W16X'#(CJ/O@'->>WZB/2O$%O'&8PUXHA
M7& 3GJ*[VU!%E;HWWA$N?KBKBV]P:T)>E'<4@/% /(JVB$Q1_KH?^NHKT)/]
M6OTKSQ3^_A_ZZ"O0T_U:_2N#$G30%/2O/Y_^/^[_ .NE>@'I7GUP?]/N_P#K
MI2PVY5;8;129HS7H6U.3H+129HS2L M86J6]S#XFT_4[:,L2AAE;NH/>MS-5
M[K4[*P=5N[I(I&'"'GBDT-%'3_#&FV<=PL\*7<DSEFED'/-3:)I2:)I[V0E:
M:$N2!V /:K\;B=?,A<.A'!'0T[!SSD^U"2"[,2'P_<V$DB6&I>5:2/N,3#)7
MZ56N?")FFNV@OC'%> ><K#+$CT-=)L;/"D9ZGTH^?.T9R.E'(F'.S ?PI$[N
MYN,;[<6V0.0!WJQ;^'X[?4-/NQ.6-C"8<'_EH/6M?;CG!/K0%8= 2>U+D2#F
M9S[^%Y0DT%IJ!ATZX??) ?O9/7FKNEZ';Z3J5S>0,3',@01GJF!C-:+#:/WG
MRD]23Q4$M_!;W\5J^X7#IN3 X(%/E079G)X<C32KZP\\D7DGF,_]WGI44WA.
MWGDN'DN)!YUN(<*<8QWK?"$#(!;OF@ GG!8^E)I;"4G<P=/\-26NIV]_->B6
M2"+RT4# (]:WR=Q#9/T['WJK-?6\%]%:3-MEEY3_  JS@@DL>IZ525AL**3-
M&:+"N+129HS0 V8_N6^E>@67_'E#_N#^5>?2_P"J;Z5Z#9?\>,'^X/Y5QXKH
M=&'W+%%%%<9UA1110 5XY\(_^1]\:_\ 7U_6O8Z\<^$?_(^^-?\ KZ_K0!['
M1110 5%<_P#'M+_N'^52U%<_\>TO^X?Y4=12V//(3^Y'U-/J.'_4CZFGYKUU
MLCS>HM&:3-&:=@N+TS]<BL*^MKF'Q=;:C;(6B>$Q2^V>];F:-W;(%#5PO8R+
M#PMIEG8S0301W,EPS.\K#D9JSHVEKI&F_P!G--YT))VL>@![5>Z\GG% R1M4
M##= >U3:P[W,6UT"ZT]S'I^H^19E]YA(R0?8U4N?!YN#=I%?^5!>,'G1AELC
MT-;4NK:?!/\ 99+U!+Z+S5P#<BL/F7L1WH44]QW:.1OO#XN/&.DLD3?9[2("
M0CHQ'3-;W]D*/$%UJZS9::+RMC=JT1N;@##^I]*0K@XVDGUI\D4'.V88\-1C
M2(=-^T-Y<,YGW?WCZ56N?!_G272QW[);W1#2(1DY'O72?,QQDCVI?FZ,"".U
M'*A<S,VVT9+;4S>"7+&W^S[?08ZU)HNF+HUG]G602 R%M^/TJ\$;/RKDFD&.
M$W88] 3WHT0:LPH_#MQ:7%W-97XC:Z<LZN,KSVJ.#PC;6R6BK-_Q[,SLW]XM
MU K92^@DO9+%"WGQC<P8<8JSM.!C(4]B.]+E3'=G-+X/*O"C7^;6&?SXX@/F
MR?4UH1:"D4.IQ^<#_: ^8]TK6V,20%)?&,U5COK6:_DL4<_:(QEE-'LT*[,L
M^&VB%G+9WQ@N+5#'YF/OCT-+8>'YM+L98;/4&$\LAD:1QE>>HQ6W_$?3%&:?
M(D',9VBZ+'HT<X$@DFG??(X& 3["M/--S1FG85QV:,TW-&:+!<=F@]*;FC/%
M'01UWAK_ ) L/U/\ZUZR/#/_ "!(OJ?YUKUY$_B/2A\(O:DI>U)2&9NO?\@:
M?Z5QBG]TOTKL]>_Y UQ]*XJ,[45O0=/6NW"[,Y:^Z'T=L]J0J0<$!6/)H*D\
M <>M=9SW%[T4@7)QU/H*5E;_ ):9]L4[@0WUG'J-A/8S<),I4GT]ZY#3T\9^
M&[4Z7;V4.HV<9(MYBV"HKM.IV@\=6I?FQNXP> ,\BHY;C4K'*:EIFNO-INNV
MWE/K%J,2Q=%E4]J?86&KZMXIM]:UNVBLTM%(AMU.>3U-=/\ C1FDXC<S$\*Z
M9=Z9<:H;M !/<-)'@\,#7+:#=^(;:[US^R;.&\ADG9=C'!C/K7HH8@@]:J66
MGVNG&9K-2LD[EY/K3<+@I',)X,N!X0-HUPO]JF;[2'QP'ZXI+JT\3>(ULM/U
M6SCM+2-U:>5&SOQ79?CFCGUI<@^8Q-$TRXT_Q1J5[+&JVTP"Q,.^!BN>N-!U
MFUU?57CTJ'4DO<F*XF/^HSV KO??EAVHY'!)SZ4^4.:QP[>&-5_X02TL JG4
MK6;S50'AN>E7]3M-9UJUTB:>QC@N;><-)&#PH'>NH_&CGUI* G,YC4=/U?2O
M%,VN:);I>1W:!9[:0XY'?-4AX>U>_M=:U&_5$U*]3RXK=?NHM=IT[T9H< 4C
MF]5T>]NO ]GID*_Z3#LWQYZXZ\UT4*E+2&,CE$4$'L0*=FC//7%-1$V+GD#U
MHH"DJ=H&#TR>:3(QP>*H0M&>0/6DS2[3MP<,&^[ZT6"XJG#X-=)X3_Y!S_\
M70US0QNX/'I72^$_^0:__70UAB?@-:/Q&_WHHI>]><=P4444 %%%% !1110
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M#<8,'FGYG ]?>B\A:&NFK17>HZ7+=":UNGCW+%T4CU-6/^$JM3(3]FE-KO\
M+%R!\I.:R[BUOM8NM)?[))$B0&*7>,%&QC\JC:+4F\/1^&?L#))YVUK@?="Y
MSNS3NPT-JZ\3VMO=SVL-O)<R0*'D*#A5JGJ^J!4TC6;.5C:R2;'&>QXIUAIU
MQ;:EK!\O]W);>4C8QO.*R;NWFB\-:1I<J;+I[C/E^@!SFC43L=WP')'0\CZ5
MTWA/_D&O_OFN8Y&T-C<% R/2NF\)?\@Q_P#?-98CX"Z/QG0TE+25YYW"T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !WI*6DJ7N G8UY[?'&JWG^_7H)/:N*O=&U)]0N)(H59';(KLPT
ME&3N<]=.6QF9HS5S^Q=6_P"?<4?V+JO_ #[BN_VD.YQ^SEV*>:,U=_L35?\
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M%U;_ )]A1_8VJ_\ /L*7M(=Q<DBA+_JVKT:Q_P"/*#_<'\JX9]$U9DQ]G')
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MG= )12T4KH!.:.:6BBZ ;]:7'N:6BG<+(6BBBF 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :2@T4
M%%%% !2TF*,4 %%%&* "BC%% !11BC% "TE&*,4 %%&** /*/CISHFDC_I]3
M^=>FZ=_R#;7_ *Y+_*O+_CE-%_9&E)YR96]0LF>>M>G:5-'/IMLT3JZ^4O0]
M.* +E0W5M%=P/;SH'A<893WJ:J]Z+@VLJVC*MP5^0L. : //_#]M!9_%[5+>
MVMXX(4LUVK&,#K2>"U%Q\2/%<\P#2I*(T+<D+[>U16'A+QM:>*Y==;4K-WG
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M^OZT >QT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$?\ R/OC7_KZ_K0!['1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\<^$?_ "/OC7_KZ_K7L=>.?"/_ )'WQK_U]?UH ]CHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"NE=]V-<!=G_B97?\ UTKLPWQ,YL1T(\T9I**[K')<4'!%<]<0W%IXR::
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3(J*E^PW_P#SY24?8;__ )\I*/:P#DF145+]AO\ _GQDH^PW_P#SY2?G1[6
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M[RWMWC2:5$:0[44G!8^PJ8,&'%>?Z*\'B/Q,/$.I311Q)F+3;>1\$^KX[UZ
MO- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)@4M%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%)0 M%%%*X!1113 **** "BBB@ HHHH **** "BBB@#R?XZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7CGPC_P"1]\:_]?7]:]>N+B&TA:>XE6.)1EF8X KQ?X3ZIIR>
M//%Q^V1 7%S^YR?]9SVH ]MHI** %HHHH **** "BBB@ HHHH **2B@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&ZV^FR8AW='ST/O7K+:_?G@PQCOFD37+U3N^S0J[]2!U]*/92#VB.JHKE_\
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MI03DYIO4XHS0 [-&:;FC- #LT9IM% #LT9IM% AV:,TVB@!U%-HI!<=13:*
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M8UVM_P#\>$_^X:XJ#_4K]:Z\,<M<DS13>E&:ZGN8V'49IN:* '49IM&>,]J
M'44VC- #LT4VB@!U%-S1GG% #L^]+D^O_P!:F9HS0 [-&:;FC-(!V:,TW-&:
M8#J*;FC- #J,TG-)G% #J*;FC- #AU%:GAI1]JNV[DUE \UK>&?]?=?6LJWP
MET]SI ,4M%%>>=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M([G5[[1;6TTV!HI]0.R9V.# AZGZUSVM^'GT2YT>:SL!?6%M"T318RV\C[U
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MZ%341_P T >O@GOTH!Y)Q7D'_"[KO_H4]0_[X-'_  O0P\W/A?44!^[B,\T
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M.=4$;F,X\Q1ZTFF--',:$]S_ ,*T\00NY1H69$);.SGH#5N/P_8:;\.+C4(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO<'2?O'4"EI*6O..\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZH<J".AI1'&LYG$2>:1@OCDBD_&C-'NA<8+2T64RK:Q"1CDL!R33Q'&H<")
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MI7G*_P"OM_\ KJ*]'0?(OTK@Q/0Z\.+2TE+7*=04444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML2TWH=M%-(=124M<ITA1110 4444 %%%% !1110 4444 %%%% !1110!7O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH #24M)WH *,TAZ^U8$WB-H[F6)+0OL.-V[K3A%RV(<K;G045SO_"2R_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/UI,_6DS1FD+0=GZTGYBDS1FF&@CL=\)/_/05W,?W%^E<*WWH?\ KJ*[I/\
M5K]*X\1H[G11U'4M%%<QTA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHKF1TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% "4M%% "'H:X&[_ .0E>?[]=Z>AK@;L_P#$SO/]^NK#
M;LYJY'FC-)17<<EQ<\CZU7GOX(+N*T<YFGSM [#O4XY.*YZU87'Q N"XW_9X
M0$7Z]ZF3L5'4W)KRUBN8[*:>,7$O^KB)Y.*=<3QVMLTUPVV*,X9A_*O-M7U"
MTN;Z_P!:-P!=V4ZI OH ?FKTBWGCO;6WNG16BFC#;#RI)'>I4KE-6*<?B#2)
M)5@CNQ)(3C:HZ5>N)5L[9[B52549X'-<=IB6EIJOB*1A# J.I$NW.SCM4<.N
M74-SJ5LD\EQ$+3SD:=-I!^GI2YAN-SM+>X6Z@2>(-M(SAA4N">#GYN_I7)Q:
MO>6L.AW4\R_9;I"LH X#5437=3CL+R&27-U<3@VIQTCS34Q<IW&UR"67(%"A
MB,*"5]#7#ZSK%Q8,DL&H/<3Q2)'(J)\G/4$U;FN-4U/7-0@AOA!#;6PE4*.=
MQ%/G0<IUA+-M7EG7M5.?5].MKC[/+=*)>F!ZU2T?4;B^\,->2';<K&P)QW'>
MJG@^SM;O0%NYH4GFFE8R.PR1@_I57 Z1<L%*$,2,YH4,W(R,>M<LCWVM:CJ4
M%M=BSAL!B-0,DG&>?:L]]=U/5DT>"WN!;R3RF.=\9S@]JER!1N=UL=NL9SVI
M!N)XRQ':N10:O>ZUJ=C'J?E6UG$61\9+,*BL];U'6VTS3$D^SR/DSS*,E@/2
MCG0>S.S().W!4]<4;6)&5.WUKB+[6M3T^PU6R2X#W%NR^5.PZ*3CGWJ[,\UI
MIUJMUJ[BXFCW[(URQ/KBCV@^5G4YQ\I*AF. '%0+?0_VB]D _G*.1MXK@;R[
MO=>T'3I9;N6&5;WR=ZC#,,]36K>ZQ=Z-K5_&LBSBWMP(R1R6]2:7.'*SL<$#
M/0 ^E+M<G.,\9Z5R;3ZEHW]EW<]X9X[X@21^Y&>*H?;]8FTW4M474-@LY]D<
M6/O+FGSBY6=BE_;/?G3E8BYV;]I':K.3SN_&N4U&X/\ PE'A^\7Y9+E K_3%
M=4QY/IGFFI7$T&<\T9YI*.]78FXH/[Z'_KH*]!3_ %:_2O/5_P!=#_UU%>A)
M_JU^E<&*.J@/HI*6N4Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(!5/[^'_ *ZBO1$_U:_2O.A_KX?^NHKT5/\ 5K]*X,6=6''4M)2UR'4%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %J ?<# 2(  A$! Q$!_\0
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M.,Y ]4KY;_96?S/"/B=O3Q9*O;G&GV SQZU]24 %%%% !1110 4444 %%%%
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MR?\ !0@_M0_&W]D&/]N#2O[)\)?L]:'^TW:?&=/@MX;_ .%B6>J:I-JVEO\
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MB3QAJ2:IJOB_QY:W($&M>+H+L,FC:AL1=*L6-K:(D("CZ1^T$<,%[*N3EF
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M=0O/#OB;PWX9O-6\(:)I]EHT6NP:EXSUZ-HX/#6G:Q931C1;N[1H]0N)$@C
M9P1Z;_I/E-.(;@0*"PD$992H8@L"/X H9F<X1=I4MO(4_BCX>T/2?@9\3O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"2-)(_\ @B[\7FC=%=&'[67P!PR,NY6&ZV#<K@_, >>0#P0#]F:*_&K_ (>
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M> _\%(_^D+?Q?_\ $LO@![?]._O_ )YP ?LM17XT_P##P'_@I%T_X<M_%_\
M\2R^ '\_L^/PYH_X> _\%(_^D+?Q?[?\W9? #_Y'_P ^V: /V6HK\:3_ ,%
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MH']--%?7_P"V8X3X9Z,2>1X]T$#Z[Y<#]1[<5^;_ -I'?:!QR20!D@#)[9)
M^IK]<X%RO 8W(:53$X/"5ZSQ&)7/7H4JE648R@DN:I&4FHWLM;+YGY?Q5C\;
MA\XJPHXO$T*2HX=J%.O5IP4I0DVU&,XQ3;U>FMM;GL(^.GQCQS\4?$&?:QT'
M_P"5U*?CI\8\''Q1\09[?Z#H/_RNKQT7!X.Q@IR-Y5@NX!F*YQU548G@@*I)
M8#&6FZ &2!M^;Y@&(POWCT/"\=NXZU]FN',J>JRO >OU6A;_ -(L?//-LR6C
MS'&+UQ5;3_R<]C_X7K\8\C_BZ'B#'?\ T'0?R_Y!W^<4O_"]/C%_T5#Q!_X
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M.VCBA^2%$0%8UW  L"<FOR96YR>W SGGMW[?I^ K]1_V2F+?!;12>IUWQ/\
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M5I4*CQ>&@ZD9NG)1E-IKFBTTGU5[,K#]I7XU\X\7:9QD'?X7LN<<G'^E]1D
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MN?UZ\>U?DYXT_;5\?^!O@OX<^+WB?X,>#M*'CZT'BGX<^$1\5$U76?%?@0Z
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M?#7A71-,\/:!HECIOAZ.UTG1M%LH=/TW3H573 -EG9V\$(? ,FW<V6)-;?\
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MDBT_7/%&EZ99"SFU.17L7DMK2TCC$UP&/Z97T/@YO&OA"XO[32F\?V&D:_\
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M#ND:OI^FZ_'/FXBU<1#$4EVS?HWYXY_>)SQN^]@$\_(3M8$8R"01U!R.03]
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M?FI '.._N.O/%?L'^QP^_P" GAA^QU;Q*0?4?V[?<^OY\^M?C&+@ @APYR.
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MX>'LZC3DFJ5?32S_ '-1ZZ')#$1YN5O=T]6[O^-!:6OW/Z*/  (\#>#<]?\
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M&1J'ZY)ZYZ5^G^UO3_QT_P"-&UO3_P =/^/N?SJ7XC\9.7,\SJN7?^S,#?\
MI@^".&FK/+=.WUB5O_2E^9^7I_X)Z:H<C_A;L..>/^$5CSC_ ,#_ ,ZB?_@G
MAJ\JM&?BW$H9<;E\*1\8(()/V\\ @<?I7ZC[#GE<_P# >OZ]S^0]:?@#&4)/
ML"0 >.Y/..OL:4_$3C"<)<^:S46G!IX3#TFU.+BVE2ISNFFTWHULM#)\"\,<
M\6LNE&4?>]VM/EERR4DI>_;=*UW\C&\,Z:=%T+2M&\XW TC3=/TQ)S&8O-2P
MLX+59"I)^:0Q-(<<#>%[5O4Q!@'MGM@#\P/\]^]/KY)RE-N<I*4IRE.4DN5.
M4I.3:72[DWZML^KA&,(0A"+A"$5",9/F<8Q2BDVKWLHKKM8P_$__ "+7B'_L
M!ZM_Z07%?E7_ ,$+?^477[,7_8-\=?\ JR/%M?JIXG_Y%KQ#_P!@/5O_ $@N
M*_*O_@A;_P HNOV8O^P;XZ_]61XMI%'ZX?2OD#XY?LIZ)\;O&%AXMU'QCK?A
M^]M-%CT06>F6%E=6\L,%S)<QW&^YE1T8/*X("G<N.,CGZ_IO8X&",XX Y]OT
MKKP.88W+,3'%Y?6J8;$PC*$:]*2A4A&:M-1ERRLI+1Z;(X\;@<+F%%X;&4HU
MJ,I*3IS5X.47>+:NM8MMK5:]S\X/^'>7ASM\3_%6.<YT;2SU[?ZT=>3GK^M
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MS_A]*_1\JW][/U)Z_K1L./O?ASCK_D].M-<=\6I67$.*2\F__E +A#AU._\
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M^T3_ /DS\OS_ ,$\M3QG_A;B'OSX7C_7_B89^O'^--/_  3UU(]/BW$,]?\
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M]%-7[H_'^9IU?)J]E??KZGU"M96VZ>G3\ HHHI@%%%% !1110 4444 %%%%
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MZCJ+W-YJ<^H7=W+<,LQ(X%A<S<XJG7I3CU;DE:R\GU\[?@=CQ.6237L*JO\
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M;?\  /PRP!YUCQ-CWQKM[R.O'TK\]\4*:IY#AU:S_M"COO;DJ/KTTWMZGU?
M-5U<\JO[,<#5Y5T3;A?YN_<^KUY /KG^9IU-3[H_'^9IU?A;W?J_S/V&/PQ_
MPK\D%%%% PHHHH **** "BBB@ HHHH **** ,/Q/_P BUXA_[ >K?^D%Q7Y5
M_P#!"W_E%U^S%_V#?'7_ *LCQ;7ZJ>)_^1:\0_\ 8#U;_P!(+BORK_X(6_\
M*+K]F+_L&^.O_5D>+: /UPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^'?V\7 ^#FF9;
M;GQ[X:P2#R5GD[C/7!!]CGZ?D>)FQ_#T_O*/T[5^_/Q?^#_A[XS^%X_"?B2\
MU2RL(=5L]8BN-(N1;7B7=D6\H"5TD7RB&(92A)ZY%?,O_#O_ .$G_0R^/_\
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M:X;3!<?83K#:<S6RZ_LEU5[:68,X9B[?N,?V /A.3SXF\>GC&#J]L<CG(/\
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MXQC\>U+YS>J_]]+7ZO?\._OA)_T,WC__ ,'%MU_\!/T_6C_AW]\)/^AF\?\
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M%7A[0+G7[]=*T&#7-9T[2)M<U5RP33-&BU"XMWU346V/BRL5GN<*6\H#!/\
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MW_R O[1P*WQN$2[O$TOUDCVG8OI^I_QK\=?V$N?^"C__  5^!Z?\+*_9G_\
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MO!,ZDL1CU.I5J7A%_O:DZEK2Z.4G;Y6_([NBBBOR\_0PHHHH **** "BBB@
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MUU_2]3UCPW'\,%BCTK4-4GU&V55N$U"%Y9T _2KPEXMN_%NC?VS>>%=?\'7
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M+VUT[3K+2#?OH<VI:6)Q:ZSJ6BSZKJUSI>JZC!<7MG=:I?7*2M+<R2'X5/\
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MFOZMK]TOQ7\2S:CX5\+_ &_5+[4/LW@KPT[W(T62X6Z5M8OFOIY]4O3<73+
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M^,?PUL];_P"$QNM=LO#/]BW/QVU!-53QI=Z7-:ZY%X5N+-W_ +:2&XA(T]G
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M_P!$TT[_ ,&.K_\ RPKZ9HI?ZQ\0_P#0]SG_ ,.>-_\ EX?V'DW_ $*LO_\
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M +94<4GPWT)9HEDC/CG0E9'YB9LS!?-3_EH 2-N0P#8)&*_.?[)IW_/E;?\
M?E/_ (BOM.'.#?[;RR&/>/EAW.M7@Z:H.J_<FM6^=6^))*VR/C<YXGJY3C98
M2&%I8CEC&3E.M[)I2UBE&S;32O>_D?MA_P )IX1_Z&SPY_X/=,_^2J/^$T\(
M_P#0V>'/_![IG_R57XGBSTX_\N5M_P!^5/\ [)_2E^Q:=S_H=K]?)&#Z\B,\
M#N:]W_B&\;2?]KSM%VD_JCM%OHW[2RW1Y:XXQ4M%EF'?IBT_O5C]K_\ A,_"
M/_0V>'/_  >Z9_\ )5'_  FGA'_H;/#G_@]TS_Y*K\4?L6G?\^EI_P!^E_\
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M_P#"1_\ RPI\;8Q:O*Z"[?[4K>O_  Y^UW_":>$?^AL\.?\ @]TS_P"2J/\
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M'8^GX)M_;2UO_L>(_.)]1#I^+?S-+2#I^+?S-+7XP?K"V7HOR"BBB@84444
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M>[/V*/PQ]%^2"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?#_[>(_XLUIWMX]\,''N9Y,CZ]_PK\B1-C!9,CIPPZ_E_
M6OVI_:XL;+4/A88+^SM;Z%?%.DN(;RWBN8@ZN-K".9'0,N3A@,C)P>:_-P>%
MO# /'AS01][_ )A&G_WO^O>OW#PVSF.7\-PHSP\J[>,Q4E.-9TG\<8M22C+F
MV33TML?BG'N%]KGTYNI.-\-A]$W_ "/LT?//VA?[GZ_X'_/>@SK@_)_X]_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !% 3@# 2(  A$! Q$!_\0
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MPV#P=2K3> 6+I5EEV,G]7JX_!QABY8+#*K"F=CX[^)WPY^%VEKK7Q)\>^#O
M.D._EQZEXQ\1Z1X<LI9/^>4-QJ]Y:1RR'C"1L[9(&WD53^'WQ?\ A3\6;6ZO
M?A?\2? OQ#M;$H+Z;P7XJT3Q*ED9"PC6\_LB]NS:,Y5@JW C+%2 ,@U_(G\0
MM8^&O[1/_!4;XK^$O^"A7CSQ?X%^'6A^*/%'@WP=I_\ :<NBZ+X>CT^YBM_
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MKLPE:OYT_P!H%1^T-_P7=^#O@6-?MNG?!E?!'VRU(\RV\GP5H5_\4-71USM
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M].-OIIN;EODO1]#U[XZ:IXN^/GQY\83^$_A'X4N+*V\=>/ELX5$06%O^$?\
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M*92;?5-4'B;7Q=S$N'_M6[P@\P8 NNB_K[S\4?@Q^V%^T_X?_8"_9R\6:_\
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MS>'X0+;2=1PNJ6=I_H<-ZMJ3#74P?LZ? ZW^#TOP C^&/A7_ (4Y/82:?<>
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MQZCXB@%MX@U?3=)>Z?0]%UK7;?=#K.M:-IEAJVIQR3+>WDXFEWZ4?[+W[/\
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex23-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !A TP# 2(  A$! Q$!_\0
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MK?0]6T:XLX[>)_#GB33'=))%N'3&IB*-*I2IU)<LJO-R>?*XI_=S+UO;<];
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MU;)JEC<6$=M=Z8_ R_MT>.U_94@_;_6WT/\ X4))\2;2)_AC_P (]=-XNB^
M4_Q8'P>F\<2^)!K)#?$>.\=/B7_9J6$?A>#PHLG@B:SDUH'QRG5+(\='$3PR
M5-U85L-AFKU::EB\9&M+#82'ML/1E*M5C0FXR4/8.+IRCB)0JTYO@CQ5E4L'
M2QS=:.'JX?'8Y-+#UG#+LMGAX8[,*GU;&8J$,-AY8JE&I%U'BXS5:G/!TZN'
MK4X_JY17PE\:_P!L?PYX1^-EG^S[X:\=?"CP)K6B^$;7XB_&'XI_&#7;/2_
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M?4__ %J0R8!(7*CN#D?3H.E8:;W5O5?Y_@=75+JW9?UT^=B6BH]Y/1<_C_\
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M5X5L=<U;POXBT#Q5XBUV[UZQO-6@O+&SAU&UU33K9!8B"[$^G;I[CRBFW/\
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MV:U@^&7[(D?P]?\ :*\;Q:1\.KSXZ?%3XB?%SQYX$^)EQX1ADUGPFWCF ?\
M"+:3J&MO;2:V;;0KL;KV#2[V"VEA:9;:*,2[:X+]@G_@I3HG[=7B?Q]X<\._
M!OQ+\/;?X?\ AK2M>U/5];\5:5KL,\NLZJ^FV6F)!IVEV;1320VNI7R3RSD/
M'8O$L)+&2/\ 4 IA"S8.0A(&,AAP<-G!Y/7OCCM77B,M^HSJX/%4VI4)S;I3
M<92IN;]HX\\7-?:T<9-Q3LFGHN'"\;YEF&&Q&-PN*I26;T\%]=Q5"F\+',5E
MN)I5:3Q=*DZ*K\U3"PJ555@XUJTJM6I&<ZM2<_RV\&?\$\_"WPC_ .&6O%/P
MLNKG2/B=\%/$=E-X^\3ZGK/C+5K'Q[X8\4>&=4T7XL:?%H&H:U<Z3H5_XLUC
M48_%EI/INGV,4.NZ98&^#V0F@D^C-0_9ZDU?]K&+]H+66T#5_#4?[/%G\'U\
M.:KH\>HW<>NVWQ'N_&KZVAOH9[(6J:;<R:>B1PI=K.7<RM&RH?CS3?\ @KIX
M)\0_MC_\,?\ AOX+^*M6U@_%JY^$\GCV/Q7HT6D0W>EW-U8ZSKO]C'39;YK/
M2I]-U/S;47(>2*R\P7,?F@+^O9"A P.<KC=C )DX#$C. 2<L2..^<5>(R6G@
MX8:G7P'L8RY,;0IJ<))N2_=XB,%.2A4BFW"?NU$V[6>HH>(^<9]/%XR&=SQF
M*^HYYPYC,:U6]O' YSC</C,?A8UIJE64:#PM*E@X0FZ5"GSTZ:C3DX/\T9OV
M(O$T_P 9)/B2/$_A]=+'[>5C^UQ%IG]F7K7/_",VW[+MK\ _^$6CE!\F+6_[
M62;7$O$7[)'IN+/RA.P86_%7[&/BSQ!HOQ_TN#Q)X>MI_B]^UA\*?VA](:72
M+U[?2="\!:Y\*=4U#P_J"HR_:]=U&V^&US;V]]$4M(I-0T^26)DM %QOVZ_^
M"GGP]_8<\7^#OA_K?PW\5_$CQ1XP\)R^,;6'P]K&CZ/9:?I2ZO=:/;_;KB_2
M\NA/<36&H7,'EV#1-:V%RRREXV0?#'A7_@X<^$E]JEM;>,?V=?B!X=TF22W6
M?5- \;>&_%E["C_*UQ_9$^D>&A(@R&"+J(EF0$0HSJL;=%'A?$8O#<]#+YO#
MU(U)1DIT87C>4ZDXJ56$FW+G;LFY2<FD[Z\^(\7,1AL>\+7S3"QQ.'P>%PTH
MK#5Y1A3PM3!U*4:KI49TH3<\%A)SG*2O3]I&<O?=_P!@?@Y\#-7^&GQ<_:,\
M?WFL:=?:5\<?&?@CQ;IVFV-C<P7>CCPM\./#G@:\BU>YD=[>\N+Z[T1[VVEM
MDC\BQDM[68EHP!]85X?\#?CQ\+_VCOAUHGQ4^$/B2W\3>$-=2:.*=%>TO[&^
MMS&+W2M9TRX1+W2M9L9)42[TV]BBN(U>.90T,L3O[A7&J<:*]C&G*'LFX/F2
M3;3=[]=&WKMV9S5\SK9O.&.K585Y5*%""JTW>-2-*G&E3=WK:-&G2IQYM5"G
M&.B22****9@%%%% !1110 4444 %%%% !1110 4444 %%%% !7Q)^VEX'^)O
MCQOV8%^&WPXUOQ]_PK[]K/X._%CQE)I>O> M#BT3P1X,DU]=?OC_ ,)IXO\
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M]/\ _!2KX:_$K]HJS_X)L_$?X:^&/$'C*^^+O[+WA7X;:+HV@:?=ZM!9^,_
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M8E217Q]X9U[XL7OP=^)?[0OPC^'WB;XB>.OVG/BC%JGAJ/PKJGPXTSQ#X5^
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M5O-\5_$77(H6L/#7AJP,I\Z1-8U>5+"S2"7R7]J']J)OC4= ^&_PUT(?"_\
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M^I7,+FVL_#GAG3[..6)/*1'@B5@(F"_MI\+?BAX0^,/@CPY\1? %]>:IX/\
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M>!_%?C;Q[\8=?LCJS:EIW@OP7!IMEK,XT>#0-:O=:O\ 5X='TG2M/T^:\O\
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MQ6>C_:)?+N[NUSN7F685U@?[-Y8K#/$?69623E43YXWM9N/-T=[;G2LEPO\
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M]O[]DBTW5=.&MSZ;;RK&TC3(P#3YK\=_@_\ \$UO^"KW[/GQ.U_1/@CK%O\
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MF@\%6TVK>%M-ET?^V+"SL6TW48]9US6KJ[U"XAN;6"+XL^$-E\3?VM?$W_!
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M?\96WB^\\2^(-7\+WQ\27=Y:WOV&UXS0OBM\1/A)<?M*7?PY\2W?AB^\:?\
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M*_B7JEA>ZO?^'M5U&PT70/"VJ:+%X>M(I)OM1]^_X*Q_'/7_ (-?L+?%*V\
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M:WJFL:3J.DQ6^G65SXQO9-5CTK4/!(?VS_VT-1_9-E\&Q?%KXB_#?XR_#O\
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M5G5IPHY=4IXBGB:$YTJDI592Q+="BHQAL5GE.7)C*V*K86E@J>'_ +1G1Q6
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MZZ5)$=K>\MH9E5T8H P)P/\ ANC]B7_H\3]EC_Q(/X2__-=7\O'[?'_!*/\
M;[^-7[8W[07Q5^&?P%_X27P%XX\?7>M^%]>_X6E\%]&_M33);"PA2Y_LOQ!\
M1=*UFRW2PRKY.HZ=:7 V[C$%92?D/_ARG_P4U_Z-I_\ ,R?L_P#_ ,]6OT_"
M<'<)5\)A:];C&C0K5L-0JUJ#K9.G1JU*-.I4I-3KJ:=.<Y4VII33A:24KH_!
MLQ\2O$3"9AC\+A?#7$XO#8;&XO#X;%+"\2-8FA0Q-:E1Q"=+"2I-5Z5.G53I
M2=-JHG!N#BW_ &A_\-T?L2_]'B?LL?\ B0?PE_\ FNH_X;H_8E_Z/$_98_\
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MZ/V)?^CQ/V6/_$@_A+_\UU'_  W1^Q+_ -'B?LL?^)!_"7_YKJ_B\_X<I_\
M!37_ *-I_P#,R?L__P#SU:/^'*?_  4U_P"C:?\ S,G[/_\ \]6C_4G@[_HM
MJ'_@_)?_ )H#_B*7B7_T:[%?^$G%'_S&?VA_\-T?L2_]'B?LL?\ B0?PE_\
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M/_!^2_\ S0'_ !%+Q+_Z-=BO_"3BC_YC/[0_^&Z/V)?^CQ/V6/\ Q(/X2_\
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M/V)?^CQ/V6/_ !(/X2__ #74?\-T?L2_]'B?LL?^)!_"7_YKJ_B\_P"'*?\
MP4U_Z-I_\S)^S_\ _/5H_P"'*?\ P4U_Z-I_\S)^S_\ _/5H_P!2>#O^BVH?
M^#\E_P#F@/\ B*7B7_T:[%?^$G%'_P QG]H?_#='[$O_ $>)^RQ_XD'\)?\
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MX2__ #75_%Y_PY3_ ."FO_1M/_F9/V?_ /YZM'_#E/\ X*:_]&T_^9D_9_\
M_GJT?ZD\'?\ 1;4/_!^2_P#S0'_$4O$O_HUV*_\ "3BC_P"8S^T/_ANC]B7_
M */$_98_\2#^$O\ \UU'_#='[$O_ $>)^RQ_XD'\)?\ YKJ_B\_X<I_\%-?^
MC:?_ #,G[/\ _P#/5H_X<I_\%-?^C:?_ #,G[/\ _P#/5H_U)X._Z+:A_P"#
M\E_^: _XBEXE_P#1KL5_X2<4?_,9_:'_ ,-T?L2_]'B?LL?^)!_"7_YKJ/\
MANC]B7_H\3]EC_Q(/X2__-=7\7G_  Y3_P""FO\ T;3_ .9D_9__ /GJT?\
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MU'_#='[$O_1XG[+'_B0?PE_^:ZOXO/\ ARG_ ,%-?^C:?_,R?L__ /SU:/\
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M;3_YF3]G_P#^>K1_PY3_ ."FO_1M/_F9/V?_ /YZM'^I/!W_ $6U#_P?DO\
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MEC_Q(/X2_P#S74?\-T?L2_\ 1XG[+'_B0?PE_P#FNK^+S_ARG_P4U_Z-I_\
M,R?L_P#_ ,]6C_ARG_P4U_Z-I_\ ,R?L_P#_ ,]6E_J3P=_T6U#_ ,'Y+_\
M- _^(I>)?_1KL5_X2<4?_,9_:'_PW1^Q+_T>)^RQ_P")!_"7_P":ZC_ANC]B
M7_H\3]EC_P 2#^$O_P UU?Q>?\.4_P#@IK_T;3_YF3]G_P#^>K1_PY3_ ."F
MO_1M/_F9/V?_ /YZM'^I/!W_ $6U#_P?DO\ \T!_Q%+Q+_Z-=BO_  DXH_\
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M^C:?_,R?L_\ _P ]6C_4G@[_ *+:A_X/R7_YH#_B*7B7_P!&NQ7_ (2<4?\
MS&?VA_\ #='[$O\ T>)^RQ_XD'\)?_FNH_X;H_8E_P"CQ/V6/_$@_A+_ /-=
M7\7G_#E/_@IK_P!&T_\ F9/V?_\ YZM'_#E/_@IK_P!&T_\ F9/V?_\ YZM'
M^I/!W_1;4/\ P?DO_P T!_Q%+Q+_ .C78K_PDXH_^8S^T/\ X;H_8E_Z/$_9
M8_\ $@_A+_\ -=1_PW1^Q+_T>)^RQ_XD'\)?_FNK^+S_ (<I_P#!37_HVG_S
M,G[/_P#\]6C_ (<I_P#!37_HVG_S,G[/_P#\]6C_ %)X._Z+:A_X/R7_ .:
M_P"(I>)?_1KL5_X2<4?_ #&?VA_\-T?L2_\ 1XG[+'_B0?PE_P#FNH_X;H_8
ME_Z/$_98_P#$@_A+_P#-=7\7G_#E/_@IK_T;3_YF3]G_ /\ GJT?\.4_^"FO
M_1M/_F9/V?\ _P">K1_J3P=_T6U#_P 'Y+_\T!_Q%+Q+_P"C78K_ ,).*/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
.*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex23-2_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  H .@# 2(  A$! Q$!_\0
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M<C;  >H444A(&,D#) &3C)/0#W/8=Z %HK\>?'G_  6L_92\._\ !1KX-?\
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G10 4T+ABV6.<\$Y R0>!CCH*** '4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>abvc-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 15 15:05:49 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:abvc="http://metuboutique.com/20250331" targetNamespace="http://metuboutique.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20250331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20250331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20250331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20250331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet" id="abvc_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Unaudited Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals" id="abvc_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement" id="abvc_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedCashFlow" id="abvc_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable" id="abvc_r_UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable">
        <link:definition>005 - Statement - Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusiness" id="abvc_r_OrganizationandDescriptionofBusiness">
        <link:definition>006 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LiquidityGoingConcernandRestatement" id="abvc_r_LiquidityGoingConcernandRestatement">
        <link:definition>007 - Disclosure - Liquidity, Going Concern, and Restatement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies" id="abvc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/CollaborativeAgreements" id="abvc_r_CollaborativeAgreements">
        <link:definition>009 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisition" id="abvc_r_PropertyandEquipmentandPrepamentforAssetAcquisition">
        <link:definition>010 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LongTermInvestments" id="abvc_r_LongTermInvestments">
        <link:definition>011 - Disclosure - Long-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConvertibleNotesPayable" id="abvc_r_ConvertibleNotesPayable">
        <link:definition>012 - Disclosure - Convertible Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilities" id="abvc_r_AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>013 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ShortTermLoans" id="abvc_r_ShortTermLoans">
        <link:definition>014 - Disclosure - Short-Term Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactions" id="abvc_r_RelatedPartiesTransactions">
        <link:definition>015 - Disclosure - Related Parties Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/IncomeTaxes" id="abvc_r_IncomeTaxes">
        <link:definition>016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/Equity" id="abvc_r_Equity">
        <link:definition>017 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/StockOptions" id="abvc_r_StockOptions">
        <link:definition>018 - Disclosure - Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LossPerShare" id="abvc_r_LossPerShare">
        <link:definition>019 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/Lease" id="abvc_r_Lease">
        <link:definition>020 - Disclosure - Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/CommitmentsandContingencies" id="abvc_r_CommitmentsandContingencies">
        <link:definition>021 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/Acquisition" id="abvc_r_Acquisition">
        <link:definition>022 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SubsequentEvents" id="abvc_r_SubsequentEvents">
        <link:definition>023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/AccountingPoliciesByPolicy" id="abvc_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LiquidityGoingConcernandRestatementTables" id="abvc_r_LiquidityGoingConcernandRestatementTables">
        <link:definition>996001 - Disclosure - Liquidity, Going Concern, and Restatement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables" id="abvc_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionTables" id="abvc_r_PropertyandEquipmentandPrepamentforAssetAcquisitionTables">
        <link:definition>996003 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LongTermInvestmentsTables" id="abvc_r_LongTermInvestmentsTables">
        <link:definition>996004 - Disclosure - Long-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConvertibleNotesPayableTables" id="abvc_r_ConvertibleNotesPayableTables">
        <link:definition>996005 - Disclosure - Convertible Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" id="abvc_r_AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>996006 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ShortTermLoansTables" id="abvc_r_ShortTermLoansTables">
        <link:definition>996007 - Disclosure - Short-Term Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsTables" id="abvc_r_RelatedPartiesTransactionsTables">
        <link:definition>996008 - Disclosure - Related Parties Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/IncomeTaxesTables" id="abvc_r_IncomeTaxesTables">
        <link:definition>996009 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/EquityTables" id="abvc_r_EquityTables">
        <link:definition>996010 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/StockOptionsTables" id="abvc_r_StockOptionsTables">
        <link:definition>996011 - Disclosure - Stock Options (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LossPerShareTables" id="abvc_r_LossPerShareTables">
        <link:definition>996012 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LeaseTables" id="abvc_r_LeaseTables">
        <link:definition>996013 - Disclosure - Lease (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/AcquisitionTables" id="abvc_r_AcquisitionTables">
        <link:definition>996014 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails" id="abvc_r_OrganizationandDescriptionofBusinessDetails">
        <link:definition>996015 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails" id="abvc_r_LiquidityGoingConcernandRestatementDetails">
        <link:definition>996016 - Disclosure - Liquidity, Going Concern, and Restatement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable" id="abvc_r_ScheduleofImpactoftheRestatementTable">
        <link:definition>996017 - Disclosure - Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails" id="abvc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996018 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable" id="abvc_r_ScheduleofEstimatedUsefulLifeTable">
        <link:definition>996019 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable" id="abvc_r_ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable">
        <link:definition>996020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable" id="abvc_r_ScheduleofReconciliationofTotalSegmentGrossProfitTable">
        <link:definition>996021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/CollaborativeAgreementsDetails" id="abvc_r_CollaborativeAgreementsDetails">
        <link:definition>996022 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails" id="abvc_r_PropertyandEquipmentandPrepamentforAssetAcquisitionDetails">
        <link:definition>996023 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable" id="abvc_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996024 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LongTermInvestmentsDetails" id="abvc_r_LongTermInvestmentsDetails">
        <link:definition>996025 - Disclosure - Long-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" id="abvc_r_ScheduleofOwnershipPercentagesofEachInvesteeTable">
        <link:definition>996026 - Disclosure - Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable" id="abvc_r_ScheduleofExtenttheInvesteeReliesTable">
        <link:definition>996027 - Disclosure - Long-Term Investments - Schedule of Extent the Investee Relies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable" id="abvc_r_ScheduleofLongTermInvestmentTable">
        <link:definition>996028 - Disclosure - Long-Term Investments - Schedule of Long-Term Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofBalanceSheetsTable" id="abvc_r_ScheduleofBalanceSheetsTable">
        <link:definition>996029 - Disclosure - Long-Term Investments - Schedule of Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofStatementsofOperationsTable" id="abvc_r_ScheduleofStatementsofOperationsTable">
        <link:definition>996030 - Disclosure - Long-Term Investments - Schedule of Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable" id="abvc_r_ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable">
        <link:definition>996031 - Disclosure - Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConvertibleNotesPayableDetails" id="abvc_r_ConvertibleNotesPayableDetails">
        <link:definition>996032 - Disclosure - Convertible Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable" id="abvc_r_ScheduleofCarryingAmountsoftheLiabilityComponentTable">
        <link:definition>996033 - Disclosure - Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" id="abvc_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable">
        <link:definition>996034 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ShortTermLoansDetails" id="abvc_r_ShortTermLoansDetails">
        <link:definition>996035 - Disclosure - Short-Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofShortTermLoansTable" id="abvc_r_ScheduleofShortTermLoansTable">
        <link:definition>996036 - Disclosure - Short-Term Loans - Schedule of Short-Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails" id="abvc_r_RelatedPartiesTransactionsDetails">
        <link:definition>996037 - Disclosure - Related Parties Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" id="abvc_r_ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable">
        <link:definition>996038 - Disclosure - Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable" id="abvc_r_ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable">
        <link:definition>996039 - Disclosure - Related Parties Transactions - Schedule of Licensing Agreement and Related Amendment with FEYE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable" id="abvc_r_ScheduleofAccountsReceivableDuefromRelatedPartiesTable">
        <link:definition>996040 - Disclosure - Related Parties Transactions - Schedule of Accounts Receivable Due from Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable" id="abvc_r_ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable">
        <link:definition>996041 - Disclosure - Related Parties Transactions - Schedule of Due from Related Party - Current and Non-current, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable" id="abvc_r_ScheduleofAmountDuetoRelatedPartiesTable">
        <link:definition>996042 - Disclosure - Related Parties Transactions - Schedule of Amount Due to Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/IncomeTaxesDetails" id="abvc_r_IncomeTaxesDetails">
        <link:definition>996043 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable" id="abvc_r_ScheduleofIncomeTaxBenefitExpenseTable">
        <link:definition>996044 - Disclosure - Income Taxes - Schedule of Income Tax (Benefit) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" id="abvc_r_ScheduleofDeferredTaxAssetsLiabilityTable">
        <link:definition>996045 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/EquityDetails" id="abvc_r_EquityDetails">
        <link:definition>996046 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable" id="abvc_r_ScheduleofWarrantsIssuedandOutstandingTable">
        <link:definition>996047 - Disclosure - Equity - Schedule of Warrants Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/StockOptionsDetails" id="abvc_r_StockOptionsDetails">
        <link:definition>996048 - Disclosure - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable" id="abvc_r_ScheduleofOptionsIssuedandOutstandingTable">
        <link:definition>996049 - Disclosure - Stock Options - Schedule of Options Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofLossPerShareTable" id="abvc_r_ScheduleofLossPerShareTable">
        <link:definition>996050 - Disclosure - Loss Per Share - Schedule of Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNpoXXXMi0ISiQMYRhfARCZqodsmYe5mpcuap9v90/VTIewyY3i091+2fVbljGWA+oIMmRhsCng8ZWIeu6RFmHqDuVsiXSHIAQzP/FPyRsu9wu9TXs5L6z+Vj4GR0/VqMj6bP7RRDRffTIrCvruey21RYJVvSYvm8Jzr52BCoL9TBOoHJS3zj4nqfZkyzhj6kVuA=] CSR-->
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" id="abvc_r_ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable">
        <link:definition>996051 - Disclosure - Lease - Schedule of Operating Leases have Remaining Lease Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable" id="abvc_r_ScheduleofCompanysLeaseExpensesTable">
        <link:definition>996052 - Disclosure - Lease - Schedule of Company&#8217;s Lease Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" id="abvc_r_ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable">
        <link:definition>996053 - Disclosure - Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/AcquisitionDetails" id="abvc_r_AcquisitionDetails">
        <link:definition>996054 - Disclosure - Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" id="abvc_r_ScheduleofAcquisitionwasAccountedforBusinessCombinationTable">
        <link:definition>996055 - Disclosure - Acquisition - Schedule of Acquisition was Accounted for Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SubsequentEventsDetails" id="abvc_r_SubsequentEventsDetails">
        <link:definition>996056 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0" id="abvc_r_ScheduleofImpactoftheRestatementTable0">
        <link:definition>996057 - Disclosure - Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0" id="abvc_r_ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0">
        <link:definition>996058 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0" id="abvc_r_ScheduleofReconciliationofTotalSegmentGrossProfitTable0">
        <link:definition>996059 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0" id="abvc_r_ScheduleofPropertyandEquipmentTable0">
        <link:definition>996060 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0" id="abvc_r_ScheduleofOwnershipPercentagesofEachInvesteeTable0">
        <link:definition>996061 - Disclosure - Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0" id="abvc_r_ScheduleofExtenttheInvesteeReliesTable0">
        <link:definition>996062 - Disclosure - Long-Term Investments - Schedule of Extent the Investee Relies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0" id="abvc_r_ScheduleofLongTermInvestmentTable0">
        <link:definition>996063 - Disclosure - Long-Term Investments - Schedule of Long-Term Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0" id="abvc_r_ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0">
        <link:definition>996064 - Disclosure - Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0" id="abvc_r_ScheduleofCarryingAmountsoftheLiabilityComponentTable0">
        <link:definition>996065 - Disclosure - Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0" id="abvc_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0">
        <link:definition>996066 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofShortTermLoansTable0" id="abvc_r_ScheduleofShortTermLoansTable0">
        <link:definition>996067 - Disclosure - Short-Term Loans - Schedule of Short-Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0" id="abvc_r_ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0">
        <link:definition>996068 - Disclosure - Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0" id="abvc_r_ScheduleofDeferredTaxAssetsLiabilityTable0">
        <link:definition>996069 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0" id="abvc_r_ScheduleofWarrantsIssuedandOutstandingTable0">
        <link:definition>996070 - Disclosure - Equity - Schedule of Warrants Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0" id="abvc_r_ScheduleofOptionsIssuedandOutstandingTable0">
        <link:definition>996071 - Disclosure - Stock Options - Schedule of Options Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofLossPerShareTable0" id="abvc_r_ScheduleofLossPerShareTable0">
        <link:definition>996072 - Disclosure - Loss Per Share - Schedule of Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofLeaseTable" id="abvc_r_ScheduleofLeaseTable">
        <link:definition>996073 - Disclosure - Lease - Schedule of Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0" id="abvc_r_ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0">
        <link:definition>996074 - Disclosure - Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:element name="UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract"/>
  <xs:element name="ScheduleOfImpactOfTheRestatementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfImpactOfTheRestatementAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLifeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfEstimatedUsefulLifeAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract"/>
  <xs:element name="ScheduleOfExtentTheInvesteeReliesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfExtentTheInvesteeReliesAbstract"/>
  <xs:element name="ScheduleOfLongTermInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfLongTermInvestmentAbstract"/>
  <xs:element name="ScheduleOfBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfBalanceSheetsAbstract"/>
  <xs:element name="ScheduleOfStatementsOfOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfStatementsOfOperationsAbstract"/>
  <xs:element name="ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract"/>
  <xs:element name="ScheduleOfShortTermLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfShortTermLoansAbstract"/>
  <xs:element name="ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract"/>
  <xs:element name="ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract"/>
  <xs:element name="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract"/>
  <xs:element name="ScheduleOfAmountDueToRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfLossPerShareAbstract"/>
  <xs:element name="ScheduleOfWarrantsIssuedAndOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfWarrantsIssuedAndOutstandingAbstract"/>
  <xs:element name="ScheduleOfLeaseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfLeaseAbstract"/>
  <xs:element name="LiabilitiesAndEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LiabilitiesAndEquityAbstract"/>
  <xs:element name="CurrentLiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CurrentLiabilitiesAbstract0"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_UnlabeledAbstract"/>
  <xs:element name="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract"/>
  <xs:element name="OperatingExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingExpensesAbstract0"/>
  <xs:element name="OtherIncomeExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OtherIncomeExpenseAbstract"/>
  <xs:element name="NetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NetLossPerShareAbstract"/>
  <xs:element name="WeightedAverageNumberOfCommonSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageNumberOfCommonSharesOutstandingAbstract"/>
  <xs:element name="CashPaidDuringTheYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CashPaidDuringTheYearForAbstract"/>
  <xs:element name="CashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
  <xs:element name="ChangesInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
  <xs:element name="CashFlowsFromInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CashFlowsFromInvestingActivitiesAbstract"/>
  <xs:element name="CashFlowsFromFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CashFlowsFromFinancingActivitiesAbstract"/>
  <xs:element name="CashAndCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CashAndCashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="SupplementalDisclosureOfCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SupplementalDisclosureOfCashFlowsAbstract"/>
  <xs:element name="CashPaidDuringTheYearForAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CashPaidDuringTheYearForAbstract0"/>
  <xs:element name="NonCashFinancingAndInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NonCashFinancingAndInvestingActivitiesAbstract"/>
  <xs:element name="LessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LessAbstract"/>
  <xs:element name="AddLessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AddLessAbstract"/>
  <xs:element name="NonMarketableCostMethodInvestmentsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NonMarketableCostMethodInvestmentsNetAbstract"/>
  <xs:element name="EquityMethodInvestmentsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_EquityMethodInvestmentsNetAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageDiscountRateAbstract"/>
  <xs:element name="LessAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LessAbstract0"/>
  <xs:element name="AddLessAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AddLessAbstract0"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AssetsAbstract0"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageRemainingLeaseTermAbstract0"/>
  <xs:element name="WeightedAverageDiscountRateAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageDiscountRateAbstract0"/>
  <xs:element name="PrepaymentForLongtermInvestmentsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_PrepaymentForLongtermInvestmentsNoncurrent"/>
  <xs:element name="StockSubscriptionReceivedInAdvance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockSubscriptionReceivedInAdvance"/>
  <xs:element name="WriteOffUnclaimedAccruedLiabilites" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_WriteOffUnclaimedAccruedLiabilites"/>
  <xs:element name="RepurchaseOfTreasuryStocks" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_RepurchaseOfTreasuryStocks"/>
  <xs:element name="ProceedsFromIssuanceOfAPromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ProceedsFromIssuanceOfAPromissoryNote"/>
  <xs:element name="ProceedsFromSubsidiarysShareholderContribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ProceedsFromSubsidiarysShareholderContribution"/>
  <xs:element name="PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty"/>
  <xs:element name="IssuanceOfCommonStockForConversionOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_IssuanceOfCommonStockForConversionOfDebt"/>
  <xs:element name="IssuanceOfSubsidiarysCommonStockForConsultingServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices"/>
  <xs:element name="PriorPeriodAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_PriorPeriodAdjustment"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty"/>
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable"/>
  <xs:element name="StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant"/>
  <xs:element name="StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant"/>
  <xs:element name="StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution"/>
  <xs:element name="StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN"/>
  <xs:element name="IssuanceOfCommonShareForLindCNRepayment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_IssuanceOfCommonShareForLindCNRepayment"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants"/>
  <xs:element name="StockSubscriptionReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockSubscriptionReceived"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService"/>
  <xs:element name="LiquidityGoingConcernAndRestatementTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LiquidityGoingConcernAndRestatementTextBlock"/>
  <xs:element name="StockReverseSplitPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockReverseSplitPolicyTextBlock"/>
  <xs:element name="ConcentrationOfClientsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConcentrationOfClientsPolicyTextBlock"/>
  <xs:element name="OtherThanTemporaryImpairmentPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OtherThanTemporaryImpairmentPolicyTextBlock"/>
  <xs:element name="ConvertibleNotesPayablePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConvertibleNotesPayablePolicyTextBlock"/>
  <xs:element name="ValuationOfDeferredTaxAssetsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock"/>
  <xs:element name="ScheduleOfExtentTheInvesteeReliesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock"/>
  <xs:element name="ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock"/>
  <xs:element name="ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock"/>
  <xs:element name="ScheduleOfAmountDueToRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock"/>
  <xs:element name="ProceedsFromSubsidiarysCommonStockSubscription" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ProceedsFromSubsidiarysCommonStockSubscription"/>
  <xs:element name="EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash"/>
  <xs:element name="PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems"/>
  <xs:element name="LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable"/>
  <xs:element name="LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable"/>
  <xs:element name="ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable"/>
  <xs:element name="DebtInstrumentIssuanceEntity" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DebtInstrumentIssuanceEntity"/>
  <xs:element name="DebtInstrumentCommonStockToBeConverted" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DebtInstrumentCommonStockToBeConverted"/>
  <xs:element name="DebtInstrumentPrincipalAmountAtBalanceSheetDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate"/>
  <xs:element name="DebtInstrumentCarryingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_DebtInstrumentCarryingValue"/>
  <xs:element name="AccruedResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AccruedResearchAndDevelopmentExpense"/>
  <xs:element name="AccruedDirectorAndOfficerCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AccruedDirectorAndOfficerCompensation"/>
  <xs:element name="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable"/>
  <xs:element name="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems"/>
  <xs:element name="RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable"/>
  <xs:element name="RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems"/>
  <xs:element name="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable"/>
  <xs:element name="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems"/>
  <xs:element name="RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable"/>
  <xs:element name="RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems"/>
  <xs:element name="OperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingLeaseLiabilities"/>
  <xs:element name="DeferredTaxAssetsOperatingLeaseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_DeferredTaxAssetsOperatingLeaseAssets"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue"/>
  <xs:element name="LeaseScheduleofCompanysLeaseExpensesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable"/>
  <xs:element name="LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities"/>
  <xs:element name="CashPortionOfTheLindNoteRepayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_CashPortionOfTheLindNoteRepayments"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_OrganizationandDescriptionofBusinessDetailsTable"/>
  <xs:element name="BenefitsReceivableForMilestoneAttained" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_BenefitsReceivableForMilestoneAttained"/>
  <xs:element name="PercentageOfRoyaltiesEqualing" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfRoyaltiesEqualing"/>
  <xs:element name="AcquisitionForNetSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AcquisitionForNetSales"/>
  <xs:element name="LiquidityGoingConcernandRestatementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_LiquidityGoingConcernandRestatementDetailsTable"/>
  <xs:element name="LiquidityGoingConcernandRestatementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LiquidityGoingConcernandRestatementDetailsLineItems"/>
  <xs:element name="WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_WorkingCapitalDeficit"/>
  <xs:element name="StockBasedExpensesAmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockBasedExpensesAmortizationPeriod"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="LaborPensionFundPerMonth" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LaborPensionFundPerMonth"/>
  <xs:element name="DefinedBenefitPlanFundedPercentages" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DefinedBenefitPlanFundedPercentages"/>
  <xs:element name="CollaborativeAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_CollaborativeAgreementsDetailsTable"/>
  <xs:element name="NonrefundableUpfrontCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_NonrefundableUpfrontCashPayment"/>
  <xs:element name="PercentageOfPaymentsUnderCodevelopmentAgreement" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
  <xs:element name="IssuanceOfStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_IssuanceOfStockValue"/>
  <xs:element name="MilestonePaymentsRoyaltyPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_MilestonePaymentsRoyaltyPercentage"/>
  <xs:element name="NetSalesProfitPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NetSalesProfitPercentage"/>
  <xs:element name="AdditionCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdditionCashPayment"/>
  <xs:element name="EquityMethodLongTermInvestment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_EquityMethodLongTermInvestment"/>
  <xs:element name="ServiceAgreementEligibilityAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ServiceAgreementEligibilityAmount"/>
  <xs:element name="MilestoneRegulatoryPaymentAmountPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_MilestoneRegulatoryPaymentAmountPeriod"/>
  <xs:element name="WorkingCapitalConvertibleLoanPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WorkingCapitalConvertibleLoanPercentage"/>
  <xs:element name="EquityMethodInvestmentsOwnershipPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_EquityMethodInvestmentsOwnershipPercentage"/>
  <xs:element name="MilestoneRegulatoryPaymentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_MilestoneRegulatoryPaymentAmount"/>
  <xs:element name="RoyaltiesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_RoyaltiesPercentage"/>
  <xs:element name="ReceivedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_ReceivedShares"/>
  <xs:element name="LicensingAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_LicensingAgreement"/>
  <xs:element name="ConsiderationPaidForAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConsiderationPaidForAgreement"/>
  <xs:element name="AdditionalMilestonePaymentInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdditionalMilestonePaymentInCash"/>
  <xs:element name="NumberOfSharesReceived" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NumberOfSharesReceived"/>
  <xs:element name="PercentageOfDevelopAndCommercialize" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfDevelopAndCommercialize"/>
  <xs:element name="LicensingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_LicensingFees"/>
  <xs:element name="PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable"/>
  <xs:element name="LongTermInvestmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_LongTermInvestmentsDetailsTable"/>
  <xs:element name="PercentageCommonStocksShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageCommonStocksShares"/>
  <xs:element name="ConvertibleNotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_ConvertibleNotesPayableDetailsTable"/>
  <xs:element name="OutstandingBalanceAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OutstandingBalanceAmount"/>
  <xs:element name="PercentageOfAverageAmount" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfAverageAmount"/>
  <xs:element name="PercentageOfCashPermium" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfCashPermium"/>
  <xs:element name="PercentageOfOutstandingPrincipalAmount" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfOutstandingPrincipalAmount"/>
  <xs:element name="PurchaseWarrantTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PurchaseWarrantTerm"/>
  <xs:element name="PurchasePriceAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_PurchasePriceAmount"/>
  <xs:element name="DebtInstrumentOutstandingPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_DebtInstrumentOutstandingPrincipal"/>
  <xs:element name="ConsiderationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConsiderationAmount"/>
  <xs:element name="PercentageOfAnnualDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfAnnualDiscountRate"/>
  <xs:element name="TradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TradingDays"/>
  <xs:element name="ConsecutiveDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConsecutiveDays"/>
  <xs:element name="ShortTermLoansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_ShortTermLoansDetailsTable"/>
  <xs:element name="ShortTermDebtMaturityDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShortTermDebtMaturityDate"/>
  <xs:element name="RelatedPartiesTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_RelatedPartiesTransactionsDetailsTable"/>
  <xs:element name="WorkingCapitalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WorkingCapitalPercentage"/>
  <xs:element name="LoanAgreementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_LoanAgreementAmount"/>
  <xs:element name="RecognizedCreditLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_RecognizedCreditLosses"/>
  <xs:element name="OutstandingPrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OutstandingPrincipalAmount"/>
  <xs:element name="PercentageOfWorkingCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfWorkingCapital"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_EquityDetailsTable"/>
  <xs:element name="AggregateCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AggregateCommonStockShares"/>
  <xs:element name="AssetConsiderationCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_AssetConsiderationCommonStock"/>
  <xs:element name="OutstandingLiabilityOwnedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OutstandingLiabilityOwnedAmount"/>
  <xs:element name="AverageIssuancePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AverageIssuancePricePerShare"/>
  <xs:element name="CommonStockSharesIssuedForRent" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CommonStockSharesIssuedForRent"/>
  <xs:element name="NonControllingInterestConsiderationShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NonControllingInterestConsiderationShare"/>
  <xs:element name="ConsultingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConsultingFee"/>
  <xs:element name="StockIssueDuringPeriodCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssueDuringPeriodCommonShares"/>
  <xs:element name="StockOptionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_StockOptionsDetailsTable"/>
  <xs:element name="SharesReceived" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SharesReceived"/>
  <xs:element name="royaltiesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_royaltiesPercentage"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_SubsequentEventsDetailsTable"/>
  <xs:element name="UnregisteredPricePerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_UnregisteredPricePerShares"/>
  <xs:element name="ABVCAndBioLiteTaiwanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ABVCAndBioLiteTaiwanMember"/>
  <xs:element name="ABVCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ABVCMember"/>
  <xs:element name="AdvisorsOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdvisorsOneMember"/>
  <xs:element name="AdvisorsTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdvisorsTwoMember"/>
  <xs:element name="AiBtlBioPharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AiBtlBioPharmaIncMember"/>
  <xs:element name="AiBtlHoldingBioPharmaIncAiBtlHoldingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember"/>
  <xs:element name="AiBtlHoldingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AiBtlHoldingMember"/>
  <xs:element name="AsRestatedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AsRestatedMember"/>
  <xs:element name="BHKCoDevelopmentAggreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BHKCoDevelopmentAggreementMember"/>
  <xs:element name="BHKCoDevelopmentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BHKCoDevelopmentAgreementMember"/>
  <xs:element name="BioFirstAustraliaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstAustraliaMember"/>
  <xs:element name="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
  <xs:element name="BioFirstCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstCorporationMember"/>
  <xs:element name="BioFirstCorporationtheBioFirstMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstCorporationtheBioFirstMember"/>
  <xs:element name="BioFirstMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstMember"/>
  <xs:element name="BioFirstReceivesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstReceivesMember"/>
  <xs:element name="BioFirstStockPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstStockPurchaseAgreementMember"/>
  <xs:element name="BioHopeKingCorporationBHKMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioHopeKingCorporationBHKMember"/>
  <xs:element name="BioHopeKingCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioHopeKingCorporationMember"/>
  <xs:element name="BioLiteBVIIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioLiteBVIIncMember"/>
  <xs:element name="BioLiteJPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioLiteJPMember"/>
  <xs:element name="BioLiteJapanKKBioLiteJPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioLiteJapanKKBioLiteJPMember"/>
  <xs:element name="BioLiteJapanKKMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioLiteJapanKKMember"/>
  <xs:element name="BioLiteJapanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioLiteJapanMember"/>
  <xs:element name="BioLiteTaiwanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioLiteTaiwanMember"/>
  <xs:element name="BraingenesisBiotechnologyCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BraingenesisBiotechnologyCoLtdMember"/>
  <xs:element name="CTBCBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CTBCBankMember"/>
  <xs:element name="CTBCLoanAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CTBCLoanAgreementsMember"/>
  <xs:element name="CashPaidMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CashPaidMember"/>
  <xs:element name="CathayUnitedBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CathayUnitedBankMember"/>
  <xs:element name="CathayUnitedLoanAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CathayUnitedLoanAgreementMember"/>
  <xs:element name="ChiefStrategicOfficerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ChiefStrategicOfficerMember"/>
  <xs:element name="ClientMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ClientMember"/>
  <xs:element name="CodevelopmentagreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CodevelopmentagreementMember"/>
  <xs:element name="CollaborativeAgreementWithForSeeConEyeCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember"/>
  <xs:element name="ConsultantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConsultantMember"/>
  <xs:element name="ConversionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConversionMember"/>
  <xs:element name="ConvertibleLoanAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConvertibleLoanAgreementMember"/>
  <xs:element name="DecemberLetterAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DecemberLetterAgreementMember"/>
  <xs:element name="DirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DirectorsMember"/>
  <xs:element name="EuroAsiaInvestmentFinanceCorpLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_EuroAsiaInvestmentFinanceCorpLtdMember"/>
  <xs:element name="ExistingWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ExistingWarrantsMember"/>
  <xs:element name="FEYEMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_FEYEMember"/>
  <xs:element name="FirstLINDNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_FirstLINDNoteMember"/>
  <xs:element name="ForSeeConEyeCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ForSeeConEyeCorporationMember"/>
  <xs:element name="GenePharmIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_GenePharmIncMember"/>
  <xs:element name="GenePharmInctheGenePharmMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_GenePharmInctheGenePharmMember"/>
  <xs:element name="GenepharmBiotechCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_GenepharmBiotechCorporationMember"/>
  <xs:element name="JaimesVargasRussmanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_JaimesVargasRussmanMember"/>
  <xs:element name="JiangsAdvancedFundsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_JiangsAdvancedFundsMember"/>
  <xs:element name="LicensingAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LicensingAgreementMember"/>
  <xs:element name="LindGlobalFundIILPLindMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LindGlobalFundIILPLindMember"/>
  <xs:element name="LindGlobalFundIILPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LindGlobalFundIILPMember"/>
  <xs:element name="LindMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LindMember"/>
  <xs:element name="LindNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LindNoteMember"/>
  <xs:element name="LindNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LindNotesMember"/>
  <xs:element name="LindNotesPayableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LindNotesPayableMember"/>
  <xs:element name="LindOfferingsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LindOfferingsMember"/>
  <xs:element name="LindWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LindWarrantMember"/>
  <xs:element name="LionArtPromotionIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LionArtPromotionIncMember"/>
  <xs:element name="LionArtsPromotionIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LionArtsPromotionIncMember"/>
  <xs:element name="LoanAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LoanAgreementMember"/>
  <xs:element name="LucidaimCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LucidaimCoLtdMember"/>
  <xs:element name="NewWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NewWarrantsMember"/>
  <xs:element name="OncoXBioPharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OncoXBioPharmaIncMember"/>
  <xs:element name="OncoXBiopPharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OncoXBiopPharmaIncMember"/>
  <xs:element name="OncoXMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OncoXMember"/>
  <xs:element name="OtherConvertibleNotesPayableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OtherConvertibleNotesPayableMember"/>
  <xs:element name="OtherIndividualMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OtherIndividualMember"/>
  <xs:element name="OtherIndividualThirdPartyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OtherIndividualThirdPartyMember"/>
  <xs:element name="OtherNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OtherNoteMember"/>
  <xs:element name="OtherNoteOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OtherNoteOneMember"/>
  <xs:element name="PostSplitMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PostSplitMember"/>
  <xs:element name="PostretirementAndPostemploymentBenefitsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PostretirementAndPostemploymentBenefitsMember"/>
  <xs:element name="PreExistingWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PreExistingWarrantsMember"/>
  <xs:element name="PreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PreFundedWarrantsMember"/>
  <xs:element name="RgeneCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RgeneCorporationMember"/>
  <xs:element name="RgeneCorporationtheRgeneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RgeneCorporationtheRgeneMember"/>
  <xs:element name="RgeneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RgeneMember"/>
  <xs:element name="RgeneStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RgeneStudiesMember"/>
  <xs:element name="SecondLINDNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SecondLINDNoteMember"/>
  <xs:element name="SecondLINDNoteOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SecondLINDNoteOneMember"/>
  <xs:element name="SecondLindNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SecondLindNoteMember"/>
  <xs:element name="ShareholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareholdersMember"/>
  <xs:element name="ShulingJiangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShulingJiangMember"/>
  <xs:element name="StockSubScriptionReceivableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockSubScriptionReceivableMember"/>
  <xs:element name="SubscribedStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SubscribedStockMember"/>
  <xs:element name="TaiwanCentralDepositInsuranceCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TaiwanCentralDepositInsuranceCorporationMember"/>
  <xs:element name="TheJiangsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TheJiangsMember"/>
  <xs:element name="TheJiangsOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TheJiangsOneMember"/>
  <xs:element name="ThirdLINDNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ThirdLINDNoteMember"/>
  <xs:element name="ThirdLetterAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ThirdLetterAgreementMember"/>
  <xs:element name="TwoClientMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TwoClientMember"/>
  <xs:element name="TwoThousandSixteenEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
  <xs:element name="USFederalDepositInsuranceCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_USFederalDepositInsuranceCorporationMember"/>
  <xs:element name="UnregisteredRestrictedSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_UnregisteredRestrictedSharesMember"/>
  <xs:element name="UnregisteredSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_UnregisteredSharesMember"/>
  <xs:element name="WarrantDebtDiscountMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WarrantDebtDiscountMember"/>
  <xs:element name="YuanGeneCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_YuanGeneCorporationMember"/>
  <xs:element name="ZhongHuiLianHeJiTuanLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ZhongHuiLianHeJiTuanLtdMember"/>
  <xs:element name="ZhonghuiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ZhonghuiMember"/>
  <xs:element name="CollaborativeAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CollaborativeAgreementsAbstract"/>
  <xs:element name="LiquidityAndGoingConcernLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LiquidityAndGoingConcernLineItems"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>abvc-20250331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 15 15:05:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedBalanceSheet" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedIncomeStatement" roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedCashFlow" roleURI="http://metuboutique.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable" roleURI="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofReconciliationofTotalSegmentGrossProfitTable" roleURI="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofPropertyandEquipmentTable" roleURI="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable" roleURI="http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofIncomeTaxBenefitExpenseTable" roleURI="http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofDeferredTaxAssetsLiabilityTable" roleURI="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" roleURI="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0" roleURI="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofReconciliationofTotalSegmentGrossProfitTable0" roleURI="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofDeferredTaxAssetsLiabilityTable0" roleURI="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0" roleURI="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"/>
  <calculationLink xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentForLongtermInvestmentsNoncurrent" xlink:href="abvc-20250331.xsd#abvc_PrepaymentForLongtermInvestmentsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="abvc_PrepaymentForLongtermInvestmentsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBorrowings" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDepositLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_SecurityDepositLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubscriptionReceivedInAdvance" xlink:href="abvc-20250331.xsd#abvc_StockSubscriptionReceivedInAdvance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="abvc_StockSubscriptionReceivedInAdvance" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_SubleaseIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnInvestments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnInvestments" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNpoXXXMi0ISiQMYRhfARCZqodsmYe5mpcuap9v90/VTIewyY3i091+2fVbljGWA+oIMmRhsCng8ZWIeu6RFmHqDuVsiXSHIAQzP/FPyRsu9wu9TXs5L6z+Vj4GR0/VqMj6bP7RRDRffTIrCvruey21RYJVvSYvm8Jzp97AamTzuDMMUwKlnyiSholDG7f+vUMQU=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_ProceedsFromIssuanceOfAPromissoryNote" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromIssuanceOfAPromissoryNote"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="abvc_ProceedsFromIssuanceOfAPromissoryNote" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_ProceedsFromSubsidiarysShareholderContribution" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromSubsidiarysShareholderContribution"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="abvc_ProceedsFromSubsidiarysShareholderContribution" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="abvc_RepurchaseOfTreasuryStocks" xlink:href="abvc-20250331.xsd#abvc_RepurchaseOfTreasuryStocks"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="abvc_RepurchaseOfTreasuryStocks" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_SubleaseIncome" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainLossOnInvestments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ShareBasedCompensation" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpenseNonoperating" order="11" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:label="abvc_AccruedResearchAndDevelopmentExpense" xlink:href="abvc-20250331.xsd#abvc_AccruedResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="abvc_AccruedResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_AccruedDirectorAndOfficerCompensation" xlink:href="abvc-20250331.xsd#abvc_AccruedDirectorAndOfficerCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="abvc_AccruedDirectorAndOfficerCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:href="abvc-20250331.xsd#abvc_DeferredTaxAssetsOperatingLeaseAssets"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeaseLiabilities" xlink:href="abvc-20250331.xsd#abvc_OperatingLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:to="abvc_OperatingLeaseLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_SubleaseIncome" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpenseNonoperating" order="10" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:href="abvc-20250331.xsd#abvc_DeferredTaxAssetsOperatingLeaseAssets"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeaseLiabilities" xlink:href="abvc-20250331.xsd#abvc_OperatingLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:to="abvc_OperatingLeaseLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>abvc-20250331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 15 15:05:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedBalanceSheet" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedIncomeStatement" roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedCashFlow" roleURI="http://metuboutique.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable" roleURI="http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_OrganizationandDescriptionofBusiness" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LiquidityGoingConcernandRestatement" roleURI="http://metuboutique.com/role/LiquidityGoingConcernandRestatement"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SummaryofSignificantAccountingPolicies" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_CollaborativeAgreements" roleURI="http://metuboutique.com/role/CollaborativeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_PropertyandEquipmentandPrepamentforAssetAcquisition" roleURI="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisition"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LongTermInvestments" roleURI="http://metuboutique.com/role/LongTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConvertibleNotesPayable" roleURI="http://metuboutique.com/role/ConvertibleNotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ShortTermLoans" roleURI="http://metuboutique.com/role/ShortTermLoans"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_RelatedPartiesTransactions" roleURI="http://metuboutique.com/role/RelatedPartiesTransactions"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_IncomeTaxes" roleURI="http://metuboutique.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_Equity" roleURI="http://metuboutique.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_StockOptions" roleURI="http://metuboutique.com/role/StockOptions"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LossPerShare" roleURI="http://metuboutique.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_Lease" roleURI="http://metuboutique.com/role/Lease"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_CommitmentsandContingencies" roleURI="http://metuboutique.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_Acquisition" roleURI="http://metuboutique.com/role/Acquisition"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SubsequentEvents" roleURI="http://metuboutique.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AccountingPoliciesByPolicy" roleURI="http://metuboutique.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LiquidityGoingConcernandRestatementTables" roleURI="http://metuboutique.com/role/LiquidityGoingConcernandRestatementTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_PropertyandEquipmentandPrepamentforAssetAcquisitionTables" roleURI="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LongTermInvestmentsTables" roleURI="http://metuboutique.com/role/LongTermInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConvertibleNotesPayableTables" roleURI="http://metuboutique.com/role/ConvertibleNotesPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ShortTermLoansTables" roleURI="http://metuboutique.com/role/ShortTermLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_RelatedPartiesTransactionsTables" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_IncomeTaxesTables" roleURI="http://metuboutique.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_EquityTables" roleURI="http://metuboutique.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_StockOptionsTables" roleURI="http://metuboutique.com/role/StockOptionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LossPerShareTables" roleURI="http://metuboutique.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LeaseTables" roleURI="http://metuboutique.com/role/LeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AcquisitionTables" roleURI="http://metuboutique.com/role/AcquisitionTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofImpactoftheRestatementTable" roleURI="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofEstimatedUsefulLifeTable" roleURI="http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable" roleURI="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofReconciliationofTotalSegmentGrossProfitTable" roleURI="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofPropertyandEquipmentTable" roleURI="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOwnershipPercentagesofEachInvesteeTable" roleURI="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofExtenttheInvesteeReliesTable" roleURI="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLongTermInvestmentTable" roleURI="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofBalanceSheetsTable" roleURI="http://metuboutique.com/role/ScheduleofBalanceSheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofStatementsofOperationsTable" roleURI="http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable" roleURI="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofCarryingAmountsoftheLiabilityComponentTable" roleURI="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofShortTermLoansTable" roleURI="http://metuboutique.com/role/ScheduleofShortTermLoansTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" roleURI="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable" roleURI="http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAccountsReceivableDuefromRelatedPartiesTable" roleURI="http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable" roleURI="http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAmountDuetoRelatedPartiesTable" roleURI="http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofIncomeTaxBenefitExpenseTable" roleURI="http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofDeferredTaxAssetsLiabilityTable" roleURI="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofWarrantsIssuedandOutstandingTable" roleURI="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOptionsIssuedandOutstandingTable" roleURI="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLossPerShareTable" roleURI="http://metuboutique.com/role/ScheduleofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" roleURI="http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofCompanysLeaseExpensesTable" roleURI="http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" roleURI="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" roleURI="http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofImpactoftheRestatementTable0" roleURI="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0" roleURI="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofReconciliationofTotalSegmentGrossProfitTable0" roleURI="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOwnershipPercentagesofEachInvesteeTable0" roleURI="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofExtenttheInvesteeReliesTable0" roleURI="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLongTermInvestmentTable0" roleURI="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0" roleURI="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofCarryingAmountsoftheLiabilityComponentTable0" roleURI="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0" roleURI="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofShortTermLoansTable0" roleURI="http://metuboutique.com/role/ScheduleofShortTermLoansTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0" roleURI="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofDeferredTaxAssetsLiabilityTable0" roleURI="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofWarrantsIssuedandOutstandingTable0" roleURI="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOptionsIssuedandOutstandingTable0" roleURI="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLossPerShareTable0" roleURI="http://metuboutique.com/role/ScheduleofLossPerShareTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLeaseTable" roleURI="http://metuboutique.com/role/ScheduleofLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0" roleURI="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_OrganizationandDescriptionofBusinessDetails" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LiquidityGoingConcernandRestatementDetails" roleURI="http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_CollaborativeAgreementsDetails" roleURI="http://metuboutique.com/role/CollaborativeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_PropertyandEquipmentandPrepamentforAssetAcquisitionDetails" roleURI="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LongTermInvestmentsDetails" roleURI="http://metuboutique.com/role/LongTermInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConvertibleNotesPayableDetails" roleURI="http://metuboutique.com/role/ConvertibleNotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ShortTermLoansDetails" roleURI="http://metuboutique.com/role/ShortTermLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_RelatedPartiesTransactionsDetails" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_IncomeTaxesDetails" roleURI="http://metuboutique.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_EquityDetails" roleURI="http://metuboutique.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_StockOptionsDetails" roleURI="http://metuboutique.com/role/StockOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AcquisitionDetails" roleURI="http://metuboutique.com/role/AcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SubsequentEventsDetails" roleURI="http://metuboutique.com/role/SubsequentEventsDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentForLongtermInvestmentsNoncurrent" xlink:href="abvc-20250331.xsd#abvc_PrepaymentForLongtermInvestmentsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_PrepaymentForLongtermInvestmentsNoncurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDepositLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDepositLiability" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubscriptionReceivedInAdvance" xlink:href="abvc-20250331.xsd#abvc_StockSubscriptionReceivedInAdvance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockSubscriptionReceivedInAdvance" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValue" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterest" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" order="39" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SubleaseIncome" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RepurchaseOfTreasuryStocks" xlink:href="abvc-20250331.xsd#abvc_RepurchaseOfTreasuryStocks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abvc_RepurchaseOfTreasuryStocks" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ProceedsFromIssuanceOfAPromissoryNote" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromIssuanceOfAPromissoryNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abvc_ProceedsFromIssuanceOfAPromissoryNote" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ProceedsFromSubsidiarysShareholderContribution" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromSubsidiarysShareholderContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abvc_ProceedsFromSubsidiarysShareholderContribution" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" xlink:href="abvc-20250331.xsd#abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfCommonStockForConversionOfDebt" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonStockForConversionOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abvc_IssuanceOfCommonStockForConversionOfDebt" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="44" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SubscribedStockMember" xlink:href="abvc-20250331.xsd#abvc_SubscribedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abvc_SubscribedStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubScriptionReceivableMember" xlink:href="abvc-20250331.xsd#abvc_StockSubScriptionReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abvc_StockSubScriptionReceivableMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PriorPeriodAdjustment" xlink:href="abvc-20250331.xsd#abvc_PriorPeriodAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_PriorPeriodAdjustment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" xlink:href="abvc-20250331.xsd#abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfCommonShareForLindCNRepayment" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonShareForLindCNRepayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_IssuanceOfCommonShareForLindCNRepayment" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubscriptionReceived" xlink:href="abvc-20250331.xsd#abvc_StockSubscriptionReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockSubscriptionReceived" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="34" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/LiquidityGoingConcernandRestatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_LiquidityGoingConcernAndRestatementTextBlock" xlink:href="abvc-20250331.xsd#abvc_LiquidityGoingConcernAndRestatementTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="abvc_LiquidityGoingConcernAndRestatementTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/CollaborativeAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsAbstract" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/LongTermInvestments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_InvestmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ConvertibleNotesPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ShortTermLoans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/RelatedPartiesTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/StockOptions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/LossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/Lease" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/Acquisition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockReverseSplitPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_StockReverseSplitPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_StockReverseSplitPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConcentrationOfClientsPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_ConcentrationOfClientsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_ConcentrationOfClientsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_OtherThanTemporaryImpairmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayablePolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayablePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_ConvertibleNotesPayablePolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/LiquidityGoingConcernandRestatementTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/LongTermInvestmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_InvestmentTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ConvertibleNotesPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ShortTermLoansTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/StockOptionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/LossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/LeaseTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/AcquisitionTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_RestatementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_MinorityInterest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_InterestExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ProceedsFromSubsidiarysCommonStockSubscription" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromSubsidiarysCommonStockSubscription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="abvc_ProceedsFromSubsidiarysCommonStockSubscription" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" xlink:href="abvc-20250331.xsd#abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" xlink:href="abvc-20250331.xsd#abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" xlink:href="abvc-20250331.xsd#abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfCommonStockForConversionOfDebt" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonStockForConversionOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="abvc_IssuanceOfCommonStockForConversionOfDebt" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" xlink:href="abvc-20250331.xsd#abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems" xlink:to="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_Depreciation" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_GrossProfit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_SubleaseIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfOtherOwnershipInterestsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_ForSeeConEyeCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioFirstCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_OncoXBioPharmaIncMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_RgeneCorporationMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAdditionalInformation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAdditionalInformation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAdditionalInformation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanKKMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioLiteJapanKKMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_ForSeeConEyeCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstCorporationMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_OncoXBioPharmaIncMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneCorporationMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_ForSeeConEyeCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneCorporationMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanKKBioLiteJPMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKBioLiteJPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioLiteJapanKKBioLiteJPMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_OncoXBioPharmaIncMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DebtSecuritiesNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermInvestments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofBalanceSheetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofStatementsofOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SecondLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLINDNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_SecondLINDNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ThirdLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLINDNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_ThirdLINDNoteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherNoteMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_OtherNoteMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherNoteOneMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_OtherNoteOneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_FirstLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_FirstLINDNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_FirstLINDNoteMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SecondLINDNoteOneMember" xlink:href="abvc-20250331.xsd#abvc_SecondLINDNoteOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_SecondLINDNoteOneMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentIssuanceEntity" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentIssuanceEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_DebtInstrumentIssuanceEntity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentCommonStockToBeConverted" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCommonStockToBeConverted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_DebtInstrumentCommonStockToBeConverted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentCarryingValue" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_DebtInstrumentCarryingValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_AccruedResearchAndDevelopmentExpense" xlink:href="abvc-20250331.xsd#abvc_AccruedResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="abvc_AccruedResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AccruedDirectorAndOfficerCompensation" xlink:href="abvc-20250331.xsd#abvc_AccruedDirectorAndOfficerCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="abvc_AccruedDirectorAndOfficerCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofShortTermLoansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedBankMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayUnitedBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCBankMember" xlink:href="abvc-20250331.xsd#abvc_CTBCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CTBCBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherIndividualMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_OtherIndividualMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstCorporationtheBioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationtheRgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneCorporationtheRgeneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmInctheGenePharmMember" xlink:href="abvc-20250331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_GenePharmInctheGenePharmMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsOneMember" xlink:href="abvc-20250331.xsd#abvc_TheJiangsOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_TheJiangsOneMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioLiteJapanMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationBHKMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationBHKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioHopeKingCorporationBHKMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_JaimesVargasRussmanMember" xlink:href="abvc-20250331.xsd#abvc_JaimesVargasRussmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_JaimesVargasRussmanMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtsPromotionIncMember" xlink:href="abvc-20250331.xsd#abvc_LionArtsPromotionIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LionArtsPromotionIncMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LicensingAgreementMember" xlink:href="abvc-20250331.xsd#abvc_LicensingAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_LicensingAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXMember" xlink:href="abvc-20250331.xsd#abvc_OncoXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_OncoXMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_FEYEMember" xlink:href="abvc-20250331.xsd#abvc_FEYEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_FEYEMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmIncMember" xlink:href="abvc-20250331.xsd#abvc_GenePharmIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_GenePharmIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstAustraliaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AiBtlHoldingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsMember" xlink:href="abvc-20250331.xsd#abvc_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_TheJiangsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareholdersMember" xlink:href="abvc-20250331.xsd#abvc_ShareholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_ShareholdersMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DirectorsMember" xlink:href="abvc-20250331.xsd#abvc_DirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_DirectorsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeaseLiabilities" xlink:href="abvc-20250331.xsd#abvc_OperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abvc_OperatingLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:href="abvc-20250331.xsd#abvc_DeferredTaxAssetsOperatingLeaseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abvc_DeferredTaxAssetsOperatingLeaseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLossPerShareAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesOperatingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CashPaidMember" xlink:href="abvc-20250331.xsd#abvc_CashPaidMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="abvc_CashPaidMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" xlink:href="abvc-20250331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_RestatementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsRestatedMember" xlink:href="abvc-20250331.xsd#abvc_AsRestatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="abvc_AsRestatedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_MinorityInterest" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_InterestExpense" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" xlink:href="abvc-20250331.xsd#abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfCommonStockForConversionOfDebt" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonStockForConversionOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="abvc_IssuanceOfCommonStockForConversionOfDebt" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_Depreciation" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_GrossProfit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_SubleaseIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfOtherOwnershipInterestsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNpoXXXMi0ISiQMYRhfARCZqodsmYe5mpcuap9v90/VTIewyY3i091+2fVbljGWA+oIMmRhsCng8ZWIeu6RFmHqDuVsiXSHIAQzP/FPyRsu9wu9TXs5L6z+Vj4GR0/VqMj6bP7RRDRffTIrCvruey21RYJVvSYvm8JzpaAVL36kvIRmQz3StZZL8iTlnP9zffrhc=] CSR-->
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_ForSeeConEyeCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioFirstCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_OncoXBioPharmaIncMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_RgeneCorporationMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanKKMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioLiteJapanKKMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAdditionalInformation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAdditionalInformation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAdditionalInformation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanKKMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioLiteJapanKKMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_ForSeeConEyeCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstCorporationMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_OncoXBioPharmaIncMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneCorporationMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_ForSeeConEyeCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneCorporationMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanKKBioLiteJPMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKBioLiteJPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioLiteJapanKKBioLiteJPMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_OncoXBioPharmaIncMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DebtSecuritiesNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermInvestments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SecondLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLINDNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_SecondLINDNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ThirdLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLINDNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_ThirdLINDNoteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherNoteMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_OtherNoteMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherNoteOneMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_OtherNoteOneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentIssuanceEntity" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentIssuanceEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_DebtInstrumentIssuanceEntity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentCommonStockToBeConverted" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCommonStockToBeConverted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_DebtInstrumentCommonStockToBeConverted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentCarryingValue" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abvc_DebtInstrumentCarryingValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_AccruedResearchAndDevelopmentExpense" xlink:href="abvc-20250331.xsd#abvc_AccruedResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="abvc_AccruedResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CashPortionOfTheLindNoteRepayments" xlink:href="abvc-20250331.xsd#abvc_CashPortionOfTheLindNoteRepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="abvc_CashPortionOfTheLindNoteRepayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofShortTermLoansTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedBankMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayUnitedBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCBankMember" xlink:href="abvc-20250331.xsd#abvc_CTBCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CTBCBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherIndividualMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_OtherIndividualMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstCorporationtheBioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationtheRgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneCorporationtheRgeneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmInctheGenePharmMember" xlink:href="abvc-20250331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_GenePharmInctheGenePharmMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsMember" xlink:href="abvc-20250331.xsd#abvc_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_TheJiangsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioLiteJapanMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationBHKMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationBHKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioHopeKingCorporationBHKMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_JaimesVargasRussmanMember" xlink:href="abvc-20250331.xsd#abvc_JaimesVargasRussmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_JaimesVargasRussmanMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtsPromotionIncMember" xlink:href="abvc-20250331.xsd#abvc_LionArtsPromotionIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_LionArtsPromotionIncMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstAustraliaMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_AiBtlHoldingMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareholdersMember" xlink:href="abvc-20250331.xsd#abvc_ShareholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_ShareholdersMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtPromotionIncMember" xlink:href="abvc-20250331.xsd#abvc_LionArtPromotionIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_LionArtPromotionIncMember" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DirectorsMember" xlink:href="abvc-20250331.xsd#abvc_DirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_DirectorsMember" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeaseLiabilities" xlink:href="abvc-20250331.xsd#abvc_OperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abvc_OperatingLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:href="abvc-20250331.xsd#abvc_DeferredTaxAssetsOperatingLeaseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abvc_DeferredTaxAssetsOperatingLeaseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofLossPerShareTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLossPerShareAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLeaseAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLeaseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:href="abvc-20250331.xsd#abvc_OrganizationandDescriptionofBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="abvc_OrganizationandDescriptionofBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ABVCMember" xlink:href="abvc-20250331.xsd#abvc_ABVCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_ABVCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteBVIIncMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteBVIIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_BioLiteBVIIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteTaiwanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_BioLiteTaiwanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShulingJiangMember" xlink:href="abvc-20250331.xsd#abvc_ShulingJiangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_ShulingJiangMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_AiBtlHoldingMember" order="4" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioLiteBVIIncMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioLiteTaiwanMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_ShulingJiangMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ABVCAndBioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_ABVCAndBioLiteTaiwanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_ABVCAndBioLiteTaiwanMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BenefitsReceivableForMilestoneAttained" xlink:href="abvc-20250331.xsd#abvc_BenefitsReceivableForMilestoneAttained"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="abvc_BenefitsReceivableForMilestoneAttained" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfRoyaltiesEqualing" xlink:href="abvc-20250331.xsd#abvc_PercentageOfRoyaltiesEqualing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="abvc_PercentageOfRoyaltiesEqualing" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AcquisitionForNetSales" xlink:href="abvc-20250331.xsd#abvc_AcquisitionForNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="abvc_AcquisitionForNetSales" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_LiquidityGoingConcernandRestatementDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LiquidityGoingConcernandRestatementDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LiquidityGoingConcernandRestatementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="abvc_LiquidityGoingConcernandRestatementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsTable" xlink:to="srt_RestatementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsTable" xlink:to="srt_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ZhongHuiLianHeJiTuanLtdMember" xlink:href="abvc-20250331.xsd#abvc_ZhongHuiLianHeJiTuanLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_ZhongHuiLianHeJiTuanLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlBioPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_AiBtlBioPharmaIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PostSplitMember" xlink:href="abvc-20250331.xsd#abvc_PostSplitMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abvc_PostSplitMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ZhonghuiMember" xlink:href="abvc-20250331.xsd#abvc_ZhonghuiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_ZhonghuiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WorkingCapitalDeficit" xlink:href="abvc-20250331.xsd#abvc_WorkingCapitalDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="abvc_WorkingCapitalDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateOwnedValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateOwnedValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_RealEstateOwnedValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_Assets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_InterestExpenseOther" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockBasedExpensesAmortizationPeriod" xlink:href="abvc-20250331.xsd#abvc_StockBasedExpensesAmortizationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="abvc_StockBasedExpensesAmortizationPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_GranteeStatusAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeAndTierIdentifierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeAndTierIdentifierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:to="us-gaap_TypeAndTierIdentifierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeAndTierIdentifierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeAndTierIdentifierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:to="us-gaap_TypeAndTierIdentifierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TaiwanCentralDepositInsuranceCorporationMember" xlink:href="abvc-20250331.xsd#abvc_TaiwanCentralDepositInsuranceCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeAndTierIdentifierDomain" xlink:to="abvc_TaiwanCentralDepositInsuranceCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_USFederalDepositInsuranceCorporationMember" xlink:href="abvc-20250331.xsd#abvc_USFederalDepositInsuranceCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeAndTierIdentifierDomain" xlink:to="abvc_USFederalDepositInsuranceCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ClientMember" xlink:href="abvc-20250331.xsd#abvc_ClientMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="abvc_ClientMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TwoClientMember" xlink:href="abvc-20250331.xsd#abvc_TwoClientMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="abvc_TwoClientMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PostretirementAndPostemploymentBenefitsMember" xlink:href="abvc-20250331.xsd#abvc_PostretirementAndPostemploymentBenefitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_PostretirementAndPostemploymentBenefitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyExcessExpenseReimbursable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LaborPensionFundPerMonth" xlink:href="abvc-20250331.xsd#abvc_LaborPensionFundPerMonth"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="abvc_LaborPensionFundPerMonth" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DefinedBenefitPlanFundedPercentages" xlink:href="abvc-20250331.xsd#abvc_DefinedBenefitPlanFundedPercentages"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="abvc_DefinedBenefitPlanFundedPercentages" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_RestrictedCash" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_CollaborativeAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_CollaborativeAgreementsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteTaiwanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioLiteTaiwanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YuanGeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_YuanGeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_YuanGeneCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXBiopPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBiopPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_OncoXBiopPharmaIncMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_RgeneCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneStudiesMember" xlink:href="abvc-20250331.xsd#abvc_RgeneStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_RgeneStudiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BHKCoDevelopmentAgreementMember" xlink:href="abvc-20250331.xsd#abvc_BHKCoDevelopmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_BHKCoDevelopmentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CodevelopmentagreementMember" xlink:href="abvc-20250331.xsd#abvc_CodevelopmentagreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_CodevelopmentagreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstStockPurchaseAgreementMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstStockPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_BioFirstStockPurchaseAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ForSeeConEyeCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServiceAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ServiceAgreementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentMilestones" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NonrefundableUpfrontCashPayment" xlink:href="abvc-20250331.xsd#abvc_NonrefundableUpfrontCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_NonrefundableUpfrontCashPayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:href="abvc-20250331.xsd#abvc_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfStockValue" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_IssuanceOfStockValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage" xlink:href="abvc-20250331.xsd#abvc_MilestonePaymentsRoyaltyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_MilestonePaymentsRoyaltyPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NetSalesProfitPercentage" xlink:href="abvc-20250331.xsd#abvc_NetSalesProfitPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_NetSalesProfitPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForParticipationLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdditionCashPayment" xlink:href="abvc-20250331.xsd#abvc_AdditionCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_AdditionCashPayment" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityMethodLongTermInvestment" xlink:href="abvc-20250331.xsd#abvc_EquityMethodLongTermInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_EquityMethodLongTermInvestment" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ServiceAgreementEligibilityAmount" xlink:href="abvc-20250331.xsd#abvc_ServiceAgreementEligibilityAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_ServiceAgreementEligibilityAmount" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestoneRegulatoryPaymentAmountPeriod" xlink:href="abvc-20250331.xsd#abvc_MilestoneRegulatoryPaymentAmountPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_MilestoneRegulatoryPaymentAmountPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LoansPayable" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WorkingCapitalConvertibleLoanPercentage" xlink:href="abvc-20250331.xsd#abvc_WorkingCapitalConvertibleLoanPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_WorkingCapitalConvertibleLoanPercentage" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityMethodInvestmentsOwnershipPercentage" xlink:href="abvc-20250331.xsd#abvc_EquityMethodInvestmentsOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_EquityMethodInvestmentsOwnershipPercentage" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesAndLicenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TaxesAndLicenses" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssued" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestoneRegulatoryPaymentAmount" xlink:href="abvc-20250331.xsd#abvc_MilestoneRegulatoryPaymentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_MilestoneRegulatoryPaymentAmount" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RoyaltiesPercentage" xlink:href="abvc-20250331.xsd#abvc_RoyaltiesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_RoyaltiesPercentage" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ReceivedShares" xlink:href="abvc-20250331.xsd#abvc_ReceivedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_ReceivedShares" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LicensingAgreement" xlink:href="abvc-20250331.xsd#abvc_LicensingAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_LicensingAgreement" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsiderationPaidForAgreement" xlink:href="abvc-20250331.xsd#abvc_ConsiderationPaidForAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_ConsiderationPaidForAgreement" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdditionalMilestonePaymentInCash" xlink:href="abvc-20250331.xsd#abvc_AdditionalMilestonePaymentInCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_AdditionalMilestonePaymentInCash" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NumberOfSharesReceived" xlink:href="abvc-20250331.xsd#abvc_NumberOfSharesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_NumberOfSharesReceived" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfDevelopAndCommercialize" xlink:href="abvc-20250331.xsd#abvc_PercentageOfDevelopAndCommercialize"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_PercentageOfDevelopAndCommercialize" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LicensingFees" xlink:href="abvc-20250331.xsd#abvc_LicensingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abvc_LicensingFees" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="41" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:href="abvc-20250331.xsd#abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TW" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TW"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TW" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ZhonghuiMember" xlink:href="abvc-20250331.xsd#abvc_ZhonghuiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_ZhonghuiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SharePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndLandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LandAndLandImprovements" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/LongTermInvestmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="abvc_LongTermInvestmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioFirstCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationtheRgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_RgeneCorporationtheRgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanKKMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioLiteJapanKKMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LucidaimCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_LucidaimCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_LucidaimCoLtdMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJPMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_BioLiteJPMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageCommonStocksShares" xlink:href="abvc-20250331.xsd#abvc_PercentageCommonStocksShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="abvc_PercentageCommonStocksShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_InvestmentOwnedBalanceShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ConvertibleNotesPayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_ConvertibleNotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="srt_StatementScenarioAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LindGlobalFundIILPMember" xlink:href="abvc-20250331.xsd#abvc_LindGlobalFundIILPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_LindGlobalFundIILPMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LindWarrantMember" xlink:href="abvc-20250331.xsd#abvc_LindWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_LindWarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherConvertibleNotesPayableMember" xlink:href="abvc-20250331.xsd#abvc_OtherConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_OtherConvertibleNotesPayableMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WarrantDebtDiscountMember" xlink:href="abvc-20250331.xsd#abvc_WarrantDebtDiscountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abvc_WarrantDebtDiscountMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abvc_LindWarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LindNotesPayableMember" xlink:href="abvc-20250331.xsd#abvc_LindNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abvc_LindNotesPayableMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LindNotesMember" xlink:href="abvc-20250331.xsd#abvc_LindNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LindNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SecondLindNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLindNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_SecondLindNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_OtherConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_LindNotesPayableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPreviousAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForPreviousAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PaymentsForPreviousAcquisition" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingBalanceAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingBalanceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_OutstandingBalanceAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfAverageAmount" xlink:href="abvc-20250331.xsd#abvc_PercentageOfAverageAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_PercentageOfAverageAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfCashPermium" xlink:href="abvc-20250331.xsd#abvc_PercentageOfCashPermium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_PercentageOfCashPermium" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfOutstandingPrincipalAmount" xlink:href="abvc-20250331.xsd#abvc_PercentageOfOutstandingPrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_PercentageOfOutstandingPrincipalAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralPartnersCapitalAccount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralPartnersCapitalAccount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_GeneralPartnersCapitalAccount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ReceivableWithImputedInterestFaceAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseWarrantTerm" xlink:href="abvc-20250331.xsd#abvc_PurchaseWarrantTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_PurchaseWarrantTerm" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchasePriceAmount" xlink:href="abvc-20250331.xsd#abvc_PurchasePriceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_PurchasePriceAmount" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentOutstandingPrincipal" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentOutstandingPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_DebtInstrumentOutstandingPrincipal" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_InterestExpenseOther" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsiderationAmount" xlink:href="abvc-20250331.xsd#abvc_ConsiderationAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_ConsiderationAmount" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfAnnualDiscountRate" xlink:href="abvc-20250331.xsd#abvc_PercentageOfAnnualDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_PercentageOfAnnualDiscountRate" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TradingDays" xlink:href="abvc-20250331.xsd#abvc_TradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_TradingDays" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsecutiveDays" xlink:href="abvc-20250331.xsd#abvc_ConsecutiveDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_ConsecutiveDays" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="35" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/ShortTermLoansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalHomeLoanBankAdvancesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_ShortTermLoansDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ShortTermLoansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="abvc_ShortTermLoansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ShortTermLoansDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ShortTermLoansDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ShortTermLoansDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedBankMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayUnitedBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCBankMember" xlink:href="abvc-20250331.xsd#abvc_CTBCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CTBCBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherIndividualMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_OtherIndividualMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherIndividualThirdPartyMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualThirdPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_OtherIndividualThirdPartyMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedLoanAgreementMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedLoanAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_CathayUnitedLoanAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCLoanAgreementsMember" xlink:href="abvc-20250331.xsd#abvc_CTBCLoanAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_CTBCLoanAgreementsMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_CathayUnitedLoanAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_InterestExpenseShortTermBorrowings" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ProceedsFromIssuanceOfAPromissoryNote" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromIssuanceOfAPromissoryNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="abvc_ProceedsFromIssuanceOfAPromissoryNote" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtPercentageBearingVariableInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShortTermDebtMaturityDate" xlink:href="abvc-20250331.xsd#abvc_ShortTermDebtMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="abvc_ShortTermDebtMaturityDate" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_RelatedPartiesTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXMember" xlink:href="abvc-20250331.xsd#abvc_OncoXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_OncoXMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementMember" xlink:href="abvc-20250331.xsd#abvc_LoanAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LoanAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BHKCoDevelopmentAggreementMember" xlink:href="abvc-20250331.xsd#abvc_BHKCoDevelopmentAggreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BHKCoDevelopmentAggreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_FEYEMember" xlink:href="abvc-20250331.xsd#abvc_FEYEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_FEYEMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleLoanAgreementMember" xlink:href="abvc-20250331.xsd#abvc_ConvertibleLoanAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_ConvertibleLoanAgreementMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_AiBtlHoldingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_JiangsAdvancedFundsMember" xlink:href="abvc-20250331.xsd#abvc_JiangsAdvancedFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_JiangsAdvancedFundsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_LoanAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstReceivesMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstReceivesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_BioFirstReceivesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConversionMember" xlink:href="abvc-20250331.xsd#abvc_ConversionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_ConversionMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LicensingAgreement" xlink:href="abvc-20250331.xsd#abvc_LicensingAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_LicensingAgreement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WorkingCapitalPercentage" xlink:href="abvc-20250331.xsd#abvc_WorkingCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_WorkingCapitalPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrincipalAmountOutstandingOnLoansSecuritized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositLiabilitiesAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDate" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionRate" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LoansPayable" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementAmount" xlink:href="abvc-20250331.xsd#abvc_LoanAgreementAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_LoanAgreementAmount" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RecognizedCreditLosses" xlink:href="abvc-20250331.xsd#abvc_RecognizedCreditLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_RecognizedCreditLosses" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingBalanceAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingBalanceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_OutstandingBalanceAmount" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingPrincipalAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingPrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_OutstandingPrincipalAmount" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseOther" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfWorkingCapital" xlink:href="abvc-20250331.xsd#abvc_PercentageOfWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_PercentageOfWorkingCapital" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityDetailsTable" xlink:href="abvc-20250331.xsd#abvc_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="srt_OwnershipAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20250331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abvc_TwoThousandSixteenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ThirdLetterAgreementMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLetterAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ThirdLetterAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PreFundedWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abvc_PreFundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NewWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_NewWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abvc_NewWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ExistingWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_ExistingWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abvc_ExistingWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_AiBtlHoldingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteTaiwanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_BioLiteTaiwanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShulingJiangMember" xlink:href="abvc-20250331.xsd#abvc_ShulingJiangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abvc_ShulingJiangMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultantMember" xlink:href="abvc-20250331.xsd#abvc_ConsultantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abvc_ConsultantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PreExistingWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_PreExistingWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abvc_PreExistingWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LindOfferingsMember" xlink:href="abvc-20250331.xsd#abvc_LindOfferingsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abvc_LindOfferingsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EuroAsiaInvestmentFinanceCorpLtdMember" xlink:href="abvc-20250331.xsd#abvc_EuroAsiaInvestmentFinanceCorpLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_EuroAsiaInvestmentFinanceCorpLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ZhonghuiMember" xlink:href="abvc-20250331.xsd#abvc_ZhonghuiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_ZhonghuiMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ABVCMember" xlink:href="abvc-20250331.xsd#abvc_ABVCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_ABVCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteBVIIncMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteBVIIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioLiteBVIIncMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LindGlobalFundIILPLindMember" xlink:href="abvc-20250331.xsd#abvc_LindGlobalFundIILPLindMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_LindGlobalFundIILPLindMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LindNoteMember" xlink:href="abvc-20250331.xsd#abvc_LindNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_LindNoteMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LindMember" xlink:href="abvc-20250331.xsd#abvc_LindMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_LindMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_LindGlobalFundIILPLindMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ThirdLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLINDNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_ThirdLINDNoteMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_LindMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ChiefStrategicOfficerMember" xlink:href="abvc-20250331.xsd#abvc_ChiefStrategicOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abvc_ChiefStrategicOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregateCommonStockShares" xlink:href="abvc-20250331.xsd#abvc_AggregateCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_AggregateCommonStockShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AssetConsiderationCommonStock" xlink:href="abvc-20250331.xsd#abvc_AssetConsiderationCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_AssetConsiderationCommonStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingLiabilityOwnedAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingLiabilityOwnedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_OutstandingLiabilityOwnedAmount" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AverageIssuancePricePerShare" xlink:href="abvc-20250331.xsd#abvc_AverageIssuancePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_AverageIssuancePricePerShare" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForRent" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockSharesIssuedForRent" xlink:href="abvc-20250331.xsd#abvc_CommonStockSharesIssuedForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_CommonStockSharesIssuedForRent" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_Cash" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NonControllingInterestConsiderationShare" xlink:href="abvc-20250331.xsd#abvc_NonControllingInterestConsiderationShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_NonControllingInterestConsiderationShare" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultingFee" xlink:href="abvc-20250331.xsd#abvc_ConsultingFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_ConsultingFee" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Land"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_Land" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseWarrantTerm" xlink:href="abvc-20250331.xsd#abvc_PurchaseWarrantTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_PurchaseWarrantTerm" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssueDuringPeriodCommonShares" xlink:href="abvc-20250331.xsd#abvc_StockIssueDuringPeriodCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abvc_StockIssueDuringPeriodCommonShares" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditDerivativeTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativeTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CreditDerivativeTerm1" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="43" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/StockOptionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_StockOptionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abvc_StockOptionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_StockOptionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_StockOptionsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20250331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abvc_TwoThousandSixteenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/AcquisitionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_SharesReceived" xlink:href="abvc-20250331.xsd#abvc_SharesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="abvc_SharesReceived" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BenefitsReceivableForMilestoneAttained" xlink:href="abvc-20250331.xsd#abvc_BenefitsReceivableForMilestoneAttained"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="abvc_BenefitsReceivableForMilestoneAttained" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_royaltiesPercentage" xlink:href="abvc-20250331.xsd#abvc_royaltiesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="abvc_royaltiesPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AcquisitionForNetSales" xlink:href="abvc-20250331.xsd#abvc_AcquisitionForNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="abvc_AcquisitionForNetSales" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://metuboutique.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_SubsequentEventsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="abvc_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdvisorsOneMember" xlink:href="abvc-20250331.xsd#abvc_AdvisorsOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abvc_AdvisorsOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdvisorsTwoMember" xlink:href="abvc-20250331.xsd#abvc_AdvisorsTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abvc_AdvisorsTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_UnregisteredSharesMember" xlink:href="abvc-20250331.xsd#abvc_UnregisteredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abvc_UnregisteredSharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_UnregisteredRestrictedSharesMember" xlink:href="abvc-20250331.xsd#abvc_UnregisteredRestrictedSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abvc_UnregisteredRestrictedSharesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DecemberLetterAgreementMember" xlink:href="abvc-20250331.xsd#abvc_DecemberLetterAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_DecemberLetterAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_AiBtlHoldingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SecondLindNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLindNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_SecondLindNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ThirdLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLINDNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abvc_ThirdLINDNoteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_UnregisteredPricePerShares" xlink:href="abvc-20250331.xsd#abvc_UnregisteredPricePerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="abvc_UnregisteredPricePerShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromContributedCapital" order="9" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>abvc-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 15 15:05:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Shareholders&#8217; Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Total Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Total Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross (loss) profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrossProfit_lbl1" xml:lang="en-US">Segment Gross Profit (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_GrossProfit_lbl2" xml:lang="en-US">Gross profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before provision income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Loss before provision for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProfitLoss_lbl2" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss attributed to ABVC and subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss attributable to ABVC&#8217;s common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash outflows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Liquidity, Going Concern, and Restatement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationRevenueAbstract_lbl" xml:lang="en-US">Schedule of Revenue and Gross Profit Information of our Reportable Segment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_SegmentReportingInformationRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_lbl" xml:lang="en-US">Schedule of Reconciliation of Total Segment Gross Profit [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsAbstract" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CollaborativeAgreementsAbstract_lbl" xml:lang="en-US">Collaborative Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementsAbstract" xlink:to="abvc_CollaborativeAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, and Prepament for Asset Acquisition [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestmentsAbstract_lbl" xml:lang="en-US">Long-Term Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xml:lang="en-US">Schedule of Components of Loss on Investment in Equity Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl0" xml:lang="en-US">Equity Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Convertible Notes Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US">Short-Term Loans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Parties Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl0" xml:lang="en-US">Due from related parties - non-current, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl1" xml:lang="en-US">Net, Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl2" xml:lang="en-US">Due from BHK</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Schedule of Income Tax (Benefit) Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total provision for income tax (benefit) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Provision for income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income tax (benefit) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets (Liability) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:href="abvc-20250331.xsd#abvc_DeferredTaxAssetsOperatingLeaseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="abvc_DeferredTaxAssetsOperatingLeaseAssets_lbl" xml:lang="en-US">Operating lease assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:to="abvc_DeferredTaxAssetsOperatingLeaseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl0" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Warrants Issued and Outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Outstanding ending (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding ending (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock Options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_lbl" xml:lang="en-US">Schedule of Options Issued and Outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl1" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesOperatingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Schedule of Operating Leases have Remaining Lease Terms [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments, undiscounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl" xml:lang="en-US">Acquisition [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xml:lang="en-US">Schedule of Acquisition was Accounted for Business Combination [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted cash amounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Accounts receivable - related parties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl1" xml:lang="en-US">Accounts receivable due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Due from related party- Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expense and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expense and other current asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermInvestments_lbl0" xml:lang="en-US">Equity Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentForLongtermInvestmentsNoncurrent" xlink:href="abvc-20250331.xsd#abvc_PrepaymentForLongtermInvestmentsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PrepaymentForLongtermInvestmentsNoncurrent_lbl" xml:lang="en-US">Prepayment for long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentForLongtermInvestmentsNoncurrent" xlink:to="abvc_PrepaymentForLongtermInvestmentsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Prepayment for asset acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term bank and other loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl1" xml:lang="en-US">Short term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating lease liabilities (current)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Amount due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable &#8211; third parties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDepositLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDepositLiability_lbl" xml:lang="en-US">Tenant security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability &#8211; non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating lease liabilities (non-current)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Ordinary shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubscriptionReceivedInAdvance" xlink:href="abvc-20250331.xsd#abvc_StockSubscriptionReceivedInAdvance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockSubscriptionReceivedInAdvance_lbl" xml:lang="en-US">Stock to be issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceivedInAdvance" xlink:to="abvc_StockSubscriptionReceivedInAdvance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LiabilitiesAndEquityAbstract" xlink:href="abvc-20250331.xsd#abvc_LiabilitiesAndEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LiabilitiesAndEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LiabilitiesAndEquityAbstract" xlink:to="abvc_LiabilitiesAndEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CurrentLiabilitiesAbstract0" xlink:href="abvc-20250331.xsd#abvc_CurrentLiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CurrentLiabilitiesAbstract0_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CurrentLiabilitiesAbstract0" xlink:to="abvc_CurrentLiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl2" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Operating sublease income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Gain (loss) on foreign exchange changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Loss on investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl0" xml:lang="en-US">Loss on investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites_lbl" xml:lang="en-US">Write off unclaimed accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites_lbl0" xml:lang="en-US">Loss on investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl2" xml:lang="en-US">Basic and diluted net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_UnlabeledAbstract" xlink:href="abvc-20250331.xsd#abvc_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnlabeledAbstract" xlink:to="abvc_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:href="abvc-20250331.xsd#abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract_lbl" xml:lang="en-US">Weighted average number of common shares outstanding (1):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted-average shares outstanding &#8211; Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted-average shares outstanding &#8211; Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingExpensesAbstract0" xlink:href="abvc-20250331.xsd#abvc_OperatingExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingExpensesAbstract0_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingExpensesAbstract0" xlink:to="abvc_OperatingExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherIncomeExpenseAbstract" xlink:href="abvc-20250331.xsd#abvc_OtherIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OtherIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherIncomeExpenseAbstract" xlink:to="abvc_OtherIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NetLossPerShareAbstract" xlink:href="abvc-20250331.xsd#abvc_NetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NetLossPerShareAbstract_lbl" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetLossPerShareAbstract" xlink:to="abvc_NetLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageNumberOfCommonSharesOutstandingAbstract" xlink:href="abvc-20250331.xsd#abvc_WeightedAverageNumberOfCommonSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageNumberOfCommonSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of common shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageNumberOfCommonSharesOutstandingAbstract" xlink:to="abvc_WeightedAverageNumberOfCommonSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Other assets &#8211; tenant security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Taxes payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Aggregate value of common stock (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from (repayment of) related party payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ProceedsFromIssuanceOfAPromissoryNote" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromIssuanceOfAPromissoryNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ProceedsFromIssuanceOfAPromissoryNote_lbl" xml:lang="en-US">Proceeds from issuance of a promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromIssuanceOfAPromissoryNote" xlink:to="abvc_ProceedsFromIssuanceOfAPromissoryNote_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_ProceedsFromIssuanceOfAPromissoryNote_lbl0" xml:lang="en-US">Proceeds from promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromIssuanceOfAPromissoryNote" xlink:to="abvc_ProceedsFromIssuanceOfAPromissoryNote_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US">Proceeds from common stock subscription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ProceedsFromSubsidiarysShareholderContribution" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromSubsidiarysShareholderContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ProceedsFromSubsidiarysShareholderContribution_lbl" xml:lang="en-US">Proceeds from subsidiary&apos;s executive contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromSubsidiarysShareholderContribution" xlink:to="abvc_ProceedsFromSubsidiarysShareholderContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CashPaidDuringTheYearForAbstract" xlink:href="abvc-20250331.xsd#abvc_CashPaidDuringTheYearForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CashPaidDuringTheYearForAbstract_lbl" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPaidDuringTheYearForAbstract" xlink:to="abvc_CashPaidDuringTheYearForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest expense paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash financing and investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" xlink:href="abvc-20250331.xsd#abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty_lbl" xml:lang="en-US">Prepayment for asset acquisition by issuing common stock to a third party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" xlink:to="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfCommonStockForConversionOfDebt" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonStockForConversionOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_IssuanceOfCommonStockForConversionOfDebt_lbl" xml:lang="en-US">Issuance of common stock for conversion of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfCommonStockForConversionOfDebt" xlink:to="abvc_IssuanceOfCommonStockForConversionOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices_lbl" xml:lang="en-US">Issuance of subsidiary&#8217;s common stock for consulting services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices" xlink:to="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CashFlowsFromOperatingActivitiesAbstract" xlink:href="abvc-20250331.xsd#abvc_CashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashFlowsFromOperatingActivitiesAbstract" xlink:to="abvc_CashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="abvc-20250331.xsd#abvc_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="abvc_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:href="abvc-20250331.xsd#abvc_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="abvc_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CashFlowsFromInvestingActivitiesAbstract" xlink:href="abvc-20250331.xsd#abvc_CashFlowsFromInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CashFlowsFromInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="abvc_CashFlowsFromInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CashFlowsFromFinancingActivitiesAbstract" xlink:href="abvc-20250331.xsd#abvc_CashFlowsFromFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CashFlowsFromFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="abvc_CashFlowsFromFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Proceeds from short-term loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Due to related parties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CashAndCashEquivalentsAndRestrictedCashAbstract" xlink:href="abvc-20250331.xsd#abvc_CashAndCashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CashAndCashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashAndCashEquivalentsAndRestrictedCashAbstract" xlink:to="abvc_CashAndCashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SupplementalDisclosureOfCashFlowsAbstract" xlink:href="abvc-20250331.xsd#abvc_SupplementalDisclosureOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SupplementalDisclosureOfCashFlowsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SupplementalDisclosureOfCashFlowsAbstract" xlink:to="abvc_SupplementalDisclosureOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CashPaidDuringTheYearForAbstract0" xlink:href="abvc-20250331.xsd#abvc_CashPaidDuringTheYearForAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CashPaidDuringTheYearForAbstract0_lbl" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPaidDuringTheYearForAbstract0" xlink:to="abvc_CashPaidDuringTheYearForAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NonCashFinancingAndInvestingActivitiesAbstract" xlink:href="abvc-20250331.xsd#abvc_NonCashFinancingAndInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NonCashFinancingAndInvestingActivitiesAbstract_lbl" xml:lang="en-US">Non-cash financing and investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonCashFinancingAndInvestingActivitiesAbstract" xlink:to="abvc_NonCashFinancingAndInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Acquiring control of the land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl0" xml:lang="en-US">Value of acquired amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Conversion of convertible note due from related parties to equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Principal amount of converted debt (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_PriorPeriodAdjustment" xlink:href="abvc-20250331.xsd#abvc_PriorPeriodAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PriorPeriodAdjustment_lbl" xml:lang="en-US">Prior period adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PriorPeriodAdjustment" xlink:to="abvc_PriorPeriodAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common shares for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Value of new shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Total common stock value issued (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common shares for cash (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Received shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common shares for consulting service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Service fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common shares for consulting service (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Common stock purchase warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US">Issued shares for consulting service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty_lbl" xml:lang="en-US">Issuance of common shares for acquisition of property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty_lbl" xml:lang="en-US">Issuance of common shares for acquisition of property (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty_lbl0" xml:lang="en-US">Issuance of common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common shares for exercise of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common shares for exercise of convertible notes (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" xlink:href="abvc-20250331.xsd#abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable_lbl" xml:lang="en-US">Warrant issued with convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" xlink:to="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of pre-funded warrant in connection to the 3rd Lind Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant_lbl" xml:lang="en-US">Exercise of pre-funded warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" xlink:to="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_lbl" xml:lang="en-US">Exercise of pre-funded warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:to="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution_lbl" xml:lang="en-US">Subsidiary executive contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" xlink:to="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cumulative transaction adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:to="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Distribute as employee compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation_lbl" xml:lang="en-US">Distribute as employee compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" xlink:to="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN_lbl" xml:lang="en-US">Issuance of common shares for Lind CN Repayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfCommonShareForLindCNRepayment" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonShareForLindCNRepayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_IssuanceOfCommonShareForLindCNRepayment_lbl" xml:lang="en-US">Issuance of common shares for Lind CN Repayment (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfCommonShareForLindCNRepayment" xlink:to="abvc_IssuanceOfCommonShareForLindCNRepayment_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty_lbl" xml:lang="en-US">Issuance of common shares for acquisition of property (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Stock-based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of common shares for exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of common shares for exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US">Repurchase of common stock from a prior employee (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubscriptionReceived" xlink:href="abvc-20250331.xsd#abvc_StockSubscriptionReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockSubscriptionReceived_lbl" xml:lang="en-US">Stock subscription received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceived" xlink:to="abvc_StockSubscriptionReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService_lbl" xml:lang="en-US">Issuance of subsidiary&apos;s common shares for consulting service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Debt discount recognized from Issuance of subsidiary&apos;s convertible note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Decrease in ownership of subsidiary due to share issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Acquiring control of the land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl0" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Other non-cash expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other non-cash income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xml:lang="en-US">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xml:lang="en-US">Prepayment for equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Repayment of short-term loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl0" xml:lang="en-US">Payments of loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayment of convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl0" xml:lang="en-US">Cash repayment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_RepurchaseOfTreasuryStocks" xlink:href="abvc-20250331.xsd#abvc_RepurchaseOfTreasuryStocks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abvc_RepurchaseOfTreasuryStocks_lbl" xml:lang="en-US">Repurchase of treasury stocks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RepurchaseOfTreasuryStocks" xlink:to="abvc_RepurchaseOfTreasuryStocks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Repurchase of common stock from a prior employee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Prior Period Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RestatementAdjustmentMember_lbl0" xml:lang="en-US">Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="srt_RestatementAdjustmentMember_lbl1" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock Amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl2" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="abvc_SubscribedStockMember" xlink:href="abvc-20250331.xsd#abvc_SubscribedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SubscribedStockMember_lbl" xml:lang="en-US">Subscribed stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SubscribedStockMember" xlink:to="abvc_SubscribedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubScriptionReceivableMember" xlink:href="abvc-20250331.xsd#abvc_StockSubScriptionReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockSubScriptionReceivableMember_lbl" xml:lang="en-US">Stock Sub scription Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubScriptionReceivableMember" xlink:to="abvc_StockSubScriptionReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LiquidityGoingConcernAndRestatementTextBlock" xlink:href="abvc-20250331.xsd#abvc_LiquidityGoingConcernAndRestatementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LiquidityGoingConcernAndRestatementTextBlock_lbl" xml:lang="en-US">LIQUIDITY, GOING CONCERN, AND RESTATEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LiquidityGoingConcernAndRestatementTextBlock" xlink:to="abvc_LiquidityGoingConcernAndRestatementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Schedule of Impact of the Restatement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConstructionInProgressGross_lbl0" xml:lang="en-US">Construction-in-Progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable &#8211; third parties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ProceedsFromSubsidiarysCommonStockSubscription" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromSubsidiarysCommonStockSubscription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ProceedsFromSubsidiarysCommonStockSubscription_lbl" xml:lang="en-US">Proceeds from subsidiary&#8217;s executive contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromSubsidiarysCommonStockSubscription" xlink:to="abvc_ProceedsFromSubsidiarysCommonStockSubscription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" xlink:href="abvc-20250331.xsd#abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" xlink:to="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" xlink:href="abvc-20250331.xsd#abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty_lbl" xml:lang="en-US">Purchase of Property and equipment by issuing common stock to a third party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" xlink:to="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" xlink:to="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Revenue and Gross Profit Information of our Reportable Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Total Segment Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LessAbstract" xlink:href="abvc-20250331.xsd#abvc_LessAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LessAbstract_lbl" xml:lang="en-US">Less:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LessAbstract" xlink:to="abvc_LessAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AddLessAbstract" xlink:href="abvc-20250331.xsd#abvc_AddLessAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AddLessAbstract_lbl" xml:lang="en-US">Add (Less):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AddLessAbstract" xlink:to="abvc_AddLessAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">COLLABORATIVE AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, AND PREPAMENT FOR ASSET ACQUISITION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Land with book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">LONG-TERM INVESTMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock_lbl" xml:lang="en-US">Schedule of Ownership Percentages of Each Investee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:to="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Percentage of note fully converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US">Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAdditionalInformation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAdditionalInformation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentAdditionalInformation_lbl" xml:lang="en-US">Accounting treatments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAdditionalInformation" xlink:to="us-gaap_EquityMethodInvestmentAdditionalInformation_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock_lbl" xml:lang="en-US">Schedule of Extent the Investee Relies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock" xlink:to="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">The extent the investee relies on the Company for its business, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0" xml:lang="en-US">Relationship with the Company and its subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Long-Term Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTableTextBlock" xlink:to="us-gaap_InvestmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract" xlink:href="abvc-20250331.xsd#abvc_NonMarketableCostMethodInvestmentsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract_lbl" xml:lang="en-US">Non-marketable Cost Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="abvc_NonMarketableCostMethodInvestmentsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesNoncurrent_lbl" xml:lang="en-US">Non-marketable Cost Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesNoncurrent" xlink:to="us-gaap_DebtSecuritiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityMethodInvestmentsNetAbstract" xlink:href="abvc-20250331.xsd#abvc_EquityMethodInvestmentsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_EquityMethodInvestmentsNetAbstract_lbl" xml:lang="en-US">Equity Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodInvestmentsNetAbstract" xlink:to="abvc_EquityMethodInvestmentsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Balance Sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Non-current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Non-current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of Statements of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Share of losses from investments accounted for using the equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US">Schedule of Components of Loss on Investment in Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Share of equity method investee losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Carrying Amounts of the Liability Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentIssuanceEntity" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentIssuanceEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DebtInstrumentIssuanceEntity_lbl" xml:lang="en-US">Issuance Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentIssuanceEntity" xlink:to="abvc_DebtInstrumentIssuanceEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuanceDate1_lbl" xml:lang="en-US">Issuance Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuanceDate1" xlink:to="us-gaap_DebtInstrumentIssuanceDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Principal Amount at Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Stated Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Effective Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Effective interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentCommonStockToBeConverted" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCommonStockToBeConverted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DebtInstrumentCommonStockToBeConverted_lbl" xml:lang="en-US">Common Stock to be converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentCommonStockToBeConverted" xlink:to="abvc_DebtInstrumentCommonStockToBeConverted_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate_lbl" xml:lang="en-US">Principal Amount at Balance Sheet Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate" xlink:to="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentCarryingValue" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DebtInstrumentCarryingValue_lbl" xml:lang="en-US">Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentCarryingValue" xlink:to="abvc_DebtInstrumentCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AccruedResearchAndDevelopmentExpense" xlink:href="abvc-20250331.xsd#abvc_AccruedResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Accrued research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccruedResearchAndDevelopmentExpense" xlink:to="abvc_AccruedResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AccruedDirectorAndOfficerCompensation" xlink:href="abvc-20250331.xsd#abvc_AccruedDirectorAndOfficerCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AccruedDirectorAndOfficerCompensation_lbl" xml:lang="en-US">Accrued directors and officers (owners) compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccruedDirectorAndOfficerCompensation" xlink:to="abvc_AccruedDirectorAndOfficerCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">SHORT-TERM LOANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US">Schedule of Short-Term Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Parties of the Company with whom Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock_lbl" xml:lang="en-US">Schedule of Licensing Agreement and Related Amendment with FEYE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" xlink:to="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Receivable Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock" xlink:to="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Due from Related Party - Current and Non-current, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" xlink:to="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent_lbl" xml:lang="en-US">Due from related parties- Non-current, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Amount Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock" xlink:to="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax (Benefit) Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets (Liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred tax assets, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Issued and Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted- Average Contractual Life Remaining in Years, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl" xml:lang="en-US">Number of Underlying Shares, Issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl0" xml:lang="en-US">Number of Underlying Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted- Average Contractual Life Remaining in Years, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Issued (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted- Average Contractual Life Remaining in Years, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercised (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK OPTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options Issued and Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Underlying Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Stock option grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Underlying Shares, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Underlying Shares, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Leases have Remaining Lease Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Lease Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Schedule of Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract" xlink:href="abvc-20250331.xsd#abvc_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating leases Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageDiscountRateAbstract" xlink:href="abvc-20250331.xsd#abvc_WeightedAverageDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted Average Discount Rate:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageDiscountRateAbstract" xlink:to="abvc_WeightedAverageDiscountRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating leases Weighted Average Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">ACQUISITION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of Acquisition was Accounted for Business Combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" xlink:href="abvc-20250331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total liabilities acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total consideration (Intangible assets)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LessAbstract0" xlink:href="abvc-20250331.xsd#abvc_LessAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LessAbstract0_lbl" xml:lang="en-US">Less:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LessAbstract0" xlink:to="abvc_LessAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Stock-compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Non-employee stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xml:lang="en-US">Share-based compensation expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl2"/>
    <loc xlink:type="locator" xlink:label="abvc_AddLessAbstract0" xlink:href="abvc-20250331.xsd#abvc_AddLessAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AddLessAbstract0_lbl" xml:lang="en-US">Add (Less):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AddLessAbstract0" xlink:to="abvc_AddLessAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherInvestmentsAbstract_lbl" xml:lang="en-US">Non-marketable Cost Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestmentsAbstract" xlink:to="us-gaap_OtherInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued directors and officers (owners) compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CashPortionOfTheLindNoteRepayments" xlink:href="abvc-20250331.xsd#abvc_CashPortionOfTheLindNoteRepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CashPortionOfTheLindNoteRepayments_lbl" xml:lang="en-US">Cash portion of the Lind Note repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPortionOfTheLindNoteRepayments" xlink:to="abvc_CashPortionOfTheLindNoteRepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AssetsAbstract0" xlink:href="abvc-20250331.xsd#abvc_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AssetsAbstract0_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AssetsAbstract0" xlink:to="abvc_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract0" xlink:href="abvc-20250331.xsd#abvc_WeightedAverageRemainingLeaseTermAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract0_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract0" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageDiscountRateAbstract0" xlink:href="abvc-20250331.xsd#abvc_WeightedAverageDiscountRateAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageDiscountRateAbstract0_lbl" xml:lang="en-US">Weighted Average Discount Rate:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageDiscountRateAbstract0" xlink:to="abvc_WeightedAverageDiscountRateAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2025 (Excluding current period)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent_lbl" xml:lang="en-US">Less: allowance for expected credit losses accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Loss on impairment of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Loss on impairment of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeaseLiabilities" xlink:href="abvc-20250331.xsd#abvc_OperatingLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abvc_OperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeaseLiabilities" xlink:to="abvc_OperatingLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Underlying Shares, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Number of Underlying Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Due to Director</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">As Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember_lbl" xml:lang="en-US">Braingenesis Biotechnology Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GenepharmBiotechCorporationMember_lbl" xml:lang="en-US">Genepharm Biotech Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenepharmBiotechCorporationMember" xlink:to="abvc_GenepharmBiotechCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioHopeKingCorporationMember_lbl" xml:lang="en-US">BioHopeKing Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioHopeKingCorporationMember" xlink:to="abvc_BioHopeKingCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ForSeeConEyeCorporationMember_lbl" xml:lang="en-US">ForSeeCon Eye Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ForSeeConEyeCorporationMember" xlink:to="abvc_ForSeeConEyeCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstCorporationMember_lbl" xml:lang="en-US">BioFirst Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationMember" xlink:to="abvc_BioFirstCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OncoXBioPharmaIncMember_lbl" xml:lang="en-US">OncoX BioPharma, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OncoXBioPharmaIncMember" xlink:to="abvc_OncoXBioPharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RgeneCorporationMember_lbl" xml:lang="en-US">Rgene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationMember" xlink:to="abvc_RgeneCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanKKMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioLiteJapanKKMember_lbl" xml:lang="en-US">BioLite Japan K.K. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJapanKKMember" xlink:to="abvc_BioLiteJapanKKMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanKKBioLiteJPMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKBioLiteJPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioLiteJapanKKBioLiteJPMember_lbl" xml:lang="en-US">BioLite Japan K.K. (BioLite JP) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJapanKKBioLiteJPMember" xlink:to="abvc_BioLiteJapanKKBioLiteJPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstMember_lbl" xml:lang="en-US">BioFirst [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstMember" xlink:to="abvc_BioFirstMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RgeneMember_lbl" xml:lang="en-US">Rgene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneMember" xlink:to="abvc_RgeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SecondLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLINDNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SecondLINDNoteMember_lbl" xml:lang="en-US">2nd LIND Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SecondLINDNoteMember" xlink:to="abvc_SecondLINDNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ThirdLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLINDNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ThirdLINDNoteMember_lbl" xml:lang="en-US">3rd LIND Note	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ThirdLINDNoteMember" xlink:to="abvc_ThirdLINDNoteMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_ThirdLINDNoteMember_lbl0" xml:lang="en-US">3rd LIND Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ThirdLINDNoteMember" xlink:to="abvc_ThirdLINDNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="abvc_ThirdLINDNoteMember_lbl1" xml:lang="en-US">3rd Lind Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ThirdLINDNoteMember" xlink:to="abvc_ThirdLINDNoteMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ThirdLINDNoteMember_lbl2" xml:lang="en-US">Third LIND Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ThirdLINDNoteMember" xlink:to="abvc_ThirdLINDNoteMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherNoteMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OtherNoteMember_lbl" xml:lang="en-US">Other Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherNoteMember" xlink:to="abvc_OtherNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherNoteOneMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OtherNoteOneMember_lbl" xml:lang="en-US">Other Note One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherNoteOneMember" xlink:to="abvc_OtherNoteOneMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_OtherNoteOneMember_lbl0" xml:lang="en-US">Other Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherNoteOneMember" xlink:to="abvc_OtherNoteOneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_FirstLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_FirstLINDNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_FirstLINDNoteMember_lbl" xml:lang="en-US">1st LIND Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_FirstLINDNoteMember" xlink:to="abvc_FirstLINDNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SecondLINDNoteOneMember" xlink:href="abvc-20250331.xsd#abvc_SecondLINDNoteOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SecondLINDNoteOneMember_lbl" xml:lang="en-US">Second LIND Note One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SecondLINDNoteOneMember" xlink:to="abvc_SecondLINDNoteOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedBankMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CathayUnitedBankMember_lbl" xml:lang="en-US">Cathay United Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayUnitedBankMember" xlink:to="abvc_CathayUnitedBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCBankMember" xlink:href="abvc-20250331.xsd#abvc_CTBCBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CTBCBankMember_lbl" xml:lang="en-US">CTBC Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CTBCBankMember" xlink:to="abvc_CTBCBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherIndividualMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OtherIndividualMember_lbl" xml:lang="en-US">Other Individual [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherIndividualMember" xlink:to="abvc_OtherIndividualMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_OtherIndividualMember_lbl0" xml:lang="en-US">Other individual [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherIndividualMember" xlink:to="abvc_OtherIndividualMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="abvc_OtherIndividualMember_lbl1" xml:lang="en-US">Other Individual &#8211; Third party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherIndividualMember" xlink:to="abvc_OtherIndividualMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstCorporationtheBioFirstMember_lbl" xml:lang="en-US">BioFirst Corporation (the &#8220;BioFirst&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationtheBioFirstMember" xlink:to="abvc_BioFirstCorporationtheBioFirstMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_BioFirstCorporationtheBioFirstMember_lbl0" xml:lang="en-US">BioFirst Corporation (the &quot;BioFirst&quot;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationtheBioFirstMember" xlink:to="abvc_BioFirstCorporationtheBioFirstMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl" xml:lang="en-US">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:to="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationtheRgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RgeneCorporationtheRgeneMember_lbl" xml:lang="en-US">Rgene Corporation (the &#8220;Rgene&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationtheRgeneMember" xlink:to="abvc_RgeneCorporationtheRgeneMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_RgeneCorporationtheRgeneMember_lbl0" xml:lang="en-US">Rgene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationtheRgeneMember" xlink:to="abvc_RgeneCorporationtheRgeneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmInctheGenePharmMember" xlink:href="abvc-20250331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GenePharmInctheGenePharmMember_lbl" xml:lang="en-US">GenePharm Inc. (the &#8220;GenePharm&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenePharmInctheGenePharmMember" xlink:to="abvc_GenePharmInctheGenePharmMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsOneMember" xlink:href="abvc-20250331.xsd#abvc_TheJiangsOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TheJiangsOneMember_lbl" xml:lang="en-US">The Jiangs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TheJiangsOneMember" xlink:to="abvc_TheJiangsOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioLiteJapanMember_lbl" xml:lang="en-US">BioLite Japan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJapanMember" xlink:to="abvc_BioLiteJapanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationBHKMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationBHKMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioHopeKingCorporationBHKMember_lbl" xml:lang="en-US">BioHopeKing Corporation (&#8220;BHK&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioHopeKingCorporationBHKMember" xlink:to="abvc_BioHopeKingCorporationBHKMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember_lbl" xml:lang="en-US">AiBtl (Holding) BioPharma, Inc. (&#8220;AiBtl Holding&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember" xlink:to="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_JaimesVargasRussmanMember" xlink:href="abvc-20250331.xsd#abvc_JaimesVargasRussmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_JaimesVargasRussmanMember_lbl" xml:lang="en-US">Jaimes Vargas Russman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_JaimesVargasRussmanMember" xlink:to="abvc_JaimesVargasRussmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtsPromotionIncMember" xlink:href="abvc-20250331.xsd#abvc_LionArtsPromotionIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LionArtsPromotionIncMember_lbl" xml:lang="en-US">Lion Arts Promotion, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionArtsPromotionIncMember" xlink:to="abvc_LionArtsPromotionIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXMember" xlink:href="abvc-20250331.xsd#abvc_OncoXMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OncoXMember_lbl" xml:lang="en-US">OncoX [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OncoXMember" xlink:to="abvc_OncoXMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_FEYEMember" xlink:href="abvc-20250331.xsd#abvc_FEYEMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_FEYEMember_lbl" xml:lang="en-US">FEYE [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_FEYEMember" xlink:to="abvc_FEYEMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LicensingAgreementMember" xlink:href="abvc-20250331.xsd#abvc_LicensingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LicensingAgreementMember_lbl" xml:lang="en-US">Licensing Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LicensingAgreementMember" xlink:to="abvc_LicensingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmIncMember" xlink:href="abvc-20250331.xsd#abvc_GenePharmIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GenePharmIncMember_lbl" xml:lang="en-US">GenePharm Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenePharmIncMember" xlink:to="abvc_GenePharmIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstAustraliaMember_lbl" xml:lang="en-US">BioFirst (Australia) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstAustraliaMember" xlink:to="abvc_BioFirstAustraliaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AiBtlHoldingMember_lbl" xml:lang="en-US">AiBtl Holding [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AiBtlHoldingMember" xlink:to="abvc_AiBtlHoldingMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_AiBtlHoldingMember_lbl0" xml:lang="en-US">AiBtl [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AiBtlHoldingMember" xlink:to="abvc_AiBtlHoldingMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsMember" xlink:href="abvc-20250331.xsd#abvc_TheJiangsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TheJiangsMember_lbl" xml:lang="en-US">The Jiangs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TheJiangsMember" xlink:to="abvc_TheJiangsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareholdersMember" xlink:href="abvc-20250331.xsd#abvc_ShareholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareholdersMember_lbl" xml:lang="en-US">Shareholders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareholdersMember" xlink:to="abvc_ShareholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DirectorsMember" xlink:href="abvc-20250331.xsd#abvc_DirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DirectorsMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DirectorsMember" xlink:to="abvc_DirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CashPaidMember" xlink:href="abvc-20250331.xsd#abvc_CashPaidMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CashPaidMember_lbl" xml:lang="en-US">Cash Paid [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPaidMember" xlink:to="abvc_CashPaidMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AsRestatedMember" xlink:href="abvc-20250331.xsd#abvc_AsRestatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AsRestatedMember_lbl" xml:lang="en-US">As restated [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AsRestatedMember" xlink:to="abvc_AsRestatedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtPromotionIncMember" xlink:href="abvc-20250331.xsd#abvc_LionArtPromotionIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LionArtPromotionIncMember_lbl" xml:lang="en-US">Lion Art Promotion Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionArtPromotionIncMember" xlink:to="abvc_LionArtPromotionIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_lbl" xml:lang="en-US">Insurance Type and Tier Identifier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:to="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Subsidiary ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Percentage of ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Received shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BenefitsReceivableForMilestoneAttained" xlink:href="abvc-20250331.xsd#abvc_BenefitsReceivableForMilestoneAttained"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BenefitsReceivableForMilestoneAttained_lbl" xml:lang="en-US">Eligible to receive amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BenefitsReceivableForMilestoneAttained" xlink:to="abvc_BenefitsReceivableForMilestoneAttained_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_BenefitsReceivableForMilestoneAttained_lbl0" xml:lang="en-US">Eligible to receive amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BenefitsReceivableForMilestoneAttained" xlink:to="abvc_BenefitsReceivableForMilestoneAttained_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfRoyaltiesEqualing" xlink:href="abvc-20250331.xsd#abvc_PercentageOfRoyaltiesEqualing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfRoyaltiesEqualing_lbl" xml:lang="en-US">Percentage of royalties equaling</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfRoyaltiesEqualing" xlink:to="abvc_PercentageOfRoyaltiesEqualing_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AcquisitionForNetSales" xlink:href="abvc-20250331.xsd#abvc_AcquisitionForNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AcquisitionForNetSales_lbl" xml:lang="en-US">Net sales (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AcquisitionForNetSales" xlink:to="abvc_AcquisitionForNetSales_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_AcquisitionForNetSales_lbl0" xml:lang="en-US">Net sales on acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AcquisitionForNetSales" xlink:to="abvc_AcquisitionForNetSales_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl" xml:lang="en-US">Incorporated state</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WorkingCapitalDeficit" xlink:href="abvc-20250331.xsd#abvc_WorkingCapitalDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WorkingCapitalDeficit" xlink:to="abvc_WorkingCapitalDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Per share of common stock (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl2" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateOwnedValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateOwnedValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstateOwnedValuationAllowance_lbl" xml:lang="en-US">Valuation amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateOwnedValuationAllowance" xlink:to="us-gaap_RealEstateOwnedValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Number of shares issued for asset acquisition (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0" xml:lang="en-US">Acquisition shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Shares of common stock issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xml:lang="en-US">Stock-compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest expense other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xml:lang="en-US">Share issued for post split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_StockBasedExpensesAmortizationPeriod" xlink:href="abvc-20250331.xsd#abvc_StockBasedExpensesAmortizationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockBasedExpensesAmortizationPeriod_lbl" xml:lang="en-US">Stock-based expenses amortization period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockBasedExpensesAmortizationPeriod" xlink:to="abvc_StockBasedExpensesAmortizationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US">Stock subscription receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0" xml:lang="en-US">Stock subscription receivables (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyExcessExpenseReimbursable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl" xml:lang="en-US">Cash investments limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration of clients rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for expected credit losses accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LaborPensionFundPerMonth" xlink:href="abvc-20250331.xsd#abvc_LaborPensionFundPerMonth"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LaborPensionFundPerMonth_lbl" xml:lang="en-US">Labor pension fund per month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LaborPensionFundPerMonth" xlink:to="abvc_LaborPensionFundPerMonth_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Monthly contribution of employees salaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl" xml:lang="en-US">Employee stock-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Employee stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl" xml:lang="en-US">Consulting services for rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanServiceCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DefinedBenefitPlanFundedPercentages" xlink:href="abvc-20250331.xsd#abvc_DefinedBenefitPlanFundedPercentages"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DefinedBenefitPlanFundedPercentages_lbl" xml:lang="en-US">Tax benefit percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DefinedBenefitPlanFundedPercentages" xlink:to="abvc_DefinedBenefitPlanFundedPercentages_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Reportable segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xml:lang="en-US">Provision credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash (in New Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones_lbl" xml:lang="en-US">Description of collaborative agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:to="us-gaap_LongTermPurchaseCommitmentMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NonrefundableUpfrontCashPayment" xlink:href="abvc-20250331.xsd#abvc_NonrefundableUpfrontCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NonrefundableUpfrontCashPayment_lbl" xml:lang="en-US">Non-refundable upfront cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonrefundableUpfrontCashPayment" xlink:to="abvc_NonrefundableUpfrontCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:href="abvc-20250331.xsd#abvc_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl" xml:lang="en-US">Data and development percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:to="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfStockValue" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_IssuanceOfStockValue_lbl" xml:lang="en-US">Total cash amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfStockValue" xlink:to="abvc_IssuanceOfStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Licensing rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage" xlink:href="abvc-20250331.xsd#abvc_MilestonePaymentsRoyaltyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePaymentsRoyaltyPercentage" xlink:to="abvc_MilestonePaymentsRoyaltyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_NetSalesProfitPercentage" xlink:href="abvc-20250331.xsd#abvc_NetSalesProfitPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NetSalesProfitPercentage_lbl" xml:lang="en-US">Net sales profit, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetSalesProfitPercentage" xlink:to="abvc_NetSalesProfitPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForParticipationLiabilities_lbl" xml:lang="en-US">Cash amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForParticipationLiabilities" xlink:to="us-gaap_PaymentsForParticipationLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdditionCashPayment" xlink:href="abvc-20250331.xsd#abvc_AdditionCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdditionCashPayment_lbl" xml:lang="en-US">Addition cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionCashPayment" xlink:to="abvc_AdditionCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash of purchase agreements (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityMethodLongTermInvestment" xlink:href="abvc-20250331.xsd#abvc_EquityMethodLongTermInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_EquityMethodLongTermInvestment_lbl" xml:lang="en-US">Equity method long term investment (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodLongTermInvestment" xlink:to="abvc_EquityMethodLongTermInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ServiceAgreementEligibilityAmount" xlink:href="abvc-20250331.xsd#abvc_ServiceAgreementEligibilityAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ServiceAgreementEligibilityAmount_lbl" xml:lang="en-US">Service agreement eligibility amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ServiceAgreementEligibilityAmount" xlink:to="abvc_ServiceAgreementEligibilityAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestoneRegulatoryPaymentAmountPeriod" xlink:href="abvc-20250331.xsd#abvc_MilestoneRegulatoryPaymentAmountPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_MilestoneRegulatoryPaymentAmountPeriod_lbl" xml:lang="en-US">Milestone regulatory payment amount period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestoneRegulatoryPaymentAmountPeriod" xlink:to="abvc_MilestoneRegulatoryPaymentAmountPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LoansPayable_lbl0" xml:lang="en-US">Loan repaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_WorkingCapitalConvertibleLoanPercentage" xlink:href="abvc-20250331.xsd#abvc_WorkingCapitalConvertibleLoanPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WorkingCapitalConvertibleLoanPercentage_lbl" xml:lang="en-US">Percentage of working capital convertible loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WorkingCapitalConvertibleLoanPercentage" xlink:to="abvc_WorkingCapitalConvertibleLoanPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Fixed conversion price equal (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl0" xml:lang="en-US">Conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityMethodInvestmentsOwnershipPercentage" xlink:href="abvc-20250331.xsd#abvc_EquityMethodInvestmentsOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_EquityMethodInvestmentsOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodInvestmentsOwnershipPercentage" xlink:to="abvc_EquityMethodInvestmentsOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl" xml:lang="en-US">Common stock consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesAndLicenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesAndLicenses_lbl" xml:lang="en-US">Licensing fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesAndLicenses" xlink:to="us-gaap_TaxesAndLicenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl" xml:lang="en-US">Upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0" xml:lang="en-US">Prepayment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares paid (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">FEYE stock (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestoneRegulatoryPaymentAmount" xlink:href="abvc-20250331.xsd#abvc_MilestoneRegulatoryPaymentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_MilestoneRegulatoryPaymentAmount_lbl" xml:lang="en-US">Milestone regulatory payment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestoneRegulatoryPaymentAmount" xlink:to="abvc_MilestoneRegulatoryPaymentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RoyaltiesPercentage" xlink:href="abvc-20250331.xsd#abvc_RoyaltiesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RoyaltiesPercentage_lbl" xml:lang="en-US">Percentage of royalties of net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RoyaltiesPercentage" xlink:to="abvc_RoyaltiesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ReceivedShares" xlink:href="abvc-20250331.xsd#abvc_ReceivedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ReceivedShares_lbl" xml:lang="en-US">Shares received (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ReceivedShares" xlink:to="abvc_ReceivedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LicensingAgreement" xlink:href="abvc-20250331.xsd#abvc_LicensingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LicensingAgreement_lbl" xml:lang="en-US">Licensing agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LicensingAgreement" xlink:to="abvc_LicensingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Recognized revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsiderationPaidForAgreement" xlink:href="abvc-20250331.xsd#abvc_ConsiderationPaidForAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConsiderationPaidForAgreement_lbl" xml:lang="en-US">Consideration paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsiderationPaidForAgreement" xlink:to="abvc_ConsiderationPaidForAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdditionalMilestonePaymentInCash" xlink:href="abvc-20250331.xsd#abvc_AdditionalMilestonePaymentInCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdditionalMilestonePaymentInCash_lbl" xml:lang="en-US">Additional milestone payment in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionalMilestonePaymentInCash" xlink:to="abvc_AdditionalMilestonePaymentInCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xml:lang="en-US">Recognized revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NumberOfSharesReceived" xlink:href="abvc-20250331.xsd#abvc_NumberOfSharesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NumberOfSharesReceived_lbl" xml:lang="en-US">Number of shares received (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumberOfSharesReceived" xlink:to="abvc_NumberOfSharesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfDevelopAndCommercialize" xlink:href="abvc-20250331.xsd#abvc_PercentageOfDevelopAndCommercialize"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfDevelopAndCommercialize_lbl" xml:lang="en-US">Percentage of develop and commercialize</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfDevelopAndCommercialize" xlink:to="abvc_PercentageOfDevelopAndCommercialize_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LicensingFees" xlink:href="abvc-20250331.xsd#abvc_LicensingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LicensingFees_lbl" xml:lang="en-US">Licensing fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LicensingFees" xlink:to="abvc_LicensingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Valuation of property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Aggregate shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndLandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandAndLandImprovements_lbl" xml:lang="en-US">Land with book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndLandImprovements" xlink:to="us-gaap_LandAndLandImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Acquisition value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageCommonStocksShares" xlink:href="abvc-20250331.xsd#abvc_PercentageCommonStocksShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageCommonStocksShares_lbl" xml:lang="en-US">Percentage of common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageCommonStocksShares" xlink:to="abvc_PercentageCommonStocksShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Owned shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xml:lang="en-US">Payment to joint venture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPreviousAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForPreviousAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForPreviousAcquisition_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPreviousAcquisition" xlink:to="us-gaap_PaymentsForPreviousAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Common stock at an initial conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Initial exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Warrant exercise price current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair value of the warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingBalanceAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingBalanceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OutstandingBalanceAmount_lbl" xml:lang="en-US">Outstanding amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingBalanceAmount" xlink:to="abvc_OutstandingBalanceAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_OutstandingBalanceAmount_lbl0" xml:lang="en-US">Outstanding balance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingBalanceAmount" xlink:to="abvc_OutstandingBalanceAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfAverageAmount" xlink:href="abvc-20250331.xsd#abvc_PercentageOfAverageAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfAverageAmount_lbl" xml:lang="en-US">Percentage of average amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfAverageAmount" xlink:to="abvc_PercentageOfAverageAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfCashPermium" xlink:href="abvc-20250331.xsd#abvc_PercentageOfCashPermium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfCashPermium_lbl" xml:lang="en-US">Percentage of cash premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfCashPermium" xlink:to="abvc_PercentageOfCashPermium_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfOutstandingPrincipalAmount" xlink:href="abvc-20250331.xsd#abvc_PercentageOfOutstandingPrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfOutstandingPrincipalAmount_lbl" xml:lang="en-US">Percentage of outstanding principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfOutstandingPrincipalAmount" xlink:to="abvc_PercentageOfOutstandingPrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralPartnersCapitalAccount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralPartnersCapitalAccount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralPartnersCapitalAccount_lbl" xml:lang="en-US">Market capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralPartnersCapitalAccount" xlink:to="us-gaap_GeneralPartnersCapitalAccount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrants exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount_lbl" xml:lang="en-US">Convertible note in principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:to="us-gaap_ReceivableWithImputedInterestFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US">Percentage of principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseWarrantTerm" xlink:href="abvc-20250331.xsd#abvc_PurchaseWarrantTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PurchaseWarrantTerm_lbl" xml:lang="en-US">Purchase warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseWarrantTerm" xlink:to="abvc_PurchaseWarrantTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchasePriceAmount" xlink:href="abvc-20250331.xsd#abvc_PurchasePriceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PurchasePriceAmount_lbl" xml:lang="en-US">Purchase price amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchasePriceAmount" xlink:to="abvc_PurchasePriceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US">Purchase warrant to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentOutstandingPrincipal" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentOutstandingPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DebtInstrumentOutstandingPrincipal_lbl" xml:lang="en-US">Outstanding principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentOutstandingPrincipal" xlink:to="abvc_DebtInstrumentOutstandingPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US">Warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl0" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Warrant exercise reduced (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Initial exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl1" xml:lang="en-US">Warrant exercise price decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsiderationAmount" xlink:href="abvc-20250331.xsd#abvc_ConsiderationAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConsiderationAmount_lbl" xml:lang="en-US">Total consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsiderationAmount" xlink:to="abvc_ConsiderationAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Maturity term period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt instrument term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl1" xml:lang="en-US">Purchase warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfAnnualDiscountRate" xlink:href="abvc-20250331.xsd#abvc_PercentageOfAnnualDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfAnnualDiscountRate_lbl" xml:lang="en-US">Percentage of annual discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfAnnualDiscountRate" xlink:to="abvc_PercentageOfAnnualDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Bearing interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Issuance of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Debit discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest expenses for loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_TradingDays" xlink:href="abvc-20250331.xsd#abvc_TradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TradingDays_lbl" xml:lang="en-US">Trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TradingDays" xlink:to="abvc_TradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsecutiveDays" xlink:href="abvc-20250331.xsd#abvc_ConsecutiveDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConsecutiveDays_lbl" xml:lang="en-US">Consecutive days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsecutiveDays" xlink:to="abvc_ConsecutiveDays_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Warrant to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US">Warrants to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Credit limit amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xml:lang="en-US">Interest rate of loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl0" xml:lang="en-US">Loans bear interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseShortTermBorrowings_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseShortTermBorrowings" xlink:to="us-gaap_InterestExpenseShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings_lbl" xml:lang="en-US">Money deposited in a savings account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings" xlink:to="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtPercentageBearingVariableInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate_lbl" xml:lang="en-US">Percentage of bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShortTermDebtMaturityDate" xlink:href="abvc-20250331.xsd#abvc_ShortTermDebtMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShortTermDebtMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShortTermDebtMaturityDate" xlink:to="abvc_ShortTermDebtMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Licensing agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Outstanding balance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WorkingCapitalPercentage" xlink:href="abvc-20250331.xsd#abvc_WorkingCapitalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WorkingCapitalPercentage_lbl" xml:lang="en-US">Percentage of working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WorkingCapitalPercentage" xlink:to="abvc_WorkingCapitalPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Discount of the stock price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrincipalAmountOutstandingOnLoansSecuritized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl" xml:lang="en-US">Outstanding loan balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositLiabilitiesAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl" xml:lang="en-US">Accrued interest amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDate" xlink:to="us-gaap_RelatedPartyTransactionDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl" xml:lang="en-US">Percentage of mature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionRate" xlink:to="us-gaap_RelatedPartyTransactionRate_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementAmount" xlink:href="abvc-20250331.xsd#abvc_LoanAgreementAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LoanAgreementAmount_lbl" xml:lang="en-US">Loan agreement amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementAmount" xlink:to="abvc_LoanAgreementAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Loan agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RecognizedCreditLosses" xlink:href="abvc-20250331.xsd#abvc_RecognizedCreditLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RecognizedCreditLosses_lbl" xml:lang="en-US">Recognized credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RecognizedCreditLosses" xlink:to="abvc_RecognizedCreditLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingPrincipalAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingPrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OutstandingPrincipalAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingPrincipalAmount" xlink:to="abvc_OutstandingPrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfWorkingCapital" xlink:href="abvc-20250331.xsd#abvc_PercentageOfWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfWorkingCapital_lbl" xml:lang="en-US">Percentage of working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfWorkingCapital" xlink:to="abvc_PercentageOfWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Shares exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregateCommonStockShares" xlink:href="abvc-20250331.xsd#abvc_AggregateCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AggregateCommonStockShares_lbl" xml:lang="en-US">Aggregate common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregateCommonStockShares" xlink:to="abvc_AggregateCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Granted restricted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Granted options to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_AssetConsiderationCommonStock" xlink:href="abvc-20250331.xsd#abvc_AssetConsiderationCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AssetConsiderationCommonStock_lbl" xml:lang="en-US">Asset consideration common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AssetConsiderationCommonStock" xlink:to="abvc_AssetConsiderationCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingLiabilityOwnedAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingLiabilityOwnedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OutstandingLiabilityOwnedAmount_lbl" xml:lang="en-US">Outstanding liability owned (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingLiabilityOwnedAmount" xlink:to="abvc_OutstandingLiabilityOwnedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AverageIssuancePricePerShare" xlink:href="abvc-20250331.xsd#abvc_AverageIssuancePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AverageIssuancePricePerShare_lbl" xml:lang="en-US">Average issuance price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AverageIssuancePricePerShare" xlink:to="abvc_AverageIssuancePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockSharesIssuedForRent" xlink:href="abvc-20250331.xsd#abvc_CommonStockSharesIssuedForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CommonStockSharesIssuedForRent_lbl" xml:lang="en-US">Number of shares issued for rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockSharesIssuedForRent" xlink:to="abvc_CommonStockSharesIssuedForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NonControllingInterestConsiderationShare" xlink:href="abvc-20250331.xsd#abvc_NonControllingInterestConsiderationShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NonControllingInterestConsiderationShare_lbl" xml:lang="en-US">Non-controlling interest consideration share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonControllingInterestConsiderationShare" xlink:to="abvc_NonControllingInterestConsiderationShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Percentage of subsidiary interest in noncontrolling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultingFee" xlink:href="abvc-20250331.xsd#abvc_ConsultingFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConsultingFee_lbl" xml:lang="en-US">Consulting fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultingFee" xlink:to="abvc_ConsultingFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Land"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Land_lbl" xml:lang="en-US">Land (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Land" xlink:to="us-gaap_Land_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssueDuringPeriodCommonShares" xlink:href="abvc-20250331.xsd#abvc_StockIssueDuringPeriodCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssueDuringPeriodCommonShares_lbl" xml:lang="en-US">Stock issue during period common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssueDuringPeriodCommonShares" xlink:to="abvc_StockIssueDuringPeriodCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditDerivativeTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativeTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditDerivativeTerm1_lbl" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditDerivativeTerm1" xlink:to="us-gaap_CreditDerivativeTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_lbl" xml:lang="en-US">Repayment of principal of 2nd lind note (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Number of shares issued on conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNpoXXXMi0ISiQMYRhfARCZqodsmYe5mpcuap9v90/VTIewyY3i091+2fVbljGWA+oIMmRhsCng8ZWIeu6RFmHqDuVsiXSHIAQzP/FPyRsu9wu9TXs5L6z+Vj4GR0/VqMj6bP7RRDRffTIrCvruey21RYJVvSYvm8Jzrt9Gxzb1HPPdaaTGzFXsT/y5DR8CjyqEw=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Unvested options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SharesReceived" xlink:href="abvc-20250331.xsd#abvc_SharesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SharesReceived_lbl" xml:lang="en-US">Shares received (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesReceived" xlink:to="abvc_SharesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_royaltiesPercentage" xlink:href="abvc-20250331.xsd#abvc_royaltiesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_royaltiesPercentage_lbl" xml:lang="en-US">Royalty percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_royaltiesPercentage" xlink:to="abvc_royaltiesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Principal amount of converted debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Conversion of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_UnregisteredPricePerShares" xlink:href="abvc-20250331.xsd#abvc_UnregisteredPricePerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_UnregisteredPricePerShares_lbl" xml:lang="en-US">Unregistered price per shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnregisteredPricePerShares" xlink:to="abvc_UnregisteredPricePerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Capital raised by private offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US">Capital raised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockReverseSplitPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_StockReverseSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockReverseSplitPolicyTextBlock_lbl" xml:lang="en-US">Stock Reverse Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockReverseSplitPolicyTextBlock" xlink:to="abvc_StockReverseSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConcentrationOfClientsPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_ConcentrationOfClientsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConcentrationOfClientsPolicyTextBlock_lbl" xml:lang="en-US">Concentration of Clients</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConcentrationOfClientsPolicyTextBlock" xlink:to="abvc_ConcentrationOfClientsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivable and allowance for expected credit losses accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Long-term Equity Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_OtherThanTemporaryImpairmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl" xml:lang="en-US">Other-Than-Temporary Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:to="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayablePolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayablePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConvertibleNotesPayablePolicyTextBlock_lbl" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayablePolicyTextBlock" xlink:to="abvc_ConvertibleNotesPayablePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xml:lang="en-US">Post-retirement and post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:to="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Share of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign-currency Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteBVIIncMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteBVIIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioLiteBVIIncMember_lbl" xml:lang="en-US">BioLite BVI, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteBVIIncMember" xlink:to="abvc_BioLiteBVIIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_BioLiteBVIIncMember_lbl0" xml:lang="en-US">BioLite BVI Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteBVIIncMember" xlink:to="abvc_BioLiteBVIIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteTaiwanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioLiteTaiwanMember_lbl" xml:lang="en-US">BioLite Taiwan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteTaiwanMember" xlink:to="abvc_BioLiteTaiwanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShulingJiangMember" xlink:href="abvc-20250331.xsd#abvc_ShulingJiangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShulingJiangMember_lbl" xml:lang="en-US">Shuling Jiang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShulingJiangMember" xlink:to="abvc_ShulingJiangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ABVCMember" xlink:href="abvc-20250331.xsd#abvc_ABVCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ABVCMember_lbl" xml:lang="en-US">ABVC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ABVCMember" xlink:to="abvc_ABVCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ABVCAndBioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_ABVCAndBioLiteTaiwanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ABVCAndBioLiteTaiwanMember_lbl" xml:lang="en-US">ABVC and BioLite Taiwan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ABVCAndBioLiteTaiwanMember" xlink:to="abvc_ABVCAndBioLiteTaiwanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ZhongHuiLianHeJiTuanLtdMember" xlink:href="abvc-20250331.xsd#abvc_ZhongHuiLianHeJiTuanLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ZhongHuiLianHeJiTuanLtdMember_lbl" xml:lang="en-US">Zhong Hui Lian He Ji Tuan, Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ZhongHuiLianHeJiTuanLtdMember" xlink:to="abvc_ZhongHuiLianHeJiTuanLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ZhonghuiMember" xlink:href="abvc-20250331.xsd#abvc_ZhonghuiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ZhonghuiMember_lbl" xml:lang="en-US">Zhonghui [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ZhonghuiMember" xlink:to="abvc_ZhonghuiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AiBtlBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlBioPharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AiBtlBioPharmaIncMember_lbl" xml:lang="en-US">AiBtl BioPharma, Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AiBtlBioPharmaIncMember" xlink:to="abvc_AiBtlBioPharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PostSplitMember" xlink:href="abvc-20250331.xsd#abvc_PostSplitMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PostSplitMember_lbl" xml:lang="en-US">Post-Split [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PostSplitMember" xlink:to="abvc_PostSplitMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TaiwanCentralDepositInsuranceCorporationMember" xlink:href="abvc-20250331.xsd#abvc_TaiwanCentralDepositInsuranceCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TaiwanCentralDepositInsuranceCorporationMember_lbl" xml:lang="en-US">Taiwan Central Deposit Insurance Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TaiwanCentralDepositInsuranceCorporationMember" xlink:to="abvc_TaiwanCentralDepositInsuranceCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_USFederalDepositInsuranceCorporationMember" xlink:href="abvc-20250331.xsd#abvc_USFederalDepositInsuranceCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_USFederalDepositInsuranceCorporationMember_lbl" xml:lang="en-US">U.S. Federal Deposit Insurance Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_USFederalDepositInsuranceCorporationMember" xlink:to="abvc_USFederalDepositInsuranceCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ClientMember" xlink:href="abvc-20250331.xsd#abvc_ClientMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ClientMember_lbl" xml:lang="en-US">Client [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ClientMember" xlink:to="abvc_ClientMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TwoClientMember" xlink:href="abvc-20250331.xsd#abvc_TwoClientMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TwoClientMember_lbl" xml:lang="en-US">Two Client [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TwoClientMember" xlink:to="abvc_TwoClientMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PostretirementAndPostemploymentBenefitsMember" xlink:href="abvc-20250331.xsd#abvc_PostretirementAndPostemploymentBenefitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PostretirementAndPostemploymentBenefitsMember_lbl" xml:lang="en-US">Post-retirement and post-employment benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PostretirementAndPostemploymentBenefitsMember" xlink:to="abvc_PostretirementAndPostemploymentBenefitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BHKCoDevelopmentAgreementMember" xlink:href="abvc-20250331.xsd#abvc_BHKCoDevelopmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BHKCoDevelopmentAgreementMember_lbl" xml:lang="en-US">BHK Co-Development Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAgreementMember" xlink:to="abvc_BHKCoDevelopmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CodevelopmentagreementMember" xlink:href="abvc-20250331.xsd#abvc_CodevelopmentagreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CodevelopmentagreementMember_lbl" xml:lang="en-US">Co-Dev Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CodevelopmentagreementMember" xlink:to="abvc_CodevelopmentagreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_YuanGeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_YuanGeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_YuanGeneCorporationMember_lbl" xml:lang="en-US">YuanGene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YuanGeneCorporationMember" xlink:to="abvc_YuanGeneCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServiceAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ServiceAgreementsMember_lbl" xml:lang="en-US">Service Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceAgreementsMember" xlink:to="us-gaap_ServiceAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneStudiesMember" xlink:href="abvc-20250331.xsd#abvc_RgeneStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RgeneStudiesMember_lbl" xml:lang="en-US">Rgene Studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneStudiesMember" xlink:to="abvc_RgeneStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US">Collaborative Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstStockPurchaseAgreementMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstStockPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstStockPurchaseAgreementMember_lbl" xml:lang="en-US">BioFirst Stock Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstStockPurchaseAgreementMember" xlink:to="abvc_BioFirstStockPurchaseAgreementMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_BioFirstStockPurchaseAgreementMember_lbl0" xml:lang="en-US">BioFirst Corporation Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstStockPurchaseAgreementMember" xlink:to="abvc_BioFirstStockPurchaseAgreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember_lbl" xml:lang="en-US">Collaborative agreement with ForSeeCon Eye Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember" xlink:to="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OncoXBiopPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBiopPharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OncoXBiopPharmaIncMember_lbl" xml:lang="en-US">OncoX BiopPharma, Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OncoXBiopPharmaIncMember" xlink:to="abvc_OncoXBiopPharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_TW" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TW"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_TW_lbl" xml:lang="en-US">TAIWAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_TW" xlink:to="country_TW_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LucidaimCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_LucidaimCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LucidaimCoLtdMember_lbl" xml:lang="en-US">Lucidaim Co Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LucidaimCoLtdMember" xlink:to="abvc_LucidaimCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJPMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioLiteJPMember_lbl" xml:lang="en-US">BioLite JP [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJPMember" xlink:to="abvc_BioLiteJPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LindGlobalFundIILPMember" xlink:href="abvc-20250331.xsd#abvc_LindGlobalFundIILPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LindGlobalFundIILPMember_lbl" xml:lang="en-US">Lind Global Fund II, LP [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindGlobalFundIILPMember" xlink:to="abvc_LindGlobalFundIILPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LindWarrantMember" xlink:href="abvc-20250331.xsd#abvc_LindWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LindWarrantMember_lbl" xml:lang="en-US">Lind Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindWarrantMember" xlink:to="abvc_LindWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WarrantDebtDiscountMember" xlink:href="abvc-20250331.xsd#abvc_WarrantDebtDiscountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WarrantDebtDiscountMember_lbl" xml:lang="en-US">Warrant Debt Discount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantDebtDiscountMember" xlink:to="abvc_WarrantDebtDiscountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Lind Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_SecondLindNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLindNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SecondLindNoteMember_lbl" xml:lang="en-US">2nd Lind Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SecondLindNoteMember" xlink:to="abvc_SecondLindNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LindNotesPayableMember" xlink:href="abvc-20250331.xsd#abvc_LindNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LindNotesPayableMember_lbl" xml:lang="en-US">Lind Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindNotesPayableMember" xlink:to="abvc_LindNotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherConvertibleNotesPayableMember" xlink:href="abvc-20250331.xsd#abvc_OtherConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OtherConvertibleNotesPayableMember_lbl" xml:lang="en-US">Other Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherConvertibleNotesPayableMember" xlink:to="abvc_OtherConvertibleNotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LindNotesMember" xlink:href="abvc-20250331.xsd#abvc_LindNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LindNotesMember_lbl" xml:lang="en-US">Lind Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindNotesMember" xlink:to="abvc_LindNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedLoanAgreementMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedLoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CathayUnitedLoanAgreementMember_lbl" xml:lang="en-US">Cathay United Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayUnitedLoanAgreementMember" xlink:to="abvc_CathayUnitedLoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCLoanAgreementsMember" xlink:href="abvc-20250331.xsd#abvc_CTBCLoanAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CTBCLoanAgreementsMember_lbl" xml:lang="en-US">CTBC Loan Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CTBCLoanAgreementsMember" xlink:to="abvc_CTBCLoanAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherIndividualThirdPartyMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualThirdPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OtherIndividualThirdPartyMember_lbl" xml:lang="en-US">Other Individual &#8211; Third party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherIndividualThirdPartyMember" xlink:to="abvc_OtherIndividualThirdPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleLoanAgreementMember" xlink:href="abvc-20250331.xsd#abvc_ConvertibleLoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConvertibleLoanAgreementMember_lbl" xml:lang="en-US">Convertible Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleLoanAgreementMember" xlink:to="abvc_ConvertibleLoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementMember" xlink:href="abvc-20250331.xsd#abvc_LoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementMember" xlink:to="abvc_LoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BHKCoDevelopmentAggreementMember" xlink:href="abvc-20250331.xsd#abvc_BHKCoDevelopmentAggreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BHKCoDevelopmentAggreementMember_lbl" xml:lang="en-US">BHK Co Development Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAggreementMember" xlink:to="abvc_BHKCoDevelopmentAggreementMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_BHKCoDevelopmentAggreementMember_lbl0" xml:lang="en-US">BHK Co Development Aggreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAggreementMember" xlink:to="abvc_BHKCoDevelopmentAggreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstReceivesMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstReceivesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstReceivesMember_lbl" xml:lang="en-US">BioFirst Receives [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstReceivesMember" xlink:to="abvc_BioFirstReceivesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConversionMember" xlink:href="abvc-20250331.xsd#abvc_ConversionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConversionMember_lbl" xml:lang="en-US">Conversion [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConversionMember" xlink:to="abvc_ConversionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_JiangsAdvancedFundsMember" xlink:href="abvc-20250331.xsd#abvc_JiangsAdvancedFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_JiangsAdvancedFundsMember_lbl" xml:lang="en-US">Jiangs Advanced Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_JiangsAdvancedFundsMember" xlink:to="abvc_JiangsAdvancedFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EuroAsiaInvestmentFinanceCorpLtdMember" xlink:href="abvc-20250331.xsd#abvc_EuroAsiaInvestmentFinanceCorpLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_EuroAsiaInvestmentFinanceCorpLtdMember_lbl" xml:lang="en-US">Euro-Asia Investment &amp; Finance Corp Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EuroAsiaInvestmentFinanceCorpLtdMember" xlink:to="abvc_EuroAsiaInvestmentFinanceCorpLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xml:lang="en-US">Receivables from Stockholder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultantMember" xlink:href="abvc-20250331.xsd#abvc_ConsultantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultantMember" xlink:to="abvc_ConsultantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PreFundedWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_PreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PreFundedWarrantsMember" xlink:to="abvc_PreFundedWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_PreFundedWarrantsMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PreFundedWarrantsMember" xlink:to="abvc_PreFundedWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20250331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2016 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:to="abvc_TwoThousandSixteenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ChiefStrategicOfficerMember" xlink:href="abvc-20250331.xsd#abvc_ChiefStrategicOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ChiefStrategicOfficerMember_lbl" xml:lang="en-US">Chief Strategic Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ChiefStrategicOfficerMember" xlink:to="abvc_ChiefStrategicOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LindGlobalFundIILPLindMember" xlink:href="abvc-20250331.xsd#abvc_LindGlobalFundIILPLindMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LindGlobalFundIILPLindMember_lbl" xml:lang="en-US">Lind Global Fund II, LP (&#8220;Lind&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindGlobalFundIILPLindMember" xlink:to="abvc_LindGlobalFundIILPLindMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LindNoteMember" xlink:href="abvc-20250331.xsd#abvc_LindNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LindNoteMember_lbl" xml:lang="en-US">Lind Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindNoteMember" xlink:to="abvc_LindNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PreExistingWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_PreExistingWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PreExistingWarrantsMember_lbl" xml:lang="en-US">Pre-Existing Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PreExistingWarrantsMember" xlink:to="abvc_PreExistingWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NewWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_NewWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NewWarrantsMember_lbl" xml:lang="en-US">New Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NewWarrantsMember" xlink:to="abvc_NewWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LindMember" xlink:href="abvc-20250331.xsd#abvc_LindMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LindMember_lbl" xml:lang="en-US">Lind [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindMember" xlink:to="abvc_LindMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LindOfferingsMember" xlink:href="abvc-20250331.xsd#abvc_LindOfferingsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LindOfferingsMember_lbl" xml:lang="en-US">Lind Offerings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindOfferingsMember" xlink:to="abvc_LindOfferingsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ThirdLetterAgreementMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLetterAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ThirdLetterAgreementMember_lbl" xml:lang="en-US">Third Letter Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ThirdLetterAgreementMember" xlink:to="abvc_ThirdLetterAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ExistingWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_ExistingWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ExistingWarrantsMember_lbl" xml:lang="en-US">Existing Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ExistingWarrantsMember" xlink:to="abvc_ExistingWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DecemberLetterAgreementMember" xlink:href="abvc-20250331.xsd#abvc_DecemberLetterAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DecemberLetterAgreementMember_lbl" xml:lang="en-US">December Letter Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DecemberLetterAgreementMember" xlink:to="abvc_DecemberLetterAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_UnregisteredSharesMember" xlink:href="abvc-20250331.xsd#abvc_UnregisteredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_UnregisteredSharesMember_lbl" xml:lang="en-US">Unregistered Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnregisteredSharesMember" xlink:to="abvc_UnregisteredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_UnregisteredRestrictedSharesMember" xlink:href="abvc-20250331.xsd#abvc_UnregisteredRestrictedSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_UnregisteredRestrictedSharesMember_lbl" xml:lang="en-US">Unregistered Restricted Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnregisteredRestrictedSharesMember" xlink:to="abvc_UnregisteredRestrictedSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdvisorsOneMember" xlink:href="abvc-20250331.xsd#abvc_AdvisorsOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdvisorsOneMember_lbl" xml:lang="en-US">Advisors One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvisorsOneMember" xlink:to="abvc_AdvisorsOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdvisorsTwoMember" xlink:href="abvc-20250331.xsd#abvc_AdvisorsTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdvisorsTwoMember_lbl" xml:lang="en-US">Advisors Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvisorsTwoMember" xlink:to="abvc_AdvisorsTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xml:lang="en-US">Condensed Financial Statements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" xlink:href="abvc-20250331.xsd#abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" xlink:to="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems_lbl" xml:lang="en-US">Schedule of Estimated Useful Life [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems" xlink:to="abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTable_lbl" xml:lang="en-US">Partners&apos; Capital, Other Ownership Interest [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:to="us-gaap_ScheduleOfOtherOwnershipInterestsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US">Schedule of Ownership Percentages of Each Investee [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable_lbl" xml:lang="en-US">Long-Term Investments - Schedule of Extent the Investee Relies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:to="abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xml:lang="en-US">Schedule of Extent the Investee Relies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable_lbl" xml:lang="en-US">Long-Term Investments - Schedule of Long-Term Investment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:to="abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xml:lang="en-US">Schedule of Long-Term Investment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US">Schedule of Balance Sheet [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable_lbl" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US">Schedule of Statement of Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable_lbl" xml:lang="en-US">Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:to="abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Schedule of Carrying Amounts of the Liability Component [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Schedule of Short-Term Bank Loan [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Schedule of Related Parties of the Company with whom Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable_lbl" xml:lang="en-US">Related Parties Transactions - Schedule of Licensing Agreement and Related Amendment with FEYE (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" xlink:to="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems_lbl" xml:lang="en-US">Schedule of Licensing Agreement and Related Amendment with FEYE [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Related Parties Transactions - Schedule of Accounts Receivable Due from Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" xlink:to="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Schedule of Accounts Receivable Due from Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable_lbl" xml:lang="en-US">Related Parties Transactions - Schedule of Due from Related Party - Current and Non-current, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" xlink:to="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems_lbl" xml:lang="en-US">Schedule of Due from Related Party - Current and Non-current, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Related Parties Transactions - Schedule of Amount Due to Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" xlink:to="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Schedule of Amount Due to Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable_lbl" xml:lang="en-US">Lease - Schedule of Company&#8217;s Lease Expenses (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable" xlink:to="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems_lbl" xml:lang="en-US">Schedule of Company&#8217;s Lease Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl0" xml:lang="en-US">Schedule of Impact of the Restatement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtLineItems_lbl0" xml:lang="en-US">Schedule of Short-Term Loans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Warrants Issued and Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:href="abvc-20250331.xsd#abvc_OrganizationandDescriptionofBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OrganizationandDescriptionofBusinessDetailsTable_lbl" xml:lang="en-US">Organization and Description of Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="abvc_OrganizationandDescriptionofBusinessDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl0" xml:lang="en-US">Organization and Description of Business[Line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LiquidityGoingConcernandRestatementDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LiquidityGoingConcernandRestatementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LiquidityGoingConcernandRestatementDetailsTable_lbl" xml:lang="en-US">Liquidity, Going Concern, and Restatement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsTable" xlink:to="abvc_LiquidityGoingConcernandRestatementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_LiquidityGoingConcernandRestatementDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LiquidityGoingConcernandRestatementDetailsLineItems_lbl" xml:lang="en-US">Liquidity, Going Concern, and Restatement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="abvc_LiquidityGoingConcernandRestatementDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeAndTierIdentifierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeAndTierIdentifierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeAndTierIdentifierDomain_lbl" xml:lang="en-US">Type and Tier Identifier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeAndTierIdentifierDomain" xlink:to="us-gaap_TypeAndTierIdentifierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="abvc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_StatutoryAccountingPracticesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CollaborativeAgreementsDetailsTable_lbl" xml:lang="en-US">Collaborative Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementsDetailsTable" xlink:to="abvc_CollaborativeAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:href="abvc-20250331.xsd#abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable_lbl" xml:lang="en-US">Property and Equipment, and Prepament for Asset Acquisition (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0" xml:lang="en-US">Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsDetailsTable_lbl" xml:lang="en-US">Long-Term Investments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsDetailsTable" xlink:to="abvc_LongTermInvestmentsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl1" xml:lang="en-US">Long-Term Investments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertibleNotesPayableDetailsTable_lbl" xml:lang="en-US">Convertible Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="abvc_ConvertibleNotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionLineItems_lbl" xml:lang="en-US">Convertible Notes Payable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShortTermLoansDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ShortTermLoansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShortTermLoansDetailsTable_lbl" xml:lang="en-US">Short-Term Loans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShortTermLoansDetailsTable" xlink:to="abvc_ShortTermLoansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalHomeLoanBankAdvancesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalHomeLoanBankAdvancesLineItems_lbl" xml:lang="en-US">Bank Loans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_FederalHomeLoanBankAdvancesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsDetailsTable_lbl" xml:lang="en-US">Related Parties Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="abvc_RelatedPartiesTransactionsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl1" xml:lang="en-US">Related Parties Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityDetailsTable" xlink:href="abvc-20250331.xsd#abvc_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityDetailsTable" xlink:to="abvc_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_StockOptionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockOptionsDetailsTable_lbl" xml:lang="en-US">Stock Options (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsDetailsTable" xlink:to="abvc_StockOptionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Stock Options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SubsequentEventsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="abvc_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AccruedDirectorAndOfficerCompensation_lbl0" xml:lang="en-US">The amouont of accrued director and officer compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccruedDirectorAndOfficerCompensation" xlink:to="abvc_AccruedDirectorAndOfficerCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AccruedResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Accrued research and development expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccruedResearchAndDevelopmentExpense" xlink:to="abvc_AccruedResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AcquisitionForNetSales_lbl1" xml:lang="en-US">The amount of acquisition for net sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AcquisitionForNetSales" xlink:to="abvc_AcquisitionForNetSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AdditionCashPayment_lbl0" xml:lang="en-US">The amount of addition cash payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionCashPayment" xlink:to="abvc_AdditionCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AdditionalMilestonePaymentInCash_lbl0" xml:lang="en-US">Additional milestone payment in cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionalMilestonePaymentInCash" xlink:to="abvc_AdditionalMilestonePaymentInCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable_lbl0" xml:lang="en-US">Represents the amount of warrant issued with convertible notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" xlink:to="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AggregateCommonStockShares_lbl0" xml:lang="en-US">Aggregate common stock shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregateCommonStockShares" xlink:to="abvc_AggregateCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AssetConsiderationCommonStock_lbl0" xml:lang="en-US">Asset consideration common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AssetConsiderationCommonStock" xlink:to="abvc_AssetConsiderationCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AverageIssuancePricePerShare_lbl0" xml:lang="en-US">Represent the average issuance price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AverageIssuancePricePerShare" xlink:to="abvc_AverageIssuancePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_BenefitsReceivableForMilestoneAttained_lbl1" xml:lang="en-US">Amount receivable for certain milestone are met  and eligible to receive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BenefitsReceivableForMilestoneAttained" xlink:to="abvc_BenefitsReceivableForMilestoneAttained_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities_lbl0" xml:lang="en-US">Accrued expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_CashPortionOfTheLindNoteRepayments_lbl0" xml:lang="en-US">The amount of cash portion of the Lind Note repayments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPortionOfTheLindNoteRepayments" xlink:to="abvc_CashPortionOfTheLindNoteRepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_CommonStockSharesIssuedForRent_lbl0" xml:lang="en-US">Number of shares issued for rent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockSharesIssuedForRent" xlink:to="abvc_CommonStockSharesIssuedForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConcentrationOfClientsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for concentration of clients.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConcentrationOfClientsPolicyTextBlock" xlink:to="abvc_ConcentrationOfClientsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConsecutiveDays_lbl0" xml:lang="en-US">Consecutive days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsecutiveDays" xlink:to="abvc_ConsecutiveDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConsiderationAmount_lbl0" xml:lang="en-US">The consideration amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsiderationAmount" xlink:to="abvc_ConsiderationAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConsiderationPaidForAgreement_lbl0" xml:lang="en-US">Consideration paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsiderationPaidForAgreement" xlink:to="abvc_ConsiderationPaidForAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConsultingFee_lbl0" xml:lang="en-US">The amount of  consulting fee .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultingFee" xlink:to="abvc_ConsultingFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConvertibleNotesPayablePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for convertible notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayablePolicyTextBlock" xlink:to="abvc_ConvertibleNotesPayablePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DebtInstrumentCarryingValue_lbl0" xml:lang="en-US">The amount of carrying value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentCarryingValue" xlink:to="abvc_DebtInstrumentCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DebtInstrumentCommonStockToBeConverted_lbl0" xml:lang="en-US">Description of common stock to be converted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentCommonStockToBeConverted" xlink:to="abvc_DebtInstrumentCommonStockToBeConverted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DebtInstrumentIssuanceEntity_lbl0" xml:lang="en-US">Description of issuance entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentIssuanceEntity" xlink:to="abvc_DebtInstrumentIssuanceEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DebtInstrumentOutstandingPrincipal_lbl0" xml:lang="en-US">Amount of outstanding principal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentOutstandingPrincipal" xlink:to="abvc_DebtInstrumentOutstandingPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate_lbl0" xml:lang="en-US">The amount of principal amount at balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate" xlink:to="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DeferredTaxAssetsOperatingLeaseAssets_lbl0" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to operating lease assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:to="abvc_DeferredTaxAssetsOperatingLeaseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DefinedBenefitPlanFundedPercentages_lbl0" xml:lang="en-US">Percentage of plan assets to benefit obligation of defined benefit plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DefinedBenefitPlanFundedPercentages" xlink:to="abvc_DefinedBenefitPlanFundedPercentages_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash_lbl0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents and restricted cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" xlink:to="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_EquityMethodInvestmentsOwnershipPercentage_lbl0" xml:lang="en-US">Represent the percent value of equity method investments ownership percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodInvestmentsOwnershipPercentage" xlink:to="abvc_EquityMethodInvestmentsOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_EquityMethodLongTermInvestment_lbl0" xml:lang="en-US">Equity method long term investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodLongTermInvestment" xlink:to="abvc_EquityMethodLongTermInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_IssuanceOfCommonShareForLindCNRepayment_lbl0" xml:lang="en-US">Issuance of common shares for Lind CN repayment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfCommonShareForLindCNRepayment" xlink:to="abvc_IssuanceOfCommonShareForLindCNRepayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_IssuanceOfCommonStockForConversionOfDebt_lbl0" xml:lang="en-US">Issuance of common stock for conversion of debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfCommonStockForConversionOfDebt" xlink:to="abvc_IssuanceOfCommonStockForConversionOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_IssuanceOfStockValue_lbl0" xml:lang="en-US">The value of Common stock newly issued. for example : newly issued shares means any common shares issued pursuant to the primary share purchases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfStockValue" xlink:to="abvc_IssuanceOfStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices_lbl0" xml:lang="en-US">Amount of issuance of subsidiary&#8217;s common stock for consulting services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices" xlink:to="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_LaborPensionFundPerMonth_lbl0" xml:lang="en-US">Labor pension fund per month.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LaborPensionFundPerMonth" xlink:to="abvc_LaborPensionFundPerMonth_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_LicensingAgreement_lbl0" xml:lang="en-US">The amount of licensing Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LicensingAgreement" xlink:to="abvc_LicensingAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_LicensingFees_lbl0" xml:lang="en-US">Amount licensing fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LicensingFees" xlink:to="abvc_LicensingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_LiquidityGoingConcernAndRestatementTextBlock_lbl0" xml:lang="en-US">Disclosure of liquidity, going concern, and restatement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LiquidityGoingConcernAndRestatementTextBlock" xlink:to="abvc_LiquidityGoingConcernAndRestatementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_LoanAgreementAmount_lbl0" xml:lang="en-US">The amount of loan agreement amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementAmount" xlink:to="abvc_LoanAgreementAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage_lbl0" xml:lang="en-US">Milestone payments royalty percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePaymentsRoyaltyPercentage" xlink:to="abvc_MilestonePaymentsRoyaltyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_MilestoneRegulatoryPaymentAmount_lbl0" xml:lang="en-US">Represent the amount of milestone regulatory payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestoneRegulatoryPaymentAmount" xlink:to="abvc_MilestoneRegulatoryPaymentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_MilestoneRegulatoryPaymentAmountPeriod_lbl0" xml:lang="en-US">Milestone Regulatory Payment Amount Period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestoneRegulatoryPaymentAmountPeriod" xlink:to="abvc_MilestoneRegulatoryPaymentAmountPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_NetSalesProfitPercentage_lbl0" xml:lang="en-US">Percentage of net sales profit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetSalesProfitPercentage" xlink:to="abvc_NetSalesProfitPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_NonControllingInterestConsiderationShare_lbl0" xml:lang="en-US">Non-controlling interest consideration share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonControllingInterestConsiderationShare" xlink:to="abvc_NonControllingInterestConsiderationShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_NonrefundableUpfrontCashPayment_lbl0" xml:lang="en-US">Non-refundable upfront cash payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonrefundableUpfrontCashPayment" xlink:to="abvc_NonrefundableUpfrontCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_NumberOfSharesReceived_lbl0" xml:lang="en-US">The number of shares received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumberOfSharesReceived" xlink:to="abvc_NumberOfSharesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_OperatingLeaseLiabilities_lbl0" xml:lang="en-US">Operating lease liabilities amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeaseLiabilities" xlink:to="abvc_OperatingLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for other than temporary impairment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:to="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_OutstandingBalanceAmount_lbl1" xml:lang="en-US">The amount of outstanding balance amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingBalanceAmount" xlink:to="abvc_OutstandingBalanceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_OutstandingLiabilityOwnedAmount_lbl0" xml:lang="en-US">Outstanding liability Owned Amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingLiabilityOwnedAmount" xlink:to="abvc_OutstandingLiabilityOwnedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_OutstandingPrincipalAmount_lbl0" xml:lang="en-US">The amount of outstanding principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingPrincipalAmount" xlink:to="abvc_OutstandingPrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageCommonStocksShares_lbl0" xml:lang="en-US">Percentage value of common stocks shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageCommonStocksShares" xlink:to="abvc_PercentageCommonStocksShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfAnnualDiscountRate_lbl0" xml:lang="en-US">The percentage of annual discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfAnnualDiscountRate" xlink:to="abvc_PercentageOfAnnualDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfAverageAmount_lbl0" xml:lang="en-US">Percentage of average amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfAverageAmount" xlink:to="abvc_PercentageOfAverageAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfCashPermium_lbl0" xml:lang="en-US">Percentage of cash premium.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfCashPermium" xlink:to="abvc_PercentageOfCashPermium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfDevelopAndCommercialize_lbl0" xml:lang="en-US">Rate of develop and commercialize.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfDevelopAndCommercialize" xlink:to="abvc_PercentageOfDevelopAndCommercialize_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfOutstandingPrincipalAmount_lbl0" xml:lang="en-US">Percentage of outstanding principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfOutstandingPrincipalAmount" xlink:to="abvc_PercentageOfOutstandingPrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl0" xml:lang="en-US">Percentage of payments under co-development agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:to="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfRoyaltiesEqualing_lbl0" xml:lang="en-US">The percentage of royalties equaling.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfRoyaltiesEqualing" xlink:to="abvc_PercentageOfRoyaltiesEqualing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfWorkingCapital_lbl0" xml:lang="en-US">Percentage of working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfWorkingCapital" xlink:to="abvc_PercentageOfWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PrepaymentForLongtermInvestmentsNoncurrent_lbl0" xml:lang="en-US">Prepayment for long-term investments noncurrent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentForLongtermInvestmentsNoncurrent" xlink:to="abvc_PrepaymentForLongtermInvestmentsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty_lbl0" xml:lang="en-US">Amount of prepayment of asset acquisition by issuing common stock to a third party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" xlink:to="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PriorPeriodAdjustment_lbl0" xml:lang="en-US">Amount of prior period adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PriorPeriodAdjustment" xlink:to="abvc_PriorPeriodAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ProceedsFromIssuanceOfAPromissoryNote_lbl1" xml:lang="en-US">Amount of proceeds from issuance of a promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromIssuanceOfAPromissoryNote" xlink:to="abvc_ProceedsFromIssuanceOfAPromissoryNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ProceedsFromSubsidiarysCommonStockSubscription_lbl0" xml:lang="en-US">Amount of proceeds from subsidiary&apos;s common stock subscription.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromSubsidiarysCommonStockSubscription" xlink:to="abvc_ProceedsFromSubsidiarysCommonStockSubscription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ProceedsFromSubsidiarysShareholderContribution_lbl0" xml:lang="en-US">Represent the amount of proceeds from subsidiary&apos;s shareholder contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromSubsidiarysShareholderContribution" xlink:to="abvc_ProceedsFromSubsidiarysShareholderContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty_lbl0" xml:lang="en-US">Amount of purchase of property and equipment by issuing common stock to a third party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" xlink:to="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PurchasePriceAmount_lbl0" xml:lang="en-US">Purchase price amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchasePriceAmount" xlink:to="abvc_PurchasePriceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PurchaseWarrantTerm_lbl0" xml:lang="en-US">Term of the purchase warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseWarrantTerm" xlink:to="abvc_PurchaseWarrantTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ReceivedShares_lbl0" xml:lang="en-US">Number of shares received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ReceivedShares" xlink:to="abvc_ReceivedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_RecognizedCreditLosses_lbl0" xml:lang="en-US">Recognized credit losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RecognizedCreditLosses" xlink:to="abvc_RecognizedCreditLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_RepurchaseOfTreasuryStocks_lbl0" xml:lang="en-US">The amount of repurchase of treasury stocks.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RepurchaseOfTreasuryStocks" xlink:to="abvc_RepurchaseOfTreasuryStocks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_RoyaltiesPercentage_lbl0" xml:lang="en-US">Percentage of Royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RoyaltiesPercentage" xlink:to="abvc_RoyaltiesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of amount due to related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock" xlink:to="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of due from related party current and non current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" xlink:to="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of estimated useful life of property and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" xlink:to="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of extent the investee relies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock" xlink:to="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock_lbl0" xml:lang="en-US">Schedule of Pursuant Licensing Agreement Related Amendment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" xlink:to="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ServiceAgreementEligibilityAmount_lbl0" xml:lang="en-US">Service agreement eligibility amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ServiceAgreementEligibilityAmount" xlink:to="abvc_ServiceAgreementEligibilityAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue_lbl1" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instrument exercise intrinsic value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instrument exercise weighted average exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instrument   exercise weighted remaining contractual term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue_lbl1" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instrument  issued intrinsic value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instrument issued weighted average exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instrument  issued weighted remaining contractual term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average contractual life remaining in years, forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">The value of estimated use full lifes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_SharesReceived_lbl0" xml:lang="en-US">Shares received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesReceived" xlink:to="abvc_SharesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShortTermDebtMaturityDate_lbl0" xml:lang="en-US">Maturity date of short-term debt, in YYYY-MM-DD format.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShortTermDebtMaturityDate" xlink:to="abvc_ShortTermDebtMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockBasedExpensesAmortizationPeriod_lbl0" xml:lang="en-US">Duration of Stock-based expenses amortization period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockBasedExpensesAmortizationPeriod" xlink:to="abvc_StockBasedExpensesAmortizationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssueDuringPeriodCommonShares_lbl0" xml:lang="en-US">Stock issue during period common shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssueDuringPeriodCommonShares" xlink:to="abvc_StockIssueDuringPeriodCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation_lbl0" xml:lang="en-US">Number of shares in distribute as employee compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" xlink:to="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_lbl0" xml:lang="en-US">The share amount of exercise of pre-funded warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:to="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty_lbl0" xml:lang="en-US">Number of shares in issuance of common shares for acquiring of Property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty_lbl1" xml:lang="en-US">The number of shares issuance of common stock for acquiring of property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants_lbl0" xml:lang="en-US">Issuance of common shares for exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty_lbl0" xml:lang="en-US">Value of stock 	issuance of common stock for acquiring of property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants_lbl0" xml:lang="en-US">Represents the amount of issuance of common shares for exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN_lbl0" xml:lang="en-US">Represents the amount of issuance of common shares for Lind CN.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService_lbl0" xml:lang="en-US">Value of stock related to issuance of subsidiary&apos;s common shares for consulting service.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant_lbl0" xml:lang="en-US">The amount of exercise of pre-funded warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" xlink:to="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution_lbl0" xml:lang="en-US">Amount of subsidiary executive contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" xlink:to="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockSubscriptionReceived_lbl0" xml:lang="en-US">Value of shares of stock subscription received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceived" xlink:to="abvc_StockSubscriptionReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockSubscriptionReceivedInAdvance_lbl0" xml:lang="en-US">The amount of stock subscription received in advance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceivedInAdvance" xlink:to="abvc_StockSubscriptionReceivedInAdvance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_TradingDays_lbl0" xml:lang="en-US">Trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TradingDays" xlink:to="abvc_TradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_UnregisteredPricePerShares_lbl0" xml:lang="en-US">Unregistered price per shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnregisteredPricePerShares" xlink:to="abvc_UnregisteredPricePerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for valuation of deferred tax assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:to="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_WorkingCapitalConvertibleLoanPercentage_lbl0" xml:lang="en-US">Percentage of working capital convertible loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WorkingCapitalConvertibleLoanPercentage" xlink:to="abvc_WorkingCapitalConvertibleLoanPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_WorkingCapitalDeficit_lbl0" xml:lang="en-US">Working capital deficit value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WorkingCapitalDeficit" xlink:to="abvc_WorkingCapitalDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites_lbl1" xml:lang="en-US">Amount of write off unclaimed accrued liabilites.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_royaltiesPercentage_lbl0" xml:lang="en-US">royalties percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_royaltiesPercentage" xlink:to="abvc_royaltiesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_TaiwanCentralDepositInsuranceCorporationMember_lbl0" xml:lang="en-US">Taiwan central deposit insurance corporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TaiwanCentralDepositInsuranceCorporationMember" xlink:to="abvc_TaiwanCentralDepositInsuranceCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_USFederalDepositInsuranceCorporationMember_lbl0" xml:lang="en-US">US federal deposit insurance corporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_USFederalDepositInsuranceCorporationMember" xlink:to="abvc_USFederalDepositInsuranceCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OtherNoteOneMember_lbl1" xml:lang="en-US">Other Note One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherNoteOneMember" xlink:to="abvc_OtherNoteOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LicensingFees_lbl1" xml:lang="en-US">Licensing Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LicensingFees" xlink:to="abvc_LicensingFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BHKCoDevelopmentAgreementMember_lbl0" xml:lang="en-US">BHKCo Development Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAgreementMember" xlink:to="abvc_BHKCoDevelopmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl2" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl0" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution_lbl1" xml:lang="en-US">Stock Issued During Period Value Subsidiary Executive Contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" xlink:to="abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstMember_lbl0" xml:lang="en-US">Bio First Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstMember" xlink:to="abvc_BioFirstMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConversionMember_lbl0" xml:lang="en-US">Conversion Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConversionMember" xlink:to="abvc_ConversionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WriteOffUnclaimedAccruedLiabilites_lbl2" xml:lang="en-US">Write Off Unclaimed Accrued Liabilites</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WriteOffUnclaimedAccruedLiabilites" xlink:to="abvc_WriteOffUnclaimedAccruedLiabilites_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LicensingAgreement_lbl1" xml:lang="en-US">Licensing Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LicensingAgreement" xlink:to="abvc_LicensingAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TheJiangsOneMember_lbl0" xml:lang="en-US">The Jiangs One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TheJiangsOneMember" xlink:to="abvc_TheJiangsOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PriorPeriodAdjustment_lbl1" xml:lang="en-US">Prior Period Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PriorPeriodAdjustment" xlink:to="abvc_PriorPeriodAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl0" xml:lang="en-US">Proceeds from Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract0_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract0" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AddLessAbstract_lbl0" xml:lang="en-US">Add Less Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AddLessAbstract" xlink:to="abvc_AddLessAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl0" xml:lang="en-US">Proceeds from Contributed Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AverageIssuancePricePerShare_lbl1" xml:lang="en-US">Average Issuance Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AverageIssuancePricePerShare" xlink:to="abvc_AverageIssuancePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LiquidityGoingConcernAndRestatementTextBlock_lbl1" xml:lang="en-US">Liquidity Going Concern And Restatement Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LiquidityGoingConcernAndRestatementTextBlock" xlink:to="abvc_LiquidityGoingConcernAndRestatementTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_lbl0" xml:lang="en-US">Investment [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UnregisteredPricePerShares_lbl1" xml:lang="en-US">Unregistered Price Per Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnregisteredPricePerShares" xlink:to="abvc_UnregisteredPricePerShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLossPerShareAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="abvc_ScheduleOfLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstReceivesMember_lbl0" xml:lang="en-US">Bio First Receives Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstReceivesMember" xlink:to="abvc_BioFirstReceivesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageNumberOfCommonSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number Of Common Shares Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageNumberOfCommonSharesOutstandingAbstract" xlink:to="abvc_WeightedAverageNumberOfCommonSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl0" xml:lang="en-US">Treasury Stock, Common [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Short-Term Debt, Percentage Bearing Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockSubscriptionReceivedInAdvance_lbl1" xml:lang="en-US">Stock Subscription Received In Advance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceivedInAdvance" xlink:to="abvc_StockSubscriptionReceivedInAdvance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TradingDays_lbl1" xml:lang="en-US">Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TradingDays" xlink:to="abvc_TradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl0" xml:lang="en-US">Collaborative Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl0" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ChiefStrategicOfficerMember_lbl0" xml:lang="en-US">Chief Strategic Officer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ChiefStrategicOfficerMember" xlink:to="abvc_ChiefStrategicOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices_lbl1" xml:lang="en-US">Issuance Of Subsidiarys Common Stock For Consulting Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices" xlink:to="abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockBasedExpensesAmortizationPeriod_lbl1" xml:lang="en-US">Stock Based Expenses Amortization Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockBasedExpensesAmortizationPeriod" xlink:to="abvc_StockBasedExpensesAmortizationPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PrepaymentForLongtermInvestmentsNoncurrent_lbl1" xml:lang="en-US">Prepayment For Longterm Investments Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentForLongtermInvestmentsNoncurrent" xlink:to="abvc_PrepaymentForLongtermInvestmentsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDepositLiability_lbl0" xml:lang="en-US">Security Deposit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAdditionalInformation_lbl0" xml:lang="en-US">Equity Method Investment, Additional Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAdditionalInformation" xlink:to="us-gaap_EquityMethodInvestmentAdditionalInformation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConsultantMember_lbl0" xml:lang="en-US">Consultant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultantMember" xlink:to="abvc_ConsultantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PostretirementAndPostemploymentBenefitsMember_lbl0" xml:lang="en-US">Postretirement And Postemployment Benefits Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PostretirementAndPostemploymentBenefitsMember" xlink:to="abvc_PostretirementAndPostemploymentBenefitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl0" xml:lang="en-US">Accrued Salaries, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Amount Due To Related Parties Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock" xlink:to="abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract" xlink:href="abvc-20250331.xsd#abvc_UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract_lbl" xml:lang="en-US">Unaudited Condensed Consolidated Statements Of Stockholders Equity Deficit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract" xlink:to="abvc_UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Subsidiarys Common Shares For Consulting Service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LaborPensionFundPerMonth_lbl1" xml:lang="en-US">Labor Pension Fund Per Month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LaborPensionFundPerMonth" xlink:to="abvc_LaborPensionFundPerMonth_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LessAbstract_lbl0" xml:lang="en-US">Less Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LessAbstract" xlink:to="abvc_LessAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EquityMethodInvestmentsOwnershipPercentage_lbl1" xml:lang="en-US">Equity Method Investments Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodInvestmentsOwnershipPercentage" xlink:to="abvc_EquityMethodInvestmentsOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EquityMethodLongTermInvestment_lbl1" xml:lang="en-US">Equity Method Long Term Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodLongTermInvestment" xlink:to="abvc_EquityMethodLongTermInvestment_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract_lbl" xml:lang="en-US">Schedule Of Related Parties Of The Company With Whom Transactions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract" xlink:to="abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl0" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0" xml:lang="en-US">Schedule of Short-Term Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock_lbl1" xml:lang="en-US">Schedule Of Pursuant Licensing Agreement Related Amendment Table Text BLock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" xlink:to="abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl1" xml:lang="en-US">Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AcquisitionForNetSales_lbl2" xml:lang="en-US">Acquisition For Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AcquisitionForNetSales" xlink:to="abvc_AcquisitionForNetSales_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LiabilitiesAndEquityAbstract_lbl0" xml:lang="en-US">Liabilities And Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LiabilitiesAndEquityAbstract" xlink:to="abvc_LiabilitiesAndEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OtherIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other Income Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherIncomeExpenseAbstract" xlink:to="abvc_OtherIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OtherNoteMember_lbl0" xml:lang="en-US">Other Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherNoteMember" xlink:to="abvc_OtherNoteMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfBalanceSheetsAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfBalanceSheetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfBalanceSheetsAbstract_lbl" xml:lang="en-US">Schedule Of Balance Sheets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfBalanceSheetsAbstract" xlink:to="abvc_ScheduleOfBalanceSheetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl0" xml:lang="en-US">Asset Acquisition [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl0" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WorkingCapitalDeficit_lbl1" xml:lang="en-US">Working Capital Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WorkingCapitalDeficit" xlink:to="abvc_WorkingCapitalDeficit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AccruedResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Accrued Research And Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccruedResearchAndDevelopmentExpense" xlink:to="abvc_AccruedResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty_lbl1" xml:lang="en-US">Purchase Of Property And Equipment By Issuing Common Stock To AThird Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" xlink:to="abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl1" xml:lang="en-US">Valuation Of Deferred Tax Assets Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:to="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl1" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfImpactOfTheRestatementAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfImpactOfTheRestatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfImpactOfTheRestatementAbstract_lbl" xml:lang="en-US">Schedule Of Impact Of The Restatement Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfImpactOfTheRestatementAbstract" xlink:to="abvc_ScheduleOfImpactOfTheRestatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Land_lbl0" xml:lang="en-US">Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Land" xlink:to="us-gaap_Land_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAndLandImprovements_lbl0" xml:lang="en-US">Land and Land Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndLandImprovements" xlink:to="us-gaap_LandAndLandImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ZhongHuiLianHeJiTuanLtdMember_lbl0" xml:lang="en-US">Zhong Hui Lian He Ji Tuan Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ZhongHuiLianHeJiTuanLtdMember" xlink:to="abvc_ZhongHuiLianHeJiTuanLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GenepharmBiotechCorporationMember_lbl0" xml:lang="en-US">Genepharm Biotech Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenepharmBiotechCorporationMember" xlink:to="abvc_GenepharmBiotechCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl0" xml:lang="en-US">Equity Method Investments [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Common Shares For Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfShortTermLoansAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfShortTermLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfShortTermLoansAbstract_lbl" xml:lang="en-US">Schedule Of Short Term Loans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfShortTermLoansAbstract" xlink:to="abvc_ScheduleOfShortTermLoansAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AiBtlBioPharmaIncMember_lbl0" xml:lang="en-US">Ai Btl Bio Pharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AiBtlBioPharmaIncMember" xlink:to="abvc_AiBtlBioPharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdvisorsOneMember_lbl0" xml:lang="en-US">Advisors One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvisorsOneMember" xlink:to="abvc_AdvisorsOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl0" xml:lang="en-US">Investment Company, Reimbursable Excess Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CommonStockSharesIssuedForRent_lbl1" xml:lang="en-US">Common Stock Shares Issued For Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockSharesIssuedForRent" xlink:to="abvc_CommonStockSharesIssuedForRent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralPartnersCapitalAccount_lbl0" xml:lang="en-US">General Partners&apos; Capital Account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralPartnersCapitalAccount" xlink:to="us-gaap_GeneralPartnersCapitalAccount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl0" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CashFlowsFromFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Financing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="abvc_CashFlowsFromFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LindOfferingsMember_lbl0" xml:lang="en-US">Lind Offerings Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindOfferingsMember" xlink:to="abvc_LindOfferingsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CashPortionOfTheLindNoteRepayments_lbl1" xml:lang="en-US">Cash Portion Of The Lind Note Repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPortionOfTheLindNoteRepayments" xlink:to="abvc_CashPortionOfTheLindNoteRepayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage_lbl1" xml:lang="en-US">Milestone Payments Royalty Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePaymentsRoyaltyPercentage" xlink:to="abvc_MilestonePaymentsRoyaltyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl0" xml:lang="en-US">Defined Benefit Plan, Service Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanServiceCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NetSalesProfitPercentage_lbl1" xml:lang="en-US">Net Sales Profit Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetSalesProfitPercentage" xlink:to="abvc_NetSalesProfitPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl0" xml:lang="en-US">Related Party Transaction, Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionRate" xlink:to="us-gaap_RelatedPartyTransactionRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant_lbl1" xml:lang="en-US">Stock Issued During Period Value Stock Exercise Of Prefunded Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" xlink:to="abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl2" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfExtentTheInvesteeReliesAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfExtentTheInvesteeReliesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfExtentTheInvesteeReliesAbstract_lbl" xml:lang="en-US">Schedule Of Extent The Investee Relies Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfExtentTheInvesteeReliesAbstract" xlink:to="abvc_ScheduleOfExtentTheInvesteeReliesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfWarrantsIssuedAndOutstandingAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfWarrantsIssuedAndOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfWarrantsIssuedAndOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Warrants Issued And Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfWarrantsIssuedAndOutstandingAbstract" xlink:to="abvc_ScheduleOfWarrantsIssuedAndOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_FEYEMember_lbl0" xml:lang="en-US">FEYEMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_FEYEMember" xlink:to="abvc_FEYEMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CashPaidMember_lbl0" xml:lang="en-US">Cash Paid Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPaidMember" xlink:to="abvc_CashPaidMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_lbl1" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Prefunded Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:to="abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl1" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Due From Related Party Current And Non Current Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" xlink:to="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ServiceAgreementEligibilityAmount_lbl1" xml:lang="en-US">Service Agreement Eligibility Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ServiceAgreementEligibilityAmount" xlink:to="abvc_ServiceAgreementEligibilityAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AsRestatedMember_lbl0" xml:lang="en-US">As Restated Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AsRestatedMember" xlink:to="abvc_AsRestatedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NumberOfSharesReceived_lbl1" xml:lang="en-US">Number Of Shares Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumberOfSharesReceived" xlink:to="abvc_NumberOfSharesReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl1" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdditionCashPayment_lbl1" xml:lang="en-US">Addition Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionCashPayment" xlink:to="abvc_AdditionCashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DebtInstrumentCarryingValue_lbl1" xml:lang="en-US">Debt Instrument Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentCarryingValue" xlink:to="abvc_DebtInstrumentCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl1" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditDerivativeTerm1_lbl0" xml:lang="en-US">Credit Derivative, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditDerivativeTerm1" xlink:to="us-gaap_CreditDerivativeTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CashPaidDuringTheYearForAbstract0_lbl0" xml:lang="en-US">Cash Paid During The Year For Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPaidDuringTheYearForAbstract0" xlink:to="abvc_CashPaidDuringTheYearForAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl0" xml:lang="en-US">Business Combination, Recognized Liability Assumed, Long-Term Debt, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ThirdLetterAgreementMember_lbl0" xml:lang="en-US">Third Letter Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ThirdLetterAgreementMember" xlink:to="abvc_ThirdLetterAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate_lbl1" xml:lang="en-US">Debt Instrument Principal Amount At Balance Sheet Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate" xlink:to="abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="abvc_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Common Shares For Acquiring Of Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CashFlowsFromInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Investing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="abvc_CashFlowsFromInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl0" xml:lang="en-US">Bio First Australia Pty Ltdthe Bio First Australia Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:to="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Product and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdditionalMilestonePaymentInCash_lbl1" xml:lang="en-US">Additional Milestone Payment In Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionalMilestonePaymentInCash" xlink:to="abvc_AdditionalMilestonePaymentInCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_lbl0" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CashPaidDuringTheYearForAbstract_lbl0" xml:lang="en-US">Cash Paid During The Year For Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPaidDuringTheYearForAbstract" xlink:to="abvc_CashPaidDuringTheYearForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Accounts Receivable Due From Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:to="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DeferredTaxAssetsOperatingLeaseAssets_lbl1" xml:lang="en-US">Deferred Tax Assets Operating Lease Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DeferredTaxAssetsOperatingLeaseAssets" xlink:to="abvc_DeferredTaxAssetsOperatingLeaseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_JaimesVargasRussmanMember_lbl0" xml:lang="en-US">Jaimes Vargas Russman Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_JaimesVargasRussmanMember" xlink:to="abvc_JaimesVargasRussmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CathayUnitedLoanAgreementMember_lbl0" xml:lang="en-US">Cathay United Loan Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayUnitedLoanAgreementMember" xlink:to="abvc_CathayUnitedLoanAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LionArtsPromotionIncMember_lbl0" xml:lang="en-US">Lion Arts Promotion Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionArtsPromotionIncMember" xlink:to="abvc_LionArtsPromotionIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl3" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl0" xml:lang="en-US">Postemployment Benefit Plans, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfDevelopAndCommercialize_lbl1" xml:lang="en-US">Percentage Of Develop And Commercialize</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfDevelopAndCommercialize" xlink:to="abvc_PercentageOfDevelopAndCommercialize_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Changes In Operating Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="abvc_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstCorporationMember_lbl0" xml:lang="en-US">Bio First Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationMember" xlink:to="abvc_BioFirstCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DebtInstrumentOutstandingPrincipal_lbl1" xml:lang="en-US">Debt Instrument Outstanding Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentOutstandingPrincipal" xlink:to="abvc_DebtInstrumentOutstandingPrincipal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl0" xml:lang="en-US">Proceeds from Stock Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BHKCoDevelopmentAggreementMember_lbl1" xml:lang="en-US">BHKCo Development Aggreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAggreementMember" xlink:to="abvc_BHKCoDevelopmentAggreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LicensingAgreementMember_lbl0" xml:lang="en-US">Licensing Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LicensingAgreementMember" xlink:to="abvc_LicensingAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TaiwanCentralDepositInsuranceCorporationMember_lbl1" xml:lang="en-US">Taiwan Central Deposit Insurance Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TaiwanCentralDepositInsuranceCorporationMember" xlink:to="abvc_TaiwanCentralDepositInsuranceCorporationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OutstandingBalanceAmount_lbl2" xml:lang="en-US">Outstanding Balance Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingBalanceAmount" xlink:to="abvc_OutstandingBalanceAmount_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract_lbl0" xml:lang="en-US">Weighted Average Number Of Common Shares Outstanding1 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LindGlobalFundIILPLindMember_lbl0" xml:lang="en-US">Lind Global Fund IILPLind Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindGlobalFundIILPLindMember" xlink:to="abvc_LindGlobalFundIILPLindMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl0" xml:lang="en-US">Payments for Repurchase of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ProceedsFromSubsidiarysShareholderContribution_lbl1" xml:lang="en-US">Proceeds From Subsidiarys Shareholder Contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromSubsidiarysShareholderContribution" xlink:to="abvc_ProceedsFromSubsidiarysShareholderContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl1" xml:lang="en-US">Interest Expense, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation_lbl1" xml:lang="en-US">Stock Issued During Period Shares Distribute As Employee Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" xlink:to="abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl1" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_IssuanceOfCommonStockForConversionOfDebt_lbl1" xml:lang="en-US">Issuance Of Common Stock For Conversion Of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfCommonStockForConversionOfDebt" xlink:to="abvc_IssuanceOfCommonStockForConversionOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConsultingFee_lbl1" xml:lang="en-US">Consulting Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultingFee" xlink:to="abvc_ConsultingFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount_lbl0" xml:lang="en-US">Receivable with Imputed Interest, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:to="us-gaap_ReceivableWithImputedInterestFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CTBCBankMember_lbl0" xml:lang="en-US">CTBCBank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CTBCBankMember" xlink:to="abvc_CTBCBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioHopeKingCorporationBHKMember_lbl0" xml:lang="en-US">Bio Hope King Corporation BHKMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioHopeKingCorporationBHKMember" xlink:to="abvc_BioHopeKingCorporationBHKMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember_lbl0" xml:lang="en-US">Braingenesis Biotechnology Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense, Operating and Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl0" xml:lang="en-US">Sublease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstStockPurchaseAgreementMember_lbl1" xml:lang="en-US">Bio First Stock Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstStockPurchaseAgreementMember" xlink:to="abvc_BioFirstStockPurchaseAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ForSeeConEyeCorporationMember_lbl0" xml:lang="en-US">For See Con Eye Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ForSeeConEyeCorporationMember" xlink:to="abvc_ForSeeConEyeCorporationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfEstimatedUsefulLifeAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfEstimatedUsefulLifeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfEstimatedUsefulLifeAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Life Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfEstimatedUsefulLifeAbstract" xlink:to="abvc_ScheduleOfEstimatedUsefulLifeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember_lbl0" xml:lang="en-US">Ai Btl Holding Bio Pharma Inc Ai Btl Holding Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember" xlink:to="abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RoyaltiesPercentage_lbl1" xml:lang="en-US">Royalties Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RoyaltiesPercentage" xlink:to="abvc_RoyaltiesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CodevelopmentagreementMember_lbl0" xml:lang="en-US">Codevelopmentagreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CodevelopmentagreementMember" xlink:to="abvc_CodevelopmentagreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfAnnualDiscountRate_lbl1" xml:lang="en-US">Percentage Of Annual Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfAnnualDiscountRate" xlink:to="abvc_PercentageOfAnnualDiscountRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SubscribedStockMember_lbl0" xml:lang="en-US">Subscribed Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SubscribedStockMember" xlink:to="abvc_SubscribedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl0" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings_lbl0" xml:lang="en-US">Percentage of Interest-Bearing Domestic Deposits to Deposits, Savings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings" xlink:to="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RgeneCorporationMember_lbl0" xml:lang="en-US">Rgene Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationMember" xlink:to="abvc_RgeneCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PurchaseWarrantTerm_lbl1" xml:lang="en-US">Purchase Warrant Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseWarrantTerm" xlink:to="abvc_PurchaseWarrantTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DebtInstrumentCommonStockToBeConverted_lbl1" xml:lang="en-US">Debt Instrument Common Stock To Be Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentCommonStockToBeConverted" xlink:to="abvc_DebtInstrumentCommonStockToBeConverted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NonControllingInterestConsiderationShare_lbl1" xml:lang="en-US">Non Controlling Interest Consideration Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonControllingInterestConsiderationShare" xlink:to="abvc_NonControllingInterestConsiderationShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_MilestoneRegulatoryPaymentAmountPeriod_lbl1" xml:lang="en-US">Milestone Regulatory Payment Amount Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestoneRegulatoryPaymentAmountPeriod" xlink:to="abvc_MilestoneRegulatoryPaymentAmountPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl1" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PreFundedWarrantsMember_lbl1" xml:lang="en-US">Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PreFundedWarrantsMember" xlink:to="abvc_PreFundedWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LindMember_lbl0" xml:lang="en-US">Lind Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindMember" xlink:to="abvc_LindMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Amount Due To Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:to="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ZhonghuiMember_lbl0" xml:lang="en-US">Zhonghui Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ZhonghuiMember" xlink:to="abvc_ZhonghuiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssueDuringPeriodCommonShares_lbl1" xml:lang="en-US">Stock Issue During Period Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssueDuringPeriodCommonShares" xlink:to="abvc_StockIssueDuringPeriodCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CashFlowsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Operating Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashFlowsFromOperatingActivitiesAbstract" xlink:to="abvc_CashFlowsFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl3" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Property And Equipment Net Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" xlink:to="abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl1" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstAustraliaMember_lbl0" xml:lang="en-US">Bio First Australia Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstAustraliaMember" xlink:to="abvc_BioFirstAustraliaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NetLossPerShareAbstract_lbl0" xml:lang="en-US">Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetLossPerShareAbstract" xlink:to="abvc_NetLossPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Other, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLongTermInvestmentAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLongTermInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfLongTermInvestmentAbstract_lbl" xml:lang="en-US">Schedule Of Long Term Investment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfLongTermInvestmentAbstract" xlink:to="abvc_ScheduleOfLongTermInvestmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfCashPermium_lbl1" xml:lang="en-US">Percentage Of Cash Permium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfCashPermium" xlink:to="abvc_PercentageOfCashPermium_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl0" xml:lang="en-US">Building and Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareholdersMember_lbl0" xml:lang="en-US">Shareholders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareholdersMember" xlink:to="abvc_ShareholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceAgreementsMember_lbl0" xml:lang="en-US">Service Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceAgreementsMember" xlink:to="us-gaap_ServiceAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl0" xml:lang="en-US">Provision for Other Credit Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AssetConsiderationCommonStock_lbl1" xml:lang="en-US">Asset Consideration Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AssetConsiderationCommonStock" xlink:to="abvc_AssetConsiderationCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl0" xml:lang="en-US">Equity Method Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OtherConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Other Convertible Notes Payable Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherConvertibleNotesPayableMember" xlink:to="abvc_OtherConvertibleNotesPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl0" xml:lang="en-US">Deposit Liabilities, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LoanAgreementAmount_lbl1" xml:lang="en-US">Loan Agreement Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementAmount" xlink:to="abvc_LoanAgreementAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl1" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl0" xml:lang="en-US">Loan, Securitized or Asset-Backed Financing Arrangement, Principal Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockSubscriptionReceived_lbl1" xml:lang="en-US">Stock Subscription Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceived" xlink:to="abvc_StockSubscriptionReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ClientMember_lbl0" xml:lang="en-US">Client Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ClientMember" xlink:to="abvc_ClientMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioLiteBVIIncMember_lbl1" xml:lang="en-US">Bio Lite BVIInc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteBVIIncMember" xlink:to="abvc_BioLiteBVIIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioHopeKingCorporationMember_lbl0" xml:lang="en-US">Bio Hope King Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioHopeKingCorporationMember" xlink:to="abvc_BioHopeKingCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PurchasePriceAmount_lbl1" xml:lang="en-US">Purchase Price Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchasePriceAmount" xlink:to="abvc_PurchasePriceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DirectorsMember_lbl0" xml:lang="en-US">Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DirectorsMember" xlink:to="abvc_DirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertibleLoanAgreementMember_lbl0" xml:lang="en-US">Convertible Loan Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleLoanAgreementMember" xlink:to="abvc_ConvertibleLoanAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones_lbl0" xml:lang="en-US">Long-Term Purchase Commitment, Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:to="us-gaap_LongTermPurchaseCommitmentMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl1" xml:lang="en-US">Other Than Temporary Impairment Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:to="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl1" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl0" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent_lbl0" xml:lang="en-US">Other Receivable, before Allowance for Credit Loss, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl1" xml:lang="en-US">Prepayment Fees on Advances, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="abvc_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SupplementalDisclosureOfCashFlowsAbstract_lbl0" xml:lang="en-US">Supplemental Disclosure Of Cash Flows Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SupplementalDisclosureOfCashFlowsAbstract" xlink:to="abvc_SupplementalDisclosureOfCashFlowsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseShortTermBorrowings_lbl0" xml:lang="en-US">Interest Expense, Short-Term Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseShortTermBorrowings" xlink:to="us-gaap_InterestExpenseShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AiBtlHoldingMember_lbl1" xml:lang="en-US">Ai Btl Holding Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AiBtlHoldingMember" xlink:to="abvc_AiBtlHoldingMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ABVCMember_lbl0" xml:lang="en-US">ABVCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ABVCMember" xlink:to="abvc_ABVCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_FirstLINDNoteMember_lbl0" xml:lang="en-US">First LINDNote Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_FirstLINDNoteMember" xlink:to="abvc_FirstLINDNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl0" xml:lang="en-US">Treasury Stock, Shares, Retired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_MilestoneRegulatoryPaymentAmount_lbl1" xml:lang="en-US">Milestone Regulatory Payment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestoneRegulatoryPaymentAmount" xlink:to="abvc_MilestoneRegulatoryPaymentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate_lbl0" xml:lang="en-US">Short-Term Debt, Percentage Bearing Variable Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl0" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_JiangsAdvancedFundsMember_lbl0" xml:lang="en-US">Jiangs Advanced Funds Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_JiangsAdvancedFundsMember" xlink:to="abvc_JiangsAdvancedFundsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_USFederalDepositInsuranceCorporationMember_lbl1" xml:lang="en-US">USFederal Deposit Insurance Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_USFederalDepositInsuranceCorporationMember" xlink:to="abvc_USFederalDepositInsuranceCorporationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl2" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DecemberLetterAgreementMember_lbl0" xml:lang="en-US">December Letter Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DecemberLetterAgreementMember" xlink:to="abvc_DecemberLetterAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NonrefundableUpfrontCashPayment_lbl1" xml:lang="en-US">Nonrefundable Upfront Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonrefundableUpfrontCashPayment" xlink:to="abvc_NonrefundableUpfrontCashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AddLessAbstract0_lbl0" xml:lang="en-US">Add Less Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AddLessAbstract0" xlink:to="abvc_AddLessAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageDiscountRateAbstract_lbl0" xml:lang="en-US">Weighted Average Discount Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageDiscountRateAbstract" xlink:to="abvc_WeightedAverageDiscountRateAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CathayUnitedBankMember_lbl0" xml:lang="en-US">Cathay United Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayUnitedBankMember" xlink:to="abvc_CathayUnitedBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RgeneMember_lbl0" xml:lang="en-US">Rgene Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneMember" xlink:to="abvc_RgeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDate_lbl0" xml:lang="en-US">Related Party Transaction, Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDate" xlink:to="us-gaap_RelatedPartyTransactionDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl0" xml:lang="en-US">Investment Owned, Balance, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PostSplitMember_lbl0" xml:lang="en-US">Post Split Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PostSplitMember" xlink:to="abvc_PostSplitMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInvestmentsAbstract_lbl0" xml:lang="en-US">Other Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestmentsAbstract" xlink:to="us-gaap_OtherInvestmentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PreExistingWarrantsMember_lbl0" xml:lang="en-US">Pre Existing Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PreExistingWarrantsMember" xlink:to="abvc_PreExistingWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl1" xml:lang="en-US">Long-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ABVCAndBioLiteTaiwanMember_lbl0" xml:lang="en-US">ABVCAnd Bio Lite Taiwan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ABVCAndBioLiteTaiwanMember" xlink:to="abvc_ABVCAndBioLiteTaiwanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EquityMethodInvestmentsNetAbstract_lbl0" xml:lang="en-US">Equity Method Investments Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodInvestmentsNetAbstract" xlink:to="abvc_EquityMethodInvestmentsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand Sixteen Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:to="abvc_TwoThousandSixteenEquityIncentivePlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract_lbl" xml:lang="en-US">Schedule Of Ownership Percentages Of Each Investee Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract" xlink:to="abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioLiteTaiwanMember_lbl0" xml:lang="en-US">Bio Lite Taiwan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteTaiwanMember" xlink:to="abvc_BioLiteTaiwanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_TW_lbl0" xml:lang="en-US">TAIWAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_TW" xlink:to="country_TW_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LindWarrantMember_lbl0" xml:lang="en-US">Lind Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindWarrantMember" xlink:to="abvc_LindWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioLiteJapanKKBioLiteJPMember_lbl0" xml:lang="en-US">Bio Lite Japan KKBio Lite JPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJapanKKBioLiteJPMember" xlink:to="abvc_BioLiteJapanKKBioLiteJPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AggregateCommonStockShares_lbl1" xml:lang="en-US">Aggregate Common Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregateCommonStockShares" xlink:to="abvc_AggregateCommonStockShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract_lbl" xml:lang="en-US">Schedule Of Licensing Agreement And Related Amendment With Feye Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract" xlink:to="abvc_ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockSubScriptionReceivableMember_lbl0" xml:lang="en-US">Stock Sub Scription Receivable Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubScriptionReceivableMember" xlink:to="abvc_StockSubScriptionReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl0" xml:lang="en-US">Accrued Royalties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertibleNotesPayablePolicyTextBlock_lbl1" xml:lang="en-US">Convertible Notes Payable Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayablePolicyTextBlock" xlink:to="abvc_ConvertibleNotesPayablePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LindNotesPayableMember_lbl0" xml:lang="en-US">Lind Notes Payable Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindNotesPayableMember" xlink:to="abvc_LindNotesPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BenefitsReceivableForMilestoneAttained_lbl2" xml:lang="en-US">Benefits Receivable For Milestone Attained</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BenefitsReceivableForMilestoneAttained" xlink:to="abvc_BenefitsReceivableForMilestoneAttained_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl2" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OtherIndividualThirdPartyMember_lbl0" xml:lang="en-US">Other Individual Third Party Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherIndividualThirdPartyMember" xlink:to="abvc_OtherIndividualThirdPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl1" xml:lang="en-US">Stockholders&apos; Equity Note, Subscriptions Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl0" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TwoClientMember_lbl0" xml:lang="en-US">Two Client Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TwoClientMember" xlink:to="abvc_TwoClientMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DefinedBenefitPlanFundedPercentages_lbl1" xml:lang="en-US">Defined Benefit Plan Funded Percentages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DefinedBenefitPlanFundedPercentages" xlink:to="abvc_DefinedBenefitPlanFundedPercentages_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfAverageAmount_lbl1" xml:lang="en-US">Percentage Of Average Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfAverageAmount" xlink:to="abvc_PercentageOfAverageAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_lbl0" xml:lang="en-US">Proceeds from Repayment of Loans to Purchase Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NewWarrantsMember_lbl0" xml:lang="en-US">New Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NewWarrantsMember" xlink:to="abvc_NewWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SecondLINDNoteMember_lbl0" xml:lang="en-US">Second LINDNote Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SecondLINDNoteMember" xlink:to="abvc_SecondLINDNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_IssuanceOfCommonShareForLindCNRepayment_lbl1" xml:lang="en-US">Issuance Of Common Share For Lind CNRepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfCommonShareForLindCNRepayment" xlink:to="abvc_IssuanceOfCommonShareForLindCNRepayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConsecutiveDays_lbl1" xml:lang="en-US">Consecutive Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsecutiveDays" xlink:to="abvc_ConsecutiveDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LindNotesMember_lbl0" xml:lang="en-US">Lind Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindNotesMember" xlink:to="abvc_LindNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl2" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfWorkingCapital_lbl1" xml:lang="en-US">Percentage Of Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfWorkingCapital" xlink:to="abvc_PercentageOfWorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl1" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent_lbl0" xml:lang="en-US">Other Receivable, Allowance for Credit Loss, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash_lbl1" xml:lang="en-US">Effect Of Exchange Rate Change On Cash And Cash Equivalents And Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" xlink:to="abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl1" xml:lang="en-US">Accounts Payable, Interest-Bearing, Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RepurchaseOfTreasuryStocks_lbl1" xml:lang="en-US">Repurchase Of Treasury Stocks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RepurchaseOfTreasuryStocks" xlink:to="abvc_RepurchaseOfTreasuryStocks_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expense And Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnlabeledAbstract" xlink:to="abvc_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SharesReceived_lbl1" xml:lang="en-US">Shares Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesReceived" xlink:to="abvc_SharesReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl0" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl0" xml:lang="en-US">Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl1" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OtherIndividualMember_lbl2" xml:lang="en-US">Other Individual Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherIndividualMember" xlink:to="abvc_OtherIndividualMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Extent The Investee Relies Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock" xlink:to="abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract_lbl" xml:lang="en-US">Schedule Of Carrying Amounts Of The Liability Component Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract" xlink:to="abvc_ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesAndLicenses_lbl0" xml:lang="en-US">Taxes and Licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesAndLicenses" xlink:to="us-gaap_TaxesAndLicenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConsiderationPaidForAgreement_lbl1" xml:lang="en-US">Consideration Paid For Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsiderationPaidForAgreement" xlink:to="abvc_ConsiderationPaidForAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl0" xml:lang="en-US">Short-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LoanAgreementMember_lbl0" xml:lang="en-US">Loan Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementMember" xlink:to="abvc_LoanAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl0" xml:lang="en-US">Payments to Acquire Long-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl2" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Common Shares For Lind CN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioLiteJapanMember_lbl0" xml:lang="en-US">Bio Lite Japan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJapanMember" xlink:to="abvc_BioLiteJapanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_royaltiesPercentage_lbl1" xml:lang="en-US">royalties Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_royaltiesPercentage" xlink:to="abvc_royaltiesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LindGlobalFundIILPMember_lbl0" xml:lang="en-US">Lind Global Fund IILPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindGlobalFundIILPMember" xlink:to="abvc_LindGlobalFundIILPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees&apos; Gross Pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl0" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Contingent Consideration, Asset, Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl1" xml:lang="en-US">Repayments of Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl1" xml:lang="en-US">Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl1" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SecondLindNoteMember_lbl0" xml:lang="en-US">Second Lind Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SecondLindNoteMember" xlink:to="abvc_SecondLindNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AccruedDirectorAndOfficerCompensation_lbl1" xml:lang="en-US">Accrued Director And Officer Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccruedDirectorAndOfficerCompensation" xlink:to="abvc_AccruedDirectorAndOfficerCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl1" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable_lbl1" xml:lang="en-US">Adjustments To Additional Paid In Capital Warrant Issued With Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" xlink:to="abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember_lbl0" xml:lang="en-US">Collaborative Agreement With For See Con Eye Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember" xlink:to="abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstCorporationtheBioFirstMember_lbl1" xml:lang="en-US">Bio First Corporationthe Bio First Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationtheBioFirstMember" xlink:to="abvc_BioFirstCorporationtheBioFirstMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OncoXBiopPharmaIncMember_lbl0" xml:lang="en-US">Onco XBiop Pharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OncoXBiopPharmaIncMember" xlink:to="abvc_OncoXBiopPharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GenePharmInctheGenePharmMember_lbl0" xml:lang="en-US">Gene Pharm Incthe Gene Pharm Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenePharmInctheGenePharmMember" xlink:to="abvc_GenePharmInctheGenePharmMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_IssuanceOfStockValue_lbl1" xml:lang="en-US">Issuance Of Stock Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfStockValue" xlink:to="abvc_IssuanceOfStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConcentrationOfClientsPolicyTextBlock_lbl1" xml:lang="en-US">Concentration Of Clients Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConcentrationOfClientsPolicyTextBlock" xlink:to="abvc_ConcentrationOfClientsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LionArtPromotionIncMember_lbl0" xml:lang="en-US">Lion Art Promotion Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionArtPromotionIncMember" xlink:to="abvc_LionArtPromotionIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Grant Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioLiteJapanKKMember_lbl0" xml:lang="en-US">Bio Lite Japan KKMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJapanKKMember" xlink:to="abvc_BioLiteJapanKKMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_YuanGeneCorporationMember_lbl0" xml:lang="en-US">Yuan Gene Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YuanGeneCorporationMember" xlink:to="abvc_YuanGeneCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl1" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ProceedsFromSubsidiarysCommonStockSubscription_lbl1" xml:lang="en-US">Proceeds From Subsidiarys Common Stock Subscription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromSubsidiarysCommonStockSubscription" xlink:to="abvc_ProceedsFromSubsidiarysCommonStockSubscription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl2" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl1" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl0" xml:lang="en-US">Treasury Stock, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RgeneCorporationtheRgeneMember_lbl1" xml:lang="en-US">Rgene Corporationthe Rgene Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationtheRgeneMember" xlink:to="abvc_RgeneCorporationtheRgeneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfRoyaltiesEqualing_lbl1" xml:lang="en-US">Percentage Of Royalties Equaling</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfRoyaltiesEqualing" xlink:to="abvc_PercentageOfRoyaltiesEqualing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl2" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DebtInstrumentIssuanceEntity_lbl1" xml:lang="en-US">Debt Instrument Issuance Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentIssuanceEntity" xlink:to="abvc_DebtInstrumentIssuanceEntity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LindNoteMember_lbl0" xml:lang="en-US">Lind Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LindNoteMember" xlink:to="abvc_LindNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl1" xml:lang="en-US">Repayments of Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WorkingCapitalConvertibleLoanPercentage_lbl1" xml:lang="en-US">Working Capital Convertible Loan Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WorkingCapitalConvertibleLoanPercentage" xlink:to="abvc_WorkingCapitalConvertibleLoanPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfOutstandingPrincipalAmount_lbl1" xml:lang="en-US">Percentage Of Outstanding Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfOutstandingPrincipalAmount" xlink:to="abvc_PercentageOfOutstandingPrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShortTermDebtMaturityDate_lbl1" xml:lang="en-US">Short Term Debt Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShortTermDebtMaturityDate" xlink:to="abvc_ShortTermDebtMaturityDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NonCashFinancingAndInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Non Cash Financing And Investing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonCashFinancingAndInvestingActivitiesAbstract" xlink:to="abvc_NonCashFinancingAndInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressGross_lbl1" xml:lang="en-US">Construction in Progress, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract_lbl" xml:lang="en-US">Schedule Of Due From Related Party Current And Non Current Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract" xlink:to="abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdvisorsTwoMember_lbl0" xml:lang="en-US">Advisors Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvisorsTwoMember" xlink:to="abvc_AdvisorsTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl2" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WorkingCapitalPercentage_lbl0" xml:lang="en-US">Working Capital Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WorkingCapitalPercentage" xlink:to="abvc_WorkingCapitalPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ExistingWarrantsMember_lbl0" xml:lang="en-US">Existing Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ExistingWarrantsMember" xlink:to="abvc_ExistingWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CurrentLiabilitiesAbstract0_lbl0" xml:lang="en-US">Current Liabilities Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CurrentLiabilitiesAbstract0" xlink:to="abvc_CurrentLiabilitiesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl0" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock_lbl0" xml:lang="en-US">Schedule of Other Ownership Interests [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:to="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuanceDate1_lbl0" xml:lang="en-US">Debt Instrument, Issuance Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuanceDate1" xlink:to="us-gaap_DebtInstrumentIssuanceDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConsiderationAmount_lbl1" xml:lang="en-US">Consideration Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsiderationAmount" xlink:to="abvc_ConsiderationAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl2" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForPreviousAcquisition_lbl0" xml:lang="en-US">Payments for Previous Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPreviousAcquisition" xlink:to="us-gaap_PaymentsForPreviousAcquisition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageCommonStocksShares_lbl1" xml:lang="en-US">Percentage Common Stocks Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageCommonStocksShares" xlink:to="abvc_PercentageCommonStocksShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageDiscountRateAbstract0_lbl0" xml:lang="en-US">Weighted Average Discount Rate Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageDiscountRateAbstract0" xlink:to="abvc_WeightedAverageDiscountRateAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesNoncurrent_lbl0" xml:lang="en-US">Debt Securities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesNoncurrent" xlink:to="us-gaap_DebtSecuritiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CTBCLoanAgreementsMember_lbl0" xml:lang="en-US">CTBCLoan Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CTBCLoanAgreementsMember" xlink:to="abvc_CTBCLoanAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingExpensesAbstract0_lbl0" xml:lang="en-US">Operating Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingExpensesAbstract0" xlink:to="abvc_OperatingExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl1" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Common Shares For Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Accounts Receivable Due From Related Parties Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock" xlink:to="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioLiteJPMember_lbl0" xml:lang="en-US">Bio Lite JPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJPMember" xlink:to="abvc_BioLiteJPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl1" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EuroAsiaInvestmentFinanceCorpLtdMember_lbl0" xml:lang="en-US">Euro Asia Investment Finance Corp Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EuroAsiaInvestmentFinanceCorpLtdMember" xlink:to="abvc_EuroAsiaInvestmentFinanceCorpLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OutstandingPrincipalAmount_lbl1" xml:lang="en-US">Outstanding Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingPrincipalAmount" xlink:to="abvc_OutstandingPrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SecondLINDNoteOneMember_lbl0" xml:lang="en-US">Second LINDNote One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SecondLINDNoteOneMember" xlink:to="abvc_SecondLINDNoteOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WarrantDebtDiscountMember_lbl0" xml:lang="en-US">Warrant Debt Discount Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantDebtDiscountMember" xlink:to="abvc_WarrantDebtDiscountMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OncoXBioPharmaIncMember_lbl0" xml:lang="en-US">Onco XBio Pharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OncoXBioPharmaIncMember" xlink:to="abvc_OncoXBioPharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RecognizedCreditLosses_lbl1" xml:lang="en-US">Recognized Credit Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RecognizedCreditLosses" xlink:to="abvc_RecognizedCreditLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UnregisteredSharesMember_lbl0" xml:lang="en-US">Unregistered Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnregisteredSharesMember" xlink:to="abvc_UnregisteredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl1" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AssetsAbstract0_lbl0" xml:lang="en-US">Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AssetsAbstract0" xlink:to="abvc_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UnregisteredRestrictedSharesMember_lbl0" xml:lang="en-US">Unregistered Restricted Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnregisteredRestrictedSharesMember" xlink:to="abvc_UnregisteredRestrictedSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateOwnedValuationAllowance_lbl0" xml:lang="en-US">Real Estate Owned, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateOwnedValuationAllowance" xlink:to="us-gaap_RealEstateOwnedValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty_lbl1" xml:lang="en-US">Prepayment Of Asset Acquisition By Issuing Common Stock To AThird Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" xlink:to="abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OutstandingLiabilityOwnedAmount_lbl1" xml:lang="en-US">Outstanding Liability Owned Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingLiabilityOwnedAmount" xlink:to="abvc_OutstandingLiabilityOwnedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShulingJiangMember_lbl0" xml:lang="en-US">Shuling Jiang Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShulingJiangMember" xlink:to="abvc_ShulingJiangMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfStatementsOfOperationsAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfStatementsOfOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfStatementsOfOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Statements Of Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfStatementsOfOperationsAbstract" xlink:to="abvc_ScheduleOfStatementsOfOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockReverseSplitPolicyTextBlock_lbl0" xml:lang="en-US">Stock Reverse Split Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockReverseSplitPolicyTextBlock" xlink:to="abvc_StockReverseSplitPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingLeaseLiabilities_lbl1" xml:lang="en-US">Operating Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeaseLiabilities" xlink:to="abvc_OperatingLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CashAndCashEquivalentsAndRestrictedCashAbstract_lbl0" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashAndCashEquivalentsAndRestrictedCashAbstract" xlink:to="abvc_CashAndCashEquivalentsAndRestrictedCashAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLeaseAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLeaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfLeaseAbstract_lbl" xml:lang="en-US">Schedule Of Lease Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfLeaseAbstract" xlink:to="abvc_ScheduleOfLeaseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Common Shares For Acquisition Of Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:to="abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTableTextBlock_lbl0" xml:lang="en-US">Investment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTableTextBlock" xlink:to="us-gaap_InvestmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RgeneStudiesMember_lbl0" xml:lang="en-US">Rgene Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneStudiesMember" xlink:to="abvc_RgeneStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ReceivedShares_lbl1" xml:lang="en-US">Received Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ReceivedShares" xlink:to="abvc_ReceivedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl3" xml:lang="en-US">Other Receivable, after Allowance for Credit Loss, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForParticipationLiabilities_lbl0" xml:lang="en-US">Payments for Participation Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForParticipationLiabilities" xlink:to="us-gaap_PaymentsForParticipationLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OncoXMember_lbl0" xml:lang="en-US">Onco XMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OncoXMember" xlink:to="abvc_OncoXMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GenePharmIncMember_lbl0" xml:lang="en-US">Gene Pharm Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenePharmIncMember" xlink:to="abvc_GenePharmIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty_lbl2" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Common Shares For Acquisition Of Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:to="abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl1" xml:lang="en-US">Percentage Of Payments Under Codevelopment Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:to="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl0" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LessAbstract0_lbl0" xml:lang="en-US">Less Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LessAbstract0" xlink:to="abvc_LessAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl1" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl1" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl0" xml:lang="en-US">Receivables from Stockholder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TheJiangsMember_lbl0" xml:lang="en-US">The Jiangs Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TheJiangsMember" xlink:to="abvc_TheJiangsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl2" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl1" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract_lbl0" xml:lang="en-US">Non Marketable Cost Method Investments Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="abvc_NonMarketableCostMethodInvestmentsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:to="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ProceedsFromIssuanceOfAPromissoryNote_lbl2" xml:lang="en-US">Proceeds From Issuance Of APromissory Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ProceedsFromIssuanceOfAPromissoryNote" xlink:to="abvc_ProceedsFromIssuanceOfAPromissoryNote_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LucidaimCoLtdMember_lbl0" xml:lang="en-US">Lucidaim Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LucidaimCoLtdMember" xlink:to="abvc_LucidaimCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl1" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>abvc-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 15 15:05:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedBalanceSheet" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedIncomeStatement" roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConsolidatedCashFlow" roleURI="http://metuboutique.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable" roleURI="http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_OrganizationandDescriptionofBusiness" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LiquidityGoingConcernandRestatement" roleURI="http://metuboutique.com/role/LiquidityGoingConcernandRestatement"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SummaryofSignificantAccountingPolicies" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_CollaborativeAgreements" roleURI="http://metuboutique.com/role/CollaborativeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_PropertyandEquipmentandPrepamentforAssetAcquisition" roleURI="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisition"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LongTermInvestments" roleURI="http://metuboutique.com/role/LongTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConvertibleNotesPayable" roleURI="http://metuboutique.com/role/ConvertibleNotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ShortTermLoans" roleURI="http://metuboutique.com/role/ShortTermLoans"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_RelatedPartiesTransactions" roleURI="http://metuboutique.com/role/RelatedPartiesTransactions"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_IncomeTaxes" roleURI="http://metuboutique.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_Equity" roleURI="http://metuboutique.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_StockOptions" roleURI="http://metuboutique.com/role/StockOptions"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LossPerShare" roleURI="http://metuboutique.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_Lease" roleURI="http://metuboutique.com/role/Lease"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_CommitmentsandContingencies" roleURI="http://metuboutique.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_Acquisition" roleURI="http://metuboutique.com/role/Acquisition"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SubsequentEvents" roleURI="http://metuboutique.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AccountingPoliciesByPolicy" roleURI="http://metuboutique.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LiquidityGoingConcernandRestatementTables" roleURI="http://metuboutique.com/role/LiquidityGoingConcernandRestatementTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_PropertyandEquipmentandPrepamentforAssetAcquisitionTables" roleURI="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LongTermInvestmentsTables" roleURI="http://metuboutique.com/role/LongTermInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConvertibleNotesPayableTables" roleURI="http://metuboutique.com/role/ConvertibleNotesPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ShortTermLoansTables" roleURI="http://metuboutique.com/role/ShortTermLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_RelatedPartiesTransactionsTables" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_IncomeTaxesTables" roleURI="http://metuboutique.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_EquityTables" roleURI="http://metuboutique.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_StockOptionsTables" roleURI="http://metuboutique.com/role/StockOptionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LossPerShareTables" roleURI="http://metuboutique.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LeaseTables" roleURI="http://metuboutique.com/role/LeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AcquisitionTables" roleURI="http://metuboutique.com/role/AcquisitionTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofImpactoftheRestatementTable" roleURI="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofEstimatedUsefulLifeTable" roleURI="http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable" roleURI="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofReconciliationofTotalSegmentGrossProfitTable" roleURI="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofPropertyandEquipmentTable" roleURI="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOwnershipPercentagesofEachInvesteeTable" roleURI="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofExtenttheInvesteeReliesTable" roleURI="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLongTermInvestmentTable" roleURI="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofBalanceSheetsTable" roleURI="http://metuboutique.com/role/ScheduleofBalanceSheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofStatementsofOperationsTable" roleURI="http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable" roleURI="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofCarryingAmountsoftheLiabilityComponentTable" roleURI="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofShortTermLoansTable" roleURI="http://metuboutique.com/role/ScheduleofShortTermLoansTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" roleURI="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable" roleURI="http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAccountsReceivableDuefromRelatedPartiesTable" roleURI="http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable" roleURI="http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAmountDuetoRelatedPartiesTable" roleURI="http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofIncomeTaxBenefitExpenseTable" roleURI="http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofDeferredTaxAssetsLiabilityTable" roleURI="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofWarrantsIssuedandOutstandingTable" roleURI="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOptionsIssuedandOutstandingTable" roleURI="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLossPerShareTable" roleURI="http://metuboutique.com/role/ScheduleofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" roleURI="http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofCompanysLeaseExpensesTable" roleURI="http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" roleURI="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" roleURI="http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofImpactoftheRestatementTable0" roleURI="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0" roleURI="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofReconciliationofTotalSegmentGrossProfitTable0" roleURI="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOwnershipPercentagesofEachInvesteeTable0" roleURI="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofExtenttheInvesteeReliesTable0" roleURI="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLongTermInvestmentTable0" roleURI="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0" roleURI="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofCarryingAmountsoftheLiabilityComponentTable0" roleURI="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0" roleURI="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofShortTermLoansTable0" roleURI="http://metuboutique.com/role/ScheduleofShortTermLoansTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0" roleURI="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofDeferredTaxAssetsLiabilityTable0" roleURI="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofWarrantsIssuedandOutstandingTable0" roleURI="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofOptionsIssuedandOutstandingTable0" roleURI="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLossPerShareTable0" roleURI="http://metuboutique.com/role/ScheduleofLossPerShareTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofLeaseTable" roleURI="http://metuboutique.com/role/ScheduleofLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0" roleURI="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_OrganizationandDescriptionofBusinessDetails" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LiquidityGoingConcernandRestatementDetails" roleURI="http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_CollaborativeAgreementsDetails" roleURI="http://metuboutique.com/role/CollaborativeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_PropertyandEquipmentandPrepamentforAssetAcquisitionDetails" roleURI="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_LongTermInvestmentsDetails" roleURI="http://metuboutique.com/role/LongTermInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ConvertibleNotesPayableDetails" roleURI="http://metuboutique.com/role/ConvertibleNotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_ShortTermLoansDetails" roleURI="http://metuboutique.com/role/ShortTermLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_RelatedPartiesTransactionsDetails" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_IncomeTaxesDetails" roleURI="http://metuboutique.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_EquityDetails" roleURI="http://metuboutique.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_StockOptionsDetails" roleURI="http://metuboutique.com/role/StockOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_AcquisitionDetails" roleURI="http://metuboutique.com/role/AcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#abvc_r_SubsequentEventsDetails" roleURI="http://metuboutique.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20250331.xsd#DocumentAndEntityInformation" roleURI="http://metuboutique.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForLongtermInvestmentsNoncurrent" xlink:href="abvc-20250331.xsd#abvc_PrepaymentForLongtermInvestmentsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PrepaymentForLongtermInvestmentsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDepositLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDepositLiability" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockSubscriptionReceivedInAdvance" xlink:href="abvc-20250331.xsd#abvc_StockSubscriptionReceivedInAdvance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockSubscriptionReceivedInAdvance" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValue" order="21.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterest" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_SubleaseIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="WriteOffUnclaimedAccruedLiabilites" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:href="abvc-20250331.xsd#abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RepurchaseOfTreasuryStocks" xlink:href="abvc-20250331.xsd#abvc_RepurchaseOfTreasuryStocks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepurchaseOfTreasuryStocks" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfAPromissoryNote" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromIssuanceOfAPromissoryNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfAPromissoryNote" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromSubsidiarysShareholderContribution" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromSubsidiarysShareholderContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromSubsidiarysShareholderContribution" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementalDisclosureOfCashFlowsAbstract" xlink:href="abvc-20250331.xsd#abvc_SupplementalDisclosureOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="SupplementalDisclosureOfCashFlowsAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidDuringTheYearForAbstract0" xlink:href="abvc-20250331.xsd#abvc_CashPaidDuringTheYearForAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalDisclosureOfCashFlowsAbstract" xlink:to="CashPaidDuringTheYearForAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" xlink:href="abvc-20250331.xsd#abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForConversionOfDebt" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonStockForConversionOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IssuanceOfCommonStockForConversionOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSubsidiarysCommonStockForConsultingServices" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IssuanceOfSubsidiarysCommonStockForConsultingServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract" xlink:href="abvc-20250331.xsd#abvc_UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SubscribedStockMember" xlink:href="abvc-20250331.xsd#abvc_SubscribedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SubscribedStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockSubScriptionReceivableMember" xlink:href="abvc-20250331.xsd#abvc_StockSubScriptionReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockSubScriptionReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockCommonMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="8.0"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAdjustmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonShareForLindCNRepayment" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonShareForLindCNRepayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonShareForLindCNRepayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="us-gaap_TreasuryStockSharesRetired" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockSubscriptionReceived" xlink:href="abvc-20250331.xsd#abvc_StockSubscriptionReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="StockSubscriptionReceived" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonShareForLindCNRepayment" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PriorPeriodAdjustment" xlink:href="abvc-20250331.xsd#abvc_PriorPeriodAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PriorPeriodAdjustment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" xlink:href="abvc-20250331.xsd#abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares_0" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/LiquidityGoingConcernandRestatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityGoingConcernAndRestatementTextBlock" xlink:href="abvc-20250331.xsd#abvc_LiquidityGoingConcernAndRestatementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="LiquidityGoingConcernAndRestatementTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/CollaborativeAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsAbstract" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/LongTermInvestments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_InvestmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ConvertibleNotesPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ShortTermLoans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/RelatedPartiesTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/StockOptions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/LossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/Lease" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/Acquisition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockReverseSplitPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_StockReverseSplitPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="StockReverseSplitPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationOfClientsPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_ConcentrationOfClientsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConcentrationOfClientsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherThanTemporaryImpairmentPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_OtherThanTemporaryImpairmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OtherThanTemporaryImpairmentPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayablePolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayablePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConvertibleNotesPayablePolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:href="abvc-20250331.xsd#abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ValuationOfDeferredTaxAssetsPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/LiquidityGoingConcernandRestatementTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/LongTermInvestmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfExtentTheInvesteeReliesTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="ScheduleOfExtentTheInvesteeReliesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_InvestmentTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ConvertibleNotesPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ShortTermLoansTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueToRelatedPartiesTableTextBlock" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfAmountDueToRelatedPartiesTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/StockOptionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/LossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/LeaseTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/AcquisitionTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfImpactOfTheRestatementAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfImpactOfTheRestatementAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfImpactOfTheRestatementAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAdjustmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_MinorityInterest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_InterestExpense" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ProfitLoss_0" order="19.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ShareBasedCompensation_0" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="21.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromSubsidiarysCommonStockSubscription" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromSubsidiarysCommonStockSubscription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="ProceedsFromSubsidiarysCommonStockSubscription" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" xlink:href="abvc-20250331.xsd#abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" xlink:href="abvc-20250331.xsd#abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" xlink:href="abvc-20250331.xsd#abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForConversionOfDebt" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonStockForConversionOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="IssuanceOfCommonStockForConversionOfDebt" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLifeAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfEstimatedUsefulLifeAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" xlink:href="abvc-20250331.xsd#abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLifeAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LessAbstract" xlink:href="abvc-20250331.xsd#abvc_LessAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="LessAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LessAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LessAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LessAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AddLessAbstract" xlink:href="abvc-20250331.xsd#abvc_AddLessAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="AddLessAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddLessAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddLessAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddLessAbstract" xlink:to="us-gaap_SubleaseIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddLessAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddLessAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddLessAbstract" xlink:to="WriteOffUnclaimedAccruedLiabilites" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddLessAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddLessAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract" xlink:to="us-gaap_ScheduleOfOtherOwnershipInterestsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ForSeeConEyeCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioFirstCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="OncoXBioPharmaIncMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="RgeneCorporationMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAdditionalInformation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAdditionalInformation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAdditionalInformation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfExtentTheInvesteeReliesAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:to="LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanKKMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioLiteJapanKKMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ForSeeConEyeCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OncoXBioPharmaIncMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermInvestmentAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermInvestmentAbstract" xlink:to="LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenepharmBiotechCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ForSeeConEyeCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanKKBioLiteJPMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKBioLiteJPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanKKBioLiteJPMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="OncoXBioPharmaIncMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonMarketableCostMethodInvestmentsNetAbstract" xlink:href="abvc-20250331.xsd#abvc_NonMarketableCostMethodInvestmentsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="NonMarketableCostMethodInvestmentsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="us-gaap_DebtSecuritiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentsNetAbstract" xlink:href="abvc-20250331.xsd#abvc_EquityMethodInvestmentsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="EquityMethodInvestmentsNetAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsNetAbstract" xlink:to="us-gaap_LongTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofBalanceSheetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalanceSheetsAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceSheetsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofStatementsofOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStatementsOfOperationsAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfStatementsOfOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatementsOfOperationsAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract" xlink:to="ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecondLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLINDNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SecondLINDNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThirdLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLINDNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ThirdLINDNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherNoteMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="OtherNoteMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherNoteOneMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="OtherNoteOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_FirstLINDNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="FirstLINDNoteMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondLINDNoteOneMember" xlink:href="abvc-20250331.xsd#abvc_SecondLINDNoteOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SecondLINDNoteOneMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentIssuanceEntity" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentIssuanceEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentIssuanceEntity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentCommonStockToBeConverted" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCommonStockToBeConverted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentCommonStockToBeConverted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentPrincipalAmountAtBalanceSheetDate" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentPrincipalAmountAtBalanceSheetDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentCarryingValue" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopmentExpense" xlink:href="abvc-20250331.xsd#abvc_AccruedResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="AccruedResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedDirectorAndOfficerCompensation" xlink:href="abvc-20250331.xsd#abvc_AccruedDirectorAndOfficerCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="AccruedDirectorAndOfficerCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofShortTermLoansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermLoansAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfShortTermLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermLoansAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedBankMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayUnitedBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CTBCBankMember" xlink:href="abvc-20250331.xsd#abvc_CTBCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CTBCBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIndividualMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="OtherIndividualMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationtheBioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationtheRgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationtheRgeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenePharmInctheGenePharmMember" xlink:href="abvc-20250331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenePharmInctheGenePharmMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsOneMember" xlink:href="abvc-20250331.xsd#abvc_TheJiangsOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TheJiangsOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationBHKMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationBHKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationBHKMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AiBtlHoldingBioPharmaIncAiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AiBtlHoldingBioPharmaIncAiBtlHoldingMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JaimesVargasRussmanMember" xlink:href="abvc-20250331.xsd#abvc_JaimesVargasRussmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JaimesVargasRussmanMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionArtsPromotionIncMember" xlink:href="abvc-20250331.xsd#abvc_LionArtsPromotionIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LionArtsPromotionIncMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract" xlink:to="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OncoXMember" xlink:href="abvc-20250331.xsd#abvc_OncoXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OncoXMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FEYEMember" xlink:href="abvc-20250331.xsd#abvc_FEYEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="FEYEMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LicensingAgreementMember" xlink:href="abvc-20250331.xsd#abvc_LicensingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="LicensingAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable" xlink:to="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:to="RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="GenePharmIncMember" xlink:href="abvc-20250331.xsd#abvc_GenePharmIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenePharmIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable" xlink:to="RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract" xlink:to="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable" xlink:to="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:to="RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AiBtlHoldingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvc-20250331.xsd#abvc_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TheJiangsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareholdersMember" xlink:href="abvc-20250331.xsd#abvc_ShareholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ShareholdersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorsMember" xlink:href="abvc-20250331.xsd#abvc_DirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DirectorsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable" xlink:to="RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilities" xlink:href="abvc-20250331.xsd#abvc_OperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="OperatingLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsOperatingLeaseAssets" xlink:href="abvc-20250331.xsd#abvc_DeferredTaxAssetsOperatingLeaseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsOperatingLeaseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShareAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesOperatingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="LeaseScheduleofCompanysLeaseExpensesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="LeaseScheduleofCompanysLeaseExpensesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseScheduleofCompanysLeaseExpensesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CashPaidMember" xlink:href="abvc-20250331.xsd#abvc_CashPaidMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="CashPaidMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseScheduleofCompanysLeaseExpensesDetailsTable" xlink:to="LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract" xlink:href="abvc-20250331.xsd#abvc_WeightedAverageRemainingLeaseTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="WeightedAverageRemainingLeaseTermAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRateAbstract" xlink:href="abvc-20250331.xsd#abvc_WeightedAverageDiscountRateAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseScheduleofCompanysLeaseExpensesDetailsLineItems" xlink:to="WeightedAverageDiscountRateAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" xlink:href="abvc-20250331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfImpactOfTheRestatementAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfImpactOfTheRestatementAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfImpactOfTheRestatementAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAdjustmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AsRestatedMember" xlink:href="abvc-20250331.xsd#abvc_AsRestatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="AsRestatedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_MinorityInterest" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_InterestExpense" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="21.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" xlink:href="abvc-20250331.xsd#abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForConversionOfDebt" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfCommonStockForConversionOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="IssuanceOfCommonStockForConversionOfDebt" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="us-gaap_Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNpoXXXMi0ISiQMYRhfARCZqodsmYe5mpcuap9v90/VTIewyY3i091+2fVbljGWA+oIMmRhsCng8ZWIeu6RFmHqDuVsiXSHIAQzP/FPyRsu9wu9TXs5L6z+Vj4GR0/VqMj6bP7RRDRffTIrCvruey21RYJVvSYvm8JzpQILHhvxqjuAau6xSilsFJ8UON3w7OYDU=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_SubleaseIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WriteOffUnclaimedAccruedLiabilites" xlink:href="abvc-20250331.xsd#abvc_WriteOffUnclaimedAccruedLiabilites"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="WriteOffUnclaimedAccruedLiabilites" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract" xlink:to="us-gaap_ScheduleOfOtherOwnershipInterestsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ForSeeConEyeCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioFirstCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="OncoXBioPharmaIncMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="RgeneCorporationMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanKKMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioLiteJapanKKMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAdditionalInformation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAdditionalInformation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAdditionalInformation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfExtentTheInvesteeReliesAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:to="LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanKKMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioLiteJapanKKMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ForSeeConEyeCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OncoXBioPharmaIncMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermInvestmentAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermInvestmentAbstract" xlink:to="LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20250331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenepharmBiotechCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ForSeeConEyeCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanKKBioLiteJPMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKBioLiteJPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanKKBioLiteJPMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OncoXBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBioPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="OncoXBioPharmaIncMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInvestmentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OtherInvestmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherInvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_LongTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract" xlink:to="ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecondLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLINDNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SecondLINDNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThirdLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLINDNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ThirdLINDNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherNoteMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="OtherNoteMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherNoteOneMember" xlink:href="abvc-20250331.xsd#abvc_OtherNoteOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="OtherNoteOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentIssuanceEntity" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentIssuanceEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentIssuanceEntity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentCommonStockToBeConverted" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCommonStockToBeConverted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentCommonStockToBeConverted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentPrincipalAmountAtBalanceSheetDate" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentPrincipalAmountAtBalanceSheetDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentCarryingValue" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopmentExpense" xlink:href="abvc-20250331.xsd#abvc_AccruedResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="AccruedResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPortionOfTheLindNoteRepayments" xlink:href="abvc-20250331.xsd#abvc_CashPortionOfTheLindNoteRepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="CashPortionOfTheLindNoteRepayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofShortTermLoansTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermLoansAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfShortTermLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermLoansAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedBankMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayUnitedBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CTBCBankMember" xlink:href="abvc-20250331.xsd#abvc_CTBCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CTBCBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIndividualMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="OtherIndividualMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationtheBioFirstMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationtheRgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationtheRgeneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenePharmInctheGenePharmMember" xlink:href="abvc-20250331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenePharmInctheGenePharmMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvc-20250331.xsd#abvc_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="TheJiangsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioLiteJapanMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationBHKMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationBHKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationBHKMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AiBtlHoldingBioPharmaIncAiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AiBtlHoldingBioPharmaIncAiBtlHoldingMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JaimesVargasRussmanMember" xlink:href="abvc-20250331.xsd#abvc_JaimesVargasRussmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JaimesVargasRussmanMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionArtsPromotionIncMember" xlink:href="abvc-20250331.xsd#abvc_LionArtsPromotionIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LionArtsPromotionIncMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstAustraliaMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AiBtlHoldingMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareholdersMember" xlink:href="abvc-20250331.xsd#abvc_ShareholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ShareholdersMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionArtPromotionIncMember" xlink:href="abvc-20250331.xsd#abvc_LionArtPromotionIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LionArtPromotionIncMember" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorsMember" xlink:href="abvc-20250331.xsd#abvc_DirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DirectorsMember" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilities" xlink:href="abvc-20250331.xsd#abvc_OperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="OperatingLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsOperatingLeaseAssets" xlink:href="abvc-20250331.xsd#abvc_DeferredTaxAssetsOperatingLeaseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsOperatingLeaseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsIssuedAndOutstandingAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfWarrantsIssuedAndOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsIssuedAndOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" xlink:href="abvc-20250331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofLossPerShareTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShareAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseAbstract" xlink:href="abvc-20250331.xsd#abvc_ScheduleOfLeaseAbstract"/>
    <loc xlink:type="locator" xlink:label="AssetsAbstract0" xlink:href="abvc-20250331.xsd#abvc_AssetsAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseAbstract" xlink:to="AssetsAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsTable" xlink:href="abvc-20250331.xsd#abvc_OrganizationandDescriptionofBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandDescriptionofBusinessDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ABVCMember" xlink:href="abvc-20250331.xsd#abvc_ABVCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ABVCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteBVIIncMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteBVIIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="BioLiteBVIIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="BioLiteTaiwanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShulingJiangMember" xlink:href="abvc-20250331.xsd#abvc_ShulingJiangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ShulingJiangMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AiBtlHoldingMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioLiteBVIIncMember_0" xlink:href="abvc-20250331.xsd#abvc_BioLiteBVIIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioLiteBVIIncMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteTaiwanMember_0" xlink:href="abvc-20250331.xsd#abvc_BioLiteTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioLiteTaiwanMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShulingJiangMember_0" xlink:href="abvc-20250331.xsd#abvc_ShulingJiangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ShulingJiangMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ABVCAndBioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_ABVCAndBioLiteTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ABVCAndBioLiteTaiwanMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BenefitsReceivableForMilestoneAttained" xlink:href="abvc-20250331.xsd#abvc_BenefitsReceivableForMilestoneAttained"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="BenefitsReceivableForMilestoneAttained" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRoyaltiesEqualing" xlink:href="abvc-20250331.xsd#abvc_PercentageOfRoyaltiesEqualing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="PercentageOfRoyaltiesEqualing" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionForNetSales" xlink:href="abvc-20250331.xsd#abvc_AcquisitionForNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="AcquisitionForNetSales" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityGoingConcernandRestatementDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LiquidityGoingConcernandRestatementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:href="abvc-20250331.xsd#abvc_LiquidityGoingConcernandRestatementDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="LiquidityGoingConcernandRestatementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ZhongHuiLianHeJiTuanLtdMember" xlink:href="abvc-20250331.xsd#abvc_ZhongHuiLianHeJiTuanLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ZhongHuiLianHeJiTuanLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AiBtlBioPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlBioPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AiBtlBioPharmaIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsTable" xlink:to="srt_RestatementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAdjustmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PostSplitMember" xlink:href="abvc-20250331.xsd#abvc_PostSplitMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="PostSplitMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ZhonghuiMember" xlink:href="abvc-20250331.xsd#abvc_ZhonghuiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ZhonghuiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsTable" xlink:to="LiquidityGoingConcernandRestatementDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalDeficit" xlink:href="abvc-20250331.xsd#abvc_WorkingCapitalDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="WorkingCapitalDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" xlink:href="abvc-20250331.xsd#abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateOwnedValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateOwnedValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_RealEstateOwnedValuationAllowance" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_Assets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_InterestExpenseOther" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockBasedExpensesAmortizationPeriod" xlink:href="abvc-20250331.xsd#abvc_StockBasedExpensesAmortizationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="StockBasedExpensesAmortizationPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityGoingConcernandRestatementDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="abvc-20250331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_GranteeStatusAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PostretirementAndPostemploymentBenefitsMember" xlink:href="abvc-20250331.xsd#abvc_PostretirementAndPostemploymentBenefitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PostretirementAndPostemploymentBenefitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeAndTierIdentifierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeAndTierIdentifierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:to="us-gaap_TypeAndTierIdentifierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TaiwanCentralDepositInsuranceCorporationMember" xlink:href="abvc-20250331.xsd#abvc_TaiwanCentralDepositInsuranceCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:to="TaiwanCentralDepositInsuranceCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="USFederalDepositInsuranceCorporationMember" xlink:href="abvc-20250331.xsd#abvc_USFederalDepositInsuranceCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:to="USFederalDepositInsuranceCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClientMember" xlink:href="abvc-20250331.xsd#abvc_ClientMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="ClientMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoClientMember" xlink:href="abvc-20250331.xsd#abvc_TwoClientMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="TwoClientMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatutoryAccountingPracticesLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyExcessExpenseReimbursable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LaborPensionFundPerMonth" xlink:href="abvc-20250331.xsd#abvc_LaborPensionFundPerMonth"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="LaborPensionFundPerMonth" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DefinedBenefitPlanFundedPercentages" xlink:href="abvc-20250331.xsd#abvc_DefinedBenefitPlanFundedPercentages"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="DefinedBenefitPlanFundedPercentages" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_RestrictedCash" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsAbstract" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsAbstract" xlink:to="CollaborativeAgreementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="RgeneCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneStudiesMember" xlink:href="abvc-20250331.xsd#abvc_RgeneStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="RgeneStudiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteTaiwanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuanGeneCorporationMember" xlink:href="abvc-20250331.xsd#abvc_YuanGeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YuanGeneCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementWithForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CollaborativeAgreementWithForSeeConEyeCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OncoXBiopPharmaIncMember" xlink:href="abvc-20250331.xsd#abvc_OncoXBiopPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="OncoXBiopPharmaIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServiceAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ServiceAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BHKCoDevelopmentAgreementMember" xlink:href="abvc-20250331.xsd#abvc_BHKCoDevelopmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BHKCoDevelopmentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CodevelopmentagreementMember" xlink:href="abvc-20250331.xsd#abvc_CodevelopmentagreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CodevelopmentagreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_CollaborativeArrangementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstStockPurchaseAgreementMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstStockPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BioFirstStockPurchaseAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ForSeeConEyeCorporationMember" xlink:href="abvc-20250331.xsd#abvc_ForSeeConEyeCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ForSeeConEyeCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentMilestones" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonrefundableUpfrontCashPayment" xlink:href="abvc-20250331.xsd#abvc_NonrefundableUpfrontCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonrefundableUpfrontCashPayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:href="abvc-20250331.xsd#abvc_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfPaymentsUnderCodevelopmentAgreement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfStockValue" xlink:href="abvc-20250331.xsd#abvc_IssuanceOfStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="IssuanceOfStockValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsRoyaltyPercentage" xlink:href="abvc-20250331.xsd#abvc_MilestonePaymentsRoyaltyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePaymentsRoyaltyPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetSalesProfitPercentage" xlink:href="abvc-20250331.xsd#abvc_NetSalesProfitPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NetSalesProfitPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForParticipationLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionCashPayment" xlink:href="abvc-20250331.xsd#abvc_AdditionCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AdditionCashPayment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodLongTermInvestment" xlink:href="abvc-20250331.xsd#abvc_EquityMethodLongTermInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="EquityMethodLongTermInvestment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServiceAgreementEligibilityAmount" xlink:href="abvc-20250331.xsd#abvc_ServiceAgreementEligibilityAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ServiceAgreementEligibilityAmount" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestoneRegulatoryPaymentAmountPeriod" xlink:href="abvc-20250331.xsd#abvc_MilestoneRegulatoryPaymentAmountPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestoneRegulatoryPaymentAmountPeriod" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LoansPayable" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalConvertibleLoanPercentage" xlink:href="abvc-20250331.xsd#abvc_WorkingCapitalConvertibleLoanPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="WorkingCapitalConvertibleLoanPercentage" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentsOwnershipPercentage" xlink:href="abvc-20250331.xsd#abvc_EquityMethodInvestmentsOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="EquityMethodInvestmentsOwnershipPercentage" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesAndLicenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TaxesAndLicenses" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssued" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestoneRegulatoryPaymentAmount" xlink:href="abvc-20250331.xsd#abvc_MilestoneRegulatoryPaymentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestoneRegulatoryPaymentAmount" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesPercentage" xlink:href="abvc-20250331.xsd#abvc_RoyaltiesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltiesPercentage" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivedShares" xlink:href="abvc-20250331.xsd#abvc_ReceivedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ReceivedShares" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicensingAgreement" xlink:href="abvc-20250331.xsd#abvc_LicensingAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LicensingAgreement" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsiderationPaidForAgreement" xlink:href="abvc-20250331.xsd#abvc_ConsiderationPaidForAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConsiderationPaidForAgreement" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalMilestonePaymentInCash" xlink:href="abvc-20250331.xsd#abvc_AdditionalMilestonePaymentInCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AdditionalMilestonePaymentInCash" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesReceived" xlink:href="abvc-20250331.xsd#abvc_NumberOfSharesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfSharesReceived" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfDevelopAndCommercialize" xlink:href="abvc-20250331.xsd#abvc_PercentageOfDevelopAndCommercialize"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfDevelopAndCommercialize" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicensingFees" xlink:href="abvc-20250331.xsd#abvc_LicensingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LicensingFees" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:href="abvc-20250331.xsd#abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ZhonghuiMember" xlink:href="abvc-20250331.xsd#abvc_ZhonghuiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ZhonghuiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_TW" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TW"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TW" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SharePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndLandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LandAndLandImprovements" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/LongTermInvestmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_LongTermInvestmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="LongTermInvestmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioFirstCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationtheRgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="RgeneCorporationtheRgeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanKKMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJapanKKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioLiteJapanKKMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LucidaimCoLtdMember" xlink:href="abvc-20250331.xsd#abvc_LucidaimCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="LucidaimCoLtdMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJPMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteJPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="BioLiteJPMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageCommonStocksShares" xlink:href="abvc-20250331.xsd#abvc_PercentageCommonStocksShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="PercentageCommonStocksShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_InvestmentOwnedBalanceShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ConvertibleNotesPayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ConvertibleNotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="ConvertibleNotesPayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecondLindNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLindNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SecondLindNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LindNotesMember" xlink:href="abvc-20250331.xsd#abvc_LindNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LindNotesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LindGlobalFundIILPMember" xlink:href="abvc-20250331.xsd#abvc_LindGlobalFundIILPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="LindGlobalFundIILPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LindWarrantMember" xlink:href="abvc-20250331.xsd#abvc_LindWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="LindWarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherConvertibleNotesPayableMember" xlink:href="abvc-20250331.xsd#abvc_OtherConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="OtherConvertibleNotesPayableMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantDebtDiscountMember" xlink:href="abvc-20250331.xsd#abvc_WarrantDebtDiscountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="WarrantDebtDiscountMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LindWarrantMember_0" xlink:href="abvc-20250331.xsd#abvc_LindWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="LindWarrantMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LindNotesPayableMember" xlink:href="abvc-20250331.xsd#abvc_LindNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="LindNotesPayableMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OtherConvertibleNotesPayableMember_0" xlink:href="abvc-20250331.xsd#abvc_OtherConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="OtherConvertibleNotesPayableMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LindNotesPayableMember_0" xlink:href="abvc-20250331.xsd#abvc_LindNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="LindNotesPayableMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="srt_StatementScenarioAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_DebtConversionLineItems" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPreviousAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForPreviousAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PaymentsForPreviousAcquisition" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingBalanceAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingBalanceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="OutstandingBalanceAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAverageAmount" xlink:href="abvc-20250331.xsd#abvc_PercentageOfAverageAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="PercentageOfAverageAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCashPermium" xlink:href="abvc-20250331.xsd#abvc_PercentageOfCashPermium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="PercentageOfCashPermium" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOutstandingPrincipalAmount" xlink:href="abvc-20250331.xsd#abvc_PercentageOfOutstandingPrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="PercentageOfOutstandingPrincipalAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralPartnersCapitalAccount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralPartnersCapitalAccount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_GeneralPartnersCapitalAccount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ReceivableWithImputedInterestFaceAmount" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseWarrantTerm" xlink:href="abvc-20250331.xsd#abvc_PurchaseWarrantTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="PurchaseWarrantTerm" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePriceAmount" xlink:href="abvc-20250331.xsd#abvc_PurchasePriceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="PurchasePriceAmount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentOutstandingPrincipal" xlink:href="abvc-20250331.xsd#abvc_DebtInstrumentOutstandingPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="DebtInstrumentOutstandingPrincipal" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_InterestExpenseOther" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsiderationAmount" xlink:href="abvc-20250331.xsd#abvc_ConsiderationAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="ConsiderationAmount" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAnnualDiscountRate" xlink:href="abvc-20250331.xsd#abvc_PercentageOfAnnualDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="PercentageOfAnnualDiscountRate" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradingDays" xlink:href="abvc-20250331.xsd#abvc_TradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="TradingDays" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsecutiveDays" xlink:href="abvc-20250331.xsd#abvc_ConsecutiveDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="ConsecutiveDays" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/ShortTermLoansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShortTermLoansDetailsTable" xlink:href="abvc-20250331.xsd#abvc_ShortTermLoansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalHomeLoanBankAdvancesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="ShortTermLoansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermLoansDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedLoanAgreementMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedLoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CathayUnitedLoanAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CTBCLoanAgreementsMember" xlink:href="abvc-20250331.xsd#abvc_CTBCLoanAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CTBCLoanAgreementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermLoansDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedBankMember" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayUnitedBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CTBCBankMember" xlink:href="abvc-20250331.xsd#abvc_CTBCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CTBCBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIndividualMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="OtherIndividualMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIndividualThirdPartyMember" xlink:href="abvc-20250331.xsd#abvc_OtherIndividualThirdPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="OtherIndividualThirdPartyMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermLoansDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedLoanAgreementMember_0" xlink:href="abvc-20250331.xsd#abvc_CathayUnitedLoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="CathayUnitedLoanAgreementMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermLoansDetailsTable" xlink:to="us-gaap_FederalHomeLoanBankAdvancesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_InterestExpenseShortTermBorrowings" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfAPromissoryNote" xlink:href="abvc-20250331.xsd#abvc_ProceedsFromIssuanceOfAPromissoryNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="ProceedsFromIssuanceOfAPromissoryNote" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtPercentageBearingVariableInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortTermDebtMaturityDate" xlink:href="abvc-20250331.xsd#abvc_ShortTermDebtMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBankAdvancesLineItems" xlink:to="ShortTermDebtMaturityDate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_RelatedPartiesTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartiesTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FEYEMember" xlink:href="abvc-20250331.xsd#abvc_FEYEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="FEYEMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleLoanAgreementMember" xlink:href="abvc-20250331.xsd#abvc_ConvertibleLoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ConvertibleLoanAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AiBtlHoldingMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangsAdvancedFundsMember" xlink:href="abvc-20250331.xsd#abvc_JiangsAdvancedFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JiangsAdvancedFundsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OncoXMember" xlink:href="abvc-20250331.xsd#abvc_OncoXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="OncoXMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAgreementMember" xlink:href="abvc-20250331.xsd#abvc_LoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LoanAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BHKCoDevelopmentAggreementMember" xlink:href="abvc-20250331.xsd#abvc_BHKCoDevelopmentAggreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BHKCoDevelopmentAggreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20250331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20250331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LoanAgreementMember_0" xlink:href="abvc-20250331.xsd#abvc_LoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="LoanAgreementMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstReceivesMember" xlink:href="abvc-20250331.xsd#abvc_BioFirstReceivesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="BioFirstReceivesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionMember" xlink:href="abvc-20250331.xsd#abvc_ConversionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConversionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LicensingAgreement" xlink:href="abvc-20250331.xsd#abvc_LicensingAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="LicensingAgreement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalPercentage" xlink:href="abvc-20250331.xsd#abvc_WorkingCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="WorkingCapitalPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrincipalAmountOutstandingOnLoansSecuritized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositLiabilitiesAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDate" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionRate" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LoansPayable" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAgreementAmount" xlink:href="abvc-20250331.xsd#abvc_LoanAgreementAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="LoanAgreementAmount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" order="21.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="RecognizedCreditLosses" xlink:href="abvc-20250331.xsd#abvc_RecognizedCreditLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="RecognizedCreditLosses" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="23.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingBalanceAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingBalanceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="OutstandingBalanceAmount" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingPrincipalAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingPrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="OutstandingPrincipalAmount" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseOther" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfWorkingCapital" xlink:href="abvc-20250331.xsd#abvc_PercentageOfWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="PercentageOfWorkingCapital" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="abvc-20250331.xsd#abvc_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EuroAsiaInvestmentFinanceCorpLtdMember" xlink:href="abvc-20250331.xsd#abvc_EuroAsiaInvestmentFinanceCorpLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EuroAsiaInvestmentFinanceCorpLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZhonghuiMember" xlink:href="abvc-20250331.xsd#abvc_ZhonghuiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ZhonghuiMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ABVCMember" xlink:href="abvc-20250331.xsd#abvc_ABVCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ABVCMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteBVIIncMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteBVIIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioLiteBVIIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LindGlobalFundIILPLindMember" xlink:href="abvc-20250331.xsd#abvc_LindGlobalFundIILPLindMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LindGlobalFundIILPLindMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LindNoteMember" xlink:href="abvc-20250331.xsd#abvc_LindNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LindNoteMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LindMember" xlink:href="abvc-20250331.xsd#abvc_LindMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LindMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20250331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSixteenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LindGlobalFundIILPLindMember_0" xlink:href="abvc-20250331.xsd#abvc_LindGlobalFundIILPLindMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="LindGlobalFundIILPLindMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThirdLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLINDNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ThirdLINDNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LindMember_0" xlink:href="abvc-20250331.xsd#abvc_LindMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="LindMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_OwnershipAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AiBtlHoldingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteTaiwanMember" xlink:href="abvc-20250331.xsd#abvc_BioLiteTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="BioLiteTaiwanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShulingJiangMember" xlink:href="abvc-20250331.xsd#abvc_ShulingJiangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ShulingJiangMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreExistingWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_PreExistingWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PreExistingWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LindOfferingsMember" xlink:href="abvc-20250331.xsd#abvc_LindOfferingsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="LindOfferingsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ThirdLetterAgreementMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLetterAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ThirdLetterAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChiefStrategicOfficerMember" xlink:href="abvc-20250331.xsd#abvc_ChiefStrategicOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ChiefStrategicOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConsultantMember" xlink:href="abvc-20250331.xsd#abvc_ConsultantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ConsultantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_NewWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="NewWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExistingWarrantsMember" xlink:href="abvc-20250331.xsd#abvc_ExistingWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ExistingWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateCommonStockShares" xlink:href="abvc-20250331.xsd#abvc_AggregateCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AggregateCommonStockShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="AssetConsiderationCommonStock" xlink:href="abvc-20250331.xsd#abvc_AssetConsiderationCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AssetConsiderationCommonStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingLiabilityOwnedAmount" xlink:href="abvc-20250331.xsd#abvc_OutstandingLiabilityOwnedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="OutstandingLiabilityOwnedAmount" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="AverageIssuancePricePerShare" xlink:href="abvc-20250331.xsd#abvc_AverageIssuancePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AverageIssuancePricePerShare" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForRent" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockSharesIssuedForRent" xlink:href="abvc-20250331.xsd#abvc_CommonStockSharesIssuedForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="CommonStockSharesIssuedForRent" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_Cash" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NonControllingInterestConsiderationShare" xlink:href="abvc-20250331.xsd#abvc_NonControllingInterestConsiderationShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NonControllingInterestConsiderationShare" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingFee" xlink:href="abvc-20250331.xsd#abvc_ConsultingFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ConsultingFee" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Land"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_Land" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="29.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseWarrantTerm" xlink:href="abvc-20250331.xsd#abvc_PurchaseWarrantTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PurchaseWarrantTerm" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssueDuringPeriodCommonShares" xlink:href="abvc-20250331.xsd#abvc_StockIssueDuringPeriodCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="StockIssueDuringPeriodCommonShares" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditDerivativeTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativeTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CreditDerivativeTerm1" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="39.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="42.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/StockOptionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_StockOptionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockOptionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20250331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSixteenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/AcquisitionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="SharesReceived" xlink:href="abvc-20250331.xsd#abvc_SharesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="SharesReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BenefitsReceivableForMilestoneAttained" xlink:href="abvc-20250331.xsd#abvc_BenefitsReceivableForMilestoneAttained"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="BenefitsReceivableForMilestoneAttained" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="royaltiesPercentage" xlink:href="abvc-20250331.xsd#abvc_royaltiesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="royaltiesPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionForNetSales" xlink:href="abvc-20250331.xsd#abvc_AcquisitionForNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="AcquisitionForNetSales" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="abvc-20250331.xsd#abvc_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnregisteredSharesMember" xlink:href="abvc-20250331.xsd#abvc_UnregisteredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="UnregisteredSharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnregisteredRestrictedSharesMember" xlink:href="abvc-20250331.xsd#abvc_UnregisteredRestrictedSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="UnregisteredRestrictedSharesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AiBtlHoldingMember" xlink:href="abvc-20250331.xsd#abvc_AiBtlHoldingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AiBtlHoldingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DecemberLetterAgreementMember" xlink:href="abvc-20250331.xsd#abvc_DecemberLetterAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="DecemberLetterAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AdvisorsOneMember" xlink:href="abvc-20250331.xsd#abvc_AdvisorsOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="AdvisorsOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvisorsTwoMember" xlink:href="abvc-20250331.xsd#abvc_AdvisorsTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="AdvisorsTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecondLindNoteMember" xlink:href="abvc-20250331.xsd#abvc_SecondLindNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SecondLindNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThirdLINDNoteMember" xlink:href="abvc-20250331.xsd#abvc_ThirdLINDNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ThirdLINDNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UnregisteredPricePerShares" xlink:href="abvc-20250331.xsd#abvc_UnregisteredPricePerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="UnregisteredPricePerShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromContributedCapital" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://metuboutique.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="abvc-20250331.xsd#abvc_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -J L%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( -J L%KAE J:\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZ;=<>HJX7$">0D)@$XA8E
MWA;1-%%BU.[M:</6@> !.,;^\_FSY%9YH5S I^ \!C(8;R;;#U$HOV5'(B\
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( -J L%I7"F?EH0@  !4<   8
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M6\)[?+J[?"B$H)'C**:3H=M[KD[2<'_[N.]B!YS<#YQW%7#FNGK>)##4%9<
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M7RY4!M65$<#W<PVC:OO&7&#WXXS+_P%02P,$%     @ VH"P6DQ5T<3_ P
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M7,9 (Q#: -=7G*NG@790_Z<P^0Y02P,$%     @ VH"P6MS4EKHB"0  A"P
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MP.+QFZ=JYC6?OMY<>,@0NU(1K3\QX.]C.:M6JB\(\OOU0Z-K6$S^A^5ZZRS
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MH=0FP(5)!Y4BJ$ &L9-S%Q:%"1WHD5BOA)E7WUW=9GGYTAI4)5E4M<H?2RB
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M)U48+)#<?OB88KB8QMQ6*"@N&&B4>"^3N5\F'[[:'5PWI/-*!\H :EG:42-
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M@^,7Z.X4]?!D?A<LN;$&]_6#7+AI'FY7+1C"ZL)/#-F&7+(AYUW8F#*ZT-X
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MB'QW\)%D%E(#K)2PN$79!WJ1K+ #&QL^G+8KN)FP/64#"I'_Q[J$%'YN,]0
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M=,*(KH>'C3B'PE<O_I!6'.KIB&-JG.A@"[7BA!&]BK_Z4M@,XL!T([KBI4X
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M/ENW+;)$H"DXHAR7KSW07(<<%,\>/[8HRC8"N@$9!I15TY5,!71)0#[,KH.
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M" C+NL!._PJ*%^ $5/$2B!9>N*5;C:"6-9&/[E2N$!"^O4%(>*0GRUK A J
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MRG4-[*CR<\,,6=6!NWQ3SJVN6J!?#(/03"P./P,ZA=$?)SCK (,JLKK4GS
M:MZL+WN0UW%!( W_K4"#"/U[Z&V'2]9@\*92.$HZ/O0V>%R'KIMPD![^.P]A
M(,&H7ILQ.M$[A7YWOHK$WVHX8'EO)>''X-#@WSM!,5XM<6J0/ 'K)7I_IAA3
M5;(K8\I]C9L8^5=S$[@(2\\Y5# ^@!"'$@U%L45G\PD/F9(/9I%.XAODI/MN
M?S]_^?*08 G_1F#=HX!%^8MN;A)3<*\?&12 74Z)*O$[9;>%:D*]VHE-[<,A
M IZ5@=(_WD:6F] C<6MT%1(G!69=@?Y3SBVOY%!5%*Q,_09X5&N09Z ;Q8\X
M/)O;<-=GUWB/=O^><YX,6FV4)7*;6$A]MW]\D!_LG?"I'1R]R ]?' S/X@)0
MM4DGH-65#1+I7/L*$>-2CJ>2!BAG5G#H3.4"[+PES1$-\4XO8W4G=A!= *!D
M]COB9;BLRJL";C7Z892? WBDDRAE)_S$78+]ZMG37PYEN$"6<<2:)&5Z\]%A
M'E1#(I//J:IHA+B*=1'F3I!!/)'B_0F4$0G_\'D/U==XRM^=[)WFAR<'CF3T
MP=[N01#2?.HG^\?YT>%A-O[[D!#.)MC&6%2$<-7,RA07>,[D*HESE*BV!08]
M=V+" PL'(4DG=M. Q:AN;[Y20$0I""0A&U01\9039J;^\E3@H/.],]YW.(K!
M-AQ[]A)1)O)"HUTI#+/_B$1E(;I>(9FOV7;N.@W'W@"--6O0&L J;EH*\F*0
M#$5=%'-&MC&A@ 0(ENP];#^?D'=!UN5!1,(9U<VRG&&@8U[RE497:%,':NC6
M*_3IT\^P40_DR.$)"4WJ$EE<(C<6D.R.;4N4DA+T('Q$%X\<A2.>'@#=E5B-
MBJNR,V1%$;K^ 2P0&R_(&@?:;SA:!$RYO3(4JAJ"B8BX-+:%1O'2!]FO01K^
M)*PP%/]15(<;K=1H3(=;P.LUJD71P G8]/5-V38U+K'KW@##JRE..<HSH;MV
MVV*V1+W3+!8!+V,2'NM7Q:*G*$S0*]#Y9AP,P3E7E5\!A.NFF3N*-P75JV35
M&([HDO6^LT<PCP" 8U7C9/\D/WQYJOSK)#_:/YH.[#]*V?@LVL)G#L*&;"7E
M#B$X&Q6+B305##*=[)WD83DZ6%#D*/>L8\HZCY3Z:=UVZX*#?^'=_O[/<FS8
MJ*'B!*? ;-\V%6(;<+LLD8]< ?I)\4#14Q)Y(]RU,D_K[^X"1:.B(\&1H:N5
M3Z=C1P11LMB&UT5]Y841@K'B1E^&BVEC.;J?UF"<&'?;XDI\C4:?-V9!R?B4
MB]C-FA7=$XM'-[*5R+U'WFH*IR'X7>]7W:OL:?E,',^+.T4$'=O3[EE@"8+R
MU_#T\''Y!*LBK)\0:P0]R*Y&K\*[:5#+I(:Q/Q0?NWE&EW&F7K710QK]WOSI
M9".O28 ]A64#6:54]131#[NU".]@K6Y!\> -WTG%:%.CTQHS*<1R0QSO(([9
MV0@PNUF\$$S,>);*#L9G?@M"4OG')(G&1\N.@YD5Z[9CRO3A1CBERV0!PO$"
MU?R061!NZQDY.OW*1 T";O,,K;7D5PB,Y8ND] \IU@TH-@#"<E^@&]VE>,%E
M05\ RXO )-8SQL>#>VH#K8BC3C\*YT*2F)9-F(F!@C8(6@<@I4^)H,=C-;RK
MB.PK->8'9.V$K,FGW 7JG^MA1)Z]81]C.M[P'/K_A+(EP29R!?;B%4M*" 4@
M:4US-FZ"*R>QLOYNQ6^NBCOE8PE/1[9)%GY5%>3OQQU]UD0)$O\'K]$>0!_O
M0'4COL6TW/F$6R9V<+B#(4Z51-+U@.]C'X@'/5_Q0'-8,O'OEW585ISXJ ?5
M\YVB0CN[\V!(2,1!Y#O2E*Z[\7R8M996TPK(0@\3AN$TNVN8(F"^[Y+O#X4K
M(:A) [J<.(#*F696J@9+BCJ?4:ZH8,R62U2V/(40RN4E2'56C=@1#>^[SW\
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MDE;=<,&2.$0=1U!J#$-JDI>V'4+C!9-LBLI:]:,B@"QI8IBA2ZU*<!LR^BG
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MDN2?R*TJ09ZG[^&'9_+VRX,7[@VZF%'4&F42_G2:[QWL\P=>G$SMWGB[25K
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M]CY00I\@%H7:T37F\H<O O=\Y=X&2-X#".Z/Z[)"=4):$$UCYCC[W]GQGON
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M&PYU'+W-.C9H@0;A4VY3;F=L9LB">4(L*FR0O1) _6XJ1W3C>>9C-%FOSC!
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M7KD@MC5.&=NA#GI%:6:59N?@ISG?AD)X-L/7:>Q4+U-H2_7PG4HR8$*BDSS
ML14>C<RGRG(A/,< A4F]+M1N 7\+'I#PM.GL@$F,5*F)^B9'^,?A1(\FDTQU
M,[V&)+6_;,/DH(PCG53=JIMVPTW'EK=\EL/<GX!2TQ<3.<8G>'J'<W""6WR%
MO^-)Y)PZQ?V<NDDO*RI Y;PL6FG#PIW<G29W,![1S4Y+A0[V/+DS;="$XW+J
MD8[R'NL;LD_(^N&1,V"Q=J@T_!R,#--'_@*=@%09X>S@:M5@0YI%JUVF+1C:
M)@HS W@>>SL-S$_KFG(&.#Z%BC50JF1F"#N#-4Y^KTE#."G4QRG1&M7J0(:W
MU*+NTV#O9[-!JS)N(*<O)E![5-WP1?I>F"2O;O3P%2=KCQY8R:[PD@Z[+%)E
M;.6O,!X:&U>JG X$<NGOFM#$:MAYB]>4Z1V<H.C">+0P^%[74CW^UF_(8LOY
M3SCUY.3H@#OX[^T>#1K\[^_EA_M'$W\5V&D&>+=I6$BVJ87V1^,"I> LD/B&
MR41Z=:FM#KVV&MPY(-)-5T[&.N^PM7]N^Y[9 S*UL2I:0Y,!9"BD@P<4=V;)
MI)5: 3H@MCCL>)YS,@R58@>#PA@^.?GD1&?XZ8GTXS+F;%#&3-<45*M841QK
M;285E_T7R@\LBG9X+K/]E?"*7?>%R)!G*#9MCA4)\)U6-.L',145,*;!_.7+
MXWSOZ"43W5ZX&?=2E]M$71-JG.0R; ((+S7JZ.%2_V:H"JZ;X[WCG>,PF)G]
M/3M<@J65:P@%"OJWEK7@&B.37+/<1,$WA3<B8LFI--A1IW0^'V>^$$<KVJKT
MK49P;0PZ]M\38ZJ-AI6I6M?J^ &ESR<K[#O__?/^Q^^?EQW\9P;_:YM;^"]9
M8F^*OOCQ^Z4'E??<5Q5Y4^K^AR?[3\QOX0.+'YZ<[;\Z.WCR'-Z,C__X_:JX
M\A] 8\8@2N47\.K>[NGQ$S8O](>^6>&2J+3US9+^B5JC;_$!^/NB:7K] 3^
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M8!U?G,J[^X/=X6!W=+@[!,Z/+6&<^FL1?,V%A>C?I;&F.G+BK-C1P,6+TE)
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M1![?0AY\I?+8!E[&9:#655^I5(<)4J6@ZR#X^G 4Q*+5C KCD%B*0QLY?KM
MM*KO?G#P@TA5K>G,5SX4:D73M34] V\<.9*"K,37'#!S-YQQ@](ZMN=< /09
M O&51N,,IQJ,[N<7MDK]Z+0(UO#+^HJ(_6)Q4=X4%SDFB6\8D];DP!R3Q#>*
M2?+C8M+P8%V:O73]OFJJ!IF)W,9RJ1^+/W4NDU>?Y36:;JMEMA4KPR"W(LXZ
M[HE&W//3V2^<NMPB\GVU' ;[M@'8ENL:M^%4V+RMCH/B&\1!KRC+_JPNJ6)W
M&Q)V+=,)WP:Y37"D+[TXOU>47+O(CX^3HD+6WS%."A\GY1>-DTU9W10PQ4K
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MW<.GW1LE3_L+H_T'A_9PLDH+%8]:";TZF:E.)I-?RKH.T5F<EHEJNW,=2SP
M'\$:%"%QCW9!V7,KQC<Q!SP,A?]<I,:Z<&' +^]LE*MUNK2EK)XX94]>NRYG
MTN#D=9)O2JW]#O0@ ;(NK7S,&U=O"8)@&BZ)XI,S__J2?<+RE>)&0GK7B:0
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M7-B%^*#S.;[ZR:8X$MS_VL2N75"UOZ^U2A.&!RWGF:%N$QM-NYVG<!SX.E6
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M\>KD(OCV:DCK><%'K>Y-ZUH0)_,\_T0WM_&KDSX1I!(5E01!XN.SNE))0H!
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MP5!'2BZ4I8N9V0'0.$PJ8R;H3#\3D30K'U>X_/)(ZH-;#WNPB8/=7&>R8IL
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M9B%W;[#-)[5\N2RU>\)N'YM2<+[51E8MF!14HMZW_*7=AR- %GX%P%H ^[>
MN 7$+M&],I?6-3=\,E)R!\I&$YOMN+UQ:,I&U+:*#T;16T$X,YGFN=IB ?,7
M\H5&#;PNX)W9H(+95BFL#=P*OA2E, +U*#"TID4&><M_M>=G7^&/X:VLS4;#
MO"ZP.(&?G<='[ Q!0,EV&;-#QE?L+.-;KBX@CGQ@(4M/"3H/O\:\@R=GY,1=
M 6+'%W^7 L!?TZ4VBLS_]ZE:[)=*3B]E#X1+W? <QQY]\1K5,WJ3GWZ(^N&O
MI_;A.Y%]LBM)MRO).?;)=#9;/,VO8?[G_?SN8?X T[MK>/?X9KZ V=-B,;][
MA-N;Z=7-[<WCS?SAU%:<Y3^M/KN ;UL7#L7#X^))5[R\+5[YL7B]7-+IIPT!
MY HH"E:RI&-4U&O@^C#7H!*RT"#J0N2<@B][9-E\XTQ'[L-J2?0TZ%D#.QOV
M#CIL*B[6ZBCPF0[IIK(J6H'P(T3^8#CTTRP^[G<$A5!TODK59K):B1QI\+/<
MU=3^ KFL+!%W1_!P&/D9BXB&A/A9?]";<;V!1BKWNLWGEA*!.VF0U#7\U<K1
MP-C 9UD"$;6#=-BM_PF_E8!54\I71%ABC2M!T"@)?98R@O;]*.SWW+>BH1\-
M_&PPA#2EMM_O/4K#2\HQ)HE]/XN&KI^&0S]A#$[Y_?_DF&.??&&:Q)HF_H],
MTYG%]J*,2GFD1+[RTAUS+$W]=,B #1**S[[)'WM? !OZ49P=[!&'S"<R2,AP
M<1H>V>-@"==/,GK[N3WV)UAP]).M4*W=W4.3HFUM]O_;;K:[WDS=7SWX&+Z_
M&]'WO!:UAA)7! TO!JD':G_?V ^,;-PO>RD-70!<=T-7-%0V@-ZO)'U/[< N
MT%WZ)O\ 4$L#!!0    ( -J L%J[B:!S%P<  #T;   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$U+GAM;.U96V_;-A1^UZ\@O'38 -76Q=?F B3.BK5HUZ+Q
MMH=A#[1$VT0ET2.I.-ZOWSF'DFPE=M!EZ["'O$0217X\EX_?.8[.-DI_-BLA
M++O+L\*<=U;6KE_U>B99B9R;KEJ+ MXLE,ZYA4>][)FU%CRE17G6BX)@V,NY
M+#H79S3V45^<J=)FLA ?-3-EGG.]O1*9VIQWPDX]\$DN5Q8'>A=G:[X4-\+^
MO/ZHX:G7H*0R%X61JF!:+,X[E^&K:1_GTX1?I-B8O7N&GLR5^HP/;]+S3H &
MB4PD%A$X7&[%5&09 H$9?U28G69+7+A_7Z._)M_!ESDW8JJR7V5J5^>=<8>E
M8L'+S'Y2FQ]%Y<\ \1*5&?K+-FYN!).3TEB55XO!@EP6[LKOJCCL+1@'1Q9$
MU8+H2Q?$U8*8''66D5O7W/*+,ZTV3.-L0,,;B@VM!F]D@5F\L1K>2EAG+VY6
M2MN7,Z%S]D[QPISU+*#BNUY2(5PYA.@(0LS>J\*N#/NA2$5Z8/WT\?5A] A
M#]QI?(IJGZZB1Q'?<]UE<>BS*(@&APQZ?/FU2)KE_4?,B9L0QX07?V&(V6^7
M<V,U$/CW0]%V8/W#8'BH7YDU3\1Y!TZM$?I6="Z^_28<!J>'//V7P%I^]QN_
M^X^A7]S\^.'3[.7LAT_OV;L/ES_=''+V<81)E]T'8=^%WS,748L1S2BBB0)9
M,=8PM6!V)=A"92!/LEB^\H ,R8K2"7D5^5QH?/"0&I1@;\KMBF_9SX6T(F57
MO/C,3E@XG/C]8 1W((=^-(B\Z>QJZMX.@\@/@H -PP"OW@?843-9I/)6IB7/
M6$SCU<6;*0MC)VP<A!7DN$^0[,#.'PKVMBP$B\9(OW#HLRNIWL%[-N-RPT'V
MBK1:Y^VO$P5$ QYD817C3!7BY59P5#AXB3%B?*F% /FU[#N,T+??C*,H.&V;
M@/1DE_5$FA*>?@^@ )D O+0LDSG\Y;DJ 4DMO)]FUVS4'8 T91G(LL_$'Z6\
MY1EN!*:<1.#):!!TV0PVI8P9RS5NUO(35,^N0-=LJ:7=LI2#Q]RVYHP<!CDS
MYQDO$L'FX*-!I\%Y8SU8P=D"9EA(/=,( H18:R@[[FF=E8:%W3A\X<#V7DE#
MY2"%V!&%R-94K)4!?PV_1<1ZHP;Z80:['N).5;[FQ1;*7 %EA_!V\2=7<8B2
M(VZ%WC),ED_)Q1>%N+-N+3 GK:R[$6OK^#MTRM9EET3X'<.)U A24]VK9<PG
M7+%8""J;;4\,6P,J+XHR9QMN6-2=3%X0#MWY8(I9NX79=B\+$@]>E@&"YIG\
M$R(PWSK'2IFE&##$D/E:JUMRW0-KVWQV/@,0SXQ",XPJP.=ER34'$W>05421
MD^'H%#9><0E5O.BR:Z ,;$4Y6T&,6>ZJB<!J<B\X% :OSD[.4Z  WZ)IC70X
MSX #=&QA$!D^B4?^ (3@ ;LG<)"!W&_J<(H[:*\,1'0#S^P$3OPH(!?A=A0/
M09BT]T66NO!3YMK1W^E0K15AY,X'+7E;9EL63MQ(HQ[>OGHT "W1L!O%S$Y7
M*\8;D90XY8".F+:0(&I;/\PA ?'N"0B%-PR.ZD<<59%'T[]T;CMB5PK/&[CG
M:@4>/\J!X7#V'TH.+X!\30S'F%SV6LPUC>+( TU.5#Z'RI7N;8+6PB%VF6UH
M!66*ZKZ3  R9!X1 M28!<$?K:VC'SOYQK1WU*?8J+34DICMA<%HJ[\#^6NVB
M[N#%3BJ:H]MPQ)U4(+78ULI)[ (@1R>(2Y)0XAL_&C:B< (8Q0E%Z*F"0%9!
M@EY+;6Q+':@@NHSLMP(8C^#!2<&?23"1L]GTNFTU64SA!\XU=NV2O%2X(>1U
MPW5Z7!IB?S0,G33$_F38_Q>DX4$C0L$)3R'74J>@=!IX#JKAX*)6::A9)XTI
MT>^"E4656 _T.X=Q!?PI%%"!6@R[AXDDME1.50(I(BT]<>V/(QHM:Q?KAE5A
MM$<J\HW.) 1*[9GJ.?F&C<IU5:%5 N8!TQ." 8OA.#A-J7[&U36^;3V2JSF:
M:#GD#^-&]#BV/49JZ'L-;4D[4"C-\0R/QV.7WZ .D/?DW![J[;]^[]PZ)O?;
MYS[:&1]NGZNF&>_Z RR1^^VS:YO9<-!_M'U^N>N<^S7:>$(%][ES_M]VSD_L
MFA'3^T^[YOLEH(\XWOW1^,F-\WCT#QIG[U[CS+YRXWRD-'H/Z\/?Z9G[?CP<
M'NJ9PT%T7#:'_GA2%4:X'>QZYBU1]G ![]?"&3_WR\_]\G.__)_WRRLPX:OW
MS.' 'PQ&U>_I@0^=A%>WGD\3A^>.^7['?"STD3\.0[8?;>](L+N'_G7<V_M"
MD0N]I \W6 6!(NYC13/:?!NZI$\BO=UT]V$)'%Q*D(Q,+&!IT!T-.DR[CS7N
MP:HU?>^8*VM53K<K 65+XP1XOU 0V^H!-VB^F%W\!5!+ P04    " #:@+!:
MU2BX18H2  #%6   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6SM7%ES
MVTB2?N>OJ-"H.Z0(B,+!T[(=(5OVV-T^%+:F9SLV]J%(%$6T08"# G3LK]\O
MLPH@0$(TU=:,N[?U8(L'*BLS*X\OLU)Z>IUF7_1<J5S<+.)$/]N;Y_GRR?&Q
MGL[50NINNE0)OIFEV4+F>)M='NMEIF3(BQ;QL>^Z@^.%C)*]YT_YL_/L^=.T
MR.,H4>>9T,5B(;/;%RI.KY_M>7OE!Y^BRWE.'QP_?[J4E^JSRO^Q/,_P[KBB
M$D8+E>@H342F9L_V3KTG+WOT/#_P2Z2N=>VU($DF:?J%WKP-G^VYQ)"*U30G
M"A(_KM1+%<=$"&S\R]+<J[:DA?77)?77+#MDF4BM7J;Q/Z,PGS_;&^V)4,UD
M$>>?TNLWRLK3)WK3--;\O[@VS_;</3$M=)XN[&)PL(@2\U/>6#W4%HSN6N#;
M!?ZN"P*[(&!!#6<LUIG,Y?.G67HM,GH:U.@%ZX970YHHH5/\G&?X-L*Z_/DG
M%<M<A>)<9GFDM+C(9*(EJU@_/<ZQ SUW/+747AAJ_AW4 O$^3?*Y%J^24(4M
MZU]N7^_Y6P@<0[1*/K^4[X6_E>)[F75%X#G"=_U^&T/;EY^I:;6\MX6=H%)W
MP/2"WZ%N\=^G$YUG>/<_;9HWA'OMA,G9G^BEG*IG>_!FK;(KM??\Q[]Y _>D
M3>H'(M;00:_206\;]>>?7KT[O7AU)LY//UV\??597'PZ_?#Y].7%VX\?/K<)
MOIV:YW;%-HKB8JX0;HS:EU;MZ4SD^'B:+I8RN87+Y7-Q/4\7G;Q^'C*CE<LT
MHZ510DNT$K,HD<DTDK'0.8@BHN7F4:G%+(T1%O43\4$N%.V"+Z/\5J29>)N$
MT544%EC'1D [S*.EV9N8>6F9D0DV TE=3'041C(CAE]$Z>LHTSF>RL 0+Q<'
MM.S'OXU\WSTI'^"WWLDA'(AWGL*=,G %"2:K=U%R*28J4;,(@F2W0L\AP#R-
M0Y41U[\6,OD[OEYM>W!:D&G&D3P4YR#[+@^[K?O7GZQX\5SW!Y%>)X:)\M&3
MA^'QTR7]?Y=>^-N*D<]-&C6U/PPS)X;D7$;(, E]8[B+M'B/.'2AB^3R"$PD
MB?@IDJ!)B\Y!:P'[F#8U6GU5<7\&$G]7R-A*O%/*$2]2F87B+,J0$E/F ZK]
MHFX=VF^=D8I<ESV"M[^#*\<ZQTZBKYLN"^PTMZ?/7[[Z6#X.+M]%N1)O0(2H
ML^CT3/E%]0$]?8X(%(5P)/Y$BH5:3,S6$Y8?+T*K FUU8"SQO>[BP(NC=[2'
M%:Q57E*P-SS1\,69:E7>S^IVF48)3'9G'E:"T)ZO"K8#<^C6&H@4\=CD0:=)
M^Q(^$\N3PXL7\K<T(YO]RI'\#GXA/'3TDTJ:+-^M.AU-V%+*4PMK5EGCI\L2
MOU=1[528^,99K5/N5DS^)$'IF]SU],4O+XG<&X#AG^G91O0H(]J;GQ\DF/)F
MI]&+/!8'UN(/:7-V1NE8Q[>;FN?L8]7VK],B84]9)\U/5[0,J9\D4+86O\CL
M$AGI4Z$U&;%UO]85[TCLTPPYYSQ+%REIP;+5*G=>A0]D7G6ED@+;\7%Y)QN9
M%K$&J?$:G"2IF$H]QQ-3%2USY,J,2>7S3"FQ8-C7403[!$#;=%ZA-K8IPE]B
M!O8V<SDG9A%'4ZHMR 0O0="D9;(_?(FJ!1@&#^BN80A[P]'!49W8+=ZQ-!UB
M%VRFETGTO_@R+#*B:]+_4F51&H+0>:Q0/E E _IY*CZDL,V> UN*8SEA:[I2
MXG3%# D<JEQ&,5:_1/I'I4%T9VJ+_MXF5AND *?AVBJY1)T5KHZO4QT?G1[Q
MM,Q28 X@$7 MS;E."BA):0U6KE##+8DW1\P+,A)$VK3(H"837Z9R&>7 *P;Q
M<$8H>6[H<Z5QN'*'Q 2.-P<JU,TR8NT!/[U6DZP@#Z%3-5O ]=,E,4;;8&$&
M/[K&ZV()(19%3G"IHFXV*\6/DFF199!_?S!RO)[']/:]GC/P1YTVXQ);C<LA
MZ9>*J\H8<>IT.H77Y=K8ZY6<Q$H<;1Q/VU-AH5HMM4/ZBS1]8H.B@8MLLQ4F
MM?8%\<)H2LN?=%8<HQPQD1QO.NP2]%_'@(Q]\(=_G8N4#LV^$Z=,N;[0BHL#
MA_GPJ3%CB"DJ[! +*/8!;4W$D2T"LG!FSX6\A1OEB'_L,%<P,SQASK;F05.0
MCG(1IYH$$[,BCKOB[ X]B=.%V?(N18I*D9U[*;)]Q]LC\9(,*<FW*+I?5_2!
M=PC5>LYH,,3/_J#O##VOLT+ _J'H!WW'[_NB/QH[0<^MSJ0?#!W/&_-RK]]W
MW+YWIQZ.$%*2HZGA#=%*[<!@*V _"(C?43!VQJ-@]:IS9P;L ;)[(V<0!/!D
MU_&]4H!Q'Y]Z S#OPM&\<=!YAU#R1$A2/\<(<CSX//RH>>PXM<J4#DHR8*VB
M) X['U1>F2WI^"- 1@%]>P.V67\]_.5DL3A?!#J)-*".;I7,R#A@AGE$EAJG
MA#ZKZ,2UE@6H_%HB0B*.1$L*,VQU9#W[8,IUZ9^%68B@^WW["38S5G ]CW 6
M$VQ)-D:\0.TR%_T?R/2P,BD659(K-)>#U-(B;9>1-9]+G&PT8X^X+5E7(=A+
MBYA<B (NN0RC")10!F,)&4*Q)FP.NKT?JDJC&2+).RU-YH)3E"0@C2P.E&!T
MQZ!"5R0JX(7J&($356XZ_4*K5,2I]" ZA-YFT0T=,!/GCAX4B>-7_Z*(#:+[
M7A?*(D4P><K$!Q%6^J@$PTA/2UT36V8'0\!^A'^(_RDT2G&''T6:C0C"L]Z1
MNS)*'C [E9V4]4J3EXAKZ-]@BL20#'^#1[ 9($9HQ0 $)F#J>E:-41XK"481
M%R&TPH&0(#-!@YRU9)N$#M&Y5G%,/R5L'59^9+\SB=?P4F0:U2'S8$Q&BDFF
M)%Y863^;7+J""K!-4,VSZ/*2#<GL7=M:  ZJK":UL?:$.9]Q0$;8P/G(&>Q2
M]&M)7]ZR#->H&W*H&(_2UIFZA(P6Y)3L07\6/X1&,^Q-A(TJ.ZV\H=UH(@(O
MMP:[38J\X;X&$I)M4RL:I& 042Q.<78Q9^8*86ED<(.;V'( :$FOH,TG->S:
M%->2UUNRWGI^8YDF,N;@=4U8==]X?>GPMN2;3K/"!!OCZ,3^OG#IN_MN7VI@
M3KF*76J56[4-0T:U^R;'&&#CC,9^$Z0X]4Q,R1)+0JCI=H7W - H'2&2KC,3
M.%5!=2&C:[*R9D!MBYUE>MD:/C]<G"%]..[0=X*!*P[D$F9T$RV0V\#:?H 4
M.'2'A\Z=$=3S=P^A!"-*="XX_AN4]Q7=-V5-S#%\J\0]=\ I8D/BWM 9C8('
MD_AA[9V9[SL]Y.2VX^H!WOCCX2%OP,\.G?Z0CG>P\2RAGK$W.FR:Z<F&]VC>
MF7#[>&AQ>S]P>KZ_#L(OUMS%.(HRC/B..W);%3[HP5D&AF6X<Z:6\I:/=%7)
M?4-E0'"*H0FV,L^Z6Y')-K-JX#0Z]_U@ $,:#6WU!J.(;QE)(P5]^E$NEB=G
MB+':-,-R>4/U9T$!"@AL:N ;W6J%5!9/TZ-:D6>J>(ELJ&[4M,C-,RP%R>B[
MWG MS*?(0"C]")E0O@1'$T+\>4'Y/$'>6N;6W%Q6@V=])%G9-J(0V_"@6X=%
M#F>#!HFAH?" BAS Z88!<;V@VU!JJ:.V)*4R)$B4HBJ^/$B_E0&RG"@LM_9[
MP,W#/I%LV[;;"+/>@POD]RL$BA"4<6XT$$";;DJQ1/8E^[8RZOIY$J2HCH^/
M_@/*M?KQ^;L>7Y>Z$E\!Y)H0&H)D4T3]%1DEA,N;6+SO#N\M=2TES'@?H-(L
M-STSD_K^_7R/1HX[]GXOVQH>#Z_^#GS[?:=_3W6?$EJUAJ9MW<T!) <\OJJ"
M[,[6]9HX,\4B;U2@--7V3J'J"5#\LYBGV<2SR4TS!Q-%%% Z4P'Q<)E3&U!H
M8J[B.DTQT9FR6762DK!U+#<8H>0?V;[7!IY<<;VY>M]#;AZ.1\:=*RQ/%A*9
MF\KZM4?]C &;Z30R9A+[.J96,67E>JBKNC5WU.]LU;:)4$*4+8@K:*9O5 3+
MI;*2FX:@%1UVEBY4Q0"W%POHTFS;Y7;$QWKWT&2K_@: M5=([3V-^EUEK;._
M%I'74F;E2,XZ 1 _.JL]615OEK+#98OI"1\:331S,:$@E,8F*G.-'(J^>]QW
M\1Y^@]J,=BFO4ZKKDW]4E1_X7I0E9(W/4B>1U@5;9JRNJ/Q<WYVSV)N?[^<3
ME?<1;^Q?9*@$Q@)GW/, %,=K8&R_;"29(L9TDYJ(ZG"[76.G=3/^1BMN\BO;
M&Z1='%[9TS35*O>!*@3Y%?38,/ZJ.KZS-4PMDEJS8HKJ6J+"S2+]17.7"*&(
M6EOUJP6[UK'-"F+K(USIOUA#KU_]^JKL(LWD5'7%9_(I0U#=1.QW8E8PF%O(
M[(O*.RO%4W=XFJ6"LE"Z0*$9JTM*$]S5O2S >YK=.O8$6'_3.$JBJ>2VA8Q-
M?(09A,6T87KV9@&A#=QRU:4W++!CK@?R%OW1P$:FYG31<T41XXKFQ(P/Z#L:
M[[6$4':"K49SOIHBS2?IREJLF:B;*;!I)Y\C\]@L4K,M',(5MXLB-E>HW_0D
M] I\YW63SFH3'S81TGFN][5+;Y<3K1+3#(/T'1UAVQE8IPL6(X.]MUTBOB!)
M0NVV,V2ZZFLY<=53;\N8C88ZB'8>Y&;"]J,;]YFV<1[T1@@"X]6K3FT@@;H5
M/I!E'W#4'_8<;^AV:E,;FJLOKX<P,AC@I^]X@=LI;\!6]Y>:;\ H<U!W/AB)
MH\Y9=>%]T <)WQGW S'"1H.J.S_RQDXPZN'5<!@X;J]?MJ%-5\JKXB!UM3RW
M?'=:7"+E4A%M/VA$3Y.N^#E61E7#ZGF:Y4<<Q@UR8MN-^*9P\[ZW7&YUZ50I
M>+TA81)UCVL%!["C?!$$4(1OF-OWO1Y5F1O]I)*F@5S<<MQH*%VPLQF6P]1>
M_P &K!H:Y.$9!:A;OB_"X81J@4]-,^IS1+:-##YV:G?)0H97Y*8(5Q!>DY76
M SMQMMX]MUQ^&ZPK>R'6,^H,U=%;:9-&>\8P6[H5E6)8(TFZJ13:IZZ0H*:0
M47O4TW7[GTM$OF_0%=_7FN5Z[=P8C\N,C*_9D?HV#=<,],Y.:NG1]@Z7W7I=
MO6_+%12K$\T!G2)78B>"RTFZZ@Q,.[?GC <6?O2=,4+!M]\-4UPYM7*T7(IS
M%;#S+EV.1_=%83CR54!K]HQ-9&.!.;RM.SFKI<P UG0:7@Y1*A5KMDWZCZ_I
M2>6$[07W1>PPR%E]E,A$*6I#*:#;69D\S"!DMVT6]7&^\W&^\W&^\W&^\W&^
M\W&^\W&^\T\VW[EV^ZKOO'[MK+5I3 VT[X_-G2E!.:GG3F->XHZY3MN',(P@
M$2?AZOK$]#W6QL^J7<H!SVF:$29*6>L&6U8C-1L-I9)3.P 4[GK?O(,D'>:9
MNS8;3%M>Q0:OWS1XVOF5>.;?KJH&"(..Z1OMBU)&&B,D38I2<?2!274TGN4[
M;K]?5<V]ZAG^?&.T=7-J<M>A5D;\B32#3IWO,\\J&O.LG?_$/*OG]AQW>Y.]
MTVA3<KM\4QHNK4J%@E^F8SKS?Z#IUH;GM ZX!ITU&%5.NI86Z;E.;Q T!E_-
M1W_>Z=?__/#K+N=0GW^U<Z_TJD<C"X.U"5@S^8IUB ZC874XJ[G7?3'LT2Q)
M<)\)V%VX?+@A6'-=(3PO</I>V2=<C:R.:6IE//Y]0["UR5=Q4/)5'X*UN_Y1
M1F$?!U\?!U__@H.O=V20UMY<L,N\'5^9[C)=.@B<D3<VC;Q@1*\W?D=E"V^;
M\R)?F3<U$Z:VP>T,!IN7 X_#IG_98=.OV=@.(Z9?'QNM1DP'3N#:\]RW^.&K
M,Z7&9\P8J1W\O-<T*2!WKWV:U//!00_LK>9(B;Y)\-I<IS*ARKO*Q^@4$683
M=9.O2HC' =+' =+' =+' =+' =(_[0#I[\V&CV.CCV.C_[_&1K=YPOV'1:L!
M43L'8AH@WWE:M.)I!^/M/8Y]WG?L<Z.C_9TG/SMF\E-\U\G/CIG\%'_<R<]=
M^K#;AS^/-L8^S52=\,;.<#1NF_KDL3#A]5$;COSZ0"="/8\Z 30'OE_UFLLI
MSGU4G]2I#1[G.?]$\YSW05F[3G%:$S/IA>WL+S?$>1^U[C2Z.81;>K;G8GWS
M@48W4?UZKOT%821A=]QK).$[APUJ$K4,;NX$7.Z>KS2!QOY.?K#^.\OW'*\T
MXY1F<SM+J%5>++DB>-!92_.G.H]K?REVH;)+_@.ZE 4@G_FCL=6GHOP;O:?\
MIVF/5X^;/_#[7F:7$8XJ5C,L=;O#_AYP!O_17/,&R)W_[BQ@7YXN^.5<2=@_
M/8#O9RERF'U#&U1_N?CY_P%02P,$%     @ VH"P6C3@XYX$!   /@L  !D
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MYKA@F]Q\DMN?L-:36KY,YKK\#]O*-DI<R#;:R*(&TPD*+JHGV]5^V ,,@@.
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M.5Q1@XO*&M#[A92FF=@-VI9Y\C=02P,$%     @ VH"P6EVM6M%Z$@  TU(
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M]@](8VX1J(EESR('5C521:[=YJ#J(.4YIA"RZ($4,%HNB$]ELHI*5N'U@;+
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MH$J@^DYF(=VYG<[#V)\#YO9O'H[#59\8KG)DR(P,T::\0TK7A;%5;E_DB',
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M-]]^OQ'+"*+OV!^%]J_5T%]6\:>CV#&[_A4$CMJ9.<SQ'-Z-5-:#O=K9Q)_
M?[NW1(?RM..0YG%(\SBD>1S2/ YI'H<T_PI#FG;6$C[?V$H=N=Z/WF9N RDW
MGN(D_(X>[2QGMS]>H&'L^6/&#0?D^ZF)0T<[?]2,80)_CIT9PR1DHR :P^?>
M?&'<&PJ<XE!@'+-HKI[UI@YU2YJ=ZY'$?0KVU?;).<?CV.'_[]BA^B5OE\[O
M#=R(:D6_3A'=%.*:^A6"]JG]C8U7](L*+[O7U:][A!IU)?$&4"QA*0KG1-7@
MYDM3;NFW$"[*IBDW]'$M(+NO\ 7X^;($O]5?\ #[>RR?_P]02P,$%     @
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MPZ6(,=Z#GQW&]\(#!#[%T@84-@%=A <9/S+5A7ZO V$0GNQSZ##\'48M?'#
MG7Z;W[[CZS\GO_#[^4(;1=+]8U^J*Z;!?B9[G<]TP2*<>'1?-:H5>M-7+WK#
MX.V^,/\ELD=!#]J@!X?8I[=WU[-?X7I^=W7]Z79?I ?A^YWK];OPB!?N4H29
MS LF-I R#4(:^K2YYEJ7& ,3,5#UTH8&7"1 &^422"51>M3(I.-VF12YJNH*
M-QPUQ*6R"%J'#3)E!P+0ZA280LNTE!F507T&7UVYP/AX:W2^0D6%L/W^5.8+
M5-;ZY0.JB&OKOG!R*%D&GXE891MK<:YXA/ ;7Q(X210FS"!<[P3Q@8F2*B_4
M44!X<MH9]0)X">&H^P:&W=$ CN%GQ03Y0Z/JCZK?$OGVRBZS2T][BUKBFO;$
MFCANHF"+#'\$]@6UJ<\%'PJJYC0Q$E:TO!M!C=DG\/],0TF=,+LF:S%54CBR
M,M"U!*A2H#O0IEJXD&A 1K9H7[TX#7NCMQIR20$J @E3TU:68$UVN;#(D"3&
M#(R&G=Z; '1**M/P4T' 8UUDW+P^HB1',L\)JUUA62,)L7&8LHAYD<D-$LPZ
M$Z$R]"(GB-#T6J-=NO)M78L46*W-RI/8ZFS)Z!:L6%:B/=(F ;6-H\91Z_1+
M=TC;_CEV>S7HTS\==H*PUS*P%>.9$POU'K7!TFK>7; PZ WA\EO)S0:NA$T2
MO=UAGC%1:ZM)=W-I!UV78>HGF,ME1%Z0$:UEQ)D-;<U-ZJB?'D25N=8M<I5.
M12:"_XEQQ_4$5#&$@SHOCY^DQ;IS1$_I_C8DDM+H%&RO4(&*R[@+YX_\WI5)
MQYI06)TA%:Y2K*JK4;-VGU?*=A+S/ZYF-V@;2[OX_+HV>%H51O^\KNT>QJ,:
MY9CWE[;G(G^HNM68?6]<?ZNERU$EKM/5I/)2F*J[:U?;9OK<]9#^W]NK3IRJ
M<L))11DN"1IT1]2[JJJ[K29&%JY!7$A#[:8;IO2# )7=0,^74IIF8@VT/S&F
M?P%02P,$%     @ VH"P6I6.&(<D!   !0T  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL[5?;;N,V$'W75PRT1= %%.OF6Q+;0.*DV +9K1&WNRB*
M/M#2V"(BB2I)Q<G?=TC)6F?A& G:?=L76R3GG+F0AQI-MD+>JPQ1PV.1EVKJ
M9EI7Y[ZOD@P+IGJBPI)6UD(63--0;GQ5262I!16Y'P7!T"\8+]W9Q,XMY&PB
M:IWS$A<25%T43#Y=82ZV4S=T=Q-W?)-I,^'/)A7;X!+U']5"TLCO6%)>8*FX
M*$'B>NI>AN?SOK&W!I\Y;M7>,YA,5D+<F\&OZ=0-3$"88Z(- Z._!YQCGALB
M"N.?EM/M7!K@_O.._1>;.^6R8@KG(O_"4YU-W;$+*:Y9G>L[L?V ;3X#PY>(
M7-E?V#:VT="%I%9:%"V8(BAXV?RSQ[8.>X!Q\ (@:@'1:P%Q"XAMHDUD-JUK
MIMEL(L46I+$F-O-@:V/1E TOS2XNM:153C@]NQ5*P0(E+#,F<>)KXC0K?M+B
MKQI\] (^AH^BU)F"FS+%] !^?AP?1D<(?$JFRRC:9705'67\R&0/XM"#*(@&
MAP(Z#K_&I(/WCX03=P6.+5_\J@+#7Y<KI24=WK\/U;JAZA^F,H(^5Q5+<.J2
M8A7*!W1G)^_"87!Q*,__B>Q9UOTNZ_XQ]MGM;\LE+&[N8/GA\N[F4*K'\6&_
M!\\YX(HIGD!NREE1.94M)U>0B**J-::P>H*4/_"4EQNGI/O/FM*DSA"V5LZ8
MGK('E'0[05D7*V(1:X,OZ#ZQ? KHHE.:E88$TEJ:/X-_0G.JKGEN/7WO(,@_
ML9 ONN&@$AI+S5G^NDAU)A&A:#2%1E,.*2+).DE8=G.X>\[OUG9??WNVW9/S
MJ2XH7BWDN?-IEQ+36O)5K=DJ)Y\"+J\^ST_>C:-P=*&Z0+5([C.1IR@5_ 0_
MC_N1%XP&\-X,(F\<][WP[ S>.]=8"KK;&A=?OJW2@7RMI_"B/1,GK*@NNLT)
M^][9<.Q%<01GWB@>>N$@<&Z?[9AS>@A(006]8-B$%_0BBNRE'=?LGB+B)27.
MDD34I79,[;]N5;-[5 .=,4WUJ/,41)+4$O@:%-(#U]PD1;M/2$DFI;T6E"DF
M5ZI&F#=57)HJTMDAM_B(,N&*XC%[2!"JD(G.!M*8.]:\!TM>)F@/!,U7K'RB
M]_1Z320I=,>2>@!8D7M[NI4'QBIM$VZ+OK619[05M*KYZ6X9B2O1O4/7S@]A
M?Q]AVTUJ% WTDD+CP=F]J':BCGL.=3?V,/Y)]JVH=^96U_N#-TO;>4':I+F
M%#T:-^H9>:/QV L&P7\6M_.-N$-O.(J]LW$ ?2^.!][P+>+N1TUX88_P/\3]
M)G$W;8"_UVG2R=G8!MRHA*K4-)W=;-?C7]K6UO]JWGP@T/MEPTL%.:X)&O1&
M Q=DTW0W RTJV[=2%M0%V\>,OE-0&@-:7PO:D79@''1?/K-_ 5!+ P04
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MA2U4OBZ)*AZ'+!@']ZU$*C2XHN$YRGECE1'Q<T/!M=*0#)B@EA?4B5JEY#&
M(Y%0:N['F,=&[:H \>\$$U8S(:71@Q3?\L@_!/O\\4N9ANAZRR"6?"%C8" ,
M!;V,^%:"!S@K)1GR3\I@8$EH8+%@BS'$\QC8&BBU^*V I#-[]E4A,0C<: @6
MI8IE1*%=<(A^B-8)U W2RU:.6E+E5$T+U*\;5FD&&GID1[=IJ!;45:DOU<B"
M;+SQ52FGPI?#^K;XM0\N+XC<%\,.Q:A%+%>\["U.PK]6+#/^G)39),F-2ZV2
MG4@PY2/T1;X#X*9IJ(DZ>-W4"3.T#GY$<WY4^;_4UL'RLDF^+/(""!!2DR(Y
MU$]MQ*$K&!5, N]#JB%J3'M=N+;_@+?5I.8-OH\<B$$%Z:+5A\?VX><9E)Y,
MP[B(#KEKU*@2T64S. XM";&AE;%AD<)J<6#,V4"W )<@F$/3E5!!U'&;LTR!
M%#C!P# C$TIB4$.3'P#V%DIK.W$@Z;[G96J_.JE.-US&?!&+0U\Z$8U(QVVN
MRC(;MZJL&H8VX:,1_"/ON0Z5> B:"@.8%J&$77*YK>FR$UNDT.BBPRQ9-@>&
M@]0$1ZMT15D$OLVW(MZ("DT<U+J1V=2;>/1W^/+#1-D-6\TNLRH /A VED=C
MRH46<1-9#*H,$*T+82<YL(?TQRQQP1B> *ZBH^R$@L&$-S"6XCQ*"0&\G@D)
ME2Z'(!QD=1%"9I/<)OX<%BU.0S"0- ."/91AR<>B>0B3@N'7$@$@?BLX$ CY
M0@'B^&&YZHA2$-I@#$0KMVI-=FZ-,(.0*TW:V)13 I=? '8H_5KBB.F(VL L
M2I4&TQ*ZTL4* ?/R9Y;S)U&B$(VBNX!7$@XA"(PN7U53MYWZ[:!&?0&28R5H
M*%_2](KL0ZG#(L$.$]H.LEW+<.W@^<T+%J#@,H/#L-#[=0$3'=0Z6TJRJ(;:
M%N0J!U;\*$E 4@-M4# ,39!8,#U;!(5*5N  !=\D]$$'>1*J[!F\%\+H*FS6
M; 3H'M<S5<WF(&.XUN@(6]1.&Z8>E=>:;]#9&*L=']NSL& S;'/T&?=$B 6V
M+#$;G@77(.(#ATF7OOW?"<"@A= H*9A>P2-G-I_?/\Z=P[3>Z])EZ?[ AD'@
M#D9]N!K!L!A,QL[[A]G;A_</CP_WQSR:@/X:(H45^88%HY$[& _9H!^XPXEW
MF@K'LYK2 \KI9,C\8.1.^F,V+^#3J<+EAP;V/AY\&5*5&P1<P&13?7"VYD.=
MWY<0&9@@][8X#JY>:(%RI'5=%C\PSQN[H"I<32?NL.^SCU1"S>9081B$K8RP
M-!40@Y@%[A[_A0)WW*P9 1W-\PF.J*9*X:BJP02X%[9WH=FG1HH6Q8\3AVY^
MI=4A")D!</$5P'N=F7;V?H3,O#Q$2L/\[B"P.8F7D_+RB-L[:6C@9I_!1RUL
MO&[@LS_ /V\*_S#6U7A0SB(\30O(B-T00N5(J82@$%-;KLH_LAAOEP)/>:-P
MJL]A0,DEU!I]L&//1X#9$HHI'6+IHTA3)ASD3:VPC=;K^R>,"7VXVTPND?$-
M.#KH^VY_[.')$?/Z W<RF.+-F U&[FA*UY/&];2Z?JSU8A?.H\(*.#GE82>,
M2L>"KX>#L=OWH'RAZUVRAR0K[)P#_*#UL=<>U.9PS-XXGPZG@].SY XBVE9X
MYVW9>5MVWI:=MV7G;=EY6W;>EIVW9>=MV7E;=MZ6G;=EYVW9>5OV/[,MVUMU
M?._"K%R3P=6D/W7]2? -"[-R40;_/7?BC_Z#A5FU*!OTQ^Y@^+LOS/X"#MSM
MJ0:XIPI.+<J&WL =^+A-#(83=S@>??.FK%7R[[ A&TP&K@>AV&G<FBW?NR6K
M5F->=QQ\^Y:,UF->=]C_?]B2@6^A0(:3\6X5!ME;KL+&;N#WRU58?3VMKK]S
M%38:#MWQQ']Y%39T@^GP6U9A5?&W_0"MU_A%8R+TBG[HB2L*4,K^N+%^6O^6
M=$8_H>SMCML?HG[@>B53'-^60-KOCH<=BT;53:XR^GTD?,SE*J'+M> 0;3P
M[Y=*Y=4-"JA_87O[3U!+ P04    " #:@+!:$C7"DWP#  !/"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6SM5DUOXT8,O>=7$"K04V#Y*^DBM0TD
M3MKF8&^P2=M#T<-(HJ7ISH<Z',7K?U]R9'M3P&L41=%+>[$U([Y'/G)(S6SK
MPT=J$"-\LL;1/&MB;&_RG,H&K:*!;]'QFXT/5D5>ACJG-J"J$LB:?#P<7N=6
M:9<M9FGO*2QFOHM&.WP*0)VU*NSNT/CM/!MEAXT/NFZB;.2+6:MJ?,;X8_L4
M>)4?62IMT9'V#@)NYMGMZ&8Y%?MD\)/&+;UY!E%2>/]1%H_5/!M*0&BPC,*@
M^.\5EVB,$'$8O^\YLZ-+ ;Y]/K!_E[2SED(1+KWY65>QF6?O,JAPHSH3/_CM
M#[C7<R5\I3>4?F';VT[98]E1]'8/YK75KO]7G_9Y> -X-_P"8+P'C/\J8+('
M3)+0/K(DZUY%M9@%OX4@ULPF#RDW"<UJM),J/L? ;S7CXF+IK=61RQ()E*M@
MZ5W4KD97:J19'MF%&.;EGNZNIQM_@6X"*R9H"!Y<A=4)_/(\?C0^0Y"SMJ/
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MW9ILNE; OJN;Y+ABEHM]I)P:\D;+5@4;KBPW$9> (F_T';9E6O6JM)'@1;_
M-%&'U>!44_Q_SOX;YXRG.MJ"4W*8[/_F4>M'9O[FFVTQU.DJ0W)B7.P_W\?=
MXVWI-ET2\L_F_56+NZ;6COCL;!@Z''QSE4'HKR_](OHVW0 *'_D^D1X;OO%A
M$ -^O_$^'A;BX'B'7/P!4$L#!!0    ( -J L%H/<I+K<P4  - +   9
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M2K--!!G7B79BB66+.I0N%GM*K;5".U59W[-N6)\7BD(M7U('+%E.W4\1!<1
M[LK]_2?W7"^,_7 0G;[G7N]T6[^S3ACY<2_\/QZJ^DL6'(Q,!:JUFR1M^$J8
M>GIJWC;#ZM3-:,&3>3WITK2QYD+3J5F1JVTO#U0]/=8/1I9N %M*0^.<6V8T
M<*.R!K2_DM+L'VR 9H2?_ U02P,$%     @ VH"P6@RT#+!5/0  >BT! !D
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M!L'STCTO;ZOBULI1VVX+PC_S 7BM1F85O$YD"],!$X6!B_L40+ZUY<XR1:^
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M&*8A4[;T7*K%Q!E>4:R4BA3BPX<]NC:[HL46MP!F ;15LV6S*[%72@>9MS9
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M0GRM'%YN0<Q2Q)7HBF7E%=6]@2*4YBI H[>1$\;B+N7H.>*%5LYT<$C?0RB
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M!Q9'K\,BD5!X[\IE=ENQ,S' S0RC%*@!A)<API# H(FIT/5W*5FS)J@Y 4W
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MNSM@1 '98FBYVC4P$B9],A6ZC(@A5)F0?SNT!4ET0\@ADO1A\Z%V5'XH0A.
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M/I<$_B6@#K-)'IISL)>6>3R&U8>>QWB(+_=33:A+"X,0$6.1*ET3!#00$""
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MM969N5^U.8]O\<N^-+Y.B-TIVDC)VT]4("EC!Y['OH&EIU1R6R)7@PGAC9R
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M*KVZF"07S]/QQ86YV9?$*+G5TW1\.DDO3B?F>K$ B '"9]B2U ?Y$0,3& R
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M_HG=H6R-+\#ORZIJ]0^< -NN$'A?_S]02P,$%     @ VH"P6E"3X6(O"0
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M*1M:@/,SK>UF0 :V_[P8_PU02P,$%     @ VH"P6FK&-/"[ P  / H  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULU59+;^,V$+[[5Q!J430 $;T?
M3FT#CO?1 AO4V*3MH>B!EL86L9*H):EXTU_?(25KG4#K;H'VT(L](\TWSX\C
M+HY"?E E@":?ZJI12Z?4NKUQ79674#-U+5IH\,U>R)II5.7!5:T$5EA07;F!
MYR5NS7CCK!;VV5:N%J+3%6]@*XGJZIK)IUNHQ''I^,[IP7M^*+5YX*X6+3O
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M:>P0V=]5>D6+UG[N=T+CY<&*)5[O0!H#?+\70I\4$V"\,*[^ E!+ P04
M" #:@+!:DT+5[;T/  ! 10  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6SM7/USFTC2_IV_8LKG7-E76 8D!,I7E>/-WNUN=N.*?7OOU=7],(*1Q :!
MC@$[?O_Z]^D>0*"O>)-+4K6OJQ(#8KJGIZ?[Z0^0GM_EQ7N]4*H4'Y9IIE\<
M+<IR]?3\7$<+M91ZD*]4ACNSO%C*$I?%_%RO"B5C)EJFYY[CC,^7,LF.7C[G
MSZZ*E\_SJDR33%T50E?+I2SN7ZDTOWMQY!XU'[Q+YHN2/CA_^7PEY^I:E7]?
M716X.F^YQ,E293K),U&HV8NC"_?IY83&\X!?$W6G.^>"5C+-\_=T\4/\XL@A
M@52JHI(X2!QNU:5*4V($,?Y3\SQJIR3"[GG#_7M>.]8RE5I=YND_DKA<O#@*
MCT2L9K)*RW?YW=]4O1Z?^$5YJOFON#-CQ^,C$56ZS)<U,218)IDYR@^U'CH$
MH;.'P*L)O(<2#&N"(2_42,;+^DZ6\N7S(K\3!8T&-SIAW3 U5I-DM(O798&[
M">C*EV_R;'YVHXJE^"&[5;K$!I5:G-S(::KTZ?/S$G/0R/.HYO?*\//V\!N*
MG_.L7&CQ.HM5O(/^\C"]ZQU@<([%M2OTFA6^\@YR_%D6 S%T;>$YGK]+H,/D
MWZFH)1\=$&?8*GS(_(:_2^'_NICJLH!-_WN7R@W'T6Z.Y.=/]4I&ZL41'%FK
MXE8=O?SSG]RQ\VS7<O]+S'J+'[6+'QWB_O(:(!17J1+Y3+R]RU2A%\E*7*DB
M@A8 &IINO);1HE:.4KO4<7B.FP78M[Q7?=Z*>"<U;R$+)=($I[&06LSR%)BF
MGW8D6U,+F!%(R1!@$6HY505?7$117F5EDLW%+W+)"VO8:[8XMAM1 F'KK7Y5
M %OG*E,ZP462ERI:9'F:S^_%93ZPQ9LR'OQ%. ,W$$^:PV6N2_&S*A=Y+/X*
MTM5"PH!J8MPM5GDA&1:=P=C0C3?I,/IO /^?2-0NA3^8.!A:'[H4P,EK!8#,
MQ.M[U:,YT=#>+YA=N,ZI<">#( 1M<]R8]?NDP'67W T'8R:HCZ__4R7E?4/R
M-HOR_R'"*UJEM&$+<,'^E-YH,*$%-L<^AW>DWMZ,PV#@T/*\\6#L;XW'7&\2
M</Y1KF0F?AK\-!"CB2%HCGV"OXB;!78ORI<@N!=WL!X9840!2YIB'V4FTYW;
MPTMY6R&,EGGT7H!'DHD2%KLJ\DAIMM%"K5(X(%D+@D&YX/MF/.[213M7(X#,
M8KZQR^YI$EU-?T/<%&4NHH6$]0UV(<,W\:N>-_TNUQK1G^'_#]<Z^[IN=?8
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M!V0S'S8;+39VQ)H+C0.;)=<X4G-I!/!\*3!_[<8 ]$/ZY M02P,$%     @
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MF7[K'C]<K[Y=8 -=)[E ^2LD-4<!MB9>?0^H-I(5^I5ZR22^H.OEAA+TMKJ
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MNH;2[)IV* S5,H^$#4WJ]DOJ]5O-AXZ-0FD!BB;*]L#54:2RO2J/P)T78?+
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M(MWP_3$B#VE1I.OJY8J%2Y:5*_#?/Z9I\?JF3/"29E^JS9G_#U!+ P04
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M7,(RX2WRP6*=KH2T838+A]F/?>YMVWRIU^96O?J67-\OBYSM=\/8T0L@4>>
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M!8L1Y;D4#V"4I16ZFP%?@OR)?J,9S2@O>#7T4@;.%>T+=*9R$L'8,V^( OD
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M7[0OQUH&BK="LJP$JP@R0HM__%*NPQ% \;0#G!+@U '>&8!; MPZ(#@#\$J
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M*:)[SAUJMWKW)_2B(Z@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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M,7T6LMF@:<E;I)N\^I\\-VTG([+8Y44:-\%J#>(HJ7^&7YL=<1!@.:\$T":
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MMV(+Y; BVU)\HON_H!,4*+Z,EKS]1?NNUK%0MN6"5AU8SJ JZL,_^=X9<0+
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MF=6#9O6AM !*"Z$TAJ(UY5R;IZ;>/-T?N][JCUFASBF4YD!I+I3F06D^E!9
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MP1';74S<O0B:9O?B'J@0-,X> X)7A*D",O^1R@F0OZ@*BNNATW\!4$L#!!0
M   ( -J L%IZZS1@704  .HB   9    >&PO=V]R:W-H965T<R]S:&5E=#4R
M+GAM;-U:;4_C.!#^*U976MU)T#9I:8%M*T&!6P[80[#W(JWN@YM,&]\F<<YV
M6KA??^,D)(U43'OK%O:^0)-XGIEY/&//)!XLN/@J P!%'J(PEL-&H%1RW&I)
M+X"(RB9/(,8G4RXBJO!2S%HR$4#]3"@*6VZ[W6M%E,6-T2"[=RM& YZJD,5P
M*XA,HXB*QU,(^6+8<!I/-^[8+%#Z1FLT2.@,[D']FMP*O&J5*#Z+():,QT3
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MF65IYP5=1X-.:[M.T:9=H=7)+&L[K_VITR.B03O@Y;C9GA]1=35'@XZ IAT
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M(09'<%;-<D.%?TD"7R7>0&U16"R2//:N"0T6F4FT OC^CJ89E1#/G5R8HQF
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M*/@4-H#[,P$<YE]P@.*G)@[_"U!+ P04    " #:@+!:V_ GA9$#  #E#0
M&0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6RU5UUOVS84_2N$.A0ML$0B
M)>HCM0TT-HH&2(<@7K>'8@^T?&T3E42/I.WNWX_ZB"S9DNI@WHLM2O<<GGM$
MW4N.#D)^5QL C7ZD2:;&UD;K[9UMJW@#*5.W8@N9>;(2,F7:#.7:5EL);%F
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M&NWX\JK):'*:(6B=.JKEJ%90FI@A;9VZ)J]3_W53WM_CX[K\WGD9KWQX[_Q
MR]-1S4 U$]4L5+-1S3GS Z8-GOO9<M'M\,YOQ_>JW'1MB(]N2(!J(:I%J!;_
M\%N?H-N1HEJ&:CFJ%90FID5;B:[)*]$_K'>'&5=W]>)K]7QBH-7GJ*:CFH%J
M)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!:?V0VIDF!!R]%1+4.U'-4*2A.#I2U'
MU\[<S/S0XF3]Z;'+R?X\>[H_M[[M/KF.EI^CFHYJ!JJ9J&:AFMUH0NE55U\2
MY](GNNCV>:CFHUJ :B&J1:@6HUJ":BFJ9:B6HUI!:6)BM$7HFKP(/:J_5!OE
M^-X@X;JNMDI<?B_W?_LMJ&X^5INN2PY^EM.]HP.M34<U ]5,5+-0S48U!]5<
M5/-0S4>U -5"5(M0+4:U!-525,M0+4>U@M*$$!JV9>[#A_K'X?/K8<_%C[][
MJN+4U<VV,X*&:/$[JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:
MBFH9JN6H5E":&$%MB?Q07B)_2:<5.=$[;)[6>8\ZEEYT=%8#U4Q4LU#-1C4'
MU5Q4\U#-1[4 U4)4BU M1K6D8^\PZ[J;.CIKAFHYJA64)@:$U@:$O/3]R2T.
M?Z2243Y'[P1!*^%1S4 U$]4L5+-1S1D^O0OZ27V8BT[HH9J/:@&JA:@6H5J,
M:@FJI:B6H5I^_M>EH"84<Z.M?A_*RS4O.K! "]Q134<U ]5,5+-0S48U!]5<
M5/-0S4>U -5"5(M0+4:U!-525,L:[7B?/WQZ9)2CDQ:4)J9(6\*^>RA+D:"L
M[S:+^KM25YN;_4'&8GW=F212IG>2D)J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&J
MA:@6H5I\9E>DWA< =8;&#PY,T>W/4"U'M8+2Q!AI2]V'\E+W2Z_V4OZMF.M-
M=55N:^D58/+I>L<-6A:/:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5J,:@FJ
MI:B6H5J.:@6EB<'4UL\/)R]U!1A:68]J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%
MJ!:B6H1J,:HEJ):B6H9J.:H5E"9&4%N4/SQS>_A+3M0\O>%WUS5;'^13]8X1
MM-P>U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[6"TL08:4OP
MA_(2_.BNWM;EZKX;V.TA4CJSY&GM]:0S2]"2>E0S4,U$-0O5;%1S4,U%-0_5
M?%0+4"U$M0C58E1+4"U%M0S5<E0K*$W,DK8X?R@OSO<7J^L>]?ARK?=2&%J/
MCVH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:CFH%I0FY,VKK
M\4<O58\_0NOQ44U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M0354E3+
M4"U'M8+2Q AJZ_%'\GK\HNE>6?U1;:X6VZHINKR\U%+N]TXB]&;VJ&:@FHEJ
M%JK9J.:,GI98G]R#R44G]%#-1[4 U4)4BU M1K4$U5)4RU M1[6"TL1XT=IX
M.7,C^T.CY$.7Y'U=36>,H!7[J*:CFH%J)JI9J&:CFG/F)VW\[/U27'0[/%3S
M42U M1#5(E2+42U!M135,E3+4:V@-#%=VIK_D;SF_W#PHE<?=_]9;*_VUY-)
M3]W(P=XQ@W8 0#4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M
M1[6"TL3H:1L%[!Z^T*F;$1I!I*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%
MJ!:C6H)J*:IEJ):C6D%I8@2U309&\B8#9KG8*%_+Y=WQ;<@Z[W$IAWI'#MH^
M -4,5#-1S4(U&]6<1A-Z/<U'@^EI3TQT5J]CUM%L,)V/Q5E]=-8 U4)4BSJ^
M(ZJFC<>CH?@MB=%I$U1+42U#M1S5"DH3$Z"MYA_)[UCM[Z];/BR"29>]T.)]
M5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,M1K: T,7':
MXOW1]*66O<CBTP^HIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHI
MJF6HEJ-:06EB!+6%_R-YX;^S6M2+<ODGKE@F2U<_H)J.:@:JF:AFH9J-:@ZJ
MN:CFH9J/:@&JA:@6-=K\>&5M\'I\NJR&M@- M135,E3+4:V@-#%AVG8 (WD[
M@#]?$X,V"$ U'=4,5#-1S4(UN]%F1_N/P>OIR?[#0>=T4<U#-1_5@D8[WCL/
M3W?.(3IEA&HQJB6HEJ):AFHYJA64)@3'N*WG'TN+-9\&QZ:ZOKNJKGM$AWR&
MOM&!:GJCS85=X$C\)370*<U&$_>ZHY/R00N=T^Z<\\F>'IW3134/U7Q4"U M
M1+4(U6)42U M1;4,U7)4*RA-C(2VOGXLKZ_W^[46DVN]=_]H-3VJ&:AFHIJ%
M:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B6HEJ&:CFJ%90FYH[6YH[V0B?JQV@E
M/JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ&:KEJ%90FAA!
M;77^6%Z=?W'O%[G3.W'0HGQ4,U#-1#4+U6Q4<U#-137OS&_!\WUI?'0[ E0+
M42U"M1C5$E1+42U#M1S5"DH3TZ4MP-\]/+NP9BW7'\NE8M[M'CO.WQ0_EJ^N
M2<G>04-J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:H5
ME":&3UMZ/QZ_U.H:6HJ/:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J
M):B6HEJ&:CFJ%90F1E!;^S^6U_Y?<AME.=$[;-"R?U0S4,U$-0O5;%1S4,U%
M-0_5?%0+4"U$M:C1A%X^T\%(G4Q/BEW0:1-42U$M0[4<U0I*$W.DK>@?2\LU
MV[,T]T4NG2F"5NZCFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J!8UFI BZG3\
MY+[I,3IM@FHIJF6HEJ-:06EBBK1%^6-Y4?Z']<W->J5LZ_75[TI9*^5*631U
M^E?W:V7;Q>Z?^]91RB?MG3QHI3ZJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEHT
MOJA2'YTS0;44U3)4RU&MH#0Q=MI*_;&\4E^(G=O3Z\WV09/NPV7;G2YHE3ZJ
MZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:E&C38[29:S-.Q;'T()^5$M1+4.U
M'-4*2A/R9=(6]$_D!?W^I0V6Y4[?+$$U'=4,5#-1S4(U&]4<5'-1S4,U']4"
M5 M1+4*U&-425$M1+4.U'-4*2A,3I^T7,%%?Z,JR"=HZ -5T5#-0S40U"]5L
M5'-0S44U#]5\5 M0+42U"-5B5$M0+46U#-5R5"LH38P@K8T@^9W4_W2#9;G?
M.XG0#@*H9J":B6H6JMFHYJ":BVH>JOFH%J!:B&I1HYTY;8/.F:!:BFH9JN6H
M5E":F#!M9X")O"9:<I C6V-#VP2@FHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%
MJ!:A6HQJ":JEJ):A6HYJ!:6)\=.V#M@]?*$UMA$:0:2FHYJ!:B:J6:AFHYJ#
M:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B6HUI!:6($M0T$)M+JT NJ;N1 [ZA!
M&P6@FH%J)JI9J&:CFH-J+JIYDX[[V _N_XCK03XZ;8!J(:I%J!:C6H)J*:IE
MJ):C6D%I8HJT/0 F\AX ?^KR9[G=.V#0Y@"H9J":B6H6JMFHYJ":BVI>HTW.
M!PQ:]X]J(:I%J!:C6H)J*:IEJ):C6D%I8L"TS0$F\N8 ?_Y2 +1W *KIJ&:@
MFHEJ%JK9J.9,GM:9G]S>S44G]%#-1[4 U4)4BU M1K4$U5)4RU M1[6"TL1X
M:;L&3.1= Z*[>EN7J^O%ZK.DBYD<Z9TA:!< 5#-0S40U"]5L5'-0S44U#]5\
M5 M0+42U"-7B1A.ZV0QFD[$J?M1(+GQ>BFY=AFHYJA64)D9$6^$_D5?XQ[L#
MCVI5EY\K9?U)*;]6F_U#25B@1?VHIJ.:@6HFJEFH9J.:@VHNJGF-I@Z.]C^#
MU_/3)2VT6!_50E2+4"V^Z+N;7/2L%-VR#-5R5"LH30B :5N"/Y67X(L!L#XZ
M8KB]H .R'.\;!ZBFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6-YH0".KK
MDT7*Y*)GI>B69:B6HUI!:6)LM'7T4VF19'.-[P]UG93+O3,#+:1'-0/53%2S
M4,U&-0?57%3S&NVX#&]X6H7GHU,&J!:B6H1J,:HEJ):B6H9J.:H5E"9&B]9&
MB[P^WOC1D^%RMW>PH'7QJ&:@FHEJ%JK9J.:@FHMJ7J-)3M3[Z(0!JH6H%J%:
MC&H)JJ6HEJ%:CFH%I8FQTA;%3^5%\4%9WVT6]7>EKC8W^R19K*\[4P0M@T<U
M'=4,5#-1S4(U&]4<5'-1S3OS2S"ZOX17^5[M/DUUKF&A=>^H%J):A&HQJB6H
MEJ):AFHYJA64)B9,6_>^>R@]E7*H$%E_NK1(1"[V#AM2TU'-0#43U2Q4LU'-
M:;2SA1@N.JV':CZJ!:@6HEJ$:C&J):B6HEJ&:CFJ%90FQDI;RSZ5U[*?[^:E
M_%N)ZB_51OFQQE_R^7N'$%H*CVH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:
MC&H)JJ6HEJ%:CFH%I8E)U=;+3Q_*)?G&7U.T6![5=%0S4,U$-0O5;%1S4,U%
M-0_5?%0+4"U$M0C58E1+4"U%M0S5<E0K*$V,H+:B?BJOJ+_X+ ]:.(]J.JH9
MJ&:BFG7FS53O3U1T9@M:(X]J+JIYJ.:C6H!J(:I%J!:C6O*C/_8INAD9JN6H
M5E":&"-MY?ST3.7\GUE.0^OI44U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+
M4"U&M0354E3+4"U'M8+2Q!!J:_.G\Y=:3D.K]%%-1S4#U4Q4LU#-1C4'U5Q4
M\U#-1[4 U4)4BU M1K4$U5)4RU M1[6"TH0(FK7= 69GN@-<T - 3O0-&U33
M4<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!M135LD83.Z ]N9HS1R<M
M*$U,D;99P$S>+.#GJMSL.\HL5G6U\VME4]:=-V61.[VC!&T-@&H&JIFH9C6:
MV*%)_/FTT1D=5'-1S4,U']4"5 M1+4*U&-62"W["4W3&#-5R5"LH34P'K4T'
M>;V_7GU<U,KU8GOU[!$&6MB/:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$
M:O'L:7N%X6PR.^DR=M&S4G3+,E3+4:V@-#$:VIK]F;Q<V3D<,%1_W%:K;?<Q
M UJOCVHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&IQHQT7V<YGH]-L0*OR
M42U#M1S5"DH3,Z2MRM\]E&6(OUA=-Z?/95=MR97>,4)J.JH9J&:BFH5J-JHY
MJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:H5E";F35NN/QN_T%5;,[0.']5T
M5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46U#-5R5"LH38R@M@Y_
M)K]O_>FR65>KOY_E1N^T04ON4<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+
M&TWH63V8#Z>G-V_I>)XZU6:G2VPING49JN6H5E":F!!MF?Q,7F*JK:Z5QX4Q
M^;H86BB/:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B6HEJ&:CFJ
M%90F1DY;4C^;O=2Z&%I0CVHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQ
MJB6HEJ):AFHYJA64)D906U _D]_L_CB"5OL#G\7JHKL<R]G> 826TZ.:@6HF
MJEFH9J.:@VHNJGF-)BR^:!UW$/#1:0-4"U$M0K48U1)42U$M0[4<U0I*$[)E
MWE;*S^65\NG=QVWUK[MJ52O&U_U_98MJ<JMOH*":CFH&JIFH9J&:C6H.JKFH
MYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:CFH%I8FITU;6S]476E2;HZ7VJ*:CFH%J
M)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!:C6H)J*:IEJ):C6D%I8@1I;03)R_=_
MX*Z7<K%W]J#U_*AF-)IX]T9MKDZFXMJ+B4YKH9J-:@ZJN:CFH9J/:@&JA:@6
MH5J,:@FJI:B6H5J.:@6EB;'2EO[/Y:7_SZZG_<F;7<JG[9T]:+L 5#-0S40U
M"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46U#-5R5"LH30RHMJ_ [N$++;V-
MT @B-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+42U#M1S5"DH3
M(ZAM-3"7UI%>U)V_(<02K:<7_WR03]4[1M!V :AFHIJ%:C:J.:CFHIJ':CZJ
M!:@6HEJ$:C&J):B6HEJ&:CFJ%90FQDC;+F N;Q<0E'\L;NYNY,MF:+< 5--1
MS4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,M1K: T,6S:S@/S
MZ4LMFZ&="%!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M
M1[6"TL0(:CL1S*5EIDT$;1?K^^K/JTJYK3;*=G^YVOV%:_IZN2PWV_:KW=>P
MH4T)4$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M:31U.'14O_@]6@^
M/.G&EJ+39JB6HUI!:6+0M/T&YO)^ \7#Y=!;9;'=WE779R^+1ML,H)J.:@:J
MF:AFH9J-:@ZJN:CFH9J/:@&JA8UV?%'_N..:_@B=-4:U!-525,M0+4>U@M*$
M1%$';9N!_>,^)VN4?S\T\FRR1GH2YXS=-V%83F<Y@^5,EK-8SF8YA^5<EO-8
MSF>Y@.5"EHM8+F:YA.52ELM8+F>Y N-.HDD]BJ:7:D9PD+%@0ML1L)S!<B;+
M62QGLYS#<B[+>2SGLUS <B'+12P7LUS"<BG+92R7LUR!<2?!I!T%D[Q%P>'8
MJ/JCVEPMMI6RJ:[OKIH%N<M.]YR9HG]"H4T+6,Y@.?/ J2-A97HZ%M=++'9:
MF^4<EG-9SF,YG^4"E@M9+F*YF.42EDM9+F.YG.4*C#N)GN%1],C;&'0LU_7J
M%'K&[Y\[:,,"EC-8SF0YB^5LEG-8SF4YC^5\E@M8+F2YB.5BEDM8+F6YC.5R
MEBLP[B2>1D?Q-'JQ);L1&TPDI[.<P7(FRUDL9[.<PW(NRWDLY[-<P'(ART4L
M%[-<PG(IRV4LE[-<@7$GP30^"B9Y:P-GM:@7Y;)=LGNX4KO/@AU9HON!Y726
M,P[<3+K 9K*S6BQGLYS#<B[+>2SGLUS <B'+12P7LUS"<BG+92R7LUR!<2>Y
M,SG*G3.]$!:KL[T0SAC]HP7MAL!R!LN9+&>QG,UR#LNY+.>QG,]R <N%+!>Q
M7,QR"<NE+)>Q7,YR!<:=1-#T*()>JD/"0<:"">V1P'(&RYDL9[&<S7(.R[DL
MY[&<SW(!RX4L%[%<S'()RZ4LE[%<SG(%QIT$T^PHF/X?^B:<F:1_1J&=$UC.
M8#F3Y2R6LUG.83F7Y3R6\UDN8+F0Y2*6BUDN.7#J<<ODP>OI?'!2WYNR$V<L
ME[-<@7$G\3,_BA^TF\(9KG_0H/T46,Y@.9/E+):S6<YA.?? ';<'&$T'L^%0
MW'UX[+P^RP4L%[)<Q'(QRR4LE[)<QG(YRQ48)^:,>M1A03W38>'D%%"O#@MR
MNW?HH)S.<@;+F2QGL9S-<@[+N2SGL9S/<@'+A2P7L5S,<@G+I2R7L5S.<@7&
MG43348<%]<4Z+*ALAP64TUG.8#F3Y2R6LUG.83F7Y3R6\UDN8+F0Y2*6BUDN
M8;F4Y3*6RUFNP+B38-*.@NGE.RS(I^B?4&R'!90S6,X\<.+UWR/MM,$".JO-
M<@[+N2SGL9S/<@'+A2P7L5S,<@G+I2R7L5S.<@7&G23/48,%]4R#A:>K=?T:
M+,C]_K'#-EA .8/E3):S6,YF.8?E7);S6,YGN8#E0I:+6"YFN83E4I;+6"YG
MN0+C3N+IJ,'"OJG9"ZW8C=A@(CF=Y0R6,UG.8CF;Y1R6<UG.8SF?Y0*6"UDN
M8KF8Y1*62UDN8[F<Y0J,.PFFHP8+ZDLW6)!/T#^?V 8+*&<<N+FXP';:7P&=
MU&(YF^4<EG-9SF,YG^4"E@M9+F*YF.42EDM9+F.YG.4*C#N)G:/^"JJ\O\*'
M]<W->J6D]?KJ]S/K<FR3!9336<Y@.9/E+):S6<YA.9?E/);S62Y@N9#E(I:+
M62YAN93E,I;+6:[ N),<.FJRH+Y8DP65;;* <CK+&2QGLIS%<C;+.2SGLIS'
M<C[+!2P7LES$<C'+)2R7LES&<CG+%1AW$DQ'3194>9.%OE6N<JY_&K'M%!KN
MN!92'73<*]E@)S:[)AX/]G^>7!+']D#H?,$=$SOLQ"[+>2SGLUS <B'+12P7
MLUS"<BG+92R7LUR!<2?I<-0#097W0&B6S[;WRV<_U'Y'/D'_O&"[(J"<P7(F
MRUD'[KC/R$G';IN=TF$YE^4\EO-9+F"YD.4BEHM9+KG@1SUEI\Q8+F>Y N/$
M)-'V70Y.OG147:I)RX3>_Z;^4XDWB_5FGR&+];6RF_ENN3L4^5)^K92/5;52
MRNO_N=O6N\.2>KW[UT_+ZJI6ZB^5HO[]TWKS=W6P^^*^15S5)-3V=KFHE>K3
MI]WS=H-VR>7>+;\KVOAOBC;0AJ^[7LN;[9>JJO6R+M^_NZDVGZL/U7*Y5:[6
M=ZMZ_\'ZZ*O[3=C]Y&AO?]5>O7GR]41[^TO7UW??A\';8O^]ZABCOOU5[1ZC
M[L=T_]O;?]S/\Z;=W/?O;LO/55!N/B]66V59?=IM^OZ&#*^4S>+SE\>_U.O;
MW5OT2OFXKNOUS?W#+U5Y76WV3]C]^Z?UNC[\93_!M_7F]_MOS_O_ U!+ P04
M    " #:@+!:\Z8I0$P+   ,9P  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6S%75MOXS8:_2N$MUA,@386J7LV"9"$'33%S#288&8?BGU0;"811I:R
MDIPT^^M7DA53%^JC2#-('SJV\WW'/,<R=8XN],ESEO\H'A@KT=^;)"U.%P]E
M^7B\7!:K![:)BJ/LD:757^ZR?!.5U=/\?ED\YBQ:-TV;9$DLRUMNHCA=G)TT
MKUWG9R?9MDSBE%WGJ-AN-E'^<L&2[/ET@1>O+WR-[Q_*^H7EV<EC=,]N6/GM
M\3JOGBWW*.MXP](BSE*4L[O3Q3D^IB&I&YJ*[S%[+CJ/44WE-LM^U$^NUJ<+
MJQX12]BJK"&BZI\G=LF2I$:JQO'?%G2Q?\^ZL?OX%?UC0[XB<QL5[#)+_AVO
MRX?31;! :W87;9/R:_;\.VL)N37>*DN*YO_HN:VU%FBU+<ILTS97(]C$Z>[?
MZ.]6B$X#]B8:2-M YC;8;8,];' G&IRVP6F4V5%I=*!1&9V=Y-DSRNOJ"JU^
MT(C9=%?TX[3^W&_*O/IK7/659Y=9^L3R,KY-&/J2E:Q U]%+5#_[%=U4&]EZ
M6SW,[M!EE.<O<7J/SC?9-BV+^K7R@:%/<70;)W'Y@BZSS6.6LK1$'R@KHS@I
M?JXPOMU0].&GGT^69378^BV7JW9@%[N!D8F!V>ASEI8/!?HM7;.UH/\2[L<$
M %A6*NVE(J]271 0\7.4'R$;_X*(15S1@.!VRE;[=D?03N>WVP ;>__!VPV>
M/8&G^^'^]:D"0E<EVQ3_$7VJNW=UQ.]:SV+'Q6.T8J>+:IHJ6/[$%F?__ ?V
MK'^)%#4)1@V!]=1V]FH[$/K9=1ZGJ_@Q2EJ)452BJZ+81NF*B53<H;D-6CUU
M/YT1XEG5?R?+IZY ,^OHN,X)+0=[_KZN1\O=TW*5:5U$2<T*W32[K6I2$A+<
MX7J= 6%+1%!0YX@(CNN(A3'V73%!;T_0 PE^2Z--5DV/_V-K1.-B59,4T?'&
M;T^<:J #-N,RUPI#UQF0&9=A3!S/M<5D_#T9'R2S_YI_CY*M\%/Q1V\<V*YK
MAP,:X[+0M2S'&] 0H 6>2XB81;!G$8 L/D9Q/LT@&&WH6/C%$=3YCF"[&M<1
M!]L.ML0DPCV)$"1!TC7Z=/6%-OM<]-=GMKEEN7 ^!7%4YU.38-006$\_;''?
M8KW+_JM]6T."&T6CIM#ZDG>L(@8WVM<=5N6HRDI4H7HPPOG%]TNA3%IM%&[3
MU8-P/<@\/:9V<I+^+]G3$<+^+TC@Z5I=#@2@,("N0MQC8M!459:YW.;U]V]2
M(5G_"\+ACI_0<A_83^%^77VX*\1F;2$>^SA,+,'N;6XAA0>H*P#WCQ@VD#=E
MM6&LT55:L@J^1%^GMI,=3#T![@F-.,MK*#P<7;K<36+83OYV=\>: QTS&.^0
M,.ZR.0J\T!G2GEE(X;'I<N?F$TO<9W.DH3E>5&WVU:SY(4X1S9(DR@OTR')4
M/$0Y$Q\I\,=;\U %:0F%QZ?+G]M6#/O6RH)L*NXW9;;Z@<H,W3*TVAU\$1[>
MN)# 3>Y*M=HHW*8K#K?#&/;#^D&R!>XY=.&,.*YSA!/B6]A:PFTM 3W<[,#9
MPO02IX?QD+6@#./ <H(!:WA4NJRYLR2PP9,GTQ:@1\2W@W!$>%Q' ARZ9$CX
M+:PCX=:1P,X-#K%M<S]U"K9I09T3"+9I>#"Z9+D+)+ +L_.Y81<&4@U?1M&H
M*;2^B-PJ$N==\BXQ9 !;R4VB45-H?<FY.26P.9V1=R4(4SMIO38*M^GJP=TK
M@=VK-.]*^O^(4AY71:= +@\%H#" KD+<XQ+8XTKSKJ3_CVW""8K/,1T(0&$
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M%U1_O\NR\O5)_0;['\ Y^S]02P,$%     @ VH"P6H<YY70Q P  ]@H  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULK59=;]LV%/TKA#H,";!%$O5A
M.;,-I':+%MBP(%G;AZ(/M'05$Z5$C:3MY-_W4E($QZ8]!^N+18KW'-YS[A7-
MR5:J[WH%8,AC)6H]]5;&-->^K_,55$Q?R09J7"FEJIC!J7KP=:. %2VH$CX-
M@M2O&*^]V:1]=ZMF$[DV@M=PJXA>5Q533V]!R.W4"[WG%W?\867L"W\V:=@#
MW(/YU-PJG/D#2\$KJ#67-5%03KV;\'J1V?@VX#.'K=X9$ZMD*>5W._E83+W
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MY.Z6N.T"J!HAGP#($FHHN7'ZD![6 %-*]E*?.\)H&@;IGL+#,#H.HR,"1X/
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M\U$M0+40U2)*:Z9675:M8=<\UM ":U334<U -1/5+%2S4<U!-1?5/%3S42U
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MBG@ATK)!\?Q-DN0O=\H!'I/TZVXQY_\'4$L#!!0    ( -J L%K\1Z:",P,
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MT8/GC!YTZ9?69KX6YK>;^_6N+84[%SXWA4E,)C&%Q%02TTA,)S&#Q,Q';/B
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M'W08>W#28>S.X<^.9%)34$U%-0W5=%0S4,U$M1FJ6:AFHYJ#:BZJ>:CFHUJ
M:B&J1:@6HUJ":BFJ9:B64UH]DJO>L7%W[]C+'=]_=!^C1BO(4$U&-0755%33
M4$U'-0/53%2;H9J%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B6HEJ&:CFEU:.Z
M*BH;CS[P&#5:5X9J,JHIJ*:BFH9J.JH9J&:BV@S5+%2S4<U!-1?5/%3S42U
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M7U]ON_<\=X)GYR*IR:BFH)J*:AJJZ:AFH)J):C-4LU#-1C4'U5Q4\U#-1[4
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MF&UOVCH8AO^*E4U3*YTU;R10!I$*83K[4*D:VSF?W>0)1$MB9AOH^??'3D*
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MD"8 [\^%T+<3TTOUO7;^!U!+ P04    " #:@+!:X2F]E,-N  !Z7@H &0
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MVH)J6=/;S:<DY6S)8U,>V_+8F,?6/#; L06.C69L-6.S&=O-V'#&EC,#R]G
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M?7OKA;"/Z&''5)M0;4JU&=7F5%M0+6N*N_G^HYPM>6S*8UL>&_/8FL<&.+;
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MHUJ=:@VJ-:G6HEJ;:AVJ=:G6HUJ?:@.J#:DVHMJ8:A.J3:DVH]J<:@NJ94W
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M\_;CVR/\P>MI'Q@T.BU7MES%<E7+U2Q7MUS#<DW+M2S7MES'<EW+]2S7M]S
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M-SB]P>T-CF]<?9^-S\,GX_.P<'S6+\YNSD[.2\M_+J].SZZ7?^@U:PL/M?E
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M+->T7,MR;<MU+->U7,]R?<L-+#>TW,AR8\M-+#>UW,QR<\LM+)=@[PWV\(E
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M6:YON8'EAI8;66YLN8GEII:;66YNN87ELJG4V^^FUL.#0/ D$#P*!,\"P<-
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M DQUD/?7E(J7"S5 N]V^_ U02P,$%     @ VH"P6C<^KV =!0  A"4  !D
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M5EUOVC 4_2M6-DVMM)$O E,'D6C3:7MH515U>YCV8)(+L>K$J6V@_/OY(V3
M0D8E\I#8SCWGYAP[]AVM&7\6.8!$KP4MQ=C)I:RN7%>D.118]%@%I7HS9[S
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MN2JN@.L ]7[.F-QV=(*F7(O_ %!+ P04    " #:@+!:--4WPZ$"  !@!P
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MX.K79K:K3@%SZ&[<:-4>ZVCOI]P&?9UFA9E'7S^9Y8W)_A,*,]A*N:N\S>U
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M* A)7\)AK8"Q=K3T)0)X2CE5N+T68 /&K@4'SJ)'D1\L??4TU"%]"1^O)_9
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M%5A%D!%:_N/G:A^. (JG&^!4 *<)\,X W K@-@'!&8!7 ;Q+%?P*X%\*""I
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MB_PHB4;YLT^^L:DOHO>$K8N:R[9S)8'.5209V.$CXV$@:--^=GND0M"J/=P
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M_V/;L]?;&T'3[.CO Q6"QMEE0/"2,%5!/G^D<@'D-ZJ!X@3\]%]02P,$%
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M]3V_H?MI>_<3%A;=APW=IP_O/JAWWP<:"RZ]@DO/X WNP/M=I"\@ 'P#8JZ
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MFK.*L.8'0Z"_U%6)+S6A'BOMP'7$E2D^Z!*(N0;7M;Y=#@U-V'<F0ZXLGU8
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MB Q.)TBAVJ;>&D;6KFNMI,$>Z*8EOH.@K /NKZ4TSX9MA/W+FOX#4$L#!!0
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MB\,/,.B)#%\N:F5_R6&(]1R2[Y06S0#&#!K>]D_V-/AP!/##5P!T -!+ <$
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M7&)G#-($X/VY$/IN8GJIOM?._P!02P,$%     @ VH"P6IAU;&#X!   H1,
M !D   !X;"]W;W)K<VAE971S+W-H965T.34N>&ULM5AM3^,X$/XKH^QJ!5(A
M=?H"E+92:5D=)[A%]%AT0OO!)&Z3VR3NV@ZE__[&3IJ^D%K;BN-#2>R99^89
MCR=C=^=<_)0A8PK>DCB5/2=4:M9Q7>F'+*'RE,]8BC,3+A*J\%5,73D3C 9&
M*8E=KUYONPF-4J??-6/WHM_EF8JCE-T+D%F24+&X8C&?]QSB+ <>HFFH](#;
M[\[HE(V9>IS="WQS2Y0@2E@J(YZ"8).>,R"=$3G3"D;B>\3F<NT9-)47SG_J
MEYN@Y]2U1RQFOM(0%/^]LB&+8XV$?OPJ0)W2IE9<?UZB?S7DD<P+E6S(XZ<H
M4&'/.7<@8!.:Q>J!S_]@!:&6QO-Y+,TOS O9N@-^)A5/"F7T((G2_#]]*P*Q
MIN"U=BAXA8*WI4 :.Q0:A4)CVT)SAT*S4&B:R.143!Q&5-%^5_ Y""V-:/K!
M!--H(_THU>L^5@)G(]13_>M?6:06< )CS*@@BQGP"3Q1(6BJ)-Q(F;$ :!K
MMTQ)A0]1.H6C$5,TBN4QZA6R\'S'DA<F?N#0XW@$1Y^/NZY"![49UR^<&>7.
M>#N<:< =3U4HX3H-6+"I[R*QDIVW9'?E60%'S#^%!JF!5_>:5?[8U>^H*-5;
M%G<:9; ;!J^Q V^?&#_?HC+<*);('Q6>7^66FM66=+7HR!GU6<_!<B"9>&5.
M_\LGTJY?5H7A@\ V@M(L@]*TH??_RG3>Z) \XJJ+>*'9CT.*EFH;$6%%\D5I
M,5V585>YL;8QIHO>:Q\7[X*TS[KNZSKE]W*D;OY*N0TVK9)-R\KFR10:%IS
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M)#2AY6-""52:2@#>KQF3AX%:H/EZ,OT?4$L#!!0    ( -J L%J(Q/X,$ 0
M  L1   9    >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;*U8VV[C-A#]%4)=
M%%F@B>X7I[8!WXH:R&*#.-M]9J2Q+:PDNB1E)W]?DE*TMFZ-6K_8(CGGS,SA
MB.9X?"+T!]L#</2:)AF;:'O.#_>ZSL(]I)C=D0-D8F5+:(JY&-*=S@X4<*1
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MQITO3@I:=-[%@).#:BU?"!>-JGK< XZ 2@.QOB6$OP^D@^K_C^D_4$L#!!0
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M7W BW^^JS3_7*Z4E+-QOMI*T#*&=P7S-5ZHB&9T[\+DJ*G?425__X<7XK:U
MORG9DW(%?;F"L>RIF31T]N=#5M0YXQM8Q5)"<5!%)1.Y=3FT":,FH6D\NS3
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M,OUO1A5R98D<R ! !B-"?@D<R#F G(\).7<@0P 9C@D9.I 1@(S&A(P<R!A
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M"V%,UT(17)"G[J%!3-="$;)01&ZA9_LI;5)R,9&%(F(+/8_91=3%1!:*R"=
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M\-$"   R.@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=N];J-
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M=^-+?K;\8_#V)U!+ 0(4 Q0    ( -J L%I&QTU(E0   ,T    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ VH"P6N&4
M"IKR    *P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ VH"P6IE<G",0!@  G"<  !,              ( !Y $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #:@+!:5PIGY:$(   5
M'   &               @($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ VH"P6LPH?2WW"0  J#$  !@              ("!_!
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( -J L%I,5='$
M_P,  %\0   8              " @2D;  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #:@+!:W-26NB()  "$+   &
M@(%>'P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ VH"P
M6G;BJEJ8#   2$T  !@              ("!MB@  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( -J L%KBIN770QX  ,N^ 0 8
M      " @80U  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #:@+!:@%DAA$X*   Z)P  &               @(']4P  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ VH"P6CK\@K;A$P  54\  !@
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M970Q,BYX;6Q02P$"% ,4    " #:@+!:V;F%^ZD.  "^0P  &0
M    @($<X0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M -J L%JX[F%)H@,    *   9              " @?SO  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ VH"P6KN)H',7!P  /1L  !D
M             ("!U?,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #:@+!:U2BX18H2  #%6   &0              @($C^P  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -J L%HTX..>! 0
M #X+   9              " @>0- 0!X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ VH"P6EVM6M%Z$@  TU(  !D              ("!
M'Q(! 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #:@+!:
M,"9 WF<$  !N#   &0              @('0) $ >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -J L%J5CAB') 0   4-   9
M      " @6XI 0!X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ VH"P6B[M3HP]"@  ;2L  !D              ("!R2T! 'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #:@+!:$C7"DWP#  !/"@
M&0              @($]. $ >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( -J L%H/<I+K<P4  - +   9              " @? [ 0!X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ VH"P6OT _8*
M!   S@L  !D              ("!FD$! 'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #:@+!:#+0,L%4]  !Z+0$ &0
M@(%11@$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -J
ML%I0D^%B+PD  "@:   9              " @=V# 0!X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ VH"P6A(P:H[5!0  R!   !D
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M=#,Q+GAM;%!+ 0(4 Q0    ( -J L%HOA@,5SP(  (0'   9
M  " @8>O 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MVH"P6F!#Z$2;$   MU   !D              ("!C;(! 'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " #:@+!:NQ$[(Q$$  #H"P  &0
M            @(%?PP$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( -J L%IV<67:%00  (,,   9              " @:?' 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ VH"P6HPG%HLQ P
MNPD  !D              ("!\\L! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " #:@+!:A#7G(X4#  "N"0  &0              @(%;
MSP$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -J L%I5
M(A^ZF04  * 1   9              " @1?3 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ VH"P6BHM=!JY @  U04  !D
M     ("!Y]@! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -J L%JDW9QA'0,  (0/   9              "
M@:@. @!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ VH"P
M6MG#;5"= P  *0\  !D              ("!_!$" 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " #:@+!:U86R5@4&   C'@  &0
M        @('0%0( >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( -J L%IV@QS()2P  *1V P 9              " @0P< @!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ VH"P6FX3D4NV"   !&$
M !D              ("!:$@" 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " #:@+!:G]$& 1,$   ;%@  &0              @(%540(
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( -J L%I\;GH7
M-0D  ')G   9              " @9]5 @!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ VH"P6C$FB$X%!@  *BH  !D
M ("!"U\" 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #:
M@+!:>NLT8%T%  #J(@  &0              @(%'90( >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( -J L%J_$V.0\ P  '9"   9
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M970U-RYX;6Q02P$"% ,4    " #:@+!:\Z8I0$P+   ,9P  &0
M    @($SIP( >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M -J L%J'.>5T,0,  /8*   9              " @;:R @!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ VH"P6JI,1V/2"@  V)P  !D
M             ("!'K8" 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " #:@+!:_$>F@C,#   C$   &0              @($GP0( >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( -J L%IPXTJUXB$
M $FM @ 9              " @9'$ @!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ VH"P6L-VA,>>!0  QA\  !D              ("!
MJN8" 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #:@+!:
M>XNC:$P#  "&#P  &0              @(%_[ ( >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( -J L%J'#J F[0(  #4/   9
M      " @0+P @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ VH"P6L=ER.#I"0  Z"L  !D              ("!)O," 'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #:@+!:1"WXR[ %  #M%P
M&0              @(%&_0( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    ( -J L%H@HH>QB (  /8'   9              " @2T# P!X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ VH"P6O0=U;&I
M P  I!0  !D              ("![ 4# 'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    " #:@+!:*5[R #D#  !W"P  &0
M@(',"0, >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( -J
ML%KA*;V4PVX  'I>"@ 9              " @3P- P!X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @ VH"P6CV&KU<&!0  @!,  !D
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M=#<V+GAM;%!+ 0(4 Q0    ( -J L%HN:'R#Y ,  'D2   9
M  " @4J2 P!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @
MVH"P6A-Q8FQ2 P  T@H  !D              ("!998# 'AL+W=O<FMS:&5E
M=',O<VAE970W."YX;6Q02P$"% ,4    " #:@+!:T.O7..0"  "Z"0  &0
M            @('NF0, >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4
M Q0    ( -J L%HTU3?#H0(  & '   9              " @0F= P!X;"]W
M;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ VH"P6@%,FD*(#P
M*@$! !D              ("!X9\# 'AL+W=O<FMS:&5E=',O<VAE970X,2YX
M;6Q02P$"% ,4    " #:@+!:D]$- YL-   06@  &0              @(&@
MKP, >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( -J L%KP
MNZT5G0,  "$/   9              " @7*] P!X;"]W;W)K<VAE971S+W-H
M965T.#,N>&UL4$L! A0#%     @ VH"P6G^1YI)W!0  %1@  !D
M     ("!1L$# 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -J L%K6%7#X@0(  &4'   9              "
M@9/D P!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ VH"P
M6@_\6US3"   'D8  !D              ("!2^<# 'AL+W=O<FMS:&5E=',O
M<VAE970Y,"YX;6Q02P$"% ,4    " #:@+!:\$/LKDH#   ,"P  &0
M        @(%5\ , >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0
M   ( -J L%HY71LE+P,  !,0   9              " @=;S P!X;"]W;W)K
M<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ VH"P6E*1.GSB$P  :)T
M !D              ("!//<# 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q0
M2P$"% ,4    " #:@+!:)[+\XCD#  !W"P  &0              @(%5"P0
M>&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( -J L%J8=6Q@
M^ 0  *$3   9              " @<4.! !X;"]W;W)K<VAE971S+W-H965T
M.34N>&UL4$L! A0#%     @ VH"P6ML7,6'C!   &"(  !D
M ("!]!,$ 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " #:
M@+!:>AGS]T@$  !)$0  &0              @($.&00 >&PO=V]R:W-H965T
M<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( -J L%J(Q/X,$ 0   L1   9
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M! !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #:@+!:M_K&\-$"   R.@
M&@              @ &-, 0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " #:@+!:%8LHOU0"   Y.   $P              @ &6,P0
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     :P!K &0=   ;-@0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0001213900-25-044880-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-044880-xbrl.zip
M4$L#!!0    ( -6 L%HV?#PV;"0  "+8 0 1    86)V8RTR,#(U,#,S,2YX
M<V3M7?MSVS;R__W^"GY],S?MM(Y?<=+DDM[(K\2I';M^Y-&;FPY%0A(2BE
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M^!E\<>EB5DX?[71OT8)IA=\1/&MJ+C=F>H["RV$49_@EDKDNZ([YVHE(N[M
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M'%,*^:L'A4?XD#]\8#LN=VB$:N&I5KMZI=IBN0?R 6X>;#A G1*H'9WGE(
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M#(0HY@(+%Z?0O!.K\R1)J"ONB6APT/==/Z)[5KO^NV.(B"0[*NGY;BJ76[)
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MFFGAO(B*P\CS6B]DYO=,1;B-G2FNXJ,N+QP4#R'O)42L-LT+9\/=(?>(>+(
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M5#8$RPM0E0)E<\'6219NTVELL&]!,C&C/_+E #6DR"_\B.<^G0U'*V\*BP:
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M9D6^Y K/[WS64_)X(&P<&L(@^@X!I,IKTR>WR@!_!-)J02-0W!'8:E"#)(Q
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M3(,3.4J0;(*6Q%0BZK5XF\1),S'0N9%+FLC.I00+D$[0ZF OGB,1U%9U$_M
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MTH9(&/^&AP%C0RZR>:KW=?HJ22N+I B4OIL?&G$E/((;F\2F9XA/0Y"R+,D
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MG_F^J+)09O>(0K\5('.X+BRSNNVU3[06%((LDXTH4:(Z;(!"W=HZ]:1V;)Y
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M).>I6M9D[&<:R/3E@6T,:N69_;3TXB>V6B>IEVYVT\CFCFG2WA0LS^8@@<H
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MO 8%B('2:M)?A6F66\]XR=?.DG"9SW;9^+7!*,9@W\5^\D\N\5[L;MYU[!M
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M^G2/P0.<&C[PLZ=TZHLZ4'G,Y4_U6FB!-*3LO.5";#IRQ0<H"GR'<<%%USE
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ME$L:TU4#C4H%L#11]8\%OT"4C[EB[F"K2MW&7]_:VT</4GW3AJ6K)&6\LU6
MN-].]?B>CURX3U6^J$_>9V0*322_RO/2"'KDDIOEP\)/:9BSN_G\8^Q'7K@K
M.M3XT0 +2@&:>3WK$PR<-M)_B#_A=O,^AE.A1)B3US3B):G#%Q#U?XKGF%(\
M![G:=81(#W4!34I3\GTJ%DJ^\:K*GFO86ZYE'L)*U'W$V9BUY-V8%(,QF.<
M@=::\39;O50(N!J,B<X,%7O$LC#F]':49#"0& 5A4*?MV>:)?TY0LP$BD8Y@
M;;4&VS7039X) !6_PHQ6O!!.4KP!(O$HQ5(4Q1P,9CJ(RS:8)$\\ ,GH=1Z
M1#JL^T!'(V4%B!NN@9!4?F@U[/2^8[#G='*TM' A\H4Z*\)(I/?AG6K^>+U:
MI\E+Y=Y(P@I,IDLSKB5?0##1*Y8W\C]X_I(K7.FFW642"E62)DB<$CC("Z>=
M.6C.;Z>,EJA^&>YNZI8$2:"BJC<M[25%J0.-L'$>7,J+G0X^_5EFF:*]6!5E
M=%/;9X__.6(E9'$P6PG[T._ESZ6=Q/8IP.K6*/=5Y3S 8X1*\Y2*Q*_/K13E
M]H4,>96W:UYK3TU* ^?=)WZF9\MP?<]2GW?,6[ LF5_RP[[RC6",R$UV:QVI
M<BE^8/DR"7;^&&8EL*ULA%K!]HG^MC*J\/T&X\:R#2^%;34PI5#"922U?9J3
MW6\#5:/II"2V;FB'/V7LUEN![:+@6N@6XLE.2PL;*62A'!9*M\$<9#8UG08R
MD6A%NC4"Z!0?;<ENC!70,*N#$=G"HQ>)4O<;PIVS*N#'HP]D'OT?__4_W[Y]
M\[]_^O#C7_[/__ZGORX^_QS_^=O@][^^+'[>Q!\OBD_O_YI^^]<?_OCOCT^;
M+/KKB__[U]'W^;O\D7W_^U__].OG;_R;_.M_75W]\?&'=R^?S\Y__OHE>$R?
M_W#GG]U][?_^[N+^O_/?_O;3TQ]>OGN_R=>;/[/?HN"W5?3OEY\_9'^8SW_X
M>OGC]T7\[B;Q@G\]W/WEPX___=/M.OGG/__Y(?SZ^C'\[P\_/RSGLX?S?_V6
M!-GJ9_;GU=HOO/6W+]]^_>['IVOV:?/SG\*OO_WF#W^<__@<_?O]3[,_)-<?
M5@_+[#Q>_.U?/UVSXB\/5ZOO?KLH?LS"?SY^=SW[[]_OWUW=;QZRXMM/Q;=/
M_\S^?/.7W__PX[__\_T#;_.W#__^R_/]7Q\>+A[F\Z?K]/R%8[7YXS<//W__
MX\OCSR^KOWW_^]J;_7CSI[_\^G+]L/KOW__TF/_K7S=_"Y^B^/[;W^?S=.G_
MX_^\.7]\>/O6RHWJ+.7T+5C,LC ["Y.<^<LXB9+%YCRYR4V*?X(:<I,/$;:#
M;QVD8)#@WN)+P2)^9+WTTE4M]3Q)UTGE:F% A+X5=[E<#)D  $)2_9:+^X[?
M[G[@T\". V4#DX%?#0-VZ$LI\BI)'QD[3^++#;.#7MV"HY1RAL!K4$ O\]BP
M?16F66X]XR5?.TM<8C[;9>/71HP8@WT7^\D_N<1[L;MYU[%O +7LV\GL*]+!
MZV,Y+.;U@SC*[2:UY%-7&94,898-'!"-8;-YW(0Y^]Y;>_$//YCM&X<?3FC+
MZ!FU-MK!*DMV[PVNQ\2+;'J$RW7H_SS(!FF +(DK5[_\71F_5KZ.HW#;+]EQ
M$!,!PQ*$83'ZE.\VE^(%)L^7K-F!'E@4LDS[6&,9YYB%0>BEF[NT;_,C>ZH!
MR[71KFZ2>/'$TE5K@FCAO6"Y%T9]SS>2DVNP$*J[B/RMQI3L[4$W'-#A+SAV
MF3%VZ5Y;(8K9V:;]&P)'=@/![IYJ4-=*-VD&'':JBJ>=3+\4?NT] HYC[E?X
ML9O/=QEMI-[KAX+0G=4E[#AT3L?FAL(E_8MX$M#O$.A/ :?' 'L.,!X!3B\
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M4%3?J5N>U20[AE2,PP2!T!MZ)R!!"A?982WJO3ZP%Q87(OB/YE#NE3&B71S
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M:%Y6FAMGO8_S(_B6:U,D)Z")Y(GR;02N/BV<%<'[PKG4_EPAR/3"Y4Y0Z3$
M59MU[I149Q24FF;203?"U8=#/:7$N?#(TI=0^#!D1$>O1-:4-"@@>OCU[DO5
M[5"J4.!8L+,X[!G9),HLI!VG9FT[S18$#Z2(N%7MBCH!ZP-;)VDN;C&/50X7
M]%H5<D$3/-I4L &"N8;:J,NDD.<I"\)<E)Q!+RRBEC7%G4^#'EWFMZ[EA]0^
M-DEB]O$!>=+3I&0[3Z)(6!FX*O/"9HN4E>^-5#G8NM)VSEY9?>.1_+I=^O4
M6+3W#L2N67DW*9F )W"#M.,@8QL%]3O/*0AV")G<;/,.5CZJ96)&<75(XG+@
M!&D]E+*HMDI86)+!_.ZFME3"I[]T69E&NK)(PH[Z95#IA; 4')"IVK%V].-$
M4@"]5Q9Z,)&4%;<I-5"(H8C!%(Z9NX0?E=@/+%\FP<[#Y?"GC EG3J0H\D'B
M'<=J&FZ*P]&&F#M,^9=)1 M(UPAP&)6.,?4;8G4P(CN$ZT6BQ+)#N',6T'X\
M^LC2%9U2;MKKEJ <FRKKXRG'YBG'YE'9.N78A+!V);!A-WPOX#MQ[L6+D&\
M5;&OLTT50!1Y&<4%W$0RX=%'NFL:H4M7/D;1C5TGS-10'*)[I3O.(6*Q(H"4
M]V--8@$P[ 7Z]FS%N=,=^[BT4^9X$L'(=_.689A@\^Z70621(]VB)6A!7ORL
MG(X.S/E>OP6?)D#64+KCK5@YDSM^1Z:H4@4!&G8$?=^U(MCIODO%,6R'-7YZ
M/ N3&[[15QF-#*)O^[YS^!YO%F';.VB*I L_%U[\GL66.9GD7T\HFED! ;;"
MH#@V?PKSY562/C+>C_AR8TF(;=L3HLL:/D (I3F9=[&?_).OUO7]TDM7WG7L
M&[ E_7@R^Y1\^/H81W.P'Q;6.Y7D4U=Y=V"O4EN890.G.!%*68]Y$83,)-E%
MSV=N7.IMX=T;,LG6?_;=#^?)!7MA4;(N-:]F^S+1:S1MN'/>M;QI[90>'3H4
MT_T\"782/0L^E VXC2H92H@:&S(+N<P;CR;GG5J84\5H ']0+"%*D=6=[2I,
ML[PL_7Q?I/[2RYC59@=I:,(['@@G"E5J^%5#?Z&8*"FP:P1NBHCS9+5*XG(:
M$.UR^^V[S*^B]&#M[EX'L) \WM1!=SL;-DTZ/HD4MTJ"Y5-EQPU:!A]1.;N;
M)%X\L735[)ABFH2E3]2',.+*/I]5V,\O()$N,RO2!#"8(8Y>MJ'<CWG_.8=%
M'(@'I8]K/O X%Z%)=5IFT&&E:^/U,0>#CL!>OXN2O9O7<K*/<2"2,0<]=SL0
M?:9MNCS<2 DU!A<Y;US9B>LL*T3NI;MY>3+WY(B3T-C[H=,;%BE9_3AIM7D[
M_3'+[^;ODR0HDWI4YW'VF$0!NB(I%?3Z]E (NMKK@-69MSU5FT7^D&R\*-_L
MUC]HP0&:<9JHFW#Q01 $9(>S]<PM\U5?\>&66;%X;\4#59,9_CKVHR((XX50
ML_G_!4_>9^1U:M.#U[N K?C0IK&SMF\>.]NJ+LWJ:Z4=F(=5E9S.XKK"\C)G
M_7V:B.PQ9ANV]./7NDW+T0(DEK/,VU(?"%=)*EZY0S]<>U5N"N\YC#BR^-E;
M !)?]4($0:Y-.6>S&F=!4 )I:C#H^^ZUKL%>C&AR%S2BO.C>"X-K+G(=YE[4
MLO,B+SV P%=(JPG<H!QSMFH.@3+SFOGJ9EQ"#^XL&1=6"19<%*G(",72, E*
M;>B6?2I_@Y_U!2+S-1KL#%$GRE)7Y@7-*O'W:>@S+KW\&3;/4CFO6K-1P(N?
MPJX\K=N^;<VSS"XI $BYT33Q*@D#80?(=6?,U_[CZ&44+L)2Z]W,5B(S'X@R
M?2MN7Y%):0- V#"'9ZWI6A$?V**(Q+_:--5@2\'55FYFBU4W]8IIA(+9<*FT
MRPQ(T[6?2.7N4\S2;!FN9<8:I,1=$+FOUP9K@'TS >2V'SNO$=Y3/N$(BNUT
MFG[-NFP7PX8GA<G&>,?]*4E_%<5$FILJGREI+ER2A&A#:RJTK5=XHS3#LO$2
MP#7VW'-N6)JRH+P!M<17?Q21JJ7*C&UMA8I]E7JN.?@-^<A%!OKW^TQ[V +N
M+)KF7N,&; QIPRJZ$:E,UO[ ,L91$<4.6P$[- 5<  )?X09N G?#M3*/$:+!
ML#)ZE+]\7/-;V)%LAH=B7_4.#@>_X1^_6,)9D?$N9MEYLGH.X_+-3CA0\,XP
M41PZSD(NV:M WP%POA1_O(ZK:]W=7/:)<#+'+@U\C!Z_XNWF*(0W\U7I>&65
MB,G[S 02-URQB?&KL!PT_WIOZX=(-J3AEO7D:NJZL@%=,9;=Q;/@1;C,9K<,
MNWB82M)KU!A!"#>D*DQM0Q^="-^97C5O70P;HA3N4%9$>5'CGD[Z."@3\XI/
M4CFT#9>XGDXZZSK*(\6K7'% ^)K #;04=E7ND=(M/629H3VD[[M7N)KD&#5T
MX&2LK^24E>/K6JJP$IA[G[Q:!O:0:<"76Y>,P:\T3>&$;Q0:V//9*WY"[0.I
MX0(_BW5?K$3CLKLAJ[ .E?H*UYHQ\ WW2LN/14ZDUJ5=>(Y>):G9JE2W\ J9
M@^#6D"4W>UB[MWO1?KS;=7SH?ZOQ=9<V\FJ5/CU\#6=*OR*;O?6B?IZK0].V
M__&311S^S@)LNZA>WNL\-@WP;KA6^1V9AX/5A:DKS:G1HT#K4O+IJUV-,J@:
M7I2A8(/R5-2/:GP0(C2"_R+T(CXI0"Q!VGF5[U1P%!L",?V$MIJPL&J:W13*
M+U[G;M<'39.A "\M3TM-;;Q*+M@SP3V@T_JK7$12*!O6M%XY^&77[]-DS?NR
M\>) >)Q4V3_CH'Q($'^><ZU6O.3-?/[;K!2@+<EN]S94]>,^\N)\UNK, 9)H
M3T1:@78ID:P!A5=6'RJ#<#^4EEV'$[P[;X9"B5!HW6@"G&H0#ZHQA+1T<.L3
MX[C)GJH3GZH3GZH3.ZA.+$0^" T-:7_=M>6T'!OR5ME"")0BP(X">*)=" E'
MK;$EV=<.9E8'4*+,N'OMHVP_^X@ZVF@@>))L$8^YEY<ZX7N6+%)OO0Q]+\)2
MR:1MOS)]2XZA/LN%,6&5YMX6A:9'R=MVJ4+I9NB6!CDR!!N15!K*MJ1APIU"
M-)@,]%U,>\\^VSSQSPFJU4(DTMGSCK[5&0%-5W5<*EX()ZDT#I%(:+<%U;0U
MF/T@+MM@DE2C $A&+V,+)-+!WDI/(T5I<%_XC*:;7YY^4A"5,?\_%LG+N_H?
M5SS5?]E1U&K*@>,,2+$2@+='3+(LA'<-_[Y\3+F..:^+E&4TE5J4HMR^'!KL
M\7OO2PKP2/BZX8<I"3NMAIV^"5I2T<8%L.V8:M\?O,_AJEBA&5:Z[3D!7&(M
M:A3JO1%C5YHO1?"!HH+::6^4H'9'3%(.]5_+)%XLB]"@ZMS>)XX.1,/ZLOOC
M1*^3M'-R6Z?,#TO_4^1-M].T2Q<TLT?C?F2PMPAMW]ZG27:T.W8E;)Q'HY(D
M'7RXU:KZ O5:WFS;K"JS><[2EB,/,HW&XD>J?RJ9-<<8O3#MOB/PD_>YJG(H
M'1'Z#@H6/,7]%8XJH)[M*;OC*%@US]FH"D2RX?3*"],R4_;=O)I7I34V14\K
M()<SP7-4 9J^Y)6=:69;4*!.-MCX\&<L?6$B#NJJR(N4-27QT.TUIO(=AJ#9
M<6H!L;: E75J#XJTC:V&)[CDVK#HRTKAF3\I+A8J2=/33)2X08I,V=H^1?8D
M_I_KU3I-7JI@ 0)#:)^4*=X0I(A!RD*A5T-IO?D>LR!*1^P4=T$PI'I7:H*,
ME<=GM4?NU.X !HB2E9+ZPHO8#%!)U*5I5-85DM"RPZ(KF39TS';.%,]9&(1>
MNKE+^^SU!]AAS2&P7*LL.5( X:%BNC:(=BAI&)@Q4[M(5QT:QX[VVFV:M3-@
M-1Y^>5LG<1DNBN]KIY9%==&%^=@!IVOWO%%"!U <[&V'6V$DSG+],NB]JA2^
M<:!Y>F@1/,")Q(&D5Q:ZYYN4%2>>Q+C$4'BVG0):C[4CX@6LHI)_BED]Q:R>
M8E:/'+-:[AUG87(5IEE^GJ3KI,HR9^ Z)?_:F?^9H1^58ORH"DB5\G3!8M:2
ME"]9^2,#Q#5-3 5V'1(D$_TFS-GWWMJ+?_C!;(X??C@5G/M'K76$,;<A%'X8
M>.'J/+G)>SVT97:#GN^FX8#9.V*(&XK]U+VWF+7W$YVP]WN0RIU !CH7$ 5[
M[+?O\I%3:8B0. 30'8([#Y^6N,P@/[JR ;?OE/9F1S4J5,[%I_=*;#+MGRVQ
MN3V501I$(*C&$?*AU%11K=V:J]5?IW'$3]^LES?!S=0 3+VR-E"UJ-^S"][I
M5.2#IE,R#B1-=MDIX:/6!0EKC,FD3'J)28 C=PBNQ-T5>2:R:_##E9JLMJC7
MQ%@'0JUOKQ5M71__X,R+Q#':I^X/IDTI:L*TJ2&D<0VN:U9D3TGMZ'\=YXS+
MRZ_C[Q,.P(_\EP6ZLQ14JD-7^V%*)115@!,QB3-5*V?X;9*SC'?8*_.':QVJ
M[.+FGO.=HG: '%J07+\46W.<&B.XSQ2D';H+L-1U2D-*NS*1'@8,9ZEAWE+G
MD9=E]1V TE/J0([K7&0&T[375^H0."(_J;8@$B>I'@'.TKF"YV=';^M!B,HD
M>"@+W3U*PL<87*/LV(#Y1)WR29ON2>8YHT\)HT\)HY'W"&<)H]LW#L:U]#B_
M?*DS@5$H,A(IA/.85H^1H08)5+$/#]D32:+/R.6XSHNJF:H:?JA5&ZE(= U'
MR9!+/0>!'WQEIQ'YP"*NA@7W7IIOVE7.SC;MWQ#L?0:"';MZ6VZ&)LB"<DD/
MI9=D7^P1X/R>9SZG9;R1QL4<"D+?$R7L.-P-L;FA"(W1]/5XF^'KV_VZVQU:
MN7N-5/*=[U#6$9:9^0X(658]L.EU0W2N2'?"?K;&N"U:$0;=$BU3."1I+@+?
MQ),%U;6X5\:4C&@:M!IV%-X:..307(4E4ISK?<JYJ:3%Y!:,R0S^)5C!C<L[
M\$!F@%O:@+>7GSQ1[3N_2Q_"Q3(GV-3D<B;Z:*D KJ$*V:VI5R+EZV6O)$=Q
MR^#YJN6(*#(9()/J55/.D]-=#XLJLE<.L<E>EVD5Q3LLP:;7(V"J;QM]6#6D
M*/P +1=15YI96@9K?O8"_-WM<?)Y*6>$,.>"3B#ZMJ:DQ>F6-HP9VOJ^CSZ+
MO31,L&O[=MJ=VO:E0*AA BUK;I6;HQ+Q,<[6S _G(0OPBO=*VW:92T8U_7;I
M?Z2H4)2YDHK#J=RKIL%]Y5XK)NB>6+^LP'>Y9^G0J'<+M_&;, [>1\FS%UT5
M<7!]?6.2SD'ZL<M("+6%;Y<I0SIP7&/^5EA];S&$M_N5TP!* V#WQDIF:Y<<
M]52E4A6RQCWC@7BAEZ(J)\1=OF2I 5.2U0!H9MPD@,' #0$_E4J%'9WFH)Y*
MI1*42JV/#K&,+L*LK+5ML$G(OW::M 5@E]_N$ H H)K)J,=GJ1]8Z5R61XWD
MTQ%<&L (VQ[O]C#;X#N&M0GRB#K$ENID*:4\,C^)@T:6 ;*]'XX&7@FF_:,E
M,E'O>9"37!7Z95 YV<.R RA#0!0N]I0:5&-JNDI2YGN9 1E  ]Q>PXYR>&HM
MOONFMWT\1GONZQ[A;*X]^@4_WF%J3E[*M^D6N-?S;4*Q,K/?]?]M[\J:&[F1
M]'^9'[ .[_/L W6Y-:,6%9+LWIVWZB)$8DQ5R76HI?GU"U056 =Q)% )HF S
MPN%0DP02^!)()!)Y9-<?*>'JPT-!LY2^)7MD@3=K*$&/)T!>"1R\O01(B,PM
M3& \%.2=YO6P4!DRDPW$8F&C"3,O>W58U+9?./V(F[)EMUE:D*3T63/83#L6
M-EHBZB4WIK9B8/LY6V5/I'AG8SEI(<9CXN&T3PNFV@+J*5FF[*Y]_4&*E)9M
MZ>/#EV7W;8F>!M5I#&'3R=GL7C>(C:DV'2^%ASKRJ\V_ZRZIW8$^,F?UM (K
M\T#V&? RI]IT>D?JTT)VR097K]PZ"GL]4C5>-N"&B>,FQYRD?%^_K-C0V!\6
M,*M;+UVO,$W>G-!R'M:72;EC_WZE]:LUTL.VBS\"]#,WIIB<!?)@)QVN9HZK
M6]-5?"S0X6(L2^]RX/Y",K:[]MPJS/XH+Y,W6C&2:7K,B]D'KI[6LN4_$"]S
M#D07)G4'^D@M\W1'U9):_'Z" 0:J4>D8*)X2^LX-CM]HM;M]?:LKLA%)?&\2
MN:*$$# .HQK'#@-C:,[4Y5@7Y844!=D8+!K8-CTHV:6K;_8X C(*S;?*/Y(-
M>7VK!-7AF3LY:/DOR2MZA8?9PXEC]\Y'W9QQQ6TUM*N1ESDC69FTZ!7<Q8H/
MM!$U3.UZIYLZV8_.#?1UX#R0:([?.6!#$DZXW/#J(MVQT[_3#+B#*.RF(6FW
M[)VHGBX@UAWW_7,BZK%-LW"Z4=C<+6"$1/,Z;Y&&B,UE7-(NHBTRFBXDT'#F
M^_ C>>LH>[-LFZA%L1V,D E>J0TB#IM@O EEYAC0G@!T$\$6@8 AWG-]1+#W
M8SSX=?3#Z5^EUHV&V3U+^CADW,81VE'*XMAQ!%KP'CV=I<Q^<T5.9O ZD(I&
MX]8#)OB$%T\FZ J[S/4'5_1)XUV(S" IB5BL(')\!#_0:XM*W3JQ'2(45*+9
M*TJ8!%NT7@WV*@6C5U+6<WL-ANO5LG81* W2Z0IHL=-(CC64XUL]\AWS</V/
M8J'+P!&,T-D YCHK9%F=[$7(W&-2P>K=&;I8NL0'P2#0UV;AFIVTLQ_%!4FX
M\]X-_>B?4(X9@IO*$T ]$LW8&E3!7K0T11(?VX>D6!=-_IC6QYV-J_'*1#_E
MS127OB6MT!.\TU@3W)X3\Y2037G#!L_O3=QI;/W"!X_^@*@D%(>Y1P.4\"[&
MMC$P[83I@?]I-)66EA#7#P4Y=@";S2,SO6AT"P!T@FOX;A:36Y6'W22CL&S=
M6XN-8 6.JT2CZCP7";<$7B6?$^NU0KT;_G[1 NEX=@(];<DCMWLA2>N*OA,P
MBM,V2S^"Y1,5@**'#TBC&>YK/H7URQ,;0\'P(>5ELM^3S<7G-+ !6X>:.9IH
M#H/9L(L%87STQR]I?U#R[_(D*P&5[-WB6@BWB.R_Y*^$T[E(LM]7FW>NXY1'
MR&*%MT!(NDA^*6+PNO::YI[.!64M>QNN]$DR--/'J&?OYG=Z+HUH2$9L7K5S
M*R+BEV(YET0\ET0\ET3$,(GR3#M_C?)?=G+.4/7+/U/.9;_.9;^6(-D67/;K
M+UGZQDZ,Z2K>X(8'G:O=G*O=G*O=  V<2;5+/G]E6) -OUM;I,]4-(TA[;YJ
MUN@G=TOM^>+2%MMQDPARM4\GB5O\I,^+V <EV:;#/VH9,,>H30+\XQE[R4T\
MH?6\HT5[#73'^:B/Z! _1L&<1<M%0@SD$5>F5MN"--9(1W$LZR,<]H"LQD8
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M>)F\T2K9>]Q:$F+1<,D$6L<J33UO=8K0O__$R?$LV_QG_P]02P,$%     @
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MR?R9N+'L2$C'YSF>=*89QI2^A?/A?)_2YE9%8V?^!IZJYYX)#HYC78V05/
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MTT5 Z/VFGU4RP^PJ:,-=Q)GC^V%O=5:$P9&YK@(1Y 5E$"TE05(VTF'E2\=
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M7[4R52"&B=14_<"K;5(TDV.-'Q;,UE 2G.%9G'=!'$1)5#>A;.I>*PZ$FY&
M]I<>MYI*'DID,+*Z:K_5'7[<1_2K0U4/D<VL411&<2KG0J2&ERC%I1I,3O-J
M=&6X53TUC\O#@+DKE7C8=UD.T\6T81+UOV1DT@FR13M3N\]&;H,7O7IPG4\@
M81U]+G3#-X[68MEKJV .'J,@=.:E>.>% >3=69>:IV:*N=NM9YD0*X'<N,F<
M='Y--YSJ7&ZOS8I8*?4__7+4D<EO9B/FHQ?#*6=-/@JZ-<FI,R9V&&]PFN*
MO8:WH!3_I &FK'>&;;^>*E@(YYXB;@*YO B_LJ2LZENT8_U36%O>&788TA6
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M]S7;PM7:,CH3BN@XD=18JSMYDG$RM=K\UFV(\M!%*?XOTUOB3:-RF]^J#8_
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M4,J^Q2D4QDA0Q8:@9-E]!XKQK'@":>D\/!Y+PK$GJ_GQ_#ORO_+!'CSV0KF
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MTQ_NR)EN9)\-ZR-"76Z2K/PNV>SQ.YQ4^Y*J_2$T*_=Y0SNUG%>F$3@8CR@
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MHX6(<45:O4,:9%0_HJ3 NS"TF_9NI<$XFR8K;K*RJFE9B@?"NC4QHT89-BZ
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MQQYP#L<.V&U$-7M7Y+76\*'?HQT;@%9D! W=W<*8J,>Q#I$!>\P8Q[@U[X@
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MI:3J(R9!T\[[25H\$3=JC*0:C2$7#-B&5@BZ02@.V;#WO7B<33LDNI6C16;
M @O:P8\GFO:Z6"?Y F]W19F4A]OM+LE*&BUVNL#\ J8A^C:Q36LQ$<J:F2)J
M;1X$&#+3EWCA]3<IA)/'^K56@+V0F!S1*J(BH^\U#49#[AA1CZ')22L2._\
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MWX-J.]>?8$_C:KXE*\Q^I2/,;4RN]F73C)["><N\2IA#@N"N!A0O'!'9!G?
M=L@R9Q+%>..$Q5&'$.$&E%.CRY$Z_&JSF>A(YM5#*1TK:GMTFJA.@&%&]-3L
M<J!(E(.P65LJ+XXMZRJK6/([GE?7V]VF.& LW[3.>9?D;$P;6"BI$.;0.G[A
MJ%[:8^A@X/AHJD;=N8I5"],1,@%HHQ&BO+-,8)/JRES[;8IB\TC%RC>]98 4
M.="3XK\>=S_.VV@8YZ[5K5;9GAU,-UI2"KYNLT)\3@*Y-M"PLWTB@-/ ? X^
MHAYU*@KY28H_[2-8)N,18/7(NBCHFF4,^@&IY*?IP-T1G]U ?"9VL/A1Z90B
MI.; ;^0 :L]1?GQJ5<I;XUDCWT;\"HJ;K7TJ<IQ(4G1T#NZ(4Z^>ON7XB[E*
M3KX3+C9VDOP?1YTQ$Y&:$>1QE9O1E)^0B6/&P?V(:<JI5;UZ:F8]QW;V_":$
M:/S),X[ZTS&*S.N_R_+T\OV))0: HLOWOSDA8<0XC6#(A)WN63(L(2G6#UU3
M]QMHWL>3-ATO)%&[HBXZ0J*OS]F*S;*9$E5LSJDXT$Y$PI&2Y<VDB1T^]&_C
MO#(C_#$3$Q0+\EXBX43(J1TVK?22E2_W=?:*76J_MB4_VZ,#A(!!T)9UG1;O
MS:C[\=Z%C-%X+Q<=MKT MQ<&._J;JT,NTCR)7LI:U-2<TQ,ACK="M9[;?)Z^
MPK7B=NH:& ,.TH3!FB2/&DS=F=4C3HS=M"@3B(:[2@[Z4HKL$Y22;^+>>])B
M!T0>(!)!*?F0E_@EJVI<XI0&$I+SU/RP*X_@=89WN!P^YX:FM!Z3 >%M2$?@
M YSX"7.R7.$5+LG*%LDGVO2C.F%G\5<Q#>O8QR9"=?*)=5R)ZK3P(,& H][D
M"__"TFW&1!235US6V?,&WQ5)[EN/M->:"G0] 0YM"+R(^] 1SP$+O>@3X][I
M+I"(6;;,M);9]ST&I>SSZ!6%E$A8>-%!-<+9^'V9U<266WW(EYLDV^)TOER6
MQ  0'='9L6WN:/,18) ?5F@OH, 1"6":+O&1J_O:T1SRR9$R,;9+Z5YKN6U]
MV+9$C!<EH%CX@/!:Y*(HQ$GV,<DO,80XD\VZ*ZJLOLV)(@!Z^F51[@H62/D.
MP^.[OEHF0$%+!H8<6!0.Y.@R0.2.:2!%/,#\D!WJW"-H%4,M?[K!*3Z&G1^>
MT(J!<&9E!)W=&<VA#N])H1,_<W<PDCEW7Z]Q"2W$[G/<SJ^ZG.B7"#Y%Y%O$
M/HZWL88+']!<A]O)E6D5=??5VY<DV;%%S)EU4STD!ZA?.L_[-U^F5PH8W04$
MQ$'0HM <")*@Q#&(O)&5>3624F>XNK2[I*E+>X/UC&H+^,)74=TXG?4.]H4"
MFR!;@DY^\?6WE\65HANV^7Z@PY T3JJ2W#^*@I/;@M.  4XT./TU;CJFKI,2
M$L\JX5JZRC;[FCF[OU2P0WR.R/>L@-L,\2$Q%&$+%JK3QHAP6-H+%Y FD?#[
MK%[?YFGVFJ7[9..46B\@ZNON?21 40MUA@1<1 %'TK*.IXB*U<?2-[0TE-EK
M J^!SI[4=L0,L3'H1_Y?&(SHZ'_'W)AZI-0,,Y,@Y-5_Y NNLO0@?8)C,!$#
MBAA45F %M7!1 QC)D&._SDWC=3RL#GB1%3=96=GTE*Q ]+,):"6=!0^5$ 4^
M(>G)7.:5U3/0?M<G:6B"]E<\(*D:I;#7AYR-"Z]+SS4\M(%-]5#B;;;75GN0
M!X(+&H8B,19]QD>_B6M@6K%372>.) G+)]/9)S(SZ3=-PUG"+7/VLNI&F8F:
M70(FRTU'3>M= !O%BW,4(51L/H*B85CO\0:BLKGH2$2&HF;LP ,4V>]PMC>A
M+^.X>QK#W.[S:3Z=AN.G68[>^]-#+JA7=)[^M*]J6C%L4<S3E";L))N')$MO
M<_Z.*^UG$3E]653Z9!@))L2JMU 1@(7@-@YXAN3S<H::1#T*/NIA> Q=E%??
MT70.YQE<K/$W&6%HU7'7ZR(:V:>3>(H8+GSXCJ?!+1QU'\A=6+(;L14*W;%&
M/Q8V:?MY/!(K5S^@L@''P$HXC>1Z3Y!BS4VU1Q;];H;:+V/='KJ5*P\5)7:!
M+FBQ"-8O$AA\FR^++;[-(3ZRTI*Z_1ZQ 3,DAD0]\75XJ AOQCG DW'WJ<Y1
MR/D#IE[4HSU4.LBZ =/  M]VRWS"+R #CW@'=FW^<INSBF_D:K\X\#]:G<9R
M#U(^!C40D01R!F7RQ1<_TOZ;2J]R'.-Q'%&4YN,Q] VJ//..V3=%B;.7?)%\
MXI78+G".5_H83SX,\7&(#$1\)/J,CWT3^>''@IJ*;T[4"+Q7[W<80GKREZ9&
MWG-%"WIJST@Q0'"D0C^*,?^.K1-HL5$>F&;4 UN92H-';T#J+,;8'- @HK;X
M##B'U8(?RF*)<5K=$%PZE3ZU20-\  +L$1WR%L907W1L'FBQ47'!@GHXLT]7
M8?@.)Q6&18GM^;FU5#D'@1H8B )!E$,-F(BY LZH#IV0GE0*%9U)-O,=KJRW
M!_D,P7<-%Z+Z('N+'A!;B=2I\VF-FO1^M]M0SV>RN4RJ]<VF^"CI>#9JR\,1
MC$< 0%:9)W1W.^*J5(A]R!30^#1&#2A;6AA[0%:-'YB_E-'?ONWU(VW#A68H
M61&S6S12VI=XLL]G:FKXOIV9:!I4G3NV'\]WN((S/J>5JY?DQT4!O^(17S3<
M6/0\<FN1)$N*-M+N^:"6*%C8C+>WK8CPT<71L&ZQ/'C%@%\WP7FPQ!G2-F:*
M?M;$XH]2HN,*2] 0M=,W4FJZ6@]Q4SU-LVZ+YVOUW"QG*B(?F.X#'2HTR^,9
MCDW0'T'5;+YWK4=IG,J*CVQ #K&R69$Z.@2]@=_C&C1!LJ[7+,7IQ>$#E9?&
MYS-?UMDKS=&Q*=%4;Q9PX([\#$"A+'^#6E\8!W> IYKE9D]KI-#0+2@4 6$O
M_%.UQAV!Q?[T4;%]+)7#>16XG2S"!3I%2;3)[=Q]T$1;T%%M DG$2%D3.D/S
MU8I[6*6X?;8 '7Y=;%)<5NQTA]Q'4<3TOGP$'T?E]S D@615'L7M#*!G2 !'
M18D8>/,+4>0G(C\"61Z)QE [J)=#J2*PRY^HM>1$);=^]DJC('F:A8N=H["(
MC<DF$[)$C+B[VQ .) P>"[$LP5-YA=E_;_.'$N^2K&G11%^Q]9$1;!3Z3(Q_
M T\?'$3S($5L58 2V\ATPU4=/>%.I;#Z+J\!2XO849>4U$55=YVR,>R$YCXK
M8%$[,*I7RH21\A'72H& (=IW&3G/4W*B?U6P7HQ+7,)^?R3V/S'W!\__ZL!@
M#@-1((A#000,DN!(1V:\AQ,?? ?JD#^QH@6*654?*4;LQ\G<98KUFV/#ACI'
MD%UCKE*HVB.=THP]:R!2(8O3EF8,'7;:ME2Q=6N=\4>/N$\7TG*UZE<''4E_
M+KIK)/].ZJ)4"6:KL]\559/OWS? UR5>L0%OO_S\RS]__J<_??&'3U7Z7RX@
M MY-YI4 E4PFW?T*P;!VFRE>C(-[49W8TWH^[00(<.)59?T_[[(\V^ZWYE0%
M_A'ZD7T6Q3LU6*Q,5 TFH6X-D87,"S97KMG5XOMAFG6\1.LN#@/)-:$:\/D<
MHI#:1&5>N!3\B^(E0#YVO]#7G'BN40MFAAI TL.-L$L&ETVDHB(^B*LNI#&D
M"ZSM<O<,9'O13F%8], "'T4-SYGDMSN1%Z-\1N$0: X=@]'TPIS1=&$(@8!G
M:@$IKG[LCK'RB<637B$]>))1+-47;@60*IS"JZ$OGR#["20X,VG[,NV;/K-0
M8+&CP'T0M[@37"D7+223M:GM=IN2O!^VA[1!>"9O>TM4/<%Z=@9+,%5Q@I&C
M-1VI,+A4CR%FX*-Y =*V+P]<+&&!EC17/J#=O)2? U4RQA;5(J/:CA;, P>1
M2='8;3GD"YQ V-M-]HD&0-"TNL>D-H1^=8+39T@J>,]A(0JLR3)$ "[VLX@7
M[FJ;? 3Y0ER:'GU@]#6YY*'"Q  .(CXZ?D^R<_3%"5M'J]=&1MEZF_?#@6^B
M57OR:(43VL]W66S(;VC5Z%<L/<3:"FE)H[KOMX,;)9;>9\)+K>C9*1'T>H$.
M?K38I/XM2QV[)BIV=A[T)O.>9T%+:5FY4"*V=2SNJMO\FR++Z^_('_>EOJF-
MPC1NKO<L1Q0&XD!B;R9'7)V,8A.90GD*+]<97CT1];W&+]GR?K4B)EQI.?%@
M"&K&(#YH"CY# S:#V\:*>2@6F!K8PB97]:_57O)-'""Q5"5P2'980)(-:D$B
M 3.:4C"* @.&'D''<&X*NA(:_-1D<DMU%%E^D%F;9@%C34)[I\ D&Q^]S:L%
M/[5"[42425239+>N/H%+_T#<),6)]^(CLN*FE!=GHHC2WAU+V) F%8UCHRR!
M-O5%_D(XL6T#0GJ5:]0%OP0$>N0*&$@"$KERCR>B@YWK2Z. +W*#X+?YOEX7
M9?:K/HI#%?V'VF'3\=_W$;)XZ]7XAWQT896U%LDGQ^+[['LHIN-4>S]6S*P2
M)Q4SS/@'V!4ISO[G.J]I<IK4^.L)H@DOH6AS>;@L4JV-QH:BSE@H^ GYLE29
MI! 0@(AE #AB*'/'BRBAC6J%H6\_P70>#_4A-A6?A_D@<Z%$4&_4(W[%^1XW
M^8/)DG8[N=Q7-=GD99-5!P7NR/^')L0Z#8&#DI(K"3#61D: D]/T!$0X&&-F
MY(V@@(JSHPD9ND@@)DH,.25XET%11%N?V<._1WQ 4TC\$)-I.BR4"KH1XX!:
M'$L">X?)=D];O;(MQR653M'>72RWCL&0=.^97,Q:@A/5)>R!KXIOWN0*:U"+
M9H2]UH.73J5.AVT99^AR&O5]S7BI&.5"B:"7&CR^06/(3K](]K )J:?F5,:F
MCV8[P*RO1XFM<$!0'6?A3)F0)E63N$[+J?4B=D0K%H@6X/$$.A6D+0Q  <W0
M(/:I:5<#T)J8C.A[SA-_Y2X<1<. B0G<89W87Z'%=Q-HY]19\?#=18E20)H^
M%%5=XCHKJ8N5;&SX!::M;&B-%U;AUA(SWP5"$Q"[8)" $[V1@A>^0P^?/[5"
MGH*:PJQFYO5*TKYM2]).)FC#B)?J*',@1$"UG6LV3\DF*>T*GE#MQ.<JO2X&
M#Y1(*(EO0#?D;M#4N+G)\B1?GJJ24 /M/Z:2D($^*FZ/I7+8<O8%K:/!R/^8
M53]?EIB<$/"308EHAR#XDFQ$.HK_P\43'^5A1(NJ^F'$0IF0.]::_#3?@@[Z
MA4Y[=\P88U#B]BIV0U3%,3\B!0SF:+)FV0*N]GA1/.(-,1C2AZ2$$X#6;;+6
MM9!3B1DH1&"A18$X-,3!H7X=J+BQT[[X#R,_QE&PZ_]U3UK_D"?DEH)B?T6>
M0J )_%"1TRR%"9]$:8U*58CJBNBYRZSVRG _Y7P!+:03+EN3.]_,@)HID#P'
M:B>AD6S2-*)6&I]H&M79SR!84C6,TW(C9%'Q\Y0+E@*>>SX;46Z5IB)&+S M
MK5/A5A-K96FB45^&HK))^?XT <$)_,BHL2K8*\ZI;+<&VG^,[6:@CX?M9J5R
M$*42XE'F1)13$.<KW.27:?TFXELD?1S'9Z);>C_<1H]>T-KNAL8,IC!R&GNB
MBB,WAVRK6LBS2NO(%J_/PG?4 ?L1JPN=FGY#P^ \' I9[Q RZ!Z@*7B1W^SS
ME"#PCARN:VUM0_@>\0$(1M""4G1,W.[G&D0&/#-C/(WK5.&DNV17'OE=<^5I
MNZ%[ND5;T.UU&OMEX3C"'.</U9,Z6#*[2^<O7=>OX#O/U/!+V>TK" G504;5
M_<><V)WK;-<6,-"==;J0+&+L"R!2Z8=H;]GNB ZXXTNCD$9Y]I)GJVP)E9A8
M- M<K^#2!V^;M9!].QJUPY$8/Z$2KVYX*JU/#PH%U"ADF8)<FT4GU\9MK\$X
MUENR'1E/CS1C9-Q4.@(<6<RTZWN^7RW6&#P027Z R.3OU\5V429Y1<Y<N+M&
MECL=.4FX@B]'KM2A8&K_78/\BL!&'#@"Z C (QG^-'R]IQ(6Q2/($>0.&\@+
MR@?&W?"Y)DA<%#JXVN,?<%(NR*[0:@(,T P-HA ;:#/PISYC&JDS0P 048AQ
M+Q=O JCNF9%4#*@K/.(ZR7*<7B<E=.ZMR'6XW^ZID/*G!9V>($8B,11])@T6
MKS=O(N=4VO%3\<V5*@$918.3X:PH\1HL\%?,4@ZAG/--46*BT;"HI.5!.D+F
M>4K_M6'N]?2G/;M*B45'#A^6;:./R.],AWC*YF<PXYL9XI,B,:M\D-/G$FEB
MU,X\0V1N:)(D9SC%D8WSD%0E3^=D7F"W"X1JM'$9CSC%6^KC%67\N=%SOR*_
MR)?9+MFPAW_X$F_UB8TTSD6.:&E!BS*K4JU (C\-?!%0(6:80+WD8PBDBX\Y
MGN@!3ROW7GPG<LZINA_^AIQSCH3Q<,YYD3IH0#=/L"'J#VT'G*?#+"EXI]P4
MU;[$5G=%DYG$X=&K1Y%*AEJ8.A=&K!CD,>102<)1E(W5?5$NC.K79+%;2G;2
M'1252"H=4TZ$";E=Y6:ZDO5Z@&7IBQ3(+85E3\"!\BIFE($)'Q5'[/B'-<PE
M4T2G55IR8^XO;]&\9EV1Z98AYC=!25/1-,Z1Z(:BYA#TH4_0H(1F<S_L2WCA
MKN^(^D861B[IEQ)CIMO1I3=1%&UP[)UC>+& C1K@J('>[,4VL$0^->]Z\<;Q
M'&]C"61PO1U'\\"5BEE^T0U1W\MD0R- R6U.5I-LB-W':^CQS#QKL!B#A3@P
M4=0'U"0*< :6N"@WB#[C4-^H@L+B' =CB*$Z&<83->1]^U62Y> 6N,^E5T7=
MOH>/N4,&$3M9&A'W!%<BH>*) =N0)S.MUUO1],J;HB06U5.R8:5#OU2:',W7
M-' +'%IT0-17"S4.@P/1A&J<XGT\D95%=CWB"I>O."5KN]E#/4P1"^;8J(=G
M^?*P.@$-K0B;&+PF(&\JC7[=T%<>:.-H&"J*1+(Z>4.H^F -S)$,]CEOED6,
MAOCM%DW(#"-WK)B'2V&C2C#3>_D59^,!\_US;[_0"R80+*7'9,  &](!8SKH
M4MX7M<4J8T2'[Z909KVW:#5]^T@=&9AQD6S@C'I:8UR/C;M0PPAUX%G6X1 T
MP<<A-G *F\Z1/PI[2T^#H*Y&*"U82TJ/W:$, Y"LXRG=Q3'\(CI4E'X0,]Z!
MFX?U,[G:/*_W1<Z*S6#+"6FMI"Y!4E9YB9IWYX"XTA_L3[G012A$FTAPB%IK
M6(F/N<M^"BWYE"BHU6TMKB%MU>^+\N<L?^$:OQ2.HG(0\(\;NXA_'D^/5JY^
M<(L8< RHNO'7,S"G"'IKHLI?X5>\*6A?6ZY7Z@@O7B#%8&K-2,.%8AW3W>J"
MG\)_X$J4D!7?"*0U.24A (+U(99;$%\<P  &>6H-YD4Q7ZRSDKWE:-L[<+#4
MK<X!-V8I8^/% 7'@W0X\BP*Q"=BS5U1M_DCJ#$3@)-0.9P%#2B$-=KA?7?%"
MXXOD$]6/*D6U?I4@-"! $@00ZC=G8-"@8%*TE!8/; >,]:944%WC^P1TG[J3
MR"\WHU;>?VS,K%>+0=6R.X+J8<)(I8'8*= Y<\=8X;?;'3'3:& Z.>)%Z9&1
MYK@%6, +PG5-#C8Z R#R&208TS+7W1BIL-L="!3*H=(KX?&(MTF6BSAZB(WQ
M[O+>@&!9""Q1:A)))\ZX#I5E/RH%+@C?R7UXA)7>KSY4F+DGI"9PDNJH](_V
MTT<HJ+?%ZNT'\$X#M!DOO) M(11XO^R'>T8O86W'7G7HCZ-@8"[3YIJ-"FAQ
M==./)1UZ$FX )0I*?NAQ#1R*?Y?DVG!Z^%MDX8<EJ C8+CO@>S-,"M$>Y#_D
M@BN+5]R$&NC(QT)DX'_D$;'CA36(Z BMQ3E"H\U.X3I=< 7[ZTP3H1C;GSM
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M@ #"L$L,+640/S+8%<^A7>Y%H'!M7K(\O5^1 PWJ,YNO5_@4-=_&#V11+'U
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M+>Y-1S4-62=2B]V(E=+2LI,AO#U"[LE^)TK>UVP.D0^\C7@]3)ZVM0TD@%D
M6_=E2'2/F^<L+%[\NY^?/H%J Z-(8[!BCB!UP H2[+F^Z65XO<E>,A:OREJ
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MBOJ=4H:*IZP8==.'JU?)NQ;)@(2F>^[94#"!UTMX[M=+X)>2OCA"TQL$(F4
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MSCMP;^V:5U\EA@$?K;H^E0=R22RS7;)A40+S^B+90!7;IS7&]17/(';Q,#6
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M![%YI2Y"J^>V&8#8"/3C1+PW6E1TSUP&O,.^81U93^L[Z,8(8:*P\R$T>5'
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M;9MIH\I:5[_61."4'AT5:VS(AXQXG6<7]>;K8D,+R67% ]&&M\EMOI1_;U9
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MI<$='K^:Y.6NCT3</-"ZZ^&1V:E.%X[\.(FCC/G*0)HH2'/M-+C<??U>[-+
M^20"GQV/XN]E N##&,&^E2C/Q) VNZ)M;[?:;7+;W$/5GCWE^1K D&"%Q6X'
M-:PFMT$/;$.0$)(L7+;&?R2N6#FC=Q%;\DS1AU/5IGZ8&=G[8API(NP%.(G4
MJ:N;Q.E=0EH=7(3A%#8S2MZ7N;>NOVAL)S"VJ/PKJHWKOA3'+\#8&MC-Q/[?
MSFPFIUN\TFCG;_**U20FO:MJBFSHHG;@87:7D^! [V_- H+". ^H,SW$*IE'
MG5=\6^[;3DT1AH:%/CW;[XNR4F##V!UD9KM*FYC/.C!80R&C$I?&HN]MGR 9
M:G5.0@B;HN9N@9#[X2@ZV(Y9Y.6NVMN9+U-REU'WG<1E0/-+%0^9@:3K/C;"
M<-T<BMW#<]D,>RK$BE[,/"8GZE+F_.'"$:Z\+RI)"L1>-C#7GNO=AC>M2KZ!
M UG8;[8.U_G^@ZXSA\B_%Z]U^Y\F7PF(K5B/G/.YY?6%3>$<=7!-%QWI,>DU
M\NW<O'4K]/ZF>=_6#7C<6@">+I^J,"H9TM78<88+<JQ';\4TQ:5U/1X5 ;;1
M<P5)NMM=$ :<BT\55&A>;R"-;EORC5JW[)'8R/HE!VA?_.WP MREU*Y;I(*+
M^N6QK H%)-$]4KT>S#Q)WK(VH,#THQ93XOY!PD-/BX_8'\(4^RC@[CU_X]6!
M=YP= 4^L:3GO5&X+?QKKJ"]FAO"(LY8O=N4H4"AD)JMQ2S R!XOVM"V4*4(D
MUBV81]J(@D1FP$?F&R=W-*1.Z:E,SU6IWFJVFW*;+X$@@3=O-Y+E05K&QI\@
M)'?/7Z%K9?4TJ8VVGLSL[+0.VEGNMQ0^T5LK74!D7U;WQMQN-?)?O#./TWGD
M=FL!$ <M><C+/D-<>%_."+^4WTNP_/?7EF\/NYMR&RS@'*F$5@084%AH173'
M(O:A)$MF.0U>=,Y%>WG@_^1%(Z[+8,WDQ.8N0(X)>IFMOXG<8]LZ2X#$7^2:
M<V%X"LXM2L+M]J8NJO:AOA./>A9+=O),(]^G),1 ALR2@ABJ) 8;;,CU,F\S
M@V-.9#_P[<Z1(56$X@O_E@9O( 8&40TRZ.?>NKV;+<!9I@;&#IYD.P&R/XBO
MV8X#^2\)<A/C&8]F3Q099>]WR*O;I+6D56,C/6DS9%LAR_<^FC"/9!KX==L>
M !D0$!WEH0B9FE=U _'<BR_V" VI$V8Z:./F)@$*,G(*-)A#))^5F\BEMT&3
MI$/IY8%69WQ]@,+JR^(]Z'YPAC$8ESFSPUTREL+ALT1:YBCS%Y)S-!9PR P6
M'4[*R(4M!$E25[OZ&Y0?B']VS2PJ@QOK-K;HKIVQ%&R97 V$5;$&_-2U"P%S
MU%)G'?G>'8YF46?Q2!\I(M1'?1*Q$^IN@>8GUECK-S]!,T@GI]O_Z1K)(-+
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MY<*8*@$\NV6.% D3)2"1M]QPA?03K]GH#?6J,S+@20\7[KL)0\P1'V?]J]-
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M55?P[O!J+4S(3JZCL7"'BL0HZ=%Q-BA0>YS',)C&.K:/<X1'[* T^#<7( ^
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MTU^NAEA7V@+1B\!J"/_R):+T-GCG,H:_R<2$3W%3>"NU&+?88Z^1>8&3PM)
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M:7C1[[(XR3QF(/K,N1"M%^L8H2(^(I_"@OXY:'H:;]0=Z]ID7*;9J*@ !**
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M^*0IUE[H7%9Y7Z[H[H3L2I-/8X:+4P 68(%V]=J*S-<$5?[U,)8+V5@\,UM
M.:BJQSCXB".\S;9@A2^;XSF\/G=TL,*\-6/0-CQJT'NOL- WQILD],T90Q>
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ML+A7Q7WPGIE'>@M*\*F['BA00A)AHA_8*G@<G\4M2<<M 5.?4L=YPN>-XRX
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M&";]--W. H>0GXT]GD_#9>S0D-;VB4Y_8SX4P4YA95;N#9:E5E%Q;9.;R.Z
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MPA$8>+.6#!\,,,-;]7*^B +=>T[/YR[\B)!"ZD,&VG*?B6VEX<0&?M=1+Z+
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MKN:LG.PWCR]$&=OV-PY+L?7CVYD<8(\U*-/X#$7^ANZ'-DJS#9([,2.YA25
M71(H,5>,C6,NM\E-SF;F*GV_<-L(PEC/I=K5 N6LF,U",DZ?:'0$(P;,=861
MO(W</7I&4<;24^P\F'-I3.S2,RA# 5)@A^-,#Q3)<$3])%G#4^78.[IL67;Y
M2CE+RL#O>X2W3UF<6 BJ5B#LV,VJ$E#:3(>2AQ:NM)6.$N3U?1*<]\Z\(-E3
MNLK":D\&%GLO*=?E$K5%W0^@_B$&4=.DLYD?B_5\:]MFK).:K7#[ 7348?O
MG)=L%E' _L/2-9[I*4QU;I&>>W&\IU-DE3F@MVXYFC/=M24!A6O)K1<.EJ0Q
M]E.4\WF>Q1;JFO%IN.[#IR53 5QPM:9T+XI5M1S.L6$MFTV2Z&RW:UE0';4&
MI]^1^(Y:@,Q:R** 'B8?291NI)RDPH^=7OF5127& *QHE,YR9'5-(Y8 2P][
M_)3E^<^A%Y6A_?%'+Z4@Y+F5Q]\7I@#P$C5@9+;+U@1\N!)3NOZ^.$-!E0)2
MA;66YPPU)FZI!6GEC%:A/%O-4((7KMZ3EBJTF:3<\3/K@15!GNXL#3@%6/5K
M2@&<(&^5*BP9="HU*E2<:)R.AD:V0ZF@[.1Z0/$S9I&4B27S0$!K7J:@)'Y@
M1:149-OEB1FK*#CZ?^3ZW<N,,X&63DIRD\(&L.:37G^ LBSD/=J1.&77O@>T
M9@YY\'X 8D*S/&_[@ ,K!67^5I%7F#NGU''*>HB MWGHIS7/C78 /X-"3Q#9
MRW4_G55_YDREUT8(K/Z2G>I+YR0,F:^'?OJ,%NL8Y8F@H.66!"3XM99$<9T#
M8ZC&E?;.6KYNDLPX!B]'C=&/%0V2\D8M^'6]]UE'5<'>$0%9<W$ 2RIE'JXK
MHRP@E7JTRVD5!4[R8G#LXD6B?"X6F_YR:3G9L!66,K?5+Q\U&''J.:B:#%D)
M'>73<&T(#VIQP^'$ATD_U^"XM1V:V]G)I>J,[_X=7@EY#D .E@M+ SCFUQ:\
M?T3IA@3'J*[N3Q%B>2I N55&Y-T(77&W- <9HAZ/JEJ(. ++T!H@X"[O"&)!
M5'(?0M&D[,/]&D6:R?^"3^>/N0@3P ![91$]I%F D4J1),YGKIXUP(730L-U
M5MF77$E.T^J7*1UG4JKHK73<*92..\/D!J>H**VCL/?QOIL#HMSY.DE+_BGS
MH@_:IH'XZWD4X^N9O9O2/OQ=]C-.-U<D?D"4T>ARKRDLW;'G(4IMY-Q$K2\C
MG_R;;@.[NXT7;[WKR%>0I/#C.>Q]XIGKQYX#A"E=X8CNR#=4>:A9FGK1&E.+
MIFC*=[8OJA^$7F+#Q:M"V95EKVG]*8$*4F\+6O9')M7\&3#RYU)WZ[S46">2
M&L&'VMR]7 9-';763L:Z@(KK$$-#>0G!<UV%@%4<6ZYJ+YT6=F8^C0D]G@[M
MOP*0($IX:84"=YZM/?Y+M9W:((K4W>ZSO?K=" 56!;53T$7IIO[]O\[)!7I&
M(=GE7%6ZJ')K'QC#Y:OH(.R# +BIV'Y.@B-/GH90>@=P?8@-2J5_^J[]QJ+8
M'4NOW;W$'-_FI;>U(<S@KNW*KLHK'"=I_AI_E\7^QDN0UBXH,]"TMT(I*$ S
MRI5$9>XR&W:,35<Z<FXOB"#969C"L*&=$!4/=4Z2&Q*M'U&\K58;BPS"^;OJ
M1QRB)"41>,"_%$FWE=G@@W;KFB.'.52U*A6MH+.CE+(H8$K_:4=AB5(6 U^V
M9)/:XH;&.$7)#N+FQH8_YHDM5R4KR:<H8)73 \Z%0TJ\JF.ZKF!J1^#*R#JJ
M8'6=)!DKT[)<Y385IU"50,S<#QV;^K:$R0<)[#Z@=\%+TN7J R%!GH9?^$R3
M!W*$!NQR)R1TBANU#+Y0KX8J<C\<_-5F<D_V7ICNC_N,U*J5&,9QW6([8I6!
M#_9^HAH>EI?LO:)@Y+5UZ%Q8($%5_OXZ\L,LP-&:/:/0_P6/WBMXT)@Z!Z>\
M 6A)!*IPEFX-RE&+3PY5G3Q=W9 L2ZE1":OC@%*ZG*$TK_]]%Q-6#4+M9!!^
M?)+G@1@JJ-)56E45RL/IBL0LI@G[>%>F>WM/.,0IAJ^M($'QQ!>S%.A@]:P4
MKV>+(,",&54?"^^[DUS(7(!T:E !EA\K6?+".P\'UY2U'4Z]L)92"1UF,$SP
M)&6O CA8Z2KM%UGX6BKN*ZB,86C!%K#2++] =8@Y@5!PD<6L3 R*,0ER:^\6
MO>2_@2_#($/S-)VGBK@;U,(R?? ]<,J*(B8%JW<Q]A'E-/\9M%8(Z9RXE=8#
ML$&QK*[X581?3RRMGNR.::=2=MK $"<JU"'@P.IIJ<FS'7E\&>(USN\ ^\66
M%0B3$NGP**YCVVR)50*_2K*C>L@.SM][M,Y"]@_VY56A8*LX5=3\Y_U#G:J$
M99&LQ&Q<"UZ_N%*["L#R):(C;_!.Y!<#*K@D0_>4_>8*Z%=:HN%K VK]<D/H
MK*@&6VCPTACZM,WT)HJ55 %\92HB_4SB7UEGBNKN3U4O3EGF$>-.T1<N.]9)
MWKVE@:PB5MQXV>XJ@ODEL<9F\4=66S>_)T [S&7)GJCIK@Y_I2:C%HWGGT+)
MH!$@<4T;&.XTMWH5/"N!.W/7Y06U[RGV%#?61;"6.V6G]X<$P9,\*E0 K[1B
M]/29 6=BX5C*?_FPHU?5D?RX7;(G?F#(PU]IRNC^O(K5LRRA,TF2<[)]PE$N
M!!8"1'E&K(MTE&#*8"F;(T[G&_;'ZZBX"2]7HD]8(CQTR]\Q.#[I'6P4D5>*
M#='L4J^"@?>*&&(WU#"+X!MU=(8_93]'%\M*O&[:9E*#?%>XXJX02I;1(GAF
M(>O)+8)N?-5'Z32M7RF,*_$#]+\T?8&T^.AXXA)NHEB)%*"/I99(O;!*.;'Z
MIBPB<](GOAC<2NJC!_L-O:Z O%"=Z (>QJY*US)W5RJ*M4@UP2A1=#KQOCO)
M)<D%J!+7N,5IB];T99-3N;Z2K4].4T(M6"KAF+OX5(13F-HLYT8I(9GSV:F^
MS_,0JF1E['C32U/MIDY5@?5[:PW99:F>Y%I5AKY2$/,JN(H'8\-)PD*WKTBL
MMK3[1SA)\0Z 5@G3W,>DDZ;BA>U$V^NH&_@^D+,B'.0T+==A["J9FCN6-"^B
M%R7),B?V\!^?K"/\.PJ@W=G#]$[U %= O-(* '^36I9IV96ZL 4KRU!JA0L^
M/<UU+<*IDAN 4TF_V$_Y0DNGR+*DZ"^P%U*]DI*BS#@G^I@I!6$EX)$#X ZV
M/_--JUV,\B].=4MMX5(5;QFU;%K-)J_BI"[0DX5K3V/T$UV$0C KT4)$FEEH
MPWX7DQWE=^]% 0NG*@H'1T'^J,3^O**&/'LI7OCTMTEN$PZU:->TYRI.[D(O
M2A<U=OC]V@%>#(?HZ1QGVG#*]WXWI6%@<PLQZZP)VT(Z$G1ZH996VOR@-E4.
MB&['*F)_:W6LHQM >P!H&^2Q&V2_=4*>>B?D_]Z0:+W)L$(9\-8G3C9>2(C;
M$$"5NU5=+/?,R@3:+X]CN8AS ][Z:L! M'-7W\9R!N3;4\C(9@*]J3OZUL!;
MU!]'%;N/WBO>9ELP])KC.;I&]L+7FK&;ZMDY(SB"A;XQWB2A;\[83=?:_&RB
M6.0>@P^(K&-OM\&^%T+9PL*Q3\/0%4,'TB%=0YAHW>8'S( 5C^W0=AU2WH.H
MQ,"8'!L^"XJ+]S\_?NX!.$'^']?D^9OR'Q<8EW\Y0EP;RIV=*@-G?<Y.6I\/
MNC+.]JS)CH6^DC(4'1TV@%N;$K[NFO\*V6/,66GX*T/1\6N!PIJ0$G4=2_..
MOBSJ)HVS_%7B.J)$UQ0A.TU#>TFY?J33E%(_?$[WXANZUUB18VW@>2ZM.C+@
MW6E.]("I/<Y M9/0#=FB-'V<XPL>G54;VFWLCOPC63.XJHZ-1ANU[PHY12@U
ME)*0_P\Q24:S 0MB4]VD>D4Y!*#^T0)6&;:69U:+'CI43EFLZ'*OQ3P "UV9
M_&0MC%X]4$<9ZD0SB:=]]%[SDR<13MI28*T$X7EN[/*XNNKF7/'Z5J427O[J
MM2<A<EYTI'_EX3@O8[Y<%9J:&Y\Q>.J^F,XLC_L>V/3-;:B3OM9OHBR>6(5^
M)RA^1BQ1YRI+LQA5[23!'0>J]*<9S]6K 1H@0S5ETR_+8:,096W@62[E.C#Z
M_=(@KLI\YY2-&U@?I3G:6[W(Z3=2,VJ"5_=>L?),]#_7VUU,GHO8<PM./AZ5
M>=ZBA)A!M3^#;KY3<]F-V7^G07:>NZ\TJ'"]U"R4[1Q?_ARZ\[LG*6!JT#<-
M9!O_XALK&5A7_>V25#Q?/(>WG22I;CN@9# )2J_S0X>.I>2G/DKJ29Y">.23
MFH;&T#VGLZ<$!]B+]\N8%Q;>T5>HE?M_V[NVYMAM(_U?\@.2S;YME5]&-WML
M6:.29)_-OJ0H#C2#F"(GO.@<Y=<O0!(SO  @+HT!<#Q5J=2Q)**!KQM =Z,O
MRG1]'M0*\M8FJR[Q%R;)Q.PB[D.L.I")(7XH\G8=\.%*<EI>W!:*.V]\S4H1
M V"EN>/Y.!DG\49\&C[WGY+TSGW),Y@@0HF.'BQ'\4/3\?VZ%K21YP#D*;7N
MDI#I\)0$2[BT2U2ZI%M^;^F65[BXPV557Q?EH>CJI&ED7HJ_]IB, P6]!!HO
M09A/.Y2CP63J/6I_I,&OA2&^ Z8M@006FZFYR>YQC7Y.#DG^RR]Z^VO^X7?
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M]/>[#H;@*^&^U O\TBNX=$"^A-<?@N)L+".5_UP<WM4$!S#-_U/  0QXP.J
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M#(B-X*78=G>W]MR]O3=3Z(QWAKUWCR4\^C;=.*((&<;N07C+DLM!;E@7OO9
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M)EW<<PR=&O@4LKY@)SM>QO'R(A= #L*LJ4V\>6.!(9I'C$M/-P^N!KK'"(]
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M-MTF_Y_[5U)KO)H-=4A A\U60QS#B7P#8BGAY^G<N%JL\_'W8P7IKALM]&O
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MIJ.]T*E@6RK""5 QH +P+22QV=F&."[:1UPQCG.1#N@5NT"@"#LT+NI!N&L
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MTVO">VZ]V44F9^VQ/-K8IM4EI=7=@TS4*;^?:1WXHO"FL]"(M\"#V4[\FM-
M;V8C^ X'LGOO-1IBF@W$=@;"NVW-[$7-\N2I_RQ"W2TL_:=>>K77#%XU6S$U
MY@IEV5+X0B%\3R$U#]&*Y+47A%863V7%8XH67#-H9"3[<<:@^OQU0WQ5=86Z
M*!&!61AJ?(Q^>%=*/RUCK*0Z[%RWXH:U^>5,8&%?WO\4YFJ)+C?/O!JK6IW=
M7S@??4E5>6!/G"NZG8^UOQPD,\V$]V! ?$4E">[%B3\7'<R/-1]AJ3_1.5VI
M$@72?91E>!)GABF0G_3$UISU-,[)S%I2A35/XL2T&4RPM-PW;<7R*FDAJH3
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MP3DC@@"^94_>E!A%O4HZD"&(\4VPS"C%JXNC>39=G.8J74<31:(XV@2NP*@
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MI#=<TVLUBK=(@JU2J%G14NHQED>PB1>DLV$(I3D"D :2W0S?E*BJ +B")2%
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M,%(KTT+57%:#BP96Q(R%O[B6G*&2R[]8[B7MMJ2/QIN%+_-/VB:/E2Q5"&G
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MG$&\EH"M1V/WD<TDY\":YEE0>7ZNNC#2>H)&"-?1$[==I0U1ML_HBNJ%=*-
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MDC]/HN 13MX">U#'>'ZL<"$OI6I\=;&WXI**V=AX?&%3>AD\*GR9%SY!OOD
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M$XAE[8NA>K1VH6:CTX[(/O JQ'>85DH7T[&8CL5TO+>FP^(%3HKMM/QYP8'
MUA+1QZ*%1;47U5Y4^[U5[6<_O>I7$@=\4[7?(3$Q:2WIG+2P2DI=$BK#O+_
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M;#P4M'2E?_4W>W&G^?=MYW#Y57:M64R:N:3O(HK\E.@>T*[VO-%!0BP$#I.
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MH=2WV,A;=<K_Y219 9=Z5U04<54 8$4C-79%+WI3MOPI 7<)HGQ_^'%CP>/
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M:#HJ8,S3<D>4T:1 942U70E%='0)?0!>^Z7&Q48?<%61H<[$<"O( !GD2H(
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MZ\+*)(D8-ZX;R7)O*2R"@#W6 P]HYO_8AL@ZZ_T)DXAE"G$ZP?OI[.72AV,
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M=)JQO&\NIQ4=B7_$8%H9+2F?:OW0M:_TA6PGDL$R$3W1&4M,V*BD;POT6<F
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M67BBR7NH_!')$"F* P<+NP()R.I@=^@J,-G-2I@PC  <'.[[SX9'/?S*A%[
MMRZPU9^F(>4'%89X=*W7VMN%MU+')HZ#2C1+[YZINY-]6WTA]NT5&+5;--DN
M];5:G_JZ88<L68/Z_!_M'O*N,N$]0=@=U%O(-.;<$?>&KZ4Q]]CO\+:YE$.+
M/]4W10='MBZ"W11F/S2ZS/9XKY%7'>T=^H.G1XUB ;CEN1Q&"VAE3]\,V1[O
M W]PQ*C UEWP3%F<IFZ:XHR1)Z6?DMS29#IGQ7DV&)=#5[2X%,&&WM8]^F"\
MJ/:Q*,J CGL.E@@9WC1Z4OV@8Z=D&3CP[Q#TMT/"JM^T> &3L?>,I@*/*]X-
MK.?K.#"Y0\VH-CAZZC\]>J9ZWKP&/Y41U,G4=2;P?11&,W(/^0?8W0X>L=5&
MW)MA;LO,/7W^S$[=KJH+W0;3D+G8Y[_:DT"&CME2E"?$$@<];QH\"C=%E*5F
MQPN1Q@]):\B[IHU!.EY=1O.2B2\YC7@583+/FF+UV6BZ6#3?<B0LJG;P%L^K
MO3-;#XX\[A6^JNO@UX/G</<.V8Y.?I6[>@NW QRIB!IW$4BNBP<+\71$P64H
MKY:;2<0I:ZBA1XL&B]>3P=[N4]%]]OV?-LP/G<[5OFC+Z6(&]*[ @K)6!A-,
M"8J5QC[1FY2BDCWN(^T6)O&.Q[B$65Y_N DL11@,PJ>[-A58:+-@H48U=G".
M]]1;#FT\N<]FIGF^07+U(KD.-DBNQWI&EM40N7[<83,0XL;W5$_F_I88GXXX
MV.B;=4":X6,V(4SDC5/M''83FXVD*R9GEN7T6X3EI2'N3C,"<L,(9E'$W0(Z
M1NB$0# *3^'(DJ#!O8$'27%_X/('&Q0UD_GE<IYX"8\#<4((D.H(3+WOBAL4
M.D00I [UZ-#OB0G@[I!?/C>_O#T0K-P(, 4$FIMC>=+>@7?QT'"I;E\I;46[
MG,0*3;&J3+3U>!NDPC%6\3N'Y Y,>WBY8L(5E?AE-_EG;:$(JR]Y/A5T!Z*=
M&B"[S_6+XF[@9*+9Z1IU1AM=ZL7( [<Q%CXE+]!LL=U"M8VD=&H&TY.=,4*:
M%2JOPU@RWYR#S+O>V<2]1**.)I,IS3N)^SH*0F86E#G'(A]V@,K(FC6*:$K#
MBBS@CA)WL@J)ZK@CH;4I#KV=D4Q"W,.F9'>$N7+ESW_J >V"TACNN?AI]#.%
MLQ$PYX:TM05.^$/&8GG2;J808YC/('H3Q]S9X3W;R+!E$:*H"**HD5O4FB:B
MP-PI#)O,?0GZP2LA:S>6C.'-?HI_[H]T(+:/8[!'X"<\'S[W)00KTW/@3(^@
MD921-]UA;^^+A+TI2^HJI([P9RNPW5@(\[6[& ^O/NY!GY0_A4J]&5'WFH%S
M3>'.F;UNC0GB$7>D[O(5@/"=4[;^ABGNFVUFM,2&O<04]J@+Z\.PQ<D< N33
M2J?7"?J?C\N, @(#1V]VN)G?Q.9X:%OD+#6)7#S%-U..Y!!, A?8K#E'2QW<
MAT% 2' (+B]T"]$D_@A:<(IU>L98IHU#5TH(IB-88?."8G T4V=CD$58T^8K
M&E? I;OZ'J#-N2BWG.H>6H5%NW+^$*12NE/+]] +F\9-W#Z+Y3OM:VIOHZT1
MO!$6 L!BL"7" T%J8*P;MUAUK%N67F4,P(?1<KNG,"[0^*BHB=K9Q,VHZQA*
M<^H)N$H%@MI:R*@VLTIC9OAEFX%#MV$TCNG@41S[5U UM#(701K=MU7QK<M/
M!\M<<WQZ_!W5]G=P"6LQX^6YWS\C 2IY73BEE0P"U88H:6"2A2H1YPD_@\S;
M?AP8N7TU$H"@@+U+OZ3MIK<F?*EOW0-QX@BUXYUD.5]J*T%&45]RGT^IGEG;
M)$:;5-T3NMGN:^F"COV*[:8D3$U)5UC>$>*=Q3SD/-Y"A"T%>L?DUZ1"=X5)
M&?!WQB5N./"AMN)M6S'.AP6V;AA+*E&L4.-!-L?S F[@W$$U*I[2:^2)$,(5
M:5R$)P6WFJ0U^VZ9Q& .T:F%[Z4CD>8&TGEPR<%2,;W)EV *C@Y=@7R\DSS"
M=T9/EHZ#M9]]#M7 ',R)"*(41X*,H(!<63TGHBG&LIEY4HH7-$-;\?4V32G7
MHSNC12-.@S%M1@0?=,WH$/PM]A/,%O=/-?$MG0/C8 J&HQ4:$H</Y9^B\HTN
MU]-;R_5LP:A:/F=<=ON<6,O8Z7-ZG^%S]F2R7'A#K[.IVE.E:V#NS>N,2[74
MZVR";AK)</N;K^1Q?F/'!(&&PW7"IW(^W%E_YUI6;^A[VP;D2^!M:QTX&S%-
M]7_<_ABV2?OP_)\Y/+I),I^?&L)MJ&-[VB,-;P'?/3F"T_/4WW]>GS(QEZ*B
MQUBJET\00.,!P&'7V:!+DI>'>YOD96_R\G"3O'RH!==_@3+B?80[1[V/BHC$
MR7L*BA1?@R_BT:1\=7LG&-?1X0OO1'=C.K6=N'Y\.*-]:+.'T8X+0@V>G=E.
M5D59,5UD?7*)/H/5G2#7A*M/JTJX@A%<EW2#(D;<+G?BBKSW :BQ:3S*PMC[
M-2O8S=FZ,.C',W+D8G AL_Q'[S3?]4ZK(+W"EH#PYO\.T@!T=<IE(Y=P57"%
M4:YPQ7M]F%9%X5W"#2L$?GW<IDYK4PR.(**3;KH(TVA!_<UNO2>V6)F ]X:M
MD>'N;T%!3V&%+N-9E8(W-N;FR*\P5ODV2D89]AJD.Q,N]X?&%^^1#R18_@*O
MDFO0_^?_#L!GI<$?5^B<)K'TD'<08;9J@MF[&/Z.6<S8W)93U:.@Q#ANIHG?
M#-T7.)M(=\(DN ]GNSZTXX-=[O?W]O:16S[%DL1+6"]4?I=90GW=-J)GJ>AQ
M-JWPX%(+0IE5;BU($ZL*F=A")E9BIA*.JACVG%$28QZ!\X@>(MSJ([J*&1'7
M+M"MA$LPJIA@N-[];M<\%,>"[G?%3#3276^>(0<0.!B9"L8(=X!_SS0@D_',
MX+86LRP!H<1!)%.7,UV$&LB?ACH0I%_,*VXB"EOM>F<E$YJBJTLUK_#8:91F
M&!::3Q?@8$RC&<EGCOA@+ S!*-FG. RD_1'^>Q2,A6Y1$/LQ9ATN\@C#72FB
M7Z@W*Y[_,F)O8[2P/2IM29YMP!Z$UW!GF/^"TAY>],D$96E9% 7%=[W75<Z9
M%:U)W'Z8!@=51C/,N^1@;H#@*>:\CJ%E265FR13E6[P10,O&T]59U#LW 9*-
M^%EKYJAMJ$X*DI$#$N&IKR;9N$*V!<*_L>WNNUN[V>:S1>8=Z(YC\P"/%)XM
MZHLQCD"8R8DF=E4?Q=B,CT8YS:D@GKNY*LL=WD%6+A&$,)M%1-']_G^"V?S%
M*15'Q"5)3) !K>ZIMO9$*WXNGG"/+<C#NAGHJT1S_3O82;$H?HVPD-\S+LZ9
M#"!R'E^W4?B@(PTTF2F_O+TPJ=JR/J](V<HQ>EB97V$"QM,*6>!1^. D7E*-
M*QBT0?Y1=^X6!FT<?Z1+)Z4!'"WO_A!M0Y3YYMZ%U2V.920]=;F!:]LVWLBH
MI4;28+@W](Y/?SVU#AKY"!L!=3N6>=\7#K(ZY#3-*G+%HA1IC:GU#!QB$ B%
MZ9QL/#LX$66WAZ<7!VTM2_H_1MY  NA0LB]$Z,9Q2=9 ENZ<4CEYZ?VZ0$6#
M&6L\-Z=Q0?$WM87KO$VE-YI@6*K]"'K)>0S?>_I<%X84C'$@VX#?!B%&IH.S
M-]RSO[R99OQK.<A2YS1\NA-B=Q#]!NP3\5O&5 ($;Y3-D)L8)'=6C9)H9Y1P
M,5\"8GB4[3@$T=3)&9VE#)PN&( 6^A+X*YPNW3I$^WL:4PT<QWM/,/,#!AZ"
M5L#G]%YC\CPNQIFW]?O)Y6N8'/S#B.$S*Z4IHT-8DY=9D(>6=Y(ZT*.LM@ 3
M\L#C4G.;D5 #)U&X(NT$Q:F2-N;HG#^<'?X78L>#3>RX-W8\W,2.'VKLF,@Z
M+SC3K^MX/3+5X/T)1I9>%7='W_E 9L$5"/2+,!J+!?XCV9\(M/_N9S3.:M/R
MC<BM>Q_/:66ZR7!GDWH\MI5SU !+M&XQ4!)=H4V H+,@Q=.'@ "7/=BM"@^C
M4>EEL(&O!-9@RN*]7]A"?HUM3L[.?._-A>XEET94:&NSG)=1&F>Y.G%N? &N
M1(P!U055,^O25^I@?&VK@[VM_31T*J;;)4&V1(2<"ZT$@\0M5"^,=\5)6J5+
MP!W(#BP"O'T5%U,]N]SQ!?]E'2=X96$<Z39WL T8-=A)$ZXF@:T.]L0\D[G%
M'CHXRBRE?J5H;U&!,H>SW!'STQF-A55<)9E)'?P#3'O&E?8AV8/Z9?%GA@:$
MH%9VE35=")S&&<=>"+*/S=HSAB62T8%0VC!.N'B'JO*Y]_:<?C:%>:C17NAL
M.J^XM]J*ZRHMZHFT=9"':MF",Q$VFT/N"\G*X#P\>:H9;TP[<*^\R72&WIUE
MS-9K,I6(7NB#N_**%LP] /*&152[#?&14'NB3W-#V0WK!ML2=D3"[QF ^3:+
MDR#7D[_#N 4YE0N'%2_-G&Z;RK)2F*":YK((ZMN0.UUI<['=NUPBF'VM/!GD
M*?>FJ2!>[6A>:.YMEU"C5C46EQHN-Q.^<Y(KKNB8Q@G&;>&>.=G9MB=-8>G2
M!2A$(14&QS$M/('R,&Z ]!JZ['X6(=E(7,P*UW<WB"$&:1.02,"'%KT]I<C%
MMV,>?Q6'5 YF)_XGT()9MHL26A40@^#(" K(;BX7#V30:8P%:G<E[>)<838)
M_"4=+B/7B( +3JGO#?R]_>?(HJ+D2+S2<>L_1=CQ*"R:5 M!K[ W#/',X-F)
M4V:*R/F!4O>@VZDZDN>5N5(_1[\'X34U44LWQ8CN^6:*%SIYFXYJY"ITA+4<
M[/S]X9[+*'+.!1_30%I^+AV[7U<;-<I!JQ'-S%%7 U"?M#S\/=RL2ID%*+0<
M4KH J7?Q&]L+I:DL-^(+\7PC^I9:P14D(19N&:Z=W5H-JUMXC>5'@Z'4)5G%
M,#4<B[(6!<(0F3\C^H1E&A1.?>0M/M8PTP^_HIG^8-JPG3N6:F?S;"T?59UV
M*I4RAV7RT=SX"\A'WPI(Y9"L=8O'>Q17JB:N]AUQ]7!4X -4R;I2<O"L:\\Y
M7&1JO\4B>&O!?\#L26Z?44LTJ#T@]#)=G\QA;=.,5<&,\REF=ZN.QA N2X4P
MW3:)Q>+")1,2AH$DRW+]_:3[.MOH@@H7Z9)=[R4:V[J JY/$##<B6!"U*9TA
M^WZ3:>KPR'_V?)^].3M?L?V5G@F7:JR^()MMOFR;6XZLP:!_H[.?^/4WNN.@
M?<V-KMR-[BW?Z$^'1\/;-_KS/?]H?\U]KC;[_/-2?AM9_F5E^='SO:/;M_BS
M9_[AWL%&E-]I =%^YP[OBR T;>->:[<=@C;TX_B]J3$RKKU?CQ98<QAC51=Y
MM*--8F4C!AA)E@-GG%XYFS :&D?613UKW8.!\/G3"^N8BGQX2*%##C=P#W<G
MYJ#J,0=W@*U0PPJV^PIQ ]=PWQ67 AQQY19[P4Z1B:@]T\ZG/+WN-LCCJ&+6
M[9&#0*E<VM>[T?18IMDTEB&F$,59C^MHAXH=@Y3S\#BA)<<^>8F;S0YJWA6\
M +V93.&F#O!SR"@/]S<Y^=Z<_---3OZ!!G2<J+:6P/W$[&IEDO!55='GD8DK
M-R5[*YFX$<1+J,*?'1SX!P<'-;EX\%-1S7_.0Q [\*<U"M?B#;_=+BT)YE^W
MV'1>$^[#*2AFB2H*#M,CHP2S_^-XE8SW=?P)IHIHMBT9-]$GP,^?(ZT]#R=
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M>N9_HHVK[RKA"46U(/ VZ)<A(864A8P)-<T46N:V/9LC#C$_0YM6@HZ..XO
M=]>A=-^+DI;V^:KV?+_I0<IA<M^'#PZRH&@'%&%MXZ! 9U.?@+H3C$0?B.*$
MC^OJ-N>H6Y:K]_\3S.8O3O%U"ZRM3%C=^D1F164RN0DWP2$><6Q7EZ=%XRE'
M;CDL=%4E7*8CV=FO<@#N+M*QEI:QW8=#;P:2- :S!Q8GP2@FJA*WU*H1$3%;
MR*WE=R]=:R 4CZ 3D'E7#(O32\>!21'2M$G,"I(GH./RSI[BW(K)J:SG79A0
MSZ[WBO&73@&$>^ P+IV%O>2?M6G4C-WK07/@KA7C<&R,W-Q?2Z9=[Q(V =57
M(B>-E+%@"1:( 88"=UR^UD"BZR"I:O-@D:E=,R)GW_>PN OE("K%))[%''+R
MN^9KO0'9ZBKA2I.D3?=N:&P9&&R%\\0L;NZ"?^[Y <D61S=%8VK"*@]<%$?7
M5/'YXD"D<[[6V[(V $B%;4BJ6%$4<!04<:%/ W&ZL6K+,Y#H&+NTQ+)2$05?
M85R<SCA=O;O64%YS_!.#Z%>< M'34?0?H;Y)<%YL3?P,5M#%L#1CTVQ.RM#J
M\5EM?I7WVG[N+A7 5Z]!^K(/XMJ?=6N=GFYJG?IJG0[W-K5.*^ZYUE&ZX[/T
M&JQ[#0<)L2 ZP0I9S)ZRKQ+&$UU6*?ZOJKDOX"R80I3+:D;<#5@Y@#4(J!&/
MK0-T 9MV;)F]N90;S)U/ <:]"@YTC3FLU2V/:Y1LE+"OE=)CTDIS\Q5?/XET
M9YE4?=^=CU$$F[_,JVCUHK63[KGEFBO8#9=1=)*EZM6B132ELW?HWRY,'.@^
M:R_<5ZR]O%Z"^ZW ZQ\/%<MAP'9_*(P#K8IP3<JER+=N<$*4-_#!0OH(7W$_
M"&+5B&G5+ :MNY[N]:M_O?+>6&!Q=[,)L]@>++9J+/;8V)C,B&.=^AXRP2WG
MV>8Y&LAI\!9QVCL1QB1O8$/B.3GJKL.GRP)J+VT^O)"'U3LUZ*S@.$.L#(VB
M\PH8@K'G%:&N?)D$/3DU0QX;)LSGR'E&P187T\$D,2\\6@TBQIA*P930QV!C
MBVJD!X:(/@Z.Z29)Y33.Y;@IAIY0)(?Y&R1Z>&&@,\=DZ@O;^42X XU5W;<E
M8,>[5W0MC%"+2GA1P;@(:&@WH1!O/3DX\(=<X4C-KY'I-&2B&).;U<  ^OF>
M+HC4H<\QM:J [18@T317S-%<6*X/RP-.;V2:6C]YZE1'"CO#@73QMM!X(52S
M'F7?M/A"=_?$O!*7Y)FTGWX37V&G+_TDBJ;6@?0I$A#D644PC33,@[A@#K1:
MIZU;UP!?"\[!52Q<([K=N(WS&[YK##-?8IB9]@1\P*+H@"MWAW51-"6:& X<
M>T-3H<J3*VSE8 R$L!(28^;(,9-BV#T@OHV"?XRE6U<0YQZZ\+0YG-4B_A.I
M[MU].#+[ >J0?U2PT0;/;E,A?I<.<5O)N6+RI]'/IJ4;:N]FQ7#'81!U 2O8
MQT+DTN2:+=MH0QB@6<;[0,CMI%XUPSA!\UQI35%K1J2/XIS8C3L.+1&ZX%_Q
M5*DMVJ.PP9\,^,)M7_,\7\%^3RD([&,4EZ/J)'T(F914,UCO:D;D/]S@KQ:$
MEO.B6])SB-?D5+2?_V3_^5,Z4:K)GF16@'13SNWKTZQ62@WO@A"OT.7]E\@%
M7 R?UX_UYB3=H5V,8-9_XLZ>7Q!:U%>:6GEC%*\CT([G>9SHLO_#?@X),#(<
M<[=O,60M#,TUW/R:>9@^TW;%.W]:M;\:P: I:T C^D2,6X8LU?")F?Q;#3^$
M&O3XY1\G)JZ.DBR)=D 8C!"_'4@\.:^N%,PR5CE9_M(0?.Q)7L4E_#)<L(8'
M4_9CY+VMBFF>P<^V?H$%RY+ >PUF5Y@5@=CB;D'5NRS=N9RA:7>"#/1O*A R
M)Q@@S>O=R>SGJFE:^]K4>D?,R4+P38_:W_/0?:G;Z+S^)%!YSEJN"4E<G4;@
M.';)#6A\N81[G*+^P D$P\_?'[):V$(>./,O\VNT8<@."<E0=&@TJ*OM@)O:
M;C?,1=J.!-=-=5^5&A7RDZ?[;"XI?5VC*4#-"C0[BQ;;L0DI.FS,0A__;;9:
M'C'=F.4H?\'O#)^2/X'YUC)A@C^P_2S8@ #%FK#AG;8'J1:H0<[8OR*^W7#<
M5<!!O]48N-O[PVONB-9[H:4_BFKOMBL#:)@QS*_8$ &UHV-HC7TFR*Z[LBW6
MBMV_HM*)BD4[+4VM;@9Y=[KX&Y/WR S2:;[6%UG=(NQO,3N_K"A6+]^\^J=W
MN'>X1"9[=R63+P*B)"SC,=.7VG]K3]_*W,!0))4(Q\%$H^])>0D#AX:6/_7/
M+$]"*F!Z2PGJHE](.XNF_IJ4]HR4UD$#/#]K"VQ5%]C[6F WW'RX=UMH.R_3
M%G <9TG=QBMM1X2&S+)>&>E *H+VYF<(]27"#S$LV+^JK+73+KC^V4NBH"B5
M]F9@2F^"/"R$$].)QA2"_*'\- 8,+/5YC[O5KUA<")N.,(!&4;T:9>F,KZ92
MVKM>WQP[UH;.?A?V4I@RY(]VX@JU[JS,((]H(RT@' _4*1?P8HX_P=:5:<^Y
M_8[V![F8#^_&WJR^F:J$1%3K";@_[@".DNA5_&(:SNO3<(HUW$;]6/4S..P+
MG]3Z^<!6TKUDP)U8TL^"MTN66Q.X*X#?%:%W]5G+*K$J3M54G'Y<\87]C164
MW)TY'A_R>(Z0KW?(8H:#?XDLO&7-^?CP[N6)57GJ'E2>WBA-H67S".#T\V+;
M-9T0;G\E/4A7ZN7\"PI1M3R8@W458N^KKJP2E5:)WE=4B4JK1.]N5&)]Q9;J
M1N7J1NUMK:;LW)W>I^:\E=6<NDLUYZVFYAZ.#OA*.FDMW-#1!C?4BQL:;'!#
M#Q6%<IO=97HM;.RNAV)WO5W ",-%,4] 9X)O=;D A9S-&FS"ERT Q;V87WJ_
M+#>_[MG6:D>+#\764CW18FUB];[.^E&'92:6NJ^HPRTFEKI[$\N[W<12/2:6
MW=/K&UAVAOJ,G[:M>?\6T-?B0OZ+V=5"&E3^^IN32U5?+9=ZQW7,*Y0H@RFQ
MO$KY.[$V>BN/6Y7 R^N$M^+M6DEOX^:-WZ]B#+0> 6+;=&!""7$:C2/=*G%_
M;S"T+7TIDZM5.@U%XR&U_"ZGL',:):6MW11GOV;SZ#<I[-)M?[6"%I;) :DC
M#$4LB42@;P;J#T=28V=]>WI*KU)CK"0J27+(G!&1X1 Y96$.^,\=* 421+D>
M%W& JJY*RUPHO?((7C6E@4Q(HQ51+C*Q)54+GBZ\*PAM@YQS,UM8%\8-B-PQ
M8*$G?^&PR&<W*5/Y.[^L58%3$3CNVP= .'"'5$X=TTRUMKJ*E>8(UF4\!068
M1(KGE@S;&OG2>!K#/^4&8 A/88(9"O_U$>M+Y9P(+,+FSPLXW?IO#<&V^E _
M1P2RE]:6@K<YO2(8;R(\?7B;!/S@MWI-FX0+K=^^\&1&K)N(][93Z<I.F!@\
M'O_[W?YW2V[8Y4G?[KI?\.9K#KAS=)WO[ S8G-S;IAL&!@.Y(C,3-T"6_^CE
M5Z.M_;U#?__@&1C1P^U>Q?3LV?==?!BO7"@N& #@(NZ<.@?%6,S-5]6;[?ON
MR6_^JNO93WKN^;SQ:Q+5W_T\T+#8WJ%T/>3S)KH]C>T[GS4(0/& G6)6>NOL
MW>FV=UF-9G&!/4SU>)=-U JSL\Z4?*EY^)P-UWZV83 _T16Z'XAM6DBLHV]X
M@E;;**##33'PA>$+KL_&W4W"P;>P2WI%NSE6QTR?3/.X]>[TN.N(+17$2R75
M[9IKA<E?[R:R/(=]R].C3>YNZ^H'XEW1E1FP+],<QR%.Y0<T;F\;\>'G3#I<
MY(59!3;0Y\]YWSVT6-A;=<X/5Y_Q.R%@>@S>\.W.[W+O]_.<W0[_%LP;;O\U
MQ>1;3&S);JB-PGT#[:K1,"K==+M5LX1W,]91/0,XSI@#(Q3"6'$H:Z0@Q"]E
M>3J*:!X0H6R5QA+R,R6[-!"I69-[4+OD:%9P=0>7]^BF9M2\'=\;(\5$Z,-\
M0L3HT$14EE/XK#8'0=$@#-(U13B*&VQXS&5HFM/64.SX+5Z\,"@#JJFPHT9_
M&R8N3FE->-ILK8G,&H)VH[3@QQ/'/D8##-\T#L1E>R;Z*RGWPP;"822.,KE]
M3+JM>^SIE7/R$NC^P=Z*N$M;F$6%U%AA&$PW(1?N"(QLQJ5EI>AY&!7@\&NV
MM\I#]=H?E4#Y'(G2E6O$65SUW9>EXT @'5=7\"C<]T]KV;B5Z$T,,GIIM59-
M?OG-L]YYK'5Q\$JCH-Z:7/9DQ"M7/@V>-D4@F_8\X'EW"R.WW<PA1O-6&@2,
M_7Q<9LZSGS/9T#3@D[N(RO6?/VSTH)EO#NA='M#KAW<^=2)0*U)SO%;:E3H<
M:<+H'$6/BWH:3>J% \,,:3J+#O:_EQB, ]S23)4Z)[/*2.!>.KCNV]-5BY/7
MRM57*$VFY@M!CCIR/493RR"W++:T.75?*.OT&9;RUN><Q*5W_'#+:C.4@W.\
M1!(VF6!7#Y3%DWA21A%;WHQ/L. +-,8PM[X4L6[3RY+ 88P(T57\(X!1/UCK
MZT& X)YM0'"](+C]#0CNH>[Q=0 0-9G40*>UJSK4 R@MO^^N7 (<I.KPP=&R
M@D%LH.XV<NBF0>)9[6$_:DUY^U(+-6PLAE@78VZ/+B382GKAR3\I_SZ"NV"O
M2H0^$(9LFB4A1X;^507I+\TA! (GTF^]=1E%WCML.#78W][U+AH%IXT7]+&^
M_8\8P]+$Q,%?6P8..VG=*$4TT8Z\7U^]W_\AC2KO(BOB#E $C&T4ISQ>)*\(
MY@M?=VP^<$NWI":XX_>.3;A_Y)U?X_3TWWW7^]T8<VX3HO;K\P>Q(;X-'0"\
MTG/ZQ&0E#"0"2<N)F@:[2=,]:(O@3:Y!R2/6A )=L,+B2P^&O$DY:.4$C="0
MUHM@S.EZ%&F%")*^@QL\:KPMA8\X-AB%]7#6\DB2[5RB@A+#@P+OT,^DVD[7
M);$35C^2/1Z& P&5)Z(W80%R<3I&S"G,N?$RU#S/)K&Q]&$T]++@)"1)1[\+
MQGF.(G9A$CE:=!VUOK/39T[!H^6;-RQ!74+31C]KD5-ER<DI4-H9/845Y1W7
MK')O[D.#3A)D4BNN?2@06WS,P!\>")T6"4\EB%MS\/@<.@#<?7\XK)&$<03W
M&>U_"57#3_'9U'^;8^8,8YI%Y30+O21+KW90<DCK3(Z;G]M(O9)PSK/F]!EL
M#V$]<:O=Y#&Y Q,.8-L;UCD7FK3<V&VQ*/24<"@-5D:W M6<S4J^1!;A.+=$
M9+C/XU+ D_QO/'GZ@R!98(1=+K:=YFI$_7)G&G"$C6!#),*KL28S2$UAC(].
M?^$+C9PALD:(&'R=S4"^1^EUG&<IC]*YBWU^4>;5F$2 7E_?13TC>I:YPTA:
M"R9*'UD#<=8]4TG&:-]-]\YC&6$:Y( @P=Z"TC#OAB@T. D>2443B WF)0^E
M=1X%%;4D$1WNEBL\;OGQH>MM;5K"(1$K,]5U_#.D^KCFB.Q@C^(X>UU\#229
MJ3,2YJ",30(B"EL>';]<V_A0=6-B-5N":?U";7T,GGNO?GG]WCYM"2=.S]V4
MV#%/O3?8I!649XG@')BC'^ 2$#WPYWO8DH@ZZ;^1R%:W+^DH<@PVV:TUDPVT
M_CF5CF/?9M)WA>JVC)QS@U(,A>68!0F'0.Z1A?S! ]5UG-[UUBZYHXV=4-7C
MM3T$0K"O98#PV=]ON&V?X(\P"H5FO^:T"=MI,8WGCDM6R^98>BQ;+X9A[M\B
MY,RLNX2KK9SK_&G:+_F1:GN*V!>DPA(FG4GG"XD"QO9M>O_+B464DY>R*LW6
MN\N3-R?;Y@[[U'>F=8>Y]:G&?"%)ZE].P T!EZOSJ02'8K$CU\SA!IPGT.UA
MZQ15%\U4E2K**HQ--Q9J)OWZ]-@[>W?JF@0U[=UVOR_Y)I8YIL>9:ZV47FB%
M?D8'\VD;[5[-V5W9M:!W)/N%O7% 5,J:/I&=NV#L0 ^899*E;AW2+2NOG#>V
M'I27C<2#<D@:;3""G_>(;0?I)NY4(S@,E@7//NDUY*T9<F2]71#*&X4 )36-
M1WN$"CYJ!XXIG'EU>G8.FQS,;8N]V@P[C8D"9#?4^NI@L/N4TU^/V\Q;+QK_
M?!.-[XW&'VRB\0]TCS=:[]743T/HD/N!!=])!E;ADX&C,73<PR>]RH)$"ZB"
M3>TPJD=IA:Y]^+UWD^4?J2%4,(])]68I95-1==&C7/V(<5VGN)E'3<%>T'@<
M;9#KH]!O/! ,":P;JE<1/]T]=$19#16#.O03<L'78W44+JA*PNHAWH_&:#*?
M]9BW2-N)<#LG$\8W8H5_%),?@MI2PJD\\$),BT:0ISXT+*V5]S0SH(2F&0F:
MV;YKW,(8AA*#-SSP,I2M>!M69!)_(O21&0MW-#3(!USX/8<W/L,+X<K]O>]-
MDS_M4O$3^ ;R48F8Q%E6E+IO28:]4JCVFO8-1GAPYI/L!F62) ?J8XG)ML68
M!85I36,LJ@V+*#E=8LQ+Z:GAR>-MPK#%0K"6.;ASU[IN.XPF 2@^(FB[0;L3
MHV7>.,^*0G]G_<8.=SWP4%!94OJ6C<R;L,SCJRLR2/G9SJ,=" :/=D(QZ7%%
M\4@J91^:,(XA+,+X6@G3"C_%Z0&K"]Y+6U8RI)@"QG0.P9R<<_>QYN/]YN;&
M"4_'\5Q:,I(<&(_S2ESK*B6$;DQ.A6EZ,,)8W"P*,8"$-:05N\U@-V+>_M&:
M"Q^ZS"K3!Z*.GU"(%4X$JCR/)9.E41-4'(\!'' _-'5N4(%6"PACDJ#_D,)0
M4=@.X3#!*63\194FN"_8%"<Q!!\G,8L9.>4LF%#\JB+^!%>GY;1H;*%=[Y7[
M8Y0VYI[=YB/7X@98[@^/XIU&MJ(P/C3N_UCW@%5ZNC\4JTU?UAWUQS\J6,"!
M./ZH3^5<=JG' KQ3C!;6Y??+#.46;)33&-W5C%9>[R=21Y3.D[-):K&N/A@E
MIO?(:;ZK_A$'*((QXG RC:,)V  (<+]:>.>32:S=9_T\%'G9>%QA$ YCQCC,
M%W@?C^YC."D0[=K3<S/!P!^+#)WA+7PE'L9@?_?9]XTK'^V>^="TNVCZ&H:$
MXR(^VHGXZ]08ALN FVELL"$D:_8/;P>'J)[V<37CVTQL#SRD<^()>&+1&IC)
MYG]%H6/M),$-L1-*2<96XXD65=*VNLQ3-6V$^Y;2!\SIN6.8)-!"P="G].T5
M-,8 .USE4585ZK(:P4R65<FP>_H<I-]LL6N?V754L]H(1A&KQ>"O@%Q4$^1"
MSS7B&+]U!:F05/ 0ZWB8^^N2>,^[O8GS:6_6>AU'K>T.V>5+H3XO7Y_L# [W
M!ETDR<'"Z3DEO"NU'CQ]V!E55W$:N7(9S4LIU]CC'#MZ(DZ3'YV0:O6!JZ-F
M5JN[XHYZ;L55:^8Z<#.K 5H<"$T=T&)Z S"BA;$L*BB*;*SSSN74-)N#K71T
M^*(;VF(RU"L!6_2[/5HE"D+?;I_]H9;\9DUK\!;561BX%-_B6F38#9$^<"J-
M6GNW!:]IX4,41EF09I7<(=A,>=1]?&R?-"UQ6W(]S,AAYC9:"3PJ984FFQ $
M,:(?QJ"#0J$Z.KX\\8X.]G8&>SO[PYT!& JC@IRN[JLY6S'^3Q47L<X"29#=
MT2TC^G'(.!\YC,T9M=W,O1G"XT8$*\FON#5)[V4R687K8^]ZOV) U;]U!DV0
M3.Y"_(.W/4HY>9JE*_V8#Q7E:^5%GR^UI"XIZ 7J:$S)P>-.4ZK]=;<IU<:O
MMJ]L(@R+*@K5X?XS?W@T<&* 75Y8+1+([%JBQJR^03WC;*'LQF:1]#/=*V,"
M]Z81^2J<\^]6*@]HMW1<U;KSZG5KYZ9Z=+C"=I'RT-Y=4[>L;Y"6LC'[O.+>
MX>#0/]K;_\P55P&'#-HV1B AA59OP7W_^1[\?S!P(OR9HV\I)O[H%>Y:6<+A
MWB9+V)LE/-QD"1_H'C]W\(J'&JY8ARRQ;P FA'+1C[W^1$VH41*'X87[>^"!
MGX&G$F3C*@%;XRS/A;3+N\R2RE1\R(_WT4M.(]C/($!S7 +]*]5J,&:OP6ZZ
M94QX0 U"H2@%W8A";?,$52[(M7$4HNE'K@U\B!! L(5GA(4%X1C&8#L5E###
MJS$DD43V34"6JU&>!>C:\Q,ETJ\?>AWD<<2LDO+"YIG%5Q&9=_0$9M5"8W^5
M0F13'-UTM2<P204&Q/528GBIT/O"K"GF/DMT9V&MLI12J[0Z\SRFX/5:@]!Y
MDP@<5<%H?T2P=D:4X MOBS1E.8W''RDK)\^RVVB;$.!IB#V+$BR"=2]?:RA;
MR-WE)<$BRCL>4]_@SKP@9BV/=6-Q33X^]N89> (!.&/K34@PCH4K!_9J2<AQ
MV;LEF2*L^/F0<$Z(#$;8%NA0)5Y6S#+X-<+3P</("CQ??"#6&L8\CW;@VJL(
M0VA\^#DT47L_Y-:)[7XA1F_.&+OCP'!@  89)NF"M4:1(X0?Y_7@ &F^O8/G
M>][LO'C+!.*8"Z/>(K1MIHM0HJ#"#<_9;18[10FS%CB8N+6&(1.@T7.8OLE0
MR]M',JB+B@VV@FWSNB2&QF/PY;AROB8$P9!,Q^MM493-6Z-M7!W.J]<.8(%I
M=6[EKA>$$D48G"(2<5R=496&)'VG40HF#*SC= 'FZC2:$<)RG=%,B.0=7IGE
M.?(">#<@A@JS?]%NQ<?"''V*Z;'X=SAGR$T/$P$_F4<"P(=;I5$%'_"V?\RY
MF%=!GF#2MZ"-ZP0*83(Q;%Y&,H5Z'14FB;%.!,6N3782'Y1,EVGR2EN!Z6[@
M4[/G;<F1WLW47IQ;O>F/*.;A!==!G 0,;@T#1D3"R59<J%)- JJ@H6(H I)0
MI'#7>RU)64,LXT8[,,8YKRC=BF%TPBV(#4%&M;0*8"KGQ[GJ3A&C$S+$B:FE
M;9SR%76$YN#>4Y]5,S%BLUQ[_S_!;/[BU'<6A% ^E*L@FA28T#A-LVN.L3'6
M ;,HU*%Z'%4$=C (5I;M%*;,DNQJX>8XL(=!Y-!/2-;'=ASI:'%2V!?4LE"X
MT$.\&0+'WWOT#MXI=7["3!#&SG>]$^PQC_SH?BL KPCGT1M1TY'"F..(UY)J
M(JB^I)JVZD'O;5]WH3)1EW>!8-=^!4F-P'S]M#,9)9B.2M]%/^H&.XN8*  #
MTD8Q9CRN\B"DH]0UFH!Z9$PPIQ1X::4I^H+P&L1D@,5KA%<>\XQTW:+ &F^P
M,>)9_%]< )UV(R"],(1JHCN8&RTETD@*%!VL'FO[^#XMXW7:9-W[$,SV7T<E
M(O:C@+VA,Z5(:T@EAQ+,#KQ?WEYX>& 1M@^;^5<,NT\KW.IZ[2[',;GF%T'^
MT1<:/7^M49BX8!#/4$J/JC@)V262,T*5W!@*0V.^FL^3A7NTN>J2I0E<,,L$
MF.2^S5H#@C=?X3C49)F$1,BDXCG8U23)AGDR7HUY2?]/3_M-5B6A-)*C)K-D
MH!K%9A)C/(]TMG?&X$\4KH"DYD.XF%B.0=V&UK.OZW)8AE;/?>,HN$,#424P
MBUM[6U'Y\?ZPW>+E;@\O"H>[.Y</&1VSC#=%,YX1PY+Z;?>WW;]I"9[F)23N
ME/U!+3\#LVV/LCH-D/8<RS U#,6)3/C>&U!;(0JRDPSF\DT9THS2_$9%5(._
M;-G[ZZOPQK[<&8X1G"<T48V U$]1]=%=.G"/^M DS6W7V--K?-N(X*J$KKJ0
MN^&-MVL)"P5WH48R?T@CF>[T%MS,Z45@1T?20Y[!08IY'E\CJC0!^Z 4-EEB
M<7&&^U/\\V_@%1;3^&/L_1;$Q33XZ8?XYVW5M$H-S>7@F<9-I.0$X-!<=*T=
M-:K#@62V,"=L #D%0FZG68X!)>D_=N#O'3YO_DQ)^H4L)0<YW9B.<WT5+5Q1
MGY0S!RZM8U0"#F[P&#M)/[/KJ-N,&OA83=EZAP9NB#O3X"?P^\-GS=^SD>WN
MK7JZ"B^L-Q+")#XE% B5#(H[HIZ V B'+;DX!PNXB/FGS*1 F@FGBT@/(K,G
M"&Y?NSV/QP#>91+J(S"@<P8&"&%,T_)&D'M>78&0T$8,?!M+17<87U'I":V"
M[Q!4^-RM+*]2#I0PC@8#*>3+A'%A,#7TI>U8A!4<:+6PKZ'&09['O$G9F>87
M;G9VE,Y%M/-]CY!="W& 3=\U_%C/2$3]<-#U9M\'2S]PF?#/D:$QPB8[#BN!
MCHPW^+#'25;(R+DRUB!.\:0:?@N$[6F:[6".$10I#B#HSYQF&A<DA7\6!6ZM
M*W014E9%<D&AF] 34&,41:GAS'VTSG4SD6]ED#ZD6@?3652T !.WRWT]Y\+[
MWOQJ>$@.->RFAJC!YQE9@1Y5FM5;0OK<BIC".9,,;4[MA.F;^\K<@)^*=50@
M0(;#UL.VAH/OMUMBQ[WJ\/EA^ZK#Y]]C_!IC@4WN'"OR%,54[8$_@ .H ? <
M#1#5XO,+%OHD#LP/<0>B]&AC&'#(^_6OZ:7C8%9#O"E^O/S0>U41=%OP\YT9
M=_&-3Z9(3R-\XPRR?ZD%FPNR;TRU?M!;."[Q%"2 =YZ"!HQ?D$&@;V[>KS$/
M'[*\@DV:>5LWT\S@\H/F[ZVQ8(8M83>K"L"T8#F@6?"IPHO0"W9[Z/L^VE/\
MH79R=96'"233(>J F=*"R((6R!13TU8-LF^\1K<>M\;[*"IO4%#"A3-!;M!=
M*<**#0E8 U*;WH;Q\89OIGIL,GRG +/F^!6+^'I)^IBV68VH29Q<M(QW'Y.7
M]44?=/M#5L&,##:8D5[,R'"#&5G>A>;.ZL;7BR5)F4<#LUAS-%@Z@M&,M85%
M)/9TRGD@QPFPG@.Q-ZTSC)IR9+EG+0A^/J*'1U$-TX[6 2C9:J9;: MY#'@V
M!==!KC<*<G-"MW:#*G2=R: L-8CC3*CK-/2D= ;L3:,?"OA_7%JC97>M<9QA
ML-=]:A%A9I11+?.LX!0-&6Z=AJ5?'P\9D<[MUIL38W<1%KJ,J#)H&A<_H'J%
MA\'VH\GG57-L9[1G"NF4#CZZ)ATR@8$UH0VL\4B-:U0V @W8<1%?"F:DMG,;
MVA;S,3G^]FU0EHWPS-HKU#HFJ.>K5'*?<$ ^$LHE&C/FDJR'A=<8@L]E]X)D
M^=PUPDU98!.WDIX8A EB2*7H7(SUEM7H>T.WY[MIKK[@Z<VCR9JCP*?,Z*WP
MF<V38ZUNU]K&^JNK+ N]24!A-01S@::[UB>JF%=@QJR[-+3AY6(TC9D]ENX;
M:H3'0.J?R7.A*>A="YI?RK6M-Q\9B,:%/J9V#;HFI>EV<=$V]C<N+2X(@\!(
ML_!BK6'$$WY'/1$!>#3Y3*H)&5_B,&IB M@W?Q/12\@W+DFHL3BL-1OZEC21
M]V69WAD(0_IGK?J_K$->V.1V0)(LFLUI4:A8A;B>->:<]K.;XS6)5[UOUAJ,
M[#'DTG"R64TM48->43.U&\UO!SH>#4@T . [J[C7W9>UD'-1451TX2&!0N,\
M['J_9C=(0.(W C3][MTZ0^%=GH!BI1=M+88FC;,J3%/*=H1E2>_IB5M/Q\G2
MF_8<((,K.#-RA-OB0X?F")U%YTH+'5K,HBUHUAI/<Q'^'I$#6C^A 2S<+8K4
M"D20IP)O%*0?,?'*7+ZM"HQ_7/P+2Y(.GW+^8HN,E$_QC!,)OU^>[A_MXS?;
MS,L4$_J/&RDV29= ")#%UZHW4H[)WC)3*3A1,.-C0-77(D4: ^>-11^:5P[L
M-4Y%'F)JW*@<H\I4$I/!HUD;6_-"X6V:%N8SQ)D9'/K/]X?^8>?,# X.96;8
M(@$+&X,Q" LZ?&ZH)V8!7%/-ZL_;5:O$@)P5Y7//T-@@39%'"?89_#0-"YV<
MRB4YA8 UXNX%=_S[NK]B:WRI6+;P58QF.0,Z*@P@QE03B_H<28+!+,XV0!D:
M@M[3ZQI6M?H!-P!7BQJ;^.F%W\?87'%U*WB,HVA-O(ZNX49CEZLLX.A(0,_9
MA1+-CE(FAM&)4$QL]]&'KJ<UK!A(HZM,6F03%G\4:68S.Q.Z8RHB>=AKLHYV
M.\8>Q+//<HS<51!K7#]$"H&9_,JNH40P:1I\=[P@:'PX?>O9%IBZRQ+R(,9Y
MQ+F4*$%>,GRVLV+XS/::H8^05<S:AA).4[9_;HV$Y/%L9;Y9*0O+M$A(W@H4
M?B"6NX(Q/,R/!N^5I6V\SF/6R :#GF;I#L9!Q]0L0.+Q^"$U+2DC-4X"*@7G
MZD@AR$5B/Z'A8E>W'EL1_5O+](ZQ=$C7B]=^+H #VM/(K ;^&-F)R.*:!JBE
M!"^AR!*3R)A359#-IZ"&DADBP>(Q&'H)URNA09T'">/8Z3N$=F$X$I0PQKE,
M"3N>T 3W<F51\$+W%& QB2GO1/6D'/5DZ]I]DZI#:+>;L_C'Q0,R\[YL]6_/
MIC)T@S'(XEF*]2G,["*B*/J$/C+/;YJ97RV(A(]X97@NF=F@)C!H&Z8$S >K
MHB*Z&_V=,,)AGYA/Z%P79!H-][HL1@5VT:$/WVT+N9^F% NNKI!3L'1M3W)E
MY#&XE]W;[YMB\0[#ZQG973I#C!&K9&'A+H@!5[3M[3OPK3WY%+;][GT!"+]B
M7PDB;WLRD#8P978#>Z>0E&L)1FXV42THS(M54[GL?=0?P4*+%%5$T3589.S+
M4&NZ_8!.[5VJ CYJ>'9CW71YL*>9N/E(*<VL:,D6.T/3%/4H&LH MWN-3]$:
M*(2ML3WHB9:SD$[FI<;RM%QT7S6"9@V S^-=-K!RJ*G1WY O[\RIRD8[O^XY
MFQ[D3P[]_<-#_W"XKV!?7!&;K81:G9(9L%3S<<Q4:"!K<C(R!-H8=_=G$I*+
M U^>/J]&6*VG"7T) @?F;TX* CND(:H.;'.EGQ4:MBSXZ=.C _#5AS0!,#/'
M=A04G#8DPD^>[AXX_,.,=]T' 287ONR]<.!<]F@W!<-X?XLP!T046\5C1G$W
MNN[UD!@6U&OQ!$5V6ACJ,=W1 \WR&Q"CB4;'ROS9]BD2([+5HM@?.K*EOR=(
MK0;"IM9%A4O'WM8*1L[SJR 5#@"E@=<GIV_/#?F/3B@+3S5>='QQ1L107)+Z
M7X'L8?08@;?87R,F0A?A;'<_= "P/K<\XUH.Z?'F?JW 0!5[R]SJ[-WI#^].
MCW\XQO\,!WN_<?JO*+C-F23HW8(875=94NTL6GWXE\+;(CDCW5+,S.ON*6?;
M#<(]5;\M4FSU% 4^UHV]'JO,_@8AU(L0>KI!"#W0/=ZL-D:AZ\A8AQK%]A%2
M1D""@8S=FD+M.Z9DSPA290S/R&9(*6T:8')8"^Z?36!%0PWGKS5ENH[A?0BY
MK\6<%V;CBLN%M8%99JI7QM8%(!8;4$$ I=1UYRO$"X-- G]+*U0;(M,X%'?^
MX<3V["$?.1>2!LE/!)(0/$N5J_FPU@!,?](7H.J,C8993FH$5!NFU7 SG"V0
M\S :$/*H*/D/8OM^^[K0L_OZ]-@7WA5[<P[\JCB58E[*\%/@"A]+@= \@_EP
MYY-:@V&9FJGF@%M_13'^<*KVSL"Z'E-LY>3\C[/3G<%S[[PJ2?S\/>KQ_@%*
M'ZVM@SV78NI/+&[5I>XU PJF,0DT$!UF-$N#ZSA'?B"9-A BAFZ17!.YRRN0
M#%?(;*)C''FJ2^K!E /G.]7E>(0UQ!;K"-*VG3K-DV,JIJ'H+?7LF\5C3&8*
MB"SX&(&(RXF#I-0U^'BBIE$R]^#HQ5<Z %#,42CI(^&^C)9<)@PL61<0#'"B
M3:M;]'CP5-%IE/!!@&U ^1?4O3*D&I_*('_D9R4H4#J-XL 1UI"ECZTSTKD%
M.S JK:N]*D(YY*54+"2LTX!+XS ?Y';3,<$5G Z.:9KNNK&<!'8[I7>NC&@2
MIR!F8E,"3@.?H<-+G6=R,ER-\4PQLJLHN\J#^90$,\X).K0&B&9+X[@:[?':
ME*>6T,1(&+UK0;A7N7&-=$?%25S@G&&G"NX+C%% "ETC^X6L$P:^SJC ^X#O
M8O(1FF8@CZC['"HG$V\P(^";['I_1DXQF, 3%&P!5"5C<; *$PC5(R5E:K,T
M,35]+ @P9$A&HD]2"513K+9V%+_"IYBO\7#@U8\ZSMS> =;E1-,K(+\9">SD
M6")7&/'Z8#TLS6#1>Z*;EU!:=*;[+.$F0:_7V2E<-.1UCLPI(%2P6[*"MI0C
M#9EK@'M*ZI(:#'*/Q]0-)_.28%0(<T3"6=(BLE?9;)I7$(:"R,.HE]4UDHN-
M ]BANNOX#7C\(P;7*DK6P!!Y.\&V1F@7/6M"1%/_/WMOUN2VE:V)ON-7H'7D
MBE0'DN8\6"Y'I#6X=,J2U4JYJL]]N0&28!(6"+ P9#K]<'_[7<.>  ),4B*9
M)!,GNETVDP3V7GOM-:]O>2+W=8>%S+ _>&J 9AA"4">Y]Z,#'Y%4PY92%'!P
M"G3C$(Z"<<T#?T8(BP5]8O$<+2R<H5?K2R1KA-6ET+ TG*(#4OR;\ KO\!>!
M[U%!K"NF4 64>Y+;P]OLB_KX>R^U"3W+NY2'9?'&!$0W+,0HT9?3CY@47 8A
MW$5)6@>7@"IB#C^;98$NM+N%4Y2#G^&" CD6B<Q">KS0.QJ&AO.AX4S(_%QB
M]O9>S5='\*]0P,F0LLTPT" 0!47U3C611'4!V=<49TZSF'2=N7]))R:#12>#
M0:*S52:?-1:+NJ>FZ2JE =X_R[NE8FM0POX4&55<)#%U08N-!7@+J3PD/\WX
MV-%H\?!G6D!1_62$R2F\,PPWAI<()0N>MO"=8%?D:ISM*5RI&EVB3\J#G]PD
MP@8!\*8C<+I("L"%L1#4:D'(;33]043UM4$%@B<50EH)$6I"%Q,6'!70"^1,
M>"GEI24@'QHB3#Q!N8G<#+;,"^LV\2Q=V6H>*APS]9R$U( ?HD_^DI[LQQ11
M%7_7?CC5]-/BR$ZG>TP@<@$E/MR$^D(HM"C:9",P<&^$"WVN//'CN+0&[I.G
MSE?$K"F21Z1\JWC@6O% P=D\-R)5U@I^SN70B&8,TE!V43#M2F-.M'(Q)B2H
M*KP.CWOKY#J%Z /C5 QP&32F8JQDLS%LHJ^E,C(8)(0KCQ++N!%P7:A4!V\H
M8F8)>$]TC?!?,?K"?1A\3RD7=CDF!&,Y&]QATQA?3Y@>DPAL?H)N4W,>U0P*
MA02A9W1:-$A=CW"=>N-4)@M\;!U'^^I>(@R0;>Z)SA"NL=)#DM3[A,VH,S+[
MJTRC?PXQIOO-9:['P\?YD0-P/,HXTTDR]+5$1K?%&-\=487V_\RQ>NL?F6__
M"EZ!_0]$.[ _9[A@Q#K*,35]=Y[Y*J&%+YQ0R3=-B)4M2JK) [E%Q"%DD1GU
MS&- )9YXJJD)E/JT,+DE5SA1-@3#[@S$X!@U$L%/B^-O$P579@!BP,LLPBU^
MWF[:4\PJQL;(6YYS1-="H,Y00X4K;7J->D86*R'7A*)P/:#KE\P]+ZV9^,'U
M7+$30'@V-&@'<0ZD 5@JD%$,Z[!%MU@3@1%^$3$4<W*,2A&>?PG2U+MU3=PT
MMB%D)D"RB)X1G#(4#J)9HL33\M:2\C8_,XN^BVKWZOIG8FDAG:]EC>"K:*H*
M!!5 U]7U*W6KAMV>_2$*@8V]%$.FGTVX!BS^EU.6J,Y[!A84.%)!IOKOR#22
M%W,J&K04>B_U)E MHC 15WZ?NRXTUO9/=K;*(5"DMP[^F7GY1% Q1L!IUH.)
M7A-#NHHYJ.G<CZ>77-J#"W$E)M;S 39XT"67/>;%ER<8G'2,@!_M1(Y>4^\3
MUB(8T*HOA:JMI$034Y.EO\BLE&<O QN%IDJUAO0G4)6\WDLQY<7\T+&2.5%?
M^^VI1%8"+8_Q8:6T4982$.8-V+?E-3DY\I*+'*"")</\@YM,W?\P2>F@.9"!
M/&NRR,6OZ,/:K1<*+QF_[,A.%7D74<0:+9U)N2?A8#&K<< VM=53R98$%](Y
M/$O5L5]IKZ$PA9Z@VV7,WXWC>XY7K?(V(U(A)B;WM)KB%UXG$P-ZY@V5T>)O
M+6.\ETH$\"UET3^C$G_%2H3^GM<T$A,NQ7'I0S$"30)L<462FQB7B<M'T!C/
M8PT)<'0RQB3B#JD@?@:IJ)PV8J4V,;E.3E>CT"OJ,Q[B/APHD[4]<OHY+9G3
MD&*@E+08$5X&(;<QZ8B]D@3E2Y!H&#%</3I$<E 3VA.!$0>*M>\,FD.G!>]5
MA-?[X)S!\UZG[_2[0P[(XF(NS9VIN7%@KS(^#>.,=@[>MW!T"G6KZI%.73U2
M63TRJ*M'3O825*[G76B_]<8Q)9O9SRGQ'5S3B[5" IB.[%_??7AM_\)QS[<8
MAW_W#KR@CPU;)-? Q166H+10T!+H#IJ7[2:AR(LL+WXZ;/4NNX5!2IAQD#&'
MHK=M/6\YK0'(ZOY@HV@#JQ+U1![LAO)]!K(V93!\[$U)S59_; JXI#FUW!AL
M3$%8H<?8HZ(__EA7XA1M$H3]R]LE!B'X&6)8O8*>\47A]K%PS!%RL%GZ7>!@
MKEKPA+]KY7K."J& DL$(;"!>^3^G0<%M81M(XO+#-L&A%_$:XFG\B;!K5IC1
ML<99:F.<*E:I-4^,$>(?8J6 ":!+LUNDSRUR/I02PQ34U",NT4PG!AIJS$PQ
MQE":K 'VDH>A%S>L:X5:H,V1<ENZ)!1%5A3M'%[<'S4&S>_6M*_GS%7M6#(A
MJ58#XUH3,Q9;9D77-Z$Z0I 0.V6)&+<K!IU+MJB,$3P@/+L.X?!FP3U-\"Q3
M$/UNUQD-U+S-"V#(]#(!V8\#OQX>OFD1<K(X?6$]ER"+-6QF5[)^.5"KHJ]T
M&]P%UOVAR4R3.'JB!Y5J+W(5%\IA8S?C([O+5G&-90ZN7 PX@=3)J:<W&"7V
MM!HY X!<YR)1VWET">$CTRLL'-"3<,N(*/ 4?O'8R[D%^?>+WML[;"14/T3_
M2*$)HP2+R?Q:"05A[FIJAL"M,K^)%O6\VVLYW6&3W1(:>]IOYI1P4L5(HC\%
M932PR9+G(HDJ!)0$&562XB!"#R$<4JM<@+8=<IJU+ZAHP#&%:Q#RD]A?TM(_
MT>[1L6>6 L.AT^LZW6ZSF(^CIDK#/ZLE3>5Z<-BYO!Q3#\N/@91C[-^GVZ6J
M-Y&;C;2.8R\#*BQ(/ X6HX1*JFRETFSLIO**"@5)"F(<\XJ@1F I5+@ 7 $;
M0-5U^4^A2]U$](5K5GKSBHI\E[$/SAA-+RZ;VO$X"4S)#P>L@:U8R8^^4:R+
M=#..&P<3[&6-_4875[H^L%^Y7DF\/2WNZ])3N3LCDZTF3(>(UUF4+D$X 7TG
M,"6H*HS$5+'<7PD'9\;-M]LE:?U$%MNC&L.BI5.X F)^HQ<$2W3GPIN_/VL^
M4V$(CLA0?]PR\7ZPY;^]Q%:V=/X#F;2;PQRH&$^"]5OA#>[FSY?/,!#Q8QK+
MMY*W.'$#N3T.<#P3X8ITNKGPQ^^F4Y/6EW<>)MWPH<'TI2WVK&,H&&W2CX'?
MRY?BUO&I?W_6TO0I>6)9G&F#P%;ECE;XK&)SI3OAD\FM,+<Y^$>\)?'7;/U;
MMIFK*_E9Q-NOZ?[N]S3;ASQ,\#I8KWK3G1[CB5-%VY$U5?*\PC&]1[GRL'I8
M[0V5#:,&B.(?[/AF?-%N=IUV9^BT>[T7JV)!J(5^][L\10)OECYT_\LJ("JV
M+K7/=^4G5OS6=FMYOOZEH\+CJ(ICW?-4KOFAS6RWS+6Z[J0(=+$G"KTX!^)<
M[IUK-I<(J_=]FU<7D^8Z74YV-A52%#:[[GQV=E=V<AS?O)KCVVI_U')&E7>R
MWO"^;MG7Z-T'#)*'UON9X'2NRJY@Y1O6"L]O7,^V?MQ6Q]SJ.MU1V^F-1E_W
M@MTN_F3)>*%*<?9#QBKM?3X4'#B#(?+BX?CP:U3]Z<OUC9]T)GJLWN^IJ.UM
M%G<UF<29F<?5W6NR3\U 5CWZ0^LX_5'?Z0R?D'UYT>H.G69[N(,=%Y7C\6VV
M@X.BG4ZO_=CW\MMNW2NC)RVD%"SXL)@S.?H#Z/5'3K?7?SK7J],:.,W^$]KP
M<-AW>NU'OV#[5GRB1M9$ZCT%!=<:=)Q69T^G<XP;[O1;3V>S>+K=454V]A&5
MVS<ZC:^$*?EKI2EY?GYXSQEUVG":>PID/)%X4 OLC4X=4_LF&O:=5K/E#(?'
M&!%ZM+#T4Q)%X!'W6TZ_/:BO42V*'ID3>YV6TVQ7^5-U</KX@Y?U?L][O\?C
MH[.FIG8C,6I8]";(_A3;3=/8'V>IA)<TVAB._@R'3F<X=)J]IQ2K[CO#3L<9
M=7>QY^./5K><7J_KM%J/7OSQ;=?P0Q26M9\>/?DOVKV!TQP\C<S(1;<#W%9E
MG9[97CO-IM/O5+DS7[_9$_!;R[0ACC%/BPKO_)R'H=/J-+'-N7;!OJW":C@8
M[*] Z/PKK%IPOSM.=U 5IS\.)W9?T3*>TGTT$J>J,KZNYWQL"CZ)4LY]$>_Q
MJCB_)V=ZQZW%6ZRE[B4^K5[B_\'V]3?E[>L5^SRGMN+K7*/_;PH&8+]'7#<8
M/SY5Z@;C*EYY,@W&#'?$2%@F7E/%UD^J1;3E]#L]M. >VLR3;3!N.=WNR!D,
M>KNET%DT&+>&6/]490"<7IOQ.XFY>"$[)4X@3(KE9QVG\V2R+0Q(NXL8^*GD
MTUI.I]5Q^H-=U,@>,A2^5?K)XW%;*\G>L#PO=?Q%W!>=41>TZRZJN(__6EZ,
MADZK_T3VBB'#P:C[B+=QYP%@O'XXA&OAV1=X#8\B[+;?#$FKZ8S@_[>'5;;O
M.40N]TK"MM-OC\ \KKH)9Q,\WR\C@OH<-IWAOLAXK!K_9S?Q)SSGR@\RC+*%
MT@; P4H2N1K!DH^!!_:60&DWNGO*,1Z%!-H7W9J-_N%2LV=&NXM6H[)Y?B_2
MIDXWU>FF.MWTE>FF5X@K_19QI>MTT[DG5NIT4Q6OG'2ZZ4#>N1%QW\Y.6??#
MG:<8]N^Y[VX[3YO2#SGXN]O,9@G#LR;V@W& ?7'UH;)KU\9$J35Y].,+^#Z4
M)#_/G-/ZM/=YA?37)[+/IM7R-X+\"Z/PDF;5")."2KU%OOOH3ZKM=%L=9]!]
M0EA=<!=;_9'3:^X^XW2,VVTY[2XP?/?1P<EJS$VS5'W8=P;[ JTZQ@T_*<3-
M/JB707\7NO[4<(+0M29EF(EQKF+&&\XGQL&93P,[Z*+K-('=1\,J%CB'3-2>
MRPDZ V>XKY34$Z!?UVF!BAEV#U*-4>,%/0457N_W5)3X-HLKQ_3]WT=_.A<D
MW_I/HTS[20'ZTLE6=_$>?V3V8QQ-/&^:V+,X6MA)-D[\J>_&>DBX+,:B3JC$
M&/Q^]&?SA(:NH07:>TI#U_:ZX=/P6I=Q=.MCF<SXWI[YH1M.CL]SW5<56\<9
M=-K[0YXX_S) =EFK%'5-O@?Y;]0:.J,#$G"OY93YU6$=DC^[WU>-Y;9KO$RC
M):U3?2!+?>BS7%UF>;7E&D$.SZ[8O+6:?F\VVCT_?/ HZ? 3_R^/=_GLIZ*#
M4J:FRHF^\BCP@.B*;/I_J]X2Z WOUH^R)+B'/W$9GNTN0(>E]IV;P&>3P$T2
M?^;#Y_#S,M7"'?%;+01,2)G[N/?<6)F7L)H$/J1J@(9))XM8_K#\/E:,/2[A
MZGV]=>5%_^ORTG[K>\'T!_NC>^.]A*?])_/""7!!K_O2_I<;9,@0]N6E^"$)
M3?XM_$,NT[P^K7;)_>GC9QM4YQ4V'D;QP@TVVG]9.> &M_I9C@9R]R_MS_=+
MV/A5[([]R4O[@[OPF$(?(J1%=VC^ZGOY,R(3TE@1J(I@X]ASOUR.O5D4PX.7
M1'ISM?V2U2)A31(9)Z[%9.7+S?7B1O21GB>KCTNUR8_^3^\6(+)3+'E&A&=1
M\DE#OP7H\WLWGLPM40C>Y5Y@?R&E$^%FRL+I'[_W?]K/MNB?0^2"+;<G:;VO
MA6VMP#\#2?T<S6.#YB"L\:.Q&P!Q/2N9>UX*;TYRM>F1@D)R*,&=_RNY*#.L
M7+==^@"_@@/<\<'I//8\>P%[G2>V1[7^=+ZV/E^E&=#!\> YC4IKX[#,NN[:
MU+TE)<7DV[S@L9M/\ESXS17G>XDZK$84ME?A7]-P57X=?@_=;.KC+7T5P44.
M$RS4Y[MA[^^M9LO,5F;HSRS2[&L2:>H6/Q)SGVS;S9$+C9-MW*GINI_6GR,*
M_WXM%-U'<-9=7Q45EM04@M?N%8<V%-Z*V&)?Q0+%QSPR^%AOY/2;556B>P:N
M.P/ZM=L=9]"L&J]0T^_!\.^PXW2:54G?TP._^QBC,Y?>*^CW):HS!U$YBIG
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M!?[A\RR/2YX\$C3=(S68#6L+>L0T1E$??=IU+*-&2M9&P0T.@C)AJ*N4V8;
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MP.; 0?\[PCE_+L+(6UP2BJ(_5[FBTE]:Y5QTC8!&KEH7->BIO>GYI81B[>/
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M.+M*?/?RHSO!6PS?O(&_->R/L7<Y@77A4QU+7 ^X/T@I>Q%-/<9\_$BQUG=
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MV/E..A"1H+Y#^C6G816L6#P2<C_YOGHNR-]&5<[V2=^3E$NTW@UQW(LXSH
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MWY9.&.<S[O4GK?14D5=YENBBNY6O"K$7\-\VW\8&K]M*-D=@\^Q@6?CA$#8
M4O"U=G[S -QO<>GT>"!30HR$6)U4 JA=CGKM8T1KN._)L 9DQ*36W3!ZWEZ9
MM^<8>]#M]P9DDI%I\F+\?,JY@6<G>[U.(-8-WL;M:>VW;)2& 2HLS<YM5VR
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M5X$QF!>'^2<:5F*(AK[DR@KM>ALT08NSW8+]G34VU G?!(U#R@K')53R4CH
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MX6B#EP",?0MZJ3'"9*W9/+RL&8I_"? B=[-(2CJ#DA>7YM</ +/T>+H"#S9
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ML9,--7;^JR%.(\7:"A,JN8E$^=UX5^(8N3#MBI/'HRP8&M0J[H&)?!E5.)R
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M*B[\J4S$J;P27Z*I%[K\@2O.9>R/7HNI%X]]@ 5_VGPMJM0D#<9,OTZ]C4"
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MX=^9# ? 60XZK\4?7I ADQ$[.^I!$G?\+/Q/\1HS2VZU*WCR+GZFV+#^[&T
MYKYH-7JPBR0*_.&+.62$43P%BK@-3N;5Y%M)BA<%'.C=OQ87US/8^&'L]?W!
M:W'J325CZ#1"7.SOV4^]TH\1FA#'!D&+$-:/I?=UIR^!J\+",T*]#>UN!;2(
MV!=5O!,_MJBK^N4VO+B1_$B_ R$^/J__#(P>F(XKOL@4>,X4H!$@T<[]J1\
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MTCXO;5Y&X)HC-WHJG$$,!JF/&@.\'B$%OAWX W*_!MZ5(1<O2*)\ 0?O]4)
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MXP?J01D+@NB*U#SRYR620^SIQ#AJ_1 =H,28G5RS9+<AA6&BJQ T[(D_HPS
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M5$3)$(,R0LH>Y9LH/U[5Y5"./>/M-V18N"V<%9+E%V.B3$SMN7>\ :F)M"-
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M"8/8.CT_^GBT;59H5ZX V @'^+<_$ -^D-CN+T? P9J=ZK=2RAXS$?7,#!;
MJ:NN<3TJG5 U!/P\P6DX)R=BH!&9I-D0>2^1O/,[ZA;OWQV*$S!U8NZ='L77
MNDTY3W3=0D 46AE7Y[R(1BDW-YP_%CU]33,=YC(">Z,'JB_=S.>;X]A]'4G!
MA:U)U??)R\#,]<CO1R-X0B!@1%"/V\*2U@NK4CM ,WD)F)H'=QJGV5R;)NU
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M2W!+C8U&?;D W*C8>,-:3=9@7'6G'%VEG1=N5[J#R0^4E#0>I'?]6*FRF>+
MVM<RE"./BKJP<P86>ZNX\YSCQ'6JG'MY,'I3CVUQQ<I):.4$5R2V8MWDM:%^
M!Q-!J=3_WQGRG*D$W7]HY2W8=0)$%10%Y4@*)1KK5%=S S\_>C>C52J(OF_?
M*SB<PUD,XB4_(LZK^LS-$SAT*\;DX!G"Y:$J /XN+_ISM$.G'!W^Y/T-W[PC
MITR"ML$[/R'=3VQ]>O=N&QWW0Q^3EUS5_J;9Y;NK7N$GXA*P,#3-*=K-;I-$
M%M7=3&0P*W):A]-4YIO<V&UQZNY6)DFRU '%=$K&5BK/(%/R3SG7+Z;0Q:&(
M'J> 'M=JMEM(ULM,]X_ NR)6=.'Y5P@@9>SEYO5UWF9)95OJA$7U(AU+M//_
MG/8!Y?_UW%QU*^:R75$3!!D.LRD9R:2OY7)M"R/"4T[YYW O!JJ';B&X.=?T
MAJ_E%.\SL&7'5F$L7HO]A$-9VI;A!K9?H3J;Q&21^,F"- [=CYA34ISJ1:I:
MVBGDY_TG?5;BS"OSEVRLD+ZMMW5 OOTA89=\=YR#@O(U][VH%,0*5JND0>S-
M9(;MB710@EKFX)7!&O3$^&8(Y7"EJ!PJ'E(4U:0(DU7FS&>(S@?.9MZUH9(M
M?SMO89.WT8%E5 ,=;%ZO&^A@*(W"OI@;P5I'D8"I<0-]X21RD,5L:)G&V1A]
M3ZGA1I21?3F6U' ";OI@(H<9^3X'J:>41NMN*U<4T.NE-!!JE3-OP>.6 \9.
M,:1H7]Q/9M>?U:X-$Z'F CY@QA-Q=.T%Z;5I#@2[PU8$D6JRBN5A&(\V'N="
M:RMQA3Q'R>L6QN]-S@2>/ 6RE=ZK<I>&)K_3Q]#427Z=1YX?))PJ0&[ET.#>
MZD!$ 4S,^L2NKEX8HNL1D(X.9O9(4ZC247E4IC.J.7;.'K5\Q7F<JN(FL/DU
MW_<JQ>X'E,&1MTUU1:MGHDP&]8Y"O>A++'9*J"R/7.O:34\&'^+H*E($\R/1
M+"P61@+S)&,N]2_79!4S^0N!"WW@IDV9.>]6\Z9EVU3+^5[V8^Y@VZYHS68(
M]FV$[A.,F^2Q@;R?E EKYP++ LYJ/&]H[F5/NRG<$H8N?8^K.)$G@%S6V>+Z
MBM@YZ4/9YZZ]Q=BJM;BC WI$>=BWH,CUDD(L2".\B)EV 3,Z!%34(2IZ7=JF
M*&>@VI(K3P5B-L94BT23JQ+Y"AHI<-?&0/8Z>]SLG_%ZB0Y;%W=I,YTE09/-
MDG07.';D2M55VL6P=N(WV1$>MLH-D;%Q=PPOGAI*#V0X3B<LFU2F20F#YJ=]
M?2D*(3<,):L(WC0:YOUXD&/8$;UB%O#<XEX&+S>N!YGS6Y4!&K%VQA>S+P.4
M)^1KI/94U?!RO8(JBH5-\1VSKY2#),5JTVP6D)Q3FZ_D.QNK-;TW6>.L2:LL
M_\H(-5XR9P5V$,M18'6"82(A8F4)PNZ/C47M;<W4+]@IZ3A!'0H36R@7;-.-
M^"4M8')YM.M6.-=*16U#.:)TH?FNA,7)3J;Q*7^:5]W--V'6#Y:J-"BH:_+H
M<D'M!*S]T+? 5E7A/W#;"R^ZAJ7%$2C7KK*3"RJ.?M-'6,%HLD4>?)/AJI9P
MYFS*\OTEX(J!DE:OT?UAD3V[H#JN>F@;Z1&?O&NG575FR^1(6;E262F*L1<9
M><6N**)OIP;:/N^2)<%)!*E)5,W-,'W$\() X4I-IB+1H_><MUY1R*$N"[%,
MLSA4J,+EKKPXI@P!^AK>J"H-M?-/M1>C[Z[@\1V3,5.5#U/&H<D6-;FF.0UQ
M>@]Y#W&C=%6T[R>_*%:QA0K<Y8&XI)B@SB5BVN30TR$H"P,4#5U@IINH;KSK
M<:7$@OTZL6!A8D&[3BQ85QJ_O7N=^^HOM$"29^!B?Z?[$]E8 .[^XW??\#V-
M*:R:0$A5?+,$+I[^UST.)RS/(KR'X6T+=4U[@/A,0?*0[YN/C]H3%+^/LLW3
M"G8KIQ6PINWDW8U(D8A"R=W8!U%(1XJ$5M6L38W@Y;9RUFQ#RW_5,CD\7$HX
ME.*E3AN"EW$[?=+*#11]2O T.J%'L[/RWF0Z6)NQAE0N(4 =T\5<?P[,JRU0
MHPBJI^$^5:HE[Q$J@MP_P"K&,9#L*NU9#6JPTVK0>ZO6)FA.(^Z$2/XPK/ G
M7.:Z-"V1%YY9FC4^I8K"MLB[/?+_(14,%T_L-H14R64Y'EL-0.),9^2@FY_\
MI>WF#Y2MK,^ PB#T)EY ]Q! -_@T2M@#33\%#9FZ)]!Y8/4/ZG[4;_6U 8(<
MF@8VM:1/T3'JK4<]S)$R62.OR"9!5#$R"6E -$&&!0LFM4TU#R:O(.6M4 0!
MNP<;*,@U-HBC)-E1O\G'OU08?)[HLX=^T2@#5JE3T/_'1&@,@P6"Y<NT;H6!
M)Z2=C$@I'W"G6O+#]_+,82H'1((M3%LH)<HK,/U$UW$,2]TA#3V;VV,JF#0L
M!>+R0QY)!!8;F0[V]=?% 7Z(O4*DMA!,1D6O(3X'U(LPD31TP?,#HJPL253D
MB4YPSS8+0#Y]_[24[P'$HEZ$%?T%R6Q=U%^0C<J7S# UKWQ=W0T03_!EDWZX
MVW'W6P<N\K<9]VH.KAOB+8V;RAESQ2(.O6\Q717H*5GKHWZLM*,5CKIPX;!&
MBE+N' [ZH0:7Y/T;B:>[^[M[?/3PSX-V\4!=UD75P![NECGT<%QD7HQ?.J'O
M,W%;']03F;&]7(==U'UQD5);_'T@1^F-([?;A9';UL)W&*Z]8H_MN;Z9K@FW
M*8?F"FU[YY7!.[;9/KUXAYV_FWMMM[,[EP#^LM/9<_>:>Z9P<EYG++2D7@F(
MY0IF0[S+IRDL:3]:[=1>M<UV9))T5\/Z/":[S=VJ7/U5X'G9Z>ZY^_N=VV+]
M1DQ:?'0E0&[#<Y>+5T)*S^WV]BO(:S6D='=[;OM@CQ-4:-T]M[>'I+L[1[:]
M3L\]:.UO%[GZZSF9S)[EE[O[[L%>:[4;1$I#Q^VVVV5=X*(DB713+P*Z[3;W
M*VLM7NYV00[M;J\.11/+F54@T)I DDZP^E6-'N.[4R%)^2 +&[ YI$,B[89A
M]O<^K7O-I-8=G"\E86%>8[PQR\54IR"FOK=?XS83!@C&55O-?_/D@$73  B:
M;Y\(0'-9[MSHGX"PFOWW>8!)OLQ#]>ZW^_$3$-4]^1D5E4 @0_&'^O7M[@'P
MQYXJ>IU[]<T-_@F(;]K8MS3NU\,W"(IEW?9O.[>!,GT6>OF41PK=.EC:5]@F
MUS43( OWZNGA[%9R6G-OY=U;VA/W<OEWYL6J3(RT3X+B3O"O!/O^OML\:"T$
MG:!8#CZWUYN#_QYA)R 6P-_N88GE2J@_#+@.$]^?F%&;. GI2F*?*ST.M$1M
M!,4BBELP!X+3;N]SM@-!<5>E;\69#0OG,! 0J\UBN/?XPSVX3+X/',CW*H92
M+!HT05#>R[");QH@06#<.$1BE<$0BSTRM09[!PVVTNFWFEK;K51K5WGCS3X9
M*PF[JRN@2GX6E83Y 33.WS#CBRG/Z@=O)8J]_?";R2<K:3"E 516A^+2 K#X
MCCU7O)Q\YJ+?GZ @-W]755$5IULE:9*GO5,@:BAZS5>]INGSBF\J]1QNB.*,
M:1V7L6#-:[(2S7A!=LA+C.N4(2 -\,-OB^<!5<D+(YT0/I(_R,#1%NZX!]T6
MV/0')5OX9:NU[^YV> 85NVC!]&CC)'C;4-U>.'^'6!V\K<S5[CQ!)V=L1;BK
MBP&Z#3A(6O(29Y9>47?RH<R-\QL,\X(%_KTXV%ID?AW4F5\+,[\Z=>;7FN8R
M+5?-RFFHPP693P[F&EC1?EW-A#-45=?!TACT2Y,3ZZIH/[*;,]"8_H>XW_OC
MOXYU>L;(&\B&.*>F7+2@_,?GT12CC!P>7"'OY$S5A8\&<230&HNFUZX(Y-A,
M/1AG 'L47[MFK#'F-9=KXFB,)D^>MD1+HE3_*3;6(B=\,F^5(%]<T%H>AU/+
M"1:>8@M4>>G#V;&<2V0U=BV#J#25-Z76O9Q1G$L"Q?ZYYX^33K#W*EM1EMR
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M:=3H:NV6J7D2K8Z>$P1"1<CLKA7DW@Q43*C($U"AGE3O9K7FN:6=*]<0!M*
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MX7.@B0J!+S-F7 &>(1DQ98@PV8KG.<"32B=R=!6'4I%@=WBT,QQ>C\X)/,C
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M<4%)H64LGRI=*"9T@X\''7*\?Z<L(Q_V.RO&"HH<,)0GKR8,?Q,-B[V%MLY
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M=?P[6\L,ET$<OX^S6-^(-+;P%/ZR(]9@J1LP)X*-*<7NHQ?K#:KC%L&2)A:
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MQ<][;%\)],K#U<*"P)_?/5S$<7/)!Y@/4WKUB>YZ;FSLTA*/VKSI[=-8&/G
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M9X!5Z4.05])-Y*(YU9G1%'X00W ^<C)A'CWP%F$$D^8D2X$Y+4J0.B=(.7
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MB%"E@+-=SU;!AD+V;O_5\6^&%]-/32[_0YLWEG)D048 R &'9@+\#5!M[XF
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M+G<DQJ8":H3ZA[)24X41G[]<V15_U)YK5!MRK5$\:9*)K.B_6+9[";V^,*V
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M7XE)4@]Q;3:IJZ,JL-19>,G%(IQL-?Y:NEE-+BU(8M5E13GPE&BAOH7Z/C1
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M_87O,5).SWI[)$,!X!T!S AX:']B;Z:.L@!V9L!NT[-"C$ S!)"%R!  WA.
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M1XYHX<05_%H[\:>JB-*)<\&T2% ?.:9S"Y=G;-S7"VO<GW(Q^CI0=$*#=$2
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MA1(=0 ?2Q+:FDB;-* G8$IG.#&M!B$AP"*-+".@M5+&HVSL73(NZO7/!M"@
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M<V7/8,%O2=AE'C;X;\D[>.0V;,:_X3K&N;FC.'(_Q%XB0=,SH#_*P4Z$@4E
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M3(\<H?F_HP!.Y.]3U_SLPAS^[IC_<,V'*:[C<]Q/5Q*@9T=3-TG$"R1:90F
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MW_+DVF<7]1JPBI5]U*>#VPUKW_+<L,5SN0SV\\KQI<T/[H H'E;9/Q:IYZ?
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MX?!N?*6+7:J3NX)ONOX4?DLJE*XIR;"1$:@Y#:N]A<MCGSE))PH\1-&+YR/
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M2R.M79R;WPOV9,XJ"M62X,E/K8ROVPKK-1:O5U_N#$C^T?&""1:'D<O&)[M
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MRM>:L (C<WO)K:MB7XJ5X9RI-H>3]/O3F9YZ4O3WYE$I:0,5.^9E6D<"GN#
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M?4">(MJA2?:ITGVS:3)S[6<%-<M"LQ>PH\BAO.-XI/D-4I%Y+%$EGYX7%<@
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M$9%5 PLZ6K5*?HDL[XFV8 >2]8F+:V!J&/811'?T-2C7U!.J5K',:KE:IUV
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M]P7KEL)+:A;<I_BY:)%?[)XBB!ZY<NR>47CW3/O=CZ;G;R,L1^VV6_@[WE5
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MVI7G^/L%Z.BY.64+!\Y"!^<>A&9J"O1=8!J?^FH%$_ET=RJDR3BW\MH@TI-
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MB+0GIQG&+!>R$SS/01?>F)'AHG!;1F6$/>>!6J3W@5UKZ5-N9,I'J)RD^MQ
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M31^+<-9'Q4C_ZZEG3$_-[Z>/YFQFP$?X_YZB;XBB6F>F^S18(16O'.DI9ZC
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MV?<1:4V*M^ZO0S9;T5"/;(H*K+U/MI=Y?>ZX5_:3Z2T</E*::S\Q*)>6$6K
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MM(YA(72^"#4I!PPU=4D2W5V$FOH54)'J##4-^ME!F9*AIC+;BQE[=",6V<<
ME&JWJW:[227M1QQ:ZI>H0=Q#<]1@6#&^5&9?M<27!J-#Q)?BJB)G?(F224(+
M-@&FG &FM).N.<!402SW%& :C%]&@"DYOI0=&AC5$QH8)H4&*+"EUAS9ZM<
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MS2=8)!D BEN>%*PL 5YRX]$YP")CKY.3-OAKNYJZFSTTI[%A/!X?6^:K8*E
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M4)7$!NF<_7[O&^2;WX;VK_PT(0:JY^Z6W6.)"Z+Y5/?P-(N-FL5&:18;[>Y
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M+YH;\0]^U"M^T@=F8RV+_IP:-&#F="ZT&.  &(@ HNM <!*4=WT"&*VQ!VK
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M;Y/D":<I<)5IODO5N +;OR.JTC:=G(2<0]YE SG][<-KWD>]@X^Y@@)RH;!
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M]K89J;Q-.&\<&O59"U7'#40'6/I4#66?"$#S;'"J[<*F+#/5!L8G=R;\#E=
MW?M.7A_A6FCL7QD3^\H<W9ZIVLW?@J!NWX(0&O&0N!-:U0!=,<,<4EP[U[S'
M6B(N]8A--?^(S0-.!0]O2LMR#(P4_,W0S6='6&O6C]MK5-J^JHTC_KIE\52)
M/-C)M2)'*X<'E:XFRMW42W!V@:KP&K+CQF*N?3+M<K H]\5N+[4@+0^)U2CM
M'6=XQ,0/3F%CMA.S)W%O$GXG09=)59E2)#Y5=4JB*DT1936U;#@>_;PW[&7*
M!?G8ZY:$O;8BJKW-=MYJL%?$1LCL+ET;-AM1L'?[6K^#[%/8X_J$,LDT4X[-
M)]->.63:$]M*T55GI8&](9KT1)-IXXM/-#MV[6:2;:(:,ZA@KT13;;PBX[J!
MQ-UWM5AF<*C=!96M*BB\]2@#S8<+%+K*V66WJXJ2MEG6GWD;095+-1JRJ^6&
MC+QDAU5$7=Q;EWN)445DM['SXJ02H:=:KBO7JEQ72RC7'2QL8R;(02'.5_T5
M'N?_:[!\AG,*6,3+?Q"9E,TK?.ESE%P(1@XY4\MVSZDTE?<%4J$.S@"8H,%
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MX<H@<KX])HP\:]<  WEC;_3.3\L)$[/4?H'JY2KJM379+U6.=>T"=-,?.V1
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M=7DQ#RHXDK[?Z?93Q_+B:;#0";Z!% (QY&!C+K(TT*4!5BF= IB>_33X?NS
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MS$J1S]"BC1/,'?=Z&;U?15+:3=:O0+/G3H7@I_RNE^P.7O9$4RB_TA#*5%E
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M5D+]<0@S66FGTL_O_X"E2B^OZD[@=47'!8C:'[#:>D!?-& )#)A0%[+2-LS
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M*VBEHSZ<_XVDU]CM![#;\Z.MAV/;Q6X-M_/EE@<YDBX/-EOH1C"B@L_SI*G
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M2%)<\F+M!U@](;S@JT2APK%BH2O2?9S!TIU:MO%O-HZ]6MRE^M693.6<4)'
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MV3Y!#!9;BUT:!GMGEVU55'M[D,W5.LN)LN-ZR7BULLUFU!V*S:0GH?OW)RD
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M/$FWC#^LW 059:5R"L[J^-FR+-&S_9+034$]OSSY9_UI,H8SMSVS:_4^ZW?
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M+QR%E"GZYO!R\@<X9<+JN*.QQX;,\:T7]N8P<_('.&72RBV[X_&$GHS_[2T
M^^1I^Z2YCNN(@EN;VK:^,=2<_ %.F;:NJ3#KS:$DCP5L'9E'%^]9=.U./\W
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M:=F\DD!4XBGU!YC-V,MD#%4J\[MNDTH,!UH @0B7TJ'0XV.=M+YPVJ!3;.L
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M9"*H/0#0;IT.!YF8MAA0 ZTL(@)C+'6C6&X!B\WCFP=*C5D)EQG4OLK91<O
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MYSXOC)WE>E'5M?"G2Q9%#)%Z4%/GNU[,G.,GJ&)CL:ZT0:OTZ.4WKD>C?;F
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MURL)@Q:'IU#R_)X[)AU,A:,VDT5))>+4Z(8Z<>'V_8"-_4_Z!^NCZ-XQF$A
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M=@>:$KT&4:FL-H'M Z_K1@%N[%U'^:Y4#CGJ\J%)#F^Q'2\C] 4EHB,T[DB
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M^BMK4?_!^U<*F<W+? 2,%KE5B_.=J@6?]="Q^HIIX,R99NIWE ]Z/_@64;\
ME9_J4!V#D9OTJ%;.+ER'S7&GQG=*$U>#.XFE%L0G4%GL533E3\94Q7BL-@^_
M&O)V8333#$S%/N<>^Y-(:=KMZV9?M"AU"G:6ITZEI$Y5\]2I3>D[/7*[:AK5
MLGRHA=JJR+B]'TSS_MM8AEY.Q)?I^FN]M;0?WFJ"I;J6.#I8[[MX#GW S6E9
MD25SA9&74^425F]B2P55N8H&VN(8@-#CU:J*EB78^:=WIY34UJ("3*GC@.LQ
MVQYCG8#S3-)Y9? (-DU-$<8^\"CYM\_ZJ]4/AKA*\9?H=P"''@U6+XY_?CY#
MQO-;X,FWHH\&JS<D?#E#.Q/L*>AGAS/^-NBKIRF\,LR<PD7M_F==G#GFF2A8
M5D DO$#N"D^,G_['63V"WS+A]5E/V=-J?G!T".+%>L(P<N$KAI%_ZWJ_7N@/
M? (I;>\:P\K\8QE;G@.C5("D;',U&,$?WAM#<GF?2,9<B/TB[.T#M,KOPX=O
MPD?Z\3AO!+!,.#Y(Q-#I(WMUO4^Z]]S]4"Y6C7*E:91KM8_QK9%K"9[;J/^R
M:%NB8FK.P27?7KC$ LQ.+Y/$D<T&"TGFWQ?OJC6U'!7RG"5T9C13"];/PM#J
M]QG\A/^_@!T_"I5*:='+"]'+2?6<!YC53K3PEITDL.=W<UGD66BMGZXE>ZUD
MR\RJ8JYKN3B;Y[H,!QOC-?OEGKVZ*S/7CLB37'R;M\FS,_/IK5V/U5ZU,C,H
MK\\,YHB'K9W\/>)M[WP%KQ Z+.D"96,N-5 B&HVLK&4W5+);'6)Z<[-Z7WD9
M+<IXR^_4BD3T2/SP!?Z15=M:^HHUR;TZQIG1(=B^VY&4*[UD9?Y4V1Y_*N^8
M/[UIA.V=,='%X?<F&UNJGUVTRLUUV=)VB&,=[6=5\MN(P+9&_"O12.:5UMI2
M#I #BL9%F[O"IF.81*Q4]1P*=_.8X?9XW8*P\?):G!A0V9A=X^RB813+I:SL
M[G0NV>X1M8%06AU13;+$F[,E4KN]_+]2<&->Z#Z1I74\,:$U@Y/?&/RZ9]D<
M+?>#>^Q!HX1'H^^=Y]N C7QLDR3S,I[<CI(DD1JXK!>K6PY<UM<*66VCM?LV
M I=*=TK*GHY!3Q6F5.@IHI&B$:,(9R8'@O\OG]=;B-J;J($C13I%>FU@_CS-
M@.8:Z*WG$<DW&Y&D;8FH9!Z1//T 6AZ1W$E$DO;QUJ.2J_D85G<CGF0X+;,[
ML)K'+@\4NZR"S;D_9UYK)6?>8<.7"][PA?G^IT-9TJ?AKLH!<K3^NT=&_78-
M_9DYS!/5/V8?&SU@'S8J )(- TX?ITNX7WU][B?@^#N'8MOIMQ,PO.8@S,08
M&\6SBWJI9E0:;]#UMS=<;B#)MHG+TME% RYJ=>_>P762<U9Y];=E,S#>/(5M
MP"TD\("VE,%=*Q%6&8RJIM&LYSSB(#QB"QBL )MO&<7Z\7&&G2L=<]H"OGF"
MVX!EM&W;Q=93<]H7KD1YU;E=#'/>L0?>L4U48J*>4:R4C'IE7Y)@7QI&N]_7
M/Z!U_3$WK]_>]7H?YO4M.L9Q>B>/=IX^VG8GX&ZCODFW!"L)NFQ\L'YV40)E
M*C>9#R/2-D-> _01HUAMO3$!%EW^ ^?%;8^ /NSR^G-@">WGSG6BWC_9B*@)
MFE"Y;+3JF<L65H'A="CN#2)OH^N_(?):P+Z;H,2F]!G?.O*.1SNXC_M@85:^
M2:-2<CUAB7=6@(H+FDSDU<2Y(& F%6<'G.3:P3X<ZFN@K'1VT=PCQO:E$V!C
M6/T#9D5^U-VXCVO4KY3_[PTXSW>H*LQO;HS0Q<292THX?3)_JK2& RIADXN(
M#J==&*U2.=<@]LPAUD3I?$RB<[UH-"K'QS]VK50@L'2:N"U-,FI:3;U_=9_U
M0H\:7YX^->Z PYC=E]ZG_P( L?O!X+O3LTUKQ/IB3-D7T7XZV: A U>IGEW4
MBD8S>SWUVV0KF1, :^LG !Y7:MA;T0QSY_6;=5ZOD5Q.M5?"4#5TAP6K)'%O
MED3[1GM[;*0-$SI4CPNWLE:)(C9K6,%8RVYLY6UACH=T-M"ZMT$Z//!2;6;N
M0W7H9C$[:07S)4.98T9XO,\6(SN-+" &$$-8%<R'W84 <>%]=1UA6_+?@87)
M_.N?@6?2A#K3FU!!,4XBAB<]EU)#T\);&0R!QME%JUHU2JVU&>T:+4SR7D0'
M"XH<"]UA:,QHE1M&/7MP;.N4MT;;@J,I_,X\/PBVI71J]T"TADZ/#VC::)30
MJNNJS0U:Q2.8LO>-89&H'A]"3YY" ?F^Z$!\:#DXG 9^>%ZSG#5H8T'+B+6I
M0<X@VH"<#M!(XM;1KP#-.!\%1SM7^'2WF_;CI9R?VG[\KM^YYQI^6RBV#/UV
MA-J2F& 6N#KGA3HP0_U*F2G[X8E&T3:JQ8]\L! N%,U4[UN^^?SLL6<Q?VUZ
M7)$IFN@CU>$<HB :+*CQ67Y8Y 0*&@V+F^IW@6/87IEMZS0^MV_A9\FQ0MS7
M*I4\[/EO6OUXEY:OQR^AD2UP8AJ.BQ_0Q!8:EFTZ0$.V&+*.NB0@@H;MF@/@
M^3%@2S4Q-UN_-CU[PF?Z4C\*V*#MN[C"R JB*7)\V=09JC0;=6C"-APWT"8L
M$.-HHTFX-($U'H5+ZBQ\B</Z\(#P1CSAJP7@L:T?C*85X( ].1908*BO0DX=
M%=QE-$W8Z=DA'\^HX=B#Q$B;U(V[.%U$##,^S(BF*=Y1;IPW5M.>YK<4V8!I
M'.;.W^$%%G>^NO#.5PM%8 K"O,0++J\M'CYQWQ^CZ=/E8F'NK5>&"..-P@%C
M:?>_!Y8@AEU[KA_P@5^R1DE0L:! N+JAUQN:/I_7B $4)W ]'%$]&MONA+%$
MM8(!FF'<*HK/:;*<P'2>:?(PGP)MCI#Q_$4_.><T@$?1EK,&FIX<3/,*]5+'
M7(USC:5,HQYM$GX_BI_7,C[?2&,Z$;_9!DO09EB"OFV6L-_!5K(UAKS^QSG7
MJI3/M4J;:U7+YUIM8:Y59N.I@RVLNBZOLFU['F;"X.V.)</*=M,*2R9,IDIC
MA\*TFRI)0:/KW'_YTKZ\_]9^NOWGM=[^_=OU]=?KNZ?'WW[M2I5AOWN26#W0
MZ[,:EPDLZR;H%$(JO%K!4+_\XQ\@]S2/V20^QJ873"()L?.3K:00;JDYW,8=
MX( [S>UO5#POKV8HIS@*%RU%39X&YLBR)Y^6'91^ZUM_,0X7)*2+#]9'CM9L
M0>-T3&VTB7M'OV%=+S2]B8X:<;D(^A/MX=)ROU@!DQ/H41F#C_YPQ^P?J/9T
M7&\LR%O_@-J2&.P+%!Q-IB>Q)V>\X_S/@EI\']&^,;T +%Y0*I5I.VWY:[FZ
M@1HP&GC4R?%U:/6&.@ZI\WE[P>B*R7N%OQ*OI\. >@R,'G4S (=^^>6V4*H6
M2X6R_N'2!<4824R_\L+GC_J39XUM1KNX(PL 5KT$<>D'>@?M2P]L_KO+SD=L
M)=G%R>H($U"</7,\@=7BE<%"ZH>]P/^(NF+;MTS4\\%X\G#8,/N)>B2"]C]-
MQ"XISS9JSK;P%01PUT"_!G6:]@(*..BSP80[CGVN+X-%($^)S_!9\"/6M^!"
MP8%"2MM6(01;)0B!\>%;?1H[3\7BS!-SD564D56"8^)A7UT.$9H9W]=KQ5]K
M1?@L>$6S',$MY]B+_II\L5GDQHCEFKC'1FC_8!H8V1MT@($%.CZL.X&M@5GA
MN2-:&G5LV@180 /+\P,%J;IOVF1MX0\%X'6^,$)^&MSGB_R_1\)Q%^@GU7IS
M6D/YXCK/3V#O/ @[$?  M@\"^JME,S]P'>87\,%(.4FJ(UF>3^@AM>8AC'I@
M8/\9@NE6;A#S K,QC7$A/2*=]37D1' (3IMC<T*4!VQJY$MB&<GC15];N(H>
M^>W04(9;B[__]U(1?V_C-8K&@@>))K6^F%4ZTSGV.,,'"US$*U*4= RO3(A;
M:SS[?G6+O_^M56^T,F>C[4"Q^#X6-P%C?G@/W 'M(%@B!3[!G9)7RD#'4JGX
MBQXU<A8W<K5@W5N\7)7U+E<YOUQOZG)QK8=7-%O<.2VT0UP,U5?]P^W=U4<L
MVAM9/F7Z"$U>E9&D>?69#9HM5SI!LS)182;!V>M1F/\9/[BY:N-X.XN1;!,>
MTK1[2YO([V[:):RN=W<K^=U]"W>W'=#-Q>B,S7A0EDM&?I?'2 GZ[:W>LRUN
MA()Y:-JY6,QT1VKK7:UJ?K7>T-6">Q.(C AQM>2ENL4KD[Q8D<,#;E@E<<,J
M;_6&K7-#:OD->0LW)%(<(_6P/1[; %R:EX-[^7!WU5;51;@6U<2UJ+Z5:W'@
MG#/,4T#U&CVVF(:EF[KC.@6/#4*GCY#3PO' <]'K:OK#R!>%3J<E><")@6*%
M>O9JTCO7B5__G;^] R]_X.^.,GGKBQ)XL3W*3.)N@H)6V7XY^^X?F(>!=O.9
MW0_$COWO&'CKN(H/.W(T1*<IE)7CC$./)<[3PGX<LSGPOZR.B%KVH]R*S+7[
M ;4?I7R'3-!OE7"WY[/[C1$0SCIF%CIDN.->>/'QA#S=1:.,//+"<[L1:<;7
M38]1!HS5I\B/S\8F92KBCLG#:L99M::O/D_A"C;R>9;?"QY9CNCJP=UR1W!K
M*/'(#\""-6UTT/*41#1H,1,2CO,70\<NQH#PSL"'S(*K:OI3$0^/SY?67X?,
M$4$6K@08<*=[0U(/C)ENT604OU* 1>Y8F,B6H^&%YJ"2;Q4)4%+9EZE8"(0Q
MQH[D.S'0X7H '1Z5PG!0-Z2<>Y[4V)U,F^NB>(<?5 UV:68<3(%](H8Q?<FA
M2%#?!?PX;B B2KAWQ.@@#$)"FI3_<U\K/>F4'C439XM>?:X!HVN'SX TX9%7
MPD <.B^,^]]]S%_MIWC< 49)/KJP"+M^=G'W=(6-1:LMWH>%^#Q@<#SVW)]P
MO0+,[D)G!= 5XQ'#Q9>W5*ZORT77O[SEQ:PS2>=:.DE+DL-0F<YPME<L= !"
MA)%SO1U%.S"&QO\.&.59=DF$H7Q"JA$&J\"<8JQJ,\;J^8$%[;%(>YDW*/G8
M#)W[4;1*$W<,\RPQ[=OFS$7<%MUS)Z8=3) !+I8YC=*:TC/2^J7H_,9?&4O5
MK *S@@VLT@6F2 [ =/;_S]Z[-S>*)'VC__,I.#X[;[A/8(U 0I?N#4>XW>X9
MS_:T?=J>V6?//QM(0C8["+2 [/;SZ4]F5A4W@0"!+F[SQOOLN&T)JC*SLO+Z
M2VS&IARM'V:X49FN)\N%L(KA=%3=J2=D5!(R"C+O< $5%*/2F\*L0RNQV%]F
M6>_DFYB1.E:$G9J\"'A=A\3J.H#PV&0?/+MY-X*?4> 1_V#(!G^;X@Z)%W=$
MY25Y]1W=KD[ZD2_D'JAEDB7RN_$?%TN(EW G^_C<3Y9/CBE?#Z_BP.]'-1QT
M';)?#_"QTMICKYVY;2S@^+D>7*;NLVGC@Q%=+/W<P7IM2*6"D+ 81#I4,4BB
M$$0Z0"%(5A&(M&T1R!O6 G!OL4.?LMHB\]I,6-<25D?P<$ ULVU(9IL>5E T
M8K:-MO"YP@I<V-95^#;_ IQ?SWL!\:A@P_7A]NNL(X/&K+A&G!$IUQG)\=?D
M7?EK4E5_3<[RUX3AOR5UD!I2:7^-D2CA(C;GK$D;G+5-5]\./#8I[;%M>G^K
M_+*-]FTTVRA'LTDU-%NO>V#-IA=IMI3@Y[@R!?Z+MJ7_\M4,[M";8%,]JWLM
M P2^R_9:R-]E9PZ=%MN"1_N\]0M;:4%O1,X,&R[?D0J=%KF"TU)\8M,5A8=I
MI"G5P*6U#5Q9#5R#MH%K3>XV]FIMJ!K8ICM+E*MNU]FU[PZL\NU&"1\K%A]&
M/^\;3E*58JT<"@$0''GST4&*S'\W7F1L2@;?:)C4X\&CYZX>,#[A8]X43&G+
MP$;LCY[U)V%K*64;81)A$L:Y];Z7&.=RFW#HKU$L)<536:#TP"\F+]SF#7%[
MP&!US+DUQ4TPI_[1M?$Z@NOL7RO#^67MQ7>F*7]UX>)7L?G]-A:X2>\A23BT
M3MD^6&U^81#GXN.?9ZK>'<J_7GW3?G;,E7SK^E9&/TY&(X["OZVJH'2=*7P\
ML*8;/D^O9U_1AO+-$U(C_],=^8_PRDXT$ZQ3@.V8@NV\O3QPF8B##Y2@3Y%!
MJ-8P"$64][/KW1I87F$M:4,".-B*(0=OM K!B>]MR#=2@ D=+1?+.4!G(F$8
M"4B.8R8P<R%!('GNB#7RJT/FK86]&/F.6HQV892YK/,6>FGK+&O$,<N6>^&7
MI5_9D5..2$&F>=C;-M-\P5]2-<T_'FWF>_*D;^<*](ZK$&#<J(<@S'Z0#9(%
M1;;F*$0LTH-$VQ!KA5,#/[V(F"L\ RRZQVPA2_CU.\5P.+QE< CSA!K0X"RK
M6;;!8SSZ)&T,7V67&\!I85R4[RQT!XC/_-),QM4IE!>_Y[&I%#_#G$E^PV.
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MGC40Y"XRXZ-K/A0QK%W];OG4%!B2@%EX$5?(%02Y%]D2+*R7UC#6%4[)N K
M80#K[@0#3X\<6 +E8C7SH:YHM0(KG/GJ/G$'>;BI<,9P>*M(N<J9[2IB$HC
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M3KW7U'V3;V]6+'\=H$_2R5!:G5AQI_TB9IUQPDF<V'[B-B9; U,7O#Z#EW7
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M!0!&3\!I9Y,<?DQ?U4J08L3ON\?W 4'2[S;9#O=(0NOPP,DAK=3!M&A";+M
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MI4$GH)N6_%M@TP2Z0 DD" @5"<T+\&-"=1457,'$(Q#DP*G<M/]*U!B7ZMM
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M8A(6@3D0%1\QXC'MH.^=!1@%L4L!]X4Q23-,='>",@M-BY99K),?6Q0>%A
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MUXF6Q1" GY67]WW_TZ3;?7)RW2F".7'<SYK]M(P1S&7Y60$0G8A22^GP!D7
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M+43%QY6"_ 9E\L]P9E&2H.@FH <^FQ8>/#ZHZ&+2_B<^Z)]JWI%(A1X?-T!
M=?!/[1VPZ(U-\5TX#FSI^#@83+?R07]]0J&T:4+ANM Z*M%N&(,5'6Q+"*F
M6B[K,5E)DO,T<+.IJW5KXA:G"CLO^X?LO'PD,O^5D3D[W0T2^^';+=\6$@_:
M/DN"B9T*I!-KFBV0[#N1_N1Z KE[PIQ""DOW'?=#XA*5X>4(@ZA.]^QY<9NO
MC""X&G\6UZ.#?L$>LV_"^M)]WS7'*Z;Q?4>^^O2WZV N:G2R\!S(VM@X'6''
M%L$-USEV]W'V!N3V[K-Y >RW-D#5^)J8"^W!P> 0&2N#M,Z[2_A?I9VR@*+:
M+N%-LT9^)AR/CH-C'".@##M=11WMNQ?\?$<IM;NU5HIJCM/SE_M)^V_\>_L
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M=VQ%BSJJ>!GV:1'&<FDASA!$;"LTK387R)$"Y*!!PKHM7-WV3&9^,%#;<,P
MO&@[$ KAH6SM.Z>8BI=-%X5R1=T/D1:';<T,H)8VEG:"G=XS[4I*[E(?1;7+
M,WUA6J\?MEV)/NN9_S$8!/#5HSZ8,7FC9>D45^H$WT'F@-#QL$<6&1BHT 3C
MDDX!+&[\,#T2)(%="Z^($#4)&K1%A=Q@3P,;U&>R 8F>B3IY"A)%D5_F!AG*
M]&WVLO07T;]TT^:'L4@X*O14^K<\L>!E@20E*WC30\67^1)W8>SCG_!K)GA\
MS-IWX3KP8L_W(L]C#XF<HI7E>Y5G./:_1>FVX;U3X[W?@(B!Y>:F/?58[P.P
M%ITAR5[ 6BOX</!)U!!3 SR)!;6E1Y@"?R>?D;=J>L1M%$+Q3- /^$FFJLD[
MA<L9-O$)>Q J_.!!= QB%T=>KMS)G!X.?UT%2RYEY'7_G#X%YV&<C[\WX?"F
M*R0*!:? <[C &]!7]LT_#=.\8:995U@1\4PRGXE_BZ8. =7B![.UEO&L6RND
M_D!?;'P.BP-1$ >_O'2-9]-9>=:K4"E<6Y'R\+BZB%EG;07_$+?;$L9>BL'>
MDO_L<&V%@RP4L@3A'8$GD#CFBVE9=)"Q$5POM!)_D[\Y+33(^Q=MK6'&AAEW
M/<&#P5Q#YOS%%8?MV!?"4@.^<VS&A^3DROJ3:T0YBMMZ+(S)OB2>D7R$C(';
M)\,V7&"B"-\1SWGL0(;UVI!U0]8[D_7<<<%D05.*41^X!<Z33=*9CF+\,!9D
M2,7UBFYY3FBS82@DXT'A0XC446*33N$?^8\A?[_[C1M,*.K9 RQ3'YL6)1T"
M1<.US(L)O*/+_&T><98MJQJ?U[!GACC-62://*B"($3]&@177./?*Q,S)U'4
M"QGGR0Z+T*!EC8D!TJYC'93P!)%N(,I RS/3UYF1Z2O">H#5(*3'L8OX7T-O
M*XI_UP!3PV.1.T/B]!;TF=)[A).0--"9)QOW$#:\,OX:.?D:9PQPU7D\2EKH
MOXM'+MF,+13-)H%QYCJ+\)5PE2 RS;\1N1J>Q$G\.7HF%/<!3R"4,6_&X<]/
M*Z&%PS3&;.6OX OH%RU6B^3YG&<C"0J9M,]B@3D2LBD1F:TH6P?W3SR;G21X
M-L!^*@$.A%]FI,)P_7XX6@STF&E/K-4T^7073R1>T9*OX...1W9OZH,]>>J@
M$)&6KO,,+A^ !+TQRYR8(%@H_A*-]J[P&QCC-8!1%CI+04Y<@@-8GV/'=5F4
M$K\:A[QIL]P[B:]GW;38</4X+*4I!9'7?55!90QO@JW"B]9P6,Q18\<1^E\C
M($4BP3\!9!D>V$C4%A+REY+*,2'D5S8XZ],DH\RBT;,$=P*M.?83,1(<W7\Q
MK&<Q$Z@EX:DCS$V>DC[%ZR*OA#'JJ+_SM ()BI)SMA:SNW -*RI<:7@_F'P
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MZ\.^UBGG?VM_\E;+2QNKG^&_\E?3GG*?O)M9^G,$XM^#-UDE"G;VW]-0$+!
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MXYXH33"V\QSI;N5[OF[C,-;=SE4<5.J:R*[+P0+9K8^?)Q_8859C;^*:2WP
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M6ZB@ZV$1;U!!R\,"3B#=7*1R,5FVGVXG4KF8+)-/-Q"I7$R6":E@"NY[C,X
MJBI/Q7T1SZ"6$,<$B<_T&/(<+5/(1.4Y7&:/^*S)JBK/+K<B?D?"0GZFB>;K
M/2)(4)8QYFL\(DA05@#/UW5$D* L_["CY4BU@K+2=0U>F0C3*13J-%+Q>S!]
M1I&X6/%[,%U*D0!9\7LP/4Z14%GQ>S#MO-!$4M1B*=.D.X4FE<)$9EEOL7XF
MPD1F&6JQWB;"1&;99+$^)Z)$9B7<Q5J>E"9Q 7^1[G[";Y&8;?T">Q8S^8%T
MQQ*. C M4V"M!MO.!-9J,)6P*WG/8J;B=B7O6<Q4]J[D/8N9^MF5O(Z$.3/L
M2EY'TF/%KQW]/:1; :8G[Z2E9X02-,>1]MT/,ME&9[9QZT^1>^9YR/>(I('K
MH@*G@;PL'&MI/=WF(PGPM7T9X/&[1U@OD'&GN\4.U]P[<$P#8T6@$4*&=^4Z
MLWL\ADN:P=R.8^(M28VS* &W]Z3%I4O/P9(;UDJ&ETIHH)$YTRWOGZ]8I7^)
MSA[OQF,TPL;][L=HJML3=(^'\(+^ZQ:G@-X4ZR7Y'V)>"]TB XT_N<=FXYHC
M/-CDN\0[O%45M5N@5IREFHE&'JO-O!NR%PM#1)L3%3A?D@P56W9LK'%>^S@U
MW5 I> QV6F0UH0XK#;T=4]N.<=:B!6:.\/8"VC?7]/'PCG_&CE0W9\@X&XWP
MLXP;4W\R+?Q=Z4D7;>N^1V73X0I/06['[QW'(.H8T1C> PX%,?'\9ZR,FM+K
M#-OM=A$2@S9OWXAVRH0[%97NT0+9 2+V?T&B#?X9W6V!0ZDS0^XZ1!%MP/]O
MX+":M*!N._R_W!I)EB7V"9P*1%4*3.87>\#/VF8CY+="#SO'JAK75(]^]^IM
M1QUT^P5\$RT93XN6"DUA%O(9^5.2)2U0F#UMFHTC=X3_UB?QE&D>D)TW)7!N
M*C/Q2#?2J%9(A362Z?89)(!O#O(^(!_:)X_*4KIT?PQQ\K"FX>D&&#>./7E$
M[FP#8/E'^*@L_]%/37B$B,*:QO13<4&(**PPVD^% 2&B,&TIY>!%B,(Z4$3M
MIWQW>:*,'<>W'1_1IYH__MW]]^H3?(N9]9.%<]A_OL*B_/SPZNVYZ5R9KN>W
M+AQW[KAT=MOZ*YYOM?[[_PVP"_C'Z@?T3^4??_L)/^41?TW60G5[V2*S3*^E
MVRU$G6?+C":/^!\MULU/6OIHY 0V665IC1VWA>-1ZMK (]\2*:)O9M0GMWQG
M=;67OG8U;BW=:\WQ;?!,X@D91(ZSAXN6IFHGK=C@DO=1U'^$+K\5^GS\&D;K
MHX/%:'W%O\&>W6O]-1J'Z!ZK87C=>K<EF;YAC/$325Z J/S1,-&G]?]!!'/F
MX0P<3R=:-/JVG'$D/4+KW^%[X!2CA=_1<CR/"N:06?#6@USR[BY^QZ=E>K!>
MM\X\<FL\546S)WREIIRTU+;:H3?#_\#C$9.PY3S;7DL9O.X-_HO^(OKGB&;@
M+8]D#Z&\]*XK:$^P$-X<3Y3,!;*6KUMQU9CI>!!T@D64Z%/,TGC%-04C/(_F
M,OA55\3[ZL'XVR>LUS3#(2^]O@S?@KR+/IFX:$)&5I\1+2&2_J=ZTAL,3KK]
M 9%UY+@&OC94D;A8%K:_4ZQ^LYAD'OD=8PC5UZU;N_4QL)8M97C"&$LO&.&L
MVQL'%OX)'L&YA?"4D/X$RV?B.6)H:',R)?9"7?:GIA=[=CB4)G8 )G[_F+#/
M6*;_5$X&P^Y)M]L[:3U/S=$4CPD9Z5"SB,CD4;&+=KS'"46:W'$4[H*F]H)'
M>3CLG'2Z;0;@H2;L5*YP'#:CGVF40P48ATC2MU/PG08=]37U<2OW]?9__N/T
M]!%[UA;^"]\NL*EUK_V=AZ@?)*AYYL1&U%\\C*;(""QJ9<3'GA(G&W,$IZ>[
M_&;O);]Y/T$VVNDTZ;<K5Q'F?N?8?%OA563,X]I"?  YY]9=&5O$Q1$-OW2Q
M(G@!EAMG\396.A-+$2G;NUMZ*VPLICO3U[#CH;S!\U'\CJ/7K0?L2!#[+E1G
MGO#(X%%"46_#%ADX<VR.=&J78RM ^/J3UE,0#GHDV4G+P=I"GT9?:5O[#400
M-B,  @\=/;EX3Z[V7O>ZH2>/_KG#DT< ;KGQ*LVNOR==H;K]4<=OVOKT^M/K
MUE_7G]W]K?67:[MU._(=,DIX8)2M@3EIW00CT]#-&?[D-?[+-_!_]?!F"*OI
M*&[.D;:L+CF)] 6_W 11_)Y-;-%;MX]Y #KGCACXE::%WC;]"GMEV+SAVJ<@
MFBI%WEK?5O76&8Z"* PBFTNC$.&:"Z*OECDSB;<?13I#M#1\,/X0/WJM:\J
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M+Y =H"](A"#2J[QTOEX!R3#O5/G'9R>3UI?D8H^*#U?QP7'I1U\/2^7E2V_
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MJOG7#N,7E0L]V#V3\* O4.71YVGUX/9)9JH,-)TKT_5\FGS?!>YHJGNHZO+
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M$:ST)H%A9MXH?E&Y)EPWWD@>X 69;E<\#50S&^C6EI59Q:NLVM\4K]<%R\<
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M-U%9\2TW!!5P5?GQ17C3,'5W^:"3,FMJ8]M[ M_AOWP\,\F\*Y!;*BN=XU7
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M Z+T""0O5+)_/JK002H$CK,J+6(<%><@Q8')E,F:T9>RJ9C; D0/)O,FX41
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M=Y+ZT=3MB7=F+'1[A(RKP#8$-KX0%?OJQCG)#V>B(4FI< [ 5F/!@E-N'ST
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M_.7:;\_^.<="_EV>_<6Q?_%K!B#!QKI*'C8%  ).SKAR@XG^,X968'5UIAV
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MM^>-._0KGAI+[T=-5'*MNID^U&E#L_%@\W-06XMF-5488-WR?Q.:D3%"P"[
MHB/':- .ECQ1070-2(8U=?#,5>%:# E!2XWL#9!HN_I)^OG6SI&5@1T-K]4D
M'\YLM0>#L;:OQZ'!TN.=GKYU$:UL]Z+AO&0ECG>=N/(X[J9%<2 -8LNKP?+5
M^M7C\'62BL2#+-^ILO!OMP L1FW:,SCS!-: -P;H%&.F1S1[U7)>""H_G=1P
MVCB8-]GP-!!S@3<DW;?2"C+JFY+F;V6=$C[O;SBP?>[%UV8K6]C(%O(M E<)
M@$<#!>#N<3LQQ(-"0ZO7(<5;FCPI*)="<_M%,LB+77@60[B@!4/)L!H\Y8N7
M)0XS*4GGOH_$D!UV%.I)H=DF,TMS]!E^N'Z]S9/DV-BC8@^9NY?F,;7TL9YC
M(KGM"M]EM]+W"/MMVQQ,.UEUWC*4,-EAAZ+"8!>:IC8=G6=$/B=0SGOD7E2,
MLD)(FSH/)R<+V%K5\PZXGIKL$R:D63 A+9"R0^O1T\)LZ;;7\\@F6,+)^#&2
MJCS6_9Q8"B2FZL'L__5540.D./O]LV>Z)*MDDJX:.,G08)H6RE$E.^S<$="?
M< 4/3P<&V">Y:LR3__7-\S^T,7L6Y,/E&%NK0<LO)7KZ'KMEPP9-H1A@E1<T
M#U'N;F65I4-TUHT^FY>*7%*83P #[K>02HX@I:1]#;+O3@K.,ZNQPA^5L442
ME]L8-A>NI\\03]IS9&?<LS[*(<L6MLFI;8S>'V*HU]PHE-M.4-!-#G:;^(4H
M'3D[S6Y5([K?>3!,VD:PRIDU%'H[=YX%15=/M8P?O)$R$YK4 %ZLQ4+)VI:;
M0&1;] $I UJ\:> :44_P&D/@^UYAP"9V[ ;-2[=A?YV))0\9+BPW)7LIVT6<
M,2NW7S@YO[=W*=C7;XQQY98E4S'6A*Z5^V;Z:K/Z<C^8ILM7*1&'"VF6(75_
ME=P!V*Y2LK,(_0I2>Q3B+>TW<H6'QVRSE/#!3*[*XO#-/3GB=)ZXJ4".C3/9
M'"CUB$;Q7/GB=9(P83C^LF@*>+$PF_WFM&F=XH? D[%@2?1H.@.!"AM;13Z(
M!Y=S34;\]Q<7-V@DMC.(!%4VK]:?*[C\*!;9"S_*9X\7&/Z-Z?/A?3TMK#+W
MR63LL'[DI-M)K,>25=^07"\G$KBJ3.&&PH.L3,GU%JRTV.3A&D \_=%HZ-RS
M>!?XDQ='/'SR!<:J4#W"V3N+,&&LE]'K_HK+Y2CE(W5BT,XI)&S6Z1XM3+9F
MI%9)?(<P!_=*%WX;XOAL##NYM^L7QDXG4V9<*9'6UI1$*)N<Y.#[P0?ON,KP
M)"*](O?0(I!-TC!)C953UR19:V>PQ_XSTN\*K'1Z<DSD$6VKM*!%D;*K>;*X
M3VQ^$N<P@J5(J?W?=JC.I";7 *XSZ^BP-"8UI)D&DEXA: 5$:@?^?AJB2K/0
M8FN" =X68P#/YH@NWILK_&_V7X&9L7+(=69P7N,3!-MN\/0%5>GU7 HAJ3H_
M,\\,89/@',[)\(PT&Y="(F M#RZ&[H?IS<?YU+T62:! ^2E:.,.B7EY"URS%
MBH6QQM#<DU:-B,YT]_4+-JT/B:^W:&J\0'"RHF0S&9BIVK8J*N_^!*]9.]_C
M&VPO/\#-.K^6D\BS0;BP0U#M0<OA $FHY/H!Q/DA'^*\Z\SQ8I[3H$ZNY\MS
MR2EEY!L,T$74=C3O &V#32(Y.]1IV5@VM8WR1^JWWTIJXX&ZJ&:7RTEP0:SO
MKL\CT^'-&LL\YB3V/$'B_ /7Y&FW!LVD_):ID=BH)R\9:&K="&STID)?F]IV
M8[GP#4>LA*40JS6I!XS,1^40WT"E+5,5)#O>M'N+ 6P36U:VMMK41J#-+L*R
M!#5(_KCKZ5= E/(H8>+QS0T,0)'_>BG-N)H+&?8U]OIW1<.19@K1Y*4 =?G6
M=YI34MD\)PK/@R4#A+0C]$;!-1SB\2K^/3V:*=]1?MWIX77,=:XO0G],"U O
M\U?6%;CZLD0MJJ#,R^RK9.^5K=Y7RD1X0\H[!O&#+VD[ CS;9!<ET@J/7TY@
MJ6GX+4L9R18Q)UZ;^9QFQ["'"\EKEV5+Z/)E-PJ.Z7LGH)H\$KW&.B%[RSM&
M+5FOAKI6-%EIH**-O4 ?I6FM1>@=G(3S;9'=G10N1UW>[ +9\CWJ3H&12DJ5
M5R9QI)LW'4(,]*><C[(C UDB'E<XJL\J$RU=0,\,U!%>^$I0.I]LN*WWKD^Q
M=$#5);5Y^%,J7JT!@0,B8 ?]I,S!]]'].#8MQ^T?V7:76P&.2:U(K[AFX=O-
M2+PT[,U]<7WOMM"K68X:[BJ'Y3DYVF+53T ^OE#3%# Q2&!%]B'\#[8%9\ Q
M5/>(+%^MGX[@EQIK44UFT%ROM?B O3+VI=FK3/432O1L_V;M\U:C^R?+8&_M
M]79Z51:O7O.W1R"C'E2V+=]></D-#C[VAQ+8(]K8@0QVU.D&83DM=KKJVZ-K
M?<(QR8/N!_9& 9,#8LZV%%G8[W\2AV;[]B"HT+[E(>[KKR=.!2+GR#XK@]VC
M.DIEKV<!G QM1, *VF#%Y[!%EXE!I8IFIK/Y'8L'UJXC<Q #JJY#J-M?I_"A
M\*D)CRJ-%.%)<3-GS:6 8YS 8*_6_/KX3..]*&,0S-Q!UNT:Z$U]SR!<CEZ6
M%;KX"/'N#)I!;4,1Q38_ G:I999$*D="9P+PU4B=F'''Z[?\EO,;;Q1]?<5/
M&R4[''9FH(#8HT!AJ^^_4Z*3#?(%!I'F"?S2 N73/V2*/N)V&F=>MZYC#@X4
M^1"P8LY@-W('7+R16/@6_II^_[N,5H%8MS%Y5S9Y%/ C'ML=LM)M;-QN5)^-
MAT7!)B,4SP7(WA[/0[2AV?FXJ$/NHV1;4[IG44T]OCND)1LSO*I%5J?/%<)=
M#B%FB+E[7S\RK9XZN0N"?@SZL42T]^1LFMN".-\V/8B-?X<5L31,T[-<X6+O
M\L+)P]BF<Y3Y* *,5FH;:S;PR>5(F&&?H?Y!Z=968S"2YMS#ISV[TK_?ZI0I
MM*=1\3!MI>O'J_PR"5T_>F#^RY3T$\=/"W/;1BI)9X*XU0(GG-!*"%H92:-1
M'6"TK5(G>K<I/RQP/WI;VF#9#BV0)UH@N.=Z3@%JG>QSN.FO,(&6< M@,YJ9
M4<=RY@&2WF&-RY<O.IH1FYIWU&YRK/1TNC)3GI3?1S!A@-A;$QYN>=/RW*DF
M"_@@]_4, S=$+#E*KI[O-=OJ63;B,PLQ;9Q69S#+^SGFT,46P &5W>7E2U:4
M8TS\U.JJI3Q?D2*O<?(NZO1LI1K3N/A>'3_]-!<_U7*L/CNJ;5\49=YXN@BQ
M7Z1ZB@':56%O,MM&'WTVEI&,!OR\LY>O5TFV'3.R6& 'I:']'#^/2.LX+6N1
M#I8:?3*T4%CK[DEQF6DD^RS'UB> W,#C^1[( (!@]P5N'FOLXA?ZY!!6MT4N
ML"(I!8TW)1_,.7#]-$P@"-W>-I:]B2RX+"KKAV& ZX;@VH+K<_GNS@4Z**%]
ME)^VAS8#_!&Q[\$3CVL&*S6OF1X)8S4@E2;F4#?6GJRI&]S@/ERK]>?S];A'
ML.FE6&ETG65N$A3)H?<UO4-@Q09$'P-;KD3A:^K>]UP+EA'[M??\O:A"#2*N
MMF+4;5?;T)QKT5S_?4=2ZMOC'#(#4_')B/.:GRR4.8X\</).HK#4F6=)S]QQ
MCLKUIRHNRO(/B4TN:PJ,M\\>GCF-.-\URP\BO,+(#'8T6??'#[?]&,+4E7B$
M\[-;3!7K'=5Y_%2R[4+NO]=['5V2/\V?DB]?=!HG^+7I2=]J@F_#;%(UUG?O
MQ?8T,XYLS=:*]QSS'\/[9.3@ID8T=MI]"6+/%A.,A [<^_VT!>96%H(EAAF]
M?5>Z9)E-)2=#5-C)5.'1<V-+CJ2"0S].O9\3<C9@@Q^I@@2&]G34FSZQ<!_*
M;& /UFB%'6BLB-> 9:W4+>\G/91^=FY@N=Q&.NM=JB9ZHT'U>8?RW2-]JHIO
M[(E3M;[:QL$"O=O1P!+K>""'X2Q?+'U*7GN>P\!7ZFM-I$1#)YKCEA$Z3><:
M0_ QU6V#?7)(0 GAJ<KV%>X7F[RD-7%@%G+2I$L1/K6^T4\KXV+:%EFM[GQ]
MX^;&KG]]IG+JXCQ;@3T)W@K[RE2T9LP%;'$F6/JXO\-,1D/<SM7ABV)A\735
M,^?93>,L'$1+SYL7+^$0FYN\E3^#9JC&L[R[ POC_4A6PG+(9;*_F;&-U,R"
ME;^=C"I2C5,GT?GR^R;J%'6 GZ 5+"#S6]D.3?%R![L[,D"YXA)%['FBFHIE
MB$N"&O#3WP4F@5;CNW?XHU,R)>^EDLPVL3XB(4[:L+"/NN&S GTW7J\E[4+
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M<0EBK%'G0N-[%/6]*O'BX6%7+@7\#+00YT\J)OS9BKILW9-;6AK9FT!O5@H
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M!)(C11N\"HNBG<%F_5K/8'RO\?29Q R4ES7PMLVSOH_^?#RF$SJG)'N0.!+
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M;[]N:\7WS<( FJ'Z-:(S6>?%ZK;][U;URN!LXV#+ZDJOVMJ8W?:(Z*N@74W
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MAYG9.C)4Z^H\92#^=SZQ?4UW3'<$6\L7MD;;VL@"GWKE-T4.0@?-8X V4]J
M(=]YO+$QF]@IIW@7N_Q!NMRO?)0?\H2?XN8F"]O$ -6Z-K&CSZBC'XVF R:C
MJNE"BL%&W$)*=E^(%>_8#5)C_?]8@G_3\EX;/;T2.A*L=#ZR'P2-WDV^,+K@
M>6,Y #J:,/!B.:LY,V *&-R(]C4@642>>.QQ>/&-U>N#-@U8CL9265R@TV:_
M!$.@-1)GQ')TXH-W[(9Q;(&33U'$0[(OHLDHK:-Z:ES/ZB)KO/T-F%_G32N[
M\'2M[:94Z-F9<31,S&I7-U<9.^EW^H]R?[_AZZ;]P8F)1DY04X-3)F'[<77)
M'K_[4?K%\WA73=A-Z\<!#@,THG5ZM$N-X39,GO=[BUR>IB4.BS,%V-T*C?<Y
MA+A.=7&=%=8Y>Y>2MJ8*K0MT[SDTP.;UMXV_)&O7UYP+D_7T]:T6E>3G2]&O
M)$]D%W!QXMN?35"8S,[Q!&2M<=,%(I3Z6(Q\59+X-_)U:?8$,Z(KA*4#YOA=
M%H4MRP=5DGK$SAJPRQ\HVFZG?]PX(X7F)Y:VU,_A@UGI01U-TCIS@(]LC9Y6
M*TVC*?AP(%'5A?;M)QE<#:9.&N BRWL=0'=IJ?'CU$MT!TD*A,9.Z)H:*W.%
MJ_?JZHV)L=W)'Q+/7?J=G9UKE\*!PK_21+UBP[*QMQT-+VM;^<YR@K\/878[
MCS@S<+'& ,S:&* >E.*ZK!^Y$/_S:M5L('O[3][[ODM<CCI)N^A ?_8-W[Z4
M*<0 KS# 7>K5?LOPX$N88)#DVZ/-\9(NY1="C);QFA(03:T;J/ #\PGA%@;U
M<!AON+KJ'6*#(C^VN(<[A-]Z?JH/UTJZF2Q\7':,L^U(,TC5CV(N>-$M\2SQ
MR^<.".E+H^_[]H@Y4Q\=(25ZK8\_\=N$=_EU755P5EKQN+5,N''6J:BJ$2;A
M?HZ1A=-%=^/2UWB;G8A10=H3Y4M/PYJ["?(44E.JON8N5T"Q,^=ES0A/\CF)
MDY1'GI#>/=[:4PT_UXWB8^I68[YV[\7Y9/&N4T'<6O0R3;0L<<ER3%B4J^]*
MM%GGF1[V)]-MKKM*\(N2YTD2@:]F1QL6)(F\Y"VF;[UD(YY+?X3,8/3LA5AV
MG)6=Q9> M]SFX.-.\;TCAPR^Z24T,=+RI:=U1F2154^[.PEMDIT_).Q&QWNX
MGFH.9%#TSOAFJVE]S *Z'E>U'@AO[.X],&Q@:5$E!\X?YRY/?^6DT:F66PGT
MG31)>B:_>@4<\'9=\0*X(<AB9JO$'@HZ$DU< 8A3'F[6,NWQ?F>;CN+7=QDD
M61=<0Y(KLBDW38TZH]CF'R3V#;QX^FPBMH]^+_6AML\!X0JER8,0J:NL":K,
M=FL5&<5SPQITH2>$@N7N$I1Q/LZTN+M+L<G=3[6I[Q!YAH:HP*')XD-S5EFJ
M$+]NFC0CFQ2\(FONI[!,_R50%+G1?+150PCW\GG2K:"AX HN3G$6]X-A!SDM
M()89[5ZHSIGF+)QC^YP:6S:D4EJHG,GO@?'Y.Q4W5JV6#3MB!D,V"-?\I892
M&O6>D )3IZ *GEJ>5?2=+&([J'I,)$Q??"""TH309R^:D,-E%BQ@)JJ]L7T[
M*S;B=FR6VZ9<_,>.G"#+GM=H#?2V6:6T! :X9==:= IM\4E&Q6^\8,T-5;P]
M />*8_;W->#*WAHY-S" 8(!>YJ "UZC+ N5SD1_A$HZ[4LQK<44)[V]ND*N5
M!_BF!V:Z>%_<CJTH!R$RNS\5>D=SUQ!'L=="0U7)WWN;R_'8JPT,\F0E3" T
M9>QH[QIJRI4Q.7?5GE&7,J<[W:FO_Z"NE!B[&C^93=[)X#-PC-PTT"CN&DA]
M+:&SK?6>4;,)*5R@(N5VX+$]4_'"_TGAHK>OJ8V2W:TWRT^-PTDW'[] VS-U
MP9O%9C2Z8@V4KVMPS@>I282^V]P7BJV5M$EC7/K"N'1@,I2W8O?"HVCL]O@N
M_Y[E-T+:WAZPE$I#93U2M+C71KT@S.J#C7,B?@YSM1OQNTVIQ"QE\P+6[Q<K
M>]_@)LV!DO%K"(["9 \7RS4?FTV]X,6)QV?9T=D:]7;@PX\?OX;Z]<9\-;I2
MNA'0MU+#DJ6L8P)?C!/>UB ;-YS9GS7I^TGP]:?Q6+(F\@U-8Z5]G2@-M6#]
M(O;W^^R4;OC<8X!6\1E2C<9%RDJ_)\_-,.MVX@H"6G#[IZF%U%/F\.9&T7$G
M-'>1 S7]''R9VN4\5( UW@?G\7?]N_<;=@P9W)*S@O4BM;T$:!D]]N FNS7+
MT_Z2O*PM=4G&I<6A3I%6J3UJ19\=:NN@,S)#18Y>#OMS3O&X'$]9](L&<QH\
M))<)5MC84H\I@_USDJ=R]A*,5OVYI8_-[D+=I1JLWNZ=/[RCD/3XN+C,-ODI
M4K:E1'B7EX]5()?MV<V%^&<_I03ORZ)>',ZXI1-\.XW'DYQBL%C6D%)"S'^H
M#EF&0:PL2'A==]P&[<RV2@-@/-N9#[K7OG-U,_/"DQ'"IV'?W9_*-AQ^@RL1
MLLIS-)T1K>4C^;+B"NS?RI/4"9G<$C .36.;FSACB;: ON3G+:A.[;YDYX?N
MQ]YHS;W2+1;9[2/M!5<=UM;D>0NZ#I[G%&W4F&PWJOWQ0?F[C(8[E&;$(=U?
MK!;\WH:NR&6ZML7-.(N6_8?ZY6G9K1\23)+ZZV$88*5;ZV30VGR)/ZW3^0H&
MU9-5V/T[;Y*H&:D9 ?9[)B(]Z#?\&& 1L@ZM-TXX)3#]M9T0]_#+. I?2ZO_
MUKN+;V0M*^T3G%Q7*^-8L1'_,E]#IE*TC]\")XA8'']3RTLEY4/^P\W8['?D
M8!^.YBPZ)X/."/,D2\GO[4RQB_<*7D[/W?6_KQZGYW%X;87"XLNL4+?&@P]Y
M48MX^NNOOC$R=R=HD\L<3X%*4''"Q@&2,]!)2#E_'AZQ!9IMX4,1*M>QOS^3
M[7&%$TA[WW"<B=&R1M;"-9/6VAJ7SDQ@PV^,T-*>*"HE\ARF-2";VQ 4P=X6
M3BPDQ%+=ZL6XGJYNW)LWB59R/\>^^$1B*_%<@5%WC88;2G57[0O ["V]_'%D
MZ2U^#H3\*ST4[%(P=!8'<:+ZL; YFY@ *W5>*:V@:XE06<S'F[&=$[.$9@MN
MB=RL.B_R=,VK$3&DO<E8>@L?!WMDW(DS?)?+MNX58N#CNZDLE'J7KUF,7YEB
MR7S?FLAV</X-8%#J$U=6))W0%Q7:> (SM0M[^:''8MBA64??4'H&58U(Y:@C
M6EOG+[G<))U+EA#<IT&,BWWV%P5X$3SV%*+2>\O6NX'O&G)E%<K3=Q=^C S>
M[1YCJN &>4_4STPO,=JR900XQB)E.B7#>L+V;M'%JX=9K9].-@W3SK6"_:SS
M[<G]2',37>X>B\,5DC9$;GX*WQ]:YDPB+EX0'V+ZMB3VJ224/;K(]^T%@<C:
M D-#+0NYQ\>88B;XS&J30H:HVU@=Q%]?.&CG([&, ,1H"T!T2\P>?5+1Y#3L
MDU+:B5]U46;R<C.YC%JVF=B%E'E(*7UIK#$76)$A\H7*K"=X$#A93_ >WOGX
M2%7ZDU 0Q1&E&^'#70FVMT0)"LHX5E^()-B1T>76PFFBU ?]!-'VUR7D?+%U
MMJ4WC*)6 V&1/-/C;=JU!5^V;T<H&RAM/!Y;_P2+.I3A>3,F?;7+)]CK (L>
MVV6M2A>(KR:GCU4BG68=18\ELY*.5?T;ZMPN[!I9N"?6,_-CST=WE 06&L!:
M732OMF]L&HFF3QT80VR<83KP/6-]&C>S:67AX[69YX*C=4^*7(WXUJ5'R(7?
MD543$)Y^P@"0W*9>##!9/E9_\^1/'S?^]!')J4C:P]+H&.IV^='M\L(K8C=]
MR4J\I?'8-T/VI_ZT"8)K4*R&:M%)4S.T2EEG;R;I[>&WS8PQ8Q*8AY_4^6+T
M2$?A(@-/HE/JNUAD=(+BS8WTRY9<\^_\>[M\L1C@A5D^ULB9_F4%3*4FP-[#
MI7C.R/3-C_-/W7<U>-JAZ8^]K&U2M]8VB=0].!=Y-GCX-31\JB4((;NW44Z%
M\DP=N6:F[XLRF!_80JNE57.FO8UD6'1',U<:;MYVN?,PYVC07166*>(O+LS]
MI* &I[)B*__D<RHS4555:\C6\O$RROB Z%'@D[RW)CVD8,/YX66PN78<2:U^
M)7N=9_#%48_(A/>LL9"WLL9'I;6QHTD@=B5A]]Q V3)W9MKA+#ZWH,!)[KF5
MQ?[KC;MA;:'5O<+G@R#W.$?WRV<1T@\62C>5;YW&>_8H3,(]+F27>Q0<"?!I
M[JV_/*!,4',^3D897]XPO=5K6"BU<Y*E&MC>:"K47EHXSS&0WO5S;8B"W:VV
M$JV:AP&<T/)CV,;WHZ>=TTW\BYAP&6O)'#/QPWD-U!'P@J:^1D_3_3Q18Y=M
M;>_QRX=Q6AF7>T4YQ67N_7W-]C[@^=UH7'G&Z^NQOLLU'E($-4YW5[0R4N)=
MPJVWHYOL%(_$ URGS>W-R*OMK:)L""I]G$(,F.[.#[XQHT9^OY.RQBYD*%3]
M8C;T_IXI22MS]7M[%1N/R\&>E*VOOA-3](HM0TUXD)UV.^W.BB,2<K R3_VN
M&S,E8N$C9"-HECY&768G68C.?\#'6X:G5C]>1 4]29Z00KOO^%X6M\IX*GU*
MNZGF]:*?<7>@"33_C+0%VF1?*CV6#QW=>3J!+I/1,));"/]RBY$BV#? 7J)'
MQF\T^:V6].J8VR+X2213NI"JHFRH B<&N(( :KM7V*";_!<VN.%V'LX\.?\#
M _2\8]DE_VGR/BM\0LSZ-S3(^6>A 4\VZO@W-#"*7K^4*?@#&BS[,7(4>O;$
M-[6!?>#A'S]O94DAZ3>-2NVGM=E/Y=FSU?;@0]/O5L0M37Y.A2S70_D]U /T
MMX;\XMGW&^^7J^DTBJ^P??A2[^=,X)VF^#&FGW.>XSO+T8>]]+;/5>;WWE3[
M[-();[_'5INM36.K#=C^%-KNZP2)<BOH-(E)_E#TTO2RAC\/5DJJI5H[7L1/
M/8&%T]_!2MG@SB(0&E1HC-+K/E,9/6E_^23)V/4\E,0#HJX>50U_4E/:*;2!
M6!24#GBHJ;5XNX5!%0&&I 4Z_VS,.M[AGT@*]"1W^*B%6,LNLJ]+)6U<7CA^
M<, ;6B(B7281[]53-T7C6QAE8==F7]5T 8LSMTN;%6&.^>20B IWO^P[QTMQ
M(XQ^^JBI]66G_BC"*<;.93/.36(_HUDH]*!C1^;S0@P, ^Q\+*\6S7/S777"
MTX<I@V7EUL1?EYK(P^S10FL5$ZDG.YNAPVE9#>7*(>/G("5JER0C!E>A+1>3
M.$AT8T073]RC66%/Z.@S"4:5R]PFCQ=5U#_)OVO(ZI@<@.F8M<+2IU(2A=2Y
M7WA!JKY5=K@L#4J Z43+O*WTNZ%,CE+MGN.;Z?'E>8.$HF#6=$'E[[#&:*LV
M\K+641Y#!Z]4[=[9+-J$_N$":N($Y)LS]ZE4:B'C_N+Y7B&J,JUJ4(/(X,:9
M4]?. L>H&6<5,<T'QFL:"WIDKT@]TA;(*IM"!BT:LV:6AR,A;]&H75*M')3-
M>,=)'4W%L$CG%/8)F'O(7KRB,%[50U5:QQ;60BMQX#^P@"M^][/+H&GH@RIH
M(*NC@/D'J[JZ4(<'\0_B)2=:B<=PS.Y,B=35V4G_\'P0*^4;O<E[Z.?'9+/W
M)%[Y8#?-L=N7XD'<MR;&>Q%H(>N O.T8/^'*&&6/NH&($SFRNYU&*659.&.Y
M$^CS$B,%JF:7##J"(Y&IZ8W41J<:-$63L%?9P%)"4_JG>Z'"I\)^3B*<Z:"J
M!N^7-'N?BGKY+<G;$X>+_!^F]_ZHS<9)/9^9'5@@[-G4\?;K\#3J19)"<\=[
M^W@B>]^^9BEP/],*<ZK.?+H5<NSWL58C=BQCE[G&^=&HT^'[W3$ZNK"5U(#Y
M*E7%N-Z??+9)ZS"JL[D!J_O.<L89P=YKC>7D*J4P#8%UCY@3!=P$<X>O4]7Z
MX^A[Y!&'1ZD/&QO[126ON;K!#:3E<TT6,8"EO>>/^+'ITH$MWY4:<; BI[M[
MFKAH&B>M C&S;,I/Y"KZUBPCF,)Q@!H?GZ%TPNJ)MQG_ZV2+GI<"3XEA/%2(
MO6/.]+79H8,H&2];X=7_C[VW#(LK6A)%&Q(@! O!@P6'8,'=0G"'X):$X$$:
MEV!)@-"XA\;=&W<+[MZXN[O[:TAR9L[,O/?FGOMG[OO>C_WMO6IYK:I:57O5
MKNV-^W[K!7&F;^;^S.[/(2IH<8[L#AF?UQ:X=/39>>HB=:9I-C+):!_.H<79
MSO*)V7J9+NZ<!JB+SX]8+!8IH$!9(O_=&#^]:;Y^^N6TG*%3;F$O7*/]63:0
MN%= L*E?H@S7X?#)XDR<Y 7-^(MRV_X-G>M;K/*JX>V\E?HJH4_1O9JV1SS'
M@B/U\A*R[]6Z/VKS!J-[=+Q@SKZU+] D(;P#A+#KJUQOZ=<YJYP'=7S&?D'+
M[L_&,7?Q2.$8(B]T(M/WFCYOS&,936BH"IO'C[L?9\)W(JYL!LSC0=)M"\S4
M6A^-_7[YW4M+D5M)(X%BO[XJ8T,MNMBL;8<]0TT2\[5#4&7!VTGD[E<ECQHI
M=F_HY)%?>JK/Q=V8.SZBH@C1;$L^0!*KE^R;8/"/HMC%FLPW <WM%]E/!3-D
MF^Q3TH^!UILR1#^K?AC(.4Z?9WNM"&F/>A0N]?9+>[1@C'V6D[J^#W<:@E5M
M;^5*=+V 6:MW@\^)=K[@3)F ].(JEYH&)=+G3QZOCB/)674I5-="D+3,Q!Y;
M57-_0)L9?8VQ)A/R98TK.9>F)=!(W2\:DU;SR<Z.*F-^1LV!/HC\Z434&&;8
M:_Q$#ZWM<@M*;[C8\RNP0HC@?&X-#R7ZB4[**G?BD_.,9NG!I(&]E"J?4SH'
M_*]?\L.AX-X1>RE+#C?Y*<W:FB(_/-S"J<S+_NP",:?D,!7Z1N20.P"F2&)?
MPA917@&E$A]M4Y2P9-H\47NT5B/--=D+^)OXLT )*@+GJ82,Z@(<I/ V$F)#
M<4,DU%_694/;_IEA/XF"^"Z'0C()5#_;?>1!!'O:8G^195N(UQ3?:<,J-,@N
MX 1M-=N>PZ/0'I]9>!A1? I&+3:&F(\B"^Q/;(N+9(W.SL"9[+S$&",#\*33
MZI#Q$6F+.%3O??<H-3"JU&AP#8W/!PT>S,50]8$:82;+D(\UCY[KF(*G/N6C
M.2 !Q4$:'_?'Y*G"#W&N(S;KZ%IQQBW(D%(YY>$6!R7VXE>ESU^A5^'CI">9
M9LKM,VR^0_'_.>O,-L;81Y]JV/^<O!JN[2!$[N4:7##2'G R79BGG[O\MH/D
MV3#Y* (4E=(!M(O#E_SY0"T9:B\GLW!;<KK$L$$P9<&BGZ#:KZ/N--BT533O
MEWJ[(2Q&^X0"\[MB:B&1 4SIL25Q+T%#TA[DJ*FD#.O,:Y$C9_I2LK=N=A+9
M=1[;WI^K*<8\SIBOB=I7R> FL%7\*7#I,('=I%V,OGU%ND;1(HC=S_5'&QM,
M>>H3:I+N7-!UPN_3DQ)6?BW9F(\!'\S<6-ZU$+%\G6909V4A^XQ"56<-8""D
M97.=A #WSDZ1.T>)K,/!Q<!+>Q;O#A!,(#3'T1]4!;,[27#_)*,H%IB"6ZR4
MQ(BWO.)3!O]%-X&(THA2P)S6_*X\!TK#Y8;NQKKYUQH8_T:N79T,^\S$G;09
M17$JSB?P7&]$6(OSJ9M#5[1(;-,V1UVH*PK:<TW9^HSBP?QB-=:"QQVEO>+,
M\)L(^9\T=BU;HLKSST+9]*(($ZN_)ZR(<=$\3I#D7TN7(,OD:=LB-1OBZ,5K
MH3=G;"U5:Z)+58H*#H*&]@KY\VN!T^M*3T<=''9K5O"-/O*JFQ#F?,6  B45
M.K\"]!K%:9?1;?N_D"[&6F HN/$>R=8=U0^<DZ'S")B;-Q_(?U$JZ#"PDQI>
M,2(6P8$6K46^4;!.37^\2W"2&B)OC+#@9VA!^&X_K[RDT:7U5+)Y^>4:T2AU
M8N;Z:+7+AE9Y3 ['LD51:D!\6-S)<:M+HT' >S=@_YKP1^$%I]UW1N$93TW\
MY7WXS F=*)2(,-N]"*ZZ=W0JO#Y3/-]"/&U%CMH!.6<ATR>Z;-E.@Y7EG7\M
M%6ZI+>8Q&7@7#QG&:AX8YJG= 8R"G-ZT #T5RD20_(S+]_W/[4MC"W9P1.&3
M]4/KT%R0K+EGMD#*+<_E>V?Z9LW<P/1Q"TREL?&L[4WE/C1A&AEH3#Q/%,P<
M$K-[YV_TU8MJAG>IK][Y:#N3$6"$#HQ9(^L9$)!D>#K-PPNTF9RZ?8L[JN.<
MO' GV?)G3 N9[A4\0"86$<B5GT3Q/E#WI=3 ;\7)4K<1W(!T _NMNL(I@5X*
M$3KM#)VOO@B/['X*]*XJ:@RMWW+%TF'TWEDRA1^]-8\81.@,V=9#Q+ R.[GZ
M85!5"AY51>11-[]ZNA+^:X@2<9"CJ@WLL1*$I"#M)U(<,9B:Y10V)N<KI:W1
MVS3W@;R=QBK?S&Q=WO]+#L;/@6?/'!=S19,W3H<G>XD^W43R5XJLUY^DV>"'
MB6\;C%%#6(9ZHD;Z>:XX.L]M4T1.U8_4SAA)>)02R@;.LZFC=?:[<_""D-6=
ME>)KU:7EG?C=L6,>!7QR!;GW8OQ<]$FZQ3BPS.58"82>.O:NBE%2T A&E@B!
M"+#D0^TFP )BIT44/]OK+'<;5VPW0N,4D9<_6+L<O/&,"UDZC,,*EZJ._;4Q
M!,KWF]9967@P(\\?S,C:<X_\[Q[#2GI?$S?'-G2XPU,\E\[DK+& KHYW %WZ
M!@%ZS\1;H=T[P%8Z ^=2?N$ M"IC4,]7)3II>Q!L09"&%M0K"G1&2&TI[BR7
M0H?J:X5S],TL[K6?X@[!-^%K0M%C3K+#BV14DL,6\:G>@IT69ZU![5&GF<:O
M@"$B5QFU1ZUL4YO5(\=[#C\NW_AXB;2=0D;'5+CJ2>24A!E&)[B7+>$CNU88
M%+(TIZ896&<EB-K/;:\W[;N7,Q!=3\U6:NDR)N?6R2\W,6T%FDMD*.R)#D!6
M/^Q-V7_.=4 CT8J_1F6E5]X!3 8FWQ0U"&8;6O$7\N>4O*G_%.HUX*IBR5%#
MZ)2_$N81M?;SEWY,;D@UE+BL.U"1\J,4^TJX*4%_.1V.%?,7]>3ILLFV%V.N
MXGC>I_"9,6@4]1<_IMV-*/AJ/GJ%P:A-BH/10*FP?I1Q]SF]N>93_R]N^W4*
MH[$I6[R9/\HZPWB&9INPU=L$C2AM7E6%V,2[$WW%=L?1M=I)N,D+J4C(C4\#
MZOB-G'1NVQ.+\_U<\FG[_.3@MLAVMD DKQM8T)/9"<(RH=*4;$0B1B/J)+.)
M%\4C%L'V'*-)VRI)?"Z14;8V]3Z!=?%-FH5@Y$AH:<@3PWX=.\&(X2I&#0>3
M7DY0$C&82\4DB8G3X"KC4MW5^!_',]98'CEF>]M_CV]DY:.XDFL8E,1PVNS_
MN\Z5BM,P@ZZT89=T1>4=E]#!#O.5[X5BQ9NH=CCDFXY+<#@'-LT9Q:;I18'N
MYV"N+!C)6)ILM9FNL]B&*RFX6IFS*\E14\:NO#TYR^8E;<?I%V2Z)6O$CJ&W
MLI0\[I49,+=UETKV>0O25#(*WZ7C9C[./(0/^IX *. Y(.YYX5/@EG5Q'BW1
M-)5EF<D_9EGMF[@PG/W+IO^S+LOX4IU<ETD14ZHQ=A,!$X6F^E?/LUSNC1G)
M?F+ZF/WR2%/G)!%7(*"JNHIJ.2(N9&)#]63'R()N)K^,V\OW*>.;YT_.! +1
MTN2WM_P^1[Z"4PJ1<($O GBZM0*!3CF[Q$PG3#&(29QEU4'?N414.&XK["'U
MT3A=VGD.7XV-B/;:K.ELR:LT1^."%]@!/<*-]Z<PBXPG.]:FY5IU/:'8YHDE
M[-+<%-PS:M<2^?T9[-$L9E)7Y3J3*6'XI"J3B:SH:O;?HT4BUZTY@^J/T9.+
MHBP!QQ#=$S1MI3&MKCZGG05M(:&;)"!X>+\O$YACRC*M\_EH,. S7D,=<F"J
M-$]JY,R'R$^&W-8\4TH*'A86#-9R3)U&W'X*+O-D4"OV[ALE"\=V*ZH)K&G:
M:477I\/0##QP@<^*>=;N_DZYR?G2;'@(;7PV*F]V&ES<DA5)68?^N0_,V'D.
M!NE*,-RJ-&59>UX-R65M.;*9HR'T*$EDAG0TS)'X@,.POO$A, "]JH*)>5VA
MG-&%NC$(>=Y?B?-/("Z,^DJCS/D,=A?/9Q*FN_E_KG&O"^1BR=9!V>L0;S54
M[/*=RYU5;5<*LK AOETNS^;M7E;0L!N5L,N4.!K4%:36OKP#Y(E\%?AQDO]J
MV(83C]TH#,0 OQI2H9^.[7NI2)&[/W;M]?$R<4V;>(NB6?\0P7_3(]Y</5SH
MQS%98>D+.CILHZV&0\3$#1T[XS.98TBWWKU.?P>07J*X Z@E2N\T?^Z3ODJ1
M@QK%BIOGM-U':*]*9=?@#2)XK^I^5I'^<?:\H?G2;;"\$DHQ6^>0S2UXGGD.
M/M45:N;UGGY\T8D[(AB30X(U<-S!SV;6;X[3<D97;_I))YIF-GFZ-'2@D9]+
M48R=B83.1UDL&YGBZ;MEES.(@0X48C<UQ8QAPI+FJ([$]]/P@[Z646+V%J^Z
MW\(@1V=RM4Q9#Q<F\"N?4H^@2F[C5ND G  <A$8*"E,+S*-#M!6LT.(C&\6-
M2-W<7O$QBK:"CR_C<-FFM-N-R9[V\5C#JA%EVB9:FCJ3.DOBM#8OF=X!%C L
M1!;T=S@2MU/XK?6Y>UG7% \4?*.ZE4:HOJX..>-0^2%=U@ZOH8M6+-\!D)-M
M= !H0(4<IV#5 ['3Z/3>QYS[".$]P#"1;;K+V_1\S0Y=>W]"%FQGR7'#- J(
M*0_RVZUE,+Y!S]"/D'+LHJOVH:1:Z([=,/Q,E5^&1;97'/@H$6O.3)!L'^*7
MW6P=2A=')LQRM+;G1I\Z:EDF\&I,''0HR00QBJ,7G 4(1O*?$?J-SB<N$/ ?
M;$@E (/,HZ$G OK*!_S5)-Z4:JLCCZ;EF!7>OP(Y1:L6E8[D,5^70S\O'7V,
MD>A:C/U9A3Z'$>2+'0-!.&G T5@_U7M9'34]V=$5_!DO!,-E#[.EJ)UVGA?Q
M>C,"0ITGQ Y;=S._^U#[O=@8(HU5$/^FVO'.VPO(9WM(<%/B(;KM[40>"\HT
M>_H!X<WZGABSRU'?P+_X!3@<G2F="1R&J [:Q!W [UXQG;T<@W-L2W>\O;'_
M4&',8<-+QR9N7MW.V$Z+:NWBF!=/J!+]KJ8AM&]*@[1;92NH+$O$9%D)FMP*
MQ,4K,)BO4R+OGJEK;L%T?>X"]L/#TA<_8!DYB8T7F,>4("0MJ13:$MY2YY?+
M[US8(2A[8G%]P?4=<XP&:)JW/F#B6(%;E*?6\UP4:=9BIM?J?+!BO;S@>4FN
M#L7G-GF,?$;I >"!\&WWT!YCRJS5"F:ET"_7T;JV_$SM611-R-<>EZ?S9:XR
M@:0MU89Q)H<:NM(E$MZ+G*W\$]WLE_&1-XO:TD<^R@<K'7> 3]!L2:*/CD6S
M4S)K%[9TSSSR8;IC;GU-NOB/7@?.AIGWW-=;X2.+X1+U5PQT=,%J@08,B)*"
MF?M9]GZ3LY-G$I(IY4&SST)W@X&QTRZJML7.Y(YXZJ=J?'(C0TG B':^7&;1
ML:@KV>J:FDAE_#5Z0KCX7VJXB92XX(Q$P;R T<"/N*R=E8@YEY9)E^Y?#YM-
MDHWKW[]XNXC3KZ/4U]X1M#MT.:;HWUOZ4S:]4'*S06FR!%+F7S%B-'3\(TPS
M27&8[YAD)'Q^J%EGE""._W.W[]OQ_&,<QKAFT0/Y[-/M5H39%P0'S09EC\>G
M;@=PRP4=\HM'O'Y-]2UMTVWE:-2EZOJG7?'>K&T$Y]M6QZ^4SE(,G?!\ZTX7
M3T>F;Q+*S@M48Z\I'ELM\6N+X<LB94:UA2HY^*0DK)E4GX8,7#18P"'_HK2_
M=('NF^$Z<O8#T9I^&EQMRW..T>2F>T=E+D155HA\!@FJDLS(&<^), YMGH'M
ME#V,^+L<X +G28 2?*3D?+D"V@K01_[:GE>(B_COET93Y6QE8IU !_B9LR^M
M!>K+^G1[3;/,RY77#T)1<7N,#74 G#?#6ZIV57B2^S+3(IEYX3)VCE9ZPC1[
M!D-!1DSO[%G/?>6"Y:J@%'&=V(_6@HEN@*HJNOY*7]O<>'?(?=0)PT0Z!4=Z
M-?,J>*,JSIC\M3XYFY8I$+/,IAV]!/<WPT^P?OR)_/KGN-OZZH>NH*XCM>$\
MR[=<7&2&-'$V2&-#B<#L":WOYK%IPEM5KVTK7=5IPR?&Y\Z].4S\^UEN!J?B
MF\M?U<<:T$&O^:,+G=,H2..LO_$;1;-_BR2\A%2_+"YO&%[3M)BT"*LX$[-$
M0OVQ*7B.Q+%6L4DQ5"MB163T>@Q$IO,>*R&E9DI1++*::Q:3R;TRU]_*VOR-
M7H0CMN>!,#^H_(>LTFTUZ>4F_<"#UU$_]NTMZ>4Z_<#P?>K;<[L![.,"H;_*
ML0O<AIZ;M<?P'TUY16W< CLFE6-=6R4\Z=[Y::@014,KO:Y'D'KXA,^D^[D/
M@7;UM]D*-M7=,CYZ)-6::LFT#TTD3FD#@Q(*^VVQQL1-_4]U.]FB3#\1':F8
M@)5-P*X3R%HF,F%([S',&@C]QGJ\FY.), >&"VW[%,J07]:PD.W?]'X/H_))
M7]&2O J0957?4(5\(3<"[R35L[0Z(<7EL;8$B^I2M_4_%8>I(X)?=@@Z-B3(
M/_3U(.VGR>^N+A'NM)8++\/-YFF?N_.YB2K48$5QOOYI[;&2=)+O5KGV^'(
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M4&4CRGFSQ-KO%>;<@HLG,P\*L\I0I6L^H8KYQBPWG,3G;S(85'A9ZG+YJ(M
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M1]Q8P9\)^.^&*4.<*XH@LN8)6A7Z_U=Y;QD6Y[(L"@\A"2%8".XA0(#@&GR
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M HN812BV+J$5LO71GTT2ZE;H(<.559KOJJSU!+F'5\=XZ*K4XAUVPS@%@K?
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MZSP2%5$] 6H-E1Z<C#8_JQNO,I/10"5(,8)K0!Q.N%$&7+7;29T#"HP'%1
M\UI&WAQOV"S>=[C3UD- -\&&DBN-.A'N5OFLN*.Y#=9R-=!5P:&ZB4!FE9)#
M%/N_NCO,_AODFOO_;*OR_RQ@T;'0NP,8^JAANQIXKF'9=7&TE6RE*\Y[E4M$
M+$'VU1MBD@XM!]$_D&(("'Z9#7^LZ;/1C0 LO/'^+G&ED4I T(\ ?)-CN[Z@
MNMJ..)<Q00H1- B E]).#N4XO>2_G5?5@Q&MZM.0DL[^-6TY4MB(0DHQ^0C
MQSC]BY_ LS'*[V*[AHZJZH+(SLG<<K3JL_\%N$07#_>,N#D!E4=Z_ =<Z18>
M:<Q::A'LYD+;X\[82'[FABX&=!$<(0"M<QAZR5W3@:D>W$I:TMX3'^!51YU6
MLRU+M$CBBL#=-X+RXM/?+-8JA]486;&W-!69O<Q/E7&L\* T]%'G*@%V/7T.
MZ0?1<K_KD^&*+._A7^5U_%O+^X]II9C_D^YZ\(9Z>]]Z%D\B2@*KB[H$Y#F6
M7(AV/(F.%D-63L8_6R/SSP+NS\J#J(JRRR9\376H>9>[$>[+],OP_9O+K;83
M?MA][THSF'P?27%;LMC4Y5 Z] 6W::2Y(%"+Z^3VKA%W[&[G/S!R2+$'QD-O
M;A44;7^A^I93I$-)+D<<I"SN?Z@XR09J@<W[4#)V;LP'QI.3N$3_HC1D^Q>F
M.0;UG]D3;M-?W5@@-PP82)K#WH8QMY$T90OHP*-!=0>J6?U<6^A9YJ];W'-^
M:>U7VLWW')5&G5CPU3F&_]DKUC\+_K3CI5Q$ -J_(=_E'H[[$ABX2NT"OW%<
M.C,3MN.ZU23Q3#I@]Y&0KZ[8:($M,39JY=#G>R3BY4B,58;*)'<(ZXP=)B*@
MJ)&*HMB<5I\#.V7H/]".S:'-*/4"S?8W'%&WM.NM=VH(;;%$LRPYI2BU;;UW
MZ9ABO^MM\A-G. RJ/OLYFZB^^T +B'SMMJK Z22[6HW'\/N1-V-SX^$&]O$"
M]JZ4E>YG3\P(E#>42D=RT%U<"!I>4.L<6.&U:\&FBV-X4QT#T"$SS"$C^ YH
MC"-4_1\0 -AI/LM^$7C-%;J7E?(A?G(V.-/"P^$FTYL''>I?Q/?SNJ+[<JA7
M1$5=Z*@+TL3PY.S28]1T&3]4CO9+=2^GL='72S7G9#</!S?GBIYWIST?;-:H
M$G!40.QU\GH VA04F$Q2UR%5T-.#T[3H"U./3RFTN"ZF/.E67BO&=<&Z4M]&
M9V3"8%0+K\UK[5,55?QZ<M!H:-+U+4M<\B<U",*W?_)I!HA7>'Z#:!K%<4?1
MJFF*P#*[N=$8ME\-FY%0II &G)I6C8"+7]\9;.]'V1/]LBE?Q>S,1]*E)%,+
M[K2B:2,MJI\(A)Z0^4NO1@6]%;[W9L33*&];JV,OH3C(.H795:C;ZPM_R)H
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M 1=%/X!P&#CZY[O_I]>?D_R_SB$F; (VK1/S$_LE+K8-6+-)3'R3F+ 50 "
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MUO&?X%6YFLXX<UJ8#\>*-@^C'QAH'8\3Z('7!"8!KNU[H(A61_2&BF'<Q9X
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MXN_EK[?NU.>IS5]Y<&AA CVDVWP&M\"@\G3N3U>%C2[$5";)MWO !RPV,X4
M'$>R/Y$U:SU0;U(Z[#IVP>V83E)4ZZ_3UO)YW>\<WD)*1]B2J0PTI&_69@:1
M7DS7&OQ*(7JED!01Y56%3+T.&U7;(QV'V(9%XYLK$#)^(=]<,\^-VWBC7GCZ
M:-;4QWE=23[AM'U\7K1=.RB5?9:#XI.7%^(7&,1[&%6!,6ZXA:R.MP?'VU,A
MHE-_L+T$SJ3^*&/AWB_! 7!EJ).19-6ZFF"I\=* <O'+@H%!KWU5$.S27<*+
MU%ORZ_*3@QX]D$-N]]1.JCFT4[4U^5U3N=3C4SJGR^Z7.ILKJ>>F:XM7>VX0
M$_=':[@4GV@65S9Z^.#X(?1G=#MF(ZYX MVR .DAFRCW$)LMPHOPVR$#L&."
MFH#: CUT8/\L9R'D\>I0 JLC2@A(H2,J$.H>[FZSV/52&YY2F@O\7*);:V^Y
M/76]?]_=V'8&44%NGE>:"(DD7DQ9\T,(5,#:A8#D-$(#[6<O#4]&;PZF)-3V
MX');!S0,(*]04ZKR0+#J^&N<8V>;V1F=^C"/!U55+D'M.RM^,.J<1P#"4O70
M&<SV$P7Q9X[W/3!SNF&W)W;CNZ;4RG6B$GI$:?+Y48L]^F?IQNN_Q=Y[_SI/
M<UXZKL,\K4EFR_W(FR>:Z4O>[#M,I22BMQ._7@#P8% -ZQU!ZJK&'O[]97][
M]5D"J@^E"45Q;A*3LW14E-HRS6@"5/_/8(,CS3G=FX*QY@Y]*ACXB!\ZX,K1
MLH$O55GP'B'@C1FVH6$D1&8E2F[$QGI7L)#9.1?"9M&IBGA5)B5>L!4JA)/J
M#T^$[^R\2S#TK:7$FAP\>PYL^Q4W^;;&*FWLY[#]%VW,GAXYK3/9B/(L]RYO
MS*Y+;8.F]RZ%%(0\CSD?$K1_K%AC(B+O]+L]-RR\F0TR31I;V+ D"_]B5YQ/
MBX=<3VGP@AR.='Z/Z_2J:=*5G-(5O?ZKO!_7YKM9H=MQCQ2"+X_5:/V>A^1S
M>&8@C"<OHI-.24(=X!<*=O/.\E^5ULN"GP/V'H(8%!SF/+N@N!BJNX!9@]_;
M;:*:Y$@[!B))!O-SA$\E4.3.5Q1DT-=R8M'GQ5"?CY58^$SC5OX?Q(DR8OE
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M=!VM1V]"R>$M>[/)7)4>_R-)DOG/H1@):GD:\WSBH >F*?FA]<.?&5:T!9)
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M9Y A#_*6)2&@8].*/NJ93;0U=AH0 E5>]R"?7+E0C8-=AU87TL57-$:<)H7
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M 28?O-L34N6:+BHP_KAFOH*A*7$:+ZT(>MH6A,#A\]48CF"JC)Q,W<+%B\*
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M'5;WA:5EPUGH9'#=:+OP%.!:X3=J/Q<9T;IEVS:A[ZE)J:*[\"U*Q^8_:97
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M2 L.DU5_9E\MU1#X5ASP5%DG_"&6K"C:*L':DK=QS^SZS]-S]C&]^\,"+;M
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MXVT#,2==Y_2=1D>%TI#$9K.\JCDN/#N!=G)VV4W=+-!+O=</MKO=P+^9D!:
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M?M)[5KS%"H_>'-N!)SXUQ0,%&SC#+4L906DKYSIWP-&+-4GHHS4!JZF7NK_
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M:EF753_<%Q1G!MOY6ZL-AM![P,2!M55!:8S$1.<ZGJ[5AK5+Z21X'I+];J9
MS;N"EIJCG% =NC>:5JC+N+BL__/+^8;L=>E+%H&B+3>;IDTTMZ#\2UR+5[G#
MX49=*6\+U*S;*$MAT=)N!.Z/HNCJA<C2>+_W/P$%3:UHNZ7 P(:\)MTQ#;?U
M+;NSTT$(.4F3N)01XD/8\]PV8MRB]S ?%E@":'<:Y;S075)@0%\TC"WC-&,8
MG8_J2!$/GO"JX&C$42?J9FAV;L[//2XVH;QN+W><(,=DUST-Z5&S\]PV/*&D
M_85:/.[72.C,,%^!+C^"F_2Y*>Q8"4VL19\/E/3/SBBP^[916I>MFU[H$O<:
MZ4Z' ,@H/0Y.[>0Z?8OXUS*]*EL9UTE )W,@%(LZ8^,=ZV::T'R2('&M-U!P
MEKPHB=9%"'Q+<YO/#74K&$U\B^ZP_X ,UO2?@7CH,SKU<X\N?; IL3Y-=!GX
MHAQTX7S[;R;CB!N02=K43EIM*D7HP 97^^YW]STRQ TO9O\VC]T&:3H9/DCM
M IUTA:CM__5;D-FZJPAI[CS0*OH!;N14$1W-*HCLM1\)M%C[@,22A>(*^T9Q
M45N^2[M>3_AIFC+3=AT6COSW;Z%C<]+^0:',T*-6=29&'+C?Y;0EG:AKJGZ]
M(<)LA53R\\O#ZNX6N_LZ/5VHKM7/\DA_ESF/^[X#R6Y1#7>K\9/DMJBRD,0C
MR1VE10E9?@;%(?!)-&\>"FYIFL"-FQD<'K>45MMUA0T"@12O]GOZ$?UXL!^?
MVH>(*V-@_>(E]6V0Z7\QF@(KW)-H3]C7C,7LE#7#Z/>;/83)2>+W26F7+Y]Y
M?.[$W;#E[E'B_6W0@VQMSOZ.U/X^= T;S)-NX>\?>&Q\UYG575CU^974#?9^
MA39K4-I%*M&,T0"N38,L;H.8>]+CHFHD,5NB$]N@M<J_6.F**),X[4PG-,UV
MO*0M90?#217@I7RO'2NX"]N,U(ZJGW\G[CSV ER(SMGXY3R]?XG;_;)=!@.3
M &*#_MOCO0VR.VD7O+OP>>'(9HS=0;,W0FM8-H/ 9TG(HC2SXHYZB+I[=],=
MA0.4]0L_KIX*2=OYC(E=BG[DC7^A_KW2\$"^"(:/:61;]9+>/,_^BPS,6G"P
MFCZVW V);W:/#/M1QOH96HD(9%ET=VA*_?DSM*89!I._4A[0@-![=:/_T*6O
MB/B55Y_2;CQT5;EV20-)8#N38+N0&> #0$VGLZP33BO/Z^-$P.":39_!OT/:
MN-/%<[3V^BHW&J3,5]\@\@WT\I] %0L_U^L?D[^M<1.*MU2 FNY(%7HL"Y(D
MW2Y2R\%7</TANQ3%+,KHUA_FZ:9<5(SZ$"JHJC_:*Y+7^P"NG*O\)!+^<SX=
MT1S6Y)*K&^@)I'!LNCW!HWSS&)0/,\58(@F[IP'\C"&I)?ZFTK8*6I)6NZ^F
M$DCLN* >G30Q?U+M&5G/IM'L\U^KX Y$PA[!L4?D#_2N1-,;PR_]+,7*C&S;
MP[5\$,?P^$W%5)6XV\61:[+YRO.,G,F"K%>/\&V4Z9;5VF7A16X9*07)!Y<@
MVQ=(FTME+UH?^$P)SO]@]=MP5;'2*5JZO55.0PQ[[9FKI7:TZ (RQ?-[[;'4
M^_]F/1I=E#8[F/N'XHK+[#CB?_A*;G1VS<$!.H\V9&W[T<F)]M+BC^92X2,:
M&2'7(Y,9>B V3@6UBPG[F>/$24P([5.T %[X!'X$HCK=O(O>(\OLZX;7>JML
M;@Z$:DOZR6H4GAJJYN<I+I7_:!+UE^H(O-^:,/ QL_&>U/27+4D ;ZIJ2CS:
M@#2Q,*MER\-OM\19#O^J]5OVP5--=LF_(PNPOTE,Q1,DL[80$1JT.Y@0[ ;5
MN+O_4<FA+U;9I3?_T/)>J9WLJ3)=:%(7%GHS%F$2O/?EYE!*>779=-/M.J?Z
MIO7C34ST\W8EKE4""E)%9MH(?)BC62SE041U8.@;W8*3MESSGU"X0<ZF<LE'
MSR-ZJ<WF81KV*EGT.9//BQ9/!MT!<_?AT\.:[SGM;96^ U<X_H?%I!V&0Z.,
M7TD$:H3_=W"&\O'/&;.'4I7F>RS'7\7""F0QBZ:LZ/O(JC#P"P6%)L[OFCAL
M1^T<FY1SRWW^_]#VGE%-=?^Z:!05%045I0KQE:8BH/0>RPN("!$0D!H5E"9$
M!"1 2!0$I$9!X 6!B#2IL0"AAXZ@U%"DAB1(%4B P"*DG+C_^^QS]Q[[P]UG
MW/MA#DC&&G/-7WM^S[,RDWE\2:8UR&$RI/F%C.Y;48E>S,<E,_^/+C#S)QIW
M$E;*'/J0C;]HA5L!E8 /78 B&B\_\F%$21\F%/M;?1B?RNG8-1^HAQGDM_<F
M^Q<4=^9U^N0TX%-R#.J3S;SAOTP>;QW$22[?%,M(3BY[75WH5M@C62?[-FMS
M ;?XX )%E6D9[S%7;&WN<D%XUF+7:(FYNMDX7^WI @&N4T/UR'P+HN/@J#6M
MYB)$=.MG3\XI[]3ZU XSDJ 7DQU9%8<DP.U+Q^=-,DNW!>2)\G>SB\-,FI[A
M@^S2[*8/5Q+PCF*^:\J^2#UX\-[6BD5+ITFS"U#1Y+E<S\_=,VVR1Q\7%VJL
MNY&^;K<=H&FUHOF@%'@4<RZ!EKAK#>/_Z9TA4NF7C\@U&0I@0TVKX-*>YWI\
MV%_?VR_!'@\6?I9XJ>HM,C#=31,74WF-^=GG0L-&(8_.\&2T,T*R8[N,'M2!
MTJ)C8O4#/SCU>*FK' -.0(^,594]/-T77#*]D*:JAP@Y:%]6FI<X]>/F]9NY
M4<JBV*W "X-F-YHUM-"!8_B'#TO6;3_GF\XLK6%*C R"\]WW5R7(9C?H3ZU]
M@!A)H/?9DY8O=,U,F%NMCDM9MWFU7JL:*G^,+QVI+:^O=DR_.+8%]0Y#OPN6
M=.OO[HDZR0"_@@AN"N@EN-ZAIX57)!@ZLN5'MJW3VB0T*E2]=&=?_USP#GJ:
M_'I;(N_+5>_[ZOD93T]H.[V41/'7LU\%*JX)30,WJ9WC1M-OY*I*9 WE&@?@
M<_2JZO'AU(C[D*AZZX_\QYT!F5L1-](KPG3%,SP2VBS?/C>1:>Q\A79=.[;<
MJ#^"A$'B]84-W[[V/(: M."EA3PJXB1]^#I0XO1G;PJ],WQ22C7E!P<-#E!-
M19\-3+MT;8T0I.\D*'U]*$9=4X JI&ANU\\TKE0-<T%- C.ER3\::NT&DWY5
M?9^>:UC[@G\7)E07@)8 0AW">QV=C05,&:)#(IUFPX55Q$KOZLVZFM_EJV4!
M7>5Y-1E#W_EZOS:Y)=YX%&MWL-.+6 O$S>PZV[4PKXXJP57T[Y=XA8B\D$_Q
M@Q=Y;BSKVJ;+XX(*S(KN.ID>+6-5B6P<_%W^E'CIPGM(-^ID!3NA<N*<\B87
M!%C4ZVA4?2V[6NZR#/Y9F^ERGE9$U.""3GF/9(-IRN_7ZW7AT0P\_8B(BUS<
M]ZI4;V_'W'U6&FT/E+&MZ*\N13,889:R\^'M&VFM&0KQ* D@M\W*<\O5'&->
M#3R<.0IM'721BT_R(332LTO\^;,NZCVZ83G;Z)G?+-KS3Z?I/3(_Z^O3IPXE
MWJ+N).*/EN*F#OV!-IO&D7H)XFP#I R-XK5/Z+O;P,=NP:ELX4X^S*;WZB7M
M;_N>:$M5G[P#ID%355U8]C*_0,#M/4E^[QP[3C/T3[MM&*%U@&@T@Z#=R!E)
M62']M*H=_5JS:[>_T5?R^T,6K4AY=SB#Z-(%OLM" ]>U.OKVF\PLL*[H:_8O
MCS^JR'C]V?GZ'#&+]"WT4<;%TL@FI;DC0A]EJ __'.'C]3<7U.7XD@N:+(W8
M6>*#9*$^'"O,*A:RLM#1[KLE7;TVZ5IV24:PE6;-T6A/\4L[X:;M_KR;7OGD
M)]Q3M_QX"YE^/,4AQG_(HG8N/O^[M%OY.],ZCT!7A/NYGI)Z6]?(N\5;MQ.@
MGN<T#I:<:[0W,E7*S?W2SVKF66I@BN""(BM%%3B1'GV<60,(+E^="VHV"+R5
MB71Z&8IN401S00JC2X(COPVQY[D@<)E\*WN "T)BZ3R*,IK+4X *\1,^<RF.
M8>N3_(S^7UR09;4K)S*."^+OXX*2(2J=+.%.RSY62C5SFU;A6H6>9_F33JX!
M0=EY#89*1A'Q7%"[$A@GQ@7%O)CG@LJ6886[CN40.I&C[@.'L@*X( Q.G12#
M]!C.]K$O[U-J<EP78H"C( MW";0/:%;Z#I)$@SI#]9%.KUP_TTJ#>0J8N2,T
M$]0BB4N 5;BO!.X:ME,"^]W9*?HFM-'6#2"]XI\UX0X%BNA+:&S[MT^B-P)R
M"PHF5*/L7[:E:X&\M[?OK]9P0<^QG :4/JKE H%&)P&*.S9\06U]8Q^E#>E@
M?D%4H8)"Q) ;]=1MND+\8+)]_M^_"7/.+^HV=\M&0^UAZ0I-DY<#N:!#,=Y?
MRK10&8WHQ7&FTZ8_%[2//H1>*#,VS!:)9W)!0U<XAMB>0LZA7T7H 4>,-$?D
M*H_8I2VQA>E3I%AUTN'EVN@(=4?("40Y\69C6NOTZ:% H_Z %7>[==.*2L*(
MLYR$#_8?K4GG@[,(LJ"K2=H]R!N4)+N>"_)<BX4<)CPR@)!'GW..>J(KH)T0
M 63(GTV_#^B&^902GMCC'*?].2BUM""N?#'C8NWC\Q0#N]MTZ9*/"TS?]"!5
M(ZEZU6E2GV3P[0XC"DS2@0L:'\:F;?GR,=<([K/@)<@1E9U4]"^>O]>?&;Q%
M-QMH*$,H*R;8W5.NRUS0"RK3"L(2[K/N@)!]VKNXH!Q;-58EWW2C+TV+=4J4
M"FZ;4C %ULCHR.E]E>S, / KPC[40>2M 0US1Z=D"I%U$^C* UP<V7;-Q*LG
M !1$ "$,HV.C \;.#G%!Q, 5@TJSY:#8&SFV4P!Z%\D*C.O8 A]JU&B?P46Z
MR UQSGC8.1#B6-XYDX"C"4WAN<3&G2HZ?WA/9/MPZ_*T0N-0F7H#?Y.+W",\
ML;):0^EZ6QK!G1C0&0*C'Z\>5.;9&E@!MTF=T;7?KFW8_!+*S\2T2G!!+8Z\
MTB!R0;^RX'.A2;S_]0-YUXI\@&PKGF%#*O@;^#F'J$7W>!D]@:'3*I"A7% G
M%[3(V.Q!O1M[(^OBYC,G<\+U28O1Y<R3BF=I2W:OJ1=FHJQ,'(WN;E&G3#D5
MI)A,+RPKH03.!5V;/$"(MN2"/DY>)EZ$ 89_4CT$,I,]GB352IG\.Z"3=?;;
M4__.L[NC_%+TE<Y)-!]*'-*B$JUK\D)V!()/3/'_.(GVBGOX===T"/Z(H%UE
M+[?^\A'UN_C3&^*4!J1",9TDD!A-PD +U*!&EEDEG?TA@M BJO3[/=F5LX]8
M-EB__6(#/9]3+JM[]MR)=[^9(+;1L964;ZQ9Z^"O5;8U(#46)#B[8Q0$4VF]
M:& G>F H7Z\%=N*I[\W!+P//IL!'D7[LUVN-EY!_-]*'"1AB:UQPWF*&YR#I
M;_/KX+'P&:6F:BT_\'1<M+1+RU4;G6_MP<?_#0C/H+L<HC&PPQWHU/?0G>5!
MPNWTIU-ZB=?HC#[\CKJJWVM5Z&/A1.HR9MGYKJ$FY7%5Y!%#8;6L"V*(C^2%
MCDB)S#=F-_*MWLWY."Q9.?5NNVO*O$2@15^5Q>">!RI2%/IL<\OD>N0G["J2
MOC1\J/AR@U7' T$E(\)<6=OE1%Y9HO7H',3*39ZC'=*@@&/,IK0(AE<V:7_.
MT' )6V;PN?HWS;.3F1L]DHZ?.EG[>/#TJ1Q/L9,PM9^K+!O[52W*%"\_1,[G
M@E1)K&HL%R2/<A$"%%(_0'D(2! 2,(9RTE#8,GWTG]PAB0J3..<].CFDC1[4
M^\>0*?!VWR\..D72D9=D4A"J&>>LB3AA)WT8MGVKB="/7H(>Y8+Z\5R0L@*O
M7X#3.CF'YHOX^MJK8^9QD;F&V$TV.\R#"XI&+#F! 4>_^(W.2"K5$+O(!4&A
M1.S0T>C=7 X H=X\R43=-,$!7!#$ 4T_44TL\+1!3VGQK2_"JV&\>Z#_W$+Q
M^[^A]R@/G3YFH\D^':A&D?A$O^3>]SK?ECGJ!-J:P0TW=,MX7#9DUA:3+20N
M$;V<%#*?C\*N_ NV$_ZW%:MHW30*1%S'7[^W) W]^P?/A@*A<&W/$GV\!>EN
M"F$S?P>;QD/!Q>+3&,#Q$S4;0CZ%T>81&RZH]P,:4(C"7:APITS>%/>K09X'
MBYT)AT[T@5YT+L(^[@H&._&N"^$T],T:> )\XM>@GV1!B%6H]O)O3VB;Q:5,
MN;Z,'J/" ]G"0J:5VM55*1?\:STKIA,>5Z@B!5I/T[V5WSX$ATZ5&=H_[3(]
M'[HUI>C,BH<?62PTZJ\HD^S5XKM!#&!?5KC\3_W0IZ_APVX73'?R+JM'GSY*
M#K5E7#ZP9R7[)]\&'VM[#8I+>OIV(C,O_WRW]=ND7Q96R<F> 77)J+*O2V2Q
MEF,OSY(/&EV[G#SG%V\5:UXRW:U8/O+_Y>^NY5DRR9NXUX8ZJ.X0A8XUL;L(
MO"4]$4_>G3 7,3AFOY@J8F>[WKK_1]KE27A-BI28?OG!PT'*VM_FEYEPUQ?A
M:HF@^8G-\GK!^PG?+U]N_\4HOO_Y4GR.Q&9>CM7QC(JAA]\5SRM)OY/!2+YH
MF3OI(BE^4^-C]TV+S.&97Z*(JO+*.)\RVX:^7B$@*"U:#PFEV^KT!OA<9*QP
M*@)GYW'+5_Y4-N#/B8V.#47_$+VY0LPC87;:48GW$Z_V4?NI)"YH-,,Y80FB
MQCFUBL;I.X,#_0XHGY?SZ$;VP.I3^-&$;W3PP2<LYVR[0UHE;]VHHF$!F(J!
M393[_*$_4R.>Q(-C#<_+<)IJ[<I#8KXR!\& 0G048:$0R M3]U'CU>CH J>#
ML<G8Y&3QXW\9CW1.LU3]S-@AE D-SB?*XVV[9[RFPJOEXM,Z/,QV,U[>Y8+8
M@R25-SLM/"1P.>V"/:EO/:J_, [C,:"\/Q6&@.OP>%,.!<<2]HS>Z0/"%#>1
M)>A0B%4(I^*Q]BXI6GN9 [6H&)6B>]DZ78\UZR)P;@N\U [4XTW?L18*[>,T
M>B^@GF !A;1H031E 5&(988O.M>BO\,M($S6(!?46L_2ZV,Y"YW<2$1_5B\G
M;8U.$TR>:>EC?FQ@'#2U7)EO2"QL&7B9)(H>,(K=Y3GQ')B9WTK:O  #)/%3
M*T*]*G_B 5GXB"CD,8_Q>\N_%3H7S?^U^#^Q0-/,"\#S.J>8D,_5.P0L^*:F
M%J[0?X*E9XT,;5]#R;1[E!'^+H-O/W&2:>W>ZGZ 8[-YS;X .X?R0__'XKB@
MF>2;+,@OO"^Z_ _T_'N<0WAH?L9<,:>3K;F%&Y@JZY!DR*SSTCTA@;TVO\)3
M"&>L>'@*U'%B3T.GN:"=3,BPM#2/)=Q!TUQ9[$+&YYU&]$PV2BQ>%!W#.3^^
MIX]E6D$<S0$3]"-X! CFSCH-P!_2TII"H,\WV19K]OB!GMFBCS"CDZ):*J'^
M<L2ZZWRU9TN33MH<>7) R"#L2L[:MS[*C<5,VN7E\<S8XDL?11<@T@UL]G+?
MC^IHW=Z%ED3O]-'.P4+#D("E[DVRGF.Z$3&:X*.3LMF_VN1F[^MH/]IT_Z_(
MS)PN'<6:7BV"8II^P\2RMU)@C?A%T\5PB-,+M@$G91VR(KRKY8P,'F9=+C*B
M;) ?T7H*\A^XZJHN69),@M558[0TV@SM4F3/$_6^&%]2@[E<$M\M165!>D/6
M#4('3XF=488(N80$S>-0IN7Z!USCNOW4Z3\/U2)J]7NSW#[,0],=G#YGO'7+
M='0JD]VJ;>C]\>Q U,-K=YV<3M*(?O-Y.*]8)>T-^X(,3PWWW-&<G0">#T->
M+])]SP2)0.@WV^/?])FQ F?O"9H:+)JPA(E6LY@XOW!3'9B  GH7+?5);W3I
M0(?!%0A-F$>^?5O!O+\RE6$JK+\3U?"L^.5GA"W?_>IUGK[?1XLH7%#1:0T<
M2WZ-L,L3+SMJZZP_?*A2WYTC0I%F 2Z048Z\.)/.4><U@7V,(0PTSN\(C]W&
MVE]="F77NQ;AAI3*)MTY>\-0A-F-%=-/7%  FL3/XN70J^0.]*8ZC@N*^@V>
M"HUFOFF%;2K!='LX3]U_ 7_J?<EME5=[M34KF"/GP4P83T%DZ]7S&BI#\"[2
MX97(DDGDARYJ^=$=!5[%0*L^+5SF@O9 J,8CO+3KA)))K%W+/ZHE01H[7OF[
M"C;V4_&O/QV[^#LO):O[>&;@K/]E#.,O+%#GMXMN5Q+C4\A$%]*!P (,H)"=
MYX>-\Y/*^W*<[':Q+-Z7?X4+"KY*/?/<PH\(_FATER&^V8VEY][__1[=! 5B
M"WGDH-(]8R3D3^O>2Y!M9'/H:)[O>!1OB.W=Q7D*N<3_ARE/O*#[7>[=0VLY
M_10A/J36:5#+.1G!.;12Q.N'OG_[-__QG0YSC@NB]X9MQ+*OC$]UXFA8.F.6
M.<AC#M*D\RR](<AQH&LM?21T?.>9D!E3';QDPFOFG]$S.RK=9@S()2CO/CPC
M/U0>Z^KJC'P]7V"B^Z))81';S_/03'9&>A-8]*_;!^RD3\;/9&:ULO7)T5=,
M9 KWC2Z)C/S^EQ--/VWSG(?,QO*837$F\@95N^1B;UD=^M$,6A,[UP: H]S*
M+G[6&!M]QP5-]*5R0>Y"8TMK,VI K2GKCKX%YUR8;'C&76+N)W/E0^2#H&RT
M7H]JU.3-E"8KM2[%I; ZPR5W_4P5<>V^0@7I*9W9 9A&8J>KOY.-$TKS=DEL
MF\:%R@OV%D]-9<=C+1UD2U-3\6;9'4*'(KY?&OJD?7<XX?"ACDR9'@_YR1K;
M+,G5CJC31?N./=5]^+FY:?E%<A=+[5OA#-]S26*X;MCES(#E3H,0]U]"XSQ<
MLAILE%H4]LPH*"PP#:2:BPC$5'Q?CA.(\4G/)ST>%>D[G7TK\FI K]B3I[JH
M4+3O<BOG$>X4%T0V*>(AHGF8B$DSD+FF$F68>-\B_J%5OLZU,HGD- W-9,_V
M,1-'N<8,4F%T!MW@8HGX1:E;1^B"Q^*'R XG!Q., C*2ZGQ'X;[1*\U\C6MM
M\;NTX#YHF638.YH,O1,'QEH, [%,3N-ES"D$+G.><\$ NMG><V%YG/YG;XP=
MI9&74^TF16S(_"R=X^?RG48ZG93<>ZG+ !=5QH9_GFO4;BWD"6LW.]^;]"KY
M9*+S5#T/O2>?JY%H#UEH*&W[_8L%M(@E\073G>GF#XL!3X3,LX\V7N1-CN&Q
MD=F,Z^7>K86Q+%OTJNLP1! /R1=H188^LZ\48LF5@Y<[)#F1/%';4@N914U&
M\N_^-&@&6TR/,4-'-R9X1=\.S%/!K\ T&SAP,2@\$/L"?,P0;.]!.H8ZZL2#
M_K:O8V8?S(/(:_L)417OI'1#$<,J!/*%P63.B0:Y,GLJ?O"T4EO44YLP]]T@
M%\B&!H*'"(<->)PIR?MLEW'*1^^,WG1T\6)M7\S#K]5T^;*'Q2Z.7M)GL!;X
M7>DL95S@D>]*FZF:V(4JS)/>>Q';'M?<>":U:71VJ#[M\?!((8QY!RT'A3I6
MX4D\?N+R9/$C%_3PSC:N2AGC'9"(@56S2^E1T1\1/.$W%Y&/B+M#2\PI6<3;
MBF3+#T1^76*>'KVL;NGE\&"J4Z.HOE+A1_3*<=-C][LS#[.&:=NL$Z,MC:<!
M;]I:4RUZ193.!!]C71QN/-,U@XM-K9V.?$AM4&LFG1K2:D-')SM/+%[KV&AM
ME&^P&?J1[)!UW6+HK\KJK]77'Z=0%''+\SITNUB@$WI\*:N/C>1AF,%Y7FW5
M;K./NBC^"90U>-??'B?HMU7;\V0-QMQ?ND5T-@:FPY\%FX?A[Q8[U2[G5I:'
MJ?PYW.]2(Q_"NF-:8D1?"8>\WH^2]) H;!4ZM0396X:\EL12HV/:H!$.C[+R
M6/I_3N2:JTJVJAL)^.XC:?S.&F_VK8(-OSVH_GWEVB'Y2LE:7 Q/.<%?<D$G
MP;8$ND*,/J)1EBZ$8> D$+GM(\P?)X"(MA"[5P&/:.U<T',5^8:JZO")YE07
MT?OO 33T2Z)X@.*C[*7N.PVU&>[ -B_&,VA>2O>QSC$LIO-XM%[7>)3!X).^
M0(<5&LKP1/^.@CH71)&< V]JM/)*3PG>^4.N4PRAGFUC4_,X-RY7"67&K(-X
M!TP92JEVCT(K]RL]+EM943IKO=[L[;WOB6.+6.JC=4J"J'_2CZN/9RGE,^Z-
M_IAZ-1Z0P= =A./&#;@J?PKA%%7?M2V$YZP);$C0UFH]9,Z;?I\)8*S[.&]Y
MBVC3_J$[5R'ZKF7$E+6&*WR/QHF%35OSZ/CACZ35JNB5TL('-,DDT Q^X?TN
M@YI=H[YP5UO6[8EJWK%@4/B==35B=@@'\FK>:?2&#MTD]MUA/^QQ+W=QJHRH
MOG33;N93[TW"EMV02B4X8MQ@) <=6N0LY=I6-;?*F3,KR3W:V!!ZY'C]>FK2
MU2,W/G<XXR\\USM,_\HYV>8F=I#J33W_P/7"P(<4W< S.P7O$H:RRCZ8YV61
MWBR[L<R.3 @S;MS+CZ[4&:Y?ZLBM<)C[&ONE821Z8-/:;A73N9,1B,QH2-E>
M7@J[5IE2M;A(I!T^]^&?_^ZP8#$43WJ^\6Z#;/$-$S;#*80+O-8125B/PXW%
M<9H;=;F@X3>4<?8=.H05Y_(7%_1)NHP+RA,]M6/'0P0E+NBM,^H';.LH?913
MBA'IYU^._+\ZL/C_#+ T:FP%$Z6K]M0>&?K^16*URKG[0,2W-=@[K,<6O)=@
M3/ ).LY2&CR=N8?*YN,7GZUX[[?XI@]/AJ5CO<'3X.TN7NS8HZU>EDBM SQ:
M,7'9;#5%;=WP,K)FR@7?2N8I83Y-PWZAVU J[!VD:G[E%)U 5FA3.8AP)<OG
M4!1#@QOYD7> $G0!X$KV26OK8OCX-V5T1/CDC2-RRA]55=/P+XYF,8B("$=B
MGE;J-YRJ;(=2].:)92M\Y:M)9Z=F;]_(XP6U&7H(FU]^)\\-_EAZ49 RHCV<
MZ'+M8\V#_0AX.WILFPSI:(#?H(,3S]#5O+.E:%N5,X *4HY*.(8PF*7A8F8K
MJ^G\D2PST>C5W[-#FP8/'!4]<>K+HP+ZJF"5L(H:>,D/VK#7H%^NQJ&"&IG
M8./%*D;C]IA!'=8@HFT@ZH)JV:&;;\\.3;VS]#$0GL QBF9UA5:BBY<<XL>U
MHI!JP71T1Z,F'1N!5*(16Z0EA^JUR+BCT^9%2/$!SGD@UY+(>ECT-@&I5C@&
M#42H5%;+-WCC,:9?JM83Z>XSVRNP,J0;'=;Q/4%SD-K*.4K3:H(* B.=UVH_
M$WWK+<G85T^\>81,WX!:IF9)B#7]'7BW8LJLN47)@'J_</*BP!FH_)P;[-H0
MX1%V;-=QP+=,J=Y )+JP';? 48APHFG%!X*%O R/C[!$R6;H?6->TM)TH6CX
M3!VMJ9+V]MC":%65Z#6!LDO:]4=^_+YTAOT6XNYH &L)X<2Y4H0$NK,%B?5\
M>8X(1XI[K+J4: =*[&N:S5#9)O:8YS.'HBIZ>]MV2._G$M*2;MSDM)?_DFC0
MTTG5'S=F[CKU]%[("K'&V,ZFE-9C87HH?M>V7TGFH8>+N:#)NBD#]?6IX/P:
M2@ADA4KI.US8!A=FW:#QP5CB@/^N-DL ^"J46,%V-(WH<%B+05W,&QF1\"TD
MOS-S]?1B3G\\BX=^JK"54+_LY&PAFT")9^XGK;PH05"W3-BYAIH(M9;:M.?(
M4)J_*5WNI>XCO 0"<Q-]_*?#F(OG."%ZS:'/_!,=E6)0]O/0Z=M&WNQ\T9]Y
MQ[OM9S=+UL8B9D1* @U22)'EOM(DLD4$+<V&]MOPW.B9BAH@['TM(6)%WRCG
M>DA_5Q'BV<K1SDBDF:QGL6?0S;6'3^J"I!-A+\$"ZGTO7<X#EKAI;V9:*UID
MS$M7*]87Z4-EPQR'<?='' [*?H&+>SM$=A349(C9=IQ[&(60O9.HZ*\IMLQP
MZMG]VF;U4FI-V6W\F:>BUH-3CQLU4_0U;B99&,X2$X:'5]P82TSO?B".C%D)
MHE<->OBBSGI;NR!@S6!QPV,(=XHKZPK@[4G#4U19EP#2C&-0/PM>C/#J#GTG
M)=/*5&@+7OF]F15DEA)5\V$2/T$)OR&%P:/Z2!6P=D@L6')%/>%!F!1'E#>)
M)]V,DM;JK#QJBJ\:IM ZHU$7'1'\3;4OF3%ORM>$'0>LUFQ2?,_:!#5^#=QW
M39%X$>)&>F';N =(H(ULM]228I :='<C8KT>77"M Z5(5XA%0BE"@AZ: W>!
M4#.TB!=>>%G3%@6./6?Q9I_0,>(3XO4JJQO1[;"O^!8N2!+POOZ5-CN>]E+I
ML:$4$$J6CZ ('5@:/=;C3DLVILLG4QRQ_![X-Y-&4FE;#1T)WMXJK_Y"KRB&
M!B7)U.0_A0N%__!41I=:E^@1IKHM34OJ] HF:H<7)Q'Q%B(5.I[$%"4E1'MW
M[_CXUMA4D.A6!/N]1E\X%W2,<_*J5#$)D+E#4^GDM6J2,3Y\Q#S(,8Z,C5BI
M-_W@N+"]4>.LN62:X1B48#(VSQY+.\QHL4=-;*?IAGJF<4%[]>WSD38CE6N1
MNN#GAJ)0JM!A<R[H4 ;2<P#'6-OG906T' B3:?6;6&3ZYBC$K*Q2D\)D'3NJ
ME@,VGH=M4""MD$A>L7/:BX%=T\H&/,_M]:[D.G-31O#F=R7%UFE]8MHUNDT>
M4;;X^5)M6*VC:3#ZHO]XO-BS3Y/!Z).H'NP!EK?WQ^92P-W&DQ$*COY4CLM#
M1#L/,%;464I5M9\!-)J,.^89E#J:H5GXWG[2J=F]U/-I\+:?A=',O3N295$_
M7$4O!!99Z.K8=RRM/$[V&9M"QB\.-S>C#U@XRQ-KGX4PH+0IDAF,A-0K]@Y)
MC,Q;DOZK7Y[66!?T2&&X7D>#D5BH'!<BE337SE!29X>S[P=.G9HJ+K5JEW7_
M'O,EPLU)N%^'*4%?.X@0:@8+KN'* SP9U2HLYP.1.5#(*Y9S&1#N;%^OL&^+
MZ?9,@"*Y_)[94%G6WE:;TE-Q_J/7K?V_-N-EG$)T:N_9WV@]WV0EZ6>9Z:N*
MG.@&M>E,[TRJ"GKW?R@./7BA5S4)_O?P2)R=:Y3%\$/MC6I3V9J4E+4PL!UQ
MP*6CU>DT^ABC:Z4/UX#*XWS[+3E3_NIG)PNJ;P5M#-P=A%(SY[F@45AR0F#-
MC7W2ASH.SNRU,)6ZI,@(VKKZ@,07( ]I+P6RTA0@*ELKVX:36[@^_5OAP:<D
M/;(A0H4?D@WKPN=[,O.]T9\I$'[A)=G=7#KG4=8-7902JT<)=1%5!HX,4>GZ
MTY];8L^]W_M?QA&(,!?TK9("WMVS1&)>]8.EH&G72#M&H[]Y3/$>20J]](WN
M@RK^?W<BNP<?X[^[Q_]D",5R0;X'.EO,SVUV8NJU+0R.?.7#%"[#4E'P75@A
M%^1 L(3XVBG2XF[I=.B'D0=Z^?>:OCJU<U-9AM'YBZ/!%B!G[3<4KW4P4>TT
M,=Z""HY^M\/A7.DHO?(%^OZ[!:6TG[;)>-9N$.D''3YNY.M&TXI4WI^_6O3!
M$RO>*+R4?6EP<\$M>VFC9:3QC%] &?S8AGLEQB9,VC'?2N3<:_-SZU;7]/5F
M<,\A'K!#+%.@ABH$1OA#,6;L]_J*5/-0%\RMT7(- 8P 8MML!+>B?^A^\=4G
MG\<],?XSBFR%UC=5X0^_&/??^3%G:PRO&ID]WYVDMVEUJ-GEZKX3?*KQ\4^-
M@\D%9(LF+62LS:4G-CH[5_G_4NW\U>44J?W-*2S!J?R4HFYBW<NM2E)MAFF)
MSS A>Q>L!E5[DO];ZK!_H,/;1[_+<Q67B,[9*SX_65F $4UF*YU7U3RR+KA8
M&Y18+Y.S5.N2HA+_5S +0FXPLQFM-Z!AVD-N+EC_;%8N<?V(4$6?%A(0UQC>
MU2RA!,]5O[.Y[I$<L6#)NLC.4^^YKQ(P"L2X%GF=GRFSMJ1+E3(57@7 CW1Z
MTN3JM7"%$2RM$-=/1/VK!<"ZO%^AQYN?^>VE_6%OYO"*Q]EG-J*-K-Z+O E_
M?7"/Z9N!IWM>*Z^_#^BR;#V&<J5MK^S'D1!V1@!/X]WLNTW#M\%.+64?!4S_
M_#YQEW\P7=1EY#%CQ=KX*\;FW>W+'I9&1==S24N.E L91J5/KJJJJ;UHOO@A
MZH1+[]TBHFWR_%QJJOF:/!7W;O1#*,18IUSFN!P#::#)O&HLP0@MV(0-8\[0
MM)ZC/;59_CDLZ' %200!AVG"]B-5*$I*+'/W(L]L&5IV#$7H1"?5C LZ-3;M
M:!(:^"Q#JB.]V-YQ\I_R@+BXU'"%# 2?!C@>O1^EN40XR8(7 #)&-77 =:&8
M31AF^G 6_#?\?AU05@I;0('IT/!1L^$,RN4"SPR;@D*J&;2B62-/S45K+-UW
MX!DS"[>2-9/@RWA<+S<#CFF\F.%SO64:;!^0 +D1*ZYO3_FF45.&/%>P1!>;
M&D>WZ)6T%SNM[)[*K(I]G6;?R@]9^4S+0D+\*< F6G(2T/R^HALV&G>&J&1G
M$=UQ&Q&RW$9DZ8=:7ZJ'G1 04/SXLKC0+/2G>;%Y96LV^F'*<*X85-+PX7D=
MPZ!@^S$?N<JLI"KF)#[F1V:NPHN"7R>' F*_A(XI*H0&,PN0K723-FP%/+P>
M39:2;'.Y#*0_?$@A20*=+D-1Z27M&B/I9*!1UI,)?;Z)%5A\INLTPOFKLIZ6
MGCJXT7K"V<3?\V&H'\ZYYVR;*^X9H$@&C_M?&>& O:35ZND:J6\*O#G@ =95
M\J/&?NN6$=3>9#+C]_BO5H]:G]++)L48:4F%8)]T-Y+XI8X'[AJ?*80):"M'
M%!\UJ!+E<KF1'CD?%= GYN$B6%-/^ZV%MZV-RB?7>;\3B/M6D T^NOQ,1/H\
M$9[00(R9C>EY?\=-EA2]547K2'?%37DS16/AL[0&4OP:ZP'3,-D'SO^\7I(L
M)&)$/A^(/9Y>+@!KQ!9;^$A3;VVX#47F#]-BM:GKXT7WU\=MG$U=YV:&K.+>
M[2JF$3:W-])'.F]F).@?U;:I?Y?T-<AW^VM*FLNT"TR/90]8[EHXF] =6Z>%
M^O7-R@!W"J0-$HL_2DX=*JM8.PHEKYUT\51=Y%Q.MC.5]U1Y$-XQ#_U*B\K?
MNNM[KU;8WBF_6=%Y+BN'\]-0AI[ZM7#I,K#;A!8J9QF1M4F[>NTA#SMRW0L]
M%1R_C$RTADR..%(&&0:J1P^L4@9;!BF*GKZ&?4<[QW-K_!=%()55"91 FFTN
M&7?$FVG\KA08)1<D%T\ 5>.*WKLD/I9-_4B T&&@L[7DH7J)SR\@O/5; W'M
M"O;W4\E4D.Y^YJKG:*B,(.8L,N=)Y(WOQL:@#=U4EP9,P<_'Y2G>W5&&Q7;P
MY+SRB9'%S8T%?]M.RJ>5:^6"J44*<MTK(TRSS256V4Y)X QDO*XM6P8(*T'4
M(TWP=/Z7=E8-7^FV,9!H#97#"'_S:@#MG^,X71@]=2_9 7C+!& KLHD>KM55
M*?&*8NO+J]AP86 '=0KA ([5?3B-H89ZAU9KQ/F8V(:Y<'[)U$ZXEDQ-]9ST
M=YSR>E:,=S>KME?>Q&C]/JJ8]^#ZPH&9$X?V928GAP<)9^Z^OM*L__R2-N7=
MO,G$,V._/O.?4YA_9C+W=,ZIF@<-=$_QGP_U')XWM9]:'\,'[IQF?#4=B;^O
M;7P\SL<Q::729SA[:M4G+UUI(\#$@'\;^I$+6F;:+6-_/R/1[[-T>H.\.'+S
M1(X"GH3=Z4'IRK4<V.>>\L0__IA-]5+(FQ6BU/*6\):Z#Q<$8JDV20=BA%U)
M$BMK,CCP3=9V^V&O[.O1ME\Y_;F-6[,?F9O$T!"L79.&L]-ZR>[EIN%?SL*^
MHCMUVX8XERN&-;S&;PZMA8#G/(<!QRDFX0<["G($W4*0/6EIQ/>?SJG^]_'_
MYU'8_Q?#4(I=[R04D?'(T1<92BX](23GGES=YW0L+!&%?4-YU$G;Y*QCB)4H
M%@L&0,AK\1Q13 M*MG[X8NE?PX\9K\K5X][X(-*>&=6_EPMX@_P@%F7U,KOF
MU(8*2X\+(BNPCS1">.:UXWDFVRV?%NC8@0BY$<;&4HXX+74*.Y1*2[GHIT@
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M9]]>G7U[A3XOFMW0%>3,$PC2#9X>(%YI_(]'P6\8=(@+2GB:?9Z.BZP_6EB
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M^3S/?=V/RPQ2B-UOZ]I^"7EYR?$XA3G@CN/W&_>=NCQA/7*EI)3I]ZG7Z^P
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MM5';E0L)1)5O \QK178(_7+JU+#DL0AHD4*ER66RA[5!==6T BI$?OC7ST_
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M+#Q24W2]TK"@=+MN<V@+Q.^^Y_',TT*KC LH?Q4(^\^7?L8..=9)L$Z;@V.
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M4Y9T]K)NHO3 [[->!+,?[B5$)B83NTSD",(QN\'#C%6D7KL5>[*X%#=.V>,
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MC]+CE9I<0BE^68!$Q1Q'GX!K_B#P,J4*X&6H$W0A@:A;-MO&H,-T5UVZMT^
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M1,R[\$R_56!1,@3E& ;]5;:X\R@KQ%_),YM))8_%\<7\'NWH MW_.)/!BYX
MX^=W!JF.J\Q$Y:1#JPS*A2Z:53DEF _1<U!'D<_C=?EL($0-3>D?KMI0A0.5
M;QHCIBS#)8=)*;N2%LA))607@W6:NCE-WDU"(59A"]\HOJE?7\F?@"X]Z^WM
MF$:IK<H7XH6*]418[6D^^+(JW!(RS:8S5M^0-+)P3M4H/$#XM[S"9EJI6Y(
MQ-)?FTU)KDE. T'^I@";K9M)E"1OS-59X20CK&1U#$RP\CC^5^,_B^Y0TGOR
M63G@ZB.KM7-$ZZ8TG+#8B /.EEG8WH6[?NH;P:2C^(['I+;A5/K7;"R?VN\?
MJ71A(.L$='X1L*Y"B@^AE0!7ZJF9)X;-A.W(;8TZ:LE!H.2L)-W^RI]52#T'
M&O037DC1B/C]A3J-X%5#)$@.E(:S33_S.A:FSN^,4=7LC[-_!2^"B2Y]H[']
M?/XN9S>['AV^,]7L]FY@K0M;Z)4]7UK\1B,0<^1QJ6/+(E"_FB];NE3@UKDL
ML"2J2HTPE+OUS]8-AY9]?__)W'6/';F@$FF=$=OV!S;ID?-]X/":8S:M*W<_
M]>1MD/=8>"03"0KNB&@JCDTC)[ROR3QLX]V5'GMA:65?Y4<>/W.]#_1YZ$?N
M)Z#!R X]US$HK]9V*2T*^B2BIQW!NW+U1U#CSK=799H^3QL;BSY^+^#ZRS1G
M6YQH2(Y_Z%JG)7<'G<3XN$*]TQ(/9\+X8"XRYEP,RNM1,*IT5C!*.8"LKT<H
MT-0-:JK#I8CZ9!MJ.(LG+L=P+[J;UB^\64;Q:>ZYKO;>]Z__4HB]1-Z8&1R'
M\=A^^FA=*EOGT!Z4CK5J7+.J-^MBR8[/MNPK;:\@%DI)E2DU"0^5U*W6'GM?
M76?Y]5EEI[;QIJ=#@LYLE:P&_PR6Y6D.0G$-TU_;,EB>#*9Z<"08\+=2F[O(
M\,<#/! ?<H:-B [*F/+Q?@><=:/H\\%62#W2T6AN5RQ[E%@TE\EJ'"+9VTE"
MM3>,LH_%/SH5(4RH0"!F;2"V7P0XI<K&X6JZ!HWCB2):+"/80[9FM!KI'Z/@
M_UM+]^U3DI[6M&*^SPR3GL)UUW?/.S]:.36VJ P:YMVVXL7*S)7430?G6]F+
M]VGQ6SU,W[<T-+^>C<#6PU"\$7GW-.2G!KT1CG5).,'9W$A*A7D$WEXN=V/(
M;MK2_$%N!6]1;D=@U&QHOQP-DP!AK_P,Y(ST2WY$B9.W-%.4]B>N;AX(BC[U
MWWN9R?-R)EP^+>"6B_/%6W-FN:_^K;]$Z7<&>(XB&>/E';Z906@1E!KM7GL(
M)6^R&6)6Y0SD#!F(4TM$5:A+V#&7ST#<H&/40;D/<\JOY&J31Z^F1>U_,I/^
M5D'_'(! 5P?*.4T3!^Y.G$>>E9(/I\E3FO-^5EW9<T9>']KU>/6XEEQ1N/SI
MEA"H-2-T[Y^-^#'Y^?>MW>%(>P*,TX;%[=>.MDUV"=;:,%!64O"A_X]Y2\T2
M%^>O G-"K#EK[?<US/G?(<WM)<&^CD6EYI-YVB;IN'.?74N=I/WVG'$\DC+O
MX WEU%EXNZC:"8B=@VHA$GH"8K48A'H,+,;(-TWWLE-QPZ(BF;MFDRCE%J3W
ML*C,5+^"ZZ9@2.>,^GCP< A\H^S:)"0TH-;EK8)6%VUYH\BDJF8S?T_WB<_=
M?T+9K&48?HRS#"*4>@LN# B1I7+6X"3/%H8ZDF!$S4CL(Y^ +M-=)YO85[+"
M@<;58J.IC@CJ^#B1J[\I3/V[PNV]6U)GF+KULK;*=_2/HA@3&"I,^3)*#Q#W
MKD+F4/BRFB"*S[][7  L5P?/_^@+)N]H3BERW>B>;[E[Z4)90?G=3"&9<US^
M+A69B/L=!RE&9>F/+)+RHIQNLT,(0BDE6\,$@0(C=@X?2YD/6-F9'-N:]?,3
M.MJV=^P^8R/XG_D(VS\CMP+I:#V^@G5^[5%FVT4?YZ6H?8]K[[!N^I";*A]*
M*ERR6QR<H@)(\_;U\P?6&9L?X*:HL.,*J,_*PMEU5#2M:E@72G ] :45)=3\
M>_CQ(\2XR=] L9_:7*C3UM631' QP3\RR:MQL^3IZ-*DON;%M(^*O]\2V()H
M4?E6)<=+//ZB_G[< =T.YAJO08Z0/NA%;P5>=AW+,)P8SM==&DB2SI87,3@,
M=!!BOV?8$],QQ%B^5),2)*9!KT7/GX#PS)DGH-7G)Z".W>TL:@NQ_'POC&IA
M,TD/QB+: 67B;ZZEY:U+E!4NOXBG6YR#(34;H:.<'\,L36997=KT+%7-W*WS
M,!4<\>74.\'GD$<'X\"3(_:- 3:Z-7D'0_9)2LEA<+'N6)CD$(I*<7&>U.].
MOXZ$(B]C!9== OXU"_QF4JG>7F(1URX%3?1.&ES=A"@$>*T9"62-W#AV:%)0
M$O$2-[.O68ONF<K.<S;$PA%2)97KO',+RLF1Z7ML'\K >J.KK1I;Z\X&E[$*
M#H$)+<_F*^+J'/*%KO3U@J4NY+HKL,E-5^V;NWVLT%7?U T]$AK&,/5S :1O
M=@,TY2<=^J:V<^'N8/>!V=ZDSMGJ>75VV5_Z0LYIMOALUL5 6ZO)ZD"YY8-E
M/QSCPZ*O>%]/HW?AS&E#6GD<U3>0N+W;+X ,WT9)5VV5B4[>]TJE+'_09R:2
M^LM;@"33OJY8BO:^)=1E/JQ4RVE6<?_:HRY21HF6H\'=XC04[DCWM/O?[N=&
M3PUTG("&P0M=@P8\\SOSY.:GE"5WM/CRIN[M,GZ:?E<\Y$;5=[ZI#=Y6<U+\
MH]_7_9LB _2GQ(I==5S^;OR.+STR. UTQX"''D/CVV'2;XG'#S#1A8]+5V>"
M4(ZTL>&H_@R..(V+@?L6#2+*1[K+)&>-\\4>[6T]L[^.$-YJQ4YS3 *]1?SP
ML0;";+#[W+NZ;L-\03PZBC_28H%2#V?[TKBN,]<@/U1D6_]U14-O"6P43^,"
MFY2QE#&GJT6IYZ&"A,ZP&804VV#-FSG86C_-WC#B$41&A:F$K9E@[;<?4"LN
MFO"(\UR(.6I$*0/1+9^7W;<,.#[B63.,!K4P[+L2+U\D%]*9,2$B2RL)++7V
M[H(!SRI+2&+UC4]'WCAZK:7,#OB6)_()!F<HAF%8_%S<)S)^L>YP.%JD79B%
M0*.Z.N?F?G[>1//UO&2,]!>1%1JS#U87"=%A^9.JKRP2G$?73D#_E7@OG$.A
M>@X/3P"WEP\/)*]P0/1JB]DM*/8_;Y"SV,WVZJO_A>23TDB%:6>X!=N=W*].
M_OG7N"]T/WZ%:GL".KN()G26=QZO# T(DI#W3A-V'6DU^KI+,#^^3*R_-\GM
MU<>,G:9=TN6B.35+SXC0^^Y3",5*-F]W@MX\N>2NM[G]SS?2R8VMOW:%E?'A
MM"O9=B3;<-F9NLL!=;6OE&/D;U)>(],W=%M?AUAY\O]3:SMBEP#Q"-BW3QS;
MFFJPJD^O;MVO)6^=4O"1AJ2 3K2 M$YWC#BUZN &X$W=-:.=<VDNQB&+/6BP
ME'T,K[]NAXO7]SL;NIGXU26NUUIS_3R=+TJ;.UP%(*K/%YS?BOOS166\_^GA
MX08WTW@K^YV3,8XY2\;CV[+(+8E34_-#A[MQ!A\4JW\VTS4H@<&,JX$1%C..
MXZ>B-=8?+2E-U.+C2PQH;U+;---UO_53:PA^%K/:< )B@_JM9,)9T1=1*J?6
M:>QH@A]YC1ZPML('=T=0D7!R5AY9ENX<2EXR.12_OADU'&]-J%GIE2(-*9I[
M!_(0IVY<;\FFPT] L3, JPD0UT*'')<8,-.-CK$_4&"-(:"*R.!R;*-V7'&R
MD'#))=G/: HV[1_W-1C_E66=_V[:LE?.$OM^,NZO=UDLCO%5\8G65M=QQO8A
M#3"V/%W;!GO9N087M]8#O+TI.,#:"KO+KZU=E@D=;IP0L>4L\7HYKUD'N:><
M':ZRD.AKZ4"<'"+_4T=N?:8S:*[M)J'2,47X&-9*PW%OFO3ZSQ8L] L!+XXX
M_:'"X; %;Y,Y=<7H-70&N84+:>I*=6<DK8D$VZ0-D=(?!)3)?=Q7ONI?9/\A
MS:#TM,3[9G<Z2#.I+DZ5=R2(X;L1 ^V807?8C:E>C7HD'VSF5\QEQI[UU%\S
M0?MZ;W\M:+">FPK>:5+&]45_ZEA<$M/^U="GX(;Q_;Q!&P[6>-5HG<>(A*YF
M_OZ-Z7#<.0$=.3)F2/V%!J7A(96;@O&\\](?<JQZ@926828$N_:=EE <PH"_
M,];KU<4[H#/P0(QU>$UX]NIUNIV*=855=44< 6+>8!4_U>)2JHNO,\TOLBKQ
M$7QD\RTB_NX7TFTRN5^;DC[!#!G_%MET&37!!Q&F_LGW,0_*OUHCS9I [-K'
MRWB)*%@I*=GE\=<CBV9RN>6L"O>"L\):%@),I]!@%#_P)(;:0M DG1/DAK)"
MN)J0:<;4Y98JTRI7=B9"RVJT,UY(Y-Z4A=!=0:MRI7^-^&<6XL3RDP_ULP97
M$J,>E5(LY>8'#\T7D&.$0]\$E*MPG2*Q3)+*R/*M11P^*FB"0=I@F,! W_K-
M1Z]AXFK&F+#F]Y+^C+ 3D!\/N$.+SA>QNOO$&]ZYL7+!<1!\'R_^OO,GBJ<"
M3K\S.SFO]_>C>>_$+]3AYTXI[_V9?Q6OM5P=7!TX!Q!&^/0,)L@P5F0<L7U7
MVX@WJ7II,_L"!(4-O 7Y7262X_D@9$Q2,&S32_43BP:..:D*[,/2;*?RZY\9
M-RSSC9_-=W,1XU.I=KO,.KZ"O@NQ'_PFU-]O_'/]\S?>.GS15[5$<3[!CE#(
M(X,'^=+Y_(5?[2K2&FP4/S1K)D#"G2<$^"E5WQA7YOM!R*Q1KN%5Z%64VCSZ
M&A)*8!HLR$?STB['U0$%A&7NZ=VVGO/'F84Q^CN)!=ZUV5?G?ER<FMLIO2.1
M2<;-]_/1.3[2+Y%+^8C+?%2'+.HN^5YQ2# Y+3!@.RHBD<Z'G2 '.K[^+8O0
MW_Y(VIAK0UK 9^EZXF;7*Z;#]8J],-'P6##U;RB;):7\"F-NI4.$TO$3:!]V
M,4U2;,:=K[FZXK$EJC,3>XL0HLP[@)5X[<MZ3L[\)_[@=-:U*"I4V+9B,S)*
M)]T1RM6+65VY*%:UDV\1P%I<+K!<_]CHV3*8M9&+<V0A/I#1P32;_$9E\@,Y
MQ_9+?;T]X6.# S)*RZ:)A:>AY5[EFJ25'64J>"5/\&%9:UI6:>P::IWZY66F
MTWOT*><XE3CPEBI,JZ19#T'0',PR#H?O_6U+OJ^]R*V2>Q16=T^;9%>$324:
M#I!<M#).0%X<? $#GSS 0,*1/I!%C!A;M;A6C3 PH-[#-;@K$V1WI0%,4"=O
MT<R\3?FES_Y:;7[)+WCQV9N6%6E/X);(T*%^(6H>?K\\,2R:G7?>=DX#>F7S
M"H)VT>O5'+XA+J+>/U1&0G_V^*W:9XL3D*)P_B[\+<<H[!/XP![0.0&=6Z R
MCR[!B45)25"$\A5 >1 M->69-MRY9TI9"A@NN.+_Z/"F!S]H@OL*@#Z4*OKQ
MX=9 N^C\#I_RRV>+O^,8E[0HNREHS>-X!EO "G?+OKZK:[2[_^C-V?W">R]G
M]N',B)Z^\8)$9:4?S19N[JK39">OEZ5EIK'\B0=W:EK 3U=5D/ =MO/.=O&J
M^ <\^OV7\P6K&BY.E&$O30?:5_Z1J)ZVE.KN&?8IH!5<N?=R8/O^5RQF>?T3
M:JY$UI=_F\!6VSTXB4VM2&F0-.6TG$W?D!:0Z?>U(IDQLJR->2AEGQRI?T[=
MN_DD?+6 SCTPBE;.0"7_@-A3N]9\6HV%>#7<13?)DZ!K^18#;!YF?WWIF%#Y
M2XOI**[E:S&#%7[$28\ QF@%9-P(1RR&M?<&36QD]W4[4FM$EAR-Q+/#+&?"
M,AP"QCE_='P)>73 QZN;L*E(&J$.7^=WJWL:^HLNF8I-&I=DV;]FGB]]R2,=
M:Q."N^PS9B/[+DC5RJ'$GO3JD<LK:,K:9QZ4AQG+,W\-><?!M=9/SPPS=&;K
MWGW>L+).T'X7:%I4@AWC\VOHXPK8\S[8.2[I%Z'+'+<PE!A3)R !#1@'<I%0
M+H!W5ULS'52.%;1J"]; B*P@)VY-[YL%&\C$E"@PN($0<M^MUI[VO<RZ-4WC
MJ5]KP37%Q?E_E$T_[N]F%N'2^@U0D;1X!A=@2K9(DP\60?ZY3[:^XN3*X#P!
MQ:]<@FC6"%FL7%U:N-D3D8A2QIH4^2:IK_;4-!U8&O!&]L\>%T-7L\'X$]#H
M*3U':72-M%Q"CI*U"$WZVV2:8P8J4D7T+T'1DN1K'WLEJS?YN#:U"MH-S^>7
MRKLV9V#%U??T+CI,^1Q785;SX50;3"I#?@JE5'ZI'TQ7/R[O%QZKW5BY'.8*
M3V5PPI(83-31HBE_M!;-^'-/>M37+DJ@RQQX!\,'--R9PLX%EWHL+U]L7.WJ
M@.6-;ZZ7<=_]$Z\M)-523H-S4FCV =[?/9<-^)TI ?9- I0&FX=VU)?.7IA/
M#[_#\O$!L\-V;;E96\J7MT*8I^%92,."*?AP/Y@Z-IC%_!)^[1VU6PE10G[I
MTN^;?W?A$;-</D?BP\\^Y'3*[2..IU,HV/"S5/N 5175!(57EV1ARF-9X\J<
M0!P%L]-'LQ@$GS,XAS(H^)LJ&J>QE#4$CX_R6:&;]8I7[3"[ 1DT<>+UR$<%
M:+&^CA1\L"CRR 6YL_.78^LT:=XREA5AD$XKSV (H]_WGYT[ ?ER+$3#85>!
M..+<TPUH!V9'K:9Z[K" N/6F&AP P*DU#Z\>W0!T:CR8@B,C[GO-H/]:&CY(
M&U*?D%I:6(,G>YP]+F.(;F':3D#;K^HS4$#Q]J'O:>9(XK"NHA4B6!#O=)=5
M^C']PJ Q(X4:;-4O)>2J#3G55D*?3PG]F>;#&WZ88.AJ[@F(:E9!;@%,3T (
M."F-8*TYT#GO"+A3RYVZ,OW4N>^:-:)<UU@%F&X>#MKD^/5P?[>U/!^L7'5D
MG<I/734 9;'KEL10SCO?*X$7FCLU*G%QR<S7Q3:X*)GUHY$6X#'MD7!N>[:>
M5#L_D^NI7P\,\@8LW* IGQ2D)QN^3SS!O3X!F:+9L1921*_KJ?9MPR-A#S?K
M6?KE%XX4[ T$D/4:(4BWRU)-M\=2]@1S)M0V\S8=*Q('3YW\H.S :HYL4!G?
M<<T)R!]\F;*.'FNBRP%&C:1KB;,J.1MEJK3A^.]&;L=C3<R$4%P!R[.6?:?T
M6*$;Q]< ')'$%XM2:T&^(I(2^I^2)UB_'R:^:MIT/"?97XY%.&0O>RS=BCH7
M2Q( ,S6??6QVMNOU?S_<L8&T09<?7W[MJ+$&9@:\*1P)X:?-%SE_LY4F'4^W
MQ2Y]+[OV,?P6ZACJ,-5"\0O:#K[V9N^O,BFYS8OZ@^>8/+YZ%CJ.AV"<1\S=
M2MZI8BV/.F1T<')A=N7*6HJ+)?MU-E/%^%Q,[L^28M:GJP:X D,6G 16=[]@
M((5XI%GER"FC%&2%MJO@>)0G/Y0;' FC<AV<@&BC]*OE!R\!,"4X;0_E0KT/
MYE?/NN3V=C7X*N <K("^YJ\[XY"A^90,O8)$N\I'AB_J-"\I!%V;H<C^T[AW
MHU;"814Z<@)J'QT>2%F^=*J991@S7," ]2P?H6<@8Q4(I%I9FB.J,_6UB('/
MI5-_]8DBBM_'B JMTR0T6PU7?!.#.X;/)M]Y?ES<=?JP/F903[$7)EH]P#P7
M:"B;\)UZ/)$%<0ZIN9ZT%__P>_96NL0+??:.U+D)OA\+;!C%F%":[\'-XW*T
M.EW\(_H<<H6\GP)8DDLMS&;#E,\##W^<@(9<K(HC*@CA%_(#UZCK(R5;[/4>
MGY^>">7.-I]ZUR(EV/?IFXX/FX'0>8LC4YX$W#//D(PU>V:(HH+Z$LPS/EUJ
M=T?R7?6ZME%!T:3;9]Q[6%)HHX.R4*&#LP&S@*/LR#HMTUW!#K'6L"9;;\&5
M67K+Y%VZV_IYP7 YG9\Z5F[U%G_J:?6G;W'J_&*O(#ENJA9;^AZD UWLQS,6
M1]W-'7L42T>B+@IXC1"+ ;^..OMF#93VC*+WM#5F]*"=.I\T< \.B$D/[B8Y
MN,34%#?3X=V 3\N63;(W7U1G.T6V@()NB4!_XM"LN)#F&5"CD%'0V?DB4<7N
M-3N:1+<XCA^X!TY=837@I0O25AY_G3$0HO-W=N*I%YYPI/0:UQA5#?MZ7BAD
M<EOZM/GHMTMN"B+H12%>]L?=B&R$2'K.F_$*VNZ!W?&S4]TZP4&' F:T',,7
M\QWE9R"Z2;$0T3+%F0[Y!FO?:LT$-IK3ADM3QD$%FZ#Y6[^FZ["K-WWT+8HL
M#(;,:WCMKZ5\<?ZJK#E<.\)7)R M+*+=XI>[;J6:I)M7Q8=V7=!<8?6N,A5B
ML5=!3[FI/7GSX+)M;9[L<-T]C7O'.0\R$!]:VA_8Y,[+9V>I/P4"CAR1<)/C
MPE,GG0)F-A F.3EO,,2!EEJZWFSOS65SR0\OZI#Y9KT^S5M<G=?G0SY)%;.H
MZF1RIW#7U\A_RP)D..+HWM0!QJ6\T\6W1E5_-#]7QCL3N _G H[%G0U&RE1/
M392:QT=RWVM[Y]R ,DG&Q)Z:Q'!0JI)UP^$_ .U(@#$![\#%HCBHNY3?L3\@
MQJLGH"1)COBP:/B5K4-AE^""JM'G1%%+(>NVHFTC+#&?FM8MQ7G%Y[:YQ?QS
ME"$@20V@E!,2 "$:UR!#E 9[O&+RX@6>FMC4Z=#9.OE7ZJA5WS2LJ"BC="ZW
M4@(_>W\]=7/.!AO$4Y)8 KTR64D-+97#UQMIC]Y##BO95;]0_V:2BI66#;7*
MT-F3U."O,S91&M>>4XZG\><]F\9Y)+#87V=KEQK['+DB/F2/2R;V4-/%QRPX
M'0HD2B1UWG$]#.D)*=@[ 9TJ),%C[ GHGCP'(-4U> ):(*QFI:*D*<>P$9+C
M4#24'0@=ZN(M2L22^\2'8-@ 4EE=PX++;O&MN7!VFW'UPL#@J^PV)Z [<\$E
MPV)X0OF_T*!@%B2!K+4M_=]$'^= #)5^#8"1V5MPVE=\U>UMGVD<C;?JN/#Y
M1KMK3^*37W_HOG?OM?\K/WQJINXS$=]!*V!Q4.IMZ"?;U8C,)KKO*C3>16,T
M(ZSPE/UNEP\+,AK6!#KD:[]<-:I%]-SKJX6[+KB?\@%M-^; -N2,EU<A_]>^
MG#7XMO>1#AT-)*UFI<'Y4 +2*1!/ZK@B?"BJ9%E\OF-+1$1]QT$QBB]&<]0:
M/RUM-]-$?I77O+/.\:7RW>V U'F.LO5/NL]<PCS3FY(JTD:^:@1XB5ML\;S(
M^SZ+,Y0K\=<VR9-VV"LNSB5]M7;EI[STUGHOZ]W@Y;_^2Q79> &>\Y% ]H5O
MOD2]8D^I<.62M2^5F2GU?Y=1-YVAP8*H#7T5"DZ!4YUCY GP]E,JECZ21;]?
MYIW<#DLSZS6M-N\)+U%M?+&$9!V*M33_:7SC:]\(KB'@]_7/'Q;+?FR:+O]X
MG7KXZJ"2YIZU?>JZSQT?ET"]UZG[9?@U.,GH]3+[<1%*7ZFK<2"1KDQ^=1Q,
MT+4J;D8.# MN*@4V=42/VY"^#/Y47"*VF3U8\>KJ,3T^=_P<ZGV:^U<'U3,H
MOC5PA@<OG!]* .[U4OLV@2J7J5]I0I%!8C-!2M@TLYD=]:,W=P/\EA$_YNP"
MPE3;(W5X%E'!QR6,BXQICS-X()(6.GCHFP&11H1ZU_N]4_H1J-P1L.7']LBE
M+*$)$:%YF%GX,-"]@H\WPOK/P=1U:*'0&3>5<6ISHJU)KRJ/05/FR#W^#7F/
M&K'>DMH/I9O2UC;9.)N0DKHC8V9+<SDK4YSMM9%&J^ADP@2KF??#]P-R8\__
M-,$N)<0F2I7:U>*-Y^.:S$O(@LMC)).&]!)NCJ^[!V&TT>'RN!5P6'E<SUQ:
M/=WIM"W'TC7GZ,I'ZBC):3Q@C[Y$USPN:+PO-A.^DJRK7L29N.G83?WR4'_I
M 'OMV7#M0B&W3E^&+A10BDCO*.=&3X/;(@9;N+;FHC )O_0-ICV N%HW2.>!
MKF5+:J\S%J%;UB1';!\_IXJ\-^;0?4$B/_Q."O\]#TR@@2AF4/L$=#<KP4"1
MJI5%9Z+N6E-W,_O!RRO+W_M5.VE=Z5B:R)X_@DTKOTQR-@C?_0-E6?,V^"+>
M4LLYX!5_T]VB99FKLM4.$:/!@#1\^^F1)>K&2Z".AB'OS*=!?,.K$47G>AH]
ME&E6A:!I]1LA(AF-CW2M6@*\^?Z=YQ/U-CW[5B)S7$TM4\^SS.?%^ /@F\65
M"E/6E/AU%O4UVRV-JFW*]^GP4ETG/UG[)I-<USQ=?'U/3I/LGK(FCNW;U3>T
M2*^F^-RMM=9P3Y:7J6U5^Q#(+,*4T]ES-@IXU\RM J3^-.?Q\ZR5LZ/2<&].
M0% &""5Z.MUR'.DG(+;BU8(T%)C"D=9I(#NMP9%$"NQ*H7O7>7@@R\VD[[06
MR>N]NK6-*UO:<?G]>_$OT_AWC^+7R-"%!HHCP>$TR#OT)/C4E_@'<_KU\_=2
M<2EH15?@PJGYX%-9V!#42H9H-8S^]\'&F?54L_[20X1E,9&6,9ZWQX5BZDDD
M5ZD 7$+Q;PLR,YV+ZT %X**!"5!> T&47,%-VD3<M[X>ZD$+- WB6(]-&&84
M1E>[O5? *WILOG/4%$R8N37]-\/VED36_>1&#0,US*#F@'=PU@H7AAQ$AP$W
M/)N1I$=M.4ZO.F?WF\1A-(D>Y,W.8F*/20$F !>@ENR5>KI>5A%!@91,H8*\
M*RS)OOP79T<,:\2UB9,C/E-#,;Y7OL/XDDH:CIQ-TF,J:VIG4]-](Z6^+$UG
MDNS(VW-A#P]S6TOTXXBK:LGW.)CCG(J<V-RUR7WIOLD%;>&B8NGKLK9X'4D>
M48<:M#!* $@AKRQZ,UAC?&A:A(CKFR<@#OH9G_H50-DA7Z#*HDF</)IXMVUR
M7_MYB42KBS^)T53OL8&=%-C^\4^WWY29<\#8">A^>8INU_; *45 CALA%N2
M !QMA0A_$K',!X1?+N<:"]7*-%#9$+TZI?[6R^E6KGN:C(:.PMWD/VGUH_^
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MEE^1/.&GQBHWH'->BW,S%GKYK]Z]KY%=9N(O(!I'W.@Q#\Z/X<&L?E#F7F@
MN33 A0I/#N[5#\50%!UONL/)\RE-*._5@#X]BUE\\98B/]*5.*<9U9\56#7H
MC4"$! 2E,#]EN5GAZ&Y_ FKJ.@$]^8*^2<< I4<.2*D]!HNC-\UV32O.0!D
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M8G9C8FEO+FAT;5!+ 0(4 Q0    ( -6 L%J!'%8?WKD  .WQ   -
M      "  <67" !I;6%G95\P,#$N:G!G4$L! A0#%     @ U8"P6NR2^D%-
M_@  ]0H!  T              ( !SE$) &EM86=E7S P,BYJ<&=02P$"% ,4
M    " #5@+!:<+KVV690   X4@  #0              @ %&4 H :6UA9V5?
=,# S+FIP9U!+!08     "@ * )$"  #7H H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>ea0241941-posam1_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abvc="http://metuboutique.com/20250331"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abvc-20250331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubScriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:SubscribedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteBVIIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ShulingJiangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ABVCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ABVCAndBioLiteTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ZhongHuiLianHeJiTuanLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-14</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2023-08-14</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abvc:PostSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">abvc:TaiwanCentralDepositInsuranceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">abvc:USFederalDepositInsuranceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abvc:ClientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abvc:ClientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abvc:TwoClientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abvc:ClientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:PostretirementAndPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-31</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-31</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-31</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-15</startDate>
            <endDate>2017-08-15</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-24</startDate>
            <endDate>2018-12-24</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-24</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2018-12-24</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2022-06-10</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2022-06-10</startDate>
            <endDate>2022-06-10</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneStudiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-30</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-25</startDate>
            <endDate>2017-09-25</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-30</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-05</startDate>
            <endDate>2019-08-05</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:CollaborativeAgreementWithForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:CollaborativeAgreementWithForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:CollaborativeAgreementWithForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-06-18</startDate>
            <endDate>2024-06-18</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-18</startDate>
            <endDate>2024-06-18</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-08</startDate>
            <endDate>2024-05-08</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-08</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-14</startDate>
            <endDate>2024-05-14</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-14</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:LucidaimCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanKKBioLiteJPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanKKBioLiteJPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LindGlobalFundIILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:WarrantDebtDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-09-12</startDate>
            <endDate>2023-09-12</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-22</startDate>
            <endDate>2024-05-22</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:SecondLindNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-17</instant>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-17</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-17</instant>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-11-17</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-17</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:WarrantDebtDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-17</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-01-17</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-01-17</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-17</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:WarrantDebtDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-17</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-17</instant>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-22</startDate>
            <endDate>2024-05-22</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-19</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-19</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-19</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-11-05</instant>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:FirstLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:FirstLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-28</instant>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-28</instant>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-12</instant>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-19</instant>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-12</startDate>
            <endDate>2017-06-12</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-19</startDate>
            <endDate>2017-06-19</endDate>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:CTBCLoanAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-19</instant>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:FEYEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-09-07</startDate>
            <endDate>2021-09-07</endDate>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-07-27</instant>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-11</instant>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-10</instant>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-15</instant>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-24</instant>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationtheBioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmInctheGenePharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationBHKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AiBtlHoldingBioPharmaIncAiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JaimesVargasRussmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionArtsPromotionIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:OncoXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:OncoXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:FEYEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:FEYEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:EuroAsiaInvestmentFinanceCorpLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-03</instant>
        </period>
    </context>
    <context id="c371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="c372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="c376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="c377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-27</instant>
        </period>
    </context>
    <context id="c381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ChiefStrategicOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-24</instant>
        </period>
    </context>
    <context id="c388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="c391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-04-11</startDate>
            <endDate>2024-04-11</endDate>
        </period>
    </context>
    <context id="c393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-11</instant>
        </period>
    </context>
    <context id="c394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-04-11</instant>
        </period>
    </context>
    <context id="c395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ABVCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteBVIIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="c399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ShulingJiangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindGlobalFundIILPLindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="c404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="c406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-05-22</startDate>
            <endDate>2024-05-22</endDate>
        </period>
    </context>
    <context id="c408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-17</instant>
        </period>
    </context>
    <context id="c409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-17</instant>
        </period>
    </context>
    <context id="c410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:PreExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-22</startDate>
            <endDate>2024-05-22</endDate>
        </period>
    </context>
    <context id="c411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindGlobalFundIILPLindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-22</startDate>
            <endDate>2024-05-22</endDate>
        </period>
    </context>
    <context id="c412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-05-22</instant>
        </period>
    </context>
    <context id="c415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-22</instant>
        </period>
    </context>
    <context id="c416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindGlobalFundIILPLindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindGlobalFundIILPLindMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-17</instant>
        </period>
    </context>
    <context id="c421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-05</instant>
        </period>
    </context>
    <context id="c422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-05</instant>
        </period>
    </context>
    <context id="c423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-05</instant>
        </period>
    </context>
    <context id="c424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="c428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">abvc:CashPaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">abvc:CashPaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-11-12</startDate>
            <endDate>2023-11-12</endDate>
        </period>
    </context>
    <context id="c432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2023-11-12</instant>
        </period>
    </context>
    <context id="c433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="c434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:DecemberLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-05</instant>
        </period>
    </context>
    <context id="c435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:DecemberLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-05</startDate>
            <endDate>2025-01-05</endDate>
        </period>
    </context>
    <context id="c436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLindNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:BioLiteBVIIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ShulingJiangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ABVCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ABVCAndBioLiteTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:AiBtlBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">abvc:AsRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">abvc:AsRestatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">abvc:AsRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">abvc:TaiwanCentralDepositInsuranceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">abvc:USFederalDepositInsuranceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-31</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="c471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2015-01-31</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-24</instant>
        </period>
    </context>
    <context id="c475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneStudiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:CollaborativeAgreementWithForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBiopPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:LucidaimCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteJapanKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ForSeeConEyeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanKKBioLiteJPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:OncoXBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="c537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-09</startDate>
            <endDate>2025-01-09</endDate>
        </period>
    </context>
    <context id="c539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-19</endDate>
        </period>
    </context>
    <context id="c540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:LindWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-09</startDate>
            <endDate>2025-01-09</endDate>
        </period>
    </context>
    <context id="c541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LindNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LindNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="c544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-05</startDate>
            <endDate>2024-11-05</endDate>
        </period>
    </context>
    <context id="c545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-11-05</startDate>
            <endDate>2024-11-05</endDate>
        </period>
    </context>
    <context id="c546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-05</instant>
        </period>
    </context>
    <context id="c547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-05</instant>
        </period>
    </context>
    <context id="c548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:SecondLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:OtherNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:CTBCLoanAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="c563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:OtherIndividualMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="c570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="c571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ConversionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="c572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ConversionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="c573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JiangsAdvancedFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JiangsAdvancedFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JiangsAdvancedFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JiangsAdvancedFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:BioFirstReceivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationtheBioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenePharmInctheGenePharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationBHKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingBioPharmaIncAiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:JaimesVargasRussmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LionArtsPromotionIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LionArtPromotionIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LionArtPromotionIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:EuroAsiaInvestmentFinanceCorpLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:ZhonghuiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-14</instant>
        </period>
    </context>
    <context id="c613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-14</startDate>
            <endDate>2024-08-14</endDate>
        </period>
    </context>
    <context id="c616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="c617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-10-29</endDate>
        </period>
    </context>
    <context id="c618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-13</startDate>
            <endDate>2024-11-13</endDate>
        </period>
    </context>
    <context id="c619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-26</startDate>
            <endDate>2024-12-26</endDate>
        </period>
    </context>
    <context id="c620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-30</endDate>
        </period>
    </context>
    <context id="c622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abvc:ShulingJiangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:LindOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="c628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="c631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:ThirdLINDNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:LindNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ThirdLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-05</startDate>
            <endDate>2025-01-05</endDate>
        </period>
    </context>
    <context id="c634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2025-01-05</startDate>
            <endDate>2025-01-05</endDate>
        </period>
    </context>
    <context id="c635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-05</startDate>
            <endDate>2025-01-05</endDate>
        </period>
    </context>
    <context id="c636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abvc:LindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-05</instant>
        </period>
    </context>
    <context id="c637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abvc:ExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-05</startDate>
            <endDate>2025-01-05</endDate>
        </period>
    </context>
    <context id="c638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abvc:UnregisteredRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:AdvisorsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:AdvisorsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:AdvisorsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvc:AdvisorsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:AiBtlHoldingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="twd">
        <measure>iso4217:TWD</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-69">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-81">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-46371">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-46372">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-46373">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="c0" id="ixv-370">This Amendment No. 4 to the registration statement on Form S-1 (Registration No. 333-276500) is filed for the purpose of including information contained in the registrant&#x2019;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 and Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on April 30, 2025 and April 15, 2025.No
                                            additional securities are being registered under this Post-Effective Amendment No. 4. All
                                            applicable registration fees were paid at the time of the original filing of the Registration
                                            Statement on April 24, 2023.Pursuant to Section 84001 of the FAST Act,
all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended,
after the date of this Post-Effective Amendment and prior to the termination of the offering covered hereby shall also be deemed to be
incorporated by reference into this Post-Effective Amendment and to be a part hereof from the date of filing of such documents.Post-Effective Amendment No. 1 to Registration
Statement on Form S-1 (File No. 333-276500)This prospectus relates to the resale, from time
to time, by the selling stockholders identified in this prospectus under the caption &#x201c;Selling Stockholders,&#x201d; of: (a) up to
342,857 shares of Common Stock of the Company, which are issuable upon conversion of a secured, convertible note pursuant to that certain
securities purchase agreement dated as of November 17, 2023 (the &#x201c;2nd Lind Transaction&#x201d;) between the Company and
Lind Global Fund II, LP (&#x201c;Lind&#x201d;) in the principal amount of $1,200,000 (the &#x201c;2nd Lind Note&#x201d;), at a
conversion price, which shall be the lesser of (i) $3.50 (the &#x201c;Fixed Price&#x201d;) and (ii) 90% of the three lowest VWAPs (as defined
in the 2nd Lind Note) during the 20 trading days prior to conversion, (b) 1,000,000 shares of Common Stock underlying a common
stock purchase warrant (the &#x201c;2nd Lind Warrant&#x201d;) at an initial exercise price of $2 per share, (c) 30,000 shares
of Common Stock underlying a placement agent common stock purchase warrant pursuant to the 2nd Lind Transaction, (the &#x201c;2nd
PA Warrant&#x201d;); (d) 285,714 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain
securities purchase agreement dated as of January 17, 2024 between the Company and Lind (the &#x201c;3rd Lind Transaction&#x201d;);
(e) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 3rd Lind Transaction; and
(f) 25,000 shares of Common Stock underlying a placement agent common stock purchase warrant pursuant to the 3rd Lind Transaction
(the &#x201c;3rd PA Warrant&#x201d;).Post-Effective Amendment No. 4 to Registration
Statement on Form S-1 (File No. 333-271416)On April 24, 2023, we filed a registration statement
with the SEC, on Form S-1 (File No. 333-271416) (the &#x201c;Prior Registration Statement&#x201d;), to initially register for resale 9,031,112
shares of our common stock, which includes: (i) 3,527,778 shares of common stock underlying secured convertible note (the &#x201c;Lind
Note&#x201d;) pursuant to that certain securities purchase agreement dated as of February 23, 2023, (ii) 5,291,667 shares of common stock
underlying a warrant dated February 23, 2023 (the &#x201c;Lind Warrant&#x201d;) and (iii) 211,667 shares of common stock underlying a placement
agent warrant dated February 23, 2023.The
                                            Prior Registration Statement was declared effective by the SEC on June 8, 2023. Pursuant
                                            to Rule 429 this registration statement shall constitute Post-Effective Amendment No. 4 to
                                            the Prior Registration Statement with respect to the offering of any unsold shares thereunder
                                            and is being filed to update certain other information in the Prior Registration Statement.
                                            No additional securities are being registered under this Post-Effective Amendment No. 4.
                                            All applicable registration fees for the Prior Registration Statement were paid at the time
                                            of the original filing of the Prior Registration Statement. Accordingly, upon effectiveness,
                                            this Registration Statement shall act as a post-effective amendment to the Prior Registration
                                            Statement.</dei:AmendmentDescription>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c1" decimals="0" id="ixv-46374" unitRef="usd">248382</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-46375" unitRef="usd">60155</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c1" decimals="0" id="ixv-46376" unitRef="usd">615433</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c2" decimals="0" id="ixv-46377" unitRef="usd">656625</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-46378" unitRef="usd">1530</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-46379" unitRef="usd">10463</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="0" id="ixv-46380" unitRef="usd">1155051</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-46381" unitRef="usd">747573</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ShortTermInvestments contextRef="c1" decimals="0" id="ixv-46382" unitRef="usd">64736</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="0" id="ixv-46383" unitRef="usd">79312</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-46384" unitRef="usd">96213</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-46385" unitRef="usd">101051</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" id="ixv-46386" unitRef="usd">2179815</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-46387" unitRef="usd">1656709</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" id="ixv-46388" unitRef="usd">511088</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-46389" unitRef="usd">569278</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" id="ixv-46390" unitRef="usd">640387</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-46391" unitRef="usd">809283</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments contextRef="c1" decimals="0" id="ixv-46392" unitRef="usd">2258754</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="0" id="ixv-46393" unitRef="usd">2527740</us-gaap:LongTermInvestments>
    <abvc:PrepaymentForLongtermInvestmentsNoncurrent contextRef="c1" decimals="0" id="ixv-46394" unitRef="usd">1124842</abvc:PrepaymentForLongtermInvestmentsNoncurrent>
    <abvc:PrepaymentForLongtermInvestmentsNoncurrent contextRef="c2" decimals="0" id="ixv-46395" unitRef="usd">1274842</abvc:PrepaymentForLongtermInvestmentsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c1" decimals="0" id="ixv-46396" unitRef="usd">691900</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c2" decimals="0" id="ixv-46397" unitRef="usd">691900</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="0" id="ixv-46398" unitRef="usd">133121</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="0" id="ixv-46399" unitRef="usd">141231</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent contextRef="c4" decimals="0" id="ixv-46400" unitRef="usd">113516</us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:Assets contextRef="c1" decimals="0" id="ixv-46401" unitRef="usd">7539907</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-46402" unitRef="usd">7784499</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings contextRef="c1" decimals="0" id="ixv-46403" unitRef="usd">840252</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="0" id="ixv-46404" unitRef="usd">899250</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-46405" unitRef="usd">3509422</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-46406" unitRef="usd">3548352</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c1" decimals="0" id="ixv-46407" unitRef="usd">81115</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c2" decimals="0" id="ixv-46408" unitRef="usd">79500</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" id="ixv-46409" unitRef="usd">112946</us-gaap:TaxesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-46410" unitRef="usd">403581</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-46411" unitRef="usd">401826</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-46412" unitRef="usd">773045</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-46413" unitRef="usd">173493</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c3" decimals="0" id="ixv-46414" unitRef="usd">950046</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c4" decimals="0" id="ixv-46415" unitRef="usd">886522</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-46416" unitRef="usd">6557461</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-46417" unitRef="usd">6101889</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecurityDepositLiability contextRef="c1" decimals="0" id="ixv-46418" unitRef="usd">21680</us-gaap:SecurityDepositLiability>
    <us-gaap:SecurityDepositLiability contextRef="c2" decimals="0" id="ixv-46419" unitRef="usd">21680</us-gaap:SecurityDepositLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-46420" unitRef="usd">236807</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-46421" unitRef="usd">407457</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="0" id="ixv-46422" unitRef="usd">6815948</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-46423" unitRef="usd">6531026</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="ixv-46424"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-46425"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ixv-46426"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ixv-46427"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="ix_8_fact"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ix_9_fact"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ix_2_fact"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ix_3_fact"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="0"
      id="ix_4_fact"
      unitRef="shares">13868484</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="0"
      id="ix_5_fact"
      unitRef="shares">13868484</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ix_6_fact"
      unitRef="shares">7940298</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ix_7_fact"
      unitRef="shares">7940298</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" id="ix_0_fact" unitRef="usd">13868</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ix_1_fact" unitRef="usd">7940</us-gaap:CommonStockValue>
    <abvc:StockSubscriptionReceivedInAdvance contextRef="c1" decimals="0" id="ixv-46438" unitRef="usd">31040</abvc:StockSubscriptionReceivedInAdvance>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" id="ixv-46439" unitRef="usd">78595065</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" id="ixv-46440" unitRef="usd">73978380</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" id="ixv-46441" unitRef="usd">-68949807</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-46442" unitRef="usd">-64046929</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="0" id="ixv-46443" unitRef="usd">445665</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" id="ixv-46444" unitRef="usd">516387</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue contextRef="c1" decimals="0" id="ixv-46445" unitRef="usd">8909691</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c2" decimals="0" id="ixv-46446" unitRef="usd">8901668</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" id="ixv-46447" unitRef="usd">1226140</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-46448" unitRef="usd">1554110</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c1" decimals="0" id="ixv-46449" unitRef="usd">-502181</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c2" decimals="0" id="ixv-46450" unitRef="usd">-300637</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-46451" unitRef="usd">723959</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-46452" unitRef="usd">1253473</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" id="ixv-46453" unitRef="usd">7539907</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-46454" unitRef="usd">7784499</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c7" decimals="0" id="ixv-46455" unitRef="usd">509589</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c8" decimals="0" id="ixv-46456" unitRef="usd">152430</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c7" decimals="0" id="ixv-46457" unitRef="usd">763</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c8" decimals="0" id="ixv-46458" unitRef="usd">302037</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c7" decimals="0" id="ixv-46459" unitRef="usd">508826</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c8" decimals="0" id="ixv-46460" unitRef="usd">-149607</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c7" decimals="0" id="ixv-46461" unitRef="usd">2261336</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c8" decimals="0" id="ixv-46462" unitRef="usd">5368278</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="0" id="ixv-46463" unitRef="usd">179272</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c8" decimals="0" id="ixv-46464" unitRef="usd">1062916</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="0" id="ixv-46465" unitRef="usd">2773460</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="0" id="ixv-46466" unitRef="usd">185933</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="0" id="ixv-46467" unitRef="usd">5214068</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c8" decimals="0" id="ixv-46468" unitRef="usd">6617127</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="0" id="ixv-46469" unitRef="usd">-4705242</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c8" decimals="0" id="ixv-46470" unitRef="usd">-6766734</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c7" decimals="0" id="ixv-46471" unitRef="usd">87358</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c8" decimals="0" id="ixv-46472" unitRef="usd">185481</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c7" decimals="0" id="ixv-46473" unitRef="usd">825899</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c8" decimals="0" id="ixv-46474" unitRef="usd">1313671</us-gaap:InterestExpenseNonoperating>
    <us-gaap:SubleaseIncome contextRef="c7" decimals="0" id="ixv-46475" unitRef="usd">48478</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c8" decimals="0" id="ixv-46476" unitRef="usd">65900</us-gaap:SubleaseIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c7" decimals="0" id="ixv-46477" unitRef="usd">-25135</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c8" decimals="0" id="ixv-46478" unitRef="usd">22690</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnInvestments contextRef="c7" decimals="0" id="ixv-46479" unitRef="usd">-339171</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c8" decimals="0" id="ixv-46480" unitRef="usd">-221888</us-gaap:GainLossOnInvestments>
    <abvc:WriteOffUnclaimedAccruedLiabilites contextRef="c7" decimals="0" id="ixv-46481" unitRef="usd">255592</abvc:WriteOffUnclaimedAccruedLiabilites>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="0" id="ixv-46482" unitRef="usd">134443</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c8" decimals="0" id="ixv-46483" unitRef="usd">3384</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="0" id="ixv-46484" unitRef="usd">-664334</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c8" decimals="0" id="ixv-46485" unitRef="usd">-1258104</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-46486" unitRef="usd">-5369576</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c8" decimals="0" id="ixv-46487" unitRef="usd">-8024838</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-46488" unitRef="usd">-110539</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c8" decimals="0" id="ixv-46489" unitRef="usd">256006</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c7" decimals="0" id="ixv-46490" unitRef="usd">-5259037</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c8" decimals="0" id="ixv-46491" unitRef="usd">-8280844</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-46492" unitRef="usd">-356159</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c8" decimals="0" id="ixv-46493" unitRef="usd">-492794</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-46494" unitRef="usd">-4902878</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="0" id="ixv-46495" unitRef="usd">-7788050</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c7" decimals="0" id="ixv-46496" unitRef="usd">-70722</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c8" decimals="0" id="ixv-46497" unitRef="usd">-741</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="0" id="ixv-46498" unitRef="usd">-4973600</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c8" decimals="0" id="ixv-46499" unitRef="usd">-7788791</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-46500"
      unitRef="usdPershares">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-46501"
      unitRef="usdPershares">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c8"
      decimals="2"
      id="ixv-46502"
      unitRef="usdPershares">-1.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c8"
      decimals="2"
      id="ixv-46503"
      unitRef="usdPershares">-1.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ix_10_fact"
      unitRef="shares">11673980</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ix_11_fact"
      unitRef="shares">11673980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ix_12_fact"
      unitRef="shares">4335650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c8"
      decimals="INF"
      id="ix_13_fact"
      unitRef="shares">4335650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c7" decimals="0" id="ixv-46508" unitRef="usd">-5259037</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c8" decimals="0" id="ixv-46509" unitRef="usd">-8280844</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="c7" decimals="0" id="ixv-46510" unitRef="usd">32025</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c8" decimals="0" id="ixv-46511" unitRef="usd">28531</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="0" id="ixv-46512" unitRef="usd">2773460</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="0" id="ixv-46513" unitRef="usd">185933</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c7" decimals="0" id="ixv-46514" unitRef="usd">11993</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c8" decimals="0" id="ixv-46515" unitRef="usd">1455101</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c7" decimals="0" id="ixv-46516" unitRef="usd">-532769</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c8" decimals="0" id="ixv-46517" unitRef="usd">-1244245</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:GainLossOnInvestments contextRef="c7" decimals="0" id="ixv-46518" unitRef="usd">-339171</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c8" decimals="0" id="ixv-46519" unitRef="usd">-221888</us-gaap:GainLossOnInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c7" decimals="0" id="ixv-46520" unitRef="usd">168896</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c8" decimals="0" id="ixv-46521" unitRef="usd">351859</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c8" decimals="0" id="ixv-46522" unitRef="usd">115668</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c8" decimals="0" id="ixv-46523" unitRef="usd">-228557</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c7" decimals="0" id="ixv-46524" unitRef="usd">-12948</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c8" decimals="0" id="ixv-46525" unitRef="usd">-101926</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c7" decimals="0" id="ixv-46526" unitRef="usd">293962</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c8" decimals="0" id="ixv-46527" unitRef="usd">321776</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c7" decimals="0" id="ixv-46528" unitRef="usd">152819</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c8" decimals="0" id="ixv-46529" unitRef="usd">638762</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c7" decimals="0" id="ixv-46530" unitRef="usd">1615</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c8" decimals="0" id="ixv-46531" unitRef="usd">68515</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="c8" decimals="0" id="ixv-46532" unitRef="usd">13700</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c7" decimals="0" id="ixv-46533" unitRef="usd">-112946</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c8" decimals="0" id="ixv-46534" unitRef="usd">112946</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c7" decimals="0" id="ixv-46535" unitRef="usd">-168896</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c8" decimals="0" id="ixv-46536" unitRef="usd">-351859</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="0" id="ixv-46537" unitRef="usd">-1809145</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c8" decimals="0" id="ixv-46538" unitRef="usd">-4186848</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c8" decimals="0" id="ixv-46539" unitRef="usd">21201</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c8" decimals="0" id="ixv-46540" unitRef="usd">338985</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c8" decimals="0" id="ixv-46541" unitRef="usd">-360186</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c8" decimals="0" id="ixv-46542" unitRef="usd">1050000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c7" decimals="0" id="ixv-46543" unitRef="usd">29152</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c8" decimals="0" id="ixv-46544" unitRef="usd">1000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c7" decimals="0" id="ixv-46545" unitRef="usd">394071</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c8" decimals="0" id="ixv-46546" unitRef="usd">2406338</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c7" decimals="0" id="ixv-46547" unitRef="usd">947500</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c7" decimals="0" id="ixv-46548" unitRef="usd">599552</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c8" decimals="0" id="ixv-46549" unitRef="usd">-186499</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c7" decimals="0" id="ixv-46550" unitRef="usd">342095</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c8" decimals="0" id="ixv-46551" unitRef="usd">1462622</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c7" decimals="0" id="ixv-46552" unitRef="usd">327017</us-gaap:RepaymentsOfConvertibleDebt>
    <abvc:RepurchaseOfTreasuryStocks contextRef="c7" decimals="0" id="ixv-46553" unitRef="usd">7320</abvc:RepurchaseOfTreasuryStocks>
    <abvc:ProceedsFromIssuanceOfAPromissoryNote contextRef="c7" decimals="0" id="ixv-46554" unitRef="usd">30000</abvc:ProceedsFromIssuanceOfAPromissoryNote>
    <us-gaap:ProceedsFromStockPlans contextRef="c7" decimals="0" id="ixv-46555" unitRef="usd">31040</us-gaap:ProceedsFromStockPlans>
    <abvc:ProceedsFromSubsidiarysShareholderContribution contextRef="c8" decimals="0" id="ixv-46556" unitRef="usd">137500</abvc:ProceedsFromSubsidiarysShareholderContribution>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="0" id="ixv-46557" unitRef="usd">1980769</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c8" decimals="0" id="ixv-46558" unitRef="usd">3869961</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="0" id="ixv-46559" unitRef="usd">-24589</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c8" decimals="0" id="ixv-46560" unitRef="usd">2125</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="0" id="ixv-46561" unitRef="usd">147035</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c8" decimals="0" id="ixv-46562" unitRef="usd">-674948</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-46563" unitRef="usd">716780</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c10" decimals="0" id="ixv-46564" unitRef="usd">1391728</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="0" id="ixv-46565" unitRef="usd">863815</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-46566" unitRef="usd">716780</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="0" id="ixv-46567" unitRef="usd">22539</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c8" decimals="0" id="ixv-46568" unitRef="usd">33180</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c7" decimals="0" id="ixv-46569" unitRef="usd">25863</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c8" decimals="0" id="ixv-46570" unitRef="usd">27392</us-gaap:IncomeTaxesPaidNet>
    <abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty contextRef="c8" decimals="0" id="ixv-46571" unitRef="usd">691900</abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c7" decimals="0" id="ixv-46572" unitRef="usd">593714</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c8" decimals="0" id="ixv-46573" unitRef="usd">1786686</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <abvc:IssuanceOfSubsidiarysCommonStockForConsultingServices contextRef="c7" decimals="0" id="ixv-46574" unitRef="usd">383500</abvc:IssuanceOfSubsidiarysCommonStockForConsultingServices>
    <us-gaap:SharesOutstanding
      contextRef="c12"
      decimals="INF"
      id="ix_14_fact"
      unitRef="shares">3286190</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="0" id="ix_15_fact" unitRef="usd">3286</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="0" id="ixv-46577" unitRef="usd">-1354440</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="0" id="ixv-46578" unitRef="usd">67937050</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c16" decimals="0" id="ixv-46579" unitRef="usd">-54904439</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c17" decimals="0" id="ixv-46580" unitRef="usd">517128</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c18"
      decimals="INF"
      id="ixv-46581"
      unitRef="shares">-27535</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c18" decimals="0" id="ixv-46582" unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c19" decimals="0" id="ixv-46583" unitRef="usd">137554</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c10" decimals="0" id="ixv-46584" unitRef="usd">3236139</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abvc:PriorPeriodAdjustment contextRef="c22" decimals="0" id="ixv-46585" unitRef="usd">1354440</abvc:PriorPeriodAdjustment>
    <abvc:PriorPeriodAdjustment contextRef="c24" decimals="0" id="ixv-46586" unitRef="usd">-1354440</abvc:PriorPeriodAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c29"
      decimals="INF"
      id="ix_16_fact"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c29" decimals="0" id="ix_17_fact" unitRef="usd">300</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c32" decimals="0" id="ixv-46589" unitRef="usd">1049700</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c8" decimals="0" id="ixv-46590" unitRef="usd">1050000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c29"
      decimals="INF"
      id="ix_18_fact"
      unitRef="shares">51941</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c29" decimals="0" id="ix_19_fact" unitRef="usd">52</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c32" decimals="0" id="ixv-46593" unitRef="usd">196048</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c8" decimals="0" id="ixv-46594" unitRef="usd">196100</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c29"
      decimals="INF"
      id="ix_20_fact"
      unitRef="shares">370000</abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty contextRef="c29" decimals="0" id="ix_21_fact" unitRef="usd">370</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty contextRef="c32" decimals="0" id="ixv-46597" unitRef="usd">691530</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty contextRef="c8" decimals="0" id="ixv-46598" unitRef="usd">691900</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c29"
      decimals="INF"
      id="ix_22_fact"
      unitRef="shares">3732167</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c29" decimals="0" id="ix_23_fact" unitRef="usd">3732</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c32" decimals="0" id="ixv-46601" unitRef="usd">1782954</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c8" decimals="0" id="ixv-46602" unitRef="usd">1786686</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable contextRef="c32" decimals="0" id="ixv-46603" unitRef="usd">1729029</abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable>
    <abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable contextRef="c8" decimals="0" id="ixv-46604" unitRef="usd">1729029</abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c32" decimals="0" id="ixv-46605" unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c8" decimals="0" id="ixv-46606" unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <abvc:StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant
      contextRef="c29"
      decimals="INF"
      id="ix_24_fact"
      unitRef="shares">200000</abvc:StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant>
    <abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant contextRef="c29" decimals="0" id="ix_25_fact" unitRef="usd">200</abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant>
    <abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant contextRef="c32" decimals="0" id="ixv-46609" unitRef="usd">-200</abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant>
    <abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution contextRef="c32" decimals="0" id="ixv-46610" unitRef="usd">82897</abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution>
    <abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution contextRef="c36" decimals="0" id="ixv-46611" unitRef="usd">54603</abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution>
    <abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution contextRef="c8" decimals="0" id="ixv-46612" unitRef="usd">137500</abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution>
    <us-gaap:ProfitLoss contextRef="c33" decimals="0" id="ixv-46613" unitRef="usd">-7788050</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c36" decimals="0" id="ixv-46614" unitRef="usd">-492794</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c8" decimals="0" id="ixv-46615" unitRef="usd">-8280844</us-gaap:ProfitLoss>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="c34" decimals="0" id="ixv-46616" unitRef="usd">-741</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="c8" decimals="0" id="ixv-46617" unitRef="usd">-741</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan contextRef="c32" decimals="0" id="ixv-46618" unitRef="usd">-190628</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <abvc:StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation
      contextRef="c35"
      decimals="INF"
      id="ixv-46619"
      unitRef="shares">982</abvc:StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan contextRef="c35" decimals="0" id="ixv-46620" unitRef="usd">198332</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan contextRef="c8" decimals="0" id="ixv-46621" unitRef="usd">7704</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:SharesOutstanding
      contextRef="c37"
      decimals="INF"
      id="ix_26_fact"
      unitRef="shares">7940298</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c37" decimals="0" id="ix_27_fact" unitRef="usd">7940</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c40" decimals="0" id="ixv-46624" unitRef="usd">73978380</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c41" decimals="0" id="ixv-46625" unitRef="usd">-64046929</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c42" decimals="0" id="ixv-46626" unitRef="usd">516387</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c43"
      decimals="INF"
      id="ixv-46627"
      unitRef="shares">-26553</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c43" decimals="0" id="ixv-46628" unitRef="usd">-8901668</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c44" decimals="0" id="ixv-46629" unitRef="usd">-300637</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-46630" unitRef="usd">1253473</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abvc:IssuanceOfCommonShareForLindCNRepayment
      contextRef="c45"
      decimals="INF"
      id="ix_28_fact"
      unitRef="shares">1705303</abvc:IssuanceOfCommonShareForLindCNRepayment>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN contextRef="c45" decimals="0" id="ix_29_fact" unitRef="usd">1706</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN contextRef="c48" decimals="0" id="ixv-46633" unitRef="usd">592008</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN contextRef="c7" decimals="0" id="ixv-46634" unitRef="usd">593714</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c48" decimals="0" id="ixv-46635" unitRef="usd">394071</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c7" decimals="0" id="ixv-46636" unitRef="usd">394071</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c45"
      decimals="INF"
      id="ix_30_fact"
      unitRef="shares">703496</abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty contextRef="c45" decimals="0" id="ix_31_fact" unitRef="usd">703</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty>
    <abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty
      contextRef="c51"
      decimals="INF"
      id="ixv-46639"
      unitRef="shares">-703496</abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty contextRef="c51" decimals="0" id="ixv-46640" unitRef="usd">-703</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c45"
      decimals="INF"
      id="ix_32_fact"
      unitRef="shares">2019387</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c45" decimals="0" id="ix_33_fact" unitRef="usd">2019</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c48" decimals="0" id="ixv-46643" unitRef="usd">2451854</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c7" decimals="0" id="ixv-46644" unitRef="usd">2453873</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants
      contextRef="c45"
      decimals="INF"
      id="ix_34_fact"
      unitRef="shares">1500000</abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants contextRef="c45" decimals="0" id="ix_35_fact" unitRef="usd">1500</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants contextRef="c48" decimals="0" id="ixv-46647" unitRef="usd">946000</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants contextRef="c7" decimals="0" id="ixv-46648" unitRef="usd">947500</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="c51"
      decimals="INF"
      id="ixv-46649"
      unitRef="shares">-592</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c51" decimals="0" id="ixv-46650" unitRef="usd">7320</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c7" decimals="0" id="ixv-46651" unitRef="usd">7320</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <abvc:StockSubscriptionReceived contextRef="c46" decimals="0" id="ixv-46652" unitRef="usd">31040</abvc:StockSubscriptionReceived>
    <abvc:StockSubscriptionReceived contextRef="c7" decimals="0" id="ixv-46653" unitRef="usd">31040</abvc:StockSubscriptionReceived>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService contextRef="c48" decimals="0" id="ixv-46654" unitRef="usd">225690</abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService contextRef="c52" decimals="0" id="ixv-46655" unitRef="usd">157810</abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService contextRef="c7" decimals="0" id="ixv-46656" unitRef="usd">383500</abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="c48" decimals="0" id="ixv-46657" unitRef="usd">2276</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="c52" decimals="0" id="ixv-46658" unitRef="usd">1591</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="c7" decimals="0" id="ixv-46659" unitRef="usd">3867</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c48" decimals="0" id="ixv-46660" unitRef="usd">4786</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c52" decimals="0" id="ixv-46661" unitRef="usd">-4786</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:ProfitLoss contextRef="c49" decimals="0" id="ixv-46662" unitRef="usd">-4902878</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c52" decimals="0" id="ixv-46663" unitRef="usd">-356159</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c7" decimals="0" id="ixv-46664" unitRef="usd">-5259037</us-gaap:ProfitLoss>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="c50" decimals="0" id="ixv-46665" unitRef="usd">-70722</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="c7" decimals="0" id="ixv-46666" unitRef="usd">-70722</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="c53"
      decimals="INF"
      id="ix_36_fact"
      unitRef="shares">13868484</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c53" decimals="0" id="ix_37_fact" unitRef="usd">13868</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c54" decimals="0" id="ixv-46669" unitRef="usd">31040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c56" decimals="0" id="ixv-46670" unitRef="usd">78595065</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c57" decimals="0" id="ixv-46671" unitRef="usd">-68949807</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c58" decimals="0" id="ixv-46672" unitRef="usd">445665</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c59"
      decimals="INF"
      id="ixv-46673"
      unitRef="shares">-730641</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c59" decimals="0" id="ixv-46674" unitRef="usd">-8909691</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c60" decimals="0" id="ixv-46675" unitRef="usd">-502181</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-46676" unitRef="usd">723959</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c7" id="ixv-23906">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ABVC BioPharma, Inc. (the &#x201c;Company&#x201d;),
formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#x2019;s operating entity, American
BriVision Corporation (&#x201c;BriVision&#x201d;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology
to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops
its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision
believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization,
BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly
respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical
trials for the Company&#x2019;s drugs and medical devices are being conducted at such world-famous institutions including Stanford University,
University of California San Fransisco (UCSF) and Cedar Sinai Medical Centre (CSMC).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has four wholly-owned subsidiaries,
BriVision, BioLite Holding Inc. (&#x201c;BioLite Holding&#x201d;), BioKey Inc. (&#x201c;BioKey&#x201d;), BioKey (Cayman), Inc (&#x201c;BioKey
Cayman&#x201d;), and a majority-owned subsidiary, AiBtl BioPharma Inc. (&#x201c;AiBtl&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioLite Holding was incorporated in the State
of Nevada with wholly owned subsidiary BioLite BVI, Inc. (&#x201c;BioLite BVI&#x201d;) that was incorporated in the British Virgin Islands.
BioLite BVI holds 73% ownership of BioLite Inc. (&#x201c;BioLite Taiwan&#x201d;), a Taiwanese corporation that was founded in February
2006. BioLite Taiwan has been in the business of developing new drugs since it was incorporated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Yunzhiyi, a Taiwanese corporation, was incorporated
in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, the Company&#x2019;s director. This entity is set up
for holding the land that AiBtl acquired in Taiwan for developing health related business in Taiwan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Incorporated in California on November 20,
2000, BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioKey Cayman was incorporated in Cayman Islands
in July 2023, which is 100% owned by ABVC. This subsidiary has no activities since inception.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Acquisition of AiBtl BioPharma Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 12, 2023, the Company and BioLite
Taiwan each entered into a multi-year, global licensing agreement with AiBtl for the Company and BioLite Taiwan&#x2019;s CNS drugs with
the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the &#x201c;Licensed
Products&#x201d;). The potential license will cover the Licensed Products&#x2019; clinical trial, registration, manufacturing, supply,
and distribution rights. The parties are determined to collaborate on the global development of the Licensed Products. The parties are
also working to strengthen new drug development and business collaboration, including technology, interoperability, and standards development.
As per each of the respective agreements, each of ABVC and BioLite Taiwan received 23 million shares of AiBtl stock and as a result,
the Company has a controlling interest over AiBtl. If certain milestones are met, the Company and BioLite Taiwan are each eligible to
receive $3,500,000 and royalties equaling 5% of net sales, up to $100 million. The financial statements of AiBtl are included in the
Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company concluded the assets acquired
and liabilities assumed did not meet the definition of a business as a limited number of inputs were acquired but no substantive business
processes or signs of output were acquired. As such, the acquisition was accounted for as an asset purchase. The purchase consideration
was nonmonetary assets (patent) and transfer on November 12, 2023. The equity interest transferred to ABVC and BioLite Taiwan on December
15, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c87" decimals="2" id="ixv-46677" unitRef="pure">0.73</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c88" decimals="2" id="ixv-46678" unitRef="pure">0.90</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c89" decimals="2" id="ixv-46679" unitRef="pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c90" decimals="2" id="ixv-46680" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c91"
      decimals="-6"
      id="ixv-46681"
      unitRef="shares">23000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <abvc:BenefitsReceivableForMilestoneAttained contextRef="c1" decimals="0" id="ixv-46682" unitRef="usd">3500000</abvc:BenefitsReceivableForMilestoneAttained>
    <abvc:PercentageOfRoyaltiesEqualing contextRef="c7" decimals="2" id="ixv-46683" unitRef="pure">0.05</abvc:PercentageOfRoyaltiesEqualing>
    <abvc:AcquisitionForNetSales contextRef="c7" decimals="-6" id="ixv-46684" unitRef="usd">100000000</abvc:AcquisitionForNetSales>
    <abvc:LiquidityGoingConcernAndRestatementTextBlock contextRef="c7" id="ixv-23960">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;2. LIQUIDITY, GOING CONCERN, AND RESTATEMENT&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The accompanying financial statements have
been prepared in conformity with the generally accepted accounting principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;)
which contemplates continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and
liabilities are settled in the ordinary course of business at amounts disclosed in the financial statements. The Company&#x2019;s ability
to continue as a going concern depends upon its ability to market and sell its products to generate positive operating cash flows. For
the year ended December 31, 2024, the Company reported net loss of $5,259,037. As of December 31, 2024, the Company&#x2019;s working capital
deficit was $4,377,646.&#160; In addition, the Company had net cash outflows of $1,809,145&#160;from operating activities for the year
ended December 31, 2024. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going
concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;To sustain its ability to support the Company&#x2019;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;cash generated from
    operations;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;other
    available sources of financing from banks and other financial institutions in the U.S. and in Taiwan; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;financial support from the Company&#x2019;s related parties and shareholders.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Management&#x2019;s plan is to continue to
improve operations to generate positive cash flows and raise additional capital through private or public offerings, or financial support
from related parties or shareholders. If the Company is not able to generate positive operating cash flows, and raise additional capital,
there is the risk that the Company may not be able to meet its short-term obligations. All of these factors raise substantial doubt about
the ability of the Company to continue as a going concern. The consolidated financial statements for the years ended December 31, 2024
and 2023 have been prepared on a going concern basis and do not include any adjustments to reflect the possible future effects on the
recoverability and classifications of assets or the amounts and classifications of liabilities that may result from the inability of
the Company to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Restatement Background and Explanation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has restated its financial statements
as of and for the year ended December 31, 2023, to correct misstatements in those prior periods related to improperly applying accounting
guidance on the share-based payments, incorrectly recognizing interest expenses upon the conversion of convertible debts, and misidentifying
the existence of non-controlling interest of our subsidiary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As disclosed in Note 5, the Company entered
into a cooperation agreement on August 14, 2023 with Zhong Hui Lian He Ji Tuan, Ltd. (the &#x201c;Zhonghui&#x201d;) to acquire 20% of the
ownership of certain property and a parcel of the land. According to the agreement, the Company issued 370,000 shares of its common stock
as the consideration, and used $20 dollar per share to recognize the right as construction in progress on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the time of preparing its 2024 financial
statements, the Company reviewed the entire transaction, its relevant agreements and documentation, as well as the applicable accounting
guidance. The Company applied FASB Accounting Standard Codification (&#x201c;ASC&#x201d;) 845 Nonmonetary Transactions to determine the
fair value of the asset acquired would be more evident than the fair value of the consideration in exchange, the Company&#x2019;s restricted
common stocks. The real estates acquired comes with a third-party valuation of $7,400,000 per the Company&#x2019;s stake, which the value
of the acquired assets is guaranteed by Zhonghui. Upon further review, the Company considered ASC 718 Compensation &#x2013; Stock Compensation,
should have been the appropriate guidance to apply given the Company&#x2019;s common stocks are listed in Nasdaq with more observable
fair value (Level 1). Furthermore, at the time of issuance of these financial statements, no real estate title was transferred to the
Company. As a result, the Company adjusted the carrying value of the asset and reclassified the balance to &#x201c;Prepayment for asset
acquisition&#x201d; account to reflect the value of 370,000 shares issued at $1.87, the closing price as of the contract date. The Company
also corrected the share price used to recognize stock compensation expense from $20 to $1.87 for the 29,600 shares of common stock issued
on the same day to several consultants. As a result, these adjustments reduced $6,708,100 for asset recognized and $536,648 for stock-compensation
expense incurred in 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In February 2023, the Company issued a convertible
note to LIND Global Fund II, LP (Note 7). Due to misapplication of ASC 470-20 instead of ASC 815-40, the Company overstated interest
expenses $1,179,669 for the year ended December 31, 2023. The overstatement is offsetting against additional paid-in capital due to the
convertible note being converted to the Company&#x2019;s own common stocks instead of being repaid or disposition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In November 2023, the Company and one of its
subsidiaries entered into a licensing agreement with AiBtl. The Company accounted for a 100% control of AiBtl as of December 31, 2023,
but later discovered that AiBtl had outstanding founder shares that were not deposited to the stock transfer agent in the timely manner.
Such shares reduced the Company&#x2019;s controlling interest from 100% to 69.70%. Accordingly, the Company adjusted the relevant accounts
in our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As discussed in Note 12, in July 2019 the
Company issued 644,972 shares (post-split) of the Company&#x2019;s common stock to four consultants for their services. Such stock-based
expenses were amortized over 5 years starting from the issuance date. Per the Company&#x2019;s further review, the services, along with
the agreements, were completed by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with the period
when services are received. Therefore, the Company reversed share-based compensation expenses of $451,480 and $902,960 for the years
ended December 31, 2024 and 2023, respectively. The accumulated deficit as of December 31, 2022 was corrected with the Stock Subscription
Receivables for $1,354,440 as a result of such adjustments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Impact of the Restatement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the year ended December 31, 2023 is presented below.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,969,278&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;569,278&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepayment for asset acquisition&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,492,599&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,708,100&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,784,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,696,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(148,028&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,548,352&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Convertible notes payable &#x2013; third parties, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;569,456&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;317,066&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;886,522&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;173,132&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;173,493&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,932,490&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;169,399&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,101,889&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,361,627&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;169,399&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,531,026&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;82,636,966&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(8,658,586&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;73,978,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,388,050&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,833,940&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,554,110&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(257,078&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(43,559&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(300,637&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,130,972&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,877,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,253,473&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Liabilities and Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,492,599&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,708,100&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,784,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,635,708&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,449,775&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;185,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,493,340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,179,669&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,313,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(394,632&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(98,162&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(492,794&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(10,910,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,629,444&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(8,280,844&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2.43&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(10,910,288&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,629,444&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(8,280,844&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,635,708&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,449,775&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;185,933&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other non-cash income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,413,746&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,169,501&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,244,245&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;786,793&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(148,031&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;638,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(186,860&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;186,860&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(4,235,845&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(48,997&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(4,186,848&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties*&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(186,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(186,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Proceeds from subsidiary&#x2019;s executive contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;137,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;137,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,918,960&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(48,999&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,869,961&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Effect of exchange rate changes on cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,125-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,123&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Purchase of Property and equipment by issuing common stock to a third party&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepayment for asset acquisition by issuing common stock to a third party&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,600&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issuance of common stock for conversion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,306,112&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,519,426&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,786,686&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Due to related parties previously reported amount was reclassified to financing activities based on current year&#x2019;s presentation.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</abvc:LiquidityGoingConcernAndRestatementTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c7" decimals="0" id="ixv-46685" unitRef="usd">5259037</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <abvc:WorkingCapitalDeficit contextRef="c7" decimals="0" id="ixv-46686" unitRef="usd">4377646</abvc:WorkingCapitalDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="0" id="ixv-46687" unitRef="usd">-1809145</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c92" decimals="2" id="ixv-46688" unitRef="pure">0.20</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c93"
      decimals="0"
      id="ixv-46689"
      unitRef="shares">370000</abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c94"
      decimals="0"
      id="ixv-46690"
      unitRef="usdPershares">20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RealEstateOwnedValuationAllowance contextRef="c95" decimals="0" id="ixv-46691" unitRef="usd">7400000</us-gaap:RealEstateOwnedValuationAllowance>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c7"
      decimals="0"
      id="ixv-46692"
      unitRef="shares">370000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c1"
      decimals="2"
      id="ixv-46693"
      unitRef="usdPershares">1.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c96"
      decimals="0"
      id="ixv-46694"
      unitRef="usdPershares">20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c97"
      decimals="2"
      id="ixv-46695"
      unitRef="usdPershares">1.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ixv-46696"
      unitRef="shares">29600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:Assets contextRef="c98" decimals="0" id="ixv-46697" unitRef="usd">-6708100</us-gaap:Assets>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c28" decimals="0" id="ixv-46698" unitRef="usd">536648</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:InterestExpenseOther contextRef="c28" decimals="0" id="ixv-46699" unitRef="usd">1179669</us-gaap:InterestExpenseOther>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c99" decimals="2" id="ixv-46700" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c100"
      decimals="2"
      id="ixv-46701"
      unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c101"
      decimals="4"
      id="ixv-46702"
      unitRef="pure">0.697</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c102"
      decimals="0"
      id="ixv-46703"
      unitRef="shares">644972</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <abvc:StockBasedExpensesAmortizationPeriod contextRef="c7" id="ixv-46704">P5Y</abvc:StockBasedExpensesAmortizationPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="0" id="ixv-46705" unitRef="usd">451480</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c8" decimals="0" id="ixv-46706" unitRef="usd">902960</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c10" decimals="0" id="ixv-46707" unitRef="usd">1354440</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="c7" id="ixv-24064">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the year ended December 31, 2023 is presented below.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,969,278&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;569,278&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepayment for asset acquisition&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,492,599&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,708,100&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,784,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,696,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(148,028&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,548,352&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Convertible notes payable &#x2013; third parties, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;569,456&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;317,066&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;886,522&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;173,132&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;173,493&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,932,490&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;169,399&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,101,889&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,361,627&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;169,399&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,531,026&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;82,636,966&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(8,658,586&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;73,978,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,388,050&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,833,940&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,554,110&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(257,078&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(43,559&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(300,637&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,130,972&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,877,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,253,473&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Liabilities and Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,492,599&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,708,100&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,784,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,635,708&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,449,775&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;185,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,493,340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,179,669&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,313,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(394,632&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(98,162&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(492,794&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(10,910,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,629,444&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(8,280,844&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2.43&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(10,910,288&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,629,444&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(8,280,844&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,635,708&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,449,775&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;185,933&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other non-cash income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,413,746&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,169,501&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,244,245&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;786,793&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(148,031&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;638,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(186,860&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;186,860&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(4,235,845&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(48,997&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(4,186,848&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties*&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(186,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(186,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Proceeds from subsidiary&#x2019;s executive contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;137,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;137,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,918,960&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(48,999&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,869,961&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Effect of exchange rate changes on cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,125-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,123&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Purchase of Property and equipment by issuing common stock to a third party&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepayment for asset acquisition by issuing common stock to a third party&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,600&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issuance of common stock for conversion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,306,112&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,519,426&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,786,686&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Due to related parties previously reported amount was reclassified to financing activities based on current year&#x2019;s presentation.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <us-gaap:ConstructionInProgressGross contextRef="c103" decimals="0" id="ixv-46708" unitRef="usd">7969278</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c98" decimals="0" id="ixv-46709" unitRef="usd">-7400000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c2" decimals="0" id="ixv-46710" unitRef="usd">569278</us-gaap:ConstructionInProgressGross>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c98" decimals="0" id="ixv-46711" unitRef="usd">691900</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c2" decimals="0" id="ixv-46712" unitRef="usd">691900</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c103" decimals="0" id="ixv-46713" unitRef="usd">14492599</us-gaap:Assets>
    <us-gaap:Assets contextRef="c98" decimals="0" id="ixv-46714" unitRef="usd">-6708100</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-46715" unitRef="usd">7784499</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c103" decimals="0" id="ixv-46716" unitRef="usd">3696380</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c98" decimals="0" id="ixv-46717" unitRef="usd">-148028</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-46718" unitRef="usd">3548352</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayable contextRef="c103" decimals="0" id="ixv-46719" unitRef="usd">569456</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="c98" decimals="0" id="ixv-46720" unitRef="usd">317066</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="c2" decimals="0" id="ixv-46721" unitRef="usd">886522</us-gaap:ConvertibleNotesPayable>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c104" decimals="0" id="ixv-46722" unitRef="usd">173132</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c105" decimals="0" id="ixv-46723" unitRef="usd">361</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-46724" unitRef="usd">173493</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c103" decimals="0" id="ixv-46725" unitRef="usd">5932490</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c98" decimals="0" id="ixv-46726" unitRef="usd">169399</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-46727" unitRef="usd">6101889</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities contextRef="c103" decimals="0" id="ixv-46728" unitRef="usd">6361627</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c98" decimals="0" id="ixv-46729" unitRef="usd">169399</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-46730" unitRef="usd">6531026</us-gaap:Liabilities>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c103" decimals="0" id="ixv-46731" unitRef="usd">82636966</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c98" decimals="0" id="ixv-46732" unitRef="usd">-8658586</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="0" id="ixv-46733" unitRef="usd">73978380</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:StockholdersEquity contextRef="c103" decimals="0" id="ixv-46734" unitRef="usd">8388050</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c98" decimals="0" id="ixv-46735" unitRef="usd">-6833940</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-46736" unitRef="usd">1554110</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c103" decimals="0" id="ixv-46737" unitRef="usd">-257078</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c98" decimals="0" id="ixv-46738" unitRef="usd">-43559</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c2" decimals="0" id="ixv-46739" unitRef="usd">-300637</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c103" decimals="0" id="ixv-46740" unitRef="usd">8130972</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c98" decimals="0" id="ixv-46741" unitRef="usd">-6877499</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-46742" unitRef="usd">1253473</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c103" decimals="0" id="ixv-46743" unitRef="usd">14492599</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c98" decimals="0" id="ixv-46744" unitRef="usd">-6708100</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-46745" unitRef="usd">7784499</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ShareBasedCompensation contextRef="c106" decimals="0" id="ixv-46746" unitRef="usd">1635708</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c28" decimals="0" id="ixv-46747" unitRef="usd">-1449775</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="0" id="ixv-46748" unitRef="usd">185933</us-gaap:ShareBasedCompensation>
    <us-gaap:InterestExpense contextRef="c106" decimals="0" id="ixv-46749" unitRef="usd">2493340</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c28" decimals="0" id="ixv-46750" unitRef="usd">-1179669</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c8" decimals="0" id="ixv-46751" unitRef="usd">1313671</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c106" decimals="0" id="ixv-46752" unitRef="usd">-394632</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c28" decimals="0" id="ixv-46753" unitRef="usd">-98162</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c8" decimals="0" id="ixv-46754" unitRef="usd">-492794</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c106" decimals="0" id="ixv-46755" unitRef="usd">-10910288</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c28" decimals="0" id="ixv-46756" unitRef="usd">2629444</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c8" decimals="0" id="ixv-46757" unitRef="usd">-8280844</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c106"
      decimals="2"
      id="ixv-46758"
      unitRef="usdPershares">-2.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c106"
      decimals="2"
      id="ixv-46759"
      unitRef="usdPershares">-2.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c28"
      decimals="2"
      id="ixv-46760"
      unitRef="usdPershares">0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c28"
      decimals="2"
      id="ixv-46761"
      unitRef="usdPershares">0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c8"
      decimals="2"
      id="ixv-46762"
      unitRef="usdPershares">-1.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c8"
      decimals="2"
      id="ixv-46763"
      unitRef="usdPershares">-1.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:ProfitLoss contextRef="c106" decimals="0" id="ixv-46764" unitRef="usd">-10910288</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c28" decimals="0" id="ixv-46765" unitRef="usd">2629444</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c8" decimals="0" id="ixv-46766" unitRef="usd">-8280844</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c106" decimals="0" id="ixv-46767" unitRef="usd">1635708</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c28" decimals="0" id="ixv-46768" unitRef="usd">-1449775</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="0" id="ixv-46769" unitRef="usd">185933</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c106" decimals="0" id="ixv-46770" unitRef="usd">-2413746</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c28" decimals="0" id="ixv-46771" unitRef="usd">1169501</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c8" decimals="0" id="ixv-46772" unitRef="usd">-1244245</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c106" decimals="0" id="ixv-46773" unitRef="usd">786793</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c28" decimals="0" id="ixv-46774" unitRef="usd">-148031</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c8" decimals="0" id="ixv-46775" unitRef="usd">638762</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c106" decimals="0" id="ixv-46776" unitRef="usd">-186860</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c28" decimals="0" id="ixv-46777" unitRef="usd">186860</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c106" decimals="0" id="ixv-46778" unitRef="usd">-4235845</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c28" decimals="0" id="ixv-46779" unitRef="usd">-48997</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c8" decimals="0" id="ixv-46780" unitRef="usd">-4186848</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c28" decimals="0" id="ix_38_fact" unitRef="usd">-186499</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c8" decimals="0" id="ix_39_fact" unitRef="usd">-186499</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <abvc:ProceedsFromSubsidiarysCommonStockSubscription contextRef="c28" decimals="0" id="ixv-46783" unitRef="usd">137500</abvc:ProceedsFromSubsidiarysCommonStockSubscription>
    <abvc:ProceedsFromSubsidiarysCommonStockSubscription contextRef="c8" decimals="0" id="ixv-46784" unitRef="usd">137500</abvc:ProceedsFromSubsidiarysCommonStockSubscription>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c106" decimals="0" id="ixv-46785" unitRef="usd">3918960</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c28" decimals="0" id="ixv-46786" unitRef="usd">-48999</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c8" decimals="0" id="ixv-46787" unitRef="usd">3869961</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash contextRef="c28" decimals="0" id="ixv-46788" unitRef="usd">-2</abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash>
    <abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash contextRef="c8" decimals="0" id="ixv-46789" unitRef="usd">2123</abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash>
    <abvc:PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty contextRef="c106" decimals="0" id="ixv-46790" unitRef="usd">7400000</abvc:PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty>
    <abvc:PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty contextRef="c28" decimals="0" id="ixv-46791" unitRef="usd">-7400000</abvc:PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty>
    <abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty contextRef="c28" decimals="0" id="ixv-46792" unitRef="usd">691600</abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty>
    <abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty contextRef="c8" decimals="0" id="ixv-46793" unitRef="usd">691900</abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c106" decimals="0" id="ixv-46794" unitRef="usd">3306112</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c28" decimals="0" id="ixv-46795" unitRef="usd">-1519426</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c8" decimals="0" id="ixv-46796" unitRef="usd">1786686</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c7" id="ixv-25089">&lt;p style="margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The accompanying consolidated financial statements
have been prepared in accordance with the U.S. GAAP and pursuant to the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).
All significant intercompany transactions and account balances have been eliminated. The Company&#x2019;s fiscal year is the calendar
year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Reclassifications of Prior Year Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Certain amounts on prior year&#x2019;s consolidated
financial statements have been reclassified for consistency with the current year presentation. These reclassifications had no effect
on the reported results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Stock Reverse Split&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 25, 2023, the Company filed a Certificate
of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its
common stock. The Company&#x2019;s stockholders previously approved the Reverse Stock Split at the Company&#x2019;s Special Shareholder
Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase
the per share trading value of the Company&#x2019;s common stock, although that outcome is not guaranteed. All shares and related financial
information in this Form 10-K reflect this 1-for-10 reverse stock split.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 820 &#x201c;Fair Value Measurements&#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#x2013;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#x2013;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#x2013;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $91,500 (NTD 3.0 million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $250,000 covered by the U.S. Federal Deposit Insurance Corporation&#x2019;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Concentration of Clients&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024, management estimated
all accounts receivable balances are uncollectible and recognized $11,993 of credit loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2023, the most major clients,
specializes in developing and commercializing of dietary supplements and therapeutics in dietary supplement industry, accounted for 87%
of the Company&#x2019;s total account receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the year ended December 31, 2024, the
out-licensing income from our two major licensees, accounts for 58% and 39% of the Company&#x2019;s total revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the year ended December 31, 2023, the
major client, distributing nutritional supplements in Asia Pacific, accounted for 80% of the Company&#x2019;s total revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of December 31, 2024 and 2023, the Company&#x2019;s
cash and cash equivalents amounted to $248,382 and $60,155, respectively. Some&#160;of the Company&#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Restricted Cash &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of December 31, 2024 and 2023, the Company&#x2019;s restricted cash amounted $615,433 (NTD
20.2 million) and $656,625 (NTD 20.1 million), respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Accounts receivable and allowance for expected credit losses
accounts&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounts receivable is recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company make estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#x2019;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Allowance for expected credit losses accounts
was $616,414 and $616,505 as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;Collaborative Revenues &#x2014; &lt;/b&gt;The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s
judgment. Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(i) Non-refundable upfront payments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If a license to the Company&#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(ii) Milestone payments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative
agreement with collaboration partners.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(iii) Multiple Element Arrangements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(iv) Royalties and Profit Sharing Payments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp;amp; Manufacturing Organization Services (&#x201c;CDMO&#x201d;))&lt;/b&gt; &#x2014;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net is carried at
cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of
the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related
gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of
the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method generally based
on the following useful lives:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Estimated&#160;Life&lt;br/&gt; in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 91%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5 ~ 50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5 ~ 10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3 ~ 6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has adopted ASC subtopic 360-10,
Property, Plant and Equipment (&#x201c;ASC 360-10&#x201d;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles
held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances
warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a
forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying
value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition
of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less
costs to sell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Long-term Equity Investment&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company acquires the equity investments
to promote business and strategic objectives. The accounting treatment for equity investments, where the Company does not have control
over the investees, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Marketable equity investments: The Company measures marketable equity
    securities at fair value at each reporting date, with unrealized gains and losses recognized in net income in accordance with &lt;span style="font-style: normal; font-weight: normal"&gt;ASC
    321. Fair value is&lt;/span&gt; determined based on quoted market prices or other observable inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable equity
    investments: When the equity method does not apply, non-marketable equity investments are accounted for at cost, adjusted for observable
    price changes in orderly transactions for identical or similar investments and for impairments, if applicable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity method investments:
    Investments in which the Company has the ability to exercise significant influence, but not control, over the investee, are accounted
    for using the equity method. The Company recognizes its proportionate share of the investee&#x2019;s income or loss in gains (losses)
    on equity investments on a monthly basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&#x2019;s non-marketable equity investments, considering this a critical accounting
estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#x2019;s
fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee,
changes in general market conditions in the investee&#x2019;s industry or geographic area, and the management and governance structure
of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches.
The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The
income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#x2019;
revenue, costs, and discount rates. The Company&#x2019;s assessment of these factors in determining whether an impairment exists could
change in the future due to new developments or changes in applied assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Other-Than-Temporary Impairment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company periodically reviews its non-marketable
equity investments and equity method investments, with recognition in profit and loss when declines in value are considered other than
temporary. the Company assesses the severity and duration of any impairment, along with qualitative and quantitative factors, such as
the investee&#x2019;s financial performance, adverse market or regulatory conditions, operational changes, or additional funding needs.
Evidence of a loss in value might include the inability to recover the carrying amount of the investment or the investee&#x2019;s failure
to sustain earnings capacity to justify its valuation. Impairments deemed other than temporary are recorded in gains (losses) on equity
investments, even if the decline exceeds the losses recognized under the equity method, where applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for convertible notes
payable in accordance with ASC 470-20, Debt with Conversion and Other Options, and ASC 815, Derivatives and Hedging, as applicable. Upon
issuance, the Company evaluates whether the embedded conversion feature should be bifurcated as a derivative under ASC 815 or classified
within equity under ASC 470-20. This assessment includes analyzing the terms of the conversion feature and determining if it requires
separate accounting. If the conversion feature is classified as equity, the proceeds from the issuance are allocated between the debt
and equity components. The debt component is recorded at its fair value, and the residual amount is allocated to equity. The debt component
is carried at amortized cost, with any discount amortized to interest expense over the term of the note using the effective interest
method. Upon conversion, the carrying amount of the debt is reclassified to equity, and no gain or loss is recognized. If the note is
settled in cash, any difference between the carrying amount and the settlement amount is recognized in profit and loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for warrants as either
equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative
guidance in ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC
815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including
whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net
cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This
assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly
period end date while the warrants are outstanding. The Company determined that upon further review of the warrant agreement, the Public
Warrants issued pursuant to the warrant agreement qualify for equity accounting treatment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For issued or modified warrants that meet
all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance.
For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded
as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated
fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for the cost of using
licensing rights in research and development cost according to ASC 730-10-25-1. This guidance provides that absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for R&amp;amp;D costs in
accordance with ASC 730, Research and Development (&#x201c;ASC 730&#x201d;). Research and development expenses are charged to expense as
incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development
expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related
overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical
and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that
will be used in future research and development activities are expensed when the activity has been performed or when the goods have been
received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research
and development services, costs are expensed as services are performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Post-retirement and post-employment benefits&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s subsidiaries in Taiwan
adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#x201c;Act&#x201d;) in Taiwan. Such labor
regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of
the worker&#x2019;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#x2019; salaries
to the employees&#x2019; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts
for such employee benefits, which were expensed as incurred, were $11,642 (NTD 0.4 million) and $10,314&#160;(NTD 0.4 million) for the
years ended December 31, 2024 and 2023, respectively. Other than the above, the Company does not provide any other post-retirement or
post-employment benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#x201c;Compensation-Stock Compensation&#x201d;.
Total director, officer, and employee stock-based compensation expenses were $1,995,049 and $0 for the years ended December 31, 2024
and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#x201c;Compensation-Stock Compensation&#x201d; and ASC 505-50 &#x201c;Equity-Based Payments
to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $506,583 for consulting services and $271,828 for rent for the year ended December 31, 2024, and
$185,933&#160;for consulting services for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for income taxes using
the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood
of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects
of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire
before the Company is able to realize their benefits, or future deductibility is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under ASC 740, a tax position is recognized
as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax examination, with a tax
examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it
is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations
based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold
to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit
that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not
recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions
that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which
the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income
tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended December
31, 2024 and 2023. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods,
disclosures and transition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Valuation of Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;A valuation allowance is recorded to reduce
the Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Loss Per Share of Common Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company calculates net loss per share
in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has adopted ASC 450 &#x201c;Contingencies&#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Foreign-currency Transactions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Company&#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#x2019;
Equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 280 &#x201c;Segment Reporting&#x201d; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company currently has&#160;one&#160;reportable
segment and assets are reviewed on a consolidated basis. As such, segment data is not provided.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following tables present revenue and gross
profit information for each of our only reportable segment:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Years Ended&lt;br/&gt;
    December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023 (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;509,589&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;152,430&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;763&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;302,037&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;508,826&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(149,607&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;32,025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28,531&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Years Ended&lt;br/&gt;
    December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023 (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;508,826&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(149,607&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,261,336&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,368,278&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;179,272&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,062,916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,773,460&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;185,933&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Add (Less):&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;87,358&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;185,481&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(825,899&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,313,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48,478&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;65,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Gain (loss) on foreign exchange changes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(25,135&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;22,690&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on investment in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(339,171&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(221,888&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Write off unclaimed accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;255,592&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;134,443&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,384&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss before provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,369,576&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(8,024,838&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In August 2023, the FASB issued ASU 2023-05,
Business Combinations&#x2014;Joint Venture Formations (Subtopic 805-60) which requires certain joint ventures to apply a new basis of
accounting upon formation by recognizing and initially measuring most of their assets and liabilities at fair value. The guidance does
not apply to joint ventures that may be proportionately consolidated and those that are collaborative arrangements. ASU 2023-05 is effective
for joint venture with a formation date on or after January 1, 2025, early adoption is permitted. The Company is currently evaluating
the impact that the standard will have on its unaudited consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#x2019;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c7" id="ixv-25094">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The accompanying consolidated financial statements
have been prepared in accordance with the U.S. GAAP and pursuant to the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).
All significant intercompany transactions and account balances have been eliminated. The Company&#x2019;s fiscal year is the calendar
year.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c7" id="ixv-25104">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Reclassifications of Prior Year Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Certain amounts on prior year&#x2019;s consolidated
financial statements have been reclassified for consistency with the current year presentation. These reclassifications had no effect
on the reported results of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates contextRef="c7" id="ixv-25114">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <abvc:StockReverseSplitPolicyTextBlock contextRef="c7" id="ixv-25124">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Stock Reverse Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 25, 2023, the Company filed a Certificate
of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its
common stock. The Company&#x2019;s stockholders previously approved the Reverse Stock Split at the Company&#x2019;s Special Shareholder
Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase
the per share trading value of the Company&#x2019;s common stock, although that outcome is not guaranteed. All shares and related financial
information in this Form 10-K reflect this 1-for-10 reverse stock split.&#160;&lt;/span&gt;&lt;/p&gt;</abvc:StockReverseSplitPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c7" id="ixv-25134">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 820 &#x201c;Fair Value Measurements&#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#x2013;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#x2013;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#x2013;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c7" id="ixv-25196">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $91,500 (NTD 3.0 million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $250,000 covered by the U.S. Federal Deposit Insurance Corporation&#x2019;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InvestmentCompanyExcessExpenseReimbursable contextRef="c107" decimals="0" id="ixv-46797" unitRef="usd">91500</us-gaap:InvestmentCompanyExcessExpenseReimbursable>
    <us-gaap:InvestmentCompanyExcessExpenseReimbursable
      contextRef="c107"
      decimals="-5"
      id="ixv-46798"
      unitRef="twd">3000000</us-gaap:InvestmentCompanyExcessExpenseReimbursable>
    <us-gaap:InvestmentCompanyExcessExpenseReimbursable contextRef="c108" decimals="0" id="ixv-46799" unitRef="usd">250000</us-gaap:InvestmentCompanyExcessExpenseReimbursable>
    <abvc:ConcentrationOfClientsPolicyTextBlock contextRef="c7" id="ixv-25211">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Concentration of Clients&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024, management estimated
all accounts receivable balances are uncollectible and recognized $11,993 of credit loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2023, the most major clients,
specializes in developing and commercializing of dietary supplements and therapeutics in dietary supplement industry, accounted for 87%
of the Company&#x2019;s total account receivable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the year ended December 31, 2024, the
out-licensing income from our two major licensees, accounts for 58% and 39% of the Company&#x2019;s total revenues.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the year ended December 31, 2023, the
major client, distributing nutritional supplements in Asia Pacific, accounted for 80% of the Company&#x2019;s total revenues.&lt;/span&gt;&lt;/p&gt;</abvc:ConcentrationOfClientsPolicyTextBlock>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c7" decimals="0" id="ixv-46800" unitRef="usd">11993</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c109"
      decimals="2"
      id="ixv-46801"
      unitRef="pure">0.87</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c110"
      decimals="2"
      id="ixv-46802"
      unitRef="pure">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c111"
      decimals="2"
      id="ixv-46803"
      unitRef="pure">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c112"
      decimals="2"
      id="ixv-46804"
      unitRef="pure">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c7" id="ixv-25236">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of December 31, 2024 and 2023, the Company&#x2019;s
cash and cash equivalents amounted to $248,382 and $60,155, respectively. Some&#160;of the Company&#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" id="ixv-46805" unitRef="usd">248382</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-46806" unitRef="usd">60155</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c7" id="ixv-25260">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Restricted Cash &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of December 31, 2024 and 2023, the Company&#x2019;s restricted cash amounted $615,433 (NTD
20.2 million) and $656,625 (NTD 20.1 million), respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashCurrent contextRef="c1" decimals="0" id="ixv-46807" unitRef="usd">615433</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c1" decimals="-5" id="ixv-46808" unitRef="twd">20200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c2" decimals="0" id="ixv-46809" unitRef="usd">656625</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c2" decimals="-5" id="ixv-46810" unitRef="twd">20100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c7" id="ixv-25270">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Accounts receivable and allowance for expected credit losses
accounts&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounts receivable is recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company make estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#x2019;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Allowance for expected credit losses accounts
was $616,414 and $616,505 as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c1" decimals="0" id="ixv-46811" unitRef="usd">616414</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c2" decimals="0" id="ixv-46812" unitRef="usd">616505</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c7" id="ixv-25290">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;Collaborative Revenues &#x2014; &lt;/b&gt;The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s
judgment. Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(i) Non-refundable upfront payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If a license to the Company&#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(ii) Milestone payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative
agreement with collaboration partners.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(iii) Multiple Element Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(iv) Royalties and Profit Sharing Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp;amp; Manufacturing Organization Services (&#x201c;CDMO&#x201d;))&lt;/b&gt; &#x2014;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c7" id="ixv-25437">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net is carried at
cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of
the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related
gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of
the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method generally based
on the following useful lives:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Estimated&#160;Life&lt;br/&gt; in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 91%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5 ~ 50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5 ~ 10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3 ~ 6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <abvc:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock contextRef="c7" id="ixv-46813">Depreciation is calculated on the straight-line method generally based
on the following useful lives:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Estimated&#160;Life&lt;br/&gt; in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 91%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5 ~ 50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5 ~ 10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3 ~ 6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvc:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c118" id="ixv-46814">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c119" id="ixv-46815">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c120" id="ixv-46816">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c121" id="ixv-46817">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c122" id="ixv-46818">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c123" id="ixv-46819">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c7" id="ixv-25482">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has adopted ASC subtopic 360-10,
Property, Plant and Equipment (&#x201c;ASC 360-10&#x201d;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles
held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances
warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a
forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying
value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition
of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less
costs to sell.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c7" id="ixv-25492">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Long-term Equity Investment&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company acquires the equity investments
to promote business and strategic objectives. The accounting treatment for equity investments, where the Company does not have control
over the investees, is as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Marketable equity investments: The Company measures marketable equity
    securities at fair value at each reporting date, with unrealized gains and losses recognized in net income in accordance with &lt;span style="font-style: normal; font-weight: normal"&gt;ASC
    321. Fair value is&lt;/span&gt; determined based on quoted market prices or other observable inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable equity
    investments: When the equity method does not apply, non-marketable equity investments are accounted for at cost, adjusted for observable
    price changes in orderly transactions for identical or similar investments and for impairments, if applicable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity method investments:
    Investments in which the Company has the ability to exercise significant influence, but not control, over the investee, are accounted
    for using the equity method. The Company recognizes its proportionate share of the investee&#x2019;s income or loss in gains (losses)
    on equity investments on a monthly basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&#x2019;s non-marketable equity investments, considering this a critical accounting
estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#x2019;s
fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee,
changes in general market conditions in the investee&#x2019;s industry or geographic area, and the management and governance structure
of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches.
The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The
income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#x2019;
revenue, costs, and discount rates. The Company&#x2019;s assessment of these factors in determining whether an impairment exists could
change in the future due to new developments or changes in applied assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <abvc:OtherThanTemporaryImpairmentPolicyTextBlock contextRef="c7" id="ixv-25544">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Other-Than-Temporary Impairment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company periodically reviews its non-marketable
equity investments and equity method investments, with recognition in profit and loss when declines in value are considered other than
temporary. the Company assesses the severity and duration of any impairment, along with qualitative and quantitative factors, such as
the investee&#x2019;s financial performance, adverse market or regulatory conditions, operational changes, or additional funding needs.
Evidence of a loss in value might include the inability to recover the carrying amount of the investment or the investee&#x2019;s failure
to sustain earnings capacity to justify its valuation. Impairments deemed other than temporary are recorded in gains (losses) on equity
investments, even if the decline exceeds the losses recognized under the equity method, where applicable.&lt;/span&gt;&lt;/p&gt;</abvc:OtherThanTemporaryImpairmentPolicyTextBlock>
    <abvc:ConvertibleNotesPayablePolicyTextBlock contextRef="c7" id="ixv-25568">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for convertible notes
payable in accordance with ASC 470-20, Debt with Conversion and Other Options, and ASC 815, Derivatives and Hedging, as applicable. Upon
issuance, the Company evaluates whether the embedded conversion feature should be bifurcated as a derivative under ASC 815 or classified
within equity under ASC 470-20. This assessment includes analyzing the terms of the conversion feature and determining if it requires
separate accounting. If the conversion feature is classified as equity, the proceeds from the issuance are allocated between the debt
and equity components. The debt component is recorded at its fair value, and the residual amount is allocated to equity. The debt component
is carried at amortized cost, with any discount amortized to interest expense over the term of the note using the effective interest
method. Upon conversion, the carrying amount of the debt is reclassified to equity, and no gain or loss is recognized. If the note is
settled in cash, any difference between the carrying amount and the settlement amount is recognized in profit and loss.&lt;/span&gt;&lt;/p&gt;</abvc:ConvertibleNotesPayablePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c7" id="ixv-25578">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for warrants as either
equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative
guidance in ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC
815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including
whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net
cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This
assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly
period end date while the warrants are outstanding. The Company determined that upon further review of the warrant agreement, the Public
Warrants issued pursuant to the warrant agreement qualify for equity accounting treatment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For issued or modified warrants that meet
all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance.
For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded
as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated
fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c7" id="ixv-25593">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for the cost of using
licensing rights in research and development cost according to ASC 730-10-25-1. This guidance provides that absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses when incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for R&amp;amp;D costs in
accordance with ASC 730, Research and Development (&#x201c;ASC 730&#x201d;). Research and development expenses are charged to expense as
incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development
expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related
overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical
and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that
will be used in future research and development activities are expensed when the activity has been performed or when the goods have been
received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research
and development services, costs are expensed as services are performed.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:PostemploymentBenefitPlansPolicy contextRef="c7" id="ixv-25608">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Post-retirement and post-employment benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s subsidiaries in Taiwan
adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#x201c;Act&#x201d;) in Taiwan. Such labor
regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of
the worker&#x2019;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#x2019; salaries
to the employees&#x2019; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts
for such employee benefits, which were expensed as incurred, were $11,642 (NTD 0.4 million) and $10,314&#160;(NTD 0.4 million) for the
years ended December 31, 2024 and 2023, respectively. Other than the above, the Company does not provide any other post-retirement or
post-employment benefits.&lt;/span&gt;&lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
    <abvc:LaborPensionFundPerMonth contextRef="c7" decimals="2" id="ixv-46820" unitRef="pure">0.06</abvc:LaborPensionFundPerMonth>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c7" decimals="2" id="ixv-46821" unitRef="pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent contextRef="c113" decimals="0" id="ixv-46822" unitRef="usd">11642</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent contextRef="c1" decimals="-5" id="ixv-46823" unitRef="twd">400000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent contextRef="c2" decimals="-5" id="ixv-46824" unitRef="twd">400000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent contextRef="c2" decimals="0" id="ixv-46825" unitRef="usd">10314</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c7" id="ixv-25619">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#x201c;Compensation-Stock Compensation&#x201d;.
Total director, officer, and employee stock-based compensation expenses were $1,995,049 and $0 for the years ended December 31, 2024
and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#x201c;Compensation-Stock Compensation&#x201d; and ASC 505-50 &#x201c;Equity-Based Payments
to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $506,583 for consulting services and $271,828 for rent for the year ended December 31, 2024, and
$185,933&#160;for consulting services for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c114" decimals="0" id="ixv-46826" unitRef="usd">1995049</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c115" decimals="0" id="ixv-46827" unitRef="usd">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c116" decimals="0" id="ixv-46828" unitRef="usd">506583</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c116" decimals="0" id="ixv-46829" unitRef="usd">271828</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c117" decimals="0" id="ixv-46830" unitRef="usd">185933</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c7" id="ixv-25649">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounts for income taxes using
the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood
of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects
of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire
before the Company is able to realize their benefits, or future deductibility is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under ASC 740, a tax position is recognized
as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax examination, with a tax
examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it
is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations
based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold
to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit
that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not
recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions
that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which
the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income
tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended December
31, 2024 and 2023. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods,
disclosures and transition.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <abvc:DefinedBenefitPlanFundedPercentages contextRef="c7" decimals="2" id="ixv-46831" unitRef="pure">0.50</abvc:DefinedBenefitPlanFundedPercentages>
    <abvc:ValuationOfDeferredTaxAssetsPolicyTextBlock contextRef="c7" id="ixv-25664">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Valuation of Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;A valuation allowance is recorded to reduce
the Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.&lt;/span&gt;&lt;/p&gt;</abvc:ValuationOfDeferredTaxAssetsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c7" id="ixv-25674">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Loss Per Share of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company calculates net loss per share
in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c7" id="ixv-25684">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has adopted ASC 450 &#x201c;Contingencies&#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c7" id="ixv-25694">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Foreign-currency Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Company&#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#x2019;
Equity.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c7" id="ixv-25716">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 280 &#x201c;Segment Reporting&#x201d; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.&lt;/span&gt;&lt;/p&gt;The Company currently has&#160;one&#160;reportable
segment and assets are reviewed on a consolidated basis.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c7" decimals="0" id="ixv-46833" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c7" id="ixv-25730">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following tables present revenue and gross
profit information for each of our only reportable segment:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Years Ended&lt;br/&gt;
    December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023 (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;509,589&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;152,430&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;763&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;302,037&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;508,826&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(149,607&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;32,025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28,531&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c7" decimals="0" id="ixv-46834" unitRef="usd">509589</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c8" decimals="0" id="ixv-46835" unitRef="usd">152430</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c7" decimals="0" id="ixv-46836" unitRef="usd">763</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c8" decimals="0" id="ixv-46837" unitRef="usd">302037</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c7" decimals="0" id="ixv-46838" unitRef="usd">508826</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c8" decimals="0" id="ixv-46839" unitRef="usd">-149607</us-gaap:GrossProfit>
    <us-gaap:Depreciation contextRef="c7" decimals="0" id="ixv-46840" unitRef="usd">32025</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c8" decimals="0" id="ixv-46841" unitRef="usd">28531</us-gaap:Depreciation>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock contextRef="c7" id="ixv-25858">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Years Ended&lt;br/&gt;
    December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023 (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;508,826&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(149,607&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,261,336&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,368,278&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;179,272&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,062,916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,773,460&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;185,933&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Add (Less):&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;87,358&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;185,481&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(825,899&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,313,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48,478&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;65,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Gain (loss) on foreign exchange changes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(25,135&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;22,690&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on investment in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(339,171&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(221,888&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Write off unclaimed accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;255,592&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;134,443&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,384&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss before provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,369,576&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(8,024,838&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <us-gaap:GrossProfit contextRef="c7" decimals="0" id="ixv-46842" unitRef="usd">508826</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c8" decimals="0" id="ixv-46843" unitRef="usd">-149607</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c7" decimals="0" id="ixv-46844" unitRef="usd">2261336</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c8" decimals="0" id="ixv-46845" unitRef="usd">5368278</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="0" id="ixv-46846" unitRef="usd">179272</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c8" decimals="0" id="ixv-46847" unitRef="usd">1062916</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="0" id="ixv-46848" unitRef="usd">2773460</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="0" id="ixv-46849" unitRef="usd">185933</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeInterest contextRef="c7" decimals="0" id="ixv-46850" unitRef="usd">87358</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c8" decimals="0" id="ixv-46851" unitRef="usd">185481</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c7" decimals="0" id="ixv-46852" unitRef="usd">825899</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c8" decimals="0" id="ixv-46853" unitRef="usd">1313671</us-gaap:InterestExpenseNonoperating>
    <us-gaap:SubleaseIncome contextRef="c7" decimals="0" id="ixv-46854" unitRef="usd">48478</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c8" decimals="0" id="ixv-46855" unitRef="usd">65900</us-gaap:SubleaseIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c7" decimals="0" id="ixv-46856" unitRef="usd">-25135</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c8" decimals="0" id="ixv-46857" unitRef="usd">22690</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnInvestments contextRef="c7" decimals="0" id="ixv-46858" unitRef="usd">-339171</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c8" decimals="0" id="ixv-46859" unitRef="usd">-221888</us-gaap:GainLossOnInvestments>
    <abvc:WriteOffUnclaimedAccruedLiabilites contextRef="c7" decimals="0" id="ixv-46860" unitRef="usd">255592</abvc:WriteOffUnclaimedAccruedLiabilites>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="0" id="ixv-46861" unitRef="usd">134443</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c8" decimals="0" id="ixv-46862" unitRef="usd">3384</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-46863" unitRef="usd">-5369576</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c8" decimals="0" id="ixv-46864" unitRef="usd">-8024838</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c7" id="ixv-26158">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In August 2023, the FASB issued ASU 2023-05,
Business Combinations&#x2014;Joint Venture Formations (Subtopic 805-60) which requires certain joint ventures to apply a new basis of
accounting upon formation by recognizing and initially measuring most of their assets and liabilities at fair value. The guidance does
not apply to joint ventures that may be proportionately consolidated and those that are collaborative arrangements. ASU 2023-05 is effective
for joint venture with a formation date on or after January 1, 2025, early adoption is permitted. The Company is currently evaluating
the impact that the standard will have on its unaudited consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#x2019;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c7" id="ixv-26194">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;4. COLLABORATIVE AGREEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreements with BHK, a
related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 24, 2015,
    BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development
    Agreement&#x201d;), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple
    Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual
    property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be
    shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date
    of first commercial sale of the Product in in Asia excluding Japan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2015, BHK has paid a non-refundable
upfront cash payment of $1 million, or 10% of $10.0 million, upon the signing of BHK Co-Development Agreement. The Company concluded
that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis
and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in
2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative
agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement.
In August 2016, the Company has received the second milestone payment of &lt;span style="-sec-ix-hidden: hidden-fact-264"&gt;NTD31,649,000&lt;/span&gt;, approximately equivalent to $1 million, and recognized
collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase
II clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on 12% of BHK&#x2019;s net sales related to BLI-1401-2 Products. As of December 31, 2024 and 2023,
the Company has not earned the royalty under the BHK Co-Development Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#x201c;BHK Collaborative Agreements&#x201d;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#x201c;Targeting Major Depressive Disorder&#x201d; (BLI-1005 Products) and BLI-1006 for
&#x201c;Targeting Inflammatory Bowel Disease&#x201d; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property
rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50
between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial
sale of the Product in in Asia excluding Japan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In 2015, the Company recognized the cash receipt
in a total of &lt;span style="-sec-ix-hidden: hidden-fact-265"&gt;NTD50 million&lt;/span&gt;, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition to the total of &lt;span style="-sec-ix-hidden: hidden-fact-266"&gt;NTD50 million&lt;/span&gt;,
approximately equivalent to $1.6 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.
As of December 31, 2024 and 2023, the Company has not earned the royalty under the BHK Collaborative Agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Co-Development agreement with Rgene
Corporation, a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 26, 2017, the Company through its subsidiary,
BriVision, entered into a co-development agreement (the &#x201c;Co-Dev Agreement&#x201d;) with Rgene Corporation (the &#x201c;Rgene&#x201d;),
a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant
to Co-Dev Agreement, the Company and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination
Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev
Agreement, Rgene is required to&#160;pay the Company $3.0 million in cash or stock of Rgene with equivalent value by August 15, 2017.
The payment is for the compensation of the Company&#x2019;s past research efforts and contributions before the Co-Dev Agreement was signed
and it does not relate to any future commitments made by the Company and Rgene in this Co-Dev Agreement. In addition to $3.0 million,
the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development
costs shall be equally shared by both the Company and Rgene.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 1, 2017, the Company has delivered
all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3.0 million
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended
December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000
in the form of newly issued shares of Rgene&#x2019;s Common Stock, at the price of NTD50 per share (approximately equivalent to $1.60
per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018.
On December 31, 2018, the Company determined to fully write off this investment based on the Company&#x2019;s assessment of the severity
and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes
in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements,
and Rgene&#x2019;s ability to remain in business. All projects that have been initiated will be managed and supported by the Company and
Rgene.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company and Rgene signed an amendment
to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer
Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination
Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized.
Other provisions of the Co-Dev Agreement remain in full force and effect.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 10, 2022, the Company expanded its
co-development partnership with Rgene. On that date, BioKey, ABVC has entered into a Clinical Development Service Agreement with Rgene
to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic
cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under the U.S. FDA
IND regulatory requirements. Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $3.0 million
over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period.
The Service Agreement shall remain in effect until the expiration date of the last patent and automatically renew for 5 more years unless
terminated earlier by either party with six months written notice. Either party may terminate the Service Agreement for cause by providing
30 days written notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Through a series of transactions over the
past 5 years, the Company and Rgene have co-developed the three drug products covered by the Service Agreement, which has resulted in
the Company owning 31.62% of Rgene.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As part of the Rgene Studies, the Company
agreed to loan $1.0 million to Rgene, for which Rgene has provided the Company with a 5% working capital convertible loan (the &#x201c;Note&#x201d;).
If the Note is fully converted, the Company will own an additional 6.4% of Rgene. The Company is expected to receive the outstanding
loan from the related party by the first half of 2025, either by cash or conversion of shares of Rgene. The Company may convert the Note
at any time into shares of Rgene&#x2019;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount
of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in
the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service
Agreement will trigger an event of default under the Note if not cured after 5 business days of written notice regarding the breach is
provided. Upon an event of default, the outstanding principal and any accrued and unpaid interest shall be immediately due and payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Service Agreement shall remain in effect
until the expiration date of the last patent and automatically renew for 5 more years unless terminated earlier by either party with
six months written notice. Either party may terminate the Service Agreement for cause by providing 30 days written notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene has further agreed, effective July 1,
2022, to provide the Company with a seat on Rgene&#x2019;s Board of Directors until the loan is repaid in full. The Company has nominated
Dr. Jiang, its Chief Strategy Officer and Director to occupy that seat; Dr. Jiang is also one of the Company&#x2019;s largest shareholders,
owning 12.8% of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Rgene Studies is a related party transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreement with BioFirst
Corporation, a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 24, 2017, the Company through its
subsidiary, BriVision, entered into a collaborative agreement (the &#x201c;BioFirst Collaborative Agreement&#x201d;) with BioFirst Corporation
(&#x201c;BioFirst&#x201d;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the
&#x201c;Product&#x201d;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling
beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See
Note 10).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3.0 million in cash or
stock of the Company before September 30, 2018. The amount of $3.0 million is in connection with the compensation for BioFirst&#x2019;s
past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate
to any future commitments in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future
net licensing income or net sales profit, if any, and any development cost shall be equally shared by both the Company and BioFirst.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to the Company. The Company determined to fully expense the entire amount of $3.0
millionsince currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative
future uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses immediately. Hence, the entire amount of $3.0 million is fully expensed as research and development expense during the year
ended December 31, 2017.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 30, 2019, BriVision entered into a
Stock Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued
&lt;span style="-sec-ix-hidden: hidden-fact-267"&gt;42,857 shares&lt;/span&gt; (post-split) of the Company&#x2019;s common stock to BioFirst in consideration for $3.0 million owed by the Company to BioFirst
(the &#x201c;Total Payment&#x201d;) in connection with BioFirst Collaborative Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On August 5, 2019, BriVision entered into
a second Stock Purchase Agreement (&#x201c;Purchase Agreement 2&#x201d;) with BioFirst. Pursuant to Purchase Agreement 2, the Company issued
41,470 shares (post-split) of the Company&#x2019;s common stock to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst
in connection with a loan provided to BriVision from BioFirst.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 4, 2020, the Company executed
an amendment to the BioFirst Collaborative Agreement to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal Storage Solution
to the agreement. ABV-2002 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while ABV-2001 has
broader utilization during a variety of ocular procedures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Initially the Company will focus on ABV-2002,
a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial
keratoplasty (back layer cornea transplant). ABV-2002 is a solution comprised of a specific poly amino acid that protects ocular tissue
from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity
to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration
results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant
phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can
be manufactured at lower cost. Further ABV-2002 product development was put on hold due the lack of funding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition, BioFirst was incorporated on
November 7, 2006, focusing on the R&amp;amp;D, manufacturing, and sales of innovative patented pharmaceutical products. The technology of
BioFirst comes from the global exclusive licensing from domestic R &amp;amp; D institutions. Currently, the main research and development
product is the vitreous substitute (Vitargus&#xae;) Licensed by the National Health Research Institutes. Vitargus is the world&#x2019;s
first bio-degradable vitreous substitute and offers a number of advantages over current vitreous substitutes by minimizing medical complications
and reducing the need for additional surgeries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst has started the construction of a
GMP factory in Hsinchu Biomedical Science Park, Taiwan, with the aim at building a production base to supply the global market, and promote
the construction of bio-degradable vitreous substitute manufacturing centers in Taiwan. Completion of this factory would allow ABVC to
manufacture Vitargus with world-class technology in a GMP certified pharmaceutical factory. BioFirst is targeting to complete the construction
in 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024, the Company has not
earned any net licensing income or net sales profit earned by BioFirst under these collaborative agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreement with ForSeeCon
Eye Corporation, a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On March 25, 2024, the Company and BioFirst
each entered into a twenty-year, global definitive licensing agreement (the &#x201c;FEYE Licensing Agreement&#x201d;) with ForSeeCon Eye
Corporation, a company registered in the British Virgin Islands (&#x201c;FEYE&#x201d;) for the products in the Company and BioFirst&#x2019;s
Ophthalmology pipeline, including Vitargus (the &#x201c;Vitargus Products&#x201d;). The license covers the Vitargus Products&#x2019; clinical
trial, registration, manufacturing, supply, and distribution rights; FEYE also has the rights to sublicense or partner with a third party
to develop the Licensed Products. As per each of the respective FEYE Licensing Agreements, each of the Company and BioFirst shall receive
a total licensing fee of $33.5 million, composed of an upfront payment of $30 million, which can instead be paid with 5 million shares
of FEYE stock at $6 per share within 30 days after the execution of the FEYE Licensing Agreement, and a $3.5 million cash milestone payment,
due 30 days upon completion of next round fundraising. Additionally, each of the Company and BioFirst are eligible to receive royalties
of 5% of net sales.&#160;As of December 31, 2024, the Company received 5 million FEYE shares but did not recognize such licensing revenue
since the fair value of FEYE stock is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 18, 2024, the Company and BioFirst,
each entered into an amendment (the &lt;span style="font-style: normal; font-weight: normal"&gt;&#x201c;Amendment&#x201d;) t&lt;/span&gt;o the Licensing
Agreement with FEYE, pursuant to which the Company and BioFirst have agreed to allow FEYE to pay the second milestone payment in the
amount of $3.5 million per Licensing Agreement, incrementally (such as $100,000), at any given time, rather than in one lump sum. During
year ended December 31, 2024, the Company received in cash and recognized revenue of $296,000, respectively, pursuant to the Amendment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreement with OncoX BiopPharma,
Inc., a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On April 16, 2024, the Company entered into
a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (&#x201c;Oncox&#x201d;),
pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#x2019;s single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the &#x201c;Lung Cancer
Products&#x201d;), within North America for 20 years (the &#x201c;April 2024 Oncox Agreement&#x201d;). In consideration thereof, Oncox shall
pay ABVC $6.25 million (or 1.25 million Oncox shares valued at $5 per share) 30 days after entering into the agreement and $625,000,
30 days following the completion of Oncox&#x2019;s next round of fundraising, of which there is no guarantee; ABVC is also entitled to
5% royalties based on the net sales, as defined in the April 2024 Oncox Agreement, from the first commercial sale of the Lung Cancer
Product in North America, of which there can be no guarantee. Oncox entered into another agreement with ABVC&#x2019;s affiliate, Rgene
Corporation, on the same terms. During the year ended December 31, 2024, the Company received in cash and recognized revenue of $200,000
pursuant to the agreement. At the time of transferring the license, the Company also received 1.25 million OncoX shares but did not recognize
such licensing revenue since the fair value of Oncox stock is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 8, 2024, the Company entered into a
definitive agreement with OncoX, pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#x2019;s
BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Pancreatic
(the Pancreatic Product), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#x201c;May 8, 2024
Oncox Agreement&#x201d;). In consideration thereof, Oncox shall pay ABVC a total of $6.25 million (or 1.25 million Oncox shares valued
at $5 per share) within 30 days of entering into the May 8, 2024 Oncox Agreement, with an additional milestone payment of $625,000 in
cash after OncoX&#x2019;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000
towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties of 5% of net sales, as
defined in the May 8, 2024 Oncox Agreement, from the first commercial sale of the Pancreatic Product in the noted territory, which remains
uncertain. The Company will permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue
to fund such payments. Oncox entered into another agreement with ABVC&#x2019;s affiliate, Rgene Corporation, on the same terms. At the
time of transferring the license, the Company also received 1.25 million OncoX shares but did not recognize such licensing revenue since
the fair value of Oncox stock is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 14, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#x201c;licensor&#x201d;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#x2019;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the TNBC Product),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#x201c;May 14, 2024 Oncox Agreements&#x201d;).
In each agreement for consideration thereof, Oncox shall pay each licensor a total of $6.25 million (or 1.25 million Oncox shares valued
at $5 per share) within 30 days of entering into the May 14, 2024 Oncox Agreements, with an additional milestone payment of $625,000
in cash after OncoX&#x2019;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least
$100,000 towards the licensing fees and deductible from the second milestone payment; each licensor is also entitled to royalties of
5% of net sales, from the first commercial sale of the TNBC Product in the noted territory, which remains uncertain. The Company will
permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue to fund such payments. At
the time of transferring the license, the Company and BioLite also each received 1.25 million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 23, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#x201c;licensor&#x201d;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#x2019;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the &#x201c;MS Products&#x201d;),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#x201c;May 23, 2024 Oncox Agreements&#x201d;).
In consideration thereof, Oncox shall pay each licensor a total of $6.25 million (or 1.25 million Oncox shares valued at $5 per share)
30 days after entering the May 23, 2024 Oncox Agreements, with an additional milestone payment of $625,000 in cash after OncoX&#x2019;s
next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000 towards the licensing
fees and deductible from the second milestone payment; each licensor is also entitled to royalties of 5% of net sales, from the first
commercial sale of the MS Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing fees.
At the time of transferring the license, the Company and BioLite also each received 1.25 million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Above mentioned p&lt;span&gt;rice
of OncoX&#x2019;s shares was determined through private negotiations between the parties; no third-party valuation was completed.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentMilestones contextRef="c124" id="ixv-26215">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:

    &#160;
    &#x25cf;
    Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment


    &#160;
    &#x25cf;
    Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment


    &#160;
    &#x25cf;
    At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment


    &#160;
    &#x25cf;
    At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment


    &#160;
    &#x25cf;
    Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment
  </us-gaap:LongTermPurchaseCommitmentMilestones>
    <abvc:NonrefundableUpfrontCashPayment
      contextRef="c125"
      decimals="-6"
      id="ixv-46865"
      unitRef="usd">1000000</abvc:NonrefundableUpfrontCashPayment>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement
      contextRef="c125"
      decimals="2"
      id="ixv-46866"
      unitRef="pure">0.10</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <abvc:IssuanceOfStockValue
      contextRef="c125"
      decimals="-5"
      id="ixv-46867"
      unitRef="usd">10000000</abvc:IssuanceOfStockValue>
    <abvc:IssuanceOfStockValue
      contextRef="c126"
      decimals="-6"
      id="ixv-46868"
      unitRef="usd">1000000</abvc:IssuanceOfStockValue>
    <abvc:MilestonePaymentsRoyaltyPercentage contextRef="c7" decimals="2" id="ixv-46869" unitRef="pure">0.12</abvc:MilestonePaymentsRoyaltyPercentage>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c128"
      decimals="-5"
      id="ixv-46870"
      unitRef="usd">1600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c130"
      decimals="-5"
      id="ixv-46871"
      unitRef="usd">1600000</us-gaap:CashEquivalentsAtCarryingValue>
    <abvc:NetSalesProfitPercentage
      contextRef="c129"
      decimals="2"
      id="ixv-46872"
      unitRef="pure">0.50</abvc:NetSalesProfitPercentage>
    <us-gaap:PaymentsForParticipationLiabilities
      contextRef="c131"
      decimals="-5"
      id="ixv-46873"
      unitRef="usd">3000000</us-gaap:PaymentsForParticipationLiabilities>
    <abvc:AdditionCashPayment
      contextRef="c132"
      decimals="-5"
      id="ixv-46874"
      unitRef="usd">3000000</abvc:AdditionCashPayment>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement
      contextRef="c132"
      decimals="2"
      id="ixv-46875"
      unitRef="pure">0.50</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="c133"
      decimals="-5"
      id="ixv-46876"
      unitRef="usd">3000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:Cash contextRef="c133" decimals="0" id="ixv-46877" unitRef="usd">450000</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c134" decimals="0" id="ixv-46878" unitRef="usd">2550000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c135"
      decimals="2"
      id="ixv-46879"
      unitRef="usdPershares">1.6</us-gaap:SharesIssuedPricePerShare>
    <abvc:EquityMethodLongTermInvestment
      contextRef="c136"
      decimals="0"
      id="ixv-46880"
      unitRef="shares">1530000</abvc:EquityMethodLongTermInvestment>
    <abvc:ServiceAgreementEligibilityAmount
      contextRef="c137"
      decimals="-5"
      id="ixv-46881"
      unitRef="usd">3000000</abvc:ServiceAgreementEligibilityAmount>
    <abvc:MilestoneRegulatoryPaymentAmountPeriod contextRef="c138" id="ixv-46882">P3Y</abvc:MilestoneRegulatoryPaymentAmountPeriod>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c139"
      decimals="4"
      id="ixv-46883"
      unitRef="pure">0.3162</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:LoansPayable
      contextRef="c140"
      decimals="-5"
      id="ixv-46884"
      unitRef="usd">1000000</us-gaap:LoansPayable>
    <abvc:WorkingCapitalConvertibleLoanPercentage contextRef="c7" decimals="2" id="ixv-46885" unitRef="pure">0.05</abvc:WorkingCapitalConvertibleLoanPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c141"
      decimals="3"
      id="ixv-46886"
      unitRef="pure">0.064</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c1"
      decimals="2"
      id="ixv-46887"
      unitRef="usdPershares">1</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c142"
      decimals="2"
      id="ixv-46888"
      unitRef="pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:EquityMethodInvestmentsOwnershipPercentage
      contextRef="c143"
      decimals="3"
      id="ixv-46889"
      unitRef="pure">0.128</abvc:EquityMethodInvestmentsOwnershipPercentage>
    <abvc:IssuanceOfStockValue
      contextRef="c144"
      decimals="-5"
      id="ixv-46890"
      unitRef="usd">3000000</abvc:IssuanceOfStockValue>
    <us-gaap:PaymentsForParticipationLiabilities
      contextRef="c145"
      decimals="-5"
      id="ixv-46891"
      unitRef="usd">3000000</us-gaap:PaymentsForParticipationLiabilities>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement
      contextRef="c145"
      decimals="2"
      id="ixv-46892"
      unitRef="pure">0.50</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c146"
      decimals="-5"
      id="ixv-46893"
      unitRef="usd">3000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c147"
      decimals="-5"
      id="ixv-46894"
      unitRef="usd">3000000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="c148"
      decimals="-5"
      id="ixv-46895"
      unitRef="usd">3000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c149"
      decimals="0"
      id="ixv-46896"
      unitRef="shares">41470</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="c149" decimals="0" id="ixv-46897" unitRef="usd">2902911</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:TaxesAndLicenses
      contextRef="c150"
      decimals="-5"
      id="ixv-46898"
      unitRef="usd">33500000</us-gaap:TaxesAndLicenses>
    <us-gaap:PrepaymentFeesOnAdvancesNet
      contextRef="c151"
      decimals="-6"
      id="ixv-46899"
      unitRef="usd">30000000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:SharesIssued
      contextRef="c152"
      decimals="-6"
      id="ixv-46900"
      unitRef="shares">5000000</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c153"
      decimals="0"
      id="ixv-46901"
      unitRef="usdPershares">6</us-gaap:SaleOfStockPricePerShare>
    <abvc:MilestoneRegulatoryPaymentAmount
      contextRef="c150"
      decimals="-5"
      id="ixv-46902"
      unitRef="usd">3500000</abvc:MilestoneRegulatoryPaymentAmount>
    <abvc:RoyaltiesPercentage
      contextRef="c153"
      decimals="2"
      id="ixv-46903"
      unitRef="pure">0.05</abvc:RoyaltiesPercentage>
    <abvc:ReceivedShares
      contextRef="c154"
      decimals="-6"
      id="ixv-46904"
      unitRef="shares">5000000</abvc:ReceivedShares>
    <abvc:MilestoneRegulatoryPaymentAmount
      contextRef="c155"
      decimals="-5"
      id="ixv-46905"
      unitRef="usd">3500000</abvc:MilestoneRegulatoryPaymentAmount>
    <abvc:LicensingAgreement contextRef="c156" decimals="0" id="ixv-46906" unitRef="usd">100000</abvc:LicensingAgreement>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-46907" unitRef="usd">296000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <abvc:ConsiderationPaidForAgreement
      contextRef="c157"
      decimals="-4"
      id="ixv-46908"
      unitRef="usd">6250000</abvc:ConsiderationPaidForAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c157"
      decimals="-4"
      id="ixv-46909"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c158"
      decimals="0"
      id="ixv-46910"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <abvc:AdditionalMilestonePaymentInCash contextRef="c157" decimals="0" id="ixv-46911" unitRef="usd">625000</abvc:AdditionalMilestonePaymentInCash>
    <abvc:MilestonePaymentsRoyaltyPercentage
      contextRef="c157"
      decimals="2"
      id="ixv-46912"
      unitRef="pure">0.05</abvc:MilestonePaymentsRoyaltyPercentage>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c7" decimals="0" id="ixv-46913" unitRef="usd">200000</us-gaap:DeferredRevenueRevenueRecognized1>
    <abvc:NumberOfSharesReceived
      contextRef="c159"
      decimals="-4"
      id="ixv-46914"
      unitRef="shares">1250000</abvc:NumberOfSharesReceived>
    <abvc:PercentageOfDevelopAndCommercialize
      contextRef="c160"
      decimals="2"
      id="ixv-46915"
      unitRef="pure">0.50</abvc:PercentageOfDevelopAndCommercialize>
    <abvc:ConsiderationPaidForAgreement
      contextRef="c160"
      decimals="-4"
      id="ixv-46916"
      unitRef="usd">6250000</abvc:ConsiderationPaidForAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c160"
      decimals="-4"
      id="ixv-46917"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c161"
      decimals="0"
      id="ixv-46918"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <abvc:AdditionalMilestonePaymentInCash contextRef="c160" decimals="0" id="ixv-46919" unitRef="usd">625000</abvc:AdditionalMilestonePaymentInCash>
    <abvc:LicensingFees contextRef="c160" decimals="0" id="ixv-46920" unitRef="usd">100000</abvc:LicensingFees>
    <abvc:MilestonePaymentsRoyaltyPercentage
      contextRef="c160"
      decimals="2"
      id="ixv-46921"
      unitRef="pure">0.05</abvc:MilestonePaymentsRoyaltyPercentage>
    <abvc:NumberOfSharesReceived
      contextRef="c160"
      decimals="-4"
      id="ixv-46922"
      unitRef="shares">1250000</abvc:NumberOfSharesReceived>
    <abvc:PercentageOfDevelopAndCommercialize
      contextRef="c162"
      decimals="2"
      id="ixv-46923"
      unitRef="pure">0.50</abvc:PercentageOfDevelopAndCommercialize>
    <abvc:ConsiderationPaidForAgreement
      contextRef="c162"
      decimals="-4"
      id="ixv-46924"
      unitRef="usd">6250000</abvc:ConsiderationPaidForAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c162"
      decimals="-4"
      id="ixv-46925"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c163"
      decimals="0"
      id="ixv-46926"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <abvc:AdditionalMilestonePaymentInCash contextRef="c162" decimals="0" id="ixv-46927" unitRef="usd">625000</abvc:AdditionalMilestonePaymentInCash>
    <abvc:LicensingFees contextRef="c162" decimals="0" id="ixv-46928" unitRef="usd">100000</abvc:LicensingFees>
    <abvc:MilestonePaymentsRoyaltyPercentage
      contextRef="c162"
      decimals="2"
      id="ixv-46929"
      unitRef="pure">0.05</abvc:MilestonePaymentsRoyaltyPercentage>
    <abvc:NumberOfSharesReceived
      contextRef="c162"
      decimals="-4"
      id="ixv-46930"
      unitRef="shares">1250000</abvc:NumberOfSharesReceived>
    <abvc:PercentageOfDevelopAndCommercialize
      contextRef="c164"
      decimals="2"
      id="ixv-46931"
      unitRef="pure">0.50</abvc:PercentageOfDevelopAndCommercialize>
    <abvc:ConsiderationPaidForAgreement
      contextRef="c164"
      decimals="-4"
      id="ixv-46932"
      unitRef="usd">6250000</abvc:ConsiderationPaidForAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c164"
      decimals="-4"
      id="ixv-46933"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c165"
      decimals="0"
      id="ixv-46934"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <abvc:AdditionalMilestonePaymentInCash contextRef="c164" decimals="0" id="ixv-46935" unitRef="usd">625000</abvc:AdditionalMilestonePaymentInCash>
    <abvc:LicensingFees contextRef="c166" decimals="0" id="ixv-46936" unitRef="usd">100000</abvc:LicensingFees>
    <abvc:MilestonePaymentsRoyaltyPercentage
      contextRef="c166"
      decimals="2"
      id="ixv-46937"
      unitRef="pure">0.05</abvc:MilestonePaymentsRoyaltyPercentage>
    <abvc:NumberOfSharesReceived
      contextRef="c166"
      decimals="-4"
      id="ixv-46938"
      unitRef="shares">1250000</abvc:NumberOfSharesReceived>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c7" id="ixv-26487">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;5. PROPERTY AND EQUIPMENT, AND PREPAMENT FOR ASSET ACQUISITION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property
and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of December 31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;338,966&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;363,416&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,219,244&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,227,431&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,131,169&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,138,675&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;163,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;174,797&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,852,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,904,319&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,341,739&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,335,041&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;511,088&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;569,278&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Depreciation expenses were $28,627&#160;and
$28,531 for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, Land with book value amounted
to approximately $338,966 and $363,416, respectively, were pledged for obtaining bank loan (see Notes 9 Bank loans).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepayment
for asset acquisition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepayment for asset acquisition consists
of the properties in Chengdu, China. The Company entered into a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan,
Ltd. (the &#x201c;Zhonghui&#x201d;). Pursuant thereto, the Company will acquire 20% of the ownership of certain property and a parcel of
the land, with a view to jointly develop the property into a healthcare center for senior living, long-term care, and medical care in
the areas of ABVC&#x2019;s special interests, such as Ophthalmology, Oncology, and Central Nervous Systems. The plan is to establish a
base for the China market and global development of these interests.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The valuation of such property is $37 million;
based on the Company&#x2019;s 20% ownership, the Company would acquire the value of $7,400,000. In exchange, the Company issued to Zhonghui
an aggregate of 370,000 shares (the &#x201c;Shares&#x201d;) of common stock, at a per share price of $20.0. The Shares are subject to a
lock-up period of one year following the closing date of the transaction. In addition, the parties agreed that, after one year following
the closing of the transaction, if the market value of the Shares or the value of the property increases or decreases, the parties will
negotiate in good faith to make reasonable adjustments. The Company&#x2019;s ownership rights to the property and the associated land
parcel, or a suitable replacement property, are safeguarded under the terms of the cooperation agreement, which is legally binding and
enforceable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As discussed in Note 2, the Company incorrectly
applied ASC 845 instead of ASC 718, resulting in an adjustment of the reported value to from $7,400,000 to $691,900, and reclassification
from Construction-in-Progress to Prepayment for Asset Acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The construction-in-progress property is planned
to finish before the end of 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c7" id="ixv-26496">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of December 31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;338,966&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;363,416&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,219,244&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,227,431&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,131,169&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,138,675&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;163,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;174,797&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,852,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,904,319&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,341,739&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,335,041&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;511,088&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;569,278&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c169" decimals="0" id="ixv-46939" unitRef="usd">338966</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c170" decimals="0" id="ixv-46940" unitRef="usd">363416</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c173" decimals="0" id="ixv-46941" unitRef="usd">2219244</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c174" decimals="0" id="ixv-46942" unitRef="usd">2227431</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c175" decimals="0" id="ixv-46943" unitRef="usd">1131169</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c176" decimals="0" id="ixv-46944" unitRef="usd">1138675</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c177" decimals="0" id="ixv-46945" unitRef="usd">163448</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c178" decimals="0" id="ixv-46946" unitRef="usd">174797</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="0" id="ixv-46947" unitRef="usd">3852827</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" id="ixv-46948" unitRef="usd">3904319</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="0" id="ixv-46949" unitRef="usd">3341739</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-46950" unitRef="usd">3335041</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c1" decimals="0" id="ixv-46951" unitRef="usd">511088</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c2" decimals="0" id="ixv-46952" unitRef="usd">569278</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:Depreciation contextRef="c167" decimals="0" id="ixv-46953" unitRef="usd">28627</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c168" decimals="0" id="ixv-46954" unitRef="usd">28531</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c169" decimals="0" id="ixv-46955" unitRef="usd">338966</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c170" decimals="0" id="ixv-46956" unitRef="usd">363416</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="c167"
      decimals="2"
      id="ixv-46957"
      unitRef="pure">0.20</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c1" decimals="-6" id="ixv-46958" unitRef="usd">37000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c171"
      decimals="2"
      id="ixv-46959"
      unitRef="pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c172" decimals="0" id="ixv-46960" unitRef="usd">7400000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c171"
      decimals="0"
      id="ixv-46961"
      unitRef="shares">370000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharePrice
      contextRef="c171"
      decimals="1"
      id="ixv-46962"
      unitRef="usdPershares">20</us-gaap:SharePrice>
    <us-gaap:ConstructionInProgressGross contextRef="c96" decimals="0" id="ixv-46963" unitRef="usd">7400000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c97" decimals="0" id="ixv-46964" unitRef="usd">691900</us-gaap:ConstructionInProgressGross>
    <us-gaap:InvestmentTextBlock contextRef="c7" id="ixv-26694">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;6. LONG-TERM INVESTMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The ownership percentages of each investee are listed as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ownership percentage&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Name of investees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;treatments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Braingenesis Biotechnology Co., Ltd.*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ForSeeCon Eye Corporation (see Note 10)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;18.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;18.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity&#160;Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;OncoX BioPharma, Inc. (see Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;24.97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;26.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;26.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The extent the investee relies on the company for its business is summarized as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 30%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of investees&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 69%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The extent the investee relies on the Company for its business &#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loaned from the investee and provides research and development support service&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. &lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term investment mainly consists of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Non-marketable Cost Method Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,727&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,213&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,540&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;22,021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon
    Eye Corporation&lt;sup&gt;(d) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;762,983&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;818,018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;790,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;847,252&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity Method Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst
    Corporation&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,468,504&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,680,488&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene
    Corporation&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite
    Japan K.K. (BioLite JP)&lt;sup&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX
    BioPharma, Inc.&lt;sup&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,258,754&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,527,740&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s
proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and
2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment
in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for
long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this
investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into
994,450 shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $1,124,842.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Summarized unaudited financial information
for the Company&#x2019;s equity method investee, BioFirst, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Balance Sheets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,323,952&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,451,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Non-current Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,083,472&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;686,206&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,508,413&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,286,058&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Non-current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;114,606&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;347,193&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,215,595&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(495,168&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Statements of operations&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;357&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;216&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;289&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(770,877&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,194,797&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share of losses from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(339,171&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(221,888&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Both Rgene and the Company are
under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise
significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment
as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include
the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of
December 31, 2024 and 2023, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Summarized unaudited financial information
for the Company&#x2019;s equity method investee, Rgene, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Balance Sheets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt; 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 72%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current Assets&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,491&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,538&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-current Assets&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;222,988&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;250,716&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,546,123&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,591,960&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-current Liabilities&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;319&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;811&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,276,963&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,291,517&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Statements of operations&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    Ended&lt;br/&gt;
    December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net sales&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross Profit&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net loss&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(118,367&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,550,123&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share of loss from investments accounted for using
    the equity method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disposition of long-term
    investment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the years ended December
31, 2024 and 2023, there is no disposition of long-term investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss on investment in
    equity securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The components of loss on investment in equity
securities for each period were as follows (not recognized since the carrying value of the investment was reduced to $0):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt;
    December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share of equity method investee losses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(339,171&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(221,888&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K. (BioLite JP)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#x201c;Lucidaim,&#x201d; together with the Company, the &#x201c;Shareholders&#x201d;), and BioLite Japan
K.K., a Japanese corporation (&#x201c;BioLite JP&#x201d;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with
3,049 ordinary shares issued and outstanding (the &#x201c;Ordinary Shares&#x201d;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000
towards the setup of the joint venture; BioLite Japan&#x2019;s other shareholder also paid $150,000 after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#x2019;s business
and financial conditions and determined to fully impair such prepayment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation (FEYE)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(e)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. (OncoX)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#x2019;s ownership. See Note 4 for detail of such transactions.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock contextRef="c7" id="ixv-26704">&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The ownership percentages of each investee are listed as follows:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ownership percentage&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Name of investees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;treatments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Braingenesis Biotechnology Co., Ltd.*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ForSeeCon Eye Corporation (see Note 10)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;18.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;18.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity&#160;Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;OncoX BioPharma, Inc. (see Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;24.97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;26.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;26.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c189"
      decimals="4"
      id="ix_40_fact"
      unitRef="pure">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c190"
      decimals="4"
      id="ix_41_fact"
      unitRef="pure">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c191" id="ix_42_fact">Cost Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c192"
      decimals="4"
      id="ixv-46967"
      unitRef="pure">0.0067</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c193"
      decimals="4"
      id="ixv-46968"
      unitRef="pure">0.0067</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c194" id="ixv-26807">Cost Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c195"
      decimals="4"
      id="ixv-46969"
      unitRef="pure">0.059</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c196"
      decimals="4"
      id="ixv-46970"
      unitRef="pure">0.059</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c197" id="ixv-26831">Cost Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c198"
      decimals="4"
      id="ixv-46971"
      unitRef="pure">0.1978</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c200" id="ixv-26857">Cost Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c185"
      decimals="4"
      id="ixv-46972"
      unitRef="pure">0.1868</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c201"
      decimals="4"
      id="ixv-46973"
      unitRef="pure">0.1868</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c179" id="ixv-26881">Equity&#160;Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c202"
      decimals="4"
      id="ixv-46974"
      unitRef="pure">0.2497</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c204" id="ixv-26906">Equity Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c140"
      decimals="4"
      id="ixv-46975"
      unitRef="pure">0.2665</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c205"
      decimals="4"
      id="ixv-46976"
      unitRef="pure">0.2665</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c206" id="ixv-26930">Equity Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <abvc:ScheduleOfExtentTheInvesteeReliesTableTextBlock contextRef="c7" id="ixv-26949">&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The extent the investee relies on the company for its business is summarized as follows:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 30%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of investees&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 69%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The extent the investee relies on the Company for its business &#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loaned from the investee and provides research and development support service&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. &lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</abvc:ScheduleOfExtentTheInvesteeReliesTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c207" id="ixv-26971">No specific business relationship</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c208" id="ixv-26979">No specific business relationship</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c209" id="ixv-26987">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c210" id="ixv-46977">The Company&#x2019;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c211" id="ixv-27002">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c212" id="ixv-27010">Loaned from the investee and provides research and development support service</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c213" id="ixv-27018">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c214" id="ixv-27026">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:InvestmentTableTextBlock contextRef="c7" id="ixv-27050">&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term investment mainly consists of the following:&lt;/span&gt;&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Non-marketable Cost Method Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,727&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,213&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,540&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;22,021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon
    Eye Corporation&lt;sup&gt;(d) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;762,983&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;818,018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;790,250&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;847,252&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity Method Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst
    Corporation&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,468,504&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,680,488&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene
    Corporation&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite
    Japan K.K. (BioLite JP)&lt;sup&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX
    BioPharma, Inc.&lt;sup&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,258,754&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,527,740&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s
proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and
2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment
in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for
long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this
investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into
994,450 shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $1,124,842.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Both Rgene and the Company are
under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise
significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment
as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include
the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of
December 31, 2024 and 2023, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K. (BioLite JP)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#x201c;Lucidaim,&#x201d; together with the Company, the &#x201c;Shareholders&#x201d;), and BioLite Japan
K.K., a Japanese corporation (&#x201c;BioLite JP&#x201d;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with
3,049 ordinary shares issued and outstanding (the &#x201c;Ordinary Shares&#x201d;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000
towards the setup of the joint venture; BioLite Japan&#x2019;s other shareholder also paid $150,000 after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#x2019;s business
and financial conditions and determined to fully impair such prepayment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation (FEYE)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(e)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. (OncoX)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#x2019;s ownership. See Note 4 for detail of such transactions.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentTableTextBlock>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c215" decimals="0" id="ixv-46978" unitRef="usd">6727</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c216" decimals="0" id="ixv-46979" unitRef="usd">7213</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c217" decimals="0" id="ixv-46980" unitRef="usd">20540</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c218" decimals="0" id="ixv-46981" unitRef="usd">22021</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c221" decimals="0" id="ixv-46982" unitRef="usd">762983</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c222" decimals="0" id="ixv-46983" unitRef="usd">818018</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c1" decimals="0" id="ixv-46984" unitRef="usd">790250</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c2" decimals="0" id="ixv-46985" unitRef="usd">847252</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="c223"
      decimals="0"
      id="ix_43_fact"
      unitRef="usd">1468504</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="c224"
      decimals="0"
      id="ix_44_fact"
      unitRef="usd">1680488</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c1" decimals="0" id="ixv-46988" unitRef="usd">2258754</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="0" id="ixv-46989" unitRef="usd">2527740</us-gaap:LongTermInvestments>
    <abvc:PercentageCommonStocksShares
      contextRef="c179"
      decimals="4"
      id="ixv-46990"
      unitRef="pure">0.1868</abvc:PercentageCommonStocksShares>
    <abvc:PercentageCommonStocksShares
      contextRef="c180"
      decimals="4"
      id="ixv-46991"
      unitRef="pure">0.1868</abvc:PercentageCommonStocksShares>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c181" decimals="0" id="ixv-46992" unitRef="usd">2688578</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c181" decimals="0" id="ixv-46993" unitRef="usd">1895556</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c181"
      decimals="0"
      id="ixv-46994"
      unitRef="shares">994450</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c179" decimals="0" id="ixv-46995" unitRef="usd">1124842</us-gaap:PrepaymentFeesOnAdvancesNet>
    <srt:CondensedStatementOfComprehensiveIncomeTableTextBlock contextRef="c7" id="ixv-27325">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Summarized unaudited financial information
for the Company&#x2019;s equity method investee, BioFirst, is as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;357&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;216&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;289&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(770,877&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,194,797&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share of losses from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(339,171&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(221,888&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Summarized unaudited financial information
for the Company&#x2019;s equity method investee, Rgene, is as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    Ended&lt;br/&gt;
    December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net sales&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross Profit&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net loss&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(118,367&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,550,123&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share of loss from investments accounted for using
    the equity method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:CondensedStatementOfComprehensiveIncomeTableTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c7" id="ixv-27326">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Summarized unaudited financial information
for the Company&#x2019;s equity method investee, BioFirst, is as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,323,952&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,451,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Non-current Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,083,472&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;686,206&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,508,413&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,286,058&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Non-current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;114,606&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;347,193&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,215,595&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(495,168&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Summarized unaudited financial information
for the Company&#x2019;s equity method investee, Rgene, is as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt; 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 72%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current Assets&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,491&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,538&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-current Assets&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;222,988&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;250,716&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,546,123&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,591,960&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-current Liabilities&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;319&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;811&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,276,963&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,291,517&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:AssetsCurrent contextRef="c231" decimals="0" id="ixv-46996" unitRef="usd">1323952</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c232" decimals="0" id="ixv-46997" unitRef="usd">1451877</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent contextRef="c231" decimals="0" id="ixv-46998" unitRef="usd">1083472</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c232" decimals="0" id="ixv-46999" unitRef="usd">686206</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c231" decimals="0" id="ixv-47000" unitRef="usd">3508413</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c232" decimals="0" id="ixv-47001" unitRef="usd">2286058</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c231" decimals="0" id="ixv-47002" unitRef="usd">114606</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c232" decimals="0" id="ixv-47003" unitRef="usd">347193</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:StockholdersEquity contextRef="c231" decimals="0" id="ixv-47004" unitRef="usd">-1215595</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c232" decimals="0" id="ixv-47005" unitRef="usd">-495168</us-gaap:StockholdersEquity>
    <us-gaap:Revenues contextRef="c235" decimals="0" id="ixv-47006" unitRef="usd">357</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c236" decimals="0" id="ixv-47007" unitRef="usd">734</us-gaap:Revenues>
    <us-gaap:GrossProfit contextRef="c235" decimals="0" id="ixv-47008" unitRef="usd">216</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c236" decimals="0" id="ixv-47009" unitRef="usd">289</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss contextRef="c235" decimals="0" id="ixv-47010" unitRef="usd">-770877</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c236" decimals="0" id="ixv-47011" unitRef="usd">-1194797</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c235" decimals="0" id="ixv-47012" unitRef="usd">-339171</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c236" decimals="0" id="ixv-47013" unitRef="usd">-221888</us-gaap:IncomeLossFromEquityMethodInvestments>
    <abvc:PercentageCommonStocksShares
      contextRef="c182"
      decimals="4"
      id="ixv-47014"
      unitRef="pure">0.2665</abvc:PercentageCommonStocksShares>
    <abvc:PercentageCommonStocksShares
      contextRef="c183"
      decimals="4"
      id="ixv-47015"
      unitRef="pure">0.2665</abvc:PercentageCommonStocksShares>
    <us-gaap:AssetsCurrent contextRef="c233" decimals="0" id="ixv-47016" unitRef="usd">46491</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c234" decimals="0" id="ixv-47017" unitRef="usd">50538</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent contextRef="c233" decimals="0" id="ixv-47018" unitRef="usd">222988</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c234" decimals="0" id="ixv-47019" unitRef="usd">250716</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c233" decimals="0" id="ixv-47020" unitRef="usd">1546123</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c234" decimals="0" id="ixv-47021" unitRef="usd">2591960</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c233" decimals="0" id="ixv-47022" unitRef="usd">319</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c234" decimals="0" id="ixv-47023" unitRef="usd">811</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:StockholdersEquity contextRef="c233" decimals="0" id="ixv-47024" unitRef="usd">-1276963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c234" decimals="0" id="ixv-47025" unitRef="usd">-2291517</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c237" decimals="0" id="ixv-47026" unitRef="usd">-118367</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c238" decimals="0" id="ixv-47027" unitRef="usd">-1550123</us-gaap:NetIncomeLoss>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c7" id="ixv-27855">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The components of loss on investment in equity
securities for each period were as follows (not recognized since the carrying value of the investment was reduced to $0):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt;
    December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share of equity method investee losses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(339,171&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(221,888&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments contextRef="c1" decimals="0" id="ixv-47028" unitRef="usd">-339171</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c2" decimals="0" id="ixv-47029" unitRef="usd">-221888</us-gaap:EquityMethodInvestments>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c184"
      decimals="0"
      id="ixv-47030"
      unitRef="shares">10000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c185"
      decimals="0"
      id="ixv-47031"
      unitRef="shares">3049</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c185"
      decimals="0"
      id="ixv-47032"
      unitRef="shares">3049</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c186"
      decimals="0"
      id="ixv-47033"
      unitRef="shares">1555</us-gaap:InvestmentOwnedBalanceShares>
    <abvc:PercentageCommonStocksShares contextRef="c7" decimals="2" id="ixv-47034" unitRef="pure">0.51</abvc:PercentageCommonStocksShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c187"
      decimals="0"
      id="ixv-47035"
      unitRef="shares">1494</us-gaap:InvestmentOwnedBalanceShares>
    <abvc:PercentageCommonStocksShares
      contextRef="c188"
      decimals="2"
      id="ixv-47036"
      unitRef="pure">0.49</abvc:PercentageCommonStocksShares>
    <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="c7" decimals="0" id="ixv-47037" unitRef="usd">150000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="c188" decimals="0" id="ixv-47038" unitRef="usd">150000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:DebtDisclosureTextBlock contextRef="c7" id="ixv-27960">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;7. CONVERTIBLE NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Lind Notes Payable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 23, 2023, the Company entered
into a securities purchase agreement with Lind Global Fund II, LP (&#x201c;Lind&#x201d;), pursuant to which the Company issued Lind a secured,
convertible note in the principal amount of $3,704,167, for a purchase price of $3,175,000 (the &#x201c;Lind Note&#x201d;), that is convertible
into shares of the Company&#x2019;s common stock at an initial conversion price of $10.5 per share, subject to adjustment. The Company
also issued Lind a common stock purchase warrant (the &#x201c;Lind Warrant&#x201d;) to purchase up to 529,167 shares (post-split) of the
Company&#x2019;s common stock at an initial exercise price of $10.5 per share for a period of 5 years, subject to adjustment that immediately
upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance or sale shall be reduced (and in no event
increased) to an Exercise Price equal to the consideration per share paid for such Additional Shares of Common Stock. The warrants were
valued using the Black-Scholes model. The fair value of the warrants was determined to be $1,225,543, which was recorded to debt discount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Beginning with the date that is six months
from the issuance date of the Lind Note and on each one (1) month anniversary thereafter, the Company shall pay Lind an amount equal
to $308,651, until the outstanding principal amount of the Lind Note has been paid in full prior to or on the Maturity Date or, if earlier,
upon acceleration, conversion or redemption of the Lind Note in accordance with the terms thereof (the &#x201c;Monthly Payments&#x201d;).
At the Company&#x2019;s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares of the Company&#x2019;s common stock, or
(iii) a combination of cash and Shares; if made in shares, the number of shares shall be determined by dividing (x) the principal amount
being paid in shares by (y) 90% of the average of the 5 lowest daily VWAPs during the 20 trading days prior to the applicable payment
date. The Lind Notes sets forth certain conditions that must be satisfied before the Company may make any Monthly Payments in shares
of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash premium of 5% of such Monthly
Payment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Upon the occurrence of any Event of Default
(as defined in the Lind Note), the Company must pay Lind an amount equal to 120%&#160;of the then outstanding principal amount of the
Lind Note (the &#x201c;Mandatory Default Amount&#x201d;), in addition to any other remedies under the Note or the other Transaction Documents.
The Company and Lind entered into a letter agreement on September 12, 2023, pursuant to which the Mandatory Default Amount was reduced
to 115% of the then outstanding principal amount of the Lind Note; pursuant to the letter agreement, Lind also agreed to waive any default
associated with the Company&#x2019;s market capitalization being below $12.5 million for 10 consecutive days through February 23, 2024,
but retained its right to convert its Note. In addition, if the Company is unable to increase its market capitalization and is unable
to obtain a further waiver or amendment to the Lind Note, then the Company could experience an event of default under the Lind Note,
which could have a material adverse effect on the Company&#x2019;s liquidity, financial condition, and results of operations. The Company
cannot make any assurances regarding the likelihood, certainty, or exact timing of the Company&#x2019;s ability to increase its market
capitalization, as such metric is not within the immediate control of the Company and depends on a variety of factors outside the Company&#x2019;s
control. &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Lind Warrant may be exercised via cashless
exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The warrant exercise price was reset to $3.5
in accordance to the issuance of common stock in relation to securities purchase agreement on July 2023.&#160;On May 22, 2024, the exercise
price of these warrants was reset to $0.75 along with the immediate exercise of existing warrants and issuance of the New Warrants. As
of December 31, 2024, these Lind Warrants associated with the first Lind Note were fully exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 17, 2023, the Company entered
another securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#x201c;2&lt;sup&gt;nd&lt;/sup&gt;
Lind Note&#x201d;) in the principal amount of $1,200,000, for a purchase price of $1,000,000, that is convertible into shares of the Company&#x2019;s
common stock at a conversion price, which shall be the lesser of (i) $3.50 and (ii) 90% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note shall be due and payable on May 19, 2025 and bear no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to the maturity, and Lind shall have the right
to convert up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined
in the 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind
Note, in addition to any other remedies under the Note or the other transaction documents. Lind also received a 5-year common stock purchase
warrant to purchase up to 1,000,000 shares of the Company&#x2019;s common stock at an initial exercise price of $2 per share for a period
of 5 years. The warrants were valued using the Black-Scholes model. The fair value of the warrants was determined to be $480,795, which
was recorded to debt discount. An amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements,
the parties entered into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $1.00. Additionally,
the amendment requires the Company to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed
to be the floor price. During the year ended December 31, 2024, Lind converted $800,000 of 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note principal amounts
into the Company&#x2019;s common stocks. Refer to the common stock issuance details in Note 12, Equity. As of April 1, 2025, Lind has
converted the remaining $400,000 principal balance into the Company&#x2019;s common stocks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 17, 2024, the Company entered another
securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#x201c;3&lt;sup&gt;rd&lt;/sup&gt;
Lind Note&#x201d;) in the principal amount of $1,000,000, for a purchase price of $833,333, that is convertible into shares of the Company&#x2019;s
common stock at a conversion price, which shall be the lesser of (i) $3.50 and (ii) 90% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note shall be due and payable on July 17, 2025 and bear no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to the maturity, and Lind shall have the right
to convert up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined
in the 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind
Note, in addition to any other remedies under the Note or the other transaction documents Lind also received a 5-year, common stock purchase
warrant to purchase up to 1,000,000 shares of the Company&#x2019;s common stock at an initial exercise price of $2 per share. The warrants
were valued using the Black-Scholes model. The fair value of the warrants was determined to be $394,071, which was recorded to debt discount.
An amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements, the parties entered into an amendment
to the Note, pursuant to which the conversion price shall have a floor price of $1.00. Additionally, the amendment requires the Company
to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor price. No conversion
or repayment to 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note has occurred during the year ended December 31, 2024. As of April 1, 2025, Lind has converted
$400,000 principal balance into the Company&#x2019;s common stock, leaving outstanding principal of $600,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In connection with above three Lind Note offerings,
the Company and its subsidiaries: BioKey, BioLite, Biolite BVI, and American BriVision, jointly and severally guaranteed all of the obligations
of the Company in connection with the offering with certain collateral, as set forth in the related transaction documents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 22, 2024 and November 19, 2024, Lind
has exercised 1,000,000 and 500,000 of the existing warrants to purchase shares of Common Stock at a reduced exercise price of $0.75
and $0.42 per share, respectively. Refer to the details in Note 12, Equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total interest expenses in connection with
the above three Lind Notes were $773,139 and $1,233,284 for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Other Convertible Notes Payable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 1, 2024 and November 5, 2024,
the Company&#x2019;s subsidiary, AiBtl, issued two convertible note payable, each with a principal amount of $30,000 to two separate individuals,
for total consideration of $60,000. Each note has a 1-year term and an implied annual discount rate of 6.89%. These convertible notes
bear 0% interest rate and are convertible by the holders into the AiBtl&#x2019;s common stock at $5 per share at any time before the maturity.
AiBtl reserves the right to repurchase the note in full at any time before the maturity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The convertible notes payable is accounted
for in accordance with ASC 470-20, Debt with Conversion and Other Options. The Company evaluated the conversion feature and determined
that it qualifies for equity classification as it meets the &#x201c;fixed-for-fixed&#x201d; criteria. The proceeds from the issuance were
allocated to the present value of the liability component in aggregate for $56,132, and to debt discount for $3,868. The debt discount
is recorded in additional paid-in capital in the statement of change in equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The debt discount is being amortized over
the 1-year term using the effective interest method. During the year ended December 31, 2024, the Company recognized $646 in interest
expense related to the amortization of the debt discount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The carrying amounts of the liability component
are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Issuance&lt;br/&gt; Entity&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Issuance&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Maturity&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Stated&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Effective&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Conversion&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Common&lt;br/&gt; Stock&lt;br/&gt; to&#160;be&lt;br/&gt; converted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Balance&lt;br/&gt; Sheet Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Unamortized&lt;br/&gt; Discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Carrying&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Fair&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;2nd LIND Note&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 17, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;May 19,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;86.94&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;118,048&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;281,952&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;480,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;3rd LIND Note&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;January 17, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;July 17,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;87.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;388,685&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;611,315&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 1, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 1, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,610&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;28,390&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 5,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 5, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,611&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;28,389&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;2,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,460,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;509,954&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;950,046&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,740,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="font-size: 8pt; vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Entity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Maturity&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Stated&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Effective&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Conversion&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Common&lt;br/&gt; Stock&lt;br/&gt; to be&lt;br/&gt; converted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Balance&lt;br/&gt; Sheet Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Unamortized&lt;br/&gt; Discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Carrying&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Fair&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 8pt; vertical-align: top; width: 10%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1st LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 6%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;February 23,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;August 23,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;3,704,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;61.42&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;3.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 6%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;811,175&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;290,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;521,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;973,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-size: 8pt; vertical-align: bottom; "&gt; &lt;td style="font-size: 8pt; vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2nd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 17,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;May 19,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;86.94&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;834,590&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;365,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,440,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;4,904,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2,011,175&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,124,653&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;886,522&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2,413,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c239" decimals="0" id="ixv-47039" unitRef="usd">3704167</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:PaymentsForPreviousAcquisition contextRef="c239" decimals="0" id="ixv-47040" unitRef="usd">3175000</us-gaap:PaymentsForPreviousAcquisition>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c239"
      decimals="1"
      id="ixv-47041"
      unitRef="usdPershares">10.5</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c239"
      decimals="0"
      id="ixv-47042"
      unitRef="shares">529167</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c240"
      decimals="1"
      id="ixv-47043"
      unitRef="usdPershares">10.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c241" decimals="0" id="ixv-47044" unitRef="usd">1225543</us-gaap:FairValueAdjustmentOfWarrants>
    <abvc:OutstandingBalanceAmount contextRef="c242" decimals="0" id="ixv-47045" unitRef="usd">308651</abvc:OutstandingBalanceAmount>
    <abvc:PercentageOfAverageAmount
      contextRef="c243"
      decimals="2"
      id="ixv-47046"
      unitRef="pure">0.90</abvc:PercentageOfAverageAmount>
    <abvc:PercentageOfCashPermium contextRef="c7" decimals="2" id="ixv-47047" unitRef="pure">0.05</abvc:PercentageOfCashPermium>
    <abvc:PercentageOfOutstandingPrincipalAmount
      contextRef="c243"
      decimals="2"
      id="ixv-47048"
      unitRef="pure">1.20</abvc:PercentageOfOutstandingPrincipalAmount>
    <abvc:PercentageOfOutstandingPrincipalAmount
      contextRef="c244"
      decimals="2"
      id="ixv-47049"
      unitRef="pure">1.15</abvc:PercentageOfOutstandingPrincipalAmount>
    <us-gaap:GeneralPartnersCapitalAccount contextRef="c1" decimals="-5" id="ixv-47050" unitRef="usd">12500000</us-gaap:GeneralPartnersCapitalAccount>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c245"
      decimals="1"
      id="ixv-47051"
      unitRef="usdPershares">3.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c246"
      decimals="2"
      id="ixv-47052"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ReceivableWithImputedInterestFaceAmount contextRef="c247" decimals="0" id="ixv-47053" unitRef="usd">1200000</us-gaap:ReceivableWithImputedInterestFaceAmount>
    <us-gaap:PaymentsForPreviousAcquisition contextRef="c248" decimals="0" id="ixv-47054" unitRef="usd">1000000</us-gaap:PaymentsForPreviousAcquisition>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c249"
      decimals="2"
      id="ixv-47055"
      unitRef="usdPershares">3.5</us-gaap:PreferredStockConvertibleConversionPrice>
    <abvc:PercentageOfAverageAmount
      contextRef="c248"
      decimals="2"
      id="ixv-47056"
      unitRef="pure">0.90</abvc:PercentageOfAverageAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c250"
      decimals="2"
      id="ixv-47057"
      unitRef="pure">1.20</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c248"
      decimals="0"
      id="ixv-47058"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice
      contextRef="c248"
      decimals="0"
      id="ixv-47059"
      unitRef="usdPershares">2</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <abvc:PurchaseWarrantTerm contextRef="c251" id="ixv-47060">P5Y</abvc:PurchaseWarrantTerm>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c252" decimals="0" id="ixv-47061" unitRef="usd">480795</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c253"
      decimals="2"
      id="ixv-47062"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c254" decimals="0" id="ixv-47063" unitRef="usd">800000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c255" decimals="0" id="ixv-47064" unitRef="usd">400000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:ReceivableWithImputedInterestFaceAmount contextRef="c256" decimals="0" id="ixv-47065" unitRef="usd">1000000</us-gaap:ReceivableWithImputedInterestFaceAmount>
    <abvc:PurchasePriceAmount contextRef="c256" decimals="0" id="ixv-47066" unitRef="usd">833333</abvc:PurchasePriceAmount>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c257"
      decimals="2"
      id="ixv-47067"
      unitRef="usdPershares">3.5</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <abvc:PercentageOfAverageAmount
      contextRef="c257"
      decimals="2"
      id="ixv-47068"
      unitRef="pure">0.90</abvc:PercentageOfAverageAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c257"
      decimals="2"
      id="ixv-47069"
      unitRef="pure">1.20</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <abvc:PurchaseWarrantTerm contextRef="c258" id="ixv-47070">P5Y</abvc:PurchaseWarrantTerm>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c257" decimals="0" id="ixv-47071" unitRef="usd">1000000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c258"
      decimals="0"
      id="ixv-47072"
      unitRef="usdPershares">2</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c259" decimals="0" id="ixv-47073" unitRef="usd">394071</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c260"
      decimals="2"
      id="ixv-47074"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c255" decimals="0" id="ixv-47075" unitRef="usd">400000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <abvc:DebtInstrumentOutstandingPrincipal contextRef="c255" decimals="0" id="ixv-47076" unitRef="usd">600000</abvc:DebtInstrumentOutstandingPrincipal>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c261"
      decimals="0"
      id="ixv-47077"
      unitRef="shares">1000000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c262"
      decimals="0"
      id="ixv-47078"
      unitRef="shares">500000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c263"
      decimals="2"
      id="ixv-47079"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c264"
      decimals="2"
      id="ixv-47080"
      unitRef="usdPershares">0.42</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:InterestExpenseOther contextRef="c7" decimals="0" id="ixv-47081" unitRef="usd">773139</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c8" decimals="0" id="ixv-47082" unitRef="usd">1233284</us-gaap:InterestExpenseOther>
    <us-gaap:ConvertibleNotesPayable contextRef="c265" decimals="0" id="ixv-47083" unitRef="usd">30000</us-gaap:ConvertibleNotesPayable>
    <abvc:ConsiderationAmount contextRef="c266" decimals="0" id="ixv-47084" unitRef="usd">60000</abvc:ConsiderationAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c267" id="ixv-47085">P1Y</us-gaap:DebtInstrumentTerm>
    <abvc:PercentageOfAnnualDiscountRate contextRef="c7" decimals="4" id="ixv-47086" unitRef="pure">0.0689</abvc:PercentageOfAnnualDiscountRate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c268"
      decimals="2"
      id="ixv-47087"
      unitRef="pure">0</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c269"
      decimals="0"
      id="ixv-47088"
      unitRef="usdPershares">5</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c7" decimals="0" id="ixv-47089" unitRef="usd">56132</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c270" decimals="0" id="ixv-47090" unitRef="usd">3868</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentTerm contextRef="c254" id="ixv-47091">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:InterestExpenseDebt contextRef="c7" decimals="0" id="ixv-47092" unitRef="usd">646</us-gaap:InterestExpenseDebt>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c7" id="ixv-28061">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The carrying amounts of the liability component
are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Issuance&lt;br/&gt; Entity&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Issuance&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Maturity&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Stated&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Effective&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Conversion&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Common&lt;br/&gt; Stock&lt;br/&gt; to&#160;be&lt;br/&gt; converted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Balance&lt;br/&gt; Sheet Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Unamortized&lt;br/&gt; Discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Carrying&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Fair&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;2nd LIND Note&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 17, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;May 19,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;86.94&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;118,048&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;281,952&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;480,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;3rd LIND Note&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;January 17, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;July 17,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;87.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;388,685&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;611,315&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 1, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 1, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,610&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;28,390&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 5,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;November 5, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,611&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;28,389&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;2,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,460,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;509,954&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;950,046&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;1,740,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="font-size: 8pt; vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Entity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Maturity&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Stated&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Effective&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Conversion&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Common&lt;br/&gt; Stock&lt;br/&gt; to be&lt;br/&gt; converted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Balance&lt;br/&gt; Sheet Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Unamortized&lt;br/&gt; Discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Carrying&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Fair&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 8pt; vertical-align: top; width: 10%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1st LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 6%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;February 23,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;August 23,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;3,704,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;61.42&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;3.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 6%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;811,175&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;290,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;521,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;973,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; width: 0.5%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-size: 8pt; vertical-align: bottom; "&gt; &lt;td style="font-size: 8pt; vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2nd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 17,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;May 19,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;86.94&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;834,590&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;365,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,440,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;4,904,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2,011,175&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,124,653&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;886,522&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2,413,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c271" id="ixv-28163">ABVC</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c271" id="ixv-28168">2023-11-17</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c271" id="ixv-28174">2025-05-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c271" decimals="0" id="ixv-47093" unitRef="usd">1200000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c272"
      decimals="2"
      id="ixv-47094"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c272"
      decimals="4"
      id="ixv-47095"
      unitRef="pure">0.8694</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c272"
      decimals="2"
      id="ixv-47096"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c271" id="ixv-28212">ABVC</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c271" decimals="0" id="ixv-47097" unitRef="usd">400000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c272" decimals="0" id="ixv-47098" unitRef="usd">118048</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c271" decimals="0" id="ixv-47099" unitRef="usd">281952</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c272" decimals="0" id="ixv-47100" unitRef="usd">480000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c273" id="ixv-28254">ABVC</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c273" id="ixv-28259">2024-01-17</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c273" id="ixv-28265">2025-07-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c273" decimals="0" id="ixv-47101" unitRef="usd">1000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c274"
      decimals="2"
      id="ixv-47102"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c274"
      decimals="4"
      id="ixv-47103"
      unitRef="pure">0.874</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c274"
      decimals="2"
      id="ixv-47104"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c273" id="ixv-28303">ABVC</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c273" decimals="0" id="ixv-47105" unitRef="usd">1000000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c274" decimals="0" id="ixv-47106" unitRef="usd">388685</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c273" decimals="0" id="ixv-47107" unitRef="usd">611315</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c274" decimals="0" id="ixv-47108" unitRef="usd">1200000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c275" id="ixv-28345">AiBtl</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c275" id="ixv-28350">2024-11-01</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c275" id="ixv-28356">2025-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c275" decimals="0" id="ixv-47109" unitRef="usd">30000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c276"
      decimals="2"
      id="ixv-47110"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c276"
      decimals="4"
      id="ixv-47111"
      unitRef="pure">0.0689</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c276"
      decimals="2"
      id="ixv-47112"
      unitRef="usdPershares">5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c275" id="ixv-28394">AiBtl</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c275" decimals="0" id="ixv-47113" unitRef="usd">30000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c276" decimals="0" id="ixv-47114" unitRef="usd">1610</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c275" decimals="0" id="ixv-47115" unitRef="usd">28390</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c276" decimals="0" id="ixv-47116" unitRef="usd">30000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c277" id="ixv-28436">AiBtl</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c277" id="ixv-28441">2024-11-05</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c277" id="ixv-28447">2025-11-05</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c277" decimals="0" id="ixv-47117" unitRef="usd">30000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c278"
      decimals="2"
      id="ixv-47118"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c278"
      decimals="4"
      id="ixv-47119"
      unitRef="pure">0.0689</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c278"
      decimals="2"
      id="ixv-47120"
      unitRef="usdPershares">5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c277" id="ixv-28485">AiBtl</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c277" decimals="0" id="ixv-47121" unitRef="usd">30000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c278" decimals="0" id="ixv-47122" unitRef="usd">1611</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c277" decimals="0" id="ixv-47123" unitRef="usd">28389</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c278" decimals="0" id="ixv-47124" unitRef="usd">30000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c7" decimals="0" id="ixv-47125" unitRef="usd">2260000</us-gaap:DebtInstrumentIssuedPrincipal>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c7" decimals="0" id="ixv-47126" unitRef="usd">1460000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c1" decimals="0" id="ixv-47127" unitRef="usd">509954</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c7" decimals="0" id="ixv-47128" unitRef="usd">950046</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c1" decimals="0" id="ixv-47129" unitRef="usd">1740000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c279" id="ixv-28699">ABVC</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c279" id="ixv-28704">2023-02-23</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c279" id="ixv-28710">2024-08-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c279" decimals="0" id="ixv-47130" unitRef="usd">3704167</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c280"
      decimals="2"
      id="ixv-47131"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c280"
      decimals="4"
      id="ixv-47132"
      unitRef="pure">0.6142</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c280"
      decimals="2"
      id="ixv-47133"
      unitRef="usdPershares">3.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c279" id="ixv-28748">ABVC</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c279" decimals="0" id="ixv-47134" unitRef="usd">811175</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c280" decimals="0" id="ixv-47135" unitRef="usd">290063</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c279" decimals="0" id="ixv-47136" unitRef="usd">521112</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c280" decimals="0" id="ixv-47137" unitRef="usd">973410</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c281" id="ixv-28790">ABVC</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c281" id="ixv-28795">2023-11-17</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c281" id="ixv-28801">2025-05-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c281" decimals="0" id="ixv-47138" unitRef="usd">1200000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c282"
      decimals="2"
      id="ixv-47139"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c282"
      decimals="4"
      id="ixv-47140"
      unitRef="pure">0.8694</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c282"
      decimals="2"
      id="ixv-47141"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c281" id="ixv-28839">ABVC</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c281" decimals="0" id="ixv-47142" unitRef="usd">1200000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c282" decimals="0" id="ixv-47143" unitRef="usd">834590</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c281" decimals="0" id="ixv-47144" unitRef="usd">365410</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c282" decimals="0" id="ixv-47145" unitRef="usd">1440000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c8" decimals="0" id="ixv-47146" unitRef="usd">4904167</us-gaap:DebtInstrumentIssuedPrincipal>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c8" decimals="0" id="ixv-47147" unitRef="usd">2011175</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c2" decimals="0" id="ixv-47148" unitRef="usd">1124653</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c8" decimals="0" id="ixv-47149" unitRef="usd">886522</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c2" decimals="0" id="ixv-47150" unitRef="usd">2413410</us-gaap:DebtInstrumentFairValue>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c7" id="ixv-28972">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,799,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,799,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued directors and officers (owners) compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,025,867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,018,253&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;255,592&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;274,028&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;126,106&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;29,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;302,274&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;427,350&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,509,422&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,548,352&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c7" id="ixv-28977">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,799,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,799,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued directors and officers (owners) compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,025,867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,018,253&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;255,592&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;274,028&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;126,106&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;29,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;302,274&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;427,350&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,509,422&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,548,352&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <abvc:AccruedResearchAndDevelopmentExpense contextRef="c1" decimals="0" id="ixv-47151" unitRef="usd">1799583</abvc:AccruedResearchAndDevelopmentExpense>
    <abvc:AccruedResearchAndDevelopmentExpense contextRef="c2" decimals="0" id="ixv-47152" unitRef="usd">1799583</abvc:AccruedResearchAndDevelopmentExpense>
    <abvc:AccruedDirectorAndOfficerCompensation contextRef="c1" decimals="0" id="ixv-47153" unitRef="usd">1025867</abvc:AccruedDirectorAndOfficerCompensation>
    <abvc:AccruedDirectorAndOfficerCompensation contextRef="c2" decimals="0" id="ixv-47154" unitRef="usd">1018253</abvc:AccruedDirectorAndOfficerCompensation>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c1" decimals="0" id="ixv-47155" unitRef="usd">255592</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c2" decimals="0" id="ixv-47156" unitRef="usd">274028</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-47157" unitRef="usd">126106</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-47158" unitRef="usd">29138</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c1" decimals="0" id="ixv-47159" unitRef="usd">302274</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c2" decimals="0" id="ixv-47160" unitRef="usd">427350</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c1" decimals="0" id="ixv-47161" unitRef="usd">3509422</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c2" decimals="0" id="ixv-47162" unitRef="usd">3548352</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:ShortTermDebtTextBlock contextRef="c7" id="ixv-29131">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;9. SHORT-TERM LOANS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term loans consists of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cathay United Bank&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;200,252&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;245,250&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;CTBC Bank&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;654,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other individual&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840,252&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;899,250&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Cathay United Bank&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 28, 2016, BioLite Taiwan and Cathay
United Bank entered into a one-year bank loan agreement (the &#x201c;Cathay United Loan Agreement&#x201d;) in a credit limit amount of
NTD 7.5 million, equivalent to $228,750. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest
at a floating rate of prime rate plus 1.31%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. The
Company renews the agreement with the bank every year, and the next renewal date is September 6, 2025. As of December 31, 2024&#160;and
December 31, 2023, the effective interest rates per annum was 2.99%&#160;and 2.87%, respectively. The loan is collateralized by the building
and improvement of BioLite Taiwan, and is also personal guaranteed by the Company&#x2019;s chairman. During the year ended December 31,
2024, the Company made payments of the loan in total of NTD 934,366, equivalent to $29,152.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses were $6,891 and $6,856 for
the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;CTBC Bank&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 12, 2017 and July 19, 2017, BioLite
Taiwan and CTBC Bank entered into two short-term saving secured bank loan agreements (the &#x201c;CTBC Loan Agreements&#x201d;) in a credit
limit amount of NTD 10 million, equivalent to $327,500, and NTD 10 million, equivalent to $327,500, respectively. Both two loans with
the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC
for one year. The Company renews the agreement with the bank every year, and the next renewal date is February 28, 2025.&#160;The loan
balances bear interest at a fixed rate of 2.5% per annum, and is secured by the money deposited in a savings account with the CTBC Bank.
This loan was also personal guaranteed by the Company&#x2019;s chairman and BioFirst. During the year ended December 31, 2020, BioLite
Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses were $15,557 and $15,610
for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Other individual &#x2013; Third party&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On March 21, 2024, the Company issued an unsecured
promissory note to a third party for the proceeds of $30,000. The note bears interest rate of 12% per annum and matures on March 21,
2025, or upon the occurrence of an event of default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses were $2,811 for the year
ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c7" id="ixv-29141">&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term loans consists of the following:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cathay United Bank&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;200,252&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;245,250&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;CTBC Bank&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;654,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other individual&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840,252&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;899,250&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c286" decimals="0" id="ixv-47163" unitRef="usd">200252</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c287" decimals="0" id="ixv-47164" unitRef="usd">245250</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c299" decimals="0" id="ixv-47165" unitRef="usd">610000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c300" decimals="0" id="ixv-47166" unitRef="usd">654000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c301" decimals="0" id="ixv-47167" unitRef="usd">30000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c1" decimals="0" id="ixv-47168" unitRef="usd">840252</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="0" id="ixv-47169" unitRef="usd">899250</us-gaap:ShortTermBorrowings>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c283"
      decimals="-5"
      id="ixv-47170"
      unitRef="twd">7500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c283" decimals="0" id="ixv-47171" unitRef="usd">228750</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c284" id="ixv-47172">2016-06-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="c285"
      decimals="4"
      id="ixv-47173"
      unitRef="pure">0.0131</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c286"
      decimals="4"
      id="ixv-47174"
      unitRef="pure">0.0299</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c287"
      decimals="4"
      id="ixv-47175"
      unitRef="pure">0.0287</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c7" decimals="0" id="ixv-47176" unitRef="twd">934366</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c7" decimals="0" id="ixv-47177" unitRef="usd">29152</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c288" decimals="0" id="ixv-47178" unitRef="usd">6891</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c289" decimals="0" id="ixv-47179" unitRef="usd">6856</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c290"
      decimals="-6"
      id="ixv-47180"
      unitRef="twd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c291"
      decimals="-6"
      id="ixv-47181"
      unitRef="twd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c290" decimals="0" id="ixv-47182" unitRef="usd">327500</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c291" decimals="0" id="ixv-47183" unitRef="usd">327500</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c293" id="ixv-47184">2018-01-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c292" id="ixv-47185">2018-01-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentTerm contextRef="c294" id="ixv-47186">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsSavings
      contextRef="c295"
      decimals="3"
      id="ixv-47187"
      unitRef="pure">0.025</us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsSavings>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c7" decimals="0" id="ixv-47188" unitRef="usd">15557</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c8" decimals="0" id="ixv-47189" unitRef="usd">15610</us-gaap:InterestExpenseShortTermBorrowings>
    <abvc:ProceedsFromIssuanceOfAPromissoryNote contextRef="c296" decimals="0" id="ixv-47190" unitRef="usd">30000</abvc:ProceedsFromIssuanceOfAPromissoryNote>
    <us-gaap:ShortTermDebtPercentageBearingVariableInterestRate
      contextRef="c297"
      decimals="2"
      id="ixv-47191"
      unitRef="pure">0.12</us-gaap:ShortTermDebtPercentageBearingVariableInterestRate>
    <abvc:ShortTermDebtMaturityDate contextRef="c297" id="ixv-47192">2025-03-21</abvc:ShortTermDebtMaturityDate>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c298" decimals="0" id="ixv-47193" unitRef="usd">2811</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c7" id="ixv-29305">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;10. RELATED PARTIES TRANSACTIONS&lt;/b&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The related parties of the company with whom
transactions are reported in these financial statements are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr&gt; &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 30%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of entity or Individual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company and its subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GenePharm Inc. (the &#x201c;GenePharm&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Jiangs&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation (&#x201c;BHK&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AiBtl (Holding) BioPharma, Inc. (&#x201c;AiBtl Holding&#x201d;) &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Founding shareholder of AiBtl BioPharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jaimes Vargas Russman &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CEO of AiBtl BioPharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lion Arts Promotion, Inc.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by the Jiangs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenues  &#x2013; related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the years ended December 31, 2024,
the Company received $296,000 in cash, pursuant to the licensing agreement and related amendment with FEYE, and recognized $296,000 revenue
correspondingly. In addition, the Company received $200,000 during the year ended December 31, 2024, pursuant to the licensing agreement
with OncoX, and recognized revenue correspondingly. Please refer to Note 4, Collaborative Agreements for details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt;
    December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;OncoX&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;FEYE&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;296,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,055&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;496,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,055&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Consulting fees - related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2024, the Company engaged Lion International
to provide operation, business development, human resources, and capital finance consulting services. The agreement is for 12 months
expiring in February 2025, and is optional for renewal upon mutual agreement. The Company incurred $104,083 for the year ended December
31, 2024. No such consulting service was engaged in year 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Accounts receivable - related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounts receivable due from related parties
consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;GenePharm Inc.&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,463&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,463&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024, management considered
the outstanding accounts receivable from Rgene may not be recoverable, and recognized credit loss in full.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Due from related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amount due from related parties consisted
of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from related party- Current&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene (1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;565,711&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;541,486&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;589,340&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;206,087&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1,155,051&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;747,573&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from related parties- Non-current, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst (Australia) (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;120,210&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;113,516&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,014,193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;953,499&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: allowance for expected credit losses accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,014,193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;113,516&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1) &#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#x2019;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024 and December 31, 2023, the outstanding loan balance were both $500,000; and accrued interest was $63,819 and $38,819, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024 and 2023, the Company has other receivables amounted $1,892 and $2,667, respectively, from Rgene due to daily operations.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify; font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of December 31, 2024 and 2023, the outstanding loan balance were NTD 17,571,076 (approximately $535,918) and NTD 6,302,360 ($206,087), respectively; accrued interest was $53,422 and $0, respectively. The Company has received NTD 4,040,000 (approximately $126,048) repayment and expects to receive other repayment within next 12 months.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of December 31, 2024 and 2023, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2024 and 2023, due from BHK was both NTD 3,941,299 (approximately $120,210 and $113,516, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of $120,210 for the year ended December 31, 2024. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s due from related parties
are subject to certain risks that our collaborative parties, including OncoX and FEYE, would face. Such risks exist in future market
conditions, macro economy, legal and regulatory, results of clinical trials and product developments, and among others. As of December
31, 2024, the Company&#x2019;s comprehensive review of these due from related party balances indicates that there are no expected losses
except those being recognized above. This conclusion is based on the business relationships with our related parties and the absence
of any significant indicators of potential default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Due to related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amount due to related parties consisted of
the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;AiBtl Holding (1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;348,219&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Jiangs (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;274,170&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,789&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shareholders (3)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;142,130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;152,382&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Directors (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,526&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,322&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;773,045&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;173,493&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2024 and 2023, the outstanding balance due to the Jiangs amounted to $274,170 and $19,789, respectively. These loans bear no interest and are due on demand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2018, the Company&#x2019;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of December 31, 2024 and 2023, the outstanding principal and accrued interest was $172,112 and $152,382, respectively. Interest expenses in connection with these loans were $21,101 and $20,094 for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify; font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2024 and 2023, due to Directors amounted to $8,526 and $1,322, respectively, were related to the daily operating expenses in 2024 and entity setup fee in 2023 paid by the Directors of AiBtl on behalf of the entity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c7" id="ixv-29310">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The related parties of the company with whom
transactions are reported in these financial statements are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr&gt; &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 30%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of entity or Individual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company and its subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GenePharm Inc. (the &#x201c;GenePharm&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Jiangs&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation (&#x201c;BHK&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AiBtl (Holding) BioPharma, Inc. (&#x201c;AiBtl Holding&#x201d;) &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Founding shareholder of AiBtl BioPharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jaimes Vargas Russman &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CEO of AiBtl BioPharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lion Arts Promotion, Inc.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by the Jiangs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c334" id="ixv-29331">Entity controlled by controlling beneficiary shareholder of YuanGene</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c335" id="ixv-29339">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c336" id="ixv-29347">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c337" id="ixv-29355">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c338" id="ixv-29363">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst &#160; Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. &#160; Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. &#160; Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company. &#160; Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c339" id="ixv-29388">Entity controlled by controlling beneficiary shareholder of ABVC</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c340" id="ixv-29396">Entity controlled by controlling beneficiary shareholder of ABVC</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c341" id="ixv-29404">Founding shareholder of AiBtl BioPharma Inc.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c342" id="ixv-29412">CEO of AiBtl BioPharma Inc.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c343" id="ixv-29420">Entity controlled by the Jiangs.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <abvc:ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock contextRef="c7" id="ixv-29428">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the years ended December 31, 2024,
the Company received $296,000 in cash, pursuant to the licensing agreement and related amendment with FEYE, and recognized $296,000 revenue
correspondingly. In addition, the Company received $200,000 during the year ended December 31, 2024, pursuant to the licensing agreement
with OncoX, and recognized revenue correspondingly. Please refer to Note 4, Collaborative Agreements for details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt;
    December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;OncoX&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;FEYE&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;296,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,055&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;496,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,055&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvc:ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock>
    <abvc:LicensingAgreement contextRef="c303" decimals="0" id="ixv-47194" unitRef="usd">296000</abvc:LicensingAgreement>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c303" decimals="0" id="ixv-47195" unitRef="usd">296000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c304" decimals="0" id="ixv-47196" unitRef="usd">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:Revenues contextRef="c344" decimals="0" id="ixv-47197" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c346" decimals="0" id="ixv-47198" unitRef="usd">296000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c349" decimals="0" id="ixv-47199" unitRef="usd">2055</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c350" decimals="0" id="ixv-47200" unitRef="usd">496000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c351" decimals="0" id="ixv-47201" unitRef="usd">2055</us-gaap:Revenues>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c7" decimals="0" id="ixv-47202" unitRef="usd">104083</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <abvc:ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock contextRef="c7" id="ixv-29552">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounts receivable due from related parties
consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;GenePharm Inc.&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,463&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,463&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvc:ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c234" decimals="0" id="ixv-47203" unitRef="usd">10463</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-47204" unitRef="usd">10463</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <abvc:ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock contextRef="c7" id="ixv-29676">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from related party- Current&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene (1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;565,711&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;541,486&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;589,340&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;206,087&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1,155,051&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;747,573&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from related parties- Non-current, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst (Australia) (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;120,210&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;113,516&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,014,193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;953,499&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: allowance for expected credit losses accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,014,193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;113,516&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1) &#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#x2019;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024 and December 31, 2023, the outstanding loan balance were both $500,000; and accrued interest was $63,819 and $38,819, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024 and 2023, the Company has other receivables amounted $1,892 and $2,667, respectively, from Rgene due to daily operations.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify; font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of December 31, 2024 and 2023, the outstanding loan balance were NTD 17,571,076 (approximately $535,918) and NTD 6,302,360 ($206,087), respectively; accrued interest was $53,422 and $0, respectively. The Company has received NTD 4,040,000 (approximately $126,048) repayment and expects to receive other repayment within next 12 months.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of December 31, 2024 and 2023, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2024 and 2023, due from BHK was both NTD 3,941,299 (approximately $120,210 and $113,516, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of $120,210 for the year ended December 31, 2024. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</abvc:ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c354"
      decimals="0"
      id="ix_45_fact"
      unitRef="usd">565711</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c355"
      decimals="0"
      id="ix_46_fact"
      unitRef="usd">541486</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c311"
      decimals="0"
      id="ix_47_fact"
      unitRef="usd">589340</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c310"
      decimals="0"
      id="ix_48_fact"
      unitRef="usd">206087</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c356" decimals="0" id="ixv-47209" unitRef="usd">1155051</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c324" decimals="0" id="ixv-47210" unitRef="usd">747573</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent
      contextRef="c357"
      decimals="0"
      id="ix_49_fact"
      unitRef="usd">839983</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent
      contextRef="c358"
      decimals="0"
      id="ix_50_fact"
      unitRef="usd">839983</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent
      contextRef="c221"
      decimals="0"
      id="ix_51_fact"
      unitRef="usd">120210</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent
      contextRef="c222"
      decimals="0"
      id="ix_52_fact"
      unitRef="usd">113516</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent contextRef="c356" decimals="0" id="ixv-47215" unitRef="usd">1014193</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent contextRef="c324" decimals="0" id="ixv-47216" unitRef="usd">953499</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent contextRef="c356" decimals="0" id="ixv-47217" unitRef="usd">1014193</us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent contextRef="c324" decimals="0" id="ixv-47218" unitRef="usd">839983</us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent contextRef="c324" decimals="0" id="ixv-47219" unitRef="usd">113516</us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c305" decimals="0" id="ixv-47220" unitRef="usd">1000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="c306"
      decimals="2"
      id="ixv-47221"
      unitRef="pure">0.05</us-gaap:AccountsPayableInterestBearingInterestRate>
    <abvc:WorkingCapitalPercentage
      contextRef="c307"
      decimals="3"
      id="ixv-47222"
      unitRef="pure">0.064</abvc:WorkingCapitalPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c306"
      decimals="2"
      id="ixv-47223"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c308"
      decimals="2"
      id="ixv-47224"
      unitRef="pure">0.20</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c3" decimals="0" id="ixv-47225" unitRef="usd">500000</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:DepositLiabilitiesAccruedInterest contextRef="c3" decimals="0" id="ixv-47226" unitRef="usd">63819</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:DepositLiabilitiesAccruedInterest contextRef="c2" decimals="0" id="ixv-47227" unitRef="usd">38819</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:OtherReceivables contextRef="c3" decimals="0" id="ixv-47228" unitRef="usd">1892</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c4" decimals="0" id="ixv-47229" unitRef="usd">2667</us-gaap:OtherReceivables>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c309" decimals="0" id="ixv-47230" unitRef="twd">11072360</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c309" decimals="0" id="ixv-47231" unitRef="usd">337707</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="c310"
      decimals="2"
      id="ixv-47232"
      unitRef="pure">0.12</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c311" decimals="0" id="ixv-47233" unitRef="twd">11406000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c311" decimals="0" id="ixv-47234" unitRef="usd">347883</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="c311"
      decimals="2"
      id="ixv-47235"
      unitRef="pure">0.12</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c312" decimals="0" id="ixv-47236" unitRef="twd">17571076</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c311" decimals="0" id="ixv-47237" unitRef="usd">535918</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c310" decimals="0" id="ixv-47238" unitRef="twd">6302360</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c310" decimals="0" id="ixv-47239" unitRef="usd">206087</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c313" decimals="0" id="ixv-47240" unitRef="usd">53422</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c314" decimals="0" id="ixv-47241" unitRef="usd">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:RepaymentsOfDebt contextRef="c7" decimals="0" id="ixv-47242" unitRef="twd">4040000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c7" decimals="0" id="ixv-47243" unitRef="usd">126048</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c315" decimals="0" id="ixv-47244" unitRef="usd">361487</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RelatedPartyTransactionDate contextRef="c316" id="ixv-47245">2021-09-30</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="c316"
      decimals="3"
      id="ixv-47246"
      unitRef="pure">0.065</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c317" decimals="0" id="ixv-47247" unitRef="usd">67873</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LoansPayable contextRef="c318" decimals="0" id="ixv-47248" unitRef="usd">249975</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c319" decimals="0" id="ixv-47249" unitRef="usd">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RelatedPartyTransactionDate contextRef="c7" id="ixv-47250">2022-11-30</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionRate contextRef="c7" decimals="3" id="ixv-47251" unitRef="pure">0.065</us-gaap:RelatedPartyTransactionRate>
    <abvc:LoanAgreementAmount contextRef="c181" decimals="0" id="ixv-47252" unitRef="usd">507000</abvc:LoanAgreementAmount>
    <abvc:LoanAgreementAmount contextRef="c320" decimals="0" id="ixv-47253" unitRef="usd">88091</abvc:LoanAgreementAmount>
    <abvc:LoanAgreementAmount contextRef="c321" decimals="0" id="ixv-47254" unitRef="usd">25500</abvc:LoanAgreementAmount>
    <us-gaap:RelatedPartyTransactionRate contextRef="c7" decimals="3" id="ixv-47255" unitRef="pure">0.065</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c1" decimals="0" id="ixv-47256" unitRef="usd">681185</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c2" decimals="0" id="ixv-47257" unitRef="usd">158798</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:AccountsReceivableNet contextRef="c2" decimals="0" id="ixv-47258" unitRef="usd">839983</us-gaap:AccountsReceivableNet>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="c322" id="ixv-47260">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent contextRef="c1" decimals="0" id="ixv-47261" unitRef="twd">3941299</us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent contextRef="c323" decimals="0" id="ixv-47262" unitRef="usd">120210</us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent contextRef="c324" decimals="0" id="ixv-47263" unitRef="usd">113516</us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent>
    <abvc:RecognizedCreditLosses contextRef="c325" decimals="0" id="ixv-47264" unitRef="usd">120210</abvc:RecognizedCreditLosses>
    <abvc:ScheduleOfAmountDueToRelatedPartiesTableTextBlock contextRef="c7" id="ixv-29984">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amount due to related parties consisted of
the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;AiBtl Holding (1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;348,219&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Jiangs (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;274,170&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,789&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shareholders (3)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;142,130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;152,382&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Directors (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,526&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,322&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;773,045&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;173,493&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2024 and 2023, the outstanding balance due to the Jiangs amounted to $274,170 and $19,789, respectively. These loans bear no interest and are due on demand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2018, the Company&#x2019;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of December 31, 2024 and 2023, the outstanding principal and accrued interest was $172,112 and $152,382, respectively. Interest expenses in connection with these loans were $21,101 and $20,094 for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify; font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2024 and 2023, due to Directors amounted to $8,526 and $1,322, respectively, were related to the daily operating expenses in 2024 and entity setup fee in 2023 paid by the Directors of AiBtl on behalf of the entity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</abvc:ScheduleOfAmountDueToRelatedPartiesTableTextBlock>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c359"
      decimals="0"
      id="ix_53_fact"
      unitRef="usd">348219</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c361"
      decimals="0"
      id="ix_54_fact"
      unitRef="usd">274170</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c362"
      decimals="0"
      id="ix_55_fact"
      unitRef="usd">19789</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c363"
      decimals="0"
      id="ix_56_fact"
      unitRef="usd">142130</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c364"
      decimals="0"
      id="ix_57_fact"
      unitRef="usd">152382</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c365"
      decimals="0"
      id="ix_58_fact"
      unitRef="usd">8526</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c366"
      decimals="0"
      id="ix_59_fact"
      unitRef="usd">1322</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c356" decimals="0" id="ixv-47272" unitRef="usd">773045</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c324" decimals="0" id="ixv-47273" unitRef="usd">173493</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings contextRef="c326" decimals="0" id="ixv-47275" unitRef="usd">40000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c327" decimals="0" id="ixv-47276" unitRef="usd">60000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c328" decimals="0" id="ixv-47277" unitRef="usd">33732</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c329" decimals="0" id="ixv-47278" unitRef="usd">214487</us-gaap:ShortTermBorrowings>
    <abvc:OutstandingBalanceAmount contextRef="c1" decimals="0" id="ixv-47279" unitRef="usd">274170</abvc:OutstandingBalanceAmount>
    <abvc:OutstandingBalanceAmount contextRef="c2" decimals="0" id="ixv-47280" unitRef="usd">19789</abvc:OutstandingBalanceAmount>
    <us-gaap:AccountsPayableInterestBearingInterestRate contextRef="c97" decimals="2" id="ixv-47281" unitRef="pure">0.12</us-gaap:AccountsPayableInterestBearingInterestRate>
    <abvc:OutstandingPrincipalAmount contextRef="c1" decimals="0" id="ixv-47282" unitRef="usd">172112</abvc:OutstandingPrincipalAmount>
    <abvc:OutstandingPrincipalAmount contextRef="c2" decimals="0" id="ixv-47283" unitRef="usd">152382</abvc:OutstandingPrincipalAmount>
    <us-gaap:InterestExpenseOther contextRef="c330" decimals="0" id="ixv-47284" unitRef="usd">21101</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c331" decimals="0" id="ixv-47285" unitRef="usd">20094</us-gaap:InterestExpenseOther>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c332" decimals="0" id="ixv-47286" unitRef="usd">8526</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c333" decimals="0" id="ixv-47287" unitRef="usd">1322</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c7" id="ixv-30166">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;11. INCOME TAXES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Income tax
(benefit) expense for the years ended December 31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(110,539&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;140,338&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(110,539&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;140,338&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;115,668&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;115,668&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total provision for income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(110,539&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;256,006&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets (liability)
as of December 31, 2024 and 2023 consist approximately of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;713,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;713,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,677,413&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,018,343&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;178,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;213,482&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(178,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(213,482&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets, Gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,390,636&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,731,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,390,636&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,731,566&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-304"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-305"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c7" id="ixv-30171">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Income tax
(benefit) expense for the years ended December 31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(110,539&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;140,338&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(110,539&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;140,338&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;115,668&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;115,668&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total provision for income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(110,539&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;256,006&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-47288" unitRef="usd">-110539</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c8" decimals="0" id="ixv-47289" unitRef="usd">140338</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-47290" unitRef="usd">-110539</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c8" decimals="0" id="ixv-47291" unitRef="usd">140338</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c8" decimals="0" id="ixv-47292" unitRef="usd">115668</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c8" decimals="0" id="ixv-47293" unitRef="usd">115668</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-47294" unitRef="usd">-110539</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c8" decimals="0" id="ixv-47295" unitRef="usd">256006</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c7" id="ixv-30419">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets (liability)
as of December 31, 2024 and 2023 consist approximately of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;713,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;713,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,677,413&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,018,343&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;178,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;213,482&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(178,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(213,482&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets, Gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,390,636&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,731,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,390,636&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,731,566&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-304"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-305"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOther contextRef="c1" decimals="0" id="ixv-47296" unitRef="usd">-713223</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c2" decimals="0" id="ixv-47297" unitRef="usd">-713223</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c1" decimals="0" id="ixv-47298" unitRef="usd">5677413</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c2" decimals="0" id="ixv-47299" unitRef="usd">5018343</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <abvc:OperatingLeaseLiabilities contextRef="c1" decimals="0" id="ixv-47300" unitRef="usd">-178014</abvc:OperatingLeaseLiabilities>
    <abvc:OperatingLeaseLiabilities contextRef="c2" decimals="0" id="ixv-47301" unitRef="usd">-213482</abvc:OperatingLeaseLiabilities>
    <abvc:DeferredTaxAssetsOperatingLeaseAssets contextRef="c1" decimals="0" id="ixv-47302" unitRef="usd">-178014</abvc:DeferredTaxAssetsOperatingLeaseAssets>
    <abvc:DeferredTaxAssetsOperatingLeaseAssets contextRef="c2" decimals="0" id="ixv-47303" unitRef="usd">-213482</abvc:DeferredTaxAssetsOperatingLeaseAssets>
    <us-gaap:DeferredTaxAssetsGross contextRef="c1" decimals="0" id="ixv-47304" unitRef="usd">6390636</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="0" id="ixv-47305" unitRef="usd">5731566</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="0" id="ixv-47306" unitRef="usd">6390636</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="0" id="ixv-47307" unitRef="usd">5731566</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c7" id="ixv-30594">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;12. EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company previously reported that during
the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp;amp; Finance Corp Ltd. (a related
party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related
party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to
the agreements, the Company issued 644,972 shares of the Company&#x2019;s common stock for the consulting service from July 2019 to July
2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable. For the years ended December 31,
2024 (through June 30, 2024) and 2023, stock subscription receivable recognized as stock-based compensation in equity was $451,480 and
$902,960, respectively.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;After further reviewed and investigation,
above services were completely provided by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with
the period when services are received. Therefore, the Company reversed share-based compensation expenses of $451,480 and $902,960 for
the years ended December 31, 2024 and 2023, respectively. The accumulated deficit as of December 31, 2022 was corrected with the Stock
Subscription Receivables for $1,354,440 as a result of such adjustments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 3, 2023, the Company issued&#160;22,341&#160;common
stock (post-split) to a consultant for providing consulting services on listing to NASDAQ in 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 27, 2023, the Company entered into
that certain securities purchase agreement. relating to the offer and sale of 30,000 shares of common stock (post-split) and 20,000 pre-funded
warrants (post-split), at an exercise price of $0.001 per share, in a registered direct offering. Pursuant to the Purchase Agreement,
the Company agreed to sell the Shares and/or Pre-funded Warrants at a per share purchase price of $3.50, for gross proceeds of $1,750,000,
before deducting any estimated offering expenses. On August 1, 2023, 200,000&#160;pre-funded warrants were exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On August 14, 2023, the Company entered into
a cooperation agreement with Zhonghui. Pursuant thereto, the Company expect to receive 20% of the ownership of a property and the parcel
of the land owned by Zhonghui in Leshan, Sichuan, China. During the third quarter of 2023, the Company issued to Zhonghui, an aggregate
of 370,000 shares (post-split) of the Company&#x2019;s common stock, at a per share price of $1.87, for $691,900.&#160;The Company also
issued 29,600 common stock to consultants for providing consulting services on the above transaction. Please refer Note 2 for the restatement
of prior year reported amounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 27, 2024, the Company granted 1,302,726
restricted shares to its employees and directors under the 2016 Equity Incentive Plan as compensation for their previous services, with
an issuance date of February 2, 2024. These shares are subject to a three-year restriction period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 6, 2024, the Company entered into
a definitive agreement with Shuling Jiang (&#x201c;Shuling&#x201d;), pursuant to which Shuling shall transfer the ownership of certain
land she owns located at Taoyuan City, Taiwan (the &#x201c;Land&#x201d;) to the Company (the &#x201c;Agreement&#x201d;). Shuling is a director
of the Company, is married to TS Jiang, the Company&#x2019;s Chief Strategic Officer and owns approximately 15.4% of the Company&#x2019;s
issued and outstanding shares of common stock. In consideration for the Land, the Company was to pay Shuling (i) 703,496 restricted shares
of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;) at a price of $3.50 per share and (ii) five-year warrants to purchase
up to 1,000,000 shares of the Company&#x2019;s common stock, with an exercise price of $2.00 per share. Under the Agreement, Shuling was
to also transfer outstanding liability owed on the Land (approximately $500,000) to the Company. On May 16, 2024, the Company&#x2019;s
board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not
proceed with the transfer of land ownership; the Company may reconsider the transaction at a later date. The shares were returned and
booked as treasury stock, and the warrants were not issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 24, 2024, the Company issued 200,000
shares of common stock to a consultant for providing business and funding opportunities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In June 2024, the Company entered into a stock
purchase agreement with an investor, which the Company issued 41,387 shares of common stock at $0.75 per share to the investor for cash.
Due to certain stock transfer processes, one of the Company&#x2019;s shareholders transferred such shares to the investor on behalf of
the company in July 2024; the company plans to issue the same number of shares to the transferring shareholder soon.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In July 2024, the Company entered into an
agreement with its landlord in California, pursuant that the Company will make the rent payments in the Company&#x2019;s common stocks.
As of December 31, 2024, the Company has issued 399,384 shares with average issuance price of $0.68 per share, for the monthly rent from
April 2024 and half month of December 2024, in total of $271,827. The Company subsequently issued 80,654 shares of its common stock for
each of the half month rent in the first quarter of 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;AiBtl was incorporated
in January 2023 and issued &lt;span style="-sec-ix-hidden: hidden-fact-310"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-311"&gt;20,000,000&lt;/span&gt;&lt;/span&gt; shares of its common stocks to the founding shareholder AiBtl Holding with the par value $0.0001,
for $2,000 at the time of incorporation. Due to certain administrative process, the previous issuance was not correctly and timely recorded
at AiBtl&#x2019;s book which resulted in the correction of the previous reported non-controlling interest equity balance. Later in December
2023, AiBtl issued 23,000,000 shares to ABVC and 23,000,000 shares to BioLite, respectively, as a consideration for the Company&#x2019;s
out-licensing products, as disclosed in Note 4. At the close of the transaction, AiBtl became the Company&#x2019;s 60.70% owned subsidiary
included in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On March 14, 2024, AiBtl issued 1,610,700
AiBtl&#x2019;s common stocks to a land acquisition transaction in Taiwan, including the 1-year business consulting fee of $383,500 incurred
beginning in November 2023, and the cost of land $7,670,000. Due to certain administrative processes and restrictions, AiBtl has not
acquired ownership of the land and no asset was recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Yunzhiyi, a Taiwan corporation, was incorporated
in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, the Company&#x2019;s director. This entity is set up
for holding the land that AiBtl acquired in Taiwan for developing health related business in Taiwan. Due to certain administrative processes
and restrictions, the title transfer has not completed, and no asset was recognized as of the issuance of this report. However, AiBtl
entered a series of agreements with the sellers in March 2025, to obtain the complete rights and obligations of the land while in the
process of transferring the title. These agreements are effective until the tile transfer is completed. AiBtl recognized such asset on
its balance sheet in March 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Lind Offerings and Repayments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 23, 2023, in connection with the
issuance of the Lind Note (referring to Note 7), the Company issued Lind a 5-year term of common stock purchase warrant to purchase up
to 529,167 shares (post-split) of the Company&#x2019;s common stock at an initial exercise price of $10.5 per share (post-split), subject
to adjustment. The warrant exercise price was reset to $3.5 in accordance with the issuance of common stock in relation to securities
purchase agreement in July 2023. On May 22, 2024, the exercise price of these warrants was further reset to $0.75 along with the immediate
exercise of existing warrants and issuance of the New Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the years ended December 31, 2024 and
2023, the Company has made repayment of Lind Note with the Company&#x2019;s common stock for 1,705,303 shares and 3,732,167 shares, respectively,
totaling $593,714 and $1,786,686, respectively. As of December 31, 2024, the first Lind Note was fully repaid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 17, 2023, in connection with the
issuance of the 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note (referring to Note 7), Lind also received a 5-year term of common stock purchase warrants to
purchase up to 1,000,000 shares of the Company&#x2019;s common stock at an initial exercise price of $2 per share. The warrants were valued
using the Black-Scholes model and the fair value was determined to be $480,795, which was recorded as a debt discount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 17, 2024, in connection with the
issuance of the 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note (referring to Note 7), Lind also received 5-year term of common stock purchase warrants to purchase
up to 1,000,000 shares of the Company&#x2019;s common stock at an initial exercise price of $2 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 22, 2024, the Company and Lind entered
into a letter agreement, pursuant to which Lind will exercise, for cash, 1,000,000 of its Pre-Existing Warrants (all of the warrants
issued to Lind on February 23, 2023, November 17, 2023 and January 17, 2024 are hereinafter referred to as the &#x201c;Pre-Existing Warrants&#x201d;),
to purchase shares of Common Stock at a reduced exercise price of $0.75 per share. Such 1,000,000 Pre-Existing Warrants exercised include
529,167 warrants issued in February 2023 and 470,833 warrants issued in November 2023. Concurrently, the exercise price of all Pre-Existing
Warrants was reduced to $0.75 per share according to this agreement. Lind also received new warrants to purchase 1,000,000 shares of
common stock, exercisable at any time on or after the date of its issuance and until the five-year anniversary thereof, for $1.00 per
share (the &#x201c;New Warrants&#x201d;). The fair value of the New Warrants was determined to be $925,210 using the Black-Scholes model.
The New Warrants may be exercised via cashless exercise or resale pursuant to the registration statement that was declared effective.
As of December 31, 2024, Lind has exercised 1,000,000 shares of Pre-Existing Warrants and received 1,000,000 shares of New Warrants according
to this agreement. All warrants issued to Lind may be exercised via cashless exercise.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the year ended December 31, 2024, the
Company issued Lind in total of 800,000 shares of the Company&#x2019;s common stock as the repayment of $800,000 principal of 2&lt;sup&gt;nd&lt;/sup&gt;
Lind Note. According to the amended agreement pursuant to Nasdaq requirements, the conversion price is subject to $1.00 floor price if
the conversion price was below such floor, resulting in effective conversion price between $0.7907 to $0.4932. The Company made additional
$327,017 cash repayments, with $127,759 unpaid cash booked in Accrued Expenses and Other Current Liabilities. As of the date of this
report, Lind has converted the remaining &lt;span style="-sec-ix-hidden: hidden-fact-309"&gt;$400,000&lt;/span&gt; principal balance on 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note into 400,000 shares of the Company&#x2019;s
common stocks.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Subsequent to December 31, 2024 through the
date of this report, Lind has converted $400,000 of 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note principal balance into 400,000 the Company&#x2019;s common
stock, leaving outstanding principal of $600,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants issued and outstanding in connection
with above Lind convertible notes as of December 31, 2024, and their activities during the year ended are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; Underlying&lt;br/&gt; Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;br/&gt; Per Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; Remaining&lt;br/&gt; in Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 52%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding as of January 1, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,529,167&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.40&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.15&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,542&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,000,000&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.70&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.22&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;190,000&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,500,000&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-306"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-307"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-308"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,029,167&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.70&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.20&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;195,542&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#x201c;December Letter Agreement&#x201d;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c367"
      decimals="0"
      id="ixv-47308"
      unitRef="shares">644972</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c367" decimals="0" id="ixv-47309" unitRef="usd">4514800</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c368" decimals="0" id="ixv-47310" unitRef="usd">451480</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c369" decimals="0" id="ixv-47311" unitRef="usd">902960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="0" id="ixv-47312" unitRef="usd">451480</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c8" decimals="0" id="ixv-47313" unitRef="usd">902960</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c10" decimals="0" id="ixv-47314" unitRef="usd">1354440</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:CommonStockSharesIssued
      contextRef="c370"
      decimals="0"
      id="ixv-47315"
      unitRef="shares">22341</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c371"
      decimals="0"
      id="ixv-47316"
      unitRef="shares">30000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c372"
      decimals="0"
      id="ixv-47317"
      unitRef="shares">20000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c373"
      decimals="3"
      id="ixv-47318"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c374"
      decimals="2"
      id="ixv-47319"
      unitRef="usdPershares">3.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c375" decimals="0" id="ixv-47320" unitRef="usd">1750000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c376"
      decimals="0"
      id="ixv-47321"
      unitRef="shares">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="c377"
      decimals="2"
      id="ixv-47322"
      unitRef="pure">0.20</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <abvc:AggregateCommonStockShares
      contextRef="c378"
      decimals="0"
      id="ixv-47323"
      unitRef="shares">370000</abvc:AggregateCommonStockShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c379"
      decimals="2"
      id="ixv-47324"
      unitRef="usdPershares">1.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c378" decimals="0" id="ixv-47325" unitRef="usd">691900</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c377"
      decimals="0"
      id="ixv-47326"
      unitRef="shares">29600</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c380"
      decimals="0"
      id="ixv-47327"
      unitRef="shares">1302726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c381"
      decimals="3"
      id="ixv-47328"
      unitRef="pure">0.154</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AssetConsiderationCommonStock
      contextRef="c382"
      decimals="0"
      id="ixv-47329"
      unitRef="shares">703496</abvc:AssetConsiderationCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c383"
      decimals="2"
      id="ixv-47330"
      unitRef="usdPershares">3.5</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c384"
      decimals="0"
      id="ixv-47331"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c385"
      decimals="2"
      id="ixv-47332"
      unitRef="usdPershares">2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <abvc:OutstandingLiabilityOwnedAmount contextRef="c386" decimals="0" id="ixv-47333" unitRef="usd">500000</abvc:OutstandingLiabilityOwnedAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="c387"
      decimals="0"
      id="ixv-47334"
      unitRef="shares">200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c388"
      decimals="0"
      id="ixv-47335"
      unitRef="shares">41387</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c388"
      decimals="2"
      id="ixv-47336"
      unitRef="usdPershares">0.75</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c7"
      decimals="0"
      id="ixv-47337"
      unitRef="shares">399384</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:AverageIssuancePricePerShare
      contextRef="c7"
      decimals="2"
      id="ixv-47338"
      unitRef="usdPershares">0.68</abvc:AverageIssuancePricePerShare>
    <us-gaap:PaymentsForRent contextRef="c7" decimals="0" id="ixv-47339" unitRef="usd">271827</us-gaap:PaymentsForRent>
    <abvc:CommonStockSharesIssuedForRent
      contextRef="c389"
      decimals="0"
      id="ixv-47340"
      unitRef="shares">80654</abvc:CommonStockSharesIssuedForRent>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c392"
      decimals="0"
      id="ixv-47341"
      unitRef="shares">20000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c393"
      decimals="4"
      id="ixv-47342"
      unitRef="usdPershares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:Cash contextRef="c394" decimals="0" id="ixv-47343" unitRef="usd">2000</us-gaap:Cash>
    <abvc:NonControllingInterestConsiderationShare
      contextRef="c395"
      decimals="0"
      id="ixv-47344"
      unitRef="shares">23000000</abvc:NonControllingInterestConsiderationShare>
    <abvc:NonControllingInterestConsiderationShare
      contextRef="c396"
      decimals="0"
      id="ixv-47345"
      unitRef="shares">23000000</abvc:NonControllingInterestConsiderationShare>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c397"
      decimals="4"
      id="ixv-47346"
      unitRef="pure">0.607</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:CommonStockSharesIssued
      contextRef="c398"
      decimals="0"
      id="ixv-47347"
      unitRef="shares">1610700</us-gaap:CommonStockSharesIssued>
    <abvc:ConsultingFee contextRef="c399" decimals="0" id="ixv-47348" unitRef="usd">383500</abvc:ConsultingFee>
    <us-gaap:Land contextRef="c400" decimals="0" id="ixv-47349" unitRef="usd">7670000</us-gaap:Land>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c401"
      decimals="2"
      id="ixv-47350"
      unitRef="pure">0.90</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c402"
      decimals="2"
      id="ixv-47351"
      unitRef="pure">0.10</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <abvc:PurchaseWarrantTerm contextRef="c403" id="ixv-47352">P5Y</abvc:PurchaseWarrantTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c404"
      decimals="0"
      id="ixv-47353"
      unitRef="shares">529167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c405"
      decimals="1"
      id="ixv-47354"
      unitRef="usdPershares">10.5</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c406"
      decimals="1"
      id="ixv-47355"
      unitRef="usdPershares">3.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c407"
      decimals="2"
      id="ixv-47356"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceIncrease>
    <abvc:StockIssueDuringPeriodCommonShares
      contextRef="c7"
      decimals="0"
      id="ixv-47357"
      unitRef="shares">1705303</abvc:StockIssueDuringPeriodCommonShares>
    <abvc:StockIssueDuringPeriodCommonShares
      contextRef="c8"
      decimals="0"
      id="ixv-47358"
      unitRef="shares">3732167</abvc:StockIssueDuringPeriodCommonShares>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c45" decimals="0" id="ixv-47359" unitRef="usd">593714</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c29" decimals="0" id="ixv-47360" unitRef="usd">1786686</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:CreditDerivativeTerm1 contextRef="c250" id="ixv-47361">P5Y</us-gaap:CreditDerivativeTerm1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c408"
      decimals="0"
      id="ixv-47362"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c250"
      decimals="0"
      id="ixv-47363"
      unitRef="usdPershares">2</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c250" decimals="0" id="ixv-47364" unitRef="usd">480795</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:CreditDerivativeTerm1 contextRef="c257" id="ixv-47365">P5Y</us-gaap:CreditDerivativeTerm1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c409"
      decimals="0"
      id="ixv-47366"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c409"
      decimals="0"
      id="ixv-47367"
      unitRef="usdPershares">2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c410"
      decimals="0"
      id="ixv-47368"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c411"
      decimals="2"
      id="ixv-47369"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c407"
      decimals="0"
      id="ixv-47370"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c412"
      decimals="0"
      id="ixv-47371"
      unitRef="shares">529167</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c413"
      decimals="0"
      id="ixv-47372"
      unitRef="shares">470833</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c407"
      decimals="2"
      id="ixv-47373"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c414"
      decimals="0"
      id="ixv-47374"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c415"
      decimals="2"
      id="ixv-47375"
      unitRef="usdPershares">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c407" decimals="0" id="ixv-47376" unitRef="usd">925210</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c416"
      decimals="0"
      id="ixv-47377"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c417"
      decimals="0"
      id="ixv-47378"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockSharesIssued
      contextRef="c418"
      decimals="0"
      id="ixv-47379"
      unitRef="shares">800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock contextRef="c7" decimals="0" id="ixv-47380" unitRef="usd">800000</us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c419"
      decimals="2"
      id="ixv-47381"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c97"
      decimals="4"
      id="ixv-47382"
      unitRef="usdPershares">0.7907</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c96"
      decimals="4"
      id="ixv-47383"
      unitRef="usdPershares">0.4932</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c7" decimals="0" id="ixv-47384" unitRef="usd">327017</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c243" decimals="0" id="ixv-47385" unitRef="usd">127759</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c420"
      decimals="0"
      id="ixv-47386"
      unitRef="shares">2</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c420"
      decimals="0"
      id="ixv-47387"
      unitRef="usdPershares">400000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c273" decimals="0" id="ixv-47388" unitRef="usd">400000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c273"
      decimals="0"
      id="ixv-47389"
      unitRef="shares">400000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c45" decimals="0" id="ixv-47390" unitRef="usd">600000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c7" id="ixv-30723">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants issued and outstanding in connection
with above Lind convertible notes as of December 31, 2024, and their activities during the year ended are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; Underlying&lt;br/&gt; Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;br/&gt; Per Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; Remaining&lt;br/&gt; in Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 52%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding as of January 1, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,529,167&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.40&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.15&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,542&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,000,000&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.70&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.22&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;190,000&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,500,000&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-306"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-307"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-308"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,029,167&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.70&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.20&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;195,542&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#x201c;December Letter Agreement&#x201d;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-47391"
      unitRef="shares">1529167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-47392"
      unitRef="usdPershares">0.4</abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c424" id="ixv-30797">P3Y1M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c2" decimals="0" id="ixv-47393" unitRef="usd">5542</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued
      contextRef="c7"
      decimals="INF"
      id="ixv-47394"
      unitRef="shares">2000000</abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-47395"
      unitRef="usdPershares">0.7</abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm contextRef="c7" id="ixv-30833">P4Y2M19D</abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue contextRef="c7" decimals="0" id="ixv-47396" unitRef="usd">190000</abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c7"
      decimals="INF"
      id="ixv-47397"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-47398"
      unitRef="shares">2029167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ix_60_fact"
      unitRef="usdPershares">0.7</abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c7" id="ixv-30907">P4Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c1" decimals="0" id="ixv-47400" unitRef="usd">195542</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c421"
      decimals="0"
      id="ixv-47401"
      unitRef="shares">1029167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c422"
      decimals="2"
      id="ixv-47402"
      unitRef="usdPershares">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c423"
      decimals="2"
      id="ixv-47403"
      unitRef="usdPershares">0.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c7" id="ixv-30943">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;13. STOCK OPTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has not granted any options during
years ended December 31, 2024 and 2023. The Company&#x2019;s most recent option grant was in 2022 that 76,190&#160;shares (post-split)
of common stock were granted to employees and certain consultants.&#160;The weighted average grant date fair value of options granted
in 2022 was $27.9 (post-split). There are 386,021&#160;options available for grant under the 2016 Equity Incentive Plan as of December
31, 2024. Compensation costs associated with the Company&#x2019;s stock options are recognized, based on the grant-date fair values of
these options over vesting period. As of December 31, 2024 and 2023, there were no unvested options.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options issued and outstanding as of December
31, 2024, and their activities during the year then ended are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Contractual&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Underlying&lt;br/&gt; Shares&lt;br/&gt; (post-split)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;br/&gt; Per&#160;Share (post-split)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Life&lt;br/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Remaining&lt;br/&gt; in Years&lt;/span&gt;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 52%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding as of January 1, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258,710&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27.9&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.74&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-312"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-313"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-314"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-315"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-316"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-317"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-318"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-319"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-320"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258,710&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27.9&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.74&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-321"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258,710&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27.9&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.74&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-322"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258,710&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27.9&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.74&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-323"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c425"
      decimals="0"
      id="ixv-47404"
      unitRef="shares">76190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c425"
      decimals="1"
      id="ixv-47405"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c426"
      decimals="0"
      id="ixv-47406"
      unitRef="shares">386021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c7" id="ixv-30952">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options issued and outstanding as of December
31, 2024, and their activities during the year then ended are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Contractual&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Underlying&lt;br/&gt; Shares&lt;br/&gt; (post-split)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;br/&gt; Per&#160;Share (post-split)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Life&lt;br/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Remaining&lt;br/&gt; in Years&lt;/span&gt;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 52%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding as of January 1, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258,710&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27.9&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.74&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-312"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-313"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-314"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-315"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-316"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-317"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-318"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-319"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-320"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258,710&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27.9&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.74&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-321"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258,710&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27.9&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.74&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-322"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258,710&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27.9&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.74&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-323"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c427"
      decimals="INF"
      id="ixv-47407"
      unitRef="shares">258710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c427"
      decimals="1"
      id="ixv-47408"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c428" id="ixv-31106">P7Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-47409"
      unitRef="shares">258710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="1"
      id="ixv-47410"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c7" id="ixv-31221">P7Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-47411"
      unitRef="shares">258710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c1"
      decimals="1"
      id="ixv-47412"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c7" id="ixv-31258">P7Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-47413"
      unitRef="shares">258710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="1"
      id="ixv-47414"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c7" id="ixv-31295">P6Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c7" id="ixv-31312">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;14. LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic loss per share is computed by dividing
net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the years ended December
31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net loss attributable to ABVC&#x2019;s
    common stockholders&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,902,878&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,788,050&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted-average shares outstanding &#x2013;  Basic
    &amp;amp; Diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,673,980&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,335,650&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss per share&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-Basic &amp;amp; Diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(0.42&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Diluted loss per share takes into account
the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common
Stock. Since the Company suffered net loss for both years, any diluted shares would have anti-diluted effect.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c7" id="ixv-47415">Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the years ended December
31, 2024 and 2023.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net loss attributable to ABVC&#x2019;s
    common stockholders&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,902,878&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,788,050&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted-average shares outstanding &#x2013;  Basic
    &amp;amp; Diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,673,980&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,335,650&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss per share&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-Basic &amp;amp; Diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(0.42&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-47416" unitRef="usd">-4902878</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="0" id="ixv-47417" unitRef="usd">-7788050</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-47418"
      unitRef="shares">11673980</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ixv-47419"
      unitRef="shares">11673980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-47420"
      unitRef="shares">4335650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c8"
      decimals="INF"
      id="ixv-47421"
      unitRef="shares">4335650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-47422"
      unitRef="usdPershares">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-47423"
      unitRef="usdPershares">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c8"
      decimals="2"
      id="ixv-47424"
      unitRef="usdPershares">-1.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c8"
      decimals="2"
      id="ixv-47425"
      unitRef="usdPershares">-1.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c7" id="ixv-31538">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;15. LEASE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#x201c;ASC 842&#x201d;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company applied the following practical
expedients in the transition to the new standard and allowed under ASC 842:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reassessment of expired
    or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained
    leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing
    leases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of hindsight: The
    Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease
    and to purchase the underlying asset) and in assessing impairment of right-to-use assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reassessment of existing
    or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted
    for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will
    be evaluated under ASU No. 2016-02.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Separation of lease
    and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term lease recognition
    exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities
    for leases with a term less than 12 months.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities. ROU assets represent the
Company&#x2019;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#x2019;s obligation to
make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#x2019;s future minimum based payments used
to determine the Company&#x2019;s lease liabilities mainly include minimum based rent payments. As most of Company&#x2019;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognized lease liabilities,
with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has no finance leases. The Company&#x2019;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#x2019;s operating leases have remaining lease terms of up to approximately five years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#x202f;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;640,387&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;809,283&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities (current)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;403,581&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;401,826&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;236,807&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;407,457&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Supplemental Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following provides details of the Company&#x2019;s
lease expenses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;514,420&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;358,576&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other information related to leases is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;484,181&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;358,576&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted Average Remaining Lease Term:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.48 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.73 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted Average Discount Rate:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating&lt;br/&gt;
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;409,587&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;104,236&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,320&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,320&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,320&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-324"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;655,782&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(15,395&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;640,387&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="c7" id="ixv-31609">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has no finance leases. The Company&#x2019;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#x2019;s operating leases have remaining lease terms of up to approximately five years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#x202f;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;640,387&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;809,283&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities (current)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;403,581&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;401,826&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;236,807&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;407,457&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" id="ixv-47426" unitRef="usd">640387</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-47427" unitRef="usd">809283</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-47428" unitRef="usd">403581</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-47429" unitRef="usd">401826</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-47430" unitRef="usd">236807</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-47431" unitRef="usd">407457</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c7" id="ixv-31744">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following provides details of the Company&#x2019;s
lease expenses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;514,420&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;358,576&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other information related to leases is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;484,181&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;358,576&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted Average Remaining Lease Term:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.48 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.73 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted Average Discount Rate:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c7" decimals="0" id="ixv-47432" unitRef="usd">514420</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c8" decimals="0" id="ixv-47433" unitRef="usd">358576</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c429" decimals="0" id="ixv-47434" unitRef="usd">484181</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c430" decimals="0" id="ixv-47435" unitRef="usd">358576</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1" id="ixv-47436">P2Y5M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-47437">P1Y8M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c1" decimals="4" id="ixv-47438" unitRef="pure">0.0119</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="4" id="ixv-47439" unitRef="pure">0.015</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c7" id="ixv-31958">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating&lt;br/&gt;
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;409,587&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;104,236&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,320&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,320&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,320&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-324"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;655,782&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(15,395&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;640,387&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c1" decimals="0" id="ixv-47440" unitRef="usd">409587</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c1" decimals="0" id="ixv-47441" unitRef="usd">104236</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c1" decimals="0" id="ixv-47442" unitRef="usd">47320</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c1" decimals="0" id="ixv-47443" unitRef="usd">47320</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c1" decimals="0" id="ixv-47444" unitRef="usd">47320</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c1" decimals="0" id="ixv-47445" unitRef="usd">655782</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c1" decimals="0" id="ixv-47446" unitRef="usd">15395</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c1" decimals="0" id="ixv-47447" unitRef="usd">640387</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c7" id="ixv-32089">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;16. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of December 31, 2024 and up through the date
of the consolidated financial statements was available to the issued.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AssetAcquisitionTextBlock contextRef="c7" id="ixv-32100">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;17. ACQUISITION&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 12, 2023, the Company and one
of its subsidiaries, BioLite, Inc. (&#x201c;BioLite Taiwan&#x201d;)&#160; each entered into a multi-year, global licensing agreement with
AiBtl BioPharma Inc. (&#x201c;AiBtl&#x201d;, or the acquired company) for the Company and BioLite Taiwan&#x2019;s CNS drugs with the indications
of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the &#x201c;Licensed Products&#x201d;).
The potential license will cover the Licensed Products&#x2019; clinical trial, registration, manufacturing, supply, and distribution rights.
The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen
new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the
respective agreements, each of ABVC and BioLite Taiwan received 23 million shares of AiBtl stock and as a result, the Company has a controlling
interest over AiBtl. If certain milestones are met, the Company and BioLite Taiwan are each eligible to receive $3,500,000 and royalties
equaling 5% of net sales, up to $100 million.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company concluded the assets acquired
and liabilities assumed did not meet the definition of a business as a limited number of inputs were acquired but no substantive business
processes or signs of output were acquired. As such, the acquisition was accounted for as an asset purchase. The purchase consideration
was nonmonetary assets (patent) and transfer on November12, 2023. The equity interest transferred to ABVC and BioLite Taiwan on December
15, 2023.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;S&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-325"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-326"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(243,888&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to Director&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(498&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total liabilities acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(243,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total consideration (Intangible assets)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-327"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AssetAcquisitionTextBlock>
    <abvc:SharesReceived
      contextRef="c431"
      decimals="-6"
      id="ixv-47448"
      unitRef="shares">23000000</abvc:SharesReceived>
    <abvc:BenefitsReceivableForMilestoneAttained contextRef="c432" decimals="0" id="ixv-47449" unitRef="usd">3500000</abvc:BenefitsReceivableForMilestoneAttained>
    <abvc:royaltiesPercentage
      contextRef="c431"
      decimals="2"
      id="ixv-47450"
      unitRef="pure">0.05</abvc:royaltiesPercentage>
    <abvc:AcquisitionForNetSales
      contextRef="c431"
      decimals="-6"
      id="ixv-47451"
      unitRef="usd">100000000</abvc:AcquisitionForNetSales>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c7" id="ixv-47452">The equity interest transferred to ABVC and BioLite Taiwan on December
15, 2023.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;S&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-325"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-326"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(243,888&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to Director&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(498&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total liabilities acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(243,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total consideration (Intangible assets)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-327"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities contextRef="c433" decimals="0" id="ixv-47453" unitRef="usd">-243888</abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="c433" decimals="0" id="ixv-47454" unitRef="usd">498</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c433" decimals="0" id="ixv-47455" unitRef="usd">-243386</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:SubsequentEventsTextBlock contextRef="c7" id="ixv-32188">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;18. SUBSEQUENT EVENTS&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 5, 2025, the Company and Lind entered
into a third letter agreement (the &#x201c;December Letter Agreement&#x201d;), pursuant to which Lind agreed to exercise for cash, 1,029,167
of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise
price of $0.40 per share.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the first quarter of 2025, Lind has
converted the remaining $400,000 principal balance on 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note into 400,000 shares of the Company&#x2019;s common stocks,
and converted $400,000 of 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note principal balance into 400,000 the Company&#x2019;s common stock, leaving 3&lt;sup&gt;rd&lt;/sup&gt;
Lind Note with outstanding principal of $600,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In April 2025, the Company conducted a private
offering of its common stock to several individual investors, issuing 502,081 unregistered shares at $0.60 per share, raising a total
of $301,250.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In April 2025, AiBtl issued 1,800 shares of
its common stock at $5 per share, raising a total of $9,000 from an individual investor.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c434"
      decimals="0"
      id="ixv-47456"
      unitRef="shares">1029167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c434"
      decimals="2"
      id="ixv-47457"
      unitRef="usdPershares">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c435"
      decimals="2"
      id="ixv-47458"
      unitRef="usdPershares">0.4</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="c436" decimals="0" id="ixv-47459" unitRef="usd">400000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c436"
      decimals="0"
      id="ixv-47460"
      unitRef="shares">400000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="c437" decimals="0" id="ixv-47461" unitRef="usd">400000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c437"
      decimals="0"
      id="ixv-47462"
      unitRef="shares">400000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="c389" decimals="0" id="ixv-47463" unitRef="usd">600000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c438"
      decimals="0"
      id="ixv-47464"
      unitRef="shares">502081</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:UnregisteredPricePerShares
      contextRef="c439"
      decimals="2"
      id="ixv-47465"
      unitRef="usdPershares">0.6</abvc:UnregisteredPricePerShares>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c438" decimals="0" id="ixv-47466" unitRef="usd">301250</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c440"
      decimals="0"
      id="ixv-47467"
      unitRef="shares">1800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c441"
      decimals="0"
      id="ixv-47468"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromContributedCapital contextRef="c440" decimals="0" id="ixv-47469" unitRef="usd">9000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c5" decimals="0" id="ixv-47470" unitRef="usd">152206</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c1" decimals="0" id="ixv-47471" unitRef="usd">248382</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c5" decimals="0" id="ixv-47472" unitRef="usd">607362</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c1" decimals="0" id="ixv-47473" unitRef="usd">615433</us-gaap:RestrictedCashCurrent>
    <us-gaap:InventoryNet contextRef="c5" decimals="0" id="ixv-47474" unitRef="usd">11460</us-gaap:InventoryNet>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c6" decimals="0" id="ixv-47475" unitRef="usd">537119</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="0" id="ixv-47476" unitRef="usd">1155051</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ShortTermInvestments contextRef="c5" decimals="0" id="ixv-47477" unitRef="usd">65052</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c1" decimals="0" id="ixv-47478" unitRef="usd">64736</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c5" decimals="0" id="ixv-47479" unitRef="usd">96362</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-47480" unitRef="usd">96213</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="0" id="ixv-47481" unitRef="usd">1469561</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" id="ixv-47482" unitRef="usd">2179815</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="0" id="ixv-47483" unitRef="usd">8168746</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" id="ixv-47484" unitRef="usd">511088</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="0" id="ixv-47485" unitRef="usd">533460</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" id="ixv-47486" unitRef="usd">640387</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments contextRef="c5" decimals="0" id="ixv-47487" unitRef="usd">2760062</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c1" decimals="0" id="ixv-47488" unitRef="usd">2258754</us-gaap:LongTermInvestments>
    <abvc:PrepaymentForLongtermInvestmentsNoncurrent contextRef="c5" decimals="0" id="ixv-47489" unitRef="usd">1124842</abvc:PrepaymentForLongtermInvestmentsNoncurrent>
    <abvc:PrepaymentForLongtermInvestmentsNoncurrent contextRef="c1" decimals="0" id="ixv-47490" unitRef="usd">1124842</abvc:PrepaymentForLongtermInvestmentsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c5" decimals="0" id="ixv-47491" unitRef="usd">691900</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c1" decimals="0" id="ixv-47492" unitRef="usd">691900</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c5" decimals="0" id="ixv-47493" unitRef="usd">127128</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="0" id="ixv-47494" unitRef="usd">133121</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c5" decimals="0" id="ixv-47495" unitRef="usd">14875699</us-gaap:Assets>
    <us-gaap:Assets contextRef="c1" decimals="0" id="ixv-47496" unitRef="usd">7539907</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings contextRef="c5" decimals="0" id="ixv-47497" unitRef="usd">801407</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c1" decimals="0" id="ixv-47498" unitRef="usd">840252</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-47499" unitRef="usd">3826819</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-47500" unitRef="usd">3509422</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c5" decimals="0" id="ixv-47501" unitRef="usd">81115</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c1" decimals="0" id="ixv-47502" unitRef="usd">81115</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="0" id="ixv-47503" unitRef="usd">366475</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-47504" unitRef="usd">403581</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c6" decimals="0" id="ixv-47505" unitRef="usd">819384</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-47506" unitRef="usd">773045</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c6" decimals="0" id="ixv-47507" unitRef="usd">835539</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c3" decimals="0" id="ixv-47508" unitRef="usd">950046</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-47509" unitRef="usd">6730739</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-47510" unitRef="usd">6557461</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecurityDepositLiability contextRef="c5" decimals="0" id="ixv-47511" unitRef="usd">21680</us-gaap:SecurityDepositLiability>
    <us-gaap:SecurityDepositLiability contextRef="c1" decimals="0" id="ixv-47512" unitRef="usd">21680</us-gaap:SecurityDepositLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="0" id="ixv-47513" unitRef="usd">166985</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-47514" unitRef="usd">236807</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c5" decimals="0" id="ixv-47515" unitRef="usd">6919404</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c1" decimals="0" id="ixv-47516" unitRef="usd">6815948</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c5"
      decimals="3"
      id="ixv-47517"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="ixv-47518"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c5"
      decimals="0"
      id="ixv-47519"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ixv-47520"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c5"
      decimals="3"
      id="ixv-47521"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="ixv-47522"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="0"
      id="ixv-47523"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ixv-47524"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="0"
      id="ixv-47525"
      unitRef="shares">15378305</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-47526"
      unitRef="shares">15378305</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="0"
      id="ixv-47527"
      unitRef="shares">13868484</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="0"
      id="ixv-47528"
      unitRef="shares">13868484</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c5" decimals="0" id="ixv-47529" unitRef="usd">15378</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" id="ixv-47530" unitRef="usd">13868</us-gaap:CommonStockValue>
    <abvc:StockSubscriptionReceivedInAdvance contextRef="c5" decimals="0" id="ixv-47531" unitRef="usd">31040</abvc:StockSubscriptionReceivedInAdvance>
    <abvc:StockSubscriptionReceivedInAdvance contextRef="c1" decimals="0" id="ixv-47532" unitRef="usd">31040</abvc:StockSubscriptionReceivedInAdvance>
    <us-gaap:AdditionalPaidInCapital contextRef="c5" decimals="0" id="ixv-47533" unitRef="usd">83615369</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" id="ixv-47534" unitRef="usd">78595065</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c5" decimals="0" id="ixv-47535" unitRef="usd">-69791882</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" id="ixv-47536" unitRef="usd">-68949807</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c5" decimals="0" id="ixv-47537" unitRef="usd">444172</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="0" id="ixv-47538" unitRef="usd">445665</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue contextRef="c5" decimals="0" id="ixv-47539" unitRef="usd">8909691</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c1" decimals="0" id="ixv-47540" unitRef="usd">8909691</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="0" id="ixv-47541" unitRef="usd">5404386</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" id="ixv-47542" unitRef="usd">1226140</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c5" decimals="0" id="ixv-47543" unitRef="usd">2551909</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c1" decimals="0" id="ixv-47544" unitRef="usd">-502181</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="0" id="ixv-47545" unitRef="usd">7956295</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-47546" unitRef="usd">723959</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="0" id="ixv-47547" unitRef="usd">14875699</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" id="ixv-47548" unitRef="usd">7539907</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c9" decimals="0" id="ixv-47549" unitRef="usd">1205</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c9" decimals="0" id="ixv-47550" unitRef="usd">277</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c9" decimals="0" id="ixv-47551" unitRef="usd">928</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-47552" unitRef="usd">615371</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c9" decimals="0" id="ixv-47553" unitRef="usd">738486</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-47554" unitRef="usd">28861</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c9" decimals="0" id="ixv-47555" unitRef="usd">69066</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-47556" unitRef="usd">48773</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c9" decimals="0" id="ixv-47557" unitRef="usd">2031631</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-47558" unitRef="usd">693005</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c9" decimals="0" id="ixv-47559" unitRef="usd">2839183</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-47560" unitRef="usd">-693005</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c9" decimals="0" id="ixv-47561" unitRef="usd">-2838255</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="0" id="ixv-47562" unitRef="usd">19071</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c9" decimals="0" id="ixv-47563" unitRef="usd">4049</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c0" decimals="0" id="ixv-47564" unitRef="usd">222967</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c9" decimals="0" id="ixv-47565" unitRef="usd">181676</us-gaap:InterestExpenseNonoperating>
    <us-gaap:SubleaseIncome contextRef="c0" decimals="0" id="ixv-47566" unitRef="usd">12000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c9" decimals="0" id="ixv-47567" unitRef="usd">8000</us-gaap:SubleaseIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c0" decimals="0" id="ixv-47568" unitRef="usd">-9912</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c9" decimals="0" id="ixv-47569" unitRef="usd">60730</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnInvestments contextRef="c0" decimals="0" id="ixv-47570" unitRef="usd">-50877</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-47571" unitRef="usd">1500</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c9" decimals="0" id="ixv-47572" unitRef="usd">19485</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-47573" unitRef="usd">-251185</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c9" decimals="0" id="ixv-47574" unitRef="usd">-89412</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-47575" unitRef="usd">-944190</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c9" decimals="0" id="ixv-47576" unitRef="usd">-2927667</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-47577" unitRef="usd">-944190</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c9" decimals="0" id="ixv-47578" unitRef="usd">-2927667</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-47579" unitRef="usd">-102115</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c9" decimals="0" id="ixv-47580" unitRef="usd">-93468</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-47581" unitRef="usd">-842075</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c9" decimals="0" id="ixv-47582" unitRef="usd">-2834199</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" id="ixv-47583" unitRef="usd">-1493</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c9" decimals="0" id="ixv-47584" unitRef="usd">-48236</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" id="ixv-47585" unitRef="usd">-843568</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c9" decimals="0" id="ixv-47586" unitRef="usd">-2882435</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-47587"
      unitRef="usdPershares">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-47588"
      unitRef="usdPershares">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c9"
      decimals="2"
      id="ixv-47589"
      unitRef="usdPershares">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c9"
      decimals="2"
      id="ixv-47590"
      unitRef="usdPershares">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-47591"
      unitRef="shares">14968232</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-47592"
      unitRef="shares">14968232</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-47593"
      unitRef="shares">9736150</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c9"
      decimals="INF"
      id="ixv-47594"
      unitRef="shares">9736150</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-47595" unitRef="usd">-944190</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c9" decimals="0" id="ixv-47596" unitRef="usd">-2927667</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-47597" unitRef="usd">7021</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c9" decimals="0" id="ixv-47598" unitRef="usd">1286</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-47599" unitRef="usd">48773</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c9" decimals="0" id="ixv-47600" unitRef="usd">2031631</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="0" id="ixv-47601" unitRef="usd">-210040</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c9" decimals="0" id="ixv-47602" unitRef="usd">-176283</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:GainLossOnInvestments contextRef="c0" decimals="0" id="ixv-47603" unitRef="usd">-50877</us-gaap:GainLossOnInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="0" id="ixv-47604" unitRef="usd">106927</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c9" decimals="0" id="ixv-47605" unitRef="usd">101260</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-47606" unitRef="usd">11460</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c0" decimals="0" id="ixv-47607" unitRef="usd">149</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c9" decimals="0" id="ixv-47608" unitRef="usd">53380</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c0" decimals="0" id="ixv-47609" unitRef="usd">-54113</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c9" decimals="0" id="ixv-47610" unitRef="usd">140364</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="c0" decimals="0" id="ixv-47611" unitRef="usd">5029</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="0" id="ixv-47612" unitRef="usd">40113</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c9" decimals="0" id="ixv-47613" unitRef="usd">-43605</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-47614" unitRef="usd">-106927</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c9" decimals="0" id="ixv-47615" unitRef="usd">-101260</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-47616" unitRef="usd">-539833</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c9" decimals="0" id="ixv-47617" unitRef="usd">-955816</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c9" decimals="0" id="ixv-47618" unitRef="usd">30000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c0" decimals="0" id="ixv-47619" unitRef="usd">29250</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c9" decimals="0" id="ixv-47620" unitRef="usd">394071</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="0" id="ixv-47621" unitRef="usd">411667</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c9" decimals="0" id="ixv-47622" unitRef="usd">282095</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c0" decimals="0" id="ixv-47623" unitRef="usd">46339</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c9" decimals="0" id="ixv-47624" unitRef="usd">217981</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-47625" unitRef="usd">428756</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c9" decimals="0" id="ixv-47626" unitRef="usd">924147</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" id="ixv-47627" unitRef="usd">6830</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c9" decimals="0" id="ixv-47628" unitRef="usd">-26109</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-47629" unitRef="usd">-104247</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c9" decimals="0" id="ixv-47630" unitRef="usd">-57778</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="0" id="ixv-47631" unitRef="usd">863815</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-47632" unitRef="usd">716780</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="0" id="ixv-47633" unitRef="usd">759568</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c11" decimals="0" id="ixv-47634" unitRef="usd">659002</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-47635" unitRef="usd">5231</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c9" decimals="0" id="ixv-47636" unitRef="usd">5701</us-gaap:InterestPaidNet>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c0" decimals="0" id="ixv-47637" unitRef="usd">7670000</us-gaap:FairValueOfAssetsAcquired>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c0" decimals="0" id="ixv-47638" unitRef="usd">47579</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c9" decimals="0" id="ixv-47639" unitRef="usd">467574</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c0" decimals="0" id="ixv-47640" unitRef="usd">563819</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:SharesOutstanding
      contextRef="c37"
      decimals="INF"
      id="ixv-47641"
      unitRef="shares">7940298</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c37" decimals="0" id="ixv-47642" unitRef="usd">7940</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c40" decimals="0" id="ixv-47643" unitRef="usd">73978380</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c41" decimals="0" id="ixv-47644" unitRef="usd">-64046929</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c42" decimals="0" id="ixv-47645" unitRef="usd">516387</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c43"
      decimals="INF"
      id="ixv-47646"
      unitRef="shares">-26553</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c43" decimals="0" id="ixv-47647" unitRef="usd">-8901668</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c44" decimals="0" id="ixv-47648" unitRef="usd">-300637</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-47649" unitRef="usd">1253473</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abvc:IssuanceOfCommonShareForLindCNRepayment
      contextRef="c61"
      decimals="INF"
      id="ixv-47650"
      unitRef="shares">751795</abvc:IssuanceOfCommonShareForLindCNRepayment>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN contextRef="c61" decimals="0" id="ixv-47651" unitRef="usd">752</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN contextRef="c63" decimals="0" id="ixv-47652" unitRef="usd">466822</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN contextRef="c9" decimals="0" id="ixv-47653" unitRef="usd">467574</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c63" decimals="0" id="ixv-47654" unitRef="usd">394071</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c9" decimals="0" id="ixv-47655" unitRef="usd">394071</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c61"
      decimals="INF"
      id="ixv-47656"
      unitRef="shares">703496</abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty contextRef="c61" decimals="0" id="ixv-47657" unitRef="usd">703</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty>
    <abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty
      contextRef="c66"
      decimals="INF"
      id="ixv-47658"
      unitRef="shares">-703496</abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty contextRef="c66" decimals="0" id="ixv-47659" unitRef="usd">-703</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c61"
      decimals="INF"
      id="ixv-47660"
      unitRef="shares">1302726</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c61" decimals="0" id="ixv-47661" unitRef="usd">1303</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c63" decimals="0" id="ixv-47662" unitRef="usd">1934452</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c9" decimals="0" id="ixv-47663" unitRef="usd">1935755</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService contextRef="c63" decimals="0" id="ixv-47664" unitRef="usd">225690</abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService contextRef="c67" decimals="0" id="ixv-47665" unitRef="usd">157810</abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService contextRef="c9" decimals="0" id="ixv-47666" unitRef="usd">383500</abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c63" decimals="0" id="ixv-47667" unitRef="usd">4786</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c67" decimals="0" id="ixv-47668" unitRef="usd">-4786</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:ProfitLoss contextRef="c64" decimals="0" id="ixv-47669" unitRef="usd">-2834199</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c67" decimals="0" id="ixv-47670" unitRef="usd">-93468</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c9" decimals="0" id="ixv-47671" unitRef="usd">-2927667</us-gaap:ProfitLoss>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="c65" decimals="0" id="ixv-47672" unitRef="usd">-48236</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="c9" decimals="0" id="ixv-47673" unitRef="usd">-48236</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="c68"
      decimals="INF"
      id="ixv-47674"
      unitRef="shares">10698315</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c68" decimals="0" id="ixv-47675" unitRef="usd">10698</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c70" decimals="0" id="ixv-47676" unitRef="usd">77004201</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c71" decimals="0" id="ixv-47677" unitRef="usd">-66881128</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c72" decimals="0" id="ixv-47678" unitRef="usd">468151</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c73"
      decimals="INF"
      id="ixv-47679"
      unitRef="shares">-730049</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c73" decimals="0" id="ixv-47680" unitRef="usd">-8902371</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c74" decimals="0" id="ixv-47681" unitRef="usd">-241081</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-47682" unitRef="usd">1458470</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c53"
      decimals="INF"
      id="ixv-47683"
      unitRef="shares">13868484</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c53" decimals="0" id="ixv-47684" unitRef="usd">13868</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c54" decimals="0" id="ixv-47685" unitRef="usd">31040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c56" decimals="0" id="ixv-47686" unitRef="usd">78595065</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c57" decimals="0" id="ixv-47687" unitRef="usd">-68949807</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c58" decimals="0" id="ixv-47688" unitRef="usd">445665</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c59"
      decimals="INF"
      id="ixv-47689"
      unitRef="shares">-730641</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c59" decimals="0" id="ixv-47690" unitRef="usd">-8909691</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c60" decimals="0" id="ixv-47691" unitRef="usd">-502181</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-47692" unitRef="usd">723959</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abvc:IssuanceOfCommonShareForLindCNRepayment
      contextRef="c75"
      decimals="INF"
      id="ixv-47693"
      unitRef="shares">400000</abvc:IssuanceOfCommonShareForLindCNRepayment>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN contextRef="c75" decimals="0" id="ixv-47694" unitRef="usd">400</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN contextRef="c76" decimals="0" id="ixv-47695" unitRef="usd">47179</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN contextRef="c0" decimals="0" id="ixv-47696" unitRef="usd">47579</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN>
    <abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants
      contextRef="c75"
      decimals="INF"
      id="ixv-47697"
      unitRef="shares">1029167</abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants contextRef="c75" decimals="0" id="ixv-47698" unitRef="usd">1029</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants contextRef="c76" decimals="0" id="ixv-47699" unitRef="usd">410638</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants contextRef="c0" decimals="0" id="ixv-47700" unitRef="usd">411667</abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c75"
      decimals="INF"
      id="ixv-47701"
      unitRef="shares">80654</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c75" decimals="0" id="ixv-47702" unitRef="usd">81</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c76" decimals="0" id="ixv-47703" unitRef="usd">48692</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="0" id="ixv-47704" unitRef="usd">48773</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c76" decimals="0" id="ixv-47705" unitRef="usd">4513795</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c77" decimals="0" id="ixv-47706" unitRef="usd">3156205</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c0" decimals="0" id="ixv-47707" unitRef="usd">7670000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:ProfitLoss contextRef="c78" decimals="0" id="ixv-47708" unitRef="usd">-842075</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c77" decimals="0" id="ixv-47709" unitRef="usd">-102115</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-47710" unitRef="usd">-944190</us-gaap:ProfitLoss>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="c79" decimals="0" id="ixv-47711" unitRef="usd">-1493</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="c0" decimals="0" id="ixv-47712" unitRef="usd">-1493</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="c80"
      decimals="INF"
      id="ixv-47713"
      unitRef="shares">15378305</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c80" decimals="0" id="ixv-47714" unitRef="usd">15378</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c81" decimals="0" id="ixv-47715" unitRef="usd">31040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c82" decimals="0" id="ixv-47716" unitRef="usd">83615369</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c83" decimals="0" id="ixv-47717" unitRef="usd">-69791882</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c84" decimals="0" id="ixv-47718" unitRef="usd">444172</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c85"
      decimals="INF"
      id="ixv-47719"
      unitRef="shares">-730641</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c85" decimals="0" id="ixv-47720" unitRef="usd">-8909691</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c86" decimals="0" id="ixv-47721" unitRef="usd">2551909</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="0" id="ixv-47722" unitRef="usd">7956295</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0" id="ixv-36885">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ABVC BioPharma, Inc. (the &#x201c;Company&#x201d;),
formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#x2019;s operating entity, American
BriVision Corporation (&#x201c;BriVision&#x201d;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology
to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops
its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision
believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization,
BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly
respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical
trials for the Company&#x2019;s drugs and medical devices are being conducted at such world-famous institutions including Stanford University,
University of California San Fransisco (UCSF) and Cedar Sinai Medical Centre (CSMC).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has four wholly-owned subsidiaries,
BriVision, BioLite Holding Inc. (&#x201c;BioLite Holding&#x201d;), BioKey Inc. (&#x201c;BioKey&#x201d;), BioKey (Cayman), Inc (&#x201c;BioKey
Cayman&#x201d;), and a majority-owned subsidiary, AiBtl BioPharma Inc. (&#x201c;AiBtl&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioLite Holding was incorporated in the State
of Nevada with wholly owned subsidiary BioLite BVI, Inc. (&#x201c;BioLite BVI&#x201d;) that was incorporated in the British Virgin Islands.
BioLite BVI holds 73% ownership of BioLite Inc. (&#x201c;BioLite Taiwan&#x201d;), a Taiwanese corporation that was founded in February
2006. BioLite Taiwan has been in the business of developing new drugs since it was incorporated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Yunzhiyi, a Taiwanese corporation, was incorporated
in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, the Company&#x2019;s director. This entity is set up
for holding the land that AiBtl is working to acquire in Puli, Taiwan for developing health related business in Taiwan.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Incorporated in California on November 20,
2000, BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioKey Cayman was incorporated in Cayman Islands
in July 2023, which is 100% owned by ABVC. This subsidiary has no activities since inception.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;AiBtl BioPharma, Inc. was acquired by the
Company with the transaction of the collaborative licensing agreements. On November 12, 2023, the Company and BioLite Taiwan each entered
into a multi-year, global licensing agreement with AiBtl for the Company and BioLite Taiwan&#x2019;s CNS drugs with the indications of
MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the &#x201c;Licensed Products&#x201d;).
The potential license will cover the Licensed Products&#x2019; clinical trial, registration, manufacturing, supply, and distribution rights.
The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen
new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the
respective agreements, each of ABVC and BioLite Taiwan received 23 million shares of AiBtl stock and as a result, the Company has a controlling
interest over AiBtl. If certain milestones are met, the Company and BioLite Taiwan are each eligible to receive $3,500,000 and royalties
equaling 5% of net sales, up to $100 million. The financial statements of AiBtl are included in the Company&#x2019;s consolidated financial
statements. As a result of these transactions, the Company became a controlling parent of AiBtl, with 58.85% of group ownership over
AiBtl.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c442" id="ixv-47723">British Virgin Islands</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c442"
      decimals="2"
      id="ixv-47724"
      unitRef="pure">0.73</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c443"
      decimals="2"
      id="ixv-47725"
      unitRef="pure">0.90</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c444"
      decimals="2"
      id="ixv-47726"
      unitRef="pure">0.10</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c445"
      decimals="2"
      id="ixv-47727"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c446"
      decimals="-6"
      id="ixv-47728"
      unitRef="shares">23000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:BenefitsReceivableForMilestoneAttained contextRef="c5" decimals="0" id="ixv-47729" unitRef="usd">3500000</abvc:BenefitsReceivableForMilestoneAttained>
    <abvc:PercentageOfRoyaltiesEqualing contextRef="c0" decimals="2" id="ixv-47730" unitRef="pure">0.05</abvc:PercentageOfRoyaltiesEqualing>
    <abvc:AcquisitionForNetSales contextRef="c0" decimals="-6" id="ixv-47731" unitRef="usd">100000000</abvc:AcquisitionForNetSales>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c447"
      decimals="4"
      id="ixv-47732"
      unitRef="pure">0.5885</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <abvc:LiquidityGoingConcernAndRestatementTextBlock contextRef="c0" id="ixv-36929">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;2. LIQUIDITY, GOING CONCERN, AND RESTATEMENT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The accompanying financial statements have
been prepared in conformity with the generally accepted accounting principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;)
which contemplates continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and
liabilities are settled in the ordinary course of business at amounts disclosed in the financial statements. The Company&#x2019;s ability
to continue as a going concern depends upon its ability to market and sell its products to generate positive operating cash flows. For
the three months ended March 31, 2025, the Company reported net loss of $944,190. As of March 31, 2025, the Company&#x2019;s working capital
deficit was $5,261,178.&#160; In addition, the Company had net cash outflows of $539,833&#160;from operating activities for the three
months ended March 31, 2025. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a
going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;To sustain its ability to support the Company&#x2019;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;cash
    generated from operations;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;other available sources
    of financing from banks and other financial institutions in the U.S. and in Taiwan; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;financial support from
    the Company&#x2019;s related parties and shareholders.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Management&#x2019;s plan is to continue to
improve operations to generate positive cash flows and raise additional capital through private or public offerings, or financial support
from related parties or shareholders. If the Company is not able to generate positive operating cash flows, and raise additional capital,
there is the risk that the Company may not be able to meet its short-term obligations. All of these factors raise substantial doubt about
the ability of the Company to continue as a going concern. The interim condensed consolidated financial statements as of March 31, 2025,
and for the three months ended March 31, 2025 and 2024 have been prepared on a going concern basis and do not include any adjustments
to reflect the possible future effects on the recoverability and classifications of assets or the amounts and classifications of liabilities
that may result from the inability of the Company to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Restatement Background and Explanation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has restated its financial statements
as of and for the year ended December 31, 2023, to correct misstatements in those prior periods related to improperly applying accounting
guidance on the share-based payments, incorrectly recognizing interest expenses upon the conversion of convertible debts, and misidentifying
the existence of non-controlling interest of our subsidiary. These restatements also resulted in the restatements of the relevant accounts
as of and for the three months ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As disclosed in Note 5, the Company entered
into a cooperation agreement on August 14, 2023 with Zhong Hui Lian He Ji Tuan, Ltd. (the &#x201c;Zhonghui&#x201d;) to acquire 20% of the
ownership of certain property and a parcel of the land. According to the agreement, the Company issued 370,000 shares of its common stock
as the consideration, and used $20 dollar per share to recognize the right as construction in progress on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the time of preparing its 2024 financial
statements, the Company reviewed the entire transaction, its relevant agreements and documentation, as well as the applicable accounting
guidance. The Company applied FASB Accounting Standard Codification (&#x201c;ASC&#x201d;) 845 Nonmonetary Transactions to determine the
fair value of the asset acquired would be more evident than the fair value of the consideration in exchange, the Company&#x2019;s restricted
common stocks. The real estates acquired comes with a third-party valuation of $7,400,000 per the Company&#x2019;s stake, which the value
of the acquired assets is guaranteed by Zhonghui. Upon further review, the Company considered ASC 718 Compensation &#x2013; Stock Compensation,
should have been the appropriate guidance to apply given the Company&#x2019;s common stocks are listed in Nasdaq with more observable
fair value (Level 1). Furthermore, at the time of issuance of these financial statements, no real estate title was transferred to the
Company. As a result, the Company adjusted the carrying value of the asset and reclassified the balance to &#x201c;Prepayment for asset
acquisition&#x201d; account to reflect the value of 370,000 shares issued at $1.87, the closing price as of the contract date. The Company
also corrected the share price used to recognize stock compensation expense from $20 to $1.87 for the 29,600 shares of common stock issued
on the same day to several consultants. As a result, these adjustments reduced $6,708,100 for asset recognized and $536,648 for stock-compensation
expense incurred in 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In February 2023, the Company issued a convertible
note to LIND Global Fund II, LP (Note 7). Due to misapplication of ASC 470-20 instead of ASC 815-40, the Company overstated interest
expenses $1,179,669 for the year ended December 31, 2023. The overstatement is offsetting against additional paid-in capital due to the
convertible note being converted to the Company&#x2019;s own common stocks instead of being repaid or disposition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In November 2023, the Company and one of its
subsidiaries entered into a licensing agreement with AiBtl. The Company accounted for a 100% control of AiBtl as of December 31, 2023,
but later discovered that AiBtl had outstanding founder shares that were not deposited to the stock transfer agent in the timely manner.
Such shares reduced the Company&#x2019;s controlling interest from 100% to 69.70% as of December 31, 2023. Accordingly, the Company adjusted
the relevant accounts in our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As discussed in Note 12, in July 2019 the
Company issued 644,972 shares (post-split) of the Company&#x2019;s common stock to four consultants for their services. Such stock-based
expenses were amortized over 5 years starting from the issuance date. Per the Company&#x2019;s further review, the services, along with
the agreements, were completed by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with the period
when services are received. Therefore, the Company reversed share-based compensation expenses of $451,480 and $902,960 for the years
ended December 31, 2024 and 2023, respectively. The accumulated deficit as of December 31, 2022 was corrected with the Stock Subscription
Receivables for $1,354,440 as a result of such adjustments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Please read the impacts of the 2023 restatement
in our audited 2024 consolidated financial statements filed in our Form 10-K with the SEC on April 15, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Impact of the Restatement to the March
31, 2024 interim financial statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the three months ended March 31, 2024 is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Unaudited
                                            Condensed&lt;/b&gt;&lt;/p&gt;
                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Balance Sheets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepaid expense and other current asset&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;159,602&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;223,707&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;383,309&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,949,150&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;549,150&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepayment for asset acquisition&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-328"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,460,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,484,392&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,976,010&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,050,845&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(605,178&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,445,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Convertible notes payable &#x2013; third parties, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;842,567&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;29,769&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;872,336&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;301,972&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;89,502&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;391,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,633,614&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(455,908&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,177,706&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,973,447&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(455,908&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,517,539&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;86,029,237&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(9,025,036&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;77,004,201&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,792,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,092,525&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,699,551&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(305,121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;64,040&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(241,081&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,486,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,028,485&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,458,470&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Liabilities and Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,460,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,484,393&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,976,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Unaudited
                                            Condensed&lt;/b&gt;&lt;/p&gt;
                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;831,257&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(92,771&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;738,486&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,544,995&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(513,364&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,031,631&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(684,683&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;503,007&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(181,676&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(48,043&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(45,425&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(93,468&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,981,019&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,053,352&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,927,667&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.11&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(0.29&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Unaudited Condensed&lt;/span&gt;&lt;/p&gt;
                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Statements
                                            of Cash Flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,981,019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,053,355&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,927,664&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,544,995&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(513,364&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,031,631&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other non-cash income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;672,016&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(495,736&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;176,280&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;354,465&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(398,070&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(43,605&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;128,840&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(128,840&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-329"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(602,001&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(353,815&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(955,816&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties*&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-330"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(217,981&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(217,981&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;805,006&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;119,141&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;924,147&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Effect of exchange rate changes on cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(260,783&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;234,674&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(26,109&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issuance of common stock for conversion of debt&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;681,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;213,426&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;467,574&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due to related parties previously reported amount was reclassified to financing activities based on current year&#x2019;s presentation.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</abvc:LiquidityGoingConcernAndRestatementTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="0" id="ixv-47733" unitRef="usd">944190</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <abvc:WorkingCapitalDeficit contextRef="c0" decimals="0" id="ixv-47734" unitRef="usd">5261178</abvc:WorkingCapitalDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-47735" unitRef="usd">-539833</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c92" decimals="2" id="ixv-47736" unitRef="pure">0.20</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c93"
      decimals="0"
      id="ixv-47737"
      unitRef="shares">370000</abvc:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c94"
      decimals="0"
      id="ixv-47738"
      unitRef="usdPershares">20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RealEstateOwnedValuationAllowance contextRef="c448" decimals="0" id="ixv-47739" unitRef="usd">7400000</us-gaap:RealEstateOwnedValuationAllowance>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c0"
      decimals="0"
      id="ixv-47740"
      unitRef="shares">370000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c5"
      decimals="2"
      id="ixv-47741"
      unitRef="usdPershares">1.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c449"
      decimals="0"
      id="ixv-47742"
      unitRef="usdPershares">20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c450"
      decimals="2"
      id="ixv-47743"
      unitRef="usdPershares">1.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c5"
      decimals="0"
      id="ixv-47744"
      unitRef="shares">29600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:Assets contextRef="c98" decimals="0" id="ixv-47745" unitRef="usd">-6708100</us-gaap:Assets>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c28" decimals="0" id="ixv-47746" unitRef="usd">536648</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:InterestExpenseOther contextRef="c28" decimals="0" id="ixv-47747" unitRef="usd">1179669</us-gaap:InterestExpenseOther>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c99" decimals="2" id="ixv-47748" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c451"
      decimals="2"
      id="ixv-47749"
      unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c452"
      decimals="4"
      id="ixv-47750"
      unitRef="pure">0.697</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c102"
      decimals="0"
      id="ixv-47751"
      unitRef="shares">644972</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <abvc:StockBasedExpensesAmortizationPeriod contextRef="c0" id="ixv-47752">P5Y</abvc:StockBasedExpensesAmortizationPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="0" id="ixv-47753" unitRef="usd">451480</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c8" decimals="0" id="ixv-47754" unitRef="usd">902960</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c10" decimals="0" id="ixv-47755" unitRef="usd">1354440</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="c0" id="ixv-37035">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the three months ended March 31, 2024 is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Unaudited
                                            Condensed&lt;/b&gt;&lt;/p&gt;
                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Balance Sheets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepaid expense and other current asset&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;159,602&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;223,707&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;383,309&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,949,150&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;549,150&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepayment for asset acquisition&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-328"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;691,900&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,460,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,484,392&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,976,010&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,050,845&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(605,178&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,445,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Convertible notes payable &#x2013; third parties, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;842,567&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;29,769&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;872,336&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;301,972&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;89,502&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;391,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,633,614&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(455,908&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,177,706&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,973,447&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(455,908&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,517,539&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;86,029,237&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(9,025,036&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;77,004,201&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,792,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,092,525&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,699,551&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(305,121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;64,040&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(241,081&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,486,955&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,028,485&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,458,470&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total Liabilities and Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,460,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,484,393&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,976,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Unaudited
                                            Condensed&lt;/b&gt;&lt;/p&gt;
                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;831,257&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(92,771&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;738,486&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,544,995&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(513,364&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,031,631&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(684,683&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;503,007&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(181,676&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(48,043&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(45,425&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(93,468&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,981,019&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,053,352&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,927,667&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.11&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(0.29&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Unaudited Condensed&lt;/span&gt;&lt;/p&gt;
                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Consolidated Statements
                                            of Cash Flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,981,019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,053,355&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,927,664&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,544,995&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(513,364&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,031,631&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other non-cash income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;672,016&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(495,736&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;176,280&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;354,465&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(398,070&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(43,605&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;128,840&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(128,840&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-329"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(602,001&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(353,815&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(955,816&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due to related parties*&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-330"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(217,981&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(217,981&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;805,006&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;119,141&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;924,147&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Effect of exchange rate changes on cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(260,783&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;234,674&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(26,109&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issuance of common stock for conversion of debt&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;681,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;213,426&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;467,574&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due to related parties previously reported amount was reclassified to financing activities based on current year&#x2019;s presentation.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c453" decimals="0" id="ixv-47756" unitRef="usd">159602</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c454" decimals="0" id="ixv-47757" unitRef="usd">223707</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c455" decimals="0" id="ixv-47758" unitRef="usd">383309</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ConstructionInProgressGross contextRef="c453" decimals="0" id="ixv-47759" unitRef="usd">7949150</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c454" decimals="0" id="ixv-47760" unitRef="usd">-7400000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c455" decimals="0" id="ixv-47761" unitRef="usd">549150</us-gaap:ConstructionInProgressGross>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c454" decimals="0" id="ixv-47762" unitRef="usd">691900</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c455" decimals="0" id="ixv-47763" unitRef="usd">691900</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c453" decimals="0" id="ixv-47764" unitRef="usd">14460402</us-gaap:Assets>
    <us-gaap:Assets contextRef="c454" decimals="0" id="ixv-47765" unitRef="usd">-6484392</us-gaap:Assets>
    <us-gaap:Assets contextRef="c455" decimals="0" id="ixv-47766" unitRef="usd">7976010</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c453" decimals="0" id="ixv-47767" unitRef="usd">4050845</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c454" decimals="0" id="ixv-47768" unitRef="usd">-605178</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c455" decimals="0" id="ixv-47769" unitRef="usd">3445667</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayable contextRef="c453" decimals="0" id="ixv-47770" unitRef="usd">842567</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="c454" decimals="0" id="ixv-47771" unitRef="usd">29769</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="c455" decimals="0" id="ixv-47772" unitRef="usd">872336</us-gaap:ConvertibleNotesPayable>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c456" decimals="0" id="ixv-47773" unitRef="usd">301972</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c457" decimals="0" id="ixv-47774" unitRef="usd">89502</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c458" decimals="0" id="ixv-47775" unitRef="usd">391474</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c453" decimals="0" id="ixv-47776" unitRef="usd">6633614</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c454" decimals="0" id="ixv-47777" unitRef="usd">-455908</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c455" decimals="0" id="ixv-47778" unitRef="usd">6177706</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities contextRef="c453" decimals="0" id="ixv-47779" unitRef="usd">6973447</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c454" decimals="0" id="ixv-47780" unitRef="usd">-455908</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c455" decimals="0" id="ixv-47781" unitRef="usd">6517539</us-gaap:Liabilities>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c453" decimals="0" id="ixv-47782" unitRef="usd">86029237</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c454" decimals="0" id="ixv-47783" unitRef="usd">-9025036</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c455" decimals="0" id="ixv-47784" unitRef="usd">77004201</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:StockholdersEquity contextRef="c453" decimals="0" id="ixv-47785" unitRef="usd">7792076</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c454" decimals="0" id="ixv-47786" unitRef="usd">-6092525</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c455" decimals="0" id="ixv-47787" unitRef="usd">1699551</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c453" decimals="0" id="ixv-47788" unitRef="usd">-305121</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c454" decimals="0" id="ixv-47789" unitRef="usd">64040</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c455" decimals="0" id="ixv-47790" unitRef="usd">-241081</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c453" decimals="0" id="ixv-47791" unitRef="usd">7486955</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c454" decimals="0" id="ixv-47792" unitRef="usd">-6028485</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c455" decimals="0" id="ixv-47793" unitRef="usd">1458470</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c453" decimals="0" id="ixv-47794" unitRef="usd">14460402</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c454" decimals="0" id="ixv-47795" unitRef="usd">-6484393</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c455" decimals="0" id="ixv-47796" unitRef="usd">7976009</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c459" decimals="0" id="ixv-47797" unitRef="usd">831257</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c460" decimals="0" id="ixv-47798" unitRef="usd">-92771</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c461" decimals="0" id="ixv-47799" unitRef="usd">738486</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ShareBasedCompensation contextRef="c459" decimals="0" id="ixv-47800" unitRef="usd">2544995</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c460" decimals="0" id="ixv-47801" unitRef="usd">-513364</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c461" decimals="0" id="ixv-47802" unitRef="usd">2031631</us-gaap:ShareBasedCompensation>
    <us-gaap:InterestExpense contextRef="c459" decimals="0" id="ixv-47803" unitRef="usd">684683</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c460" decimals="0" id="ixv-47804" unitRef="usd">-503007</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c461" decimals="0" id="ixv-47805" unitRef="usd">181676</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c459" decimals="0" id="ixv-47806" unitRef="usd">-48043</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c460" decimals="0" id="ixv-47807" unitRef="usd">-45425</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c461" decimals="0" id="ixv-47808" unitRef="usd">-93468</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c459" decimals="0" id="ixv-47809" unitRef="usd">-3981019</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c460" decimals="0" id="ixv-47810" unitRef="usd">1053352</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c461" decimals="0" id="ixv-47811" unitRef="usd">-2927667</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c459"
      decimals="2"
      id="ixv-47812"
      unitRef="usdPershares">-0.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c459"
      decimals="2"
      id="ixv-47813"
      unitRef="usdPershares">-0.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c460"
      decimals="2"
      id="ixv-47814"
      unitRef="usdPershares">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c460"
      decimals="2"
      id="ixv-47815"
      unitRef="usdPershares">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c461"
      decimals="2"
      id="ixv-47816"
      unitRef="usdPershares">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c461"
      decimals="2"
      id="ixv-47817"
      unitRef="usdPershares">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c459" decimals="0" id="ixv-47818" unitRef="usd">-3981019</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c460" decimals="0" id="ixv-47819" unitRef="usd">1053355</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c461" decimals="0" id="ixv-47820" unitRef="usd">-2927664</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ShareBasedCompensation contextRef="c459" decimals="0" id="ixv-47821" unitRef="usd">2544995</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c460" decimals="0" id="ixv-47822" unitRef="usd">-513364</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c461" decimals="0" id="ixv-47823" unitRef="usd">2031631</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c459" decimals="0" id="ixv-47824" unitRef="usd">-672016</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c460" decimals="0" id="ixv-47825" unitRef="usd">495736</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c461" decimals="0" id="ixv-47826" unitRef="usd">-176280</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c459" decimals="0" id="ixv-47827" unitRef="usd">354465</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c460" decimals="0" id="ixv-47828" unitRef="usd">-398070</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c461" decimals="0" id="ixv-47829" unitRef="usd">-43605</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c459" decimals="0" id="ixv-47830" unitRef="usd">128840</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c460" decimals="0" id="ixv-47831" unitRef="usd">-128840</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c459" decimals="0" id="ixv-47832" unitRef="usd">-602001</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c460" decimals="0" id="ixv-47833" unitRef="usd">-353815</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c461" decimals="0" id="ixv-47834" unitRef="usd">-955816</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c460"
      decimals="0"
      id="ix_61_fact"
      unitRef="usd">217981</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c461"
      decimals="0"
      id="ix_62_fact"
      unitRef="usd">217981</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c459" decimals="0" id="ixv-47837" unitRef="usd">805006</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c460" decimals="0" id="ixv-47838" unitRef="usd">119141</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c461" decimals="0" id="ixv-47839" unitRef="usd">924147</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash contextRef="c459" decimals="0" id="ixv-47840" unitRef="usd">-260783</abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash>
    <abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash contextRef="c460" decimals="0" id="ixv-47841" unitRef="usd">234674</abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash>
    <abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash contextRef="c461" decimals="0" id="ixv-47842" unitRef="usd">-26109</abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c459" decimals="0" id="ixv-47843" unitRef="usd">681000</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c460" decimals="0" id="ixv-47844" unitRef="usd">213426</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <abvc:IssuanceOfCommonStockForConversionOfDebt contextRef="c461" decimals="0" id="ixv-47845" unitRef="usd">467574</abvc:IssuanceOfCommonStockForConversionOfDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-38090">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration: none"&gt;The accompanying
unaudited interim condensed consolidated financial statements have been prepared in accordance with the generally accepted accounting
principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;). All significant intercompany transactions and account balances
have been eliminated. These financial statements do not include all the information and footnotes required by the U.S. GAAP for complete
financial statements. Certain information and note disclosures normally included in the annual financial statements prepared in accordance
with the U.S. GAAP have been condensed or omitted consistent with Article 8 of Regulation S-X. In the opinion of the Company&#x2019;s
management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial
statements and include all adjustments, in a normal recurring nature, as necessary for the fair statement of the Company&#x2019;s financial
position as of March 31, 2025, and results of operations and cash flows for the three months ended March 31, 2025 and 2024. The unaudited
interim condensed consolidated balance sheet as of March 31, 2025 has been derived from the audited financial statements at December
31, 2024, and interim results of operations are not necessarily indicative of the results expected for the full fiscal year or for any
future period. These financial statements should be read in conjunction with the audited consolidated financial statements as of and
for the years ended December 31, 2024 and 2023, and related notes included in the Company&#x2019;s audited consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration: none"&gt;This basis
of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses
and losses are recognized when incurred. The Company&#x2019;s unaudited financial statements are expressed in U.S. dollars.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Reclassifications&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration: none"&gt;Certain
amounts on the prior year&#x2019;s condensed consolidated balance sheets, condensed consolidated statements of operations and condensed
cash flows were reclassified to conform to the current-year presentation, with no effect on ending stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 820 &#x201c;Fair Value Measurements&#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#x2013;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#x2013;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#x2013;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $91,500 (NTD 3.0 million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $250,000 covered by the U.S. Federal Deposit Insurance Corporation&#x2019;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Concentration of Clients&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of March 31, 2025 and December 31, 2024,
management estimated all accounts receivable balances are uncollectible. Provision credit loss balances were $11,993 and $11,993 as of
March 31, 2025 and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the three months ended March 31, 2024,
the Company&#x2019;s revenue was generated from one customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of March 31, 2025 and December 31, 2024, the Company&#x2019;s
cash and cash equivalents amounted to $152,206 and $248,382, respectively. Some&#160;of the Company&#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Restricted Cash &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of March 31, 2025 and December 31, 2024, the Company&#x2019;s restricted cash amounted $607,362
(NTD 20.2 million) and $615,433 (NTD 20.2 million), respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Accounts receivable and allowance for expected credit losses
accounts&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounts receivable are recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company makes estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#x2019;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Allowance for expected credit losses accounts
were $616,397 and $616,414 as of March 31, 2025 and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;Collaborative Revenues &#x2014; &lt;/b&gt;The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s
judgment. Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(i) Non-refundable upfront payments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If a license to the Company&#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(ii) Milestone payments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative
agreement with collaboration partners.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(iii) Multiple Element Arrangements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(iv) Royalties and Profit Sharing Payments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp;amp; Manufacturing Organization Services (&#x201c;CDMO&#x201d;))&lt;/b&gt; &#x2014;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advances from customers upon receipt
or when due, and may require deferral of revenue recognition for a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#x201c;Compensation-Stock Compensation&#x201d;.
Total director, officer, and employee stock-based compensation expenses were $0 and $1,935,755 for the three months ended March 31, 2025
and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#x201c;Compensation-Stock Compensation&#x201d; and ASC 505-50 &#x201c;Equity-Based Payments
to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $48,773 for rent for the three months ended March 31, 2025, and $95,876&#160;for consulting services
for the three months ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has adopted ASC 450 &#x201c;Contingencies&#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in financial statements when
it is at least reasonably possible that a material loss could be incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Foreign-currency Transactions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Company&#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#x2019;
Equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 280 &#x201c;Segment Reporting&#x201d; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company currently has&#160;one&#160;reportable
segment, and assets are reviewed on a consolidated basis. As such, segmental data is not provided.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following tables present revenue and gross
profit information for each of our only reportable segment:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Three-Month&lt;br/&gt; Periods
    Ended&lt;br/&gt; March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;br/&gt; (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-331"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-332"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-333"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;928&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Three-Month&lt;br/&gt;
    Periods Ended&lt;br/&gt; March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;br/&gt;
    (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-334"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;928&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;615,371&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;738,486&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28,861&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;69,066&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48,773&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,031,631&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Add (Less):&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,071&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,049&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(222,967&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(181,676&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Gain (loss) on foreign exchange changes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(9,912&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,730&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on investment in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(50,877&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-335"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,485&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss before provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(944,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,927,667&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#x2019;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-38095">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration: none"&gt;The accompanying
unaudited interim condensed consolidated financial statements have been prepared in accordance with the generally accepted accounting
principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;). All significant intercompany transactions and account balances
have been eliminated. These financial statements do not include all the information and footnotes required by the U.S. GAAP for complete
financial statements. Certain information and note disclosures normally included in the annual financial statements prepared in accordance
with the U.S. GAAP have been condensed or omitted consistent with Article 8 of Regulation S-X. In the opinion of the Company&#x2019;s
management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial
statements and include all adjustments, in a normal recurring nature, as necessary for the fair statement of the Company&#x2019;s financial
position as of March 31, 2025, and results of operations and cash flows for the three months ended March 31, 2025 and 2024. The unaudited
interim condensed consolidated balance sheet as of March 31, 2025 has been derived from the audited financial statements at December
31, 2024, and interim results of operations are not necessarily indicative of the results expected for the full fiscal year or for any
future period. These financial statements should be read in conjunction with the audited consolidated financial statements as of and
for the years ended December 31, 2024 and 2023, and related notes included in the Company&#x2019;s audited consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration: none"&gt;This basis
of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses
and losses are recognized when incurred. The Company&#x2019;s unaudited financial statements are expressed in U.S. dollars.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0" id="ixv-38110">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Reclassifications&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration: none"&gt;Certain
amounts on the prior year&#x2019;s condensed consolidated balance sheets, condensed consolidated statements of operations and condensed
cash flows were reclassified to conform to the current-year presentation, with no effect on ending stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-38121">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-38131">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 820 &#x201c;Fair Value Measurements&#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#x2013;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#x2013;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#x2013;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-38191">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $91,500 (NTD 3.0 million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $250,000 covered by the U.S. Federal Deposit Insurance Corporation&#x2019;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InvestmentCompanyExcessExpenseReimbursable contextRef="c462" decimals="0" id="ixv-47846" unitRef="usd">91500</us-gaap:InvestmentCompanyExcessExpenseReimbursable>
    <us-gaap:InvestmentCompanyExcessExpenseReimbursable
      contextRef="c462"
      decimals="-5"
      id="ixv-47847"
      unitRef="twd">3000000</us-gaap:InvestmentCompanyExcessExpenseReimbursable>
    <us-gaap:InvestmentCompanyExcessExpenseReimbursable contextRef="c463" decimals="0" id="ixv-47848" unitRef="usd">250000</us-gaap:InvestmentCompanyExcessExpenseReimbursable>
    <abvc:ConcentrationOfClientsPolicyTextBlock contextRef="c0" id="ixv-38206">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Concentration of Clients&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of March 31, 2025 and December 31, 2024,
management estimated all accounts receivable balances are uncollectible. Provision credit loss balances were $11,993 and $11,993 as of
March 31, 2025 and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the three months ended March 31, 2024,
the Company&#x2019;s revenue was generated from one customer.&lt;/span&gt;&lt;/p&gt;</abvc:ConcentrationOfClientsPolicyTextBlock>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c0" decimals="0" id="ixv-47849" unitRef="usd">11993</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c7" decimals="0" id="ixv-47850" unitRef="usd">11993</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-38221">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of March 31, 2025 and December 31, 2024, the Company&#x2019;s
cash and cash equivalents amounted to $152,206 and $248,382, respectively. Some&#160;of the Company&#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="0" id="ixv-47851" unitRef="usd">152206</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" id="ixv-47852" unitRef="usd">248382</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0" id="ixv-38231">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Restricted Cash &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of March 31, 2025 and December 31, 2024, the Company&#x2019;s restricted cash amounted $607,362
(NTD 20.2 million) and $615,433 (NTD 20.2 million), respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashCurrent contextRef="c5" decimals="0" id="ixv-47853" unitRef="usd">607362</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCash contextRef="c5" decimals="-5" id="ixv-47854" unitRef="twd">20200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c1" decimals="-5" id="ixv-47855" unitRef="twd">20200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashCurrent contextRef="c1" decimals="0" id="ixv-47856" unitRef="usd">615433</us-gaap:RestrictedCashCurrent>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0" id="ixv-38241">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Accounts receivable and allowance for expected credit losses
accounts&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounts receivable are recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company makes estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#x2019;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Allowance for expected credit losses accounts
were $616,397 and $616,414 as of March 31, 2025 and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c5" decimals="0" id="ixv-47857" unitRef="usd">616397</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c1" decimals="0" id="ixv-47858" unitRef="usd">616414</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-38261">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;Collaborative Revenues &#x2014; &lt;/b&gt;The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s
judgment. Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(i) Non-refundable upfront payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If a license to the Company&#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(ii) Milestone payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative
agreement with collaboration partners.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(iii) Multiple Element Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(iv) Royalties and Profit Sharing Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp;amp; Manufacturing Organization Services (&#x201c;CDMO&#x201d;))&lt;/b&gt; &#x2014;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advances from customers upon receipt
or when due, and may require deferral of revenue recognition for a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-38404">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#x201c;Compensation-Stock Compensation&#x201d;.
Total director, officer, and employee stock-based compensation expenses were $0 and $1,935,755 for the three months ended March 31, 2025
and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#x201c;Compensation-Stock Compensation&#x201d; and ASC 505-50 &#x201c;Equity-Based Payments
to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $48,773 for rent for the three months ended March 31, 2025, and $95,876&#160;for consulting services
for the three months ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent contextRef="c5" decimals="0" id="ixv-47859" unitRef="usd">0</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent contextRef="c1" decimals="0" id="ixv-47860" unitRef="usd">1935755</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c464" decimals="0" id="ixv-47861" unitRef="usd">48773</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c465" decimals="0" id="ixv-47862" unitRef="usd">95876</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-38419">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has adopted ASC 450 &#x201c;Contingencies&#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in financial statements when
it is at least reasonably possible that a material loss could be incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-38429">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Foreign-currency Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Company&#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#x2019;
Equity.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-38440">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 280 &#x201c;Segment Reporting&#x201d; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company currently has&#160;one&#160;reportable
segment, and assets are reviewed on a consolidated basis. As such, segmental data is not provided.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following tables present revenue and gross
profit information for each of our only reportable segment:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Three-Month&lt;br/&gt; Periods
    Ended&lt;br/&gt; March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;br/&gt; (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-331"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-332"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-333"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;928&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Three-Month&lt;br/&gt;
    Periods Ended&lt;br/&gt; March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;br/&gt;
    (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-334"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;928&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;615,371&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;738,486&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28,861&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;69,066&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48,773&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,031,631&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Add (Less):&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,071&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,049&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(222,967&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(181,676&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Gain (loss) on foreign exchange changes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(9,912&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,730&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on investment in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(50,877&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-335"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,485&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss before provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(944,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,927,667&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" id="ixv-47863" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-38469">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following tables present revenue and gross
profit information for each of our only reportable segment:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Three-Month&lt;br/&gt; Periods
    Ended&lt;br/&gt; March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;br/&gt; (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-331"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cost of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-332"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-333"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;928&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c9" decimals="0" id="ixv-47864" unitRef="usd">1205</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c9" decimals="0" id="ixv-47865" unitRef="usd">277</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c9" decimals="0" id="ixv-47866" unitRef="usd">928</us-gaap:GrossProfit>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-47867" unitRef="usd">7021</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c9" decimals="0" id="ixv-47868" unitRef="usd">1286</us-gaap:Depreciation>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock contextRef="c0" id="ixv-38604">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For The Three-Month&lt;br/&gt;
    Periods Ended&lt;br/&gt; March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;br/&gt;
    (Restated)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Gross Profit (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-334"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;928&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;615,371&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;738,486&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28,861&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;69,066&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48,773&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,031,631&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Add (Less):&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,071&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,049&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(222,967&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(181,676&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Gain (loss) on foreign exchange changes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(9,912&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,730&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on investment in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(50,877&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-335"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,485&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss before provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(944,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,927,667&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <us-gaap:GrossProfit contextRef="c467" decimals="0" id="ixv-47869" unitRef="usd">928</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c466" decimals="0" id="ixv-47870" unitRef="usd">615371</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c467" decimals="0" id="ixv-47871" unitRef="usd">738486</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c466" decimals="0" id="ixv-47872" unitRef="usd">28861</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c467" decimals="0" id="ixv-47873" unitRef="usd">69066</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c466" decimals="0" id="ixv-47874" unitRef="usd">48773</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c467" decimals="0" id="ixv-47875" unitRef="usd">2031631</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="c466" decimals="0" id="ixv-47876" unitRef="usd">19071</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c467" decimals="0" id="ixv-47877" unitRef="usd">4049</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c466" decimals="0" id="ixv-47878" unitRef="usd">222967</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c467" decimals="0" id="ixv-47879" unitRef="usd">181676</us-gaap:InterestExpenseNonoperating>
    <us-gaap:SubleaseIncome contextRef="c466" decimals="0" id="ixv-47880" unitRef="usd">12000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c467" decimals="0" id="ixv-47881" unitRef="usd">8000</us-gaap:SubleaseIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c466" decimals="0" id="ixv-47882" unitRef="usd">-9912</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c467" decimals="0" id="ixv-47883" unitRef="usd">60730</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <abvc:WriteOffUnclaimedAccruedLiabilites contextRef="c466" decimals="0" id="ixv-47884" unitRef="usd">-50877</abvc:WriteOffUnclaimedAccruedLiabilites>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c466" decimals="0" id="ixv-47885" unitRef="usd">1500</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c467" decimals="0" id="ixv-47886" unitRef="usd">19485</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c466" decimals="0" id="ixv-47887" unitRef="usd">-944190</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c467" decimals="0" id="ixv-47888" unitRef="usd">-2927667</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-38909">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#x2019;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c0" id="ixv-38937">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;4. COLLABORATIVE AGREEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreements with BHK, a
related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 24, 2015,
    BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development
    Agreement&#x201d;), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple
    Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual
    property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be
    shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date
    of first commercial sale of the Product in in Asia excluding Japan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2015, BHK has paid a non-refundable
upfront cash payment of $1 million, or 10% of $10.0 million, upon the signing of BHK Co-Development Agreement. The Company concluded
that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis
and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in
2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative
agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement.
In August 2016, the Company received the second milestone payment of &lt;span style="-sec-ix-hidden: hidden-fact-336"&gt;NTD31,649,000&lt;/span&gt;, approximately equivalent to $1 million, and recognized
collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase
II clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on 12% of BHK&#x2019;s net sales related to BLI-1401-2 Products. As of March 31, 2025, the Company
has not earned the royalty under the BHK Co-Development Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#x201c;BHK Collaborative Agreements&#x201d;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#x201c;Targeting Major Depressive Disorder&#x201d; (BLI-1005 Products) and BLI-1006 for
&#x201c;Targeting Inflammatory Bowel Disease&#x201d; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property
rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50
between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial
sale of the Product in in Asia excluding Japan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In 2015, the Company recognized the cash receipt
in a total of &lt;span style="-sec-ix-hidden: hidden-fact-337"&gt;NTD50 million&lt;/span&gt;, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition to the total of &lt;span style="-sec-ix-hidden: hidden-fact-338"&gt;NTD50 million&lt;/span&gt;,
approximately equivalent to $1.6 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.
As of March 31, 2025, the Company has not earned the royalty under the BHK Collaborative Agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Co-Development agreement with Rgene
Corporation, a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 26, 2017, the Company through its subsidiary, BriVision, entered into a co-development agreement (the &#x201c;Co-Dev Agreement&#x201d;) with Rgene Corporation (the &#x201c;Rgene&#x201d;), a related party controlled by the controlling beneficiary shareholder of YuanGene Corporation (See Note 10). Pursuant to Co-Dev Agreement, the Company and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to&#160;pay the Company $3.0 million in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of the Company&#x2019;s past research efforts and contributions before the Co-Dev Agreement was signed and it does not relate to any future commitments made by the Company and Rgene in this Co-Dev Agreement. In addition to $3.0 million, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both the Company and Rgene.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 1, 2017, the Company has delivered
all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under control by
a controlling beneficiary shareholder of YuanGene Corporation and a director and officer of the Company, the Company has recorded the
full amount of $3.0 million in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31,
2017. During the year ended December 31, 2017, the Company received $450,000 in cash. On December 24, 2018, the Company received the
remaining balance of $2,550,000 in the form of newly issued shares of Rgene&#x2019;s Common Stock, at the price of &lt;span style="-sec-ix-hidden: hidden-fact-340"&gt;NTD50&lt;/span&gt; per share (approximately
equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as
of December 31, 2018. On December 31, 2018, the Company determined to fully write off this investment based on the Company&#x2019;s assessment
of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee,
adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional
funding requirements, and Rgene&#x2019;s ability to remain in business. All projects that have been initiated will be managed and supported
by the Company and Rgene.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company and Rgene signed an amendment
to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer
Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination
Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized.
Other provisions of the Co-Dev Agreement remain in full force and effect.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 10, 2022, the Company expanded its
co-development partnership with Rgene. On that date, BioKey, ABVC has entered into a Clinical Development Service Agreement with Rgene
to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic
cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under the U.S. FDA
IND regulatory requirements. Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $3.0 million
over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period.
The Service Agreement shall remain in effect until the expiration date of the last patent and automatically renew for 5 more years unless
terminated earlier by either party with six months&#x2019; written notice. Either party may terminate the Service Agreement for cause
by providing 30 days written notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Through a series of transactions over the
past 5 years, the Company and Rgene have co-developed the three drug products covered by the Service Agreement, which has resulted in
the Company owning 26.65% of Rgene.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As part of the Rgene Studies, the Company
agreed to loan $1.0 million and made $0.5 million to Rgene, for which Rgene has provided the Company with a 5% interest rate convertible
loan (the &#x201c;Note&#x201d;). If the Note is fully converted, the Company will own an additional 6.4% of Rgene. The Company is expected
to receive the outstanding loan from the related party by the first half of 2025, either by cash or conversion of shares of Rgene. The
Company may convert the Note at any time into shares of Rgene&#x2019;s common stock at either (i) a fixed conversion price equal to $1.00
per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject
to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to
which a breach of the Service Agreement will trigger an event of default under the Note if not cured after 5 business days of written
notice regarding the breach is provided. Upon an event of default, the outstanding principal and any accrued and unpaid interest shall
be immediately due and payable. The Note was fully converted to Rgene&#x2019;s common stocks in 2024. See Note 6 for details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Service Agreement shall remain in effect
until the expiration date of the last patent and automatically renew for 5 more years unless terminated earlier by either party with
six months&#x2019; written notice. Either party may terminate the Service Agreement for cause by providing 30 days written notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene has further agreed, effective July 1,
2022, to provide the Company with a seat on Rgene&#x2019;s Board of Directors until the loan is repaid in full. The Company has nominated
Dr. Jiang, its Chief Strategy Officer and Director to occupy that seat; Dr. Jiang is also one of the Company&#x2019;s director and officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Rgene Studies is a related party transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreement with BioFirst
Corporation, a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 24, 2017, the Company through its
subsidiary, BriVision, entered into a collaborative agreement (the &#x201c;BioFirst Collaborative Agreement&#x201d;) with BioFirst Corporation
(&#x201c;BioFirst&#x201d;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the
&#x201c;Product&#x201d;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling
beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and common stock shareholders of BioFirst (See
Note 10).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3.0 million in cash or
stock of the Company before September 30, 2018. The amount of $3.0 million is in connection with the compensation for BioFirst&#x2019;s
past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate
to any future commitments in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future
net licensing income or net sales profit, if any, and any development cost shall be equally shared by both the Company and BioFirst.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On September 25, 2017, BioFirst delivered
all research, technical, data and development data to the Company. The Company determined to fully expense the entire amount of $3.0
million since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative
future uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses immediately. Hence, the entire amount of $3.0 million is fully expensed as research and development expense during the year
ended December 31, 2017.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 30, 2019, BriVision entered into a
Stock Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued
&lt;span style="-sec-ix-hidden: hidden-fact-339"&gt;42,857 shares&lt;/span&gt; (post-split) of the Company&#x2019;s common stock to BioFirst in consideration for $3.0 million owed by the Company to BioFirst
(the &#x201c;Total Payment&#x201d;) in connection with BioFirst Collaborative Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On August 5, 2019, BriVision entered into
a second Stock Purchase Agreement (&#x201c;Purchase Agreement 2&#x201d;) with BioFirst. Pursuant to Purchase Agreement 2, the Company issued
41,470 shares (post-split) of the Company&#x2019;s common stock to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst
in connection with a loan provided to BriVision from BioFirst.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 4, 2020, the Company executed
an amendment to the BioFirst Collaborative Agreement to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal Storage Solution
to the agreement. ABV-2002 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while ABV-2001 has
broader utilization during a variety of ocular procedures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Initially the Company will focus on ABV-2002,
a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial
keratoplasty (back layer cornea transplant). ABV-2002 is a solution comprised of a specific poly amino acid that protects ocular tissue
from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity
to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration
results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant
phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can
be manufactured at lower cost. Further ABV-2002 product development was put on hold due to the lack of funding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition, BioFirst was incorporated on
November 7, 2006, focusing on the R&amp;amp;D, manufacturing, and sales of innovative patented pharmaceutical products. The technology of
BioFirst comes from the global exclusive licensing from domestic R &amp;amp; D institutions. Currently, the main research and development
product is the vitreous substitute (Vitargus&#xae;) Licensed by the National Health Research Institutes. Vitargus is the world&#x2019;s
first bio-degradable vitreous substitute and offers a number of advantages over current vitreous substitutes by minimizing medical complications
and reducing the need for additional surgeries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst has started the construction of a
GMP factory in Hsinchu Biomedical Science Park, Taiwan, with the aim at building a production base to supply the global market, and promote
the construction of bio-degradable vitreous substitute manufacturing centers in Taiwan. Completion of this factory would allow ABVC to
manufacture Vitargus with world-class technology in a GMP certified pharmaceutical factory. BioFirst is targeting to complete the construction
in 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of March 31, 2025, the Company has not
earned any net licensing income or net sales profit earned by BioFirst under these collaborative agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreement with ForSeeCon
Eye Corporation, a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On March 25, 2024, the Company and BioFirst
each entered into a twenty-year, global definitive licensing agreement (the &#x201c;FEYE Licensing Agreement&#x201d;) with ForSeeCon Eye
Corporation, a company registered in the British Virgin Islands (&#x201c;FEYE&#x201d;) for the products in the Company and BioFirst&#x2019;s
Ophthalmology pipeline, including Vitargus (the &#x201c;Vitargus Products&#x201d;). The license covers Vitargus Products&#x2019; clinical
trial, registration, manufacturing, supply, and distribution rights; FEYE also has the rights to sublicense or partner with a third party
to develop the Licensed Products. As per each of the respective FEYE Licensing Agreements, each of the Company and BioFirst shall receive
a total licensing fee of $33.5 million, composed of an upfront payment of $30 million, which can instead be paid with 5 million shares
of FEYE stock at $6 per share within 30 days after the execution of the FEYE Licensing Agreement, and a $3.5 million cash milestone payment,
due 30 days upon completion of next round fundraising. Additionally, each of the Company and BioFirst are eligible to receive royalties
of 5% of net sales.&#160;As of March 31, 2025, the Company received 5 million FEYE shares but did not recognize such licensing revenue
since the fair value of FEYE stock is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 18, 2024, the Company and BioFirst,
each entered into an amendment (the &#x201c;Amendment&#x201d;) to the Licensing Agreement with FEYE, pursuant to which the Company and
BioFirst have agreed to allow FEYE to pay the second milestone payment in the amount of $3.5 million per Licensing Agreement, incrementally
(such as $100,000), at any given time, rather than in one lump sum. During the year ended December 31, 2024, the Company received in
cash and recognized revenue of $296,000, pursuant to the Amendment. There was no cash receipt in the three months periods ended March
31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreement with OncoX BiopPharma,
Inc., a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On April 16, 2024, the Company entered into
a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (&#x201c;Oncox&#x201d;),
pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#x2019;s single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the &#x201c;Lung Cancer
Products&#x201d;), within North America for 20 years (the &#x201c;April 2024 Oncox Agreement&#x201d;). In consideration thereof, Oncox shall
pay ABVC $6.25 million (or 1.25 million Oncox shares valued at $5 per share) 30 days after entering into the agreement and $625,000,
30 days following the completion of Oncox&#x2019;s next round of fundraising, of which there is no guarantee; ABVC is also entitled to
5% royalties based on the net sales, as defined in the April 2024 Oncox Agreement, from the first commercial sale of the Lung Cancer
Product in North America, of which there can be no guarantee. Oncox entered into another agreement with ABVC&#x2019;s affiliate, Rgene
Corporation, on the same terms. During the year ended December 31, 2024, the Company received in cash and recognized revenue of $200,000
pursuant to the agreement. At the time of transferring the license, the Company also received 1.25 million OncoX shares but did not recognize
such licensing revenue since the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended
March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 8, 2024, the Company entered into a
definitive agreement with OncoX, pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#x2019;s
BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Pancreatic
(the Pancreatic Product), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#x201c;May 8, 2024
Oncox Agreement&#x201d;). In consideration thereof, Oncox shall pay ABVC a total of $6.25 million (or 1.25 million Oncox shares valued
at $5 per share) within 30 days of entering into the May 8, 2024 Oncox Agreement, with an additional milestone payment of $625,000 in
cash after OncoX&#x2019;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000
towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties of 5% of net sales, as
defined in the May 8, 2024 Oncox Agreement, from the first commercial sale of the Pancreatic Product in the noted territory, which remains
uncertain. The Company will permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue
to fund such payments. Oncox entered into another agreement with ABVC&#x2019;s affiliate, Rgene Corporation, on the same terms. At the
time of transferring the license, the Company also received 1.25 million OncoX shares but did not recognize such licensing revenue since
the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 14, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#x201c;licensor&#x201d;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#x2019;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the TNBC Product),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#x201c;May 14, 2024 Oncox Agreements&#x201d;).
In each agreement for consideration thereof, Oncox shall pay each licensor a total of $6.25 million (or 1.25 million Oncox shares valued
at $5 per share) within 30 days of entering into the May 14, 2024 Oncox Agreements, with an additional milestone payment of $625,000
in cash after OncoX&#x2019;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least
$100,000 towards the licensing fees and deductible from the second milestone payment; each licensor is also entitled to royalties of
5% of net sales, from the first commercial sale of the TNBC Product in the noted territory, which remains uncertain. The Company will
permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue to fund such payments. At
the time of transferring the license, the Company and BioLite also each received 1.25 million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended March
31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 23, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#x201c;licensor&#x201d;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#x2019;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the &#x201c;MS Products&#x201d;),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#x201c;May 23, 2024 Oncox Agreements&#x201d;).
In consideration thereof, Oncox shall pay each licensor a total of $6.25 million (or 1.25 million Oncox shares valued at $5 per share)
30 days after entering the May 23, 2024 Oncox Agreements, with an additional milestone payment of $625,000 in cash after OncoX&#x2019;s
next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000 towards the licensing
fees and deductible from the second milestone payment; each licensor is also entitled to royalties of 5% of net sales, from the first
commercial sale of the MS Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing fees.
At the time of transferring the license, the Company and BioLite also each received 1.25 million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended March
31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Above mentioned price of OncoX&#x2019;s shares
was determined through private negotiations between the parties; no third-party valuation was completed.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentMilestones contextRef="c468" id="ixv-38958">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:

    &#160;
    &#x25cf;
    Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment


    &#160;
    &#x25cf;
    Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment


    &#160;
    &#x25cf;
    At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment


    &#160;
    &#x25cf;
    At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment


    &#160;
    &#x25cf;
    Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment
  </us-gaap:LongTermPurchaseCommitmentMilestones>
    <abvc:NonrefundableUpfrontCashPayment
      contextRef="c469"
      decimals="-6"
      id="ixv-47889"
      unitRef="usd">1000000</abvc:NonrefundableUpfrontCashPayment>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement
      contextRef="c469"
      decimals="2"
      id="ixv-47890"
      unitRef="pure">0.10</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <abvc:IssuanceOfStockValue
      contextRef="c469"
      decimals="-5"
      id="ixv-47891"
      unitRef="usd">10000000</abvc:IssuanceOfStockValue>
    <abvc:IssuanceOfStockValue
      contextRef="c126"
      decimals="-6"
      id="ixv-47892"
      unitRef="usd">1000000</abvc:IssuanceOfStockValue>
    <abvc:MilestonePaymentsRoyaltyPercentage
      contextRef="c471"
      decimals="2"
      id="ixv-47893"
      unitRef="pure">0.12</abvc:MilestonePaymentsRoyaltyPercentage>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c128"
      decimals="-5"
      id="ixv-47894"
      unitRef="usd">1600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c130"
      decimals="-5"
      id="ixv-47895"
      unitRef="usd">1600000</us-gaap:CashEquivalentsAtCarryingValue>
    <abvc:NetSalesProfitPercentage
      contextRef="c472"
      decimals="2"
      id="ixv-47896"
      unitRef="pure">0.50</abvc:NetSalesProfitPercentage>
    <us-gaap:PaymentsForParticipationLiabilities
      contextRef="c131"
      decimals="-5"
      id="ixv-47897"
      unitRef="usd">3000000</us-gaap:PaymentsForParticipationLiabilities>
    <abvc:AdditionCashPayment
      contextRef="c473"
      decimals="-5"
      id="ixv-47898"
      unitRef="usd">3000000</abvc:AdditionCashPayment>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement
      contextRef="c473"
      decimals="2"
      id="ixv-47899"
      unitRef="pure">0.50</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="c133"
      decimals="-5"
      id="ixv-47900"
      unitRef="usd">3000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:Cash contextRef="c133" decimals="0" id="ixv-47901" unitRef="usd">450000</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c134" decimals="0" id="ixv-47902" unitRef="usd">2550000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c135"
      decimals="2"
      id="ixv-47903"
      unitRef="usdPershares">1.6</us-gaap:SharesIssuedPricePerShare>
    <abvc:EquityMethodLongTermInvestment
      contextRef="c136"
      decimals="0"
      id="ixv-47904"
      unitRef="shares">1530000</abvc:EquityMethodLongTermInvestment>
    <abvc:ServiceAgreementEligibilityAmount
      contextRef="c137"
      decimals="-5"
      id="ixv-47905"
      unitRef="usd">3000000</abvc:ServiceAgreementEligibilityAmount>
    <abvc:MilestoneRegulatoryPaymentAmountPeriod contextRef="c138" id="ixv-47906">P3Y</abvc:MilestoneRegulatoryPaymentAmountPeriod>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c475"
      decimals="4"
      id="ixv-47907"
      unitRef="pure">0.2665</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:LoansPayable
      contextRef="c476"
      decimals="-5"
      id="ixv-47908"
      unitRef="usd">1000000</us-gaap:LoansPayable>
    <us-gaap:ConvertibleDebt
      contextRef="c476"
      decimals="-5"
      id="ixv-47909"
      unitRef="usd">500000</us-gaap:ConvertibleDebt>
    <abvc:WorkingCapitalConvertibleLoanPercentage contextRef="c0" decimals="2" id="ixv-47910" unitRef="pure">0.05</abvc:WorkingCapitalConvertibleLoanPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c477"
      decimals="3"
      id="ixv-47911"
      unitRef="pure">0.064</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c5"
      decimals="2"
      id="ixv-47912"
      unitRef="usdPershares">1</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c478"
      decimals="2"
      id="ixv-47913"
      unitRef="pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:IssuanceOfStockValue
      contextRef="c144"
      decimals="-5"
      id="ixv-47914"
      unitRef="usd">3000000</abvc:IssuanceOfStockValue>
    <us-gaap:PaymentsForParticipationLiabilities
      contextRef="c479"
      decimals="-5"
      id="ixv-47915"
      unitRef="usd">3000000</us-gaap:PaymentsForParticipationLiabilities>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement
      contextRef="c479"
      decimals="2"
      id="ixv-47916"
      unitRef="pure">0.50</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c146"
      decimals="-5"
      id="ixv-47917"
      unitRef="usd">3000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c147"
      decimals="-5"
      id="ixv-47918"
      unitRef="usd">3000000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="c148"
      decimals="-5"
      id="ixv-47919"
      unitRef="usd">3000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c149"
      decimals="0"
      id="ixv-47920"
      unitRef="shares">41470</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="c149" decimals="0" id="ixv-47921" unitRef="usd">2902911</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:TaxesAndLicenses
      contextRef="c150"
      decimals="-5"
      id="ixv-47922"
      unitRef="usd">33500000</us-gaap:TaxesAndLicenses>
    <us-gaap:PrepaymentFeesOnAdvancesNet
      contextRef="c151"
      decimals="-6"
      id="ixv-47923"
      unitRef="usd">30000000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:SharesIssued
      contextRef="c152"
      decimals="-6"
      id="ixv-47924"
      unitRef="shares">5000000</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c153"
      decimals="0"
      id="ixv-47925"
      unitRef="usdPershares">6</us-gaap:SaleOfStockPricePerShare>
    <abvc:MilestoneRegulatoryPaymentAmount
      contextRef="c150"
      decimals="-5"
      id="ixv-47926"
      unitRef="usd">3500000</abvc:MilestoneRegulatoryPaymentAmount>
    <abvc:RoyaltiesPercentage
      contextRef="c153"
      decimals="2"
      id="ixv-47927"
      unitRef="pure">0.05</abvc:RoyaltiesPercentage>
    <abvc:ReceivedShares
      contextRef="c480"
      decimals="-6"
      id="ixv-47928"
      unitRef="shares">5000000</abvc:ReceivedShares>
    <abvc:MilestoneRegulatoryPaymentAmount
      contextRef="c155"
      decimals="-5"
      id="ixv-47929"
      unitRef="usd">3500000</abvc:MilestoneRegulatoryPaymentAmount>
    <abvc:LicensingAgreement contextRef="c156" decimals="0" id="ixv-47930" unitRef="usd">100000</abvc:LicensingAgreement>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-47931" unitRef="usd">296000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <abvc:ConsiderationPaidForAgreement
      contextRef="c157"
      decimals="-4"
      id="ixv-47932"
      unitRef="usd">6250000</abvc:ConsiderationPaidForAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c157"
      decimals="-4"
      id="ixv-47933"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c158"
      decimals="0"
      id="ixv-47934"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <abvc:AdditionalMilestonePaymentInCash contextRef="c157" decimals="0" id="ixv-47935" unitRef="usd">625000</abvc:AdditionalMilestonePaymentInCash>
    <abvc:MilestonePaymentsRoyaltyPercentage
      contextRef="c157"
      decimals="2"
      id="ixv-47936"
      unitRef="pure">0.05</abvc:MilestonePaymentsRoyaltyPercentage>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c0" decimals="0" id="ixv-47937" unitRef="usd">200000</us-gaap:DeferredRevenueRevenueRecognized1>
    <abvc:NumberOfSharesReceived
      contextRef="c481"
      decimals="-4"
      id="ixv-47938"
      unitRef="shares">1250000</abvc:NumberOfSharesReceived>
    <abvc:PercentageOfDevelopAndCommercialize
      contextRef="c160"
      decimals="2"
      id="ixv-47939"
      unitRef="pure">0.50</abvc:PercentageOfDevelopAndCommercialize>
    <abvc:ConsiderationPaidForAgreement
      contextRef="c160"
      decimals="-4"
      id="ixv-47940"
      unitRef="usd">6250000</abvc:ConsiderationPaidForAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c160"
      decimals="-4"
      id="ixv-47941"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c161"
      decimals="0"
      id="ixv-47942"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <abvc:AdditionalMilestonePaymentInCash contextRef="c160" decimals="0" id="ixv-47943" unitRef="usd">625000</abvc:AdditionalMilestonePaymentInCash>
    <abvc:LicensingFees contextRef="c160" decimals="0" id="ixv-47944" unitRef="usd">100000</abvc:LicensingFees>
    <abvc:MilestonePaymentsRoyaltyPercentage
      contextRef="c160"
      decimals="2"
      id="ixv-47945"
      unitRef="pure">0.05</abvc:MilestonePaymentsRoyaltyPercentage>
    <abvc:NumberOfSharesReceived
      contextRef="c160"
      decimals="-4"
      id="ixv-47946"
      unitRef="shares">1250000</abvc:NumberOfSharesReceived>
    <abvc:PercentageOfDevelopAndCommercialize
      contextRef="c162"
      decimals="2"
      id="ixv-47947"
      unitRef="pure">0.50</abvc:PercentageOfDevelopAndCommercialize>
    <abvc:ConsiderationPaidForAgreement
      contextRef="c162"
      decimals="-4"
      id="ixv-47948"
      unitRef="usd">6250000</abvc:ConsiderationPaidForAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c162"
      decimals="-4"
      id="ixv-47949"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c163"
      decimals="0"
      id="ixv-47950"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <abvc:AdditionalMilestonePaymentInCash contextRef="c162" decimals="0" id="ixv-47951" unitRef="usd">625000</abvc:AdditionalMilestonePaymentInCash>
    <abvc:LicensingFees contextRef="c162" decimals="0" id="ixv-47952" unitRef="usd">100000</abvc:LicensingFees>
    <abvc:MilestonePaymentsRoyaltyPercentage
      contextRef="c162"
      decimals="2"
      id="ixv-47953"
      unitRef="pure">0.05</abvc:MilestonePaymentsRoyaltyPercentage>
    <abvc:NumberOfSharesReceived
      contextRef="c162"
      decimals="-4"
      id="ixv-47954"
      unitRef="shares">1250000</abvc:NumberOfSharesReceived>
    <abvc:PercentageOfDevelopAndCommercialize
      contextRef="c164"
      decimals="2"
      id="ixv-47955"
      unitRef="pure">0.50</abvc:PercentageOfDevelopAndCommercialize>
    <abvc:ConsiderationPaidForAgreement
      contextRef="c164"
      decimals="-4"
      id="ixv-47956"
      unitRef="usd">6250000</abvc:ConsiderationPaidForAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c164"
      decimals="-4"
      id="ixv-47957"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c165"
      decimals="0"
      id="ixv-47958"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <abvc:AdditionalMilestonePaymentInCash contextRef="c164" decimals="0" id="ixv-47959" unitRef="usd">625000</abvc:AdditionalMilestonePaymentInCash>
    <abvc:LicensingFees contextRef="c164" decimals="0" id="ixv-47960" unitRef="usd">100000</abvc:LicensingFees>
    <abvc:MilestonePaymentsRoyaltyPercentage
      contextRef="c164"
      decimals="2"
      id="ixv-47961"
      unitRef="pure">0.05</abvc:MilestonePaymentsRoyaltyPercentage>
    <abvc:NumberOfSharesReceived
      contextRef="c164"
      decimals="-4"
      id="ixv-47962"
      unitRef="shares">1250000</abvc:NumberOfSharesReceived>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-39224">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;5. PROPERTY AND EQUIPMENT, AND PREPAMENT FOR ASSET ACQUISITION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Property
and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of March 31, 2025 and December 31, 2024 are summarized
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,004,520&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;338,966&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,217,756&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,219,244&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,129,804&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,131,169&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;161,384&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;163,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11,513,464&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,852,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,344,718&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,341,739&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,168,746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;511,088&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Depreciation expenses were $7,021&#160;and $1,286 for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025 and December 31, 2024, the land with book value amounted to approximately $334,520 and $338,966 (except for the recently acquired land in Puli, Taiwan, amounted to $7,670,000), respectively, were pledged for obtaining bank loan (see Notes 9 Bank loans).&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Prepayment
for asset acquisition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepayment for asset acquisition consists
of the properties in Chengdu, China. The Company entered into a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan,
Ltd. (the &#x201c;Zhonghui&#x201d;). Pursuant thereto, the Company will acquire 20% of the ownership of certain property and a parcel of
the land, with a view to jointly develop the property into a healthcare center for senior living, long-term care, and medical care in
the areas of ABVC&#x2019;s special interests, such as Ophthalmology, Oncology, and Central Nervous Systems. The plan is to establish a
base for the China market and global development of these interests.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The valuation of such property is $37 million;
based on the Company&#x2019;s 20% ownership, the Company would acquire the value of $7,400,000. In exchange, the Company issued to Zhonghui
an aggregate of 370,000 shares (the &#x201c;Shares&#x201d;) of common stock, at a per share price of $20.0. The Shares are subject to a
lock-up period of one year following the closing date of the transaction. In addition, the parties agreed that, after one year following
the closing of the transaction, if the market value of the Shares or the value of the property increases or decreases, the parties will
negotiate in good faith to make reasonable adjustments. The Company&#x2019;s ownership rights to the property and the associated land
parcel, or a suitable replacement property, are safeguarded under the terms of the cooperation agreement, which is legally binding and
enforceable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As discussed in Note 2, the Company incorrectly
applied ASC 845 instead of ASC 718, resulting in an adjustment of the reported value to from $7,400,000 to $691,900, and reclassification
from Construction-in-Progress to Prepayment for Asset Acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The construction-in-progress property is planned
to finish before the end of 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Acquisition of land in Taiwan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2024, AiBtl issued 1,534,000 AiBtl&#x2019;s
common stocks to acquire farmland in Taiwan, which land will be used for developing health related businesses. As of the date of issuance
of these financial statements, the transfer of the land&#x2019;s title is under government review, pending completion of the title transfer
registration. However, upon the closing of the transaction, both parties are aware of such Taiwan&#x2019;s legal restrictions prohibiting
foreign entities directly owning farmland. In addition to newly incorporated controlling subsidiary, Yunzhiyi, to be holding the title
of the land upon government&#x2019;s approval, on March 31, 2025, the Company and the landowners executed the Nominee Holding Agreement,
Land Lease Agreement, and Consulting Agreement, under the witness of and confirmed by a legal counsel in Taiwan, in which the landowners
unconditionally grant the full legal rights to the land to the Company before the completion of the title transfer. Based on the execution
of the agreement, the Company recognized $7,670,000 ($5 per share of AiBtl&#x2019;s common stock) of land on its balance sheet.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-39233">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of March 31, 2025 and December 31, 2024 are summarized
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,004,520&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;338,966&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,217,756&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,219,244&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,129,804&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,131,169&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;161,384&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;163,448&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11,513,464&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,852,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,344,718&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,341,739&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,168,746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;511,088&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c490" decimals="0" id="ixv-47963" unitRef="usd">8004520</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c169" decimals="0" id="ixv-47964" unitRef="usd">338966</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c491" decimals="0" id="ixv-47965" unitRef="usd">2217756</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c173" decimals="0" id="ixv-47966" unitRef="usd">2219244</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c492" decimals="0" id="ixv-47967" unitRef="usd">1129804</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c175" decimals="0" id="ixv-47968" unitRef="usd">1131169</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c493" decimals="0" id="ixv-47969" unitRef="usd">161384</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c177" decimals="0" id="ixv-47970" unitRef="usd">163448</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="0" id="ixv-47971" unitRef="usd">11513464</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="0" id="ixv-47972" unitRef="usd">3852827</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="0" id="ixv-47973" unitRef="usd">3344718</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="0" id="ixv-47974" unitRef="usd">3341739</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="0" id="ixv-47975" unitRef="usd">8168746</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" id="ixv-47976" unitRef="usd">511088</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c482" decimals="0" id="ixv-47977" unitRef="usd">7021</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c483" decimals="0" id="ixv-47978" unitRef="usd">1286</us-gaap:Depreciation>
    <us-gaap:LandAndLandImprovements contextRef="c5" decimals="0" id="ixv-47979" unitRef="usd">334520</us-gaap:LandAndLandImprovements>
    <us-gaap:LandAndLandImprovements contextRef="c1" decimals="0" id="ixv-47980" unitRef="usd">338966</us-gaap:LandAndLandImprovements>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c484" decimals="0" id="ixv-47981" unitRef="usd">7670000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="c485"
      decimals="2"
      id="ixv-47982"
      unitRef="pure">0.20</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c5" decimals="-6" id="ixv-47983" unitRef="usd">37000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c486"
      decimals="2"
      id="ixv-47984"
      unitRef="pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c487" decimals="0" id="ixv-47985" unitRef="usd">7400000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c486"
      decimals="0"
      id="ixv-47986"
      unitRef="shares">370000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharePrice
      contextRef="c486"
      decimals="1"
      id="ixv-47987"
      unitRef="usdPershares">20</us-gaap:SharePrice>
    <us-gaap:ConstructionInProgressGross contextRef="c449" decimals="0" id="ixv-47988" unitRef="usd">7400000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c450" decimals="0" id="ixv-47989" unitRef="usd">691900</us-gaap:ConstructionInProgressGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c488"
      decimals="0"
      id="ixv-47990"
      unitRef="shares">1534000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c488" decimals="0" id="ixv-47991" unitRef="usd">7670000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c489"
      decimals="0"
      id="ixv-47992"
      unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:InvestmentTextBlock contextRef="c0" id="ixv-39440">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;6. LONG-TERM INVESTMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The ownership percentages of each investee are listed as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership percentage&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accounting&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of investees&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;treatments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.*&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 20%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.67&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.67&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.90&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.90&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation (see Note 10)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.78&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.78&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.68&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.68&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&#160;Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. (see Note 10)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24.97&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24.97&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;37.00&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26.65&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49.00&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49.00&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The extent the investee relies on the company for its business is summarized as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 30%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of investees&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 69%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The extent the investee relies on the Company for its business &#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loaned from the investee and provides research and development support service&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. &lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term investment mainly consists of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Non-marketable Cost Method Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,640&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,727&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,271&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,540&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon
    Eye Corporation&lt;sup&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-341"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-342"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;752,880&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;762,983&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;779,791&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;790,250&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity Method Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst
    Corporation&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,420,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,468,504&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene
    Corporation&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;559,471&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-343"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite
    Japan K.K. (BioLite JP)&lt;sup&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-344"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-345"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX
    BioPharma, Inc.&lt;sup&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-346"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-347"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,760,062&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,258,754&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s
proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of March 31, 2025 and
December 31, 2024, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for
equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded
as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration
process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and
was converted into 994,450 shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term
investments in Biofirst is both $1,124,842.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As described in Note 4, the Company
acquired 26.65% of Rgene&#x2019;s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting
this equity investment with equity method as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;).
Equity method adjustments include the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required
by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with
Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment
Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request
for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to
the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company
owns 37% of outstanding shares of Rgene.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disposition of long-term
    investment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the three-month periods
ended March 31, 2025and 2024, there is no disposition of long-term investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss on investment in
    equity securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The components of loss on investment in equity
securities for each period were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share of equity method investee losses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(50,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-348"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K. (BioLite JP)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#x201c;Lucidaim,&#x201d; together with the Company, the &#x201c;Shareholders&#x201d;), and BioLite Japan
K.K., a Japanese corporation (&#x201c;BioLite JP&#x201d;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with
3,049 ordinary shares issued and outstanding (the &#x201c;Ordinary Shares&#x201d;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000
towards the setup of the joint venture; BioLite Japan&#x2019;s other shareholder also paid $150,000 after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#x2019;s business
and financial conditions and determined to fully impair such prepayment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation (FEYE)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(e)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. (OncoX)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#x2019;s ownership. See Note 4 for detail of such transactions.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock contextRef="c0" id="ixv-39450">&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The ownership percentages of each investee are listed as follows:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership percentage&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accounting&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of investees&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;treatments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.*&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 20%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.67&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.67&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.90&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.90&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation (see Note 10)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.78&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.78&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.68&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.68&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&#160;Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. (see Note 10)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24.97&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24.97&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;37.00&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26.65&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49.00&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49.00&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c503"
      decimals="4"
      id="ix_63_fact"
      unitRef="pure">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c189"
      decimals="4"
      id="ix_64_fact"
      unitRef="pure">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c504" id="ix_65_fact">Cost Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c505"
      decimals="4"
      id="ixv-47995"
      unitRef="pure">0.0067</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c192"
      decimals="4"
      id="ixv-47996"
      unitRef="pure">0.0067</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c506" id="ixv-39561">Cost Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c507"
      decimals="4"
      id="ixv-47997"
      unitRef="pure">0.059</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c195"
      decimals="4"
      id="ixv-47998"
      unitRef="pure">0.059</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c508" id="ixv-39585">Cost Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c509"
      decimals="4"
      id="ixv-47999"
      unitRef="pure">0.1978</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c198"
      decimals="4"
      id="ixv-48000"
      unitRef="pure">0.1978</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c510" id="ixv-39609">Cost Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c511"
      decimals="4"
      id="ixv-48001"
      unitRef="pure">0.1868</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c185"
      decimals="4"
      id="ixv-48002"
      unitRef="pure">0.1868</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c494" id="ixv-39633">Equity&#160;Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c512"
      decimals="4"
      id="ixv-48003"
      unitRef="pure">0.2497</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c202"
      decimals="4"
      id="ixv-48004"
      unitRef="pure">0.2497</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c513" id="ixv-39657">Equity Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c476"
      decimals="4"
      id="ixv-48005"
      unitRef="pure">0.37</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c140"
      decimals="4"
      id="ixv-48006"
      unitRef="pure">0.2665</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c514" id="ixv-39681">Equity Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c515"
      decimals="4"
      id="ixv-48007"
      unitRef="pure">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c184"
      decimals="4"
      id="ixv-48008"
      unitRef="pure">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAdditionalInformation contextRef="c516" id="ixv-39705">Equity Method</us-gaap:EquityMethodInvestmentAdditionalInformation>
    <abvc:ScheduleOfExtentTheInvesteeReliesTableTextBlock contextRef="c0" id="ixv-39725">&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The extent the investee relies on the company for its business is summarized as follows:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 30%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of investees&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 69%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The extent the investee relies on the Company for its business &#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loaned from the investee and provides research and development support service&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. &lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</abvc:ScheduleOfExtentTheInvesteeReliesTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c517" id="ixv-39746">No specific business relationship</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c518" id="ixv-39754">No specific business relationship</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c519" id="ixv-39762">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c520" id="ixv-48009">The Company&#x2019;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c521" id="ixv-39777">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c522" id="ixv-39785">Loaned from the investee and provides research and development support service</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c523" id="ixv-39793">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c524" id="ixv-39801">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:InvestmentTableTextBlock contextRef="c0" id="ixv-39824">&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term investment mainly consists of the following:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Non-marketable Cost Method Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,640&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,727&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,271&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,540&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon
    Eye Corporation&lt;sup&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-341"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-342"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;752,880&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;762,983&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;779,791&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;790,250&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity Method Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst
    Corporation&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,420,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,468,504&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene
    Corporation&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;559,471&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-343"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite
    Japan K.K. (BioLite JP)&lt;sup&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-344"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-345"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX
    BioPharma, Inc.&lt;sup&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-346"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-347"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,760,062&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,258,754&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s
proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of March 31, 2025 and
December 31, 2024, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for
equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded
as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration
process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and
was converted into 994,450 shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term
investments in Biofirst is both $1,124,842.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As described in Note 4, the Company
acquired 26.65% of Rgene&#x2019;s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting
this equity investment with equity method as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;).
Equity method adjustments include the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required
by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with
Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment
Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request
for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to
the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company
owns 37% of outstanding shares of Rgene.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan K.K. (BioLite JP)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#x201c;Lucidaim,&#x201d; together with the Company, the &#x201c;Shareholders&#x201d;), and BioLite Japan
K.K., a Japanese corporation (&#x201c;BioLite JP&#x201d;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with
3,049 ordinary shares issued and outstanding (the &#x201c;Ordinary Shares&#x201d;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000
towards the setup of the joint venture; BioLite Japan&#x2019;s other shareholder also paid $150,000 after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#x2019;s business
and financial conditions and determined to fully impair such prepayment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ForSeeCon Eye Corporation (FEYE)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(e)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OncoX BioPharma, Inc. (OncoX)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#x2019;s ownership. See Note 4 for detail of such transactions.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentTableTextBlock>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c525" decimals="0" id="ixv-48010" unitRef="usd">6640</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c215" decimals="0" id="ixv-48011" unitRef="usd">6727</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c526" decimals="0" id="ixv-48012" unitRef="usd">20271</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c217" decimals="0" id="ixv-48013" unitRef="usd">20540</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c528" decimals="0" id="ixv-48014" unitRef="usd">752880</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c221" decimals="0" id="ixv-48015" unitRef="usd">762983</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c5" decimals="0" id="ixv-48016" unitRef="usd">779791</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent contextRef="c1" decimals="0" id="ixv-48017" unitRef="usd">790250</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="c529"
      decimals="0"
      id="ix_66_fact"
      unitRef="usd">1420800</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="c223"
      decimals="0"
      id="ix_67_fact"
      unitRef="usd">1468504</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="c530"
      decimals="0"
      id="ix_68_fact"
      unitRef="usd">559471</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c5" decimals="0" id="ixv-48021" unitRef="usd">2760062</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c1" decimals="0" id="ixv-48022" unitRef="usd">2258754</us-gaap:LongTermInvestments>
    <abvc:PercentageCommonStocksShares
      contextRef="c494"
      decimals="4"
      id="ixv-48023"
      unitRef="pure">0.1868</abvc:PercentageCommonStocksShares>
    <abvc:PercentageCommonStocksShares
      contextRef="c179"
      decimals="4"
      id="ixv-48024"
      unitRef="pure">0.1868</abvc:PercentageCommonStocksShares>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c181" decimals="0" id="ixv-48025" unitRef="usd">2688578</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c181" decimals="0" id="ixv-48026" unitRef="usd">1895556</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c0"
      decimals="0"
      id="ixv-48027"
      unitRef="shares">994450</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c179" decimals="0" id="ixv-48028" unitRef="usd">1124842</us-gaap:PrepaymentFeesOnAdvancesNet>
    <abvc:PercentageCommonStocksShares
      contextRef="c495"
      decimals="4"
      id="ixv-48029"
      unitRef="pure">0.2665</abvc:PercentageCommonStocksShares>
    <abvc:PercentageCommonStocksShares
      contextRef="c496"
      decimals="2"
      id="ixv-48030"
      unitRef="pure">0.37</abvc:PercentageCommonStocksShares>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c0" id="ixv-40130">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The components of loss on investment in equity
securities for each period were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share of equity method investee losses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(50,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-348"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments contextRef="c5" decimals="0" id="ixv-48031" unitRef="usd">-50877</us-gaap:EquityMethodInvestments>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c497"
      decimals="0"
      id="ixv-48032"
      unitRef="shares">10000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c498"
      decimals="0"
      id="ixv-48033"
      unitRef="shares">3049</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c498"
      decimals="0"
      id="ixv-48034"
      unitRef="shares">3049</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c499"
      decimals="0"
      id="ixv-48035"
      unitRef="shares">1555</us-gaap:InvestmentOwnedBalanceShares>
    <abvc:PercentageCommonStocksShares
      contextRef="c500"
      decimals="2"
      id="ixv-48036"
      unitRef="pure">0.51</abvc:PercentageCommonStocksShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c501"
      decimals="0"
      id="ixv-48037"
      unitRef="shares">1494</us-gaap:InvestmentOwnedBalanceShares>
    <abvc:PercentageCommonStocksShares
      contextRef="c502"
      decimals="2"
      id="ixv-48038"
      unitRef="pure">0.49</abvc:PercentageCommonStocksShares>
    <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="c500" decimals="0" id="ixv-48039" unitRef="usd">150000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="c502" decimals="0" id="ixv-48040" unitRef="usd">150000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-40237">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;7. CONVERTIBLE NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Lind Notes Payable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 23, 2023, the Company entered
into a securities purchase agreement with Lind Global Fund II, LP (&#x201c;Lind&#x201d;), pursuant to which the Company issued Lind a secured,
convertible note in the principal amount of $3,704,167, for a purchase price of $3,175,000 (the &#x201c;Lind Note&#x201d;), that is convertible
into shares of the Company&#x2019;s common stock at an initial conversion price of $10.5 per share, subject to adjustment. The Company
also issued Lind a common stock purchase warrant (the &#x201c;Lind Warrant&#x201d;) to purchase up to 529,167 shares (post-split) of the
Company&#x2019;s common stock at an initial exercise price of $10.5 per share for a period of 5 years, subject to adjustment that immediately
upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance or sale shall be reduced (and in no event
increased) to an Exercise Price equal to the consideration per share paid for such Additional Shares of Common Stock. The warrants were
valued using the Black-Scholes model. The fair value of the warrants was determined to be $1,225,543, which was recorded to debt discount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Beginning with the date that is six months
from the issuance date of the Lind Note and on each one (1) month anniversary thereafter, the Company shall pay Lind an amount equal
to $308,651, until the outstanding principal amount of the Lind Note has been paid in full prior to or on the Maturity Date or, if earlier,
upon acceleration, conversion or redemption of the Lind Note in accordance with the terms thereof (the &#x201c;Monthly Payments&#x201d;).
At the Company&#x2019;s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares of the Company&#x2019;s common stock, or
(iii) a combination of cash and Shares; if made in shares, the number of shares shall be determined by dividing (x) the principal amount
being paid in shares by (y) 90% of the average of the 5 lowest daily VWAPs during the 20 trading days prior to the applicable payment
date. The Lind Notes sets forth certain conditions that must be satisfied before the Company may make any Monthly Payments in shares
of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash premium of 5% of such Monthly
Payment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Upon the occurrence of any Event of Default
(as defined in the Lind Note), the Company must pay Lind an amount equal to 120%&#160;of the then outstanding principal amount of the
Lind Note (the &#x201c;Mandatory Default Amount&#x201d;), in addition to any other remedies under the Note or the other Transaction Documents.
The Company and Lind entered into a letter agreement on September 12, 2023, pursuant to which the Mandatory Default Amount was reduced
to 115% of the then outstanding principal amount of the Lind Note; pursuant to the letter agreement, Lind also agreed to waive any default
associated with the Company&#x2019;s market capitalization being below $12.5 million for 10 consecutive days through February 23, 2024,
but retained its right to convert its Note. In addition, if the Company is unable to increase its market capitalization and is unable
to obtain a further waiver or amendment to the Lind Note, then the Company could experience an event of default under the Lind Note,
which could have a material adverse effect on the Company&#x2019;s liquidity, financial condition, and results of operations. The Company
cannot make any assurances regarding the likelihood, certainty, or exact timing of the Company&#x2019;s ability to increase its market
capitalization, as such metric is not within the immediate control of the Company and depends on a variety of factors outside the Company&#x2019;s
control. &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Lind Warrant may be exercised via cashless
exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The warrant exercise price was reset to $3.5
in accordance to the issuance of common stock in relation to securities purchase agreement on July 2023.&#160;On May 22, 2024, the exercise
price of these warrants was reset to $0.75 along with the immediate exercise of existing warrants and issuance of the New Warrants. As
of March 31, 2025, these Lind Warrants associated with the first Lind Note were fully exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 17, 2023, the Company entered
another securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#x201c;2&lt;sup&gt;nd&lt;/sup&gt;
Lind Note&#x201d;) in the principal amount of $1,200,000, for a purchase price of $1,000,000, that is convertible into shares of the Company&#x2019;s
common stock at a conversion price, which shall be the lesser of (i) $3.50 and (ii) 90% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note shall be due and payable on May 19, 2025, and bears no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to maturity, and Lind shall have the right to convert
up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined in the 2&lt;sup&gt;nd&lt;/sup&gt;
Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind Note, in addition
to any other remedies under the Note or the other transaction documents. Lind also received a 5-year common stock purchase warrant to
purchase up to 1,000,000 shares of the Company&#x2019;s common stock at an initial exercise price of $2 per share for a period of 5 years.
The warrants were valued using the Black-Scholes model. The fair value of the warrants was determined to be $480,795, which was recorded
to debt discount. An amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements, the parties entered
into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $1.00. Additionally, the amendment
requires the Company to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor
price. During the year ended December 31, 2024, Lind converted $800,000 of 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note principal amounts into the Company&#x2019;s
common stocks. Refer to the common stock issuance details in Note 12, Equity. On March 3 and April 1, 2025, Lind converted the remaining
$400,000 principal balance ($200,000 for each conversion) into the Company&#x2019;s common stocks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 17, 2024, the Company entered another
securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#x201c;3&lt;sup&gt;rd&lt;/sup&gt;
Lind Note&#x201d;) in the principal amount of $1,000,000, for a purchase price of $833,333, that is convertible into shares of the Company&#x2019;s
common stock at a conversion price, which shall be the lesser of (i) $3.50 and (ii) 90% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note shall be due and payable on July 17, 2025 and bear no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to maturity, and Lind shall have the right to convert
up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined in the 3&lt;sup&gt;rd&lt;/sup&gt;
Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind Note, in addition
to any other remedies under the Note or the other transaction documents Lind also received a 5-year, common stock purchase warrant to
purchase up to 1,000,000 shares of the Company&#x2019;s common stock at an initial exercise price of $2 per share. The warrants were valued
using the Black-Scholes model. The fair value of the warrants was determined to be $394,071, which was recorded to debt discount. An
amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements, the parties entered into an amendment
to the Note, pursuant to which the conversion price shall have a floor price of $1.00. Additionally, the amendment requires the Company
to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor price. No conversion
or repayment to 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note has occurred during the year ended December 31, 2024. On March 3 and April 1, 2025, Lind converted
$400,000 principal balance ($200,000 for each conversion) into the Company&#x2019;s common stock, leaving outstanding principal of $600,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In connection with above three Lind Note offerings,
the Company and its subsidiaries: BioKey, BioLite, Biolite BVI, and American BriVision, jointly and severally guaranteed all of the obligations
of the Company in connection with the offering with certain collateral, as set forth in the related transaction documents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 22, 2024, November 19, 2024, and January
9, 2025, Lind exercised 1,000,000, 500,000, 1,029,167 of the existing warrants to purchase shares of Common Stock at a reduced exercise
price of $0.75, $0.42, and $0.40 per share, respectively. Refer to the details in Note 12, Equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total interest expenses in connection with the above three Lind Notes were $209,372 and $172,884 for the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Other Convertible Notes Payable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 1, 2024 and November 5, 2024,
the Company&#x2019;s subsidiary, AiBtl, issued two convertible notes payable, each with a principal amount of $30,000 to two separate
individuals, for total consideration of $60,000. Each note has a 1-year term and an implied annual discount rate of 6.89%. These convertible
notes bear a 0% interest rate and are convertible by the holders into the AiBtl&#x2019;s common stock at $5 per share at any time before
the maturity. AiBtl reserves the right to repurchase the note in full at any time before maturity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The convertible notes payable is accounted
for in accordance with ASC 470-20, Debt with Conversion and Other Options. The Company evaluated the conversion feature and determined
that it qualifies for equity classification as it meets the &#x201c;fixed-for-fixed&#x201d; criteria. The proceeds from the issuance were
allocated to the present value of the liability component in aggregate for $56,132, and to debt discount for $3,868. The debt discount
is recorded in additional paid-in capital in the statement of change in equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The debt discount is being amortized over
the 1-year term using the effective interest method. During the three months ended March 31, 2025, the Company recognized $984 in interest
expense related to the amortization of the debt discount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The carrying amounts of the liability component
are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: left; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;March 31, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Entity&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Maturity&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Stated&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Effective&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Conversion&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Common&lt;br/&gt; Stock&lt;br/&gt; to&#160;be&lt;br/&gt; converted&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Balance&lt;br/&gt; Sheet Date&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Unamortized&lt;br/&gt; Discount&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Carrying&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Fair&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2nd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 4%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 17, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;May 19, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;86.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 4%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;26,110&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;173,890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;3rd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;January 17, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;July 17, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;87.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;196,114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;603,886&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;960,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,119&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;28,881&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 5, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,118&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;28,882&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,060,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;224,460&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;835,539&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; text-align: left; white-space: nowrap; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Entity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Maturity&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Stated&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Effective&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Conversion&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Common&lt;br/&gt; Stock&lt;br/&gt; to&#160;be&lt;br/&gt; converted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Balance&lt;br/&gt; Sheet Date&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Unamortized&lt;br/&gt; Discount&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Carrying&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Fair&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2nd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 4%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 17, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;May 19, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;86.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 4%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;118,048&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;281,952&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;480,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;3rd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;January 17, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;July 17, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;87.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;388,685&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;611,315&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,610&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;28,390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 5, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;28,389&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,460,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;509,954&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;950,046&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,740,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c239" decimals="0" id="ixv-48041" unitRef="usd">3704167</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:PaymentsForPreviousAcquisition contextRef="c239" decimals="0" id="ixv-48042" unitRef="usd">3175000</us-gaap:PaymentsForPreviousAcquisition>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c239"
      decimals="1"
      id="ixv-48043"
      unitRef="usdPershares">10.5</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c239"
      decimals="0"
      id="ixv-48044"
      unitRef="shares">529167</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c533"
      decimals="1"
      id="ixv-48045"
      unitRef="usdPershares">10.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c241" decimals="0" id="ixv-48046" unitRef="usd">1225543</us-gaap:FairValueAdjustmentOfWarrants>
    <abvc:OutstandingBalanceAmount contextRef="c534" decimals="0" id="ixv-48047" unitRef="usd">308651</abvc:OutstandingBalanceAmount>
    <abvc:PercentageOfAverageAmount
      contextRef="c535"
      decimals="2"
      id="ixv-48048"
      unitRef="pure">0.90</abvc:PercentageOfAverageAmount>
    <abvc:TradingDays contextRef="c0" id="ixv-48049">P20D</abvc:TradingDays>
    <abvc:PercentageOfCashPermium contextRef="c0" decimals="2" id="ixv-48050" unitRef="pure">0.05</abvc:PercentageOfCashPermium>
    <abvc:PercentageOfOutstandingPrincipalAmount
      contextRef="c535"
      decimals="2"
      id="ixv-48051"
      unitRef="pure">1.20</abvc:PercentageOfOutstandingPrincipalAmount>
    <abvc:PercentageOfOutstandingPrincipalAmount
      contextRef="c244"
      decimals="2"
      id="ixv-48052"
      unitRef="pure">1.15</abvc:PercentageOfOutstandingPrincipalAmount>
    <us-gaap:GeneralPartnersCapitalAccount contextRef="c5" decimals="-5" id="ixv-48053" unitRef="usd">12500000</us-gaap:GeneralPartnersCapitalAccount>
    <abvc:ConsecutiveDays contextRef="c0" id="ixv-48054">P10D</abvc:ConsecutiveDays>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c245"
      decimals="1"
      id="ixv-48055"
      unitRef="usdPershares">3.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c246"
      decimals="2"
      id="ixv-48056"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ReceivableWithImputedInterestFaceAmount contextRef="c247" decimals="0" id="ixv-48057" unitRef="usd">1200000</us-gaap:ReceivableWithImputedInterestFaceAmount>
    <us-gaap:PaymentsForPreviousAcquisition contextRef="c248" decimals="0" id="ixv-48058" unitRef="usd">1000000</us-gaap:PaymentsForPreviousAcquisition>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c249"
      decimals="2"
      id="ixv-48059"
      unitRef="usdPershares">3.5</us-gaap:PreferredStockConvertibleConversionPrice>
    <abvc:PercentageOfAverageAmount
      contextRef="c248"
      decimals="2"
      id="ixv-48060"
      unitRef="pure">0.90</abvc:PercentageOfAverageAmount>
    <abvc:TradingDays contextRef="c250" id="ixv-48061">P20Y</abvc:TradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c250"
      decimals="2"
      id="ixv-48062"
      unitRef="pure">1.20</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c248"
      decimals="0"
      id="ixv-48063"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice
      contextRef="c248"
      decimals="0"
      id="ixv-48064"
      unitRef="usdPershares">2</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>
    <abvc:PurchaseWarrantTerm contextRef="c251" id="ixv-48065">P5Y</abvc:PurchaseWarrantTerm>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c252" decimals="0" id="ixv-48066" unitRef="usd">480795</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c253"
      decimals="2"
      id="ixv-48067"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c254" decimals="0" id="ixv-48068" unitRef="usd">800000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c536" decimals="0" id="ixv-48069" unitRef="usd">400000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c537" decimals="0" id="ixv-48070" unitRef="usd">200000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:ReceivableWithImputedInterestFaceAmount contextRef="c256" decimals="0" id="ixv-48071" unitRef="usd">1000000</us-gaap:ReceivableWithImputedInterestFaceAmount>
    <abvc:PurchasePriceAmount contextRef="c256" decimals="0" id="ixv-48072" unitRef="usd">833333</abvc:PurchasePriceAmount>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c257"
      decimals="2"
      id="ixv-48073"
      unitRef="usdPershares">3.5</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <abvc:PercentageOfAverageAmount
      contextRef="c257"
      decimals="2"
      id="ixv-48074"
      unitRef="pure">0.90</abvc:PercentageOfAverageAmount>
    <abvc:TradingDays contextRef="c257" id="ixv-48075">P20D</abvc:TradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c257"
      decimals="2"
      id="ixv-48076"
      unitRef="pure">1.20</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <abvc:PurchaseWarrantTerm contextRef="c258" id="ixv-48077">P5Y</abvc:PurchaseWarrantTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c256"
      decimals="0"
      id="ixv-48078"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c258"
      decimals="0"
      id="ixv-48079"
      unitRef="usdPershares">2</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c259" decimals="0" id="ixv-48080" unitRef="usd">394071</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c260"
      decimals="2"
      id="ixv-48081"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c536" decimals="0" id="ixv-48082" unitRef="usd">400000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c537" decimals="0" id="ixv-48083" unitRef="usd">200000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <abvc:DebtInstrumentOutstandingPrincipal contextRef="c255" decimals="0" id="ixv-48084" unitRef="usd">600000</abvc:DebtInstrumentOutstandingPrincipal>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c261"
      decimals="0"
      id="ixv-48085"
      unitRef="shares">1000000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c262"
      decimals="0"
      id="ixv-48086"
      unitRef="shares">500000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c538"
      decimals="0"
      id="ixv-48087"
      unitRef="shares">1029167</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c246"
      decimals="2"
      id="ixv-48088"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c539"
      decimals="2"
      id="ixv-48089"
      unitRef="usdPershares">0.42</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c540"
      decimals="2"
      id="ixv-48090"
      unitRef="usdPershares">0.4</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:InterestExpenseOther contextRef="c541" decimals="0" id="ixv-48091" unitRef="usd">209372</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c542" decimals="0" id="ixv-48092" unitRef="usd">172884</us-gaap:InterestExpenseOther>
    <us-gaap:ConvertibleNotesPayable contextRef="c543" decimals="0" id="ixv-48093" unitRef="usd">30000</us-gaap:ConvertibleNotesPayable>
    <abvc:ConsiderationAmount contextRef="c266" decimals="0" id="ixv-48094" unitRef="usd">60000</abvc:ConsiderationAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c544" id="ixv-48095">P1Y</us-gaap:DebtInstrumentTerm>
    <abvc:PercentageOfAnnualDiscountRate
      contextRef="c545"
      decimals="4"
      id="ixv-48096"
      unitRef="pure">0.0689</abvc:PercentageOfAnnualDiscountRate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c546"
      decimals="2"
      id="ixv-48097"
      unitRef="pure">0</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c547"
      decimals="0"
      id="ixv-48098"
      unitRef="usdPershares">5</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c0" decimals="0" id="ixv-48099" unitRef="usd">56132</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c548" decimals="0" id="ixv-48100" unitRef="usd">3868</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentTerm contextRef="c549" id="ixv-48101">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:InterestExpenseDebt contextRef="c548" decimals="0" id="ixv-48102" unitRef="usd">984</us-gaap:InterestExpenseDebt>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c0" id="ixv-40336">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The carrying amounts of the liability component
are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: left; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;March 31, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Entity&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Maturity&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Stated&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Effective&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Conversion&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Common&lt;br/&gt; Stock&lt;br/&gt; to&#160;be&lt;br/&gt; converted&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Balance&lt;br/&gt; Sheet Date&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Unamortized&lt;br/&gt; Discount&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Carrying&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Fair&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2nd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 4%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 17, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;May 19, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;86.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 4%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;26,110&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;173,890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;3rd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;January 17, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;July 17, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;87.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;196,114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;603,886&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;960,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,119&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;28,881&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 5, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,118&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;28,882&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,060,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;224,460&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;835,539&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; text-align: left; white-space: nowrap; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Entity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Issuance&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Maturity&lt;br/&gt; Date&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Stated&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Effective&lt;br/&gt; Interest&lt;br/&gt; Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Conversion&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Common&lt;br/&gt; Stock&lt;br/&gt; to&#160;be&lt;br/&gt; converted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Principal&lt;br/&gt; Amount at&lt;br/&gt; Balance&lt;br/&gt; Sheet Date&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Unamortized&lt;br/&gt; Discount&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Carrying&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Fair&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2nd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 4%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 17, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;May 19, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;86.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 4%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;118,048&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;281,952&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;480,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;3rd LIND Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;January 17, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;July 17, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;87.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;ABVC&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;388,685&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;611,315&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,610&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;28,390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;Other Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 5, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;November 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;AiBtl&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;28,389&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;2,260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,460,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;509,954&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;950,046&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;1,740,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c550" id="ixv-40435">ABVC</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c550" id="ixv-40440">2023-11-17</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c550" id="ixv-40445">2025-05-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c550" decimals="0" id="ixv-48103" unitRef="usd">1200000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c551"
      decimals="2"
      id="ixv-48104"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c551"
      decimals="4"
      id="ixv-48105"
      unitRef="pure">0.8694</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c551"
      decimals="INF"
      id="ixv-48106"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c550" id="ixv-40482">ABVC</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c550" decimals="0" id="ixv-48107" unitRef="usd">200000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c551" decimals="0" id="ixv-48108" unitRef="usd">26110</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c550" decimals="0" id="ixv-48109" unitRef="usd">173890</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c551" decimals="0" id="ixv-48110" unitRef="usd">240000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c552" id="ixv-40522">ABVC</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c552" id="ixv-40527">2024-01-17</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c552" id="ixv-40532">2025-07-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c552" decimals="0" id="ixv-48111" unitRef="usd">1000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c553"
      decimals="2"
      id="ixv-48112"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c553"
      decimals="4"
      id="ixv-48113"
      unitRef="pure">0.874</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c553"
      decimals="INF"
      id="ixv-48114"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c552" id="ixv-40569">ABVC</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c552" decimals="0" id="ixv-48115" unitRef="usd">800000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c553" decimals="0" id="ixv-48116" unitRef="usd">196114</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c552" decimals="0" id="ixv-48117" unitRef="usd">603886</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c553" decimals="0" id="ixv-48118" unitRef="usd">960000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c554" id="ixv-40609">AiBtl</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c554" id="ixv-40614">2024-11-01</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c554" id="ixv-40619">2025-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c554" decimals="0" id="ixv-48119" unitRef="usd">30000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c555"
      decimals="2"
      id="ixv-48120"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c555"
      decimals="4"
      id="ixv-48121"
      unitRef="pure">0.0689</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c555"
      decimals="INF"
      id="ixv-48122"
      unitRef="usdPershares">5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c554" id="ixv-40656">AiBtl</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c554" decimals="0" id="ixv-48123" unitRef="usd">30000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c555" decimals="0" id="ixv-48124" unitRef="usd">1119</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c554" decimals="0" id="ixv-48125" unitRef="usd">28881</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c555" decimals="0" id="ixv-48126" unitRef="usd">30000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c556" id="ixv-40696">AiBtl</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c556" id="ixv-40701">2024-11-05</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c556" id="ixv-40706">2025-11-05</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c556" decimals="0" id="ixv-48127" unitRef="usd">30000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c557"
      decimals="2"
      id="ixv-48128"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c557"
      decimals="4"
      id="ixv-48129"
      unitRef="pure">0.0689</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c557"
      decimals="INF"
      id="ixv-48130"
      unitRef="usdPershares">5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c556" id="ixv-40743">AiBtl</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c556" decimals="0" id="ixv-48131" unitRef="usd">30000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c557" decimals="0" id="ixv-48132" unitRef="usd">1118</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c556" decimals="0" id="ixv-48133" unitRef="usd">28882</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c557" decimals="0" id="ixv-48134" unitRef="usd">30000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c0" decimals="0" id="ixv-48135" unitRef="usd">2260000</us-gaap:DebtInstrumentIssuedPrincipal>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c0" decimals="0" id="ixv-48136" unitRef="usd">1060000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c5" decimals="0" id="ixv-48137" unitRef="usd">224460</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c0" decimals="0" id="ixv-48138" unitRef="usd">835539</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c5" decimals="0" id="ixv-48139" unitRef="usd">1260000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c271" id="ixv-40956">ABVC</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c271" id="ixv-40961">2023-11-17</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c271" id="ixv-40966">2025-05-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c271" decimals="0" id="ixv-48140" unitRef="usd">1200000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c272"
      decimals="2"
      id="ixv-48141"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c272"
      decimals="4"
      id="ixv-48142"
      unitRef="pure">0.8694</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c272"
      decimals="INF"
      id="ixv-48143"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c271" id="ixv-41003">ABVC</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c271" decimals="0" id="ixv-48144" unitRef="usd">400000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c272" decimals="0" id="ixv-48145" unitRef="usd">118048</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c271" decimals="0" id="ixv-48146" unitRef="usd">281952</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c272" decimals="0" id="ixv-48147" unitRef="usd">480000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c273" id="ixv-41043">ABVC</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c273" id="ixv-41048">2024-01-17</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c273" id="ixv-41053">2025-07-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c273" decimals="0" id="ixv-48148" unitRef="usd">1000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c274"
      decimals="2"
      id="ixv-48149"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c274"
      decimals="4"
      id="ixv-48150"
      unitRef="pure">0.874</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c274"
      decimals="INF"
      id="ixv-48151"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c273" id="ixv-41090">ABVC</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c273" decimals="0" id="ixv-48152" unitRef="usd">1000000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c274" decimals="0" id="ixv-48153" unitRef="usd">388685</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c273" decimals="0" id="ixv-48154" unitRef="usd">611315</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c274" decimals="0" id="ixv-48155" unitRef="usd">1200000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c275" id="ixv-41130">AiBtl</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c275" id="ixv-41135">2024-11-01</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c275" id="ixv-41140">2025-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c275" decimals="0" id="ixv-48156" unitRef="usd">30000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c276"
      decimals="2"
      id="ixv-48157"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c276"
      decimals="4"
      id="ixv-48158"
      unitRef="pure">0.0689</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c276"
      decimals="INF"
      id="ixv-48159"
      unitRef="usdPershares">5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c275" id="ixv-41177">AiBtl</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c275" decimals="0" id="ixv-48160" unitRef="usd">30000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c276" decimals="0" id="ixv-48161" unitRef="usd">1610</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c275" decimals="0" id="ixv-48162" unitRef="usd">28390</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c276" decimals="0" id="ixv-48163" unitRef="usd">30000</us-gaap:DebtInstrumentFairValue>
    <abvc:DebtInstrumentIssuanceEntity contextRef="c277" id="ixv-41217">AiBtl</abvc:DebtInstrumentIssuanceEntity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c277" id="ixv-41222">2024-11-05</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c277" id="ixv-41227">2025-11-05</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c277" decimals="0" id="ixv-48164" unitRef="usd">30000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c278"
      decimals="2"
      id="ixv-48165"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c278"
      decimals="4"
      id="ixv-48166"
      unitRef="pure">0.0689</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c278"
      decimals="INF"
      id="ixv-48167"
      unitRef="usdPershares">5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:DebtInstrumentCommonStockToBeConverted contextRef="c277" id="ixv-41264">AiBtl</abvc:DebtInstrumentCommonStockToBeConverted>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c277" decimals="0" id="ixv-48168" unitRef="usd">30000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c278" decimals="0" id="ixv-48169" unitRef="usd">1611</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c277" decimals="0" id="ixv-48170" unitRef="usd">28389</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c278" decimals="0" id="ixv-48171" unitRef="usd">30000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c7" decimals="0" id="ixv-48172" unitRef="usd">2260000</us-gaap:DebtInstrumentIssuedPrincipal>
    <abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate contextRef="c7" decimals="0" id="ixv-48173" unitRef="usd">1460000</abvc:DebtInstrumentPrincipalAmountAtBalanceSheetDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c1" decimals="0" id="ixv-48174" unitRef="usd">509954</us-gaap:DebtInstrumentUnamortizedDiscount>
    <abvc:DebtInstrumentCarryingValue contextRef="c7" decimals="0" id="ixv-48175" unitRef="usd">950046</abvc:DebtInstrumentCarryingValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c1" decimals="0" id="ixv-48176" unitRef="usd">1740000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-41396">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,799,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,799,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued directors and officers (owners) compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;991,821&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,025,867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash portion of the Lind Note repayments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;227,284&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;127,759&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;140,252&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;126,106&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;617,879&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;557,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,826,819&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,509,422&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-41401">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,799,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,799,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued directors and officers (owners) compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;991,821&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,025,867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash portion of the Lind Note repayments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;227,284&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;127,759&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;140,252&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;126,106&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;617,879&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;557,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,826,819&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,509,422&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <abvc:AccruedResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-48177" unitRef="usd">1799583</abvc:AccruedResearchAndDevelopmentExpense>
    <abvc:AccruedResearchAndDevelopmentExpense contextRef="c1" decimals="0" id="ixv-48178" unitRef="usd">1799583</abvc:AccruedResearchAndDevelopmentExpense>
    <us-gaap:AccruedSalariesCurrent contextRef="c5" decimals="0" id="ixv-48179" unitRef="usd">991821</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c1" decimals="0" id="ixv-48180" unitRef="usd">1025867</us-gaap:AccruedSalariesCurrent>
    <abvc:CashPortionOfTheLindNoteRepayments contextRef="c5" decimals="0" id="ixv-48181" unitRef="usd">227284</abvc:CashPortionOfTheLindNoteRepayments>
    <abvc:CashPortionOfTheLindNoteRepayments contextRef="c1" decimals="0" id="ixv-48182" unitRef="usd">127759</abvc:CashPortionOfTheLindNoteRepayments>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-48183" unitRef="usd">140252</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-48184" unitRef="usd">126106</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-48185" unitRef="usd">617879</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-48186" unitRef="usd">557866</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="0" id="ixv-48187" unitRef="usd">3826819</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c1" decimals="0" id="ixv-48188" unitRef="usd">3509422</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:ShortTermDebtTextBlock contextRef="c0" id="ixv-41555">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;9. SHORT-TERM LOANS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term loans consists of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cathay United Bank&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;169,407&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;200,252&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;CTBC Bank&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;602,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other individual&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;801,407&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840,252&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Cathay United Bank&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 28, 2016, BioLite Taiwan and Cathay
United Bank entered into a one-year bank loan agreement (the &#x201c;Cathay United Loan Agreement&#x201d;) in a credit limit amount of
NTD 7.5 million, equivalent to $228,750. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest
at a floating rate of prime rate plus 1.31%. The prime rate is based on the term deposit saving interest rate of Cathay United Bank.
The Company renews the agreement with the bank every year, and the next renewal date is September 6, 2025. As of March 31, 2025 and December
31, 2024, the effective interest rates per annum was 2.99% and 2.99%, respectively. The loan is collateralized by the building and improvement
of BioLite Taiwan, and is also personal guaranteed by the Company&#x2019;s chairman. During the three months ended March 31, 2025, the
Company made payments of the loan in total of NTD 937,500, equivalent to $29,250.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses were $1,470 and $1,736 for
the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;CTBC Bank&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 12, 2017 and July 19, 2017, BioLite
Taiwan and CTBC Bank entered into two short-term saving secured bank loan agreements (the &#x201c;CTBC Loan Agreements&#x201d;) in a credit
limit amount of NTD 10 million, equivalent to $327,500, and NTD 10 million, equivalent to $327,500, respectively. Both two loans with
the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC
for one year. The Company renews the agreement with the bank every year, and the next renewal date is February 28, 2025.&#160;The loan
balances bear interest at a fixed rate of 2.5% per annum, and is secured by the money deposited in a savings account with the CTBC Bank.
This loan was also personal guaranteed by the Company&#x2019;s chairman and BioFirst. During the year ended December 31, 2020, BioLite
Taiwan opened a TCD account with CTBC bank to guarantee the loan going forward.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses were $3,761 and $3,964 for
the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Other individual &#x2013; Third party&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On March 21, 2024, the Company issued an unsecured
promissory note to a third party for the proceeds of $30,000. The note bears interest rate of 12% per annum and matures on March 21,
2025, or upon the occurrence of an event of default. The promissory note was extended for anther year and matures on March 21, 2026,
with the same terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expenses were $888 and $0 for the
three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c0" id="ixv-41565">&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term loans consists of the following:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cathay United Bank&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;169,407&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;200,252&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;CTBC Bank&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;602,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other individual&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;801,407&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840,252&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c559" decimals="0" id="ixv-48189" unitRef="usd">169407</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c286" decimals="0" id="ixv-48190" unitRef="usd">200252</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c567" decimals="0" id="ixv-48191" unitRef="usd">602000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c299" decimals="0" id="ixv-48192" unitRef="usd">610000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c568" decimals="0" id="ixv-48193" unitRef="usd">30000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c301" decimals="0" id="ixv-48194" unitRef="usd">30000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c5" decimals="0" id="ixv-48195" unitRef="usd">801407</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c1" decimals="0" id="ixv-48196" unitRef="usd">840252</us-gaap:ShortTermBorrowings>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c283"
      decimals="-5"
      id="ixv-48197"
      unitRef="twd">7500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c283" decimals="0" id="ixv-48198" unitRef="usd">228750</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c558" id="ixv-48199">2017-06-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="c285"
      decimals="4"
      id="ixv-48200"
      unitRef="pure">0.0131</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c559"
      decimals="4"
      id="ixv-48201"
      unitRef="pure">0.0299</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c286"
      decimals="4"
      id="ixv-48202"
      unitRef="pure">0.0299</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c0" decimals="0" id="ixv-48203" unitRef="twd">937500</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c0" decimals="0" id="ixv-48204" unitRef="usd">29250</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c560" decimals="0" id="ixv-48205" unitRef="usd">1470</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c561" decimals="0" id="ixv-48206" unitRef="usd">1736</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c290"
      decimals="-6"
      id="ixv-48207"
      unitRef="twd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c291"
      decimals="-6"
      id="ixv-48208"
      unitRef="twd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c290" decimals="0" id="ixv-48209" unitRef="usd">327500</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c291" decimals="0" id="ixv-48210" unitRef="usd">327500</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c293" id="ixv-48211">2018-01-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c292" id="ixv-48212">2018-01-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentTerm contextRef="c294" id="ixv-48213">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsSavings
      contextRef="c562"
      decimals="3"
      id="ixv-48214"
      unitRef="pure">0.025</us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsSavings>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c563" decimals="0" id="ixv-48215" unitRef="usd">3761</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c564" decimals="0" id="ixv-48216" unitRef="usd">3964</us-gaap:InterestExpenseShortTermBorrowings>
    <abvc:ProceedsFromIssuanceOfAPromissoryNote contextRef="c296" decimals="0" id="ixv-48217" unitRef="usd">30000</abvc:ProceedsFromIssuanceOfAPromissoryNote>
    <us-gaap:ShortTermDebtPercentageBearingVariableInterestRate
      contextRef="c297"
      decimals="2"
      id="ixv-48218"
      unitRef="pure">0.12</us-gaap:ShortTermDebtPercentageBearingVariableInterestRate>
    <abvc:ShortTermDebtMaturityDate contextRef="c297" id="ixv-48219">2025-03-21</abvc:ShortTermDebtMaturityDate>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c565" decimals="0" id="ixv-48220" unitRef="usd">888</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c566" decimals="0" id="ixv-48221" unitRef="usd">0</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-41728">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;10. RELATED PARTIES TRANSACTIONS&lt;/b&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The related parties of the company with whom
transactions are reported in these financial statements are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr&gt; &lt;td style="border-bottom: black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of entity or Individual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company and its subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GenePharm Inc. (the &#x201c;GenePharm&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Jiangs&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst&lt;br/&gt; &lt;br/&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.&lt;br/&gt; &lt;br/&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.&lt;br/&gt; &lt;br/&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company.&lt;br/&gt; &lt;br/&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation (&#x201c;BHK&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AiBtl (Holding) BioPharma, Inc. (&#x201c;AiBtl Holding&#x201d;) &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Founding shareholder of AiBtl BioPharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jaimes Vargas Russman &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CEO of AiBtl BioPharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lion Arts Promotion, Inc.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by the Jiangs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenues &#x2013; related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;There was no cash receipt for the three months
ended March 31, 2025 and 2024 from related parties on the licensing agreements or other services. Therefore, no related party revenue
was recognized during these periods. Please refer to Note 4, Collaborative Agreements for details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Consulting fees &#x2013; related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2024, the Company engaged Lion Arts
Promotion Inc to provide operation, business development, human resources, and capital finance consulting services. The agreement is
for 12 months expiring in February 2025, and is optional for renewal upon mutual agreement. The Company incurred $68,141 and $14,628
for the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Accounts receivable - related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounts receivable due from related parties
consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-349"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-350"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-351"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-352"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024, management considered
the outstanding accounts receivable from Rgene may not be recoverable, and recognized credit loss in full.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Due from related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amounts due from related parties consisted
of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from related party- Current&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,867&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;565,711&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;535,252&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;589,340&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;537,119&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,155,051&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from related parties- Non-current, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst (Australia) (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;118,633&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;120,210&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;958,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,014,193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: allowance for expected credit losses accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(958,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,014,193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-353"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-354"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1) &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 and made $500,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#x2019;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided. The loan was converted to Rgene&#x2019;s common stock in May 2024 but the Company was not informed until April 2025. Please see detail discussion in Note 7.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of March 31, 2025 and December 31, 2024, the outstanding loan balance were $0 and $500,000; and accrued interest was $&lt;span style="-sec-ix-hidden: hidden-fact-356"&gt;0and&lt;/span&gt; $63,819, respectively. Both principal and accrued interest were converted to Rgene&#x2019;s common stocks.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of March 31, 2025 and December 31, 2024, the Company has other receivables amounted to $1,867 and $1,892, respectively, from Rgene due to daily operations.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of March 31, 2025 and December 31, 2024, the outstanding loan balance were NTD 15,458,360 (approximately $465,297) and NTD 17,571,076 (approximately $535,918), respectively; accrued interests were$68,971 and $53,422, respectively. The Company has received NTD 2,080,000 (approximately $64,896) and $0 repayment during the three months ended March 31, 2025 and 2024, respectively. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of March 31, 2025 and December 31, 2024, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2025 and December 31, 2024, due from BHK was both NTD 3,941,299 (approximately$118,633 and $120,210, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of NTD 3,941,299 as of December 31, 2024. No recovery was made during three months ended March 31, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s due from related parties
are subject to certain risks that our collaborative parties, including OncoX and FEYE, would face. Such risks exist in future market
conditions, macro economy, legal and regulatory, results of clinical trials and product developments, and among others. As of March 31,
2025, the Company&#x2019;s comprehensive review of these due from related party balances indicates that there are no expected losses except
those being recognized above. This conclusion is based on the business relationships with our related parties and the absence of any
significant indicators of potential default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Due to related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amount due to related parties consisted of
the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;AiBtl Holding (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;348,219&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;348,219&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Jiangs (2)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;222,522&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;274,170&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shareholders (3)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;140,266&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;142,130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Lion Art Promotions Inc (4)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;65,738&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-355"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Directors (5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12,953&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,526&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;819,384&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;773,045&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2025 and December 31, 2024, the outstanding balance due to the Jiangs amounted to $222,522 and $274,170, respectively. These loans bear no interest and are due on demand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2018, the Company&#x2019;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of March 31, 2025 and December 31, 2024, the outstanding principal and accrued interest was $140,266 and $142,130, respectively. Interest expenses in connection with these loans were $4,963 and $5,938 for the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued consulting services fee for the three months ended March 31, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of March 31, 2025 and December 31, 2024, due to Directors amounted to $12,953 and $8,526, respectively, were related to the daily operating expenses since inception in 2023 paid by the Directors of AiBtl on behalf of the entity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-41733">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The related parties of the company with whom
transactions are reported in these financial statements are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr&gt; &lt;td style="border-bottom: black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of entity or Individual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company and its subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GenePharm Inc. (the &#x201c;GenePharm&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Jiangs&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst&lt;br/&gt; &lt;br/&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.&lt;br/&gt; &lt;br/&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.&lt;br/&gt; &lt;br/&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company.&lt;br/&gt; &lt;br/&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation (&#x201c;BHK&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AiBtl (Holding) BioPharma, Inc. (&#x201c;AiBtl Holding&#x201d;) &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Founding shareholder of AiBtl BioPharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jaimes Vargas Russman &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CEO of AiBtl BioPharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lion Arts Promotion, Inc.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by the Jiangs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accounts receivable due from related parties
consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-349"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-350"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-351"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-352"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from related party- Current&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rgene (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,867&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;565,711&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;535,252&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;589,340&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;537,119&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,155,051&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from related parties- Non-current, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioFirst (Australia) (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;839,983&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;BioHopeKing Corporation (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;118,633&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;120,210&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;958,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,014,193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: allowance for expected credit losses accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(958,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,014,193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-353"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-354"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1) &#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 and made $500,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#x2019;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided. The loan was converted to Rgene&#x2019;s common stock in May 2024 but the Company was not informed until April 2025. Please see detail discussion in Note 7.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of March 31, 2025 and December 31, 2024, the outstanding loan balance were $0 and $500,000; and accrued interest was $&lt;span style="-sec-ix-hidden: hidden-fact-356"&gt;0and&lt;/span&gt; $63,819, respectively. Both principal and accrued interest were converted to Rgene&#x2019;s common stocks.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of March 31, 2025 and December 31, 2024, the Company has other receivables amounted to $1,867 and $1,892, respectively, from Rgene due to daily operations.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of March 31, 2025 and December 31, 2024, the outstanding loan balance were NTD 15,458,360 (approximately $465,297) and NTD 17,571,076 (approximately $535,918), respectively; accrued interests were$68,971 and $53,422, respectively. The Company has received NTD 2,080,000 (approximately $64,896) and $0 repayment during the three months ended March 31, 2025 and 2024, respectively. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of March 31, 2025 and December 31, 2024, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2025 and December 31, 2024, due from BHK was both NTD 3,941,299 (approximately$118,633 and $120,210, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of NTD 3,941,299 as of December 31, 2024. No recovery was made during three months ended March 31, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amount due to related parties consisted of
the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;AiBtl Holding (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;348,219&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;348,219&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Jiangs (2)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;222,522&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;274,170&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shareholders (3)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;140,266&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;142,130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Lion Art Promotions Inc (4)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;65,738&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-355"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Directors (5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12,953&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,526&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;819,384&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;773,045&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2025 and December 31, 2024, the outstanding balance due to the Jiangs amounted to $222,522 and $274,170, respectively. These loans bear no interest and are due on demand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2018, the Company&#x2019;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of March 31, 2025 and December 31, 2024, the outstanding principal and accrued interest was $140,266 and $142,130, respectively. Interest expenses in connection with these loans were $4,963 and $5,938 for the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued consulting services fee for the three months ended March 31, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of March 31, 2025 and December 31, 2024, due to Directors amounted to $12,953 and $8,526, respectively, were related to the daily operating expenses since inception in 2023 paid by the Directors of AiBtl on behalf of the entity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c583" id="ixv-41754">Entity controlled by controlling beneficiary shareholder of YuanGene</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c584" id="ixv-41762">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c585" id="ixv-41770">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c586" id="ixv-41778">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c587" id="ixv-41788">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst  Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.  Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.  Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company.  Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c588" id="ixv-41815">Entity controlled by controlling beneficiary shareholder of ABVC</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c589" id="ixv-41823">Entity controlled by controlling beneficiary shareholder of ABVC</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c590" id="ixv-41831">Founding shareholder of AiBtl BioPharma Inc.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c591" id="ixv-41839">CEO of AiBtl BioPharma Inc.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c592" id="ixv-41847">Entity controlled by the Jiangs.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c0" decimals="0" id="ixv-48225" unitRef="usd">68141</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c9" decimals="0" id="ixv-48226" unitRef="usd">14628</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c593"
      decimals="0"
      id="ix_69_fact"
      unitRef="usd">1867</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c233"
      decimals="0"
      id="ix_70_fact"
      unitRef="usd">565711</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c594"
      decimals="0"
      id="ix_71_fact"
      unitRef="usd">535252</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c231"
      decimals="0"
      id="ix_72_fact"
      unitRef="usd">589340</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c6" decimals="0" id="ixv-48231" unitRef="usd">537119</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="0" id="ixv-48232" unitRef="usd">1155051</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent
      contextRef="c595"
      decimals="0"
      id="ix_73_fact"
      unitRef="usd">839983</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent
      contextRef="c596"
      decimals="0"
      id="ix_74_fact"
      unitRef="usd">839983</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent
      contextRef="c597"
      decimals="0"
      id="ix_75_fact"
      unitRef="usd">118633</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent
      contextRef="c598"
      decimals="0"
      id="ix_76_fact"
      unitRef="usd">120210</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent contextRef="c5" decimals="0" id="ixv-48237" unitRef="usd">958616</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent contextRef="c1" decimals="0" id="ixv-48238" unitRef="usd">1014193</us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent contextRef="c5" decimals="0" id="ixv-48239" unitRef="usd">958616</us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent contextRef="c1" decimals="0" id="ixv-48240" unitRef="usd">1014193</us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c305" decimals="0" id="ixv-48241" unitRef="usd">1000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c569" decimals="0" id="ixv-48242" unitRef="usd">500000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="c306"
      decimals="2"
      id="ixv-48243"
      unitRef="pure">0.05</us-gaap:AccountsPayableInterestBearingInterestRate>
    <abvc:PercentageOfWorkingCapital
      contextRef="c570"
      decimals="3"
      id="ixv-48244"
      unitRef="pure">0.064</abvc:PercentageOfWorkingCapital>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c571"
      decimals="2"
      id="ixv-48245"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c572"
      decimals="2"
      id="ixv-48246"
      unitRef="pure">0.20</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DepositLiabilitiesAccruedInterest contextRef="c6" decimals="0" id="ixv-48247" unitRef="usd">0</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c3" decimals="0" id="ixv-48248" unitRef="usd">500000</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:DepositLiabilitiesAccruedInterest contextRef="c3" decimals="0" id="ixv-48249" unitRef="usd">63819</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:OtherReceivables contextRef="c6" decimals="0" id="ixv-48250" unitRef="usd">1867</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c3" decimals="0" id="ixv-48251" unitRef="usd">1892</us-gaap:OtherReceivables>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c309" decimals="0" id="ixv-48253" unitRef="twd">11072360</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c309" decimals="0" id="ixv-48254" unitRef="usd">337707</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="c310"
      decimals="2"
      id="ixv-48255"
      unitRef="pure">0.12</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c311" decimals="0" id="ixv-48256" unitRef="twd">11406000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c311" decimals="0" id="ixv-48257" unitRef="usd">347883</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="c311"
      decimals="2"
      id="ixv-48258"
      unitRef="pure">0.12</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c573" decimals="0" id="ixv-48259" unitRef="twd">15458360</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c574" decimals="0" id="ixv-48260" unitRef="usd">465297</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c312" decimals="0" id="ixv-48261" unitRef="twd">17571076</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c311" decimals="0" id="ixv-48262" unitRef="usd">535918</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c575" decimals="0" id="ixv-48263" unitRef="usd">68971</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c313" decimals="0" id="ixv-48264" unitRef="usd">53422</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:RepaymentsOfDebt contextRef="c0" decimals="0" id="ixv-48265" unitRef="twd">2080000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c0" decimals="0" id="ixv-48266" unitRef="usd">64896</us-gaap:RepaymentsOfDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c7" decimals="0" id="ixv-48267" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c315" decimals="0" id="ixv-48268" unitRef="usd">361487</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RelatedPartyTransactionDate contextRef="c316" id="ixv-48269">2021-09-30</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="c316"
      decimals="3"
      id="ixv-48270"
      unitRef="pure">0.065</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c317" decimals="0" id="ixv-48271" unitRef="usd">67873</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LoansPayable contextRef="c318" decimals="0" id="ixv-48272" unitRef="usd">249975</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c319" decimals="0" id="ixv-48273" unitRef="usd">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RelatedPartyTransactionDate contextRef="c0" id="ixv-48274">2022-11-30</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionRate contextRef="c0" decimals="3" id="ixv-48275" unitRef="pure">0.065</us-gaap:RelatedPartyTransactionRate>
    <abvc:LoanAgreementAmount contextRef="c181" decimals="0" id="ixv-48276" unitRef="usd">507000</abvc:LoanAgreementAmount>
    <abvc:LoanAgreementAmount contextRef="c320" decimals="0" id="ixv-48277" unitRef="usd">88091</abvc:LoanAgreementAmount>
    <abvc:LoanAgreementAmount contextRef="c576" decimals="0" id="ixv-48278" unitRef="usd">25500</abvc:LoanAgreementAmount>
    <us-gaap:RelatedPartyTransactionRate contextRef="c0" decimals="3" id="ixv-48279" unitRef="pure">0.065</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c11" decimals="0" id="ixv-48280" unitRef="usd">681185</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c2" decimals="0" id="ixv-48281" unitRef="usd">158798</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:AccountsReceivableNet contextRef="c2" decimals="0" id="ixv-48282" unitRef="usd">839983</us-gaap:AccountsReceivableNet>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="c577" id="ixv-48283">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent contextRef="c5" decimals="0" id="ixv-48284" unitRef="twd">3941299</us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent contextRef="c528" decimals="0" id="ixv-48285" unitRef="usd">118633</us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent contextRef="c221" decimals="0" id="ixv-48286" unitRef="usd">120210</us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent>
    <abvc:RecognizedCreditLosses contextRef="c7" decimals="0" id="ixv-48287" unitRef="usd">3941299</abvc:RecognizedCreditLosses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c599"
      decimals="0"
      id="ix_77_fact"
      unitRef="usd">348219</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c600"
      decimals="0"
      id="ix_78_fact"
      unitRef="usd">348219</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c601"
      decimals="0"
      id="ix_79_fact"
      unitRef="usd">222522</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c602"
      decimals="0"
      id="ix_80_fact"
      unitRef="usd">274170</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c603"
      decimals="0"
      id="ix_81_fact"
      unitRef="usd">140266</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c604"
      decimals="0"
      id="ix_82_fact"
      unitRef="usd">142130</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c605"
      decimals="0"
      id="ix_83_fact"
      unitRef="usd">65738</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c607"
      decimals="0"
      id="ix_84_fact"
      unitRef="usd">12953</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c608"
      decimals="0"
      id="ix_85_fact"
      unitRef="usd">8526</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c6" decimals="0" id="ixv-48297" unitRef="usd">819384</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-48298" unitRef="usd">773045</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings contextRef="c326" decimals="0" id="ixv-48300" unitRef="usd">40000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c327" decimals="0" id="ixv-48301" unitRef="usd">60000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c328" decimals="0" id="ixv-48302" unitRef="usd">33732</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c329" decimals="0" id="ixv-48303" unitRef="usd">214487</us-gaap:ShortTermBorrowings>
    <abvc:OutstandingBalanceAmount contextRef="c5" decimals="0" id="ixv-48304" unitRef="usd">222522</abvc:OutstandingBalanceAmount>
    <abvc:OutstandingBalanceAmount contextRef="c1" decimals="0" id="ixv-48305" unitRef="usd">274170</abvc:OutstandingBalanceAmount>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="c450"
      decimals="2"
      id="ixv-48306"
      unitRef="pure">0.12</us-gaap:AccountsPayableInterestBearingInterestRate>
    <abvc:OutstandingPrincipalAmount contextRef="c578" decimals="0" id="ixv-48307" unitRef="usd">140266</abvc:OutstandingPrincipalAmount>
    <abvc:OutstandingPrincipalAmount contextRef="c579" decimals="0" id="ixv-48308" unitRef="usd">142130</abvc:OutstandingPrincipalAmount>
    <us-gaap:InterestExpenseDebt contextRef="c580" decimals="0" id="ixv-48309" unitRef="usd">4963</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c581" decimals="0" id="ixv-48310" unitRef="usd">5938</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c582" decimals="0" id="ixv-48311" unitRef="usd">12953</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c332" decimals="0" id="ixv-48312" unitRef="usd">8526</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-42491">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;11. INCOME TAXES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Income tax
(benefit) expense for the three months ended March 31, 2025 and 2024 were &lt;span style="-sec-ix-hidden: hidden-fact-359"&gt;$0&lt;/span&gt; and &lt;span style="-sec-ix-hidden: hidden-fact-360"&gt;$0&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets (liability)
as of March 31, 2025 and December 31, 2024 consist approximately of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;713,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;713,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,870,805&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,677,413&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;155,559&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;178,014&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(155,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(178,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,584,028&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,390,636&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,584,028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,390,636&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-357"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-358"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-42502">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets (liability)
as of March 31, 2025 and December 31, 2024 consist approximately of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;713,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;713,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,870,805&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,677,413&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;155,559&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;178,014&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(155,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(178,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,584,028&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,390,636&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,584,028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(6,390,636&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-357"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-358"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOther contextRef="c5" decimals="0" id="ixv-48313" unitRef="usd">-713223</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c1" decimals="0" id="ixv-48314" unitRef="usd">-713223</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c5" decimals="0" id="ixv-48315" unitRef="usd">5870805</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c1" decimals="0" id="ixv-48316" unitRef="usd">5677413</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <abvc:OperatingLeaseLiabilities contextRef="c5" decimals="0" id="ixv-48317" unitRef="usd">-155559</abvc:OperatingLeaseLiabilities>
    <abvc:OperatingLeaseLiabilities contextRef="c1" decimals="0" id="ixv-48318" unitRef="usd">-178014</abvc:OperatingLeaseLiabilities>
    <abvc:DeferredTaxAssetsOperatingLeaseAssets contextRef="c5" decimals="0" id="ixv-48319" unitRef="usd">-155559</abvc:DeferredTaxAssetsOperatingLeaseAssets>
    <abvc:DeferredTaxAssetsOperatingLeaseAssets contextRef="c1" decimals="0" id="ixv-48320" unitRef="usd">-178014</abvc:DeferredTaxAssetsOperatingLeaseAssets>
    <us-gaap:DeferredTaxAssetsGross contextRef="c5" decimals="0" id="ixv-48321" unitRef="usd">6584028</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c1" decimals="0" id="ixv-48322" unitRef="usd">6390636</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" id="ixv-48323" unitRef="usd">6584028</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="0" id="ixv-48324" unitRef="usd">6390636</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-42677">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;12. EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company previously reported that during
the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp;amp; Finance Corp Ltd. (a related
party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related
party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to
the agreements, the Company issued 644,972 shares of the Company&#x2019;s common stock for the consulting service from July 2019 to July
2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable. For the three months ended March
31, 2024, stock subscription receivable recognized as stock-based compensation in equity was $225,740.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;After further reviewed and investigation,
above services were completely provided by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with
the period when services are received. Therefore, the Company reversed share-based compensation expenses of $225,740 for the three months
ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On August 14, 2023, the Company entered into
a cooperation agreement with Zhonghui. Pursuant thereto, the Company expect to receive 20% of the ownership of a property and the parcel
of the land owned by Zhonghui in Leshan, Sichuan, China. During the third quarter of 2023, the Company issued to Zhonghui, an aggregate
of 370,000 shares (post-split) of the Company&#x2019;s common stock, at a per share price of $1.87, for $691,900.&#160;The Company also
issued 29,600 common stock to consultants for providing consulting services on the above transaction. Please refer Note 2 for the restatement
of prior period reported amounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 27, 2024, the Company granted 1,302,726
restricted shares to its employees and directors under the 2016 Equity Incentive Plan as compensation for their previous services, with
an issuance date of February 2, 2024. These shares are subject to a three-year restriction period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 6, 2024, the Company entered into
a definitive agreement with Shuling Jiang (&#x201c;Shuling&#x201d;), pursuant to which Shuling shall transfer the ownership of certain
land she owns located at Taoyuan City, Taiwan (the &#x201c;Land&#x201d;) to the Company (the &#x201c;Agreement&#x201d;). Shuling is a director
of the Company, is married to TS Jiang, the Company&#x2019;s Chief Strategic Officer and owns approximately 15.4% of the Company&#x2019;s
issued and outstanding shares of common stock. In consideration for the Land, the Company was to pay Shuling (i) 703,496 restricted shares
of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;) at a price of $3.50 per share and (ii) five-year warrants to purchase
up to 1,000,000 shares of the Company&#x2019;s common stock, with an exercise price of $2.00 per share. Under the Agreement, Shuling was
to also transfer outstanding liability owed on the Land (approximately $500,000) to the Company. On May 16, 2024, the Company&#x2019;s
board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not
proceed with the transfer of land ownership; the Company may reconsider the transaction at a later date. The shares were returned and
booked as treasury stock, and the warrants were not issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In July 2024, the Company entered into an
agreement with its landlord in California, pursuant that the Company issued 169,992 shares of common stock for the rent payable through
July 2024, in total of $127,494. The Company also issued 43,458 shares on August 14, 2024 for the August 2024 rent, and 46,072 shares
were issued on September 3, 2024 for the September 2024 rent. Further, we issued 64,147 shares on October 29, 2024 for October rent,
45,293 shares on November 13, 2024 for November rent, and 30,422 shares on December 26, 2024 for half month of December rent. In 2025,
the Company issued 28,135 shares, 22,031 shares, and 30,488 shares for each of the half month rent from January 2025 to March 2025, respectively.
On April 9, 2025, the Company entered another agreement with the landlord to settle remaining balance of each half month of February
and March 2025 rent, and April 2025 rent, by issuing 120,398 of the Company&#x2019;s common stock, in the value of $66,219.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On March 14, 2024, AiBtl issued 1,610,700
AiBtl&#x2019;s common stocks to a land acquisition transaction in Taiwan, including the 1-year business consulting fee of $383,500 incurred
beginning in November 2023, and the cost of land $7,670,000. Due to certain administrative processes and restrictions, AiBtl has not
acquired ownership of the land and no asset was recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Yunzhiyi, a Taiwan corporation, was incorporated
in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, the Company&#x2019;s director. This entity is set up
for holding the land that AiBtl acquired in Taiwan for developing health related business in Taiwan. Due to certain administrative processes
and restrictions, the title transfer has not completed, and no asset was recognized as of the issuance of this report. However, AiBtl
entered a series of agreements with the sellers in March 2025, to obtain the complete rights and obligations of the land while in the
process of transferring the title. These agreements are effective until the title transfer is completed. AiBtl recognized such asset
on its balance sheet on March 31, 2025. Refer to Note 6 for details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Lind Offerings and Repayments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 23, 2023, in connection with the
issuance of the Lind Note (referring to Note 7), the Company issued Lind a 5-year term of common stock purchase warrant to purchase up
to 529,167 shares (post-split) of the Company&#x2019;s common stock at an initial exercise price of $10.5 per share (post-split), subject
to adjustment. The warrant exercise price was reset to $3.5 in accordance with the issuance of common stock in relation to securities
purchase agreement in July 2023. On May 22, 2024, the exercise price of these warrants was further reset to $0.75 along with the immediate
exercise of existing warrants and issuance of the New Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the three months ended March 31, 2024,
the Company has made repayment of Lind Note with the Company&#x2019;s common stock for 751,795 shares, totaling $681,000. As of December
31, 2024, the first Lind Note was fully repaid.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 17, 2023, in connection with the
issuance of the 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note (referring to Note 7), Lind also received a 5-year term of common stock purchase warrants to
purchase up to 1,000,000 shares of the Company&#x2019;s common stock at an initial exercise price of $2 per share. The warrants were valued
using the Black-Scholes model and the fair value was determined to be $480,795, which was recorded as a debt discount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 17, 2024, in connection with the
issuance of the 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note (referring to Note 7), Lind also received 5-year term of common stock purchase warrants to purchase
up to 1,000,000 shares of the Company&#x2019;s common stock at an initial exercise price of $2 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 22, 2024, the Company and Lind entered
into a letter agreement, pursuant to which Lind will exercise, for cash, 1,000,000 of its Pre-Existing Warrants (all of the warrants
issued to Lind on February 23, 2023, November 17, 2023 and January 17, 2024 are hereinafter referred to as the &#x201c;Pre-Existing Warrants&#x201d;),
to purchase shares of Common Stock at a reduced exercise price of $0.75 per share. Such 1,000,000 Pre-Existing Warrants exercised include
529,167 warrants issued in February 2023 and 470,833 warrants issued in November 2023. Concurrently, the exercise price of all Pre-Existing
Warrants was reduced to $0.75 per share according to this agreement. Lind also received new warrants to purchase 1,000,000 shares of
common stock, exercisable at any time on or after the date of its issuance and until the five-year anniversary thereof, for $1.00 per
share (the &#x201c;New Warrants&#x201d;). The fair value of the New Warrants was determined to be $925,210 using the Black-Scholes model.
The New Warrants may be exercised via cashless exercise or resale pursuant to the registration statement that was declared effective.
As of December 31, 2024, Lind has exercised 1,000,000 shares of Pre-Existing Warrants and received 1,000,000 shares of New Warrants according
to this agreement. All warrants issued to Lind may be exercised via cashless exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the year ended December 31, 2024, the
Company issued Lind in total of 800,000 shares of the Company&#x2019;s common stock as the repayment of $800,000 principal of 2&lt;sup&gt;nd&lt;/sup&gt;
Lind Note. According to the amended agreement pursuant to Nasdaq requirements, the conversion price is subject to $1.00 floor price if
the conversion price was below such floor, resulting in effective conversion price between $0.7907 to $0.4932. The Company made additional
$327,017 cash repayments, with $127,759 unpaid cash booked in Accrued Expenses and Other Current Liabilities as of December 31, 2024.
On March 3, 2025 and April 1, 2025, Lind converted the remaining $400,000 ($200,000 in each conversion) principal balance on 2&lt;sup&gt;nd&lt;/sup&gt;
Lind Note into 400,000 shares of the Company&#x2019;s common stocks. All principal balance of 2&lt;sup&gt;nd&lt;/sup&gt; Lind Note was fully converted
as of April 1, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On March 3, 2025 and April 1, 2025, Lind converted
$400,000 ($200,000 in each conversion) principal balance on 3&lt;sup&gt;rd&lt;/sup&gt; Lind Note into 400,000 shares of the Company&#x2019;s common
stocks, leaving outstanding principal of $600,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 5, 2025, the Company and Lind entered
into a third letter agreement, pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares
of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants issued and outstanding in connection
with above Lind convertible notes as of March 31, 2025, and their activities during the three-month period ended are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of&lt;br/&gt; Underlying&lt;br/&gt; Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;br/&gt; Per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; Remaining&lt;br/&gt; in Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,029,167&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;195,542&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-361"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-362"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-363"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-364"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,029,167&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-365"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-366"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#x201c;December Letter Agreement&#x201d;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c367"
      decimals="0"
      id="ixv-48325"
      unitRef="shares">644972</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c367" decimals="0" id="ixv-48326" unitRef="usd">4514800</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c609" decimals="0" id="ixv-48327" unitRef="usd">225740</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c610" decimals="0" id="ixv-48328" unitRef="usd">225740</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="c377"
      decimals="2"
      id="ixv-48329"
      unitRef="pure">0.20</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <abvc:AggregateCommonStockShares
      contextRef="c611"
      decimals="0"
      id="ixv-48330"
      unitRef="shares">370000</abvc:AggregateCommonStockShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c612"
      decimals="2"
      id="ixv-48331"
      unitRef="usdPershares">1.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c611" decimals="0" id="ixv-48332" unitRef="usd">691900</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c377"
      decimals="0"
      id="ixv-48333"
      unitRef="shares">29600</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c380"
      decimals="0"
      id="ixv-48334"
      unitRef="shares">1302726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c381"
      decimals="3"
      id="ixv-48335"
      unitRef="pure">0.154</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AssetConsiderationCommonStock
      contextRef="c382"
      decimals="0"
      id="ixv-48336"
      unitRef="shares">703496</abvc:AssetConsiderationCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c383"
      decimals="2"
      id="ixv-48337"
      unitRef="usdPershares">3.5</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c384"
      decimals="0"
      id="ixv-48338"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c385"
      decimals="2"
      id="ixv-48339"
      unitRef="usdPershares">2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <abvc:OutstandingLiabilityOwnedAmount contextRef="c386" decimals="0" id="ixv-48340" unitRef="usd">500000</abvc:OutstandingLiabilityOwnedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c613"
      decimals="0"
      id="ixv-48341"
      unitRef="shares">169992</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PaymentsForRent contextRef="c614" decimals="0" id="ixv-48342" unitRef="usd">127494</us-gaap:PaymentsForRent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c615"
      decimals="0"
      id="ixv-48343"
      unitRef="shares">43458</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c616"
      decimals="0"
      id="ixv-48344"
      unitRef="shares">46072</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c617"
      decimals="0"
      id="ixv-48345"
      unitRef="shares">64147</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c618"
      decimals="0"
      id="ixv-48346"
      unitRef="shares">45293</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c619"
      decimals="0"
      id="ixv-48347"
      unitRef="shares">30422</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c75"
      decimals="0"
      id="ixv-48348"
      unitRef="shares">28135</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c620"
      decimals="0"
      id="ixv-48349"
      unitRef="shares">22031</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c621"
      decimals="0"
      id="ixv-48350"
      unitRef="shares">30488</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c622"
      decimals="0"
      id="ixv-48351"
      unitRef="shares">120398</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c623"
      decimals="0"
      id="ixv-48352"
      unitRef="shares">66219</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesIssued
      contextRef="c398"
      decimals="0"
      id="ixv-48353"
      unitRef="shares">1610700</us-gaap:CommonStockSharesIssued>
    <abvc:ConsultingFee contextRef="c399" decimals="0" id="ixv-48354" unitRef="usd">383500</abvc:ConsultingFee>
    <us-gaap:Land contextRef="c400" decimals="0" id="ixv-48355" unitRef="usd">7670000</us-gaap:Land>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c624"
      decimals="2"
      id="ixv-48356"
      unitRef="pure">0.90</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c625"
      decimals="2"
      id="ixv-48357"
      unitRef="pure">0.10</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <abvc:PurchaseWarrantTerm contextRef="c403" id="ixv-48358">P5Y</abvc:PurchaseWarrantTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c404"
      decimals="0"
      id="ixv-48359"
      unitRef="shares">529167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c405"
      decimals="1"
      id="ixv-48360"
      unitRef="usdPershares">10.5</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c406"
      decimals="1"
      id="ixv-48361"
      unitRef="usdPershares">3.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c407"
      decimals="2"
      id="ixv-48362"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c626"
      decimals="0"
      id="ixv-48363"
      unitRef="shares">751795</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c626" decimals="0" id="ixv-48364" unitRef="usd">681000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CreditDerivativeTerm1 contextRef="c250" id="ixv-48365">P5Y</us-gaap:CreditDerivativeTerm1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c408"
      decimals="0"
      id="ixv-48366"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c250"
      decimals="0"
      id="ixv-48367"
      unitRef="usdPershares">2</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c250" decimals="0" id="ixv-48368" unitRef="usd">480795</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:CreditDerivativeTerm1 contextRef="c257" id="ixv-48369">P5Y</us-gaap:CreditDerivativeTerm1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c409"
      decimals="0"
      id="ixv-48370"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c409"
      decimals="0"
      id="ixv-48371"
      unitRef="usdPershares">2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c410"
      decimals="0"
      id="ixv-48372"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c411"
      decimals="2"
      id="ixv-48373"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c407"
      decimals="0"
      id="ixv-48374"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c412"
      decimals="0"
      id="ixv-48375"
      unitRef="shares">529167</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c413"
      decimals="0"
      id="ixv-48376"
      unitRef="shares">470833</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c407"
      decimals="2"
      id="ixv-48377"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c414"
      decimals="0"
      id="ixv-48378"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c415"
      decimals="2"
      id="ixv-48379"
      unitRef="usdPershares">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c407" decimals="0" id="ixv-48380" unitRef="usd">925210</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c416"
      decimals="0"
      id="ixv-48381"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c417"
      decimals="0"
      id="ixv-48382"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockSharesIssued
      contextRef="c418"
      decimals="0"
      id="ixv-48383"
      unitRef="shares">800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock contextRef="c7" decimals="0" id="ixv-48384" unitRef="usd">800000</us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c419"
      decimals="2"
      id="ixv-48385"
      unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c97"
      decimals="4"
      id="ixv-48386"
      unitRef="usdPershares">0.7907</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c96"
      decimals="4"
      id="ixv-48387"
      unitRef="usdPershares">0.4932</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c7" decimals="0" id="ixv-48388" unitRef="usd">327017</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c243" decimals="0" id="ixv-48389" unitRef="usd">127759</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c627" decimals="0" id="ixv-48390" unitRef="usd">400000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c628" decimals="0" id="ixv-48391" unitRef="usd">200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c629"
      decimals="0"
      id="ixv-48392"
      unitRef="shares">400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c630" decimals="0" id="ixv-48393" unitRef="usd">400000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c631" decimals="0" id="ixv-48394" unitRef="usd">200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c630"
      decimals="0"
      id="ixv-48395"
      unitRef="shares">400000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c632" decimals="0" id="ixv-48396" unitRef="usd">600000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c633"
      decimals="0"
      id="ixv-48397"
      unitRef="shares">1029167</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c634"
      decimals="2"
      id="ixv-48398"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c635"
      decimals="2"
      id="ixv-48399"
      unitRef="usdPershares">0.4</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-42789">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants issued and outstanding in connection
with above Lind convertible notes as of March 31, 2025, and their activities during the three-month period ended are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of&lt;br/&gt; Underlying&lt;br/&gt; Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;br/&gt; Per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; Remaining&lt;br/&gt; in Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,029,167&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;195,542&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-361"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-362"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-363"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-364"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,029,167&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-365"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-366"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#x201c;December Letter Agreement&#x201d;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c638"
      decimals="INF"
      id="ixv-48400"
      unitRef="shares">2029167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c638"
      decimals="2"
      id="ixv-48401"
      unitRef="usdPershares">0.7</abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c639" id="ix_86_fact">P4Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c638" decimals="0" id="ixv-48402" unitRef="usd">195542</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c640"
      decimals="INF"
      id="ixv-48403"
      unitRef="shares">1029167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="c640"
      decimals="2"
      id="ixv-48404"
      unitRef="usdPershares">0.4</abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c641"
      decimals="INF"
      id="ixv-48405"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c641"
      decimals="2"
      id="ixv-48406"
      unitRef="usdPershares">0.4</abvc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c640" id="ixv-42971">P4Y1M20D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c641" decimals="0" id="ixv-48407" unitRef="usd">60000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c636"
      decimals="0"
      id="ixv-48408"
      unitRef="shares">1029167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c637"
      decimals="2"
      id="ixv-48409"
      unitRef="usdPershares">0.75</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c637"
      decimals="2"
      id="ixv-48410"
      unitRef="usdPershares">0.4</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-43006">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;13. STOCK OPTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has &lt;span style="-sec-ix-hidden: hidden-fact-377"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-378"&gt;not&lt;/span&gt;&lt;/span&gt; granted any options during
three months ended March 31, 2025 and 2024. The Company&#x2019;s most recent option grant was in 2022 that 76,190&#160;shares (post-split)
of common stock were granted to employees and certain consultants.&#160;The weighted average grant date fair value of options granted
in 2022 was $27.9 (post-split). There are 386,021&#160;options available for grant under the 2016 Equity Incentive Plan as of December
31, 2024. Compensation costs associated with the Company&#x2019;s stock options are recognized, based on the grant-date fair values of
these options over vesting period. As of March 31, 2025 and December 31, 2024, there were &lt;span style="-sec-ix-hidden: hidden-fact-379"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-380"&gt;no&lt;/span&gt;&lt;/span&gt; unvested options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options issued and outstanding as of March
31, 2025, and their activities during the year then ended are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Underlying&lt;br/&gt; Shares&lt;br/&gt; (post-split)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Price&lt;br/&gt; Per&#160;Share&lt;br/&gt; (post-split)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Life&lt;br/&gt; Remaining&lt;br/&gt; in Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;258,710&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.74&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-367"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-368"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-369"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-370"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-371"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-372"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-373"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;258,710&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-374"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercisable as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;258,710&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-375"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;258,710&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-376"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c425"
      decimals="0"
      id="ixv-48411"
      unitRef="shares">76190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c425"
      decimals="1"
      id="ixv-48412"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c426"
      decimals="0"
      id="ixv-48413"
      unitRef="shares">386021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-43019">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options issued and outstanding as of March
31, 2025, and their activities during the year then ended are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Underlying&lt;br/&gt; Shares&lt;br/&gt; (post-split)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Price&lt;br/&gt; Per&#160;Share&lt;br/&gt; (post-split)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Life&lt;br/&gt; Remaining&lt;br/&gt; in Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;258,710&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.74&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-367"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-368"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-369"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-370"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-371"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-372"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-373"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;258,710&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-374"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercisable as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;258,710&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-375"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;258,710&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-376"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c642"
      decimals="INF"
      id="ixv-48414"
      unitRef="shares">258710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c642"
      decimals="1"
      id="ixv-48415"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c643" id="ixv-43165">P6Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-48416"
      unitRef="shares">258710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="1"
      id="ixv-48417"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-43278">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-48418"
      unitRef="shares">258710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c5"
      decimals="1"
      id="ixv-48419"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-43315">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-48420"
      unitRef="shares">258710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="1"
      id="ixv-48421"
      unitRef="usdPershares">27.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-43352">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-43369">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;14. LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic loss per share is computed by dividing
net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended
March 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months &#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss attributable to ABVC&#x2019;s common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(842,075&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,834,199&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-average shares outstanding &#x2013; Basic &amp;amp; Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,968,232&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,736,150&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-Basic &amp;amp; Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(0.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(0.29&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Diluted loss per share takes into account
the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common
Stock. Since the Company suffered net loss for both years, any diluted shares would have anti-diluted effect.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-48422">Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended
March 31, 2025 and 2024.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months &#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net loss attributable to ABVC&#x2019;s common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(842,075&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,834,199&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-average shares outstanding &#x2013; Basic &amp;amp; Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14,968,232&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,736,150&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-Basic &amp;amp; Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(0.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(0.29&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-48423" unitRef="usd">-842075</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c9" decimals="0" id="ixv-48424" unitRef="usd">-2834199</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-48425"
      unitRef="shares">14968232</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-48426"
      unitRef="shares">14968232</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-48427"
      unitRef="shares">9736150</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c9"
      decimals="INF"
      id="ixv-48428"
      unitRef="shares">9736150</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-48429"
      unitRef="usdPershares">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-48430"
      unitRef="usdPershares">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c9"
      decimals="2"
      id="ixv-48431"
      unitRef="usdPershares">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c9"
      decimals="2"
      id="ixv-48432"
      unitRef="usdPershares">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-43592">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;15. LEASE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#x201c;ASC 842&#x201d;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company applied the following practical
expedients in the transition to the new standard and allowed under ASC 842:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reassessment of expired
    or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained
    leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing
    leases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of hindsight: The
    Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease
    and to purchase the underlying asset) and in assessing impairment of right-to-use assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reassessment of existing
    or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted
    for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will
    be evaluated under ASU No. 2016-02.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Separation of lease
    and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term lease recognition
    exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities
    for leases with a term less than 12 months.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities. ROU assets represent the
Company&#x2019;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#x2019;s obligation to
make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#x2019;s future minimum based payments used
to determine the Company&#x2019;s lease liabilities mainly include minimum based rent payments. As most of Company&#x2019;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recognized lease liabilities,
with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has no finance leases. The Company&#x2019;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#x2019;s operating leases have remaining lease terms of up to approximately five years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#x202f;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;533,460&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;640,387&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities (current)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;366,475&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;403,581&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;166,985&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;236,807&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Supplemental Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following provides details of the Company&#x2019;s
lease expenses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;117,166&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;98,502&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other information related to leases is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;117,166&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;98,502&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted Average Remaining Lease Term:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.43 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.48 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted Average Discount Rate:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating&lt;br/&gt; leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025 (Excluding current period)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;302,071&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;104,849&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;46,699&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;46,699&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;46,699&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-381"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;547,017&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(13,557&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;533,460&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-43667">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#x202f;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;533,460&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;640,387&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities (current)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;366,475&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;403,581&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;166,985&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;236,807&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following provides details of the Company&#x2019;s
lease expenses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;117,166&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;98,502&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other information related to leases is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;117,166&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;98,502&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted Average Remaining Lease Term:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.43 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.48 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted Average Discount Rate:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="0" id="ixv-48433" unitRef="usd">533460</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" id="ixv-48434" unitRef="usd">640387</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="0" id="ixv-48435" unitRef="usd">366475</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-48436" unitRef="usd">403581</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="0" id="ixv-48437" unitRef="usd">166985</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-48438" unitRef="usd">236807</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="0" id="ixv-48439" unitRef="usd">117166</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c9" decimals="0" id="ixv-48440" unitRef="usd">98502</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-48441" unitRef="usd">117166</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c9" decimals="0" id="ixv-48442" unitRef="usd">98502</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-48443">P2Y5M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1" id="ixv-48444">P2Y5M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="4" id="ixv-48445" unitRef="pure">0.0132</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c1" decimals="4" id="ixv-48446" unitRef="pure">0.0119</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-44010">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating&lt;br/&gt; leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025 (Excluding current period)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;302,071&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;104,849&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;46,699&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;46,699&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;46,699&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-381"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;547,017&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(13,557&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;533,460&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c5" decimals="0" id="ixv-48447" unitRef="usd">302071</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c5" decimals="0" id="ixv-48448" unitRef="usd">104849</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c5" decimals="0" id="ixv-48449" unitRef="usd">46699</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c5" decimals="0" id="ixv-48450" unitRef="usd">46699</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c5" decimals="0" id="ixv-48451" unitRef="usd">46699</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c5" decimals="0" id="ixv-48452" unitRef="usd">547017</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c5" decimals="0" id="ixv-48453" unitRef="usd">13557</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c5" decimals="0" id="ixv-48454" unitRef="usd">533460</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-44129">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;16. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of March 31, 2025 and up through the date
of the consolidated financial statements was available to the issued.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-44140">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;17. SUBSEQUENT EVENTS&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In April 2025, the Company conducted a private
offering of its common stock to several individual investors, issuing 724,372 unregistered shares at $0.60 to $0.65 per share, raising
a total of $436,125.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In April 2025, the Company issued 9,909 unregistered
restricted shares to an individual consultant as a consideration of $9,800 ($0.99 per share) for the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In April 2025, the Company issued 50,000 and
90,277 shares of common stock to two advisors for their financial and business advisory services, as the consideration of $52,500 and
$94,791 ($1.05 and $1.05 per share), respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In April 2025, AiBtl issued 1,800 shares of
its common stock at $5 per share, raising a total of $9,000 from an individual investor.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c644"
      decimals="0"
      id="ixv-48455"
      unitRef="shares">724372</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:UnregisteredPricePerShares
      contextRef="c645"
      decimals="2"
      id="ixv-48456"
      unitRef="usdPershares">0.6</abvc:UnregisteredPricePerShares>
    <abvc:UnregisteredPricePerShares
      contextRef="c646"
      decimals="2"
      id="ixv-48457"
      unitRef="usdPershares">0.65</abvc:UnregisteredPricePerShares>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c644" decimals="0" id="ixv-48458" unitRef="usd">436125</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c647"
      decimals="0"
      id="ixv-48459"
      unitRef="shares">9909</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromContributedCapital contextRef="c647" decimals="0" id="ixv-48460" unitRef="usd">9800</us-gaap:ProceedsFromContributedCapital>
    <abvc:UnregisteredPricePerShares
      contextRef="c648"
      decimals="2"
      id="ixv-48461"
      unitRef="usdPershares">0.99</abvc:UnregisteredPricePerShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c649"
      decimals="0"
      id="ixv-48462"
      unitRef="shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c650"
      decimals="0"
      id="ixv-48463"
      unitRef="shares">90277</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromContributedCapital contextRef="c649" decimals="0" id="ixv-48464" unitRef="usd">52500</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital contextRef="c650" decimals="0" id="ixv-48465" unitRef="usd">94791</us-gaap:ProceedsFromContributedCapital>
    <abvc:UnregisteredPricePerShares
      contextRef="c651"
      decimals="2"
      id="ixv-48466"
      unitRef="usdPershares">1.05</abvc:UnregisteredPricePerShares>
    <abvc:UnregisteredPricePerShares
      contextRef="c652"
      decimals="2"
      id="ixv-48467"
      unitRef="usdPershares">1.05</abvc:UnregisteredPricePerShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c653"
      decimals="0"
      id="ixv-48468"
      unitRef="shares">1800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:UnregisteredPricePerShares
      contextRef="c654"
      decimals="0"
      id="ixv-48469"
      unitRef="usdPershares">5</abvc:UnregisteredPricePerShares>
    <us-gaap:ProceedsFromContributedCapital contextRef="c653" decimals="0" id="ixv-48470" unitRef="usd">9000</us-gaap:ProceedsFromContributedCapital>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">POS AM</dei:DocumentType>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c1"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TaxesPayableCurrent
      contextRef="c1"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c1"
      id="hidden-fact-8"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      id="hidden-fact-9"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c1"
      id="hidden-fact-10"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      id="hidden-fact-11"
      unitRef="shares"
      xsi:nil="true"/>
    <abvc:StockSubscriptionReceivedInAdvance
      contextRef="c2"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c5"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c5"
      id="hidden-fact-15"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c1"
      id="hidden-fact-16"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c5"
      id="hidden-fact-17"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c1"
      id="hidden-fact-18"
      unitRef="shares"
      xsi:nil="true"/>
    <abvc:WriteOffUnclaimedAccruedLiabilites
      contextRef="c8"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c0"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="c0"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c0"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c9"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c9"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c7"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="c7"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c7"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="c7"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c7"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c7"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c8"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="c8"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:RepurchaseOfTreasuryStocks
      contextRef="c8"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:ProceedsFromIssuanceOfAPromissoryNote
      contextRef="c8"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockPlans
      contextRef="c8"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:ProceedsFromSubsidiarysShareholderContribution
      contextRef="c7"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty
      contextRef="c7"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:IssuanceOfSubsidiarysCommonStockForConsultingServices
      contextRef="c8"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="c0"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c9"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c9"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="c9"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c0"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c9"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="c0"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="c9"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c0"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c9"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c0"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c9"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="c9"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c9"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c13"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PriorPeriodAdjustment
      contextRef="c20"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PriorPeriodAdjustment
      contextRef="c21"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PriorPeriodAdjustment
      contextRef="c23"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PriorPeriodAdjustment
      contextRef="c25"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PriorPeriodAdjustment
      contextRef="c26"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PriorPeriodAdjustment
      contextRef="c27"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PriorPeriodAdjustment
      contextRef="c28"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c30"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c31"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c33"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c34"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c35"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c36"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c30"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c31"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c33"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c34"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c35"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c36"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c30"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c31"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c33"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c34"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c35"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c36"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c30"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c31"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c33"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c34"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c35"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c36"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable
      contextRef="c29"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable
      contextRef="c30"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable
      contextRef="c31"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable
      contextRef="c33"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable
      contextRef="c34"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable
      contextRef="c35"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable
      contextRef="c36"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c29"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c30"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c31"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c33"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c34"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c35"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c36"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant
      contextRef="c30"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant
      contextRef="c31"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant
      contextRef="c33"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant
      contextRef="c34"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant
      contextRef="c35"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant
      contextRef="c36"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant
      contextRef="c8"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution
      contextRef="c29"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution
      contextRef="c30"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution
      contextRef="c31"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution
      contextRef="c33"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution
      contextRef="c34"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c29"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c30"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c31"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c32"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c34"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c35"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c29"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c30"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c31"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c32"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c33"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c35"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c36"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="c29"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="c30"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="c31"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="c33"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="c34"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="c36"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c38"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c39"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c46"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c47"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c49"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c50"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c51"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c52"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c45"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c46"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c47"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c49"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c50"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c51"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c52"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c46"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c47"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c48"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c49"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c50"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c52"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c7"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c46"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c49"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c50"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c51"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c52"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants
      contextRef="c46"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants
      contextRef="c47"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants
      contextRef="c49"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants
      contextRef="c50"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants
      contextRef="c51"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants
      contextRef="c52"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c45"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c46"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c47"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c48"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c49"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c50"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c52"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockSubscriptionReceived
      contextRef="c45"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockSubscriptionReceived
      contextRef="c47"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockSubscriptionReceived
      contextRef="c48"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockSubscriptionReceived
      contextRef="c49"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockSubscriptionReceived
      contextRef="c50"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockSubscriptionReceived
      contextRef="c51"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockSubscriptionReceived
      contextRef="c52"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c45"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c46"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c47"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c49"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c50"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c51"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="c45"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="c46"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="c47"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="c49"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="c50"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="c51"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c45"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c46"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c47"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c49"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c50"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c45"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c46"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c47"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c48"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c50"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c51"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c45"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c46"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c47"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c48"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c49"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c51"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c52"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c55"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c38"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c62"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c64"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c65"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c66"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN
      contextRef="c67"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c61"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c62"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c64"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c65"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c66"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c67"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c62"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c63"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c64"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c65"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c67"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty
      contextRef="c9"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c62"
      id="hidden-fact-229"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c64"
      id="hidden-fact-230"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c65"
      id="hidden-fact-231"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c66"
      id="hidden-fact-232"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c67"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c61"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c62"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c64"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c65"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService
      contextRef="c66"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c61"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c62"
      id="hidden-fact-240"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c64"
      id="hidden-fact-241"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c65"
      id="hidden-fact-242"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c66"
      id="hidden-fact-243"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c9"
      id="hidden-fact-244"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c61"
      id="hidden-fact-245"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c62"
      id="hidden-fact-246"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c63"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c65"
      id="hidden-fact-248"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c66"
      id="hidden-fact-249"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c61"
      id="hidden-fact-250"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c62"
      id="hidden-fact-251"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c63"
      id="hidden-fact-252"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c66"
      id="hidden-fact-253"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="c67"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c69"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="c103"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="c8"
      id="hidden-fact-257"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="c106"
      id="hidden-fact-258"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:ProceedsFromSubsidiarysCommonStockSubscription
      contextRef="c106"
      id="hidden-fact-259"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash
      contextRef="c106"
      decimals="0"
      id="hidden-fact-260"
      unitRef="usd">2125</abvc:EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash>
    <abvc:PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty
      contextRef="c8"
      id="hidden-fact-261"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty
      contextRef="c106"
      id="hidden-fact-262"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:WriteOffUnclaimedAccruedLiabilites
      contextRef="c8"
      id="hidden-fact-263"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c126"
      decimals="0"
      id="hidden-fact-264"
      unitRef="twd">31649000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c127"
      decimals="-6"
      id="hidden-fact-265"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c129"
      decimals="-6"
      id="hidden-fact-266"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c148"
      decimals="0"
      id="hidden-fact-267"
      unitRef="shares">42857</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c199"
      id="hidden-fact-268"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c203"
      id="hidden-fact-269"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="c219"
      id="hidden-fact-270"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="c220"
      id="hidden-fact-271"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c225"
      id="hidden-fact-272"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c226"
      id="hidden-fact-273"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c227"
      id="hidden-fact-274"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c228"
      id="hidden-fact-275"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c229"
      id="hidden-fact-276"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c230"
      id="hidden-fact-277"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c237"
      id="hidden-fact-278"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c238"
      id="hidden-fact-279"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c237"
      id="hidden-fact-280"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c238"
      id="hidden-fact-281"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="c237"
      id="hidden-fact-282"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="c238"
      id="hidden-fact-283"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c302"
      id="hidden-fact-284"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c345"
      id="hidden-fact-285"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c347"
      id="hidden-fact-286"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c348"
      id="hidden-fact-287"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="c352"
      id="hidden-fact-288"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="c353"
      id="hidden-fact-289"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="c233"
      id="hidden-fact-290"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="c3"
      id="hidden-fact-291"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent
      contextRef="c356"
      id="hidden-fact-292"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c360"
      id="hidden-fact-293"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-294"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c8"
      id="hidden-fact-295"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-296"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c8"
      id="hidden-fact-297"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-298"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c8"
      id="hidden-fact-299"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-300"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c8"
      id="hidden-fact-301"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-302"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-303"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c1"
      id="hidden-fact-304"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c2"
      id="hidden-fact-305"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="c7"
      id="hidden-fact-306"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm contextRef="c7" id="hidden-fact-307" xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue
      contextRef="c7"
      id="hidden-fact-308"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentTerm contextRef="c248" id="hidden-fact-309">P400000Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c390"
      decimals="0"
      id="hidden-fact-310"
      unitRef="shares">20000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c391"
      decimals="0"
      id="hidden-fact-311"
      unitRef="shares">20000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c427"
      id="hidden-fact-312"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c7"
      id="hidden-fact-313"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      id="hidden-fact-314"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm contextRef="c7" id="hidden-fact-315" xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue
      contextRef="c7"
      id="hidden-fact-316"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c7"
      id="hidden-fact-317"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      id="hidden-fact-318"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm contextRef="c7" id="hidden-fact-319" xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue
      contextRef="c7"
      id="hidden-fact-320"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c1"
      id="hidden-fact-321"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c1"
      id="hidden-fact-322"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c1"
      id="hidden-fact-323"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c1"
      id="hidden-fact-324"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="c433"
      id="hidden-fact-325"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="c433"
      id="hidden-fact-326"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="c433"
      id="hidden-fact-327"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="c453"
      id="hidden-fact-328"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="c461"
      id="hidden-fact-329"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c459"
      id="hidden-fact-330"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c0"
      id="hidden-fact-331"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="c0"
      id="hidden-fact-332"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c0"
      id="hidden-fact-333"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c466"
      id="hidden-fact-334"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:WriteOffUnclaimedAccruedLiabilites
      contextRef="c467"
      id="hidden-fact-335"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c470"
      decimals="0"
      id="hidden-fact-336"
      unitRef="twd">31649000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c127"
      decimals="-6"
      id="hidden-fact-337"
      unitRef="twd">50000000000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c472"
      decimals="-6"
      id="hidden-fact-338"
      unitRef="twd">50000000000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c148"
      decimals="0"
      id="hidden-fact-339"
      unitRef="shares">42857</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c474"
      decimals="0"
      id="hidden-fact-340"
      unitRef="usdPershares">50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="c527"
      id="hidden-fact-341"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="c219"
      id="hidden-fact-342"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c225"
      id="hidden-fact-343"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c531"
      id="hidden-fact-344"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c227"
      id="hidden-fact-345"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c532"
      id="hidden-fact-346"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c229"
      id="hidden-fact-347"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c11"
      id="hidden-fact-348"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="c593"
      id="hidden-fact-349"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="c233"
      id="hidden-fact-350"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="c6"
      id="hidden-fact-351"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="c3"
      id="hidden-fact-352"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent
      contextRef="c6"
      id="hidden-fact-353"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent
      contextRef="c3"
      id="hidden-fact-354"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c606"
      id="hidden-fact-355"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="c6"
      decimals="0"
      id="hidden-fact-356"
      unitRef="usd">0</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c5"
      id="hidden-fact-357"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c1"
      id="hidden-fact-358"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-359"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c9"
      id="hidden-fact-360"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued
      contextRef="c640"
      id="hidden-fact-361"
      unitRef="shares"
      xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice
      contextRef="c640"
      id="hidden-fact-362"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm contextRef="c640" id="hidden-fact-363" xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue
      contextRef="c640"
      id="hidden-fact-364"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm contextRef="c640" id="hidden-fact-365" xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue
      contextRef="c640"
      id="hidden-fact-366"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c642"
      id="hidden-fact-367"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      id="hidden-fact-368"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-369"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue
      contextRef="c0"
      id="hidden-fact-370"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c0"
      id="hidden-fact-371"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-372"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue
      contextRef="c0"
      id="hidden-fact-373"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c5"
      id="hidden-fact-374"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c5"
      id="hidden-fact-375"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c5"
      id="hidden-fact-376"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c5"
      id="hidden-fact-377"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c11"
      id="hidden-fact-378"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c5"
      id="hidden-fact-379"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c1"
      id="hidden-fact-380"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c5"
      id="hidden-fact-381"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-48862">0001173313</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-48863">true</dei:AmendmentFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-127"
          xlink:label="hidden-fact-127"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-141"
          xlink:label="hidden-fact-141"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-197"
          xlink:label="hidden-fact-197"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_36_fact"
          xlink:label="ix_36_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-173"
          xlink:label="hidden-fact-173"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_34_fact"
          xlink:label="ix_34_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-203"
          xlink:label="hidden-fact-203"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_31_fact"
          xlink:label="ix_31_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-186"
          xlink:label="hidden-fact-186"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-95"
          xlink:label="hidden-fact-95"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_37_fact"
          xlink:label="ix_37_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-114"
          xlink:label="hidden-fact-114"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_35_fact"
          xlink:label="ix_35_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_32_fact"
          xlink:label="ix_32_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_33_fact"
          xlink:label="ix_33_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-120"
          xlink:label="hidden-fact-120"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-180"
          xlink:label="hidden-fact-180"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-166"
          xlink:label="hidden-fact-166"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-88"
          xlink:label="hidden-fact-88"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-127"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-141"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-197"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_36_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-173"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_34_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-203"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_31_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-186"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-95"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_37_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-114"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_35_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_32_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_33_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-120"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-180"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-166"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-88"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_39_fact"
          xlink:label="ix_39_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-258"
          xlink:label="hidden-fact-258"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_38_fact"
          xlink:label="ix_38_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#x2019;s presentation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_39_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-258"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_38_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_42_fact"
          xlink:label="ix_42_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_41_fact"
          xlink:label="ix_41_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_40_fact"
          xlink:label="ix_40_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="-keep: true">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_42_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_41_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_40_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_44_fact"
          xlink:label="ix_44_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_43_fact"
          xlink:label="ix_43_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">BioFirst Corporation (the &#x201c;BioFirst&#x201d;):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $1,124,842.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_44_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_43_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-272"
          xlink:label="hidden-fact-272"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-273"
          xlink:label="hidden-fact-273"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Rgene Corporation (the &#x201c;Rgene&#x201d;)
Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-272"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-273"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-345"
          xlink:label="hidden-fact-345"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-274"
          xlink:label="hidden-fact-274"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-344"
          xlink:label="hidden-fact-344"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-275"
          xlink:label="hidden-fact-275"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">BioLite Japan K.K. (BioLite JP)
In October 2021, the Company, Lucidaim Co., Ltd., a Japanese corporation (&#x201c;Lucidaim,&#x201d; together with the Company, the &#x201c;Shareholders&#x201d;), and BioLite Japan K.K., a Japanese corporation (&#x201c;BioLite JP&#x201d;) entered into a Joint Venture Agreement. BioLite JP is a private limited company incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with 3,049 ordinary shares issued and outstanding (the &#x201c;Ordinary Shares&#x201d;). Pursuant to the Agreement and the related share transfer agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000 towards the setup of the joint venture; BioLite Japan&#x2019;s other shareholder also paid $150,000 after the Letter of Intent was signed. This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#x2019;s business and financial conditions and determined to fully impair such prepayment.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-345"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-274"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-344"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-275"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-270"
          xlink:label="hidden-fact-270"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-341"
          xlink:label="hidden-fact-341"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-342"
          xlink:label="hidden-fact-342"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-271"
          xlink:label="hidden-fact-271"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">ForSeeCon Eye Corporation (FEYE)
FEYE is a private company registered in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus. The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-270"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-341"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-342"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-271"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-276"
          xlink:label="hidden-fact-276"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-346"
          xlink:label="hidden-fact-346"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-277"
          xlink:label="hidden-fact-277"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-347"
          xlink:label="hidden-fact-347"
          xlink:type="locator"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">OncoX BioPharma, Inc. (OncoX)
OncoX is a private company registered in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain licensed products in exchange of OncoX&#x2019;s ownership. See Note 4 for detail of such transactions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-276"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-346"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-277"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-347"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_46_fact"
          xlink:label="ix_46_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_45_fact"
          xlink:label="ix_45_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_10_footnote" xlink:label="ix_10_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="margin-top: 0; margin-bottom: 0"><xhtml:span style="-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#x2019;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.</xhtml:span></xhtml:p><xhtml:p style="margin-top: 0; margin-bottom: 0"><xhtml:span style="-keep: true">&#160;</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">As of December 31, 2024 and December 31, 2023, the outstanding loan balance were both $500,000; and accrued interest was $63,819 and $38,819, respectively.</xhtml:span></xhtml:p><xhtml:p style="margin-top: 0; margin-bottom: 0"><xhtml:span style="-keep: true">&#160;</xhtml:span></xhtml:p><xhtml:p style="margin-top: 0; margin-bottom: 0"><xhtml:span style="-keep: true">As of December 31, 2024 and 2023, the Company has other receivables amounted $1,892 and $2,667, respectively, from Rgene due to daily operations.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_46_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_45_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_47_fact"
          xlink:label="ix_47_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_48_fact"
          xlink:label="ix_48_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_11_footnote" xlink:label="ix_11_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of December 31, 2024 and 2023, the outstanding loan balance were NTD 17,571,076 (approximately $535,918) and NTD 6,302,360 ($206,087), respectively; accrued interest was $53,422 and $0, respectively. The Company has received NTD 4,040,000 (approximately $126,048) repayment and expects to receive other repayment within next 12 months.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_47_fact"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_48_fact"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_49_fact"
          xlink:label="ix_49_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_50_fact"
          xlink:label="ix_50_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_12_footnote" xlink:label="ix_12_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of December 31, 2024 and 2023, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">&#160;</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_49_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_50_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_51_fact"
          xlink:label="ix_51_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_52_fact"
          xlink:label="ix_52_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_13_footnote" xlink:label="ix_13_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2024 and 2023, due from BHK was both NTD 3,941,299 (approximately $120,210 and $113,516, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of $120,210 for the year ended December 31, 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_51_fact"
          xlink:to="ix_13_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_52_fact"
          xlink:to="ix_13_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-293"
          xlink:label="hidden-fact-293"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_53_fact"
          xlink:label="ix_53_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_14_footnote" xlink:label="ix_14_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-293"
          xlink:to="ix_14_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_53_fact"
          xlink:to="ix_14_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_55_fact"
          xlink:label="ix_55_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_54_fact"
          xlink:label="ix_54_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_15_footnote" xlink:label="ix_15_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2024 and 2023, the outstanding balance due to the Jiangs amounted to $274,170 and $19,789, respectively. These loans bear no interest and are due on demand.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_55_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_54_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_57_fact"
          xlink:label="ix_57_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_56_fact"
          xlink:label="ix_56_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_16_footnote" xlink:label="ix_16_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#x2019;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of December 31, 2024 and 2023, the outstanding principal and accrued interest was $172,112 and $152,382, respectively. Interest expenses in connection with these loans were $21,101 and $20,094 for the years ended December 31, 2024 and 2023, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_57_fact"
          xlink:to="ix_16_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_56_fact"
          xlink:to="ix_16_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_59_fact"
          xlink:label="ix_59_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_58_fact"
          xlink:label="ix_58_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_17_footnote" xlink:label="ix_17_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024 and 2023, due to Directors amounted to $8,526 and $1,322, respectively, were related to the daily operating expenses in 2024 and entity setup fee in 2023 paid by the Directors of AiBtl on behalf of the entity.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_59_fact"
          xlink:to="ix_17_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_58_fact"
          xlink:to="ix_17_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_60_fact"
          xlink:label="ix_60_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_18_footnote" xlink:label="ix_18_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="-keep: true">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#x201c;December Letter Agreement&#x201d;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_60_fact"
          xlink:to="ix_18_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-330"
          xlink:label="hidden-fact-330"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_61_fact"
          xlink:label="ix_61_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_62_fact"
          xlink:label="ix_62_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_19_footnote" xlink:label="ix_19_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#x2019;s presentation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-330"
          xlink:to="ix_19_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_61_fact"
          xlink:to="ix_19_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_62_fact"
          xlink:to="ix_19_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_64_fact"
          xlink:label="ix_64_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_63_fact"
          xlink:label="ix_63_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_65_fact"
          xlink:label="ix_65_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_20_footnote" xlink:label="ix_20_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_64_fact"
          xlink:to="ix_20_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_63_fact"
          xlink:to="ix_20_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_65_fact"
          xlink:to="ix_20_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_67_fact"
          xlink:label="ix_67_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_66_fact"
          xlink:label="ix_66_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_21_footnote" xlink:label="ix_21_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">BioFirst Corporation (the &#x201c;BioFirst&#x201d;):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of March 31, 2025 and December 31, 2024, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term investments in Biofirst is both $1,124,842.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_67_fact"
          xlink:to="ix_21_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_66_fact"
          xlink:to="ix_21_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-343"
          xlink:label="hidden-fact-343"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_68_fact"
          xlink:label="ix_68_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_22_footnote" xlink:label="ix_22_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Rgene Corporation (the &#x201c;Rgene&#x201d;)
As described in Note 4, the Company acquired 26.65% of Rgene&#x2019;s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting this equity investment with equity method as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company owns 37% of outstanding shares of Rgene.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-343"
          xlink:to="ix_22_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_68_fact"
          xlink:to="ix_22_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_70_fact"
          xlink:label="ix_70_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_69_fact"
          xlink:label="ix_69_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_23_footnote" xlink:label="ix_23_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 and made $500,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#x2019;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided. The loan was converted to Rgene&#x2019;s common stock in May 2024 but the Company was not informed until April 2025. Please see detail discussion in Note 7.</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">&#160;</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">As of March 31, 2025 and December 31, 2024, the outstanding loan balance were $0 and $500,000; and accrued interest was $<xhtml:span style="-sec-ix-hidden: hidden-fact-356">0and</xhtml:span> $63,819, respectively. Both principal and accrued interest were converted to Rgene&#x2019;s common stocks.</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">&#160;</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">As of March 31, 2025 and December 31, 2024, the Company has other receivables amounted to $1,867 and $1,892, respectively, from Rgene due to daily operations.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_70_fact"
          xlink:to="ix_23_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_69_fact"
          xlink:to="ix_23_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_71_fact"
          xlink:label="ix_71_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_72_fact"
          xlink:label="ix_72_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_24_footnote" xlink:label="ix_24_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of March 31, 2025 and December 31, 2024, the outstanding loan balance were NTD 15,458,360 (approximately $465,297) and NTD 17,571,076 (approximately $535,918), respectively; accrued interests were$68,971 and $53,422, respectively. The Company has received NTD 2,080,000 (approximately $64,896) and $0 repayment during the three months ended March 31, 2025 and 2024, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_71_fact"
          xlink:to="ix_24_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_72_fact"
          xlink:to="ix_24_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_74_fact"
          xlink:label="ix_74_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_73_fact"
          xlink:label="ix_73_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_25_footnote" xlink:label="ix_25_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of March 31, 2025 and December 31, 2024, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">&#160;</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_74_fact"
          xlink:to="ix_25_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_73_fact"
          xlink:to="ix_25_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_76_fact"
          xlink:label="ix_76_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_75_fact"
          xlink:label="ix_75_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_26_footnote" xlink:label="ix_26_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2025 and December 31, 2024, due from BHK was both NTD 3,941,299 (approximately$118,633 and $120,210, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of NTD 3,941,299 as of December 31, 2024. No recovery was made during three months ended March 31, 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_76_fact"
          xlink:to="ix_26_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_75_fact"
          xlink:to="ix_26_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_78_fact"
          xlink:label="ix_78_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_77_fact"
          xlink:label="ix_77_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_27_footnote" xlink:label="ix_27_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_78_fact"
          xlink:to="ix_27_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_77_fact"
          xlink:to="ix_27_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_80_fact"
          xlink:label="ix_80_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_79_fact"
          xlink:label="ix_79_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_28_footnote" xlink:label="ix_28_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2025 and December 31, 2024, the outstanding balance due to the Jiangs amounted to $222,522 and $274,170, respectively. These loans bear no interest and are due on demand.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_80_fact"
          xlink:to="ix_28_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_79_fact"
          xlink:to="ix_28_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_81_fact"
          xlink:label="ix_81_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_82_fact"
          xlink:label="ix_82_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_29_footnote" xlink:label="ix_29_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#x2019;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of March 31, 2025 and December 31, 2024, the outstanding principal and accrued interest was $140,266 and $142,130, respectively. Interest expenses in connection with these loans were $4,963 and $5,938 for the three months ended March 31, 2025 and 2024, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_81_fact"
          xlink:to="ix_29_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_82_fact"
          xlink:to="ix_29_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-355"
          xlink:label="hidden-fact-355"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_83_fact"
          xlink:label="ix_83_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_30_footnote" xlink:label="ix_30_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued consulting services fee for the three months ended March 31, 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-355"
          xlink:to="ix_30_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_83_fact"
          xlink:to="ix_30_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_85_fact"
          xlink:label="ix_85_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_84_fact"
          xlink:label="ix_84_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_31_footnote" xlink:label="ix_31_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2025 and December 31, 2024, due to Directors amounted to $12,953 and $8,526, respectively, were related to the daily operating expenses since inception in 2023 paid by the Directors of AiBtl on behalf of the entity.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_85_fact"
          xlink:to="ix_31_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_84_fact"
          xlink:to="ix_31_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_86_fact"
          xlink:label="ix_86_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_32_footnote" xlink:label="ix_32_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#x201c;December Letter Agreement&#x201d;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_86_fact"
          xlink:to="ix_32_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Amendment No. 4 to the registration statement on Form S-1 (Registration No. 333-276500) is filed for the purpose of including information contained in the registrant&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 and Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on April 30, 2025 and April 15, 2025.No
                                            additional securities are being registered under this Post-Effective Amendment No. 4. All
                                            applicable registration fees were paid at the time of the original filing of the Registration
                                            Statement on April 24, 2023.Pursuant to Section 84001 of the FAST Act,
all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended,
after the date of this Post-Effective Amendment and prior to the termination of the offering covered hereby shall also be deemed to be
incorporated by reference into this Post-Effective Amendment and to be a part hereof from the date of filing of such documents.Post-Effective Amendment No. 1 to Registration
Statement on Form S-1 (File No. 333-276500)This prospectus relates to the resale, from time
to time, by the selling stockholders identified in this prospectus under the caption &#8220;Selling Stockholders,&#8221; of: (a) up to
342,857 shares of Common Stock of the Company, which are issuable upon conversion of a secured, convertible note pursuant to that certain
securities purchase agreement dated as of November 17, 2023 (the &#8220;2nd Lind Transaction&#8221;) between the Company and
Lind Global Fund II, LP (&#8220;Lind&#8221;) in the principal amount of $1,200,000 (the &#8220;2nd Lind Note&#8221;), at a
conversion price, which shall be the lesser of (i) $3.50 (the &#8220;Fixed Price&#8221;) and (ii) 90% of the three lowest VWAPs (as defined
in the 2nd Lind Note) during the 20 trading days prior to conversion, (b) 1,000,000 shares of Common Stock underlying a common
stock purchase warrant (the &#8220;2nd Lind Warrant&#8221;) at an initial exercise price of $2 per share, (c) 30,000 shares
of Common Stock underlying a placement agent common stock purchase warrant pursuant to the 2nd Lind Transaction, (the &#8220;2nd
PA Warrant&#8221;); (d) 285,714 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain
securities purchase agreement dated as of January 17, 2024 between the Company and Lind (the &#8220;3rd Lind Transaction&#8221;);
(e) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 3rd Lind Transaction; and
(f) 25,000 shares of Common Stock underlying a placement agent common stock purchase warrant pursuant to the 3rd Lind Transaction
(the &#8220;3rd PA Warrant&#8221;).Post-Effective Amendment No. 4 to Registration
Statement on Form S-1 (File No. 333-271416)On April 24, 2023, we filed a registration statement
with the SEC, on Form S-1 (File No. 333-271416) (the &#8220;Prior Registration Statement&#8221;), to initially register for resale 9,031,112
shares of our common stock, which includes: (i) 3,527,778 shares of common stock underlying secured convertible note (the &#8220;Lind
Note&#8221;) pursuant to that certain securities purchase agreement dated as of February 23, 2023, (ii) 5,291,667 shares of common stock
underlying a warrant dated February 23, 2023 (the &#8220;Lind Warrant&#8221;) and (iii) 211,667 shares of common stock underlying a placement
agent warrant dated February 23, 2023.The
                                            Prior Registration Statement was declared effective by the SEC on June 8, 2023. Pursuant
                                            to Rule 429 this registration statement shall constitute Post-Effective Amendment No. 4 to
                                            the Prior Registration Statement with respect to the offering of any unsold shares thereunder
                                            and is being filed to update certain other information in the Prior Registration Statement.
                                            No additional securities are being registered under this Post-Effective Amendment No. 4.
                                            All applicable registration fees for the Prior Registration Statement were paid at the time
                                            of the original filing of the Prior Registration Statement. Accordingly, upon effectiveness,
                                            this Registration Statement shall act as a post-effective amendment to the Prior Registration
                                            Statement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Balance Sheets<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 152,206<span></span>
</td>
<td class="nump">$ 248,382<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 60,155<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">607,362<span></span>
</td>
<td class="nump">615,433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">656,625<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">11,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,530<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">65,052<span></span>
</td>
<td class="nump">64,736<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">79,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="nump">96,362<span></span>
</td>
<td class="nump">96,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">101,051<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">1,469,561<span></span>
</td>
<td class="nump">2,179,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,656,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,168,746<span></span>
</td>
<td class="nump">511,088<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">569,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">533,460<span></span>
</td>
<td class="nump">640,387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">809,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">2,760,062<span></span>
</td>
<td class="nump">2,258,754<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,527,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PrepaymentForLongtermInvestmentsNoncurrent', window );">Prepayment for long-term investments</a></td>
<td class="nump">1,124,842<span></span>
</td>
<td class="nump">1,124,842<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,274,842<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepayment for asset acquisition</a></td>
<td class="nump">691,900<span></span>
</td>
<td class="nump">691,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">691,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">127,128<span></span>
</td>
<td class="nump">133,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">141,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">14,875,699<span></span>
</td>
<td class="nump">7,539,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,784,499<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term bank and other loans</a></td>
<td class="nump">801,407<span></span>
</td>
<td class="nump">840,252<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">899,250<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,826,819<span></span>
</td>
<td class="nump">3,509,422<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,548,352<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">81,115<span></span>
</td>
<td class="nump">81,115<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">79,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">366,475<span></span>
</td>
<td class="nump">403,581<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">401,826<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">6,730,739<span></span>
</td>
<td class="nump">6,557,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,101,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Tenant security deposit</a></td>
<td class="nump">21,680<span></span>
</td>
<td class="nump">21,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability &#8211; non-current</a></td>
<td class="nump">166,985<span></span>
</td>
<td class="nump">236,807<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">407,457<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">6,919,404<span></span>
</td>
<td class="nump">6,815,948<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,531,026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">15,378<span></span>
</td>
<td class="nump">13,868<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockSubscriptionReceivedInAdvance', window );">Stock to be issued</a></td>
<td class="nump">31,040<span></span>
</td>
<td class="nump">31,040<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">83,615,369<span></span>
</td>
<td class="nump">78,595,065<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">73,978,380<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(69,791,882)<span></span>
</td>
<td class="num">(68,949,807)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(64,046,929)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">444,172<span></span>
</td>
<td class="nump">445,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">516,387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="num">(8,909,691)<span></span>
</td>
<td class="num">(8,909,691)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,901,668)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; equity</a></td>
<td class="nump">5,404,386<span></span>
</td>
<td class="nump">1,226,140<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,554,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">2,551,909<span></span>
</td>
<td class="num">(502,181)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(300,637)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="nump">7,956,295<span></span>
</td>
<td class="nump">723,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,253,473<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">14,875,699<span></span>
</td>
<td class="nump">7,539,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,784,499<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable - related parties, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="nump">537,119<span></span>
</td>
<td class="nump">1,155,051<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">747,573<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Due from related parties - non-current, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">113,516<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">819,384<span></span>
</td>
<td class="nump">773,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">173,493<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable &#8211; third parties, net</a></td>
<td class="nump">$ 835,539<span></span>
</td>
<td class="nump">$ 950,046<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 886,522<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PrepaymentForLongtermInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment for long-term investments noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PrepaymentForLongtermInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockSubscriptionReceivedInAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of stock subscription received in advance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockSubscriptionReceivedInAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Liquidity, Going Concern, and Restatement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">15,378,305<span></span>
</td>
<td class="nump">13,868,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,940,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">15,378,305<span></span>
</td>
<td class="nump">13,868,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,940,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="nump">$ 509,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 152,430<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">763<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">302,037<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross (loss) profit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">928<span></span>
</td>
<td class="nump">508,826<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(149,607)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">615,371<span></span>
</td>
<td class="nump">738,486<span></span>
</td>
<td class="nump">2,261,336<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,368,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">28,861<span></span>
</td>
<td class="nump">69,066<span></span>
</td>
<td class="nump">179,272<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,062,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">48,773<span></span>
</td>
<td class="nump">2,031,631<span></span>
</td>
<td class="nump">2,773,460<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">185,933<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">693,005<span></span>
</td>
<td class="nump">2,839,183<span></span>
</td>
<td class="nump">5,214,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,617,127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(693,005)<span></span>
</td>
<td class="num">(2,838,255)<span></span>
</td>
<td class="num">(4,705,242)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,766,734)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">19,071<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">87,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">185,481<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(222,967)<span></span>
</td>
<td class="num">(181,676)<span></span>
</td>
<td class="num">(825,899)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,313,671)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Operating sublease income</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">48,478<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">65,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain (loss) on foreign exchange changes</a></td>
<td class="num">(9,912)<span></span>
</td>
<td class="nump">60,730<span></span>
</td>
<td class="num">(25,135)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on investment in equity securities</a></td>
<td class="num">(50,877)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(339,171)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(221,888)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WriteOffUnclaimedAccruedLiabilites', window );">Write off unclaimed accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expenses)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">19,485<span></span>
</td>
<td class="nump">134,443<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses)</a></td>
<td class="num">(251,185)<span></span>
</td>
<td class="num">(89,412)<span></span>
</td>
<td class="num">(664,334)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,258,104)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision income tax</a></td>
<td class="num">(944,190)<span></span>
</td>
<td class="num">(2,927,667)<span></span>
</td>
<td class="num">(5,369,576)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,024,838)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(110,539)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">256,006<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(944,190)<span></span>
</td>
<td class="num">(2,927,667)<span></span>
</td>
<td class="num">(5,259,037)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,280,844)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(102,115)<span></span>
</td>
<td class="num">(93,468)<span></span>
</td>
<td class="num">(356,159)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(492,794)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributed to ABVC and subsidiaries</a></td>
<td class="num">(842,075)<span></span>
</td>
<td class="num">(2,834,199)<span></span>
</td>
<td class="num">(4,902,878)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,788,050)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,493)<span></span>
</td>
<td class="num">(48,236)<span></span>
</td>
<td class="num">(70,722)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(741)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (843,568)<span></span>
</td>
<td class="num">$ (2,882,435)<span></span>
</td>
<td class="num">$ (4,973,600)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7,788,791)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, Basic (in Dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, Diluted (in Dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract', window );"><strong>Weighted average number of common shares outstanding (1):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, Basic (in Shares)</a></td>
<td class="nump">14,968,232<span></span>
</td>
<td class="nump">9,736,150<span></span>
</td>
<td class="nump">11,673,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,335,650<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, Diluted (in Shares)</a></td>
<td class="nump">14,968,232<span></span>
</td>
<td class="nump">9,736,150<span></span>
</td>
<td class="nump">11,673,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,335,650<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WriteOffUnclaimedAccruedLiabilites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write off unclaimed accrued liabilites.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WriteOffUnclaimedAccruedLiabilites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Cash Flows<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (944,190)<span></span>
</td>
<td class="num">$ (2,927,667)<span></span>
</td>
<td class="num">$ (5,259,037)<span></span>
</td>
<td class="num">$ (8,280,844)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">7,021<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">32,025<span></span>
</td>
<td class="nump">28,531<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">48,773<span></span>
</td>
<td class="nump">2,031,631<span></span>
</td>
<td class="nump">2,773,460<span></span>
</td>
<td class="nump">185,933<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,993<span></span>
</td>
<td class="nump">1,455,101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash expenses</a></td>
<td class="nump">210,040<span></span>
</td>
<td class="nump">176,283<span></span>
</td>
<td class="nump">532,769<span></span>
</td>
<td class="nump">1,244,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on investment in equity securities</a></td>
<td class="nump">50,877<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">339,171<span></span>
</td>
<td class="nump">221,888<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">106,927<span></span>
</td>
<td class="nump">101,260<span></span>
</td>
<td class="nump">168,896<span></span>
</td>
<td class="nump">351,859<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">115,668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">228,557<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(11,460)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(53,380)<span></span>
</td>
<td class="nump">12,948<span></span>
</td>
<td class="nump">101,926<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from related parties</a></td>
<td class="nump">54,113<span></span>
</td>
<td class="num">(140,364)<span></span>
</td>
<td class="num">(293,962)<span></span>
</td>
<td class="num">(321,776)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">40,113<span></span>
</td>
<td class="num">(43,605)<span></span>
</td>
<td class="nump">152,819<span></span>
</td>
<td class="nump">638,762<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">68,515<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Other assets &#8211; tenant security deposit</a></td>
<td class="nump">5,029<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Taxes payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112,946)<span></span>
</td>
<td class="nump">112,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(106,927)<span></span>
</td>
<td class="num">(101,260)<span></span>
</td>
<td class="num">(168,896)<span></span>
</td>
<td class="num">(351,859)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(539,833)<span></span>
</td>
<td class="num">(955,816)<span></span>
</td>
<td class="num">(1,809,145)<span></span>
</td>
<td class="num">(4,186,848)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,201)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Prepayment for equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(338,985)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(360,186)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term loans</a></td>
<td class="num">(29,250)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(29,152)<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">394,071<span></span>
</td>
<td class="nump">394,071<span></span>
</td>
<td class="nump">2,406,338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">411,667<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">947,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Proceeds from (repayment of) related party payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,552<span></span>
</td>
<td class="num">(186,499)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">282,095<span></span>
</td>
<td class="nump">342,095<span></span>
</td>
<td class="nump">1,462,622<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Due to related parties, net</a></td>
<td class="nump">46,339<span></span>
</td>
<td class="nump">217,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327,017)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RepurchaseOfTreasuryStocks', window );">Repurchase of treasury stocks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,320)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ProceedsFromIssuanceOfAPromissoryNote', window );">Proceeds from issuance of a promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from common stock subscription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,040<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ProceedsFromSubsidiarysShareholderContribution', window );">Proceeds from subsidiary's executive contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">137,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">428,756<span></span>
</td>
<td class="nump">924,147<span></span>
</td>
<td class="nump">1,980,769<span></span>
</td>
<td class="nump">3,869,961<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="nump">6,830<span></span>
</td>
<td class="num">(26,109)<span></span>
</td>
<td class="num">(24,589)<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents and restricted cash</a></td>
<td class="num">(104,247)<span></span>
</td>
<td class="num">(57,778)<span></span>
</td>
<td class="nump">147,035<span></span>
</td>
<td class="num">(674,948)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning</a></td>
<td class="nump">863,815<span></span>
</td>
<td class="nump">716,780<span></span>
</td>
<td class="nump">716,780<span></span>
</td>
<td class="nump">1,391,728<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Ending</a></td>
<td class="nump">759,568<span></span>
</td>
<td class="nump">659,002<span></span>
</td>
<td class="nump">863,815<span></span>
</td>
<td class="nump">716,780<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expense paid</a></td>
<td class="nump">5,231<span></span>
</td>
<td class="nump">5,701<span></span>
</td>
<td class="nump">22,539<span></span>
</td>
<td class="nump">33,180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,863<span></span>
</td>
<td class="nump">27,392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing and investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty', window );">Prepayment for asset acquisition by issuing common stock to a third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">691,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Acquiring control of the land</a></td>
<td class="nump">7,670,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonStockForConversionOfDebt', window );">Issuance of common stock for conversion of debt</a></td>
<td class="nump">47,579<span></span>
</td>
<td class="nump">467,574<span></span>
</td>
<td class="nump">593,714<span></span>
</td>
<td class="nump">1,786,686<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible note due from related parties to equity investment</a></td>
<td class="nump">$ 563,819<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices', window );">Issuance of subsidiary&#8217;s common stock for consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#8217;s presentation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_IssuanceOfCommonStockForConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for conversion of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_IssuanceOfCommonStockForConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance of subsidiary&#8217;s common stock for consulting services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment of asset acquisition by issuing common stock to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ProceedsFromIssuanceOfAPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds from issuance of a promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ProceedsFromIssuanceOfAPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ProceedsFromSubsidiarysShareholderContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of proceeds from subsidiary's shareholder contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ProceedsFromSubsidiarysShareholderContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RepurchaseOfTreasuryStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of repurchase of treasury stocks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RepurchaseOfTreasuryStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th">
<div>Common Stock Amounts </div>
<div>Prior Period Adjustment</div>
</th>
<th class="th" colspan="2"><div>Common Stock Amounts</div></th>
<th class="th">
<div>Subscribed stock </div>
<div>Prior Period Adjustment</div>
</th>
<th class="th"><div>Subscribed stock</div></th>
<th class="th">
<div>Stock Sub scription Receivable </div>
<div>Prior Period Adjustment</div>
</th>
<th class="th"><div>Stock Sub scription Receivable</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Prior Period Adjustment</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Prior Period Adjustment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Comprehensive Income </div>
<div>Prior Period Adjustment</div>
</th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th">
<div>Treasury Stock </div>
<div>Prior Period Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Prior Period Adjustment</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th"><div>Prior Period Adjustment</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,286<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,354,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,937,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (54,904,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 517,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,236,139<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,286,190<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PriorPeriodAdjustment', window );">Prior period adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,354,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,354,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,049,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common shares for consulting service</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common shares for consulting service (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty', window );">Issuance of common shares for acquisition of property</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty', window );">Issuance of common shares for acquisition of property (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares for exercise of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,732<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,782,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,786,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares for exercise of convertible notes (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,732,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable', window );">Warrant issued with convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrant in connection to the 3rd Lind Note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant', window );">Exercise of pre-funded warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant', window );">Exercise of pre-funded warrant (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution', window );">Subsidiary executive contribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,788,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(492,794)<span></span>
</td>
<td class="nump">2,629,444<span></span>
</td>
<td class="num">(8,280,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Cumulative transaction adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Distribute as employee compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation', window );">Distribute as employee compensation (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,978,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,046,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,901,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,637)<span></span>
</td>
<td class="num">(6,877,499)<span></span>
</td>
<td class="nump">1,253,473<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,940,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN', window );">Issuance of common shares for Lind CN Repayment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 752<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonShareForLindCNRepayment', window );">Issuance of common shares for Lind CN Repayment (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751,795<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based compensation for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,934,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,935,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock based compensation for services (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService', window );">Issuance of subsidiary's common shares for consulting service</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Decrease in ownership of subsidiary due to share issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty', window );">Issuance of common shares for acquisition of property</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 703<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty', window );">Issuance of common shares for acquisition of property (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,496<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty', window );">Issuance of common shares for acquisition of property (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(703,496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrant in connection to the 3rd Lind Note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,834,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,927,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Cumulative transaction adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,236)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,004,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,881,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,902,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(241,081)<span></span>
</td>
<td class="num">(6,028,485)<span></span>
</td>
<td class="nump">1,458,470<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,698,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(730,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,978,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,046,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,901,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,637)<span></span>
</td>
<td class="num">$ (6,877,499)<span></span>
</td>
<td class="nump">1,253,473<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,940,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN', window );">Issuance of common shares for Lind CN Repayment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,706<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonShareForLindCNRepayment', window );">Issuance of common shares for Lind CN Repayment (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,705,303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based compensation for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,451,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,453,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock based compensation for services (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,019,387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants', window );">Issuance of common shares for exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants', window );">Issuance of common shares for exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Repurchase of common stock from a prior employee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Repurchase of common stock from a prior employee (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockSubscriptionReceived', window );">Stock subscription received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService', window );">Issuance of subsidiary's common shares for consulting service</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Debt discount recognized from Issuance of subsidiary's convertible note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Decrease in ownership of subsidiary due to share issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty', window );">Issuance of common shares for acquisition of property</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 703<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty', window );">Issuance of common shares for acquisition of property (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,496<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty', window );">Issuance of common shares for acquisition of property (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(703,496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrant in connection to the 3rd Lind Note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,902,878)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(356,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,259,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Cumulative transaction adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,722)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,868<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,595,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,949,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,909,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(502,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,959<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,868,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(730,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN', window );">Issuance of common shares for Lind CN Repayment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonShareForLindCNRepayment', window );">Issuance of common shares for Lind CN Repayment (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based compensation for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock based compensation for services (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,654<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants', window );">Issuance of common shares for exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants', window );">Issuance of common shares for exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,135<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Acquiring control of the land</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,513,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,156,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,670,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(842,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(944,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Cumulative transaction adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,493)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,378<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,615,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (69,791,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,909,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,551,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,956,295<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378,305<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(730,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="20"></td></tr>
<tr><td colspan="20"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of warrant issued with convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_IssuanceOfCommonShareForLindCNRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares for Lind CN repayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_IssuanceOfCommonShareForLindCNRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PriorPeriodAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior period adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PriorPeriodAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares in distribute as employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The share amount of exercise of pre-funded warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares in issuance of common shares for acquiring of Property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issuance of common stock for acquiring of property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock 	issuance of common stock for acquiring of property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of issuance of common shares for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of issuance of common shares for Lind CN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to issuance of subsidiary's common shares for consulting service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exercise of pre-funded warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subsidiary executive contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockSubscriptionReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock subscription received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockSubscriptionReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-51<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cumulative translation adjustment before transfers included in determining net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480520/718-40-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ABVC BioPharma, Inc. (the &#8220;Company&#8221;),
formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#8217;s operating entity, American
BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology
to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops
its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision
believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization,
BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly
respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical
trials for the Company&#8217;s drugs and medical devices are being conducted at such world-famous institutions including Stanford University,
University of California San Fransisco (UCSF) and Cedar Sinai Medical Centre (CSMC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has four wholly-owned subsidiaries,
BriVision, BioLite Holding Inc. (&#8220;BioLite Holding&#8221;), BioKey Inc. (&#8220;BioKey&#8221;), BioKey (Cayman), Inc (&#8220;BioKey
Cayman&#8221;), and a majority-owned subsidiary, AiBtl BioPharma Inc. (&#8220;AiBtl&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">BioLite Holding was incorporated in the State
of Nevada with wholly owned subsidiary BioLite BVI, Inc. (&#8220;BioLite BVI&#8221;) that was incorporated in the British Virgin Islands.
BioLite BVI holds 73% ownership of BioLite Inc. (&#8220;BioLite Taiwan&#8221;), a Taiwanese corporation that was founded in February
2006. BioLite Taiwan has been in the business of developing new drugs since it was incorporated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Yunzhiyi, a Taiwanese corporation, was incorporated
in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, the Company&#8217;s director. This entity is set up
for holding the land that AiBtl is working to acquire in Puli, Taiwan for developing health related business in Taiwan.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Incorporated in California on November 20,
2000, BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">BioKey Cayman was incorporated in Cayman Islands
in July 2023, which is 100% owned by ABVC. This subsidiary has no activities since inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">AiBtl BioPharma, Inc. was acquired by the
Company with the transaction of the collaborative licensing agreements. On November 12, 2023, the Company and BioLite Taiwan each entered
into a multi-year, global licensing agreement with AiBtl for the Company and BioLite Taiwan&#8217;s CNS drugs with the indications of
MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the &#8220;Licensed Products&#8221;).
The potential license will cover the Licensed Products&#8217; clinical trial, registration, manufacturing, supply, and distribution rights.
The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen
new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the
respective agreements, each of ABVC and BioLite Taiwan received 23 million shares of AiBtl stock and as a result, the Company has a controlling
interest over AiBtl. If certain milestones are met, the Company and BioLite Taiwan are each eligible to receive $3,500,000 and royalties
equaling 5% of net sales, up to $100 million. The financial statements of AiBtl are included in the Company&#8217;s consolidated financial
statements. As a result of these transactions, the Company became a controlling parent of AiBtl, with 58.85% of group ownership over
AiBtl.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ABVC BioPharma, Inc. (the &#8220;Company&#8221;),
formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#8217;s operating entity, American
BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology
to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops
its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision
believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization,
BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly
respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical
trials for the Company&#8217;s drugs and medical devices are being conducted at such world-famous institutions including Stanford University,
University of California San Fransisco (UCSF) and Cedar Sinai Medical Centre (CSMC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has four wholly-owned subsidiaries,
BriVision, BioLite Holding Inc. (&#8220;BioLite Holding&#8221;), BioKey Inc. (&#8220;BioKey&#8221;), BioKey (Cayman), Inc (&#8220;BioKey
Cayman&#8221;), and a majority-owned subsidiary, AiBtl BioPharma Inc. (&#8220;AiBtl&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">BioLite Holding was incorporated in the State
of Nevada with wholly owned subsidiary BioLite BVI, Inc. (&#8220;BioLite BVI&#8221;) that was incorporated in the British Virgin Islands.
BioLite BVI holds 73% ownership of BioLite Inc. (&#8220;BioLite Taiwan&#8221;), a Taiwanese corporation that was founded in February
2006. BioLite Taiwan has been in the business of developing new drugs since it was incorporated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Yunzhiyi, a Taiwanese corporation, was incorporated
in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, the Company&#8217;s director. This entity is set up
for holding the land that AiBtl acquired in Taiwan for developing health related business in Taiwan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Incorporated in California on November 20,
2000, BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">BioKey Cayman was incorporated in Cayman Islands
in July 2023, which is 100% owned by ABVC. This subsidiary has no activities since inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Acquisition of AiBtl BioPharma Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 12, 2023, the Company and BioLite
Taiwan each entered into a multi-year, global licensing agreement with AiBtl for the Company and BioLite Taiwan&#8217;s CNS drugs with
the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the &#8220;Licensed
Products&#8221;). The potential license will cover the Licensed Products&#8217; clinical trial, registration, manufacturing, supply,
and distribution rights. The parties are determined to collaborate on the global development of the Licensed Products. The parties are
also working to strengthen new drug development and business collaboration, including technology, interoperability, and standards development.
As per each of the respective agreements, each of ABVC and BioLite Taiwan received 23 million shares of AiBtl stock and as a result,
the Company has a controlling interest over AiBtl. If certain milestones are met, the Company and BioLite Taiwan are each eligible to
receive $3,500,000 and royalties equaling 5% of net sales, up to $100 million. The financial statements of AiBtl are included in the
Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company concluded the assets acquired
and liabilities assumed did not meet the definition of a business as a limited number of inputs were acquired but no substantive business
processes or signs of output were acquired. As such, the acquisition was accounted for as an asset purchase. The purchase consideration
was nonmonetary assets (patent) and transfer on November 12, 2023. The equity interest transferred to ABVC and BioLite Taiwan on December
15, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity, Going Concern, and Restatement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Liquidity, Going Concern, and Restatement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernAndRestatementTextBlock', window );">LIQUIDITY, GOING CONCERN, AND RESTATEMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">2. LIQUIDITY, GOING CONCERN, AND RESTATEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Liquidity and Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The accompanying financial statements have
been prepared in conformity with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;)
which contemplates continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and
liabilities are settled in the ordinary course of business at amounts disclosed in the financial statements. The Company&#8217;s ability
to continue as a going concern depends upon its ability to market and sell its products to generate positive operating cash flows. For
the three months ended March 31, 2025, the Company reported net loss of $944,190. As of March 31, 2025, the Company&#8217;s working capital
deficit was $5,261,178.&#160; In addition, the Company had net cash outflows of $539,833&#160;from operating activities for the three
months ended March 31, 2025. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a
going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">To sustain its ability to support the Company&#8217;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">cash
    generated from operations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">other available sources
    of financing from banks and other financial institutions in the U.S. and in Taiwan; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">financial support from
    the Company&#8217;s related parties and shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management&#8217;s plan is to continue to
improve operations to generate positive cash flows and raise additional capital through private or public offerings, or financial support
from related parties or shareholders. If the Company is not able to generate positive operating cash flows, and raise additional capital,
there is the risk that the Company may not be able to meet its short-term obligations. All of these factors raise substantial doubt about
the ability of the Company to continue as a going concern. The interim condensed consolidated financial statements as of March 31, 2025,
and for the three months ended March 31, 2025 and 2024 have been prepared on a going concern basis and do not include any adjustments
to reflect the possible future effects on the recoverability and classifications of assets or the amounts and classifications of liabilities
that may result from the inability of the Company to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Restatement Background and Explanation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has restated its financial statements
as of and for the year ended December 31, 2023, to correct misstatements in those prior periods related to improperly applying accounting
guidance on the share-based payments, incorrectly recognizing interest expenses upon the conversion of convertible debts, and misidentifying
the existence of non-controlling interest of our subsidiary. These restatements also resulted in the restatements of the relevant accounts
as of and for the three months ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As disclosed in Note 5, the Company entered
into a cooperation agreement on August 14, 2023 with Zhong Hui Lian He Ji Tuan, Ltd. (the &#8220;Zhonghui&#8221;) to acquire 20% of the
ownership of certain property and a parcel of the land. According to the agreement, the Company issued 370,000 shares of its common stock
as the consideration, and used $20 dollar per share to recognize the right as construction in progress on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the time of preparing its 2024 financial
statements, the Company reviewed the entire transaction, its relevant agreements and documentation, as well as the applicable accounting
guidance. The Company applied FASB Accounting Standard Codification (&#8220;ASC&#8221;) 845 Nonmonetary Transactions to determine the
fair value of the asset acquired would be more evident than the fair value of the consideration in exchange, the Company&#8217;s restricted
common stocks. The real estates acquired comes with a third-party valuation of $7,400,000 per the Company&#8217;s stake, which the value
of the acquired assets is guaranteed by Zhonghui. Upon further review, the Company considered ASC 718 Compensation &#8211; Stock Compensation,
should have been the appropriate guidance to apply given the Company&#8217;s common stocks are listed in Nasdaq with more observable
fair value (Level 1). Furthermore, at the time of issuance of these financial statements, no real estate title was transferred to the
Company. As a result, the Company adjusted the carrying value of the asset and reclassified the balance to &#8220;Prepayment for asset
acquisition&#8221; account to reflect the value of 370,000 shares issued at $1.87, the closing price as of the contract date. The Company
also corrected the share price used to recognize stock compensation expense from $20 to $1.87 for the 29,600 shares of common stock issued
on the same day to several consultants. As a result, these adjustments reduced $6,708,100 for asset recognized and $536,648 for stock-compensation
expense incurred in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In February 2023, the Company issued a convertible
note to LIND Global Fund II, LP (Note 7). Due to misapplication of ASC 470-20 instead of ASC 815-40, the Company overstated interest
expenses $1,179,669 for the year ended December 31, 2023. The overstatement is offsetting against additional paid-in capital due to the
convertible note being converted to the Company&#8217;s own common stocks instead of being repaid or disposition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In November 2023, the Company and one of its
subsidiaries entered into a licensing agreement with AiBtl. The Company accounted for a 100% control of AiBtl as of December 31, 2023,
but later discovered that AiBtl had outstanding founder shares that were not deposited to the stock transfer agent in the timely manner.
Such shares reduced the Company&#8217;s controlling interest from 100% to 69.70% as of December 31, 2023. Accordingly, the Company adjusted
the relevant accounts in our consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As discussed in Note 12, in July 2019 the
Company issued 644,972 shares (post-split) of the Company&#8217;s common stock to four consultants for their services. Such stock-based
expenses were amortized over 5 years starting from the issuance date. Per the Company&#8217;s further review, the services, along with
the agreements, were completed by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with the period
when services are received. Therefore, the Company reversed share-based compensation expenses of $451,480 and $902,960 for the years
ended December 31, 2024 and 2023, respectively. The accumulated deficit as of December 31, 2022 was corrected with the Stock Subscription
Receivables for $1,354,440 as a result of such adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Please read the impacts of the 2023 restatement
in our audited 2024 consolidated financial statements filed in our Form 10-K with the SEC on April 15, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Impact of the Restatement to the March
31, 2024 interim financial statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the three months ended March 31, 2024 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Unaudited
                                            Condensed</b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Consolidated Balance Sheets</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepaid expense and other current asset</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">159,602</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">223,707</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">383,309</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,949,150</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,400,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">549,150</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepayment for asset acquisition</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-328"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Assets</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,460,402</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,484,392</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,976,010</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,050,845</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(605,178</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,445,667</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Convertible notes payable &#8211; third parties, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">842,567</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">29,769</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">872,336</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">301,972</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">89,502</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">391,474</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current Liabilities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,633,614</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(455,908</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,177,706</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Liabilities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,973,447</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(455,908</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,517,539</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Additional paid-in capital</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">86,029,237</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(9,025,036</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">77,004,201</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total stockholders&#8217; equity</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,792,076</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,092,525</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,699,551</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Noncontrolling interest</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(305,121</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">64,040</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(241,081</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Equity</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,486,955</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,028,485</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,458,470</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Liabilities and Equity</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,460,402</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,484,393</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,976,009</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Unaudited
                                            Condensed</b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Consolidated Statements of Operations</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative expenses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">831,257</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(92,771</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">738,486</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock based compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,544,995</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(513,364</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,031,631</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(684,683</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">503,007</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(181,676</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss attributable to noncontrolling interests</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(48,043</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(45,425</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(93,468</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,981,019</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,053,352</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,927,667</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Basic and diluted net loss per common share</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(0.40</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.11</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(0.29</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">Unaudited Condensed</span></p>
                                                                    <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">Consolidated Statements
                                            of Cash Flows</span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss</span></td><td style="width: 1%; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,981,019</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,053,355</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,927,664</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock-based compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,544,995</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(513,364</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,031,631</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other non-cash income and expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">672,016</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(495,736</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">176,280</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">354,465</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(398,070</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(43,605</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">128,840</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(128,840</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-329"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net cash used in operating activities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(602,001</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(353,815</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(955,816</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties*</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-330"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(217,981</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(217,981</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net cash provided by financing activities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">805,006</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">119,141</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">924,147</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(260,783</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">234,674</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(26,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Issuance of common stock for conversion of debt</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">681,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">213,426</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">467,574</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#8217;s presentation.</span></td>
</tr></table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">2. LIQUIDITY, GOING CONCERN, AND RESTATEMENT</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Liquidity and Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The accompanying financial statements have
been prepared in conformity with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;)
which contemplates continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and
liabilities are settled in the ordinary course of business at amounts disclosed in the financial statements. The Company&#8217;s ability
to continue as a going concern depends upon its ability to market and sell its products to generate positive operating cash flows. For
the year ended December 31, 2024, the Company reported net loss of $5,259,037. As of December 31, 2024, the Company&#8217;s working capital
deficit was $4,377,646.&#160; In addition, the Company had net cash outflows of $1,809,145&#160;from operating activities for the year
ended December 31, 2024. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going
concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">To sustain its ability to support the Company&#8217;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">cash generated from
    operations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    available sources of financing from banks and other financial institutions in the U.S. and in Taiwan; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">financial support from the Company&#8217;s related parties and shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management&#8217;s plan is to continue to
improve operations to generate positive cash flows and raise additional capital through private or public offerings, or financial support
from related parties or shareholders. If the Company is not able to generate positive operating cash flows, and raise additional capital,
there is the risk that the Company may not be able to meet its short-term obligations. All of these factors raise substantial doubt about
the ability of the Company to continue as a going concern. The consolidated financial statements for the years ended December 31, 2024
and 2023 have been prepared on a going concern basis and do not include any adjustments to reflect the possible future effects on the
recoverability and classifications of assets or the amounts and classifications of liabilities that may result from the inability of
the Company to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Restatement Background and Explanation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has restated its financial statements
as of and for the year ended December 31, 2023, to correct misstatements in those prior periods related to improperly applying accounting
guidance on the share-based payments, incorrectly recognizing interest expenses upon the conversion of convertible debts, and misidentifying
the existence of non-controlling interest of our subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As disclosed in Note 5, the Company entered
into a cooperation agreement on August 14, 2023 with Zhong Hui Lian He Ji Tuan, Ltd. (the &#8220;Zhonghui&#8221;) to acquire 20% of the
ownership of certain property and a parcel of the land. According to the agreement, the Company issued 370,000 shares of its common stock
as the consideration, and used $20 dollar per share to recognize the right as construction in progress on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the time of preparing its 2024 financial
statements, the Company reviewed the entire transaction, its relevant agreements and documentation, as well as the applicable accounting
guidance. The Company applied FASB Accounting Standard Codification (&#8220;ASC&#8221;) 845 Nonmonetary Transactions to determine the
fair value of the asset acquired would be more evident than the fair value of the consideration in exchange, the Company&#8217;s restricted
common stocks. The real estates acquired comes with a third-party valuation of $7,400,000 per the Company&#8217;s stake, which the value
of the acquired assets is guaranteed by Zhonghui. Upon further review, the Company considered ASC 718 Compensation &#8211; Stock Compensation,
should have been the appropriate guidance to apply given the Company&#8217;s common stocks are listed in Nasdaq with more observable
fair value (Level 1). Furthermore, at the time of issuance of these financial statements, no real estate title was transferred to the
Company. As a result, the Company adjusted the carrying value of the asset and reclassified the balance to &#8220;Prepayment for asset
acquisition&#8221; account to reflect the value of 370,000 shares issued at $1.87, the closing price as of the contract date. The Company
also corrected the share price used to recognize stock compensation expense from $20 to $1.87 for the 29,600 shares of common stock issued
on the same day to several consultants. As a result, these adjustments reduced $6,708,100 for asset recognized and $536,648 for stock-compensation
expense incurred in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In February 2023, the Company issued a convertible
note to LIND Global Fund II, LP (Note 7). Due to misapplication of ASC 470-20 instead of ASC 815-40, the Company overstated interest
expenses $1,179,669 for the year ended December 31, 2023. The overstatement is offsetting against additional paid-in capital due to the
convertible note being converted to the Company&#8217;s own common stocks instead of being repaid or disposition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In November 2023, the Company and one of its
subsidiaries entered into a licensing agreement with AiBtl. The Company accounted for a 100% control of AiBtl as of December 31, 2023,
but later discovered that AiBtl had outstanding founder shares that were not deposited to the stock transfer agent in the timely manner.
Such shares reduced the Company&#8217;s controlling interest from 100% to 69.70%. Accordingly, the Company adjusted the relevant accounts
in our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As discussed in Note 12, in July 2019 the
Company issued 644,972 shares (post-split) of the Company&#8217;s common stock to four consultants for their services. Such stock-based
expenses were amortized over 5 years starting from the issuance date. Per the Company&#8217;s further review, the services, along with
the agreements, were completed by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with the period
when services are received. Therefore, the Company reversed share-based compensation expenses of $451,480 and $902,960 for the years
ended December 31, 2024 and 2023, respectively. The accumulated deficit as of December 31, 2022 was corrected with the Stock Subscription
Receivables for $1,354,440 as a result of such adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Impact of the Restatement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 8pt; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the year ended December 31, 2023 is presented below.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Consolidated Balance Sheets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,969,278</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,400,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">569,278</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepayment for asset acquisition</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Assets</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,492,599</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,708,100</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,784,499</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,696,380</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(148,028</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,548,352</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Convertible notes payable &#8211; third parties, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">569,456</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">317,066</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">886,522</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">173,132</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">361</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">173,493</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current Liabilities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,932,490</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">169,399</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,101,889</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Liabilities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,361,627</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">169,399</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,531,026</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Additional paid-in capital</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">82,636,966</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(8,658,586</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">73,978,380</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total stockholders&#8217; equity</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,388,050</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,833,940</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,554,110</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Noncontrolling interest</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(257,078</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(43,559</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(300,637</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Equity</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,130,972</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,877,499</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,253,473</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Liabilities and Equity</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,492,599</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,708,100</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,784,499</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Consolidated Statements of Operations</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock based compensation</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,635,708</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,449,775</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">185,933</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,493,340</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,179,669</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,313,671</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss attributable to noncontrolling interests</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(394,632</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(98,162</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(492,794</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(10,910,288</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,629,444</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(8,280,844</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Basic and diluted net loss per common share</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2.43</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.63</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1.80</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended December
    31, 2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Consolidated Statements of Cash Flows</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net income (loss)</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(10,910,288</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,629,444</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(8,280,844</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock-based compensation</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,635,708</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,449,775</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">185,933</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other non-cash income and expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,413,746</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,169,501</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,244,245</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">786,793</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(148,031</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">638,762</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(186,860</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">186,860</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net cash used in operating activities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(4,235,845</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(48,997</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(4,186,848</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties*</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(186,499</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(186,499</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Proceeds from subsidiary&#8217;s executive contribution</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">137,500</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">137,500</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net cash provided by financing activities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,918,960</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(48,999</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,869,961</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2,125-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,123</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Purchase of Property and equipment by issuing common stock to a third party</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,400,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,400,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepayment for asset acquisition by issuing common stock to a third party</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,600</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Issuance of common stock for conversion of debt</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,306,112</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,519,426</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,786,686</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#8217;s presentation.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LiquidityGoingConcernAndRestatementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of liquidity, going concern, and restatement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LiquidityGoingConcernAndRestatementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Basis of Presentation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration: none">The accompanying
unaudited interim condensed consolidated financial statements have been prepared in accordance with the generally accepted accounting
principles in the United States of America (the &#8220;U.S. GAAP&#8221;). All significant intercompany transactions and account balances
have been eliminated. These financial statements do not include all the information and footnotes required by the U.S. GAAP for complete
financial statements. Certain information and note disclosures normally included in the annual financial statements prepared in accordance
with the U.S. GAAP have been condensed or omitted consistent with Article 8 of Regulation S-X. In the opinion of the Company&#8217;s
management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial
statements and include all adjustments, in a normal recurring nature, as necessary for the fair statement of the Company&#8217;s financial
position as of March 31, 2025, and results of operations and cash flows for the three months ended March 31, 2025 and 2024. The unaudited
interim condensed consolidated balance sheet as of March 31, 2025 has been derived from the audited financial statements at December
31, 2024, and interim results of operations are not necessarily indicative of the results expected for the full fiscal year or for any
future period. These financial statements should be read in conjunction with the audited consolidated financial statements as of and
for the years ended December 31, 2024 and 2023, and related notes included in the Company&#8217;s audited consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration: none">This basis
of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses
and losses are recognized when incurred. The Company&#8217;s unaudited financial statements are expressed in U.S. dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Reclassifications</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration: none">Certain
amounts on the prior year&#8217;s condensed consolidated balance sheets, condensed consolidated statements of operations and condensed
cash flows were reclassified to conform to the current-year presentation, with no effect on ending stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Use of Estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Fair Value Measurements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 820 &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8211;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8211;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8211;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Concentration of Credit Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $91,500 (NTD 3.0 million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $250,000 covered by the U.S. Federal Deposit Insurance Corporation&#8217;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Concentration of Clients</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025 and December 31, 2024,
management estimated all accounts receivable balances are uncollectible. Provision credit loss balances were $11,993 and $11,993 as of
March 31, 2025 and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the three months ended March 31, 2024,
the Company&#8217;s revenue was generated from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Cash and Cash Equivalents</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of March 31, 2025 and December 31, 2024, the Company&#8217;s
cash and cash equivalents amounted to $152,206 and $248,382, respectively. Some&#160;of the Company&#8217;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Restricted Cash </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of March 31, 2025 and December 31, 2024, the Company&#8217;s restricted cash amounted $607,362
(NTD 20.2 million) and $615,433 (NTD 20.2 million), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Accounts receivable and allowance for expected credit losses
accounts</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accounts receivable are recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company makes estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#8217;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Allowance for expected credit losses accounts
were $616,397 and $616,414 as of March 31, 2025 and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Revenue Recognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b>Collaborative Revenues &#8212; </b>The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s
judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(i) Non-refundable upfront payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(ii) Milestone payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative
agreement with collaboration partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">(iii) Multiple Element Arrangements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">(iv) Royalties and Profit Sharing Payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b>Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp; Manufacturing Organization Services (&#8220;CDMO&#8221;))</b> &#8212;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advances from customers upon receipt
or when due, and may require deferral of revenue recognition for a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Stock-based Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221;.
Total director, officer, and employee stock-based compensation expenses were $0 and $1,935,755 for the three months ended March 31, 2025
and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="-sec-ix-redline:true;-keep: true">The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221; and ASC 505-50 &#8220;Equity-Based Payments
to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $48,773 for rent for the three months ended March 31, 2025, and $95,876&#160;for consulting services
for the three months ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Commitments and Contingencies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has adopted ASC 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in financial statements when
it is at least reasonably possible that a material loss could be incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Foreign-currency Transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#8217;
Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Segment Reporting</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 280 &#8220;Segment Reporting&#8221; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company currently has&#160;one&#160;reportable
segment, and assets are reviewed on a consolidated basis. As such, segmental data is not provided.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following tables present revenue and gross
profit information for each of our only reportable segment:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Three-Month<br/> Periods
    Ended<br/> March 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024<br/> (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Revenue</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-331"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,205</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Cost of Revenue</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-332"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">277</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-333"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">928</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Depreciation expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,021</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,286</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Three-Month<br/>
    Periods Ended<br/> March 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024<br/>
    (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">928</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">Less:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">615,371</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">738,486</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Research and development expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">28,861</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">69,066</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock-based compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">48,773</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,031,631</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Add (Less):</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,071</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,049</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(222,967</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(181,676</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating sublease income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">12,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gain (loss) on foreign exchange changes</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(9,912</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,730</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on investment in equity securities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(50,877</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-335"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,500</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,485</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Loss before provision for income tax</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(944,190</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,927,667</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Recent Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.</span></p><span></span>
</td>
<td class="text"><p style="margin: 0"><b style="-sec-ix-redline:true;-keep: true">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Basis of Presentation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The accompanying consolidated financial statements
have been prepared in accordance with the U.S. GAAP and pursuant to the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).
All significant intercompany transactions and account balances have been eliminated. The Company&#8217;s fiscal year is the calendar
year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Reclassifications of Prior Year Presentation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Certain amounts on prior year&#8217;s consolidated
financial statements have been reclassified for consistency with the current year presentation. These reclassifications had no effect
on the reported results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Use of Estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Stock Reverse Split</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 25, 2023, the Company filed a Certificate
of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its
common stock. The Company&#8217;s stockholders previously approved the Reverse Stock Split at the Company&#8217;s Special Shareholder
Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase
the per share trading value of the Company&#8217;s common stock, although that outcome is not guaranteed. All shares and related financial
information in this Form 10-K reflect this 1-for-10 reverse stock split.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Fair Value Measurements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 820 &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8211;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8211;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8211;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Concentration of Credit Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $91,500 (NTD 3.0 million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $250,000 covered by the U.S. Federal Deposit Insurance Corporation&#8217;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Concentration of Clients</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024, management estimated
all accounts receivable balances are uncollectible and recognized $11,993 of credit loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2023, the most major clients,
specializes in developing and commercializing of dietary supplements and therapeutics in dietary supplement industry, accounted for 87%
of the Company&#8217;s total account receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the year ended December 31, 2024, the
out-licensing income from our two major licensees, accounts for 58% and 39% of the Company&#8217;s total revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the year ended December 31, 2023, the
major client, distributing nutritional supplements in Asia Pacific, accounted for 80% of the Company&#8217;s total revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Cash and Cash Equivalents</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of December 31, 2024 and 2023, the Company&#8217;s
cash and cash equivalents amounted to $248,382 and $60,155, respectively. Some&#160;of the Company&#8217;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Restricted Cash </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of December 31, 2024 and 2023, the Company&#8217;s restricted cash amounted $615,433 (NTD
20.2 million) and $656,625 (NTD 20.1 million), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Accounts receivable and allowance for expected credit losses
accounts</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accounts receivable is recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company make estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#8217;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Allowance for expected credit losses accounts
was $616,414 and $616,505 as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Revenue Recognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b>Collaborative Revenues &#8212; </b>The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s
judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(i) Non-refundable upfront payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(ii) Milestone payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative
agreement with collaboration partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">(iii) Multiple Element Arrangements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">(iv) Royalties and Profit Sharing Payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b>Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp; Manufacturing Organization Services (&#8220;CDMO&#8221;))</b> &#8212;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Property and Equipment, net</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net is carried at
cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of
the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related
gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of
the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method generally based
on the following useful lives:</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Estimated&#160;Life<br/> in Years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 91%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Buildings and leasehold improvements</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">5 ~ 50</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">5 ~ 10</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Office equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3 ~ 6</span></td></tr>
  </table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Impairment of Long-Lived Assets</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has adopted ASC subtopic 360-10,
Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles
held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances
warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a
forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying
value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition
of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less
costs to sell.</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Long-term Equity Investment</span>&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company acquires the equity investments
to promote business and strategic objectives. The accounting treatment for equity investments, where the Company does not have control
over the investees, is as follows:</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Marketable equity investments: The Company measures marketable equity
    securities at fair value at each reporting date, with unrealized gains and losses recognized in net income in accordance with <span style="font-style: normal; font-weight: normal">ASC
    321. Fair value is</span> determined based on quoted market prices or other observable inputs.</span></td></tr>
  </table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable equity
    investments: When the equity method does not apply, non-marketable equity investments are accounted for at cost, adjusted for observable
    price changes in orderly transactions for identical or similar investments and for impairments, if applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity method investments:
    Investments in which the Company has the ability to exercise significant influence, but not control, over the investee, are accounted
    for using the equity method. The Company recognizes its proportionate share of the investee&#8217;s income or loss in gains (losses)
    on equity investments on a monthly basis.</span></td></tr>
  </table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, considering this a critical accounting
estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#8217;s
fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee,
changes in general market conditions in the investee&#8217;s industry or geographic area, and the management and governance structure
of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches.
The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The
income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#8217;
revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment exists could
change in the future due to new developments or changes in applied assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Other-Than-Temporary Impairment</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company periodically reviews its non-marketable
equity investments and equity method investments, with recognition in profit and loss when declines in value are considered other than
temporary. the Company assesses the severity and duration of any impairment, along with qualitative and quantitative factors, such as
the investee&#8217;s financial performance, adverse market or regulatory conditions, operational changes, or additional funding needs.
Evidence of a loss in value might include the inability to recover the carrying amount of the investment or the investee&#8217;s failure
to sustain earnings capacity to justify its valuation. Impairments deemed other than temporary are recorded in gains (losses) on equity
investments, even if the decline exceeds the losses recognized under the equity method, where applicable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Convertible Notes Payable</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for convertible notes
payable in accordance with ASC 470-20, Debt with Conversion and Other Options, and ASC 815, Derivatives and Hedging, as applicable. Upon
issuance, the Company evaluates whether the embedded conversion feature should be bifurcated as a derivative under ASC 815 or classified
within equity under ASC 470-20. This assessment includes analyzing the terms of the conversion feature and determining if it requires
separate accounting. If the conversion feature is classified as equity, the proceeds from the issuance are allocated between the debt
and equity components. The debt component is recorded at its fair value, and the residual amount is allocated to equity. The debt component
is carried at amortized cost, with any discount amortized to interest expense over the term of the note using the effective interest
method. Upon conversion, the carrying amount of the debt is reclassified to equity, and no gain or loss is recognized. If the note is
settled in cash, any difference between the carrying amount and the settlement amount is recognized in profit and loss.</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Warrants</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for warrants as either
equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative
guidance in ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC
815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including
whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net
cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This
assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly
period end date while the warrants are outstanding. The Company determined that upon further review of the warrant agreement, the Public
Warrants issued pursuant to the warrant agreement qualify for equity accounting treatment.</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For issued or modified warrants that meet
all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance.
For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded
as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated
fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.&#160;</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Research and Development Expenses</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for the cost of using
licensing rights in research and development cost according to ASC 730-10-25-1. This guidance provides that absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses when incurred.</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for R&amp;D costs in
accordance with ASC 730, Research and Development (&#8220;ASC 730&#8221;). Research and development expenses are charged to expense as
incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development
expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related
overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical
and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that
will be used in future research and development activities are expensed when the activity has been performed or when the goods have been
received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research
and development services, costs are expensed as services are performed.</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Post-retirement and post-employment benefits</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s subsidiaries in Taiwan
adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor
regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of
the worker&#8217;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#8217; salaries
to the employees&#8217; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts
for such employee benefits, which were expensed as incurred, were $11,642 (NTD 0.4 million) and $10,314&#160;(NTD 0.4 million) for the
years ended December 31, 2024 and 2023, respectively. Other than the above, the Company does not provide any other post-retirement or
post-employment benefits.</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Stock-based Compensation</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221;.
Total director, officer, and employee stock-based compensation expenses were $1,995,049 and $0 for the years ended December 31, 2024
and 2023, respectively.</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221; and ASC 505-50 &#8220;Equity-Based Payments
to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $506,583 for consulting services and $271,828 for rent for the year ended December 31, 2024, and
$185,933&#160;for consulting services for the year ended December 31, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Income Taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for income taxes using
the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood
of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects
of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire
before the Company is able to realize their benefits, or future deductibility is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under ASC 740, a tax position is recognized
as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax
examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it
is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations
based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold
to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit
that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not
recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions
that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which
the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income
tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended December
31, 2024 and 2023. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods,
disclosures and transition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Valuation of Deferred Tax Assets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A valuation allowance is recorded to reduce
the Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Loss Per Share of Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company calculates net loss per share
in accordance with ASC 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Commitments and Contingencies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has adopted ASC 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Foreign-currency Transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#8217;
Equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Segment Reporting</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 280 &#8220;Segment Reporting&#8221; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company currently has&#160;one&#160;reportable
segment and assets are reviewed on a consolidated basis. As such, segment data is not provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following tables present revenue and gross
profit information for each of our only reportable segment:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Years Ended<br/>
    December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023 (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Revenue</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">509,589</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">152,430</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Cost of Revenue</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">763</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">302,037</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">508,826</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(149,607</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Depreciation expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">32,025</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">28,531</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Years Ended<br/>
    December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023 (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">508,826</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(149,607</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">Less:</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,261,336</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,368,278</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Research and development expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">179,272</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,062,916</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock-based compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,773,460</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">185,933</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Add (Less):</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">87,358</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">185,481</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(825,899</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,313,671</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating sublease income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">48,478</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">65,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gain (loss) on foreign exchange changes</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(25,135</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">22,690</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on investment in equity securities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(339,171</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(221,888</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Write off unclaimed accrued liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">255,592</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">134,443</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,384</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss before provision for income tax</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,369,576</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(8,024,838</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Recent Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In August 2023, the FASB issued ASU 2023-05,
Business Combinations&#8212;Joint Venture Formations (Subtopic 805-60) which requires certain joint ventures to apply a new basis of
accounting upon formation by recognizing and initially measuring most of their assets and liabilities at fair value. The guidance does
not apply to joint ventures that may be proportionately consolidated and those that are collaborative arrangements. ASU 2023-05 is effective
for joint venture with a formation date on or after January 1, 2025, early adoption is permitted. The Company is currently evaluating
the impact that the standard will have on its unaudited consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CollaborativeAgreementsAbstract', window );"><strong>Collaborative Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">4. COLLABORATIVE AGREEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Collaborative agreements with BHK, a
related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015,
    BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development
    Agreement&#8221;), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple
    Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual
    property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be
    shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date
    of first commercial sale of the Product in in Asia excluding Japan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2015, BHK has paid a non-refundable
upfront cash payment of $1 million, or 10% of $10.0 million, upon the signing of BHK Co-Development Agreement. The Company concluded
that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis
and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in
2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative
agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement.
In August 2016, the Company received the second milestone payment of <span style="-sec-ix-hidden: hidden-fact-336">NTD31,649,000</span>, approximately equivalent to $1 million, and recognized
collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase
II clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on 12% of BHK&#8217;s net sales related to BLI-1401-2 Products. As of March 31, 2025, the Company
has not earned the royalty under the BHK Co-Development Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#8220;BHK Collaborative Agreements&#8221;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#8220;Targeting Major Depressive Disorder&#8221; (BLI-1005 Products) and BLI-1006 for
&#8220;Targeting Inflammatory Bowel Disease&#8221; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property
rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50
between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial
sale of the Product in in Asia excluding Japan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In 2015, the Company recognized the cash receipt
in a total of <span style="-sec-ix-hidden: hidden-fact-337">NTD50 million</span>, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition to the total of <span style="-sec-ix-hidden: hidden-fact-338">NTD50 million</span>,
approximately equivalent to $1.6 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.
As of March 31, 2025, the Company has not earned the royalty under the BHK Collaborative Agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Co-Development agreement with Rgene
Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 26, 2017, the Company through its subsidiary, BriVision, entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party controlled by the controlling beneficiary shareholder of YuanGene Corporation (See Note 10). Pursuant to Co-Dev Agreement, the Company and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to&#160;pay the Company $3.0 million in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of the Company&#8217;s past research efforts and contributions before the Co-Dev Agreement was signed and it does not relate to any future commitments made by the Company and Rgene in this Co-Dev Agreement. In addition to $3.0 million, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both the Company and Rgene.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 1, 2017, the Company has delivered
all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under control by
a controlling beneficiary shareholder of YuanGene Corporation and a director and officer of the Company, the Company has recorded the
full amount of $3.0 million in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31,
2017. During the year ended December 31, 2017, the Company received $450,000 in cash. On December 24, 2018, the Company received the
remaining balance of $2,550,000 in the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of <span style="-sec-ix-hidden: hidden-fact-340">NTD50</span> per share (approximately
equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as
of December 31, 2018. On December 31, 2018, the Company determined to fully write off this investment based on the Company&#8217;s assessment
of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee,
adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional
funding requirements, and Rgene&#8217;s ability to remain in business. All projects that have been initiated will be managed and supported
by the Company and Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company and Rgene signed an amendment
to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer
Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination
Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized.
Other provisions of the Co-Dev Agreement remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 10, 2022, the Company expanded its
co-development partnership with Rgene. On that date, BioKey, ABVC has entered into a Clinical Development Service Agreement with Rgene
to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic
cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under the U.S. FDA
IND regulatory requirements. Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $3.0 million
over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period.
The Service Agreement shall remain in effect until the expiration date of the last patent and automatically renew for 5 more years unless
terminated earlier by either party with six months&#8217; written notice. Either party may terminate the Service Agreement for cause
by providing 30 days written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Through a series of transactions over the
past 5 years, the Company and Rgene have co-developed the three drug products covered by the Service Agreement, which has resulted in
the Company owning 26.65% of Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As part of the Rgene Studies, the Company
agreed to loan $1.0 million and made $0.5 million to Rgene, for which Rgene has provided the Company with a 5% interest rate convertible
loan (the &#8220;Note&#8221;). If the Note is fully converted, the Company will own an additional 6.4% of Rgene. The Company is expected
to receive the outstanding loan from the related party by the first half of 2025, either by cash or conversion of shares of Rgene. The
Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00
per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject
to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to
which a breach of the Service Agreement will trigger an event of default under the Note if not cured after 5 business days of written
notice regarding the breach is provided. Upon an event of default, the outstanding principal and any accrued and unpaid interest shall
be immediately due and payable. The Note was fully converted to Rgene&#8217;s common stocks in 2024. See Note 6 for details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Service Agreement shall remain in effect
until the expiration date of the last patent and automatically renew for 5 more years unless terminated earlier by either party with
six months&#8217; written notice. Either party may terminate the Service Agreement for cause by providing 30 days written notice.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Rgene has further agreed, effective July 1,
2022, to provide the Company with a seat on Rgene&#8217;s Board of Directors until the loan is repaid in full. The Company has nominated
Dr. Jiang, its Chief Strategy Officer and Director to occupy that seat; Dr. Jiang is also one of the Company&#8217;s director and officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Rgene Studies is a related party transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Collaborative agreement with BioFirst
Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 24, 2017, the Company through its
subsidiary, BriVision, entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst Corporation
(&#8220;BioFirst&#8221;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the
&#8220;Product&#8221;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling
beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and common stock shareholders of BioFirst (See
Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3.0 million in cash or
stock of the Company before September 30, 2018. The amount of $3.0 million is in connection with the compensation for BioFirst&#8217;s
past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate
to any future commitments in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future
net licensing income or net sales profit, if any, and any development cost shall be equally shared by both the Company and BioFirst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On September 25, 2017, BioFirst delivered
all research, technical, data and development data to the Company. The Company determined to fully expense the entire amount of $3.0
million since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative
future uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses immediately. Hence, the entire amount of $3.0 million is fully expensed as research and development expense during the year
ended December 31, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 30, 2019, BriVision entered into a
Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued
<span style="-sec-ix-hidden: hidden-fact-339">42,857 shares</span> (post-split) of the Company&#8217;s common stock to BioFirst in consideration for $3.0 million owed by the Company to BioFirst
(the &#8220;Total Payment&#8221;) in connection with BioFirst Collaborative Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 5, 2019, BriVision entered into
a second Stock Purchase Agreement (&#8220;Purchase Agreement 2&#8221;) with BioFirst. Pursuant to Purchase Agreement 2, the Company issued
41,470 shares (post-split) of the Company&#8217;s common stock to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst
in connection with a loan provided to BriVision from BioFirst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 4, 2020, the Company executed
an amendment to the BioFirst Collaborative Agreement to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal Storage Solution
to the agreement. ABV-2002 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while ABV-2001 has
broader utilization during a variety of ocular procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Initially the Company will focus on ABV-2002,
a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial
keratoplasty (back layer cornea transplant). ABV-2002 is a solution comprised of a specific poly amino acid that protects ocular tissue
from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity
to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration
results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant
phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can
be manufactured at lower cost. Further ABV-2002 product development was put on hold due to the lack of funding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition, BioFirst was incorporated on
November 7, 2006, focusing on the R&amp;D, manufacturing, and sales of innovative patented pharmaceutical products. The technology of
BioFirst comes from the global exclusive licensing from domestic R &amp; D institutions. Currently, the main research and development
product is the vitreous substitute (Vitargus&#174;) Licensed by the National Health Research Institutes. Vitargus is the world&#8217;s
first bio-degradable vitreous substitute and offers a number of advantages over current vitreous substitutes by minimizing medical complications
and reducing the need for additional surgeries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">BioFirst has started the construction of a
GMP factory in Hsinchu Biomedical Science Park, Taiwan, with the aim at building a production base to supply the global market, and promote
the construction of bio-degradable vitreous substitute manufacturing centers in Taiwan. Completion of this factory would allow ABVC to
manufacture Vitargus with world-class technology in a GMP certified pharmaceutical factory. BioFirst is targeting to complete the construction
in 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025, the Company has not
earned any net licensing income or net sales profit earned by BioFirst under these collaborative agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Collaborative agreement with ForSeeCon
Eye Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 25, 2024, the Company and BioFirst
each entered into a twenty-year, global definitive licensing agreement (the &#8220;FEYE Licensing Agreement&#8221;) with ForSeeCon Eye
Corporation, a company registered in the British Virgin Islands (&#8220;FEYE&#8221;) for the products in the Company and BioFirst&#8217;s
Ophthalmology pipeline, including Vitargus (the &#8220;Vitargus Products&#8221;). The license covers Vitargus Products&#8217; clinical
trial, registration, manufacturing, supply, and distribution rights; FEYE also has the rights to sublicense or partner with a third party
to develop the Licensed Products. As per each of the respective FEYE Licensing Agreements, each of the Company and BioFirst shall receive
a total licensing fee of $33.5 million, composed of an upfront payment of $30 million, which can instead be paid with 5 million shares
of FEYE stock at $6 per share within 30 days after the execution of the FEYE Licensing Agreement, and a $3.5 million cash milestone payment,
due 30 days upon completion of next round fundraising. Additionally, each of the Company and BioFirst are eligible to receive royalties
of 5% of net sales.&#160;As of March 31, 2025, the Company received 5 million FEYE shares but did not recognize such licensing revenue
since the fair value of FEYE stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 18, 2024, the Company and BioFirst,
each entered into an amendment (the &#8220;Amendment&#8221;) to the Licensing Agreement with FEYE, pursuant to which the Company and
BioFirst have agreed to allow FEYE to pay the second milestone payment in the amount of $3.5 million per Licensing Agreement, incrementally
(such as $100,000), at any given time, rather than in one lump sum. During the year ended December 31, 2024, the Company received in
cash and recognized revenue of $296,000, pursuant to the Amendment. There was no cash receipt in the three months periods ended March
31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Collaborative agreement with OncoX BiopPharma,
Inc., a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 16, 2024, the Company entered into
a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (&#8220;Oncox&#8221;),
pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the &#8220;Lung Cancer
Products&#8221;), within North America for 20 years (the &#8220;April 2024 Oncox Agreement&#8221;). In consideration thereof, Oncox shall
pay ABVC $6.25 million (or 1.25 million Oncox shares valued at $5 per share) 30 days after entering into the agreement and $625,000,
30 days following the completion of Oncox&#8217;s next round of fundraising, of which there is no guarantee; ABVC is also entitled to
5% royalties based on the net sales, as defined in the April 2024 Oncox Agreement, from the first commercial sale of the Lung Cancer
Product in North America, of which there can be no guarantee. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene
Corporation, on the same terms. During the year ended December 31, 2024, the Company received in cash and recognized revenue of $200,000
pursuant to the agreement. At the time of transferring the license, the Company also received 1.25 million OncoX shares but did not recognize
such licensing revenue since the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended
March 31, 2025 and 2024, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 8, 2024, the Company entered into a
definitive agreement with OncoX, pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s
BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Pancreatic
(the Pancreatic Product), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 8, 2024
Oncox Agreement&#8221;). In consideration thereof, Oncox shall pay ABVC a total of $6.25 million (or 1.25 million Oncox shares valued
at $5 per share) within 30 days of entering into the May 8, 2024 Oncox Agreement, with an additional milestone payment of $625,000 in
cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000
towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties of 5% of net sales, as
defined in the May 8, 2024 Oncox Agreement, from the first commercial sale of the Pancreatic Product in the noted territory, which remains
uncertain. The Company will permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue
to fund such payments. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene Corporation, on the same terms. At the
time of transferring the license, the Company also received 1.25 million OncoX shares but did not recognize such licensing revenue since
the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 14, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the TNBC Product),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 14, 2024 Oncox Agreements&#8221;).
In each agreement for consideration thereof, Oncox shall pay each licensor a total of $6.25 million (or 1.25 million Oncox shares valued
at $5 per share) within 30 days of entering into the May 14, 2024 Oncox Agreements, with an additional milestone payment of $625,000
in cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least
$100,000 towards the licensing fees and deductible from the second milestone payment; each licensor is also entitled to royalties of
5% of net sales, from the first commercial sale of the TNBC Product in the noted territory, which remains uncertain. The Company will
permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue to fund such payments. At
the time of transferring the license, the Company and BioLite also each received 1.25 million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended March
31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 23, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the &#8220;MS Products&#8221;),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 23, 2024 Oncox Agreements&#8221;).
In consideration thereof, Oncox shall pay each licensor a total of $6.25 million (or 1.25 million Oncox shares valued at $5 per share)
30 days after entering the May 23, 2024 Oncox Agreements, with an additional milestone payment of $625,000 in cash after OncoX&#8217;s
next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000 towards the licensing
fees and deductible from the second milestone payment; each licensor is also entitled to royalties of 5% of net sales, from the first
commercial sale of the MS Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing fees.
At the time of transferring the license, the Company and BioLite also each received 1.25 million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain. There was no cash receipt in the three months periods ended March
31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Above mentioned price of OncoX&#8217;s shares
was determined through private negotiations between the parties; no third-party valuation was completed.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">4. COLLABORATIVE AGREEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Collaborative agreements with BHK, a
related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015,
    BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development
    Agreement&#8221;), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple
    Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual
    property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be
    shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date
    of first commercial sale of the Product in in Asia excluding Japan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2015, BHK has paid a non-refundable
upfront cash payment of $1 million, or 10% of $10.0 million, upon the signing of BHK Co-Development Agreement. The Company concluded
that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis
and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in
2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative
agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement.
In August 2016, the Company has received the second milestone payment of <span style="-sec-ix-hidden: hidden-fact-264">NTD31,649,000</span>, approximately equivalent to $1 million, and recognized
collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase
II clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on 12% of BHK&#8217;s net sales related to BLI-1401-2 Products. As of December 31, 2024 and 2023,
the Company has not earned the royalty under the BHK Co-Development Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#8220;BHK Collaborative Agreements&#8221;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#8220;Targeting Major Depressive Disorder&#8221; (BLI-1005 Products) and BLI-1006 for
&#8220;Targeting Inflammatory Bowel Disease&#8221; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property
rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50
between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial
sale of the Product in in Asia excluding Japan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In 2015, the Company recognized the cash receipt
in a total of <span style="-sec-ix-hidden: hidden-fact-265">NTD50 million</span>, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition to the total of <span style="-sec-ix-hidden: hidden-fact-266">NTD50 million</span>,
approximately equivalent to $1.6 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.
As of December 31, 2024 and 2023, the Company has not earned the royalty under the BHK Collaborative Agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Co-Development agreement with Rgene
Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 26, 2017, the Company through its subsidiary,
BriVision, entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;),
a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant
to Co-Dev Agreement, the Company and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination
Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev
Agreement, Rgene is required to&#160;pay the Company $3.0 million in cash or stock of Rgene with equivalent value by August 15, 2017.
The payment is for the compensation of the Company&#8217;s past research efforts and contributions before the Co-Dev Agreement was signed
and it does not relate to any future commitments made by the Company and Rgene in this Co-Dev Agreement. In addition to $3.0 million,
the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development
costs shall be equally shared by both the Company and Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 1, 2017, the Company has delivered
all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3.0 million
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended
December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000
in the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of NTD50 per share (approximately equivalent to $1.60
per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018.
On December 31, 2018, the Company determined to fully write off this investment based on the Company&#8217;s assessment of the severity
and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes
in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements,
and Rgene&#8217;s ability to remain in business. All projects that have been initiated will be managed and supported by the Company and
Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company and Rgene signed an amendment
to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer
Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination
Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized.
Other provisions of the Co-Dev Agreement remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 10, 2022, the Company expanded its
co-development partnership with Rgene. On that date, BioKey, ABVC has entered into a Clinical Development Service Agreement with Rgene
to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic
cancer and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under the U.S. FDA
IND regulatory requirements. Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $3.0 million
over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period.
The Service Agreement shall remain in effect until the expiration date of the last patent and automatically renew for 5 more years unless
terminated earlier by either party with six months written notice. Either party may terminate the Service Agreement for cause by providing
30 days written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Through a series of transactions over the
past 5 years, the Company and Rgene have co-developed the three drug products covered by the Service Agreement, which has resulted in
the Company owning 31.62% of Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As part of the Rgene Studies, the Company
agreed to loan $1.0 million to Rgene, for which Rgene has provided the Company with a 5% working capital convertible loan (the &#8220;Note&#8221;).
If the Note is fully converted, the Company will own an additional 6.4% of Rgene. The Company is expected to receive the outstanding
loan from the related party by the first half of 2025, either by cash or conversion of shares of Rgene. The Company may convert the Note
at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount
of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in
the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service
Agreement will trigger an event of default under the Note if not cured after 5 business days of written notice regarding the breach is
provided. Upon an event of default, the outstanding principal and any accrued and unpaid interest shall be immediately due and payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Service Agreement shall remain in effect
until the expiration date of the last patent and automatically renew for 5 more years unless terminated earlier by either party with
six months written notice. Either party may terminate the Service Agreement for cause by providing 30 days written notice.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Rgene has further agreed, effective July 1,
2022, to provide the Company with a seat on Rgene&#8217;s Board of Directors until the loan is repaid in full. The Company has nominated
Dr. Jiang, its Chief Strategy Officer and Director to occupy that seat; Dr. Jiang is also one of the Company&#8217;s largest shareholders,
owning 12.8% of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Rgene Studies is a related party transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Collaborative agreement with BioFirst
Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 24, 2017, the Company through its
subsidiary, BriVision, entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst Corporation
(&#8220;BioFirst&#8221;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the
&#8220;Product&#8221;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling
beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See
Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3.0 million in cash or
stock of the Company before September 30, 2018. The amount of $3.0 million is in connection with the compensation for BioFirst&#8217;s
past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate
to any future commitments in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future
net licensing income or net sales profit, if any, and any development cost shall be equally shared by both the Company and BioFirst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to the Company. The Company determined to fully expense the entire amount of $3.0
millionsince currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative
future uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses immediately. Hence, the entire amount of $3.0 million is fully expensed as research and development expense during the year
ended December 31, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 30, 2019, BriVision entered into a
Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued
<span style="-sec-ix-hidden: hidden-fact-267">42,857 shares</span> (post-split) of the Company&#8217;s common stock to BioFirst in consideration for $3.0 million owed by the Company to BioFirst
(the &#8220;Total Payment&#8221;) in connection with BioFirst Collaborative Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 5, 2019, BriVision entered into
a second Stock Purchase Agreement (&#8220;Purchase Agreement 2&#8221;) with BioFirst. Pursuant to Purchase Agreement 2, the Company issued
41,470 shares (post-split) of the Company&#8217;s common stock to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst
in connection with a loan provided to BriVision from BioFirst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">On November 4, 2020, the Company executed
an amendment to the BioFirst Collaborative Agreement to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal Storage Solution
to the agreement. ABV-2002 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while ABV-2001 has
broader utilization during a variety of ocular procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Initially the Company will focus on ABV-2002,
a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial
keratoplasty (back layer cornea transplant). ABV-2002 is a solution comprised of a specific poly amino acid that protects ocular tissue
from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity
to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration
results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant
phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can
be manufactured at lower cost. Further ABV-2002 product development was put on hold due the lack of funding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition, BioFirst was incorporated on
November 7, 2006, focusing on the R&amp;D, manufacturing, and sales of innovative patented pharmaceutical products. The technology of
BioFirst comes from the global exclusive licensing from domestic R &amp; D institutions. Currently, the main research and development
product is the vitreous substitute (Vitargus&#174;) Licensed by the National Health Research Institutes. Vitargus is the world&#8217;s
first bio-degradable vitreous substitute and offers a number of advantages over current vitreous substitutes by minimizing medical complications
and reducing the need for additional surgeries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">BioFirst has started the construction of a
GMP factory in Hsinchu Biomedical Science Park, Taiwan, with the aim at building a production base to supply the global market, and promote
the construction of bio-degradable vitreous substitute manufacturing centers in Taiwan. Completion of this factory would allow ABVC to
manufacture Vitargus with world-class technology in a GMP certified pharmaceutical factory. BioFirst is targeting to complete the construction
in 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024, the Company has not
earned any net licensing income or net sales profit earned by BioFirst under these collaborative agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Collaborative agreement with ForSeeCon
Eye Corporation, a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 25, 2024, the Company and BioFirst
each entered into a twenty-year, global definitive licensing agreement (the &#8220;FEYE Licensing Agreement&#8221;) with ForSeeCon Eye
Corporation, a company registered in the British Virgin Islands (&#8220;FEYE&#8221;) for the products in the Company and BioFirst&#8217;s
Ophthalmology pipeline, including Vitargus (the &#8220;Vitargus Products&#8221;). The license covers the Vitargus Products&#8217; clinical
trial, registration, manufacturing, supply, and distribution rights; FEYE also has the rights to sublicense or partner with a third party
to develop the Licensed Products. As per each of the respective FEYE Licensing Agreements, each of the Company and BioFirst shall receive
a total licensing fee of $33.5 million, composed of an upfront payment of $30 million, which can instead be paid with 5 million shares
of FEYE stock at $6 per share within 30 days after the execution of the FEYE Licensing Agreement, and a $3.5 million cash milestone payment,
due 30 days upon completion of next round fundraising. Additionally, each of the Company and BioFirst are eligible to receive royalties
of 5% of net sales.&#160;As of December 31, 2024, the Company received 5 million FEYE shares but did not recognize such licensing revenue
since the fair value of FEYE stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 18, 2024, the Company and BioFirst,
each entered into an amendment (the <span style="font-style: normal; font-weight: normal">&#8220;Amendment&#8221;) t</span>o the Licensing
Agreement with FEYE, pursuant to which the Company and BioFirst have agreed to allow FEYE to pay the second milestone payment in the
amount of $3.5 million per Licensing Agreement, incrementally (such as $100,000), at any given time, rather than in one lump sum. During
year ended December 31, 2024, the Company received in cash and recognized revenue of $296,000, respectively, pursuant to the Amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Collaborative agreement with OncoX BiopPharma,
Inc., a related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 16, 2024, the Company entered into
a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (&#8220;Oncox&#8221;),
pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the &#8220;Lung Cancer
Products&#8221;), within North America for 20 years (the &#8220;April 2024 Oncox Agreement&#8221;). In consideration thereof, Oncox shall
pay ABVC $6.25 million (or 1.25 million Oncox shares valued at $5 per share) 30 days after entering into the agreement and $625,000,
30 days following the completion of Oncox&#8217;s next round of fundraising, of which there is no guarantee; ABVC is also entitled to
5% royalties based on the net sales, as defined in the April 2024 Oncox Agreement, from the first commercial sale of the Lung Cancer
Product in North America, of which there can be no guarantee. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene
Corporation, on the same terms. During the year ended December 31, 2024, the Company received in cash and recognized revenue of $200,000
pursuant to the agreement. At the time of transferring the license, the Company also received 1.25 million OncoX shares but did not recognize
such licensing revenue since the fair value of Oncox stock is uncertain.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 8, 2024, the Company entered into a
definitive agreement with OncoX, pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s
BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Pancreatic
(the Pancreatic Product), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 8, 2024
Oncox Agreement&#8221;). In consideration thereof, Oncox shall pay ABVC a total of $6.25 million (or 1.25 million Oncox shares valued
at $5 per share) within 30 days of entering into the May 8, 2024 Oncox Agreement, with an additional milestone payment of $625,000 in
cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000
towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties of 5% of net sales, as
defined in the May 8, 2024 Oncox Agreement, from the first commercial sale of the Pancreatic Product in the noted territory, which remains
uncertain. The Company will permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue
to fund such payments. Oncox entered into another agreement with ABVC&#8217;s affiliate, Rgene Corporation, on the same terms. At the
time of transferring the license, the Company also received 1.25 million OncoX shares but did not recognize such licensing revenue since
the fair value of Oncox stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 14, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the TNBC Product),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 14, 2024 Oncox Agreements&#8221;).
In each agreement for consideration thereof, Oncox shall pay each licensor a total of $6.25 million (or 1.25 million Oncox shares valued
at $5 per share) within 30 days of entering into the May 14, 2024 Oncox Agreements, with an additional milestone payment of $625,000
in cash after OncoX&#8217;s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least
$100,000 towards the licensing fees and deductible from the second milestone payment; each licensor is also entitled to royalties of
5% of net sales, from the first commercial sale of the TNBC Product in the noted territory, which remains uncertain. The Company will
permit Oncox to pay the license fee in installments or in a lump sum and will allow Oncox to use its revenue to fund such payments. At
the time of transferring the license, the Company and BioLite also each received 1.25 million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 23, 2024, the Company and its subsidiary,
BioLite Inc (collectively, the &#8220;licensor&#8221;), each entered into a licensing agreement with OncoX, on the same terms, pursuant
to which the licensors will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical drug
extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the &#8220;MS Products&#8221;),
within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;May 23, 2024 Oncox Agreements&#8221;).
In consideration thereof, Oncox shall pay each licensor a total of $6.25 million (or 1.25 million Oncox shares valued at $5 per share)
30 days after entering the May 23, 2024 Oncox Agreements, with an additional milestone payment of $625,000 in cash after OncoX&#8217;s
next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000 towards the licensing
fees and deductible from the second milestone payment; each licensor is also entitled to royalties of 5% of net sales, from the first
commercial sale of the MS Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing fees.
At the time of transferring the license, the Company and BioLite also each received 1.25 million OncoX shares but did not recognize such
licensing revenue since the fair value of Oncox stock is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Above mentioned p<span>rice
of OncoX&#8217;s shares was determined through private negotiations between the parties; no third-party valuation was completed.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CollaborativeAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CollaborativeAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, and Prepament for Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, and Prepament for Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, AND PREPAMENT FOR ASSET ACQUISITION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">5. PROPERTY AND EQUIPMENT, AND PREPAMENT FOR ASSET ACQUISITION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;text-decoration:underline">Property
and Equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of March 31, 2025 and December 31, 2024 are summarized
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Land</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,004,520</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">338,966</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Buildings and leasehold improvements</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,217,756</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,219,244</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,129,804</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,169</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">161,384</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">163,448</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">11,513,464</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,852,827</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,344,718</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,341,739</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,168,746</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">511,088</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Depreciation expenses were $7,021&#160;and $1,286 for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025 and December 31, 2024, the land with book value amounted to approximately $334,520 and $338,966 (except for the recently acquired land in Puli, Taiwan, amounted to $7,670,000), respectively, were pledged for obtaining bank loan (see Notes 9 Bank loans).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;text-decoration:underline">Prepayment
for asset acquisition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Prepayment for asset acquisition consists
of the properties in Chengdu, China. The Company entered into a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan,
Ltd. (the &#8220;Zhonghui&#8221;). Pursuant thereto, the Company will acquire 20% of the ownership of certain property and a parcel of
the land, with a view to jointly develop the property into a healthcare center for senior living, long-term care, and medical care in
the areas of ABVC&#8217;s special interests, such as Ophthalmology, Oncology, and Central Nervous Systems. The plan is to establish a
base for the China market and global development of these interests.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The valuation of such property is $37 million;
based on the Company&#8217;s 20% ownership, the Company would acquire the value of $7,400,000. In exchange, the Company issued to Zhonghui
an aggregate of 370,000 shares (the &#8220;Shares&#8221;) of common stock, at a per share price of $20.0. The Shares are subject to a
lock-up period of one year following the closing date of the transaction. In addition, the parties agreed that, after one year following
the closing of the transaction, if the market value of the Shares or the value of the property increases or decreases, the parties will
negotiate in good faith to make reasonable adjustments. The Company&#8217;s ownership rights to the property and the associated land
parcel, or a suitable replacement property, are safeguarded under the terms of the cooperation agreement, which is legally binding and
enforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As discussed in Note 2, the Company incorrectly
applied ASC 845 instead of ASC 718, resulting in an adjustment of the reported value to from $7,400,000 to $691,900, and reclassification
from Construction-in-Progress to Prepayment for Asset Acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The construction-in-progress property is planned
to finish before the end of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Acquisition of land in Taiwan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2024, AiBtl issued 1,534,000 AiBtl&#8217;s
common stocks to acquire farmland in Taiwan, which land will be used for developing health related businesses. As of the date of issuance
of these financial statements, the transfer of the land&#8217;s title is under government review, pending completion of the title transfer
registration. However, upon the closing of the transaction, both parties are aware of such Taiwan&#8217;s legal restrictions prohibiting
foreign entities directly owning farmland. In addition to newly incorporated controlling subsidiary, Yunzhiyi, to be holding the title
of the land upon government&#8217;s approval, on March 31, 2025, the Company and the landowners executed the Nominee Holding Agreement,
Land Lease Agreement, and Consulting Agreement, under the witness of and confirmed by a legal counsel in Taiwan, in which the landowners
unconditionally grant the full legal rights to the land to the Company before the completion of the title transfer. Based on the execution
of the agreement, the Company recognized $7,670,000 ($5 per share of AiBtl&#8217;s common stock) of land on its balance sheet.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">5. PROPERTY AND EQUIPMENT, AND PREPAMENT FOR ASSET ACQUISITION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">Property
and Equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of December 31, 2024 and 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Land</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">338,966</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">363,416</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Buildings and leasehold improvements</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,219,244</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,227,431</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,169</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,138,675</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Office equipment</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">163,448</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">174,797</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,852,827</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,904,319</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: accumulated depreciation</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,341,739</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,335,041</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">511,088</span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">569,278</span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Depreciation expenses were $28,627&#160;and
$28,531 for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, Land with book value amounted
to approximately $338,966 and $363,416, respectively, were pledged for obtaining bank loan (see Notes 9 Bank loans).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">Prepayment
for asset acquisition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Prepayment for asset acquisition consists
of the properties in Chengdu, China. The Company entered into a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan,
Ltd. (the &#8220;Zhonghui&#8221;). Pursuant thereto, the Company will acquire 20% of the ownership of certain property and a parcel of
the land, with a view to jointly develop the property into a healthcare center for senior living, long-term care, and medical care in
the areas of ABVC&#8217;s special interests, such as Ophthalmology, Oncology, and Central Nervous Systems. The plan is to establish a
base for the China market and global development of these interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The valuation of such property is $37 million;
based on the Company&#8217;s 20% ownership, the Company would acquire the value of $7,400,000. In exchange, the Company issued to Zhonghui
an aggregate of 370,000 shares (the &#8220;Shares&#8221;) of common stock, at a per share price of $20.0. The Shares are subject to a
lock-up period of one year following the closing date of the transaction. In addition, the parties agreed that, after one year following
the closing of the transaction, if the market value of the Shares or the value of the property increases or decreases, the parties will
negotiate in good faith to make reasonable adjustments. The Company&#8217;s ownership rights to the property and the associated land
parcel, or a suitable replacement property, are safeguarded under the terms of the cooperation agreement, which is legally binding and
enforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As discussed in Note 2, the Company incorrectly
applied ASC 845 instead of ASC 718, resulting in an adjustment of the reported value to from $7,400,000 to $691,900, and reclassification
from Construction-in-Progress to Prepayment for Asset Acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The construction-in-progress property is planned
to finish before the end of 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">LONG-TERM INVESTMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b style="-sec-ix-redline:true;-keep: true">6. LONG-TERM INVESTMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b style="-sec-ix-redline:true;-keep: true">&#160;&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership percentage</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March&#160;31,</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting</b></span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of investees</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>treatments</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.*</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 20%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.67</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.67</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">5.90</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">5.90</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation (see Note 10)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">19.78</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">19.78</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">18.68</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">18.68</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity&#160;Method</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. (see Note 10)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">24.97</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">24.97</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">37.00</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">26.65</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">49.00</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">49.00</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The extent the investee relies on the company for its business is summarized as follows:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of investees</b></span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 69%; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The extent the investee relies on the Company for its business &#160;</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan </span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned from the investee and provides research and development support service</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. </span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term investment mainly consists of the following:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Non-marketable Cost Method Investments, net</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Braingenesis Biotechnology Co., Ltd.</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,640</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,727</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Genepharm Biotech Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,271</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,540</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon
    Eye Corporation<sup>(d)</sup></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-341"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-342"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">752,880</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">762,983</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="-sec-ix-redline:true;-keep: true">Subtotal</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">779,791</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">790,250</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity Method Investments, net</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst
    Corporation<sup>(a)</sup></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,420,800</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,468,504</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene
    Corporation<sup>(b)</sup></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">559,471</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-343"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    Japan K.K. (BioLite JP)<sup>(c)</sup></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-344"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-345"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX
    BioPharma, Inc.<sup>(e)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.25in"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,760,062</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,258,754</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2025 and
December 31, 2024, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for
equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded
as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration
process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and
was converted into 994,450 shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term
investments in Biofirst is both $1,124,842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As described in Note 4, the Company
acquired 26.65% of Rgene&#8217;s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting
this equity investment with equity method as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;).
Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required
by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with
Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment
Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request
for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to
the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company
owns 37% of outstanding shares of Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposition of long-term
    investment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the three-month periods
ended March 31, 2025and 2024, there is no disposition of long-term investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on investment in
    equity securities</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The components of loss on investment in equity
securities for each period were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Share of equity method investee losses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(50,877</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K. (BioLite JP)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#8220;Lucidaim,&#8221; together with the Company, the &#8220;Shareholders&#8221;), and BioLite Japan
K.K., a Japanese corporation (&#8220;BioLite JP&#8221;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with
3,049 ordinary shares issued and outstanding (the &#8220;Ordinary Shares&#8221;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000
towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#8217;s business
and financial conditions and determined to fully impair such prepayment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation (FEYE)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. (OncoX)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#8217;s ownership. See Note 4 for detail of such transactions.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b style="-sec-ix-redline:true;-keep: true">6. LONG-TERM INVESTMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b style="-sec-ix-redline:true;-keep: true">&#160;&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Ownership percentage</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Accounting</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Name of investees</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">treatments</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Braingenesis Biotechnology Co., Ltd.*</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.17</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.17</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 11%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Genepharm Biotech Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.67</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.67</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cost Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.90</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.90</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">ForSeeCon Eye Corporation (see Note 10)</span></p></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">19.78</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-268"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cost Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">BioFirst Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">18.68</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">18.68</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity&#160;Method</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">OncoX BioPharma, Inc. (see Note 10)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">24.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-269"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Rgene Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">26.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">26.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity Method</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The extent the investee relies on the company for its business is summarized as follows:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; width: 30%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of investees</b></span></td> <td style="padding-bottom: 1.5pt; width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 69%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The extent the investee relies on the Company for its business &#160;</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan </span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned from the investee and provides research and development support service</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. </span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term investment mainly consists of the following:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Non-marketable Cost Method Investments, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Braingenesis Biotechnology Co., Ltd.</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,727</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,213</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Genepharm Biotech Corporation</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,540</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">22,021</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon
    Eye Corporation<sup>(d) </sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">762,983</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">818,018</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 0.25in"><span style="-sec-ix-redline:true;-keep: true">Subtotal</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">790,250</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">847,252</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity Method Investments, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst
    Corporation<sup>(a)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,468,504</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,680,488</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene
    Corporation<sup>(b)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    Japan K.K. (BioLite JP)<sup>(c)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX
    BioPharma, Inc.<sup>(e)</sup></span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 0.25in"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,258,754</span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,527,740</span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and
2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment
in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for
long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this
investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into
994,450 shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $1,124,842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Summarized unaudited financial information
for the Company&#8217;s equity method investee, BioFirst, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-sec-ix-redline:true;-keep: true">Balance Sheets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,323,952</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,451,877</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Non-current Assets</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,083,472</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">686,206</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current Liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,508,413</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,286,058</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Non-current Liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">114,606</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">347,193</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stockholders&#8217; Deficit</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,215,595</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(495,168</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-sec-ix-redline:true;-keep: true">Statements of operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">357</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">734</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gross profit</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">216</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">289</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(770,877</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,194,797</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Share of losses from investments accounted for using the equity method</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(339,171</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(221,888</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Both Rgene and the Company are
under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise
significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment
as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include
the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of
December 31, 2024 and 2023, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Summarized unaudited financial information
for the Company&#8217;s equity method investee, Rgene, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">Balance Sheets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/> 2024</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/> 2023</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Assets</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">46,491</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">50,538</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current Assets</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">222,988</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">250,716</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Liabilities</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1,546,123</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2,591,960</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current Liabilities</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">319</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">811</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&#8217; Deficit</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,276,963</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,291,517</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-sec-ix-redline:true;-keep: true">Statements of operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    Ended<br/>
    December 31,</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Net sales</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-278"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross Profit</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-280"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-281"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(118,367</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,550,123</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Share of loss from investments accounted for using
    the equity method</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposition of long-term
    investment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the years ended December
31, 2024 and 2023, there is no disposition of long-term investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on investment in
    equity securities</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The components of loss on investment in equity
securities for each period were as follows (not recognized since the carrying value of the investment was reduced to $0):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/>
    December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Share of equity method investee losses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(339,171</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(221,888</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K. (BioLite JP)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#8220;Lucidaim,&#8221; together with the Company, the &#8220;Shareholders&#8221;), and BioLite Japan
K.K., a Japanese corporation (&#8220;BioLite JP&#8221;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with
3,049 ordinary shares issued and outstanding (the &#8220;Ordinary Shares&#8221;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000
towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#8217;s business
and financial conditions and determined to fully impair such prepayment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation (FEYE)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. (OncoX)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#8217;s ownership. See Note 4 for detail of such transactions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">7. CONVERTIBLE NOTES PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Lind Notes Payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 23, 2023, the Company entered
into a securities purchase agreement with Lind Global Fund II, LP (&#8220;Lind&#8221;), pursuant to which the Company issued Lind a secured,
convertible note in the principal amount of $3,704,167, for a purchase price of $3,175,000 (the &#8220;Lind Note&#8221;), that is convertible
into shares of the Company&#8217;s common stock at an initial conversion price of $10.5 per share, subject to adjustment. The Company
also issued Lind a common stock purchase warrant (the &#8220;Lind Warrant&#8221;) to purchase up to 529,167 shares (post-split) of the
Company&#8217;s common stock at an initial exercise price of $10.5 per share for a period of 5 years, subject to adjustment that immediately
upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance or sale shall be reduced (and in no event
increased) to an Exercise Price equal to the consideration per share paid for such Additional Shares of Common Stock. The warrants were
valued using the Black-Scholes model. The fair value of the warrants was determined to be $1,225,543, which was recorded to debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Beginning with the date that is six months
from the issuance date of the Lind Note and on each one (1) month anniversary thereafter, the Company shall pay Lind an amount equal
to $308,651, until the outstanding principal amount of the Lind Note has been paid in full prior to or on the Maturity Date or, if earlier,
upon acceleration, conversion or redemption of the Lind Note in accordance with the terms thereof (the &#8220;Monthly Payments&#8221;).
At the Company&#8217;s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares of the Company&#8217;s common stock, or
(iii) a combination of cash and Shares; if made in shares, the number of shares shall be determined by dividing (x) the principal amount
being paid in shares by (y) 90% of the average of the 5 lowest daily VWAPs during the 20 trading days prior to the applicable payment
date. The Lind Notes sets forth certain conditions that must be satisfied before the Company may make any Monthly Payments in shares
of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash premium of 5% of such Monthly
Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Upon the occurrence of any Event of Default
(as defined in the Lind Note), the Company must pay Lind an amount equal to 120%&#160;of the then outstanding principal amount of the
Lind Note (the &#8220;Mandatory Default Amount&#8221;), in addition to any other remedies under the Note or the other Transaction Documents.
The Company and Lind entered into a letter agreement on September 12, 2023, pursuant to which the Mandatory Default Amount was reduced
to 115% of the then outstanding principal amount of the Lind Note; pursuant to the letter agreement, Lind also agreed to waive any default
associated with the Company&#8217;s market capitalization being below $12.5 million for 10 consecutive days through February 23, 2024,
but retained its right to convert its Note. In addition, if the Company is unable to increase its market capitalization and is unable
to obtain a further waiver or amendment to the Lind Note, then the Company could experience an event of default under the Lind Note,
which could have a material adverse effect on the Company&#8217;s liquidity, financial condition, and results of operations. The Company
cannot make any assurances regarding the likelihood, certainty, or exact timing of the Company&#8217;s ability to increase its market
capitalization, as such metric is not within the immediate control of the Company and depends on a variety of factors outside the Company&#8217;s
control. &#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Lind Warrant may be exercised via cashless
exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The warrant exercise price was reset to $3.5
in accordance to the issuance of common stock in relation to securities purchase agreement on July 2023.&#160;On May 22, 2024, the exercise
price of these warrants was reset to $0.75 along with the immediate exercise of existing warrants and issuance of the New Warrants. As
of March 31, 2025, these Lind Warrants associated with the first Lind Note were fully exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 17, 2023, the Company entered
another securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#8220;2<sup>nd</sup>
Lind Note&#8221;) in the principal amount of $1,200,000, for a purchase price of $1,000,000, that is convertible into shares of the Company&#8217;s
common stock at a conversion price, which shall be the lesser of (i) $3.50 and (ii) 90% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 2<sup>nd</sup> Lind Note shall be due and payable on May 19, 2025, and bears no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to maturity, and Lind shall have the right to convert
up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined in the 2<sup>nd</sup>
Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind Note, in addition
to any other remedies under the Note or the other transaction documents. Lind also received a 5-year common stock purchase warrant to
purchase up to 1,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $2 per share for a period of 5 years.
The warrants were valued using the Black-Scholes model. The fair value of the warrants was determined to be $480,795, which was recorded
to debt discount. An amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements, the parties entered
into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $1.00. Additionally, the amendment
requires the Company to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor
price. During the year ended December 31, 2024, Lind converted $800,000 of 2<sup>nd</sup> Lind Note principal amounts into the Company&#8217;s
common stocks. Refer to the common stock issuance details in Note 12, Equity. On March 3 and April 1, 2025, Lind converted the remaining
$400,000 principal balance ($200,000 for each conversion) into the Company&#8217;s common stocks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 17, 2024, the Company entered another
securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#8220;3<sup>rd</sup>
Lind Note&#8221;) in the principal amount of $1,000,000, for a purchase price of $833,333, that is convertible into shares of the Company&#8217;s
common stock at a conversion price, which shall be the lesser of (i) $3.50 and (ii) 90% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 3<sup>rd</sup> Lind Note shall be due and payable on July 17, 2025 and bear no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to maturity, and Lind shall have the right to convert
up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined in the 3<sup>rd</sup>
Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind Note, in addition
to any other remedies under the Note or the other transaction documents Lind also received a 5-year, common stock purchase warrant to
purchase up to 1,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $2 per share. The warrants were valued
using the Black-Scholes model. The fair value of the warrants was determined to be $394,071, which was recorded to debt discount. An
amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements, the parties entered into an amendment
to the Note, pursuant to which the conversion price shall have a floor price of $1.00. Additionally, the amendment requires the Company
to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor price. No conversion
or repayment to 3<sup>rd</sup> Lind Note has occurred during the year ended December 31, 2024. On March 3 and April 1, 2025, Lind converted
$400,000 principal balance ($200,000 for each conversion) into the Company&#8217;s common stock, leaving outstanding principal of $600,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In connection with above three Lind Note offerings,
the Company and its subsidiaries: BioKey, BioLite, Biolite BVI, and American BriVision, jointly and severally guaranteed all of the obligations
of the Company in connection with the offering with certain collateral, as set forth in the related transaction documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 22, 2024, November 19, 2024, and January
9, 2025, Lind exercised 1,000,000, 500,000, 1,029,167 of the existing warrants to purchase shares of Common Stock at a reduced exercise
price of $0.75, $0.42, and $0.40 per share, respectively. Refer to the details in Note 12, Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Total interest expenses in connection with the above three Lind Notes were $209,372 and $172,884 for the three months ended March 31, 2025 and 2024, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Other Convertible Notes Payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 1, 2024 and November 5, 2024,
the Company&#8217;s subsidiary, AiBtl, issued two convertible notes payable, each with a principal amount of $30,000 to two separate
individuals, for total consideration of $60,000. Each note has a 1-year term and an implied annual discount rate of 6.89%. These convertible
notes bear a 0% interest rate and are convertible by the holders into the AiBtl&#8217;s common stock at $5 per share at any time before
the maturity. AiBtl reserves the right to repurchase the note in full at any time before maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The convertible notes payable is accounted
for in accordance with ASC 470-20, Debt with Conversion and Other Options. The Company evaluated the conversion feature and determined
that it qualifies for equity classification as it meets the &#8220;fixed-for-fixed&#8221; criteria. The proceeds from the issuance were
allocated to the present value of the liability component in aggregate for $56,132, and to debt discount for $3,868. The debt discount
is recorded in additional paid-in capital in the statement of change in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The debt discount is being amortized over
the 1-year term using the effective interest method. During the three months ended March 31, 2025, the Company recognized $984 in interest
expense related to the amortization of the debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying amounts of the liability component
are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: left; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">March 31, <br/> 2025</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Entity</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Date</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Maturity<br/> Date</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Issuance</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Conversion<br/> Price</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Common<br/> Stock<br/> to&#160;be<br/> converted</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Unamortized<br/> Discount</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Carrying<br/> Value</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Fair<br/> Value</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"><span style="-sec-ix-redline:true;font-size: 8pt">2nd LIND Note</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 17, 2023</span></td><td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">May 19, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">86.94</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">200,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">26,110</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">173,890</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">240,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">3rd LIND Note</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">January 17, 2024</span></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">July 17, 2025</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,000,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">87.40</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">800,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">196,114</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">603,886</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">960,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">Other Note</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 1, 2024</span></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 1, 2025</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">6.89</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">5.00</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,119</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">28,881</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">Other Note</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 5, 2024</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 5, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">6.89</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">5.00</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,118</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">28,882</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">2,260,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,060,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">224,460</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">835,539</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,260,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; text-align: left; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">December 31, <br/> 2024</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Entity</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Date</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Maturity<br/> Date</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Issuance</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Conversion<br/> Price</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Common<br/> Stock<br/> to&#160;be<br/> converted</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Unamortized<br/> Discount</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Carrying<br/> Value</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Fair<br/> Value</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"><span style="-sec-ix-redline:true;font-size: 8pt">2nd LIND Note</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 17, 2023</span></td><td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">May 19, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">86.94</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">400,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">118,048</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">281,952</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">480,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">3rd LIND Note</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">January 17, 2024</span></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">July 17, 2025</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,000,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">87.40</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,000,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">388,685</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">611,315</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">Other Note</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 1, 2024</span></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 1, 2025</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">6.89</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">5.00</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,610</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">28,390</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">Other Note</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 5, 2024</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 5, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">6.89</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">5.00</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,611</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">28,389</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">2,260,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,460,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">509,954</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">950,046</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,740,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">7. CONVERTIBLE NOTES PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Lind Notes Payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 23, 2023, the Company entered
into a securities purchase agreement with Lind Global Fund II, LP (&#8220;Lind&#8221;), pursuant to which the Company issued Lind a secured,
convertible note in the principal amount of $3,704,167, for a purchase price of $3,175,000 (the &#8220;Lind Note&#8221;), that is convertible
into shares of the Company&#8217;s common stock at an initial conversion price of $10.5 per share, subject to adjustment. The Company
also issued Lind a common stock purchase warrant (the &#8220;Lind Warrant&#8221;) to purchase up to 529,167 shares (post-split) of the
Company&#8217;s common stock at an initial exercise price of $10.5 per share for a period of 5 years, subject to adjustment that immediately
upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance or sale shall be reduced (and in no event
increased) to an Exercise Price equal to the consideration per share paid for such Additional Shares of Common Stock. The warrants were
valued using the Black-Scholes model. The fair value of the warrants was determined to be $1,225,543, which was recorded to debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Beginning with the date that is six months
from the issuance date of the Lind Note and on each one (1) month anniversary thereafter, the Company shall pay Lind an amount equal
to $308,651, until the outstanding principal amount of the Lind Note has been paid in full prior to or on the Maturity Date or, if earlier,
upon acceleration, conversion or redemption of the Lind Note in accordance with the terms thereof (the &#8220;Monthly Payments&#8221;).
At the Company&#8217;s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares of the Company&#8217;s common stock, or
(iii) a combination of cash and Shares; if made in shares, the number of shares shall be determined by dividing (x) the principal amount
being paid in shares by (y) 90% of the average of the 5 lowest daily VWAPs during the 20 trading days prior to the applicable payment
date. The Lind Notes sets forth certain conditions that must be satisfied before the Company may make any Monthly Payments in shares
of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash premium of 5% of such Monthly
Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Upon the occurrence of any Event of Default
(as defined in the Lind Note), the Company must pay Lind an amount equal to 120%&#160;of the then outstanding principal amount of the
Lind Note (the &#8220;Mandatory Default Amount&#8221;), in addition to any other remedies under the Note or the other Transaction Documents.
The Company and Lind entered into a letter agreement on September 12, 2023, pursuant to which the Mandatory Default Amount was reduced
to 115% of the then outstanding principal amount of the Lind Note; pursuant to the letter agreement, Lind also agreed to waive any default
associated with the Company&#8217;s market capitalization being below $12.5 million for 10 consecutive days through February 23, 2024,
but retained its right to convert its Note. In addition, if the Company is unable to increase its market capitalization and is unable
to obtain a further waiver or amendment to the Lind Note, then the Company could experience an event of default under the Lind Note,
which could have a material adverse effect on the Company&#8217;s liquidity, financial condition, and results of operations. The Company
cannot make any assurances regarding the likelihood, certainty, or exact timing of the Company&#8217;s ability to increase its market
capitalization, as such metric is not within the immediate control of the Company and depends on a variety of factors outside the Company&#8217;s
control. &#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Lind Warrant may be exercised via cashless
exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The warrant exercise price was reset to $3.5
in accordance to the issuance of common stock in relation to securities purchase agreement on July 2023.&#160;On May 22, 2024, the exercise
price of these warrants was reset to $0.75 along with the immediate exercise of existing warrants and issuance of the New Warrants. As
of December 31, 2024, these Lind Warrants associated with the first Lind Note were fully exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 17, 2023, the Company entered
another securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#8220;2<sup>nd</sup>
Lind Note&#8221;) in the principal amount of $1,200,000, for a purchase price of $1,000,000, that is convertible into shares of the Company&#8217;s
common stock at a conversion price, which shall be the lesser of (i) $3.50 and (ii) 90% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 2<sup>nd</sup> Lind Note shall be due and payable on May 19, 2025 and bear no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to the maturity, and Lind shall have the right
to convert up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined
in the 2<sup>nd</sup> Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind
Note, in addition to any other remedies under the Note or the other transaction documents. Lind also received a 5-year common stock purchase
warrant to purchase up to 1,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $2 per share for a period
of 5 years. The warrants were valued using the Black-Scholes model. The fair value of the warrants was determined to be $480,795, which
was recorded to debt discount. An amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements,
the parties entered into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $1.00. Additionally,
the amendment requires the Company to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed
to be the floor price. During the year ended December 31, 2024, Lind converted $800,000 of 2<sup>nd</sup> Lind Note principal amounts
into the Company&#8217;s common stocks. Refer to the common stock issuance details in Note 12, Equity. As of April 1, 2025, Lind has
converted the remaining $400,000 principal balance into the Company&#8217;s common stocks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 17, 2024, the Company entered another
securities purchase agreement with Lind, pursuant to which the Company issued Lind a secured, convertible note (the &#8220;3<sup>rd</sup>
Lind Note&#8221;) in the principal amount of $1,000,000, for a purchase price of $833,333, that is convertible into shares of the Company&#8217;s
common stock at a conversion price, which shall be the lesser of (i) $3.50 and (ii) 90% of the average of the three lowest VWAPs during
the 20 trading days prior to conversion. The 3<sup>rd</sup> Lind Note shall be due and payable on July 17, 2025 and bear no interest.
The Company may prepay all, but not less than all, outstanding principal amount prior to the maturity, and Lind shall have the right
to convert up to one third of the principal amount when the Company prepays. Upon the occurrence of any Event of Default (as defined
in the 3<sup>rd</sup> Lind Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind
Note, in addition to any other remedies under the Note or the other transaction documents Lind also received a 5-year, common stock purchase
warrant to purchase up to 1,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $2 per share. The warrants
were valued using the Black-Scholes model. The fair value of the warrants was determined to be $394,071, which was recorded to debt discount.
An amendment was filed with the SEC on February 29, 2024 to disclose that due to Nasdaq requirements, the parties entered into an amendment
to the Note, pursuant to which the conversion price shall have a floor price of $1.00. Additionally, the amendment requires the Company
to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor price. No conversion
or repayment to 3<sup>rd</sup> Lind Note has occurred during the year ended December 31, 2024. As of April 1, 2025, Lind has converted
$400,000 principal balance into the Company&#8217;s common stock, leaving outstanding principal of $600,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In connection with above three Lind Note offerings,
the Company and its subsidiaries: BioKey, BioLite, Biolite BVI, and American BriVision, jointly and severally guaranteed all of the obligations
of the Company in connection with the offering with certain collateral, as set forth in the related transaction documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 22, 2024 and November 19, 2024, Lind
has exercised 1,000,000 and 500,000 of the existing warrants to purchase shares of Common Stock at a reduced exercise price of $0.75
and $0.42 per share, respectively. Refer to the details in Note 12, Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Total interest expenses in connection with
the above three Lind Notes were $773,139 and $1,233,284 for the years ended December 31, 2024 and 2023, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Other Convertible Notes Payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 1, 2024 and November 5, 2024,
the Company&#8217;s subsidiary, AiBtl, issued two convertible note payable, each with a principal amount of $30,000 to two separate individuals,
for total consideration of $60,000. Each note has a 1-year term and an implied annual discount rate of 6.89%. These convertible notes
bear 0% interest rate and are convertible by the holders into the AiBtl&#8217;s common stock at $5 per share at any time before the maturity.
AiBtl reserves the right to repurchase the note in full at any time before the maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The convertible notes payable is accounted
for in accordance with ASC 470-20, Debt with Conversion and Other Options. The Company evaluated the conversion feature and determined
that it qualifies for equity classification as it meets the &#8220;fixed-for-fixed&#8221; criteria. The proceeds from the issuance were
allocated to the present value of the liability component in aggregate for $56,132, and to debt discount for $3,868. The debt discount
is recorded in additional paid-in capital in the statement of change in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The debt discount is being amortized over
the 1-year term using the effective interest method. During the year ended December 31, 2024, the Company recognized $646 in interest
expense related to the amortization of the debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying amounts of the liability component
are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"><td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">December 31, 2024</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance<br/> Entity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance<br/> Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Maturity<br/> Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Principal<br/> Amount at<br/> Issuance</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion<br/> Price</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Common<br/> Stock<br/> to&#160;be<br/> converted</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Unamortized<br/> Discount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Carrying<br/> Value</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Fair<br/> Value</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">2nd LIND Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 17, <br/> 2023</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">May 19,<br/> 2025</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,200,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">0</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">86.94</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1.00</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">400,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">118,048</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">281,952</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">480,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">3rd LIND Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">January 17, <br/> 2024</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">July 17,<br/> 2025</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">0</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">87.40</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1.00</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">388,685</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">611,315</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,200,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Other Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 1, <br/> 2024</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 1, <br/> 2025</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">0</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">6.89</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">5.00</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,610</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">28,390</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Other Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 5,<br/> 2024</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 5, <br/> 2025</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">0</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">6.89</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">5.00</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,611</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">28,389</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">2,260,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,460,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">509,954</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">950,046</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,740,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="font-size: 8pt; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt"><b>December 31, 2023</b></span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Entity</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Date</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Maturity<br/> Date</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Conversion<br/> Price</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Common<br/> Stock<br/> to be<br/> converted</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Unamortized<br/> Discount</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Carrying<br/> Value</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Fair<br/> Value</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; vertical-align: top; width: 10%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">1st LIND Note</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 6%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">February 23,<br/> 2023</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">August 23,<br/> 2024</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">3,704,167</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">61.42</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">3.50</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 6%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">811,175</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">290,063</span></p></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">521,112</span></p></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">973,410</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; "> <td style="font-size: 8pt; vertical-align: top; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">2nd LIND Note</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 17,<br/> 2023</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">May 19,<br/> 2025</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">86.94</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">834,590</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">365,410</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,440,000</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">4,904,167</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">2,011,175</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,124,653</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">886,522</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">2,413,410</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued research and development expense</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,799,583</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,799,583</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued directors and officers (owners) compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">991,821</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,025,867</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cash portion of the Lind Note repayments</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">227,284</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">127,759</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued compensation and employee benefits</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,252</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">126,106</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Others</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">617,879</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">557,866</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,826,819</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,509,422</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued research and development expense</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,799,583</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,799,583</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued directors and officers (owners) compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,025,867</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,018,253</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued royalties</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">255,592</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">274,028</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued compensation and employee benefits</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">126,106</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">29,138</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Others</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">302,274</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">427,350</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,509,422</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,548,352</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Loans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-Term Loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">SHORT-TERM LOANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">9. SHORT-TERM LOANS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term loans consists of the following:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Cathay United Bank</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">169,407</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">200,252</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">CTBC Bank</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">602,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">610,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Other individual</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">801,407</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">840,252</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Cathay United Bank</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 28, 2016, BioLite Taiwan and Cathay
United Bank entered into a one-year bank loan agreement (the &#8220;Cathay United Loan Agreement&#8221;) in a credit limit amount of
NTD 7.5 million, equivalent to $228,750. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest
at a floating rate of prime rate plus 1.31%. The prime rate is based on the term deposit saving interest rate of Cathay United Bank.
The Company renews the agreement with the bank every year, and the next renewal date is September 6, 2025. As of March 31, 2025 and December
31, 2024, the effective interest rates per annum was 2.99% and 2.99%, respectively. The loan is collateralized by the building and improvement
of BioLite Taiwan, and is also personal guaranteed by the Company&#8217;s chairman. During the three months ended March 31, 2025, the
Company made payments of the loan in total of NTD 937,500, equivalent to $29,250.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Interest expenses were $1,470 and $1,736 for
the three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">CTBC Bank</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 12, 2017 and July 19, 2017, BioLite
Taiwan and CTBC Bank entered into two short-term saving secured bank loan agreements (the &#8220;CTBC Loan Agreements&#8221;) in a credit
limit amount of NTD 10 million, equivalent to $327,500, and NTD 10 million, equivalent to $327,500, respectively. Both two loans with
the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC
for one year. The Company renews the agreement with the bank every year, and the next renewal date is February 28, 2025.&#160;The loan
balances bear interest at a fixed rate of 2.5% per annum, and is secured by the money deposited in a savings account with the CTBC Bank.
This loan was also personal guaranteed by the Company&#8217;s chairman and BioFirst. During the year ended December 31, 2020, BioLite
Taiwan opened a TCD account with CTBC bank to guarantee the loan going forward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Interest expenses were $3,761 and $3,964 for
the three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Other individual &#8211; Third party</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 21, 2024, the Company issued an unsecured
promissory note to a third party for the proceeds of $30,000. The note bears interest rate of 12% per annum and matures on March 21,
2025, or upon the occurrence of an event of default. The promissory note was extended for anther year and matures on March 21, 2026,
with the same terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Interest expenses were $888 and $0 for the
three months ended March 31, 2025 and 2024, respectively.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">9. SHORT-TERM LOANS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term loans consists of the following:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Cathay United Bank</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">200,252</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">245,250</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">CTBC Bank</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">610,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">654,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Other individual</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-284"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">840,252</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">899,250</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Cathay United Bank</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 28, 2016, BioLite Taiwan and Cathay
United Bank entered into a one-year bank loan agreement (the &#8220;Cathay United Loan Agreement&#8221;) in a credit limit amount of
NTD 7.5 million, equivalent to $228,750. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest
at a floating rate of prime rate plus 1.31%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. The
Company renews the agreement with the bank every year, and the next renewal date is September 6, 2025. As of December 31, 2024&#160;and
December 31, 2023, the effective interest rates per annum was 2.99%&#160;and 2.87%, respectively. The loan is collateralized by the building
and improvement of BioLite Taiwan, and is also personal guaranteed by the Company&#8217;s chairman. During the year ended December 31,
2024, the Company made payments of the loan in total of NTD 934,366, equivalent to $29,152.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Interest expenses were $6,891 and $6,856 for
the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">CTBC Bank</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 12, 2017 and July 19, 2017, BioLite
Taiwan and CTBC Bank entered into two short-term saving secured bank loan agreements (the &#8220;CTBC Loan Agreements&#8221;) in a credit
limit amount of NTD 10 million, equivalent to $327,500, and NTD 10 million, equivalent to $327,500, respectively. Both two loans with
the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC
for one year. The Company renews the agreement with the bank every year, and the next renewal date is February 28, 2025.&#160;The loan
balances bear interest at a fixed rate of 2.5% per annum, and is secured by the money deposited in a savings account with the CTBC Bank.
This loan was also personal guaranteed by the Company&#8217;s chairman and BioFirst. During the year ended December 31, 2020, BioLite
Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Interest expenses were $15,557 and $15,610
for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Other individual &#8211; Third party</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 21, 2024, the Company issued an unsecured
promissory note to a third party for the proceeds of $30,000. The note bears interest rate of 12% per annum and matures on March 21,
2025, or upon the occurrence of an event of default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Interest expenses were $2,811 for the year
ended December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">10. RELATED PARTIES TRANSACTIONS</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The related parties of the company with whom
transactions are reported in these financial statements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of entity or Individual</b></span></td> <td style="vertical-align: top; width: 1%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The Jiangs</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst<br/> <br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.<br/> <br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.<br/> <br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company.<br/> <br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</span></p></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation (&#8220;BHK&#8221;)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">AiBtl (Holding) BioPharma, Inc. (&#8220;AiBtl Holding&#8221;) &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Founding shareholder of AiBtl BioPharma Inc.</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Jaimes Vargas Russman &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO of AiBtl BioPharma Inc.</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Lion Arts Promotion, Inc.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by the Jiangs.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Revenues &#8211; related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">There was no cash receipt for the three months
ended March 31, 2025 and 2024 from related parties on the licensing agreements or other services. Therefore, no related party revenue
was recognized during these periods. Please refer to Note 4, Collaborative Agreements for details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Consulting fees &#8211; related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2024, the Company engaged Lion Arts
Promotion Inc to provide operation, business development, human resources, and capital finance consulting services. The agreement is
for 12 months expiring in February 2025, and is optional for renewal upon mutual agreement. The Company incurred $68,141 and $14,628
for the three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Accounts receivable - related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accounts receivable due from related parties
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Rgene</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-350"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-351"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-352"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024, management considered
the outstanding accounts receivable from Rgene may not be recoverable, and recognized credit loss in full.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Due from related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Amounts due from related parties consisted
of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Due from related party- Current</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Rgene (1)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,867</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">565,711</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">BioFirst (2)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">535,252</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">589,340</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">537,119</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,155,051</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">Due from related parties- Non-current, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">BioFirst (Australia) (3)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">839,983</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">839,983</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation (4)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">118,633</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">120,210</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">958,616</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,014,193</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: allowance for expected credit losses accounts</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(958,616</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,014,193</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-353"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-354"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) &#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 and made $500,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided. The loan was converted to Rgene&#8217;s common stock in May 2024 but the Company was not informed until April 2025. Please see detail discussion in Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025 and December 31, 2024, the outstanding loan balance were $0 and $500,000; and accrued interest was $<span style="-sec-ix-hidden: hidden-fact-356">0and</span> $63,819, respectively. Both principal and accrued interest were converted to Rgene&#8217;s common stocks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025 and December 31, 2024, the Company has other receivables amounted to $1,867 and $1,892, respectively, from Rgene due to daily operations.</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of March 31, 2025 and December 31, 2024, the outstanding loan balance were NTD 15,458,360 (approximately $465,297) and NTD 17,571,076 (approximately $535,918), respectively; accrued interests were$68,971 and $53,422, respectively. The Company has received NTD 2,080,000 (approximately $64,896) and $0 repayment during the three months ended March 31, 2025 and 2024, respectively. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of March 31, 2025 and December 31, 2024, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</span></p></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2025 and December 31, 2024, due from BHK was both NTD 3,941,299 (approximately$118,633 and $120,210, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of NTD 3,941,299 as of December 31, 2024. No recovery was made during three months ended March 31, 2025.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s due from related parties
are subject to certain risks that our collaborative parties, including OncoX and FEYE, would face. Such risks exist in future market
conditions, macro economy, legal and regulatory, results of clinical trials and product developments, and among others. As of March 31,
2025, the Company&#8217;s comprehensive review of these due from related party balances indicates that there are no expected losses except
those being recognized above. This conclusion is based on the business relationships with our related parties and the absence of any
significant indicators of potential default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Due to related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Amount due to related parties consisted of
the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">AiBtl Holding (1)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">348,219</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">348,219</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">The Jiangs (2)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,522</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">274,170</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Shareholders (3)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,266</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">142,130</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lion Art Promotions Inc (4)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">65,738</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-355"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Directors (5)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12,953</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,526</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">819,384</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">773,045</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand. </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2025 and December 31, 2024, the outstanding balance due to the Jiangs amounted to $222,522 and $274,170, respectively. These loans bear no interest and are due on demand.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of March 31, 2025 and December 31, 2024, the outstanding principal and accrued interest was $140,266 and $142,130, respectively. Interest expenses in connection with these loans were $4,963 and $5,938 for the three months ended March 31, 2025 and 2024, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued consulting services fee for the three months ended March 31, 2025.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2025 and December 31, 2024, due to Directors amounted to $12,953 and $8,526, respectively, were related to the daily operating expenses since inception in 2023 paid by the Directors of AiBtl on behalf of the entity.</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">10. RELATED PARTIES TRANSACTIONS</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The related parties of the company with whom
transactions are reported in these financial statements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 30%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of entity or Individual</b></span></td> <td style="vertical-align: top; width: 1%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The Jiangs</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</span></p></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation (&#8220;BHK&#8221;)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">AiBtl (Holding) BioPharma, Inc. (&#8220;AiBtl Holding&#8221;) &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Founding shareholder of AiBtl BioPharma Inc.</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Jaimes Vargas Russman &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO of AiBtl BioPharma Inc.</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Lion Arts Promotion, Inc.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by the Jiangs.</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Revenues  &#8211; related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the years ended December 31, 2024,
the Company received $296,000 in cash, pursuant to the licensing agreement and related amendment with FEYE, and recognized $296,000 revenue
correspondingly. In addition, the Company received $200,000 during the year ended December 31, 2024, pursuant to the licensing agreement
with OncoX, and recognized revenue correspondingly. Please refer to Note 4, Collaborative Agreements for details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/>
    December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">OncoX</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">200,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-285"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">FEYE</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">296,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Rgene</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,055</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">496,000</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,055</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Consulting fees - related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2024, the Company engaged Lion International
to provide operation, business development, human resources, and capital finance consulting services. The agreement is for 12 months
expiring in February 2025, and is optional for renewal upon mutual agreement. The Company incurred $104,083 for the year ended December
31, 2024. No such consulting service was engaged in year 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Accounts receivable - related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accounts receivable due from related parties
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">GenePharm Inc.</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Rgene</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-290"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,463</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,463</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024, management considered
the outstanding accounts receivable from Rgene may not be recoverable, and recognized credit loss in full.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Due from related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Amount due from related parties consisted
of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Due from related party- Current</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene (1)</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">565,711</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">541,486</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (2)</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">589,340</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">206,087</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,155,051</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>747,573</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">Due from related parties- Non-current, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">BioFirst (Australia) (3)</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">839,983</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">839,983</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation (4)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">120,210</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,516</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,014,193</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">953,499</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: allowance for expected credit losses accounts</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,014,193</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(839,983</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Net</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,516</span></td><td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">(1) &#160;</span></td> <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024 and December 31, 2023, the outstanding loan balance were both $500,000; and accrued interest was $63,819 and $38,819, respectively.</span></p>
<p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024 and 2023, the Company has other receivables amounted $1,892 and $2,667, respectively, from Rgene due to daily operations.</span></p></td></tr>
</table>

<p style="margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>


<table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 12pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify; font-size: 12pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of December 31, 2024 and 2023, the outstanding loan balance were NTD 17,571,076 (approximately $535,918) and NTD 6,302,360 ($206,087), respectively; accrued interest was $53,422 and $0, respectively. The Company has received NTD 4,040,000 (approximately $126,048) repayment and expects to receive other repayment within next 12 months.</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of December 31, 2024 and 2023, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</span></p></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2024 and 2023, due from BHK was both NTD 3,941,299 (approximately $120,210 and $113,516, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of $120,210 for the year ended December 31, 2024. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s due from related parties
are subject to certain risks that our collaborative parties, including OncoX and FEYE, would face. Such risks exist in future market
conditions, macro economy, legal and regulatory, results of clinical trials and product developments, and among others. As of December
31, 2024, the Company&#8217;s comprehensive review of these due from related party balances indicates that there are no expected losses
except those being recognized above. This conclusion is based on the business relationships with our related parties and the absence
of any significant indicators of potential default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Due to related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Amount due to related parties consisted of
the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">AiBtl Holding (1)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">348,219</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-293"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">The Jiangs (2)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">274,170</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,789</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Shareholders (3)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">142,130</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">152,382</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Directors (4)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,526</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,322</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">773,045</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">173,493</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand. </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2024 and 2023, the outstanding balance due to the Jiangs amounted to $274,170 and $19,789, respectively. These loans bear no interest and are due on demand.</span></td></tr> </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of December 31, 2024 and 2023, the outstanding principal and accrued interest was $172,112 and $152,382, respectively. Interest expenses in connection with these loans were $21,101 and $20,094 for the years ended December 31, 2024 and 2023, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 12pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify; font-size: 12pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024 and 2023, due to Directors amounted to $8,526 and $1,322, respectively, were related to the daily operating expenses in 2024 and entity setup fee in 2023 paid by the Directors of AiBtl on behalf of the entity.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">11. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="-sec-ix-redline:true;-keep: true">Income tax
(benefit) expense for the three months ended March 31, 2025 and 2024 were <span style="-sec-ix-hidden: hidden-fact-359">$0</span> and <span style="-sec-ix-hidden: hidden-fact-360">$0</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets (liability)
as of March 31, 2025 and December 31, 2024 consist approximately of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">713,223</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">713,223</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net operating loss carryforwards</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,870,805</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,677,413</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">155,559</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">178,014</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Operating lease assets</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(155,559</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(178,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets, gross</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,584,028</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,390,636</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,584,028</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,390,636</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets, net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-357"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-358"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">11. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="-sec-ix-redline:true;-keep: true">Income tax
(benefit) expense for the years ended December 31, 2024 and 2023 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">Current:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Federal</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-294"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-295"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">State</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-296"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(110,539</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,338</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total Current</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(110,539</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,338</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Deferred:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">Federal</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">State</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-300"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-301"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-302"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">115,668</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total Deferred</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-303"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">115,668</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total provision for income tax (benefit) expense</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(110,539</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">256,006</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets (liability)
as of December 31, 2024 and 2023 consist approximately of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">713,223</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">713,223</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net operating loss carryforwards</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,677,413</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,018,343</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">178,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">213,482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Operating lease assets</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(178,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(213,482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets, Gross</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,390,636</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,731,566</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,390,636</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,731,566</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets, net</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-304"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">12. EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company previously reported that during
the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related
party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related
party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to
the agreements, the Company issued 644,972 shares of the Company&#8217;s common stock for the consulting service from July 2019 to July
2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable. For the three months ended March
31, 2024, stock subscription receivable recognized as stock-based compensation in equity was $225,740.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">After further reviewed and investigation,
above services were completely provided by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with
the period when services are received. Therefore, the Company reversed share-based compensation expenses of $225,740 for the three months
ended March 31, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 14, 2023, the Company entered into
a cooperation agreement with Zhonghui. Pursuant thereto, the Company expect to receive 20% of the ownership of a property and the parcel
of the land owned by Zhonghui in Leshan, Sichuan, China. During the third quarter of 2023, the Company issued to Zhonghui, an aggregate
of 370,000 shares (post-split) of the Company&#8217;s common stock, at a per share price of $1.87, for $691,900.&#160;The Company also
issued 29,600 common stock to consultants for providing consulting services on the above transaction. Please refer Note 2 for the restatement
of prior period reported amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 27, 2024, the Company granted 1,302,726
restricted shares to its employees and directors under the 2016 Equity Incentive Plan as compensation for their previous services, with
an issuance date of February 2, 2024. These shares are subject to a three-year restriction period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 6, 2024, the Company entered into
a definitive agreement with Shuling Jiang (&#8220;Shuling&#8221;), pursuant to which Shuling shall transfer the ownership of certain
land she owns located at Taoyuan City, Taiwan (the &#8220;Land&#8221;) to the Company (the &#8220;Agreement&#8221;). Shuling is a director
of the Company, is married to TS Jiang, the Company&#8217;s Chief Strategic Officer and owns approximately 15.4% of the Company&#8217;s
issued and outstanding shares of common stock. In consideration for the Land, the Company was to pay Shuling (i) 703,496 restricted shares
of the Company&#8217;s common stock (the &#8220;Shares&#8221;) at a price of $3.50 per share and (ii) five-year warrants to purchase
up to 1,000,000 shares of the Company&#8217;s common stock, with an exercise price of $2.00 per share. Under the Agreement, Shuling was
to also transfer outstanding liability owed on the Land (approximately $500,000) to the Company. On May 16, 2024, the Company&#8217;s
board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not
proceed with the transfer of land ownership; the Company may reconsider the transaction at a later date. The shares were returned and
booked as treasury stock, and the warrants were not issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In July 2024, the Company entered into an
agreement with its landlord in California, pursuant that the Company issued 169,992 shares of common stock for the rent payable through
July 2024, in total of $127,494. The Company also issued 43,458 shares on August 14, 2024 for the August 2024 rent, and 46,072 shares
were issued on September 3, 2024 for the September 2024 rent. Further, we issued 64,147 shares on October 29, 2024 for October rent,
45,293 shares on November 13, 2024 for November rent, and 30,422 shares on December 26, 2024 for half month of December rent. In 2025,
the Company issued 28,135 shares, 22,031 shares, and 30,488 shares for each of the half month rent from January 2025 to March 2025, respectively.
On April 9, 2025, the Company entered another agreement with the landlord to settle remaining balance of each half month of February
and March 2025 rent, and April 2025 rent, by issuing 120,398 of the Company&#8217;s common stock, in the value of $66,219.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Noncontrolling Interests</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 14, 2024, AiBtl issued 1,610,700
AiBtl&#8217;s common stocks to a land acquisition transaction in Taiwan, including the 1-year business consulting fee of $383,500 incurred
beginning in November 2023, and the cost of land $7,670,000. Due to certain administrative processes and restrictions, AiBtl has not
acquired ownership of the land and no asset was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Yunzhiyi, a Taiwan corporation, was incorporated
in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, the Company&#8217;s director. This entity is set up
for holding the land that AiBtl acquired in Taiwan for developing health related business in Taiwan. Due to certain administrative processes
and restrictions, the title transfer has not completed, and no asset was recognized as of the issuance of this report. However, AiBtl
entered a series of agreements with the sellers in March 2025, to obtain the complete rights and obligations of the land while in the
process of transferring the title. These agreements are effective until the title transfer is completed. AiBtl recognized such asset
on its balance sheet on March 31, 2025. Refer to Note 6 for details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Lind Offerings and Repayments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 23, 2023, in connection with the
issuance of the Lind Note (referring to Note 7), the Company issued Lind a 5-year term of common stock purchase warrant to purchase up
to 529,167 shares (post-split) of the Company&#8217;s common stock at an initial exercise price of $10.5 per share (post-split), subject
to adjustment. The warrant exercise price was reset to $3.5 in accordance with the issuance of common stock in relation to securities
purchase agreement in July 2023. On May 22, 2024, the exercise price of these warrants was further reset to $0.75 along with the immediate
exercise of existing warrants and issuance of the New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the three months ended March 31, 2024,
the Company has made repayment of Lind Note with the Company&#8217;s common stock for 751,795 shares, totaling $681,000. As of December
31, 2024, the first Lind Note was fully repaid.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 17, 2023, in connection with the
issuance of the 2<sup>nd</sup> Lind Note (referring to Note 7), Lind also received a 5-year term of common stock purchase warrants to
purchase up to 1,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $2 per share. The warrants were valued
using the Black-Scholes model and the fair value was determined to be $480,795, which was recorded as a debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 17, 2024, in connection with the
issuance of the 3<sup>rd</sup> Lind Note (referring to Note 7), Lind also received 5-year term of common stock purchase warrants to purchase
up to 1,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $2 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 22, 2024, the Company and Lind entered
into a letter agreement, pursuant to which Lind will exercise, for cash, 1,000,000 of its Pre-Existing Warrants (all of the warrants
issued to Lind on February 23, 2023, November 17, 2023 and January 17, 2024 are hereinafter referred to as the &#8220;Pre-Existing Warrants&#8221;),
to purchase shares of Common Stock at a reduced exercise price of $0.75 per share. Such 1,000,000 Pre-Existing Warrants exercised include
529,167 warrants issued in February 2023 and 470,833 warrants issued in November 2023. Concurrently, the exercise price of all Pre-Existing
Warrants was reduced to $0.75 per share according to this agreement. Lind also received new warrants to purchase 1,000,000 shares of
common stock, exercisable at any time on or after the date of its issuance and until the five-year anniversary thereof, for $1.00 per
share (the &#8220;New Warrants&#8221;). The fair value of the New Warrants was determined to be $925,210 using the Black-Scholes model.
The New Warrants may be exercised via cashless exercise or resale pursuant to the registration statement that was declared effective.
As of December 31, 2024, Lind has exercised 1,000,000 shares of Pre-Existing Warrants and received 1,000,000 shares of New Warrants according
to this agreement. All warrants issued to Lind may be exercised via cashless exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the year ended December 31, 2024, the
Company issued Lind in total of 800,000 shares of the Company&#8217;s common stock as the repayment of $800,000 principal of 2<sup>nd</sup>
Lind Note. According to the amended agreement pursuant to Nasdaq requirements, the conversion price is subject to $1.00 floor price if
the conversion price was below such floor, resulting in effective conversion price between $0.7907 to $0.4932. The Company made additional
$327,017 cash repayments, with $127,759 unpaid cash booked in Accrued Expenses and Other Current Liabilities as of December 31, 2024.
On March 3, 2025 and April 1, 2025, Lind converted the remaining $400,000 ($200,000 in each conversion) principal balance on 2<sup>nd</sup>
Lind Note into 400,000 shares of the Company&#8217;s common stocks. All principal balance of 2<sup>nd</sup> Lind Note was fully converted
as of April 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 3, 2025 and April 1, 2025, Lind converted
$400,000 ($200,000 in each conversion) principal balance on 3<sup>rd</sup> Lind Note into 400,000 shares of the Company&#8217;s common
stocks, leaving outstanding principal of $600,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 5, 2025, the Company and Lind entered
into a third letter agreement, pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares
of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Warrants issued and outstanding in connection
with above Lind convertible notes as of March 31, 2025, and their activities during the three-month period ended are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number of<br/> Underlying<br/> Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average<br/> Contractual<br/> Life<br/> Remaining<br/> in Years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Outstanding as of January 1, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,029,167</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.70</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">*</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.20</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,542</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Issued</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-361"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-362"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-363"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-364"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,029,167</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.40</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-365"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-366"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Outstanding as of March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,000,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.40</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</span></td>
</tr></table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">12. EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company previously reported that during
the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related
party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related
party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to
the agreements, the Company issued 644,972 shares of the Company&#8217;s common stock for the consulting service from July 2019 to July
2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable. For the years ended December 31,
2024 (through June 30, 2024) and 2023, stock subscription receivable recognized as stock-based compensation in equity was $451,480 and
$902,960, respectively.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">After further reviewed and investigation,
above services were completely provided by December 31, 2022. Pursuant to ASC 718, the costs of services should be recognized along with
the period when services are received. Therefore, the Company reversed share-based compensation expenses of $451,480 and $902,960 for
the years ended December 31, 2024 and 2023, respectively. The accumulated deficit as of December 31, 2022 was corrected with the Stock
Subscription Receivables for $1,354,440 as a result of such adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 3, 2023, the Company issued&#160;22,341&#160;common
stock (post-split) to a consultant for providing consulting services on listing to NASDAQ in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 27, 2023, the Company entered into
that certain securities purchase agreement. relating to the offer and sale of 30,000 shares of common stock (post-split) and 20,000 pre-funded
warrants (post-split), at an exercise price of $0.001 per share, in a registered direct offering. Pursuant to the Purchase Agreement,
the Company agreed to sell the Shares and/or Pre-funded Warrants at a per share purchase price of $3.50, for gross proceeds of $1,750,000,
before deducting any estimated offering expenses. On August 1, 2023, 200,000&#160;pre-funded warrants were exercised.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 14, 2023, the Company entered into
a cooperation agreement with Zhonghui. Pursuant thereto, the Company expect to receive 20% of the ownership of a property and the parcel
of the land owned by Zhonghui in Leshan, Sichuan, China. During the third quarter of 2023, the Company issued to Zhonghui, an aggregate
of 370,000 shares (post-split) of the Company&#8217;s common stock, at a per share price of $1.87, for $691,900.&#160;The Company also
issued 29,600 common stock to consultants for providing consulting services on the above transaction. Please refer Note 2 for the restatement
of prior year reported amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 27, 2024, the Company granted 1,302,726
restricted shares to its employees and directors under the 2016 Equity Incentive Plan as compensation for their previous services, with
an issuance date of February 2, 2024. These shares are subject to a three-year restriction period.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 6, 2024, the Company entered into
a definitive agreement with Shuling Jiang (&#8220;Shuling&#8221;), pursuant to which Shuling shall transfer the ownership of certain
land she owns located at Taoyuan City, Taiwan (the &#8220;Land&#8221;) to the Company (the &#8220;Agreement&#8221;). Shuling is a director
of the Company, is married to TS Jiang, the Company&#8217;s Chief Strategic Officer and owns approximately 15.4% of the Company&#8217;s
issued and outstanding shares of common stock. In consideration for the Land, the Company was to pay Shuling (i) 703,496 restricted shares
of the Company&#8217;s common stock (the &#8220;Shares&#8221;) at a price of $3.50 per share and (ii) five-year warrants to purchase
up to 1,000,000 shares of the Company&#8217;s common stock, with an exercise price of $2.00 per share. Under the Agreement, Shuling was
to also transfer outstanding liability owed on the Land (approximately $500,000) to the Company. On May 16, 2024, the Company&#8217;s
board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not
proceed with the transfer of land ownership; the Company may reconsider the transaction at a later date. The shares were returned and
booked as treasury stock, and the warrants were not issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 24, 2024, the Company issued 200,000
shares of common stock to a consultant for providing business and funding opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In June 2024, the Company entered into a stock
purchase agreement with an investor, which the Company issued 41,387 shares of common stock at $0.75 per share to the investor for cash.
Due to certain stock transfer processes, one of the Company&#8217;s shareholders transferred such shares to the investor on behalf of
the company in July 2024; the company plans to issue the same number of shares to the transferring shareholder soon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In July 2024, the Company entered into an
agreement with its landlord in California, pursuant that the Company will make the rent payments in the Company&#8217;s common stocks.
As of December 31, 2024, the Company has issued 399,384 shares with average issuance price of $0.68 per share, for the monthly rent from
April 2024 and half month of December 2024, in total of $271,827. The Company subsequently issued 80,654 shares of its common stock for
each of the half month rent in the first quarter of 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Noncontrolling Interests</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5pt"><span style="-sec-ix-redline:true;-keep: true">AiBtl was incorporated
in January 2023 and issued <span style="-sec-ix-hidden: hidden-fact-310"><span style="-sec-ix-hidden: hidden-fact-311">20,000,000</span></span> shares of its common stocks to the founding shareholder AiBtl Holding with the par value $0.0001,
for $2,000 at the time of incorporation. Due to certain administrative process, the previous issuance was not correctly and timely recorded
at AiBtl&#8217;s book which resulted in the correction of the previous reported non-controlling interest equity balance. Later in December
2023, AiBtl issued 23,000,000 shares to ABVC and 23,000,000 shares to BioLite, respectively, as a consideration for the Company&#8217;s
out-licensing products, as disclosed in Note 4. At the close of the transaction, AiBtl became the Company&#8217;s 60.70% owned subsidiary
included in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 14, 2024, AiBtl issued 1,610,700
AiBtl&#8217;s common stocks to a land acquisition transaction in Taiwan, including the 1-year business consulting fee of $383,500 incurred
beginning in November 2023, and the cost of land $7,670,000. Due to certain administrative processes and restrictions, AiBtl has not
acquired ownership of the land and no asset was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Yunzhiyi, a Taiwan corporation, was incorporated
in August 2024, with 90% owned by BioLite Taiwan and 10% owned by Shuling Jiang, the Company&#8217;s director. This entity is set up
for holding the land that AiBtl acquired in Taiwan for developing health related business in Taiwan. Due to certain administrative processes
and restrictions, the title transfer has not completed, and no asset was recognized as of the issuance of this report. However, AiBtl
entered a series of agreements with the sellers in March 2025, to obtain the complete rights and obligations of the land while in the
process of transferring the title. These agreements are effective until the tile transfer is completed. AiBtl recognized such asset on
its balance sheet in March 2025.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Lind Offerings and Repayments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 23, 2023, in connection with the
issuance of the Lind Note (referring to Note 7), the Company issued Lind a 5-year term of common stock purchase warrant to purchase up
to 529,167 shares (post-split) of the Company&#8217;s common stock at an initial exercise price of $10.5 per share (post-split), subject
to adjustment. The warrant exercise price was reset to $3.5 in accordance with the issuance of common stock in relation to securities
purchase agreement in July 2023. On May 22, 2024, the exercise price of these warrants was further reset to $0.75 along with the immediate
exercise of existing warrants and issuance of the New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the years ended December 31, 2024 and
2023, the Company has made repayment of Lind Note with the Company&#8217;s common stock for 1,705,303 shares and 3,732,167 shares, respectively,
totaling $593,714 and $1,786,686, respectively. As of December 31, 2024, the first Lind Note was fully repaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 17, 2023, in connection with the
issuance of the 2<sup>nd</sup> Lind Note (referring to Note 7), Lind also received a 5-year term of common stock purchase warrants to
purchase up to 1,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $2 per share. The warrants were valued
using the Black-Scholes model and the fair value was determined to be $480,795, which was recorded as a debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 17, 2024, in connection with the
issuance of the 3<sup>rd</sup> Lind Note (referring to Note 7), Lind also received 5-year term of common stock purchase warrants to purchase
up to 1,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $2 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 22, 2024, the Company and Lind entered
into a letter agreement, pursuant to which Lind will exercise, for cash, 1,000,000 of its Pre-Existing Warrants (all of the warrants
issued to Lind on February 23, 2023, November 17, 2023 and January 17, 2024 are hereinafter referred to as the &#8220;Pre-Existing Warrants&#8221;),
to purchase shares of Common Stock at a reduced exercise price of $0.75 per share. Such 1,000,000 Pre-Existing Warrants exercised include
529,167 warrants issued in February 2023 and 470,833 warrants issued in November 2023. Concurrently, the exercise price of all Pre-Existing
Warrants was reduced to $0.75 per share according to this agreement. Lind also received new warrants to purchase 1,000,000 shares of
common stock, exercisable at any time on or after the date of its issuance and until the five-year anniversary thereof, for $1.00 per
share (the &#8220;New Warrants&#8221;). The fair value of the New Warrants was determined to be $925,210 using the Black-Scholes model.
The New Warrants may be exercised via cashless exercise or resale pursuant to the registration statement that was declared effective.
As of December 31, 2024, Lind has exercised 1,000,000 shares of Pre-Existing Warrants and received 1,000,000 shares of New Warrants according
to this agreement. All warrants issued to Lind may be exercised via cashless exercise.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the year ended December 31, 2024, the
Company issued Lind in total of 800,000 shares of the Company&#8217;s common stock as the repayment of $800,000 principal of 2<sup>nd</sup>
Lind Note. According to the amended agreement pursuant to Nasdaq requirements, the conversion price is subject to $1.00 floor price if
the conversion price was below such floor, resulting in effective conversion price between $0.7907 to $0.4932. The Company made additional
$327,017 cash repayments, with $127,759 unpaid cash booked in Accrued Expenses and Other Current Liabilities. As of the date of this
report, Lind has converted the remaining <span style="-sec-ix-hidden: hidden-fact-309">$400,000</span> principal balance on 2<sup>nd</sup> Lind Note into 400,000 shares of the Company&#8217;s
common stocks.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Subsequent to December 31, 2024 through the
date of this report, Lind has converted $400,000 of 3<sup>rd</sup> Lind Note principal balance into 400,000 the Company&#8217;s common
stock, leaving outstanding principal of $600,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Warrants issued and outstanding in connection
with above Lind convertible notes as of December 31, 2024, and their activities during the year ended are as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Underlying<br/> Shares</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per Share</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-<br/> Average<br/> Contractual<br/> Life<br/> Remaining<br/> in Years</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2024</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1,529,167</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.40</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">5,542</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">190,000</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,500,000</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-306"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-307"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2024</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2,029,167</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">195,542</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">13. STOCK OPTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has <span style="-sec-ix-hidden: hidden-fact-377"><span style="-sec-ix-hidden: hidden-fact-378">not</span></span> granted any options during
three months ended March 31, 2025 and 2024. The Company&#8217;s most recent option grant was in 2022 that 76,190&#160;shares (post-split)
of common stock were granted to employees and certain consultants.&#160;The weighted average grant date fair value of options granted
in 2022 was $27.9 (post-split). There are 386,021&#160;options available for grant under the 2016 Equity Incentive Plan as of December
31, 2024. Compensation costs associated with the Company&#8217;s stock options are recognized, based on the grant-date fair values of
these options over vesting period. As of March 31, 2025 and December 31, 2024, there were <span style="-sec-ix-hidden: hidden-fact-379"><span style="-sec-ix-hidden: hidden-fact-380">no</span></span> unvested options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Options issued and outstanding as of March
31, 2025, and their activities during the year then ended are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number&#160;of</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Exercise</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Contractual</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Underlying<br/> Shares<br/> (post-split)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Price<br/> Per&#160;Share<br/> (post-split)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Life<br/> Remaining<br/> in Years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding as of January 1, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">258,710</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27.9</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.74</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-367"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-368"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-369"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">-</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-370"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-371"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-372"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-373"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding as of March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">258,710</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27.9</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-374"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable as of March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">258,710</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27.9</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-375"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Vested and expected to vest</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">258,710</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27.9</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-376"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">13. STOCK OPTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has not granted any options during
years ended December 31, 2024 and 2023. The Company&#8217;s most recent option grant was in 2022 that 76,190&#160;shares (post-split)
of common stock were granted to employees and certain consultants.&#160;The weighted average grant date fair value of options granted
in 2022 was $27.9 (post-split). There are 386,021&#160;options available for grant under the 2016 Equity Incentive Plan as of December
31, 2024. Compensation costs associated with the Company&#8217;s stock options are recognized, based on the grant-date fair values of
these options over vesting period. As of December 31, 2024 and 2023, there were no unvested options.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Options issued and outstanding as of December
31, 2024, and their activities during the year then ended are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number&#160;of</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Contractual</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying<br/> Shares<br/> (post-split)</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price<br/> Per&#160;Share (post-split)</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Life<br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining<br/> in Years</span></b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2024</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">258,710</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">27.9</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">7.74</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-313"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-314"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-315"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-316"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-318"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-319"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-320"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2024</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">258,710</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">27.9</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">7.74</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable as of December 31, 2024</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">258,710</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">27.9</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">7.74</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested and expected to vest</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">258,710</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">27.9</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">6.74</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-323"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">14. LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Basic loss per share is computed by dividing
net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended
March 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months &#160;Ended</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">Numerator:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss attributable to ABVC&#8217;s common stockholders</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(842,075</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,834,199</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Denominator:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Weighted-average shares outstanding &#8211; Basic &amp; Diluted</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,968,232</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,736,150</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Loss per share</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">-Basic &amp; Diluted</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(0.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(0.29</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Diluted loss per share takes into account
the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common
Stock. Since the Company suffered net loss for both years, any diluted shares would have anti-diluted effect.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">14. LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Basic loss per share is computed by dividing
net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the years ended December
31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the Year Ended</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2024</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2023</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator:</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss attributable to ABVC&#8217;s
    common stockholders</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,902,878</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,788,050</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average shares outstanding &#8211;  Basic
    &amp; Diluted</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">11,673,980</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">4,335,650</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss per share</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-Basic &amp; Diluted</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.42</span></td>
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.80</span></td>
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Diluted loss per share takes into account
the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common
Stock. Since the Company suffered net loss for both years, any diluted shares would have anti-diluted effect.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">15. LEASE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#8220;ASC 842&#8221;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company applied the following practical
expedients in the transition to the new standard and allowed under ASC 842:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of expired
    or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained
    leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing
    leases.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of hindsight: The
    Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease
    and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of existing
    or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted
    for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will
    be evaluated under ASU No. 2016-02.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation of lease
    and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease recognition
    exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities
    for leases with a term less than 12 months.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities. ROU assets represent the
Company&#8217;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#8217;s obligation to
make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#8217;s future minimum based payments used
to determine the Company&#8217;s lease liabilities mainly include minimum based rent payments. As most of Company&#8217;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognized lease liabilities,
with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has no finance leases. The Company&#8217;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#8217;s operating leases have remaining lease terms of up to approximately five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#8239;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">ASSETS</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease right-of-use assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">533,460</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">640,387</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">LIABILITIES</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities (current)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">366,475</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">403,581</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities (non-current)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">166,985</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">236,807</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true"><i>Supplemental Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following provides details of the Company&#8217;s
lease expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease expenses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">117,166</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">98,502</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Other information related to leases is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">117,166</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">98,502</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Weighted Average Remaining Lease Term:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating leases</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.43 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.48 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Weighted Average Discount Rate:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating leases</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.32</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.19</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Operating<br/> leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="-sec-ix-redline:true;-keep: true">2025 (Excluding current period)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">302,071</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">104,849</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,699</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2028</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,699</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2029</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,699</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-381"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total future minimum lease payments, undiscounted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">547,017</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(13,557</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Present value of future minimum lease payments</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">533,460</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true">15. LEASE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#8220;ASC 842&#8221;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company applied the following practical
expedients in the transition to the new standard and allowed under ASC 842:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of expired
    or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained
    leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing
    leases.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of hindsight: The
    Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease
    and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of existing
    or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted
    for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will
    be evaluated under ASU No. 2016-02.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation of lease
    and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease recognition
    exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities
    for leases with a term less than 12 months.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities. ROU assets represent the
Company&#8217;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#8217;s obligation to
make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#8217;s future minimum based payments used
to determine the Company&#8217;s lease liabilities mainly include minimum based rent payments. As most of Company&#8217;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognized lease liabilities,
with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has no finance leases. The Company&#8217;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#8217;s operating leases have remaining lease terms of up to approximately five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#8239;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">ASSETS</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease right-of-use assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">640,387</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">809,283</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">LIABILITIES</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities (current)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">403,581</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">401,826</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities (non-current)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">236,807</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">407,457</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true"><i>Supplemental Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following provides details of the Company&#8217;s
lease expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease expenses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">514,420</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">358,576</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Other information related to leases is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">484,181</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">358,576</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Weighted Average Remaining Lease Term:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating leases</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.48 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1.73 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Weighted Average Discount Rate:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating leases</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.19</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Operating<br/>
    leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">409,587</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">104,236</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,320</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2028</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,320</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2029</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,320</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-324"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total future minimum lease payments, undiscounted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">655,782</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(15,395</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Present value of future minimum lease payments</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">640,387</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">16. COMMITMENTS AND CONTINGENCIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of March 31, 2025 and up through the date
of the consolidated financial statements was available to the issued.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">16. COMMITMENTS AND CONTINGENCIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of December 31, 2024 and up through the date
of the consolidated financial statements was available to the issued.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">ACQUISITION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">17. ACQUISITION</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 12, 2023, the Company and one
of its subsidiaries, BioLite, Inc. (&#8220;BioLite Taiwan&#8221;)&#160; each entered into a multi-year, global licensing agreement with
AiBtl BioPharma Inc. (&#8220;AiBtl&#8221;, or the acquired company) for the Company and BioLite Taiwan&#8217;s CNS drugs with the indications
of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the &#8220;Licensed Products&#8221;).
The potential license will cover the Licensed Products&#8217; clinical trial, registration, manufacturing, supply, and distribution rights.
The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen
new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the
respective agreements, each of ABVC and BioLite Taiwan received 23 million shares of AiBtl stock and as a result, the Company has a controlling
interest over AiBtl. If certain milestones are met, the Company and BioLite Taiwan are each eligible to receive $3,500,000 and royalties
equaling 5% of net sales, up to $100 million.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company concluded the assets acquired
and liabilities assumed did not meet the definition of a business as a limited number of inputs were acquired but no substantive business
processes or signs of output were acquired. As such, the acquisition was accounted for as an asset purchase. The purchase consideration
was nonmonetary assets (patent) and transfer on November12, 2023. The equity interest transferred to ABVC and BioLite Taiwan on December
15, 2023.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cash and cash equivalents</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">S</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-325"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total assets acquired</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-326"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expense</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(243,888</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Due to Director</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(498</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Total liabilities acquired</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(243,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Total consideration (Intangible assets)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-50/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">17. SUBSEQUENT EVENTS</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In April 2025, the Company conducted a private
offering of its common stock to several individual investors, issuing 724,372 unregistered shares at $0.60 to $0.65 per share, raising
a total of $436,125.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In April 2025, the Company issued 9,909 unregistered
restricted shares to an individual consultant as a consideration of $9,800 ($0.99 per share) for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In April 2025, the Company issued 50,000 and
90,277 shares of common stock to two advisors for their financial and business advisory services, as the consideration of $52,500 and
$94,791 ($1.05 and $1.05 per share), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In April 2025, AiBtl issued 1,800 shares of
its common stock at $5 per share, raising a total of $9,000 from an individual investor.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">18. SUBSEQUENT EVENTS</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 5, 2025, the Company and Lind entered
into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, 1,029,167
of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise
price of $0.40 per share.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the first quarter of 2025, Lind has
converted the remaining $400,000 principal balance on 2<sup>nd</sup> Lind Note into 400,000 shares of the Company&#8217;s common stocks,
and converted $400,000 of 3<sup>rd</sup> Lind Note principal balance into 400,000 the Company&#8217;s common stock, leaving 3<sup>rd</sup>
Lind Note with outstanding principal of $600,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In April 2025, the Company conducted a private
offering of its common stock to several individual investors, issuing 502,081 unregistered shares at $0.60 per share, raising a total
of $301,250.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">In April 2025, AiBtl issued 1,800 shares of
its common stock at $5 per share, raising a total of $9,000 from an individual investor.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Basis of Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration: none">The accompanying
unaudited interim condensed consolidated financial statements have been prepared in accordance with the generally accepted accounting
principles in the United States of America (the &#8220;U.S. GAAP&#8221;). All significant intercompany transactions and account balances
have been eliminated. These financial statements do not include all the information and footnotes required by the U.S. GAAP for complete
financial statements. Certain information and note disclosures normally included in the annual financial statements prepared in accordance
with the U.S. GAAP have been condensed or omitted consistent with Article 8 of Regulation S-X. In the opinion of the Company&#8217;s
management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial
statements and include all adjustments, in a normal recurring nature, as necessary for the fair statement of the Company&#8217;s financial
position as of March 31, 2025, and results of operations and cash flows for the three months ended March 31, 2025 and 2024. The unaudited
interim condensed consolidated balance sheet as of March 31, 2025 has been derived from the audited financial statements at December
31, 2024, and interim results of operations are not necessarily indicative of the results expected for the full fiscal year or for any
future period. These financial statements should be read in conjunction with the audited consolidated financial statements as of and
for the years ended December 31, 2024 and 2023, and related notes included in the Company&#8217;s audited consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration: none">This basis
of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses
and losses are recognized when incurred. The Company&#8217;s unaudited financial statements are expressed in U.S. dollars.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Basis of Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The accompanying consolidated financial statements
have been prepared in accordance with the U.S. GAAP and pursuant to the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).
All significant intercompany transactions and account balances have been eliminated. The Company&#8217;s fiscal year is the calendar
year.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Reclassifications</span>:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration: none">Certain
amounts on the prior year&#8217;s condensed consolidated balance sheets, condensed consolidated statements of operations and condensed
cash flows were reclassified to conform to the current-year presentation, with no effect on ending stockholders&#8217; equity.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Reclassifications of Prior Year Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Certain amounts on prior year&#8217;s consolidated
financial statements have been reclassified for consistency with the current year presentation. These reclassifications had no effect
on the reported results of operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of financial statements in
conformity with the U.S. GAAP that requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of
revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockReverseSplitPolicyTextBlock', window );">Stock Reverse Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Stock Reverse Split</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 25, 2023, the Company filed a Certificate
of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its
common stock. The Company&#8217;s stockholders previously approved the Reverse Stock Split at the Company&#8217;s Special Shareholder
Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase
the per share trading value of the Company&#8217;s common stock, although that outcome is not guaranteed. All shares and related financial
information in this Form 10-K reflect this 1-for-10 reverse stock split.&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Fair Value Measurements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 820 &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8211;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8211;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8211;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Fair Value Measurements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 820 &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8211;&#160;Inputs
    are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
    date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active
    markets that are readily and regularly available.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8211;&#160;Inputs
    other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as
    quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8211;&#160;Valuations
    based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally
    determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market
    participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying values of certain assets and
liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid
expenses and other current assets, accrued expenses and other current liabilities, and due to related parties, approximate fair value
due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loans, convertible notes payable,
and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration
to maturity is short.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $91,500 (NTD 3.0 million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $250,000 covered by the U.S. Federal Deposit Insurance Corporation&#8217;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s financial instruments
that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of the limit of $91,500 (NTD 3.0 million)
covered by Taiwan Central Deposit Insurance Corporation, and the limit of $250,000 covered by the U.S. Federal Deposit Insurance Corporation&#8217;s
insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments
for hedging, trading or speculative purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company performs ongoing credit evaluation
of its customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the
collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical
collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit
losses may differ from our estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConcentrationOfClientsPolicyTextBlock', window );">Concentration of Clients</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Concentration of Clients</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025 and December 31, 2024,
management estimated all accounts receivable balances are uncollectible. Provision credit loss balances were $11,993 and $11,993 as of
March 31, 2025 and December 31, 2024, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the three months ended March 31, 2024,
the Company&#8217;s revenue was generated from one customer.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Concentration of Clients</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024, management estimated
all accounts receivable balances are uncollectible and recognized $11,993 of credit loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2023, the most major clients,
specializes in developing and commercializing of dietary supplements and therapeutics in dietary supplement industry, accounted for 87%
of the Company&#8217;s total account receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the year ended December 31, 2024, the
out-licensing income from our two major licensees, accounts for 58% and 39% of the Company&#8217;s total revenues.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the year ended December 31, 2023, the
major client, distributing nutritional supplements in Asia Pacific, accounted for 80% of the Company&#8217;s total revenues.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Cash and Cash Equivalents</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of March 31, 2025 and December 31, 2024, the Company&#8217;s
cash and cash equivalents amounted to $152,206 and $248,382, respectively. Some&#160;of the Company&#8217;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Cash and Cash Equivalents</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company considers highly liquid investments
with maturities of three months or less to be cash equivalents when purchased. As of December 31, 2024 and 2023, the Company&#8217;s
cash and cash equivalents amounted to $248,382 and $60,155, respectively. Some&#160;of the Company&#8217;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Restricted Cash </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of March 31, 2025 and December 31, 2024, the Company&#8217;s restricted cash amounted $607,362
(NTD 20.2 million) and $615,433 (NTD 20.2 million), respectively.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Restricted Cash </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Restricted cash primarily consist of cash
held in a reserve bank account in Taiwan. As of December 31, 2024 and 2023, the Company&#8217;s restricted cash amounted $615,433 (NTD
20.2 million) and $656,625 (NTD 20.1 million), respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable and allowance for expected credit losses accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Accounts receivable and allowance for expected credit losses
accounts</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accounts receivable are recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company makes estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#8217;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Allowance for expected credit losses accounts
were $616,397 and $616,414 as of March 31, 2025 and December 31, 2024, respectively.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Accounts receivable and allowance for expected credit losses
accounts</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accounts receivable is recorded and carried
at the original invoiced amount less an allowance for any potential uncollectible amounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company make estimates of expected credit
and collectability trends for the allowance for credit losses and allowance for unbilled receivables based upon our assessment of various
factors, including historical experience, the age of the accounts receivable balances, credit quality of customers, current economic
conditions reasonable and supportable forecasts of future economic conditions, and other factors that may affect our ability to collect
from customers. The provision is recorded against accounts receivable balances, with a corresponding charge recorded in the consolidated
statements of income. Actual amounts received may differ from management&#8217;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Allowance for expected credit losses accounts
was $616,414 and $616,505 as of December 31, 2024 and 2023, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b>Collaborative Revenues &#8212; </b>The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s
judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(i) Non-refundable upfront payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(ii) Milestone payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative
agreement with collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">(iii) Multiple Element Arrangements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">(iv) Royalties and Profit Sharing Payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b>Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp; Manufacturing Organization Services (&#8220;CDMO&#8221;))</b> &#8212;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advances from customers upon receipt
or when due, and may require deferral of revenue recognition for a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes revenue in accordance
with ASC 606, Revenue from Contracts with Customers. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the
Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or
services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope
of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b>Collaborative Revenues &#8212; </b>The
Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements.
The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront
license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties
on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net
sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue
is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company had multiple deliverables under
the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development,
and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s
judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(i) Non-refundable upfront payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">(ii) Milestone payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative
agreement with collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The former category of milestone payments
consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">(iii) Multiple Element Arrangements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">(iv) Royalties and Profit Sharing Payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the collaborative agreement with the
collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net
sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those
criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable
contingency is resolved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b>Revenues Derived from Research and Development
Activities Services (Also known as the Contract Development &amp; Manufacturing Organization Services (&#8220;CDMO&#8221;))</b> &#8212;
Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed,
in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which
is to perform research and development services. The Company may also provide its customers with an option to request that the Company
provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions.
The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option
is a material right, the Company will consider the option a separate performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If the Company is entitled to reimbursement
from its customers for specified research and development expenses, the Company accounts for the related services that it provides as
separate performance obligations if it determines that these services represent a material right. The Company also determines whether
the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses
in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the
corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company then determines the transaction
price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration.
Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential
milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by
the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development
expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction
price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine
if the Company should include additional payments in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Property and Equipment, net</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net is carried at
cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of
the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related
gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of
the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method generally based
on the following useful lives:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Estimated&#160;Life<br/> in Years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 91%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Buildings and leasehold improvements</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">5 ~ 50</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">5 ~ 10</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Office equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3 ~ 6</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Impairment of Long-Lived Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has adopted ASC subtopic 360-10,
Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles
held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances
warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a
forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying
value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition
of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less
costs to sell.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Long-term Equity Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Long-term Equity Investment</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company acquires the equity investments
to promote business and strategic objectives. The accounting treatment for equity investments, where the Company does not have control
over the investees, is as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Marketable equity investments: The Company measures marketable equity
    securities at fair value at each reporting date, with unrealized gains and losses recognized in net income in accordance with <span style="font-style: normal; font-weight: normal">ASC
    321. Fair value is</span> determined based on quoted market prices or other observable inputs.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable equity
    investments: When the equity method does not apply, non-marketable equity investments are accounted for at cost, adjusted for observable
    price changes in orderly transactions for identical or similar investments and for impairments, if applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity method investments:
    Investments in which the Company has the ability to exercise significant influence, but not control, over the investee, are accounted
    for using the equity method. The Company recognizes its proportionate share of the investee&#8217;s income or loss in gains (losses)
    on equity investments on a monthly basis.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, considering this a critical accounting
estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#8217;s
fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee,
changes in general market conditions in the investee&#8217;s industry or geographic area, and the management and governance structure
of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches.
The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The
income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#8217;
revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment exists could
change in the future due to new developments or changes in applied assumptions.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OtherThanTemporaryImpairmentPolicyTextBlock', window );">Other-Than-Temporary Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;text-decoration:underline">Other-Than-Temporary Impairment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company periodically reviews its non-marketable
equity investments and equity method investments, with recognition in profit and loss when declines in value are considered other than
temporary. the Company assesses the severity and duration of any impairment, along with qualitative and quantitative factors, such as
the investee&#8217;s financial performance, adverse market or regulatory conditions, operational changes, or additional funding needs.
Evidence of a loss in value might include the inability to recover the carrying amount of the investment or the investee&#8217;s failure
to sustain earnings capacity to justify its valuation. Impairments deemed other than temporary are recorded in gains (losses) on equity
investments, even if the decline exceeds the losses recognized under the equity method, where applicable.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertibleNotesPayablePolicyTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Convertible Notes Payable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for convertible notes
payable in accordance with ASC 470-20, Debt with Conversion and Other Options, and ASC 815, Derivatives and Hedging, as applicable. Upon
issuance, the Company evaluates whether the embedded conversion feature should be bifurcated as a derivative under ASC 815 or classified
within equity under ASC 470-20. This assessment includes analyzing the terms of the conversion feature and determining if it requires
separate accounting. If the conversion feature is classified as equity, the proceeds from the issuance are allocated between the debt
and equity components. The debt component is recorded at its fair value, and the residual amount is allocated to equity. The debt component
is carried at amortized cost, with any discount amortized to interest expense over the term of the note using the effective interest
method. Upon conversion, the carrying amount of the debt is reclassified to equity, and no gain or loss is recognized. If the note is
settled in cash, any difference between the carrying amount and the settlement amount is recognized in profit and loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Warrants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for warrants as either
equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative
guidance in ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC
815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including
whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net
cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This
assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly
period end date while the warrants are outstanding. The Company determined that upon further review of the warrant agreement, the Public
Warrants issued pursuant to the warrant agreement qualify for equity accounting treatment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For issued or modified warrants that meet
all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance.
For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded
as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated
fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Research and Development Expenses</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for the cost of using
licensing rights in research and development cost according to ASC 730-10-25-1. This guidance provides that absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses when incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for R&amp;D costs in
accordance with ASC 730, Research and Development (&#8220;ASC 730&#8221;). Research and development expenses are charged to expense as
incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development
expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related
overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical
and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that
will be used in future research and development activities are expensed when the activity has been performed or when the goods have been
received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research
and development services, costs are expensed as services are performed.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitPlansPolicy', window );">Post-retirement and post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Post-retirement and post-employment benefits</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s subsidiaries in Taiwan
adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor
regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of
the worker&#8217;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#8217; salaries
to the employees&#8217; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts
for such employee benefits, which were expensed as incurred, were $11,642 (NTD 0.4 million) and $10,314&#160;(NTD 0.4 million) for the
years ended December 31, 2024 and 2023, respectively. Other than the above, the Company does not provide any other post-retirement or
post-employment benefits.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Stock-based Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221;.
Total director, officer, and employee stock-based compensation expenses were $0 and $1,935,755 for the three months ended March 31, 2025
and 2024, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="-sec-ix-redline:true;-keep: true">The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221; and ASC 505-50 &#8220;Equity-Based Payments
to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $48,773 for rent for the three months ended March 31, 2025, and $95,876&#160;for consulting services
for the three months ended March 31, 2024.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Stock-based Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221;.
Total director, officer, and employee stock-based compensation expenses were $1,995,049 and $0 for the years ended December 31, 2024
and 2023, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounted for stock-based compensation
to non-employees in accordance with ASC 718 &#8220;Compensation-Stock Compensation&#8221; and ASC 505-50 &#8220;Equity-Based Payments
to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier
of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee
stock-based compensation expenses were $506,583 for consulting services and $271,828 for rent for the year ended December 31, 2024, and
$185,933&#160;for consulting services for the year ended December 31, 2023.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Income Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for income taxes using
the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood
of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects
of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire
before the Company is able to realize their benefits, or future deductibility is uncertain.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under ASC 740, a tax position is recognized
as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax
examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it
is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations
based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold
to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit
that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not
recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions
that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which
the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income
tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended December
31, 2024 and 2023. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods,
disclosures and transition.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock', window );">Valuation of Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Valuation of Deferred Tax Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A valuation allowance is recorded to reduce
the Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Loss Per Share of Common Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company calculates net loss per share
in accordance with ASC 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Commitments and Contingencies</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has adopted ASC 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in financial statements when
it is at least reasonably possible that a material loss could be incurred.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Commitments and Contingencies</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has adopted ASC 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign-currency Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Foreign-currency Transactions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#8217;
Equity.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Foreign-currency Transactions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan Dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into NTD, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of
conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing
exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments
in shares of stock where such differences are accounted for as translation adjustments under the Statements of Changes in Stockholders&#8217;
Equity.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Segment Reporting</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 280 &#8220;Segment Reporting&#8221; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company currently has&#160;one&#160;reportable
segment, and assets are reviewed on a consolidated basis. As such, segmental data is not provided.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following tables present revenue and gross
profit information for each of our only reportable segment:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Three-Month<br/> Periods
    Ended<br/> March 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024<br/> (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Revenue</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-331"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,205</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Cost of Revenue</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-332"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">277</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-333"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">928</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Depreciation expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,021</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,286</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Three-Month<br/>
    Periods Ended<br/> March 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024<br/>
    (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">928</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">Less:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">615,371</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">738,486</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Research and development expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">28,861</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">69,066</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock-based compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">48,773</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,031,631</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Add (Less):</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,071</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,049</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(222,967</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(181,676</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating sublease income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">12,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gain (loss) on foreign exchange changes</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(9,912</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,730</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on investment in equity securities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(50,877</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-335"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,500</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,485</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Loss before provision for income tax</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(944,190</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,927,667</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Segment Reporting</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 280 &#8220;Segment Reporting&#8221; requires
public companies to report financial and descriptive information about their reportable operating segments. The Company identifies the
operating segments based on how the chief operating decision maker internally evaluates separate financial information, business activities
and management responsibility.</span></p>The Company currently has&#160;one&#160;reportable
segment and assets are reviewed on a consolidated basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In August 2023, the FASB issued ASU 2023-05,
Business Combinations&#8212;Joint Venture Formations (Subtopic 805-60) which requires certain joint ventures to apply a new basis of
accounting upon formation by recognizing and initially measuring most of their assets and liabilities at fair value. The guidance does
not apply to joint ventures that may be proportionately consolidated and those that are collaborative arrangements. ASU 2023-05 is effective
for joint venture with a formation date on or after January 1, 2025, early adoption is permitted. The Company is currently evaluating
the impact that the standard will have on its unaudited consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2023, the FASB issued ASU No.
2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s
effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis
for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not
yet been issued or made available for issuance. This ASU will likely result in the required additional disclosures being included in
our consolidated financial statements once adopted.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In November 2024, the FASB issued ASU No.
2024-03, Expense Disaggregation Disclosures (Subtopic 220-40). The ASU requires disclosure of specified information about certain costs
and expenses. This includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization.&#160; The
ASU is effective on a prospective or retrospective basis for annual reporting period beginning after December 15, 2026, and interim reporting
period beginning after December 15, 2027. Early adoption is permitted. This ASU will likely result in the required additional disclosures
being included in our consolidated financial statements once adopted.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConcentrationOfClientsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for concentration of clients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConcentrationOfClientsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConvertibleNotesPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConvertibleNotesPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OtherThanTemporaryImpairmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other than temporary impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OtherThanTemporaryImpairmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockReverseSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockReverseSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for valuation of deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity, Going Concern, and Restatement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Liquidity, Going Concern, and Restatement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of Impact of the Restatement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the three months ended March 31, 2024 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Unaudited
                                            Condensed</b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Consolidated Balance Sheets</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepaid expense and other current asset</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">159,602</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">223,707</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">383,309</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,949,150</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,400,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">549,150</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepayment for asset acquisition</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-328"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Assets</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,460,402</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,484,392</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,976,010</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,050,845</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(605,178</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,445,667</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Convertible notes payable &#8211; third parties, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">842,567</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">29,769</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">872,336</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">301,972</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">89,502</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">391,474</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current Liabilities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,633,614</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(455,908</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,177,706</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Liabilities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,973,447</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(455,908</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,517,539</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Additional paid-in capital</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">86,029,237</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(9,025,036</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">77,004,201</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total stockholders&#8217; equity</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,792,076</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,092,525</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,699,551</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Noncontrolling interest</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(305,121</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">64,040</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(241,081</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Equity</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,486,955</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,028,485</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,458,470</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Liabilities and Equity</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,460,402</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,484,393</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,976,009</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Unaudited
                                            Condensed</b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Consolidated Statements of Operations</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative expenses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">831,257</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(92,771</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">738,486</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock based compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,544,995</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(513,364</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,031,631</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(684,683</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">503,007</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(181,676</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss attributable to noncontrolling interests</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(48,043</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(45,425</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(93,468</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,981,019</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,053,352</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,927,667</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Basic and diluted net loss per common share</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(0.40</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.11</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(0.29</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">Unaudited Condensed</span></p>
                                                                    <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">Consolidated Statements
                                            of Cash Flows</span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss</span></td><td style="width: 1%; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,981,019</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,053,355</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,927,664</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock-based compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,544,995</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(513,364</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,031,631</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other non-cash income and expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">672,016</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(495,736</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">176,280</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">354,465</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(398,070</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(43,605</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">128,840</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(128,840</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-329"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net cash used in operating activities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(602,001</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(353,815</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(955,816</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties*</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-330"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(217,981</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(217,981</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net cash provided by financing activities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">805,006</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">119,141</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">924,147</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(260,783</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">234,674</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(26,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Issuance of common stock for conversion of debt</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">681,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">213,426</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">467,574</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#8217;s presentation.</span></td>
</tr></table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The impact of the restatement on the balance
sheets, statements of operations, and statements of cash flows as of and for the year ended December 31, 2023 is presented below.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Consolidated Balance Sheets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,969,278</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,400,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">569,278</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepayment for asset acquisition</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Assets</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,492,599</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,708,100</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,784,499</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,696,380</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(148,028</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,548,352</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Convertible notes payable &#8211; third parties, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">569,456</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">317,066</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">886,522</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">173,132</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">361</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">173,493</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current Liabilities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,932,490</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">169,399</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,101,889</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Liabilities</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,361,627</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">169,399</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,531,026</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Additional paid-in capital</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">82,636,966</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(8,658,586</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">73,978,380</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total stockholders&#8217; equity</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,388,050</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,833,940</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,554,110</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Noncontrolling interest</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(257,078</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(43,559</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(300,637</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Equity</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,130,972</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,877,499</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,253,473</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total Liabilities and Equity</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,492,599</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,708,100</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,784,499</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Consolidated Statements of Operations</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock based compensation</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,635,708</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,449,775</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">185,933</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,493,340</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,179,669</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,313,671</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss attributable to noncontrolling interests</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(394,632</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(98,162</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(492,794</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(10,910,288</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,629,444</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(8,280,844</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Basic and diluted net loss per common share</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2.43</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.63</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1.80</span></td><td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended December
    31, 2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Consolidated Statements of Cash Flows</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Reported</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Adjustments</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">As Restated</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net income (loss)</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(10,910,288</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,629,444</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(8,280,844</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock-based compensation</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,635,708</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,449,775</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">185,933</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other non-cash income and expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,413,746</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,169,501</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,244,245</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">786,793</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(148,031</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">638,762</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(186,860</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">186,860</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net cash used in operating activities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(4,235,845</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(48,997</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(4,186,848</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due to related parties*</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(186,499</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(186,499</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Proceeds from subsidiary&#8217;s executive contribution</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">137,500</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">137,500</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net cash provided by financing activities</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,918,960</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(48,999</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,869,961</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2,125-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,123</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Purchase of Property and equipment by issuing common stock to a third party</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,400,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,400,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepayment for asset acquisition by issuing common stock to a third party</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,600</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">691,900</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Issuance of common stock for conversion of debt</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,306,112</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,519,426</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,786,686</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#8217;s presentation.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock', window );">Schedule of Estimated Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Depreciation is calculated on the straight-line method generally based
on the following useful lives:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Estimated&#160;Life<br/> in Years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 91%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Buildings and leasehold improvements</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">5 ~ 50</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">5 ~ 10</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Office equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3 ~ 6</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Revenue and Gross Profit Information of our Reportable Segment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following tables present revenue and gross
profit information for each of our only reportable segment:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Three-Month<br/> Periods
    Ended<br/> March 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024<br/> (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Revenue</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-331"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,205</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Cost of Revenue</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-332"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">277</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-333"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">928</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Depreciation expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,021</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,286</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following tables present revenue and gross
profit information for each of our only reportable segment:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Years Ended<br/>
    December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023 (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Revenue</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">509,589</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">152,430</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Cost of Revenue</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">763</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">302,037</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">508,826</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(149,607</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Depreciation expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">32,025</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">28,531</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Total Segment Gross Profit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Three-Month<br/>
    Periods Ended<br/> March 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024<br/>
    (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">928</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">Less:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">615,371</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">738,486</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Research and development expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">28,861</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">69,066</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock-based compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">48,773</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,031,631</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Add (Less):</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,071</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,049</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(222,967</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(181,676</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating sublease income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">12,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gain (loss) on foreign exchange changes</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(9,912</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,730</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on investment in equity securities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(50,877</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-335"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,500</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,485</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Loss before provision for income tax</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(944,190</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,927,667</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table provides a reconciliation
of total segment gross profit to the Company's loss before provision for income tax:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">For The Years Ended<br/>
    December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023 (Restated)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Segment Gross Profit (Loss)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">508,826</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(149,607</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">Less:</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,261,336</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,368,278</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Research and development expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">179,272</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,062,916</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock-based compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,773,460</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">185,933</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Add (Less):</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">87,358</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">185,481</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Interest expense</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(825,899</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,313,671</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating sublease income</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">48,478</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">65,900</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gain (loss) on foreign exchange changes</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(25,135</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">22,690</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on investment in equity securities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(339,171</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(221,888</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Write off unclaimed accrued liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">255,592</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">134,443</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,384</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss before provision for income tax</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,369,576</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(8,024,838</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful life of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, and Prepament for Asset Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, and Prepament for Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of March 31, 2025 and December 31, 2024 are summarized
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Land</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,004,520</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">338,966</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Buildings and leasehold improvements</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,217,756</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,219,244</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,129,804</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,169</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">161,384</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">163,448</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">11,513,464</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,852,827</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,344,718</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,341,739</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,168,746</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">511,088</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has offices and labs located in
Taiwan, and a GMP manufacturing facility in Fremont, CA. Property and equipment as of December 31, 2024 and 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Land</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">338,966</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">363,416</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Buildings and leasehold improvements</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,219,244</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,227,431</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,169</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,138,675</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Office equipment</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">163,448</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">174,797</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,852,827</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,904,319</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: accumulated depreciation</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,341,739</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,335,041</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">511,088</span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">569,278</span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock', window );">Schedule of Ownership Percentages of Each Investee</a></td>
<td class="text"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership percentage</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March&#160;31,</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting</b></span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of investees</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>treatments</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.*</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 20%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.67</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.67</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">5.90</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">5.90</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation (see Note 10)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">19.78</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">19.78</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">18.68</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">18.68</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity&#160;Method</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. (see Note 10)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">24.97</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">24.97</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">37.00</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">26.65</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">49.00</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">49.00</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></td></tr> </table><span></span>
</td>
<td class="text"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Ownership percentage</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Accounting</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Name of investees</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">treatments</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Braingenesis Biotechnology Co., Ltd.*</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.17</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.17</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 11%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Genepharm Biotech Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.67</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.67</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cost Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.90</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.90</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">ForSeeCon Eye Corporation (see Note 10)</span></p></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">19.78</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-268"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cost Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">BioFirst Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">18.68</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">18.68</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity&#160;Method</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">OncoX BioPharma, Inc. (see Note 10)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">24.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-269"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Rgene Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">26.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">26.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity Method</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock', window );">Schedule of Extent the Investee Relies</a></td>
<td class="text"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The extent the investee relies on the company for its business is summarized as follows:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of investees</b></span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 69%; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The extent the investee relies on the Company for its business &#160;</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan </span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned from the investee and provides research and development support service</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. </span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></td></tr> </table><span></span>
</td>
<td class="text"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The extent the investee relies on the company for its business is summarized as follows:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; width: 30%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of investees</b></span></td> <td style="padding-bottom: 1.5pt; width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 69%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The extent the investee relies on the Company for its business &#160;</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan </span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned from the investee and provides research and development support service</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. </span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of Long-Term Investment</a></td>
<td class="text"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term investment mainly consists of the following:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Non-marketable Cost Method Investments, net</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Braingenesis Biotechnology Co., Ltd.</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,640</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,727</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Genepharm Biotech Corporation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,271</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,540</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon
    Eye Corporation<sup>(d)</sup></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-341"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-342"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">752,880</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">762,983</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="-sec-ix-redline:true;-keep: true">Subtotal</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">779,791</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">790,250</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity Method Investments, net</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst
    Corporation<sup>(a)</sup></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,420,800</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,468,504</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene
    Corporation<sup>(b)</sup></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">559,471</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-343"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    Japan K.K. (BioLite JP)<sup>(c)</sup></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-344"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-345"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX
    BioPharma, Inc.<sup>(e)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.25in"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,760,062</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,258,754</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2025 and
December 31, 2024, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for
equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded
as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration
process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and
was converted into 994,450 shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term
investments in Biofirst is both $1,124,842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As described in Note 4, the Company
acquired 26.65% of Rgene&#8217;s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting
this equity investment with equity method as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;).
Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required
by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with
Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment
Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request
for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to
the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company
owns 37% of outstanding shares of Rgene.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K. (BioLite JP)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#8220;Lucidaim,&#8221; together with the Company, the &#8220;Shareholders&#8221;), and BioLite Japan
K.K., a Japanese corporation (&#8220;BioLite JP&#8221;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with
3,049 ordinary shares issued and outstanding (the &#8220;Ordinary Shares&#8221;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000
towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#8217;s business
and financial conditions and determined to fully impair such prepayment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation (FEYE)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. (OncoX)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#8217;s ownership. See Note 4 for detail of such transactions.</span></p><span></span>
</td>
<td class="text"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term investment mainly consists of the following:</span><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Non-marketable Cost Method Investments, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Braingenesis Biotechnology Co., Ltd.</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,727</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,213</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Genepharm Biotech Corporation</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,540</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">22,021</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon
    Eye Corporation<sup>(d) </sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">762,983</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">818,018</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 0.25in"><span style="-sec-ix-redline:true;-keep: true">Subtotal</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">790,250</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">847,252</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity Method Investments, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst
    Corporation<sup>(a)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,468,504</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,680,488</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene
    Corporation<sup>(b)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    Japan K.K. (BioLite JP)<sup>(c)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX
    BioPharma, Inc.<sup>(e)</sup></span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 0.25in"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,258,754</span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,527,740</span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and
2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment
in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for
long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this
investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into
994,450 shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $1,124,842.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Both Rgene and the Company are
under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise
significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment
as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include
the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of
December 31, 2024 and 2023, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K. (BioLite JP)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In October 2021, the Company, Lucidaim
Co., Ltd., a Japanese corporation (&#8220;Lucidaim,&#8221; together with the Company, the &#8220;Shareholders&#8221;), and BioLite Japan
K.K., a Japanese corporation (&#8220;BioLite JP&#8221;) entered into a Joint Venture Agreement. BioLite JP is a private limited company
incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital
media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries
in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with
3,049 ordinary shares issued and outstanding (the &#8220;Ordinary Shares&#8221;). Pursuant to the Agreement and the related share transfer
agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000
towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed.
This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#8217;s business
and financial conditions and determined to fully impair such prepayment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ForSeeCon Eye Corporation (FEYE)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">FEYE is a private company registered
in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus.
The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc. (OncoX)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">OncoX is a private company registered
in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain
licensed products in exchange of OncoX&#8217;s ownership. See Note 4 for detail of such transactions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Balance Sheets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Summarized unaudited financial information
for the Company&#8217;s equity method investee, BioFirst, is as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,323,952</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,451,877</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Non-current Assets</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,083,472</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">686,206</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current Liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,508,413</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,286,058</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Non-current Liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">114,606</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">347,193</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stockholders&#8217; Deficit</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,215,595</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(495,168</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Summarized unaudited financial information
for the Company&#8217;s equity method investee, Rgene, is as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/> 2024</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/> 2023</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Assets</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">46,491</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">50,538</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current Assets</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">222,988</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">250,716</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Liabilities</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1,546,123</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2,591,960</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current Liabilities</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">319</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">811</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&#8217; Deficit</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,276,963</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,291,517</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock', window );">Schedule of Statements of Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Summarized unaudited financial information
for the Company&#8217;s equity method investee, BioFirst, is as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">357</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">734</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gross profit</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">216</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">289</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(770,877</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,194,797</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Share of losses from investments accounted for using the equity method</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(339,171</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(221,888</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Summarized unaudited financial information
for the Company&#8217;s equity method investee, Rgene, is as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    Ended<br/>
    December 31,</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Net sales</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-278"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross Profit</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-280"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-281"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(118,367</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,550,123</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Share of loss from investments accounted for using
    the equity method</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Components of Loss on Investment in Equity Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The components of loss on investment in equity
securities for each period were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Share of equity method investee losses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(50,877</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The components of loss on investment in equity
securities for each period were as follows (not recognized since the carrying value of the investment was reduced to $0):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/>
    December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Share of equity method investee losses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(339,171</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(221,888</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of extent the investee relies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other units or shares or classes of ownership in a partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Carrying Amounts of the Liability Component</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying amounts of the liability component
are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: left; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">March 31, <br/> 2025</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Entity</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Date</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Maturity<br/> Date</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Issuance</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Conversion<br/> Price</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Common<br/> Stock<br/> to&#160;be<br/> converted</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Unamortized<br/> Discount</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Carrying<br/> Value</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Fair<br/> Value</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"><span style="-sec-ix-redline:true;font-size: 8pt">2nd LIND Note</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 17, 2023</span></td><td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">May 19, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">86.94</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">200,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">26,110</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">173,890</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">240,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">3rd LIND Note</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">January 17, 2024</span></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">July 17, 2025</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,000,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">87.40</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">800,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">196,114</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">603,886</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">960,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">Other Note</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 1, 2024</span></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 1, 2025</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">6.89</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">5.00</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,119</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">28,881</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">Other Note</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 5, 2024</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 5, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">6.89</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">5.00</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,118</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">28,882</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">2,260,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,060,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">224,460</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">835,539</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,260,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; text-align: left; white-space: nowrap; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">December 31, <br/> 2024</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Entity</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Date</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Maturity<br/> Date</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Issuance</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Conversion<br/> Price</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Common<br/> Stock<br/> to&#160;be<br/> converted</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Unamortized<br/> Discount</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Carrying<br/> Value</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Fair<br/> Value</span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10%"><span style="-sec-ix-redline:true;font-size: 8pt">2nd LIND Note</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 17, 2023</span></td><td style="white-space: nowrap; text-align: center; width: 1%; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; width: 7%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">May 19, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">86.94</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; width: 4%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">400,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">118,048</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">281,952</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">480,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">3rd LIND Note</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">January 17, 2024</span></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">July 17, 2025</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,000,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">87.40</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,000,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">388,685</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">611,315</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">Other Note</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 1, 2024</span></td><td style="white-space: nowrap; text-align: center; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">November 1, 2025</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">6.89</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">5.00</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,610</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">28,390</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">Other Note</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 5, 2024</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 5, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">6.89</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">5.00</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">AiBtl</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,611</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">28,389</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="text-align: center; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">2,260,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,460,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">509,954</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">950,046</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,740,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying amounts of the liability component
are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"><td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">December 31, 2024</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance<br/> Entity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance<br/> Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Maturity<br/> Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Principal<br/> Amount at<br/> Issuance</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion<br/> Price</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Common<br/> Stock<br/> to&#160;be<br/> converted</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Unamortized<br/> Discount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Carrying<br/> Value</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Fair<br/> Value</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 10.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">2nd LIND Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 17, <br/> 2023</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 6%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">May 19,<br/> 2025</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,200,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">0</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">86.94</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1.00</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">400,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">118,048</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">281,952</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">480,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">3rd LIND Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">January 17, <br/> 2024</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">July 17,<br/> 2025</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">0</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">87.40</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1.00</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">ABVC</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">388,685</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">611,315</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,200,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Other Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 1, <br/> 2024</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 1, <br/> 2025</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">0</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">6.89</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">5.00</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,610</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">28,390</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">Other Note</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 5,<br/> 2024</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">November 5, <br/> 2025</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">0</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">6.89</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">5.00</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">AiBtl</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,611</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">28,389</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">30,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">2,260,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,460,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">509,954</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">950,046</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">1,740,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="font-size: 8pt; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt"><b>December 31, 2023</b></span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Entity</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Issuance<br/> Date</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Maturity<br/> Date</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Stated<br/> Interest<br/> Rate</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Effective<br/> Interest<br/> Rate</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Conversion<br/> Price</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Common<br/> Stock<br/> to be<br/> converted</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Principal<br/> Amount at<br/> Balance<br/> Sheet Date</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Unamortized<br/> Discount</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Carrying<br/> Value</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">Fair<br/> Value</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; vertical-align: top; width: 10%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">1st LIND Note</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 6%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">February 23,<br/> 2023</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; width: 8%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">August 23,<br/> 2024</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">3,704,167</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">61.42</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">3.50</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 6%; text-align: center"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">811,175</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">290,063</span></p></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">521,112</span></p></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.5%"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 6%; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">973,410</span></td><td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; "> <td style="font-size: 8pt; vertical-align: top; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">2nd LIND Note</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">November 17,<br/> 2023</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">May 19,<br/> 2025</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">0</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">86.94</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">%</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1.00</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">ABVC</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,200,000</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">834,590</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">365,410</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,440,000</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: center; padding-bottom: 4pt; vertical-align: top"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">4,904,167</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">2,011,175</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">1,124,653</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">886,522</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 4pt"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td> <td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 8pt; text-align: right"><span style="-sec-ix-redline:true;font-size: 8pt">2,413,410</span></td><td style="font-size: 8pt; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;font-size: 8pt">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued research and development expense</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,799,583</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,799,583</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued directors and officers (owners) compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">991,821</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,025,867</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cash portion of the Lind Note repayments</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">227,284</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">127,759</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued compensation and employee benefits</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,252</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">126,106</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Others</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">617,879</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">557,866</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,826,819</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,509,422</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses and other current liabilities
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued research and development expense</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,799,583</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,799,583</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued directors and officers (owners) compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,025,867</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,018,253</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued royalties</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">255,592</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">274,028</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued compensation and employee benefits</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">126,106</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">29,138</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Others</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">302,274</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">427,350</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,509,422</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,548,352</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-Term Loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-Term Loans</a></td>
<td class="text"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term loans consists of the following:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Cathay United Bank</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">169,407</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">200,252</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">CTBC Bank</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">602,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">610,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Other individual</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">801,407</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">840,252</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term loans consists of the following:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Cathay United Bank</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">200,252</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">245,250</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">CTBC Bank</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">610,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">654,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Other individual</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-284"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">840,252</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">899,250</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Parties of the Company with whom Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The related parties of the company with whom
transactions are reported in these financial statements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of entity or Individual</b></span></td> <td style="vertical-align: top; width: 1%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The Jiangs</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst<br/> <br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.<br/> <br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.<br/> <br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company.<br/> <br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</span></p></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation (&#8220;BHK&#8221;)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">AiBtl (Holding) BioPharma, Inc. (&#8220;AiBtl Holding&#8221;) &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Founding shareholder of AiBtl BioPharma Inc.</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Jaimes Vargas Russman &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO of AiBtl BioPharma Inc.</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Lion Arts Promotion, Inc.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by the Jiangs.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accounts receivable due from related parties
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Rgene</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-350"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-351"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-352"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Due from related party- Current</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Rgene (1)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,867</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">565,711</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">BioFirst (2)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">535,252</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">589,340</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">537,119</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,155,051</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">Due from related parties- Non-current, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">BioFirst (Australia) (3)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">839,983</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">839,983</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation (4)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">118,633</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">120,210</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">958,616</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,014,193</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: allowance for expected credit losses accounts</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(958,616</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,014,193</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-353"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-354"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) &#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 and made $500,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided. The loan was converted to Rgene&#8217;s common stock in May 2024 but the Company was not informed until April 2025. Please see detail discussion in Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025 and December 31, 2024, the outstanding loan balance were $0 and $500,000; and accrued interest was $<span style="-sec-ix-hidden: hidden-fact-356">0and</span> $63,819, respectively. Both principal and accrued interest were converted to Rgene&#8217;s common stocks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025 and December 31, 2024, the Company has other receivables amounted to $1,867 and $1,892, respectively, from Rgene due to daily operations.</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of March 31, 2025 and December 31, 2024, the outstanding loan balance were NTD 15,458,360 (approximately $465,297) and NTD 17,571,076 (approximately $535,918), respectively; accrued interests were$68,971 and $53,422, respectively. The Company has received NTD 2,080,000 (approximately $64,896) and $0 repayment during the three months ended March 31, 2025 and 2024, respectively. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of March 31, 2025 and December 31, 2024, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</span></p></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2025 and December 31, 2024, due from BHK was both NTD 3,941,299 (approximately$118,633 and $120,210, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of NTD 3,941,299 as of December 31, 2024. No recovery was made during three months ended March 31, 2025.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Amount due to related parties consisted of
the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">AiBtl Holding (1)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">348,219</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">348,219</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">The Jiangs (2)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,522</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">274,170</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Shareholders (3)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,266</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">142,130</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lion Art Promotions Inc (4)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">65,738</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-355"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Directors (5)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12,953</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,526</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">819,384</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">773,045</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand. </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2025 and December 31, 2024, the outstanding balance due to the Jiangs amounted to $222,522 and $274,170, respectively. These loans bear no interest and are due on demand.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of March 31, 2025 and December 31, 2024, the outstanding principal and accrued interest was $140,266 and $142,130, respectively. Interest expenses in connection with these loans were $4,963 and $5,938 for the three months ended March 31, 2025 and 2024, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued consulting services fee for the three months ended March 31, 2025.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2025 and December 31, 2024, due to Directors amounted to $12,953 and $8,526, respectively, were related to the daily operating expenses since inception in 2023 paid by the Directors of AiBtl on behalf of the entity.</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The related parties of the company with whom
transactions are reported in these financial statements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 30%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of entity or Individual</b></span></td> <td style="vertical-align: top; width: 1%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 69%; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The Jiangs</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</span></p></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation (&#8220;BHK&#8221;)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">AiBtl (Holding) BioPharma, Inc. (&#8220;AiBtl Holding&#8221;) &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Founding shareholder of AiBtl BioPharma Inc.</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Jaimes Vargas Russman &#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO of AiBtl BioPharma Inc.</span></td></tr> <tr style="vertical-align: top; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Lion Arts Promotion, Inc.</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by the Jiangs.</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock', window );">Schedule of Licensing Agreement and Related Amendment with FEYE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the years ended December 31, 2024,
the Company received $296,000 in cash, pursuant to the licensing agreement and related amendment with FEYE, and recognized $296,000 revenue
correspondingly. In addition, the Company received $200,000 during the year ended December 31, 2024, pursuant to the licensing agreement
with OncoX, and recognized revenue correspondingly. Please refer to Note 4, Collaborative Agreements for details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/>
    December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">OncoX</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">200,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-285"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">FEYE</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">296,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Rgene</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,055</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">496,000</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,055</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock', window );">Schedule of Accounts Receivable Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accounts receivable due from related parties
consisted of the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">GenePharm Inc.</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Rgene</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-290"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,463</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,463</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock', window );">Schedule of Due from Related Party - Current and Non-current, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Due from related party- Current</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene (1)</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">565,711</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">541,486</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (2)</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">589,340</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">206,087</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,155,051</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>747,573</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">Due from related parties- Non-current, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">BioFirst (Australia) (3)</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">839,983</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">839,983</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">BioHopeKing Corporation (4)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">120,210</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,516</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,014,193</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">953,499</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: allowance for expected credit losses accounts</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,014,193</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(839,983</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 4pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Net</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,516</span></td><td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">(1) &#160;</span></td> <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024 and December 31, 2023, the outstanding loan balance were both $500,000; and accrued interest was $63,819 and $38,819, respectively.</span></p>
<p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024 and 2023, the Company has other receivables amounted $1,892 and $2,667, respectively, from Rgene due to daily operations.</span></p></td></tr>
</table>

<p style="margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>


<table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 12pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify; font-size: 12pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of December 31, 2024 and 2023, the outstanding loan balance were NTD 17,571,076 (approximately $535,918) and NTD 6,302,360 ($206,087), respectively; accrued interest was $53,422 and $0, respectively. The Company has received NTD 4,040,000 (approximately $126,048) repayment and expects to receive other repayment within next 12 months.</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of December 31, 2024 and 2023, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</span></p></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2024 and 2023, due from BHK was both NTD 3,941,299 (approximately $120,210 and $113,516, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of $120,210 for the year ended December 31, 2024. </span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock', window );">Schedule of Amount Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Amount due to related parties consisted of
the following as of the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">AiBtl Holding (1)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">348,219</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-293"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">The Jiangs (2)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">274,170</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,789</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Shareholders (3)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">142,130</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">152,382</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Directors (4)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,526</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,322</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">773,045</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">173,493</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand. </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2024 and 2023, the outstanding balance due to the Jiangs amounted to $274,170 and $19,789, respectively. These loans bear no interest and are due on demand.</span></td></tr> </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of December 31, 2024 and 2023, the outstanding principal and accrued interest was $172,112 and $152,382, respectively. Interest expenses in connection with these loans were $21,101 and $20,094 for the years ended December 31, 2024 and 2023, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 12pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify; font-size: 12pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024 and 2023, due to Directors amounted to $8,526 and $1,322, respectively, were related to the daily operating expenses in 2024 and entity setup fee in 2023 paid by the Directors of AiBtl on behalf of the entity.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amount due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of due from related party current and non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Pursuant Licensing Agreement Related Amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax (Benefit) Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="-sec-ix-redline:true;-keep: true">Income tax
(benefit) expense for the years ended December 31, 2024 and 2023 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">Current:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Federal</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-294"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-295"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">State</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-296"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(110,539</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,338</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total Current</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(110,539</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,338</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Deferred:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">Federal</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">State</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-300"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-301"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-302"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">115,668</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total Deferred</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-303"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">115,668</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total provision for income tax (benefit) expense</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(110,539</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">256,006</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets (Liability)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets (liability)
as of March 31, 2025 and December 31, 2024 consist approximately of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">713,223</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">713,223</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net operating loss carryforwards</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,870,805</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,677,413</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">155,559</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">178,014</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Operating lease assets</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(155,559</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(178,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets, gross</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,584,028</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,390,636</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,584,028</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,390,636</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets, net</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-357"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-358"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets (liability)
as of December 31, 2024 and 2023 consist approximately of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">713,223</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">713,223</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net operating loss carryforwards</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,677,413</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,018,343</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">178,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">213,482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Operating lease assets</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(178,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(213,482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets, Gross</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,390,636</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,731,566</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(6,390,636</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,731,566</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Deferred tax assets, net</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-304"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Issued and Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Warrants issued and outstanding in connection
with above Lind convertible notes as of March 31, 2025, and their activities during the three-month period ended are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number of<br/> Underlying<br/> Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average<br/> Contractual<br/> Life<br/> Remaining<br/> in Years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Outstanding as of January 1, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,029,167</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.70</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">*</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.20</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,542</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Issued</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-361"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-362"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-363"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-364"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,029,167</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.40</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-365"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-366"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Outstanding as of March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,000,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.40</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</span></td>
</tr></table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Warrants issued and outstanding in connection
with above Lind convertible notes as of December 31, 2024, and their activities during the year ended are as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Underlying<br/> Shares</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per Share</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-<br/> Average<br/> Contractual<br/> Life<br/> Remaining<br/> in Years</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value</b></span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2024</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1,529,167</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.40</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">5,542</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">190,000</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,500,000</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-306"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-307"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2024</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2,029,167</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">195,542</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">*</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options Issued and Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Options issued and outstanding as of March
31, 2025, and their activities during the year then ended are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number&#160;of</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Exercise</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Contractual</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Underlying<br/> Shares<br/> (post-split)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Price<br/> Per&#160;Share<br/> (post-split)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Life<br/> Remaining<br/> in Years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding as of January 1, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">258,710</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27.9</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.74</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-367"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-368"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-369"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">-</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-370"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-371"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-372"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-373"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding as of March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">258,710</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27.9</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-374"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable as of March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">258,710</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27.9</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-375"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Vested and expected to vest</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">258,710</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27.9</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-376"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Options issued and outstanding as of December
31, 2024, and their activities during the year then ended are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number&#160;of</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Contractual</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="text-align: center"></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying<br/> Shares<br/> (post-split)</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price<br/> Per&#160;Share (post-split)</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Life<br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining<br/> in Years</span></b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value</b></span></td> <td><b style="-sec-ix-redline:true;-keep: true">&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2024</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">258,710</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">27.9</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">7.74</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></div></td> <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-313"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-314"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-315"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-316"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-318"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-319"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-320"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2024</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">258,710</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">27.9</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">7.74</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable as of December 31, 2024</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">258,710</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">27.9</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">7.74</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested and expected to vest</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">258,710</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">27.9</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">6.74</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-323"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Loss Per Share</a></td>
<td class="text">Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended
March 31, 2025 and 2024.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months &#160;Ended</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">Numerator:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net loss attributable to ABVC&#8217;s common stockholders</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(842,075</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,834,199</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Denominator:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Weighted-average shares outstanding &#8211; Basic &amp; Diluted</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14,968,232</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,736,150</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Loss per share</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">-Basic &amp; Diluted</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(0.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(0.29</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><span></span>
</td>
<td class="text">Diluted loss per share is computed by dividing
net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the years ended December
31, 2024 and 2023.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the Year Ended</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2024</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2023</b></span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator:</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss attributable to ABVC&#8217;s
    common stockholders</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,902,878</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,788,050</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average shares outstanding &#8211;  Basic
    &amp; Diluted</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">11,673,980</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">4,335,650</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss per share</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-Basic &amp; Diluted</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.42</span></td>
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.80</span></td>
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of Operating Leases have Remaining Lease Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has no finance leases. The Company&#8217;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#8217;s operating leases have remaining lease terms of up to approximately five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#8239;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">ASSETS</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease right-of-use assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">640,387</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">809,283</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">LIABILITIES</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities (current)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">403,581</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">401,826</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities (non-current)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">236,807</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">407,457</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Company&#8217;s Lease Expenses</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#8239;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">ASSETS</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease right-of-use assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">533,460</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">640,387</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">LIABILITIES</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities (current)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">366,475</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">403,581</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease liabilities (non-current)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">166,985</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">236,807</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following provides details of the Company&#8217;s
lease expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease expenses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">117,166</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">98,502</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Other information related to leases is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">117,166</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">98,502</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">March&#160;31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Weighted Average Remaining Lease Term:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating leases</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.43 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.48 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Weighted Average Discount Rate:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating leases</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.32</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.19</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following provides details of the Company&#8217;s
lease expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating lease expenses</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">514,420</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">358,576</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Other information related to leases is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Year Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">484,181</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">358,576</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Weighted Average Remaining Lease Term:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating leases</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.48 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1.73 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Weighted Average Discount Rate:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating leases</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.19</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Operating<br/> leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="-sec-ix-redline:true;-keep: true">2025 (Excluding current period)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">302,071</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">104,849</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,699</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2028</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,699</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2029</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,699</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-381"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total future minimum lease payments, undiscounted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">547,017</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(13,557</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Present value of future minimum lease payments</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">533,460</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">Operating<br/>
    leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">409,587</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">104,236</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,320</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2028</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,320</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2029</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,320</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-324"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total future minimum lease payments, undiscounted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">655,782</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(15,395</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Present value of future minimum lease payments</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">640,387</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Acquisition was Accounted for Business Combination</a></td>
<td class="text">The equity interest transferred to ABVC and BioLite Taiwan on December
15, 2023.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Cash and cash equivalents</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">S</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-325"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total assets acquired</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-326"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued expense</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(243,888</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Due to Director</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(498</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Total liabilities acquired</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(243,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Total consideration (Intangible assets)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquired and liability assumed in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BenefitsReceivableForMilestoneAttained', window );">Eligible to receive amount (in Dollars)</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfRoyaltiesEqualing', window );">Percentage of royalties equaling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AcquisitionForNetSales', window );">Net sales (in Dollars)</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Received shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteBVIIncMember', window );">BioLite BVI, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteTaiwanMember', window );">BioLite Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ShulingJiangMember', window );">Shuling Jiang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ABVCAndBioLiteTaiwanMember', window );">ABVC and BioLite Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Received shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Received shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_ABVCMember', window );">ABVC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Subsidiary ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_BioLiteBVIIncMember', window );">BioLite BVI, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Incorporated state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">British Virgin Islands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_BioLiteTaiwanMember', window );">BioLite Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Subsidiary ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_ShulingJiangMember', window );">Shuling Jiang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Subsidiary ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_AiBtlHoldingMember', window );">AiBtl [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Description of Business[Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Subsidiary ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AcquisitionForNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition for net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AcquisitionForNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BenefitsReceivableForMilestoneAttained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable for certain milestone are met  and eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BenefitsReceivableForMilestoneAttained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfRoyaltiesEqualing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalties equaling.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfRoyaltiesEqualing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State in which the subsidiary of the limited liability company or limited partnership was organized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteBVIIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteBVIIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ShulingJiangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ShulingJiangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ABVCAndBioLiteTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ABVCAndBioLiteTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_ABVCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_ABVCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_BioLiteBVIIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_BioLiteBVIIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_BioLiteTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_BioLiteTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_ShulingJiangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_ShulingJiangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_AiBtlHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_AiBtlHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity, Going Concern, and Restatement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 944,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,259,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,261,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,377,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash outflows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (539,833)<span></span>
</td>
<td class="num">$ (955,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,809,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,186,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty', window );">Issuance of common shares (in Shares)</a></td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued per share (in Dollars per share)</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of shares issued for asset acquisition (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,875,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,875,699<span></span>
</td>
<td class="nump">$ 7,539,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,784,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 773,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockBasedExpensesAmortizationPeriod', window );">Stock-based expenses amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,773<span></span>
</td>
<td class="nump">$ 451,480<span></span>
</td>
<td class="nump">$ 2,031,631<span></span>
</td>
<td class="nump">902,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Stock subscription receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,354,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ZhonghuiMember', window );">Zhonghui [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateOwnedValuationAllowance', window );">Valuation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abvc_PostSplitMember', window );">Post-Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Share issued for post split (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash outflows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(353,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,484,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,484,392)<span></span>
</td>
<td class="num">(6,708,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Stock-compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,179,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_ZhongHuiLianHeJiTuanLtdMember', window );">Zhong Hui Lian He Ji Tuan, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_AiBtlBioPharmaIncMember', window );">AiBtl BioPharma, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_AiBtlBioPharmaIncMember', window );">AiBtl BioPharma, Inc [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_AiBtlBioPharmaIncMember', window );">AiBtl BioPharma, Inc [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems', window );"><strong>Liquidity, Going Concern, and Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LiquidityGoingConcernandRestatementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LiquidityGoingConcernandRestatementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockBasedExpensesAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Duration of Stock-based expenses amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockBasedExpensesAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issuance of common stock for acquiring of property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital deficit value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateOwnedValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each period for which an income statement is required, disclosure of the changes in the allowance, including balances at end of period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateOwnedValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ZhonghuiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ZhonghuiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abvc_PostSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abvc_PostSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_ZhongHuiLianHeJiTuanLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_ZhongHuiLianHeJiTuanLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_AiBtlBioPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_AiBtlBioPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 569,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepayment for asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 691,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691,900<span></span>
</td>
<td class="nump">691,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,875,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,539,907<span></span>
</td>
<td class="nump">7,784,499<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,826,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,509,422<span></span>
</td>
<td class="nump">3,548,352<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable &#8211; third parties, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886,522<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,730,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,557,461<span></span>
</td>
<td class="nump">6,101,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,919,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,815,948<span></span>
</td>
<td class="nump">6,531,026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,978,380<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,404,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,140<span></span>
</td>
<td class="nump">1,554,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,551,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(502,181)<span></span>
</td>
<td class="num">(300,637)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,956,295<span></span>
</td>
<td class="nump">$ 1,458,470<span></span>
</td>
<td class="nump">723,959<span></span>
</td>
<td class="nump">1,253,473<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3,236,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,875,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,539,907<span></span>
</td>
<td class="nump">7,784,499<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,773<span></span>
</td>
<td class="nump">2,031,631<span></span>
</td>
<td class="nump">2,773,460<span></span>
</td>
<td class="nump">185,933<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,313,671)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(102,115)<span></span>
</td>
<td class="num">(93,468)<span></span>
</td>
<td class="num">(356,159)<span></span>
</td>
<td class="num">(492,794)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (944,190)<span></span>
</td>
<td class="num">$ (2,927,667)<span></span>
</td>
<td class="num">$ (5,259,037)<span></span>
</td>
<td class="num">$ (8,280,844)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (944,190)<span></span>
</td>
<td class="num">$ (2,927,667)<span></span>
</td>
<td class="num">$ (5,259,037)<span></span>
</td>
<td class="num">$ (8,280,844)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,773<span></span>
</td>
<td class="nump">2,031,631<span></span>
</td>
<td class="nump">2,773,460<span></span>
</td>
<td class="nump">185,933<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">210,040<span></span>
</td>
<td class="nump">176,283<span></span>
</td>
<td class="nump">532,769<span></span>
</td>
<td class="nump">1,244,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,113<span></span>
</td>
<td class="num">(43,605)<span></span>
</td>
<td class="nump">152,819<span></span>
</td>
<td class="nump">638,762<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,186,848)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,552<span></span>
</td>
<td class="num">(186,499)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ProceedsFromSubsidiarysCommonStockSubscription', window );">Proceeds from subsidiary&#8217;s executive contribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,869,961<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty', window );">Purchase of Property and equipment by issuing common stock to a third party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty', window );">Prepayment for asset acquisition by issuing common stock to a third party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">691,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonStockForConversionOfDebt', window );">Issuance of common stock for conversion of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,579<span></span>
</td>
<td class="nump">467,574<span></span>
</td>
<td class="nump">593,714<span></span>
</td>
<td class="nump">1,786,686<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 819,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 773,045<span></span>
</td>
<td class="nump">173,493<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,949,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,969,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepayment for asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,460,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,492,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,050,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,696,380<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable &#8211; third parties, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569,456<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,633,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,932,490<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,973,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,361,627<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,029,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,636,966<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,792,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,388,050<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(305,121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(257,078)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,486,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,130,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,460,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,492,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,544,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,635,708<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(684,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,493,340)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(394,632)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,910,288)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,910,288)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,544,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,635,708<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,413,746<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(186,860)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,235,845)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ProceedsFromSubsidiarysCommonStockSubscription', window );">Proceeds from subsidiary&#8217;s executive contribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,918,960<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty', window );">Purchase of Property and equipment by issuing common stock to a third party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty', window );">Prepayment for asset acquisition by issuing common stock to a third party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonStockForConversionOfDebt', window );">Issuance of common stock for conversion of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,306,112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported [Member] | Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,400,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepayment for asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,484,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,708,100)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(605,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148,028)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable &#8211; third parties, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(455,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(455,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,025,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,658,586)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,092,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,833,940)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,559)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,028,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,877,499)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,484,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,708,100)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(513,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,449,775)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98,162)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,629,444<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,629,444<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (513,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,449,775)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(495,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,169,501)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(398,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148,031)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,860<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,997)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(186,499)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ProceedsFromSubsidiarysCommonStockSubscription', window );">Proceeds from subsidiary&#8217;s executive contribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,999)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty', window );">Purchase of Property and equipment by issuing common stock to a third party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,400,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty', window );">Prepayment for asset acquisition by issuing common stock to a third party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonStockForConversionOfDebt', window );">Issuance of common stock for conversion of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,519,426)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments [Member] | Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#8217;s presentation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of exchange rate changes on cash and cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_IssuanceOfCommonStockForConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for conversion of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_IssuanceOfCommonStockForConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment of asset acquisition by issuing common stock to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ProceedsFromSubsidiarysCommonStockSubscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds from subsidiary's common stock subscription.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ProceedsFromSubsidiarysCommonStockSubscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase of property and equipment by issuing common stock to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 1.B.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-7<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481003/205-10-S50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity attributable to continuing operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity attributable to continuing operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>TWD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,455,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">152,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,206<span></span>
</td>
<td class="nump">248,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash amounted</a></td>
<td class="nump">607,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607,362<span></span>
</td>
<td class="nump">615,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="nump">$ 20.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for expected credit losses accounts</a></td>
<td class="nump">616,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,397<span></span>
</td>
<td class="nump">$ 616,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LaborPensionFundPerMonth', window );">Labor pension fund per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Monthly contribution of employees salaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent', window );">Employee stock-based compensation expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,935,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Non-employee stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,773<span></span>
</td>
<td class="nump">$ 451,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,031,631<span></span>
</td>
<td class="nump">$ 902,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DefinedBenefitPlanFundedPercentages', window );">Tax benefit percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reportable segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Provision credit loss</a></td>
<td class="nump">$ 11,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash (in New Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Client [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of clients rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Client [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of clients rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Two Client [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of clients rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=abvc_TaiwanCentralDepositInsuranceCorporationMember', window );">Taiwan Central Deposit Insurance Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyExcessExpenseReimbursable', window );">Cash investments limit</a></td>
<td class="nump">91,500<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,500<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=abvc_USFederalDepositInsuranceCorporationMember', window );">U.S. Federal Deposit Insurance Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyExcessExpenseReimbursable', window );">Cash investments limit</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_PostretirementAndPostemploymentBenefitsMember', window );">Post-retirement and post-employment benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent', window );">Employee stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee stock-based compensation expense</a></td>
<td class="nump">$ 48,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,995,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Consulting services for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Non-employee stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Consulting services for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DefinedBenefitPlanFundedPercentages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of plan assets to benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DefinedBenefitPlanFundedPercentages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LaborPensionFundPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Labor pension fund per month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LaborPensionFundPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyExcessExpenseReimbursable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of carryover of excess expense potentially reimbursable to adviser but not recorded as liability by investment company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyExcessExpenseReimbursable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-5<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=abvc_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=abvc_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=abvc_TwoClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=abvc_TwoClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=abvc_TaiwanCentralDepositInsuranceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=abvc_TaiwanCentralDepositInsuranceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=abvc_USFederalDepositInsuranceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=abvc_USFederalDepositInsuranceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_PostretirementAndPostemploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_PostretirementAndPostemploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Buildings and leasehold improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems', window );"><strong>Schedule of Estimated Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Buildings and leasehold improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems', window );"><strong>Schedule of Estimated Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems', window );"><strong>Schedule of Estimated Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems', window );"><strong>Schedule of Estimated Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems', window );"><strong>Schedule of Estimated Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems', window );"><strong>Schedule of Estimated Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Schedule of Revenue and Gross Profit Information of our Reportable Segment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 509,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Segment Gross Profit (Loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">928<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">508,826<span></span>
</td>
<td class="nump">$ 928<span></span>
</td>
<td class="num">(149,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 7,021<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Schedule of Reconciliation of Total Segment Gross Profit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Segment Gross Profit (Loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 928<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 508,826<span></span>
</td>
<td class="nump">$ 928<span></span>
</td>
<td class="num">$ (149,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LessAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">615,371<span></span>
</td>
<td class="nump">738,486<span></span>
</td>
<td class="nump">615,371<span></span>
</td>
<td class="nump">2,261,336<span></span>
</td>
<td class="nump">738,486<span></span>
</td>
<td class="nump">5,368,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">28,861<span></span>
</td>
<td class="nump">69,066<span></span>
</td>
<td class="nump">28,861<span></span>
</td>
<td class="nump">179,272<span></span>
</td>
<td class="nump">69,066<span></span>
</td>
<td class="nump">1,062,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">48,773<span></span>
</td>
<td class="nump">2,031,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,773,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AddLessAbstract', window );"><strong>Add (Less):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">19,071<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">19,071<span></span>
</td>
<td class="nump">87,358<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">185,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(222,967)<span></span>
</td>
<td class="num">(181,676)<span></span>
</td>
<td class="num">(222,967)<span></span>
</td>
<td class="num">(825,899)<span></span>
</td>
<td class="num">(181,676)<span></span>
</td>
<td class="num">(1,313,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Operating sublease income</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">48,478<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">65,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain (loss) on foreign exchange changes</a></td>
<td class="num">(9,912)<span></span>
</td>
<td class="nump">60,730<span></span>
</td>
<td class="num">(9,912)<span></span>
</td>
<td class="num">(25,135)<span></span>
</td>
<td class="nump">60,730<span></span>
</td>
<td class="nump">22,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on investment in equity securities</a></td>
<td class="num">(50,877)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(221,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WriteOffUnclaimedAccruedLiabilites', window );">Write off unclaimed accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,877)<span></span>
</td>
<td class="nump">255,592<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">19,485<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">134,443<span></span>
</td>
<td class="nump">19,485<span></span>
</td>
<td class="nump">3,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income tax</a></td>
<td class="num">$ (944,190)<span></span>
</td>
<td class="num">$ (2,927,667)<span></span>
</td>
<td class="num">$ (944,190)<span></span>
</td>
<td class="num">$ (5,369,576)<span></span>
</td>
<td class="num">$ (2,927,667)<span></span>
</td>
<td class="num">$ (8,024,838)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AddLessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AddLessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WriteOffUnclaimedAccruedLiabilites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write off unclaimed accrued liabilites.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WriteOffUnclaimedAccruedLiabilites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 23, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 14, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 08, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 16, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 25, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 24, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 25, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 23, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 14, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th">
<div>Jul. 27, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_MilestonePaymentsRoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,206<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 248,382<span></span>
</td>
<td class="nump">$ 60,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,978,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of new shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodLongTermInvestment', window );">Equity method long term investment (in Shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ServiceAgreementEligibilityAmount', window );">Service agreement eligibility amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_MilestoneRegulatoryPaymentAmountPeriod', window );">Milestone regulatory payment amount period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WorkingCapitalConvertibleLoanPercentage', window );">Percentage of working capital convertible loan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Fixed conversion price equal (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesAndLicenses', window );">Licensing fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Upfront payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,895,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">FEYE stock (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_MilestoneRegulatoryPaymentAmount', window );">Milestone regulatory payment amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RoyaltiesPercentage', window );">Percentage of royalties of net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Recognized revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Recognized revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember', window );">BHK Co-Development Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentMilestones', window );">Description of collaborative agreements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:

    &#160;
    &#9679;
    Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment


    &#160;
    &#9679;
    Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment


    &#160;
    &#9679;
    At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment


    &#160;
    &#9679;
    At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment


    &#160;
    &#9679;
    Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment
  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:

    &#160;
    &#9679;
    Upon the signing of
    the BHK Co-Development Agreement: $1 million, or 10% of total payment


    &#160;
    &#9679;
    Upon the first Investigational
    New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or
    10% of total payment


    &#160;
    &#9679;
    At the completion of
    first phase II clinical trial: $1 million, or 10% of total payment


    &#160;
    &#9679;
    At the initiation of
    phase III of clinical trial research: $3 million, or 30% of total payment


    &#160;
    &#9679;
    Upon the New Drug Application
    (NDA) submission: $4 million, or 40% of total payment
  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonrefundableUpfrontCashPayment', window );">Non-refundable upfront cash payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfPaymentsUnderCodevelopmentAgreement', window );">Data and development percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfStockValue', window );">Total cash amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Licensing rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember', window );">Co-Dev Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfPaymentsUnderCodevelopmentAgreement', window );">Data and development percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForParticipationLiabilities', window );">Cash amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AdditionCashPayment', window );">Addition cash payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfPaymentsUnderCodevelopmentAgreement', window );">Data and development percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfStockValue', window );">Total cash amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Licensing rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForParticipationLiabilities', window );">Cash amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_BioFirstStockPurchaseAgreementMember', window );">BioFirst Corporation Purchase Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Shares issued (in Shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,470<span></span>
</td>
<td class="nump">42,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Common stock consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,902,911<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ForSeeConEyeCorporationMember', window );">ForSeeCon Eye Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LicensingAgreement', window );">Licensing agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteTaiwanMember', window );">BioLite Taiwan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NetSalesProfitPercentage', window );">Net sales profit, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember', window );">Collaborative agreement with ForSeeCon Eye Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Upfront payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares paid (in Shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ReceivedShares', window );">Shares received (in Shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBiopPharmaIncMember', window );">OncoX BiopPharma, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_MilestonePaymentsRoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Shares issued (in Shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConsiderationPaidForAgreement', window );">Consideration paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AdditionalMilestonePaymentInCash', window );">Additional milestone payment in cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NumberOfSharesReceived', window );">Number of shares received (in Shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfDevelopAndCommercialize', window );">Percentage of develop and commercialize</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LicensingFees', window );">Licensing fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of new shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of note fully converted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.65%<span></span>
</td>
<td class="nump">26.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible loan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member] | Co-Dev Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of note fully converted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member] | Service Agreements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of note fully converted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of new shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | YuanGene Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Rgene Studies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of note fully converted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="31"></td></tr>
<tr><td colspan="31"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AdditionCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of addition cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AdditionCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AdditionalMilestonePaymentInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AdditionalMilestonePaymentInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConsiderationPaidForAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConsiderationPaidForAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_EquityMethodInvestmentsOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the percent value of equity method investments ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_EquityMethodInvestmentsOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_EquityMethodLongTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method long term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_EquityMethodLongTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_IssuanceOfStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of Common stock newly issued. for example : newly issued shares means any common shares issued pursuant to the primary share purchases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_IssuanceOfStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of licensing Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount licensing fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_MilestonePaymentsRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_MilestonePaymentsRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_MilestoneRegulatoryPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of milestone regulatory payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_MilestoneRegulatoryPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_MilestoneRegulatoryPaymentAmountPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Regulatory Payment Amount Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_MilestoneRegulatoryPaymentAmountPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NetSalesProfitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net sales profit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NetSalesProfitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NonrefundableUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NonrefundableUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NumberOfSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NumberOfSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfDevelopAndCommercialize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of develop and commercialize.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfDevelopAndCommercialize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfPaymentsUnderCodevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of payments under co-development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfPaymentsUnderCodevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ReceivedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ReceivedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ServiceAgreementEligibilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Service agreement eligibility amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ServiceAgreementEligibilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WorkingCapitalConvertibleLoanPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of working capital convertible loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WorkingCapitalConvertibleLoanPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of asset in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the nature of achievements or target goals that are to be reached by specified dates to maintain the arrangement or extend it, generally without adjustment of the present financial terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForParticipationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments related to participation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477628/926-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForParticipationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesAndLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesAndLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_BioFirstStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_BioFirstStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ForSeeConEyeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ForSeeConEyeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBiopPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBiopPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, and Prepament for Asset Acquisition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,021<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="nump">$ 32,025<span></span>
</td>
<td class="nump">$ 28,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Land with book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,513,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,852,827<span></span>
</td>
<td class="nump">3,904,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Valuation of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Value of acquired amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,670,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction-in-Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandAndLandImprovements', window );">Land with book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 334,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 338,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquisition value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,688,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Acquisition shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Per share of common stock (in Dollars per share)</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,021<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="nump">$ 28,627<span></span>
</td>
<td class="nump">28,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Ownership percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Land with book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,004,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 338,966<span></span>
</td>
<td class="nump">$ 363,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TW', window );">TAIWAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquisition value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TW', window );">TAIWAN | Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquisition value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Acquisition shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Per share of common stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction-in-Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Per share of common stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction-in-Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Per share of common stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ZhonghuiMember', window );">Zhonghui [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Value of acquired amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandAndLandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandAndLandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TW">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TW</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ZhonghuiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ZhonghuiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 11,513,464<span></span>
</td>
<td class="nump">$ 3,852,827<span></span>
</td>
<td class="nump">$ 3,904,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(3,344,718)<span></span>
</td>
<td class="num">(3,341,739)<span></span>
</td>
<td class="num">(3,335,041)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,088<span></span>
</td>
<td class="nump">569,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,004,520<span></span>
</td>
<td class="nump">338,966<span></span>
</td>
<td class="nump">363,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,217,756<span></span>
</td>
<td class="nump">2,219,244<span></span>
</td>
<td class="nump">2,227,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,129,804<span></span>
</td>
<td class="nump">1,131,169<span></span>
</td>
<td class="nump">1,138,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 161,384<span></span>
</td>
<td class="nump">$ 163,448<span></span>
</td>
<td class="nump">$ 174,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>May 24, 2024</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Long-Term Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageCommonStocksShares', window );">Percentage of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,688,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,895,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">994,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378,305<span></span>
</td>
<td class="nump">13,868,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,940,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378,305<span></span>
</td>
<td class="nump">13,868,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,940,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Payment to joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Long-Term Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageCommonStocksShares', window );">Percentage of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.68%<span></span>
</td>
<td class="nump">18.68%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18.68%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,124,842<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,049<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,049<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationtheRgeneMember', window );">Rgene Corporation (the &#8220;Rgene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Long-Term Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageCommonStocksShares', window );">Percentage of common stock shares</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.65%<span></span>
</td>
<td class="nump">26.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteJapanKKMember', window );">BioLite Japan K.K. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Long-Term Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageCommonStocksShares', window );">Percentage of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Payment to joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteJPMember', window );">BioLite JP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Long-Term Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Owned shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Long-Term Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,387<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Lucidaim Co Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Long-Term Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Owned shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageCommonStocksShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage value of common stocks shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageCommonStocksShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationtheRgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationtheRgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteJapanKKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteJapanKKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteJPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteJPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_LucidaimCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_LucidaimCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.17%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.17%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0.17%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.67%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.67%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.67%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ForSeeConEyeCorporationMember', window );">ForSeeCon Eye Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">19.78%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19.78%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">18.68%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18.68%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18.68%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Equity&#160;Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Equity&#160;Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_OncoXBioPharmaIncMember', window );">OncoX BioPharma, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">24.97%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24.97%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Equity Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Equity Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;-keep: true">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAdditionalInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This serves as a place to record data that is not required by accounting literature but is useful for readers of the financial statements as it relates to the details of an equity method investment in common stock. Such information may include the amount of change for a change in ownership (equity) percentage in a given period and the amount and type of the consideration given or received in relation to the change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAdditionalInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ForSeeConEyeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ForSeeConEyeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_OncoXBioPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_OncoXBioPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Extent the Investee Relies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanKKMember', window );">BioLite Japan K.K. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan<span></span>
</td>
<td class="text">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ForSeeConEyeCorporationMember', window );">ForSeeCon Eye Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Loaned from the investee and provides research and development support service<span></span>
</td>
<td class="text">Loaned from the investee and provides research and development support service<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXBioPharmaIncMember', window );">OncoX BioPharma, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanKKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanKKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ForSeeConEyeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ForSeeConEyeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXBioPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXBioPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Long-Term Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 779,791<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 790,250<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 847,252<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,760,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,258,754<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,527,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,727<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,271<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,021<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ForSeeConEyeCorporationMember', window );">ForSeeCon Eye Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">752,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">762,983<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">818,018<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,420,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,468,504<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">1,680,488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">559,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanKKBioLiteJPMember', window );">BioLite Japan K.K. (BioLite JP) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBioPharmaIncMember', window );">OncoX BioPharma, Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">ForSeeCon Eye Corporation (FEYE)
FEYE is a private company registered in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus. The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">BioFirst Corporation (the &#8220;BioFirst&#8221;):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2025 and December 31, 2024, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term investments in Biofirst is both $1,124,842.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">BioFirst Corporation (the &#8220;BioFirst&#8221;):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $1,124,842.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Rgene Corporation (the &#8220;Rgene&#8221;)
As described in Note 4, the Company acquired 26.65% of Rgene&#8217;s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting this equity investment with equity method as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company owns 37% of outstanding shares of Rgene.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Rgene Corporation (the &#8220;Rgene&#8221;)
Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">BioLite Japan K.K. (BioLite JP)
In October 2021, the Company, Lucidaim Co., Ltd., a Japanese corporation (&#8220;Lucidaim,&#8221; together with the Company, the &#8220;Shareholders&#8221;), and BioLite Japan K.K., a Japanese corporation (&#8220;BioLite JP&#8221;) entered into a Joint Venture Agreement. BioLite JP is a private limited company incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with 3,049 ordinary shares issued and outstanding (the &#8220;Ordinary Shares&#8221;). Pursuant to the Agreement and the related share transfer agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000 towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed. This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#8217;s business and financial conditions and determined to fully impair such prepayment.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">OncoX BioPharma, Inc. (OncoX)
OncoX is a private company registered in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain licensed products in exchange of OncoX&#8217;s ownership. See Note 4 for detail of such transactions.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_EquityMethodInvestmentsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_EquityMethodInvestmentsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NonMarketableCostMethodInvestmentsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_ForSeeConEyeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_ForSeeConEyeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanKKBioLiteJPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanKKBioLiteJPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBioPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBioPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Balance Sheets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Schedule of Balance Sheet [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current Assets</a></td>
<td class="nump">$ 1,323,952<span></span>
</td>
<td class="nump">$ 1,451,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current Assets</a></td>
<td class="nump">1,083,472<span></span>
</td>
<td class="nump">686,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="nump">3,508,413<span></span>
</td>
<td class="nump">2,286,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current Liabilities</a></td>
<td class="nump">114,606<span></span>
</td>
<td class="nump">347,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders&#8217; Deficit</a></td>
<td class="num">(1,215,595)<span></span>
</td>
<td class="num">(495,168)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Schedule of Balance Sheet [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current Assets</a></td>
<td class="nump">46,491<span></span>
</td>
<td class="nump">50,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current Assets</a></td>
<td class="nump">222,988<span></span>
</td>
<td class="nump">250,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="nump">1,546,123<span></span>
</td>
<td class="nump">2,591,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current Liabilities</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders&#8217; Deficit</a></td>
<td class="num">$ (1,276,963)<span></span>
</td>
<td class="num">$ (2,291,517)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Statements of Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Schedule of Statement of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(770,877)<span></span>
</td>
<td class="num">(1,194,797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of losses from investments accounted for using the equity method</a></td>
<td class="num">(339,171)<span></span>
</td>
<td class="num">(221,888)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Schedule of Statement of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(118,367)<span></span>
</td>
<td class="num">(1,550,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of losses from investments accounted for using the equity method</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Schedule of Components of Loss on Investment in Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Share of equity method investee losses</a></td>
<td class="num">$ (50,877)<span></span>
</td>
<td class="num">$ (339,171)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (221,888)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Jan. 09, 2025</div></th>
<th class="th"><div>Jan. 05, 2025</div></th>
<th class="th"><div>Nov. 19, 2024</div></th>
<th class="th"><div>Nov. 05, 2024</div></th>
<th class="th"><div>May 22, 2024</div></th>
<th class="th"><div>Jan. 17, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 17, 2023</div></th>
<th class="th"><div>Sep. 12, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common stock at an initial conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingBalanceAmount', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,522<span></span>
</td>
<td class="nump">$ 274,170<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 19,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfAverageAmount', window );">Percentage of average amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfCashPermium', window );">Percentage of cash premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfOutstandingPrincipalAmount', window );">Percentage of outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralPartnersCapitalAccount', window );">Market capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestFaceAmount', window );">Convertible note in principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchasePriceAmount', window );">Purchase price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Purchase warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise reduced (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 773,139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,233,284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 886,522<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConsiderationAmount', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfAnnualDiscountRate', window );">Percentage of annual discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.89%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,132<span></span>
</td>
<td class="nump">$ 56,132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_TradingDays', window );">Trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConsecutiveDays', window );">Consecutive days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_OtherConvertibleNotesPayableMember', window );">Other Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_OtherConvertibleNotesPayableMember', window );">Other Convertible Notes Payable [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Principal amount</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentOutstandingPrincipal', window );">Outstanding principal</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_LindNotesPayableMember', window );">Lind Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchaseWarrantTerm', window );">Purchase warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_WarrantDebtDiscountMember', window );">Warrant Debt Discount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_LindWarrantMember', window );">Lind Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise reduced (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_LindNotesPayableMember', window );">Lind Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchaseWarrantTerm', window );">Purchase warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_LindGlobalFundIILPMember', window );">Lind Global Fund II, LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,704,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPreviousAcquisition', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common stock at an initial conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock purchase warrant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_LindWarrantMember', window );">Lind Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPreviousAcquisition', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock purchase warrant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingBalanceAmount', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308,651<span></span>
</td>
<td class="nump">$ 308,651<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfAverageAmount', window );">Percentage of average amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfOutstandingPrincipalAmount', window );">Percentage of outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">400000 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member] | Other Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherConvertibleNotesPayableMember', window );">Other Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debit discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,868<span></span>
</td>
<td class="nump">$ 3,868<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LindNotesMember', window );">Lind Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209,372<span></span>
</td>
<td class="nump">$ 172,884<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_SecondLindNoteMember', window );">2nd Lind Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestFaceAmount', window );">Convertible note in principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Other Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Principal amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Lind Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise reduced (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Lind Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise reduced (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Convertible Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="23"></td></tr>
<tr><td colspan="23"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConsecutiveDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consecutive days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConsecutiveDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consideration amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OutstandingBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding balance amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OutstandingBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfAnnualDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfAnnualDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfAverageAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of average amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfAverageAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfCashPermium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfCashPermium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfOutstandingPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfOutstandingPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PurchasePriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PurchasePriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PurchaseWarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the purchase warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PurchaseWarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_TradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_TradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share price that the individual must pay to acquire shares under the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralPartnersCapitalAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the general partner's ownership interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralPartnersCapitalAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPreviousAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow representing an adjustment to the purchase price of a previous acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPreviousAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The principal amount of the receivable or note before consideration of the discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_OtherConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_OtherConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_LindNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_LindNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_WarrantDebtDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abvc_WarrantDebtDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_LindWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abvc_LindWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_LindNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abvc_LindNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_LindGlobalFundIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_LindGlobalFundIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_LindWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_LindWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_OtherConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LindNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LindNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_SecondLindNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_SecondLindNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 2,260,000<span></span>
</td>
<td class="nump">$ 2,260,000<span></span>
</td>
<td class="nump">$ 4,904,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">1,060,000<span></span>
</td>
<td class="nump">1,460,000<span></span>
</td>
<td class="nump">2,011,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">224,460<span></span>
</td>
<td class="nump">509,954<span></span>
</td>
<td class="nump">1,124,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">835,539<span></span>
</td>
<td class="nump">950,046<span></span>
</td>
<td class="nump">886,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 1,260,000<span></span>
</td>
<td class="nump">$ 1,740,000<span></span>
</td>
<td class="nump">$ 2,413,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_SecondLINDNoteMember', window );">2nd LIND Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">ABVC<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">May 19,  2025<span></span>
</td>
<td class="text">May 19,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">86.94%<span></span>
</td>
<td class="nump">86.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">ABVC<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">26,110<span></span>
</td>
<td class="nump">118,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">173,890<span></span>
</td>
<td class="nump">281,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember', window );">3rd LIND Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">ABVC<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Jan. 17,  2024<span></span>
</td>
<td class="text">Jan. 17,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Jul. 17,  2025<span></span>
</td>
<td class="text">Jul. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">87.40%<span></span>
</td>
<td class="nump">87.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">ABVC<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">196,114<span></span>
</td>
<td class="nump">388,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">603,886<span></span>
</td>
<td class="nump">611,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_OtherNoteMember', window );">Other Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Nov.  01,  2024<span></span>
</td>
<td class="text">Nov.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Nov.  01,  2025<span></span>
</td>
<td class="text">Nov.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">6.89%<span></span>
</td>
<td class="nump">6.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">28,881<span></span>
</td>
<td class="nump">28,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_OtherNoteOneMember', window );">Other Note One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Nov.  05,  2024<span></span>
</td>
<td class="text">Nov.  05,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Nov.  05,  2025<span></span>
</td>
<td class="text">Nov.  05,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">6.89%<span></span>
</td>
<td class="nump">6.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">28,882<span></span>
</td>
<td class="nump">28,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_FirstLINDNoteMember', window );">1st LIND Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 23,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,704,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 973,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_SecondLINDNoteOneMember', window );">Second LIND Note One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 17,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 19,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">834,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,440,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of carrying value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentCommonStockToBeConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of common stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentCommonStockToBeConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentIssuanceEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of issuance entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentIssuanceEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of principal amount at balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_SecondLINDNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_SecondLINDNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_OtherNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_OtherNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_OtherNoteOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_OtherNoteOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_FirstLINDNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_FirstLINDNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_SecondLINDNoteOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_SecondLINDNoteOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccruedResearchAndDevelopmentExpense', window );">Accrued research and development expense</a></td>
<td class="nump">$ 1,799,583<span></span>
</td>
<td class="nump">$ 1,799,583<span></span>
</td>
<td class="nump">$ 1,799,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccruedDirectorAndOfficerCompensation', window );">Accrued directors and officers (owners) compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025,867<span></span>
</td>
<td class="nump">1,018,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,592<span></span>
</td>
<td class="nump">274,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">140,252<span></span>
</td>
<td class="nump">126,106<span></span>
</td>
<td class="nump">29,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,274<span></span>
</td>
<td class="nump">427,350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Total</a></td>
<td class="nump">$ 3,826,819<span></span>
</td>
<td class="nump">$ 3,509,422<span></span>
</td>
<td class="nump">$ 3,548,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AccruedDirectorAndOfficerCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amouont of accrued director and officer compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AccruedDirectorAndOfficerCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Loans (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 21, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th">
<div>Jun. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 12, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 19, 2017 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jun. 12, 2017 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2016 </div>
<div>TWD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesLineItems', window );"><strong>Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,250<span></span>
</td>
<td class="nump">$ 937,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,152<span></span>
</td>
<td class="nump">$ 934,366<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseShortTermBorrowings', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ProceedsFromIssuanceOfAPromissoryNote', window );">Proceeds from promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_CathayUnitedLoanAgreementMember', window );">Cathay United Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesLineItems', window );"><strong>Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 28,  2017<span></span>
</td>
<td class="text">Jun. 28,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 28,  2016<span></span>
</td>
<td class="text">Jun. 28,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember', window );">Cathay United Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesLineItems', window );"><strong>Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit limit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 228,750<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="nump">2.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseShortTermBorrowings', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">$ 6,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember', window );">CTBC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesLineItems', window );"><strong>Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit limit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327,500<span></span>
</td>
<td class="nump">$ 327,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2018<span></span>
</td>
<td class="text">Jan. 19,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseShortTermBorrowings', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualMember', window );">Other Individual &#8211; Third party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesLineItems', window );"><strong>Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseShortTermBorrowings', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ProceedsFromIssuanceOfAPromissoryNote', window );">Proceeds from promissory note</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingVariableInterestRate', window );">Percentage of bears interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShortTermDebtMaturityDate', window );">Maturity date</a></td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualThirdPartyMember', window );">Other Individual &#8211; Third party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesLineItems', window );"><strong>Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseShortTermBorrowings', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_CathayUnitedLoanAgreementMember', window );">Cathay United Loan Agreement [Member] | Cathay United Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesLineItems', window );"><strong>Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Interest rate of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.31%<span></span>
</td>
<td class="nump">1.31%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_CTBCLoanAgreementsMember', window );">CTBC Loan Agreements [Member] | CTBC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesLineItems', window );"><strong>Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings', window );">Money deposited in a savings account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ProceedsFromIssuanceOfAPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds from issuance of a promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ProceedsFromIssuanceOfAPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShortTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity date of short-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShortTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableInterestBearingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalHomeLoanBankAdvancesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalHomeLoanBankAdvancesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate interest expense incurred on short-term borrowings including commercial paper and Federal funds purchased and securities sold under agreements to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest-bearing domestic savings deposit liabilities to total deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_CathayUnitedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_CathayUnitedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_CathayUnitedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_CathayUnitedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_CTBCLoanAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_CTBCLoanAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Loans - Schedule of Short-Term Loans (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Schedule of Short-Term Bank Loan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 801,407<span></span>
</td>
<td class="nump">$ 840,252<span></span>
</td>
<td class="nump">$ 899,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember', window );">Cathay United Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Schedule of Short-Term Bank Loan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">169,407<span></span>
</td>
<td class="nump">200,252<span></span>
</td>
<td class="nump">245,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember', window );">CTBC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Schedule of Short-Term Bank Loan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="nump">654,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualMember', window );">Other Individual [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Schedule of Short-Term Bank Loan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 16, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 07, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 24, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 27, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Outstanding balance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WorkingCapitalPercentage', window );">Percentage of working capital</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 681,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Accrued interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,896<span></span>
</td>
<td class="nump">$ 2,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,048<span></span>
</td>
<td class="nump">$ 4,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Percentage of mature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LoanAgreementAmount', window );">Loan agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500<span></span>
</td>
<td class="nump">$ 88,091<span></span>
</td>
<td class="nump">$ 25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 507,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Due from BHK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,941,299<span></span>
</td>
<td class="nump">$ 3,941,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RecognizedCreditLosses', window );">Recognized credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,941,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 801,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingBalanceAmount', window );">Outstanding balance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingPrincipalAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfWorkingCapital', window );">Percentage of working capital</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expenses for loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,072,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_BioFirstReceivesMember', window );">BioFirst Receives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal amount</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_OncoXMember', window );">OncoX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Loans bear interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,302,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,406,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member] | BioFirst Receives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,458,360<span></span>
</td>
<td class="nump">$ 17,571,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BHKCoDevelopmentAggreementMember', window );">BHK Co Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.<span></span>
</td>
<td class="text">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.<span></span>
</td>
<td class="text">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Due from BHK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Due from BHK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RecognizedCreditLosses', window );">Recognized credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member] | Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Due from BHK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_FEYEMember', window );">FEYE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LicensingAgreement', window );">Licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ConvertibleLoanAgreementMember', window );">Convertible Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Loans bear interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Discount of the stock price percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ConvertibleLoanAgreementMember', window );">Convertible Loan Agreement [Member] | Conversion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Discount of the stock price percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Accrued interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Due from BHK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingMember', window );">AiBtl Holding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,487<span></span>
</td>
<td class="nump">$ 33,732<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_JiangsAdvancedFundsMember', window );">Jiangs Advanced Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingPrincipalAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expenses for loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Loans bear interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of licensing Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LoanAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loan agreement amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LoanAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OutstandingBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding balance amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OutstandingBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OutstandingPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OutstandingPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RecognizedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognized credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RecognizedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WorkingCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WorkingCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableInterestBearingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of annual principal payment for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued but unpaid interest on deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is the principal amount outstanding for securitized loans only (across all types of loans).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)<br> -Paragraph 4<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOnLoansSecuritized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_BioFirstReceivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_BioFirstReceivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_OncoXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_OncoXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BHKCoDevelopmentAggreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BHKCoDevelopmentAggreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_FEYEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_FEYEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ConvertibleLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ConvertibleLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_ConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_ConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_JiangsAdvancedFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_JiangsAdvancedFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationtheBioFirstMember', window );">BioFirst Corporation (the &#8220;BioFirst&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember', window );">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationtheRgeneMember', window );">Rgene Corporation (the &#8220;Rgene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmInctheGenePharmMember', window );">GenePharm Inc. (the &#8220;GenePharm&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsOneMember', window );">The Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst &#160; Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. &#160; Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. &#160; Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company. &#160; Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of ABVC<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationBHKMember', window );">BioHopeKing Corporation (&#8220;BHK&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of ABVC<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember', window );">AiBtl (Holding) BioPharma, Inc. (&#8220;AiBtl Holding&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">Founding shareholder of AiBtl BioPharma Inc.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_JaimesVargasRussmanMember', window );">Jaimes Vargas Russman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">CEO of AiBtl BioPharma Inc.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionArtsPromotionIncMember', window );">Lion Arts Promotion, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Parties of the Company with whom Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="text">Entity controlled by the Jiangs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationtheBioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationtheBioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationtheRgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationtheRgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmInctheGenePharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmInctheGenePharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationBHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationBHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_JaimesVargasRussmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_JaimesVargasRussmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionArtsPromotionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LionArtsPromotionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions - Schedule of Licensing Agreement and Related Amendment with FEYE (Details) - Licensing Agreement [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXMember', window );">OncoX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems', window );"><strong>Schedule of Licensing Agreement and Related Amendment with FEYE [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_FEYEMember', window );">FEYE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems', window );"><strong>Schedule of Licensing Agreement and Related Amendment with FEYE [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">296,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems', window );"><strong>Schedule of Licensing Agreement and Related Amendment with FEYE [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems', window );"><strong>Schedule of Licensing Agreement and Related Amendment with FEYE [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 496,000<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_LicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_LicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_FEYEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_FEYEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions - Schedule of Accounts Receivable Due from Related Parties (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenePharmIncMember', window );">GenePharm Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Accounts Receivable Due from Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Accounts Receivable Due from Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Accounts Receivable Due from Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenePharmIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenePharmIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions - Schedule of Due from Related Party - Current and Non-current, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems', window );"><strong>Schedule of Due from Related Party - Current and Non-current, Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party- Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 565,711<span></span>
</td>
<td class="nump">$ 541,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems', window );"><strong>Schedule of Due from Related Party - Current and Non-current, Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party- Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,340<span></span>
</td>
<td class="nump">206,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems', window );"><strong>Schedule of Due from Related Party - Current and Non-current, Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party- Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,155,051<span></span>
</td>
<td class="nump">747,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent', window );">Due from related parties- Non-current, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014,193<span></span>
</td>
<td class="nump">953,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent', window );">Less: allowance for expected credit losses accounts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,014,193)<span></span>
</td>
<td class="num">(839,983)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">113,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems', window );"><strong>Schedule of Due from Related Party - Current and Non-current, Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent', window );">Due from related parties- Non-current, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839,983<span></span>
</td>
<td class="nump">839,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems', window );"><strong>Schedule of Due from Related Party - Current and Non-current, Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent', window );">Due from related parties- Non-current, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,210<span></span>
</td>
<td class="nump">$ 113,516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 118,633<span></span>
</td>
<td class="nump">$ 120,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024 and December 31, 2023, the outstanding loan balance were both $500,000; and accrued interest was $63,819 and $38,819, respectively.</span></p>
<p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024 and 2023, the Company has other receivables amounted $1,892 and $2,667, respectively, from Rgene due to daily operations.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of December 31, 2024 and 2023, the outstanding loan balance were NTD 17,571,076 (approximately $535,918) and NTD 6,302,360 ($206,087), respectively; accrued interest was $53,422 and $0, respectively. The Company has received NTD 4,040,000 (approximately $126,048) repayment and expects to receive other repayment within next 12 months.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of December 31, 2024 and 2023, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2024 and 2023, due from BHK was both NTD 3,941,299 (approximately $120,210 and $113,516, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of $120,210 for the year ended December 31, 2024.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions - Schedule of Amount Due to Related Parties (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AiBtlHoldingMember', window );">AiBtl Holding [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Amount Due to Related Parties [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Amount due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 348,219<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Amount Due to Related Parties [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Amount due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">274,170<span></span>
</td>
<td class="nump">19,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ShareholdersMember', window );">Shareholders [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Amount Due to Related Parties [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Amount due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">142,130<span></span>
</td>
<td class="nump">152,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_DirectorsMember', window );">Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Amount Due to Related Parties [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Amount due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">8,526<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Amount Due to Related Parties [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Amount due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 773,045<span></span>
</td>
<td class="nump">$ 173,493<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2024 and 2023, the outstanding balance due to the Jiangs amounted to $274,170 and $19,789, respectively. These loans bear no interest and are due on demand.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of December 31, 2024 and 2023, the outstanding principal and accrued interest was $172,112 and $152,382, respectively. Interest expenses in connection with these loans were $21,101 and $20,094 for the years ended December 31, 2024 and 2023, respectively.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024 and 2023, due to Directors amounted to $8,526 and $1,322, respectively, were related to the daily operating expenses in 2024 and entity setup fee in 2023 paid by the Directors of AiBtl on behalf of the entity.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AiBtlHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AiBtlHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_ShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_ShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (110,539)<span></span>
</td>
<td class="nump">$ 256,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax (Benefit) Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110,539)<span></span>
</td>
<td class="nump">140,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110,539)<span></span>
</td>
<td class="nump">140,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">115,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">115,668<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income tax (benefit) expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (110,539)<span></span>
</td>
<td class="nump">$ 256,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Schedule of Deferred Tax Assets (Liability) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Loss on impairment of Assets</a></td>
<td class="nump">$ 713,223<span></span>
</td>
<td class="nump">$ 713,223<span></span>
</td>
<td class="nump">$ 713,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net operating loss carryforwards</a></td>
<td class="nump">5,870,805<span></span>
</td>
<td class="nump">5,677,413<span></span>
</td>
<td class="nump">5,018,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">155,559<span></span>
</td>
<td class="nump">178,014<span></span>
</td>
<td class="nump">213,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DeferredTaxAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="num">(155,559)<span></span>
</td>
<td class="num">(178,014)<span></span>
</td>
<td class="num">(213,482)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, Gross</a></td>
<td class="nump">6,584,028<span></span>
</td>
<td class="nump">6,390,636<span></span>
</td>
<td class="nump">5,731,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(6,584,028)<span></span>
</td>
<td class="num">(6,390,636)<span></span>
</td>
<td class="num">(5,731,566)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DeferredTaxAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DeferredTaxAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="7">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Jan. 09, 2025</div></th>
<th class="th"><div>Jan. 05, 2025</div></th>
<th class="th"><div>Dec. 26, 2024</div></th>
<th class="th"><div>Nov. 19, 2024</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
<th class="th"><div>Oct. 29, 2024</div></th>
<th class="th"><div>Sep. 03, 2024</div></th>
<th class="th"><div>Aug. 15, 2024</div></th>
<th class="th"><div>Aug. 14, 2024</div></th>
<th class="th"><div>May 22, 2024</div></th>
<th class="th"><div>May 10, 2024</div></th>
<th class="th"><div>Apr. 11, 2024</div></th>
<th class="th"><div>Jan. 17, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 17, 2023</div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 30, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 05, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>May 24, 2024</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Jan. 27, 2024</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Jan. 03, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 24, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Service fee (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,773<span></span>
</td>
<td class="nump">$ 1,935,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,453,873<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,773<span></span>
</td>
<td class="nump">$ 451,480<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,031,631<span></span>
</td>
<td class="nump">$ 902,960<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Stock subscription receivables (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,354,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378,305<span></span>
</td>
<td class="nump">13,868,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,940,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate value of common stock (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Granted restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AverageIssuancePricePerShare', window );">Average issuance price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent payable (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,827<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash of purchase agreements (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConsultingFee', window );">Consulting fee (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Initial exercise price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssueDuringPeriodCommonShares', window );">Stock issue during period common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,705,303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,732,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Cash repayment (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327,017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditDerivativeTerm1', window );">Warrant term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock', window );">Repayment of principal of 2nd lind note (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Principal amount of converted debt (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,819<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Total common stock value issued (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_NewWarrantsMember', window );">New Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_ExistingWarrantsMember', window );">Existing Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Initial exercise price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvc_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ChiefStrategicOfficerMember', window );">Chief Strategic Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ReceivablesFromStockholderMember', window );">Receivables from Stockholder [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 451,480<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 902,960<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issued shares for consulting service</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Service fee (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 1,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,387<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,293<span></span>
</td>
<td class="nump">64,147<span></span>
</td>
<td class="nump">46,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,219<span></span>
</td>
<td class="nump">30,488<span></span>
</td>
<td class="nump">120,398<span></span>
</td>
<td class="nump">22,031<span></span>
</td>
<td class="nump">169,992<span></span>
</td>
<td class="nump">28,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Cash repayment (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593,714<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,786,686<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Principal amount of converted debt (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Total common stock value issued (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ThirdLetterAgreementMember', window );">Third Letter Agreement [Member] | Common Stock [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockSharesIssuedForRent', window );">Number of shares issued for rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_PreExistingWarrantsMember', window );">Pre-Existing Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_LindOfferingsMember', window );">Lind Offerings [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Total common stock value issued (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 681,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_AiBtlHoldingMember', window );">AiBtl Holding [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of subsidiary interest in noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.70%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_BioLiteTaiwanMember', window );">BioLite Taiwan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=abvc_ShulingJiangMember', window );">Shuling Jiang [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_LindGlobalFundIILPLindMember', window );">Lind Global Fund II, LP (&#8220;Lind&#8221;) [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember', window );">Third LIND Note [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Principal amount of converted debt (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued on conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_LindMember', window );">Lind [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Initial exercise price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Principal amount of converted debt (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingLiabilityOwnedAmount', window );">Outstanding liability owned (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LandMember', window );">Land [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AssetConsiderationCommonStock', window );">Asset consideration common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Granted restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,021<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan [Member] | Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Granted restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issued shares for consulting service</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Cash repayment (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,759<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Purchase warrant term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">400000 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Principal amount of converted debt (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdMember', window );">Euro-Asia Investment &amp; Finance Corp Ltd. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issued shares for consulting service</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">644,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Service fee (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,514,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdMember', window );">Euro-Asia Investment &amp; Finance Corp Ltd. [Member] | Receivables from Stockholder [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ZhonghuiMember', window );">Zhonghui [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issued shares for consulting service</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ZhonghuiMember', window );">Zhonghui [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregateCommonStockShares', window );">Aggregate common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate value of common stock (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ABVCMember', window );">ABVC [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonControllingInterestConsiderationShare', window );">Non-controlling interest consideration share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteBVIIncMember', window );">BioLite BVI Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonControllingInterestConsiderationShare', window );">Non-controlling interest consideration share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LindGlobalFundIILPLindMember', window );">Lind Global Fund II, LP (&#8220;Lind&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchaseWarrantTerm', window );">Purchase warrant term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Initial exercise price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LindNoteMember', window );">Lind Note [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Principal amount of converted debt (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LindMember', window );">Lind [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">1.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="49"></td></tr>
<tr><td colspan="49"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AggregateCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AggregateCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AssetConsiderationCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset consideration common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AssetConsiderationCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AverageIssuancePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the average issuance price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AverageIssuancePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CommonStockSharesIssuedForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CommonStockSharesIssuedForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConsultingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of  consulting fee .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConsultingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NonControllingInterestConsiderationShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-controlling interest consideration share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NonControllingInterestConsiderationShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OutstandingLiabilityOwnedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Outstanding liability Owned Amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OutstandingLiabilityOwnedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PurchaseWarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the purchase warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PurchaseWarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssueDuringPeriodCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issue during period common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssueDuringPeriodCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditDerivativeTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the credit risk derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditDerivativeTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from repayment of loans for purchasing common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abvc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abvc_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abvc_ExistingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abvc_ExistingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvc_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvc_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ChiefStrategicOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ChiefStrategicOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ReceivablesFromStockholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ReceivablesFromStockholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ThirdLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ThirdLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_PreExistingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abvc_PreExistingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_LindOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abvc_LindOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_AiBtlHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_AiBtlHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_BioLiteTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_BioLiteTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abvc_ShulingJiangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abvc_ShulingJiangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_LindGlobalFundIILPLindMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_LindGlobalFundIILPLindMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_LindMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_LindMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ZhonghuiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ZhonghuiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ABVCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ABVCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteBVIIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteBVIIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LindGlobalFundIILPLindMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LindGlobalFundIILPLindMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LindNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LindNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LindMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LindMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrants Issued and Outstanding (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Schedule of Warrants Issued and Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued', window );">Number of Underlying Shares, Issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm', window );">Weighted- Average Contractual Life Remaining in Years, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 19 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue', window );">Aggregate Intrinsic Value, Issued (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Underlying Shares, Exercised (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm', window );">Weighted- Average Contractual Life Remaining in Years, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Underlying Shares, Outstanding ending (in Shares)</a></td>
<td class="nump">1,529,167<span></span>
</td>
<td class="nump">2,029,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Outstanding ending</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted- Average Contractual Life Remaining in Years, Outstanding ending</a></td>
<td class="text">3 years 1 month 24 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Outstanding ending (in Dollars)</a></td>
<td class="nump">$ 5,542<span></span>
</td>
<td class="nump">$ 195,542<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;-keep: true">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument exercise intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument exercise weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument   exercise weighted remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument  issued intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument issued weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument  issued weighted remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option grant</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Granted options to purchase</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Granted options to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Schedule of Options Issued and Outstanding (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Schedule of Options Issued and Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Underlying Shares, Outstanding ending</a></td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding Ending</a></td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Contractual Life Remaining in Years, Outstanding Ending</a></td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Underlying Shares, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Contractual Life Remaining in Years, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Underlying Shares, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Underlying Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm', window );">Weighted-Average Contractual Life Remaining in Years, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Underlying Shares, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm', window );">Weighted-Average Contractual Life Remaining in Years, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue', window );">Aggregate Intrinsic Value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average contractual life remaining in years, forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of estimated use full lifes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to ABVC&#8217;s common stockholders</a></td>
<td class="num">$ (842,075)<span></span>
</td>
<td class="num">$ (2,834,199)<span></span>
</td>
<td class="num">$ (4,902,878)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7,788,050)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; Basic</a></td>
<td class="nump">14,968,232<span></span>
</td>
<td class="nump">9,736,150<span></span>
</td>
<td class="nump">11,673,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,335,650<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; Diluted</a></td>
<td class="nump">14,968,232<span></span>
</td>
<td class="nump">9,736,150<span></span>
</td>
<td class="nump">11,673,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,335,650<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease - Schedule of Operating Leases have Remaining Lease Terms (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 533,460<span></span>
</td>
<td class="nump">$ 640,387<span></span>
</td>
<td class="nump">$ 809,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities (current)</a></td>
<td class="nump">366,475<span></span>
</td>
<td class="nump">403,581<span></span>
</td>
<td class="nump">401,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities (non-current)</a></td>
<td class="nump">$ 166,985<span></span>
</td>
<td class="nump">$ 236,807<span></span>
</td>
<td class="nump">$ 407,457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease - Schedule of Company&#8217;s Lease Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems', window );"><strong>Schedule of Company&#8217;s Lease Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expenses</a></td>
<td class="nump">$ 117,166<span></span>
</td>
<td class="nump">$ 98,502<span></span>
</td>
<td class="nump">$ 514,420<span></span>
</td>
<td class="nump">$ 358,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 23 days<span></span>
</td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">1.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.19%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=abvc_CashPaidMember', window );">Cash Paid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems', window );"><strong>Schedule of Company&#8217;s Lease Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 484,181<span></span>
</td>
<td class="nump">$ 358,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=abvc_CashPaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=abvc_CashPaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 104,849<span></span>
</td>
<td class="nump">$ 409,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">46,699<span></span>
</td>
<td class="nump">104,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">46,699<span></span>
</td>
<td class="nump">47,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">46,699<span></span>
</td>
<td class="nump">47,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">547,017<span></span>
</td>
<td class="nump">655,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(13,557)<span></span>
</td>
<td class="num">(15,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 533,460<span></span>
</td>
<td class="nump">$ 640,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharesReceived', window );">Shares received (in Shares)</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BenefitsReceivableForMilestoneAttained', window );">Eligible to receive amount</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_royaltiesPercentage', window );">Royalty percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AcquisitionForNetSales', window );">Net sales on acquisition</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AcquisitionForNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition for net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AcquisitionForNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BenefitsReceivableForMilestoneAttained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable for certain milestone are met  and eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BenefitsReceivableForMilestoneAttained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_royaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>royalties percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_royaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition - Schedule of Acquisition was Accounted for Business Combination (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Schedule of Acquisition was Accounted for Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities', window );">Accrued expense</a></td>
<td class="num">(243,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Due to Director</a></td>
<td class="num">(498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total liabilities acquired</a></td>
<td class="num">(243,386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration (Intangible assets)</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent acquired in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt assumed in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Jan. 05, 2025</div></th>
<th class="th"><div>May 22, 2024</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Jan. 17, 2024</div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingMember', window );">AiBtl Holding [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Capital raised</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount of converted debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2nd Lind Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount of converted debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Third LIND Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount of converted debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | December Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | AiBtl Holding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnregisteredPricePerShares', window );">Unregistered price per shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Capital raised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member] | Advisors One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnregisteredPricePerShares', window );">Unregistered price per shares</a></td>
<td class="nump">1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Capital raised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member] | Advisors Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnregisteredPricePerShares', window );">Unregistered price per shares</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Capital raised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Offering [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">502,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnregisteredPricePerShares', window );">Unregistered price per shares</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Capital raised by private offering</a></td>
<td class="nump">$ 301,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_UnregisteredSharesMember', window );">Unregistered Shares [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Capital raised by private offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 436,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_UnregisteredSharesMember', window );">Unregistered Shares [Member] | Minimum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnregisteredPricePerShares', window );">Unregistered price per shares</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_UnregisteredSharesMember', window );">Unregistered Shares [Member] | Maximum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnregisteredPricePerShares', window );">Unregistered price per shares</a></td>
<td class="nump">0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_UnregisteredRestrictedSharesMember', window );">Unregistered Restricted Shares [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnregisteredPricePerShares', window );">Unregistered price per shares</a></td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Capital raised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_UnregisteredPricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unregistered price per shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_UnregisteredPricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_SecondLindNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_SecondLindNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_DecemberLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_DecemberLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvc_AdvisorsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvc_AdvisorsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvc_AdvisorsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvc_AdvisorsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_UnregisteredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abvc_UnregisteredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abvc_UnregisteredRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abvc_UnregisteredRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Impact of the Restatement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 159,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,949,150<span></span>
</td>
<td class="nump">$ 7,969,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepayment for asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,460,402<span></span>
</td>
<td class="nump">14,492,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,050,845<span></span>
</td>
<td class="nump">3,696,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable &#8211; third parties, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">842,567<span></span>
</td>
<td class="nump">569,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,633,614<span></span>
</td>
<td class="nump">5,932,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,973,447<span></span>
</td>
<td class="nump">6,361,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,029,237<span></span>
</td>
<td class="nump">82,636,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,792,076<span></span>
</td>
<td class="nump">8,388,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(305,121)<span></span>
</td>
<td class="num">(257,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,486,955<span></span>
</td>
<td class="nump">8,130,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,460,402<span></span>
</td>
<td class="nump">14,492,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">831,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,544,995<span></span>
</td>
<td class="nump">1,635,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(684,683)<span></span>
</td>
<td class="num">(2,493,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48,043)<span></span>
</td>
<td class="num">$ (394,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,981,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (2.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (2.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,981,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">672,016<span></span>
</td>
<td class="nump">$ 2,413,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">354,465<span></span>
</td>
<td class="nump">786,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128,840<span></span>
</td>
<td class="num">(186,860)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(602,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">805,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(260,783)<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonStockForConversionOfDebt', window );">Issuance of common stock for conversion of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">681,000<span></span>
</td>
<td class="nump">3,306,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported [Member] | Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Impact of the Restatement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">301,972<span></span>
</td>
<td class="nump">173,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Impact of the Restatement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">223,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,400,000)<span></span>
</td>
<td class="num">(7,400,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepayment for asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">691,900<span></span>
</td>
<td class="nump">691,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,484,392)<span></span>
</td>
<td class="num">(6,708,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(605,178)<span></span>
</td>
<td class="num">(148,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable &#8211; third parties, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,769<span></span>
</td>
<td class="nump">317,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(455,908)<span></span>
</td>
<td class="nump">169,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(455,908)<span></span>
</td>
<td class="nump">169,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,025,036)<span></span>
</td>
<td class="num">(8,658,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,092,525)<span></span>
</td>
<td class="num">(6,833,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">64,040<span></span>
</td>
<td class="num">(43,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,028,485)<span></span>
</td>
<td class="num">(6,877,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,484,393)<span></span>
</td>
<td class="num">(6,708,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(92,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(513,364)<span></span>
</td>
<td class="num">(1,449,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">503,007<span></span>
</td>
<td class="nump">1,179,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(45,425)<span></span>
</td>
<td class="num">$ (98,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,053,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,053,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(495,736)<span></span>
</td>
<td class="num">$ (1,169,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(398,070)<span></span>
</td>
<td class="num">(148,031)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(128,840)<span></span>
</td>
<td class="nump">186,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(353,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(217,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">119,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">234,674<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonStockForConversionOfDebt', window );">Issuance of common stock for conversion of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">213,426<span></span>
</td>
<td class="num">(1,519,426)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments [Member] | Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Impact of the Restatement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89,502<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=abvc_AsRestatedMember', window );">As restated [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Impact of the Restatement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">383,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">549,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepayment for asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">691,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,976,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,445,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable &#8211; third parties, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">872,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,177,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,517,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,004,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,699,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(241,081)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,458,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,976,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">738,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,031,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(181,676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(93,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,927,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,927,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">176,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43,605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(955,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(217,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">924,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonStockForConversionOfDebt', window );">Issuance of common stock for conversion of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">467,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=abvc_AsRestatedMember', window );">As restated [Member] | Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Impact of the Restatement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 391,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to related parties previously reported amount was reclassified to financing activities based on current year&#8217;s presentation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of exchange rate changes on cash and cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_IssuanceOfCommonStockForConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for conversion of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_IssuanceOfCommonStockForConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 1.B.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-7<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481003/205-10-S50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=abvc_AsRestatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=abvc_AsRestatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Schedule of Revenue and Gross Profit Information of our Reportable Segment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 509,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">928<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">508,826<span></span>
</td>
<td class="nump">$ 928<span></span>
</td>
<td class="num">(149,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 7,021<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Schedule of Reconciliation of Total Segment Gross Profit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Segment Gross Profit (Loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 928<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 508,826<span></span>
</td>
<td class="nump">$ 928<span></span>
</td>
<td class="num">$ (149,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">615,371<span></span>
</td>
<td class="nump">738,486<span></span>
</td>
<td class="nump">615,371<span></span>
</td>
<td class="nump">2,261,336<span></span>
</td>
<td class="nump">738,486<span></span>
</td>
<td class="nump">5,368,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">28,861<span></span>
</td>
<td class="nump">69,066<span></span>
</td>
<td class="nump">28,861<span></span>
</td>
<td class="nump">179,272<span></span>
</td>
<td class="nump">69,066<span></span>
</td>
<td class="nump">1,062,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,773<span></span>
</td>
<td class="nump">451,480<span></span>
</td>
<td class="nump">2,031,631<span></span>
</td>
<td class="nump">902,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">19,071<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">19,071<span></span>
</td>
<td class="nump">87,358<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">185,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(222,967)<span></span>
</td>
<td class="num">(181,676)<span></span>
</td>
<td class="num">(222,967)<span></span>
</td>
<td class="num">(825,899)<span></span>
</td>
<td class="num">(181,676)<span></span>
</td>
<td class="num">(1,313,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Operating sublease income</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">48,478<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">65,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain (loss) on foreign exchange changes</a></td>
<td class="num">(9,912)<span></span>
</td>
<td class="nump">60,730<span></span>
</td>
<td class="num">(9,912)<span></span>
</td>
<td class="num">(25,135)<span></span>
</td>
<td class="nump">60,730<span></span>
</td>
<td class="nump">22,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WriteOffUnclaimedAccruedLiabilites', window );">Loss on investment in equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,877)<span></span>
</td>
<td class="nump">255,592<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">19,485<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">134,443<span></span>
</td>
<td class="nump">19,485<span></span>
</td>
<td class="nump">3,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income tax</a></td>
<td class="num">$ (944,190)<span></span>
</td>
<td class="num">$ (2,927,667)<span></span>
</td>
<td class="num">$ (944,190)<span></span>
</td>
<td class="num">$ (5,369,576)<span></span>
</td>
<td class="num">$ (2,927,667)<span></span>
</td>
<td class="num">$ (8,024,838)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WriteOffUnclaimedAccruedLiabilites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write off unclaimed accrued liabilites.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WriteOffUnclaimedAccruedLiabilites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 11,513,464<span></span>
</td>
<td class="nump">$ 3,852,827<span></span>
</td>
<td class="nump">$ 3,904,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(3,344,718)<span></span>
</td>
<td class="num">(3,341,739)<span></span>
</td>
<td class="num">(3,335,041)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,168,746<span></span>
</td>
<td class="nump">511,088<span></span>
</td>
<td class="nump">569,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,004,520<span></span>
</td>
<td class="nump">338,966<span></span>
</td>
<td class="nump">363,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,217,756<span></span>
</td>
<td class="nump">2,219,244<span></span>
</td>
<td class="nump">2,227,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,129,804<span></span>
</td>
<td class="nump">1,131,169<span></span>
</td>
<td class="nump">1,138,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 161,384<span></span>
</td>
<td class="nump">$ 163,448<span></span>
</td>
<td class="nump">$ 174,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.17%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.17%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0.17%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.67%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.67%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.67%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ForSeeConEyeCorporationMember', window );">ForSeeCon Eye Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">19.78%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19.78%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Cost Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">18.68%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18.68%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18.68%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Equity&#160;Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Equity&#160;Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_OncoXBioPharmaIncMember', window );">OncoX BioPharma, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">24.97%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24.97%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Equity Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Equity Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteJapanKKMember', window );">BioLite Japan K.K. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Ownership Percentages of Each Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">49.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAdditionalInformation', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;-keep: true">This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAdditionalInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This serves as a place to record data that is not required by accounting literature but is useful for readers of the financial statements as it relates to the details of an equity method investment in common stock. Such information may include the amount of change for a change in ownership (equity) percentage in a given period and the amount and type of the consideration given or received in relation to the change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAdditionalInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ForSeeConEyeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ForSeeConEyeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_OncoXBioPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_OncoXBioPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteJapanKKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioLiteJapanKKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Extent the Investee Relies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanKKMember', window );">BioLite Japan K.K. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan<span></span>
</td>
<td class="text">The Company&#8217;s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ForSeeConEyeCorporationMember', window );">ForSeeCon Eye Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Loaned from the investee and provides research and development support service<span></span>
</td>
<td class="text">Loaned from the investee and provides research and development support service<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXBioPharmaIncMember', window );">OncoX BioPharma, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Extent the Investee Relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">The extent the investee relies on the Company for its business, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanKKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanKKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ForSeeConEyeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ForSeeConEyeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXBioPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXBioPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Long-Term Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 779,791<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 790,250<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 847,252<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,760,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,258,754<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,527,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,727<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,271<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,021<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ForSeeConEyeCorporationMember', window );">ForSeeCon Eye Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Non-marketable Cost Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">752,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">762,983<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">818,018<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,420,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,468,504<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">1,680,488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">559,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanKKBioLiteJPMember', window );">BioLite Japan K.K. (BioLite JP) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBioPharmaIncMember', window );">OncoX BioPharma, Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity Method Investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">ForSeeCon Eye Corporation (FEYE)
FEYE is a private company registered in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus. The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">BioFirst Corporation (the &#8220;BioFirst&#8221;):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2025 and December 31, 2024, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term investments in Biofirst is both $1,124,842.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">BioFirst Corporation (the &#8220;BioFirst&#8221;):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $1,124,842.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Rgene Corporation (the &#8220;Rgene&#8221;)
As described in Note 4, the Company acquired 26.65% of Rgene&#8217;s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting this equity investment with equity method as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company owns 37% of outstanding shares of Rgene.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Rgene Corporation (the &#8220;Rgene&#8221;)
Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">BioLite Japan K.K. (BioLite JP)
In October 2021, the Company, Lucidaim Co., Ltd., a Japanese corporation (&#8220;Lucidaim,&#8221; together with the Company, the &#8220;Shareholders&#8221;), and BioLite Japan K.K., a Japanese corporation (&#8220;BioLite JP&#8221;) entered into a Joint Venture Agreement. BioLite JP is a private limited company incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with 3,049 ordinary shares issued and outstanding (the &#8220;Ordinary Shares&#8221;). Pursuant to the Agreement and the related share transfer agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000 towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed. This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee&#8217;s business and financial conditions and determined to fully impair such prepayment.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">OncoX BioPharma, Inc. (OncoX)
OncoX is a private company registered in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain licensed products in exchange of OncoX&#8217;s ownership. See Note 4 for detail of such transactions.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_ForSeeConEyeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_ForSeeConEyeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanKKBioLiteJPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanKKBioLiteJPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBioPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBioPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Schedule of Components of Loss on Investment in Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Share of equity method investee losses</a></td>
<td class="num">$ (50,877)<span></span>
</td>
<td class="num">$ (339,171)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (221,888)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 2,260,000<span></span>
</td>
<td class="nump">$ 2,260,000<span></span>
</td>
<td class="nump">$ 4,904,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">1,060,000<span></span>
</td>
<td class="nump">1,460,000<span></span>
</td>
<td class="nump">2,011,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">224,460<span></span>
</td>
<td class="nump">509,954<span></span>
</td>
<td class="nump">1,124,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">835,539<span></span>
</td>
<td class="nump">950,046<span></span>
</td>
<td class="nump">886,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 1,260,000<span></span>
</td>
<td class="nump">$ 1,740,000<span></span>
</td>
<td class="nump">$ 2,413,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_SecondLINDNoteMember', window );">2nd LIND Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">ABVC<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">May 19,  2025<span></span>
</td>
<td class="text">May 19,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">86.94%<span></span>
</td>
<td class="nump">86.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">ABVC<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">26,110<span></span>
</td>
<td class="nump">118,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">173,890<span></span>
</td>
<td class="nump">281,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember', window );">3rd LIND Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">ABVC<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Jan. 17,  2024<span></span>
</td>
<td class="text">Jan. 17,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Jul. 17,  2025<span></span>
</td>
<td class="text">Jul. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">87.40%<span></span>
</td>
<td class="nump">87.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">ABVC<span></span>
</td>
<td class="text">ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">196,114<span></span>
</td>
<td class="nump">388,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">603,886<span></span>
</td>
<td class="nump">611,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_OtherNoteMember', window );">Other Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Nov.  01,  2024<span></span>
</td>
<td class="text">Nov.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Nov.  01,  2025<span></span>
</td>
<td class="text">Nov.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">6.89%<span></span>
</td>
<td class="nump">6.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">28,881<span></span>
</td>
<td class="nump">28,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abvc_OtherNoteOneMember', window );">Other Note One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Carrying Amounts of the Liability Component [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentIssuanceEntity', window );">Issuance Entity</a></td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Nov.  05,  2024<span></span>
</td>
<td class="text">Nov.  05,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Nov.  05,  2025<span></span>
</td>
<td class="text">Nov.  05,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal Amount at Issuance</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">6.89%<span></span>
</td>
<td class="nump">6.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCommonStockToBeConverted', window );">Common Stock to be converted</a></td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">AiBtl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate', window );">Principal Amount at Balance Sheet Date</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentCarryingValue', window );">Carrying Value</a></td>
<td class="nump">28,882<span></span>
</td>
<td class="nump">28,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of carrying value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentCommonStockToBeConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of common stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentCommonStockToBeConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentIssuanceEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of issuance entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentIssuanceEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of principal amount at balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_SecondLINDNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_SecondLINDNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_ThirdLINDNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_OtherNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_OtherNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abvc_OtherNoteOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abvc_OtherNoteOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccruedResearchAndDevelopmentExpense', window );">Accrued research and development expense</a></td>
<td class="nump">$ 1,799,583<span></span>
</td>
<td class="nump">$ 1,799,583<span></span>
</td>
<td class="nump">$ 1,799,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued directors and officers (owners) compensation</a></td>
<td class="nump">991,821<span></span>
</td>
<td class="nump">1,025,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CashPortionOfTheLindNoteRepayments', window );">Cash portion of the Lind Note repayments</a></td>
<td class="nump">227,284<span></span>
</td>
<td class="nump">127,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">140,252<span></span>
</td>
<td class="nump">126,106<span></span>
</td>
<td class="nump">29,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Others</a></td>
<td class="nump">617,879<span></span>
</td>
<td class="nump">557,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Total</a></td>
<td class="nump">$ 3,826,819<span></span>
</td>
<td class="nump">$ 3,509,422<span></span>
</td>
<td class="nump">$ 3,548,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CashPortionOfTheLindNoteRepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash portion of the Lind Note repayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CashPortionOfTheLindNoteRepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Loans - Schedule of Short-Term Loans (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Schedule of Short-Term Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 801,407<span></span>
</td>
<td class="nump">$ 840,252<span></span>
</td>
<td class="nump">$ 899,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember', window );">Cathay United Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Schedule of Short-Term Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">169,407<span></span>
</td>
<td class="nump">200,252<span></span>
</td>
<td class="nump">245,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember', window );">CTBC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Schedule of Short-Term Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="nump">654,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualMember', window );">Other individual [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Schedule of Short-Term Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_OtherIndividualMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent', window );">Due from related parties- Non-current, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 958,616<span></span>
</td>
<td class="nump">$ 1,014,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent', window );">Less: allowance for expected credit losses accounts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (958,616)<span></span>
</td>
<td class="num">(1,014,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Net, Due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,941,299<span></span>
</td>
<td class="nump">$ 3,941,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationtheBioFirstMember', window );">BioFirst Corporation (the "BioFirst") [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember', window );">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationtheRgeneMember', window );">Rgene Corporation (the &#8220;Rgene&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenePharmInctheGenePharmMember', window );">GenePharm Inc. (the &#8220;GenePharm&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst  Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.  Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.  Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company.  Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 222,522<span></span>
</td>
<td class="nump">274,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationBHKMember', window );">BioHopeKing Corporation (&#8220;BHK&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of ABVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember', window );">AiBtl (Holding) BioPharma, Inc. (&#8220;AiBtl Holding&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Founding shareholder of AiBtl BioPharma Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_JaimesVargasRussmanMember', window );">Jaimes Vargas Russman [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">CEO of AiBtl BioPharma Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LionArtsPromotionIncMember', window );">Lion Arts Promotion, Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Entity controlled by the Jiangs.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party- Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">565,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party- Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">537,119<span></span>
</td>
<td class="nump">1,155,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Net, Due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">819,384<span></span>
</td>
<td class="nump">773,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party- Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">535,252<span></span>
</td>
<td class="nump">589,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent', window );">Due from related parties- Non-current, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 839,983<span></span>
</td>
<td class="nump">$ 839,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship with the Company and its subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent', window );">Due from related parties- Non-current, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 118,633<span></span>
</td>
<td class="nump">$ 120,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingMember', window );">AiBtl Holding [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">348,219<span></span>
</td>
<td class="nump">348,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ShareholdersMember', window );">Shareholders [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">140,266<span></span>
</td>
<td class="nump">142,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LionArtPromotionIncMember', window );">Lion Art Promotion Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">65,738<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_DirectorsMember', window );">Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="nump">$ 12,953<span></span>
</td>
<td class="nump">$ 8,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2025 and December 31, 2024, the outstanding balance due to the Jiangs amounted to $222,522 and $274,170, respectively. These loans bear no interest and are due on demand.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 16, 2022, the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 and made $500,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided. The loan was converted to Rgene&#8217;s common stock in May 2024 but the Company was not informed until April 2025. Please see detail discussion in Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025 and December 31, 2024, the outstanding loan balance were $0 and $500,000; and accrued interest was $<span style="-sec-ix-hidden: hidden-fact-356">0and</span> $63,819, respectively. Both principal and accrued interest were converted to Rgene&#8217;s common stocks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025 and December 31, 2024, the Company has other receivables amounted to $1,867 and $1,892, respectively, from Rgene due to daily operations.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">On December&#160;31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of NTD 11,072,360 (approximately $337,707), which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of NTD 11,406,000 (approximately $347,883), which bears interest at 12% per annum for the use of working capital. As of March 31, 2025 and December 31, 2024, the outstanding loan balance were NTD 15,458,360 (approximately $465,297) and NTD 17,571,076 (approximately $535,918), respectively; accrued interests were$68,971 and $53,422, respectively. The Company has received NTD 2,080,000 (approximately $64,896) and $0 repayment during the three months ended March 31, 2025 and 2024, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects. &#160;During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of March 31, 2025 and December 31, 2024, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2025 and December 31, 2024, due from BHK was both NTD 3,941,299 (approximately$118,633 and $120,210, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of NTD 3,941,299 as of December 31, 2024. No recovery was made during three months ended March 31, 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">On April 11, 2024, May 10, 2024, August 15, 2024, and December 24, 2024, AiBtl received short-term loans from its founding shareholder, AiBtl Holding, for the principal amounts of $40,000, $60,000, $33,732, and $214,487, respectively, for the purpose of daily operations. These loans do not bear interest and are payable on demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate around 12% per annum. As of March 31, 2025 and December 31, 2024, the outstanding principal and accrued interest was $140,266 and $142,130, respectively. Interest expenses in connection with these loans were $4,963 and $5,938 for the three months ended March 31, 2025 and 2024, respectively.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued consulting services fee for the three months ended March 31, 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2025 and December 31, 2024, due to Directors amounted to $12,953 and $8,526, respectively, were related to the daily operating expenses since inception in 2023 paid by the Directors of AiBtl on behalf of the entity.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationtheBioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationtheBioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationtheRgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationtheRgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenePharmInctheGenePharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenePharmInctheGenePharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationBHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationBHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_JaimesVargasRussmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_JaimesVargasRussmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LionArtsPromotionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LionArtsPromotionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_AiBtlHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LionArtPromotionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_LionArtPromotionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Schedule of Deferred Tax Assets (Liability) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Loss on impairment of assets</a></td>
<td class="nump">$ 713,223<span></span>
</td>
<td class="nump">$ 713,223<span></span>
</td>
<td class="nump">$ 713,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net operating loss carryforwards</a></td>
<td class="nump">5,870,805<span></span>
</td>
<td class="nump">5,677,413<span></span>
</td>
<td class="nump">5,018,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">155,559<span></span>
</td>
<td class="nump">178,014<span></span>
</td>
<td class="nump">213,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DeferredTaxAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="num">(155,559)<span></span>
</td>
<td class="num">(178,014)<span></span>
</td>
<td class="num">(213,482)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">6,584,028<span></span>
</td>
<td class="nump">6,390,636<span></span>
</td>
<td class="nump">5,731,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(6,584,028)<span></span>
</td>
<td class="num">(6,390,636)<span></span>
</td>
<td class="num">(5,731,566)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DeferredTaxAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DeferredTaxAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrants Issued and Outstanding (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Issued and Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Underlying Shares, Outstanding ending (in Shares)</a></td>
<td class="nump">2,029,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Outstanding ending</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted- Average Contractual Life Remaining in Years, Outstanding ending</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">4 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Outstanding ending (in Dollars)</a></td>
<td class="nump">$ 195,542<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued', window );">Number of Underlying Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm', window );">Weighted- Average Contractual Life Remaining in Years, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue', window );">Aggregate Intrinsic Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Underlying Shares, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,029,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm', window );">Weighted- Average Contractual Life Remaining in Years, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2025, the Company and Lind entered into a third letter agreement (the &#8220;December Letter Agreement&#8221;), pursuant to which Lind agreed to exercise for cash, 1,029,167 of the Existing Warrants to purchase shares of Common Stock, with a current exercise price of $0.75 per share, at a reduced exercise price of $0.40 per share. The weighted average exercise price per share as of December 31, 2024 was adjusted to the reduction accordingly.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument exercise intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument exercise weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument   exercise weighted remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument  issued intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument issued weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instrument  issued weighted remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Schedule of Options Issued and Outstanding (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Schedule of Options Issued and Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Underlying Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Underlying Shares, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue', window );">Aggregate Intrinsic Value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Underlying Shares, Outstanding ending</a></td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding Ending</a></td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Contractual Life Remaining in Years, Outstanding Ending</a></td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Underlying Shares, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Contractual Life Remaining in Years, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Underlying Shares, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
<td class="nump">258,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to ABVC&#8217;s common stockholders</a></td>
<td class="num">$ (842,075)<span></span>
</td>
<td class="num">$ (2,834,199)<span></span>
</td>
<td class="num">$ (4,902,878)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7,788,050)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; Basic</a></td>
<td class="nump">14,968,232<span></span>
</td>
<td class="nump">9,736,150<span></span>
</td>
<td class="nump">11,673,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,335,650<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; Diluted</a></td>
<td class="nump">14,968,232<span></span>
</td>
<td class="nump">9,736,150<span></span>
</td>
<td class="nump">11,673,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,335,650<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease - Schedule of Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AssetsAbstract0', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 533,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,387<span></span>
</td>
<td class="nump">$ 809,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities (current)</a></td>
<td class="nump">366,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,581<span></span>
</td>
<td class="nump">401,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities (non-current)</a></td>
<td class="nump">166,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,807<span></span>
</td>
<td class="nump">407,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expenses</a></td>
<td class="nump">117,166<span></span>
</td>
<td class="nump">$ 98,502<span></span>
</td>
<td class="nump">$ 514,420<span></span>
</td>
<td class="nump">$ 358,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 117,166<span></span>
</td>
<td class="nump">$ 98,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases Weighted Average Remaining Lease Term</a></td>
<td class="text">2 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 23 days<span></span>
</td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases Weighted Average Discount Rate</a></td>
<td class="nump">1.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.19%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AssetsAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AssetsAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (Excluding current period)</a></td>
<td class="nump">$ 302,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">104,849<span></span>
</td>
<td class="nump">$ 409,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">46,699<span></span>
</td>
<td class="nump">104,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">46,699<span></span>
</td>
<td class="nump">47,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">46,699<span></span>
</td>
<td class="nump">47,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">547,017<span></span>
</td>
<td class="nump">655,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(13,557)<span></span>
</td>
<td class="num">(15,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 533,460<span></span>
</td>
<td class="nump">$ 640,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>655</ContextCount>
  <ElementCount>504</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>187</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Unaudited Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Unaudited Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Unaudited Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Unaudited Condensed Consolidated Statements of Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Liquidity, Going Concern, and Restatement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LiquidityGoingConcernandRestatement</Role>
      <ShortName>Liquidity, Going Concern, and Restatement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisition</Role>
      <ShortName>Property and Equipment, and Prepament for Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Long-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LongTermInvestments</Role>
      <ShortName>Long-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Short-Term Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ShortTermLoans</Role>
      <ShortName>Short-Term Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Related Parties Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactions</Role>
      <ShortName>Related Parties Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Lease</Role>
      <ShortName>Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Liquidity, Going Concern, and Restatement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LiquidityGoingConcernandRestatementTables</Role>
      <ShortName>Liquidity, Going Concern, and Restatement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LiquidityGoingConcernandRestatement</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionTables</Role>
      <ShortName>Property and Equipment, and Prepament for Asset Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisition</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Long-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LongTermInvestmentsTables</Role>
      <ShortName>Long-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Convertible Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/ConvertibleNotesPayableTables</Role>
      <ShortName>Convertible Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Short-Term Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ShortTermLoansTables</Role>
      <ShortName>Short-Term Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/ShortTermLoans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Related Parties Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactionsTables</Role>
      <ShortName>Related Parties Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Equity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/StockOptionsTables</Role>
      <ShortName>Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LossPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LeaseTables</Role>
      <ShortName>Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Lease</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/AcquisitionTables</Role>
      <ShortName>Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Acquisition</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Liquidity, Going Concern, and Restatement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails</Role>
      <ShortName>Liquidity, Going Concern, and Restatement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LiquidityGoingConcernandRestatementTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable</Role>
      <ShortName>Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/CollaborativeAgreements</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails</Role>
      <ShortName>Property and Equipment, and Prepament for Asset Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Long-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LongTermInvestmentsDetails</Role>
      <ShortName>Long-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable</Role>
      <ShortName>Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Long-Term Investments - Schedule of Extent the Investee Relies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable</Role>
      <ShortName>Long-Term Investments - Schedule of Extent the Investee Relies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Long-Term Investments - Schedule of Long-Term Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofLongTermInvestmentTable</Role>
      <ShortName>Long-Term Investments - Schedule of Long-Term Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Long-Term Investments - Schedule of Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofBalanceSheetsTable</Role>
      <ShortName>Long-Term Investments - Schedule of Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Long-Term Investments - Schedule of Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofStatementsofOperationsTable</Role>
      <ShortName>Long-Term Investments - Schedule of Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable</Role>
      <ShortName>Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Convertible Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/ConvertibleNotesPayableDetails</Role>
      <ShortName>Convertible Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/ConvertibleNotesPayableTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable</Role>
      <ShortName>Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Short-Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ShortTermLoansDetails</Role>
      <ShortName>Short-Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/ShortTermLoansTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Short-Term Loans - Schedule of Short-Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofShortTermLoansTable</Role>
      <ShortName>Short-Term Loans - Schedule of Short-Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Related Parties Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactionsDetails</Role>
      <ShortName>Related Parties Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable</Role>
      <ShortName>Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Related Parties Transactions - Schedule of Licensing Agreement and Related Amendment with FEYE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable</Role>
      <ShortName>Related Parties Transactions - Schedule of Licensing Agreement and Related Amendment with FEYE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Related Parties Transactions - Schedule of Accounts Receivable Due from Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable</Role>
      <ShortName>Related Parties Transactions - Schedule of Accounts Receivable Due from Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Related Parties Transactions - Schedule of Due from Related Party - Current and Non-current, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable</Role>
      <ShortName>Related Parties Transactions - Schedule of Due from Related Party - Current and Non-current, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Related Parties Transactions - Schedule of Amount Due to Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable</Role>
      <ShortName>Related Parties Transactions - Schedule of Amount Due to Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/IncomeTaxesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Income Taxes - Schedule of Income Tax (Benefit) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable</Role>
      <ShortName>Income Taxes - Schedule of Income Tax (Benefit) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/EquityTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Equity - Schedule of Warrants Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable</Role>
      <ShortName>Equity - Schedule of Warrants Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/StockOptionsDetails</Role>
      <ShortName>Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptionsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Stock Options - Schedule of Options Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable</Role>
      <ShortName>Stock Options - Schedule of Options Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Loss Per Share - Schedule of Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofLossPerShareTable</Role>
      <ShortName>Loss Per Share - Schedule of Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Lease - Schedule of Operating Leases have Remaining Lease Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable</Role>
      <ShortName>Lease - Schedule of Operating Leases have Remaining Lease Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Lease - Schedule of Company???s Lease Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable</Role>
      <ShortName>Lease - Schedule of Company???s Lease Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable</Role>
      <ShortName>Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/AcquisitionDetails</Role>
      <ShortName>Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/AcquisitionTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Acquisition - Schedule of Acquisition was Accounted for Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable</Role>
      <ShortName>Acquisition - Schedule of Acquisition was Accounted for Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0</Role>
      <ShortName>Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996060 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0</Role>
      <ShortName>Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996061 - Disclosure - Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0</Role>
      <ShortName>Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996062 - Disclosure - Long-Term Investments - Schedule of Extent the Investee Relies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0</Role>
      <ShortName>Long-Term Investments - Schedule of Extent the Investee Relies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996063 - Disclosure - Long-Term Investments - Schedule of Long-Term Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0</Role>
      <ShortName>Long-Term Investments - Schedule of Long-Term Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996064 - Disclosure - Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0</Role>
      <ShortName>Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0</Role>
      <ShortName>Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996066 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996067 - Disclosure - Short-Term Loans - Schedule of Short-Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofShortTermLoansTable0</Role>
      <ShortName>Short-Term Loans - Schedule of Short-Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996068 - Disclosure - Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0</Role>
      <ShortName>Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996069 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996070 - Disclosure - Equity - Schedule of Warrants Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0</Role>
      <ShortName>Equity - Schedule of Warrants Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>996071 - Disclosure - Stock Options - Schedule of Options Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0</Role>
      <ShortName>Stock Options - Schedule of Options Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>996072 - Disclosure - Loss Per Share - Schedule of Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofLossPerShareTable0</Role>
      <ShortName>Loss Per Share - Schedule of Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>996073 - Disclosure - Lease - Schedule of Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofLeaseTable</Role>
      <ShortName>Lease - Schedule of Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="ea0241941-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>996074 - Disclosure - Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0</Role>
      <ShortName>Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abvc-20250331.xsd</File>
    <File>abvc-20250331_cal.xml</File>
    <File>abvc-20250331_def.xml</File>
    <File>abvc-20250331_lab.xml</File>
    <File>abvc-20250331_pre.xml</File>
    <File doctype="POS AM" isDefinitelyFs="true" isUsgaap="true" original="ea0241941-posam1_abvcbio.htm">ea0241941-posam1_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="2216">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>226
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0241941-posam1_abvcbio.htm": {
   "nsprefix": "abvc",
   "nsuri": "http://metuboutique.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "abvc-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "abvc-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abvc-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0241941-posam1_abvcbio.htm"
     ]
    }
   },
   "keyStandard": 387,
   "keyCustom": 117,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 33,
   "memberCustom": 101,
   "hidden": {
    "total": 384,
    "http://metuboutique.com/20250331": 108,
    "http://fasb.org/us-gaap/2025": 273,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 655,
   "entityCount": 1,
   "segmentCount": 187,
   "elementCount": 831,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 2216,
    "http://xbrl.sec.gov/dei/2025": 9,
    "http://fasb.org/srt/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://metuboutique.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://metuboutique.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Unaudited Condensed Consolidated Balance Sheets",
     "shortName": "Unaudited Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:InventoryNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://metuboutique.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://metuboutique.com/role/ConsolidatedCashFlow",
     "longName": "004 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows",
     "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable",
     "longName": "005 - Statement - Unaudited Condensed Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "shortName": "Unaudited Condensed Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://metuboutique.com/role/OrganizationandDescriptionofBusiness",
     "longName": "006 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://metuboutique.com/role/LiquidityGoingConcernandRestatement",
     "longName": "007 - Disclosure - Liquidity, Going Concern, and Restatement",
     "shortName": "Liquidity, Going Concern, and Restatement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "abvc:LiquidityGoingConcernAndRestatementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abvc:LiquidityGoingConcernAndRestatementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://metuboutique.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://metuboutique.com/role/CollaborativeAgreements",
     "longName": "009 - Disclosure - Collaborative Agreements",
     "shortName": "Collaborative Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisition",
     "longName": "010 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition",
     "shortName": "Property and Equipment, and Prepament for Asset Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://metuboutique.com/role/LongTermInvestments",
     "longName": "011 - Disclosure - Long-Term Investments",
     "shortName": "Long-Term Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://metuboutique.com/role/ConvertibleNotesPayable",
     "longName": "012 - Disclosure - Convertible Notes Payable",
     "shortName": "Convertible Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "013 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://metuboutique.com/role/ShortTermLoans",
     "longName": "014 - Disclosure - Short-Term Loans",
     "shortName": "Short-Term Loans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://metuboutique.com/role/RelatedPartiesTransactions",
     "longName": "015 - Disclosure - Related Parties Transactions",
     "shortName": "Related Parties Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://metuboutique.com/role/IncomeTaxes",
     "longName": "016 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://metuboutique.com/role/Equity",
     "longName": "017 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://metuboutique.com/role/StockOptions",
     "longName": "018 - Disclosure - Stock Options",
     "shortName": "Stock Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://metuboutique.com/role/LossPerShare",
     "longName": "019 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://metuboutique.com/role/Lease",
     "longName": "020 - Disclosure - Lease",
     "shortName": "Lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://metuboutique.com/role/CommitmentsandContingencies",
     "longName": "021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://metuboutique.com/role/Acquisition",
     "longName": "022 - Disclosure - Acquisition",
     "shortName": "Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://metuboutique.com/role/SubsequentEvents",
     "longName": "023 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://metuboutique.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://metuboutique.com/role/LiquidityGoingConcernandRestatementTables",
     "longName": "996001 - Disclosure - Liquidity, Going Concern, and Restatement (Tables)",
     "shortName": "Liquidity, Going Concern, and Restatement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996002 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "abvc:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "abvc:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionTables",
     "longName": "996003 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition (Tables)",
     "shortName": "Property and Equipment, and Prepament for Asset Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://metuboutique.com/role/LongTermInvestmentsTables",
     "longName": "996004 - Disclosure - Long-Term Investments (Tables)",
     "shortName": "Long-Term Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://metuboutique.com/role/ConvertibleNotesPayableTables",
     "longName": "996005 - Disclosure - Convertible Notes Payable (Tables)",
     "shortName": "Convertible Notes Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "996006 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://metuboutique.com/role/ShortTermLoansTables",
     "longName": "996007 - Disclosure - Short-Term Loans (Tables)",
     "shortName": "Short-Term Loans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://metuboutique.com/role/RelatedPartiesTransactionsTables",
     "longName": "996008 - Disclosure - Related Parties Transactions (Tables)",
     "shortName": "Related Parties Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://metuboutique.com/role/IncomeTaxesTables",
     "longName": "996009 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://metuboutique.com/role/EquityTables",
     "longName": "996010 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://metuboutique.com/role/StockOptionsTables",
     "longName": "996011 - Disclosure - Stock Options (Tables)",
     "shortName": "Stock Options (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://metuboutique.com/role/LossPerShareTables",
     "longName": "996012 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://metuboutique.com/role/LeaseTables",
     "longName": "996013 - Disclosure - Lease (Tables)",
     "shortName": "Lease (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://metuboutique.com/role/AcquisitionTables",
     "longName": "996014 - Disclosure - Acquisition (Tables)",
     "shortName": "Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
     "longName": "996015 - Disclosure - Organization and Description of Business (Details)",
     "shortName": "Organization and Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c432",
      "name": "abvc:BenefitsReceivableForMilestoneAttained",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abvc:PercentageOfRoyaltiesEqualing",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
     "longName": "996016 - Disclosure - Liquidity, Going Concern, and Restatement (Details)",
     "shortName": "Liquidity, Going Concern, and Restatement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "abvc:LiquidityGoingConcernAndRestatementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "abvc:LiquidityGoingConcernAndRestatementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
     "longName": "996017 - Disclosure - Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)",
     "shortName": "Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ConstructionInProgressGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:InterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996018 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable",
     "longName": "996019 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c118",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c118",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable",
     "longName": "996020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
     "longName": "996021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://metuboutique.com/role/CollaborativeAgreementsDetails",
     "longName": "996022 - Disclosure - Collaborative Agreements (Details)",
     "shortName": "Collaborative Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c471",
      "name": "abvc:MilestonePaymentsRoyaltyPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c471",
      "name": "abvc:MilestonePaymentsRoyaltyPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
     "longName": "996023 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition (Details)",
     "shortName": "Property and Equipment, and Prepament for Asset Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996024 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PropertyPlantAndEquipmentOtherNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://metuboutique.com/role/LongTermInvestmentsDetails",
     "longName": "996025 - Disclosure - Long-Term Investments (Details)",
     "shortName": "Long-Term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c500",
      "name": "abvc:PercentageCommonStocksShares",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c500",
      "name": "abvc:PercentageCommonStocksShares",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
     "longName": "996026 - Disclosure - Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)",
     "shortName": "Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c503",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
     "longName": "996027 - Disclosure - Long-Term Investments - Schedule of Extent the Investee Relies (Details)",
     "shortName": "Long-Term Investments - Schedule of Extent the Investee Relies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c517",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
     "longName": "996028 - Disclosure - Long-Term Investments - Schedule of Long-Term Investment (Details)",
     "shortName": "Long-Term Investments - Schedule of Long-Term Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:DebtSecuritiesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://metuboutique.com/role/ScheduleofBalanceSheetsTable",
     "longName": "996029 - Disclosure - Long-Term Investments - Schedule of Balance Sheets (Details)",
     "shortName": "Long-Term Investments - Schedule of Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c231",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c231",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable",
     "longName": "996030 - Disclosure - Long-Term Investments - Schedule of Statements of Operations (Details)",
     "shortName": "Long-Term Investments - Schedule of Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c235",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c235",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable",
     "longName": "996031 - Disclosure - Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)",
     "shortName": "Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
     "longName": "996032 - Disclosure - Convertible Notes Payable (Details)",
     "shortName": "Convertible Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c257",
      "name": "us-gaap:CommonStockConvertibleConversionPriceIncrease",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c257",
      "name": "us-gaap:CommonStockConvertibleConversionPriceIncrease",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
     "longName": "996033 - Disclosure - Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)",
     "shortName": "Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtInstrumentIssuedPrincipal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c279",
      "name": "abvc:DebtInstrumentIssuanceEntity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable",
     "longName": "996034 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "abvc:AccruedResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "abvc:AccruedDirectorAndOfficerCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://metuboutique.com/role/ShortTermLoansDetails",
     "longName": "996035 - Disclosure - Short-Term Loans (Details)",
     "shortName": "Short-Term Loans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RepaymentsOfShortTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RepaymentsOfShortTermDebt",
      "unitRef": "twd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://metuboutique.com/role/ScheduleofShortTermLoansTable",
     "longName": "996036 - Disclosure - Short-Term Loans - Schedule of Short-Term Loans (Details)",
     "shortName": "Short-Term Loans - Schedule of Short-Term Loans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
     "longName": "996037 - Disclosure - Related Parties Transactions (Details)",
     "shortName": "Related Parties Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
     "longName": "996038 - Disclosure - Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)",
     "shortName": "Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c334",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c334",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable",
     "longName": "996039 - Disclosure - Related Parties Transactions - Schedule of Licensing Agreement and Related Amendment with FEYE (Details)",
     "shortName": "Related Parties Transactions - Schedule of Licensing Agreement and Related Amendment with FEYE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c344",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c344",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable",
     "longName": "996040 - Disclosure - Related Parties Transactions - Schedule of Accounts Receivable Due from Related Parties (Details)",
     "shortName": "Related Parties Transactions - Schedule of Accounts Receivable Due from Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c234",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
     "longName": "996041 - Disclosure - Related Parties Transactions - Schedule of Due from Related Party - Current and Non-current, Net (Details)",
     "shortName": "Related Parties Transactions - Schedule of Due from Related Party - Current and Non-current, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c354",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c354",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable",
     "longName": "996042 - Disclosure - Related Parties Transactions - Schedule of Amount Due to Related Parties (Details)",
     "shortName": "Related Parties Transactions - Schedule of Amount Due to Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c359",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfAmountDueToRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c359",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfAmountDueToRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://metuboutique.com/role/IncomeTaxesDetails",
     "longName": "996043 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable",
     "longName": "996044 - Disclosure - Income Taxes - Schedule of Income Tax (Benefit) Expense (Details)",
     "shortName": "Income Taxes - Schedule of Income Tax (Benefit) Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable",
     "longName": "996045 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:DeferredTaxAssetsOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://metuboutique.com/role/EquityDetails",
     "longName": "996046 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c407",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
     "longName": "996047 - Disclosure - Equity - Schedule of Warrants Issued and Outstanding (Details)",
     "shortName": "Equity - Schedule of Warrants Issued and Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://metuboutique.com/role/StockOptionsDetails",
     "longName": "996048 - Disclosure - Stock Options (Details)",
     "shortName": "Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c426",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c425",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
     "longName": "996049 - Disclosure - Stock Options - Schedule of Options Issued and Outstanding (Details)",
     "shortName": "Stock Options - Schedule of Options Issued and Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c642",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://metuboutique.com/role/ScheduleofLossPerShareTable",
     "longName": "996050 - Disclosure - Loss Per Share - Schedule of Loss Per Share (Details)",
     "shortName": "Loss Per Share - Schedule of Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable",
     "longName": "996051 - Disclosure - Lease - Schedule of Operating Leases have Remaining Lease Terms (Details)",
     "shortName": "Lease - Schedule of Operating Leases have Remaining Lease Terms (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable",
     "longName": "996052 - Disclosure - Lease - Schedule of Company\u2019s Lease Expenses (Details)",
     "shortName": "Lease - Schedule of Company\u2019s Lease Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c429",
      "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable",
     "longName": "996053 - Disclosure - Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)",
     "shortName": "Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://metuboutique.com/role/AcquisitionDetails",
     "longName": "996054 - Disclosure - Acquisition (Details)",
     "shortName": "Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c431",
      "name": "abvc:SharesReceived",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c431",
      "name": "abvc:SharesReceived",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable",
     "longName": "996055 - Disclosure - Acquisition - Schedule of Acquisition was Accounted for Business Combination (Details)",
     "shortName": "Acquisition - Schedule of Acquisition was Accounted for Business Combination (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c433",
      "name": "abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c433",
      "name": "abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://metuboutique.com/role/SubsequentEventsDetails",
     "longName": "996056 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c414",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c440",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
     "longName": "996057 - Disclosure - Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)",
     "shortName": "Liquidity, Going Concern, and Restatement - Schedule of Impact of the Restatement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c453",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c453",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0",
     "longName": "996058 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Revenue and Gross Profit Information of our Reportable Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R84": {
     "role": "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0",
     "longName": "996059 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Total Segment Gross Profit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R85": {
     "role": "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0",
     "longName": "996060 - Disclosure - Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment, and Prepament for Asset Acquisition - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R86": {
     "role": "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0",
     "longName": "996061 - Disclosure - Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)",
     "shortName": "Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c503",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c515",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
     "longName": "996062 - Disclosure - Long-Term Investments - Schedule of Extent the Investee Relies (Details)",
     "shortName": "Long-Term Investments - Schedule of Extent the Investee Relies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c517",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R88": {
     "role": "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
     "longName": "996063 - Disclosure - Long-Term Investments - Schedule of Long-Term Investment (Details)",
     "shortName": "Long-Term Investments - Schedule of Long-Term Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:DebtSecuritiesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0",
     "longName": "996064 - Disclosure - Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)",
     "shortName": "Long-Term Investments - Schedule of Components of Loss on Investment in Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R90": {
     "role": "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0",
     "longName": "996065 - Disclosure - Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)",
     "shortName": "Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtInstrumentIssuedPrincipal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R91": {
     "role": "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0",
     "longName": "996066 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "abvc:AccruedResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://metuboutique.com/role/ScheduleofShortTermLoansTable0",
     "longName": "996067 - Disclosure - Short-Term Loans - Schedule of Short-Term Loans (Details)",
     "shortName": "Short-Term Loans - Schedule of Short-Term Loans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R93": {
     "role": "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0",
     "longName": "996068 - Disclosure - Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)",
     "shortName": "Related Parties Transactions - Schedule of Related Parties of the Company with whom Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0",
     "longName": "996069 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Liability) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:DeferredTaxAssetsOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R95": {
     "role": "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0",
     "longName": "996070 - Disclosure - Equity - Schedule of Warrants Issued and Outstanding (Details)",
     "shortName": "Equity - Schedule of Warrants Issued and Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c638",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c638",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0",
     "longName": "996071 - Disclosure - Stock Options - Schedule of Options Issued and Outstanding (Details)",
     "shortName": "Stock Options - Schedule of Options Issued and Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c642",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R97": {
     "role": "http://metuboutique.com/role/ScheduleofLossPerShareTable0",
     "longName": "996072 - Disclosure - Loss Per Share - Schedule of Loss Per Share (Details)",
     "shortName": "Loss Per Share - Schedule of Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R98": {
     "role": "http://metuboutique.com/role/ScheduleofLeaseTable",
     "longName": "996073 - Disclosure - Lease - Schedule of Lease (Details)",
     "shortName": "Lease - Schedule of Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0",
     "longName": "996074 - Disclosure - Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)",
     "shortName": "Lease - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0241941-posam1_abvcbio.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "abvc_ABVCAndBioLiteTaiwanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ABVCAndBioLiteTaiwanMember",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ABVC and BioLite Taiwan [Member]",
        "label": "ABVCAnd Bio Lite Taiwan Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ABVCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ABVCMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ABVC [Member]",
        "label": "ABVCMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable - related parties, net",
        "verboseLabel": "Total",
        "netLabel": "Accounts receivable due from related parties",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r61",
      "r1158"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableInterestBearingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableInterestBearingInterestRate",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate of loan",
        "verboseLabel": "Loans bear interest rate",
        "label": "Accounts Payable, Interest-Bearing, Interest Rate",
        "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables."
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r1085"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit losses",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r845",
      "r967",
      "r1211",
      "r1212"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "abvc_AccruedDirectorAndOfficerCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AccruedDirectorAndOfficerCompensation",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued directors and officers (owners) compensation",
        "documentation": "The amouont of accrued director and officer compensation.",
        "label": "Accrued Director And Officer Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedEmployeeBenefitsCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock-based compensation expenses",
        "label": "Accrued Employee Benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AccruedResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AccruedResearchAndDevelopmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable",
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expense",
        "documentation": "Accrued research and development expense.",
        "label": "Accrued Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalties",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r867"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued directors and officers (owners) compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r867"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r192",
      "r687"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r71",
      "r201",
      "r681",
      "r713",
      "r717",
      "r1172"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r18",
      "r556",
      "r559",
      "r613",
      "r708",
      "r709",
      "r1010",
      "r1011",
      "r1012",
      "r1075",
      "r1076",
      "r1077",
      "r1080"
     ]
    },
    "abvc_AcquisitionForNetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AcquisitionForNetSales",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/AcquisitionDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales (in Dollars)",
        "verboseLabel": "Net sales on acquisition",
        "documentation": "The amount of acquisition for net sales.",
        "label": "Acquisition For Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AddLessAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AddLessAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add (Less):",
        "label": "Add Less Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AdditionCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AdditionCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Addition cash payment",
        "documentation": "The amount of addition cash payment.",
        "label": "Addition Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AdditionalMilestonePaymentInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AdditionalMilestonePaymentInCash",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone payment in cash",
        "documentation": "Additional milestone payment in cash.",
        "label": "Additional Milestone Payment In Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r945",
      "r1249"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r1075",
      "r1076",
      "r1077",
      "r1080",
      "r1173",
      "r1252"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount recognized from Issuance of subsidiary's convertible note",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r100",
      "r515"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquiring control of the land",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in ownership of subsidiary due to share issuance",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r100"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of pre-funded warrant in connection to the 3rd Lind Note",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r39",
      "r100"
     ]
    },
    "abvc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWithConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issued with convertible notes payable",
        "documentation": "Represents the amount of warrant issued with convertible notes payable.",
        "label": "Adjustments To Additional Paid In Capital Warrant Issued With Convertible Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AdvisorsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AdvisorsOneMember",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advisors One [Member]",
        "label": "Advisors One Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AdvisorsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AdvisorsTwoMember",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advisors Two [Member]",
        "label": "Advisors Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AggregateCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AggregateCommonStockShares",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate common stock",
        "documentation": "Aggregate common stock shares.",
        "label": "Aggregate Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AiBtlBioPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AiBtlBioPharmaIncMember",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AiBtl BioPharma, Inc [Member]",
        "label": "Ai Btl Bio Pharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AiBtlHoldingBioPharmaIncAiBtlHoldingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AiBtlHoldingBioPharmaIncAiBtlHoldingMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AiBtl (Holding) BioPharma, Inc. (\u201cAiBtl Holding\u201d) [Member]",
        "label": "Ai Btl Holding Bio Pharma Inc Ai Btl Holding Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AiBtlHoldingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AiBtlHoldingMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AiBtl Holding [Member]",
        "verboseLabel": "AiBtl [Member]",
        "label": "Ai Btl Holding Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0",
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-compensation expense",
        "netLabel": "Non-employee stock-based compensation expense",
        "label": "Share-based compensation expenses (in Dollars)",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r483",
      "r492"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-compensation expense",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for expected credit losses accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r313",
      "r324",
      "r325",
      "r327",
      "r1212"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debit discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r82",
      "r381",
      "r1184"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "abvc_AsRestatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AsRestatedMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "As restated [Member]",
        "label": "As Restated Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://metuboutique.com/role/Acquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACQUISITION",
        "label": "Asset Acquisition [Text Block]",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r1171"
     ]
    },
    "abvc_AssetConsiderationCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AssetConsiderationCommonStock",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset consideration common stock",
        "documentation": "Asset consideration common stock.",
        "label": "Asset Consideration Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "terseLabel": "Total Assets",
        "verboseLabel": "Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r128",
      "r194",
      "r231",
      "r234",
      "r235",
      "r277",
      "r288",
      "r305",
      "r306",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r539",
      "r543",
      "r577",
      "r668",
      "r669",
      "r675",
      "r781",
      "r883",
      "r884",
      "r893",
      "r945",
      "r961",
      "r962",
      "r974",
      "r1122",
      "r1123",
      "r1196"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_AssetsAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AssetsAbstract0",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "terseLabel": "Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r204",
      "r231",
      "r234",
      "r235",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r539",
      "r543",
      "r577",
      "r945",
      "r1122",
      "r1123",
      "r1196"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current Assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r234",
      "r235",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r539",
      "r543",
      "r577",
      "r1122",
      "r1123",
      "r1196"
     ]
    },
    "abvc_AverageIssuancePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "AverageIssuancePricePerShare",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average issuance price per share (in Dollars per share)",
        "documentation": "Represent the average issuance price per share.",
        "label": "Average Issuance Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BHKCoDevelopmentAggreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BHKCoDevelopmentAggreementMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BHK Co Development Agreement [Member]",
        "verboseLabel": "BHK Co Development Aggreement [Member]",
        "label": "BHKCo Development Aggreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BHKCoDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BHKCoDevelopmentAgreementMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BHK Co-Development Agreement [Member]",
        "label": "BHKCo Development Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "abvc_BenefitsReceivableForMilestoneAttained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BenefitsReceivableForMilestoneAttained",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/AcquisitionDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eligible to receive amount (in Dollars)",
        "verboseLabel": "Eligible to receive amount",
        "documentation": "Amount receivable for certain milestone are met  and eligible to receive.",
        "label": "Benefits Receivable For Milestone Attained"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioFirstAustraliaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioFirstAustraliaMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioFirst (Australia) [Member]",
        "label": "Bio First Australia Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioFirst (Australia) Pty Ltd. (the \u201cBioFirst (Australia)\u201d) [Member]",
        "label": "Bio First Australia Pty Ltdthe Bio First Australia Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioFirstCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioFirstCorporationMember",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioFirst Corporation [Member]",
        "label": "Bio First Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioFirstCorporationtheBioFirstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioFirstCorporationtheBioFirstMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioFirst Corporation (the \u201cBioFirst\u201d) [Member]",
        "verboseLabel": "BioFirst Corporation (the \"BioFirst\") [Member]",
        "label": "Bio First Corporationthe Bio First Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioFirstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioFirstMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable",
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0",
      "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioFirst [Member]",
        "label": "Bio First Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioFirstReceivesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioFirstReceivesMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioFirst Receives [Member]",
        "label": "Bio First Receives Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioFirstStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioFirstStockPurchaseAgreementMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioFirst Stock Purchase Agreement [Member]",
        "verboseLabel": "BioFirst Corporation Purchase Agreement [Member]",
        "label": "Bio First Stock Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioHopeKingCorporationBHKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioHopeKingCorporationBHKMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioHopeKing Corporation (\u201cBHK\u201d) [Member]",
        "label": "Bio Hope King Corporation BHKMember"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioHopeKingCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioHopeKingCorporationMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioHopeKing Corporation [Member]",
        "label": "Bio Hope King Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioLiteBVIIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioLiteBVIIncMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioLite BVI, Inc. [Member]",
        "verboseLabel": "BioLite BVI Inc [Member]",
        "label": "Bio Lite BVIInc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioLiteJPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioLiteJPMember",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioLite JP [Member]",
        "label": "Bio Lite JPMember"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioLiteJapanKKBioLiteJPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioLiteJapanKKBioLiteJPMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioLite Japan K.K. (BioLite JP) [Member]",
        "label": "Bio Lite Japan KKBio Lite JPMember"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioLiteJapanKKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioLiteJapanKKMember",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioLite Japan K.K. [Member]",
        "label": "Bio Lite Japan KKMember"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioLiteJapanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioLiteJapanMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioLite Japan [Member]",
        "label": "Bio Lite Japan Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BioLiteTaiwanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BioLiteTaiwanMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioLite Taiwan [Member]",
        "label": "Bio Lite Taiwan Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_BraingenesisBiotechnologyCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BraingenesisBiotechnologyCoLtdMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Braingenesis Biotechnology Co., Ltd. [Member]",
        "label": "Braingenesis Biotechnology Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and leasehold improvements [Member]",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and leasehold improvements [Member]",
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock consideration",
        "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Asset, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in value of asset in contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r1063"
     ]
    },
    "abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expense",
        "documentation": "Accrued expense.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expense And Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets acquired",
        "label": "Business Combination, Recognized Asset Acquired, Asset",
        "documentation": "Amount of asset acquired in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Acquisition was Accounted for Business Combination [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent acquired in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due to Director",
        "label": "Business Combination, Recognized Liability Assumed, Long-Term Debt, Current",
        "documentation": "Amount of long-term debt assumed in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities acquired",
        "label": "Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)",
        "documentation": "Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r906",
      "r1169",
      "r1170"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration (Intangible assets)",
        "label": "Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill",
        "documentation": "Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1066"
     ]
    },
    "abvc_CTBCBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CTBCBankMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CTBC Bank [Member]",
        "label": "CTBCBank Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CTBCLoanAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CTBCLoanAgreementsMember",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CTBC Loan Agreements [Member]",
        "label": "CTBCLoan Agreements Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received",
        "verboseLabel": "Cash of purchase agreements (in Dollars)",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r678",
      "r749",
      "r774",
      "r945",
      "r961",
      "r962",
      "r974",
      "r1003"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r189",
      "r865"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r107"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning",
        "periodEndLabel": "Ending",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r88",
      "r228"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r88"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash equivalent",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1209"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash financing and investing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CashPaidDuringTheYearForAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CashPaidDuringTheYearForAbstract0",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid during the year for:",
        "label": "Cash Paid During The Year For Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CashPaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CashPaidMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Paid [Member]",
        "label": "Cash Paid Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CashPortionOfTheLindNoteRepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CashPortionOfTheLindNoteRepayments",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash portion of the Lind Note repayments",
        "documentation": "The amount of cash portion of the Lind Note repayments.",
        "label": "Cash Portion Of The Lind Note Repayments"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CathayUnitedBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CathayUnitedBankMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cathay United Bank [Member]",
        "label": "Cathay United Bank Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CathayUnitedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CathayUnitedLoanAgreementMember",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cathay United Loan Agreement [Member]",
        "label": "Cathay United Loan Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ChiefStrategicOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ChiefStrategicOfficerMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Strategic Officer [Member]",
        "label": "Chief Strategic Officer Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r197",
      "r198",
      "r199",
      "r231",
      "r235",
      "r265",
      "r266",
      "r269",
      "r271",
      "r280",
      "r281",
      "r319",
      "r350",
      "r352",
      "r353",
      "r354",
      "r357",
      "r358",
      "r390",
      "r391",
      "r393",
      "r394",
      "r396",
      "r399",
      "r402",
      "r403",
      "r407",
      "r410",
      "r417",
      "r577",
      "r726",
      "r727",
      "r728",
      "r729",
      "r737",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r750",
      "r766",
      "r789",
      "r812",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r977",
      "r1069",
      "r1071",
      "r1081"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r280",
      "r393",
      "r402",
      "r403",
      "r405",
      "r407",
      "r410",
      "r415",
      "r417",
      "r552",
      "r726",
      "r727",
      "r728",
      "r729",
      "r894",
      "r977",
      "r1067",
      "r1069"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial exercise price (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "netLabel": "Warrant exercise price current",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r237",
      "r418"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Issued and Outstanding [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares exercised",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of warrant (in Shares)",
        "verboseLabel": "Warrant to purchase",
        "netLabel": "Warrants to purchase",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "abvc_ClientMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ClientMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Client [Member]",
        "label": "Client Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CodevelopmentagreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CodevelopmentagreementMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Co-Dev Agreement [Member]",
        "label": "Codevelopmentagreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CollaborativeAgreementWithForSeeConEyeCorporationMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement with ForSeeCon Eye Corporation [Member]",
        "label": "Collaborative Agreement With For See Con Eye Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CollaborativeAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CollaborativeAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_CollaborativeAgreementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CollaborativeAgreementsDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Agreements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COLLABORATIVE AGREEMENTS",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r535",
      "r536"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Agreement [Member]",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Agreements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r114",
      "r677",
      "r765"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://metuboutique.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r342",
      "r343",
      "r847",
      "r1114",
      "r1119"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r848"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares (in Shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConvertibleConversionPriceIncrease",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock at an initial conversion price (in Dollars per share)",
        "label": "Common Stock, Convertible, Conversion Price, Increase",
        "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/StockOptionsDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock Number of shares",
        "netLabel": "Common Stock Amounts",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1075",
      "r1076",
      "r1080",
      "r1173",
      "r1247",
      "r1252"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common stock per share (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r766"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Ordinary shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "abvc_CommonStockSharesIssuedForRent": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "CommonStockSharesIssuedForRent",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued for rent",
        "documentation": "Number of shares issued for rent.",
        "label": "Common Stock Shares Issued For Rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Ordinary shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r65",
      "r766",
      "r787",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r391",
      "r398",
      "r680",
      "r945"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets (Liability) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax (Benefit) Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r206",
      "r208",
      "r214",
      "r666",
      "r695",
      "r696"
     ]
    },
    "abvc_ConcentrationOfClientsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConcentrationOfClientsPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Clients",
        "documentation": "Disclosure of accounting policy for concentration of clients.",
        "label": "Concentration Of Clients Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r311",
      "r721",
      "r722",
      "r846",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r311",
      "r721",
      "r722",
      "r846",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r311",
      "r721",
      "r722",
      "r846",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of clients rate",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r311",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r311",
      "r721",
      "r722",
      "r846",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "srt_CondensedBalanceSheetStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedBalanceSheetStatementTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheet Statement [Table]",
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r232",
      "r241",
      "r672",
      "r982"
     ]
    },
    "srt_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Balance Sheet [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r232",
      "r241",
      "r672",
      "r982"
     ]
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Schedule of Impact of the Restatement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r172",
      "r173",
      "r174",
      "r184",
      "r185",
      "r982",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Statement of Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r232",
      "r241",
      "r672",
      "r982"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedStatementOfComprehensiveIncomeTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statement of Comprehensive Income [Table]",
        "documentation": "Disclosure of information about condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r232",
      "r241",
      "r672",
      "r982"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Statements of Operations",
        "label": "Condensed Statement of Comprehensive Income [Table Text Block]",
        "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "abvc_ConsecutiveDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConsecutiveDays",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive days",
        "documentation": "Consecutive days.",
        "label": "Consecutive Days"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration",
        "documentation": "The consideration amount.",
        "label": "Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ConsiderationPaidForAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConsiderationPaidForAgreement",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration paid",
        "documentation": "Consideration paid.",
        "label": "Consideration Paid For Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Construction-in-Progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in Progress [Member]",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConsultantMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consultant [Member]",
        "label": "Consultant Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ConsultingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConsultingFee",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting fee (in Dollars)",
        "documentation": "The amount of  consulting fee .",
        "label": "Consulting Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r434"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized revenue",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r434"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing agreement",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "abvc_ConversionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConversionMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion [Member]",
        "label": "Conversion Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted shares",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued on conversion",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loan",
        "label": "Convertible Debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r113",
      "r1208"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt [Member]",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r360",
      "r361",
      "r371",
      "r372",
      "r373",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Amounts of the Liability Component",
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ConvertibleLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConvertibleLoanAgreementMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Loan Agreement [Member]",
        "label": "Convertible Loan Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable \u2013 third parties, net",
        "verboseLabel": "Principal amount",
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r113",
      "r1208"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable \u2013 third parties, net",
        "label": "Convertible Notes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "abvc_ConvertibleNotesPayableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConvertibleNotesPayableDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Payable [Member]",
        "verboseLabel": "Lind Note [Member]",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r111"
     ]
    },
    "abvc_ConvertibleNotesPayablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConvertibleNotesPayablePolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Payable",
        "documentation": "Disclosure of accounting policy for convertible notes payable.",
        "label": "Convertible Notes Payable Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ConvertibleNotesPayableScheduleofCarryingAmountsoftheLiabilityComponentDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable - Schedule of Carrying Amounts of the Liability Component (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing rights",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r629",
      "r869",
      "r874",
      "r938",
      "r1053"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable",
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenues",
        "verboseLabel": "Cost of Revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r231",
      "r234",
      "r235",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r577",
      "r883",
      "r1122"
     ]
    },
    "us-gaap_CreditDerivativeTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditDerivativeTerm1",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant term",
        "label": "Credit Derivative, Term",
        "documentation": "Term of the credit risk derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative transaction adjustments",
        "label": "Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)",
        "documentation": "The increase (decrease) in cumulative translation adjustment before transfers included in determining net income."
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1067",
      "r1073",
      "r1164"
     ]
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1067",
      "r1073"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r1067",
      "r1073"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1067",
      "r1073",
      "r1164"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r1085"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible note due from related parties to equity investment",
        "verboseLabel": "Principal amount of converted debt (in Dollars)",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r28"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of debt",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r28"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued (in Shares)",
        "verboseLabel": "Warrants issued",
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r28"
     ]
    },
    "us-gaap_DebtConversionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionLineItems",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of converted debt",
        "label": "Debt Conversion, Original Debt, Amount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r28"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE NOTES PAYABLE",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r231",
      "r233",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r348",
      "r349",
      "r359",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r375",
      "r382",
      "r383",
      "r385",
      "r552",
      "r592"
     ]
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Annual Principal Payment",
        "documentation": "Amount of annual principal payment for debt instrument."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r54",
      "r55",
      "r111",
      "r113",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r943",
      "r1067",
      "r1068",
      "r1070",
      "r1074",
      "r1115",
      "r1116",
      "r1117",
      "r1183",
      "r1185",
      "r1206"
     ]
    },
    "abvc_DebtInstrumentCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DebtInstrumentCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value",
        "documentation": "The amount of carrying value.",
        "label": "Debt Instrument Carrying Value"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_DebtInstrumentCommonStockToBeConverted": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DebtInstrumentCommonStockToBeConverted",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock to be converted",
        "documentation": "Description of common stock to be converted.",
        "label": "Debt Instrument Common Stock To Be Converted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Price (in Dollars per share)",
        "verboseLabel": "Conversion price per share (in Dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r362"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount of the stock price percentage",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r592",
      "r593",
      "r889",
      "r890",
      "r943"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r571",
      "r572",
      "r573",
      "r576",
      "r889",
      "r890",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1070"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Interest Rate",
        "verboseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r386",
      "r592",
      "r593",
      "r943"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated Interest Rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r361"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan agreement, description",
        "label": "Debt Instrument, Interest Rate Terms",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_DebtInstrumentIssuanceDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIssuanceDate1",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance Date",
        "label": "Debt Instrument, Issuance Date",
        "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r1124"
     ]
    },
    "abvc_DebtInstrumentIssuanceEntity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DebtInstrumentIssuanceEntity",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance Entity",
        "documentation": "Description of issuance entity.",
        "label": "Debt Instrument Issuance Entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Amount at Issuance",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Carrying Amounts of the Liability Component [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r552",
      "r672",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r943",
      "r1067",
      "r1068",
      "r1070",
      "r1074",
      "r1183",
      "r1185"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity Date",
        "verboseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r888",
      "r1177",
      "r1178"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r943",
      "r1067",
      "r1068",
      "r1070",
      "r1074",
      "r1115",
      "r1116",
      "r1117",
      "r1183",
      "r1185",
      "r1206"
     ]
    },
    "abvc_DebtInstrumentOutstandingPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DebtInstrumentOutstandingPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding principal",
        "documentation": "Amount of outstanding principal.",
        "label": "Debt Instrument Outstanding Principal"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_DebtInstrumentPrincipalAmountAtBalanceSheetDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DebtInstrumentPrincipalAmountAtBalanceSheetDate",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Amount at Balance Sheet Date",
        "documentation": "The amount of principal amount at balance sheet date.",
        "label": "Debt Instrument Principal Amount At Balance Sheet Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of principal amount",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity term period",
        "verboseLabel": "Debt instrument term",
        "netLabel": "Purchase warrant term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized Discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1125",
      "r1182",
      "r1183",
      "r1185"
     ]
    },
    "us-gaap_DebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-marketable Cost Method Investments, net",
        "label": "Debt Securities, Noncurrent",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_DecemberLetterAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DecemberLetterAgreementMember",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Letter Agreement [Member]",
        "label": "December Letter Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualExercisePrice",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Deferred Compensation Arrangement with Individual, Exercise Price",
        "documentation": "The per share price that the individual must pay to acquire shares under the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1073",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1073",
      "r1163"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Deferred",
        "terseLabel": "Deferred tax expense",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r137",
      "r1067",
      "r1073"
     ]
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenueRevenueRecognized1",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized revenue",
        "label": "Deferred Revenue, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1073",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable",
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, Gross",
        "verboseLabel": "Deferred tax assets, gross",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable",
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "abvc_DeferredTaxAssetsOperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DeferredTaxAssetsOperatingLeaseAssets",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable",
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating lease assets",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to operating lease assets.",
        "label": "Deferred Tax Assets Operating Lease Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable",
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable",
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on impairment of Assets",
        "negatedTerseLabel": "Loss on impairment of assets",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation of property",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable",
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "abvc_DefinedBenefitPlanFundedPercentages": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DefinedBenefitPlanFundedPercentages",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit percentage",
        "documentation": "Percentage of plan assets to benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan Funded Percentages"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanServiceCost",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting services for rent",
        "label": "Defined Benefit Plan, Service Cost",
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r439",
      "r442",
      "r899",
      "r900"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly contribution of employees salaries",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositLiabilitiesAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositLiabilitiesAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest amount",
        "label": "Deposit Liabilities, Accrued Interest",
        "documentation": "Amount of accrued but unpaid interest on deposit liabilities."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable",
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "netLabel": "Depreciation expenses",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r36",
      "r221",
      "r868",
      "r869",
      "r871",
      "r873"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r240",
      "r259",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r554"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1095",
      "r1248"
     ]
    },
    "abvc_DirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DirectorsMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "label": "Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://metuboutique.com/role/StockOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK OPTIONS",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r448",
      "r479",
      "r480",
      "r481",
      "r902"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]",
        "terseLabel": "Net loss per share:",
        "verboseLabel": "Loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, Basic (in Dollars per share)",
        "verboseLabel": "Basic net loss per common share (in Dollars per share)",
        "netLabel": "Basic",
        "label": "Basic and diluted net loss per common share (in Dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r215",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r256",
      "r262",
      "r265",
      "r269",
      "r270",
      "r271",
      "r276",
      "r389",
      "r482",
      "r527",
      "r534",
      "r568",
      "r569",
      "r667",
      "r697",
      "r875"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, Diluted (in Dollars per share)",
        "verboseLabel": "Diluted net loss per common share (in Dollars per share)",
        "netLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r215",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r256",
      "r265",
      "r269",
      "r270",
      "r271",
      "r276",
      "r389",
      "r482",
      "r527",
      "r534",
      "r568",
      "r569",
      "r667",
      "r697",
      "r875"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share of Common Stock",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r273"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r272",
      "r274",
      "r275"
     ]
    },
    "abvc_EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "EffectOfExchangeRateChangeOnCashAndCashEquivalentsAndRestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents and restricted cash",
        "documentation": "Effect of exchange rate changes on cash and cash equivalents and restricted cash.",
        "label": "Effect Of Exchange Rate Change On Cash And Cash Equivalents And Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock-based compensation expense",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable",
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/StockOptionsDetails",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r179",
      "r181",
      "r182",
      "r210",
      "r211",
      "r212",
      "r242",
      "r243",
      "r244",
      "r246",
      "r254",
      "r257",
      "r259",
      "r279",
      "r320",
      "r323",
      "r336",
      "r388",
      "r419",
      "r482",
      "r516",
      "r517",
      "r524",
      "r525",
      "r526",
      "r528",
      "r533",
      "r534",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r594",
      "r597",
      "r613",
      "r694",
      "r708",
      "r709",
      "r710",
      "r737",
      "r812"
     ]
    },
    "abvc_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r523",
      "r577",
      "r979",
      "r980",
      "r981",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_EquityMethodInvestmentAdditionalInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentAdditionalInformation",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting treatments",
        "label": "Equity Method Investment, Additional Information",
        "documentation": "This serves as a place to record data that is not required by accounting literature but is useful for readers of the financial statements as it relates to the details of an equity method investment in common stock. Such information may include the amount of change for a change in ownership (equity) percentage in a given period and the amount and type of the consideration given or received in relation to the change in ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "verboseLabel": "Percentage of note fully converted",
        "netLabel": "Ownership Percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r577"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable",
      "http://metuboutique.com/role/ScheduleofComponentsofLossonInvestmentinEquitySecuritiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of equity method investee losses",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r296",
      "r306",
      "r314",
      "r1004",
      "r1101"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Loss on Investment in Equity Securities [Abstract]",
        "terseLabel": "Equity Method Investments, net"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_EquityMethodInvestmentsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "EquityMethodInvestmentsNetAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments, net",
        "label": "Equity Method Investments Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_EquityMethodInvestmentsOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "EquityMethodInvestmentsOwnershipPercentage",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "documentation": "Represent the percent value of equity method investments ownership percentage.",
        "label": "Equity Method Investments Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Equity Investment",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r317",
      "r577"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Loss on Investment in Equity Securities",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "abvc_EquityMethodLongTermInvestment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "EquityMethodLongTermInvestment",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method long term investment (in Shares)",
        "documentation": "Equity method long term investment.",
        "label": "Equity Method Long Term Investment"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_EuroAsiaInvestmentFinanceCorpLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "EuroAsiaInvestmentFinanceCorpLtdMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euro-Asia Investment &amp; Finance Corp Ltd. [Member]",
        "label": "Euro Asia Investment Finance Corp Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ExistingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ExistingWarrantsMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Existing Warrants [Member]",
        "label": "Existing Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_FEYEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "FEYEMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FEYE [Member]",
        "label": "FEYEMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of warrants",
        "verboseLabel": "Fair value of the warrants (in Dollars)",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquiring control of the land",
        "verboseLabel": "Value of acquired amount",
        "label": "Fair Value of Assets Acquired",
        "documentation": "The fair value of assets acquired in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_FederalHomeLoanBankAdvancesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalHomeLoanBankAdvancesLineItems",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Loans [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r630",
      "r631",
      "r720",
      "r860",
      "r864",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r720",
      "r860",
      "r864",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "abvc_FirstLINDNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "FirstLINDNoteMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1st LIND Note [Member]",
        "label": "First LINDNote Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ForSeeConEyeCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ForSeeConEyeCorporationMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ForSeeCon Eye Corporation [Member]",
        "label": "For See Con Eye Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on foreign exchange changes",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r579",
      "r580",
      "r581",
      "r582",
      "r809"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign-currency Transactions",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on investment in equity securities",
        "negatedLabel": "Loss on investment in equity securities",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83",
      "r976"
     ]
    },
    "abvc_GenePharmIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "GenePharmIncMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GenePharm Inc. [Member]",
        "label": "Gene Pharm Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_GenePharmInctheGenePharmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "GenePharmInctheGenePharmMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GenePharm Inc. (the \u201cGenePharm\u201d) [Member]",
        "label": "Gene Pharm Incthe Gene Pharm Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_GenepharmBiotechCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "GenepharmBiotechCorporationMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genepharm Biotech Corporation [Member]",
        "label": "Genepharm Biotech Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralPartnersCapitalAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralPartnersCapitalAccount",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market capitalization",
        "label": "General Partners' Capital Account",
        "documentation": "The amount of the general partner's ownership interest."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0",
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable",
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0",
      "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross (loss) profit",
        "terseLabel": "Gross Profit",
        "verboseLabel": "Segment Gross Profit (Loss)",
        "netLabel": "Gross profit (loss)",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r77",
      "r127",
      "r231",
      "r234",
      "r235",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r577",
      "r879",
      "r883",
      "r1083",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1122"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r94"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before provision income tax",
        "terseLabel": "Net loss",
        "verboseLabel": "Loss before provision for income tax",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r121",
      "r127",
      "r668",
      "r670",
      "r690",
      "r870",
      "r872",
      "r874",
      "r879",
      "r883",
      "r1083",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of losses from investments accounted for using the equity method",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r74",
      "r120",
      "r277",
      "r293",
      "r306",
      "r314",
      "r689"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://metuboutique.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r236",
      "r497",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r510",
      "r518",
      "r520",
      "r521",
      "r522",
      "r674",
      "r719",
      "r731",
      "r904"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/IncomeTaxesDetails",
      "http://metuboutique.com/role/ScheduleofIncomeTaxBenefitExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total provision for income tax (benefit) expense",
        "terseLabel": "Provision for income tax expense",
        "verboseLabel": "Income tax (benefit) expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r138",
      "r231",
      "r258",
      "r259",
      "r277",
      "r294",
      "r306",
      "r500",
      "r501",
      "r519",
      "r698",
      "r870",
      "r872",
      "r874",
      "r904"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r498",
      "r499",
      "r505",
      "r506",
      "r509",
      "r513",
      "r725"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r227",
      "r511",
      "r512"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payables",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r1063"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due from related parties",
        "label": "Increase (Decrease) in Due from Related Parties",
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Increase (Decrease) in Due to Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r989",
      "r1063"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets \u2013 tenant security deposit",
        "label": "Increase (Decrease) in Security Deposits",
        "documentation": "The increase (decrease) during the reporting period in security deposits."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expenses",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r288",
      "r292",
      "r295",
      "r306",
      "r591",
      "r883",
      "r884",
      "r1251"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "verboseLabel": "Interest expenses for loan",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r379",
      "r387",
      "r891",
      "r892",
      "r1251"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 7.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r870",
      "r874",
      "r1015"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expenses",
        "verboseLabel": "Interest expense other",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseShortTermBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expenses",
        "label": "Interest Expense, Short-Term Borrowings",
        "documentation": "The aggregate interest expense incurred on short-term borrowings including commercial paper and Federal funds purchased and securities sold under agreements to repurchase."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r141",
      "r142"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r225",
      "r226"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r866",
      "r945"
     ]
    },
    "us-gaap_InvestmentCompanyExcessExpenseReimbursable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentCompanyExcessExpenseReimbursable",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash investments limit",
        "label": "Investment Company, Reimbursable Excess Expense",
        "documentation": "Amount of carryover of excess expense potentially reimbursable to adviser but not recorded as liability by investment company."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r291",
      "r306",
      "r883",
      "r1014"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Owned shares",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r755",
      "r822",
      "r828",
      "r831",
      "r966"
     ]
    },
    "us-gaap_InvestmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Investment",
        "label": "Investment [Table Text Block]",
        "documentation": "Tabular disclosure of investment."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r1100"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONG-TERM INVESTMENTS",
        "label": "Investment [Text Block]",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r1100"
     ]
    },
    "abvc_IssuanceOfCommonShareForLindCNRepayment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "IssuanceOfCommonShareForLindCNRepayment",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for Lind CN Repayment (in Shares)",
        "documentation": "Issuance of common shares for Lind CN repayment.",
        "label": "Issuance Of Common Share For Lind CNRepayment"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_IssuanceOfCommonStockForConversionOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "IssuanceOfCommonStockForConversionOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for conversion of debt",
        "documentation": "Issuance of common stock for conversion of debt.",
        "label": "Issuance Of Common Stock For Conversion Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_IssuanceOfStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "IssuanceOfStockValue",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash amount",
        "documentation": "The value of Common stock newly issued. for example : newly issued shares means any common shares issued pursuant to the primary share purchases.",
        "label": "Issuance Of Stock Value"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_IssuanceOfSubsidiarysCommonStockForConsultingServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "IssuanceOfSubsidiarysCommonStockForConsultingServices",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of subsidiary\u2019s common stock for consulting services",
        "documentation": "Amount of issuance of subsidiary\u2019s common stock for consulting services.",
        "label": "Issuance Of Subsidiarys Common Stock For Consulting Services"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_JaimesVargasRussmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "JaimesVargasRussmanMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jaimes Vargas Russman [Member]",
        "label": "Jaimes Vargas Russman Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_JiangsAdvancedFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "JiangsAdvancedFundsMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiangs Advanced Funds [Member]",
        "label": "Jiangs Advanced Funds Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LaborPensionFundPerMonth": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LaborPensionFundPerMonth",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Labor pension fund per month",
        "documentation": "Labor pension fund per month.",
        "label": "Labor Pension Fund Per Month"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Land": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Land",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land (in Dollars)",
        "label": "Land",
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_LandAndLandImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandAndLandImprovements",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land with book value",
        "label": "Land and Land Improvements",
        "documentation": "Amount before accumulated depreciation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land [Member]",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Lease Expenses",
        "verboseLabel": "Schedule of Lease",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1187"
     ]
    },
    "abvc_LeaseScheduleofCompanysLeaseExpensesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LeaseScheduleofCompanysLeaseExpensesDetailsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Lease Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LeaseScheduleofCompanysLeaseExpensesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LeaseScheduleofCompanysLeaseExpensesDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease - Schedule of Company\u2019s Lease Expenses (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesOperatingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Leases have Remaining Lease Terms [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LessAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LessAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Less Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1188"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable",
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments, undiscounted",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable",
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable",
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable",
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "verboseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable",
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "verboseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable",
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (Excluding current period)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1188"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable",
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://metuboutique.com/role/Lease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASE",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "terseLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r54",
      "r55",
      "r56",
      "r60",
      "r61",
      "r62",
      "r63",
      "r231",
      "r234",
      "r235",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r540",
      "r543",
      "r544",
      "r577",
      "r764",
      "r878",
      "r893",
      "r974",
      "r1122",
      "r1196",
      "r1197"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLeaseTable",
      "http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "verboseLabel": "LIABILITIES",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Equity",
        "terseLabel": "Total Liabilities and Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r116",
      "r684",
      "r945",
      "r961",
      "r962",
      "r1067",
      "r1072",
      "r1102",
      "r1180"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "terseLabel": "Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r188",
      "r231",
      "r234",
      "r235",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r540",
      "r543",
      "r544",
      "r577",
      "r945",
      "r1122",
      "r1196",
      "r1197"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r60",
      "r61",
      "r62",
      "r63",
      "r231",
      "r234",
      "r235",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r540",
      "r543",
      "r544",
      "r577",
      "r1122",
      "r1196",
      "r1197"
     ]
    },
    "abvc_LicensingAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LicensingAgreement",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing agreement",
        "documentation": "The amount of licensing Agreement.",
        "label": "Licensing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LicensingAgreementMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing Agreement [Member]",
        "label": "Licensing Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LicensingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LicensingFees",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing fees",
        "documentation": "Amount licensing fee.",
        "label": "Licensing Fees"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LindGlobalFundIILPLindMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LindGlobalFundIILPLindMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lind Global Fund II, LP (\u201cLind\u201d) [Member]",
        "label": "Lind Global Fund IILPLind Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LindGlobalFundIILPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LindGlobalFundIILPMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lind Global Fund II, LP [Member]",
        "label": "Lind Global Fund IILPMember"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LindMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LindMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lind [Member]",
        "label": "Lind Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LindNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LindNoteMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lind Note [Member]",
        "label": "Lind Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LindNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LindNotesMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lind Notes [Member]",
        "label": "Lind Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LindNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LindNotesPayableMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lind Notes Payable [Member]",
        "label": "Lind Notes Payable Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LindOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LindOfferingsMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lind Offerings [Member]",
        "label": "Lind Offerings Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LindWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LindWarrantMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lind Warrant [Member]",
        "label": "Lind Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit limit amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r59"
     ]
    },
    "abvc_LionArtPromotionIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LionArtPromotionIncMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lion Art Promotion Inc [Member]",
        "label": "Lion Art Promotion Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LionArtsPromotionIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LionArtsPromotionIncMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lion Arts Promotion, Inc. [Member]",
        "label": "Lion Arts Promotion Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LiquidityGoingConcernAndRestatementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LiquidityGoingConcernAndRestatementTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIQUIDITY, GOING CONCERN, AND RESTATEMENT",
        "documentation": "Disclosure of liquidity, going concern, and restatement.",
        "label": "Liquidity Going Concern And Restatement Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LiquidityGoingConcernandRestatementDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LiquidityGoingConcernandRestatementDetailsLineItems",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity, Going Concern, and Restatement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LiquidityGoingConcernandRestatementDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LiquidityGoingConcernandRestatementDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity, Going Concern, and Restatement (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LoanAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LoanAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan agreement amount",
        "documentation": "The amount of loan agreement amount.",
        "label": "Loan Agreement Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Agreement [Member]",
        "label": "Loan Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amount",
        "verboseLabel": "Loan repaid",
        "label": "Loans Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r113",
      "r1208"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "verboseLabel": "Equity Method Investments, net",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LongTermInvestmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LongTermInvestmentsDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LongTermInvestmentsScheduleofExtenttheInvesteeReliesDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments - Schedule of Extent the Investee Relies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LongTermInvestmentsScheduleofLongTermInvestmentDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments - Schedule of Long-Term Investment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Investment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentMilestones": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentMilestones",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of collaborative agreements",
        "label": "Long-Term Purchase Commitment, Milestones",
        "documentation": "Discloses the nature of achievements or target goals that are to be reached by specified dates to maintain the arrangement or extend it, generally without adjustment of the present financial terms of the arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_LucidaimCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "LucidaimCoLtdMember",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lucidaim Co Ltd [Member]",
        "label": "Lucidaim Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment [Member]",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r895",
      "r898",
      "r955",
      "r959",
      "r1213",
      "r1214",
      "r1215",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1245",
      "r1246"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r148",
      "r149",
      "r151",
      "r168",
      "r170",
      "r171",
      "r177",
      "r178",
      "r287",
      "r344",
      "r345",
      "r346",
      "r347",
      "r443",
      "r474",
      "r475",
      "r476",
      "r494",
      "r570",
      "r627",
      "r706",
      "r707",
      "r718",
      "r756",
      "r757",
      "r821",
      "r824",
      "r826",
      "r827",
      "r830",
      "r840",
      "r841",
      "r843",
      "r844",
      "r858",
      "r859",
      "r887",
      "r894",
      "r901",
      "r905",
      "r907",
      "r908",
      "r939",
      "r940",
      "r941",
      "r942",
      "r956",
      "r1124",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203"
     ]
    },
    "abvc_MilestonePaymentsRoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "MilestonePaymentsRoyaltyPercentage",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty percentage",
        "documentation": "Milestone payments royalty percentage.",
        "label": "Milestone Payments Royalty Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_MilestoneRegulatoryPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "MilestoneRegulatoryPaymentAmount",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone regulatory payment amount",
        "documentation": "Represent the amount of milestone regulatory payment.",
        "label": "Milestone Regulatory Payment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_MilestoneRegulatoryPaymentAmountPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "MilestoneRegulatoryPaymentAmountPeriod",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone regulatory payment amount period",
        "documentation": "Milestone Regulatory Payment Amount Period.",
        "label": "Milestone Regulatory Payment Amount Period"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r148",
      "r149",
      "r151",
      "r168",
      "r170",
      "r171",
      "r177",
      "r178",
      "r287",
      "r344",
      "r345",
      "r346",
      "r347",
      "r443",
      "r474",
      "r475",
      "r476",
      "r494",
      "r570",
      "r627",
      "r706",
      "r707",
      "r718",
      "r756",
      "r757",
      "r821",
      "r824",
      "r826",
      "r827",
      "r830",
      "r840",
      "r841",
      "r843",
      "r844",
      "r858",
      "r859",
      "r887",
      "r894",
      "r901",
      "r905",
      "r907",
      "r908",
      "r939",
      "r940",
      "r941",
      "r956",
      "r1124",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r115",
      "r231",
      "r234",
      "r235",
      "r319",
      "r350",
      "r352",
      "r353",
      "r354",
      "r357",
      "r358",
      "r683",
      "r768",
      "r1180"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of subsidiary interest in noncontrolling interests",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary ownership percentage",
        "verboseLabel": "Percentage of ownership",
        "netLabel": "Ownership percentage",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r895",
      "r898",
      "r955",
      "r959",
      "r1213",
      "r1214",
      "r1215",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "terseLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Continuing Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity attributable to continuing operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash used in operating activities",
        "verboseLabel": "Cash outflows from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Continuing Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity attributable to continuing operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable0",
      "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributed to ABVC and subsidiaries",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss attributable to ABVC\u2019s common stockholders",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r90",
      "r122",
      "r182",
      "r186",
      "r205",
      "r207",
      "r212",
      "r231",
      "r234",
      "r235",
      "r239",
      "r245",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r258",
      "r259",
      "r267",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r389",
      "r392",
      "r395",
      "r400",
      "r482",
      "r527",
      "r534",
      "r569",
      "r577",
      "r693",
      "r788",
      "r810",
      "r811",
      "r870",
      "r872",
      "r874",
      "r972",
      "r1122"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r106",
      "r205",
      "r207",
      "r254",
      "r258",
      "r259",
      "r692",
      "r1012"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r217",
      "r249",
      "r250",
      "r252",
      "r253",
      "r262",
      "r263",
      "r268",
      "r271",
      "r392",
      "r395",
      "r400",
      "r534"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLossPerShareTable",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_NetSalesProfitPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "NetSalesProfitPercentage",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales profit, percentage",
        "documentation": "Percentage of net sales profit.",
        "label": "Net Sales Profit Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Warrants [Member]",
        "label": "New Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_NonControllingInterestConsiderationShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "NonControllingInterestConsiderationShare",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interest consideration share",
        "documentation": "Non-controlling interest consideration share.",
        "label": "Non Controlling Interest Consideration Share"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_NonMarketableCostMethodInvestmentsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "NonMarketableCostMethodInvestmentsNetAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-marketable Cost Method Investments, net",
        "label": "Non Marketable Cost Method Investments Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non controlling Interest",
        "verboseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r419",
      "r1075",
      "r1076",
      "r1077",
      "r1080",
      "r1252"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expenses)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_NonrefundableUpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "NonrefundableUpfrontCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront cash payment",
        "documentation": "Non-refundable upfront cash payment.",
        "label": "Nonrefundable Upfront Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r886",
      "r1089"
     ]
    },
    "abvc_NumberOfSharesReceived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "NumberOfSharesReceived",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares received (in Shares)",
        "documentation": "The number of shares received.",
        "label": "Number Of Shares Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OncoXBioPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OncoXBioPharmaIncMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OncoX BioPharma, Inc. [Member]",
        "label": "Onco XBio Pharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OncoXBiopPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OncoXBiopPharmaIncMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OncoX BiopPharma, Inc [Member]",
        "label": "Onco XBiop Pharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OncoXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OncoXMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OncoX [Member]",
        "label": "Onco XMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r870",
      "r874",
      "r879",
      "r1083",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable",
      "http://metuboutique.com/role/ScheduleofLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expenses",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1186"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r610"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leases have Remaining Lease Terms",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "documentation": "Tabular disclosure of components of income from operating lease."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r609"
     ]
    },
    "abvc_OperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": {
       "parentTag": "abvc_DeferredTaxAssetsOperatingLeaseAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0": {
       "parentTag": "abvc_DeferredTaxAssetsOperatingLeaseAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable",
      "http://metuboutique.com/role/ScheduleofDeferredTaxAssetsLiabilityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease liabilities",
        "documentation": "Operating lease liabilities amount.",
        "label": "Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable",
      "http://metuboutique.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of future minimum lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofLeaseTable",
      "http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities (current)",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofLeaseTable",
      "http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability \u2013 non-current",
        "verboseLabel": "Operating lease liabilities (non-current)",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r602"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofLeaseTable",
      "http://metuboutique.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable",
      "http://metuboutique.com/role/ScheduleofLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "verboseLabel": "Operating leases Weighted Average Discount Rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r944"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable",
      "http://metuboutique.com/role/ScheduleofLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "verboseLabel": "Operating leases Weighted Average Remaining Lease Term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r944"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OrganizationandDescriptionofBusinessDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OrganizationandDescriptionofBusinessDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable",
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Total",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r694"
     ]
    },
    "abvc_OtherConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OtherConvertibleNotesPayableMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Convertible Notes Payable [Member]",
        "label": "Other Convertible Notes Payable Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OtherIndividualMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OtherIndividualMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Individual [Member]",
        "verboseLabel": "Other individual [Member]",
        "netLabel": "Other Individual \u2013 Third party [Member]",
        "label": "Other Individual Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OtherIndividualThirdPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OtherIndividualThirdPartyMember",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Individual \u2013 Third party [Member]",
        "label": "Other Individual Third Party Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherInvestmentsAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-marketable Cost Method Investments, net",
        "label": "Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "verboseLabel": "Amount due to related parties",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r945"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-cash expenses",
        "negatedTerseLabel": "Other non-cash income and expenses",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expenses)",
        "verboseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r938"
     ]
    },
    "abvc_OtherNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OtherNoteMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Note [Member]",
        "label": "Other Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OtherNoteOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OtherNoteOneMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Note One [Member]",
        "verboseLabel": "Other Note [Member]",
        "label": "Other Note One Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivableAfterAllowanceForCreditLossNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      },
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net",
        "terseLabel": "Due from related parties - non-current, net",
        "verboseLabel": "Net, Due from related parties",
        "netLabel": "Due from BHK",
        "label": "Other Receivable, after Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, after allowance for credit loss, of receivable classified as other and noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivableAllowanceForCreditLossNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable": {
       "parentTag": "us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: allowance for expected credit losses accounts",
        "label": "Other Receivable, Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount of allowance for credit loss on receivable classified as other and noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivableBeforeAllowanceForCreditLossNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable": {
       "parentTag": "us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from related parties- Non-current, net",
        "label": "Other Receivable, before Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, before allowance for credit loss, of receivable classified as other and noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r775",
      "r884",
      "r961",
      "r962",
      "r1211"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from related parties",
        "verboseLabel": "Due from related party- Current",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "abvc_OtherThanTemporaryImpairmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OtherThanTemporaryImpairmentPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other-Than-Temporary Impairment",
        "documentation": "Disclosure of accounting policy for other than temporary impairment.",
        "label": "Other Than Temporary Impairment Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OutstandingBalanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OutstandingBalanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding amount",
        "verboseLabel": "Outstanding balance amount",
        "documentation": "The amount of outstanding balance amount.",
        "label": "Outstanding Balance Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OutstandingLiabilityOwnedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OutstandingLiabilityOwnedAmount",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding liability owned (in Dollars)",
        "documentation": "Outstanding liability Owned Amount.",
        "label": "Outstanding Liability Owned Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_OutstandingPrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "OutstandingPrincipalAmount",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "documentation": "The amount of outstanding principal amount.",
        "label": "Outstanding Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForParticipationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForParticipationLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash amount",
        "label": "Payments for Participation Liabilities",
        "documentation": "Cash payments related to participation costs."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_PaymentsForPreviousAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForPreviousAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Payments for Previous Acquisition",
        "documentation": "Cash outflow representing an adjustment to the purchase price of a previous acquisition."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent payable (in Dollars)",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase warrant to purchase",
        "label": "Payments for Repurchase of Warrants",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to joint venture",
        "label": "Payments to Acquire Interest in Joint Venture",
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireLongtermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepayment for equity investment",
        "label": "Payments to Acquire Long-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "abvc_PercentageCommonStocksShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PercentageCommonStocksShares",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common stock shares",
        "documentation": "Percentage value of common stocks shares.",
        "label": "Percentage Common Stocks Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PercentageOfAnnualDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PercentageOfAnnualDiscountRate",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of annual discount rate",
        "documentation": "The percentage of annual discount rate.",
        "label": "Percentage Of Annual Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PercentageOfAverageAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PercentageOfAverageAmount",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of average amount",
        "documentation": "Percentage of average amount.",
        "label": "Percentage Of Average Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PercentageOfCashPermium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PercentageOfCashPermium",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of cash premium",
        "documentation": "Percentage of cash premium.",
        "label": "Percentage Of Cash Permium"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PercentageOfDevelopAndCommercialize": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PercentageOfDevelopAndCommercialize",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of develop and commercialize",
        "documentation": "Rate of develop and commercialize.",
        "label": "Percentage Of Develop And Commercialize"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsSavings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PercentageOfInterestBearingDomesticDepositsToDepositsSavings",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money deposited in a savings account",
        "label": "Percentage of Interest-Bearing Domestic Deposits to Deposits, Savings",
        "documentation": "Percentage of interest-bearing domestic savings deposit liabilities to total deposit liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PercentageOfOutstandingPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PercentageOfOutstandingPrincipalAmount",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding principal amount",
        "documentation": "Percentage of outstanding principal amount.",
        "label": "Percentage Of Outstanding Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PercentageOfPaymentsUnderCodevelopmentAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PercentageOfPaymentsUnderCodevelopmentAgreement",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Data and development percentage",
        "documentation": "Percentage of payments under co-development agreement.",
        "label": "Percentage Of Payments Under Codevelopment Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PercentageOfRoyaltiesEqualing": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PercentageOfRoyaltiesEqualing",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalties equaling",
        "documentation": "The percentage of royalties equaling.",
        "label": "Percentage Of Royalties Equaling"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PercentageOfWorkingCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PercentageOfWorkingCapital",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of working capital",
        "documentation": "Percentage of working capital.",
        "label": "Percentage Of Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "abvc_PostSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PostSplitMember",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-Split [Member]",
        "label": "Post Split Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PostemploymentBenefitPlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PostemploymentBenefitPlansPolicy",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-retirement and post-employment benefits",
        "label": "Postemployment Benefit Plans, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "abvc_PostretirementAndPostemploymentBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PostretirementAndPostemploymentBenefitsMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-retirement and post-employment benefits [Member]",
        "label": "Postretirement And Postemployment Benefits Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PreExistingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PreExistingWarrantsMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Existing Warrants [Member]",
        "label": "Pre Existing Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "verboseLabel": "Warrants [Member]",
        "label": "Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed conversion price equal (in Dollars per share)",
        "verboseLabel": "Conversion price (in Dollars per share)",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r402"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r766"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r402"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r766",
      "r787",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r391",
      "r397",
      "r679",
      "r945"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expense and other current assets",
        "verboseLabel": "Prepaid expense and other current asset",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment for asset acquisition",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r1007"
     ]
    },
    "us-gaap_PrepaymentFeesOnAdvancesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaymentFeesOnAdvancesNet",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "verboseLabel": "Prepayment amount",
        "label": "Prepayment Fees on Advances, Net",
        "documentation": "Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PrepaymentForLongtermInvestmentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PrepaymentForLongtermInvestmentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment for long-term investments",
        "documentation": "Prepayment for long-term investments noncurrent.",
        "label": "Prepayment For Longterm Investments Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PrepaymentOfAssetAcquisitionByIssuingCommonStockToAThirdParty",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment for asset acquisition by issuing common stock to a third party",
        "documentation": "Amount of prepayment of asset acquisition by issuing common stock to a third party.",
        "label": "Prepayment Of Asset Acquisition By Issuing Common Stock To AThird Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrincipalAmountOutstandingOnLoansSecuritized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrincipalAmountOutstandingOnLoansSecuritized",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding loan balance",
        "label": "Loan, Securitized or Asset-Backed Financing Arrangement, Principal Outstanding",
        "documentation": "This is the principal amount outstanding for securitized loans only (across all types of loans)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "abvc_PriorPeriodAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PriorPeriodAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior period adjustment",
        "documentation": "Amount of prior period adjustment.",
        "label": "Prior Period Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Offering [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromContributedCapital",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital raised",
        "label": "Proceeds from Contributed Capital",
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from convertible notes payable",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "abvc_ProceedsFromIssuanceOfAPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ProceedsFromIssuanceOfAPromissoryNote",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of a promissory note",
        "verboseLabel": "Proceeds from promissory note",
        "documentation": "Amount of proceeds from issuance of a promissory note.",
        "label": "Proceeds From Issuance Of APromissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "verboseLabel": "Aggregate value of common stock (in Dollars)",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of debt",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital raised by private offering",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties, net",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRepaymentOfLoansToPurchaseCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of principal of 2nd lind note (in Dollars)",
        "label": "Proceeds from Repayment of Loans to Purchase Common Stock",
        "documentation": "Cash inflow from repayment of loans for purchasing common stock."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from (repayment of) related party payables",
        "verboseLabel": "Due to related parties",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from short-term loans",
        "label": "Proceeds from Short-Term Debt",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from common stock subscription",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "abvc_ProceedsFromSubsidiarysCommonStockSubscription": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ProceedsFromSubsidiarysCommonStockSubscription",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from subsidiary\u2019s executive contribution",
        "documentation": "Amount of proceeds from subsidiary's common stock subscription.",
        "label": "Proceeds From Subsidiarys Common Stock Subscription"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ProceedsFromSubsidiarysShareholderContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ProceedsFromSubsidiarysShareholderContribution",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from subsidiary's executive contribution",
        "documentation": "Represent the amount of proceeds from subsidiary's shareholder contribution.",
        "label": "Proceeds From Subsidiarys Shareholder Contribution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r175",
      "r308",
      "r629",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r862",
      "r869",
      "r872",
      "r874",
      "r895",
      "r896",
      "r954",
      "r956",
      "r957",
      "r960",
      "r963",
      "r988",
      "r1000",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1120",
      "r1121",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1245",
      "r1246"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r175",
      "r308",
      "r629",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r862",
      "r869",
      "r872",
      "r874",
      "r895",
      "r896",
      "r954",
      "r956",
      "r957",
      "r960",
      "r963",
      "r988",
      "r1000",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1120",
      "r1121",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss for the period",
        "netLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r186",
      "r205",
      "r207",
      "r223",
      "r231",
      "r234",
      "r235",
      "r239",
      "r245",
      "r254",
      "r258",
      "r259",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r389",
      "r482",
      "r527",
      "r534",
      "r538",
      "r541",
      "r542",
      "r569",
      "r577",
      "r668",
      "r670",
      "r691",
      "r736",
      "r788",
      "r810",
      "r811",
      "r936",
      "r937",
      "r973",
      "r1012",
      "r1122"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, and Prepament for Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r607"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, AND PREPAMENT FOR ASSET ACQUISITION",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r134",
      "r135",
      "r136"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "verboseLabel": "Land with book value",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r191",
      "r688"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "terseLabel": "Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r607",
      "r673",
      "r688",
      "r945"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Other, Net",
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r134",
      "r135",
      "r686"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r607"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PropertyandEquipmentandPrepamentforAssetAcquisitionDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, and Prepament for Asset Acquisition (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for doubtful accounts",
        "verboseLabel": "Credit loss",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r326"
     ]
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision credit loss",
        "label": "Provision for Other Credit Losses",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r119"
     ]
    },
    "abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of Property and equipment by issuing common stock to a third party",
        "documentation": "Amount of purchase of property and equipment by issuing common stock to a third party.",
        "label": "Purchase Of Property And Equipment By Issuing Common Stock To AThird Party"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PurchasePriceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PurchasePriceAmount",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price amount",
        "documentation": "Purchase price amount.",
        "label": "Purchase Price Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_PurchaseWarrantTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "PurchaseWarrantTerm",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase warrant term",
        "documentation": "Term of the purchase warrant.",
        "label": "Purchase Warrant Term"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r148",
      "r149",
      "r151",
      "r168",
      "r170",
      "r171",
      "r177",
      "r178",
      "r287",
      "r344",
      "r345",
      "r346",
      "r347",
      "r438",
      "r443",
      "r474",
      "r475",
      "r476",
      "r481",
      "r494",
      "r570",
      "r625",
      "r626",
      "r627",
      "r706",
      "r707",
      "r718",
      "r756",
      "r757",
      "r821",
      "r824",
      "r826",
      "r827",
      "r830",
      "r840",
      "r841",
      "r843",
      "r844",
      "r858",
      "r859",
      "r887",
      "r894",
      "r901",
      "r905",
      "r907",
      "r908",
      "r939",
      "r940",
      "r941",
      "r942",
      "r956",
      "r966",
      "r1118",
      "r1124",
      "r1177",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r148",
      "r149",
      "r151",
      "r168",
      "r170",
      "r171",
      "r177",
      "r178",
      "r287",
      "r344",
      "r345",
      "r346",
      "r347",
      "r438",
      "r443",
      "r474",
      "r475",
      "r476",
      "r481",
      "r494",
      "r570",
      "r625",
      "r626",
      "r627",
      "r706",
      "r707",
      "r718",
      "r756",
      "r757",
      "r821",
      "r824",
      "r826",
      "r827",
      "r830",
      "r840",
      "r841",
      "r843",
      "r844",
      "r858",
      "r859",
      "r887",
      "r894",
      "r901",
      "r905",
      "r907",
      "r908",
      "r939",
      "r940",
      "r941",
      "r942",
      "r956",
      "r966",
      "r1118",
      "r1124",
      "r1177",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203"
     ]
    },
    "us-gaap_RealEstateOwnedValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstateOwnedValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation amount",
        "label": "Real Estate Owned, Valuation Allowance",
        "documentation": "For each period for which an income statement is required, disclosure of the changes in the allowance, including balances at end of period."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_ReceivableWithImputedInterestFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivableWithImputedInterestFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note in principal amount",
        "label": "Receivable with Imputed Interest, Face Amount",
        "documentation": "The principal amount of the receivable or note before consideration of the discount or premium."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r943"
     ]
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesFromStockholderMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables from Stockholder [Member]",
        "label": "Receivables from Stockholder [Member]",
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ReceivedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ReceivedShares",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares received (in Shares)",
        "documentation": "Number of shares received.",
        "label": "Received Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RecognizedCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RecognizedCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized credit losses",
        "documentation": "Recognized credit losses.",
        "label": "Recognized Credit Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Total Segment Gross Profit",
        "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "abvc_RelatedPartiesTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RelatedPartiesTransactionsDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Receivable Due from Related Parties [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RelatedPartiesTransactionsScheduleofAccountsReceivableDuefromRelatedPartiesDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions - Schedule of Accounts Receivable Due from Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amount Due to Related Parties [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RelatedPartiesTransactionsScheduleofAmountDuetoRelatedPartiesDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions - Schedule of Amount Due to Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Due from Related Party - Current and Non-current, Net [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RelatedPartiesTransactionsScheduleofDuefromRelatedPartyCurrentandNoncurrentNetDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions - Schedule of Due from Related Party - Current and Non-current, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Licensing Agreement and Related Amendment with FEYE [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RelatedPartiesTransactionsScheduleofLicensingAgreementandRelatedAmendmentwithFEYEDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions - Schedule of Licensing Agreement and Related Amendment with FEYE (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r238",
      "r239",
      "r312",
      "r440",
      "r441",
      "r617",
      "r618",
      "r676",
      "r685",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r786",
      "r820",
      "r1250"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r238",
      "r239",
      "r617",
      "r618",
      "r619",
      "r620",
      "r676",
      "r685",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r786",
      "r820"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding balance amount",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r238",
      "r239",
      "r617",
      "r618",
      "r1195"
     ]
    },
    "us-gaap_RelatedPartyTransactionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDate",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Related Party Transaction, Date",
        "documentation": "Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The extent the investee relies on the Company for its business, description",
        "verboseLabel": "Relationship with the Company and its subsidiaries",
        "label": "Related Party Transaction, Description of Transaction",
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r196",
      "r606",
      "r608",
      "r611",
      "r616"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r238",
      "r239",
      "r1195"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Parties of the Company with whom Transactions [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "verboseLabel": "Related Parties Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r238",
      "r239",
      "r312",
      "r617",
      "r618",
      "r620",
      "r792",
      "r793",
      "r796"
     ]
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionRate",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of mature",
        "label": "Related Party Transaction, Rate",
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0",
      "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable",
      "http://metuboutique.com/role/ShortTermLoansDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r238",
      "r239",
      "r312",
      "r440",
      "r441",
      "r617",
      "r618",
      "r676",
      "r685",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r786",
      "r820",
      "r1195",
      "r1250"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTIES TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615",
      "r616",
      "r618",
      "r621",
      "r732",
      "r733",
      "r734",
      "r794",
      "r795",
      "r796",
      "r816",
      "r818"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of convertible notes payable",
        "terseLabel": "Cash repayment (in Dollars)",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments amount",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due to related parties",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of short-term loans",
        "terseLabel": "Payments of loan",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "abvc_RepurchaseOfTreasuryStocks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RepurchaseOfTreasuryStocks",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of treasury stocks",
        "documentation": "The amount of repurchase of treasury stocks.",
        "label": "Repurchase Of Treasury Stocks"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 8.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r860",
      "r870",
      "r871",
      "r883",
      "r1204"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Period Adjustment",
        "verboseLabel": "Adjustments [Member]",
        "netLabel": "Revision of Prior Period, Adjustment [Member]",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r256",
      "r257",
      "r276",
      "r567",
      "r568",
      "r595",
      "r984",
      "r985",
      "r986",
      "r987",
      "r992",
      "r993",
      "r1079",
      "r1094"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAxis",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r180",
      "r181",
      "r182",
      "r183",
      "r220",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r276",
      "r321",
      "r322",
      "r388",
      "r389",
      "r482",
      "r525",
      "r526",
      "r527",
      "r528",
      "r533",
      "r534",
      "r566",
      "r567",
      "r568",
      "r569",
      "r595",
      "r612",
      "r613",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r723",
      "r1094"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementDomain",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r180",
      "r181",
      "r182",
      "r183",
      "r220",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r276",
      "r321",
      "r322",
      "r388",
      "r389",
      "r482",
      "r525",
      "r526",
      "r527",
      "r528",
      "r533",
      "r534",
      "r566",
      "r567",
      "r568",
      "r569",
      "r595",
      "r612",
      "r613",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r723",
      "r1094"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash (in New Dollars)",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1065",
      "r1205",
      "r1209"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash amounted",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1065"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r100",
      "r682",
      "r712",
      "r717",
      "r730",
      "r767",
      "r945"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r182",
      "r242",
      "r243",
      "r244",
      "r246",
      "r254",
      "r257",
      "r259",
      "r320",
      "r323",
      "r336",
      "r388",
      "r482",
      "r516",
      "r517",
      "r524",
      "r525",
      "r526",
      "r528",
      "r533",
      "r534",
      "r555",
      "r557",
      "r558",
      "r560",
      "r567",
      "r594",
      "r597",
      "r708",
      "r710",
      "r737",
      "r1252"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash",
        "verboseLabel": "Loan amount",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r277",
      "r289",
      "r290",
      "r304",
      "r306",
      "r308",
      "r309",
      "r311",
      "r431",
      "r432",
      "r433",
      "r629"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r861"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable",
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable",
      "http://metuboutique.com/role/ScheduleofRevenueandGrossProfitInformationofourReportableSegmentTable0",
      "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue",
        "netLabel": "Net sales",
        "label": "Total",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r213",
      "r231",
      "r234",
      "r235",
      "r277",
      "r289",
      "r290",
      "r304",
      "r306",
      "r308",
      "r309",
      "r311",
      "r319",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r577",
      "r668",
      "r670",
      "r883",
      "r938",
      "r961",
      "r962",
      "r1122"
     ]
    },
    "abvc_RgeneCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RgeneCorporationMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable",
      "http://metuboutique.com/role/ScheduleofLongTermInvestmentTable0",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rgene Corporation [Member]",
        "label": "Rgene Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RgeneCorporationtheRgeneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RgeneCorporationtheRgeneMember",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rgene Corporation (the \u201cRgene\u201d) [Member]",
        "verboseLabel": "Rgene Corporation [Member]",
        "label": "Rgene Corporationthe Rgene Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RgeneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RgeneMember",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofAccountsReceivableDuefromRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable",
      "http://metuboutique.com/role/ScheduleofDuefromRelatedPartyCurrentandNoncurrentNetTable",
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0",
      "http://metuboutique.com/role/ScheduleofStatementsofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rgene [Member]",
        "label": "Rgene Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RgeneStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RgeneStudiesMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rgene Studies [Member]",
        "label": "Rgene Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_RoyaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "RoyaltiesPercentage",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalties of net sales",
        "documentation": "Percentage of Royalties.",
        "label": "Royalties Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of shares",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FEYE stock (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r1085",
      "r1086"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r997"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "As Reported [Member]",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r242",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r259",
      "r276",
      "r388",
      "r389",
      "r482",
      "r525",
      "r527",
      "r528",
      "r533",
      "r534",
      "r566",
      "r567",
      "r568",
      "r595",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r723",
      "r990",
      "r991",
      "r992",
      "r1078",
      "r1079",
      "r1094",
      "r1103",
      "r1104",
      "r1174",
      "r1189",
      "r1190"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r184",
      "r185",
      "r260",
      "r444",
      "r978"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accounts Receivable Due From Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfAccountsReceivableDueFromRelatedPartiesTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable Due from Related Parties",
        "label": "Schedule Of Accounts Receivable Due From Related Parties Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfAmountDueToRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfAmountDueToRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Amount Due To Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfAmountDueToRelatedPartiesTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount Due to Related Parties",
        "documentation": "Tabular disclosure of amount due to related parties.",
        "label": "Schedule Of Amount Due To Related Parties Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfBalanceSheetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfBalanceSheetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balance Sheets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfCarryingAmountsOfTheLiabilityComponentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Carrying Amounts Of The Liability Component Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax (Benefit) Expense",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheets",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r174",
      "r184",
      "r185",
      "r982",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impact of the Restatement",
        "label": "Condensed Financial Statements [Table Text Block]",
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1068",
      "r1074",
      "r1206"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets (Liability)",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Due From Related Party Current And Non Current Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfDueFromRelatedPartyCurrentAndNonCurrentTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Due from Related Party - Current and Non-current, Net",
        "documentation": "Tabular disclosure of due from related party current and non current.",
        "label": "Schedule Of Due From Related Party Current And Non Current Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r523",
      "r577",
      "r979",
      "r980",
      "r981",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Ownership Percentages of Each Investee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r235",
      "r316",
      "r317",
      "r318",
      "r319",
      "r577"
     ]
    },
    "abvc_ScheduleOfEstimatedUsefulLifeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfEstimatedUsefulLifeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Life Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentNetTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Life",
        "documentation": "Tabular disclosure of estimated useful life of property and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property And Equipment Net Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfExtentTheInvesteeReliesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfExtentTheInvesteeReliesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Extent The Investee Relies Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfExtentTheInvesteeReliesTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Extent the Investee Relies",
        "documentation": "Tabular disclosure of extent the investee relies.",
        "label": "Schedule Of Extent The Investee Relies Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfImpactOfTheRestatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfImpactOfTheRestatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Impact Of The Restatement Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfLeaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfLeaseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfLicensingAgreementAndRelatedAmendmentWithFeyeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Licensing Agreement And Related Amendment With Feye Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfLongTermInvestmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfLongTermInvestmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Long Term Investment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Type and Tier Identifier [Axis]",
        "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_ScheduleOfOtherOwnershipInterestsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherOwnershipInterestsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable",
      "http://metuboutique.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partners' Capital, Other Ownership Interest [Table]",
        "documentation": "Disclosure of information about other ownership interest in partnership. Includes, but is not limited to, description of ownership interest, capital contributed, capital account balance, unit of other ownership interest authorized to be issued, issued, and outstanding, cumulative cash distribution made, and cumulative net income shared by other unit holder in partnership. Excludes general and limited partners' ownership interests."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherOwnershipInterestsTextBlock",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Ownership Percentages of Each Investee",
        "label": "Schedule of Other Ownership Interests [Table Text Block]",
        "documentation": "Tabular disclosure of other units or shares or classes of ownership in a partnership."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Ownership Percentages Of Each Investee Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable",
      "http://metuboutique.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r607"
     ]
    },
    "abvc_ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Licensing Agreement and Related Amendment with FEYE",
        "documentation": "Schedule of Pursuant Licensing Agreement Related Amendment.",
        "label": "Schedule Of Pursuant Licensing Agreement Related Amendment Table Text BLock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquisition was Accounted for Business Combination",
        "label": "Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of asset acquired and liability assumed in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170"
     ]
    },
    "abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Related Parties Of The Company With Whom Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r238",
      "r239",
      "r617",
      "r618",
      "r620",
      "r792",
      "r793",
      "r796"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Parties of the Company with whom Transactions",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1192",
      "r1193"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue and Gross Profit Information of our Reportable Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Options Issued and Outstanding",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r102"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-Term Loans",
        "label": "Schedule of Short-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "abvc_ScheduleOfShortTermLoansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfShortTermLoansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Short Term Loans Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ScheduleOfStatementsOfOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfStatementsOfOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Statements Of Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://metuboutique.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Issued and Outstanding",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "abvc_ScheduleOfWarrantsIssuedAndOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ScheduleOfWarrantsIssuedAndOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrants Issued And Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SecondLINDNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SecondLINDNoteMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2nd LIND Note [Member]",
        "label": "Second LINDNote Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SecondLINDNoteOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SecondLINDNoteOneMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second LIND Note One [Member]",
        "label": "Second LINDNote One Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SecondLindNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SecondLindNoteMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2nd Lind Note [Member]",
        "label": "Second Lind Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecurityDepositLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDepositLiability",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant security deposit",
        "label": "Security Deposit Liability",
        "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing."
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r150",
      "r152",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r284",
      "r309",
      "r310",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r752",
      "r753",
      "r754",
      "r823",
      "r825",
      "r829",
      "r832",
      "r840",
      "r842",
      "r843",
      "r844",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r863",
      "r876",
      "r895",
      "r897",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r958",
      "r966",
      "r1213",
      "r1214",
      "r1215",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_SegmentReportingInformationRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue and Gross Profit Information of our Reportable Segment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Total Segment Gross Profit [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r307",
      "r309",
      "r881",
      "r882",
      "r885"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 7.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r869",
      "r870",
      "r871",
      "r874",
      "r1053"
     ]
    },
    "abvc_ServiceAgreementEligibilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ServiceAgreementEligibilityAmount",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service agreement eligibility amount",
        "documentation": "Service agreement eligibility amount.",
        "label": "Service Agreement Eligibility Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceAgreementsMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Agreements [Member]",
        "label": "Service Agreements [Member]",
        "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Contractual Life Remaining in Years, Outstanding ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r481"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Underlying Shares, Exercised (in Shares)",
        "negatedTerseLabel": "Number of Underlying Shares, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercised (in Dollars)",
        "verboseLabel": "Aggregate Intrinsic Value, Exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instrument exercise intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Per Share, Exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instrument exercise weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Contractual Life Remaining in Years, Exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instrument   exercise weighted remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Underlying Shares, Issued (in Shares)",
        "verboseLabel": "Number of Underlying Shares, Issued",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Issued (in Dollars)",
        "verboseLabel": "Aggregate Intrinsic Value, Issued",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instrument  issued intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Per Share, Issued",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instrument issued weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Contractual Life Remaining in Years, Issued",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instrument  issued weighted remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Underlying Shares, Outstanding ending (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock issued (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted restricted shares",
        "verboseLabel": "Granted options to purchase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Underlying Shares, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Forfeited",
        "documentation": "Aggregate Intrinsic Value, Forfeited.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Underlying Shares, Forfeited",
        "negatedLabel": "Number of Underlying Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Granted",
        "documentation": "Aggregate Intrinsic Value, Granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Underlying Shares, Granted",
        "verboseLabel": "Stock option grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Underlying Shares, Outstanding ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Underlying Shares, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "abvc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted- Average Exercise Price Per Share, Outstanding ending",
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Granted",
        "verboseLabel": "Exercise price per share (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r452",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Employee [Member]",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding ending (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Forfeited",
        "documentation": "Weighted average contractual life remaining in years, forfeited.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Granted",
        "documentation": "The value of estimated use full lifes.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Grant Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable",
      "http://metuboutique.com/role/ScheduleofOptionsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "abvc_ShareholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShareholdersMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders [Member]",
        "label": "Shareholders Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares paid (in Shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued per share (in Dollars per share)",
        "verboseLabel": "Price per share (in Dollars per share)",
        "netLabel": "Per share of common stock (in Dollars per share)",
        "label": "Price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SharesReceived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SharesReceived",
     "presentation": [
      "http://metuboutique.com/role/AcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares received (in Shares)",
        "documentation": "Shares received.",
        "label": "Shares Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term bank and other loans",
        "verboseLabel": "Total",
        "netLabel": "Short term debt",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r111",
      "r945",
      "r1207"
     ]
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermBorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Loans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Bank Loan [Line Items]",
        "terseLabel": "Schedule of Short-Term Loans [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ShortTermDebtMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShortTermDebtMaturityDate",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "documentation": "Maturity date of short-term debt, in YYYY-MM-DD format.",
        "label": "Short Term Debt Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bearing interest rate",
        "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate",
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtPercentageBearingVariableInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtPercentageBearingVariableInterestRate",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of bears interest rate",
        "label": "Short-Term Debt, Percentage Bearing Variable Interest Rate",
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date, which accrues interest at a rate subject to change from time to time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTextBlock",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHORT-TERM LOANS",
        "label": "Short-Term Debt [Text Block]",
        "documentation": "The entire disclosure for short-term debt."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r1115",
      "r1116",
      "r1117"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable",
      "http://metuboutique.com/role/ScheduleofShortTermLoansTable0",
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r1115",
      "r1116",
      "r1117"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r1008"
     ]
    },
    "abvc_ShortTermLoansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShortTermLoansDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Loans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ShulingJiangMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ShulingJiangMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shuling Jiang [Member]",
        "label": "Shuling Jiang Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r197",
      "r198",
      "r199",
      "r231",
      "r235",
      "r265",
      "r266",
      "r269",
      "r271",
      "r280",
      "r281",
      "r319",
      "r350",
      "r352",
      "r353",
      "r354",
      "r357",
      "r358",
      "r390",
      "r391",
      "r393",
      "r394",
      "r396",
      "r399",
      "r402",
      "r403",
      "r407",
      "r410",
      "r417",
      "r577",
      "r726",
      "r727",
      "r728",
      "r729",
      "r737",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r750",
      "r766",
      "r789",
      "r812",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r977",
      "r1069",
      "r1071",
      "r1081"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/StockOptionsDetails",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r65",
      "r68",
      "r69",
      "r179",
      "r181",
      "r182",
      "r210",
      "r211",
      "r212",
      "r242",
      "r243",
      "r244",
      "r246",
      "r254",
      "r257",
      "r259",
      "r279",
      "r320",
      "r323",
      "r336",
      "r388",
      "r419",
      "r482",
      "r516",
      "r517",
      "r524",
      "r525",
      "r526",
      "r528",
      "r533",
      "r534",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r594",
      "r597",
      "r613",
      "r694",
      "r708",
      "r709",
      "r710",
      "r737",
      "r812"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r150",
      "r152",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r284",
      "r309",
      "r310",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r752",
      "r753",
      "r754",
      "r823",
      "r825",
      "r829",
      "r832",
      "r840",
      "r842",
      "r843",
      "r844",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r863",
      "r876",
      "r895",
      "r897",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r958",
      "r966",
      "r1213",
      "r1214",
      "r1215",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r279",
      "r390",
      "r391",
      "r393",
      "r396",
      "r597",
      "r629",
      "r724",
      "r738",
      "r750",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r766",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r777",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r790",
      "r791",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r812",
      "r872",
      "r874",
      "r967",
      "r1250"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity, Going Concern, and Restatement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r184",
      "r185",
      "r260",
      "r444",
      "r978",
      "r983"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r279",
      "r312",
      "r390",
      "r391",
      "r393",
      "r396",
      "r597",
      "r629",
      "r724",
      "r738",
      "r750",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r766",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r777",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r790",
      "r791",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r812",
      "r872",
      "r874",
      "r967",
      "r1250"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatutoryAccountingPracticesLineItems",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1210",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244"
     ]
    },
    "abvc_StockBasedExpensesAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockBasedExpensesAmortizationPeriod",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based expenses amortization period",
        "documentation": "Duration of Stock-based expenses amortization period.",
        "label": "Stock Based Expenses Amortization Period"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockIssueDuringPeriodCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssueDuringPeriodCommonShares",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issue during period common shares",
        "documentation": "Stock issue during period common shares.",
        "label": "Stock Issue During Period Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Issued and Outstanding [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued for asset acquisition (in Shares)",
        "verboseLabel": "Acquisition shares (in Shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r100"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for exercise of convertible notes (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r42",
      "r65",
      "r68",
      "r100",
      "r376"
     ]
    },
    "abvc_StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesDistributeAsEmployeeCompensation",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribute as employee compensation (in Shares)",
        "documentation": "Number of shares in distribute as employee compensation.",
        "label": "Stock Issued During Period Shares Distribute As Employee Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrant (in Shares)",
        "documentation": "The share amount of exercise of pre-funded warrant.",
        "label": "Stock Issued During Period Shares Exercise Of Prefunded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquiringOfProperty",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for acquisition of property (in Shares)",
        "documentation": "Number of shares in issuance of common shares for acquiring of Property.",
        "label": "Stock Issued During Period Shares Issuance Of Common Shares For Acquiring Of Property"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForAcquisitionOfProperty",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for acquisition of property (in Shares)",
        "verboseLabel": "Issuance of common shares (in Shares)",
        "documentation": "The number of shares issuance of common stock for acquiring of property.",
        "label": "Stock Issued During Period Shares Issuance Of Common Shares For Acquisition Of Property"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForExerciseOfWarrants",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for exercise of warrants (in Shares)",
        "documentation": "Issuance of common shares for exercise of warrants.",
        "label": "Stock Issued During Period Shares Issuance Of Common Shares For Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for consulting service (in Shares)",
        "verboseLabel": "Common stock purchase warrant (in Shares)",
        "netLabel": "Issued shares for consulting service",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for cash (in Shares)",
        "verboseLabel": "Received shares (in Shares)",
        "netLabel": "Issuance of common stock",
        "label": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r100",
      "r726",
      "r812",
      "r834"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received shares (in Shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation for services (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r100"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r100",
      "r458"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued for post split (in Shares)",
        "verboseLabel": "Shares issued (in Shares)",
        "label": "Stock Issued During Period, Shares, Stock Splits",
        "documentation": "Number of shares issued during the period as a result of a stock split."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r100"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition value",
        "verboseLabel": "Aggregate amount",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r65",
      "r68",
      "r69",
      "r100"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for exercise of convertible notes",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r65",
      "r68",
      "r69",
      "r100"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribute as employee compensation",
        "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan",
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r100",
      "r493"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock from a prior employee",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r100"
     ]
    },
    "abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonSharesForAcquisitionOfProperty",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for acquisition of property",
        "documentation": "Value of stock \tissuance of common stock for acquiring of property.",
        "label": "Stock Issued During Period Value Issuance Of Common Shares For Acquisition Of Property"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonSharesForExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for exercise of warrants",
        "documentation": "Represents the amount of issuance of common shares for exercise of warrants.",
        "label": "Stock Issued During Period Value Issuance Of Common Shares For Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonSharesForLindCN",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for Lind CN Repayment",
        "documentation": "Represents the amount of issuance of common shares for Lind CN.",
        "label": "Stock Issued During Period Value Issuance Of Common Shares For Lind CN"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfSubsidiarysCommonSharesForConsultingService",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of subsidiary's common shares for consulting service",
        "documentation": "Value of stock related to issuance of subsidiary's common shares for consulting service.",
        "label": "Stock Issued During Period Value Issuance Of Subsidiarys Common Shares For Consulting Service"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for consulting service",
        "verboseLabel": "Service fee (in Dollars)",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares for cash",
        "verboseLabel": "Value of new shares issued",
        "netLabel": "Total common stock value issued (in Dollars)",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r100",
      "r737",
      "r812",
      "r834",
      "r973"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation for services",
        "verboseLabel": "Stock-based compensation (in Dollars)",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r64",
      "r65",
      "r100"
     ]
    },
    "abvc_StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrant",
        "documentation": "The amount of exercise of pre-funded warrant.",
        "label": "Stock Issued During Period Value Stock Exercise Of Prefunded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockIssuedDuringPeriodValueSubsidiaryExecutiveContribution",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary executive contribution",
        "documentation": "Amount of subsidiary executive contribution.",
        "label": "Stock Issued During Period Value Subsidiary Executive Contribution"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockOptionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockOptionsDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockReverseSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockReverseSplitPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Reverse Split",
        "label": "Stock Reverse Split Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockSubScriptionReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockSubScriptionReceivableMember",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Sub scription Receivable",
        "label": "Stock Sub Scription Receivable Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockSubscriptionReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockSubscriptionReceived",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription received",
        "documentation": "Value of shares of stock subscription received.",
        "label": "Stock Subscription Received"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_StockSubscriptionReceivedInAdvance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "StockSubscriptionReceivedInAdvance",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock to be issued",
        "documentation": "The amount of stock subscription received in advance.",
        "label": "Stock Subscription Received In Advance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofBalanceSheetsTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 equity",
        "terseLabel": "Total stockholders\u2019 equity",
        "verboseLabel": "Shareholders\u2019 Deficit",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r91",
      "r768",
      "r787",
      "r813",
      "r814",
      "r945",
      "r974",
      "r1067",
      "r1071",
      "r1072",
      "r1102",
      "r1180",
      "r1252"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable",
      "http://metuboutique.com/role/ScheduleofImpactoftheRestatementTable0",
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "terseLabel": "Total Equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r179",
      "r180",
      "r181",
      "r182",
      "r211",
      "r242",
      "r243",
      "r244",
      "r246",
      "r254",
      "r257",
      "r320",
      "r323",
      "r336",
      "r388",
      "r419",
      "r482",
      "r516",
      "r517",
      "r524",
      "r525",
      "r526",
      "r528",
      "r533",
      "r534",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r567",
      "r584",
      "r585",
      "r589",
      "r595",
      "r613",
      "r709",
      "r710",
      "r735",
      "r768",
      "r787",
      "r813",
      "r814",
      "r838",
      "r961",
      "r962",
      "r973",
      "r1067",
      "r1071",
      "r1072",
      "r1102",
      "r1180",
      "r1252"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://metuboutique.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r401",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r419",
      "r552",
      "r565",
      "r815",
      "r817",
      "r839"
     ]
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription receivables",
        "verboseLabel": "Stock subscription receivables (in Dollars)",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r64",
      "r65",
      "r68",
      "r819"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r944"
     ]
    },
    "abvc_SubscribedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SubscribedStockMember",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscribed stock",
        "label": "Subscribed Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r623"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r623"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r623"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r623"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r624"
     ]
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest",
        "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incorporated state",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, State",
        "documentation": "State in which the subsidiary of the limited liability company or limited partnership was organized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable",
      "http://metuboutique.com/role/ScheduleofExtenttheInvesteeReliesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Extent the Investee Relies [Line Items]",
        "terseLabel": "Organization and Description of Business[Line items]",
        "verboseLabel": "Long-Term Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsLineItems",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Life [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLifeDetailsTable",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofEstimatedUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flows",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_SupplementalDisclosureOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "SupplementalDisclosureOfCashFlowsAbstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flows",
        "label": "Supplemental Disclosure Of Cash Flows Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "country_TW": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "TW",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAIWAN",
        "label": "TAIWAN"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_TaiwanCentralDepositInsuranceCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "TaiwanCentralDepositInsuranceCorporationMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiwan Central Deposit Insurance Corporation [Member]",
        "documentation": "Taiwan central deposit insurance corporation.",
        "label": "Taiwan Central Deposit Insurance Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesAndLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesAndLicenses",
     "crdr": "debit",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing fee",
        "label": "Taxes and Licenses",
        "documentation": "Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payables",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "abvc_TheJiangsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "TheJiangsMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofAmountDuetoRelatedPartiesTable",
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Jiangs [Member]",
        "label": "The Jiangs Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_TheJiangsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "TheJiangsOneMember",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Jiangs [Member]",
        "label": "The Jiangs One Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ThirdLINDNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ThirdLINDNoteMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable",
      "http://metuboutique.com/role/ScheduleofCarryingAmountsoftheLiabilityComponentTable0",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3rd LIND Note\t[Member]",
        "verboseLabel": "3rd LIND Note [Member]",
        "netLabel": "3rd Lind Note [Member]",
        "label": "Third LIND Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ThirdLetterAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ThirdLetterAgreementMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Letter Agreement [Member]",
        "label": "Third Letter Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1194"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable and allowance for expected credit losses accounts",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1098",
      "r1099"
     ]
    },
    "abvc_TradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "TradingDays",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading days",
        "documentation": "Trading days.",
        "label": "Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesRetired",
     "presentation": [
      "http://metuboutique.com/role/UnauditedCondensedConsolidatedStatementsofStockholdersEquityDeficitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of common stock from a prior employee (in Shares)",
        "label": "Treasury Stock, Shares, Retired",
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r65",
      "r100"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r65",
      "r68"
     ]
    },
    "abvc_TwoClientMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "TwoClientMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Client [Member]",
        "label": "Two Client Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_TwoThousandSixteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "TwoThousandSixteenEquityIncentivePlanMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Equity Incentive Plan [Member]",
        "label": "Two Thousand Sixteen Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeAndTierIdentifierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeAndTierIdentifierDomain",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type and Tier Identifier [Domain]",
        "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/ScheduleofLicensingAgreementandRelatedAmendmentwithFEYETable",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "abvc_USFederalDepositInsuranceCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "USFederalDepositInsuranceCorporationMember",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal Deposit Insurance Corporation [Member]",
        "documentation": "US federal deposit insurance corporation.",
        "label": "USFederal Deposit Insurance Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Condensed Consolidated Statements Of Stockholders Equity Deficit Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_UnregisteredPricePerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "UnregisteredPricePerShares",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unregistered price per shares",
        "documentation": "Unregistered price per shares.",
        "label": "Unregistered Price Per Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_UnregisteredRestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "UnregisteredRestrictedSharesMember",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unregistered Restricted Shares [Member]",
        "label": "Unregistered Restricted Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_UnregisteredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "UnregisteredSharesMember",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unregistered Shares [Member]",
        "label": "Unregistered Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r282",
      "r285",
      "r286",
      "r287",
      "r668",
      "r670",
      "r877"
     ]
    },
    "abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ValuationOfDeferredTaxAssetsPolicyTextBlock",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation of Deferred Tax Assets",
        "documentation": "Disclosure of accounting policy for valuation of deferred tax assets.",
        "label": "Valuation Of Deferred Tax Assets Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_WarrantDebtDiscountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "WarrantDebtDiscountMember",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Debt Discount [Member]",
        "label": "Warrant Debt Discount Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise reduced (in Dollars per share)",
        "verboseLabel": "Initial exercise price per share (in Dollars per share)",
        "netLabel": "Warrant exercise price decrease",
        "label": "Warrant, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in Dollars per share)",
        "verboseLabel": "Warrants exercise price per share (in Dollars per share)",
        "label": "Warrant, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/ScheduleofWarrantsIssuedandOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Issued and Outstanding [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_WeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "WeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Discount Rate:",
        "label": "Weighted Average Discount Rate Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_WeightedAverageNumberOfCommonSharesOutstanding1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "WeightedAverageNumberOfCommonSharesOutstanding1Abstract",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding (1):",
        "label": "Weighted Average Number Of Common Shares Outstanding1 Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding, Diluted (in Shares)",
        "verboseLabel": "Weighted-average shares outstanding \u2013 Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r271"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofLossPerShareTable",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable",
      "http://metuboutique.com/role/ScheduleofLossPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding, Basic (in Shares)",
        "verboseLabel": "Weighted-average shares outstanding \u2013 Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r271"
     ]
    },
    "abvc_WeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofCompanysLeaseExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Lease Term:",
        "label": "Weighted Average Remaining Lease Term Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_WorkingCapitalConvertibleLoanPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "WorkingCapitalConvertibleLoanPercentage",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of working capital convertible loan",
        "documentation": "Percentage of working capital convertible loan.",
        "label": "Working Capital Convertible Loan Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "WorkingCapitalDeficit",
     "crdr": "credit",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital deficit",
        "documentation": "Working capital deficit value.",
        "label": "Working Capital Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_WorkingCapitalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "WorkingCapitalPercentage",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of working capital",
        "label": "Working Capital Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_WriteOffUnclaimedAccruedLiabilites": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "WriteOffUnclaimedAccruedLiabilites",
     "crdr": "credit",
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable",
      "http://metuboutique.com/role/ScheduleofReconciliationofTotalSegmentGrossProfitTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write off unclaimed accrued liabilities",
        "verboseLabel": "Loss on investment in equity securities",
        "documentation": "Amount of write off unclaimed accrued liabilites.",
        "label": "Write Off Unclaimed Accrued Liabilites"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_YuanGeneCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "YuanGeneCorporationMember",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "YuanGene Corporation [Member]",
        "label": "Yuan Gene Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ZhongHuiLianHeJiTuanLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ZhongHuiLianHeJiTuanLtdMember",
     "presentation": [
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zhong Hui Lian He Ji Tuan, Ltd. [Member]",
        "label": "Zhong Hui Lian He Ji Tuan Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_ZhonghuiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "ZhonghuiMember",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LiquidityGoingConcernandRestatementDetails",
      "http://metuboutique.com/role/PropertyandEquipmentandPrepamentforAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zhonghui [Member]",
        "label": "Zhonghui Member"
       }
      }
     },
     "auth_ref": []
    },
    "abvc_royaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metuboutique.com/20250331",
     "localname": "royaltiesPercentage",
     "presentation": [
      "http://metuboutique.com/role/AcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty percentage",
        "documentation": "royalties percentage.",
        "label": "royalties Percentage"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)",
   "Paragraph": "4",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "926",
   "SubTopic": "230",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477628/926-230-45-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "5",
   "Subsection": "04",
   "Paragraph": "c",
   "Subparagraph": "Schedule I",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "7",
   "Subsection": "05",
   "Paragraph": "c",
   "Subparagraph": "Schedule II",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "9",
   "Subsection": "06",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480520/718-40-45-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-51"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-50/tableOfContent"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-3"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-5"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
